PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lee, YC; Chen, SS; Koh, CL; Hsueh, IP; Yao, KP; Hsieh, CL				Lee, Ya-Chen; Chen, Sheng-Shiung; Koh, Chia-Lin; Hsueh, I-Ping; Yao, Kai-Ping; Hsieh, Ching-Lin			Development of Two Barthel Index-Based Supplementary Scales for Patients with Stroke	PLOS ONE			English	Article							DAILY LIVING INDEX; PERCEIVED DIFFICULTY; OUTCOME MEASURES; PERFORMANCE; HEALTH; DISABILITY; REHABILITATION; RELIABILITY; LIFE; CONSTRUCTS	Background: The Barthel Index (BI) assesses actual performance of activities of daily living (ADL). However, comprehensive assessment of ADL functions should include two other constructs: self-perceived difficulty and ability. Objective: The aims of this study were to develop two BI-based Supplementary Scales (BI-SS), namely, the Self-perceived Difficulty Scale and the Ability Scale, and to examine the construct validity of the BI-SS in patients with stroke. Method: The BI-SS was first developed by consultation with experts and then tested on patients to confirm the clarity and feasibility of administration. A total of 306 participants participated in the construct validity study. Construct validity was investigated using Mokken scale analysis and analyzing associations between scales. The agreement between each pair of the scales' scores was further examined. Results: The Self-perceived Difficulty Scale consisted of 10 items, and the Ability Scale included 8 items (excluding both bladder and bowel control items). Items in each individual scale were unidimensional (H >= 0.5). The scores of the Self-perceived Difficulty and Ability Scales were highly correlated with those of the BI (rho = 0.78 and 0.90, respectively). The scores of the two BI-SS scales and BI were significantly different from each other (p<.001). These results indicate that both BI-SS scales assessed unique constructs. Conclusions: The BI-SS had overall good construct validity in patients with stroke. The BI-SS can be used as supplementary scales for the BI to comprehensively assess patients' ADL functions in order to identify patients' difficulties in performing ADL tasks, plan intervention strategies, and assess outcomes.	[Lee, Ya-Chen; Koh, Chia-Lin; Hsueh, I-Ping; Hsieh, Ching-Lin] Natl Taiwan Univ, Coll Med, Sch Occupat Therapy, Taipei 10764, Taiwan; [Chen, Sheng-Shiung] I Shou Univ, E Da Hosp, Dept Phys Med & Rehabil, Kaohsiung, Taiwan; [Hsueh, I-Ping; Hsieh, Ching-Lin] Natl Taiwan Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Yao, Kai-Ping] Natl Taiwan Univ, Coll Med, Dept Psychol, Taipei 10764, Taiwan	National Taiwan University; E-Da Hospital; I Shou University; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Hsueh, IP (corresponding author), Natl Taiwan Univ, Coll Med, Sch Occupat Therapy, Taipei 10764, Taiwan.	iping@ntu.edu.tw	Koh, Chia-Lin/G-2127-2010; Hsieh, Ching-Lin/G-6057-2011	Koh, Chia-Lin/0000-0002-9927-2553; Hsieh, Ching-Lin/0000-0001-9468-9969; YAO, KAI-PING GRACE/0000-0003-0841-3507; HSUEH, I-PING/0000-0002-8852-8242	E-Da Hospital [EDAHT 101016]	E-Da Hospital	This study was supported by a research grant from the E-Da Hospital (EDAHT 101016), http://www.edah.org.tw/index.asp. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barkat-Masih M, 2011, J CHILD NEUROL, V26, P44, DOI 10.1177/0883073810372805; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Chang HY, 2006, TAIWAN J PHYS MED RE, V34, P63; Chen HC, 2009, BRAIN INJURY, V23, P715, DOI 10.1080/02699050903013602; Collin C, 1988, Int Disabil Stud, V10, P61; Flansbjer UB, 2005, J REHABIL MED, V37, P75, DOI 10.1080/16501970410017215; Gill TM, 1998, ANN INTERN MED, V128, P96, DOI 10.7326/0003-4819-128-2-199801150-00004; Grimby G, 1998, STROKE, V29, P1843, DOI 10.1161/01.STR.29.9.1843; Holsbeeke L, 2009, ARCH PHYS MED REHAB, V90, P849, DOI 10.1016/j.apmr.2008.11.015; Hsieh CL, 2012, J REHABIL MED, V44, P720, DOI 10.2340/16501977-1008; Hsieh CL, 2002, STROKE, V33, P2626, DOI 10.1161/01.STR.0000033930.05931.93; Hsieh YW, 2007, NEUROREHAB NEURAL RE, V21, P233, DOI 10.1177/1545968306294729; Hsueh IP, 2001, J FORMOS MED ASSOC, V100, P526; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; JETTE AM, 1994, PHYS THER, V74, P380, DOI 10.1093/ptj/74.5.380; Koh CL, 2006, J REHABIL MED, V38, P375, DOI 10.1080/16501970600803252; Kwakkel G, 1996, AGE AGEING, V25, P479, DOI 10.1093/ageing/25.6.479; Laditka S B, 2001, J Health Soc Policy, V13, P1, DOI 10.1300/J045v13n03_01; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; Lee YC, 2010, OCCUP THER INT, V17, P152, DOI 10.1002/oti.301; Michielsen ME, 2009, J REHABIL MED, V41, P327, DOI 10.2340/16501977-0351; Ostir GV, 2001, AGING CLIN EXP RES, V13, P465; Owens PL, 2002, ANN INTERN MED, V136, P802, DOI 10.7326/0003-4819-136-11-200206040-00008; Quinn TJ, 2011, STROKE, V42, P1146, DOI 10.1161/STROKEAHA.110.598540; Salter K, 2005, DISABIL REHABIL, V27, P507, DOI 10.1080/0963828040008552; Sangha H, 2005, INT J REHABIL RES, V28, P135, DOI 10.1097/00004356-200506000-00006; Schunemann HJ, 2005, HEALTH SERV RES, V40, P593, DOI 10.1111/j.1475-6773.2005.0k375.x; Sijtsma K, 2008, QUAL LIFE RES, V17, P275, DOI 10.1007/s11136-007-9281-6; Sinoff G, 1997, J AM GERIATR SOC, V45, P832, DOI 10.1111/j.1532-5415.1997.tb01510.x; SMITH DS, 1995, DISABIL REHABIL, V17, P15, DOI 10.3109/09638289509166623; Stochl J, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-74; Thoren-Jonsson AL, 2001, J REHABIL MED, V33, P4; van der Ark LA, 2012, J STAT SOFTW, V48, P1; van der Heijden PGM, 2003, QUAL LIFE RES, V12, P189, DOI 10.1023/A:1022269315437; VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1; Wade D T, 1988, Int Disabil Stud, V10, P64; Wade DT., 1992, MEASUREMENT NEUROLOG; Williams LS, 1999, STROKE, V30, P1362, DOI 10.1161/01.STR.30.7.1362; Wilson R, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-68; World Health Organisation, 2001, ICF INT CLASFUNCT; Young NL, 1996, J CLIN EPIDEMIOL, V49, P1097, DOI 10.1016/0895-4356(96)00214-4; Yu WH, 2013, PHYS THER, V93, P798, DOI 10.2522/ptj.20120259	42	13	16	3	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2014	9	10							e110494	10.1371/journal.pone.0110494	http://dx.doi.org/10.1371/journal.pone.0110494			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AS0AY	25329051	Green Submitted, gold, Green Published			2023-01-03	WOS:000343942100066
J	Lewis, B				Lewis, Barbara			ESSAY Joan's family bill of rights: an essay by Barbara Lewis	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Joans Family Bill Rights, Los Angeles, CA 90077 USA		Lewis, B (corresponding author), Joans Family Bill Rights, 2934 Beverly Glen Circle,Suite 240, Los Angeles, CA 90077 USA.	BarbaraLewis@JoansFamilyBillOfRights.com							0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 17	2014	349								g6022	10.1136/bmj.g6022	http://dx.doi.org/10.1136/bmj.g6022			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AR7NY	25353644				2023-01-03	WOS:000343767700002
J	Neuman, MD; Wirtalla, C; Werner, RM				Neuman, Mark D.; Wirtalla, Christopher; Werner, Rachel M.			Association Between Skilled Nursing Facility Quality Indicators and Hospital Readmissions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POST-ACUTE CARE; OF-CARE; RACIAL DISPARITIES; MEDICAID PAYMENT; HOME QUALITY; FOR-PROFIT; REHOSPITALIZATION; RESIDENTS; COST	IMPORTANCE Hospital readmissions are common, costly, and potentially preventable. Little is known about the association between available skilled nursing facility (SNF) performance measures and the risk of hospital readmission. OBJECTIVE To measure the association between SNF performance measures and hospital readmissions among Medicare beneficiaries receiving postacute care at SNFs in the United States. DESIGN AND PARTICIPANTS Using national Medicare data on fee-for-service Medicare beneficiaries discharged to a SNF after an acute care hospitalization between September 1, 2009, and August 31, 2010, we examined the association between SNF performance on publicly available metrics (SNF staffing intensity, health deficiencies identified through site inspections, and the percentages of SNF patients with delirium, moderate to severe pain, and new or worsening pressure ulcers) and the risk of readmission or death 30 days after discharge to a SNF. Adjusted analyses controlled for patient case mix, SNF facility factors, and the discharging hospital. MAIN OUTCOMES AND MEASURES Readmission to an acute care hospital or death within 30 days of the index hospital discharge. RESULTS Of 1 530 824 patients discharged, 357 752 (23.3%; 99% CI, 23.3%-23.5%) were readmitted or died within 30 days; 72 472 died within 30 days (4.7%; 99% CI, 4.7%-4.8%), and 321 709 were readmitted (21.0%; 99% CI, 20.9%-21.1%). The unadjusted risk of readmission or death was lower at SNFs with better staffing ratings and better facility inspection ratings. [GRAPHICS] Adjustment for patient factors, SNF facility factors, and the discharging hospital attenuated these associations; we observed small differences in the adjusted risk of readmission or death according to SNF facility inspection ratings. Other measures did not predict clinically meaningful differences in the adjusted risk of readmission or death. CONCLUSIONS AND RELEVANCE Among fee-for-service Medicare beneficiaries discharged to a SNF after an acute care hospitalization, available performance measures were not consistently associated with differences in the adjusted risk of readmission or death. Copyright 2014 American Medical Association. All rights reserved.	[Neuman, Mark D.] Univ Penn, Dept Anesthesiol & Crit Care, Perelman Sch Med, Philadelphia, PA 19104 USA; [Neuman, Mark D.; Werner, Rachel M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Wirtalla, Christopher; Werner, Rachel M.] Univ Penn, Div Gen Internal Med, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Werner, Rachel M.] Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Pennsylvania Medicine; Philadelphia Veterans Affairs Medical Center	Neuman, MD (corresponding author), Univ Penn, Dept Anesthesiol & Crit Care, Perelman Sch Med, 423 Guardian Dr,1119A Blockley Hall, Philadelphia, PA 19104 USA.	neumanm@mail.med.upenn.edu		Werner, Rachel/0000-0003-3435-4221	National Institute on Aging [K08AG043548, R01 AG034182]; NATIONAL INSTITUTE ON AGING [K08AG043548, R01AG034182] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by grants from the National Institute on Aging (grant K08AG043548 to Dr Neuman; grant R01 AG034182 to Dr Werner).	Ackerly DC, 2014, NEW ENGL J MED, V370, P689, DOI 10.1056/NEJMp1315350; Berenson RA, 2012, NEW ENGL J MED, V366, P1364, DOI 10.1056/NEJMp1201268; Bostick JE, 2006, J AM MED DIR ASSOC, V7, P366, DOI 10.1016/j.jamda.2006.01.024; Centers for Medicare and Medicaid Services, 2012, DES NURS HOM COMP 5; Comondore VR, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2732; Cutler DM, 2012, NEW ENGL J MED, V366, P1075, DOI 10.1056/NEJMp1113361; Diehr P, 2005, J CLIN EPIDEMIOL, V58, P1115, DOI 10.1016/j.jclinepi.2005.05.002; Fisher ES, 2011, NEW ENGL J MED, V365, P2445, DOI 10.1056/NEJMp1112442; Gorodeski EZ, 2010, NEW ENGL J MED, V363, P297, DOI 10.1056/NEJMc1001882; Grabowski DC, 2004, HEALTH SERV RES, V39, P793, DOI 10.1111/j.1475-6773.2004.00258.x; Grabowski DC, 2004, HEALTH AFFAIR, V23, P243, DOI 10.1377/hlthaff.23.5.243; Harrington C, 2000, J GERONTOL B-PSYCHOL, V55, pS278, DOI 10.1093/geronb/55.5.S278; Harrington C, 2004, J HEALTH POLIT POLIC, V29, P43, DOI 10.1215/03616878-29-1-43; Harrington C, 2001, AM J PUBLIC HEALTH, V91, P1452, DOI 10.2105/AJPH.91.9.1452; Harrington C, 2012, HEALTH SERV RES, V47, P106, DOI 10.1111/j.1475-6773.2011.01311.x; Hillmer MP, 2005, MED CARE RES REV, V62, P139, DOI 10.1177/1077558704273769; Horwitz LI, 2013, MEASURE UPDATES SPEC; Hughes CM, 2000, MED CARE, V38, P1164, DOI 10.1097/00005650-200012000-00003; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kim H, 2009, GERONTOLOGIST, V49, P81, DOI 10.1093/geront/gnp014; Kim H, 2009, J GERONTOL B-PSYCHOL, V64, P269, DOI 10.1093/geronb/gbn019; Li Y, 2011, AM J PUBLIC HEALTH, V101, P875, DOI 10.2105/AJPH.2010.300055; Mechanic R, 2014, NEW ENGL J MED, V370, P692, DOI 10.1056/NEJMp1315607; Mechanic RE, 2011, NEW ENGL J MED, V365, P777, DOI 10.1056/NEJMp1105963; Mor V, 2004, MILBANK Q, V82, P227, DOI 10.1111/j.0887-378X.2004.00309.x; Mor V, 2010, HEALTH AFFAIR, V29, P57, DOI 10.1377/hlthaff.2009.0629; Morris JN., 2003, VALIDATION LONG TERM; Ouslander JG, 2011, NEW ENGL J MED, V365, P1165, DOI 10.1056/NEJMp1105449; Ouslander JG, 2010, J AM GERIATR SOC, V58, P627, DOI 10.1111/j.1532-5415.2010.02768.x; Rantz MJ, 2004, GERONTOLOGIST, V44, P24, DOI 10.1093/geront/44.1.24; Saliba D, 2000, J AM GERIATR SOC, V48, P154, DOI 10.1111/j.1532-5415.2000.tb03906.x; Saliba D, 2005, DESIGN VALIDATION PO; Smith DB, 2007, HEALTH AFFAIR, V26, P1448, DOI 10.1377/hlthaff.26.5.1448; Song Z, 2011, NEW ENGL J MED, V365, P909, DOI 10.1056/NEJMsa1101416; Unroe KT, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2011.04.020; US Department of Health and Human Services; Office of the Inspector General, 2013, MED NURS HOM RES HOS	36	99	99	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2014	312	15					1542	1551		10.1001/jama.2014.13513	http://dx.doi.org/10.1001/jama.2014.13513			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AQ7HL	25321909	Green Accepted			2023-01-03	WOS:000342983200018
J	Bass, MB; Yao, B; Hei, YJ; Ye, YN; Davis, GJ; Davis, MT; Kaesdorf, BA; Chan, SS; Patterson, SD				Bass, Michael B.; Yao, Bin; Hei, Yong-Jiang; Ye, Yining; Davis, Gerard J.; Davis, Michael T.; Kaesdorf, Barbara A.; Chan, Sabrina S.; Patterson, Scott D.			Challenges in Developing a Validated Biomarker for Angiogenesis Inhibitors: The Motesanib Experience	PLOS ONE			English	Article							CELL LUNG-CANCER; ENDOTHELIAL GROWTH-FACTOR; PHASE-II; MULTIKINASE INHIBITOR; THYROID-CANCER; SOLID TUMORS; BEVACIZUMAB; REVASCULARIZATION; CARBOPLATIN; COMBINATION	Purpose: We sought to develop placental growth factor as a predictive pharmacodynamic biomarker for motesanib efficacy as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer. Experimental Design: Placental growth factor was evaluated at baseline and study week 4 (after 3 weeks treatment) in an exploratory analysis of data from a randomized phase 2 study of motesanib 125 mg once daily plus carboplatin/paclitaxel and in a prespecified analysis of data from a randomized, double-blind phase 3 study of motesanib 125 mg once daily plus carboplatin/paclitaxel vs placebo plus carboplatin/paclitaxel (MONET1). Associations between fold-change from baseline in placental growth factor and overall survival were evaluated using Cox proportional hazards models. Results: In the phase 2 study, serum placental growth factor increased from baseline a mean 2.8-fold at study week 4. Patients with >= 2.2-fold change from baseline in placental growth factor (n = 18) had significantly longer overall survival than those with <2.2-fold change (n = 19; 22.9 vs 7.9 months; hazard ratio, 0.30; 95% CI, 0.12-0.74; P = 0.009). Consequently, placental growth factor was investigated as a pharmacodynamic biomarker in the phase 3 MONET1 study. There was no association between log-transformed placental growth factor fold-change from baseline to week 4 (continuous variable) and overall survival (hazard ratio, 0.98; 95% CI, 0.79-1.22; P = 0.868). MONET1 did not meet its primary endpoint of overall survival. Likewise, median overall survival was similar among patients with >= 2.0-fold change in placental growth factor (n = 229) compared with <2.0-fold change (n = 127; 14.8 vs 13.8 months; hazard ratio, 0.88; 95% CI, 0.67-1.15, P = 0.340). Conclusions: Our results illustrate the challenges of successfully translating phase 2 biomarker results into phase 3 studies.	[Bass, Michael B.; Davis, Michael T.] Amgen Inc, Mol Sci & Computat Biol, Thousand Oaks, CA 91320 USA; [Yao, Bin] Amgen Inc, Global Biostat Sci, Thousand Oaks, CA 91320 USA; [Hei, Yong-Jiang] Amgen Inc, Oncol Dev, Thousand Oaks, CA 91320 USA; [Ye, Yining] Amgen Inc, Global Biostat Sci, San Francisco, CA USA; [Davis, Gerard J.; Kaesdorf, Barbara A.; Chan, Sabrina S.] Abbott Labs, Diagnost Div Res & Dev, Abbott Pk, IL 60064 USA; [Patterson, Scott D.] Amgen Inc, Med Sci, Thousand Oaks, CA 91320 USA	Amgen; Amgen; Amgen; Amgen; Abbott Laboratories; Amgen	Bass, MB (corresponding author), Amgen Inc, Mol Sci & Computat Biol, Thousand Oaks, CA 91320 USA.	mbass@amgen.com			Amgen Inc.	Amgen Inc.(Amgen)	This study was funded by Amgen Inc. (http://www.amgen.com). Employees of Amgen Inc. participated in the study design, data collection and analysis, decision to publish, and preparation of the manuscript.	Autiero M, 2003, J THROMB HAEMOST, V1, P1356, DOI 10.1046/j.1538-7836.2003.00263.x; Bass MB, 2010, J CLIN ONCOL, V28; Bass MB, 2010, J CLIN ENDOCR METAB, V95, P5018, DOI 10.1210/jc.2010-0947; Batchelor TT, 2010, J CLIN ONCOL, V28, P2817, DOI 10.1200/JCO.2009.26.3988; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blumenschein GR, 2011, ANN ONCOL, V22, P2057, DOI 10.1093/annonc/mdq731; Blumenschein GR, 2012, INVEST NEW DRUG, V30, P1802, DOI 10.1007/s10637-011-9750-1; Cao YH, 1996, J CLIN INVEST, V98, P2507, DOI 10.1172/JCI119069; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; DePrimo SE, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-32; Freidlin B, 2012, J CLIN ONCOL, V30, P3304, DOI 10.1200/JCO.2012.43.3946; Green CJ, 2001, CANCER RES, V61, P2696; Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; Hung HMJ, 2006, PHARM STAT, V5, P99, DOI 10.1002/pst.219; Kelly RJ, 2011, CLIN CANCER RES, V17, P1190, DOI 10.1158/1078-0432.CCR-10-2331; Kern SE, 2012, CANCER RES, V72, P6097, DOI 10.1158/0008-5472.CAN-12-3232; Korn EL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004018; Korpanty G, 2012, CURR PHARM DESIGN, V18, P2680, DOI 10.2174/138161212800626166; Kutner MH, 2005, APPL LINEAR STAT MOD, P1; Lambrechts D, 2013, J CLIN ONCOL, DOI [10.1200/JCO.2012.1246.2762, DOI 10.1200/JCO.2012.1246.2762]; LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Metcalfe TA, 2010, SCAND J CLIN LAB INV, V70, P23, DOI 10.3109/00365513.2010.493361; MILLER R, 1982, BIOMETRICS, V38, P1011, DOI 10.2307/2529881; Mok T, 2014, J THORAC ONCOL, V9, P848, DOI 10.1097/JTO.0000000000000160; Nikolinakos PG, 2010, CANCER RES, V70, P2171, DOI 10.1158/0008-5472.CAN-09-2533; Oakes, 1984, ANAL SURVIVAL DATA, DOI DOI 10.1201/9781315137438; Patterson SD, 2010, J CLIN ONCOL, V28; Polverino A, 2006, CANCER RES, V66, P8715, DOI 10.1158/0008-5472.CAN-05-4665; Rini BI, 2008, J CLIN ONCOL, V26, P3743, DOI 10.1200/JCO.2007.15.5416; Rosen LS, 2007, J CLIN ONCOL, V25, P2369, DOI 10.1200/JCO.2006.07.8170; Russell Chris B., 2008, P1, DOI 10.1007/978-1-59745-463-6_1; Scagliotti GV, 2012, J CLIN ONCOL, V30, P2829, DOI 10.1200/JCO.2011.41.4987; Schlumberger MJ, 2009, J CLIN ONCOL, V27, P3794, DOI 10.1200/JCO.2008.18.7815; Sharma PS, 2011, CURR CANCER DRUG TAR, V11, P624; Sherman SI, 2008, NEW ENGL J MED, V359, P31, DOI 10.1056/NEJMoa075853; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; US Food and Drug Administration, 2010, GUID IND QUAL PROC D; Willett CG, 2009, J CLIN ONCOL, V27, P3020, DOI 10.1200/JCO.2008.21.1771; Zhang Lijian, 2005, World J Surg Oncol, V3, P68, DOI 10.1186/1477-7819-3-68	41	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2014	9	10							e108048	10.1371/journal.pone.0108048	http://dx.doi.org/10.1371/journal.pone.0108048			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR5ZW	25314641	Green Submitted, Green Published, gold			2023-01-03	WOS:000343662500009
J	Wu, CL; Wu, HM; Chiu, PF; Liou, HH; Chang, CB; Tarng, DC; Chang, CC				Wu, Chia-Lin; Wu, Hung-Ming; Chiu, Ping-Fang; Liou, Hung-Hsiang; Chang, Chirn-Bin; Tarng, Der-Cherng; Chang, Chia-Chu			Associations between the Duration of Dialysis, Endotoxemia, Monocyte Chemoattractant Protein-1, and the Effects of a Short-Dwell Exchange in Patients Requiring Continuous Ambulatory Peritoneal Dialysis	PLOS ONE			English	Article							CHRONIC-RENAL-FAILURE; SYSTEMIC INFLAMMATION; MESENCHYMAL TRANSITION; CARDIOVASCULAR-DISEASE; PLASMA-LEVELS; TNF-ALPHA; MCP-1; HEMODIALYSIS; CELLS; SERUM	Background: Endotoxemia is exaggerated and contributes to systemic inflammation and atherosclerosis in patients requiring continuous ambulatory peritoneal dialysis (CAPD). The risk of mortality is substantially increased in patients requiring CAPD for >2 years. However, little is known about the effects of long-term CAPD on circulating endotoxin and cytokine levels. Therefore, the present study evaluated the associations between plasma endotoxin levels, cytokine levels, and clinical parameters with the effects of a short-dwell exchange on endotoxemia and cytokine levels in patients on longterm CAPD. Methods: A total of 26 patients were enrolled and divided into two groups (short-term or long-term CAPD) according to the 2-year duration of CAPD. Plasma endotoxin and cytokine levels were measured before and after a short-dwell exchange (4-h dwell) during a peritoneal equilibration test (a standardized method to evaluate the solute transport function of peritoneal membrane). These data were analyzed to determine the relationship of circulating endotoxemia, cytokines and clinical characteristics between the two groups. Results: Plasma endotoxin and monocyte chemotactic protein-1 (MCP-1) levels were significantly elevated in the long-term group. PD duration was significantly correlated with plasma endotoxin (r = 0.479, P = 0.016) and MCP-1 (r = 0.486, P = 0.012). PD duration was also independently associated with plasma MCP-1 levels in multivariate regression. Plasma MCP-1 levels tended to decrease (13.3% reduction, P = 0.077) though endotoxin levels did not decrease in the long-term PD group after the 4-h short-dwell exchange. Conclusion: Long-term PD may result in exaggerated endotoxemia and elevated plasma MCP-1 levels. The duration of PD was significantly correlated with circulating endotoxin and MCP-1 levels, and was an independent predictor of plasma MCP1 levels. Short-dwell exchange seemed to have favorable effects on circulating MCP-1 levels in patients on long-term PD.	[Wu, Chia-Lin; Chiu, Ping-Fang; Chang, Chirn-Bin; Chang, Chia-Chu] Changhua Christian Hosp, Dept Internal Med, Div Nephrol, Changhua, Taiwan; [Wu, Chia-Lin; Chiu, Ping-Fang; Chang, Chirn-Bin; Chang, Chia-Chu] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Wu, Chia-Lin; Tarng, Der-Cherng] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan; [Wu, Hung-Ming] Changhua Christian Hosp, Inflammat Res & Drug Dev Ctr, Changhua, Taiwan; [Liou, Hung-Hsiang] Hsin Jen Hosp, Dept Internal Med, Div Nephrol, Taipei, Taiwan; [Tarng, Der-Cherng] Taipei Vet Gen Hosp, Div Nephrol, Dept Med, Taipei, Taiwan; [Tarng, Der-Cherng] Natl Yang Ming Univ, Dept & Inst Physiol, Taipei 112, Taiwan	Changhua Christian Hospital; Chung Shan Medical University; National Yang Ming Chiao Tung University; Changhua Christian Hospital; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University	Tarng, DC (corresponding author), Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan.	dctarng@vghtpe.gov.tw; Chiachu@cch.org.tw	Wu, Chia-Lin/V-8888-2017; Bin Chang, Chirn/E-8605-2010	Wu, Chia-Lin/0000-0001-6045-6956; Chang, Chirn-Bin/0000-0001-9423-7655	Changhua Christian Hospital Research Foundation [100-CCH-IRP-17, 102-CCH-IRP-010]	Changhua Christian Hospital Research Foundation	This study was funded by grants 100-CCH-IRP-17 and 102-CCH-IRP-010 from the Changhua Christian Hospital Research Foundation. The funder had no role in study design, data collection and analysis, the decision to publish the results, or the preparation of the manuscript.	Al-Attas OS, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-20; Anker SD, 1997, AM J CARDIOL, V79, P1426, DOI 10.1016/S0002-9149(97)00159-8; Aoyama T, 2010, TOLL LIKE RECEPTOR S; Borazan A, 2004, MEDIAT INFLAMM, V13, P201, DOI 10.1080/09511920410001713493; Braun N, 2011, NEPHROL THER, V7, P162, DOI 10.1016/j.nephro.2010.12.011; Cengiz MI, 2007, J PERIODONTOL, V78, P1926, DOI 10.1902/jop.2007.060499; Chaudhary K, 2011, CLIN J AM SOC NEPHRO, V6, P447, DOI 10.2215/CJN.07920910; Chiu Y W, 2010, Indian J Nephrol, V20, P59, DOI 10.4103/0971-4065.65296; Davi G, 2009, J ATHEROSCLER THROMB, V16, P707; de Lemos JA, 2003, CIRCULATION, V107, P690, DOI 10.1161/01.CIR.0000049742.68848.99; DESCAMPSLATSCHA B, 1995, J IMMUNOL, V154, P882; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Dunzendorfer S, 2004, FASEB J, V18, P1117, DOI 10.1096/fj.03-1263fje; Estruch M, 2013, ATHEROSCLEROSIS, V229, P356, DOI 10.1016/j.atherosclerosis.2013.05.011; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; Goldstein SL, 2006, CLIN J AM SOC NEPHRO, V1, P979, DOI 10.2215/CJN.02291205; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Heesen M, 2006, CLIN VACCINE IMMUNOL, V13, P156, DOI 10.1128/CVI.13.1.156-159.2006; Heumann D, 2002, CLIN CHIM ACTA, V323, P59, DOI 10.1016/S0009-8981(02)00180-8; Jaar BG, 2005, ANN INTERN MED, V143, P174, DOI 10.7326/0003-4819-143-3-200508020-00003; Jialal I, 2012, DIABETES CARE, V35, P900, DOI 10.2337/dc11-2375; Juskewitch JE, 2012, AM J PATHOL, V180, P32, DOI 10.1016/j.ajpath.2011.10.001; Kato S, 2004, J AM SOC NEPHROL, V15, P1289; Kubotera N, 2013, INT J NEPHROL, V2013, DOI 10.1155/2013/954956; Lambie M, 2013, J AM SOC NEPHROL, V24, P2071, DOI 10.1681/ASN.2013030314; Lassenius MI, 2011, DIABETES CARE, V34, P1809, DOI 10.2337/dc10-2197; Lee JK, 2012, NUTR METAB CARDIOVAS, V22, P974, DOI 10.1016/j.numecd.2011.01.001; Lee SH, 2012, LAB INVEST, V92, P1698, DOI 10.1038/labinvest.2012.132; Lee YC, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-35; Leypoldt JK, 2002, J AM SOC NEPHROL, V13, pS84; Lucas R, 2013, CYTOKINE, V64, P310, DOI 10.1016/j.cyto.2013.05.025; LUMSDEN AB, 1988, HEPATOLOGY, V8, P232, DOI 10.1002/hep.1840080207; Malik AR, 2007, J NEPHROL, V20, P340; McIntyre CW, 2011, CLIN J AM SOC NEPHRO, V6, P133, DOI 10.2215/CJN.04610510; Mehta NN, 2010, DIABETES, V59, P172, DOI 10.2337/db09-0367; Mortier S, 2003, J AM SOC NEPHROL, V14, P1296, DOI 10.1097/01.ASN.0000060681.91079.30; Mujais S, 1999, Contrib Nephrol, V129, P255; Navarro-Gonzalez JF, 2011, CLIN J AM SOC NEPHRO, V6, P2272, DOI 10.2215/CJN.01650211; Okyay GU, 2013, THER APHER DIAL, V17, P193, DOI 10.1111/j.1744-9987.2012.01141.x; Pawlak K, 2007, CLIN BIOCHEM, V40, P81, DOI 10.1016/j.clinbiochem.2006.09.001; PEREIRA BJG, 1994, KIDNEY INT, V45, P890, DOI 10.1038/ki.1994.117; Purohit V, 2008, ALCOHOL, V42, P349, DOI 10.1016/j.alcohol.2008.03.131; Pussinen PJ, 2007, ARTERIOSCL THROM VAS, V27, P1433, DOI 10.1161/ATVBAHA.106.138743; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Ramnath RD, 2008, INT IMMUNOPHARMACOL, V8, P810, DOI 10.1016/j.intimp.2008.01.033; Rucker D, 2009, NAT REV NEPHROL, V5, P287, DOI 10.1038/nrneph.2009.42; Shioya M, 2013, NEPHROLOGY, V18, P539, DOI 10.1111/nep.12106; STRAUSS FG, 1993, ADV PERIT D, V9, P49; Szeto CC, 2008, CLIN J AM SOC NEPHRO, V3, P431, DOI 10.2215/CJN.03600807; Tang XY, 2013, AM J PATHOL, V183, P470, DOI 10.1016/j.ajpath.2013.04.020; Termorshuizen F, 2003, J AM SOC NEPHROL, V14, P2851, DOI 10.1097/01.ASN.0000091585.45723.9E; Tobias PS, 1997, J BIOL CHEM, V272, P18682, DOI 10.1074/jbc.272.30.18682; TWARDOWSKI ZJ, 1987, PERITON DIALYSIS INT, V7, P138; United States Renal Data System (USRDS), 2013, USRDS 2013 ANN DAT R; Viedt C, 2002, ARTERIOSCL THROM VAS, V22, P914, DOI 10.1161/01.ATV.0000019009.73586.7F; Wu M-S, 2012, ACTA NEPHROLOGICA, V26, P104; Wu MS, 2011, ACTA NEPHROL, V25, P148	57	4	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2014	9	10							e109558	10.1371/journal.pone.0109558	http://dx.doi.org/10.1371/journal.pone.0109558			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU6XC	25286027	Green Submitted, gold, Green Published			2023-01-03	WOS:000345743700072
J	Friedland, JS				Friedland, Jon S.			Targeting the Inflammatory Response in Tuberculosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis & Immun, London, England	Imperial College London	Friedland, JS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis & Immun, London, England.			Friedland, Jonathan S/0000-0001-7789-9649				Mayer-Barber KD, 2014, NATURE, V511, P99, DOI 10.1038/nature13489	1	11	11	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 2	2014	371	14					1354	1356		10.1056/NEJMcibr1408663	http://dx.doi.org/10.1056/NEJMcibr1408663			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AP9VS	25271609				2023-01-03	WOS:000342429800015
J	Djeddi, D; Cantin, D; Samson, N; Praud, JP				Djeddi, Djamal; Cantin, Danny; Samson, Nathalie; Praud, Jean-Paul			Nasal Continuous Positive Airway Pressure Inhibits Gastroesophageal Reflux in Newborn Lambs	PLOS ONE			English	Article							LOWER ESOPHAGEAL SPHINCTER; INFANT-DEATH-SYNDROME; APNEA; CPAP; MECHANISMS; PRETERM; MUSCLE; CONTRACTION; RELAXATION; RELEVANCE	Background: Using esophageal pHmetry, nasal CPAP (nCPAP) has been shown to decrease acid gastroesophageal reflux (GER) in adult humans. Although both GER (mainly non-acid) and nCPAP use are very frequent in newborns, the effect of nCPAP on GER in early life is unknown. Having recently shown that the newborn lamb is a unique model for studying neonatal GER, our main objective was to assess the effect of nCPAP on GER in newborn lambs. Methods: Eight newborn lambs, aged 2-3 days, were studied. Continuous esophageal pH-Impedance monitoring and polysomnography were performed for six hours during both spontaneous breathing and nCPAP application at 6 cmH(2)O (nCPAP6), in a randomized order. Results were compared in the two experimental conditions, as well as without CPAP during the following 6 hours. Results: i) nCPAP(6) virtually abolished GER [mean +/- SD reflux number for 6 h = 9.1 +/- 8.6 without nCPAP(6) vs. 0.6 +/- 1 with nCPAP(6), P<0.05]; ii) GER number was also reduced during the 6 h-period following nCPAP6 application (18 +/- 16 without nCPAP(6) vs. 7 +/- 8.1 with nCPAP(6,) P<0.05); iii) nCPAP(6) decreased the depth and duration of lower esophageal sphincter relaxation. Conclusions: nCPAP inhibits GER in the newborn lamb. Further clinical studies using different levels of nasal CPAP are needed to confirm this result in human infants.	[Djeddi, Djamal; Cantin, Danny; Samson, Nathalie; Praud, Jean-Paul] Univ Sherbrooke, Neonatal Resp Res Unit, Dept Pediat, Sherbrooke, PQ J1K 2R1, Canada; [Djeddi, Djamal; Cantin, Danny; Samson, Nathalie; Praud, Jean-Paul] Univ Sherbrooke, Neonatal Resp Res Unit, Dept Physiol, Sherbrooke, PQ J1K 2R1, Canada; [Djeddi, Djamal] Amiens Univ, Med Ctr, Dept Pediat, Amiens, France	University of Sherbrooke; University of Sherbrooke; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens	Djeddi, D (corresponding author), Univ Sherbrooke, Neonatal Resp Res Unit, Dept Pediat, Sherbrooke, PQ J1K 2R1, Canada.	Djeddi.Djamal-Dine@chu-amiens.fr		Djeddi, Djamal-Dine/0000-0002-9513-0275				Babaei A, 2008, GASTROENTEROLOGY, V134, P1322, DOI 10.1053/j.gastro.2008.02.031; Bernier A, 2012, J APPL PHYSIOL, V112, P1984, DOI 10.1152/japplphysiol.01559.2011; Boudaa N, 2013, J APPL PHYSIOL, V114, P637, DOI 10.1152/japplphysiol.00599.2012; Cavusoglu H, 2009, J NEUROSURG-SPINE, V11, P547, DOI 10.3171/2009.6.SPINE09216; Czinn SJ, 2013, PEDIATR DRUGS, V15, P19, DOI 10.1007/s40272-012-0004-2; Djeddi D, 2013, J PEDIATR GASTR NUTR, V57, P188, DOI 10.1097/MPG.0b013e318292b3b2; Djeddi D, 2012, J PEDIATR GASTR NUTR, V55, P745, DOI 10.1097/MPG.0b013e318263cae0; Farre R, 2008, BRIT J PHARMACOL, V153, P858, DOI 10.1038/sj.bjp.0707572; Fournier MR, 1999, J OTOLARYNGOL, V28, P142; Green BT, 2003, ARCH INTERN MED, V163, P41, DOI 10.1001/archinte.163.1.41; Ing Alvin J., 2000, American Journal of Medicine, V108, p120S; KERR P, 1992, CHEST, V101, P1539, DOI 10.1378/chest.101.6.1539; KERR P, 1993, J CLIN GASTROENTEROL, V17, P276, DOI 10.1097/00004836-199312000-00002; Kim HR, 2005, CAN J PHYSIOL PHARM, V83, P811, DOI 10.1139/Y05-060; Laptook AR, 2005, PEDIATRICS, V115, P673, DOI 10.1542/peds.2004-0667; Leiter JC, 2007, RESP PHYSIOL NEUROBI, V159, P127, DOI 10.1016/j.resp.2007.05.014; Mahmoud RA, 2011, PAEDIATR RESPIR REV, V12, P196, DOI 10.1016/j.prrv.2010.12.001; Mittal RK, 2013, J NEUROGASTROENTEROL, V19, P126, DOI 10.5056/jnm.2013.19.2.126; Mittal RK, 2005, NEUROGASTROENT MOTIL, V17, P187, DOI 10.1111/j.1365-2982.2004.00600.x; Pandolifino JE, 2006, GASTROENTEROLOGY, V131, P1725, DOI 10.1053/j.gastro.2006.09.009; Pfannkuche H, 2003, J ANAT; Praud JP, 2010, PAEDIATR RESPIR REV, V11, P208, DOI 10.1016/j.prrv.2010.07.001; Ramanathan R, 2010, J PERINATOL, V30, pS67, DOI 10.1038/jp.2010.99; Roehr CC, 2007, EUR J MED RES, V12, P139; ROSEN CL, 1986, AM J DIS CHILD, V140, P547, DOI 10.1001/archpedi.1986.02140200057027; Samson N, 2005, J APPL PHYSIOL, V99, P1636, DOI 10.1152/japplphysiol.00464.2005; Shepherd K, 2011, SLEEP BREATH, V15, P561, DOI 10.1007/s11325-010-0404-x; Shepherd KL, 2007, AM J PHYSIOL-GASTR L, V292, pG1200, DOI 10.1152/ajpgi.00476.2006; SHOENUT JP, 1994, CHEST, V106, P738, DOI 10.1378/chest.106.3.738; Staiano A, 2007, GASTROENTEROLOGY, V132, P1718, DOI 10.1053/j.gastro.2007.03.042; Tawk M, 2006, CHEST, V130, P1003, DOI 10.1378/chest.130.4.1003; Thach B, 2008, EMBO REP, V9, P114, DOI 10.1038/sj.embor.7401163; Vandenplas Y, 2009, J PEDIATR GASTR NUTR, V49, P498, DOI 10.1097/MPG.0b013e3181b7f563	33	16	16	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2014	9	9							e107736	10.1371/journal.pone.0107736	http://dx.doi.org/10.1371/journal.pone.0107736			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS5NP	25226514	gold, Green Submitted, Green Published			2023-01-03	WOS:000344317700078
J	Belinova, L; Kahleova, H; Malinska, H; Topolcan, O; Vrzalova, J; Oliyarnyk, O; Kazdova, L; Hill, M; Pelikanova, T				Belinova, Lenka; Kahleova, Hana; Malinska, Hana; Topolcan, Ondrej; Vrzalova, Jindra; Oliyarnyk, Olena; Kazdova, Ludmila; Hill, Martin; Pelikanova, Terezie			Differential Acute Postprandial Effects of Processed Meat and Isocaloric Vegan Meals on the Gastrointestinal Hormone Response in Subjects Suffering from Type 2 Diabetes and Healthy Controls: A Randomized Crossover Study	PLOS ONE			English	Article							GLUCAGON-LIKE PEPTIDE-1; INSULIN-RESISTANCE; OXIDATIVE STRESS; BETA-CELL; FOOD-INTAKE; FAT; INCRETIN; GLUCOSE; CARBOHYDRATE; GLP-1	Background: The intake of meat, particularly processed meat, is a dietary risk factor for diabetes. Meat intake impairs insulin sensitivity and leads to increased oxidative stress. However, its effect on postprandial gastrointestinal hormone (GIH) secretion is unclear. We aimed to investigate the acute effects of two standardized isocaloric meals: a processed hamburger meat meal rich in protein and saturated fat (M-meal) and a vegan meal rich in carbohydrates (V-meal). We hypothesized that the meat meal would lead to abnormal postprandial increases in plasma lipids and oxidative stress markers and impaired GIH responses. Methods: In a randomized crossover study, 50 patients suffering from type 2 diabetes (T2D) and 50 healthy subjects underwent two 3-h meal tolerance tests. For statistical analyses, repeated-measures ANOVA was performed. Results: The M-meal resulted in a higher postprandial increase in lipids in both groups (p<0.001) and persistent postprandial hyperinsulinemia in patients with diabetes (p<0.001). The plasma glucose levels were significantly higher after the V-meal only at the peak level. The plasma concentrations of glucose-dependent insulinotropic peptide (GIP), peptide tyrosine-tyrosine (PYY) and pancreatic polypeptide (PP) were higher (p<0.05, p<0.001, p<0.001, respectively) and the ghrelin concentration was lower (p<0.001) after the M-meal in healthy subjects. In contrast, the concentrations of GIP, PYY and PP were significantly lower after the M-meal in T2D patients (p<0.001). Compared with the V-meal, the M-meal was associated with a larger increase in lipoperoxidation in T2D patients (p<0.05). Conclusion/Interpretation: Our results suggest that the diet composition and the energy content, rather than the carbohydrate count, should be important considerations for dietary management and demonstrate that processed meat consumption is accompanied by impaired GIH responses and increased oxidative stress marker levels in diabetic patients.	[Belinova, Lenka; Kahleova, Hana; Malinska, Hana; Oliyarnyk, Olena; Kazdova, Ludmila; Pelikanova, Terezie] Inst Clin & Expt Med, Prague, Czech Republic; [Belinova, Lenka] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Topolcan, Ondrej; Vrzalova, Jindra] Univ Hosp Plzen, Plzen, Czech Republic; [Hill, Martin] Inst Endocrinol, Prague, Czech Republic	Institute for Clinical & Experimental Medicine (IKEM); Charles University Prague; University Hospital Plzen; Institute of Endocrinology - Prague	Belinova, L (corresponding author), Inst Clin & Expt Med, Prague, Czech Republic.	bell@ikem.cz	Oliyarnyk, Olena/Q-6380-2019; Hill, Martin/G-7699-2019; Topolcan, Ondrej/K-7753-2017; Windrichova, Jindra/V-6744-2018; Kahleova, Hana/V-9080-2019	Topolcan, Ondrej/0000-0001-6622-390X; Windrichova, Jindra/0000-0003-0365-0968; Kahleova, Hana/0000-0003-0491-3993; Hill, Martin/0000-0002-1705-0835; Oliyarnyk, Olena/0000-0002-4912-6187	Ministry of Health, Czech Republic [NT/11238-4]; Grant Agency of Charles University GAUK [702312]	Ministry of Health, Czech Republic(Ministry of Health, Czech RepublicCzech Republic Government); Grant Agency of Charles University GAUK	This study was supported by: the grant project NT/11238-4 from the Ministry of Health, Czech Republic, and the Grant Agency of Charles University GAUK, Project No. 702312. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADRIAN TE, 1985, GASTROENTEROLOGY, V89, P1070, DOI 10.1016/0016-5085(85)90211-2; Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS11, DOI 10.2337/dc13-S011; Aune D, 2009, DIABETOLOGIA, V52, P2277, DOI 10.1007/s00125-009-1481-x; Bajaj M, 2004, J CLIN ENDOCR METAB, V89, P4649, DOI 10.1210/jc.2004-0224; Barnard ND, 2009, NUTR REV, V67, P255, DOI 10.1111/j.1753-4887.2009.00198.x; Batterham RL, 2003, J CLIN ENDOCR METAB, V88, P3989, DOI 10.1210/jc.2003-030630; Blom WAM, 2005, AM J CLIN NUTR, V81, P367; Calanna S, 2013, DIABETOLOGIA, V56, P965, DOI 10.1007/s00125-013-2841-0; Cardona F, 2008, EUR J CLIN INVEST, V38, P510, DOI 10.1111/j.1365-2362.2008.01959.x; Carr RD, 2008, AM J PHYSIOL-ENDOC M, V295, pE779, DOI 10.1152/ajpendo.90233.2008; Carrel G, 2011, AM J CLIN NUTR, V94, P997, DOI 10.3945/ajcn.111.017574; Ceriello A, 2004, ARTERIOSCL THROM VAS, V24, P816, DOI 10.1161/01.ATV.0000122852.22604.78; Ceriello A, 2011, DIABETES CARE, V34, P697, DOI 10.2337/dc10-1949; Cernea Simona, 2011, Rev Diabet Stud, V8, P323, DOI 10.1900/RDS.2011.8.323; CREUTZFELDT W, 1979, DIABETOLOGIA, V16, P75, DOI 10.1007/BF01225454; ESTRICH D, 1967, DIABETES, V16, P232, DOI 10.2337/diab.16.4.232; Feinle-Bisset C, 2005, AM J PHYSIOL-ENDOC M, V289, pE948, DOI 10.1152/ajpendo.00220.2005; Fernandez-Garcia JC, 2014, CLIN ENDOCRINOL, V80, P671, DOI 10.1111/cen.12221; FESKENS EJM, 1995, DIABETES CARE, V18, P1104, DOI 10.2337/diacare.18.8.1104; Gentilcore D, 2006, J CLIN ENDOCR METAB, V91, P2062, DOI 10.1210/jc.2005-2644; Goldberg T, 2004, J AM DIET ASSOC, V104, P1287, DOI 10.1016/j.jada.2004.05.214; Gormsen LC, 2011, ACTA PHYSIOL, V201, P349, DOI 10.1111/j.1748-1716.2010.02181.x; Hagemann D, 2007, REGUL PEPTIDES, V143, P64, DOI 10.1016/j.regpep.2007.03.002; Kahleova H, 2011, DIABETIC MED, V28, P549, DOI 10.1111/j.1464-5491.2010.03209.x; Kang ZF, 2013, DIABETOLOGIA, V56, P423, DOI 10.1007/s00125-012-2776-x; Kellar KL, 2002, EXP HEMATOL, V30, P1227, DOI 10.1016/S0301-472X(02)00922-0; Kim BJ, 2005, J CLIN ENDOCR METAB, V90, P6665, DOI 10.1210/jc.2005-0409; Kjems LL, 2003, DIABETES, V52, P380, DOI 10.2337/diabetes.52.2.380; Knop FK, 2007, DIABETES, V56, P1951, DOI 10.2337/db07-0100; Li ZP, 2010, AM J CLIN NUTR, V91, P1180, DOI 10.3945/ajcn.2009.28526; Lodefalk M, 2008, DIABETIC MED, V25, P1030, DOI 10.1111/j.1464-5491.2008.02530.x; MARON DJ, 1991, CIRCULATION, V84, P2020, DOI 10.1161/01.CIR.84.5.2020; Meier JJ, 2010, DIABETES, V59, P1117, DOI 10.2337/db09-1899; Meloun M, 2000, CLIN CHEM LAB MED, V38, P553, DOI 10.1515/CCLM.2000.081; Nakagawa K, 1997, ANAL BIOCHEM, V254, P31, DOI 10.1006/abio.1997.2372; NAUCK M, 1986, DIABETOLOGIA, V29, P46, DOI 10.1007/BF02427280; NAUCK MA, 1986, J CLIN ENDOCR METAB, V63, P492, DOI 10.1210/jcem-63-2-492; NUTTALL FQ, 1985, J AM COLL NUTR, V4, P437, DOI 10.1080/07315724.1985.10720086; Pan A, 2011, AM J CLIN NUTR, V94, P1088, DOI 10.3945/ajcn.111.018978; Perez-Martinez P, 2010, CLIN SCI, V119, P251, DOI 10.1042/CS20100015; PETERS AL, 1993, AM J CLIN NUTR, V58, P555, DOI 10.1093/ajcn/58.4.555; Rijkelijkhuizen JM, 2010, METABOLISM, V59, P502, DOI 10.1016/j.metabol.2009.07.039; Runchey SS, 2013, METABOLISM, V62, P188, DOI 10.1016/j.metabol.2012.07.006; Savage DB, 2007, PHYSIOL REV, V87, P507, DOI 10.1152/physrev.00024.2006; Tolhurst Gwen, 2012, Handb Exp Pharmacol, P309, DOI 10.1007/978-3-642-24716-3_14; Vang A, 2008, ANN NUTR METAB, V52, P96, DOI 10.1159/000121365; Vilsboll T, 2001, DIABETES, V50, P609, DOI 10.2337/diabetes.50.3.609; Vollmer K, 2008, DIABETES, V57, P678, DOI 10.2337/db07-1124; Wolpert HA, 2013, DIABETES CARE, V36, P810, DOI 10.2337/dc12-0092; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325; Xu G, 2007, DIABETES, V56, P1551, DOI 10.2337/db06-1033; YOKODE M, 1988, J CLIN INVEST, V81, P720, DOI 10.1172/JCI113377	52	28	28	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2014	9	9							e107561	10.1371/journal.pone.0107561	http://dx.doi.org/10.1371/journal.pone.0107561			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AP0SR	25222490	Green Published, gold, Green Submitted			2023-01-03	WOS:000341774800083
J	Gordon, RR; Wu, MC; Huang, CY; Harris, WP; Sim, HG; Lucas, JM; Coleman, I; Higano, CS; Gulati, R; True, LD; Vessella, R; Lange, PH; Garzotto, M; Beer, TM; Nelson, PS				Gordon, Ryan R.; Wu, Mengchu; Huang, Chung-Ying; Harris, William P.; Sim, Hong Gee; Lucas, Jared M.; Coleman, Ilsa; Higano, Celestia S.; Gulati, Roman; True, Lawrence D.; Vessella, Robert; Lange, Paul H.; Garzotto, Mark; Beer, Tomasz M.; Nelson, Peter S.			Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes	PLOS ONE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; NEOADJUVANT DOCETAXEL; RADICAL PROSTATECTOMY; IN-VIVO; CANCER-CELLS; IONIZING-RADIATION; L-DEPRENYL; PHASE-II; MITOXANTRONE; CLORGYLINE	To identify molecular alterations in prostate cancers associating with relapse following neoadjuvant chemotherapy and radical prostatectomy patients with high-risk localized prostate cancer were enrolled into a phase I-II clinical trial of neoadjuvant chemotherapy with docetaxel and mitoxantrone followed by prostatectomy. Pre-treatment prostate tissue was acquired by needle biopsy and post-treatment tissue was acquired by prostatectomy. Prostate cancer gene expression measurements were determined in 31 patients who completed 4 cycles of neoadjuvant chemotherapy. We identified 141 genes with significant transcript level alterations following chemotherapy that associated with subsequent biochemical relapse. This group included the transcript encoding monoamine oxidase A (MAOA). In vitro, cytotoxic chemotherapy induced the expression of MAOA and elevated MAOA levels enhanced cell survival following docetaxel exposure. MAOA activity increased the levels of reactive oxygen species and increased the expression and nuclear translocation of HIF1 alpha. The suppression of MAOA activity using the irreversible inhibitor clorgyline augmented the apoptotic responses induced by docetaxel. In summary, we determined that the expression of MAOA is induced by exposure to cytotoxic chemotherapy, increases HIF1 alpha, and contributes to docetaxel resistance. As MAOA inhibitors have been approved for human use, regimens combining MAOA inhibitors with docetaxel may improve clinical outcomes.	[Gordon, Ryan R.; Wu, Mengchu; Huang, Chung-Ying; Harris, William P.; Sim, Hong Gee; Lucas, Jared M.; Coleman, Ilsa; Gulati, Roman; Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA; [Gordon, Ryan R.; Wu, Mengchu; Huang, Chung-Ying; Harris, William P.; Sim, Hong Gee; Lucas, Jared M.; Coleman, Ilsa; Gulati, Roman; Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; [Beer, Tomasz M.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; [Higano, Celestia S.; Nelson, Peter S.] Univ Washington, Dept Med, Seattle, WA USA; [True, Lawrence D.; Nelson, Peter S.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Higano, Celestia S.; True, Lawrence D.; Vessella, Robert; Lange, Paul H.; Nelson, Peter S.] Univ Washington, Dept Urol, Seattle, WA 98195 USA; [Garzotto, Mark] Oregon Hlth & Sci Univ, Dept Urol, Portland, OR 97201 USA; [Garzotto, Mark] Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97201 USA; [Garzotto, Mark] Portland VA Med Ctr, Urol Sect, Portland, OR USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Oregon Health & Science University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center	Nelson, PS (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol, 1124 Columbia St, Seattle, WA 98104 USA.	pnelson@fhcrc.org	Gulati, Roman/AAE-4298-2019	Gulati, Roman/0000-0002-7592-6567	AUA Foundation; DOD CDMRP in Prostate Cancer [PC050489, PC110257]; PNW Prostate Cancer SPORE [CA097186];  [R01CA119125];  [PC093509];  [P01CA085859]; NATIONAL CANCER INSTITUTE [R01CA119125, P30CA069533, P50CA097186, P01CA085859] Funding Source: NIH RePORTER	AUA Foundation; DOD CDMRP in Prostate Cancer; PNW Prostate Cancer SPORE; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	MW was supported by a fellowship from the AUA Foundation. CYH was supported by a fellowship from the DOD CDMRP in Prostate Cancer (PC050489). RG was supported by a fellowship from the DOD CDMRP in Prostate Cancer (PC110257). This work was supported by grants R01CA119125, PC093509, P01CA085859, and the PNW Prostate Cancer SPORE (CA097186). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beer TM, 2004, CLIN CANCER RES, V10, P1306, DOI 10.1158/1078-0432.CCR-1021-03; Burgess DJ, 2008, P NATL ACAD SCI USA, V105, P9053, DOI 10.1073/pnas.0803513105; Cannito S, 2008, CARCINOGENESIS, V29, P2267, DOI 10.1093/carcin/bgn216; Chi KN, 2008, J UROLOGY, V180, P565, DOI 10.1016/j.juro.2008.04.012; Chi KN, 2008, J UROLOGY, V180, P570; Cubas R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-253; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Dizeyi N, 2004, PROSTATE, V59, P328, DOI 10.1002/pros.10374; Dreicer R, 2004, UROLOGY, V63, P1138, DOI 10.1016/j.urology.2004.01.040; Febbo PG, 2005, CLIN CANCER RES, V11, P5233, DOI 10.1158/1078-0432.CCR-05-0299; Fowler JS, 2002, METHODS, V27, P263, DOI 10.1016/S1046-2023(02)00083-X; FRY AM, 1991, CANCER RES, V51, P6592; Garzotto M, 2006, UROL ONCOL-SEMIN ORI, V24, P254, DOI 10.1016/j.urolonc.2005.11.034; Ghavami S, 2010, CELL RES, V20, P314, DOI 10.1038/cr.2009.129; Haase VH, 2009, KIDNEY INT, V76, P492, DOI 10.1038/ki.2009.222; Harada H, 2007, ONCOGENE, V26, P7508, DOI 10.1038/sj.onc.1210556; Higgins DF, 2007, J CLIN INVEST, V117, P3810, DOI 10.1172/JCI30487; Huang CY, 2007, CLIN CANCER RES, V13, P5825, DOI 10.1158/1078-0432.CCR-07-1037; Hussain M, 2003, UROLOGY, V61, P774, DOI 10.1016/S0090-4295(02)02519-0; Jung SN, 2008, CARCINOGENESIS, V29, P713, DOI 10.1093/carcin/bgn032; Magi-Galluzzi C, 2007, CANCER-AM CANCER SOC, V110, P1248, DOI 10.1002/cncr.22897; Maragos WF, 2004, NEUROCHEM RES, V29, P741, DOI 10.1023/B:NERE.0000018845.82808.45; Maragos WF, 1999, BRAIN RES, V834, P168, DOI 10.1016/S0006-8993(99)01487-0; O'Brien C, AM J CLIN PATHOL, V133, P654; O'Connell Michael J, 2004, Oncology (Williston Park), V18, P751; O'Connell MJ, 2004, ONCOLOGY WILLISTON P, V18, P755; Orlefors H, 2003, NUCL MED BIOL, V30, P669, DOI 10.1016/S0969-8051(03)00034-9; Patiar S, 2006, ENDOCR-RELAT CANCER, V13, pS61, DOI 10.1677/erc.1.01290; Perez-Pinera P, 2006, P NATL ACAD SCI USA, V103, P17795, DOI 10.1073/pnas.0607299103; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Seymour CB, 2003, BRIT J CANCER, V89, P1979, DOI 10.1038/sj.bjc.6601361; Shannon C, 2003, CRIT REV ONCOL HEMAT, V45, P77, DOI 10.1016/S1040-8428(02)00091-4; Siddiqui EJ, 2006, J UROLOGY, V176, P1648, DOI 10.1016/j.juro.2006.06.087; Singh RP, 2004, CLIN CANCER RES, V10, P244, DOI 10.1158/1078-0432.CCR-1080-3; Stephenson AJ, 2006, J CLIN ONCOL, V24, P3973, DOI 10.1200/JCO.2005.04.0756; Takahashi N, 2011, NAT CHEM BIOL, V7, P701, DOI [10.1038/NCHEMBIO.640, 10.1038/nchembio.640]; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; ThyagaRajan S, 1998, CANCER LETT, V123, P177, DOI 10.1016/S0304-3835(97)00431-X; Toninello A, 2006, BBA-REV CANCER, V1765, P1, DOI 10.1016/j.bbcan.2005.09.001; True L, 2006, P NATL ACAD SCI USA, V103, P10991, DOI 10.1073/pnas.0603678103; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wright GW, 2003, BIOINFORMATICS, V19, P2448, DOI 10.1093/bioinformatics/btg345; Xie Y, 2007, CARCINOGENESIS, V28, P2122, DOI 10.1093/carcin/bgm147; Yi H, 2006, J NEUROCHEM, V96, P541, DOI 10.1111/j.1471-4159.2005.03573.x; Zhao H, 2008, DIFFERENTIATION; Zhao HJ, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-55	46	19	20	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2014	9	9							e104271	10.1371/journal.pone.0104271	http://dx.doi.org/10.1371/journal.pone.0104271			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4JX	25198178	Green Published, Green Submitted, gold			2023-01-03	WOS:000341304700008
J	Patel, DA; Snedecor, SJ; Tang, WY; Sudharshan, L; Lim, JW; Cuffe, R; Pulgar, S; Gilchrist, KA; Camejo, RR; Stephens, J; Nichols, G				Patel, Dipen A.; Snedecor, Sonya J.; Tang, Wing Yu; Sudharshan, Lavanya; Lim, Jessica W.; Cuffe, Robert; Pulgar, Sonia; Gilchrist, Kim A.; Camejo, Rodrigo Refoios; Stephens, Jennifer; Nichols, Garrett			48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1-Infected Patients: A Systematic Review and Network Meta-Analysis	PLOS ONE			English	Review							REVERSE-TRANSCRIPTASE INHIBITOR; TENOFOVIR DISOPROXIL FUMARATE; TWICE-DAILY LOPINAVIR/RITONAVIR; ONCE-DAILY ATAZANAVIR/RITONAVIR; CO-FORMULATED ELVITEGRAVIR; HIV TYPE-1 INFECTION; ANTIRETROVIRAL-NAIVE; INITIAL TREATMENT; DOUBLE-BLIND; DAILY DARUNAVIR/RITONAVIR	Background: A network meta-analysis can provide estimates of relative efficacy for treatments not directly studied in head-to- head randomized controlled trials. We estimated the relative efficacy and safety of dolutegravir (DTG) versus third agents currently recommended by guidelines, including ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV), cobicistat-boosted elvitegravir (EVG/c), ritonavir-boosted lopinavir (LPV/r), raltegravir (RAL), and rilpivirine (RPV), in treatment-naive HIV-1-infected patients. Methods: A systematic review of published literature was conducted to identify phase 3/4 randomized controlled clinical trials (up to August 2013) including at least one third agent of interest in combination with a backbone nucleoside reverse transcriptase inhibitor (NRTI) regimen. Bayesian fixed-effect network meta-analysis models adjusting for the type of nucleoside reverse transcriptase inhibitor backbone (tenofovir disoproxil fumarate/emtricitabine [TDF/FTC] or abacavir/lamivudine [ABC/3TC]) were used to evaluate week 48 efficacy (HIV-RNA suppression to <50 copies/mL and change in CD4+ cells/mu L) and safety (lipid changes, adverse events, and discontinuations due to adverse events) of DTG relative to all other treatments. Sensitivity analyses assessing the impact of NRTI treatment adjustment and random-effects models were performed. Results: Thirty-one studies including 17,000 patients were combined in the analysis. Adjusting for the effect of NRTI backbone, treatment with DTG resulted in significantly higher odds of virologic suppression (HIV RNA<50 copies/mL) and increase in CD4+ cells/mu L versus ATV/r, DRV/r, EFV, LPV/r, and RPV. Dolutegravir had better or equivalent changes in total cholesterol, LDL, triglycerides, and lower odds of adverse events and discontinuation due to adverse events compared to all treatments. Random-effects and unadjusted models resulted in similar conclusions. Conclusion: Three clinical trials of DTG have demonstrated comparable or superior efficacy and safety to DRV, RAL, and EFV in HIV-1-infected treatment-naive patients. This network meta-analysis suggests DTG is also favorable or comparable to other commonly used third agents (ATV/r, LPV/r, RPV, and EVG/c).	[Patel, Dipen A.; Snedecor, Sonya J.; Tang, Wing Yu; Sudharshan, Lavanya; Stephens, Jennifer] Pharmerit Int, Bethesda, MD 20814 USA; [Lim, Jessica W.] GlaxoSmithKline, Stockley Pk, Middx, England; [Cuffe, Robert] ViiV Healthcare, Brentford, Middx, England; [Gilchrist, Kim A.] GlaxoSmithKline, Renaissance, PA USA; [Camejo, Rodrigo Refoios] GlaxoSmithKline, Brentford, Middx, England; [Pulgar, Sonia; Nichols, Garrett] GlaxoSmithKline, Res Triangle Pk, NC USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Snedecor, SJ (corresponding author), Pharmerit Int, Bethesda, MD 20814 USA.	ssnedecor@pharmerit.com			ViiV Healthcare; Pharmerit International; GlaxoSmithKline	ViiV Healthcare; Pharmerit International; GlaxoSmithKline(GlaxoSmithKline)	This study was funded by ViiV Healthcare. Pharmerit International, ViiV Healthcare and GlaxoSmithKline provided support in the form of salaries for all authors as employees but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aberg JA, 2012, AIDS RES HUM RETROV, V28, P1184, DOI 10.1089/aid.2011.0327; Andersson LM, 2013, SCAND J INFECT DIS, V45, P543, DOI 10.3109/00365548.2012.756985; [Anonymous], 2014, GUIDELINES USE ANTIR, P1; Bartlett JA, 2006, JAIDS-J ACQ IMM DEF, V43, P284, DOI 10.1097/01.qai.0000243092.40490.26; Behrens G, 2012, ANTIVIR THER, V17, P1011, DOI 10.3851/IMP2305; Berenguer J, 2008, CLIN INFECT DIS, V47, P1083, DOI 10.1086/592114; Bonnet M, 2013, LANCET INFECT DIS, V13, P303, DOI 10.1016/S1473-3099(13)70007-0; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Campbell TB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001290; Clotet B, 2014, LANCET, V383, P2222, DOI 10.1016/S0140-6736(14)60084-2; Cohen C, 2013, 7 AIS C HIV APTH TE; Cohen CJ, 2011, LANCET, V378, P229, DOI 10.1016/S0140-6736(11)60983-5; Daar ES, 2011, ANN INTERN MED, V154, DOI 10.7326/0003-4819-154-7-201104050-00316; DeJesus E, 2004, CLIN INFECT DIS, V39, P1038, DOI 10.1086/424009; DeJesus E, 2004, CLIN INFECT DIS, V39, P411, DOI 10.1086/422143; DeJesus E, 2011, INT J CLIN PRACT, V65, P1240, DOI 10.1111/j.1742-1241.2011.02807.x; DeJesus E, 2012, LANCET, V379, P2429, DOI 10.1016/S0140-6736(12)60918-0; Despiegel N, 2014, VALUE HEALTH, V17, pA273, DOI 10.1016/j.jval.2014.03.1589; Despiegel N, 2013, 14 HIV EUR AIDS C; deWolf F, 1997, AIDS, V11, P1799, DOI 10.1097/00002030-199715000-00003; Dias S, 2013, MED DECIS MAKING, V33, P657, DOI 10.1177/0272989X13485155; Dias S, 2013, MED DECIS MAKING, V33, P597, DOI 10.1177/0272989X13487604; Dias S, 2013, MED DECIS MAKING, V33, P607, DOI 10.1177/0272989X12458724; Dore GJ, 2004, J INFECT DIS, V189, P1185, DOI 10.1086/380398; Echeverria P, 2010, ANTIVIR RES, V85, P403, DOI 10.1016/j.antiviral.2009.11.008; Joseph E, 2006, LANCET, V368, P476, DOI 10.1016/S0140-6736(06)69155-1; European AIDS Clinical Society, 2013, GUID VERS 7 0; Fong R, 2013, SEX HEALTH, V10, P442, DOI 10.1071/SH13043; Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Goujard C, 2006, CLIN INFECT DIS, V42, P709, DOI 10.1086/500213; Gulick RM, 2006, JAMA-J AM MED ASSOC, V296, P769, DOI 10.1001/jama.296.7.769; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hogg R, 2013, 7 IAS C HIV PATH TRE; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; Jemsek JG, 2006, CLIN INFECT DIS, V42, P273, DOI 10.1086/498505; Lennox JL, 2009, LANCET, V374, P796, DOI 10.1016/S0140-6736(09)60918-1; Lockman S, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001236; Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; Maggiolo F, 2003, CLIN INFECT DIS, V37, P41, DOI 10.1086/375598; Mankhatitham Wiroj, 2012, Journal of the Medical Association of Thailand, V95, P163; Mannheimer S, 2002, CLIN INFECT DIS, V34, P1115, DOI 10.1086/339074; Manosuthi W, 2009, CLIN INFECT DIS, V48, P1752, DOI 10.1086/599114; Martin S, 2007, 4 IAS C HIV PATH TRE; Mills AM, 2009, AIDS, V23, P1679, DOI 10.1097/QAD.0b013e32832d7350; Moher David, 2009, Open Med, V3, pe123; Molina JM, 2008, LANCET, V372, P646, DOI 10.1016/S0140-6736(08)61081-8; Molina JM, 2013, AIDS, V27, P889, DOI 10.1097/QAD.0b013e32835e1554; Molina JM, 2011, LANCET, V378, P238, DOI 10.1016/S0140-6736(11)60936-7; Montaner Julio S G, 2006, MedGenMed, V8, P36; Nelson MR, 2013, HIV CLIN TRIALS, V14, P81, DOI 10.1310/hct1403-81; Nelson M, 2012, J ANTIMICROB CHEMOTH, V67, P2020, DOI 10.1093/jac/dks130; Malan DR, 2008, JAIDS-J ACQ IMM DEF, V47, P161, DOI 10.1097/QAI.0b013e31815ace6a; Nishijima T, 2013, INTERNAL MED, V52, P735, DOI 10.2169/internalmedicine.52.9155; Ortiz R, 2008, AIDS, V22, P1389, DOI 10.1097/QAD.0b013e32830285fb; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Phillips AN, 2006, CURR OPIN HIV AIDS, V1, P43, DOI 10.1097/01.COH.0000194106.12816.b1; Pinola M., 2010, J ANTIVIRALS ANTIRET, V2, P56, DOI [10.4172/jaa.1000024, DOI 10.4172/JAA.1000024]; Post FA, 2010, JAIDS-J ACQ IMM DEF, V55, P49, DOI 10.1097/QAI.0b013e3181dd911e; Puls RL, 2010, CLIN INFECT DIS, V51, P855, DOI 10.1086/656363; Raffi F, 2013, LANCET, V381, P735, DOI 10.1016/S0140-6736(12)61853-4; Riddler SA, 2008, NEW ENGL J MED, V358, P2095, DOI 10.1056/NEJMoa074609; Rockstroh JK, 2013, JAIDS-J ACQ IMM DEF, V63, P77, DOI 10.1097/QAI.0b013e31828ace69; Rodger AJ, 2013, AIDS, V27, P973, DOI 10.1097/QAD.0b013e32835cae9c; Sax PE, 2012, LANCET, V379, P2439, DOI 10.1016/S0140-6736(12)60917-9; Sierra-Madero J, 2010, JAIDS-J ACQ IMM DEF, V53, P582, DOI 10.1097/QAI.0b013e3181cae4a1; Smith Kimberly Y, 2008, AIDS Res Ther, V5, P5, DOI 10.1186/1742-6405-5-5; Smith KY, 2009, AIDS, V23, P1547, DOI 10.1097/QAD.0b013e32832cbcc2; Solem CT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098152; Soriano V, 2011, ANTIVIR THER, V16, P339, DOI 10.3851/IMP1745; Squires K, 2004, JAIDS-J ACQ IMM DEF, V36, P1011, DOI 10.1097/00126334-200408150-00003; US Department of Health and Human Services  U.S. Department of Health and Human Services, 2013, GUID IND HUM IMM VIR; Uy J, 2011, AIDS CARE, V23, P1500, DOI 10.1080/09540121.2011.565033; van Leth F, 2004, ANTIVIR THER, V9, P721; Fernandez-Montero JV, 2014, EXPERT OPIN PHARMACO, V15, P1051, DOI 10.1517/14656566.2014.913023; Vieira MC, 2011, HIV CLIN TRIALS, V12, P175, DOI [10.1310/hct1204-175, 10.1310/HCT1204-175]; Vrouenraets SME, 2011, HIV MED, V12, P620, DOI 10.1111/j.1468-1293.2011.00941.x; Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354; Walmsley S, 2009, JAIDS-J ACQ IMM DEF, V50, P367, DOI 10.1097/QAI.0b013e318198a815; Walmsley SL, 2013, NEW ENGL J MED, V369, P1807, DOI 10.1056/NEJMoa1215541; Wester CW, 2010, AIDS, V24, pS27, DOI 10.1097/01.aids.0000366080.91192.55; Yeni P, 2006, LANCET, V368, P287, DOI 10.1016/S0140-6736(06)69074-0	83	52	55	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2014	9	9							e105653	10.1371/journal.pone.0105653	http://dx.doi.org/10.1371/journal.pone.0105653			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO3XV	25188312	gold, Green Submitted, Green Published			2023-01-03	WOS:000341271500011
J	McCartney, M				McCartney, Margaret			Talking about death is not outrageous-reducing it to a tickbox exercise is	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ADMISSIONS					margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Appleby J, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1563; Huntley AL, 2013, FAM PRACT, V30, P266, DOI 10.1093/fampra/cms081; NHS Employers, 2014, 01778 NHS EMPL; Prynne M., 2014, DAILY TELEGRAPH; Roland M, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e6017	5	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 29	2014	349								g5369	10.1136/bmj.g5369	http://dx.doi.org/10.1136/bmj.g5369			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AO2SA	25171925	Green Published, Bronze			2023-01-03	WOS:000341174500007
J	Qin, YJ; Chu, KO; Yip, YWY; Li, WY; Yang, YP; Chan, KP; Ren, JL; Chan, SO; Pang, CP				Qin, Yong Jie; Chu, Kai On; Yip, Yolanda Wong Ying; Li, Wai Ying; Yang, Ya Ping; Chan, Kwok Ping; Ren, Jia Lin; Chan, Sun On; Pang, Chi Pui			Green Tea Extract Treatment Alleviates Ocular Inflammation in a Rat Model of Endotoxin-Induced Uveitis	PLOS ONE			English	Article							EPIGALLOCATECHIN GALLATE; SIGNALING PATHWAYS; TNF-ALPHA; EXPRESSION; RECOGNITION; MECHANISMS; CYTOKINES; (-)-EPIGALLOCATECHIN-3-GALLATE; POLYPHENOLS; CATECHINS	Green tea extract (GTE) ingested by rats exerted anti-oxidative activities in various ocular tissues as shown in our previous studies. The present work investigated anti-inflammatory effects of GTE on endotoxin-induced uveitis (EIU). EIU was generated in adult rats by a footpad injection of 1 mg/kg lipopolysaccharide (LPS). Oral administration of GTE (550 mg/kg) was given one, two or four times after LPS injection. Twenty-four hours later, LPS produced severe hyperemia and edema in the iris. Immunocytochemical examinations showed an accumulation of infiltrating cells in the aqueous humor that were immunopositive for cluster of differentiation 43 (CD43) and CD68, markers for leucocytes and macrophages, respectively. Analyses of the aqueous humor showed an increase in pro-inflammatory mediators including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1). GTE treatments improved the clinical manifestations and reduced infiltrating cells and protein exudation in the aqueous humor, which were not observed under half dose of GTE (275 mg/kg). The number of CD68 positive macrophages residing in the iris and ciliary was also reduced. GTE suppressed production of TNF-alpha, IL-6 and MCP-1 in the aqueous humor, which was associated with a down-regulation of LPS receptor complex subunits, Toll-like receptor 4 (TLR-4) and CD14, and suppression of nuclear factor-kappa Bp65 (NF-kappa Bp65) in the iris and ciliary body. Our findings show that GTE is a potent anti-inflammatory agent against the inflammation of EIU, and suggest a potential use in treatment of acute uveitis.	[Qin, Yong Jie; Chu, Kai On; Yip, Yolanda Wong Ying; Li, Wai Ying; Yang, Ya Ping; Chan, Kwok Ping; Pang, Chi Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China; [Ren, Jia Lin; Chan, Sun On] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong	Chan, SO (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.	sunonchan@cuhk.edu.hk; cppang@cuhk.edu.hk	Chan, Kwok Ping/E-6044-2016; Chan, Sun-On/R-6547-2018	Chan, Kwok Ping/0000-0003-2416-1995; Chan, Sun-On/0000-0002-3221-3786; Qin, Yong Jie/0000-0003-3117-0865	University Grants Committee Hong Kong, a GRF Grant [CUHK461612]; Lui Che Woo Institute of Innovative Medicine [8303107]; Endowment Fund for Lim Por-Yen Eye Genetics Research Centre, Hong Kong	University Grants Committee Hong Kong, a GRF Grant; Lui Che Woo Institute of Innovative Medicine; Endowment Fund for Lim Por-Yen Eye Genetics Research Centre, Hong Kong	This work was supported in part by a block grant of the University Grants Committee Hong Kong, a GRF Grant (Project No. CUHK461612), a seed grant from Lui Che Woo Institute of Innovative Medicine (Project No. 8303107) and the Endowment Fund for Lim Por-Yen Eye Genetics Research Centre, Hong Kong. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akhtar N, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3368; BHATTACHERJEE P, 1983, INVEST OPHTH VIS SCI, V24, P196; Brito BE, 2004, EXP EYE RES, V79, P203, DOI 10.1016/j.exer.2004.03.012; Byun EH, 2010, J IMMUNOL, V185, P33, DOI 10.4049/jimmunol.0903742; Cavet ME, 2011, MOL VIS, V17, P533; Chertin B, 2003, EUR UROL, V44, P144, DOI 10.1016/S0302-2838(03)00190-8; Chu KO, 2010, J AGR FOOD CHEM, V58, P1523, DOI 10.1021/jf9032602; da Silva PS, 2011, MOL VIS, V17, P1310; de Visser L, 2009, INFECTIOUS UVEITIS N, P148; DEVOS AF, 1994, INVEST OPHTH VIS SCI, V35, P3873; Durrani OM, 2004, BRIT J OPHTHALMOL, V88, P1159, DOI 10.1136/bjo.2003.037226; GREWAL HP, 1994, AM J SURG, V167, P214, DOI 10.1016/0002-9610(94)90076-0; Gritz DC, 2004, OPHTHALMOLOGY, V111, P491, DOI 10.1016/j.ophtha.2003.06.014; Heiligenhaus A, 2010, GRAEF ARCH CLIN EXP, V248, P1531, DOI 10.1007/s00417-010-1485-8; Jimenez-Sainz MC, 2003, MOL PHARMACOL, V64, P773, DOI 10.1124/mol.64.3.773; Kalariya NM, 2011, INVEST OPHTH VIS SCI, V52, P5144, DOI 10.1167/iovs.10-7047; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Koizumi K, 2003, INVEST OPHTH VIS SCI, V44, P2184, DOI 10.1167/iovs.02-0589; Lee FF, 2010, EXPERT OPIN PHARMACO, V11, P1135, DOI 10.1517/14656561003713534; Lee HS, 2011, CORNEA, V30, P1465, DOI 10.1097/ICO.0b013e31821c9b5a; Lin S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-46; Lin YL, 1997, MOL PHARMACOL, V52, P465, DOI 10.1124/mol.52.3.465; Masukawa Y, 2006, J CHROMATOGR B, V834, P26, DOI 10.1016/j.jchromb.2006.02.008; Nam S, 2001, J BIOL CHEM, V276, P13322, DOI 10.1074/jbc.M004209200; Nguyen QD, 2006, RETINA-J RET VIT DIS, P1; Nguyen QD, 2011, OPHTHALMOLOGY, V118, P184, DOI 10.1016/j.ophtha.2010.03.029; Ohgami K, 2005, INVEST OPHTH VIS SCI, V46, P275, DOI 10.1167/iovs.04-0715; OKUMURA A, 1990, INT OPHTHALMOL, V14, P31, DOI 10.1007/BF00131166; OKUMURA A, 1988, JPN J OPHTHALMOL, V32, P457; Ooi KGJ, 2006, CLIN MED RES, V4, P294, DOI 10.3121/cmr.4.4.294; Piazza M, 2009, J MED CHEM, V52, P1209, DOI 10.1021/jm801333m; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pooran N, 2003, J CLIN GASTROENTEROL, V37, P263, DOI 10.1097/00004836-200309000-00013; Poulaki V, 2007, FASEB J, V21, P2113, DOI 10.1096/fj.06-7637com; Pouvreau I, 1998, J NEUROIMMUNOL, V86, P171, DOI 10.1016/S0165-5728(98)00042-3; ROSENBAUM JT, 1980, NATURE, V286, P611, DOI 10.1038/286611a0; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Serhan CN, 2010, AM J PATHOL, V177, P1576, DOI 10.2353/ajpath.2010.100322; Siddique SS, 2011, EXPERT OPIN INV DRUG, V20, P1497, DOI 10.1517/13543784.2011.617741; Smith JR, 1998, IMMUNOL CELL BIOL, V76, P497, DOI 10.1046/j.1440-1711.1998.00783.x; Stangl V, 2007, CARDIOVASC RES, V73, P348, DOI 10.1016/j.cardiores.2006.08.022; Su GL, 2002, AM J PHYSIOL-GASTR L, V283, pG256, DOI 10.1152/ajpgi.00550.2001; Suzuki J, 2011, INVEST OPHTH VIS SCI, V52, P6565, DOI 10.1167/iovs.11-7331; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Triantafilou M, 2002, J CELL SCI, V115, P2603; Tuaillon N, 2002, INVEST OPHTH VIS SCI, V43, P1493; VANKESSEL KPM, 1991, J IMMUNOL, V147, P3862; Wakefield D, 2010, BRIT J OPHTHALMOL, V94, P271, DOI 10.1136/bjo.2008.146753; Yang XL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029155; Youn HS, 2006, BIOCHEM PHARMACOL, V72, P850, DOI 10.1016/j.bcp.2006.06.021	50	25	27	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2014	9	8							e103995	10.1371/journal.pone.0103995	http://dx.doi.org/10.1371/journal.pone.0103995			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO5BW	25093862	Green Submitted, Green Published, gold			2023-01-03	WOS:000341357200056
J	Sagnia, B; Fedeli, D; Casetti, R; Montesano, C; Falcioni, G; Colizzi, V				Sagnia, Bertrand; Fedeli, Donatella; Casetti, Rita; Montesano, Carla; Falcioni, Giancarlo; Colizzi, Vittorio			Antioxidant and Anti-Inflammatory Activities of Extracts from Cassia alata, Eleusine indica, Eremomastax speciosa, Carica papaya and Polyscias fulva Medicinal Plants Collected in Cameroon	PLOS ONE			English	Article							FREE-RADICALS; IN-VITRO; OXIDATIVE STRESS; DENDRITIC CELLS; AQUEOUS EXTRACT; ASSAY; ACID; GLUTATHIONE; TRITERPENE; LEAVES	Background: The vast majority of the population around the world has always used medicinal plants as first source of health care to fight infectious and non infectious diseases. Most of these medicinal plants may have scientific evidence to be considered in general practice. Objective: The aim of this work was to investigate the antioxidant capacities and anti-inflammatory activities of ethanol extracts of leaves of Cassia alata, Eleusine indica, Carica papaya, Eremomastax speciosa and the stem bark of Polyscias fulva, collected in Cameroon. Methods: Chemiluminescence was used to analyze the antioxidant activities of plant extracts against hydrogen peroxide or superoxide anion. Comet assays were used to analyze the protection against antioxidant-induced DNA damage induced in white blood cells after treating with hydrogen peroxide. Flow cytometry was used to measure gamma delta T cells proliferation and anti-inflammatory activity of gamma delta T cells and of immature dendritic cells (imDC) in the presence of different concentrations of plant extracts. Results: Ethanol extracts showed strong antioxidant properties against both hydrogen peroxide and superoxide anion. Cassia alata showed the highest antioxidant activity. The effect of plant extracts on gamma delta T cells and imDC was evidenced by the dose dependent reduction in TNF-alpha production in the presence of Cassia alata, Carica papaya, Eremomastax speciosa Eleusine indica, and Polyscias fulva. gamma delta T cells proliferation was affected to the greatest extent by Polyscias fulva. Conclusion: These results clearly show the antioxidant capacity and anti-inflammatory activities of plant extracts collected in Cameroon. These properties of leaves and stem bark extracts may contribute to the value for these plants in traditional medicine and in general medical practice.	[Sagnia, Bertrand] Chantal BIYA Int Reference Ctr Res Prevent & Mana, Lab Microbiol & Immunol, Yaounde, Cameroon; [Fedeli, Donatella; Falcioni, Giancarlo] Univ Camerino, Sch Pharm, I-62032 Camerino, MC, Italy; [Casetti, Rita; Colizzi, Vittorio] Natl Inst Infect Dis Lazzaro Spallanzani, Cellular Immunol Lab, Rome, Italy; [Montesano, Carla; Colizzi, Vittorio] Univ Roma Tor Vergata, Dept Biol, I-00173 Rome, Italy	University of Camerino; IRCCS Lazzaro Spallanzani; University of Rome Tor Vergata	Sagnia, B (corresponding author), Chantal BIYA Int Reference Ctr Res Prevent & Mana, Lab Microbiol & Immunol, Yaounde, Cameroon.	bertrandsagnia@yahoo.fr	Casetti, Rita/K-8631-2016	Casetti, Rita/0000-0002-7574-8780; Montesano, Carla/0000-0002-9865-6619	School of Advanced Studies, University of Camerino, Italy; University of Rome Tor Vergata, Italy	School of Advanced Studies, University of Camerino, Italy; University of Rome Tor Vergata, Italy	This work was supported by the School of Advanced Studies, University of Camerino, Italy, and the University of Rome Tor Vergata, Italy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afolabi IS, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-262; Aruoma OI, 2010, TOXICOLOGY, V278, P6, DOI 10.1016/j.tox.2010.09.006; Bedir E, 2001, J NAT PROD, V64, P95, DOI 10.1021/np0003589; Birdi T, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-33; Brusotti G, 2013, J PHARM BIOMED ANAL; Cesari I, 2013, J ETHNOPHARMACOL, V146, P264, DOI 10.1016/j.jep.2012.12.041; Cheynier V, 2013, PLANT PHYSL BIOCH; Cunningham AL, 2013, ADV EXP MED BIOL, V762, P1, DOI 10.1007/978-1-4614-4433-6_1; De Melo GO, 2005, PLANTA MED, V71, P362, DOI 10.1055/s-2005-864104; Dunne MR, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/704941; Ettebong EO, 2012, ASIAN PAC J TROP MED, V5, P673, DOI 10.1016/S1995-7645(12)60105-9; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; Focho DA, 2009, J ETHNOBIOL ETHNOMED, V5, DOI 10.1186/1746-4269-5-17; Gabbianelli R, 2004, COMP BIOCHEM PHYS C, V137, P355, DOI 10.1016/j.cca.2004.03.006; Gabbianelli R, 2003, ARCH ENVIRON CON TOX, V45, P350, DOI 10.1007/s00244-003-2171-1; Ghoti H, 2011, ANN HEMATOL, V90, P509, DOI 10.1007/s00277-010-1110-2; Huang LF, 2011, EUR J PHARMACOL, V672, P169, DOI 10.1016/j.ejphar.2011.09.175; Huang SS, 2013, J ETHNOPHARMACOL, V147, P395, DOI 10.1016/j.jep.2013.03.025; Iqbal Mohammad, 2012, Environmental Health and Preventive Medicine, V17, P307, DOI 10.1007/s12199-011-0255-5; Iweala EEJ, 2010, AFR J TRADIT COMPLEM, V7, P113; Khan M, 2012, J PHARMACEUT BIOMED, V59, P162, DOI 10.1016/j.jpba.2011.09.025; KIRKPATRICK D T, 1986, Journal of Biochemical Toxicology, V1, P93, DOI 10.1002/jbt.2570010110; Kisangau DP, 2007, AFR J TRADIT COMPLEM, V4, P510; Kumar H, 2012, CNS NEUROL DISORD-DR, V11, P1015; Mandas A, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/749575; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Mitchelmore CL, 1998, MUTAT RES-FUND MOL M, V399, P135, DOI 10.1016/S0027-5107(97)00252-2; Mitchelmore CL, 1998, ECOTOX ENVIRON SAFE, V41, P51, DOI 10.1006/eesa.1998.1666; Momo CEN, 2006, ANN TROP MED PARASIT, V100, P69, DOI 10.1179/136485906X78517; Morris D, 2013, BBA-GEN SUBJECTS, V1830, P3329, DOI 10.1016/j.bbagen.2012.10.012; Njateng GSS, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-95; Nussbaumer O, 2011, BLOOD, V118, P2743, DOI 10.1182/blood-2011-01-328526; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Ouedraogo M, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/162651; Rao Chandana Venkateswara, 2007, Acta Pharmaceutica (Zagreb), V57, P491, DOI 10.2478/v10007-007-0039-z; RICEEVANS CA, 1995, FREE RADICAL RES, V22, P375, DOI 10.3109/10715769509145649; Sen TA, 2010, ANADOLU KARDIYOL DER, V10, P465, DOI 10.5152/akd.2010.149; Sripanidkulchai B, 2001, J ETHNOPHARMACOL, V75, P185, DOI 10.1016/S0378-8741(01)00173-8; Tan PV, 1996, J ETHNOPHARMACOL, V54, P139, DOI 10.1016/S0378-8741(96)01461-4; Thomas E, 2009, J ETHNOPHARMACOL, V122, P60, DOI 10.1016/j.jep.2008.11.021; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Varghese GK, 2013, PHARM BIOL, V51, P345, DOI 10.3109/13880209.2012.729066; World Health Organization, 2002, WHO TRAD MED STRAT 2	45	49	50	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2014	9	8							e103999	10.1371/journal.pone.0103999	http://dx.doi.org/10.1371/journal.pone.0103999			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM4GX	25090613	Green Published, Green Submitted, gold			2023-01-03	WOS:000339812700075
J	Van Biesen, W; van der Veer, SN; Murphey, M; Loblova, O; Davies, S				Van Biesen, Wim; van der Veer, Sabine N.; Murphey, Mark; Loblova, Olga; Davies, Simon			Patients' Perceptions of Information and Education for Renal Replacement Therapy: An Independent Survey by the European Kidney Patients' Federation on Information and Support on Renal Replacement Therapy	PLOS ONE			English	Article							SHARED DECISION-MAKING; DIALYSIS MODALITY SELECTION; PERITONEAL-DIALYSIS; REFERRAL PATTERN; DISEASE PATIENTS; ESRD PATIENTS; HEALTH-CARE; EXPERIENCE; INITIATION; CONTRAINDICATIONS	Background: Selection of an appropriate renal replacement modality is of utmost importance for patients with end stage renal disease. Previous studies showed provision of information to and free modality choice by patients to be suboptimal. Therefore, the European Kidney Patients' Federation (CEAPIR) explored European patients' perceptions regarding information, education and involvement on the modality selection process. Methods: CEAPIR developed a survey, which was disseminated by the national kidney patient organisations in Europe. Results: In total, 3867 patients from 36 countries completed the survey. Respondents were either on in-centre haemodialysis (53%) or had a functioning graft (38%) at the time of survey. The majority (78%) evaluated the general information about kidney disease and treatment as helpful, but 39% did not recall being told about alternative treatment options than their current one. Respondents were more often satisfied with information provided on in-centre haemodialysis (90%) and transplantation (87%) than with information provided on peritoneal dialysis (79%) or home haemodialysis (61%), and were more satisfied with information from health care professionals vs other sources such as social media. Most (75%) felt they had been involved in treatment selection, 29% perceived they had no free choice. Involvement in modality selection was associated with enhanced satisfaction with treatment (OR 3.13; 95% CI 2.72-3.60). Many respondents (64%) could not remember receiving education on how to manage their kidney disease in daily life. Perceptions on information seem to differ between countries. Conclusions: Kidney patients reported to be overall satisfied with the information they received on their disease and treatment, although information seemed mostly to have been focused on one modality. Patients involved in modality selection were more satisfied with their treatment. However, in the perception of the patients, the freedom to choose an alternative modality showed room for improvement.	[Van Biesen, Wim] Ghent Univ Hosp, Div Renal, Ghent, Belgium; [van der Veer, Sabine N.] Univ Amsterdam, Acad Med Ctr, Dept Med Informat, NL-1105 AZ Amsterdam, Netherlands; [Murphey, Mark] Irish Kidney Assoc, Dublin, Ireland; [Loblova, Olga] A&R Edelman, London, England; [Loblova, Olga] Cent European Univ, Dept Publ Policy, Budapest, Hungary; [Davies, Simon] Univ Hosp North Staffordshire, Dept Nephrol, Stoke On Trent, Staffs, England	Ghent University; Ghent University Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Central European University	Van Biesen, W (corresponding author), Ghent Univ Hosp, Div Renal, Ghent, Belgium.	wim.vanbiesen@ugent.be		Davies, Simon/0000-0001-5127-4755; van der Veer, Sabine/0000-0003-0929-436X; Loblova, Olga/0000-0003-2481-8440	Baxter Healthcare	Baxter Healthcare	Baxter Healthcare provided logistical and financial support for this initiative through an unrestricted scientific grant to CEAPIR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ameling JM, 2012, BMC MED INFORM DECIS, V12, DOI 10.1186/1472-6947-12-140; Caring for Australians with Renal Impairment (CARI), 2005, ACC ONT DIAL GUID; Chewning B, 2012, PATIENT EDUC COUNS, V86, P9, DOI 10.1016/j.pec.2011.02.004; Covic A, 2010, NEPHROL DIAL TRANSPL, V25, P1757, DOI 10.1093/ndt/gfq206; Crow R, 2002, Health Technol Assess, V6, P1; Curtin R B, 2001, Nephrol Nurs J, V28, P385; Curtin RB, 2001, NEPHROL NURS J, V28, P393; Fadem SZ, 2011, CLIN J AM SOC NEPHRO, V6, P605, DOI 10.2215/CJN.06970810; Finkelstein FO, 2008, KIDNEY INT, V74, P1178, DOI 10.1038/ki.2008.376; Flynn KE, 2006, SOC SCI MED, V63, P1158, DOI 10.1016/j.socscimed.2006.03.030; Hingwala J, 2013, NEPHROL DIAL TRANSPL, V28, P732, DOI 10.1093/ndt/gfs323; Jager KJ, 2004, AM J KIDNEY DIS, V43, P891, DOI 10.1053/j.ajkd.2003.12.051; Kurella Tamura M, 2013, KIDNEY INT; Lameire N, 1999, NEPHROL DIAL TRANSPL, V14, P16, DOI 10.1093/ndt/14.suppl_6.16; Lameire N, 2002, KIDNEY INT, V61, pS27, DOI 10.1046/j.1523-1755.61.s80.6.x; Lee A, 2008, NEPHROL DIAL TRANSPL, V23, P3953, DOI 10.1093/ndt/gfn365; Lobbedez T, 2008, NEPHROL DIAL TRANSPL, V23, P3290, DOI 10.1093/ndt/gfn213; Lobbedez T, 2013, NEPHROL DIAL TRANSPL, V28, P1276, DOI 10.1093/ndt/gft018; Mehrotra R, 2005, KIDNEY INT, V68, P378; Morton RL, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c112; Morton RL, 2012, AM J KIDNEY DIS, V60, P102, DOI 10.1053/j.ajkd.2011.12.030; Moss AH, 2001, AM J KIDNEY DIS, V37, P1081; Muthalagappan S, 2013, NEPHROL DIAL TRANSPL, V28, P2717, DOI 10.1093/ndt/gft245; Oliver MJ, 2010, NEPHROL DIAL TRANSPL, V25, P2737, DOI 10.1093/ndt/gfq085; Povlsen JV, 2009, CONTRIB NEPHROL, V163, P261, DOI 10.1159/000223808; Song MK, 2013, NEPHROL DIAL TRANSPL, V28, P2815, DOI 10.1093/ndt/gft238; Stehman-Breen CO, 2000, KIDNEY INT, V57, P639, DOI 10.1046/j.1523-1755.2000.t01-1-00885.x; Stiggelbout AM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e256; Streiner D, 2008, HLTH MEASUREMENT SCA; Tennankore KK, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-192; Van Biesen W, 1999, PERITON DIALYSIS INT, V19, pS273; Van Biesen W, 2013, NEPHROL DIAL TRANSPL, V28, P1980, DOI 10.1093/ndt/gft291; van der Veer SN, 2012, NEPHROL DIAL TRANSPL, V27, P4188, DOI 10.1093/ndt/gfs351; van der Veer SN, 2012, NEPHROL DIAL TRANSPL, V27, P3284, DOI 10.1093/ndt/gfs023; van der Weijden T, 2013, BMJ QUAL SAF, V22, P855, DOI 10.1136/bmjqs-2012-001502; Winterbottom A, 2007, NEPHROL DIAL TRANSPL, V22, P2291, DOI 10.1093/ndt/gfm095; Winterbottom AE, 2012, NEPHROL DIAL TRANSPL, V27, P325, DOI 10.1093/ndt/gfr266; Wright JA, 2011, AM J KIDNEY DIS, V57, P387, DOI 10.1053/j.ajkd.2010.09.018	38	52	52	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2014	9	7							e103914	10.1371/journal.pone.0103914	http://dx.doi.org/10.1371/journal.pone.0103914			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6EF	25079071	Green Published, Green Submitted, gold			2023-01-03	WOS:000339954800094
J	Ojikutu, B; Higgins-Biddle, M; Greeson, D; Phelps, BR; Amzel, A; Okechukwu, E; Kolapo, U; Cabral, H; Cooper, E; Hirschhorn, LR				Ojikutu, Bisola; Higgins-Biddle, Molly; Greeson, Dana; Phelps, Benjamin R.; Amzel, Anouk; Okechukwu, Emeka; Kolapo, Usman; Cabral, Howard; Cooper, Ellen; Hirschhorn, Lisa R.			The Association between Quality of HIV Care, Loss to Follow-Up and Mortality in Pediatric and Adolescent Patients Receiving Antiretroviral Therapy in Nigeria	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1-INFECTED CHILDREN; TREATMENT OUTCOMES; CLINICAL CARE; HEALTH-CARE; SCALE-UP; OF-CARE; PROGRAM; IMPROVEMENT; INITIATION	Access to pediatric HIV treatment in resource-limited settings has risen significantly. However, little is known about the quality of care that pediatric or adolescent patients receive. The objective of this study is to explore quality of HIV care and treatment in Nigeria and to determine the association between quality of care, loss-to-follow-up and mortality. A retrospective cohort study was conducted including patients <= 18 years of age who initiated ART between November 2002 and December 2011 at 23 sites across 10 states. 1,516 patients were included. A quality score comprised of 6 process indicators was calculated for each patient. More than half of patients (55.5%) were found to have a high quality score, using the median score as the cut-off. Most patients were screened for tuberculosis at entry into care (81.3%), had adherence measurement and counseling at their last visit (88.7% and 89.7% respectively), and were prescribed co-trimoxazole at some point during enrollment in care (98.8%). Thirty-seven percent received a CD4 count in the six months prior to chart review. Mortality within 90 days of ART initiation was 1.9%. A total of 4.2% of patients died during the period of follow-up (mean: 27 months) with 19.0% lost to follow-up. In multivariate regression analyses, weight for age z-score (Adjusted Hazard Ratio (AHR): 0.90; 95% CI: 0.85, 0.95) and high quality indicator score (compared a low score, AHR: 0.43; 95% CI: 0.26, 0.73) had a protective effect on mortality. Patients with a high quality score were less likely to be lost to follow-up (Adjusted Odds Ratio (AOR): 0.42; 95% CI: 0.32, 0.56), compared to those with low score. These findings indicate that providing high quality care to children and adolescents living with HIV is important to improve outcomes, including lowering loss to follow-up and decreasing mortality in this age group.	[Ojikutu, Bisola; Higgins-Biddle, Molly] John Snow Inc, Boston, MA 02210 USA; [Ojikutu, Bisola] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; [Greeson, Dana] Columbia Univ, Dept Epidemiol, New York, NY USA; [Phelps, Benjamin R.; Amzel, Anouk] US Agcy Int Dev, Washington, DC 20523 USA; [Okechukwu, Emeka] US Agcy Int Dev, Abuja, Nigeria; [Kolapo, Usman] Indepth Precis, Abuja, Nigeria; [Cabral, Howard] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Cooper, Ellen] Boston Univ, Sch Med, Boston, MA 02118 USA; [Hirschhorn, Lisa R.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Columbia University; United States Agency for International Development (USAID); United States Agency for International Development (USAID); Boston University; Boston University; Harvard University; Harvard Medical School	Ojikutu, B (corresponding author), John Snow Inc, Boston, MA 02210 USA.	bojikutu@jsi.com	Okechukwu, Emeka Franklin/AAH-1130-2020	Hirschhorn, Lisa/0000-0002-4355-7437; Ojikutu, Bisola/0000-0001-7957-8881	President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Agency for International Development [GHH-I-00-07-00059-00]	President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Agency for International Development(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Agency for International Development under the terms of contract no. GHH-I-00-07-00059-00. Bisola Ojikutu and Molly-Higgins Biddle are employed by John Snow Inc. Usman Kolapo is employed by Indepth Precision. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrams EJ, 2012, JAIDS-J ACQ IMM DEF, V60, pS105, DOI 10.1097/QAI.0b013e31825cf4f5; Alemayehu YK, 2009, INT J QUAL HEALTH C, V21, P356, DOI 10.1093/intqhc/mzp030; Anigilaje EA, 2013, ISRN PEDIATR; Arrive E, 2008, JAIDS-J ACQ IMM DEF, V49, P523, DOI 10.1097/QAI.0b013e31818aadce; Braitstein P, 2011, JAIDS-J ACQ IMM DEF, V57, pE40, DOI 10.1097/QAI.0b013e3182167f0d; Brennan AT, 2011, AIDS, V25, P2027, DOI 10.1097/QAD.0b013e32834b6480; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; BROOK RH, 1977, MED CARE, V15, P1; Bygrave H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052856; Campbell SM, 2000, SOC SCI MED, V51, P1611, DOI 10.1016/S0277-9536(00)00057-5; Ciampa PJ, 2012, JAIDS-J ACQ IMM DEF, V60, pE46, DOI 10.1097/QAI.0b013e31824c0267; Davies MA, 2013, PEDIAT INFECT DIS J; Doherty T, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-406; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; DONABEDIAN A, 1988, INQUIRY-J HEALTH CAR, V25, P173; Ekouevi DK, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-519; Emdin CA, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18445; Evans D, 2013, AIDS RES HUM RETROV, V29, P892, DOI [10.1089/aid.2012.0215, 10.1089/AID.2012.0215]; Fayorsey RN, 2013, JAIDS-J ACQ IMM DEF, V62, pE124, DOI 10.1097/QAI.0b013e3182869558; Federal Ministry of Health of Nigeria, 2010, NAT GUID PED HIV AID; George E, 2007, J INFECT DIS, V195, P1411, DOI 10.1086/514823; Horberg M, 2011, AIDS PATIENT CARE ST, V25, P21, DOI 10.1089/apc.2010.0315; Kline MW, 2006, PEDIATRICS, V117, P1388, DOI 10.1542/peds.2005-1348; Lamb MR, 2014, AIDS, V28, P559, DOI 10.1097/QAD.0000000000000054; Leatherman S, 2010, INT J QUAL HEALTH C, V22, P237, DOI 10.1093/intqhc/mzq028; Leroy V, 2013, JAIDS-J ACQ IMM DEF, V62, P208, DOI 10.1097/QAI.0b013e31827b70bf; Lolekha R, 2010, JT COMM J QUAL PATIE, V36, P541, DOI 10.1016/S1553-7250(10)36082-X; Mainz J, 2003, INT J QUAL HEALTH C, V15, P523, DOI 10.1093/intqhc/mzg081; Marazzi MC, 2014, PEDIATR INFECT DIS J, V33, P295, DOI 10.1097/INF.0b013e3182a0994b; Meyers T, 2007, J INFECT DIS, V196, pS474, DOI 10.1086/521116; Moon TD, 2011, INT J STD AIDS, V22, P621, DOI 10.1258/ijsa.2011.010442; Morris MB, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-5; Mukhtar-Yola Mariya, 2006, Afr J AIDS Res, V5, P141, DOI 10.2989/16085900609490374; Nyandiko W, 2013, JAIDS-J ACQ IMM DEF, V63, pE49, DOI 10.1097/QAI.0b013e31828e1e2c; Peduzzi P, 1995, J CLIN EPIDEMIOL, V48, P1503, DOI 10.1016/0895-4356(95)00048-8; Sripipatana T, 2007, AM J OBSTET GYNECOL, V197, pS107, DOI 10.1016/j.ajog.2007.03.069; Sutcliffe CG, 2010, PEDIATR INFECT DIS J, V29, P849, DOI 10.1097/INF.0b013e3181e753a8; Thanprasertsuk S, 2012, INT J QUAL HEALTH C, V24, P338, DOI 10.1093/intqhc/mzs008; The Institute of Medicine, 1998, CROSS QUAL CHASM IOM; UNAIDS, 2011, GLOB HIV AIDS RESP E; UNAIDS, COUNTR PROF NIG; Virga PH, 2012, INT J MED INFORM, V81, pE39, DOI 10.1016/j.ijmedinf.2012.06.006; Walker AS, 2012, CLIN INFECT DIS, V55, P1707, DOI 10.1093/cid/cis797; Weigel R, 2012, AIDS, V26, P365, DOI 10.1097/QAD.0b013e32834ed814; Were MC, 2013, PEDIATRICS, V131, pE789, DOI 10.1542/peds.2012-2072; World Health Organization, 2013, TREATM HIV CHILDR; World Health Organization, 2011, GUID INT CAS FIND PE; World Health Organization, 2010, ANT THER HIV INF INF; Zanoni BC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022706; Zhao Y, 2013, CLIN INFECT DIS, V56, P735, DOI 10.1093/cid/cis941	50	24	24	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2014	9	7							e100039	10.1371/journal.pone.0100039	http://dx.doi.org/10.1371/journal.pone.0100039			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AM7EZ	25075742	Green Submitted, gold, Green Published			2023-01-03	WOS:000340028800004
J	Chamberlain, PI				Chamberlain, Paul Ivor			An assisted dying law might save me from a lingering and unpleasant death Paul Ivor Chamberlain has motor neurone disease and explains why he backs Lord Falconer's bill	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												paul.chamberlain@sky.com						Dyer C, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4739	1	1	1	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 22	2014	349								g4784	10.1136/bmj.g4784	http://dx.doi.org/10.1136/bmj.g4784			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AM0VN	25052048				2023-01-03	WOS:000339565700015
J	Adham, M; Stoker, SD; Wildeman, MA; Rachmadi, L; Gondhowiardjo, S; Atmakusumah, D; Gatot, D; Fles, R; Greijer, AE; Hermani, B; Middeldorp, JM; Tan, IB				Adham, Marlinda; Stoker, Sharon D.; Wildeman, Maarten A.; Rachmadi, Lisnawati; Gondhowiardjo, Soehartati; Atmakusumah, Djumhana; Gatot, Djayadiman; Fles, Renske; Greijer, Astrid E.; Hermani, Bambang; Middeldorp, Jaap M.; Tan, I. Bing			Current Status of Cancer Care for Young Patients with Nasopharyngeal Carcinoma in Jakarta, Indonesia	PLOS ONE			English	Article							CHILDREN; RADIOTHERAPY; MANAGEMENT	Background: Nasopharyngeal carcinoma (NPC) is endemic in Indonesia and 20% of the patients are diagnosed before the age of 31. This study evaluates presentation and treatment outcome of young patients in Jakarta, in a tertiary referral centre. Methods: Forty-nine patients under the age of 31, diagnosed with NPC between July 2004 and January 2007, were evaluated. Baseline data included histological type, stage of disease and presenting symptoms. We intended to follow all patients after diagnosis to reveal treatment outcome and overall survival (OS). Results: All but two patients had advanced stage disease (94%), 7 (14%) had distant metastasis. The median interval between start of complaints and diagnosis was 9 months. Forty-two patients were planned for curative intent treatment. Eleven patients (26%) never started treatment, 2 patients did not complete treatment and 3 patients did not return after finishing treatment. Four patients died before radiation could start. Three patients died within 4 months after treatment. Nine patients (21%) had a complete response. Due to the high number of patients who were lost to follow-up (LFU), OS was analyzed as follows: a best-case (patients censored at last contact) and a worst-case scenario (assuming that patients who did not finish treatment or had disease at last contact would have died). The 2-year OS for patients without distant metastases was 39-71%. Conclusion: Treatment outcome for young patients with NPC in this institute was poor. Improvement can be achieved when NPC is diagnosed at an earlier stage and when there is better treatment compliance.	[Adham, Marlinda; Rachmadi, Lisnawati; Gondhowiardjo, Soehartati; Atmakusumah, Djumhana; Hermani, Bambang] Univ Indonesia, Dr Cipto Mangunkusumo Hosp, Jakarta, Indonesia; [Gatot, Djayadiman] Univ Indonesia, Dr Cipto Mangunkusumo Hosp, Med Oncol Pediat Dept, Jakarta, Indonesia; [Stoker, Sharon D.; Wildeman, Maarten A.; Fles, Renske; Tan, I. Bing] Netherlands Canc Inst, Dept Head & Neck Oncol & Surg, Amsterdam, Netherlands; [Greijer, Astrid E.; Middeldorp, Jaap M.] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands; [Tan, I. Bing] Gadjah Mada Univ, Ear Nose & Throat Dept, Yogyakarta, Indonesia; [Wildeman, Maarten A.] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1105 AZ Amsterdam, Netherlands; [Tan, I. Bing] Univ Amsterdam, Acad Med Ctr, Dept Oral & Maxillofacial Surg, NL-1105 AZ Amsterdam, Netherlands	University of Indonesia; University of Indonesia; Netherlands Cancer Institute; Vrije Universiteit Amsterdam; Gadjah Mada University; University of Amsterdam; Academic Medical Center Amsterdam; Academic Center for Dentistry Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Tan, IB (corresponding author), Netherlands Canc Inst, Dept Head & Neck Oncol & Surg, Amsterdam, Netherlands.	I.tan@nki.nl		Adham, Marlinda/0000-0003-2461-9628; Middeldorp, Jaap Michiel/0000-0002-0765-4125	Dutch Cancer Society [KWF-VUmc IN2006-21]	Dutch Cancer Society(KWF Kankerbestrijding)	This study was sponsored by a grant of the Dutch Cancer Society, project number KWF-VUmc IN2006-21. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adham M, 2012, CHIN J CANCER, V31, P185, DOI 10.5732/cjc.011.10328; Akimoto T, 1997, JPN J CLIN ONCOL, V27, P240, DOI 10.1093/jjco/27.4.240; Ayan I, 2003, LANCET ONCOL, V4, P13, DOI 10.1016/S1470-2045(03)00956-2; Ayan I, 1996, INT J RADIAT ONCOL, V35, P485, DOI 10.1016/0360-3016(96)00018-1; Buehrlen M, 2012, CANCER-AM CANCER SOC, V118, P4892, DOI 10.1002/cncr.27395; Cheuk DKL, 2011, CANCER-AM CANCER SOC, V117, P197, DOI 10.1002/cncr.25376; Devi BCR, 2007, ANN ONCOL, V18, P1172, DOI 10.1093/annonc/mdm105; Downing NL, 2009, INT J RADIAT ONCOL, V75, P1064, DOI 10.1016/j.ijrobp.2008.12.030; Farmer P, 2010, LANCET, V376, P1186, DOI 10.1016/S0140-6736(10)61152-X; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fles R, 2010, BMC MED EDUC, V10, DOI 10.1186/1472-6920-10-81; Gondhowiardjo Sa, 2008, Biomed Imaging Interv J, V4, pe42, DOI 10.2349/biij.4.3.e42; Ho KY, 2008, J OTOLARYNGOL-HEAD N, V37, P362, DOI 10.2310/7070.2008.0071; Hutajulu SH, 2012, THESIS; Ji Ming-fang, 2011, Chin J Cancer, V30, P120; Kimman M, 2012, ASIAN PAC J CANCER P, V13, P411, DOI 10.7314/APJCP.2012.13.2.411; Laskar S, 2004, INT J RADIAT ONCOL, V58, P189, DOI 10.1016/S0360-3016(03)00773-9; Lee A. W. M., 1997, Hong Kong Medical Journal, V3, P355; Lee AWM, 2012, SEMIN RADIAT ONCOL, V22, P233, DOI 10.1016/j.semradonc.2012.03.008; Mertens R, 2005, CANCER-AM CANCER SOC, V104, P1083, DOI 10.1002/cncr.21258; Ozyar E, 2006, RADIOTHER ONCOL, V81, P39, DOI 10.1016/j.radonc.2006.08.019; Platek ME, 2012, HEAD NECK-J SCI SPEC, V35, P684; Satriana S, 2012, SOCIAL PROTECTION AS; Slotman BJ, 2005, RADIOTHER ONCOL, V75, P349, DOI 10.1016/j.radonc.2004.12.005; Stoker SD, 2014, PLOS ONE, V23; Tangcharoensathien V, 2011, LANCET, V377, P863, DOI 10.1016/S0140-6736(10)61890-9; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Wildeman MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063706; Wildeman MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032756; Wildeman MA, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-190; Wolden SL, 2000, INT J RADIAT ONCOL, V46, P859, DOI 10.1016/S0360-3016(99)00493-9	31	10	10	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2014	9	7							e102353	10.1371/journal.pone.0102353	http://dx.doi.org/10.1371/journal.pone.0102353			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM1PC	25019625	gold, Green Published, Green Submitted			2023-01-03	WOS:000339618600072
J	Marti, H; Koschwanez, M; Pesch, T; Blenn, C; Borel, N				Marti, Hanna; Koschwanez, Maria; Pesch, Theresa; Blenn, Christian; Borel, Nicole			Water-Filtered Infrared A Irradiation in Combination with Visible Light Inhibits Acute Chlamydial Infection	PLOS ONE			English	Article							ENDOCERVICAL EPITHELIAL-CELLS; TRACHOMATIS INFECTION; HELA-CELLS; HOST-CELLS; EXPRESSION; SECRETION; CYTOKINE; RESISTANCE; PERSISTENCE; ACTIVATION	New therapeutic strategies are needed to overcome drawbacks in treatment of infections with intracellular bacteria. Chlamydiaceae are Gram-negative bacteria implicated in acute and chronic diseases such as abortion in animals and trachoma in humans. Water-filtered infrared A (wIRA) is short wavelength infrared radiation with a spectrum ranging from 780 to 1400 nm. In clinical settings, wIRA alone and in combination with visible light (VIS) has proven its efficacy in acute and chronic wound healing processes. This is the first study to demonstrate that wIRA irradiation combined with VIS (wIRA/VIS) diminishes recovery of infectious elementary bodies (EBs) of both intra-and extracellular Chlamydia (C.) in two different cell lines (Vero, HeLa) regardless of the chlamydial strain (C. pecorum, C. trachomatis serovar E) as shown by indirect immunofluorescence and titration by subpassage. Moreover, a single exposure to wIRA/VIS at 40 hours post infection (hpi) led to a significant reduction of C. pecorum inclusion frequency in Vero cells and C. trachomatis in HeLa cells, respectively. A triple dose of irradiation (24, 36, 40 hpi) during the course of C. trachomatis infection further reduced chlamydial inclusion frequency in HeLa cells without inducing the chlamydial persistence/stress response, as ascertained by electron microscopy. Irradiation of host cells (HeLa, Vero) neither affected cell viability nor induced any molecular markers of cytotoxicity as investigated by Alamar blue assay and Western blot analysis. Chlamydial infection, irradiation, and the combination of both showed a similar release pattern of a subset of pro-inflammatory cytokines (MIF/GIF, Serpin E1, RANTES, IL-6, IL-8) and chemokines (IL-16, IP-10, ENA-78, MIG, MIP-1 alpha/beta) from host cells. Initial investigation into the mechanism indicated possible thermal effects on Chlamydia due to irradiation. In summary, we demonstrate a non-chemical reduction of chlamydial infection using the combination of water-filtered infrared A and visible light.	[Marti, Hanna; Koschwanez, Maria; Borel, Nicole] Univ Zurich Vetsuisse, Inst Vet Pathol, Zurich, Switzerland; [Pesch, Theresa; Blenn, Christian] Univ Zurich Vetsuisse, Inst Pharmacol & Toxicol, Zurich, Switzerland	University of Zurich; University of Zurich	Borel, N (corresponding author), Univ Zurich Vetsuisse, Inst Vet Pathol, Zurich, Switzerland.	n.borel@access.uzh.ch	Borel, Nicole/GPP-1073-2022; Marti, Hanna/AAA-3955-2021; Borel, Nicole/M-6204-2016	Borel, Nicole/0000-0002-1556-9262; Marti, Hanna/0000-0002-8398-4708; Borel, Nicole/0000-0002-1556-9262	Dr. Erwin Braun Foundation, Basel, Switzerland	Dr. Erwin Braun Foundation, Basel, Switzerland	This work was financially supported by the Dr. Erwin Braun Foundation, Basel, Switzerland, awarded to Christian Blenn and Nicole Borel. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen AA., 2010, PATHOGENESIS BACTERI, P575; Bastidas RJ, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a010256; Blenn C, 2011, CELL MOL LIFE SCI, V68, P1455, DOI 10.1007/s00018-010-0533-1; Borel N, 2012, VET MICROBIOL, V156, P143, DOI 10.1016/j.vetmic.2011.10.011; Borel N, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-201; Buckner LR, 2013, CYTOKINE, V63, P151, DOI 10.1016/j.cyto.2013.04.022; Burton MJ, 2011, INFECT IMMUN, V79, P4977, DOI 10.1128/IAI.05718-11; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Chancey ST, 2012, FUTURE MICROBIOL, V7, P959, DOI [10.2217/FMB.12.63, 10.2217/fmb.12.63]; Cheng W, 2008, INFECT IMMUN, V76, P942, DOI 10.1128/IAI.01313-07; Cohausz O, 2008, CELL MOL LIFE SCI, V65, P644, DOI 10.1007/s00018-008-7516-5; Cunha LD, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00076; Dean D, 2013, EMERG INFECT DIS, V19, P1948, DOI 10.3201/eid1912.130656; Deka S, 2006, CELL MICROBIOL, V8, P149, DOI 10.1111/j.1462-5822.2005.00608.x; Dessus-Babus S, 2000, CELL MICROBIOL, V2, P317, DOI 10.1046/j.1462-5822.2000.00058.x; Di Francesco A, 2008, VET REC, V163, P253, DOI 10.1136/vr.163.8.251; Di Paolo NC, 2014, METHODS MOL BIOL, V1089, P133, DOI 10.1007/978-1-62703-679-5_10; Dreses-Werringloer U, 2003, ANTIMICROB AGENTS CH, V47, P2316, DOI 10.1128/AAC.47.7.2316-2318.2003; Dugan J, 2004, ANTIMICROB AGENTS CH, V48, P3989, DOI 10.1128/AAC.48.10.3989-3995.2004; Ermolaeva SA, 2012, J MED MICROBIOL, V61, P793, DOI 10.1099/jmm.0.038117-0; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; GALASSO GJ, 1961, J IMMUNOL, V86, P382; Gervassi A, 2004, INFECT IMMUN, V72, P7231, DOI 10.1128/IAI.72.12.7231-7239.2004; Guseva NV, 2007, INFECT IMMUN, V75, P553, DOI 10.1128/IAI.01517-06; Hammerschlag MR, 2012, EXPERT OPIN PHARMACO, V13, P545, DOI 10.1517/14656566.2012.658776; Hartel M, 2006, BRIT J SURG, V93, P952, DOI 10.1002/bjs.5429; Hoffmann G, 2007, GMS KRANKENHHYG INTE, V2, pDoc54; Hogan RJ, 2004, INFECT IMMUN, V72, P1843, DOI 10.1128/IAI.72.4.1843-1855.2004; Jiang QQ, 1999, AM J PHYSIOL-REG I, V276, pR1653; Johnson RM, 2004, INFECT IMMUN, V72, P3951, DOI 10.1128/IAI.72.7.3951-3960.2004; Jung T, 2010, FREE RADICAL BIO MED, V48, P153, DOI 10.1016/j.freeradbiomed.2009.10.036; KAHANE S, 1992, FEMS MICROBIOL LETT, V97, P25; Kutlin A, 2005, ANTIMICROB AGENTS CH, V49, P903, DOI 10.1128/AAC.49.3.903-907.2005; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Maxion HK, 2002, INFECT IMMUN, V70, P1538, DOI 10.1128/IAI.70.3.1538-1546.2002; Mohamad KY, 2010, VET RES, V41, DOI 10.1051/vetres/2009075; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; Muschiol S, 2006, P NATL ACAD SCI USA, V103, P14566, DOI 10.1073/pnas.0606412103; Rank RG, 2010, INFECT IMMUN, V78, P536, DOI 10.1128/IAI.00772-09; Rasmussen SJ, 1997, J CLIN INVEST, V99, P77, DOI 10.1172/JCI119136; Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMc1207269; Rotondi M, 2007, ENDOCR REV, V28, P492, DOI 10.1210/er.2006-0044; Samarakoon R, 2013, CELL SIGNAL, V25, P264, DOI 10.1016/j.cellsig.2012.10.003; Sandoz KM, 2010, FUTURE MICROBIOL, V5, P1427, DOI [10.2217/fmb.10.96, 10.2217/FMB.10.96]; Schachter J., 1999, CHLAMYDIA, P156; Schautteet K, 2013, J MED MICROBIOL, V62, P331, DOI 10.1099/jmm.0.042861-0; Schieke SM, 2002, J INVEST DERMATOL, V119, P1323, DOI 10.1046/j.1523-1747.2002.19630.x; Schoborg RV, 2011, MICROBES INFECT, V13, P649, DOI 10.1016/j.micinf.2011.03.004; Schroeder P, 2007, FREE RADICAL BIO MED, V43, P128, DOI 10.1016/j.freeradbiomed.2007.04.002; Shah A, 2002, INT J HYPERTHER, V18, P534, DOI 10.1080/02656730210157843; Suchland RJ, 2005, ANTIMICROB AGENTS CH, V49, P1120, DOI 10.1128/AAC.49.3.1120-1126.2005; Tormakangas L, 2010, INFECT IMMUN, V78, P2714, DOI 10.1128/IAI.01456-09; Wasson CJ, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-176; Wright J, 2013, MED CLIN N AM, V97, P667, DOI 10.1016/j.mcna.2013.02.006; Wyrsch P, 2012, MOL CELL BIOL, V32, P3541, DOI 10.1128/MCB.00437-12; Yang HT, 2008, CELL SIGNAL, V20, P375, DOI 10.1016/j.cellsig.2007.10.025	56	17	17	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2014	9	7							e102239	10.1371/journal.pone.0102239	http://dx.doi.org/10.1371/journal.pone.0102239			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM1PC	25019934	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000339618600056
J	Chen, W; Lewith, G; Wang, LQ; Ren, J; Xiong, WJ; Lu, F; Liu, JP				Chen, Wei; Lewith, George; Wang, Li-qiong; Ren, Jun; Xiong, Wen-jing; Lu, Fang; Liu, Jian-ping			Chinese Proprietary Herbal Medicine Listed in 'China National Essential Drug List' for Common Cold: A Systematic Literature Review	PLOS ONE			English	Review							PRESCRIBING STRATEGIES	Objective: Chinese proprietary herbal medicines (CPHMs) have long history in China for the treatment of common cold, and lots of them have been listed in the 'China national essential drug list' by the Chinese Ministry of Health. The aim of this review is to provide a well-round clinical evidence assessment on the potential benefits and harms of CPHMs for common cold based on a systematic literature search to justify their clinical use and recommendation. Methods: We searched CENTRAL, MEDLINE, EMBASE, SinoMed, CNKI, VIP, China Important Conference Papers Database, China Dissertation Database, and online clinical trial registry websites from their inception to 31 March 2013 for clinical studies of CPHMs listed in the 'China national essential drug list' for common cold. There was no restriction on study design. Results: A total of 33 CPHMs were listed in 'China national essential drug list 2012' for the treatment of common cold but only 7 had supportive clinical evidences. A total of 6 randomised controlled trials (RCTs) and 7 case series (CSs) were included; no other study design was identified. All studies were conducted in China and published in Chinese between 1995 and 2012. All included studies had poor study design and methodological quality, and were graded as very low quality. Conclusions: The use of CPHMs for common cold is not supported by robust evidence. Further rigorous well designed placebo-controlled, randomized trials are needed to substantiate the clinical claims made for CPHMs.	[Chen, Wei; Wang, Li-qiong; Ren, Jun; Xiong, Wen-jing; Lu, Fang; Liu, Jian-ping] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China; [Lewith, George] Univ Southampton, Sch Med, Southampton, Hants, England	Beijing University of Chinese Medicine; University of Southampton	Liu, JP (corresponding author), Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China.	jianping_l@hotmail.com		Liu, Jianping/0000-0002-0320-061X	State Administration of Chinese Medicine [201207007]; Program for Innovative Research Team of Beijing University of Chinese Medicine [2011-CXTD-09]; research fund for the outstanding young teachers of Beijing University of Chinese Medicine	State Administration of Chinese Medicine; Program for Innovative Research Team of Beijing University of Chinese Medicine; research fund for the outstanding young teachers of Beijing University of Chinese Medicine	This work is supported by a research capacity establishment grant from the State Administration of Chinese Medicine (201207007), the Program for Innovative Research Team of Beijing University of Chinese Medicine (2011-CXTD-09), and research fund for the outstanding young teachers of Beijing University of Chinese Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	An R., 2011, THESIS BEIJING U CHI; [Anonymous], 2000, BMJ-BRIT MED J, V320, P1623; Chen W, 2014, J ALTERN COMPLEM MED, V5, pA128; Dai LH, 1995, J HENAN COLL TRADITI, V10, P45; Di JH, 2012, CHIN PEDIAT INTEGR T, V4, P277; Eccles R, 2005, LANCET INFECT DIS, V5, P718, DOI 10.1016/S1473-3099(05)70270-X; Han M, 2013, MODERNIZATION TRADIT, V15, P1771; Ishizaki T, 1996, EUR RESPIR J, V9, P2691, DOI 10.1183/09031936.96.09122691; Jiang XQ, 2012, GUANGMING J CHINESE, V27, P386; Kenealy T, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000247.pub3; Li QF, 2007, SHANDONG MED J, V47, P24; Li ZX, 1997, SHANXI J TRADITIONAL, V13, P16; Little P, 2001, BMJ-BRIT MED J, V322, P336, DOI 10.1136/bmj.322.7282.336; Little P, 2005, JAMA-J AM MED ASSOC, V293, P3029, DOI 10.1001/jama.293.24.3029; Lv GQ, 2010, INNER MONGOL J TRADI, V29, P151; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Melchart D, 1999, JAMA-J AM MED ASSOC, V282, P28, DOI 10.1001/jama.282.1.28; Moher David, 2010, BMJ, V340, pc869, DOI [10.1016/j.jclinepi.2010.03.004, 10.1136/bmj.c869]; National Health and Family Planning Commission of the People's Republic of China, 2013, CHIN NAT ESS DRUG LI; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; Simasek M, 2007, AM FAM PHYSICIAN, V75, P515; The Central People's Government of the People's Republic of China, 2009, HLTH MIN CHIN PROJ E; Turner LA, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-67; Turner RB, 2001, ANTIVIR RES, V49, P1, DOI 10.1016/S0166-3542(00)00135-2; Wang HR, 1997, QINGDAO MED J, V29, P40; Wang LZ, 1999, SHANDONG J TRADITION, V18, P282; Wang ZY, 2003, J EMERGENCY TRADITIO, V12, P503; Wells GA, NEWCASTLE OTTAWA SCA; Williamson IG, 2007, JAMA-J AM MED ASSOC, V298, P2487, DOI 10.1001/jama.298.21.2487; Wu CF, 2012, STRAIT PHARM J, V24, P239; Wu T, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004782.pub2; Xu HQ, 2010, MED J CHINESE PEOPLE, V22, P132; Yang SS, 1965, INNER CANON HUANGDI; Zhang HY, 2009, QINGDAO MED J, V36, P431; Zhang Y, 2010, INT J TRADTIONAL CHI, V32, P523; Zhao MD, 2012, CHINESE COMMUNITY DO, V14, P223	36	3	3	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2014	9	10							e110560	10.1371/journal.pone.0110560	http://dx.doi.org/10.1371/journal.pone.0110560			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0AY	25329481	Green Submitted, Green Published, gold			2023-01-03	WOS:000343942100074
J	Takakusagi, Y; Matsumoto, S; Saito, K; Matsuo, M; Kishimoto, S; Wojtkowiak, JW; DeGraff, W; Kesarwala, AH; Choudhuri, R; Devasahayam, N; Subramanian, S; Munasinghe, JP; Gillies, RJ; Mitchell, JB; Hart, CP; Krishna, MC				Takakusagi, Yoichi; Matsumoto, Shingo; Saito, Keita; Matsuo, Masayuki; Kishimoto, Shun; Wojtkowiak, Jonathan W.; DeGraff, William; Kesarwala, Aparna H.; Choudhuri, Rajani; Devasahayam, Nallathamby; Subramanian, Sankaran; Munasinghe, Jeeva P.; Gillies, Robert J.; Mitchell, James B.; Hart, Charles P.; Krishna, Murali C.			Pyruvate Induces Transient Tumor Hypoxia by Enhancing Mitochondrial Oxygen Consumption and Potentiates the Anti-Tumor Effect of a Hypoxia-Activated Prodrug TH-302	PLOS ONE			English	Article							HYPERBARIC-OXYGEN; CYCLING HYPOXIA; CANCER-THERAPY; MICE; MICROVASCULATURE; PHARMACOKINETICS; FLUCTUATIONS; MISONIDAZOLE; IRRADIATION; CARCINOMA	Background: TH-302 is a hypoxia-activated prodrug (HAP) of bromo isophosphoramide mustard that is selectively activated within hypoxic regions in solid tumors. Our recent study showed that intravenously administered bolus pyruvate can transiently induce hypoxia in tumors. We investigated the mechanism underlying the induction of transient hypoxia and the combination use of pyruvate to potentiate the anti-tumor effect of TH-302. Methodology/Results: The hypoxia-dependent cytotoxicity of TH-302 was evaluated by a viability assay in murine SCCVII and human HT29 cells. Modulation in cellular oxygen consumption and in vivo tumor oxygenation by the pyruvate treatment was monitored by extracellular flux analysis and electron paramagnetic resonance (EPR) oxygen imaging, respectively. The enhancement of the anti-tumor effect of TH-302 by pyruvate treatment was evaluated by monitoring the growth suppression of the tumor xenografts inoculated subcutaneously in mice. TH-302 preferentially inhibited the growth of both SCCVII and HT29 cells under hypoxic conditions (0.1% O-2), with minimal effect under aerobic conditions (21% O-2). Basal oxygen consumption rates increased after the pyruvate treatment in SCCVII cells in a concentration-dependent manner, suggesting that pyruvate enhances the mitochondrial respiration to consume excess cellular oxygen. In vivo EPR oxygen imaging showed that the intravenous administration of pyruvate globally induced the transient hypoxia 30 min after the injection in SCCVII and HT29 tumors at the size of 500-1500 mm(3). Pretreatment of SCCVII tumor bearing mice with pyruvate 30 min prior to TH-302 administration, initiated with small tumors (similar to 550 mm(3)), significantly delayed tumor growth. Conclusions/Significance: Our in vitro and in vivo studies showed that pyruvate induces transient hypoxia by enhancing mitochondrial oxygen consumption in tumor cells. TH-302 therapy can be potentiated by pyruvate pretreatment if started at the appropriate tumor size and oxygen concentration.	[Takakusagi, Yoichi; Matsumoto, Shingo; Saito, Keita; Matsuo, Masayuki; Kishimoto, Shun; DeGraff, William; Choudhuri, Rajani; Devasahayam, Nallathamby; Subramanian, Sankaran; Mitchell, James B.; Krishna, Murali C.] NCI, Radiat Biol Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Wojtkowiak, Jonathan W.; Gillies, Robert J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; [Kesarwala, Aparna H.] NCI, Radiat Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Munasinghe, Jeeva P.] NINDS, Bethesda, MD 20892 USA; [Hart, Charles P.] Threshold Pharmaceut, San Francisco, CA USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Krishna, MC (corresponding author), NCI, Radiat Biol Branch, Ctr Canc Res, Bethesda, MD 20892 USA.	murali@helix.nih.gov	Takakusagi, Yoichi/AAA-1998-2021	Takakusagi, Yoichi/0000-0002-6786-0748; Hart, Charles/0000-0003-4440-726X; Gillies, Robert/0000-0002-8888-7747; Kesarwala, Aparna/0000-0001-8297-9643; Matsumoto, Shingo/0000-0003-2698-0839	Intramural Research Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH); NATIONAL CANCER INSTITUTE [ZIABC011577] Funding Source: NIH RePORTER	Intramural Research Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Intramural Research Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brizel DM, 1997, INT J RADIAT ONCOL, V38, P285, DOI 10.1016/S0360-3016(97)00101-6; Brown JM, 2007, METHOD ENZYMOL, V435, P297, DOI 10.1016/S0076-6879(07)35015-5; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; BUSH RS, 1978, BRIT J CANCER, V37, P302; Cairns RA, 2009, CLIN CANCER RES, V15, P7170, DOI 10.1158/1078-0432.CCR-09-1676; Cardenas-Navia LI, 2004, CANCER RES, V64, P6010, DOI 10.1158/0008-5472.CAN-03-0947; CHAPLIN DJ, 1987, CANCER RES, V47, P597; Duan JX, 2008, J MED CHEM, V51, P2412, DOI 10.1021/jm701028q; Farrar CT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017228; FU KK, 1984, INT J RADIAT ONCOL, V10, P1473, DOI 10.1016/0360-3016(84)90371-7; Fukumura D, 2007, MICROVASC RES, V74, P72, DOI 10.1016/j.mvr.2007.05.003; Ganjoo KN, 2011, ONCOLOGY-BASEL, V80, P50, DOI 10.1159/000327739; GRAY LH, 1953, BRIT J RADIOL, V26, P638, DOI 10.1259/0007-1285-26-312-638; GUICHARD M, 1986, RADIAT RES, V105, P115, DOI 10.2307/3576731; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Hu JS, 2010, BLOOD, V116, P1524, DOI 10.1182/blood-2010-02-269126; Kimura H, 1996, CANCER RES, V56, P5522; Matsumoto S, 2008, J CLIN INVEST, V118, P1965, DOI 10.1172/JCI34928; Matsumoto S, 2011, CANCER RES, V71, P6350, DOI 10.1158/0008-5472.CAN-11-2025; Meng FY, 2012, MOL CANCER THER, V11, P740, DOI 10.1158/1535-7163.MCT-11-0634; Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893; National Research Council, 1996, GUIDE CARE USE LAB A, V7th ed., P140, DOI [10.17226/5140, DOI 10.17226/5140]; Nelson SJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006070; Saito K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049456; Saito K, 2012, MAGN RESON MED, V67, P801, DOI 10.1002/mrm.23065; Sorg BS, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2003369; SUIT HD, 1981, RADIAT RES, V87, P360, DOI 10.2307/3575590; SUIT HD, 1967, RADIOLOGY, V89, P713, DOI 10.1148/89.4.713; Sun JD, 2012, CLIN CANCER RES, V18, P758, DOI 10.1158/1078-0432.CCR-11-1980; TEICHER BA, 1980, J MED CHEM, V23, P955, DOI 10.1021/jm00182a027; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Weiss GJ, 2011, CLIN CANCER RES, V17, P2997, DOI 10.1158/1078-0432.CCR-10-3425; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Yasui H, 2010, CANCER RES, V70, P6427, DOI 10.1158/0008-5472.CAN-10-1350; Zhang X, 2012, ISMRM 20 ANN M	35	27	28	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2014	9	9							e107995	10.1371/journal.pone.0107995	http://dx.doi.org/10.1371/journal.pone.0107995			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT3UZ	25254649	Green Published, Green Submitted, gold			2023-01-03	WOS:000344862300050
J	Zhang, H; Liang, X; Duan, C; Liu, CG; Zhao, ZW				Zhang, Hao; Liang, Xi; Duan, Chao; Liu, Caigang; Zhao, Zuowei			Galectin-3 as a Marker and Potential Therapeutic Target in Breast Cancer	PLOS ONE			English	Article							ESTROGEN-RECEPTOR-ALPHA; ARSENIC TRIOXIDE; CARCINOMA CELLS; PROGESTERONE-RECEPTOR; EXPRESSION; TUMORIGENICITY	Galectin-3 has a relatively high level of expression in triple-negative breast cancers and is a potential marker for this disease. However, the clinical and prognostic implications of galectin-3 expression in breast cancer remain unclear. We examined mastectomy specimens from 1086 breast cancer cases and matching, adjacent non-cancerous tissues using immunohistochemistry. Overall, triple-negative breast cancers expressed galectin-3 more strongly than did other breast cancers types (63.59% vs 21.36%, P = 0.001). Galectin-3 expression was not found to be an independent prognostic factor for breast cancer by Cox regression analysis, but was associated with chemotherapeutic resistance. Apoptosis was only weakly induced by arsenic trioxide (ATO) treatment in galectin-3-positive breast cancer cells (MDA-MB-231 and MCF-7), although ATO treatment up-regulated galectin-3 expression. Knockdown of galectin-3 in MDA-MB-231 cells sensitized them to killing by ATO. These findings support a possible role for galectin-3 as a marker for triple-negative breast cancer progression and as a therapeutic target in combination with ATO treatment, although the mechanisms that underlie this synergy require further investigation.	[Zhang, Hao; Liang, Xi; Liu, Caigang; Zhao, Zuowei] Dalian Med Univ, Hosp 2, Dept Breast Surg, Dalian, Peoples R China; [Duan, Chao] Benxi Cent Hosp, Dept Cardiothorac, Benxi, Peoples R China	Dalian Medical University	Liu, CG (corresponding author), Dalian Med Univ, Hosp 2, Dept Breast Surg, Dalian, Peoples R China.	angel-s205@163.com	Liu, Caigang/C-7179-2018	Liu, Caigang/0000-0003-2083-235X; Zhang, Hao/0000-0002-0049-1220	China National Natural Science Foundation [81102029, 81172047]; Liaoning National Natural Science Foundation [2013021006]	China National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Liaoning National Natural Science Foundation	This study was funded by the China National Natural Science Foundation (No. 81102029 and 81172047) and Liaoning National Natural Science Foundation (No. 2013021006). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baj G, 2002, BREAST CANCER RES TR, V73, P61, DOI 10.1023/A:1015272401822; BAO Q, 1995, J CELL SCI, V108, P2791; Berenson JR, 2006, CLIN LYMPHOMA MYELOM, V7, P192, DOI 10.3816/CLM.2006.n.058; Chen Z, 2002, SEMIN HEMATOL, V39, P22, DOI 10.1053/shem.2002.33611; Chow SKY, 2004, J ENDOCRINOL, V182, P325, DOI 10.1677/joe.0.1820325; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Dilda PJ, 2007, CANCER TREAT REV, V33, P542, DOI 10.1016/j.ctrv.2007.05.001; Evens AM, 2004, LEUKEMIA RES, V28, P891, DOI 10.1016/j.leukres.2004.01.011; Gaffan J, 2006, J CLIN ONCOL, V24, P1932, DOI 10.1200/JCO.2005.02.6617; Honjo Y, 2001, CLIN CANCER RES, V7, P661; Kasami M, 2008, BREAST, V17, P523, DOI 10.1016/j.breast.2008.04.002; Koo JS, 2011, YONSEI MED J, V52, P89, DOI 10.3349/ymj.2011.52.1.89; LeMarer N, 1996, J CELL PHYSIOL, V168, P51, DOI 10.1002/(SICI)1097-4652(199607)168:1<51::AID-JCP7>3.0.CO;2-7; Ma CX, 2009, ONCOLOGY-NY, V23, P133; Moon BK, 2001, AM J PATHOL, V159, P1055, DOI 10.1016/S0002-9440(10)61780-4; Murgo AJ, 2001, ONCOLOGIST, V6, P22, DOI 10.1634/theoncologist.6-suppl_2-22; NANGIAMAKKER P, 1995, INT J ONCOL, V7, P1079; Pal SK, 2011, BREAST CANCER RES TR, V125, P627, DOI 10.1007/s10549-010-1293-1; Rody A, 2004, ONCOL REP, V12, P695; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; SATO S, 1992, J BIOL CHEM, V267, P6983; Schneider BP, 2008, CLIN CANCER RES, V14, P8010, DOI 10.1158/1078-0432.CCR-08-1208; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tallman MS, 2008, BEST PRACT RES CL HA, V21, P659, DOI 10.1016/j.beha.2008.09.002; Tischkowitz M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-134; Verstovsek S, 2006, HEMATOL ONCOL, V24, P181, DOI 10.1002/hon.787	26	39	40	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2014	9	9							e103482	10.1371/journal.pone.0103482	http://dx.doi.org/10.1371/journal.pone.0103482			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT3UZ	25254965	Green Published, gold, Green Submitted			2023-01-03	WOS:000344862300003
J	Jacquot, A; Francius, G; Razafitianamaharavo, A; Dehghani, F; Tamayol, A; Linder, M; Arab-Tehrany, E				Jacquot, Adrien; Francius, Gregory; Razafitianamaharavo, Angelina; Dehghani, Fariba; Tamayol, Ali; Linder, Michel; Arab-Tehrany, Elmira			Morphological and Physical Analysis of Natural Phospholipids-Based Biomembranes	PLOS ONE			English	Article							ATOMIC-FORCE MICROSCOPY; SUPPORTED LIPID-BILAYERS; MEMBRANES; SPECTROSCOPY; PROBE; AFM; NANOMECHANICS; LIPOSOMES; MODEL; FLUORESCENCE	Background: Liposomes are currently an important part of biological, pharmaceutical, medical and nutritional research, as they are considered to be among the most effective carriers for the introduction of various types of bioactive agents into target cells. Scope of Review: In this work, we study the lipid organization and mechanical properties of biomembranes made of marine and plant phospholipids. Membranes based on phospholipids extracted from rapeseed and salmon are studied in the form of liposome and as supported lipid bilayer. Dioleylphosphatidylcholine (DOPC) and dipalmitoylphosphatidylcholine (DPPC) are used as references to determine the lipid organization of marine and plant phospholipid based membranes. Atomic force microscopy (AFM) imaging and force spectroscopy measurements are performed to investigate the membranes' topography at the micrometer scale and to determine their mechanical properties. Major Conclusions: The mechanical properties of the membranes are correlated to the fatty acid composition, the morphology, the electrophoretic mobility and the membrane fluidity. Thus, soft and homogeneous mechanical properties are evidenced for salmon phospholipids membrane containing various polyunsaturated fatty acids. Besides, phase segregation in rapeseed membrane and more important mechanical properties were emphasized for this type of membranes by contrast to the marine phospholipids based membranes. General Significance: This paper provides new information on the nanomechanical and morphological properties of membrane in form of liposome by AFM. The originality of this work is to characterize the physico/chemical properties of the nanoliposome from the natural sources containing various fatty acids and polar head.	[Jacquot, Adrien; Linder, Michel; Arab-Tehrany, Elmira] Univ Lorraine, Lab Ingn Biomol, TSA, F-40602 Vandoeuvre Les Nancy, France; [Francius, Gregory] Univ Lorraine, Lab Chim Phys & Microbiol Environm, UMR 7564, Villers Les Nancy, France; [Francius, Gregory] CNRS, Lab Chim Phys & Microbiol Environm, UMR 7564, Villers Les Nancy, France; [Razafitianamaharavo, Angelina] Univ Lorraine, Lab Interdisciplinaire Environm Continentaux, UMR 7360, Vandoeuvre Les Nancy, France; [Razafitianamaharavo, Angelina] CNRS, UMR 7360, Vandoeuvre Les Nancy, France; [Dehghani, Fariba] Univ Sydney, Sch Chem & Biomol Engn, Sydney, NSW 2006, Australia; [Tamayol, Ali] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Biomed Engn,Dept Med, Cambridge, MA 02138 USA	Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Universite de Lorraine; University of Sydney; Harvard University; Brigham & Women's Hospital	Arab-Tehrany, E (corresponding author), Univ Lorraine, Lab Ingn Biomol, TSA, F-40602 Vandoeuvre Les Nancy, France.	elmira.arab-tehrany@univ-lorraine.fr	Francius, Gregory/P-6058-2019; Francius, Gregory/A-4246-2015; Rafitianamaharavo, Angelina/F-3630-2019; LINDER, Michel/C-9058-2016	Francius, Gregory/0000-0001-8533-9449; Francius, Gregory/0000-0001-8533-9449; arab tehrany, elmira/0000-0002-2182-8531; Rafitianamaharavo, Angelina/0000-0002-7199-3017; Dehghani, Fariba/0000-0002-7805-8101; LINDER, Michel/0000-0002-8658-6828	French Ministry of Research and Education (MESR)	French Ministry of Research and Education (MESR)(Ministry of Research, France)	This work was supported by French Ministry of Research and Education (MESR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackman RG, 1998, J AM OIL CHEM SOC, V75, P541, DOI 10.1007/s11746-998-0263-9; An HJ, 2010, BIOPHYS J, V99, P834, DOI 10.1016/j.bpj.2010.04.072; Attwood SJ, 2013, INT J MOL SCI, V14, P3514, DOI 10.3390/ijms14023514; Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3; Chiantia S, 2006, CHEMPHYSCHEM, V7, P2409, DOI 10.1002/cphc.200600464; Choucair A, 2007, BBA-BIOMEMBRANES, V1768, P146, DOI 10.1016/j.bbamem.2006.09.005; Deleu M, 2013, BBA-BIOMEMBRANES, V1828, P801, DOI 10.1016/j.bbamem.2012.11.007; Dufrene YF, 1997, LANGMUIR, V13, P4779, DOI 10.1021/la970221r; Fathi M, 2012, TRENDS FOOD SCI TECH, V23, P13, DOI 10.1016/j.tifs.2011.08.003; Garcia-Manyes S, 2005, BIOPHYS J, V89, P4261, DOI 10.1529/biophysj.105.065581; Garcia-Manyes S, 2006, ELECTROCHIM ACTA, V51, P5029, DOI 10.1016/j.electacta.2006.03.062; Garcia-Manyes S, 2010, BBA-BIOMEMBRANES, V1798, P741, DOI 10.1016/j.bbamem.2009.12.019; Ikai A, 2003, CELL BIOCHEM BIOPHYS, V39, P257, DOI 10.1385/CBB:39:3:257; Levy R, 2002, NANOTECHNOLOGY, V13, P33, DOI 10.1088/0957-4484/13/1/307; Linder M, 2002, EUR J LIPID SCI TECH, V104, P455, DOI 10.1002/1438-9312(200208)104:8<455::AID-EJLT455>3.0.CO;2-Q; Maherani B, 2011, CURR NANOSCI, V7, P436, DOI 10.2174/157341311795542453; Mingeot-Leclercq MP, 2008, NAT PROTOC, V3, P1654, DOI 10.1038/nprot.2008.149; Montano GA, 2013, ADV FUNCT MATER, V23, P2576, DOI 10.1002/adfm.201203429; Morandat S, 2013, ANAL BIOANAL CHEM, V405, P1445, DOI 10.1007/s00216-012-6383-y; Pera I, 2004, BIOPHYS J, V87, P2446, DOI 10.1529/biophysj.104.044214; Picas L, 2012, CHEM PHYS LIPIDS, V165, P845, DOI 10.1016/j.chemphyslip.2012.10.005; PRENDERGAST FG, 1981, BIOCHEMISTRY-US, V20, P7333, DOI 10.1021/bi00529a002; Re F, 2011, NANOMED-NANOTECHNOL, V7, P551, DOI 10.1016/j.nano.2011.05.004; Redondo-Morata L, 2012, LANGMUIR, V28, P12851, DOI 10.1021/la302620t; Shimanouchi T, 2009, COLLOID SURFACE B, V73, P156, DOI 10.1016/j.colsurfb.2009.05.014; Sneddon I.N., 1965, INT J ENG SCI, V3, P47, DOI [10.1016/0020-7225(65)90019-4, DOI 10.1016/0020-7225(65)90019-4]; Sullan RMA, 2009, LANGMUIR, V25, P12874, DOI 10.1021/la903442s; Tehrany EA, 2012, COLLOID SURFACE B, V95, P75, DOI 10.1016/j.colsurfb.2012.02.024; Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632; Yokokawa M, 2008, J MICROSC-OXFORD, V232, P82, DOI 10.1111/j.1365-2818.2008.02071.x	30	20	20	2	70	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2014	9	9							e107435	10.1371/journal.pone.0107435	http://dx.doi.org/10.1371/journal.pone.0107435			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ0RY	25238543	Green Published, gold, Green Submitted			2023-01-03	WOS:000342491600025
J	Ojha, D; Mukherjee, H; Mondal, S; Jena, A; Dwivedi, VP; Mondal, KC; Malhotra, B; Samanta, A; Chattopadhyay, D				Ojha, Durbadal; Mukherjee, Hemanta; Mondal, Supriya; Jena, Aditya; Dwivedi, Ved Prakash; Mondal, Keshab C.; Malhotra, Bharti; Samanta, Amalesh; Chattopadhyay, Debprasad			Anti-Inflammatory Activity of Odina wodier Roxb, an Indian Folk Remedy, through Inhibition of Toll-Like Receptor 4 Signaling Pathway	PLOS ONE			English	Article							NITRIC-OXIDE; PERMEABILITY; INFLAMMATION; INNATE; FAMILY; TLR4; MICE; LPS	Inflammation is part of self-limiting non-specific immune response, which occurs during bodily injury. In some disorders the inflammatory process becomes continuous, leading to the development of chronic inflammatory diseases including cardiovascular diseases, diabetes, cancer etc. Several Indian tribes used the bark of Odina wodier (OWB) for treating inflammatory disorders. Thus, we have evaluated the immunotherapeutic potential of OWB methanol extract and its major constituent chlorogenic acid (CA), using three popular in vivo antiinflammatory models: Carrageenan-and Dextran-induced paw edema, Cotton pellet granuloma, and Acetic acid-induced vascular permeability. To elucidate the possible antiinflammatory mechanism of action we determine the level of major inflammatory mediators (NO, iNOS, COX-2-dependent prostaglandin E2 or PGE2), and pro-inflammatory cytokines (TNF-alpha, IL-1 beta, IL-6, and IL-12). Further, we determine the toll-like receptor 4 (TLR4), Myeloid differentiation primary response gene 88 (MyD88), c-Jun N-terminal kinases (JNK), nuclear factor kappa-B cells (NF-kappa B), and NF-kappa B inhibitor alpha (IK-B alpha) by protein and mRNA expression, and Western blot analysis in drug treated LPS-induced murine macrophage model. Moreover, we determined the acute and sub-acute toxicity of OWB extract in BALB/c mice. Our study demonstrated a significant anti-inflammatory activity of OWB extract and CA along with the inhibition of TNF-alpha, IL-1 beta, IL-6 and IL-12 expressions. Further, the expression of TLR4, NF-kappa Bp65, MyD88, iNOS and COX-2 molecules were reduced in drug-treated groups, but not in the LPS-stimulated untreated or control groups, Thus, our results collectively indicated that the OWB extract and CA can efficiently inhibit inflammation through the down regulation of TLR4/MyD88/NF-kappa B signaling pathway.	[Ojha, Durbadal; Mukherjee, Hemanta; Mondal, Supriya; Jena, Aditya; Dwivedi, Ved Prakash; Chattopadhyay, Debprasad] ID & BG Hosp, ICMR Virus Unit, Kolkata, India; [Ojha, Durbadal; Samanta, Amalesh] Jadavpur Univ, Dept Pharmaceut Technol, Div Microbiol, Kolkata, India; [Mondal, Keshab C.] Vidyasagar Univ, Dept Microbiol, Midnapore, W Bengal, India; [Malhotra, Bharti] SMS Med Coll & Hosp, Dept Microbiol, Jaipur, Rajasthan, India	Indian Council of Medical Research (ICMR); ICMR - National Institute of Cholera & Enteric Diseases (NICED); ICMR - Virus Unit, Kolkata; Jadavpur University; Vidyasagar University; SMS Medical College & Hospital	Samanta, A (corresponding author), Jadavpur Univ, Dept Pharmaceut Technol, Div Microbiol, Kolkata, India.	asamanta61@yahoo.co.in; debprasadc@yahoo.co.in	; Mondal, Keshab Chandra/B-3538-2019	CHATTOPADHYAY, Dr DEBPRASAD/0000-0002-7999-329X; Mondal, Keshab Chandra/0000-0003-3180-1567; Dwivedi, Ved Prakash/0000-0003-4321-2567				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Arunachalam G, 2002, PHYTOMEDICINE, V9, P632, DOI 10.1078/094471102321616445; Bag P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077937; BETZ M, 1991, J IMMUNOL, V146, P108; Biswajit Mukherjee, 2006, Trends in Applied Sciences Research, V1, P309; Brown JN., 2006, GOODMAN GILMANS PHAR, V11, P645; Calixto JB, 2003, PLANTA MED, V69, P973, DOI [10.1055/s-2003-45141, 10.1055/s-2004-815483]; Chagas-Paula DA, 2011, J ETHNOPHARMACOL, V136, P355, DOI 10.1016/j.jep.2011.04.067; Chattopadhyay D, 2002, J ETHNOPHARMACOL, V82, P229, DOI 10.1016/S0378-8741(02)00165-4; Chattopadhyay D., 2012, EVIDENCED BASED COMP, V2012, DOI [10.1155/2012/254849, DOI 10.1155/2012/254849]; Chattopadhyay D, 2008, BIOTECHNOL ANN REV, V14, P297, DOI 10.1016/S1387-2656(08)00012-4; COLDITZ IG, 1985, SURV SYN PATHOL RES, V4, P44; dos Santos MD, 2006, BIOL PHARM BULL, V29, P2236, DOI 10.1248/bpb.29.2236; Ferrero-Miliani L, 2007, CLIN EXP IMMUNOL, V147, P227, DOI 10.1111/j.1365-2249.2006.03261.x; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Fujihara M, 2003, PHARMACOL THERAPEUT, V100, P171, DOI 10.1016/j.pharmthera.2003.08.003; Gaddi A, 2004, ARCH GERONTOL GERIAT, V38, P201, DOI 10.1016/j.archger.2003.10.001; Ghosh S, 2013, MED CHEM RES, V22, P4347, DOI 10.1007/s00044-012-0449-4; Griffon B, 1998, HEPATOLOGY, V28, P1300, DOI 10.1002/hep.510280519; Harbrecht BG, 1997, J LEUKOCYTE BIOL, V61, P712, DOI 10.1002/jlb.61.6.712; Havsteen BH, 2002, PHARMACOL THERAPEUT, V96, P67, DOI 10.1016/S0163-7258(02)00298-X; Heller A, 1998, DRUGS, V55, P487, DOI 10.2165/00003495-199855040-00001; Imler JL, 2003, NAT IMMUNOL, V4, P105, DOI 10.1038/ni0203-105; Jagavelu K, 2010, HEPATOLOGY, V52, P590, DOI 10.1002/hep.23739; KASAMA T, 1993, J EXP MED, V178, P63, DOI 10.1084/jem.178.1.63; Kirtikar KR, 1999, INDIAN MED PLANTS; KLINGEMANN HG, 1986, BLOOD, V68, P102; Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006; MAROTTA P, 1992, BRIT J PHARMACOL, V107, P640, DOI 10.1111/j.1476-5381.1992.tb14499.x; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Miller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068; MIZUSHIM.Y, 1965, LANCET, V1, P169; MOTA MLR, 1985, J ETHNOPHARMACOL, V13, P289, DOI 10.1016/0378-8741(85)90074-1; Mukherjee H, 2013, MICROBIOL RES, V168, P238, DOI 10.1016/j.micres.2012.11.002; Muthu C, 2006, J ETHNOBIOL ETHNOMED, V2, DOI 10.1186/1746-4269-2-43; Nagy LE, 2003, EXP BIOL MED, V228, P882, DOI 10.1177/153537020322800803; O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079; Ojha D, 2013, J APPL MICROBIOL, V115, P1317, DOI 10.1111/jam.12330; REED L. J., 1938, AMER JOUR HYG, V27, P493; Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663; Sekiya T, 2004, BIOCHEM BIOPH RES CO, V320, P680, DOI 10.1016/j.bbrc.2004.06.017; Sur TK, 2002, PHYTOTHER RES, V16, P669, DOI 10.1002/ptr.942; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Wang QY, 2005, P NATL ACAD SCI USA, V102, P16055, DOI 10.1073/pnas.0505850102; WHITTLE BA, 1964, BRIT J PHARM CHEMOTH, V22, P246, DOI 10.1111/j.1476-5381.1964.tb02030.x; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; WILLIAMS TJ, 1973, NATURE, V246, P215, DOI 10.1038/246215a0	47	12	13	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 25	2014	9	8							e104939	10.1371/journal.pone.0104939	http://dx.doi.org/10.1371/journal.pone.0104939			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN9TR	25153081	Green Published, Green Submitted, gold			2023-01-03	WOS:000340952200031
J	Rhon, DI; Boyles, RB; Cleland, JA				Rhon, Daniel I.; Boyles, Robert B.; Cleland, Joshua A.			One-Year Outcome of Subacromial Corticosteroid Injection Compared With Manual Physical Therapy for the Management of the Unilateral Shoulder Impingement Syndrome	ANNALS OF INTERNAL MEDICINE			English	Article							FEAR-AVOIDANCE BELIEFS; QUALITY-OF-LIFE; PATIENT CHARACTERISTICS; MANIPULATIVE THERAPY; MULTIPLE IMPUTATION; GENERAL-PRACTICE; MEDICAL-CARE; DOUBLE-BLIND; PAIN; PHYSIOTHERAPY	Background: Corticosteroid injections (CSIs) and physical therapy are used to treat patients with the shoulder impingement syndrome (SIS) but have never been directly compared. Objective: To compare the effectiveness of 2 common nonsurgical treatments for SIS. Design: Randomized, single-blind, comparative-effectiveness, parallel-group trial. (ClinicalTrials.gov: NCT01190891) Setting: Military hospital-based outpatient clinic in the United States. Patients: 104 patients aged 18 to 65 years with unilateral SIS between June 2010 and March 2012. Intervention: Random assignment into 2 groups: 40-mg triamcinolone acetonide subacromial CSI versus 6 sessions of manual physical therapy. Measurements: The primary outcome was change in Shoulder Pain and Disability Index scores at 1 year. Secondary outcomes included the Global Rating of Change scores, the Numeric Pain Rating Scale scores, and 1-year health care use. Results: Both groups demonstrated approximately 50% improvement in Shoulder Pain and Disability Index scores maintained through 1 year; however, the mean difference between groups was not significant (1.5% [95% CI, -6.3% to 9.4%]). Both groups showed improvements in Global Rating of Change scale and pain rating scores, but between-group differences in scores for the Global Rating of Change scale (0 [CI, -2 to 1]) and pain rating (0.4 [CI, -0.5 to 1.2]) were not significant. During the 1-year follow-up, patients receiving CSI had more SIS-related visits to their primary care provider (60% vs. 37%) and required additional steroid injections (38% vs. 20%), and 19% needed physical therapy. Transient pain from the CSI was the only adverse event reported. Limitation: The study occurred at 1 center with patients referred to physical therapy. Conclusion: Both groups experienced significant improvement. The manual physical therapy group used less 1-year SIS-related health care resources than the CSI group.	Madigan Army Med, Tacoma, WA USA; Univ Puget Sound, Tacoma, WA 98416 USA; Franklin Pierce Univ, Manchester, NH USA	Madigan Army Medical Center	Rhon, DI (corresponding author), Brooke Army Med Ctr, Ctr Intrepid, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.		Rhon, Daniel/C-9542-2011	Rhon, Daniel/0000-0002-4320-990X	Cardon Rehabilitation Products through the American Academy of Orthopaedic Manual Physical Therapists	Cardon Rehabilitation Products through the American Academy of Orthopaedic Manual Physical Therapists	Primary Funding Source: Cardon Rehabilitation Products through the American Academy of Orthopaedic Manual Physical Therapists.	ADEBAJO AO, 1990, J RHEUMATOL, V17, P1207; Akgun K, 2004, CLIN RHEUMATOL, V23, P496, DOI 10.1007/s10067-004-0930-7; Alvarez CM, 2005, AM J SPORT MED, V33, P255, DOI 10.1177/0363546504267345; [Anonymous], 2010, LANCET, V375, P1225, DOI 10.1016/S0140-6736(10)60523-5; [Anonymous], 1998, OBES RES, p51S; Arroll B, 2005, BRIT J GEN PRACT, V55, P224; Bang MD, 2000, J ORTHOP SPORT PHYS, V30, P126, DOI 10.2519/jospt.2000.30.3.126; Bergman GJD, 2004, ANN INTERN MED, V141, P432, DOI 10.7326/0003-4819-141-6-200409210-00008; Bisset L, 2006, BMJ-BRIT MED J, V333, P939, DOI 10.1136/bmj.38961.584653.AE; Bot SDM, 2005, SPINE, V30, pE459, DOI 10.1097/01.brs.0000174279.44855.02; Boyles RE, 2009, MANUAL THER, V14, P375, DOI 10.1016/j.math.2008.05.005; Buchbinder R, 2003, COCHRANE DATABASE SY; Calis M, 2000, ANN RHEUM DIS, V59, P44, DOI 10.1136/ard.59.1.44; Cho CH, 2013, J SHOULDER ELB SURG, V22, P222, DOI 10.1016/j.jse.2012.04.001; Conroy DE, 1998, J ORTHOP SPORT PHYS, V28, P3, DOI 10.2519/jospt.1998.28.1.3; Coombes BK, 2013, JAMA-J AM MED ASSOC, V309, P461, DOI 10.1001/jama.2013.129; Coombes BK, 2010, LANCET, V376, P1751, DOI 10.1016/S0140-6736(10)61160-9; Fritz JM, 2001, PHYS THER, V81, P776, DOI 10.1093/ptj/81.2.776; Galgano RC, 2005, ANN INTERN MED, V142, P226, DOI 10.7326/0003-4819-142-3-200502010-00021; Gaujoux-Viala C, 2009, ANN RHEUM DIS, V68, P1843, DOI 10.1136/ard.2008.099572; Gebremariam L, 2013, BR J SPORTS MED; Gialanella B, 2011, PAIN MED, V12, P1559, DOI 10.1111/j.1526-4637.2011.01238.x; Graham JW, 2007, PREV SCI, V8, P206, DOI 10.1007/s11121-007-0070-9; Greving K, 2012, SCAND J RHEUMATOL, V41, P150, DOI 10.3109/03009742.2011.605390; Gruson KI, 2008, J SHOULDER ELB SURG, V17, p118S, DOI 10.1016/j.jse.2007.07.009; Hanchard NCA, 2013, COCHRANE DB SYST REV, V4; Hay EM, 2003, ANN RHEUM DIS, V62, P394, DOI 10.1136/ard.62.5.394; Helliwell PS, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c3037; Ho CYC, 2009, MANUAL THER, V14, P463, DOI 10.1016/j.math.2009.03.008; Huisstede BMA, 2007, OCCUP ENVIRON MED, V64, P313, DOI 10.1136/oem.2005.023861; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; James M, 2005, RHEUMATOLOGY, V44, P1447, DOI 10.1093/rheumatology/kei043; JENSEN MP, 1993, PAIN, V55, P195, DOI 10.1016/0304-3959(93)90148-I; JENSEN MP, 1994, PAIN, V58, P387, DOI 10.1016/0304-3959(94)90133-3; Johansson K, 2011, FAM PRACT, V28, P355, DOI 10.1093/fampra/cmq119; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Kachingwe AF, 2008, J MAN MANIP THER, V16, P238, DOI 10.1179/106698108790818314; Knapik JJ, 2001, MIL MED, V166, P641; Knapik JJ, 2002, MIL MED, V167, P593; Koester MC, 2007, J AM ACAD ORTHOP SUR, V15, P3, DOI 10.5435/00124635-200701000-00002; Kromer TO, 2009, J REHABIL MED, V41, P870, DOI 10.2340/16501977-0453; Laslett LL, 2007, CLIN EXP RHEUMATOL, V25, P422; LETHEM J, 1983, BEHAV RES THER, V21, P401, DOI 10.1016/0005-7967(83)90009-8; Lewis JS, 2012, J PHYSIOTHER, V58, P127, DOI 10.1016/S1836-9553(12)70093-0; Lozman P R, 1995, J South Orthop Assoc, V4, P177; Mall NA, 2013, AM J SPORT MED, V41, P2684, DOI 10.1177/0363546513485359; Michener LA, 2011, J SPORT REHABIL, V20, P115, DOI 10.1123/jsr.20.1.115; MILGROM C, 1995, J BONE JOINT SURG BR, V77B, P296, DOI 10.1302/0301-620X.77B2.7706351; Mintken PE, 2010, ARCH PHYS MED REHAB, V91, P1128, DOI 10.1016/j.apmr.2010.04.009; Penning LIF, 2012, J BONE JOINT SURG BR, V94B, P1246, DOI 10.1302/0301-620X.94B9.28750; PRICE DD, 1994, PAIN, V56, P217, DOI 10.1016/0304-3959(94)90097-3; Ramirez J, 2013, MOD RHEUMATOL; Rechardt M, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-165; Reuter RM, 2008, SKELETAL RADIOL, V37, P737, DOI 10.1007/s00256-008-0516-6; Rhon DI, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000137; Rigsby R, 2010, J ATHL TRAINING, V45, P404, DOI 10.4085/1062-6050-45.4.404; Roach K E, 1991, Arthritis Care Res, V4, P143, DOI 10.1002/art.1790040403; Roy JS, 2009, ARTHRIT RHEUM-ARTHR, V61, P623, DOI 10.1002/art.24396; Senbursa G, 2007, KNEE SURG SPORT TR A, V15, P915, DOI 10.1007/s00167-007-0288-x; SHER JS, 1995, J BONE JOINT SURG AM, V77A, P10, DOI 10.2106/00004623-199501000-00002; Sindhu BS, 2012, PHYS THER, V92, P992, DOI 10.2522/ptj.20110309; Spielmann AL, 1999, RADIOLOGY, V213, P705, DOI 10.1148/radiology.213.3.r99dc09705; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; Tallia AF, 2003, AM FAM PHYSICIAN, V67, P1271; Tashjian RZ, 2011, J AM ACAD ORTHOP SUR, V19, P380, DOI 10.5435/00124635-201106000-00008; Tekeoglu I, 2013, EUR REV MED PHARMACO, V17, P370; van der Sande R, 2013, ARCH PHYS MED REHAB, V94, P961, DOI 10.1016/j.apmr.2012.11.041; VANDERWINDT DAWM, 1995, ANN RHEUM DIS, V54, P959, DOI 10.1136/ard.54.12.959; Walch G, 1998, J BONE JOINT SURG BR, V80B, P624, DOI 10.1302/0301-620X.80B4.8651; WILLIAMS JW, 1995, J RHEUMATOL, V22, P727; Winters JC, 1997, BRIT MED J, V314, P1320, DOI 10.1136/bmj.314.7090.1320; Wofford JL, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-4; Yu Chung-Ming, 2006, Chang Gung Med J, V29, P474; Zwarenstein M, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2390	74	54	56	1	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 5	2014	161	3					161	U108		10.7326/M13-2199	http://dx.doi.org/10.7326/M13-2199			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AN3KH	25089860				2023-01-03	WOS:000340486000001
J	Yu, KR; Lee, JY; Kim, HS; Hong, IS; Choi, SW; Seo, Y; Kang, I; Kim, JJ; Lee, BC; Lee, S; Kurtz, A; Seo, KW; Kang, KS				Yu, Kyung-Rok; Lee, Jin Young; Kim, Hyung-Sik; Hong, In-Sun; Choi, Soon Won; Seo, Yoojin; Kang, Insung; Kim, Jae-Jun; Lee, Byung-Chul; Lee, SeungHee; Kurtz, Andreas; Seo, Kwang-Won; Kang, Kyung-Sun			A p38 MAPK-Mediated Alteration of COX-2/PGE(2) Regulates Immunomodulatory Properties in Human Mesenchymal Stem Cell Aging	PLOS ONE			English	Article							MARROW STROMAL CELLS; ACTIVATED PROTEIN-KINASE; IMMUNOSUPPRESSION; SENESCENCE; RESPONSES; COLITIS; PATHWAY; DISEASE; PROLIFERATION; MACROPHAGES	Because human mesenchymal stem cells (hMSC) have profound immunomodulatory effects, many attempts have been made to use hMSCs in preclinical and clinical trials. For hMSCs to be used in therapy, a large population of hMSCs must be generated by in vitro expansion. However, the immunomodulatory changes following the in vitro expansion of hMSCs have not been elucidated. In this study, we evaluated the effect of replicative senescence on the immunomodulatory ability of hMSCs in vitro and in vivo. Late-passage hMSCs showed impaired suppressive effect on mitogen-induced mononuclear cell proliferation. Strikingly, late-passage hMSCs had a significantly compromised protective effect against mouse experimental colitis, which was confirmed by gross and histologic examination. Among the anti-inflammatory cytokines, the production of prostaglandin E-2 (PGE(2)) and the expression of its primary enzyme, cyclooxygenase-2 (COX-2), were profoundly increased by pre-stimulation with interferon gamma (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha), and this response was significantly decreased with consecutive passages. We demonstrated that the impaired phosphorylation activity of p38 MAP kinase (p38 MAPK) in late-passage hMSCs led to a compromised immunomodulatory ability through the regulation of COX-2. In conclusion, our data indicate that the immunomodulatory ability of hMSCs gradually declines with consecutive passages via a p38-mediated alteration of COX-2 and PGE(2) levels.	[Yu, Kyung-Rok; Lee, Jin Young; Kim, Hyung-Sik; Hong, In-Sun; Choi, Soon Won; Seo, Yoojin; Kang, Insung; Kim, Jae-Jun; Lee, Byung-Chul; Lee, SeungHee; Kurtz, Andreas; Seo, Kwang-Won; Kang, Kyung-Sun] Seoul Natl Univ, Coll Vet Med, Adult Stem Cell Res Ctr, Seoul, South Korea; [Yu, Kyung-Rok; Lee, Jin Young; Hong, In-Sun; Choi, Soon Won; Seo, Yoojin; Kang, Insung; Kim, Jae-Jun; Lee, Byung-Chul; Kurtz, Andreas; Kang, Kyung-Sun] Seoul Natl Univ, Coll Vet Med, Vet Med Res Inst, Seoul, South Korea; [Kim, Hyung-Sik; Lee, SeungHee; Seo, Kwang-Won] Seoul Natl Univ, Biotechnol Incubating Ctr, Inst Stem Cell & Regenerat Med Kangstem Biotech, Seoul, South Korea; [Kurtz, Andreas] Berlin Brandenburg Ctr Regenerat Therapies, Berlin, Germany	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Seo, KW (corresponding author), Seoul Natl Univ, Coll Vet Med, Adult Stem Cell Res Ctr, Seoul, South Korea.	kwang_wons@hotmail.com; kangpub@snu.ac.kr	Yu, Kyung-Rok/AAR-6227-2021; Kang, Kyung-Sun/G-6205-2013; Seo, Kwang Won/AAB-4821-2020; Choi, Soon Won/S-3052-2017	Yu, Kyung-Rok/0000-0002-4685-3223; Seo, Kwang Won/0000-0003-1025-6133; Choi, Soon Won/0000-0001-8642-6093; Kurtz, Andreas/0000-0003-3301-6546; Lee, Jin Young/0000-0001-8559-7077	National Research Foundation (NRF) - Korean government [2012M3A9C6049716]; Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [A120176]; Research Institute for Veterinary Science, Seoul National University	National Research Foundation (NRF) - Korean government(Korean Government); Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea; Research Institute for Veterinary Science, Seoul National University	This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (No. 2012M3A9C6049716), a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A120176), and the Research Institute for Veterinary Science, Seoul National University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; ANDRE C, 1981, GUT, V22, P571, DOI 10.1136/gut.22.7.571; Banfi A, 2002, TISSUE ENG, V8, P901, DOI 10.1089/107632702320934001; Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007-0197; Chen BC, 1999, IMMUNOLOGY, V97, P124, DOI 10.1046/j.1365-2567.1999.00747.x; COOPER HS, 1993, LAB INVEST, V69, P238; Crisostomo PR, 2006, SHOCK, V26, P575, DOI 10.1097/01.shk.0000235087.45798.93; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Gruber HE, 2012, BIOTECH HISTOCHEM, V87, P303, DOI 10.3109/10520295.2011.649785; Gu ZF, 2012, CELL SIGNAL, V24, P2307, DOI 10.1016/j.cellsig.2012.07.012; Jung JW, 2010, CELL MOL LIFE SCI, V67, P1165, DOI 10.1007/s00018-009-0242-9; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Kim H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011608; Kim HS, 2013, GASTROENTEROLOGY, V145, P1392, DOI 10.1053/j.gastro.2013.08.033; Lee S, 2009, CELL PROLIFERAT, V42, P711, DOI 10.1111/j.1365-2184.2009.00633.x; Lin CS, 2012, STEM CELLS DEV, V21, P2770, DOI 10.1089/scd.2012.0176; Liu H, 2012, J CELL SCI, V125, P200, DOI 10.1242/jcs.093070; Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Ren GW, 2009, STEM CELLS, V27, P1954, DOI 10.1002/stem.118; Saklatvala J, 2004, CURR OPIN PHARMACOL, V4, P372, DOI 10.1016/j.coph.2004.03.009; Scruggs BA, 2013, STEM CELL TRANSL MED, V2, P797, DOI 10.5966/sctm.2013-0026; Shi YF, 2012, TRENDS IMMUNOL, V33, P136, DOI 10.1016/j.it.2011.11.004; Shi YF, 2010, CELL RES, V20, P510, DOI 10.1038/cr.2010.44; Spaggiari GM, 2008, BLOOD, V111, P1327, DOI 10.1182/blood-2007-02-074997; Spaggiari GM, 2009, BLOOD, V113, P6576, DOI 10.1182/blood-2009-02-203943; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; Wagner W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002213; Yang YB, 2007, J BIOL CHEM, V282, P36223, DOI 10.1074/jbc.M703079200; Yu KR, 2013, J CELL SCI, V126, P5422, DOI 10.1242/jcs.133314; Yu KR, 2013, GERONTOLOGY, V59, P557, DOI 10.1159/000353857; Yu KR, 2012, STEM CELLS, V30, P876, DOI 10.1002/stem.1052; Zaim M, 2012, ANN HEMATOL, V91, P1175, DOI 10.1007/s00277-012-1438-x	37	67	69	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2014	9	8							e102426	10.1371/journal.pone.0102426	http://dx.doi.org/10.1371/journal.pone.0102426			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM4GX	25090227	Green Published, Green Submitted, gold			2023-01-03	WOS:000339812700007
J	Millard, C; Brhlikova, P; Pollock, AM				Millard, Colin; Brhlikova, Petra; Pollock, Allyson M.			Commentary: Evidence versus influence in the WHO procedure for approving essential medicines: misoprostol for maternal health	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							POSTPARTUM HEMORRHAGE		[Millard, Colin; Brhlikova, Petra; Pollock, Allyson M.] Univ London, Global Hlth Policy & Innovat Unit, London, England	University of London	Millard, C (corresponding author), Univ London, Global Hlth Policy & Innovat Unit, London, England.	colin.millard@qmul.ac.uk		Brhlikova, Petra/0000-0003-2085-0304; pollock, allyson/0000-0002-7388-3110				Chu CS, 2012, J ROY SOC MED, V105, P336, DOI 10.1258/jrsm.2012.120044; Derman RJ, 2006, LANCET, V368, P1248, DOI 10.1016/S0140-6736(06)69522-6; Gynuity Health Projects, MIS POSTP HEM MOV RE; Hofmeyr GJ, 2013, COCHRANE DB SYST REV, V7; Hoj L, 2005, BMJ-BRIT MED J, V331, P723, DOI 10.1136/bmj.331.7519.723; Laing R, 2003, LANCET, V361, P1723, DOI 10.1016/S0140-6736(03)13375-2; Mobeen N, 2011, BJOG-INT J OBSTET GY, V118, P353, DOI 10.1111/j.1471-0528.2010.02807.x; Pollock AM, 2013, BJOG, V120, P287; Starrs A, 2012, INT J GYNECOL OBSTET, V116, P1, DOI 10.1016/j.ijgo.2011.10.005; Tuncalp O, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000494.pub4; Venture Strategies Innovations, 2009, REACH WOM THEY AR; Venture Strategies Innovations, 2011, CONN WOM CAR; Walraven G, 2005, BJOG-INT J OBSTET GY, V112, P1277, DOI 10.1111/j.1471-0528.2005.00711.x; WHO, 2012, SEL US ESS MED REP W; WHO Expert Committee on the Selection and Use of Essential Medicines, 2009, SEL US ESS MED REP W; World Health Organization, ESS MED SEL	16	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 31	2014	349								g4823	10.1136/bmj.g4823	http://dx.doi.org/10.1136/bmj.g4823			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AM5NW	25081251				2023-01-03	WOS:000339907800003
J	Xu, HY; Zhang, YQ; Lei, Y; Gao, XM; Zhai, HQ; Lin, N; Tang, SH; Liang, RX; Ma, Y; Li, DF; Zhang, Y; Zhu, GR; Yang, HJ; Huang, LQ				Xu, Haiyu; Zhang, Yanqiong; Lei, Yun; Gao, Xiumei; Zhai, Huaqiang; Lin, Na; Tang, Shihuan; Liang, Rixin; Ma, Yan; Li, Defeng; Zhang, Yi; Zhu, Guangrong; Yang, Hongjun; Huang, Luqi			A Systems Biology-Based Approach to Uncovering the Molecular Mechanisms Underlying the Effects of Dragon's Blood Tablet in Colitis, Involving the Integration of Chemical Analysis, ADME Prediction, and Network Pharmacology	PLOS ONE			English	Article							INTERACTION DATABASE; DAEMONOROPS-DRACO; ULCERATIVE-COLITIS; IDENTIFICATION; KNOWLEDGEBASE; PERMEABILITY; FLAVONOIDS; UPDATE; DRUGS; RESIN	Traditional Chinese medicine (TCM) is one of the oldest East Asian medical systems. The present study adopted a systems biology-based approach to provide new insights relating to the active constituents and molecular mechanisms underlying the effects of dragon's blood (DB) tablets for the treatment of colitis. This study integrated chemical analysis, prediction of absorption, distribution, metabolism, and excretion (ADME), and network pharmacology. Firstly, a rapid, reliable, and accurate ultra-performance liquid chromatography-electrospray ionization-tandem mass spectrometry method was employed to identify 48 components of DB tablets. In silico prediction of the passive absorption of these compounds, based on Caco-2 cell permeability, and their P450 metabolism enabled the identification of 22 potentially absorbed components and 8 metabolites. Finally, networks were constructed to analyze interactions between these DB components/metabolites absorbed and their putative targets, and between the putative DB targets and known therapeutic targets for colitis. This study provided a great opportunity to deepen the understanding of the complex pharmacological mechanisms underlying the effects of DB in colitis treatment.	[Xu, Haiyu; Zhang, Yanqiong; Lei, Yun; Gao, Xiumei; Lin, Na; Tang, Shihuan; Liang, Rixin; Ma, Yan; Li, Defeng; Zhang, Yi; Yang, Hongjun] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China; [Xu, Haiyu; Huang, Luqi] China Acad Chinese Med Sci, Natl Resource Ctr Chinese Mat Med, Beijing, Peoples R China; [Lei, Yun; Zhai, Huaqiang] Beijing Univ Chinese Med, Beijing, Peoples R China; [Gao, Xiumei] Tianjin Univ Tradit Chinese Med, Tianjin, Peoples R China; [Zhu, Guangrong] Yunnan Datang Hanfang Pharm Co Ltd, Simao, Yunnan, Peoples R China	China Academy of Chinese Medical Sciences; Institute of Chinese Materia Medica, CACMS; China Academy of Chinese Medical Sciences; National Resource Center for Chinese Materia Medica, CACMS; Beijing University of Chinese Medicine; Tianjin University of Traditional Chinese Medicine	Yang, HJ (corresponding author), China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China.	hongjun0420@vip.sina.com; huangluqi@263.net	MA, YAN/HHN-2912-2022	Tang, Shihuan/0000-0003-0589-4499	Key Projects in the National Science Technology [2008BAI51B03]; National Natural Science Foundation of China [81202793]; Beijing Joint Project Specific Funds; Operational expenses for basic research of China Academy of Chinese Medical Sciences [Z02063]; Fundamental Research Funds for the Central public welfare research institutes [ZZ070819, ZZ070831, ZZ070830]	Key Projects in the National Science Technology; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Joint Project Specific Funds; Operational expenses for basic research of China Academy of Chinese Medical Sciences; Fundamental Research Funds for the Central public welfare research institutes	Financial support was provided by Key Projects in the National Science & Technology Pillar Program during the 11th Five-Year Plan Period (No. 2008BAI51B03), the National Natural Science Foundation of China (No. 81202793), Beijing Joint Project Specific Funds and independent topics supported by Operational expenses for basic research of China Academy of Chinese Medical Sciences (No. Z02063), Beijing Joint Project Specific Funds and the Fundamental Research Funds for the Central public welfare research institutes (Nos. ZZ070819, ZZ070831 and ZZ070830). Support was also provided in the form of salary for Guangrong Zhu as an employee at Datang Hanfang Pharmacy co.ltd. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aranda B, 2010, NUCLEIC ACIDS RES, V38, pD525, DOI 10.1093/nar/gkp878; ARNONE A, 1990, J CHEM SOC PERK T 1, P2637, DOI 10.1039/p19900002637; ARTURSSON P, 1991, BIOCHEM BIOPH RES CO, V175, P880, DOI 10.1016/0006-291X(91)91647-U; Azuaje FJ, 2011, SCI REP-UK, V1, DOI 10.1038/srep00052; Badib AS, 1991, MED PLANTS YEMEN MAK, P15; Barnes Patricia M, 2004, Adv Data, P1; Baumer U, 2010, ANAL BIOANAL CHEM, V397, P1363, DOI 10.1007/s00216-010-3620-0; Beuming T, 2005, BIOINFORMATICS, V21, P827, DOI 10.1093/bioinformatics/bti098; Brown KR, 2005, BIOINFORMATICS, V21, P2076, DOI 10.1093/bioinformatics/bti273; Ceol A, 2010, NUCLEIC ACIDS RES, V38, pD532, DOI 10.1093/nar/gkp983; Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939; Chen JY, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-S1-S16; De Marino S, 2008, MOLECULES, V13, P1219, DOI 10.3390/molecules13061219; Feng SH, 2011, WORLD J INTEGRA TRAD, V6, P496; Guillarme D, 2010, TRAC-TREND ANAL CHEM, V29, P15, DOI 10.1016/j.trac.2009.09.008; Horwitz Bruce, 2005, J Pediatr Gastroenterol Nutr, V40 Suppl 1, pS22, DOI 10.1097/00005176-200504001-00012; Hu WB, 2011, J PRAC TRAD CHIN MED, V25, P56; Lehne Benjamin, 2009, Human Genomics, V3, P291; Li S, 2007, IET SYST BIOL, V1, P51, DOI 10.1049/iet-syb:20060032; Li S, 2011, HERBBIOMAP DATABASE; Lv RX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086692; Matthews L, 2009, NUCLEIC ACIDS RES, V37, pD619, DOI 10.1093/nar/gkn863; Michalski A, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.011015; Milbum M., 1984, AFRICA, V39, P486; NASINI G, 1981, PHYTOCHEMISTRY, V20, P514, DOI 10.1016/S0031-9422(00)84180-1; National Medical Products Administration, 2006, NOT PRINT DISTR SPEC; PIOZZI F, 1974, PHYTOCHEMISTRY, V13, P2231, DOI 10.1016/0031-9422(74)85033-8; Ponce YM, 2004, J PHARM PHARM SCI, V7, P186; Ponce YM, 2003, INT J MOL SCI, V4, P512, DOI 10.3390/i4080512; Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892; Rubino SJ, 2012, CURR OPIN IMMUNOL, V24, P398, DOI 10.1016/j.coi.2012.04.010; Shen CC, 2007, NAT PROD RES, V21, P377, DOI 10.1080/14786410701194575; Shi JM, 2009, J SEP SCI, V32, P4040, DOI 10.1002/jssc.200900392; Sikander A, 2010, CLIN CHIM ACTA, V411, P59, DOI 10.1016/j.cca.2009.10.003; State Pharmacopoeia Committee, 2010, PHARM PEOPL REP CHIN, P133; Tao Y, 2013, J CHROMATOGR B, V935, P1, DOI 10.1016/j.jchromb.2013.07.015; The Editorial Committee, 1999, MAT MED CHIN, V8, P455; Theodoridis GA, 2012, ANAL CHIM ACTA, V711, P7, DOI 10.1016/j.aca.2011.09.042; Tomasello G, 2011, EUR J HISTOCHEM, V55, P210, DOI 10.4081/ejh.2011.e38; U.S. Department of Health and Human Services FDA, 2000, CTR DRUG EV RES CDER, P1; WANG Y, 2012, EVID-BASED COMPL ALT, V2012, DOI DOI 10.1155/2012/698531; Wangensteen H, 2013, NUTRIENTS, V5, P1757, DOI 10.3390/nu5051757; Wine E, 2013, J CROHNS COLITIS, V7, P916, DOI 10.1016/j.crohns.2012.12.012; Wixon J, 2000, YEAST, V17, P48, DOI 10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H; Wuchty S, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-24; Xu HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081135; Xu HY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/658531; Yazdanian M, 1998, PHARMACEUT RES, V15, P1490, DOI 10.1023/A:1011930411574; Yi T, 2012, CHEM CENT J, V6, DOI 10.1186/1752-153X-6-116; Zhang B, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/456747; Zhang GB, 2013, EVID-BASED COMPL ALT, V2013, P1, DOI DOI 10.1016/J.MATCHAR.2013.04.007; Zhang J, 2010, BIOORG MED CHEM LETT, V20, P718, DOI 10.1016/j.bmcl.2009.11.073; Zhang Y., 2013, MATH PROB ENG, V2013, DOI DOI 10.4018/JIIT.2013010101; Zhou LM, 2009, INT J PHARMACEUT, V379, P109, DOI 10.1016/j.ijpharm.2009.06.016; Zhu F, 2012, NUCLEIC ACIDS RES, V40, pD1128, DOI 10.1093/nar/gkr797; Zhu ZY, 2012, J CLIN MED PRAC, V16, P47	57	33	46	1	61	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2014	9	7							e101432	10.1371/journal.pone.0101432	http://dx.doi.org/10.1371/journal.pone.0101432			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6RZ	25068885	Green Published, gold, Green Submitted			2023-01-03	WOS:000339993700002
J	Aitken, SL; Joseph, TB; Shah, DN; Lasco, TM; Palmer, HR; DuPont, HL; Xie, Y; Garey, KW				Aitken, Samuel L.; Joseph, Tiby B.; Shah, Dhara N.; Lasco, Todd M.; Palmer, Hannah R.; DuPont, Herbert L.; Xie, Yang; Garey, Kevin W.			Healthcare Resource Utilization for Recurrent Clostridium difficile Infection in a Large University Hospital in Houston, Texas	PLOS ONE			English	Article							EPIDEMIOLOGY; DISEASE; COSTS	Background: There are limited data examining healthcare resource utilization in patients with recurrent Clostridium difficile infection (CDI). Methods: Patients with CDI at a tertiary-care hospital in Houston, TX, were prospectively enrolled into an observational cohort study. Recurrence was assessed via follow-up phone calls. Patients with one or more recurrence were included in this study. The location at which healthcare was obtained by patients with recurrent CDI was identified along with hospital length of stay. CDI-attributable readmissions, defined as a positive toxin test within 48 hours of admission and a primary CDI diagnosis, were also assessed. Results: 372 primary cases of CDI were identified of whom 64 (17.2%) experienced at least one CDI recurrence. Twelve of 64 patients experienced 18 further episodes of CDI recurrence. Of these 64 patients, 33 (50.8%) patients with recurrent CDI were readmitted of which 6 (18.2%) required ICU care, 29 (45.3%) had outpatient care only, and 2 (3.1%) had an ED visit. Nineteen (55.9%) readmissions were defined as CDI-attributable. For patients with CDI-attributable readmission, the average length of stay was 666 days. Conclusion: Recurrent CDI leads to significant healthcare resource utilization. Methods of reducing the burden of recurrent CDI should be further studied.	[Aitken, Samuel L.; Shah, Dhara N.; DuPont, Herbert L.; Garey, Kevin W.] Univ Houston, Coll Pharm, Houston, TX 77030 USA; [Aitken, Samuel L.; Joseph, Tiby B.; Shah, Dhara N.; Lasco, Todd M.; Palmer, Hannah R.; DuPont, Herbert L.; Garey, Kevin W.] Baylor St Lukes Med Ctr, Houston, TX USA; [DuPont, Herbert L.; Garey, Kevin W.] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA; [DuPont, Herbert L.] Baylor Coll Med, Houston, TX 77030 USA; [Xie, Yang] Merck & Co Inc, Whitehouse Stn, NJ USA	University of Houston System; University of Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Baylor College of Medicine; Merck & Company	Garey, KW (corresponding author), Univ Houston, Coll Pharm, Houston, TX 77030 USA.	kgarey@uh.edu	Garey, Kevin/AAH-5540-2019; DuPont, Herbert/AAH-6776-2021; Aitken, Samuel/J-5045-2019	Garey, Kevin/0000-0003-2063-7503; Aitken, Samuel/0000-0002-8659-4238; Lasco, Todd/0000-0002-5405-7067	Cubist Pharmaceuticals; Summit Pharmaceuticals International; Merck Co.; Glaxo-Smith-Kline	Cubist Pharmaceuticals; Summit Pharmaceuticals International; Merck Co.(Merck & Company); Glaxo-Smith-Kline(GlaxoSmithKline)	KWG reports receiving research support from Cubist Pharmaceuticals, Summit Pharmaceuticals International, and Merck & Co. DNS reports ongoing research support from Cubist Pharmaceuticals and Merck & Co. HLD receives research support from Glaxo-Smith-Kline and Merck & Co. XY is an employee of Merck & Co. All other authors have no potential conflicts of interest to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.	BARBUT F, 1993, J CLIN MICROBIOL, V31, P963, DOI 10.1128/JCM.31.4.963-967.1993; Cohen SH, 2010, INFECT CONT HOSP EP, V31, P431, DOI 10.1086/651706; Dubberke ER, 2008, CLIN INFECT DIS, V46, P497, DOI 10.1086/526530; Dubberke ER, 2014, INFECT CONT HOSP EP, V35, P628, DOI [10.1086/676023, 10.1017/S0899823X00193857]; Eyre DW, 2012, CLIN INFECT DIS, V55, pS77, DOI 10.1093/cid/cis356; Friedman B, 2004, MED CARE RES REV, V61, P225, DOI 10.1177/1077558704263799; Ghantoji SS, 2010, J HOSP INFECT, V74, P309, DOI 10.1016/j.jhin.2009.10.016; Jardin CGM, 2013, J HOSP INFECT, V85, P28, DOI 10.1016/j.jhin.2013.04.017; Kelly Ciaran P, 2008, N Engl J Med, V359, P1932, DOI 10.1056/NEJMra0707500; Kuntz JL, 2012, INFECT CONT HOSP EP, V33, P1031, DOI 10.1086/667733; McFarland LV, 1999, INFECT CONT HOSP EP, V20, P43, DOI 10.1086/501553; Zar FA, 2007, CLIN INFECT DIS, V45, P302, DOI 10.1086/519265	12	19	19	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2014	9	7							e102848	10.1371/journal.pone.0102848	http://dx.doi.org/10.1371/journal.pone.0102848			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO5BG	25057871	Green Submitted, gold, Green Published			2023-01-03	WOS:000341354800035
J	Russo, RIC; Beguelin, W; Flaque, MCD; Proietti, CJ; Venturutti, L; Galigniana, N; Tkach, M; Guzman, P; Roa, JC; O'Brien, NA; Charreau, EH; Schillaci, R; Elizalde, PV				Cordo Russo, R. I.; Beguelin, W.; Diaz Flaque, M. C.; Proietti, C. J.; Venturutti, L.; Galigniana, N.; Tkach, M.; Guzman, P.; Roa, J. C.; O'Brien, N. A.; Charreau, E. H.; Schillaci, R.; Elizalde, P. V.			Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR RECEPTOR; PROGESTERONE-RECEPTOR; CYCLIN D1; CELL-PROLIFERATION; SIGNALING PATHWAYS; IN-VIVO; PI3K INHIBITOR; THERAPY; HER2	Membrane overexpression of ErbB-2/HER2 receptor tyrosine kinase (membrane ErbB-2 (MErbB-2)) has a critical role in breast cancer (BC). We and others have also shown the role of nuclear ErbB-2 (NErbB-2) in BC, whose presence we identified as a poor prognostic factor in MErbB-2-positive tumors. Current anti-ErbB-2 therapies, as with the antibody trastuzumab (Ttzm), target only MErbB-2. Here, we found that blockade of NErbB-2 action abrogates growth of BC cells, sensitive and resistant to Ttzm, in a scenario in which ErbB-2, ErbB-3 and Akt are phosphorylated, and ErbB-2/ErbB-3 dimers are formed. Also, inhibition of NErbB-2 presence suppresses growth of a preclinical BC model resistant to Ttzm. We showed that at the cyclin D1 promoter, ErbB-2 assembles a transcriptional complex with Stat3 (signal transducer and activator of transcription 3) and ErbB-3, another member of the ErbB family, which reveals the first nuclear function of ErbB-2/ErbB-3 dimer. We identified NErbB-2 as the major proliferation driver in Ttzm-resistant BC, and demonstrated that Ttzm inability to disrupt the Stat3/ErbB-2/ErbB-3 complex underlies its failure to inhibit growth. Furthermore, our results in the clinic revealed that nuclear interaction between ErbB-2 and Stat3 correlates with poor overall survival in primary breast tumors. Our findings challenge the paradigm of anti-ErbB-2 drug design and highlight NErbB-2 as a novel target to overcome Ttzm resistance.	[Cordo Russo, R. I.; Beguelin, W.; Diaz Flaque, M. C.; Proietti, C. J.; Venturutti, L.; Galigniana, N.; Tkach, M.; Charreau, E. H.; Schillaci, R.; Elizalde, P. V.] Consejo Nacl Invest Cient & Tecn, Lab Mol Mech Carcinogenesis, Inst Biol & Med Expt IBYME, RA-1428 Buenos Aires, DF, Argentina; [Guzman, P.; Roa, J. C.] Univ La Frontera, Dept Anat Patol BIOREN, Temuco, Chile; [O'Brien, N. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; Universidad de La Frontera; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Elizalde, PV (corresponding author), Consejo Nacl Invest Cient & Tecn, Lab Mol Mech Carcinogenesis, Inst Biol & Med Expt IBYME, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	patriciaelizalde@ibyme.conicet.gov.ar	Russo, Rosalia Cordo/O-9149-2017; Roa, Juan C./K-4749-2014	Russo, Rosalia Cordo/0000-0002-5984-9717; Roa, Juan C./0000-0001-8313-8774; Elizalde, Patricia V./0000-0002-5923-9898; Galigniana, Natalia/0000-0002-0712-719X; Schillaci, Roxana/0000-0002-7776-3378; Diaz Flaque, Maria Celeste/0000-0003-4167-6149	Susan G Komen for the Cure investigator-initiated research Grant [KG090250]; National Agency of Scientific Promotion of Argentina [IDB/PICT 2012-668, PID 2012-066, IDB/PICT 2012-382]; Henry Moore Institute of Argentina [CONICET 1819/03]	Susan G Komen for the Cure investigator-initiated research Grant; National Agency of Scientific Promotion of Argentina(ANPCyT); Henry Moore Institute of Argentina	We thank Mien-Chie Hung (MD Anderson Cancer Center, Houston, TX, USA) for his generous gift of the hErbB-2.NLS, which indeed made this work possible, and AA Molinolo (NIH, Bethesda, MD, USA) for his constant help and support. We also thank J Giudice (Baylor College of Medicine, Houston, TX, USA) for help with quantification of confocal images, and V Chiauzzi for her excellent technical assistance. This work was supported by the Susan G Komen for the Cure KG090250 investigator-initiated research Grant, IDB/PICT 2012-668 and PID 2012-066 from the National Agency of Scientific Promotion of Argentina (all of them awarded to PVE), IDB/PICT 2012-382 from the National Agency of Scientific Promotion of Argentina (awarded to RS) and Oncomed-Reno CONICET 1819/03, from the Henry Moore Institute of Argentina (awarded to PVE and RS).	Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Andrique L, 2012, CELL SIGNAL, V24, P1074, DOI 10.1016/j.cellsig.2012.01.002; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Balana ME, 1999, ONCOGENE, V18, P6370, DOI 10.1038/sj.onc.1203028; Beguelin W, 2010, MOL CELL BIOL, V30, P5456, DOI 10.1128/MCB.00012-10; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Brand TM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071518; Breuleux M, 2006, MOL CANCER RES, V4, P27, DOI 10.1158/1541-7786.MCR-05-0016; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Browne BC, 2009, CURR CANCER DRUG TAR, V9, P419, DOI 10.2174/156800909788166484; Chiu CG, 2010, ANN SURG, V251, P1107, DOI 10.1097/SLA.0b013e3181dbb77e; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Flaque MCD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3587; Diermeier S, 2005, EXP CELL RES, V304, P604, DOI 10.1016/j.yexcr.2004.12.008; Dolled-Filhart M, 2003, CLIN CANCER RES, V9, P594; Esteva FJ, 2002, J CLIN ONCOL, V20, P1800, DOI 10.1200/JCO.2002.07.058; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Ghosh R, 2011, CANCER RES, V71, P1871, DOI 10.1158/0008-5472.CAN-10-1872; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Henderson IC, 1998, BREAST CANCER RES TR, V52, P261, DOI 10.1023/A:1006141703224; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hsieh AC, 2007, BRIT J CANCER, V97, P453, DOI 10.1038/sj.bjc.6603910; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Kataoka Y, 2010, ANN ONCOL, V21, P255, DOI 10.1093/annonc/mdp304; Koninki K, 2010, CANCER LETT, V294, P211, DOI 10.1016/j.canlet.2010.02.002; Koumakpayi IH, 2006, CLIN CANCER RES, V12, P2730, DOI 10.1158/1078-0432.CCR-05-2242; Labriola L, 2003, MOL CELL BIOL, V23, P1095, DOI 10.1128/MCB.23.3.1095-1111.2003; Landgraf R, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1633; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Lenferink AEG, 2001, CANCER RES, V61, P6583; Leow CC, 2009, MOL CANCER THER, V8, P2131, DOI 10.1158/1535-7163.MCT-08-1038; Leslie K, 2006, CANCER RES, V66, P2544, DOI 10.1158/0008-5472.CAN-05-2203; Li LY, 2011, CANCER RES, V71, P4269, DOI 10.1158/0008-5472.CAN-10-3504; Li WL, 1996, ONCOGENE, V12, P2473; Maegawa M, 2007, MOL CANCER RES, V5, P393, DOI 10.1158/1541-7786.MCR-06-0303; Marshall C, 2006, BREAST CANCER RES TR, V96, P163, DOI 10.1007/s10549-005-9073-z; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; O'Brien NA, 2010, MOL CANCER THER, V9, P1489, DOI 10.1158/1535-7163.MCT-09-1171; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; Ostrander JH, 2007, CANCER RES, V67, P4199, DOI 10.1158/0008-5472.CAN-06-3409; Proietti CJ, 2009, MOL CELL BIOL, V29, P1249, DOI 10.1128/MCB.00853-08; Rexer Brent N., 2012, Critical Reviews in Oncogenesis, V17, P1; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Rivas MA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3187; Rivas MA, 2010, BREAST CANCER RES TR, V122, P111, DOI 10.1007/s10549-009-0546-3; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Rusnak DW, 2001, MOL CANCER THER, V1, P85; Salatino M, 2004, ONCOGENE, V23, P5161, DOI 10.1038/sj.onc.1207659; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Schillaci R, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-74; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith I, 2007, LANCET, V369, P29, DOI 10.1016/S0140-6736(07)60028-2; Tanner M, 2004, MOL CANCER THER, V3, P1585; Tao RH, 2008, J CELL SCI, V121, P3207, DOI 10.1242/jcs.033399; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Wang YC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3067; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yakes FM, 2002, CANCER RES, V62, P4132; Yao E, 2009, CLIN CANCER RES, V15, P4147, DOI 10.1158/1078-0432.CCR-08-2814	67	39	40	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3413	3428		10.1038/onc.2014.272	http://dx.doi.org/10.1038/onc.2014.272			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25174405	Green Published			2023-01-03	WOS:000356871700007
J	Spasojevic, M; Paredes-Juarez, GA; Vorenkamp, J; de Haan, BJ; Schouten, AJ; de Vos, P				Spasojevic, Milica; Paredes-Juarez, Genaro A.; Vorenkamp, Joop; de Haan, Bart J.; Schouten, Arend Jan; de Vos, Paul			Reduction of the Inflammatory Responses against Alginate-Poly-L-Lysine Microcapsules by Anti-Biofouling Surfaces of PEG-b-PLL Diblock Copolymers	PLOS ONE			English	Article							MICROENCAPSULATED PANCREATIC-ISLETS; MOLECULAR-WEIGHT CUTOFF; POLYLYSINE MICROCAPSULES; FIBROTIC OVERGROWTH; HOST-REACTION; RAT ISLETS; IN-VIVO; CELLS; BIOCOMPATIBILITY; CAPSULES	Large-scale application of alginate-poly-L-lysine (alginate-PLL) capsules used for microencapsulation of living cells is hampered by varying degrees of success, caused by tissue responses against the capsules in the host. A major cause is proinflammatory PLL which is applied at the surface to provide semipermeable properties and immunoprotection. In this study, we investigated whether application of poly(ethylene glycol)-block-poly(L-lysine hydrochloride) diblock copolymers (PEG-b-PLL) can reduce the responses against PLL on alginate-matrices. The application of PEG-b-PLL was studied in two manners: (i) as a substitute for PLL or (ii) as an anti-biofouling layer on top of a proinflammatory, but immunoprotective, semipermeable alginate-PLL100 membrane. Transmission FTIR was applied to monitor the binding of PEG-b-PLL. When applied as a substitute for PLL, strong host responses in mice were observed. These responses were caused by insufficient binding of the PLL block of the diblock copolymers confirmed by FTIR. When PEG-b-PLL was applied as an anti-biofouling layer on top of PLL100 the responses in mice were severely reduced. Building an effective anti-biofouling layer required 50 hours as confirmed by FTIR, immunocytochemistry and XPS. Our study provides new insight in the binding requirements of polyamino acids necessary to provide an immunoprotective membrane. Furthermore, we present a relatively simple method to mask proinflammatory components on the surface of microcapsules to reduce host responses. Finally, but most importantly, our study illustrates the importance of combining physicochemical and biological methods to understand the complex interactions at the capsules' surface that determine the success or failure of microcapsules applicable for cell-encapsulation.	[Spasojevic, Milica; Vorenkamp, Joop; Schouten, Arend Jan] Univ Groningen, Dept Polymer Chem, Zernike Inst Adv Mat, NL-9747 AG Groningen, Netherlands; [Spasojevic, Milica; Paredes-Juarez, Genaro A.; de Haan, Bart J.; de Vos, Paul] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol, Groningen, Netherlands; [Spasojevic, Milica; Paredes-Juarez, Genaro A.; de Haan, Bart J.; de Vos, Paul] Univ Groningen, Univ Med Ctr Groningen, Dept Lab Med, Sect Med Biol,Div Immunoendocrinol, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	de Vos, P (corresponding author), Univ Groningen, Dept Pathol, Groningen, Netherlands.	P.de.Vos@umcg.nl	Institute, Zernike/W-7033-2019; de Vos, Paul/A-3170-2013; Paredes, Genaro A/R-6633-2016	Paredes, Genaro A/0000-0002-6621-7830; de vos, paul/0000-0001-9618-2408	Kollf institute; Juvenile Diabetes research foundation	Kollf institute; Juvenile Diabetes research foundation(Juvenile Diabetes Research Foundation)	This work was supported by a project from The Kollf institute and the Juvenile Diabetes research foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AEBISCHER P, 1994, EXP NEUROL, V126, P151, DOI 10.1006/exnr.1994.1053; Basta G, 2004, TRANSPL IMMUNOL, V13, P289, DOI 10.1016/j.trim.2004.10.003; Bruns H, 2013, CLIN TRANSPLANT, V27, P30, DOI 10.1111/ctr.12153; Bunger CM, 2005, BIOMATERIALS, V26, P2353, DOI 10.1016/j.biomaterials.2004.07.017; BYSTRICKY S, 1991, CARBOHYD POLYM, V15, P299, DOI 10.1016/0144-8617(91)90044-D; CHANG PL, 1993, HUM GENE THER, V4, P433, DOI 10.1089/hum.1993.4.4-433; CIESLINSKI DA, 1994, BIOTECHNOL BIOENG, V43, P678, DOI 10.1002/bit.260430718; COLTON CK, 1995, CELL TRANSPLANT, V4, P415, DOI 10.1016/0963-6897(95)00025-S; COROMILI V, 1993, BIOMAT ARTIF CELL IM, V21, P427, DOI 10.3109/10731199309117382; de Haan BJ, 2011, J BIOMED MATER RES A, V98A, P394, DOI 10.1002/jbm.a.33123; de Haan BJ, 2003, CELL TRANSPLANT, V12, P617, DOI 10.3727/000000003108747226; De Haan BJ, 2002, BIOTECHNIQUES, V32, P612, DOI 10.2144/02323rr03; De Vos P, 1999, DIABETES, V48, P1381, DOI 10.2337/diabetes.48.7.1381; de Vos P, 2002, J BIOMED MATER RES, V62, P430, DOI 10.1002/jbm.10345; de Vos P, 2003, DIABETOLOGIA, V46, P666, DOI 10.1007/s00125-003-1087-7; de Vos P, 2003, BIOMATERIALS, V24, P305, DOI 10.1016/S0142-9612(02)00319-8; de Vos P, 2002, J BIOMED MATER RES, V60, P252, DOI 10.1002/jbm.10060; de Vos P, 2007, J BIOMED MATER RES A, V80A, P813, DOI 10.1002/jbm.a.30979; de Vos P, 2006, BIOMATERIALS, V27, P5603, DOI 10.1016/j.biomaterials.2006.07.010; de Vos P, 2012, BIOMATERIALS, V33, P5552, DOI 10.1016/j.biomaterials.2012.04.039; de Vos P, 2009, BIOMATERIALS, V30, P2559, DOI 10.1016/j.biomaterials.2009.01.014; DEENEN GJ, 1987, J IMMUNOL, V139, P702; DeVos P, 1997, BIOMATERIALS, V18, P1085, DOI 10.1016/S0142-9612(97)00040-9; DeVos P, 1996, TRANSPLANTATION, V62, P888, DOI 10.1097/00007890-199610150-00003; DeVos P, 1996, TRANSPLANTATION, V62, P893, DOI 10.1097/00007890-199610150-00004; DeVos P, 1997, DIABETOLOGIA, V40, P262; DEVOS P, 1994, TRANSPLANT P, V26, P782; DeVos P, 1997, BIOMATERIALS, V18, P273, DOI 10.1016/S0142-9612(96)00135-4; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; Goto Y, 2008, BIOMACROMOLECULES, V9, P828, DOI 10.1021/bm701161d; Hesse M.S., 1997, STARCH STARKE, V49, P257, DOI [10.1002/star.19970490613, DOI 10.1002/STAR.19970490613]; Holland NB, 1998, NATURE, V392, P799, DOI 10.1038/33894; HUNIG T, 1989, J EXP MED, V169, P73, DOI 10.1084/jem.169.1.73; KING GA, 1987, BIOTECHNOL PROGR, V3, P231, DOI 10.1002/btpr.5420030407; KOO J, 1993, INT J ARTIF ORGANS, V16, P557, DOI 10.1177/039139889301600710; Leblond FA, 1996, BIOMATERIALS, V17, P2097, DOI 10.1016/0142-9612(96)00027-0; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; LIU HW, 1993, HUM GENE THER, V4, P291, DOI 10.1089/hum.1993.4.3-291; Omer A, 2003, XENOTRANSPLANTATION, V10, P240, DOI 10.1034/j.1399-3089.2003.01150.x; Orive G, 2006, BIOMATERIALS, V27, P3691, DOI 10.1016/j.biomaterials.2006.02.048; Orive G, 2005, J BIOMED MATER RES B, V74B, P429, DOI 10.1002/jbm.b.30146; Orive G, 2014, NAT MED, V20, P233, DOI 10.1038/nm.3486; Paredes-Juarez GA, 2013, J CONTROL RELEASE, V172, P983, DOI 10.1016/j.jconrel.2013.09.009; Ponce S, 2006, BIOMATERIALS, V27, P4831, DOI 10.1016/j.biomaterials.2006.05.014; Ratner BD, 2004, ANNU REV BIOMED ENG, V6, P41, DOI 10.1146/annurev.bioeng.6.040803.140027; Robitaille R, 2000, J BIOMED MATER RES, V50, P420, DOI 10.1002/(SICI)1097-4636(20000605)50:3<420::AID-JBM17>3.0.CO;2-S; Rokstad AM, 2013, BIOMATERIALS, V34, P621, DOI 10.1016/j.biomaterials.2012.10.012; Rokstad AM, 2011, ACTA BIOMATER, V7, P2566, DOI 10.1016/j.actbio.2011.03.011; Rokstad AMA, 2014, ADV DRUG DELIVER REV, V67-68, P111, DOI 10.1016/j.addr.2013.07.010; SAWHNEY AS, 1993, BIOMATERIALS, V14, P1008, DOI 10.1016/0142-9612(93)90194-7; SAWHNEY AS, 1992, BIOMATERIALS, V13, P863, DOI 10.1016/0142-9612(92)90180-V; SKJAKBRAEK G, 1989, BIOTECHNOL BIOENG, V33, P90, DOI 10.1002/bit.260330112; Smelt MJ, 2012, PANCREAS, V41, P39, DOI 10.1097/MPA.0b013e31821fc90c; Sobol M, 2013, J BIOMED MATER RES A, V101, P1907, DOI 10.1002/jbm.a.34500; Spasojevic M, 2014, J BIOMED MATER RES A, V102, P1887, DOI 10.1002/jbm.a.34863; STOKKE BT, 1991, MACROMOLECULES, V24, P4637, DOI 10.1021/ma00016a026; Strand BL, 2001, CELL TRANSPLANT, V10, P263, DOI 10.3727/000000001783986800; Tam SK, 2011, ACTA BIOMATER, V7, P1683, DOI 10.1016/j.actbio.2010.12.006; Tam SK, 2011, J BIOMED MATER RES A, V98A, P40, DOI 10.1002/jbm.a.33047; Tatarkiewicz K, 2001, DIABETOLOGIA, V44, P646, DOI 10.1007/s001250051672; Thu B, 1996, BIOMATERIALS, V17, P1031, DOI 10.1016/0142-9612(96)84680-1; Thu B, 1997, CARBOHYD RES, V297, P101, DOI 10.1016/S0008-6215(96)00257-1; Thu B, 1996, BIOMATERIALS, V17, P1069, DOI 10.1016/0142-9612(96)85907-2; ULUDAG H, 1993, CELL TRANSPLANT, V2, P175, DOI 10.1177/096368979300200210; Uludag H, 2000, ADV DRUG DELIVER REV, V42, P29, DOI 10.1016/S0169-409X(00)00053-3; van Hoogmoed CG, 2003, J BIOMED MATER RES A, V67A, P172, DOI 10.1002/jbm.a.10086; van Schilfgaarde R, 1999, J MOL MED-JMM, V77, P199, DOI 10.1007/s001090050336; VANDENBOSSCHE GMR, 1993, J PHARM PHARMACOL, V45, P115, DOI 10.1111/j.2042-7158.1993.tb03694.x; VANDENBOSSCHE GMR, 1993, J PHARM PHARMACOL, V45, P121, DOI 10.1111/j.2042-7158.1993.tb03695.x; VANDENBOSSCHE GMR, 1991, J PHARM PHARMACOL, V43, P275, DOI 10.1111/j.2042-7158.1991.tb06683.x; VANDENBOSSCHE GMR, 1993, BIOTECHNOL BIOENG, V42, P381, DOI 10.1002/bit.260420316; Weir GC, 2013, DIABETOLOGIA, V56, P1458, DOI 10.1007/s00125-013-2921-1; Xu Y, 2009, BIOMACROMOLECULES, V10, P267, DOI 10.1021/bm801279y	73	34	34	2	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2014	9	10							e109837	10.1371/journal.pone.0109837	http://dx.doi.org/10.1371/journal.pone.0109837			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AZ1JF	25347191	Green Published, gold			2023-01-03	WOS:000347994900014
J	Lieb, K; Scheurich, A				Lieb, Klaus; Scheurich, Armin			Contact between Doctors and the Pharmaceutical Industry, Their Perceptions, and the Effects on Prescribing Habits	PLOS ONE			English	Article							SALES REPRESENTATIVES; PHYSICIANS; BEHAVIOR; INFORMATION; HOUSESTAFF; ATTITUDES	Background: The prescribing behaviour of doctors is influenced by the pharmaceutical industry. This study investigated the extent to which contacts with pharmaceutical sales representatives (PSR) and the perception of these contacts influence prescribing habits. Method: An online questionnaire regarding contact with PSRs and perceptions of this contact was sent to 1,388 doctors, 11.5% (n = 160) of whom completed the survey. Individual prescribing data over a year (number of prescriptions, expenditure, and daily doses) for all on-patent branded, off-patent branded, and generic drugs were obtained from the Bavarian Association of Statutory Health Insurance Physicians. Results: 84% of the doctors saw PSR at least once a week, and 14% daily. 69% accepted drug samples, 39% accepted stationery and 37% took part in sponsored continuing medical education (CME) frequently. 5 physicians (3%) accepted no benefits at all. 43% of doctors believed that they received adequate and accurate information from PSRs frequently or always and 42% believed that their prescribing habits were influenced by PSR visits occasionally or frequently. Practices that saw PSRs frequently had significantly higher total prescriptions and total daily doses (but not expenditure) than practices that were less frequently visited. Doctors who believed that they received accurate information from PSRs showed higher expenditures on off-patent branded drugs (thus available as generics) and a lower proportion of generics. The eschewal of sponsored CME was associated with a lower proportion of on patent-branded drug prescriptions, lower expenditure on off-patent branded drug prescriptions and a higher proportion of generics. Acceptance of office stationery was associated with higher daily doses. Conclusions: Avoidance of industry-sponsored CME is associated with more rational prescribing habits. Furthermore, gift acceptance and the belief that one is receiving adequate information from a PSR are associated with changed prescribing habits. Further studies with larger sample sizes are needed.	[Lieb, Klaus; Scheurich, Armin] Univ Med Ctr Mainz, Dept Psychiat & Psychotherapy, Mainz, Germany	Johannes Gutenberg University of Mainz	Lieb, K (corresponding author), Univ Med Ctr Mainz, Dept Psychiat & Psychotherapy, Mainz, Germany.	klaus.lieb@unimedizin-mainz.de						AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; BECKER MH, 1972, MOL CRYST LIQ CRYST, V16, P118; Bowman M A, 1988, J Contin Educ Health Prof, V8, P13, DOI 10.1002/chp.4750080104; Caamano F, 2002, EUR J PUBLIC HEALTH, V12, P187, DOI 10.1093/eurpub/12.3.187; Campbell EG, 2007, NEW ENGL J MED, V356, P1742, DOI 10.1056/NEJMsa064508; Campbell EG, 2010, ARCH INTERN MED, V170, P1820, DOI 10.1001/archinternmed.2010.383; CHREN MM, 1994, JAMA-J AM MED ASSOC, V271, P684, DOI 10.1001/jama.271.9.684; Darlington RB, 1990, REGRESSION LINEAR MO, P249; Korzilius H, 2007, DTSCH ARZTEBLATT, V104, P143; Lexchin Joel, 2012, Mens Sana Monogr, V10, P143, DOI 10.4103/0973-1229.91294; Lieb K, 2010, DTSCH ARZTEBL INT, V107, P392, DOI 10.3238/arztebl.2010.0392; LURIE N, 1990, J GEN INTERN MED, V5, P240, DOI 10.1007/BF02600542; Mintzes B, 2013, J GEN INTERN MED, V28, P1368, DOI 10.1007/s11606-013-2411-7; ORLOWSKI JP, 1992, CHEST, V102, P270, DOI 10.1378/chest.102.1.270; Pronin E, 2004, PSYCHOL REV, V111, P781, DOI 10.1037/0033-295X.111.3.781; Rodwin MA, 2010, J LAW MED ETHICS, V38, P807, DOI 10.1111/j.1748-720X.2010.00534.x; Spurling GK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000352; Steinman MA, 2001, AM J MED, V110, P551, DOI 10.1016/S0002-9343(01)00660-X; Watkins C, 2003, QUAL SAF HEALTH CARE, V12, P29, DOI 10.1136/qhc.12.1.29	19	78	79	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2014	9	10							e110130	10.1371/journal.pone.0110130	http://dx.doi.org/10.1371/journal.pone.0110130			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AQ9XC	25330392	Green Published, gold, Green Submitted			2023-01-03	WOS:000343210800059
J	Amrein, K; Schnedl, C; Holl, A; Riedl, R; Christopher, KB; Pachler, C; Purkart, TU; Waltensdorfer, A; Munch, A; Warnkross, H; Stojakovic, T; Bisping, E; Toller, W; Smolle, KH; Berghold, A; Pieber, TR; Dobnig, H				Amrein, Karin; Schnedl, Christian; Holl, Alexander; Riedl, Regina; Christopher, Kenneth B.; Pachler, Christoph; Purkart, Tadeja Urbanic; Waltensdorfer, Andreas; Muench, Andreas; Warnkross, Helga; Stojakovic, Tatjana; Bisping, Egbert; Toller, Wolfgang; Smolle, Karl-Heinz; Berghold, Andrea; Pieber, Thomas R.; Dobnig, Harald			Effect of High-Dose Vitamin D-3 on Hospital Length of Stay in Critically Ill Patients With Vitamin D Deficiency The VITdAL-ICU Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLE-BLIND; D SUPPLEMENTATION; RISK; METAANALYSIS; ASSOCIATION; OUTCOMES; HEALTH	IMPORTANCE Low vitamin D status is linked to increased mortality and morbidity in patients who are critically ill. It is unknown if this association is causal. OBJECTIVE To investigate whether a vitamin D-3 treatment regimen intended to restore and maintain normal vitamin D status over 6 months is of health benefit for patients in ICUs. DESIGN, SETTING, AND PARTICIPANTS A randomized double-blind, placebo-controlled, single-center trial, conducted from May 2010 through September 2012 at 5 ICUs that included a medical and surgical population of 492 critically ill adult white patients with vitamin D deficiency (<= 20 ng/mL) assigned to receive either vitamin D-3 (n = 249) or a placebo (n = 243). INTERVENTIONS Vitamin D-3 or placebo was given orally or via nasogastric tube once at a dose of 540 000 IU followed by monthly maintenance doses of 90 000 IU for 5 months. MAIN OUTCOMES AND MEASURES The primary outcome was hospital length of stay. Secondary outcomes included, among others, length of ICU stay, the percentage of patients with 25-hydroxyvitamin D levels higher than 30 ng/mL at day 7, hospital mortality, and 6-month mortality. A predefined severe vitamin D deficiency (<= 12 ng/mL) subgroup analysis was specified before data unblinding and analysis. RESULTS A total of 475 patients were included in the final analysis (237 in the vitamin D-3 group and 238 in the placebo group). The median (IQR) length of hospital stay was not significantly different between groups (20.1 days [IQR, 11.1-33.3] for vitamin D-3 vs 19.3 days [IQR, 11.1-34.9] for placebo; P = .98). Hospital mortality and 6-month mortality were also not significantly different (hospital mortality: 28.3%[95% CI, 22.6%-34.5%] for vitamin D-3 vs 35.3%[95% CI, 29.2%-41.7%] for placebo; hazard ratio [HR], 0.81 [95% CI, 0.58-1.11]; P = .18; 6-month mortality: 35.0%[95% CI, 29.0%-41.5%] for vitamin D-3 vs 42.9%[95% CI, 36.5%-49.4%] for placebo; HR, 0.78 [95% CI, 0.58-1.04]; P = .09). For the severe vitamin D deficiency subgroup analysis (n = 200), length of hospital stay was not significantly different between the 2 study groups: 20.1 days (IQR, 12.9-39.1) for vitamin D-3 vs 19.0 days (IQR, 11.6-33.8) for placebo. Hospital mortality was significantly lower with 28 deaths among 98 patients (28.6%[95% CI, 19.9%-38.6%]) for vitamin D-3 compared with 47 deaths among 102 patients (46.1% [95% CI, 36.2%-56.2%]) for placebo (HR, 0.56 [95% CI, 0.35-0.90], P for interaction = .04), but not 6-month mortality (34.7%[95% CI, 25.4%-45.0%] for vitamin D-3 vs 50.0%[95% CI, 39.9%-60.1%] for placebo; HR, 0.60 [95% CI, 0.39-0.93], P for interaction = .12). CONCLUSIONS AND RELEVANCE Among critically ill patients with vitamin D deficiency, administration of high-dose vitamin D-3 compared with placebo did not reduce hospital length of stay, hospital mortality, or 6-month mortality. Lower hospital mortality was observed in the severe vitamin D deficiency subgroup, but this finding should be considered hypothesis generating and requires further study. Copyright 2014 American Medical Association. All rights reserved.	[Amrein, Karin; Schnedl, Christian; Warnkross, Helga; Pieber, Thomas R.; Dobnig, Harald] Med Univ Graz, Div Endocrinol & Metab, Dept Internal Med, A-8036 Graz, Austria; [Holl, Alexander] Med Univ Graz, Div Neurogeriatr, Dept Neurol, A-8036 Graz, Austria; [Riedl, Regina; Berghold, Andrea] Med Univ Graz, Inst Med Informat Stat & Documentat, A-8036 Graz, Austria; [Christopher, Kenneth B.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Renal, Boston, MA 02115 USA; [Pachler, Christoph; Waltensdorfer, Andreas; Muench, Andreas; Toller, Wolfgang] Med Univ Graz, Dept Anesthesiol & Intens Care Med, A-8036 Graz, Austria; [Purkart, Tadeja Urbanic] Med Univ Graz, Div Gen Neurol, Dept Neurol, A-8036 Graz, Austria; [Stojakovic, Tatjana] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, A-8036 Graz, Austria; [Bisping, Egbert] Med Univ Graz, Dept Internal Med, Div Cardiol, A-8036 Graz, Austria; [Smolle, Karl-Heinz] Med Univ Graz, Med Intens Care Unit, Dept Internal Med, A-8036 Graz, Austria; [Dobnig, Harald] Schilddrusen Endokrinol Osteoporose Inst Dobnig, Graz, Austria	Medical University of Graz; Medical University of Graz; Medical University of Graz; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Medical University of Graz; Medical University of Graz; Medical University of Graz; Medical University of Graz; Medical University of Graz	Amrein, K (corresponding author), Med Univ Graz, Div Endocrinol & Metab, Dept Internal Med, Auenbruggerpl 15, A-8036 Graz, Austria.	karin.amrein@medunigraz.at	Christopher, Kenneth B./C-5243-2012; Christopher, Kenneth/AAD-6801-2021	Christopher, Kenneth B./0000-0001-6067-972X; Christopher, Kenneth/0000-0001-6067-972X; Pieber, Thomas/0000-0003-3554-0405; Amrein, Karin/0000-0003-0915-085X	European Society for Clinical Nutrition and Metabolism (ESPEN); Fresenius Kabi (Germany); Austrian National Bank (Jubilaumsfonds) [14143]	European Society for Clinical Nutrition and Metabolism (ESPEN); Fresenius Kabi (Germany); Austrian National Bank (Jubilaumsfonds)	The study was supported by the European Society for Clinical Nutrition and Metabolism (ESPEN), a research grant including provision of study medication from Fresenius Kabi (Germany), and the Austrian National Bank (Jubilaumsfonds, Project Nr. 14143).	Amrein K, 2012, BMC ENDOCR DISORD, V12, DOI 10.1186/1472-6823-12-27; Amrein K, 2011, CRIT CARE, V15, DOI 10.1186/cc10120; Autier P, 2014, LANCET DIABETES ENDO, V2, P76, DOI 10.1016/S2213-8587(13)70165-7; Bacon CJ, 2009, OSTEOPOROSIS INT, V20, P1407, DOI 10.1007/s00198-008-0814-9; Bjelakovic G, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007470.pub2; Bolland MJ, 2014, LANCET DIABETES ENDO, V2, P307, DOI 10.1016/S2213-8587(13)70212-2; Braun AB, 2012, CRIT CARE MED, V40, P3170, DOI 10.1097/CCM.0b013e318260c928; Chowdhury R, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1903; Cluse ZN, 2012, ANN CLIN BIOCHEM, V49, P159, DOI 10.1258/acb.2011.011018; Committee to Review Dietary Reference Intakes for Vitamin D and Calcium Institute of Medicine, 2011, DIETARY REFERENCE IN; Dobnig H, 2008, ARCH INTERN MED, V168, P1340, DOI 10.1001/archinte.168.12.1340; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385; Knox S, 2009, ANN CLIN BIOCHEM, V46, P226, DOI 10.1258/acb.2009.008206; Lee P, 2009, NEW ENGL J MED, V360, P1912, DOI 10.1056/NEJMc0809996; McNally JD, 2014, J PEDIAT-BRAZIL, V90, P99, DOI 10.1016/j.jped.2013.12.002; Mehlhorn J, 2014, CRIT CARE MED, V42, P1263, DOI 10.1097/CCM.0000000000000148; Michaud J, 2010, J AM SOC NEPHROL, V21, P1488, DOI 10.1681/ASN.2009080815; Moromizato T, 2014, CRIT CARE MED, V42, P97, DOI 10.1097/CCM.0b013e31829eb7af; Perron Rachel M., 2013, Inflammation & Allergy Drug Targets, V12, P273; Sanders KM, 2010, JAMA-J AM MED ASSOC, V303, P1815, DOI 10.1001/jama.2010.594; Smith H, 2007, RHEUMATOLOGY, V46, P1852, DOI 10.1093/rheumatology/kem240; Spriet I, 2009, INTENS CARE MED, V35, P603, DOI 10.1007/s00134-008-1383-2; Theodoratou E, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2035; Vieth R, 2006, J NUTR, V136, P1117, DOI 10.1093/jn/136.4.1117; von Restorff C, 2009, BONE, V45, P747, DOI 10.1016/j.bone.2009.06.012; World Medical Association, DECL HELS ETH PRINC; Zittermann A, 2012, AM J CLIN NUTR, V95, P91, DOI 10.3945/ajcn.111.014779	29	292	303	1	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2014	312	15					1520	1530		10.1001/jama.2014.13204	http://dx.doi.org/10.1001/jama.2014.13204			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AQ7HL	25268295	Bronze			2023-01-03	WOS:000342983200016
J	Derksen, A; Hensel, A; Hafezi, W; Herrmann, F; Schmidt, TJ; Ehrhardt, C; Ludwig, S; Kuhn, J				Derksen, Andrea; Hensel, Andreas; Hafezi, Wali; Herrmann, Fabian; Schmidt, Thomas J.; Ehrhardt, Christina; Ludwig, Stephan; Kuehn, Joachim			3-0-Galloylated Procyanidins from Rumex acetosa L. Inhibit the Attachment of Influenza A Virus	PLOS ONE			English	Article							ACTIVITY IN-VITRO; ANTIVIRAL ACTIVITY; GREEN TEA; COLORIMETRIC ASSAY; DERMAL FIBROBLASTS; SCREENING ASSAYS; B VIRUSES; POLYPHENOLS; AGENTS; RESISTANCE	Infections by influenza A viruses (IAV) are a major health burden to mankind. The current antiviral arsenal against IAV is limited and novel drugs are urgently required. Medicinal plants are known as an abundant source for bioactive compounds, including antiviral agents. The aim of the present study was to characterize the anti-IAV potential of a proanthocyanidinenriched extract derived from the aerial parts of Rumex acetosa (RA), and to identify active compounds of RA, their mode of action, and structural features conferring anti-AV activity. In a modified KU (MTTIAv) assay, RA was shown to inhibit growth of the IAV strain PR8 (H1N1) and a clinical isolate of lAV(H1N1)pdm09 with a half-maximal inhibitory concentration (IC50) of 2.5 pg/mL and 2.2;Ag/mL, and a selectivity index (SD (half-maximal cytotoxic concentration (CC50)/1(50)) of 32 and 36, respectively. At RA concentrations>1 pg/mL plaque formation of lAV(H1N1)pdm09 was abrogated. RA was also active against an oseltamivir-resistant isolate of lAV(H1N1)pdm09. TNF-iy. and EGF-induced signal transduction in A549 cells was not affected by RA. The dimeric proanthocyanidin epicatechin-3-0-gallate-(4f1 >8)-epicatechin-3'-0-gallate (procyanidin B2di-gallate) was identified as the main active principle of RA (IC50 approx. 15 uM, SI_?..13). RA and procyanidin B2-di-gallate blocked attachment of IAV and interfered with viral penetration at higher concentrations. Galloylation of the procyanidin core structure was shown to be a prerequisite for anti-AV activity; o-trihydroxylation in the B-ring increased the anti-IAV activity. In silico docking studies indicated that procyanidin B2-di-gallate is able to interact with the receptor binding site of IAV(H1N1)pdm09 hemagglutinin (HA). In conclusion, the proanthocyanidin-enriched extract RA and its main active constituent procyanidin B2-di-gallate protect cells from IAV infection by inhibiting viral entry into the host cell. RA and procyanidin B2-di-gallate appear to be a promising expansion of the currently available anti-influenza agents.	[Derksen, Andrea; Hensel, Andreas; Herrmann, Fabian; Schmidt, Thomas J.] Univ Munster, Inst Pharmaceut Biol & Phytochem, D-48149 Munster, Germany; [Hafezi, Wali; Kuehn, Joachim] Univ Hosp Munster, Inst Med Microbiol Clin Virol, Munster, Germany; [Ehrhardt, Christina; Ludwig, Stephan] Univ Munster, Inst Mol Virol, D-48149 Munster, Germany	University of Munster; University of Munster; University of Munster	Kuhn, J (corresponding author), Univ Hosp Munster, Inst Med Microbiol Clin Virol, Munster, Germany.	kuehnj@uni-muenster.de	Schmidt, Thomas J/M-1678-2016	Schmidt, Thomas J/0000-0003-2634-9705; Herrmann, Fabian/0000-0002-2411-7671; Ludwig, Stephan/0000-0003-4490-3052	Deutsche Forschungsgemeinschaft; University of Muenster	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); University of Muenster	The authors acknowledge support by Deutsche Forschungsgemeinschaft and Open Access Publication Fund of University of Muenster. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agyare C, 2011, PHYTOMEDICINE, V18, P617, DOI 10.1016/j.phymed.2010.08.020; Beyleveld G, 2013, ANTIVIR RES, V100, P120, DOI 10.1016/j.antiviral.2013.07.018; Bicker J, 2009, FITOTERAPIA, V80, P483, DOI 10.1016/j.fitote.2009.08.015; Daglia M, 2012, CURR OPIN BIOTECH, V23, P174, DOI 10.1016/j.copbio.2011.08.007; DANNE A, 1994, PHYTOCHEMISTRY, V37, P533, DOI 10.1016/0031-9422(94)85094-1; De Bruyne T, 1999, J NAT PROD, V62, P954, DOI 10.1021/np980481o; De Clercq E, 2013, MED RES REV, V33, P1249, DOI 10.1002/med.21281; De Clercq E, 2013, BIOCHEM PHARMACOL, V85, P727, DOI 10.1016/j.bcp.2012.12.011; Dixit Rashmi, 2013, Infectious Disorders - Drug Targets, V13, P34; Ehrhardt C, 2007, ANTIVIR RES, V76, P38, DOI 10.1016/j.antiviral.2007.05.002; Ehrhardt C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063657; Ekiert DC, 2012, NATURE, V489, P526, DOI 10.1038/nature11414; Fiore Anthony E., 2011, Morbidity and Mortality Weekly Report, V60, P1; Ge H, 2010, NAT PROD REP, V27, P1758, DOI 10.1039/c0np00005a; Gescher K, 2011, J ETHNOPHARMACOL, V134, P468, DOI 10.1016/j.jep.2010.12.038; Gescher K, 2011, ANTIVIR RES, V89, P9, DOI 10.1016/j.antiviral.2010.10.007; Glatthaar-Saalmuller B, 2011, PHYTOMEDICINE, V19, P1, DOI 10.1016/j.phymed.2011.10.010; Haidari M, 2009, PHYTOMEDICINE, V16, P1127, DOI 10.1016/j.phymed.2009.06.002; Haslam E, 1996, J NAT PROD, V59, P205, DOI 10.1021/np960040+; Hrincius ER, 2010, CELL MICROBIOL, V12, P831, DOI 10.1111/j.1462-5822.2010.01436.x; Imanishi N, 2002, MICROBIOL IMMUNOL, V46, P491, DOI 10.1111/j.1348-0421.2002.tb02724.x; Jassim SAA, 2003, J APPL MICROBIOL, V95, P412, DOI 10.1046/j.1365-2672.2003.02026.x; Kamali Amanda, 2013, Infect Drug Resist, V6, P187, DOI 10.2147/IDR.S36601; Karoline D, 2007, ANTIVIR RES, V76, P1, DOI 10.1016/j.antiviral.2007.04.001; Khandaker I, 2013, VIRUS GENES; Lambert LC, 2010, NEW ENGL J MED, V363, P2036, DOI 10.1056/NEJMra1002842; Laursen NS, 2013, ANTIVIR RES, V98, P476, DOI 10.1016/j.antiviral.2013.03.021; Liu G, 2011, ARCH VIROL, V156, P1359, DOI 10.1007/s00705-011-0989-9; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAKAYAMA M, 1993, ANTIVIR RES, V21, P289, DOI 10.1016/0166-3542(93)90008-7; Pabst D, 2011, EUR J INTERN MED, V22, pE119, DOI 10.1016/j.ejim.2011.08.014; Pariani E, 2013, HUM VACCIN IMMUNOTHE, V9; Park S, 2013, BIOCHEM BIOPH RES CO, V440, P14, DOI 10.1016/j.bbrc.2013.08.090; PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6; SAUTER NK, 1992, BIOCHEMISTRY-US, V31, P9609, DOI 10.1021/bi00155a013; Song JM, 2007, EXPERT REV ANTI-INFE, V5, P497, DOI 10.1586/14787210.5.3.497; Song JM, 2005, ANTIVIR RES, V68, P66, DOI 10.1016/j.antiviral.2005.06.010; Steinmann J, 2013, BRIT J PHARMACOL, V168, P1059, DOI 10.1111/bph.12009; Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979; Theisen LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088062; Theisen LL, 2012, ANTIVIR RES, V94, P147, DOI 10.1016/j.antiviral.2012.03.006; Thorlund K, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-134; Ubillas R, 1994, Phytomedicine, V1, P77, DOI 10.1016/S0944-7113(11)80026-7; Wang RX, 2013, FITOTERAPIA, V84, P308, DOI 10.1016/j.fitote.2012.12.020; Wang XY, 2006, PHYTOTHER RES, V20, P335, DOI 10.1002/ptr.1892; Williamson MP, 2006, J ALLERGY CLIN IMMUN, V118, P1369, DOI 10.1016/j.jaci.2006.08.016; Xu R, 2013, NAT STRUCT MOL BIOL, V20, P363, DOI 10.1038/nsmb.2500; Xu R, 2010, SCIENCE, V328, P357, DOI 10.1126/science.1186430; Yang ZF, 2014, FITOTERAPIA, V93, P47, DOI 10.1016/j.fitote.2013.12.011; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; Zumdick S, 2012, FITOTERAPIA, V83, P1210, DOI 10.1016/j.fitote.2012.06.013	51	34	36	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2014	9	10							e110089	10.1371/journal.pone.0110089	http://dx.doi.org/10.1371/journal.pone.0110089			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR6ZS	25303676	Green Published, gold, Green Submitted			2023-01-03	WOS:000343730400110
J	O'Reilly, CE; Taylor, EV; Ayers, T; Fantu, R; Abayneh, SA; Marston, B; Molla, YB; Sewnet, T; Abebe, F; Hoekstra, RM; Quick, R				O'Reilly, Ciara E.; Taylor, Ethel V.; Ayers, Tracy; Fantu, Ribka; Abayneh, Sisay Alemayehu; Marston, Barbara; Molla, Yordanos B.; Sewnet, Tegene; Abebe, Fitsum; Hoekstra, Robert M.; Quick, Robert			Improved Health among People Living with HIV/AIDS Who Received Packages of Proven Preventive Health Interventions, Amhara, Ethiopia	PLOS ONE			English	Article							POINT-OF-USE; USE WATER-TREATMENT; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED ADULTS; COTRIMOXAZOLE PROPHYLAXIS; ANTIRETROVIRAL THERAPY; TREATING COINFECTIONS; COST-EFFECTIVENESS; VIRAL LOAD; DIARRHEA	In 2009, basic care packages (BCP) containing health products were distributed to HIV-infected persons in Ethiopia who were clients of antiretroviral therapy clinics. To measure health impact, we enrolled clients from an intervention hospital and comparison hospital, and then conducted a baseline survey, and 7 bi-weekly home visits. We enrolled 405 intervention group clients and 344 comparison clients. Intervention clients were more likely than comparison clients to have detectable chlorine in stored water (40% vs. 1%, p<0.001), soap (51% vs. 36%, p<0.001), and a BCP water container (65% vs. 0%, p<0.001) at every home visit. Intervention clients were less likely than comparison clients to report illness (44% vs. 67%, p<0.001) or health facility visits for illness (74% vs. 95%, p<0.001), and had lower median illness scores (1.0 vs. 3.0, p<0.05). Participation in the BCP program appeared to improve reported health outcomes.	[O'Reilly, Ciara E.; Taylor, Ethel V.; Ayers, Tracy; Hoekstra, Robert M.; Quick, Robert] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA; [Taylor, Ethel V.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA; [Fantu, Ribka; Abayneh, Sisay Alemayehu] Ctr Dis Control & Prevent, Addis Ababa, Ethiopia; [Marston, Barbara] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA; [Molla, Yordanos B.; Sewnet, Tegene; Abebe, Fitsum] Michael Dejene Publ Hlth Consultancy Serv, Addis Ababa, Ethiopia	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	O'Reilly, CE (corresponding author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA.	bwf1@cdc.gov		Ayers, Tracy/0000-0003-4140-3263; Hoekstra, Robert Michael/0000-0002-0340-8015	US President's Emergency Plan for AIDS Relief; Global AIDS Program; Centers for Disease Control and Prevention, Ethiopia; U.S. Agency for International Development through an Inter-Agency Agreement; U.S. Centers for Disease Control and Prevention; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [T35OD010991] Funding Source: NIH RePORTER	US President's Emergency Plan for AIDS Relief(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Global AIDS Program; Centers for Disease Control and Prevention, Ethiopia; U.S. Agency for International Development through an Inter-Agency Agreement(United States Agency for International Development (USAID)); U.S. Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding for the study was provided by the US President's Emergency Plan for AIDS Relief, Global AIDS Program, and Centers for Disease Control and Prevention, Ethiopia. Additional support for technical assistance was provided by the U.S. Agency for International Development through an Inter-Agency Agreement with the U.S. Centers for Disease Control and Prevention. Michael Dejene Public Health Consultancy Services was formally contracted by the Centers for Disease Control and Prevention, Ethiopia to carry out the data collection component of this study only. Co-authors YM, TS, and FA were employed by Michael Dejene Public Health Consultancy Services, Addis Ababa, Ethiopia.	Abebe LS, 2014, J WATER HEALTH, V12, P288, DOI 10.2166/wh.2013.185; Arnold B, 2009, INT J EPIDEMIOL, V38, P1651, DOI 10.1093/ije/dyp241; Arnold BF, 2007, AM J TROP MED HYG, V76, P354, DOI 10.4269/ajtmh.2007.76.354; Barnabas RV, 2011, AIDS, V25, P1559, DOI 10.1097/QAD.0b013e3283491e3e; Barzilay EJ, 2011, AIDS CARE, V23, P330, DOI 10.1080/09540121.2010.507749; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brink AK, 2002, J INFECTION, V45, P99, DOI 10.1053/jinf.2002.1002; COLEBUNDERS R, 1987, AM J GASTROENTEROL, V82, P859; Colford John M. Jr, 2005, Journal of Water and Health, V3, P173; Colindres R, 2008, AIDS CARE, V20, P139, DOI 10.1080/09540120701506804; Doocy S, 2006, TROP MED INT HEALTH, V11, P1542, DOI 10.1111/j.1365-3156.2006.01704.x; Federal Ministry of Health, 2006, GUID COTR PROPH HIV; Federal Ministry of Health HIV/AIDS Prevention and Control Office, 2006, AIDS ETH; Federal Ministry of Health HIV/AIDS Prevention and Control Office, 2010, ART UPD OCT 8 2009 P; Fletcher RH, 2005, RANDOMIZED CONTROL T, P128; Freeman MC, 2009, J WATER HEALTH, V7, P527, DOI 10.2166/wh.2009.063; Grant A D, 1997, AIDS, V11 Suppl B, pS43; Hoffmann CJ, 2010, AIDS, V24, P1709, DOI 10.1097/QAD.0b013e32833ac6bc; Kaplan JE, 1996, AM J TROP MED HYG, V55, P1; Lowrance D, 2007, JAIDS-J ACQ IMM DEF, V46, P56; Luby SP, 2008, AM J TROP MED HYG, V78, P382, DOI 10.4269/ajtmh.2008.78.382; Lule JR, 2005, AM J TROP MED HYG, V73, P926, DOI 10.4269/ajtmh.2005.73.926; Mermin J, 2004, LANCET, V364, P1428, DOI 10.1016/S0140-6736(04)17225-5; Mermin J, 2005, TROP MED INT HEALTH, V10, P961, DOI 10.1111/j.1365-3156.2005.01488.x; Modjarrad K, 2008, AIDS, V22, P2179, DOI 10.1097/QAD.0b013e328312c756; Modjarrad K, 2011, LANCET INFECT DIS, V11, P81, DOI 10.1016/S1473-3099(11)70013-5; Modjarrad K, 2010, LANCET INFECT DIS, V10, P455, DOI 10.1016/S1473-3099(10)70093-1; Olembo Lynette, 2004, SAFE WATER SYSTEMS E; Peletz R, 2013, AIDS, V27, P2593, DOI 10.1097/QAD.0b013e3283633a5f; Pitter C, 2007, JAIDS-J ACQ IMM DEF, V44, P336, DOI 10.1097/QAI.0b013e31802f12b5; Sheth AN, 2010, AM J TROP MED HYG, V83, P1315, DOI 10.4269/ajtmh.2010.10-0211; Shrestha RK, 2006, AM J TROP MED HYG, V74, P884, DOI 10.4269/ajtmh.2006.74.884; Stockman LJ, 2007, EMERG INFECT DIS, V13, P1077, DOI 10.3201/eid1307.060767; The US President's Emergency Plan for AIDS Relief, 2009, ETH 2009 COUNTR OP P, P1; The US President's Emergency Plan for AIDS Relief, 2009, 5 YEAR STRAT, P1; Walker AS, 2010, LANCET, V375, P1278, DOI 10.1016/S0140-6736(10)60057-8; World Health Organization, 2007, PROM SAF MED CHILDR, P1	37	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2014	9	9							e107662	10.1371/journal.pone.0107662	http://dx.doi.org/10.1371/journal.pone.0107662			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ6KR	25233345	Green Published, Green Submitted, gold			2023-01-03	WOS:000342921200041
J	Hsieh, C; Kong, J; Kirsch, I; Edwards, RR; Jensen, KB; Kaptchuk, TJ; Gollub, RL				Hsieh, Christine; Kong, Jian; Kirsch, Irving; Edwards, Robert R.; Jensen, Karin B.; Kaptchuk, Ted J.; Gollub, Randy L.			Well-Loved Music Robustly Relieves Pain: A Randomized, Controlled Trial	PLOS ONE			English	Article							PLACEBO-INDUCED EXPECTATIONS; DOPAMINE RELEASE; NUCLEUS-ACCUMBENS; OPIOID SYSTEMS; ANALGESIA; EXPECTANCY; EMOTION; REWARD; DEPRESSION; RESPONSES	Music has pain-relieving effects, but its mechanisms remain unclear. We sought to verify previously studied analgesic components and further elucidate the underpinnings of music analgesia. Using a well-characterized conditioning-enhanced placebo model, we examined whether boosting expectations would enhance or interfere with analgesia from strongly preferred music. A two-session experiment was performed with 48 healthy, pain experiment-naive participants. In a first cohort, 36 were randomized into 3 treatment groups, including music enhanced with positive expectancy, non-musical sound enhanced with positive expectancy, and no expectancy enhancement. A separate replication cohort of 12 participants received only expectancy-enhanced music following the main experiment to verify the results of expectancy-manipulation on music. Primary outcome measures included the change in subjective pain ratings to calibrated experimental noxious heat stimuli, as well as changes in treatment expectations. Without conditioning, expectations were strongly in favor of music compared to non-musical sound. While measured expectations were enhanced by conditioning, this failed to affect either music or sound analgesia significantly. Strongly preferred music on its own was as pain relieving as conditioning-enhanced strongly preferred music, and more analgesic than enhanced sound. Our results demonstrate the pain-relieving power of personal music even over enhanced expectations.	[Hsieh, Christine; Kong, Jian; Jensen, Karin B.; Gollub, Randy L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Hsieh, Christine; Kong, Jian; Jensen, Karin B.; Gollub, Randy L.] Harvard Univ, Sch Med, Boston, MA USA; [Kirsch, Irving; Kaptchuk, Ted J.] Harvard Univ, Sch Med, Program Placebo Studies & Therapeut Encounter PiP, Boston, MA USA; [Kirsch, Irving; Kaptchuk, Ted J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Kirsch, Irving] Univ Plymouth, Dept Psychol, Plymouth PL4 8AA, Devon, England; [Edwards, Robert R.] Brigham & Womens Hosp, Dept Anesthesiol, Boston, MA 02115 USA; [Jensen, Karin B.; Gollub, Randy L.] Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA USA; [Jensen, Karin B.; Gollub, Randy L.] Massachusetts Gen Hosp, Charlestown, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Plymouth; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital	Hsieh, C (corresponding author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.	xtine.hsieh@gmail.com	Kirsch, Irving/P-9316-2019	Gollub, Randy L./0000-0002-9434-4044; Jensen, Karin/0000-0003-2521-3160	Harvard-MIT Health Sciences and Technology IDEA2 award; NIH [R01 AT 005280]; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [R01AT005280] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT006364, P01AT006663] Funding Source: NIH RePORTER	Harvard-MIT Health Sciences and Technology IDEA2 award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding was provided by the Harvard-MIT Health Sciences and Technology IDEA2 award (Hsieh) and NIH grant R01 AT 005280 (Gollub/Kaptchuk). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amanzio M, 1999, J NEUROSCI, V19, P484, DOI 10.1523/JNEUROSCI.19-01-00484.1999; Baliki MN, 2010, NEURON, V66, P149, DOI 10.1016/j.neuron.2010.03.002; Benedetti F, 2003, J NEUROSCI, V23, P4315; Benedetti F, 1999, J NEUROSCI, V19, P3639; Benedetti F, 2011, NEUROPSYCHOPHARMACOL, V36, P339, DOI 10.1038/npp.2010.81; Bernatzky G, 2011, NEUROSCI BIOBEHAV R, V35, P1989, DOI 10.1016/j.neubiorev.2011.06.005; Bingel U, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001244; Blood AJ, 2001, P NATL ACAD SCI USA, V98, P11818, DOI 10.1073/pnas.191355898; BRADLEY MM, 1994, J BEHAV THER EXP PSY, V25, P49, DOI 10.1016/0005-7916(94)90063-9; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Corlett PR, 2010, PROG NEUROBIOL, V92, P345, DOI 10.1016/j.pneurobio.2010.06.007; de la Fuente-Fernandez R, 2001, SCIENCE, V293, P1164, DOI 10.1126/science.1060937; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; Gabrielsson A., 2001, MUSIC EMOTION THEORY; GARDNER WJ, 1960, SCIENCE, V132, P32, DOI 10.1126/science.132.3418.32; Geisser ME, 1997, CLIN J PAIN, V13, P163, DOI 10.1097/00002508-199706000-00011; GOLDSTEIN A, 1980, PHYSIOL PSYCHOL, V8, P126; Hall KT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048135; Janata P, 2009, CEREB CORTEX, V19, P2579, DOI 10.1093/cercor/bhp008; Juslin PN, 2008, BEHAV BRAIN SCI, V31, P559, DOI 10.1017/S0140525X08005293; Juslin PN, 2001, MUSIC EMOTION THEORY; Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25; Kirsch I, 2000, AM J CLIN HYPN, V42, P274, DOI 10.1080/00029157.2000.10734362; Koelsch S, 2006, HUM BRAIN MAPP, V27, P239, DOI 10.1002/hbm.20180; Koelsch S, 2009, ANN NY ACAD SCI, V1169, P374, DOI 10.1111/j.1749-6632.2009.04592.x; Kong J, 2006, J NEUROSCI, V26, P381, DOI 10.1523/JNEUROSCI.3556-05.2006; Kong J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067485; Kong J, 2009, NEUROIMAGE, V45, P940, DOI 10.1016/j.neuroimage.2008.12.025; Kong J, 2008, J NEUROSCI, V28, P13354, DOI 10.1523/JNEUROSCI.2944-08.2008; Laverdure-Dupont D, 2009, J NEUROSCI, V29, P11745, DOI 10.1523/JNEUROSCI.1224-09.2009; Leknes S, 2008, NAT REV NEUROSCI, V9, P314, DOI 10.1038/nrn2333; Lidstone SC, 2010, ARCH GEN PSYCHIAT, V67, P857, DOI 10.1001/archgenpsychiatry.2010.88; Mitchell LA, 2006, EUR J PAIN, V10, P343, DOI 10.1016/j.ejpain.2005.03.005; Mitchell LA, 2006, J MUSIC THER, V43, P295, DOI 10.1093/jmt/43.4.295; Montgomery GH, 1997, PAIN, V72, P107, DOI 10.1016/S0304-3959(97)00016-X; Perlini AH, 1996, CAN J BEHAV SCI, V28, P292, DOI 10.1037/0008-400X.28.4.292; Petrovic P, 2005, NEURON, V46, P957, DOI 10.1016/j.neuron.2005.05.023; Price DD, 1999, PAIN, V83, P147, DOI 10.1016/S0304-3959(99)00081-0; Roy M, 2012, EUR J PAIN, V16, P870, DOI 10.1002/j.1532-2149.2011.00030.x; Roy M, 2008, PAIN, V134, P140, DOI 10.1016/j.pain.2007.04.003; Salimpoor VN, 2013, SCIENCE, V340, P216, DOI 10.1126/science.1231059; Salimpoor VN, 2011, NAT NEUROSCI, V14, P257, DOI 10.1038/nn.2726; Scott DJ, 2007, NEURON, V55, P325, DOI 10.1016/j.neuron.2007.06.028; TURNER JA, 1984, J CLIN PSYCHOL, V40, P909, DOI 10.1002/1097-4679(198407)40:4<909::AID-JCLP2270400407>3.0.CO;2-J; Villarreal EAG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029397; VOUDOURIS NJ, 1990, PAIN, V43, P121, DOI 10.1016/0304-3959(90)90057-K; VOUDOURIS NJ, 1989, PAIN, V38, P109, DOI 10.1016/0304-3959(89)90080-8; Wager TD, 2007, P NATL ACAD SCI USA, V104, P11056, DOI 10.1073/pnas.0702413104; Zatorre RJ, 2013, P NATL ACAD SCI USA, V110, P10430, DOI 10.1073/pnas.1301228110	49	21	22	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2014	9	9							e107390	10.1371/journal.pone.0107390	http://dx.doi.org/10.1371/journal.pone.0107390			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AP1UA	25211164	Green Published, Green Submitted, gold			2023-01-03	WOS:000341855900070
J	Shen, DD; Xie, XJ; Zhu, ZJ; Yu, X; Liu, HL; Wang, HZ; Fan, HW; Wang, DW; Jiang, GR; Hong, M				Shen, Dandan; Xie, Xuejian; Zhu, Zhijie; Yu, Xi; Liu, Hailiang; Wang, Huizhu; Fan, Hongwei; Wang, Dawei; Jiang, Guorong; Hong, Min			Screening Active Components from Yu-Ping-Feng-San for Regulating Initiative Key Factors in Allergic Sensitization	PLOS ONE			English	Article							THYMIC STROMAL LYMPHOPOIETIN; HUMAN EPITHELIAL-CELLS; INFLAMMATION; EXTRACTION; CYTOKINE	Yu-ping-feng-san (YPFS) is a Chinese medical formula that is used clinically for allergic diseases and characterized by reducing allergy relapse. Our previous studies demonstrated that YPFS efficiently inhibited T helper 2 cytokines in allergic inflammation. The underlying mechanisms of action of YPFS and its effective components remain unclear. In this study, it was shown that YPFS significantly inhibited production of thymic stromal lymphopoietin (TSLP), an epithelial cell-derived initiative factor in allergic inflammation, in vitro and in vivo. A method of human bronchial epithelial cell (16HBE) binding combined with HPLC-MS (named 16HBE-HPLC-MS) was established to explore potential active components of YPFS. The following five components bound to 16HBE cells: calycosin-7-glucoside, ononin, claycosin, sec-o-glucosylhamaudol and formononetin. Serum from YPFS-treated mice was analyzed and three major components were detected claycosin, formononetin and cimifugin. Among these, claycosin and formononetin were detected by 16HBE-HPLC-MS and in the serum of YPFS-treated mice. Claycosin and formononetin decreased the level of TSLP markedly at the initial stage of allergic inflammation in vivo. Nuclear factor (NF)-kappa B, a key transcription factor in TSLP production, was also inhibited by claycosin and formononetin, either in terms of transcriptional activation or its nuclear translocation in vitro. Allergic inflammation was reduced by claycosin and formononetin when they are administered only at the initial stage in a murine model of atopic contact dermatitis. Thus, epithelial cell binding combined with HPLC-MS is a valid method for screening active components from complex mixtures of Chinese medicine. It was demonstrated that the compounds screened from YPFS significantly attenuated allergic inflammation probably by reducing TSLP production via regulating NF-kappa B activation.	[Shen, Dandan; Zhu, Zhijie; Yu, Xi; Liu, Hailiang; Wang, Huizhu; Hong, Min] Nanjing Univ Chinese Med, Natl Stand Lab Pharmacol Chinese Mat Med, Jiangsu Key Lab Pharmacol & Safety Evaluat Chines, Nanjing, Jiangsu, Peoples R China; [Xie, Xuejian] Nanjing Mil Command, Nanjing Gen Hosp, Nanjing, Jiangsu, Peoples R China; [Fan, Hongwei] Nanjing Med Univ, Dept Clin Pharmacol Lab, Nanjing Hosp 1, Nanjing, Jiangsu, Peoples R China; [Jiang, Guorong] Suzhou Hosp Trad Chinese Med, Suzhou, Peoples R China; [Wang, Dawei] Jiangsu Acad Tradit Chinese Med, Nanjing, Jiangsu, Peoples R China; [Shen, Dandan] First Peoples Hosp Taicang, Dept Pharm, Taicang, Peoples R China	Nanjing University of Chinese Medicine; Nanjing General Hospital; Nanjing Medical University	Fan, HW (corresponding author), Nanjing Med Univ, Dept Clin Pharmacol Lab, Nanjing Hosp 1, Nanjing, Jiangsu, Peoples R China.	fanhongwei178@sina.com; hongmin72@hotmail.com			National Natural Science Foundation of China [81073121, 81373549, 81102885]; Priority Academic Program Development of Jiangsu Higher Education Institutions; Qing Lan Project	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions; Qing Lan Project(Jiangsu Polytech Institute)	This research was funded by Project 81073121, 81373549 and 81102885 supported by National Natural Science Foundation of China, Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions and Qing Lan Project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Brigadeau F, 2005, J CARDIOVASC ELECTR, V16, P629, DOI 10.1046/j.1540-8167.2005.40584.x; Chen XT, 2006, AM J CHINESE MED, V34, P631, DOI 10.1142/S0192415X06004168; Comeau MR, 2010, MUCOSAL IMMUNOL, V3, P138, DOI 10.1038/mi.2009.134; Dong ZB, 2005, J PHARMACEUT BIOMED, V38, P664, DOI 10.1016/j.jpba.2005.02.008; Fan HW, 2004, CHINESE PHARM J, V41, P63; Gu J, 2005, SHANGHAI J TRADITION, V39, P50; Hong M, 2008, CHINA J CHINESE MAT, V34, P450; Hong M, 2012, MOLECULES, V17, P1468, DOI 10.3390/molecules17021468; Huang C, 2011, CHIN J EXP TRADIT ME, V17, P266, DOI DOI 10.13422/j.cnki.syfjx.2011.10.078; Hulse KE, 2010, J ALLERGY CLIN IMMUN, V125, P247, DOI 10.1016/j.jaci.2009.10.027; Kong XF, 2004, INT IMMUNOPHARMACOL, V4, P975, DOI 10.1016/j.intimp.2004.03.008; Kuang WenJuan, 2011, Tumor, V31, P789; Li Y, 1999, CHINESE LITERATURE, P95; Li Y, 2007, J PHARM BIOMED ANAL, V44, P439; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Saenz SA, 2008, IMMUNOL REV, V226, P172, DOI 10.1111/j.1600-065X.2008.00713.x; Shao JH, 2011, CHINA J EXPT TRADITI, V17, P173; Shen CB, 2009, SHANGHAI J TRADITION, V43, P58; Sheng, 2009, ZHEJIANG CHINESE MED, V33, P701; Soumelis V, 2004, SPRINGER SEMIN IMMUN, V25, P325, DOI 10.1007/s00281-003-0152-0; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Sun L, 2012, MOL CARDIOLOGY CHINA, V3, P186; Tang D., 1984, CHINESE PHARMACOL B, V19, P43; Tang XH, 1998, TRADITIONAL CHINESE, V11, P7; Wang Hui-Zhu, 2013, Zhongguo Zhong Yao Za Zhi, V38, P1052; Wang YH, 2007, J CLIN INVEST, V117, P3655, DOI 10.1172/JCI34182; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; [王志洁 Wang Zhijie], 2003, [中国现代应用药学, Chinese Journal of Modern Applied Pharmacy], V20, P452; Xia DX, 2009, CHINESE J GERONTOLOG, V29, P2340; Xiao WH, 2008, CHINESE J ANAL CHEM, V36, P1399; Yang, 2009, GUIDING J TRADITIONA, V15, P39; Yesilada E, 2005, J ETHNOPHARMACOL, V96, P71, DOI 10.1016/j.jep.2004.08.036; Yuan XJ, 2009, GUIDING J TRADITIONA, V15, P8; Zeng WJ, 2008, CHIN J DERMATO VENER, V7, P16; Zhang Dan, 2010, Nan Fang Yi Ke Da Xue Xue Bao, V30, P963; Zhang Y, 1995, CHINESE PHARMACOL B, V11, P136; ZHANG Y, 1997, J CHENGDU U TCM, V20, P39; Zhang Z, 2009, IND ROBOT, V36, P36, DOI 10.1108/01439910910924657; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	40	38	42	2	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2014	9	9							e107279	10.1371/journal.pone.0107279	http://dx.doi.org/10.1371/journal.pone.0107279			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4JX	25198676	Green Published, gold, Green Submitted			2023-01-03	WOS:000341304700102
J	Weniger, BG				Weniger, Bruce G.			Influenza vaccination in the off-label grey zone	LANCET			English	Editorial Material									Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50200, Thailand	Chiang Mai University	Weniger, BG (corresponding author), Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50200, Thailand.	bgweniger@siamlotus.com		Weniger, Bruce/0000-0002-5450-5464				[Anonymous], 1982, FDA Drug Bull, V12, P4; Kroger Andrew T., 2011, Morbidity and Mortality Weekly Report, V60, P3; International Organization for Standardization, 216492006 ISODIS; McAllister L, 2014, LANCET, V384, P674, DOI 10.1016/S0140-6736(14)60524-9; Mohammed AJ, 2010, NEW ENGL J MED, V362, P2351, DOI 10.1056/NEJMoa0909383; Parrish TN, 2011, PITTSBURGH TRIB 1021; PATH, SHOTS NEEDL SAF EFF; PATH WHO (Project Optimize), LANDSC AN TRENDS VAC; Potters H., 2011, SUMMARY REPORT ADVIS, P183; US Food and Drug Administration, LAB INV US MARK DRUG; US Food and Drug Administration, 2011, FDA COMM US JET INJ; US Food and Drug Administration, 2011, FDA UPD COMM US JET; Weniger B.G., 2013, VACCINES, P1200, DOI [DOI 10.1016/B978-1-4557-0090-5.00063, 10.1016/B978-1-4557-0090-5.00063-X]; Weniger BG, 2011, JET INJECTION IMMUNI; Weniger BG, 2011, RES NEW VACCINE DELI	15	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2014	384	9944					642	644		10.1016/S0140-6736(14)61367-2	http://dx.doi.org/10.1016/S0140-6736(14)61367-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AO5CJ	25152263				2023-01-03	WOS:000341359100008
J	Reich, O; Rosemann, T; Rapold, R; Blozik, E; Senn, O				Reich, Oliver; Rosemann, Thomas; Rapold, Roland; Blozik, Eva; Senn, Oliver			Potentially Inappropriate Medication Use in Older Patients in Swiss Managed Care Plans: Prevalence, Determinants and Association with Hospitalization	PLOS ONE			English	Article							BEERS CRITERIA; DRUG-USE; ELDERLY OUTPATIENTS; PHARMACY DATA; OUTCOMES; POPULATION; RISK; PRESCRIPTIONS; EXPENDITURES; POLYPHARMACY	Objectives: To describe the prevalence and determinants of potentially inappropriate medication (PIM) use and association with hospitalizations in an elderly managed care population in Switzerland. Methods: Using health care claims data of four health insurers for a sample of managed care patients 65 years of age and older to compare persons on PIM with persons not on PIM. Beers' 2012 and PRISCUS criteria were used to determine the potential inappropriateness of prescribed medications. The sample included 16'490 elderly patients on PIM and 33'178 patients not on PIM in the time period of January 1, 2008 through December 31, 2012. Prevalence estimates are standardized to the population of Switzerland. Associations between PIM and hospitalizations were examined by multivariate Cox regression analyses controlling for possible confounding variables. Results: The estimated prevalence of PIM use in our managed care sample was 22.5%. Logistic regression analysis showed that number of different medications used in the previous year, total costs in the previous year and hospitalization in the previous year all significantly increased the likelihood of receiving PIM. Multiple Cox regression analysis revealed that those on cumulative levels of PIM use acted significantly as a factor related to greater hospitalization rates: the adjusted HR was 1.13 (95% CI 1.07-1.19) for 1 PIM, 1.27 (95% CI 1.19-1.35) for 2 PIM, 1.35 (95% CI 1.22-1.50) for 3 PIM, and 1.63 (95% CI 1.40-1.90) for more than 3 PIM compared to no PIM use. Conclusions: The prevalence of PIM in managed care health plans are widely found but seem to be much lower than rates of non-managed care plans. Furthermore, our study revealed a significant association with adverse outcomes in terms of hospitalizations. These findings stress the need for further development of interventions to decrease drug-related problems and manage patients with multiple chronic conditions.	[Reich, Oliver; Rapold, Roland] Helsana Grp, Dept Hlth Sci, Zurich, Switzerland; [Rosemann, Thomas; Senn, Oliver] Univ Zurich Hosp, Inst Gen Practice & Hlth Serv Res, CH-8091 Zurich, Switzerland; [Blozik, Eva] Univ Med Ctr Hamburg Eppendorf, Dept Primary Med Care, Hamburg, Germany	University of Zurich; University Zurich Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf	Reich, O (corresponding author), Helsana Grp, Dept Hlth Sci, Zurich, Switzerland.	oliver.reich@helsana.ch		Senn, Oliver/0000-0003-4422-7250; Rapold, Roland/0000-0001-8287-290X	Swiss Academy of Medical Sciences (SAMS), Basel, Switzerland	Swiss Academy of Medical Sciences (SAMS), Basel, Switzerland	This work was supported by an unconditional grant from the Swiss Academy of Medical Sciences (SAMS), Basel, Switzerland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert SM, 2010, DRUG AGING, V27, P407, DOI 10.2165/11315990-000000000-00000; Aparasu RR, 2000, ANN PHARMACOTHER, V34, P338, DOI 10.1345/aph.19006; Barnett MJ, 2006, J MANAGE CARE PHARM, V12, P362, DOI 10.18553/jmcp.2006.12.5.362; Barry Patrick J, 2008, Curr Psychiatry Rep, V10, P37, DOI 10.1007/s11920-008-0008-3; Blozik E, 2013, DRUG AGING, V30, P561, DOI 10.1007/s40266-013-0073-0; Bodenheimer T, 2008, NEW ENGL J MED, V358, P1064, DOI 10.1056/NEJMhpr0706165; Cahir C, 2010, BRIT J CLIN PHARMACO, V69, P543, DOI 10.1111/j.1365-2125.2010.03628.x; Cannon Katrina T, 2006, Am J Geriatr Pharmacother, V4, P134, DOI 10.1016/j.amjopharm.2006.06.010; Chini F, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-688; Cossman RE, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-25; Dedhiya SD, 2010, AM J GERIATR PHARMAC, V8, P562, DOI 10.1016/S1543-5946(10)80005-4; Federal Office of Public Health FOPH, 2013, STAT ONL KRANK 2012; Federal Statistical Office, 2010, SZEN BEV SCHW 2010 2; Fick D, 2001, J MANAGE CARE PHARM, V7, P407, DOI [10.18553/jmcp.2001.7.5.407, DOI 10.18553/JMCP.2001.7.5.407]; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Fick DM, 2008, RES NURS HEALTH, V31, P42, DOI 10.1002/nur.20232; Fu AZ, 2007, MED CARE, V45, P472, DOI 10.1097/01.mlr.0000254571.05722.34; Galvin R, 2014, EUR J CLIN PHARMACOL, V70, P599, DOI 10.1007/s00228-014-1651-8; Giron MST, 2001, J AM GERIATR SOC, V49, P277, DOI 10.1046/j.1532-5415.2001.4930277.x; Goltz L, 2012, INT J CLIN PHARM TH, V50, P185, DOI 10.5414/CP201441; Hanlon JT, 2002, J AM GERIATR SOC, V50, P26, DOI 10.1046/j.1532-5415.2002.50004.x; Harugeri A, 2010, J POSTGRAD MED, V56, P186, DOI 10.4103/0022-3859.68642; Hilmer SN, 2009, CLIN PHARMACOL THER, V85, P86, DOI 10.1038/clpt.2008.224; Holt S, 2010, DTSCH ARZTEBL INT, V107, P543, DOI 10.3238/arztebl.2010.0543; Huber CA, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1030; Huber CA, 2013, J CLIN EPIDEMIOL, V66, P1118, DOI 10.1016/j.jclinepi.2013.04.011; Jano E, 2007, ANN PHARMACOTHER, V41, P438, DOI 10.1345/aph.1H473; Klarin I, 2005, DRUG AGING, V22, P69, DOI 10.2165/00002512-200522010-00005; Lau DT, 2005, ARCH INTERN MED, V165, P68, DOI 10.1001/archinte.165.1.68; Lin HY, 2008, DRUG AGING, V25, P49, DOI 10.2165/00002512-200825010-00006; Liu Gordon G, 2002, J Am Pharm Assoc (Wash), V42, P847; Maio V, 2006, DRUG AGING, V23, P915, DOI 10.2165/00002512-200623110-00006; McLean AJ, 2004, PHARMACOL REV, V56, P163, DOI 10.1124/pr.56.2.4; O'Mahony D, 2010, EUR GERIATR MED, V1, P45, DOI 10.1016/j.eurger.2010.01.007; O'Shea M, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-23; Oliveira MG, 2012, INT J CLIN PHARM-NET, V34, P626, DOI 10.1007/s11096-012-9656-9; Opondo D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043617; Price SD, 2014, ANN PHARMACOTHER, V48, P6, DOI 10.1177/1060028013504904; Reich O, 2012, INT J INTEGR CARE, V12; Rothberg MB, 2008, J HOSP MED, V3, P91, DOI 10.1002/jhm.290; Ruggiero C, 2010, DRUG AGING, V27, P747, DOI 10.2165/11538240-000000000-00000; Schubert I, 2013, PHARMACOEPIDEM DR S, V22, P719, DOI 10.1002/pds.3429; Sichieri K, 2013, ADV PHARMACOL PHARM, V1, P74, DOI 10.13189/app.2013.010205; Siebert S, 2013, Z GERONTOL GERIATR, V46, P35, DOI 10.1007/s00391-012-0324-4; Simon SR, 2005, J AM GERIATR SOC, V53, P227, DOI 10.1111/j.1532-5415.2005.53107.x; Stockl KM, 2010, AM J MANAG CARE, V16, pE1; Swiss Federal Office of Statistics SFOS, 2013, STAND WOHNB NACH GES; Tamura BK, 2012, CLIN GERIATR MED, V28, P217, DOI 10.1016/j.cger.2012.01.005; Tragni E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078827; de Lima TJV, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-52; Zuckerman IH, 2006, MED CARE, V44, P722, DOI 10.1097/01.mlr.0000215849.15769.be	52	84	89	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2014	9	8							e105425	10.1371/journal.pone.0105425	http://dx.doi.org/10.1371/journal.pone.0105425			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AN6XM	25136981	Green Submitted, Green Published, gold			2023-01-03	WOS:000340742100093
J	Han, SL; Zhang, XP; Zou, LL; Lu, CH; Zhang, J; Li, J; Li, MQ				Han, Shilong; Zhang, Xiaoping; Zou, Liling; Lu, Chenhui; Zhang, Jun; Li, Jue; Li, Maoquan			Does Drug-Eluting Bead Transcatheter Arterial Chemoembolization Improve the Management of Patients with Hepatocellular Carcinoma? A Meta-Analysis	PLOS ONE			English	Article							PHASE-II TRIAL; TRANSARTERIAL CHEMOEMBOLIZATION; IN-VITRO; DC BEAD; DEB TACE; DOXORUBICIN; IRINOTECAN; SURVIVAL; LIVER; MICROSPHERES	Background: Drug eluting beads (DEB) are relatively new embolic agents that allow sustained release of chemotherapeutic agents in a localized fashion to the tumor. This technique is associated with reduced systemic side effects relative to systemic chemotherapy and an increase in the dose of antineoplastic agent delivered to the lesion. The meta-analysis was undertaken to assess the effectiveness of DEB-transcatheter arterial chemoembolization (TACE) in the management of hepatocellular cancer. Methods: We searched the Web of Science, PubMed, EBSCO, EMBASE, the Wiley Library and Google Scholar for studies on DEB-TACE in the management of hepatocellular cancer from 1979 to April 2013. The risk of bias was assessed using RevMan 5.1. Random and fixed-effects meta-analytical models were used where indicated, and between-study heterogeneity was assessed. Disease control, complications and severe complications were recorded. Results: Five studies met the selection criteria, three RCTs and two case-control studies, published from 2010 to 2012, included 217 patients in the DEB-TACE group and 237 in the conventional-TACE group. There was no significance over disease control (OR 2.27, 95% CI 0.78-6.63) with moderate between-study heterogeneity (chi(2) = 6.83, degrees of freedom [df] = 3; p<0.08; I-2 = 56%). Complications in both groups were assessed and no significant difference was observed (chi(2) = 6.34, degrees of freedom [df] = 4; p<0.18; I-2 = 37%). Severe complications were also assessed and no significant difference was observed (chi(2) = 6.47, degrees of freedom [df] = 4; p<0.17; I-2 = 38%). No publication bias relating to the above outcomes was detected by funnel plot. DEB-TACE benefited disease control without an increase in complications and severe complications.	[Han, Shilong; Zhang, Xiaoping; Lu, Chenhui; Li, Maoquan] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Intervent & Vasc Surg, Shanghai 200092, Peoples R China; [Zou, Liling; Zhang, Jun; Li, Jue] Tongji Univ, Sch Med, Heart Lung & Blood Vessel Ctr, Shanghai 200092, Peoples R China	Tongji University; Tongji University	Li, J (corresponding author), Tongji Univ, Sch Med, Heart Lung & Blood Vessel Ctr, Shanghai 200092, Peoples R China.	Jueli@tongji.edu.cn; cjr.limaoquan@163.vip.com			National Key Technology Research and Development Program of the Ministry of Science and Technology of China [2012BAI15B06]	National Key Technology Research and Development Program of the Ministry of Science and Technology of China(National Key Technology R&D Program)	This work was supported by the National Key Technology Research and Development Program of the Ministry of Science and Technology of China (2012BAI15B06). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Burrel M, 2012, J HEPATOL, V56, P1330, DOI 10.1016/j.jhep.2012.01.008; Camma C, 2002, RADIOLOGY, V224, P47, DOI 10.1148/radiol.2241011262; Cannon RM, 2012, ONKOLOGIE, V35, P184, DOI 10.1159/000337402; Chung WS, 2012, AM J ROENTGENOL, V199, P349, DOI 10.2214/AJR.11.7563; Clarke M, 2001, LANCET, V357, P1728, DOI 10.1016/S0140-6736(00)04934-5; Dhanasekaran R, 2010, HPB, V12, P174, DOI 10.1111/j.1477-2574.2009.00138.x; Doi SAR, 2011, CONTEMP CLIN TRIALS, V32, P288, DOI 10.1016/j.cct.2010.12.006; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Eyol E, 2008, CLIN EXP METASTAS, V25, P273, DOI 10.1007/s10585-008-9142-x; Alonso MGH, 2010, RADIOLOGIA-MADRID, V52, P425, DOI 10.1016/j.rx.2010.05.008; Grosso M, 2008, CARDIOVASC INTER RAD, V31, P1141, DOI 10.1007/s00270-008-9409-2; Gupta S, 2011, CARDIOVASC INTER RAD, V34, P1021, DOI 10.1007/s00270-011-0154-6; Han KH, 2011, ONCOLOGY-BASEL, V81, P158, DOI 10.1159/000333280; Hong K, 2006, CLIN CANCER RES, V12, P2563, DOI 10.1158/1078-0432.CCR-05-2225; Jordan O, 2010, J VASC INTERV RADIOL, V21, P1084, DOI 10.1016/j.jvir.2010.02.042; Lammer J, 2010, CARDIOVASC INTER RAD, V33, P41, DOI 10.1007/s00270-009-9711-7; Lewis AL, 2006, J VASC INTERV RADIOL, V17, P335, DOI 10.1097/01.RVI.0000195323.46152.B3; Lewis AL, 2006, J VASC INTERV RADIOL, V17, P1335, DOI 10.1097/01.RVI.0000228416.21560.7F; Liu DM, 2012, CARDIOVASC INTER RAD, V35, P391, DOI 10.1007/s00270-011-0168-0; Maeda N, 2010, J VASC INTERV RADIOL, V21, P877, DOI 10.1016/j.jvir.2010.02.009; Malagari K, 2008, CARDIOVASC INTER RAD, V31, P269, DOI 10.1007/s00270-007-9226-z; Malagari K, 2012, CARDIOVASC INTER RAD, V35, P1119, DOI 10.1007/s00270-012-0394-0; Malagari K, 2011, CARDIOVASC INTER RAD, V34, P774, DOI 10.1007/s00270-010-0044-3; Malagari K, 2010, CARDIOVASC INTER RAD, V33, P541, DOI 10.1007/s00270-009-9750-0; Martin RCG, 2010, CARDIOVASC INTER RAD, V33, P960, DOI 10.1007/s00270-010-9937-4; Martin R, 2012, HEPATO-GASTROENTEROL, V59, P255, DOI 10.5754/hge10240; Moschouris H, 2010, CARDIOVASC INTER RAD, V33, P1022, DOI 10.1007/s00270-010-9800-7; Namur J, 2011, J HEPATOL, V55, P1332, DOI 10.1016/j.jhep.2011.03.024; Osuga K, 2012, INT J CLIN ONCOL, V17, P306, DOI 10.1007/s10147-012-0445-1; Pawlik TM, 2011, J CLIN ONCOL, V29, P3960, DOI 10.1200/JCO.2011.37.1021; Pomoni M, 2012, HEPATO-GASTROENTEROL, V59, P820, DOI 10.5754/hge11347; Poon RTP, 2007, CLIN GASTROENTEROL H, V5, P1100, DOI 10.1016/j.cgh.2007.04.021; Prajapati HJ, 2013, ANN ONCOL, V24, P965, DOI 10.1093/annonc/mds605; Prajapati HJ, 2012, J VASC INTERV RADIOL, V23, P1286, DOI 10.1016/j.jvir.2012.07.003; Reyes DK, 2009, CANCER J, V15, P526, DOI 10.1097/PPO.0b013e3181c5214b; Sacco R, 2011, J VASC INTERV RADIOL, V22, P1545, DOI 10.1016/j.jvir.2011.07.002; Sadick M, 2010, ONKOLOGIE, V33, P31, DOI 10.1159/000264620; Seki A, 2012, CARDIOVASC INTER RAD, V35, P555, DOI 10.1007/s00270-011-0176-0; Seki A, 2011, CARDIOVASC INTER RAD, V34, P557, DOI 10.1007/s00270-010-9975-y; Skowasch M, 2012, EUR J RADIOL, V81, P3857, DOI 10.1016/j.ejrad.2012.07.002; Smith BW, 2009, J GASTROEN HEPATOL, V24, pA307; Song MJ, 2012, J HEPATOL, V57, P1244, DOI 10.1016/j.jhep.2012.07.017; Sottani C, 2012, ANTICANCER RES, V32, P1769; Syha R, 2012, EUR J GASTROEN HEPAT, V24, P1325, DOI 10.1097/MEG.0b013e32835724bc; Takayasu K, 2012, JPN J CLIN ONCOL, V42, P247, DOI 10.1093/jjco/hys020; Tam KY, 2011, EUR J PHARM SCI, V44, P1, DOI 10.1016/j.ejps.2011.06.013; Taylor RR, 2007, EUR J PHARM SCI, V30, P7, DOI 10.1016/j.ejps.2006.09.002; van Malenstein H, 2011, ONKOLOGIE, V34, P368, DOI 10.1159/000329602; Varela M, 2007, J HEPATOL, V46, P474, DOI 10.1016/j.jhep.2006.10.020; Vogl TJ, 2011, AM J ROENTGENOL, V197, pW562, DOI 10.2214/AJR.10.4379; Walzer N, 2008, CURR OPIN GASTROEN, V24, P312, DOI 10.1097/MOG.0b013e3282fafef3; Weng LH, 2011, INT J PHARMACEUT, V409, P185, DOI 10.1016/j.ijpharm.2011.02.058; Wiggermann P, 2011, MED SCI MONITOR, V17, pCR189, DOI 10.12659/MSM.881714	53	23	26	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2014	9	8							e102686	10.1371/journal.pone.0102686	http://dx.doi.org/10.1371/journal.pone.0102686			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM4JL	25083860	Green Published, Green Submitted, gold			2023-01-03	WOS:000339819800011
J	Barbui, C; Purgato, M				Barbui, Corrado; Purgato, Marianna			Decisions on WHO's essential medicines need more scrutiny	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ANTIPSYCHOTIC-DRUGS; SCHIZOPHRENIA; LIST		[Barbui, Corrado; Purgato, Marianna] Univ Verona, WHO Collaborating Ctr Res & Training Mental Hlth, Dept Publ Hlth & Community Med, Sect Psychiat,Policlini GB Rossi, I-37134 Verona, Italy	University of Verona	Barbui, C (corresponding author), Univ Verona, WHO Collaborating Ctr Res & Training Mental Hlth, Dept Publ Hlth & Community Med, Sect Psychiat,Policlini GB Rossi, Piazzale Scuro 10, I-37134 Verona, Italy.	corrado.barbui@univr.it						Barbui C, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001530; Barbui C, 2013, LANCET, V382, P1234, DOI 10.1016/S0140-6736(13)60255-X; Barbui C, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000322; Chirac P, 2001, LANCET, V357, P1134, DOI 10.1016/S0140-6736(00)04291-4; Hill S, 2007, LANCET, V369, P1842, DOI 10.1016/S0140-6736(07)60676-X; Laing R, 2003, LANCET, V361, P1723, DOI 10.1016/S0140-6736(03)13375-2; Leucht S, 2013, LANCET, V382, P951, DOI 10.1016/S0140-6736(13)60733-3; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; Purgato M, 2012, EPIDEMIOL PSYCH SCI, V21, P343, DOI 10.1017/S204579601200039X; WHO, WHO MED STRAT REV PR	10	10	10	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 31	2014	349								g4798	10.1136/bmj.g4798	http://dx.doi.org/10.1136/bmj.g4798			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AM5NW	25081250				2023-01-03	WOS:000339907800002
J	Ali, BH; Al-Salam, S; Al Za'abi, M; Al Balushi, KA; Ramkumar, A; Waly, MI; Yasin, J; Adham, SA; Nemmar, A				Ali, Badreldin H.; Al-Salam, Suhail; Al Za'abi, Mohammed; Al Balushi, Khalid A.; Ramkumar, Aishwarya; Waly, Mostafa I.; Yasin, Javid; Adham, Sirin A.; Nemmar, Abderrahim			Does Swimming Exercise Affect Experimental Chronic Kidney Disease in Rats Treated with Gum Acacia?	PLOS ONE			English	Article							CHRONIC-RENAL-FAILURE; OXIDATIVE STRESS BIOMARKERS; WATER-BASED EXERCISE; DAMAGE; HEMODIALYSIS; HEALTH; CKD	Different modes of exercise are reported to be beneficial in subjects with chronic kidney disease (CKD). Similar benefits have also been ascribed to the dietary supplement gum acacia (GA). Using several physiological, biochemical, immunological, and histopathological measurements, we assessed the effect of swimming exercise (SE) on adenine -induced CKD, and tested whether SE would influence the salutary action of GA in rats with CKD. Eight groups of rats were used, the first four of which were fed normal chow for 5 weeks, feed mixed with adenine (0.25% w/w) to induce CKD, GA in the drinking water (15% w/v), or were given adenine plus GA, as above. Another four groups were similarly treated, but were subjected to SE during the experimental period, while the first four groups remained sedentary. The pre-SE program lasted for four days (before the start of the experimental treatments), during which the rats were made to swim for 5 to 10 min, and then gradually extended to 20 min per day. Thereafter, the rats in the 5th, 6th, 7th, and 8th groups started to receive their respective treatments, and were subjected to SE three days a week for 45 min each. Adenine induced the typical signs of CKD as confirmed by histopathology, and the other measurements, and GA significantly ameliorated all these signs. SE did not affect the salutary action of GA on renal histology, but it partially improved some of the above biochemical and physiological analytes, suggesting that addition of this mode of exercise to GA supplementation may improve further the benefits of GA supplementation.	[Ali, Badreldin H.; Al Za'abi, Mohammed; Al Balushi, Khalid A.; Ramkumar, Aishwarya] Sultan Qaboos Univ, Dept Pharmacol & Clin Pharm, Coll Med & Hlth Sci, Muscat, Oman; [Al-Salam, Suhail] Coll Med & Hlth Sci, Dept Pathol, Alin, U Arab Emirates; [Waly, Mostafa I.] Sultan Qaboos Univ, Coll Agr & Marine Sci, Dept Food Sci & Nutr, Muscat, Oman; [Yasin, Javid] Coll Med & Hlth Sci, Dept Med, Alin, U Arab Emirates; [Adham, Sirin A.] Sultan Qaboos Univ, Dept Biol, Coll Sci, Muscat, Oman; [Nemmar, Abderrahim] Coll Med & Hlth Sci, Dept Physiol, Alin, U Arab Emirates	Sultan Qaboos University; Sultan Qaboos University; Sultan Qaboos University	Ali, BH (corresponding author), Sultan Qaboos Univ, Dept Pharmacol & Clin Pharm, Coll Med & Hlth Sci, Muscat, Oman.	alibadreldin@hotmail.com	Za'abi, Mohammed Al/C-6591-2013; Adham, Sirin A/ABB-8842-2020; PATHAN, JAVED YASIN/GOE-4396-2022; Waly, Mostafa/P-7516-2016	Za'abi, Mohammed Al/0000-0002-2019-1022; Adham, Sirin A/0000-0002-8349-6202; Waly, Mostafa/0000-0002-8197-3378; PATHAN, JAVED YASIN/0000-0002-5867-2833; Al-Salam, Suhail/0000-0003-0109-5964; Al Balushi, Khalid/0000-0003-4638-8787	Research Council of Oman [RC/Med/Phar/10/01]; Sultan Qaboos University (SQU)	Research Council of Oman(Ministry of Higher Education, Research & Innovation, OmanThe Research Council Oman); Sultan Qaboos University (SQU)	This work was financially supported by a grant from the Research Council of Oman (RC/Med/Phar/10/01), and the Sultan Qaboos University (SQU). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al Za'abi M, 2013, J CHROMATOGR SCI, V51, P40, DOI 10.1093/chromsci/bms103; Ali AA, 2008, NAT PROD RES, V22, P12, DOI 10.1080/14786410500463544; Ali BH, 2014, PHYSIOL RES, V63, P351, DOI 10.33549/physiolres.932685; Ali BH, 2013, J PHARMACOL TOX MET, V68, P384, DOI 10.1016/j.vascn.2013.05.001; Ali BH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055242; Ali BH, 2011, PHYTOMEDICINE, V18, P1176, DOI 10.1016/j.phymed.2011.03.005; Ali BH, 2010, EXP BIOL MED, V235, P373, DOI 10.1258/ebm.2009.009214; Ali BH, 2009, FOOD CHEM TOXICOL, V47, P1, DOI 10.1016/j.fct.2008.07.001; Babiker R, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-111; Neto OB, 2013, J SPORT SCI MED, V12, P52; Briasoulis A, 2013, CURR CARDIOL REP, V15, DOI 10.1007/s11886-012-0340-4; Bronas UG, 2009, ADV CHRONIC KIDNEY D, V16, P449, DOI 10.1053/j.ackd.2009.07.005; Cechella JL, 2014, AMINO ACIDS IN PRESS; Clapp EL, 2012, PEDIATR NEPHROL, V27, P165, DOI 10.1007/s00467-010-1753-1; Deminice R, 2010, J SPORT MED PHYS FIT, V50, P356; Deminice R, 2012, AMINO ACIDS, V43, P709, DOI 10.1007/s00726-011-1121-x; Diwan V, 2013, J PHARMACOL TOX MET, V68, P197, DOI 10.1016/j.vascn.2013.05.006; Fuchs TC, 2011, AAPS J, V13, P615, DOI 10.1208/s12248-011-9301-x; Gegentonglaga, 2013, LIFE SCI, V93, P773, DOI 10.1016/j.lfs.2013.09.022; Harambat J, 2012, PEDIATR NEPHROL, V27, P363, DOI 10.1007/s00467-011-1939-1; Heiwe S, 2011, COCHRANE DB SYST REV, V5; Heiwe S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003236.pub2; Hossain MP, 2009, AM J KIDNEY DIS, V53, P166, DOI 10.1053/j.ajkd.2007.10.047; Howden EJ, 2012, SPORTS MED, V42, P473, DOI 10.2165/11630800-000000000-00000; Ishikawa Y, 2012, EXP DIABETES RES, DOI 10.1155/2012/702948; Johansen KL, 2012, AM J KIDNEY DIS, V59, P126, DOI 10.1053/j.ajkd.2011.10.008; Knight SF, 2010, AM J PHYSIOL-RENAL, V298, pF86, DOI 10.1152/ajprenal.00351.2009; Koufaki P, 2002, CLIN PHYSIOL FUNCT I, V22, P115, DOI 10.1046/j.1365-2281.2002.00405.x; Kucukkoylu S, 2013, DEUT MED WOCHENSCHR, V138, P721, DOI 10.1055/s-0032-1332979; Kutner NG, 2007, INT UROL NEPHROL, V39, P1281, DOI 10.1007/s11255-007-9281-z; Luiz Rda S, 2013, PLOS ONE, V8, DOI DOI 10.1371/J0URNAL.P0NE.0055363; Meredith-Jones K, 2011, COMPLEMENT THER MED, V19, P93, DOI 10.1016/j.ctim.2011.02.002; Mosawi AJ, 2009, CLIN EXP NEPHROL, V13, P494, DOI 10.1007/s10157-009-0181-7; Pechter U, 2003, INT J REHABIL RES, V26, P153, DOI 10.1097/01.mrr.0000070755.63544.5a; Peng CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037388; Ranadive SM, 2014, EXP PHYSL IN PRESS; Sakr HF, 2013, J PHYSIOL PHARMACOL, V64, P231; Segura-Orti E, 2010, SEMIN DIALYSIS, V23, P422, DOI 10.1111/j.1525-139X.2010.00766.x; Smart N, 2011, NEPHROLOGY, V16, P626, DOI 10.1111/j.1440-1797.2011.01471.x; Tanaka H, 2009, SPORTS MED, V39, P377, DOI 10.2165/00007256-200939050-00004	40	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2014	9	7							e102528	10.1371/journal.pone.0102528	http://dx.doi.org/10.1371/journal.pone.0102528			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM0SW	25048380	gold, Green Published, Green Submitted			2023-01-03	WOS:000339558100041
J	Li, N; Yang, L; Ou, W; Zhang, L; Zhang, SL; Wang, SY				Li, Ning; Yang, Lu; Ou, Wei; Zhang, Liang; Zhang, Song-liang; Wang, Si-yu			Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer	PLOS ONE			English	Article							PHASE-III TRIAL; PROGRESSION-FREE SURVIVAL; OPEN-LABEL; RANDOMIZED-TRIAL; SUPPORTIVE CARE; GEFITINIB; DOCETAXEL; ERLOTINIB; EFFICACY; MULTICENTER	Background: Since efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) versus chemotherapy in the treatment of patients with pretreated advanced non-small cell lung cancer (NSCLC) remain controversial, we performed a meta-analysis to compare them. Methods: An internet search of several databases was performed, including PubMed, Embase, and the Cochrane database. Randomized trials that compared an EGFR-TKI with chemotherapy in the second-line setting were included. The outcomes were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and grade 3-4 toxicities. The PFS, OS for the EGFR mutation-positive (EGFR M+) and EGFR mutation-negative (EGFR M-) subgroups were pooled. The pooled hazard ratios (HRs) and odds ratios (ORs) with their corresponding confidence intervals (CIs) were calculated on the STATA software. Results: Our meta-analysis combined 3,825 patients from 10 randomized trials. Overall, EGFR-TKIs and second-line chemotherapy have equivalent efficacy in terms of PFS (HR, 1.03; 95% CI, 0.87-1.21; P = 0.73; I-2 = 78.7%, P-heterogeneity<0.001), OS (HR, 1.00; 95% CI, 0.92-1.08; P = 0.90; I-2 = 0.0%, P-heterogeneity = 0.88), and ORR (OR, 1.34; 95% CI, 0.86-2.08; P = 0.20; I-2 = 73.1%, P-heterogeneity<0.001). However, subgroup analysis based on EGFR mutation status showed that second-line chemotherapy significantly improved PFS (HR, 1.35; 95% CI, 1.09-1.66; P = 0.01; I-2 = 55.7%, P-heterogeneity = 0.046) for EGFR M- patients, whereas OS was equal (HR, 0.96; 95% CI, 0.77-1.19; P = 0.69; I-2 = 0.0%, P-heterogeneity = 0.43); EGFR-TKIs significantly improved PFS (HR, 0.28; 95% CI, 0.15-0.53; P<0.001; I-2 = 4.1%, P-heterogeneity = 0.35) for EGFR M+ patients, whereas OS was equal (HR, 0.86; 95% CI, 0.44-1.68; P = 0.65; I-2 = 0.0%, P-heterogeneity = 0.77). Compared with chemotherapy, EGFR-TKIs led to more grade 3-4 rash, but less fatigue/asthenia disorder, leukopenia and thrombocytopenia. Conclusions: Our analysis suggests that chemotherapy in the second-line setting can prolong PFS in EGFR M- patients, whereas it has no impact on OS. EGFR-TKIs seem superior over chemotherapy as second-line therapy for EGFR M+ patients. Our findings support obtaining information on EGFR mutational status before initiation of second-line treatment.	[Li, Ning; Ou, Wei; Zhang, Song-liang; Wang, Si-yu] Sun Yat Sen Univ, Dept Thorac Surg, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China; [Yang, Lu] Sun Yat Sen Univ, Dept Breast Oncol, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China; [Zhang, Liang] Tianjin First Ctr Hosp, Dept Thorac Surg, Tianjin, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Wang, SY (corresponding author), Sun Yat Sen Univ, Dept Thorac Surg, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China.	wsysums@163.net		Wang, Si-Yu/0000-0002-7603-2012				BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Ciuleanu T, 2012, LANCET ONCOL, V13, P300, DOI 10.1016/S1470-2045(11)70385-0; Cufer T, 2006, ANTI-CANCER DRUG, V17, P401, DOI 10.1097/01.cad.0000203381.99490.ab; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fossella FV, 2000, J CLIN ONCOL, V18, P2354, DOI 10.1200/JCO.2000.18.12.2354; Fukuoka M, 2011, J CLIN ONCOL, V29, P2866, DOI 10.1200/JCO.2010.33.4235; Gao GH, 2013, J CLIN ONCOL, V31; Garassino MC, 2012, J CLIN ONCOL S, V30; Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hotta K, 2013, LUNG CANCER, V79, P20, DOI 10.1016/j.lungcan.2012.10.007; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Karampeazis A, 2013, CANCER-AM CANCER SOC, V119, P2754, DOI 10.1002/cncr.28132; Kim ES, 2008, LANCET, V372, P1809, DOI 10.1016/S0140-6736(08)61758-4; KURITZ SJ, 1988, ANNU REV PUBL HEALTH, V9, P123, DOI 10.1146/annurev.pu.09.050188.001011; Lee CK, 2013, JNCI-J NATL CANCER I, V105, P595, DOI 10.1093/jnci/djt072; Lee DH, 2010, CLIN CANCER RES, V16, P1307, DOI 10.1158/1078-0432.CCR-09-1903; Maruyama R, 2008, J CLIN ONCOL, V26, P4244, DOI 10.1200/JCO.2007.15.0185; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Mok TSK, 2009, J CLIN ONCOL, V27, P5080, DOI 10.1200/JCO.2008.21.5541; Okano Y, 2013, J CLIN ONCOL, V31; Paz-Ares L, 2012, LANCET ONCOL, V13, P225, DOI 10.1016/S1470-2045(12)70001-3; Qi WX, 2012, ASIAN PAC J CANCER P, V13, P5177, DOI 10.7314/APJCP.2012.13.10.5177; Scagliotti GV, 2002, J CLIN ONCOL, V20, P4285, DOI 10.1200/JCO.2002.02.068; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095; Soria JC, 2010, ANN ONCOL, V21, P2324, DOI 10.1093/annonc/mdq204; Sun JM, 2012, CANCER-AM CANCER SOC, V118, P6234, DOI 10.1002/cncr.27630; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Wang SY, 2013, J CLIN ONCOL S, V31, P2013; Yang JJ, 2013, J CLIN ONCOL, V31	34	29	31	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2014	9	7							e102777	10.1371/journal.pone.0102777	http://dx.doi.org/10.1371/journal.pone.0102777			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4KM	25029199	Green Published, gold, Green Submitted			2023-01-03	WOS:000341306600099
J	Zhang, X; Woolley, DG; Swinnen, SP; Feys, H; Meesen, R; Wenderoth, N				Zhang, Xue; Woolley, Daniel G.; Swinnen, Stephan P.; Feys, Hilde; Meesen, Raf; Wenderoth, Nicole			Changes in Corticomotor Excitability and Intracortical Inhibition of the Primary Motor Cortex Forearm Area Induced by Anodal tDCS	PLOS ONE			English	Article							DIRECT-CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; NONINVASIVE CORTICAL STIMULATION; STROKE PATIENTS; SILENT PERIOD; CORTICOCORTICAL INHIBITION; EFFECTIVE CONNECTIVITY; HUMANS; FACILITATION; MODULATION	Objective: Previous studies have investigated how tDCS over the primary motor cortex modulates excitability in the intrinsic hand muscles. Here, we tested if tDCS changes corticomotor excitability and/or cortical inhibition when measured in the extensor carpi radialis (ECR) and if these aftereffects can be successfully assessed during controlled muscle contraction. Methods: We implemented a double blind cross-over design in which participants (n = 16) completed two sessions where the aftereffects of 20 min of 1 mA (0.04 mA/cm(2)) anodal vs sham tDCS were tested in a resting muscle, and two more sessions where the aftereffects of anodal vs sham tDCS were tested in an active muscle. Results: Anodal tDCS increased corticomotor excitability in ECR when aftereffects were measured with a low-level controlled muscle contraction. Furthermore, anodal tDCS decreased short interval intracortical inhibition but only when measured at rest and after non-responders (n = 2) were removed. We found no changes in the cortical silent period. Conclusion: These findings suggest that targeting more proximal muscles in the upper limb with anodal tDCS is achievable and corticomotor excitability can be assessed in the presence of a low-level controlled contraction of the target muscle.	[Zhang, Xue; Woolley, Daniel G.; Swinnen, Stephan P.; Meesen, Raf; Wenderoth, Nicole] Katholieke Univ Leuven, Dept Kinesiol, Motor Control Lab, Movement Control & Neuroplast Res Grp, Leuven, Belgium; [Feys, Hilde] Katholieke Univ Leuven, Res Grp Neuromotor Rehabil, Dept Rehabil Sci, Leuven, Belgium; [Meesen, Raf] Hasselt Univ, Biomed Res Inst, REVAL Rehabil Res Ctr, Hasselt, Belgium; [Wenderoth, Nicole] ETH, Dept Hlth Sci & Technol, Neural Control Movement Lab, Zurich, Switzerland	KU Leuven; KU Leuven; Hasselt University; Swiss Federal Institutes of Technology Domain; ETH Zurich	Wenderoth, N (corresponding author), Katholieke Univ Leuven, Dept Kinesiol, Motor Control Lab, Movement Control & Neuroplast Res Grp, Leuven, Belgium.	nicole.wenderoth@hest.ethz.ch	Cuypers, Koen/N-9918-2018; Wenderoth, Nicole/D-7262-2015; Meesen, Raf L/F-2582-2019	Wenderoth, Nicole/0000-0002-3246-9386; Meesen, Raf L/0000-0002-7938-3758	Flanders Fund for Scientific Research [G. 0758.10]	Flanders Fund for Scientific Research(FWO)	This work was funded by the Flanders Fund for Scientific Research (Project G. 0758.10). Xue Zhang is a pre-doctoral fellow of the Flanders Fund for Scientific Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbruzzese G, 1999, J PHYSIOL-LONDON, V514, P895, DOI 10.1111/j.1469-7793.1999.895ad.x; Antal A, 2007, EUR J NEUROSCI, V26, P2687, DOI 10.1111/j.1460-9568.2007.05896.x; Batsikadze G, 2013, J PHYSIOL-LONDON, V591, P1987, DOI 10.1113/jphysiol.2012.249730; Boggio PS, 2006, NEUROSCI LETT, V404, P232, DOI 10.1016/j.neulet.2006.05.051; Boros K, 2008, EUR J NEUROSCI, V27, P1292, DOI 10.1111/j.1460-9568.2008.06090.x; Bradnam LV, 2010, J NEUROPHYSIOL, V103, P2382, DOI 10.1152/jn.01046.2009; Byblow WD, 2012, PLOS ONE, V7, DOI [10.1371/journal.-pone.0033882, DOI 10.1371/JOURNAL.-PONE.0033882]; Cash RFH, 2013, J NEUROPHYSIOL, V109, P106, DOI 10.1152/jn.00584.2011; Cengiz B, 2013, EXP BRAIN RES, V225, P321, DOI 10.1007/s00221-012-3369-0; Chen R, 1998, J NEUROPHYSIOL, V80, P2870, DOI 10.1152/jn.1998.80.6.2870; Daskalakis ZJ, 2003, CLIN NEUROPHYSIOL, V114, P938, DOI 10.1016/S1388-2457(03)00038-5; Datta Abhishek, 2012, Front Psychiatry, V3, P91, DOI 10.3389/fpsyt.2012.00091; Di Lazzaro V, 1998, EXP BRAIN RES, V119, P265; Edwards DJ, 2009, RESTOR NEUROL NEUROS, V27, P199, DOI 10.3233/RNN-2009-0470; Fregni F, 2005, NEUROREPORT, V16, P1551, DOI 10.1097/01.wnr.0000177010.44602.5e; Furubayashi T, 2008, EXP BRAIN RES, V185, P279, DOI 10.1007/s00221-007-1149-z; Garvey MA, 2001, CLIN NEUROPHYSIOL, V112, P1451, DOI 10.1016/S1388-2457(01)00581-8; Hendy AM, 2013, MED SCI SPORT EXER, V45, P1721, DOI 10.1249/MSS.0b013e31828d2923; Hummel F, 2005, BRAIN, V128, P490, DOI 10.1093/brain/awh369; Hummel FC, 2010, NEUROBIOL AGING, V31, P2160, DOI 10.1016/j.neurobiolaging.2008.12.008; Ilic TV, 2002, J PHYSIOL-LONDON, V545, P153, DOI 10.1113/jphysiol.2002.030122; Jeffery DT, 2007, EXP BRAIN RES, V182, P281, DOI 10.1007/s00221-007-1093-y; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Lang N, 2004, EXP BRAIN RES, V156, P439, DOI 10.1007/s00221-003-1800-2; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Lindenberg R, 2010, NEUROLOGY, V75, P2176, DOI 10.1212/WNL.0b013e318202013a; Lopez-Alonso V, 2014, BRAIN STIMUL, V7, P372, DOI 10.1016/j.brs.2014.02.004; MacKinnon CD, 2005, ANN NEUROL, V58, P516, DOI 10.1002/ana.20599; Marquez CMS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027292; Martin PG, 2006, CLIN NEUROPHYSIOL, V117, P2684, DOI 10.1016/j.clinph.2006.08.008; Massimini M, 2005, SCIENCE, V309, P2228, DOI 10.1126/science.1117256; Miranda PC, 2006, CLIN NEUROPHYSIOL, V117, P1623, DOI 10.1016/j.clinph.2006.04.009; Nilsson J, 1997, J CLIN NEUROPHYSIOL, V14, P136, DOI 10.1097/00004691-199703000-00006; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PALMER E, 1992, J PHYSIOL-LONDON, V448, P397, DOI 10.1113/jphysiol.1992.sp019048; Paulus W, 2008, BRAIN STIMUL, V1, P151, DOI 10.1016/j.brs.2008.06.002; Pennisi G, 1999, STROKE, V30, P2666, DOI 10.1161/01.STR.30.12.2666; Peurala SH, 2008, CLIN NEUROPHYSIOL, V119, P2291, DOI 10.1016/j.clinph.2008.05.031; Reis J, 2009, P NATL ACAD SCI USA, V106, P1590, DOI 10.1073/pnas.0805413106; RIDDING MC, 1995, J PHYSIOL-LONDON, V487, P541, DOI 10.1113/jphysiol.1995.sp020898; Rosanova M, 2012, BRAIN, V135, P1308, DOI 10.1093/brain/awr340; Rosenkranz K, 2003, J PHYSIOL-LONDON, V551, P649, DOI 10.1113/jphysiol.2003.043752; Rosenkranz K, 2005, BRAIN, V128, P918, DOI 10.1093/brain/awh402; Roshan L, 2003, EXP BRAIN RES, V151, P330, DOI 10.1007/s00221-003-1502-9; Rutiku R, 2013, EUR J NEUROSCI, V38, P3768, DOI 10.1111/ejn.12374; Sanger TD, 2001, J PHYSIOL-LONDON, V530, P307, DOI 10.1111/j.1469-7793.2001.0307l.x; Shimizu T, 1999, CLIN NEUROPHYSIOL, V110, P575, DOI 10.1016/S1388-2457(98)00081-9; Siebner HR, 1998, MUSCLE NERVE, V21, P1209, DOI 10.1002/(SICI)1097-4598(199809)21:9<1209::AID-MUS15>3.3.CO;2-O; Smith MJ, 2002, ANN NEUROL, V51, P599, DOI 10.1002/ana.10180; Squeri V, 2014, IEEE T NEUR SYS REH, V22, P312, DOI 10.1109/TNSRE.2013.2250521; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614; Stagg CJ, 2009, J NEUROSCI, V29, P5202, DOI 10.1523/JNEUROSCI.4432-08.2009; Stinear CM, 2004, MOVEMENT DISORD, V19, P1312, DOI 10.1002/mds.20160; Suzuki K, 2012, INT J NEUROSCI, V122, P675, DOI 10.3109/00207454.2012.707715; Uy J, 2003, J NEUROSCI METH, V127, P193, DOI 10.1016/S0165-0270(03)00142-0; WASSERMANN EM, 1992, ELECTROEN CLIN NEURO, V85, P1, DOI 10.1016/0168-5597(92)90094-R; Wiethoff S, 2014, BRAIN STIMUL, V7, P468, DOI 10.1016/j.brs.2014.02.003	60	7	7	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2014	9	7							e101496	10.1371/journal.pone.0101496	http://dx.doi.org/10.1371/journal.pone.0101496			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK7WB	24999827	gold, Green Published, Green Submitted			2023-01-03	WOS:000338637300050
J	Opava, CH; Bjork, M				Opava, Christina H.; Bjork, Mathilda			Towards evidence-based hand exercises in rheumatoid arthritis	LANCET			English	Editorial Material							PHYSICAL-ACTIVITY; DISABILITY; DIAGNOSIS; PEOPLE		[Opava, Christina H.] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Physiotherapy, SE-14183 Huddinge, Sweden; [Opava, Christina H.] Karolinska Univ Hosp, Dept Rheumatol, Stockholm, Sweden; [Bjork, Mathilda] Linkoping Univ, Rehabil Ctr, Linkoping, Sweden; [Bjork, Mathilda] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden; [Bjork, Mathilda] Jonkoping Univ, Sch Hlth Sci, Dept Rehabil, Jonkoping, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Linkoping University; Linkoping University; Jonkoping University	Opava, CH (corresponding author), Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Physiotherapy, SE-14183 Huddinge, Sweden.	christina.opava@ki.se						Bergstra SA, 2014, CLIN RHEUMATOL, V33, P1539, DOI 10.1007/s10067-014-2691-2; Bjork M, 2009, J RHEUMATOL, V36, P1170, DOI 10.3899/jrheum.080523; BLAKE DR, 1989, LANCET, V1, P289, DOI 10.1016/S0140-6736(89)91305-6; Bodur H, 2006, RHEUMATOL INT, V26, P541, DOI 10.1007/s00296-005-0023-1; Filaire E, 2012, JOINT BONE SPINE, V79, P341, DOI 10.1016/j.jbspin.2012.03.007; Krishnan E, 2012, ANN RHEUM DIS, V71, P213, DOI 10.1136/annrheumdis-2011-200354; Lamb SE, 2014, LANCET; Nessen T, 2014, PHYS THER, V94, P644, DOI 10.2522/ptj.20130393; Nordgren B, 2014, ARTHRIT CARE RES, V66, P662, DOI 10.1002/acr.22189; Taylor P, 2010, J INT MED RES, V38, P1213, DOI 10.1177/147323001003800402; Thyberg I, 2012, CLIN RHEUMATOL, V31, P775, DOI 10.1007/s10067-012-1937-0	11	3	5	1	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	2015	385	9966					396	398		10.1016/S0140-6736(14)61285-X	http://dx.doi.org/10.1016/S0140-6736(14)61285-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AZ9CT	25308291				2023-01-03	WOS:000348509900005
J	Balachandran, JS; Patel, SR				Balachandran, Jay S.; Patel, Sanjay R.			Obstructive Sleep Apnea	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							POSITIVE AIRWAY PRESSURE; CLINICAL-PRACTICE GUIDELINE; PRACTICE PARAMETERS; DAYTIME SLEEPINESS; BLOOD-PRESSURE; WEIGHT-LOSS; THERAPY; CPAP; RISK; HYPERTENSION	The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including ACP Smart Medicine and MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic from these primary sources in collaboration with the ACP's Medical Education and Publishing divisions and with the assistance of science writers and physician writers. Editorial consultants from ACP Smart Medicine and MKSAP provide expert review of the content. Readers who are interested in these primary resources for more detail can consult http://smartmedicine.acponline.org, http://www.acponline.org/products_services/mksap/15/?pr31, and other resources referenced in each issue of In the Clinic. CME Objective: To review current evidence for the screening and prevention, diagnosis, treatment, and practice improvement of obstructive sleep apnea. The information contained herein should never be used as a substitute for clinical judgment. (C) 2014 American College of Physicians						Patel, Sanjay/0000-0002-9142-5172; Balachandran, Jay/0000-0001-5574-4662				Abrishami A, 2010, CAN J ANAESTH, V57, P423, DOI 10.1007/s12630-010-9280-x; [Anonymous], 2011, CAN RESPIR J, V18, P25, DOI 10.1155/2011/506189; Arias MA, 2006, EUR HEART J, V27, P1106, DOI 10.1093/eurheartj/ehi807; Aurora RN, 2010, SLEEP, V33, P1408, DOI 10.1093/sleep/33.10.1408; Barbe F, 2012, JAMA-J AM MED ASSOC, V307, P2161, DOI 10.1001/jama.2012.4366; Benbadis SR, 1999, ANN INTERN MED, V130, P289, DOI 10.7326/0003-4819-130-4-199902160-00014; Bhasin S, 2006, J CLIN ENDOCR METAB, V91, P1995, DOI 10.1210/jc.2005-2847; Chai CL, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005308.pub2; Chai-Coetzer CL, 2013, JAMA-J AM MED ASSOC, V309, P997, DOI 10.1001/jama.2013.1823; Chung F, 2012, BRIT J ANAESTH, V108, P768, DOI 10.1093/bja/aes022; Dixon JB, 2012, JAMA-J AM MED ASSOC, V308, P1142, DOI 10.1001/2012.jama.11580; Duran-Cantolla J, 2010, BMJ-BRIT MED J, V341, pc5991; Epstein LJ, 2009, J CLIN SLEEP MED, V5, P263; Foster GD, 2009, ARCH INTERN MED, V169, P1619, DOI 10.1001/archinternmed.2009.266; Frey WC, 2003, OBES SURG, V13, P676, DOI 10.1381/096089203322509228; Gottlieb DJ, 2014, NEW ENGL J MED, V370, P2276, DOI 10.1056/NEJMoa1306766; Gottlieb DJ, 2010, CIRCULATION, V122, P352, DOI 10.1161/CIRCULATIONAHA.109.901801; Gross JB, 2014, ANESTHESIOLOGY, V120, P268, DOI 10.1097/ALN.0000000000000053; Haentjens P, 2007, ARCH INTERN MED, V167, P757, DOI 10.1001/archinte.167.8.757; Hallowell PT, 2007, SURGERY, V142, P608, DOI 10.1016/j.surg.2007.08.002; Hallowell PT, 2007, SURGERY, P142; Ip S, 2012, SYST REV, V1, DOI 10.1186/2046-4053-1-20; Johansson K, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4609; Kapur Vishesh, 2002, Sleep Breath, V6, P49, DOI 10.1007/s11325-002-0049-5; Kaw R, 2012, CHEST, V141, P436, DOI 10.1378/chest.11-0283; Kuna ST, 2011, AM J RESP CRIT CARE, V183, P1238, DOI 10.1164/rccm.201011-1770OC; Lettieri CJ, 2009, ANN INTERN MED, V151, P696, DOI 10.7326/0003-4819-151-10-200911170-00006; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Marin JM, 2012, JAMA-J AM MED ASSOC, V307, P2169, DOI 10.1001/jama.2012.3418; Martinez-Garcia MA, 2013, JAMA-J AM MED ASSOC, V310, P2407, DOI 10.1001/jama.2013.281250; Montserrat JM, 2001, AM J RESP CRIT CARE, V164, P608, DOI 10.1164/ajrccm.164.4.2006034; Morgenthaler TI, 2006, SLEEP, V29, P1031; Myers KA, 2013, JAMA-J AM MED ASSOC, V310, P731, DOI 10.1001/jama.2013.276185; Netzer NC, 1999, ANN INTERN MED, V131, P485, DOI 10.7326/0003-4819-131-7-199910050-00002; Newman AB, 2005, ARCH INTERN MED, V165, P2408, DOI 10.1001/archinte.165.20.2408; Pack AI, 2001, AM J RESP CRIT CARE, V164, P1675, DOI 10.1164/ajrccm.164.9.2103032; Parthasarathy S, 2014, J CLIN SLEEP MED, V10, P243, DOI 10.5664/jcsm.3518; Patel SR, 2003, ARCH INTERN MED, V163, P565, DOI 10.1001/archinte.163.5.565; Peppard PE, 2013, AM J EPIDEMIOL, V177, P1006, DOI 10.1093/aje/kws342; Peppard PE, 2000, JAMA-J AM MED ASSOC, V284, P3015, DOI 10.1001/jama.284.23.3015; Phillips CL, 2013, AM J RESP CRIT CARE, V187, P879, DOI 10.1164/rccm.201212-2223OC; Proczko MA, 2014, J ANESTH; Punjabi NM, 2008, AM J RESP CRIT CARE, V177, P1150, DOI 10.1164/rccm.200712-1884OC; Qaseem A, 2014, ANN INTERN MED, V161, P210, DOI 10.7326/M12-3187; Rosen CL, 2012, SLEEP, V35, P757, DOI 10.5665/sleep.1870; Sawyer AM, 2011, SLEEP MED REV, V15, P343, DOI 10.1016/j.smrv.2011.01.003; Schwab RJ, 2013, AM J RESP CRIT CARE, V188, P613, DOI 10.1164/rccm.201307-1282ST; Strohl KP, 2013, AM J RESP CRIT CARE, V187, P1259, DOI 10.1164/rccm.201304-0726ST; Strollo P, 2014, ASSURANCE OBSTRUCTIV; Teran-Santos J, 1999, NEW ENGL J MED, V340, P847, DOI 10.1056/NEJM199903183401104; Tishler PV, 2003, JAMA-J AM MED ASSOC, V289, P2230, DOI 10.1001/jama.289.17.2230; Tuomilehto HPI, 2009, AM J RESP CRIT CARE, V179, P320, DOI 10.1164/rccm.200805-669OC; Weaver TE, 2012, AM J RESP CRIT CARE, V186, P677, DOI 10.1164/rccm.201202-0200OC; Young T, 2005, J APPL PHYSIOL, V99, P1592, DOI 10.1152/japplphysiol.00587.2005; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 1996, ARCH INTERN MED, V156, P2445, DOI 10.1001/archinte.156.21.2445	56	15	16	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 4	2014	161	9							ITC1	10.7326/0003-4819-161-9-201411040-01005	http://dx.doi.org/10.7326/0003-4819-161-9-201411040-01005			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AX9TE	25364899				2023-01-03	WOS:000347244100001
J	Raman, S; Srinivasan, K; Kurpad, A; Razee, H; Ritchie, J				Raman, Shanti; Srinivasan, Krishnamachari; Kurpad, Anura; Razee, Husna; Ritchie, Jan			"Nothing Special, Everything Is Maamuli'': Socio-Cultural and Family Practices Influencing the Perinatal Period in Urban India	PLOS ONE			English	Article							NEWBORN-CARE PRACTICES; DEVELOPING-COUNTRIES; CHILDBIRTH PRACTICES; SYSTEMATIC ANALYSIS; NEONATAL HEALTH; BIRTH-WEIGHT; SOUTH-INDIA; INFERTILITY; SURVIVAL; BANGLADESH	Background: Globally, India contributes the largest share in sheer numbers to the burden of maternal and infant under-nutrition, morbidity and mortality. A major gap in our knowledge is how socio-cultural practices and beliefs influence the perinatal period and thus perinatal outcomes, particularly in the rapidly growing urban setting. Methods and Findings: Using data from a qualitative study in urban south India, including in-depth interviews with 36 women who had recently been through childbirth as well as observations of family life and clinic encounters, we explored the territory of familial, cultural and traditional practices and beliefs influencing women and their families through pregnancy, childbirth and infancy. We found that while there were some similarities in cultural practices to those described before in studies from low resource village settings, there are changing practices and ideas. Fertility concerns dominate women's experience of married life; notions of gender preference and ideal family size are changing rapidly in response to the urban context; however inter-generational family pressures are still considerable. While a rich repertoire of cultural practices persists throughout the perinatal continuum, their existence is normalised and even underplayed. In terms of diet and nutrition, traditional messages including notions of 'hot' and 'cold' foods, are stronger than health messages; however breastfeeding is the cultural norm and the practice of delayed breastfeeding appears to be disappearing in this urban setting. Marriage, pregnancy and childbirth are so much part of the norm for women, that there is little expectation of individual choice in any of these major life events. Conclusions: A greater understanding is needed of the dynamic factors shaping the perinatal period in urban India, including an acknowledgment of the health promoting as well as potentially harmful cultural practices and the critical role of the family. This will help plan culturally appropriate integrated perinatal health care.	[Raman, Shanti] Liverpool Hosp, South Western Sydney Local Hlth Dist, Dept Community Paediat, Liverpool, NSW, England; [Srinivasan, Krishnamachari] St Johns Med Coll, Dept Psychiat, Bangalore, Karnataka, India; [Kurpad, Anura] St Johns Med Coll, Dept Physiol, Bangalore, Karnataka, India; [Razee, Husna; Ritchie, Jan] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia	St. John's National Academy of Health Sciences; St. John's Medical College; St. John's National Academy of Health Sciences; St. John's Medical College; University of New South Wales Sydney	Raman, S (corresponding author), Liverpool Hosp, South Western Sydney Local Hlth Dist, Dept Community Paediat, Liverpool, NSW, England.	shanti.raman@sswahs.nsw.gov.au		Razee, Husna/0000-0002-6845-8136				Aborigo RA, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-76; Bandyopadhyay Mridula, 2003, Health Care Women Int, V24, P910, DOI 10.1080/07399330390244220; Barnett S, 2006, J HEALTH POPUL NUTR, V24, P394; Bharadwaj A, 2003, SOC SCI MED, V56, P1867, DOI 10.1016/S0277-9536(02)00210-1; Bhutta ZA, 2005, PEDIATRICS, V115, P519, DOI 10.1542/peds.2004-1441; Bhutta ZA, 2010, LANCET, V375, P2032, DOI 10.1016/S0140-6736(10)60678-2; Bhutta ZA, 2010, LANCET, V375, P1142, DOI 10.1016/S0140-6736(10)60324-8; Blanchet T., 1984, WOMEN POLLUTION MARG; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Callaghan-Koru JA, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-198; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Chatterjee N, 2013, THIS IS NORMAL PREGN; Chi Z, 2013, INDIAN J GEND STUD, V20, P51, DOI 10.1177/0971521512465936; CLELAND JG, 1988, SOC SCI MED, V27, P1357, DOI 10.1016/0277-9536(88)90201-8; Darmstadt GL, 2006, J HEALTH POPUL NUTR, V24, P380; Dwarkanath P, 2007, ASIA PAC J CLIN NUTR, V16, P704; FELDMANSAVELSBERG P, 1994, SOC SCI MED, V39, P463, DOI 10.1016/0277-9536(94)90090-6; Fikree FF, 2005, SOC SCI MED, V60, P911, DOI 10.1016/j.socscimed.2004.06.034; FITZGERALD MH, 1997, QUALITATIVE RES DISC, P48; Forsey MG, 2010, ETHNOGRAPHY, V11, P558, DOI 10.1177/1466138110372587; Galloway R, 2002, SOC SCI MED, V55, P529, DOI 10.1016/S0277-9536(01)00185-X; GIDEON H, 1962, AM ANTHROPOL, V64, P1220, DOI 10.1525/aa.1962.64.6.02a00060; Gragnolati M, 2005, INDIAS UNDERNOURISHE; Grbich C., 2003, QUALITATIVE RES HLTH; Green J, 2009, QUALITATIVE METHODS; Holder Kelly, 2011, East Afr J Public Health, V8, P38; Hollos M, 2008, CULT HEALTH SEX, V10, P159, DOI 10.1080/13691050701656789; Inhorn MC, 2009, INT J GYNECOL OBSTET, V106, P172, DOI 10.1016/j.ijgo.2009.03.034; INHORN MC, 1994, SOC SCI MED, V39, P459, DOI 10.1016/0277-9536(94)90089-2; Iyengar SD, 2008, J PERINATOL, V28, pS23, DOI 10.1038/jp.2008.174; Kassebaum N.J, 2014, LANCET; Kesterton AJ, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-20; Kimani-Murage EW, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-396; Kodzi IA, 2012, SOC SCI MED, V74, P966, DOI 10.1016/j.socscimed.2011.12.035; Kumar V, 2008, LANCET, V372, P1151, DOI 10.1016/S0140-6736(08)61483-X; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lee HMH, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-223; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Maimbolwa MC, 2003, J ADV NURS, V43, P263, DOI 10.1046/j.1365-2648.2003.02709.x; Ministry of Health and Family Welfare, 2008, 2005 2006 NAT FAM HL; Moran AC, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-54; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Muthayya S, 2006, ASIA PAC J CLIN NUTR, V15, P538; Nachtigall RD, 2006, FERTIL STERIL, V85, P871, DOI 10.1016/j.fertnstert.2005.08.066; NEFF DL, 1994, SOC SCI MED, V39, P475, DOI 10.1016/0277-9536(94)90091-4; NICHTER M, 1983, HUM ORGAN, V42, P235, DOI 10.17730/humo.42.3.43081445235366lk; NICHTER M, 1985, SOC SCI MED, V21, P667, DOI 10.1016/0277-9536(85)90206-0; NICHTER M, 1987, SOC SCI MED, V25, P377, DOI 10.1016/0277-9536(87)90276-0; Oestergaard MZ, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001080; Papreen N, 2000, REPROD HEALTH MATTER, V8, P33, DOI 10.1016/S0968-8080(00)90004-1; Puri S, 2011, SOC SCI MED, V72, P1169, DOI 10.1016/j.socscimed.2011.01.027; Ram K., 1994, Reproductive Health Matters, P20, DOI 10.1016/0968-8080(94)90004-3; Raman S., 2014, Health, Culture and Society, V6, P73; Raman S, 2014, MIDWIFERY, V30, P130, DOI 10.1016/j.midw.2013.03.003; Rodrigues M, 2003, SOC SCI MED, V57, P1797, DOI 10.1016/S0277-9536(03)00062-5; ROWE PJ, 1987, FERTIL STERIL, V47, P964; Rozario S., 1998, MATERNITIES MODERNIT, P144; Sahni M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002224; Tabong PTN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054429; Thomas T., 2009, RAISING MINIMUM ED G; UNFPA, 1994, PROGR ACT AD INT C P, DOI UNFPA; Veena SR, 2010, ARCH DIS CHILD, V95, P347, DOI 10.1136/adc.2009.165159	62	15	15	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2014	9	11							e111900	10.1371/journal.pone.0111900	http://dx.doi.org/10.1371/journal.pone.0111900			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AS6XG	25369447	gold, Green Published, Green Submitted			2023-01-03	WOS:000344402000120
J	Itakura, S; Hama, S; Ohgita, T; Kogure, K				Itakura, Shoko; Hama, Susumu; Ohgita, Takashi; Kogure, Kentaro			Development of Nanoparticles Incorporating a Novel Liposomal Membrane Destabilization Peptide for Efficient Release of Cargos into Cancer Cells	PLOS ONE			English	Article							PH-SENSITIVE LIPOSOMES; GAMMA-SECRETASE; SOLID TUMORS; THERAPY; DELIVERY; IMPROVEMENT; INHIBITION; EXPRESSION; BIOLOGY; DRUGS	In anti-cancer therapy mediated by a nanoparticle-based drug delivery system (DDS), overall efficacy depends on the release efficiency of cargos from the nanoparticles in the cancer cells as well as the specificity of delivery to tumor tissue. However, conventional liposome-based DDS have no mechanism for specifically releasing the encapsulated cargos inside the cancer cells. To overcome this barrier, we developed nanoparticles containing a novel liposomal membrane destabilization peptide (LMDP) that can destabilize membranes by cleavage with intramembranous proteases on/in cancer cells. Calcein encapsulated in liposomes modified with LMDP (LMDP-lipo) was effectively released in the presence of a membrane fraction containing an LMDP-cleavable protease. The release was inhibited by a protease inhibitor, suggesting that LMD-Plipo could effectively release its cargo into cells in response to a cancer-specific protease. Moreover, when LMDP-lipo contained fusogenic lipids, the release of cargo was accelerated, suggesting that the fusion of LMDP-lipo with cellular membranes was the initial step in the intracellular delivery. Time-lapse microscopic observations showed that the release of cargo from LMDP-lipo occurred immediately after association of LMDP-lipo with target cells. Consequently, LMDP-lipo could be a useful nanoparticle capable of effective release of cargos specifically into targeted cancer cells.	[Itakura, Shoko; Hama, Susumu; Ohgita, Takashi; Kogure, Kentaro] Kyoto Pharmaceut Univ, Dept Biophys Chem, Kyoto 607, Japan	Kyoto Pharmaceutical University	Kogure, K (corresponding author), Kyoto Pharmaceut Univ, Dept Biophys Chem, Kyoto 607, Japan.	kogure@mb.kyoto-phu.ac.jp		Hama, Susumu/0000-0002-2989-6168	JSPS KAKENHI [25860030, 26-9314]; Kyoto Pharmaceutical University Fund for the Promotion of Scientific Research; Grants-in-Aid for Scientific Research [14J09314] Funding Source: KAKEN	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Kyoto Pharmaceutical University Fund for the Promotion of Scientific Research; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by JSPS KAKENHI Grant Numbers 25860030, 26-9314, and by the Kyoto Pharmaceutical University Fund for the Promotion of Scientific Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abu Lila AS, 2010, PHARM RES-DORDR, V27, P1171, DOI 10.1007/s11095-010-0110-1; Banerjee J, 2009, BIOCONJUGATE CHEM, V20, P1332, DOI 10.1021/bc9000646; Biswas S, NAT CHEM, V5, P613; Biswas S, 2013, EUR J PHARM BIOPHARM, V84, P517, DOI 10.1016/j.ejpb.2012.12.021; Bulic B, 2011, CURR NEUROPHARMACOL, V9, P598, DOI 10.2174/157015911798376352; Capaccione KM, 2013, CARCINOGENESIS, V34, P1420, DOI 10.1093/carcin/bgt127; Carvalho FLF, 2014, PROSTATE, V74, P933, DOI 10.1002/pros.22811; Chen YQ, 2011, CANCER BIOL THER, V11, P14, DOI 10.4161/cbt.11.1.13730; Cho S, 2011, P NATL ACAD SCI USA, V108, P20778, DOI 10.1073/pnas.1019452108; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Gomi M., 2004, CHEM BIO INFORMATICS, V4, P142, DOI DOI 10.1273/CBIJ.4.142; Hatakeyama H, 2007, GENE THER, V14, P68, DOI 10.1038/sj.gt.3302843; Hayashi I, 2012, ONCOGENE, V31, P787, DOI 10.1038/onc.2011.265; Huang L, 2014, ADV DRUG DELIV REV, V66, P110; Kano MR, 2007, P NATL ACAD SCI USA, V104, P3460, DOI 10.1073/pnas.0611660104; Lehtinen J, 2008, J CONTROL RELEASE, V131, P145, DOI 10.1016/j.jconrel.2008.07.018; Maeda H, 2013, ADV DRUG DELIVER REV, V65, P71, DOI 10.1016/j.addr.2012.10.002; Maraver A, 2012, CANCER CELL, V22, P222, DOI 10.1016/j.ccr.2012.06.014; Maruyama K, 2011, ADV DRUG DELIVER REV, V63, P161, DOI 10.1016/j.addr.2010.09.003; Momekova D, 2007, EUR J PHARM SCI, V32, P308, DOI 10.1016/j.ejps.2007.08.009; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; Peppicelli S, 2014, CANCER METAST REV, V33, P823, DOI 10.1007/s10555-014-9506-4; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Sahay G, 2013, NAT BIOTECHNOL, V31, P653, DOI 10.1038/nbt.2614; Sandin P, 2012, ACS NANO, V6, P1513, DOI 10.1021/nn204448x; Schwendener RA, 2007, ADV EXP MED BIOL, V620, P117; Shih IM, 2007, CANCER RES, V67, P1879, DOI 10.1158/0008-5472.CAN-06-3958; Svastova E, 2004, FEBS LETT, V577, P439, DOI 10.1016/j.febslet.2004.10.043; Toita R, 2009, J CONTROL RELEASE, V139, P133, DOI 10.1016/j.jconrel.2009.06.011; Tomiyama T, 2010, J CONTROL RELEASE, V148, P101, DOI 10.1016/j.jconrel.2010.08.017; Vanic Z, 2012, J LIPOSOME RES, V22, P148, DOI 10.3109/08982104.2011.633267; Varkouhi AK, 2011, J CONTROL RELEASE, V151, P220, DOI 10.1016/j.jconrel.2010.11.004; Wolfe MS, 2006, BIOCHEMISTRY-US, V45, P7931, DOI 10.1021/bi060799c; Wu XL, 2010, BIOCONJUGATE CHEM, V21, P208, DOI 10.1021/bc9005283; Yingyuad Peerada, 2014, J RNAi Gene Silencing, V10, P490	35	5	5	0	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2014	9	10							e111181	10.1371/journal.pone.0111181	http://dx.doi.org/10.1371/journal.pone.0111181			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0BL	25343714	Green Published, Green Submitted, gold			2023-01-03	WOS:000343943500085
J	Piper, BJ; Gray, HM; Corbett, SM; Birkett, MA; Raber, J				Piper, Brian J.; Gray, Hilary M.; Corbett, Selena M.; Birkett, Melissa A.; Raber, Jacob			Executive Function and Mental Health in Adopted Children with a History of Recreational Drug Exposures	PLOS ONE			English	Article							PRENATAL ALCOHOL EXPOSURE; BEHAVIOR PROBLEMS; MATERNAL SMOKING; SPECTRUM DISORDERS; HAIR ANALYSIS; PREGNANCY; ATTENTION	Adoptive children are at increased risk for problematic behaviors but the origin of these individual differences in neurobehavioral function is unclear. This investigation examined whether adopted children with prenatal exposure to a wide variety of recreational drugs exhibited higher scores (i.e. more problems) with executive function and psychiatric symptomology. Caregivers of children ages 5 to 18 completed an online survey with items about use of alcohol, nicotine, or methamphetamine during pregnancy followed by the Behavior Rating Inventory of Executive Function (BRIEF, N = 437 including 59 adoptive parents) or the Child Behavior Checklist (CBCL, N = 549 including 54 adoptive parents). Relative to a comparison group of children raised by their biological parents, adoptive children that were polysubstance exposed during prenatal development exhibited higher rates of academic difficulties and were behind their classmates in math and reading. Adoptive children had statistically and clinically significant higher BRIEF ratings and this pattern was similar for boys and girls. CBCL ratings were significantly increased in adoptive children, particularly for Externalizing and Attention problems. Adoptive children with a history of polysubstance exposures including alcohol, nicotine, and methamphetamine are at heightened risk for difficulties with executive function as well as various psychopathologies. These findings suggest that increased monitoring to identify and implement remediation strategies may be warranted for adopted children with a history of in utero drug exposures.	[Piper, Brian J.] Husson Univ, Dept Basic Pharmaceut Sci, Bangor, ME 04401 USA; [Piper, Brian J.; Gray, Hilary M.; Corbett, Selena M.; Raber, Jacob] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA; [Gray, Hilary M.] Portland State Univ, Sch Community Hlth, Portland, OR 97207 USA; [Gray, Hilary M.] Portland State Univ, Dept Counselor Educ, Portland, OR 97207 USA; [Corbett, Selena M.] Western Univ Hlth Sci, Coll Osteopath Med Pacific NW, Pomona, CA USA; [Birkett, Melissa A.] No Arizona Univ, Dept Psychol Sci, Flagstaff, AZ 86011 USA; [Raber, Jacob] Oregon Hlth & Sci Univ, ONPRC, Dept Neurol & Radiat Med, Portland, OR 97201 USA; [Raber, Jacob] Oregon Hlth & Sci Univ, ONPRC, Div Neurosci, Portland, OR 97201 USA	Oregon Health & Science University; Portland State University; Portland State University; Western University of Health Sciences; Northern Arizona University; Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon National Primate Research Center	Piper, BJ (corresponding author), Husson Univ, Dept Basic Pharmaceut Sci, Bangor, ME 04401 USA.	piperbj@husson.edu	Birkett, Melissa A/O-1313-2013	Birkett, Melissa A/0000-0001-7376-4851	National Institute of Drug Abuse [L30 DA027582, T32 DA07262]; National Institute of Environmental Health Sciences [T32 ES007060-31A1]; Oregon Clinical Translational Research Institute [UL1 RR024140]; Husson University School of Pharmacy; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007262] Funding Source: NIH RePORTER	National Institute of Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Oregon Clinical Translational Research Institute; Husson University School of Pharmacy; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by the National Institute of Drug Abuse (L30 DA027582, T32 DA07262), the National Institute of Environmental Health Sciences (T32 ES007060-31A1), the Oregon Clinical Translational Research Institute (UL1 RR024140, and the Husson University School of Pharmacy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achenbach T M, 2000, Pediatr Rev, V21, P265, DOI 10.1542/pir.21-8-265; Achenbach T.M., 2001, MULTICULTURAL SUPPLE; Almeida ND, 2011, NICOTINE TOB RES, V13, P328, DOI 10.1093/ntr/ntq259; Carter S, 2008, EARLY HUM DEV, V84, P59, DOI 10.1016/j.earlhumdev.2007.03.009; Chang L, 2009, NEUROIMAGE, V48, P391, DOI 10.1016/j.neuroimage.2009.06.062; Davies JK, 2005, PEDIATR CLIN N AM, V52, P1369, DOI 10.1016/j.pcl.2005.06.015; Dixon DR, 2008, RES DEV DISABIL, V29, P483, DOI 10.1016/j.ridd.2007.05.006; Gioia G.A, 2000, BEHAV RATING INVENTO; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Grotevant HD, 2014, ANNU REV PSYCHOL, V65, P235, DOI 10.1146/annurev-psych-010213-115020; Han E, 2013, INT J LEGAL MED, V127, P405, DOI 10.1007/s00414-012-0766-7; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hoyme HE, 2005, PEDIATRICS, V115, P39, DOI 10.1542/peds.2004-0259; Jacobs E, 2010, CHILD PSYCHIAT HUM D, V41, P15, DOI 10.1007/s10578-009-0149-6; Juffer F, 2005, JAMA-J AM MED ASSOC, V293, P2501, DOI 10.1001/jama.293.20.2501; Julvez J, 2007, INT J EPIDEMIOL, V36, P825, DOI 10.1093/ije/dym107; Kesmodel US, 2012, BJOG-INT J OBSTET GY, V119, P1180, DOI 10.1111/j.1471-0528.2012.03393.x; Kiblawi ZN, 2013, J DEV BEHAV PEDIATR, V34, P31, DOI 10.1097/DBP.0b013e318277a1c5; LaGasse LL, 2012, PEDIATRICS, V129, P681, DOI 10.1542/peds.2011-2209; Landgren M, 2010, PEDIATRICS, V125, pE1178, DOI 10.1542/peds.2009-0712; Langberg JM, 2013, J ABNORM CHILD PSYCH, V41, P1145, DOI 10.1007/s10802-013-9750-z; Lange S, 2013, PEDIATRICS, V132, pE980, DOI 10.1542/peds.2013-0066; Lendoiro E, 2013, THER DRUG MONIT, V35, P296, DOI 10.1097/FTD.0b013e318288453f; Merz EC, 2011, J CHILD PSYCHOL PSYC, V52, P537, DOI 10.1111/j.1469-7610.2010.02335.x; Meyer JS, 2011, REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY, P341, DOI 10.1016/B978-0-12-382032-7.10026-8; Minnes S, 2014, J YOUTH ADOLESCENCE, V43, P53, DOI 10.1007/s10964-013-9927-3; Morini L, 2013, THER DRUG MONIT, V35, P402, DOI 10.1097/FTD.0b013e318283f719; Nulman I, 2001, CLIN INVEST MED, V24, P129; O'Leary CM, 2010, ADDICTION, V105, P74, DOI 10.1111/j.1360-0443.2009.02756.x; Palacios J, 2010, INT J BEHAV DEV, V34, P270, DOI 10.1177/0165025410362837; Piper BJ, 2012, NICOTINE TOB RES, V14, P191, DOI 10.1093/ntr/ntr181; Piper BJ, 2012, DRUG ALCOHOL DEPEN, V121, P62, DOI 10.1016/j.drugalcdep.2011.08.004; Piper BJ, 2011, PHARMACOL BIOCHEM BE, V98, P432, DOI 10.1016/j.pbb.2011.02.013; Rasmussen C, 2007, J FAS INT, V5, pe2; Robinson M, 2010, BJOG-INT J OBSTET GY, V117, P1139, DOI 10.1111/j.1471-0528.2010.02596.x; Sayal K, 2007, PEDIATRICS, V119, pE426, DOI 10.1542/peds.2006-1840	36	5	5	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 22	2014	9	10							e110459	10.1371/journal.pone.0110459	http://dx.doi.org/10.1371/journal.pone.0110459			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR6DY	25337917	Green Submitted, Green Published, gold			2023-01-03	WOS:000343674800044
J	Yazar, Y; Bergstrom, ZM; Simons, JS				Yazar, Yasemin; Bergstroem, Zara M.; Simons, Jon S.			Continuous Theta Burst Stimulation of Angular Gyrus Reduces Subjective Recollection	PLOS ONE			English	Article							EPISODIC MEMORY RETRIEVAL; POSTERIOR PARIETAL CORTEX; TRANSCRANIAL MAGNETIC STIMULATION; LOBE; LESIONS; SYSTEM; DAMAGE; BRAIN; INTERFERENCE; RECOGNITION	The contribution of lateral parietal regions such as the angular gyrus to human episodic memory has been the subject of much debate following widespread observations of left parietal activity in healthy volunteers during functional neuroimaging studies of memory retrieval. Patients with lateral parietal lesions are not amnesic, but recent evidence indicates that their memory abilities may not be entirely preserved. Whereas recollection appears intact when objective measures such as source accuracy are used, patients often exhibit reduced subjective confidence in their accurate recollections. When asked to recall autobiographical memories, they may produce spontaneous narratives that lack richness and specificity, but can remember specific details when prompted. Two distinct theoretical accounts have been proposed to explain these results: that the patients have a deficit in the bottom-up capturing of attention by retrieval output, or that they have an impairment in the subjective experience of recollection. The present study aimed to differentiate between these accounts using continuous theta burst stimulation (cTBS) in healthy participants to disrupt function of specific left parietal subregions, including angular gyrus. Inconsistent with predictions of the attentional theory, angular gyrus cTBS did not result in greater impairment of free recall than cued recall. Supporting predictions of the subjective recollection account, temporary disruption of angular gyrus was associated with highly accurate source recollection accuracy but a selective reduction in participants' rated source confidence. The findings are consistent with a role for angular gyrus in the integration of memory features into a conscious representation that enables the subjective experience of remembering.	[Yazar, Yasemin; Simons, Jon S.] Univ Cambridge, Dept Psychol, Cambridge, England; [Yazar, Yasemin; Bergstroem, Zara M.; Simons, Jon S.] Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge, England; [Bergstroem, Zara M.] Univ Kent, Dept Psychol, Canterbury CT2 7NZ, Kent, England	University of Cambridge; University of Cambridge; University of Kent	Simons, JS (corresponding author), Univ Cambridge, Dept Psychol, Cambridge, England.	jss30@cam.ac.uk	Simons, Jon/AAG-7104-2020	Simons, Jon/0000-0002-7508-9084; Bergstrom, Zara/0000-0001-8794-0182	James S. McDonnell Foundation; German Academic Exchange Service; Medical Research Council [G0001354, G0001354B, G1000183B] Funding Source: researchfish	James S. McDonnell Foundation; German Academic Exchange Service(Deutscher Akademischer Austausch Dienst (DAAD)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by a James S. McDonnell Foundation Scholar Award to JSS. YY was supported by a scholarship from the German Academic Exchange Service. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ally BA, 2008, NEUROPSYCHOLOGIA, V46, P1800, DOI 10.1016/j.neuropsychologia.2008.02.026; [Anonymous], 1983, CANADIAN PSYCHOL; Berryhill ME, 2007, J NEUROSCI, V27, P14415, DOI 10.1523/JNEUROSCI.4163-07.2007; Binder JR, 2009, CEREB CORTEX, V19, P2767, DOI 10.1093/cercor/bhp055; Cabeza R, 2008, NAT REV NEUROSCI, V9, P613, DOI 10.1038/nrn2459; Chua EF, 2006, NEUROIMAGE, V29, P1150, DOI 10.1016/j.neuroimage.2005.09.058; Ciaramelli E, 2010, J EXP PSYCHOL LEARN, V36, P619, DOI 10.1037/a0019181; Ciaramelli E, 2010, J NEUROSCI, V30, P4943, DOI 10.1523/JNEUROSCI.1209-09.2010; Corbetta M, 2008, NEURON, V58, P306, DOI 10.1016/j.neuron.2008.04.017; Davidson PSR, 2008, NEUROPSYCHOLOGIA, V46, P1743, DOI 10.1016/j.neuropsychologia.2008.01.011; Dobbins IG, 2012, NEUROPSYCHOLOGIA, V50, P2992, DOI 10.1016/j.neuropsychologia.2012.07.037; Duarte A, 2008, CEREB CORTEX, V18, P2169, DOI 10.1093/cercor/bhm243; Flegal KE, 2014, J COGNITIVE NEUROSCI, V26, P1694, DOI 10.1162/jocn_a_00587; Holdstock JS, 2000, NEUROPSYCHOLOGIA, V38, P410, DOI 10.1016/S0028-3932(99)00099-8; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Hutchinson JB, 2009, LEARN MEMORY, V16, P343, DOI 10.1101/lm.919109; JOHNSON MK, 1993, PSYCHOL BULL, V114, P3, DOI 10.1037/0033-2909.114.1.3; Mayes A, 2007, TRENDS COGN SCI, V11, P126, DOI 10.1016/j.tics.2006.12.003; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; MCGRAW KO, 1992, PSYCHOL BULL, V111, P361, DOI 10.1037/0033-2909.111.2.361; Nelson SM, 2010, NEURON, V67, P156, DOI 10.1016/j.neuron.2010.05.025; Okamoto M, 2004, NEUROIMAGE, V21, P99, DOI 10.1016/j.neuroimage.2003.08.026; Rossi S, 2006, EUR J NEUROSCI, V23, P793, DOI 10.1111/j.1460-9568.2006.04600.x; Schmitz TW, 2013, 2013 NEUR M PLANN; Seghier ML, 2013, NEUROSCIENTIST, V19, P43, DOI 10.1177/1073858412440596; Sestieri C, 2013, NEUROPSYCHOLOGIA, V51, P900, DOI 10.1016/j.neuropsychologia.2013.01.023; Sestieri C, 2011, J NEUROSCI, V31, P4407, DOI 10.1523/JNEUROSCI.3335-10.2011; Shimamura AP, 2011, COGN AFFECT BEHAV NE, V11, P277, DOI 10.3758/s13415-011-0031-4; Simons JS, 2008, NEUROPSYCHOLOGIA, V46, P1185, DOI 10.1016/j.neuropsychologia.2007.07.024; Simons JS, 2010, CEREB CORTEX, V20, P479, DOI 10.1093/cercor/bhp116; Vilberg KL, 2008, NEUROPSYCHOLOGIA, V46, P1787, DOI 10.1016/j.neuropsychologia.2008.01.004; Wagner AD, 2005, TRENDS COGN SCI, V9, P445, DOI 10.1016/j.tics.2005.07.001; Walsh V, 2000, NAT REV NEUROSCI, V1, P73, DOI 10.1038/35036239; Yazar Y, 2012, CORTEX, V48, P1381, DOI 10.1016/j.cortex.2012.05.011; Zaehle T, 2007, BRAIN RES, V1137, P92, DOI 10.1016/j.brainres.2006.12.044	35	51	51	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2014	9	10							e110414	10.1371/journal.pone.0110414	http://dx.doi.org/10.1371/journal.pone.0110414			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR7AB	25333985	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000343731200035
J	Dawson, A; Tran, NT; Westley, E; Mangiaterra, V; Festin, M				Dawson, Angela; Nguyen-Toan Tran; Westley, Elizabeth; Mangiaterra, Viviana; Festin, Mario			Improving Access to Emergency Contraception Pills through Strengthening Service Delivery and Demand Generation: A Systematic Review of Current Evidence in Low and Middle-Income Countries	PLOS ONE			English	Review							REPRODUCTIVE HEALTH; INJECTABLE CONTRACEPTIVES; UNINTENDED PREGNANCY; SCALING-UP; PROVISION; ABORTION; TRENDS	Objectives: Emergency contraception pills (ECP) are among the 13 essential commodities in the framework for action established by the UN Commission on Life-Saving Commodities for Women and Children. Despite having been on the market for nearly 20 years, a number of barriers still limit women's access to ECP in low-and middle-income countries (LMIC) including limited consumer knowledge and poor availability. This paper reports the results of a review to synthesise the current evidence on service delivery strategies to improve access to ECP. Methods: A narrative synthesis methodology was used to examine peer reviewed research literature (2003 to 2013) from diverse methodological traditions to provide critical insights into strategies to improve access from a service delivery perspective. The studies were appraised using established scoring systems and the findings of included papers thematically analysed and patterns mapped across all findings using concept mapping. Findings: Ten papers were included in the review. Despite limited research of adequate quality, promising strategies to improve access were identified including: advance provision of ECP; task shifting and sharing; intersectoral collaboration for sexual assault; m-health for information provision; and scale up through national family planning programs. Conclusion: There are a number of gaps in the research concerning service delivery and ECP in LMIC. These include a lack of knowledge concerning private/commercial sector contributions to improving access, the needs of vulnerable groups of women, approaches to enhancing intersectoral collaboration, evidence for social marketing models and investment cases for ECP.	[Dawson, Angela] Univ Technol Sydney, World Hlth Org, Collaborating Ctr Nursing Midwifery & Hlth Dev, Fac Hlth, Sydney, NSW 2007, Australia; [Nguyen-Toan Tran] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia; [Westley, Elizabeth] Int Consortium Emergency Contracept, New York, NY USA; [Mangiaterra, Viviana] Global Fund Fight AIDS TB & Malaria, RMNCH & HSS Tech Advice & Partnerships Dept, Vernier Geneva, Switzerland; [Festin, Mario] World Hlth Org, Dept Reprod Hlth & Res, Geneva, Switzerland	University of Technology Sydney; World Health Organization; University of New South Wales Sydney; World Health Organization	Dawson, A (corresponding author), Univ Technol Sydney, World Hlth Org, Collaborating Ctr Nursing Midwifery & Hlth Dev, Fac Hlth, Sydney, NSW 2007, Australia.	angela.dawson@uts.edu.au	Festin, Mario Philip/GQQ-9749-2022; Dawson, Angela/A-6872-2011	Dawson, Angela/0000-0003-0926-2202; Tran, Nguyen-Toan/0000-0001-7134-7878; MANGIATERRA, VIVIANA/0000-0002-8815-0841	WHO Department of Reproductive Health and Research	WHO Department of Reproductive Health and Research	This study was funded by WHO Department of Reproductive Health and Research on behalf of the Technical Resource Team for Emergency Contraceptive Pills of the United Nations Commission on Life-Saving Commodities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson C, 2006, HUM REPROD, V21, P272, DOI 10.1093/humrep/dei287; Arai L., 2007, EVID POLICY, V3, P361, DOI DOI 10.1332/174426407781738029; Awoonor-Williams JK, 2013, GLOB HEALTH-SCI PRAC, V1, P117, DOI 10.9745/GHSP-D-12-00012; Centre for Reviews and Disssemination, 2008, SYSTEMATIC REV CRDS; Cooper H., 2009, HDB RES SYNTHESIS; Curry L, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-39; d'Arcangues CM, 2013, EUROPEAN J CONTRACEP, V0, P1; Ensor T, 2004, HEALTH POLICY PLANN, V19, P69, DOI 10.1093/heapol/czh009; Fernandez-Cerdeno A, 2009, POPULATION REV, V48; Frost L, 2013, DO GOOD HLTH TECHNOL; Gertler PJ, 2011, IMPACT EVALUATION IN PRACTICE, P1, DOI 10.1596/978-0-8213-8541-8; Gulliford Martin, 2002, J Health Serv Res Policy, V7, P186, DOI 10.1258/135581902760082517; Heimburger A, 2003, REPROD HEALTH MATTER, V11, P150, DOI 10.1016/S0968-8080(03)02172-4; Hoke TH, 2012, HEALTH POLICY PLANN, V27, P52, DOI 10.1093/heapol/czr003; ICEC, 2006, PARTN PROV EC ACC SE; ICEC, 2013, UNF AG NEXT STEPS IN; Jackson RA, 2003, OBSTET GYNECOL, V102, P8, DOI 10.1016/S0029-7844(03)00478-2; Janovsky K, 2006, WHOEPIHEALTHSYSTEMS2; Kassa M., 2009, ETHIOPIAN J REPROD H, V3, P24; Keesbury J, 2007, POPULATION COUNCIL E; Keesbury J, 2009, COPPERBELT MODEL INT; Keesbury J, 2009, ETHIOPIAN J REPROD H, V3, P4; Kennedy CE, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-26; Khan ME, 2008, SITUATION ANAL CARE; Khan ME, 2008, FRONTIERS REPROD HLT; Khan ME, 2008, INTRO SCALING DELIVE; Kumar S, 2007, PROVISION EMERGENCY; L'Engle KL, 2013, CONTRACEPTION, V87, P251, DOI 10.1016/j.contraception.2012.07.009; Lucas PJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-4; Mahmood A, 2012, INTRO EMERGENCY CONT; Marek T., 2005, TRENDS OPPORTUNITIES; Mbizvo MT, 2010, INT J GYNECOL OBSTET, V110, pS3, DOI 10.1016/j.ijgo.2010.04.001; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Nations U., 2012, COMMISSION LIFE SAVI; Ngo AD, 2009, SOC MARK Q, V15, P71, DOI 10.1080/15245000802632417; NHS, 2006, CRIT APPR SKILLS PRO; Ononge Samuel, 2005, Afr Health Sci, V5, P50; Parker C., 2005, ADOLESCENTS EMERGENC; Patouillard Edith, 2007, Int J Equity Health, V6, P17, DOI 10.1186/1475-9276-6-17; Peters DH, 2004, HEALTH POLICY PLANN, V19, pI5, DOI 10.1093/heapol/czh041; Peters DH, 2009, DIR DEV, P1, DOI 10.1596/978-0-8213-7888-5; Pluye P, 2009, INT J NURS STUD, V46, P529, DOI 10.1016/j.ijnurstu.2009.01.009; Popay J, 2005, J EPIDEMIOLOLGY COMM, V59; Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat, 2012, WORLD POP PROSP 2012; Prata N, 2011, B WORLD HEALTH ORGAN, V89, P556, DOI 10.2471/BLT.11.086710; Raine TR, 2005, JAMA-J AM MED ASSOC, V293, P54, DOI 10.1001/jama.293.1.54; Rodgers M., 2009, EVALUATION-US, V15, P49, DOI [10.1177/1356389008097871, DOI 10.1177/1356389008097871]; Rutta Edmund, 2009, Prog Community Health Partnersh, V3, P145, DOI 10.1353/cpr.0.0063; Sedgh G, 2007, LANCET, V370, P1338, DOI 10.1016/S0140-6736(07)61575-X; Shrestha MP, 2008, STRENGTHENING EMERGE; Singh S, 2010, STUD FAMILY PLANN, V41, P241, DOI 10.1111/j.1728-4465.2010.00250.x; TANAHASHI T, 1978, B WORLD HEALTH ORGAN, V56, P295; Tyndall, 2010, THE AACODS CHECKLIST; UN, 2013, TECHN REF TEAM COMM; Walsh TL, 2006, CONTRACEPTION, V74, P110, DOI 10.1016/j.contraception.2006.02.005; Westley E, 2013, INT J GYNECOL OBSTET, V123, P4, DOI 10.1016/j.ijgo.2013.04.019; WHO, 2013, HLTH SYST; WHO, 2004, MAT MORT 2000 EST DE; WHO/EMRO, 2006, STRAT DIR PROM AD HL; WHO/UNFPA/UNAIDS/FHI, 2011, TCU380A INTR CONTR D; World Health Organization, 2004, EQ ACC ESS MED FRAM	61	4	4	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2014	9	10							e109315	10.1371/journal.pone.0109315	http://dx.doi.org/10.1371/journal.pone.0109315			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AU6XC	25285438	Green Published, gold			2023-01-03	WOS:000345743700058
J	Zhang, H; Han, MQ; Zhang, XN; Sun, XT; Ling, F				Zhang, Hao; Han, Mengqi; Zhang, Xiaonian; Sun, Xinting; Ling, Feng			The Effect and Mechanism of Growth Hormone Replacement on Cognitive Function in Rats with Traumatic Brain Injury	PLOS ONE			English	Article							NEUROTROPHIC FACTOR; SYNAPTIC PLASTICITY; GH DEFICIENCY; PERFORMANCE; THERAPY; NEURONS; MEMORY; MODEL; HYPOPITUITARISM; EXPRESSION	Objective: The effects of growth hormone on cognitive dysfunction were observed in a controlled cortical impact (CCI) rat model and the underlying mechanism was explored. Method: Three-month-old male SD rats were randomly divided into sham (n = 10), control (n = 10), and CCI groups (n = 40) The parameters were set as follows: striking speed, 3.5 m/s; impact depth, 1.5 mm; and dwell time, 400 msec. Eight and ten weeks post-injury, the GH levels were measured the water maze test and novel object recognition test were performed. CCI rats were divided into normal and decreased GH groups, and further randomly divided into two sub-groups (rhGH treatment and saline vehicle groups). All rats were tested for SYN, BDNF, and TrkB mRNA in the prefrontal cortex and hippocampus by RT-PCR. Results: CCI rats 8 weeks post-injury had cognitive dysfunction regardless of the GH level (P, 0.05). rhGH treatment improved cognitive function in CCI rats. There was a positive correlation between the expression of prefrontal BDNF and SYN mRNA in CCI rats after rhGH therapy and the water maze test score (r = 0.773 and 0.534, respectively; P<0.05). Furthermore, the expression of BDNF, TrkB, and SYN mRNA in the hippocampus was negatively correlated with the water maze test score (r = 0.602, 0.773, 0.672, and 0.783, respectively; P<0.05). There was a difference in the expression of hippocampal and prefrontal BDNF, TrkB, and SYN mRNA (P<0.05) Conclusion: rhGH treatment had a positive effect on cognitive function, which was more evident in GH-deficient rats. The increased expression of hippocampal and prefrontal BDNF and TrkB mRNA is implicated in rhGH therapy to improve cognitive function. Changes in the expression of hippocampal SYN mRNA following rhGH therapy may also play a role in improving cognitive function.	[Zhang, Hao; Zhang, Xiaonian; Sun, Xinting] Capital Med Univ, China Rehabil Res Ctr, Beijing, Peoples R China; [Han, Mengqi] Beijing Jishuitan Hosp, Beijing, Peoples R China; [Ling, Feng] Capital Med Univ, Beijing Xuanwu Hosp, Beijing, Peoples R China	Capital Medical University; Capital Medical University	Ling, F (corresponding author), Capital Med Univ, China Rehabil Res Ctr, Beijing, Peoples R China.	crrck3@sina.com			Chinese central public research institutes [2011CZ-6, 2012CZ-5]	Chinese central public research institutes	The special basic research fund for Chinese central public research institutes (2011CZ-6,2012CZ-5) http://www.most.gov.cn/ztzl/gjzctx/ptzckjtr/200802/t20080222_59209.htm. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beca SG, 2012, PITUITARY, V15, P10, DOI 10.1007/s11102-008-0133-3; Bhagia V, 2010, BRAIN INJURY, V24, P560, DOI 10.3109/02699051003601705; Brandoli C, 1998, J NEUROSCI, V18, P7953; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Christophidis LJ, 2009, GROWTH HORM IGF RES, V19, P497, DOI 10.1016/j.ghir.2009.05.001; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Creyghton Wouter M, 2004, Semin Vasc Med, V4, P167, DOI 10.1055/s-2004-835375; Crispino M, 1999, EXP NEUROL, V159, P574, DOI 10.1006/exnr.1999.7186; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Deijen JB, 1998, PSYCHONEUROENDOCRINO, V23, P45, DOI 10.1016/S0306-4530(97)00092-9; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOU Yi, 2009, Zhonghua Shao Shang Za Zhi, V25, P275; Doulah AH, 2009, NEUROSCI LETT, V466, P47, DOI 10.1016/j.neulet.2009.09.016; Eastwood SL, 2000, BRIT J PSYCHIAT, V176, P236, DOI 10.1192/bjp.176.3.236; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; Ferrer I, 1999, DEMENT GERIATR COGN, V10, P55, DOI 10.1159/000051214; GRANON S, 1995, BEHAV NEUROSCI, V109, P474, DOI 10.1037/0735-7044.109.3.474; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Guseva MV, 2008, J NEUROTRAUM, V25, P975, DOI 10.1089/neu.2008.0516; Hao LY, 2010, NEUROSCIENCE, V166, P763, DOI 10.1016/j.neuroscience.2010.01.006; High WM, 2010, J NEUROTRAUM, V27, P1565, DOI 10.1089/neu.2009.1253; Isgaard J, 2007, Minerva Endocrinol, V32, P103; Kasturi BS, 2009, J NEUROTRAUM, V26, P1315, DOI [10.1089/neu.2008.0751, 10.1089/neu.2008-0751]; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kinney BA, 2001, PHYSIOL BEHAV, V72, P653, DOI 10.1016/S0031-9384(01)00423-1; Kurihara M, 2011, GEN COMP ENDOCR, V170, P156, DOI 10.1016/j.ygcen.2010.09.020; Kwak MJ, 2009, J KOREAN MED SCI, V24, P729, DOI 10.3346/jkms.2009.24.4.729; LAI ZN, 1993, BRAIN RES, V621, P260, DOI 10.1016/0006-8993(93)90114-3; Leeds P, 2005, NEUROCHEM INT, V46, P61, DOI 10.1016/j.neuint.2004.07.001; Leon-Carrion J, 2007, BRAIN INJURY, V21, P871, DOI 10.1080/02699050701484849; Lippert-Gruner M, 2007, PHYSIOL RES, V56, P359, DOI 10.33549/physiolres.930971; Maiya B, 2008, INTENS CARE MED, V34, P468, DOI 10.1007/s00134-007-0902-x; Maric NP, 2010, J ENDOCRINOL INVEST, V33, P770, DOI [10.1007/BF03350340, 10.3275/7045]; Miladi-Gorji H, 2011, NEUROBIOL LEARN MEM, V96, P479, DOI 10.1016/j.nlm.2011.08.001; Moreau OK, 2013, J NEUROTRAUM, V30, P998, DOI 10.1089/neu.2012.2705; Morris GM, 2008, SCHOLARPEDIA US, V3, P6315; Morselli L L, 2008, J Endocrinol Invest, V31, P39; Nieuwpoort IC, 2008, EUR J ENDOCRINOL ENG, V159, pS53; Oertel H, 2004, PSYCHONEUROENDOCRINO, V29, P839, DOI 10.1016/S0306-4530(03)00151-3; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; Pathipati P, 2009, BEHAV BRAIN RES, V204, P93, DOI 10.1016/j.bbr.2009.05.023; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; Quik EH, 2012, GROWTH HORM IGF RES, V22, P42, DOI 10.1016/j.ghir.2011.12.007; Rocha M, 1999, BRAIN RES, V827, P79, DOI 10.1016/S0006-8993(99)01307-4; Schober ME, 2012, METAB BRAIN DIS, V27, P167, DOI 10.1007/s11011-012-9309-7; Shojo H, 2006, BRAIN RES, V1078, P198, DOI 10.1016/j.brainres.2006.01.063; Tarsa L, 2002, P NATL ACAD SCI USA, V99, P1012, DOI 10.1073/pnas.022575999; Thornton PL, 2000, J GERONTOL A-BIOL, V55, pB106; Tong LQ, 2012, J NEUROSCI, V32, P17714, DOI 10.1523/JNEUROSCI.1253-12.2012; Urban RJ, 2006, GROWTH HORM IGF RES, V16, pS25, DOI 10.1016/j.ghir.2006.03.017; VanGuilder HD, 2011, NEUROBIOL DIS, V43, P201, DOI 10.1016/j.nbd.2011.03.012; Wass JAH, 2010, J ENDOCRINOL, V207, P125, DOI 10.1677/JOE-10-0126; Ying XG, 2004, J CLIN CARDIOVASCU D, V10, P613; Zhou JP, 2007, INFLUENCE GNRH ANALO	54	25	26	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2014	9	9							e108518	10.1371/journal.pone.0108518	http://dx.doi.org/10.1371/journal.pone.0108518			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR6CW	25268832	Green Published, gold, Green Submitted			2023-01-03	WOS:000343671700105
J	Munson, J; Amati, V; Collard, M; Macri, MJ				Munson, Jessica; Amati, Viviana; Collard, Mark; Macri, Martha J.			Classic Maya Bloodletting and the Cultural Evolution of Religious Rituals: Quantifying Patterns of Variation in Hieroglyphic Texts	PLOS ONE			English	Article							SPATIAL ASSOCIATION; SIGNALING THEORY; COOPERATION; STATISTICS; NETWORKS; WAR	Religious rituals that are painful or highly stressful are hypothesized to be costly signs of commitment essential for the evolution of complex society. Yet few studies have investigated how such extreme ritual practices were culturally transmitted in past societies. Here, we report the first study to analyze temporal and spatial variation in bloodletting rituals recorded in Classic Maya (ca. 250-900 CE) hieroglyphic texts. We also identify the sociopolitical contexts most closely associated with these ancient recorded rituals. Sampling an extensive record of 2,480 hieroglyphic texts, this study identifies every recorded instance of the logographic sign for the word ch'ahb' that is associated with ritual bloodletting. We show that documented rituals exhibit low frequency whose occurrence cannot be predicted by spatial location. Conversely, network ties better capture the distribution of bloodletting rituals across the southern Maya region. Our results indicate that bloodletting rituals by Maya nobles were not uniformly recorded, but were typically documented in association with antagonistic statements and may have signaled royal commitments among connected polities.	[Munson, Jessica; Macri, Martha J.] Univ Calif Davis, Dept Linguist, Davis, CA 95616 USA; [Amati, Viviana] Univ Konstanz, Dept Comp & Informat Sci, Constance, Germany; [Collard, Mark] Simon Fraser Univ, Human Evolutionary Studies Program, Burnaby, BC V5A 1S6, Canada; [Collard, Mark] Simon Fraser Univ, Dept Archaeol, Burnaby, BC V5A 1S6, Canada; [Collard, Mark] Univ Aberdeen, Dept Archaeol, Aberdeen, Scotland; [Macri, Martha J.] Univ Calif Davis, Dept Native Amer Studies, Davis, CA 95616 USA	University of California System; University of California Davis; University of Konstanz; Simon Fraser University; Simon Fraser University; University of Aberdeen; University of California System; University of California Davis	Munson, J (corresponding author), Univ Calif Davis, Dept Linguist, Davis, CA 95616 USA.	jmunson@ucdavis.edu		Munson, Jessica/0000-0002-2362-3804; Collard, Mark/0000-0002-2725-4989	National Science Foundation [IBSS1328928, SBR9710961, SBR9905357]; National Endowment for the Humanities [RT21365-92, RT21608-94, PA22844-96]; Social Sciences and Humanities Research Council [895-2011-1009]	National Science Foundation(National Science Foundation (NSF)); National Endowment for the Humanities; Social Sciences and Humanities Research Council(Social Sciences and Humanities Research Council of Canada (SSHRC))	The work was supported by the following: National Science Foundation, IBSS1328928 (MJM, JM); National Science Foundation, SBR9710961 (MJM); National Science Foundation, SBR9905357 (MJM); the National Endowment for the Humanities, RT21365-92, RT21608-94, PA22844-96 (MJM), Social Sciences and Humanities Research Council, Partnership Grant, grant ID 895-2011-1009 (MC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2003, HUMAN MOSAIC; [Anonymous], 2010, SACRIFICIO HUMANO TR; [Anonymous], RELACION COAS YUCATA; [Anonymous], 2012, CREATING CONSILIENCE; [Anonymous], 1995, STUDY MAYA INSCRIPTI; [Anonymous], ROYAL AUTO SACRIFICE; [Anonymous], 1984, RITUAL HUMAN SACRIFI; [Anonymous], 2013, NETWORK ANAL ARCHAEO, DOI DOI 10.1093/ACPROF:OSO/9780199697090.003.0005; [Anonymous], 1997, ITZAJ MAYA SPANISH E; [Anonymous], 1977, CORPUS MAYA HIEROGLY; [Anonymous], ECOLOGY POWER RELIG; [Anonymous], DICCIONARIO BASICO T; [Anonymous], EXTREME RITUALS PROM; [Anonymous], MAYA HIEROGLYPHIC DA; [Anonymous], 1991, CLASSIC MAYA POLITIC; [Anonymous], 1998, DICT MAYA LANGUAGE S; [Anonymous], 1997, ARCHAEOLOGICAL PAPER; [Anonymous], 2011, CREATING CONSILIENCE; [Anonymous], 2007, NEW PERSPECTIVES HUM; [Anonymous], 2005, CATALYST IDEAS ANTHR; [Anonymous], TREATISE HEATHEN SUP; [Anonymous], ELECT ATLAS ANCIENT; [Anonymous], 1950, MAT CHORTI LANGUAGE; [Anonymous], 2003, NEW CATALOG MAYA HIE; [Anonymous], PRELIMINARY MAYAN EN; [Anonymous], 1941, LANDAS RELACION COSA; [Anonymous], MAYAB; [Anonymous], 2011, MOPAN MAYA SPANISH E; [Anonymous], DICCIONARIO CHUJ AUT; [Anonymous], 1984, RITUAL HUMAN SACRIFI; [Anonymous], 1974, PRIMERA MESA REDONDA; [Anonymous], 2010, SACRIFICIO HUMANO TR; [Anonymous], 1994, CLASSIC MAYA PLACE N; [Anonymous], 2009, WARFARE CULTURAL CON; [Anonymous], 1984, RITUAL HUMAN SACRIFI; ANSELIN L, 1995, GEOGR ANAL, V27, P93, DOI 10.1111/j.1538-4632.1995.tb00338.x; Ardren T., 2011, CHILDHOOD, V4, P133; Atran S., 2002, GODS WE TRUST EVOLUT; Atran Scott, 2010, Biology Theory, V5, P18, DOI 10.1162/BIOT_a_00018; Barrera Vasquez Alfredo, 1980, DICCIONARIO MAYA COR; Bellah R. N., 2011, RELIG HUMAN EVOLUTIO; Bird RB, 2005, CURR ANTHROPOL, V46, P221, DOI 10.1086/427115; Borgatti S.P., 2002, UCINET 6 WINDOWS SOF; Borgatti S.P., 2018, ANAL SOCIAL NETWORKS; Boyd R, 2009, PHILOS T R SOC B, V364, P3281, DOI 10.1098/rstb.2009.0134; Bulbulia J, 2011, RELIGION, V41, P363, DOI 10.1080/0048721X.2011.604508; Carrasco David, 1999, CITY SACRIFICE AZTEC; CRONK L, 1994, ZYGON, V29, P81, DOI 10.1111/j.1467-9744.1994.tb00651.x; Durkheim E., 1965, ELEMENTARY FORCES RE; GETIS A, 1992, GEOGR ANAL, V24, P189, DOI 10.1111/j.1538-4632.1992.tb00261.x; Haines HR, 2008, LAT AM ANTIQ, V19, P83, DOI 10.2307/25478210; Henrich J, 2009, EVOL HUM BEHAV, V30, P244, DOI 10.1016/j.evolhumbehav.2009.03.005; Houston S, 2009, CAMB ARCHAEOL J, V19, P149, DOI 10.1017/S0959774309000250; Irons W., 2001, EVOLUTION CAPACITY C, P292; Konvalinka I, 2011, P NATL ACAD SCI USA, V108, P8514, DOI 10.1073/pnas.1016955108; Laughlin Robert M, 1988, GREAT TZOTZIL DICT S; Looper Matthew G., 2009, BE GODS DANCE ANCIEN; MARCUS J, 1976, EMBLEM STATE CLASSIC; Martin Simon, 2008, CHRONICLE MAYA KINGS, V2nd; Martin Simon, 2000, CHRONICLE MAYA KINGS; McPherson M, 2001, ANNU REV SOCIOL, V27, P415, DOI 10.1146/annurev.soc.27.1.415; Munson JL, 2009, J ANTHROPOL ARCHAEOL, V28, P424, DOI 10.1016/j.jaa.2009.08.002; Norenzayan A., 2013, BIG GODS RELIG TRANS; Norenzayan A, 2008, SCIENCE, V322, P58, DOI 10.1126/science.1158757; Pennock CD, 2008, EARLY MOD HIST-SOC C, P1, DOI 10.1057/9780230582330; Premo LS, 2004, J ARCHAEOL SCI, V31, P855, DOI 10.1016/j.jas.2003.12.002; Rappaport Roy., 1999, RITUAL RELIG MAKING, DOI DOI 10.1017/CBO9780511814686; Rogers E.M, 1995, DIFFUSION INNOVATION; Schele Linda, 1986, BLOOD KINGS DYNASTY; Shalizi CR, 2011, SOCIOL METHOD RES, V40, P211, DOI 10.1177/0049124111404820; Slingerland E, 2011, RELIGION, V41, P307, DOI 10.1080/0048721X.2011.604513; Snijders TAB, 2010, SOC NETWORKS, V32, P44, DOI 10.1016/j.socnet.2009.02.004; Sosis R, 2003, CURR ANTHROPOL, V44, P713, DOI 10.1086/379260; Sosis R, 2007, EVOL HUM BEHAV, V28, P234, DOI 10.1016/j.evolhumbehav.2007.02.007; Steglich C, 2010, SOCIOL METHODOL, V40, P329, DOI 10.1111/j.1467-9531.2010.01225.x; Sugiyama Saburo, 2005, HUMAN SACRIFICE MILI; Taube Karl A., 2010, MURALS SAN BARTOLO P; Tiesler V, 2006, LAT AM ANTIQ, V17, P493, DOI 10.2307/25063069; Vail G, 2007, INTERD CONTRIB ARCH, P120, DOI 10.1007/978-0-387-48871-4_6; Webster D, 2000, J WORLD PREHIST, V14, P65, DOI 10.1023/A:1007813518630; Wilson CG, 2008, EVOL HUM BEHAV, V29, P149, DOI 10.1016/j.evolhumbehav.2007.11.008	81	20	20	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2014	9	9							e107982	10.1371/journal.pone.0107982	http://dx.doi.org/10.1371/journal.pone.0107982			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	AT3UZ	25254359	Green Published, Green Submitted, gold			2023-01-03	WOS:000344862300048
J	Cesar, C; Shepherd, BE; Jenkins, CA; Ghidinelli, M; Castro, JL; Veloso, VG; Cortes, CP; Padgett, D; Crabtree-Ramirez, B; Gotuzzo, E; Fink, V; Duran, A; Sued, O; McGowan, CC; Cahn, P				Cesar, Carina; Shepherd, Bryan E.; Jenkins, Cathy A.; Ghidinelli, Massimo; Castro, Jose Luis; Veloso, Valdilea Goncalves; Cortes, Claudia P.; Padgett, Denis; Crabtree-Ramirez, Brenda; Gotuzzo, Eduardo; Fink, Valeria; Duran, Adriana; Sued, Omar; McGowan, Catherine C.; Cahn, Pedro		Caribbean Cent & South Amer Networ	Use of Third Line Antiretroviral Therapy in Latin America	PLOS ONE			English	Article							VIROLOGICAL FAILURE; MORTALITY; AFRICA; COHORT; AGE	Background: Access to highly active antiretroviral therapy (HAART) is expanding in Latin America. Many patients require second and third line therapy due to toxicity, tolerability, failure, or a combination of factors. The need for third line HAART, essential for program planning, is not known. Methods: Antiretroviral-naive patients >= 18 years who started first HAART after January 1, 2000 in Caribbean, Central and South America Network (CCASAnet) sites in Argentina, Brazil, Honduras, Mexico, and Peru were included. Clinical trials participants were excluded. Third line HAART was defined as use of darunavir, tipranavir, etravirine, enfuvirtide, maraviroc or raltegravir. Need for third line HAART was defined as virologic failure while on second line HAART. Results: Of 5853 HAART initiators followed for a median of 3.5 years, 310 (5.3%) failed a second line regimen and 44 (0.8%) received a third line regimen. Cumulative incidence of failing a 2nd or starting a 3rd line regimen was 2.7% and 6.0% three and five years after HAART initiation, respectively. Predictors at HAART initiation for failing a second or starting a third line included female sex (hazard ratio [HR] = 1.54, 95% confidence interval [CI] 1.18-2.00, p = 0.001), younger age (HR = 2.76 for 20 vs. 40 years, 95% CI 1.86-4.10, p<0.001), and prior AIDS (HR = 2.17, 95% CI 1.62-2.90, p<0.001). Conclusions: Third line regimens may be needed for at least 6% of patients in Latin America within 5 years of starting HAART, a substantial proportion given the large numbers of patients on HAART in the region. Improved accessibility to third line regimens is warranted.	[Cesar, Carina; Fink, Valeria; Sued, Omar; Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina; [Shepherd, Bryan E.; Jenkins, Cathy A.; McGowan, Catherine C.] Vanderbilt Univ, Nashville, TN 37235 USA; [Ghidinelli, Massimo; Castro, Jose Luis] Pan Amer Hlth Org, Washington, DC USA; [Veloso, Valdilea Goncalves] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil; [Cortes, Claudia P.] Univ Chile, Santiago, Chile; [Padgett, Denis] Inst Hondureno Seguridad Social, Tegucigalpa, Honduras; [Padgett, Denis] Hosp Escuela Tegucigalpa, Tegucigalpa, Honduras; [Crabtree-Ramirez, Brenda] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico; [Gotuzzo, Eduardo] Inst Med Trop Alexander Von Humboldt, Lima, Peru; [Duran, Adriana] Minist Salud Ciudad Autonoma Buenos Aires, Coordinac Sida, Buenos Aires, DF, Argentina	Vanderbilt University; Pan American Health Organization; Fundacao Oswaldo Cruz; Universidad de Chile; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Universidad Peruana Cayetano Heredia	Cesar, C (corresponding author), Fdn Huesped, Buenos Aires, DF, Argentina.	carina.cesar@huesped.org.ar	Cortes, Claudia P/AAF-7326-2020; Sued, Omar/H-3325-2019; Cesar, Carina/H-2831-2019	Cortes, Claudia P/0000-0001-9101-9783; Sued, Omar/0000-0001-5818-770X; Crabtree-Ramirez, Brenda/0000-0002-2587-1123	National Institute of Allergy and Infectious Diseases (NIAID), International Epidemiologic Databases to Evaluate AIDS (IeDEA) [U01 AI069923]; FOGARTY INTERNATIONAL CENTER [D43TW009763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI069923] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID), International Epidemiologic Databases to Evaluate AIDS (IeDEA); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) as part of the International Epidemiologic Databases to Evaluate AIDS (IeDEA): U01 AI069923. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ajose O, 2012, AIDS, V26, P929, DOI 10.1097/QAD.0b013e328351f5b2; Alave J, 2013, REV CHIL INFECTOL, V30, P42, DOI 10.4067/S0716-10182013000100006; [Anonymous], 2013, PAIS AM PODR ADQ INS; [Anonymous], 2013, WHO REPORT PARTNERSH; [Anonymous], 2013, UNAIDS REP GLOB AIDS; Caseiro MM, 2008, BRAZ J INFECT DIS, V12, P162, DOI 10.1590/S1413-86702008000300001; Cesar C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010490; Crabtree-Ramirez B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020272; Fox MP, 2010, JAIDS-J ACQ IMM DEF, V53, P500, DOI 10.1097/QAI.0b013e3181bcdac1; Greenbaum AH, 2008, AIDS, V22, P2331, DOI 10.1097/QAD.0b013e32831883f9; Keiser O, 2010, TROP MED INT HEALTH, V15, P251, DOI 10.1111/j.1365-3156.2009.02445.x; Kumarasamy N, 2011, J Int Assoc Physicians AIDS Care (Chic), V10, P71, DOI 10.1177/1545109710382780; McGowan CC, 2007, INT J EPIDEMIOL, V36, P969, DOI 10.1093/ije/dym073; Nagles J, 2007, MED UPB, V26, P109; PAHO/WHO, 2013, ANT TREATM SPOTL PUB; Parienti JJ, 2004, CLIN INFECT DIS, V38, P1311, DOI 10.1086/383572; Pujades-Rodriguez M, 2010, JAMA-J AM MED ASSOC, V304, P303, DOI 10.1001/jama.2010.980; Silverberg MJ, 2007, ARCH INTERN MED, V167, P684, DOI 10.1001/archinte.167.7.684; Siripassorn K, 2010, AIDS RES HUM RETROV, V26, P139, DOI 10.1089/aid.2009.0125; Tuboi SH, 2009, JAIDS-J ACQ IMM DEF, V51, P615, DOI 10.1097/QAI.0b013e3181a44f0a; *UNAIDS WHO, 2003, AIDS EP UPD; Win May Myat, 2011, J Int Assoc Physicians AIDS Care (Chic), V10, P57, DOI 10.1177/1545109710387301	22	11	11	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2014	9	9							e106887	10.1371/journal.pone.0106887	http://dx.doi.org/10.1371/journal.pone.0106887			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AP0SR	25221931	Green Published, gold, Green Submitted			2023-01-03	WOS:000341774800031
J	Rousseau, C; Beauregard, C; Daignault, K; Petrakos, H; Thombs, BD; Steele, R; Vasiliadis, HM; Hechtman, L				Rousseau, Cecile; Beauregard, Caroline; Daignault, Katherine; Petrakos, Harriet; Thombs, Brett D.; Steele, Russell; Vasiliadis, Helen-Maria; Hechtman, Lily			A Cluster Randomized-Controlled Trial of a Classroom-Based Drama Workshop Program to Improve Mental Health Outcomes among Immigrant and Refugee Youth in Special Classes	PLOS ONE			English	Article							SELF-CONTAINED CLASSROOMS; DIFFICULTIES QUESTIONNAIRE; PSYCHOMETRIC PROPERTIES; ACADEMIC ENGAGEMENT; CHILDREN; INTERVENTION; STRENGTHS; STUDENTS; SCHOOLS; ADOLESCENTS	Objectives: The aim of this cluster randomized trial was to evaluate the effectiveness of a school-based theatre intervention program for immigrant and refugee youth in special classes for improving mental health and academic outcomes. The primary hypothesis was that students in the theatre intervention group would report a greater reduction in impairment from symptoms compared to students in the control and tutoring groups. Methods: Special classrooms in five multiethnic high schools were randomly assigned to theater intervention (n = 10), tutoring (n = 10) or control status (n = 9), for a total of 477 participants. Students and teachers were non-blinded to group assignment. The primary outcome was impairment from emotional and behavioural symptoms assessed by the Impact Supplement of the Strengths and Difficulties Questionnaire (SDQ) completed by the adolescents. The secondary outcomes were the SDQ global scores (teacher and youth reports), impairment assessed by teachers and school performance. The effect of the interventions was assessed through linear mixed effect models which incorporate the correlation between students in the same class, due to the nature of the randomization of the interventions by classroom. Results: The theatre intervention was not associated with a greater reduction in self-reported impairment and symptoms in youth placed in special class because of learning, emotional and behavioural difficulties than a tutoring intervention or a non-active control group. The estimates of the different models show a non-significant decrease in both self-reported and impairment scores in the theatre intervention group for the overall group, but the impairment score decreased significantly for first generation adolescents while it increased for second generation adolescents. Conclusion: The difference between the population of immigrant and refugee youth newcomers studied previously and the sample of this trial may explain some of the differences in the observed impact of the theatre intervention.	[Rousseau, Cecile] McGill Univ, Div Social & Cultural Psychiat, Montreal, PQ, Canada; [Beauregard, Caroline] Univ Montreal, Dept Educ Psychol & Adult Educ, Montreal, PQ, Canada; [Daignault, Katherine; Steele, Russell] McGill Univ, Dept Math & Stat, Montreal, PQ, Canada; [Petrakos, Harriet] Concordia Univ, Dept Educ, Montreal, PQ, Canada; [Thombs, Brett D.] McGill Univ, Dept Psychiat, Lady Davis Inst Med Res, Montreal, PQ, Canada; [Vasiliadis, Helen-Maria] Univ Sherbrooke, Dept Community Hlth Sci, Sherbrooke, PQ J1K 2R1, Canada; [Hechtman, Lily] McGill Univ, Div Child Psychiat, Montreal, PQ, Canada	McGill University; Universite de Montreal; McGill University; Concordia University - Canada; Lady Davis Institute; McGill University; University of Sherbrooke; McGill University	Rousseau, C (corresponding author), McGill Univ, Div Social & Cultural Psychiat, Montreal, PQ, Canada.	cecile.rousseau@mcgill.ca	Steele, Russell J/G-6926-2017		Canadian Institute for Health Research [IRSC-229984]	Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR))	This research was funded by a grant from the Canadian Institute for Health Research, No. IRSC-229984. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akhundov N, 1999, FORCED MIGRATION DEC, V1999, P20; Anderson JA, 2001, J EMOT BEHAV DISORD, V9, P106, DOI 10.1177/106342660100900205; Bibeau G, 1992, SANTE MENTALE VISAGE; Bourdon KH, 2005, J AM ACAD CHILD PSY, V44, P557, DOI 10.1097/01.chi.0000159157.57075.c8; Danev M., 1998, ART THERAPISTS REFUG; Everitt B. S., 2008, CLIN TRIALS PSYCHIAT; Glick JE, 2003, DEMOGRAPHY, V40, P759, DOI 10.2307/1515207; Goodman A, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-258; Goodman R, 1999, J CHILD PSYCHOL PSYC, V40, P791, DOI 10.1111/1469-7610.00494; Goodman R, 2001, J AM ACAD CHILD PSY, V40, P1337, DOI 10.1097/00004583-200111000-00015; Hodes M., 2000, CHILD PSYCHOL PSYCHI, V5, P57, DOI [DOI 10.1017/S136064170000215X, 10.1017/S136064170000215X]; Jordans MJD, 2010, J CHILD PSYCHOL PSYC, V51, P818, DOI 10.1111/j.1469-7610.2010.02209.x; Kanoute F., 2002, REV SCI LEDUCATION, V28, P171; Lane KL, 2005, BEHAV DISORDERS, V30, P363; Lane KL, 2005, BEHAV DISORDERS, V30, P349; Layne CM, 2008, J AM ACAD CHILD PSY, V47, P1048, DOI 10.1097/CHI.0b013e31817eecae; Lopez A, 1992, NUESTRO ORIGEN NUEST; Manassis K, 2010, DEPRESSION ANXIETY; MILLER KE, 1994, AM J ORTHOPSYCHIAT, V64, P346, DOI 10.1037/h0079548; Moneta I, 2008, ART PSYCHOTHER, V35, P329, DOI 10.1016/j.aip.2008.07.001; National Collaborating Centre for Mental Health, 2005, POSTTRAUMATIC STRESS; Nylund B. V., 1999, FORCED MIGRATION REV, V6, P16; Rasco LM, 2004, MENTAL HEALTH OF REFUGEES, P375; Reddy LA, 2009, J SCHOOL PSYCHOL, V47, P77, DOI 10.1016/j.jsp.2008.11.001; Rousseau C, 2005, J CHILD PSYCHOL PSYC, V46, P180, DOI 10.1111/j.1469-7610.2004.00344.x; Rousseau C, 1996, AM J ORTHOPSYCHIAT, V66, P239, DOI 10.1037/h0080175; Rousseau C, 2008, CHILD ADOL PSYCH CL, V17, P533, DOI 10.1016/j.chc.2008.02.002; Rousseau Cecile, 2007, Clin Child Psychol Psychiatry, V12, P451; Rousseau C, 2012, CHILD ADOL MENT H-UK, V17, P187, DOI 10.1111/j.1475-3588.2011.00629.x; Rumbaut RG., 2001, ETHNICITIES CHILDREN; Stein BD, 2003, JAMA-J AM MED ASSOC, V290, P603, DOI 10.1001/jama.290.5.603; Suarez-Orozco C, 2009, TEACH COLL REC, V111, P712; Tol WA, 2008, JAMA-J AM MED ASSOC, V300, P655, DOI 10.1001/jama.300.6.655; Tol WA, 2012, WORLD PSYCHIATRY, V11, P114, DOI 10.1016/j.wpsyc.2012.05.008; Tucker CM, 2002, PSYCHOL SCHOOLS, V39, P477, DOI 10.1002/pits.10038; Van Hook J, 2002, DEMOGRAPHY, V39, P639, DOI 10.1353/dem.2002.0042; Wilson SJ, 2007, AM J PREV MED, V33, pS130, DOI 10.1016/j.amepre.2007.04.011	38	17	17	1	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2014	9	8							e104704	10.1371/journal.pone.0104704	http://dx.doi.org/10.1371/journal.pone.0104704			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AN8UD	25127251	Green Published, gold			2023-01-03	WOS:000340879300044
J	Watts, G				Watts, Geoff			Jeannie Isabelle Rosoff obituary	LANCET			English	Biographical-Item																			0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	2014	384	9942					488	488		10.1016/S0140-6736(14)61327-1	http://dx.doi.org/10.1016/S0140-6736(14)61327-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AM9JR	25115004				2023-01-03	WOS:000340198300013
J	Fontana, L; Kennedy, BK; Longo, VD				Fontana, Luigi; Kennedy, Brian K.; Longo, Valter D.			Prepare for human testing	NATURE			English	Editorial Material									[Fontana, Luigi] Washington Univ, St Louis, MO 63130 USA; [Fontana, Luigi] Univ Brescia, I-25121 Brescia, Italy; [Kennedy, Brian K.] Buck Inst Res Aging, Novato, CA USA; [Longo, Valter D.] Univ So Calif, Longev Inst, Los Angeles, CA USA	Washington University (WUSTL); University of Brescia; Buck Institute for Research on Aging; University of Southern California	Fontana, L (corresponding author), Washington Univ, St Louis, MO 63130 USA.	fontana.luigi@gmail.com		Kennedy, Brian/0000-0002-5754-1874; Fontana, Luigi/0000-0001-8500-5537					0	158	168	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 24	2014	511	7510					405	406		10.1038/511405a	http://dx.doi.org/10.1038/511405a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AL7SO	25056047	Bronze			2023-01-03	WOS:000339335700021
J	Neuman, MD; Rosenbaum, PR; Ludwig, JM; Zubizarreta, JR; Silber, JH				Neuman, Mark D.; Rosenbaum, Paul R.; Ludwig, Justin M.; Zubizarreta, Jose R.; Silber, Jeffrey H.			Anesthesia Technique, Mortality, and Length of Stay After Hip Fracture Surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENERAL-ANESTHESIA; ELDERLY-PATIENTS; POSTOPERATIVE DELIRIUM; CONFIDENCE-INTERVALS; SENSITIVITY-ANALYSIS; BIAS REDUCTION; OUTCOMES; CARE; ASSOCIATION; INSTRUMENT	IMPORTANCE More than 300 000 hip fractures occur each year in the United States. Recent practice guidelines have advocated greater use of regional anesthesia for hip fracture surgery. OBJECTIVE To test the association of regional (ie, spinal or epidural) anesthesia vs general anesthesia with 30-day mortality and hospital length of stay after hip fracture. DESIGN, SETTING, AND PATIENTS We conducted a matched retrospective cohort study involving patients 50 years or older who were undergoing surgery for hip fracture at general acute care hospitals in New York State between July 1, 2004, and December 31, 2011. Our main analysis was a near-far instrumental variable match that paired patients who lived at different distances from hospitals that specialized in regional or general anesthesia. Supplementary analyses included a within-hospital match that paired patients within the same hospital and an across-hospital match that paired patients at different hospitals. EXPOSURES Spinal or epidural anesthesia; general anesthesia. MAIN OUTCOMES AND MEASURES Thirty-day mortality and hospital length of stay. Because the distribution of length of stay had long tails, we characterized this outcome using the Huber M estimate with Huber weights, a robust estimator similar to a trimmed mean. RESULTS Of 56 729 patients, 15 904 (28%) received regional anesthesia and 40 825 (72%) received general anesthesia. Overall, 3032 patients (5.3%) died. The M estimate of the length of stay was 6.2 days (95% CI, 6.2 to 6.2). The near-far matched analysis showed no significant difference in 30-day mortality by anesthesia type among the 21 514 patients included in this match: 583 of 10 757 matched patients (5.4%) who lived near a regional anesthesia-specialized hospital died vs 629 of 10 757 matched patients (5.8%) who lived near a general anesthesia-specialized hospital (instrumental variable estimate of risk difference, -1.1%; 95% CI, -2.8 to 0.5; P = .20). Supplementary analyses of within and across hospital patient matches yielded mortality findings to be similar to the main analysis. In the near-far match, regional anesthesia was associated with a 0.6-day shorter length of stay than general anesthesia (95% CI, -0.8 to -0.4, P < .001). Supplementary analyses also showed regional anesthesia to be associated with shorter length of stay, although the observed association was smaller in magnitude than in the main analysis. CONCLUSIONS AND RELEVANCE Among adults in acute care hospitals in New York State undergoing hip repair, the use of regional anesthesia compared with general anesthesia was not associated with lower 30-day mortality but was associated with a modestly shorter length of stay. These findings do not support a mortality benefit for regional anesthesia in this setting.	[Neuman, Mark D.; Silber, Jeffrey H.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Neuman, Mark D.; Rosenbaum, Paul R.; Silber, Jeffrey H.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Rosenbaum, Paul R.] Univ Penn, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA; [Ludwig, Justin M.; Silber, Jeffrey H.] Childrens Hosp Philadelphia, Ctr Outcomes Res, Philadelphia, PA USA; [Zubizarreta, Jose R.] Columbia Business Sch, Div Decis Risk & Operat, New York, NY USA; [Zubizarreta, Jose R.] Columbia Univ, Dept Stat, New York, NY USA; [Silber, Jeffrey H.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Silber, Jeffrey H.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Columbia University; Columbia University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Neuman, MD (corresponding author), Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, 1119 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	neumanm@mail.med.upenn.edu	Rosenbaum, Paul R/H-8687-2012		Foundation for Anesthesia Education and Research; National Institute on Aging [1K08AG043548]; National Science Foundation [1260782]; NATIONAL INSTITUTE ON AGING [K08AG043548] Funding Source: NIH RePORTER	Foundation for Anesthesia Education and Research; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Science Foundation(National Science Foundation (NSF)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by grants to MDN from the Foundation for Anesthesia Education and Research and 1K08AG043548 from the National Institute on Aging (Dr Neuman) and by grant 1260782 the from the National Science Foundation, (Dr Rosenbaum).	Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629; Baiocchi M, 2012, HEALTH SERV OUTCOME, V12, P237, DOI 10.1007/s10742-012-0091-0; Baiocchi M, 2010, J AM STAT ASSOC, V105, P1285, DOI 10.1198/jasa.2010.ap09490; BERGGREN D, 1987, ANESTH ANALG, V66, P497; Blackman D K, 1999, MMWR CDC Surveill Summ, V48, P1; Boulton C, 2014, NATL HIP FRACTURE DA; Brauer CA, 2009, JAMA-J AM MED ASSOC, V302, P1573, DOI 10.1001/jama.2009.1462; COCHRAN WG, 1973, SANKHYA SER A, V35, P417; DAVIS FM, 1987, BRIT J ANAESTH, V59, P561, DOI 10.1093/bja/59.5.561; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Foss NB, 2005, ANESTHESIOLOGY, V102, P1197, DOI 10.1097/00000542-200506000-00020; Griffiths R, 2012, ANAESTHESIA, V67, P85, DOI 10.1111/j.1365-2044.2011.06957.x; Horlocker TT, 2010, REGION ANESTH PAIN M, V35, P64, DOI 10.1097/AAP.0b013e3181c15c70; Huber P.J., 1981, ROBUST STAT; HUBER PJ, 1964, ANN MATH STAT, V35, P73, DOI 10.1214/aoms/1177703732; Imbens GW, 2005, J ROY STAT SOC A STA, V168, P109, DOI 10.1111/j.1467-985X.2004.00339.x; Lee HB, 2011, J AM GERIATR SOC, V59, P2306, DOI 10.1111/j.1532-5415.2011.03725.x; Lorch SA, 2012, PEDIATRICS, V130, P270, DOI 10.1542/peds.2011-2820; Magaziner J, 2000, J GERONTOL A-BIOL, V55, pM498, DOI 10.1093/gerona/55.9.M498; Mahalanobis P., 1936, P NATL I SCI INDIA, P49; Maritz J. S., 1995, DISTRIBUTION FREE ST, V2nd; Neuman MD, 2012, ANESTHESIOLOGY, V117, P72, DOI 10.1097/ALN.0b013e3182545e7c; Neuman MD, 2010, MED CARE, V48, P314, DOI 10.1097/MLR.0b013e3181ca4126; O'Hara DA, 2000, ANESTHESIOLOGY, V92, P947, DOI 10.1097/00000542-200004000-00011; Parker MJ, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000521.PUB2; Polsky D, 2008, HEALTH SERV RES, V43, P1388, DOI 10.1111/j.1475-6773.2008.00837.x; Radcliff TA, 2008, J BONE JOINT SURG AM, V90A, P34, DOI 10.2106/JBJS.G.00065; Regan EA, 2013, COPD, V10, P11, DOI 10.3109/15412555.2012.723072; Rosenbaum PR, 2007, BIOMETRICS, V63, P456, DOI 10.1111/j.1541-0420.2006.00717.x; Rosenbaum PR, 2007, J AM STAT ASSOC, V102, P75, DOI 10.1198/016214506000001059; Rosenbaum PR, 2012, J COMPUT GRAPH STAT, V21, P57, DOI 10.1198/jcgs.2011.09219; Rosenbaum PR, 2010, SPRINGER SER STAT, P1, DOI 10.1007/978-1-4419-1213-8; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; RUBIN DB, 1980, BIOMETRICS, V36, P293, DOI 10.2307/2529981; Rubin DB, 2007, STAT MED, V26, P20, DOI 10.1002/sim.2739; Scheinin H, 2000, ACTA ANAESTH SCAND, V44, P1061, DOI 10.1034/j.1399-6576.2000.440905.x; Scottish Intercollegiate Guidelines Network, 2009, MAN HIP FRACT OLD PE; Sheffield KM, 2013, JAMA-J AM MED ASSOC, V310, P812, DOI 10.1001/jama.2013.276205; Sieber FE, 2010, J CLIN ANESTH, V22, P179, DOI 10.1016/j.jclinane.2009.06.005; Sieber FE, 2010, MAYO CLIN PROC, V85, P18, DOI 10.4065/mcp.2009.0469; Silber JH, 2007, MED CARE, V45, P918, DOI 10.1097/MLR.0b013e31812e01cc; Silber JH, 2001, MED CARE, V39, P1048, DOI 10.1097/00005650-200110000-00003; Small DS, 2008, J AM STAT ASSOC, V103, P924, DOI 10.1198/016214507000001247; UK National Clinical Guideline Centre, 2011, MAN HIP FRACT AD; VALENTIN N, 1986, BRIT J ANAESTH, V58, P284, DOI 10.1093/bja/58.3.284; White SM, 2014, ANAESTHESIA, V69, P224, DOI 10.1111/anae.12542; White SM, 2010, ANAESTHESIA, V65, P243, DOI 10.1111/j.1365-2044.2009.06208.x; Zubizarreta JR, 2012, J AM STAT ASSOC, V107, P1360, DOI 10.1080/01621459.2012.703874	49	178	191	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	2014	311	24					2508	2517		10.1001/jama.2014.6499	http://dx.doi.org/10.1001/jama.2014.6499			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AJ5VE	25058085	Green Accepted, Green Published			2023-01-03	WOS:000337757000024
J	Fatkenheuer, G; Hirschel, B; Harbarth, S				Faetkenheuer, Gerd; Hirschel, Bernard; Harbarth, Stephan			Screening and isolation to control meticillin-resistant Staphylococcus aureus: sense, nonsense, and evidence	LANCET			English	Editorial Material							INTERRUPTED TIME-SERIES; INTENSIVE-CARE UNITS; OF-THE-LITERATURE; SURGICAL-PATIENTS; CONTACT ISOLATION; INFECTION-CONTROL; RANDOMIZED-TRIAL; IMPACT; ACQUISITION; HOSPITALS		[Faetkenheuer, Gerd] Univ Hosp Cologne, Dept Internal Med 1, D-50937 Cologne, Germany; [Faetkenheuer, Gerd] German Ctr Infect Res DZIF, Bonn, Germany; [Hirschel, Bernard] Univ Hosp Geneva, Div Infect Dis, Geneva, Switzerland; [Hirschel, Bernard; Harbarth, Stephan] Fac Med, Geneva, Switzerland; [Harbarth, Stephan] Univ Hosp Geneva, Infect Control Program, Geneva, Switzerland	University of Cologne; German Center for Infection Research; University of Geneva; University of Geneva; University of Geneva	Fatkenheuer, G (corresponding author), Univ Hosp Cologne, Dept Internal Med 1, Kerpener Str 62, D-50937 Cologne, Germany.	g.faetkenheuer@uni-koeln.de						Bessesen MT, 2013, AM J INFECT CONTROL, V41, P1048, DOI 10.1016/j.ajic.2013.01.032; Bouadma L, 2010, CLIN INFECT DIS, V51, P1115, DOI 10.1086/656737; Climo MW, 2013, NEW ENGL J MED, V368, P533, DOI 10.1056/NEJMoa1113849; Cooper BS, 2004, BMJ-BRIT MED J, V329, P533, DOI 10.1136/bmj.329.7465.533; Derde LPG, 2014, LANCET INFECT DIS, V14, P31, DOI 10.1016/S1473-3099(13)70295-0; Evans HL, 2003, SURGERY, V134, P180, DOI 10.1067/msy.2003.222; Glick SB, 2014, AM J INFECT CONTROL, V42, P148, DOI 10.1016/j.ajic.2013.07.020; Gurieva T, 2012, CLIN INFECT DIS, V54, P1618, DOI 10.1093/cid/cis272; Harbarth S, 2008, JAMA-J AM MED ASSOC, V299, P1149, DOI 10.1001/jama.299.10.1149; Hardy K, 2010, CLIN MICROBIOL INFEC, V16, P333, DOI 10.1111/j.1469-0691.2009.02899.x; Harris AD, 2013, JAMA-J AM MED ASSOC, V310, P1571, DOI 10.1001/jama.2013.277815; Huang SS, 2013, NEW ENGL J MED, V368, P2255, DOI 10.1056/NEJMoa1207290; Huskins WC, 2011, NEW ENGL J MED, V364, P1407, DOI 10.1056/NEJMoa1000373; Jain R, 2011, NEW ENGL J MED, V364, P1419, DOI 10.1056/NEJMoa1007474; Jeyaratnam D, 2008, BMJ-BRIT MED J, V336, P927, DOI 10.1136/bmj.39525.579063.BE; Kirkland KB, 2012, BMJ QUAL SAF, V21, P1019, DOI 10.1136/bmjqs-2012-000800; Lee AS, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003126; Lee AS, 2011, CLIN INFECT DIS, V52, P1422, DOI 10.1093/cid/cir233; Lee AS, 2011, INFECT DIS CLIN N AM, V25, P155, DOI 10.1016/j.idc.2010.11.002; MacKenzie FM, 2007, CLIN MICROBIOL INFEC, V13, P269, DOI 10.1111/j.1469-0691.2006.01592.x; McGinigle KL, 2008, CLIN INFECT DIS, V46, P1717, DOI 10.1086/587901; Morgan DJ, 2009, AM J INFECT CONTROL, V37, P85, DOI 10.1016/j.ajic.2008.04.257; Robicsek A, 2008, ANN INTERN MED, V148, P409, DOI 10.7326/0003-4819-148-6-200803180-00003; Saint S, 2003, AM J INFECT CONTROL, V31, P354, DOI 10.1016/S0196-6553(02)48250-8; Sroka S, 2010, J HOSP INFECT, V74, P204, DOI 10.1016/j.jhin.2009.08.023; Stelfox HT, 2003, JAMA-J AM MED ASSOC, V290, P1899, DOI 10.1001/jama.290.14.1899; Stone SP, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3005; Tarzi S, 2001, J HOSP INFECT, V49, P250, DOI 10.1053/jhin.2001.1098; Zingg W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093898	29	47	48	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 21	2015	385	9973					1146	1149		10.1016/S0140-6736(14)60660-7	http://dx.doi.org/10.1016/S0140-6736(14)60660-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CD7KX	25150745				2023-01-03	WOS:000351270400033
J	Amrolia, PJ; Pule, M				Amrolia, Persis J.; Pule, Martin			Chimeric antigen receptor T cells for ALL	LANCET			English	Editorial Material							LYMPHOMA		[Amrolia, Persis J.] UCL, Inst Child Hlth, London WC1N 1EH, England; UCL, Inst Canc, London WC1N 1EH, England	University of London; University College London; University of London; University College London	Amrolia, PJ (corresponding author), UCL, Inst Child Hlth, London WC1N 1EH, England.	persis.amrolia@gosh.nhs.uk		Pule, Martin/0000-0002-8347-9867				Brentjens RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005930; Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Kalos M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002842; Kershaw MH, 2013, NAT REV CANCER, V13, P525, DOI 10.1038/nrc3565; Kochenderfer JN, 2015, J CLIN ONCOL, V33, P540, DOI 10.1200/JCO.2014.56.2025; Kochenderfer JN, 2013, BLOOD, V122, P4129, DOI 10.1182/blood-2013-08-519413; Kochenderfer JN, 2010, BLOOD, V116, P3875, DOI 10.1182/blood-2010-01-265041; Lee DW, 2014, LANCET; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Savoldo B, 2011, J CLIN INVEST, V121, P1822, DOI 10.1172/JCI46110	11	14	16	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	2015	385	9967					488	490		10.1016/S0140-6736(14)61729-3	http://dx.doi.org/10.1016/S0140-6736(14)61729-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CA9AV	25319502				2023-01-03	WOS:000349213600008
J	Rid, A; Emanuel, EJ				Rid, Annette; Emanuel, Ezekiel J.			Ethical considerations of experimental interventions in the Ebola outbreak	LANCET			English	Editorial Material									[Rid, Annette] Kings Coll London, Dept Social Sci Hlth & Med, London WC2R 2LS, England; [Emanuel, Ezekiel J.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA	University of London; King's College London; University of Pennsylvania; Pennsylvania Medicine	Rid, A (corresponding author), Kings Coll London, Dept Social Sci Hlth & Med, London WC2R 2LS, England.	annette.rid@kcl.ac.uk						Arie S, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4997; Bernstein L, 2014, WASHINGTON POST; Calain P, 2009, PUBLIC HEALTH ETH-UK, V2, P7, DOI 10.1093/phe/phn037; Edwards SJL, 2013, AM J BIOETHICS, V13, P3, DOI 10.1080/15265161.2013.813597; Emanuel EJ, 2004, J INFECT DIS, V189, P930, DOI 10.1086/381709; Fauci AS, 2014, NEW ENGL J MED, V371, P1084, DOI 10.1056/NEJMp1409494; Fink S., 2014, NY TIMES; Ford Nathan, 2009, Confl Health, V3, P7, DOI 10.1186/1752-1505-3-7; Gostin LO, 2014, JAMA-J AM MED ASSOC, V312, P1095, DOI 10.1001/jama.2014.11176; Institute for Health Metrics and Evaluation, GLOB BURD DIS DAT; IPBES (Intergovernmental Panel on Biodiversity and Ecosystems), 2021, POLICY DISCUSSION PA; Lenzer Jeanne, 2006, BMJ, V332, P1233, DOI 10.1136/bmj.332.7552.1233-a; London Alex John, 2009, Seton Hall Law Rev, V39, P1173; Medecins Sans Frontieres, 2013, RES ETH FRAM GUID DO; Millum J, 2012, GLOBAL JUSTICE BIOET; National Health Research Ethics Committee Nigeria, 2014, STAT US INN NONV MED; Paul SM, 2010, NAT REV DRUG DISCOV, V9, P203, DOI 10.1038/nrd3078; Persad G, 2009, LANCET, V373, P423, DOI 10.1016/S0140-6736(09)60137-9; Pollack A., 2014, NY TIMES; Rid A, 2011, KENNEDY INST ETHIC J, V21, P141; Schopper D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000115; UNDP, HUM DEV REP 2014 SUS; VIENS AM, 2013, EMERGENCY RES ETHICS; WHO, EB VIR DIS; WHO, 2014, ETH CONS US UNR INT; World Health Organization, 2014, WHO STAT M INT HLTH; World Health Organization, 2007, EVERYBODYS BUSINESS; World Health Organization, 2010, RES ETH INT EP RESP	28	82	87	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	2014	384	9957					1896	1899		10.1016/S0140-6736(14)61315-5	http://dx.doi.org/10.1016/S0140-6736(14)61315-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AT7LA	25155413				2023-01-03	WOS:000345116800030
J	Alassaad, A; Bertilsson, M; Gillespie, U; Sundstrom, J; Hammarlund-Udenaes, M; Melhus, H				Alassaad, Anna; Bertilsson, Maria; Gillespie, Ulrika; Sundstrom, Johan; Hammarlund-Udenaes, Margareta; Melhus, Hakan			The Effects of Pharmacist Intervention on Emergency Department Visits in Patients 80 Years and Older: Subgroup Analyses by Number of Prescribed Drugs and Appropriate Prescribing	PLOS ONE			English	Article							STOPP SCREENING TOOL; POTENTIALLY INAPPROPRIATE; ELDERLY-PEOPLE; ALERT DOCTORS; PERSONS PRESCRIPTIONS; CONTROLLED-TRIAL; NURSING-HOMES; MEDICATION; QUALITY; CARE	Background: Clinical pharmacist interventions have been shown to have positive effect on occurrence of drug-related issues as well as on clinical outcomes. However, evidence about which patients benefiting most from the interventions is limited. We aimed to explore whether pharmacist intervention is equally effective in preventing emergency department (ED) visits in patients with few or many prescribed drugs and in those with different levels of inappropriate prescribing. Methods: Patient and outcome data from a randomized controlled trial exploring the clinical effects of a ward-based pharmacist intervention in patients, 80 years and older, were used. The patients were divided into subgroups according to the number of prescribed drugs (< 5 or >= 5 drugs) and the level of inappropriate prescribing [using the Screening Tool Of Older People's potentially inappropriate Prescriptions (STOPP) and the Screening Tool to Alert doctors to Right Treatment (START) with a score of >= 2 (STOPP) and >= 1 (START) as cutoff points]. The effect of the intervention on the number of times the different subgroups visited the ED was analyzed. Results: The pharmacist intervention was more effective with respect to the number of subsequent ED visits in patients taking < 5 drugs on admission than in those taking >= 5 drugs. The rate ratio (RR) for a subsequent ED visit was 0.22 [95% confidence interval (CI) 0.09-0.52] for,5 drugs and 0.70 (95% CI 0.47-1.04) for >= 5 drugs (p = 0.02 for the interaction). The effect of intervention did not differ between patients with high or low STOPP or START scores. Conclusion: In this exploratory study, the pharmacist intervention appeared to be more effective in preventing visits to the ED for patients who were taking fewer drugs before the intervention. Our analysis of STOPP and START scores indicated that the level of inappropriate prescribing on admission had no effect on the outcomes of intervention with respect to ED visits.	[Alassaad, Anna; Sundstrom, Johan; Melhus, Hakan] Uppsala Univ, Dept Med Sci, Uppsala, Sweden; [Alassaad, Anna; Gillespie, Ulrika] Univ Uppsala Hosp, Uppsala, Sweden; [Bertilsson, Maria; Sundstrom, Johan] Uppsala Clin Res Ctr, Uppsala, Sweden; [Hammarlund-Udenaes, Margareta] Uppsala Univ, Dept Pharmaceut Sci, Uppsala, Sweden	Uppsala University; Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University	Alassaad, A (corresponding author), Uppsala Univ, Dept Med Sci, Uppsala, Sweden.	anna.alassaad@medsci.uu.se	Sundstrom, Johan/R-2139-2019; Sundström, Johan/A-6286-2009	Sundstrom, Johan/0000-0003-2247-8454; Sundström, Johan/0000-0003-2247-8454	Swedish Academy for Pharmaceutical Sciences	Swedish Academy for Pharmaceutical Sciences	The study was funded by the non-profit organization Swedish Academy for Pharmaceutical Sciences (one PhD student via scholarship). Uppsala University funded biostatistic consulting. The University Hospital of Uppsala and Uppsala University co-funded the study by letting involved physician and pharmacists participate in meetings during work hours. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alassaad A, 2013, J EVAL CLIN PRACT, V19, P185, DOI 10.1111/j.1365-2753.2011.01798.x; Barry PJ, 2007, AGE AGEING, V36, P632, DOI 10.1093/ageing/afm118; Daniel SB, 2011, NEW ENGL J MED, V365, P2002, DOI 10.1056/NEJMsa1103053; Cahir C, 2010, BRIT J CLIN PHARMACO, V69, P543, DOI 10.1111/j.1365-2125.2010.03628.x; Coleman EA, 2005, ARCH INTERN MED, V165, P1842, DOI 10.1001/archinte.165.16.1842; Dormann H, 2013, DTSCH ARZTEBL INT, V110, P213, DOI 10.3238/arztebl.2013.0213; Fialova D, 2005, JAMA-J AM MED ASSOC, V293, P1348, DOI 10.1001/jama.293.11.1348; Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72; Gallagher P, 2009, AGE AGEING, V38, P603, DOI 10.1093/ageing/afp058; Gallagher PF, 2008, AGE AGEING, V37, P96, DOI 10.1093/ageing/afm116; Gillespie U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062401; Gillespie U, 2009, ARCH INTERN MED, V169, P894, DOI 10.1001/archinternmed.2009.71; Gordon AL, 2014, AGE AGEING, V43, P97, DOI 10.1093/ageing/aft077; Hanlon JT, 2001, J AM GERIATR SOC, V49, P200, DOI 10.1046/j.1532-5415.2001.49042.x; Hellstrom LM, 2011, EUR J CLIN PHARMACOL, V67, P741, DOI 10.1007/s00228-010-0982-3; Hughes CM, 2009, DRUG AGING, V26, P505, DOI 10.2165/00002512-200926060-00007; Kaboli PJ, 2006, ARCH INTERN MED, V166, P955, DOI 10.1001/archinte.166.9.955; KOCH GG, 1982, BIOMETRICS, V38, P563, DOI 10.2307/2530041; Lee DS, 2005, JAMA-J AM MED ASSOC, V294, P1240, DOI 10.1001/jama.294.10.1240; Olsson J, 2010, CLIN DRUG INVEST, V30, P289, DOI 10.2165/11534320-000000000-00000; PARKIN DM, 1976, BMJ-BRIT MED J, V2, P686, DOI 10.1136/bmj.2.6037.686; Patterson SM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008165.pub2; Scott I, 2010, INTERN MED J, V40, P7, DOI 10.1111/j.1445-5994.2009.02040.x; Simonson W, 2005, DRUG AGING, V22, P559, DOI 10.2165/00002512-200522070-00002; Spinewine A, 2007, J AM GERIATR SOC, V55, P658, DOI 10.1111/j.1532-5415.2007.01132.x; Spinewine A, 2007, LANCET, V370, P173, DOI 10.1016/S0140-6736(07)61091-5; Steinman MA, 2006, J AM GERIATR SOC, V54, P1516, DOI 10.1111/j.1532-5415.2006.00889.x; Stokes ME, 2000, CATEGORICAL DATA ANA	28	14	14	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2014	9	11							e111797	10.1371/journal.pone.0111797	http://dx.doi.org/10.1371/journal.pone.0111797			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AU4DB	25364817	Green Published, Green Submitted, gold			2023-01-03	WOS:000345558100122
J	Zeitoun, JD; Lefevre, JH; Downing, N; Bergeron, H; Ross, JS				Zeitoun, Jean-David; Lefevre, Jeremie H.; Downing, Nicholas; Bergeron, Henri; Ross, Joseph S.			Inconsistencies among European Union Pharmaceutical Regulator Safety Communications: A Cross-Country Comparison	PLOS ONE			English	Article								Background: The European Medicines Agency (EMA) and national regulators share the responsibility to communicate to healthcare providers postmarketing safety events but little is known about the consistency of this process. We aimed to compare public availability of safety-related communications and drug withdrawals from the EMA and European Union member countries for novel medicines. Methods and Findings: We performed a cross-sectional analysis using public Dear Healthcare Professional Communications (DHPCs) for all novel medicines authorized between 2001 and 2010 by the EMA and available for use in France, Netherlands, Spain, and the United Kingdom. Between 2001 and 2010, the EMA approved 185 novel medicines. DHPCs could not be ascertained for the EMA. Among the 4 national regulators, as of April 30, 2013, at least one safety DHPC or withdrawal occurred for 53 (28.6%) medicines, totaling 90 DHPCs and 5 withdrawals. Among these 53 medicines, all 4 national agencies issued at least one communication for 17 (32.1%), three of the four for 25 (47.2%), two of the four for 6 (11.3%), and one of the four for 5 (9.4%). Five drugs were reported to be withdrawn, three by all four countries, one by three and one by two. Among the 95 DHPCs and withdrawals, 20 (21.1%) were issued by all 4 national regulators, 37 (38.9%) by 3 of the 4, 22 (23.2%) by 2 of the 4, and 16 (16.8%) by one. Consistency of making publicly available all identified safety DHPC or withdrawal across regulator pairs varied from 33% to 73% agreement. Conclusions: Safety communications were not made publicly available by the EMA. Among the 4 European member countries with national regulators that make DHPCs publicly available since at least 2001, there were substantial inconsistencies in safety communications for novel medicines. The impact of those inconsistencies in terms of public health remains to be determined.	[Zeitoun, Jean-David; Bergeron, Henri] Sciences Po, Paris, France; [Zeitoun, Jean-David] St Antoine Hosp, AP HP, Dept Gastroenterol & Nutr, Paris, France; [Zeitoun, Jean-David] Deaconesses Hosp, Dept Proctol, Paris, France; [Lefevre, Jeremie H.] St Antoine Hosp, AP HP, Dept Digest & Gen Surg, Paris, France; [Lefevre, Jeremie H.] Univ Paris 06, F-75252 Paris 05, France; [Downing, Nicholas] Yale Univ, Sch Med, New Haven, CT USA; [Bergeron, Henri] Natl Ctr Sci Res CNRS, Paris, France; [Ross, Joseph S.] Yale Univ, Sch Med, Dept Internal Med, Gen Internal Med Sect, New Haven, CT 06510 USA; [Ross, Joseph S.] Yale Univ, Sch Med, Dept Internal Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA; [Ross, Joseph S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Yale University; Centre National de la Recherche Scientifique (CNRS); Yale University; Yale University; Yale University	Zeitoun, JD (corresponding author), Sciences Po, Paris, France.	jdzeitoun@yahoo.fr	Lefevre, Jeremie/I-6952-2019	Lefevre, Jeremie/0000-0001-7601-7464; Ross, Joseph/0000-0002-9218-3320	Pew Charitable Trusts; Medtronic, Inc.; Centers of Medicare and Medicaid Services (CMS); Food and Drug Administration (FDA); National Institute on Aging [K08 AG032886]; American Federation for Aging Research; NATIONAL INSTITUTE ON AGING [K08AG032886] Funding Source: NIH RePORTER	Pew Charitable Trusts; Medtronic, Inc.(Medtronic); Centers of Medicare and Medicaid Services (CMS); Food and Drug Administration (FDA)(United States Department of Health & Human Services); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); American Federation for Aging Research; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This project was not supported by any external grants or funds. Mr. Downing and Dr. Ross receive support from The Pew Charitable Trusts to examine FDA regulatory issues. Dr. Ross receives support from Medtronic, Inc. to develop methods of clinical trial data sharing, from the Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting, and from the Food and Drug Administration (FDA) to develop methods for post-market surveillance of medical devices and is also supported by the National Institute on Aging (K08 AG032886) and by the American Federation for Aging Research through the Paul B. Beeson Career Development Award Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Carpenter D, 2010, PRINC STUD AM POLIT, P1; Downing NS, 2012, NEW ENGL J MED, V366, P2284, DOI 10.1056/NEJMsa1200223; Eichler HG, 2008, NAT REV DRUG DISCOV, V7, P818, DOI 10.1038/nrd2664; Giezen TJ, 2008, JAMA-J AM MED ASSOC, V300, P1887, DOI 10.1001/jama.300.16.1887; Groves T, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2961; Mol PGM, 2010, DRUG SAFETY, V33, P463, DOI 10.2165/11532840-000000000-00000; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; Psaty BM, 2013, JAMA-J AM MED ASSOC, V309, P2103, DOI 10.1001/jama.2013.4503; Psaty BM, 2012, JAMA-J AM MED ASSOC, V307, P2491, DOI 10.1001/jama.2012.5545; Viera AJ, 2005, FAM MED, V37, P360	10	13	13	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2014	9	10							e109100	10.1371/journal.pone.0109100	http://dx.doi.org/10.1371/journal.pone.0109100			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR7AB	25333986	gold, Green Published			2023-01-03	WOS:000343731200010
J	Quinteros, D; Vicario-de-la-Torre, M; Andres-Guerrero, V; Palma, S; Allemandi, D; Herrero-Vanrell, R; Molina-Martinez, IT				Quinteros, Daniela; Vicario-de-la-Torre, Marta; Andres-Guerrero, Vanessa; Palma, Santiago; Allemandi, Daniel; Herrero-Vanrell, Rocio; Molina-Martinez, Irene T.			Hybrid Formulations of Liposomes and Bioadhesive Polymers Improve the Hypotensive Effect of the Melatonin Analogue 5-MCA-NAT in Rabbit Eyes	PLOS ONE			English	Article							OPHTHALMIC DRUG-DELIVERY; IN-VITRO EVALUATION; INTRAOCULAR-PRESSURE; BENZALKONIUM CHLORIDE; CHANG CONJUNCTIVAL; OCULAR EVALUATION; HUMAN TEARS; GLAUCOMA; PRESERVATIVES; SURFACE	For the treatment of chronic ocular diseases such as glaucoma, continuous instillations of eye drops are needed. However, frequent administrations of hypotensive topical formulations can produce adverse ocular surface effects due to the active substance or other components of the formulation, such as preservatives or other excipients. Thus the development of unpreserved formulations that are well tolerated after frequent instillations is an important challenge to improve ophthalmic chronic topical therapies. Furthermore, several components can improve the properties of the formulation in terms of efficacy. In order to achieve the mentioned objectives, we have developed formulations of liposomes (150-200 nm) containing components similar to those in the tear film and loaded with the hypotensive melatonin analog 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT, 100 mu M). These formulations were combined with mucoadhesive (sodium hyaluronate or carboxymethylcellulose) or amphiphilic block thermosensitive (poloxamer) polymers to prolong the hypotensive efficacy of the drug. In rabbit eyes, the decrease of intraocular pressure with 5-MCA-NAT-loaded liposomes that were dispersed with 0.2% sodium hyaluronate, 39.1 +/- 2.2%, was remarkably higher compared to other liposomes formulated without or with other bioadhesive polymers, and the effect lasted more than 8 hours. According to the results obtained in the present work, these technological strategies could provide an improved modality for delivering therapeutic agents in patients with glaucoma.	[Quinteros, Daniela; Palma, Santiago; Allemandi, Daniel] Univ Nacl Cordoba, Fac Ciencias Quim, Dept Pharm, RA-5000 Cordoba, Argentina; [Quinteros, Daniela; Palma, Santiago; Allemandi, Daniel] Consejo Nacl Invest Cient & Tecn, Ciudad Univ, Cordoba, Argentina; [Vicario-de-la-Torre, Marta; Andres-Guerrero, Vanessa; Herrero-Vanrell, Rocio; Molina-Martinez, Irene T.] Univ Complutense Madrid, Fac Pharm, Dept Pharm & Pharmaceut Technol, Madrid, Spain; [Vicario-de-la-Torre, Marta; Andres-Guerrero, Vanessa; Herrero-Vanrell, Rocio; Molina-Martinez, Irene T.] Inst Hlth Carlos III, Ocular Pathol Natl Net OFTARED, San Carlos Clin Hosp IdISSC, Pharmaceut Innovat Ophthalmol Res Grp,Sanit Res I, Madrid, Spain	National University of Cordoba; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Complutense University of Madrid	Molina-Martinez, IT (corresponding author), Univ Complutense Madrid, Fac Pharm, Dept Pharm & Pharmaceut Technol, Madrid, Spain.	iremm@farm.ucm.es	Andrés-Guerrero, Vanessa/K-8077-2015; Martínez, Irene Teresa Molina/G-4970-2017; Herrero-Vanrell, Rocio/G-6849-2017	Andrés-Guerrero, Vanessa/0000-0003-0157-1932; Martínez, Irene Teresa Molina/0000-0002-9157-571X; Herrero-Vanrell, Rocio/0000-0001-9764-7975; Vicario-de-la-Torre, Marta/0000-0002-0048-1794; Quinteros, Daniela/0000-0001-7459-7442	Research Group UCM [920415]; FIS [PI10/00645, PI10/00993]; Spanish Ministry of Science and Innovation [MAT 2010-18242]; RETICS RD [12/0034/0003]; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); FONCyT PICT [2010-0380, 2437/OC-AR]; SECyT-UNC	Research Group UCM; FIS(Instituto de Salud Carlos III); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); RETICS RD; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); FONCyT PICT(ANPCyTFONCyT); SECyT-UNC(Secretaria de Ciencia y Tecnologia (SECYT))	Research Group UCM 920415, FIS PI10/00645 and FIS PI10/00993, Spanish Ministry of Science and Innovation (MAT 2010-18242), RETICS RD 12/0034/0003. Financial support from Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), FONCyT PICT 2010-0380 (Prestamo BID No 2437/OC-AR) and SECyT-UNC is greatly acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrés-Guerrero V., 2008, Arch Soc Esp Oftalmol, V83, P683; Andres-Guerrero V, 2011, INVEST OPHTH VIS SCI, V52, P3548, DOI 10.1167/iovs.10-6338; Andres-Guerrero V, 2011, INVEST OPHTH VIS SCI, V52, P1507, DOI 10.1167/iovs.10-6099; Andres-Guerrero V, 2009, EXP EYE RES, V88, P504, DOI 10.1016/j.exer.2008.11.004; Ayaki M, 2008, CLIN EXP OPHTHALMOL, V36, P553, DOI 10.1111/j.1442-9071.2008.01803.x; BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6; Bartlett JD, 2012, OPHTHALMIC DRUG FACT; Baudouin C, 2008, ACTA OPHTHALMOL, V86, P716, DOI 10.1111/j.1755-3768.2008.01250.x; Baudouin C, 2010, PROG RETIN EYE RES, V29, P312, DOI 10.1016/j.preteyeres.2010.03.001; Bhatia A, 2004, J PHARM PHARM SCI, V7, P252; Brasnu E, 2008, MOL VIS, V14, P394; Burstein N, 1997, CLIN OCULAR PHARM, P21; Burstein N, 1997, CLIN OCULAR PHARM; Camras CB, 1999, DRUG AGING, V15, P377, DOI 10.2165/00002512-199915050-00005; Cao F, 2010, DRUG DELIV, V17, P500, DOI 10.3109/10717544.2010.483255; CHRAI SS, 1974, J PHARM SCI, V63, P1218, DOI 10.1002/jps.2600630810; de Salamanca AE, 2006, INVEST OPHTH VIS SCI, V47, P1416, DOI 10.1167/iovs.05-0495; Debbasch C, 2001, INVEST OPHTH VIS SCI, V42, P642; Dumortier G, 2006, PHARM RES-DORDR, V23, P2709, DOI 10.1007/s11095-006-9104-4; Flanagan JG, 1998, OPHTHAL PHYSL OPT, V18, P126, DOI 10.1016/S0275-5408(97)00108-7; Ishibashi T, 2003, J GLAUCOMA, V12, P486, DOI 10.1097/00061198-200312000-00008; Kaur IP, 2002, DRUG DEV IND PHARM, V28, P353, DOI 10.1081/DDC-120002997; Krause WE, 2001, BIOMACROMOLECULES, V2, P65, DOI 10.1021/bm0055798; Law SL, 2000, J CONTROL RELEASE, V63, P135, DOI 10.1016/S0168-3659(99)00192-3; Le Bourlais C, 1998, PROG RETIN EYE RES, V17, P33, DOI 10.1016/S1350-9462(97)00002-5; Leung EW, 2008, J GLAUCOMA, V17, P350, DOI 10.1097/IJG.0b013e31815c5f4f; Lin HH, 1996, J PHARM PHARMACOL, V48, P801, DOI 10.1111/j.2042-7158.1996.tb03977.x; Ludwig A, 2005, ADV DRUG DELIVER REV, V57, P1595, DOI 10.1016/j.addr.2005.07.005; Lundmark PO, 2007, EXP EYE RES, V84, P1021, DOI 10.1016/j.exer.2006.10.018; Martinez-Aguila A, 2013, EUR J PHARMACOL, V701, P213, DOI 10.1016/j.ejphar.2012.12.009; Moon JW, 2006, INVEST OPHTH VIS SCI, V47, P3968, DOI 10.1167/iovs.05-1345; Moss SE, 2000, ARCH OPHTHALMOL-CHIC, V118, P1264; Nii T, 2005, INT J PHARMACEUT, V298, P198, DOI 10.1016/j.ijpharm.2005.04.029; PATTON TF, 1975, J PHARM SCI, V64, P1312, DOI 10.1002/jps.2600640811; Purslow Christine, 2005, Eye Contact Lens, V31, P117, DOI 10.1097/01.ICL.0000141921.80061.17; Schuman JS, 2000, CLIN THER, V22, P167, DOI 10.1016/S0149-2918(00)88478-7; Serle JB, 2004, J GLAUCOMA, V13, P385, DOI 10.1097/01.ijg.0000133150.44686.0b; SIMMONS ST, 1988, BRIT J OPHTHALMOL, V72, P688, DOI 10.1136/bjo.72.9.688; STEIN PJ, 1994, INVEST OPHTH VIS SCI, V35, P2765; TIFFANY JM, 1994, ADV EXP MED BIOL, V350, P267; TIFFANY JM, 1991, INT OPHTHALMOL, V15, P371, DOI 10.1007/BF00137947; Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027; Vemuri S, 1995, Pharm Acta Helv, V70, P95, DOI 10.1016/0031-6865(95)00010-7; Vicario-de-la-Torre M., 2007, Arch Soc Esp Oftalmol, V82, P395; Vicario-de-la-Torre M, 2010, INVEST OPHTHALMOL VI, V51; Whitson JT, 2006, OPHTHALMOLOGY, V113, P1333, DOI 10.1016/j.ophtha.2006.03.025; Wiechmann AF, 2001, VISUAL NEUROSCI, V18, P695, DOI 10.1017/S0952523801185032; Zhao M, 2008, INVEST OPHTH VIS SCI, V49, P550, DOI 10.1167/iovs.07-1037	48	27	27	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2014	9	10							e110344	10.1371/journal.pone.0110344	http://dx.doi.org/10.1371/journal.pone.0110344			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0AY	25329636	gold, Green Published, Green Submitted			2023-01-03	WOS:000343942100056
J	Fallesen, P; Emanuel, N; Wildeman, C				Fallesen, Peter; Emanuel, Natalia; Wildeman, Christopher			Cumulative Risks of Foster Care Placement for Danish Children	PLOS ONE			English	Article							MALTREATMENT; OUTCOMES; IMPACT	Although recent research suggests that the cumulative risk of foster care placement is far higher for American children than originally suspected, little is known about the cumulative risk of foster care placement in other countries, which makes it difficult to gauge the degree to which factor foster care placement is salient in other contexts. In this article, we provide companion estimates to those provided in recent work on the US by using Danish registry data and synthetic cohort life tables to show how high and unequally distributed the cumulative risk of foster care placement is for Danish children. Results suggest that at the beginning of the study period (in 1998) the cumulative risk of foster care placement for Danish children was roughly in line with the risk for American children. Yet, by the end of the study period (2010), the risk had declined to half the risk for American children. Our results also show some variations by parental ethnicity and sex, but these differences are small. Indeed, they appear quite muted relative to racial/ethnic differences in these risks in the United States. Last, though cumulative risks are similar between Danish and American children (especially at the beginning of the study period), the age-specific risk profiles are markedly different, with higher risks for older Danish children than for older American children.	[Fallesen, Peter] Rockwool Fdn Res Unit, Copenhagen, Denmark; [Fallesen, Peter] Univ Copenhagen, Dept Sociol, Copenhagen, Denmark; [Emanuel, Natalia] Yale Univ, Dept Econ, New Haven, CT 06520 USA; [Wildeman, Christopher] Cornell Univ, Dept Policy Anal & Management, Ithaca, NY USA	University of Copenhagen; Yale University; Cornell University	Fallesen, P (corresponding author), Rockwool Fdn Res Unit, Copenhagen, Denmark.	pf@rff.dk	Fallesen, Peter/AAO-4801-2021	Fallesen, Peter/0000-0003-0544-9977	Rockwool Foundation	Rockwool Foundation	The study was funded by the Rockwool Foundation (http://www.rockwoolfonden.dk/). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen S. H., 2010, NAR MAN ANBRINGER BA, P13; Andersen SH, 2014, SOC FORCES, V93, P269, DOI 10.1093/sf/sou027; Berger LM, 2009, CHILD DEV, V80, P1856, DOI 10.1111/j.1467-8624.2009.01372.x; Dalsgaard S, 2013, J CHILD ADOL PSYCHOP, V23, P432, DOI 10.1089/cap.2012.0111; Doyle JJ, 2008, J POLITICAL EC, V116, P1583; Doyle JJ, 2007, AM ECON REV, V97, P1583, DOI 10.1257/aer.97.5.1583; Ejrnaes M, 2011, CHILD INDIC RES, V4, P21, DOI 10.1007/s12187-010-9066-2; Fallesen P, 2013, J ADOLESCENCE, V36, P1003, DOI 10.1016/j.adolescence.2013.08.010; Frederiksen S., 2012, THESIS AARHUS U; Harman JS, 2000, ARCH PEDIAT ADOL MED, V154, P1114, DOI 10.1001/archpedi.154.11.1114; Hestbak A.D., 2011, CHILD PROTECTION SYS, P131; Kvist AP, 2013, SOC SCI MED, V88, P30, DOI 10.1016/j.socscimed.2013.04.001; Lery B, 2009, CHILD YOUTH SERV REV, V31, P331, DOI 10.1016/j.childyouth.2008.08.001; Magruder J, 2008, CHILD WELFARE, V87, P169; Preston S. H., 2001, DEMOGRAPHY MEASURING; Putnam-Hornstein E, 2011, CHILD MALTREATMENT, V16, P163, DOI 10.1177/1077559511411179; Putnam-Hornstein E, 2011, CHILD ABUSE REV, V20, P256, DOI 10.1002/car.1191; Sabol W, 2004, CHILD ABUSE NEGLECT, V28, P967, DOI 10.1016/j.chiabu.2004.03.014; Simkiss DE, 2013, CHILD CARE HLTH DEV, V39, P628, DOI 10.1111/cch.12010; Statistics Denmark, 2013, QUAL DECL ASS CHILDR; Swann CA, 2006, DEMOGRAPHY, V43, P309, DOI 10.1353/dem.2006.0019; U. S. Department of Health and Human Services, 2006, 12 AFCARS US DEP HLT; U.S. Department of Health and Human Services Administration for Children and Families Administration on Children Youth and Families Children's Bureau, 2012, FED REP SYST AD FOST; U.S. Department of Health and Human Services Centers for Disease Control and Prevention National Center for Health Statistics CDC WONDER Online Database, 2011, BRIDG RAC POP EST 19; United States Department of Health and Human Services), 2012, 19 AFCARS US DEP HLT; US Dep. Health Hum. Serv, 2012, TRENDS FOST CAR AD F; WALD MS, 1988, PROTECTING ABUSED NE; Waldfogel Jane, 2004, REV ECON HOUSEHOLD, V2, P387, DOI DOI 10.1007/S11150-004-5654-6; Warburton WP, 2014, CAN J ECON, V47, P35, DOI 10.1111/caje.12064; Wildeman C, 2014, ANN REV SOC IN PRESS; Wildeman C, 2004, JAMA PEDIAT IN PRESS; Wildeman C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092785; Wulczyn F, 2009, FUTURE CHILD, V19, P39	33	21	21	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2014	9	10							e109207	10.1371/journal.pone.0109207	http://dx.doi.org/10.1371/journal.pone.0109207			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AS0AP	25299657	gold, Green Submitted, Green Published			2023-01-03	WOS:000343941200041
J	Amaral, NO; de Oliveira, TS; Naves, LM; Filgueira, FP; Ferreira-Neto, ML; Schoorlemmer, GHM; de Castro, CH; Freiria-Oliveira, AH; Xavier, CH; Colugnati, DB; Rosa, DA; Blanch, GT; Borges, CL; Soares, CMA; Reis, AAS; Cravo, SL; Pedrino, GR				Amaral, Nathalia O.; de Oliveira, Thiago S.; Naves, Lara M.; Filgueira, Fernando P.; Ferreira-Neto, Marcos L.; Schoorlemmer, Gerard H. M.; de Castro, Carlos H.; Freiria-Oliveira, Andre H.; Xavier, Carlos H.; Colugnati, Diego B.; Rosa, Daniel A.; Blanch, Graziela T.; Borges, Clayton L.; Soares, Celia M. A.; Reis, Angela A. S.; Cravo, Sergio L.; Pedrino, Gustavo R.			Efferent Pathways in Sodium Overload-Induced Renal Vasodilation in Rats	PLOS ONE			English	Article							ATRIAL-NATRIURETIC-PEPTIDE; HYPERTONIC SALINE INFUSION; SYMPATHETIC-NERVE ACTIVITY; CARDIOVASCULAR-RESPONSES; BARORECEPTOR INFLUENCES; VASOPRESSIN SECRETION; CIRCULATING VOLUME; ARTERIAL-PRESSURE; RENIN SECRETION; BLOOD-PRESSURE	Hypernatremia stimulates the secretion of oxytocin (OT), but the physiological role of OT remains unclear. The present study sought to determine the involvement of OT and renal nerves in the renal responses to an intravenous infusion of hypertonic saline. Male Wistar rats (280-350 g) were anesthetized with sodium thiopental (40 mg. kg(-1), i.v.). A bladder cannula was implanted for collection of urine. Animals were also instrumented for measurement of mean arterial pressure (MAP) and renal blood flow (RBF). Renal vascular conductance (RVC) was calculated as the ratio of RBF by MAP. In anesthetized rats (n = 6), OT infusion (0.03 mu g . kg(-1), i.v.) induced renal vasodilation. Consistent with this result, ex vivo experiments demonstrated that OT caused renal artery relaxation. Blockade of OT receptors (OXTR) reduced these responses to OT, indicating a direct effect of this peptide on OXTR on this artery. Hypertonic saline (3 M NaCl, 1.8 ml . kg(-1) b.wt., i.v.) was infused over 60 s. In sham rats (n = 6), hypertonic saline induced renal vasodilation. The OXTR antagonist (AT; atosiban, 40 mu g . kg(-1) . h(-1), i.v.; n = 7) and renal denervation (RX) reduced the renal vasodilation induced by hypernatremia. The combination of atosiban and renal denervation (RX+AT; n = 7) completely abolished the renal vasodilation induced by sodium overload. Intact rats excreted 51% of the injected sodium within 90 min. Natriuresis was slightly blunted by atosiban and renal denervation (42% and 39% of load, respectively), whereas atosiban with renal denervation reduced sodium excretion to 16% of the load. These results suggest that OT and renal nerves are involved in renal vasodilation and natriuresis induced by acute plasma hypernatremia.	[Amaral, Nathalia O.; de Oliveira, Thiago S.; Naves, Lara M.; Filgueira, Fernando P.; de Castro, Carlos H.; Freiria-Oliveira, Andre H.; Xavier, Carlos H.; Colugnati, Diego B.; Rosa, Daniel A.; Blanch, Graziela T.; Pedrino, Gustavo R.] Univ Fed Goias, Ctr Neurosci & Cardiovasc Physiol, Inst Biol Sci, Dept Physiol Sci, Goiania, Go, Brazil; [Ferreira-Neto, Marcos L.] Univ Fed Uberlandia, Fac Phys Educ, Inst Biol Sci, BR-38400 Uberlandia, MG, Brazil; [Schoorlemmer, Gerard H. M.; Cravo, Sergio L.] Univ Fed Sao Paulo, Dept Physiol, Sao Paulo, Brazil; [Borges, Clayton L.; Soares, Celia M. A.] Univ Fed Goias, Inst Biol Sci, Mol Biol Lab, Goiania, Go, Brazil; [Reis, Angela A. S.] Univ Fed Goias, Inst Biol Sci, Dept Biochem & Mol Biol, Goiania, Go, Brazil	Universidade Federal de Goias; Universidade Federal de Uberlandia; Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Goias; Universidade Federal de Goias	Pedrino, GR (corresponding author), Univ Fed Goias, Ctr Neurosci & Cardiovasc Physiol, Inst Biol Sci, Dept Physiol Sci, Goiania, Go, Brazil.	pedrino@pq.cnpq.br	Filgueira, Fernando/C-5668-2013; FERREIRA-NETO, MARCOS LUIZ/O-3368-2014; Pedrino, Gustavo R/I-5614-2015; Colugnati, Diego/AAD-2977-2019; Rosa, Daniel A/E-5429-2018; Freiria-Oliveira, Andre/F-2756-2012; Ferreira-Neto, Marcos Luiz/AHC-8135-2022; DA SILVA, ANGELA ADAMSKI/AAJ-1403-2021; de Oliveira, Thiago Sardinha/W-7145-2018; Xavier, Carlos Henrique/AAE-8390-2022; Naves, Lara/ABC-4334-2021; Xavier, Carlos H/C-8561-2013; BORGES, CLAYTON LUIZ/GQB-5595-2022; Custodio, Carlos Henrique Xavier/F-8450-2010	Filgueira, Fernando/0000-0001-8910-1796; Pedrino, Gustavo R/0000-0003-0488-5400; Colugnati, Diego/0000-0002-6565-0042; Rosa, Daniel A/0000-0002-7036-0840; Ferreira-Neto, Marcos Luiz/0000-0002-9695-7100; DA SILVA, ANGELA ADAMSKI/0000-0002-8281-7334; de Oliveira, Thiago Sardinha/0000-0002-2825-5959; Xavier, Carlos Henrique/0000-0003-4006-8213; Naves, Lara/0000-0002-4749-869X; Xavier, Carlos H/0000-0003-4006-8213; Freiria-Oliveira, Andre Henrique/0000-0002-7511-5035; Schoorlemmer, Gus/0000-0002-2966-1457	Fundacao de Amparo a Pesquisa do Estado de Goias (FAPEG) [2012/0055431086, 2009/10267000352]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [477832/2010-5, 483411/2012-4]	Fundacao de Amparo a Pesquisa do Estado de Goias (FAPEG)(Fundacao de Amparo a Pesquisa do Estado do Goias (FAPEG)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Goias (FAPEG; www.fapeg.go.gov.br) grants 2012/0055431086 (GRP) and 2009/10267000352 (GRP) and by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; www.cnpq.br) grants 477832/2010-5 (GRP) and 483411/2012-4 (GRP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Badoer E, 2003, AM J PHYSIOL-RENAL, V285, pF640, DOI 10.1152/ajprenal.00372.2002; BALMENT RJ, 1980, J PHYSIOL-LONDON, V308, P439, DOI 10.1113/jphysiol.1980.sp013481; BEALER SL, 1983, AM J PHYSIOL, V244, pR815, DOI 10.1152/ajpregu.1983.244.6.R815; BEALER SL, 1988, AM J PHYSIOL, V254, pR84, DOI 10.1152/ajpregu.1988.254.1.R84; Blanch GT, 2013, AM J PHYSIOL-REG I, V304, pR531, DOI 10.1152/ajpregu.00191.2012; Boer PA, 2005, LIFE SCI, V76, P1805, DOI 10.1016/j.lfs.2004.09.029; Bookout Angie L, 2006, Curr Protoc Mol Biol, VChapter 15, DOI 10.1002/0471142727.mb1508s73; Bourque CW, 2008, NAT REV NEUROSCI, V9, P519, DOI 10.1038/nrn2400; BOURQUE CW, 1994, FRONT NEUROENDOCRIN, V15, P231, DOI 10.1006/frne.1994.1010; Callahan MF, 1997, NEUROENDOCRINOLOGY, V65, P238, DOI 10.1159/000127181; CONRAD KP, 1986, AM J PHYSIOL, V251, pF290, DOI 10.1152/ajprenal.1986.251.2.F290; CONRAD KP, 1993, ANN NY ACAD SCI, V689, P346, DOI 10.1111/j.1749-6632.1993.tb55559.x; Cravo SL, 2011, BRAZ J MED BIOL RES, V44, P877, DOI 10.1590/S0100-879X2011000900008; da Silva EF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073187; Dale HH, 1906, J PHYSIOL-LONDON, V34, P163; DiBona GF, 1997, PHYSIOL REV, V77, P75, DOI 10.1152/physrev.1997.77.1.75; FUJITA T, 1991, JPN J PHYSIOL, V41, P653, DOI 10.2170/jjphysiol.41.653; Godino A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074689; Guadagnini D, 2006, LIFE SCI, V79, P1666, DOI 10.1016/j.lfs.2006.06.005; Gutkowska J, 1997, P NATL ACAD SCI USA, V94, P11704, DOI 10.1073/pnas.94.21.11704; HAANWINCKEL MA, 1995, P NATL ACAD SCI USA, V92, P7902, DOI 10.1073/pnas.92.17.7902; HORAN MJ, 1985, HYPERTENSION, V7, P818, DOI 10.1161/01.HYP.7.5.818; HUANG W, 1995, AM J PHYSIOL-REG I, V268, pR634, DOI 10.1152/ajpregu.1995.268.3.R634; HUANG W, 1994, KIDNEY INT, V45, P692, DOI 10.1038/ki.1994.93; Huang W, 2000, AM J PHYSIOL-REG I, V278, pR226, DOI 10.1152/ajpregu.2000.278.1.R226; Jacob F, 2005, CLIN EXP PHARMACOL P, V32, P255, DOI 10.1111/j.1440-1681.2005.04179.x; Jacob F, 2003, AM J PHYSIOL-HEART C, V284, pH2302, DOI 10.1152/ajpheart.01029.2002; Khan SA, 2014, ACTA PHYSIOL, V210, P690, DOI 10.1111/apha.12237; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001; MORRIS M, 1989, HYPERTENSION, V13, P110, DOI 10.1161/01.HYP.13.2.110; MORRIS M, 1988, ENDOCRINOLOGY, V122, P373, DOI 10.1210/endo-122-1-373; Nishida Y, 1998, AM J PHYSIOL-REG I, V274, pR97, DOI 10.1152/ajpregu.1998.274.1.R97; Ott I, 1910, P SOC EXP BIOL, V8, P48; Pedrino GR, 2005, AUTON NEUROSCI-BASIC, V117, P9, DOI 10.1016/j.autneu.2004.09.005; Pedrino GR, 2009, CLIN EXP PHARMACOL P, V36, pe83, DOI 10.1111/j.1440-1681.2009.05280.x; Pedrino GR, 2008, AUTON NEUROSCI-BASIC, V142, P55, DOI 10.1016/j.autneu.2008.06.006; Pedrino GR, 2006, EXP PHYSIOL, V91, P995, DOI 10.1113/expphysiol.2006.034611; Pedrino GR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037587; RAUCH AL, 1990, AM J PHYSIOL, V258, pR531, DOI 10.1152/ajpregu.1990.258.2.R531; Schoorlemmer GHM, 2000, AM J PHYSIOL-REG I, V278, pR917, DOI 10.1152/ajpregu.2000.278.4.R917; SimonsMorton DG, 1997, PEDIATR NEPHROL, V11, P244, DOI 10.1007/s004670050271; Sjoquist M, 1999, ENDOCRINOLOGY, V140, P2814, DOI 10.1210/en.140.6.2814; Soares TJ, 1999, P NATL ACAD SCI USA, V96, P278, DOI 10.1073/pnas.96.1.278; Stoop R, 2012, NEURON, V76, P142, DOI 10.1016/j.neuron.2012.09.025; Strange K, 1993, CELLULAR MOL PHYSL C; Toney GM, 2003, ACTA PHYSIOL SCAND, V177, P43, DOI 10.1046/j.1365-201X.2003.01046.x; TROSTEL KA, 1992, AM J PHYSIOL, V263, pR1265, DOI 10.1152/ajpregu.1992.263.6.R1265; VERBALIS JG, 1991, ENDOCRINOLOGY, V128, P1317, DOI 10.1210/endo-128-3-1317; Weiss ML, 1996, J AUTONOM NERV SYST, V57, P109, DOI 10.1016/0165-1838(95)00108-5; Young WS, 2003, NEUROENDOCRINOLOGY, V78, P185, DOI 10.1159/000073702	51	5	5	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2014	9	10							e109620	10.1371/journal.pone.0109620	http://dx.doi.org/10.1371/journal.pone.0109620			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ3DZ	25279805	Green Published, Green Submitted, gold			2023-01-03	WOS:000342670800093
J	Mukkavilli, R; Gundala, SR; Yang, CH; Donthamsetty, S; Cantuaria, G; Jadhav, GR; Vangala, S; Reid, MD; Aneja, R				Mukkavilli, Rao; Gundala, Sushma R.; Yang, Chunhua; Donthamsetty, Shashikiran; Cantuaria, Guilherme; Jadhav, Gajanan R.; Vangala, Subrahmanyam; Reid, Michelle D.; Aneja, Ritu			Modulation of Cytochrome P450 Metabolism and Transport across Intestinal Epithelial Barrier by Ginger Biophenolics	PLOS ONE			English	Article							DRUG-INTERACTIONS; LIVER-MICROSOMES; CYP1A2 ACTIVITY; P-GLYCOPROTEIN; CACO-2 CELLS; ENZYMES; EXPRESSION; 3A; PHARMACOKINETICS; GLUCURONIDATION	Natural and complementary therapies in conjunction with mainstream cancer care are steadily gaining popularity. Ginger extract (GE) confers significant health-promoting benefits owing to complex additive and/or synergistic interactions between its bioactive constituents. Recently, we showed that preservation of natural "milieu'' confers superior anticancer activity on GE over its constituent phytochemicals, 6-gingerol (6G), 8-gingerol (8G), 10-gingerol (10G) and 6-shogaol (6S), through enterohepatic recirculation. Here we further evaluate and compare the effects of GE and its major bioactive constituents on cytochrome P450 (CYP) enzyme activity in human liver microsomes by monitoring metabolites of CYP-specific substrates using LC/MS/MS detection methods. Our data demonstrate that individual gingerols are potent inhibitors of CYP isozymes, whereas GE exhibits a much higher half-maximal inhibition value, indicating no possible herb-drug interactions. However, GE's inhibition of CYP1A2 and CYP2C8 reflects additive interactions among the constituents. In addition, studies performed to evaluate transporter-mediated intestinal efflux using Caco-2 cells revealed that GE and its phenolics are not substrates of P-glycoprotein (Pgp). Intriguingly, however, 10G and 6S were not detected in the receiver compartment, indicating possible biotransformation across the Caco-2 monolayer. These data strengthen the notion that an interplay of complex interactions among ginger phytochemicals when fed as whole extract dictates its bioactivity highlighting the importance of consuming whole foods over single agents. Our study substantiates the need for an in-depth analysis of hepatic biotransformation events and distribution profiles of GE and its active phenolics for the design of safe regimens.	[Mukkavilli, Rao; Jadhav, Gajanan R.; Vangala, Subrahmanyam] Advinus Therapeut Ltd, Bangalore, Karnataka, India; [Gundala, Sushma R.; Yang, Chunhua; Donthamsetty, Shashikiran; Aneja, Ritu] Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA; [Cantuaria, Guilherme] Northside Hosp Canc Inst, Atlanta, GA USA; [Reid, Michelle D.] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA	University System of Georgia; Georgia State University; Emory University	Aneja, R (corresponding author), Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA.	raneja@gsu.edu	Yang, C./N-5421-2014	Yang, C./0000-0003-0805-1008	National Cancer Institute at the National Institutes of Health [R00CA131489, R01 CA169127]; American Cancer Society [121728-RSG-12-004-01-CNE]; Advinus Therapeutics Limited; NATIONAL CANCER INSTITUTE [R00CA131489, R01CA169127] Funding Source: NIH RePORTER	National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Advinus Therapeutics Limited; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by grants to RA from the National Cancer Institute at the National Institutes of Health (R00CA131489, R01 CA169127) (http://www.cancer.gov/) and American Cancer Society (121728-RSG-12-004-01-CNE) (http://www.cancer.org/). Advinus Therapeutics Limited provided support in the form of salaries for authors [CY,SD,RA], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Ameer B, 1997, CLIN PHARMACOKINET, V33, P103, DOI 10.2165/00003088-199733020-00003; ARTURSSON P, 1991, BIOCHEM BIOPH RES CO, V175, P880, DOI 10.1016/0006-291X(91)91647-U; Bailey David G, 2004, Am J Cardiovasc Drugs, V4, P281, DOI 10.2165/00129784-200404050-00002; BAILEY DG, 1989, CLIN INVEST MED, V12, P357; BAILEY DG, 1994, CLIN PHARMACOKINET, V26, P91, DOI 10.2165/00003088-199426020-00002; Bear WL, 2000, ANTICANCER RES, V20, P3323; Bear WL, 2000, ANTICANCER RES, V20, P3609; Brahmbhatt M, 2013, NUTR CANCER, V65, P263, DOI 10.1080/01635581.2013.749925; Chavez ML, 2006, LIFE SCI, V78, P2146, DOI 10.1016/j.lfs.2005.12.009; Chen CY, 2009, MOLECULES, V14, P959, DOI 10.3390/molecules14030959; Coleman M. D, 2010, HUMAN DRUG METABOLIS; Du LP, 2004, TOXICOL APPL PHARM, V195, P278, DOI 10.1016/j.taap.2003.09.020; Dugasani S, 2010, J ETHNOPHARMACOL, V127, P515, DOI 10.1016/j.jep.2009.10.004; FDA, 2014, CONS REG SUBST ADD F; Fontana RJ, 1999, GASTROENTEROLOGY, V117, P89, DOI 10.1016/S0016-5085(99)70554-8; Gibbs MA, 1999, DRUG METAB DISPOS, V27, P180; GOLDSTEIN JA, 1994, PHARMACOGENETICS, V4, P285, DOI 10.1097/00008571-199412000-00001; GOVINDARAJAN VS, 1982, CRC CR REV FOOD SCI, V17, P189; GOVINDARAJAN VS, 1982, CRC CR REV FOOD SCI, V17, P1; Gundala SR, 2014, CARCINOGENESIS; HUKKINEN SK, 1995, CLIN PHARMACOL THER, V58, P127, DOI 10.1016/0009-9236(95)90188-4; Ioannides C, 2002, XENOBIOTICA, V32, P451, DOI 10.1080/00498250210124147; Jeong CH, 2009, CANCER RES, V69, P5584, DOI 10.1158/0008-5472.CAN-09-0491; Karna P, 2011, BR J NUTR, V18, P1; Kim SO, 2005, ONCOGENE, V24, P2558, DOI 10.1038/sj.onc.1208446; Kimura Y, 2010, FOOD CHEM TOXICOL, V48, P429, DOI 10.1016/j.fct.2009.10.041; Kundu JK, 2005, MUTAT RES-FUND MOL M, V591, P123, DOI 10.1016/j.mrfmmm.2005.04.019; Li M, 2013, ACTA PHARMACOL SIN, V34, P1237, DOI 10.1038/aps.2013.49; Lin JH, 2003, CLIN PHARMACOKINET, V42, P59, DOI 10.2165/00003088-200342010-00003; Markowitz JS, 2003, JAMA-J AM MED ASSOC, V290, P1500, DOI 10.1001/jama.290.11.1500; McFadyen MCE, 2004, MOL CANCER THER, V3, P363; Meinl W, 2008, DRUG METAB DISPOS, V36, P276, DOI 10.1124/dmd.107.018036; Misaka S, 2013, DRUG METAB PHARMACOK, V28, P244, DOI 10.2133/dmpk.DMPK-12-RG-101; Murray M, 2006, CURR DRUG METAB, V7, P67, DOI 10.2174/138920006774832569; Nebert DW, 2006, NAT REV CANCER, V6, P947, DOI 10.1038/nrc2015; Nelson DR, 2011, BBA-PROTEINS PROTEOM, V1814, P14, DOI 10.1016/j.bbapap.2010.08.008; Paine MF, 2006, DRUG METAB DISPOS, V34, P880, DOI 10.1124/dmd.105.008672; Perera V, 2012, CLIN PHARMACOL THER, V92, P511, DOI 10.1038/clpt.2012.139; PETERS WHN, 1989, BIOCHEM J, V264, P613, DOI 10.1042/bj2640613; Rees DC, 2009, NAT REV MOL CELL BIO, V10, P218, DOI 10.1038/nrm2646; Rendic S, 2010, CURR DRUG METAB, V11, P4, DOI 10.2174/138920010791110917; Rodriguez-Antona C, 2006, ONCOGENE, V25, P1679, DOI 10.1038/sj.onc.1209377; Rodriguez-Fragoso L, 2011, J FOOD SCI, V76, pR112, DOI 10.1111/j.1750-3841.2011.02155.x; Sabolovic N, 2000, LIFE SCI, V67, P185, DOI 10.1016/S0024-3205(00)00616-0; Scheepens A, 2010, GENES NUTR, V5, P75, DOI 10.1007/s12263-009-0148-z; Schinkel AH, 1997, SEMIN CANCER BIOL, V8, P161, DOI 10.1006/scbi.1997.0068; SchmiedlinRen P, 1997, MOL PHARMACOL, V51, P741, DOI 10.1124/mol.51.5.741; Seow A, 2001, CARCINOGENESIS, V22, P673, DOI 10.1093/carcin/22.4.673; SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414; Tanaka E, 1998, J CLIN PHARM THER, V23, P403, DOI 10.1046/j.1365-2710.1998.00086.x; Vasala PA, 2004, HDB HERBS SPICES; Walle UK, 1999, BIOCHEM PHARMACOL, V58, P431, DOI 10.1016/S0006-2952(99)00133-1; Wang B, 2009, DRUG METAB REV, V41, P573, DOI 10.1080/03602530903118729; Williamson G, 2005, AM J CLIN NUTR, V81, p243S, DOI [10.1093/ajcn/81.1.230S, 10.1093/ajcn/81.1.243S]; Youdim KA, 2003, J NEUROCHEM, V85, P180, DOI 10.1046/j.1471-4159.2003.01652.x; Zhang L, 2007, MOL PHARMACEUT, V4, P833, DOI 10.1021/mp700077z; Zhang YC, 2001, CLIN PHARMACOKINET, V40, P159, DOI 10.2165/00003088-200140030-00002; Zick SM, 2008, CANCER EPIDEM BIOMAR, V17, P1930, DOI 10.1158/1055-9965.EPI-07-2934; Zick Suzanna M, 2010, Int J Biomed Sci, V6, P233	59	26	28	1	46	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2014	9	9							e108386	10.1371/journal.pone.0108386	http://dx.doi.org/10.1371/journal.pone.0108386			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ0SJ	25251219	Green Published, gold			2023-01-03	WOS:000342492700121
J	Gagne, JJ; Choudhry, NK; Kesselheim, AS; Polinski, JM; Hutchins, D; Matlin, OS; Brennan, TA; Avorn, J; Shrank, WH				Gagne, Joshua J.; Choudhry, Niteesh K.; Kesselheim, Aaron S.; Polinski, Jennifer M.; Hutchins, David; Matlin, Olga S.; Brennan, Troyen A.; Avorn, Jerry; Shrank, William H.			Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							POSITIVE PREDICTIVE-VALUE; MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; MEDICATION ADHERENCE; CHOLESTEROL LEVELS; PROPENSITY SCORE; HEART-DISEASE; CANCER-RISK; METAANALYSIS; THERAPY	Background: Statins are effective in preventing cardiovascular events, but patients do not fully adhere to them. Objective: To determine whether patients are more adherent to generic statins versus brand-name statins (lovastatin, pravastatin, or simvastatin) and whether greater adherence improves health outcomes. Design: Observational, propensity score-matched, new-user cohort study. Setting: Linked electronic data from medical and pharmacy claims. Participants: Medicare beneficiaries aged 65 years or older with prescription drug coverage between 2006 and 2008. Intervention: Initiation of a generic or brand-name statin. Measurements: Adherence to statin therapy (measured as the proportion of days covered [PDC] up to 1 year) and a composite outcome comprising hospitalization for an acute coronary syndrome or stroke and all-cause mortality. Hazard ratios (HRs) and absolute rate differences were estimated. Results: A total of 90 111 patients who initiated a statin during the study was identified; 83 731 (93%) initiated a generic drug, and 6380 (7%) initiated a brand-name drug. The mean age of patients was 75.6 years, and most (61%) were female. The average PDC was 77% for patients in the generic group and 71% for those in the brand-name group (P < 0.001). An 8% reduction in the rate of the clinical outcome was observed among patients in the generic group versus those in the brand-name group (HR, 0.92 [95% CI, 0.86 to 0.99]). The absolute difference was -1.53 events per 100 person-years (CI, -2.69 to -0.19 events per 100 person-years). Limitation: Results may not be generalizable to other populations with different incomes or drug benefit structures. Conclusion: Compared with those initiating brand-name statins, patients initiating generic statins were more likely to adhere and had a lower rate of a composite clinical outcome.	[Gagne, Joshua J.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA; [Gagne, Joshua J.] Harvard Univ, Sch Med, Boston, MA 02120 USA; CVS Caremark, Woonsocket, RI 02895 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Gagne, JJ (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	jgagne1@partners.org	Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666	Teva Pharmaceuticals [2010A057139]	Teva Pharmaceuticals(Teva Pharmaceutical Industries)	By Teva Pharmaceuticals (2010A057139).	[Anonymous], 1998, N ENGL J MED, V339, P1349; Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458; Benner JS, 2002, JAMA-J AM MED ASSOC, V288, P455, DOI 10.1001/jama.288.4.455; Boudreau DM, 2010, EXPERT OPIN DRUG SAF, V9, P603, DOI 10.1517/14740331003662620; Brookhart MA, 2007, AM J EPIDEMIOL, V166, P348, DOI 10.1093/aje/kwm070; Chan DC, 2010, MED CARE, V48, P196, DOI 10.1097/MLR.0b013e3181c132ad; Choudhry NK, 2008, J GEN INTERN MED, V23, P216, DOI 10.1007/s11606-007-0478-8; Choudhry NK, 2012, J AM COLL CARDIOL, V60, P1817, DOI 10.1016/j.jacc.2012.06.050; Choudhry NK, 2011, NEW ENGL J MED, V365, P2088, DOI 10.1056/NEJMsa1107913; Choudhry NK, 2009, AM J MANAG CARE, V15, P457; Claxton G, 2012, EMPLOYER HLTH BENEFI; Dale KM, 2006, JAMA-J AM MED ASSOC, V295, P74, DOI 10.1001/jama.295.1.74; Desai NR, 2013, CURR CARDIOL REP, V15, DOI 10.1007/s11886-012-0322-6; Federman AD, 2007, MED CARE, V45, P109, DOI 10.1097/01.mlr.0000250293.24939.2e; Federman AD, 2006, AM J MANAG CARE, V12, P611; Gagne JJ, 2011, JAMA-J AM MED ASSOC, V305, P711, DOI 10.1001/jama.2011.152; Gagne JJ, 2011, J CLIN EPIDEMIOL, V64, P749, DOI 10.1016/j.jclinepi.2010.10.004; Glynn RJ, 2001, EPIDEMIOLOGY, V12, P682, DOI 10.1097/00001648-200111000-00017; Goldman DP, 2007, JAMA-J AM MED ASSOC, V298, P61, DOI 10.1001/jama.298.1.61; Green JB, 2013, JAMA INTERN MED, V173, P229, DOI 10.1001/jamainternmed.2013.1529; Hippisley-Cox J, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2197; IMS Institute for Healthcare Informatics, 2011, US MED US RE 2010; Kesselheim AS, 2008, JAMA-J AM MED ASSOC, V300, P2514, DOI 10.1001/jama.2008.758; Kesselheim AS, 2010, DRUGS, V70, P605, DOI 10.2165/10898530-000000000-00000; Kiyota Y, 2004, AM HEART J, V148, P99, DOI 10.1016/j.ahj.2004.02.013; Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423; Lipsitch M, 2010, EPIDEMIOLOGY, V21, P383, DOI 10.1097/EDE.0b013e3181d61eeb; Mihaylova B, 2012, LANCET, V380, P581, DOI 10.1016/S0140-6736(12)60367-5; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Setoguchi S, 2007, CIRCULATION, V115, P27, DOI 10.1161/CIRCULATIONAHA.106.650176; Shrank WH, 2006, ARCH INTERN MED, V166, P332, DOI 10.1001/archinte.166.3.332; Shrank WH, 2007, J GEN INTERN MED, V22, P1298, DOI 10.1007/s11606-007-0284-3; Shrank WH, 2011, AM J MED, V124, P309, DOI 10.1016/j.amjmed.2010.11.020; Shrank WH, 2011, J GEN INTERN MED, V26, P546, DOI 10.1007/s11606-010-1609-1; Shroufi A, 2010, J EPIDEMIOL COMMUN H, V64, P109, DOI 10.1136/jech.2009.091033; Sturmer T, 2010, AM J EPIDEMIOL, V172, P843, DOI 10.1093/aje/kwq198; Taira DA, 2006, AM J MANAG CARE, V12, P678; Thavendiranathan P, 2006, ARCH INTERN MED, V166, P2307, DOI 10.1001/archinte.166.21.2307; Tirschwell DL, 2002, STROKE, V33, P2465, DOI 10.1161/01.STR.0000032240.28636.BD; United States Food and Drug Administration, 2012, OR BOOK APPR DRUG PR; Varas-Lorenzo C, 2008, PHARMACOEPIDEM DR S, V17, P842, DOI 10.1002/pds.1619	42	126	127	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2014	161	6					400	U56		10.7326/M13-2942	http://dx.doi.org/10.7326/M13-2942			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AR9LF	25222387	Green Published			2023-01-03	WOS:000343894400015
J	Yang, JJ; Huang, CH; Liu, CE; Tang, HJ; Yang, CJ; Lee, YC; Lee, KY; Tsai, MS; Lin, SW; Chen, YH; Lu, PL; Hung, CC				Yang, Jen-Jia; Huang, Chung-Hao; Liu, Chun-Eng; Tang, Hung-Jen; Yang, Chia-Jui; Lee, Yi-Chien; Lee, Kuan-Yeh; Tsai, Mao-Song; Lin, Shu-Wen; Chen, Yen-Hsu; Lu, Po-Liang; Hung, Chien-Ching			Multicenter Study of Trimethoprim/Sulfamethoxazole-Related Hepatotoxicity: Incidence and Associated Factors among HIV-Infected Patients Treated for Pneumocystis jirovecii Pneumonia	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INDUCED LIVER-INJURY; SULFAMETHOXAZOLE HYDROXYLAMINE FORMATION; DEPENDENT FLUCONAZOLE HEPATOTOXICITY; TRIMETHOPRIM-SULFAMETHOXAZOLE; CAUSALITY ASSESSMENT; CARINII-PNEUMONIA; ADVERSE REACTIONS; UNITED-STATES; AIDS	The incidence of hepatotoxicity related to trimethoprim/sulfamethoxazole (TMP/SMX) administered at a therapeutic dose may vary among study populations of different ethnicities and hepatotoxic metabolites of TMP/SMX may be decreased by drug-drug interaction with fluconazole. We aimed to investigate the incidence of hepatotoxicity and the role of concomitant use of fluconazole in HIV-infected patients receiving TMP/SMX for Pneumocystis jirovecii pneumonia. We reviewed medical records to collect clinical characteristics and laboratory data of HIV-infected patients who received TMP/SMX for treatment of P. jirovecii pneumonia at 6 hospitals around Taiwan between September 2009 and February 2013. Hepatotoxicity was defined as 2-fold or greater increase of aminotransferase or total bilirubin level from baselines. Roussel UCLAF Causality Assessment Method (RUCAM) was used to analyze the causality of drug-induced liver injuries. NAT1 and NAT2 acetylator types were determined with the use of polymerase-chain-reaction (PCR) restriction fragment length polymorphism to differentiate common single-nucleotide polymorphisms (SNPs) predictive of the acetylator phenotypes in a subgroup of patients. During the study period, 286 courses of TMP/SMX treatment administered to 284 patients were analyzed. One hundred and fifty-two patients (53.1%) developed hepatotoxicity, and TMP/SMX was considered causative in 47 (16.4%) who had a RUCAM score of 6 or greater. In multivariate analysis, concomitant use of fluconazole for candidiasis was the only factor associated with reduced risk for hepatotoxicity (adjusted odds ratio, 0.372; 95% confidence interval, 0.145-0.957), while serostatus of hepatitis B or C virus, NAT1 and NAT2 acetylator types, or receipt of combination antiretroviral therapy was not. The incidence of hepatotoxicity decreased with an increasing daily dose of fluconazole up to 4.0 mg/kg. We conclude that the incidence of TMP/SMX-related hepatotoxicity was 16.4% in HIV-infected Taiwanese patients who received TMP/SMX for pneumocystosis. Concomitant use of fluconazole was associated with decreased risk for TMP/SMX-related hepatotoxicity.	[Yang, Jen-Jia; Hung, Chien-Ching] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Yang, Jen-Jia; Hung, Chien-Ching] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan; [Yang, Jen-Jia] Po Jen Gen Hosp, Dept Internal Med, Taipei, Taiwan; [Huang, Chung-Hao; Chen, Yen-Hsu; Lu, Po-Liang] Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Huang, Chung-Hao; Chen, Yen-Hsu; Lu, Po-Liang] Kaohsiung Med Univ, Kaohsiung, Taiwan; [Liu, Chun-Eng] Changhua Christian Hosp, Dept Internal Med, Changhua, Taiwan; [Tang, Hung-Jen] Chi Mei Med Ctr, Dept Internal Med, Tainan, Taiwan; [Yang, Chia-Jui; Tsai, Mao-Song] Far Eastern Mem Hosp, Dept Internal Med, New Taipei City, Taiwan; [Lee, Yi-Chien] Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Internal Med, Chiayi, Taiwan; [Lee, Kuan-Yeh] Natl Taiwan Univ Hosp, Dept Internal Med, Hsin Chu Branch, Hsinchu, Taiwan; [Lin, Shu-Wen] Natl Taiwan Univ, Grad Inst Clin Pharm, Taipei 10764, Taiwan; [Lin, Shu-Wen] Natl Taiwan Univ Hosp, Dept Pharm, Taipei, Taiwan; [Lin, Shu-Wen] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan; [Hung, Chien-Ching] China Med Univ Hosp, Dept Med Res, Taichung, Taiwan; [Hung, Chien-Ching] China Med Univ, Taichung, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Changhua Christian Hospital; Chi Mei Hospital; Far Eastern Memorial Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan	Lu, PL (corresponding author), Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan.	idpaul@gmail.com; hcc0401@ntu.edu.tw	Lu, Po-Liang/D-4499-2009	Lu, Po-Liang/0000-0002-7423-6783; Chen, Yen-hsu/0000-0002-8667-4844; Hung, Chien-Ching/0000-0001-7345-0836; LIN, SHU-WEN/0000-0002-9940-0850	Centers for Disease Control, Taiwan [DOH102-DC-1401]	Centers for Disease Control, Taiwan	This study was supported by grants from the Centers for Disease Control, Taiwan (grant number DOH102-DC-1401 to C.-C. H.). The funding source played no role in study design and conduct, data collection, analysis or interpretation, writing of the manuscript, or the decision to submit it for publication.	Abrescia N, 2005, CURR PHARM DESIGN, V11, P3697, DOI 10.2174/138161205774580804; Andrade RJ, 2005, GASTROENTEROLOGY, V129, P512, DOI 10.1053/j.gastro.2005.05.006; Bell Tara L, 2010, Pharmacotherapy, V30, P539, DOI 10.1592/phco.30.5.539; BENICHOU C, 1990, J HEPATOL, V11, P272; Berg P A, 1987, Infection, V15 Suppl 5, pS259, DOI 10.1007/BF01643200; Bernstein L S, 1975, Can Med Assoc J, V112, P96; Bjornsson E, 2005, HEPATOLOGY, V42, P481, DOI 10.1002/hep.20800; Bronstein JA, 1997, CLIN INFECT DIS, V25, P1266, DOI 10.1086/516975; Chalasani N, 2008, GASTROENTEROLOGY, V135, P1924, DOI 10.1053/j.gastro.2008.09.011; CRIBB AE, 1995, DRUG METAB DISPOS, V23, P406; DANAN G, 1993, J CLIN EPIDEMIOL, V46, P1323, DOI 10.1016/0895-4356(93)90101-6; Deitz AC, 1997, ANAL BIOCHEM, V253, P219, DOI 10.1006/abio.1997.2379; DEWIT S, 1989, LANCET, V1, P746; Garcia-Cortes M, 2011, J HEPATOL, V55, P683, DOI 10.1016/j.jhep.2011.02.007; Hein DW, 2012, PHARMACOGENOMICS, V13, P31, DOI [10.2217/pgs.11.122, 10.2217/PGS.11.122]; Hellden A, 2010, EUR J CLIN PHARMACOL, V66, P791, DOI 10.1007/s00228-010-0820-7; HUGHES WT, 1995, J INFECT DIS, V171, P1295, DOI 10.1093/infdis/171.5.1295; JICK H, 1995, PHARMACOTHERAPY, V15, P428; Kantola T, 2000, EUR J CLIN PHARMACOL, V56, P225, DOI 10.1007/s002280000127; Kaplan JE, 2000, CLIN INFECT DIS, V30, pS5, DOI 10.1086/313843; KLEIN NC, 1992, AIDS, V6, P301, DOI 10.1097/00002030-199203000-00007; LAWSON DH, 1982, REV INFECT DIS, V4, P429; LEE BL, 1994, CLIN PHARMACOL THER, V56, P184, DOI 10.1038/clpt.1994.122; Lee KY, 2012, J ANTIMICROB CHEMOTH, V67, P2749, DOI 10.1093/jac/dks283; Lee KY, 2012, J MICROBIOL IMMUNOL; Lemoine M, 2012, CURR OPIN INFECT DIS, V25, P10, DOI 10.1097/QCO.0b013e32834ef599; Mainra Rahul Rai, 2003, Can J Clin Pharmacol, V10, P175; Masters PA, 2003, ARCH INTERN MED, V163, P402, DOI 10.1001/archinte.163.4.402; Miljkovic MM, 2012, J CLIN PHARM THER, V37, P196, DOI 10.1111/j.1365-2710.2011.01282.x; Miller RF, 2013, CLIN CHEST MED, V34, P229, DOI 10.1016/j.ccm.2013.02.001; Mitra AK, 1996, CLIN PHARMACOL THER, V59, P332, DOI 10.1016/S0009-9236(96)80011-7; Novelli V, 1999, ANTIMICROB AGENTS CH, V43, P1955, DOI 10.1128/AAC.43.8.1955; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; Schwarz UI, 2003, EUR J CLIN INVEST, V33, P23, DOI 10.1046/j.1365-2362.33.s2.6.x; Smith CL, 1997, CLIN INFECT DIS, V25, P1477, DOI 10.1086/516993; STEVENS RC, 1991, ANTIMICROB AGENTS CH, V35, P1884, DOI 10.1128/AAC.35.9.1884; von Moltke LL, 2001, J CLIN PHARMACOL, V41, P85, DOI 10.1177/00912700122009728; Vyas PM, 2006, J PHARMACOL EXP THER, V319, P488, DOI 10.1124/jpet.106.105858; Wang D, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-32; Wang JL, 2010, ANTIMICROB AGENTS CH, V54, P2409, DOI 10.1128/AAC.01657-09; WELLS C, 1992, J INFECTION, V24, P111, DOI 10.1016/0163-4453(92)91346-D; Winter HR, 2004, CLIN PHARMACOL THER, V76, P313, DOI 10.1016/j.clpt.2004.06.002; Xie HG, 1997, PHARMACOGENETICS, V7, P503, DOI 10.1097/00008571-199712000-00009	43	28	30	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2014	9	9							e106141	10.1371/journal.pone.0106141	http://dx.doi.org/10.1371/journal.pone.0106141			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO3TB	25184238	gold, Green Published, Green Submitted			2023-01-03	WOS:000341257700033
J	Nuotio, I; Hartikainen, JEK; Gronberg, T; Biancari, F; Airaksinen, KEJ				Nuotio, Ilpo; Hartikainen, Juha E. K.; Gronberg, Toni; Biancari, Fausto; Airaksinen, K. E. Juhani			Time to Cardioversion for Acute Atrial Fibrillation and Thromboembolic Complications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Nuotio, Ilpo] Turku Univ Hosp, Div Med, Turku 20521, Finland; [Hartikainen, Juha E. K.] Kuopio Univ Hosp, Ctr Heart, SF-70210 Kuopio, Finland; [Gronberg, Toni; Airaksinen, K. E. Juhani] Turku Univ Hosp, Ctr Heart, Turku 20521, Finland; [Biancari, Fausto] Oulu Univ Hosp, Dept Surg, Oulu, Finland	University of Turku; Kuopio University Hospital; University of Eastern Finland; University of Turku; University of Oulu	Airaksinen, KEJ (corresponding author), Turku Univ Hosp, Ctr Heart, POB 52, Turku 20521, Finland.	juhani.airaksinen@tyks.fi	Biancari, Fausto/A-1039-2008; Airaksinen, Juhani/AAC-7857-2021	Biancari, Fausto/0000-0001-5028-8186; Airaksinen, Juhani/0000-0002-0193-568X				Airaksinen KEJ, 2013, J AM COLL CARDIOL, V62, P1187, DOI 10.1016/j.jacc.2013.04.089; Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350]; Fuster V, 2006, CIRCULATION, V114, pE257, DOI 10.1161/CIRCULATIONAHA.106.177292; You JJ, 2012, CHEST, V141, pE531S, DOI 10.1378/chest.11-2304	4	114	119	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2014	312	6					647	649		10.1001/jama.2014.3824	http://dx.doi.org/10.1001/jama.2014.3824			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AM8OU	25117135	Bronze			2023-01-03	WOS:000340136400025
J	Du, CZ; Li, Z; Wang, S; Zhou, ZM; Wang, JK; Dong, J; Chen, CS				Du, Chengzhi; Li, Zhen; Wang, Shuang; Zhou, Zhongmei; Wang, Jingkun; Dong, Jian; Chen, Ceshi			Tongshu Capsule Down-Regulates the Expression of Estrogen Receptor alpha and Suppresses Human Breast Cancer Cell Proliferation	PLOS ONE			English	Article							TAMOXIFEN; BETA; PHOSPHORYLATION; ESTRADIOL; DISEASE	The Tongshu Capsule (TSC) is a prevalent form of traditional Chinese medicine widely used for its purported effects in treating mammary gland hyperplasia and inflammation. Though successful in several clinical studies, there is no clear evidence as to why TSC has a positive treatment effect, and little known about underlying mechanism that may account for it. In this study, we examined the effects of TSC and found that it has a comparatively strong growth inhibition on ER alpha positive breast cancer cells. TSC seems to cause G1 cell cycle arrest instead of apoptosis. Interestingly, TSC also down-regulated the expression of ER alpha and Cyclin D1. Consistently, TSC suppressed E2 mediated ER alpha downstream gene expression and cell proliferation in ER alpha positive breast cancer cell lines MCF7 and T47D. Depletion of ER alpha partially abolished the effects of TSC on the decrease of Cyclin D1 and cell viability. Our findings suggest that TSC may have therapeutic effects on ER alpha positive breast cancers and moreover that TSC may suppress breast epithelial cell proliferation by inhibiting the estrogen pathway.	[Du, Chengzhi; Wang, Shuang; Zhou, Zhongmei; Chen, Ceshi] Chinese Acad Sci & Yunnan Prov, Key Lab Anim Models & Human Dis Mech, Kunming Inst Zool, Kunming, Yunnan, Peoples R China; [Li, Zhen; Dong, Jian] Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China; [Wang, Jingkun] Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Kunming Medical University; Kunming Medical University	Chen, CS (corresponding author), Chinese Acad Sci & Yunnan Prov, Key Lab Anim Models & Human Dis Mech, Kunming Inst Zool, Kunming, Yunnan, Peoples R China.	chenc@mail.kiz.ac.cn			Yunnan Institute of Materia Medica; National Nature Science Foundation of China [81120108019, U1132605, 81325016]; Yunnan Province High-Profile Scientist Program [2010CI114]	Yunnan Institute of Materia Medica; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Yunnan Province High-Profile Scientist Program	This study was partially funded by Yunnan Institute of Materia Medica, which is the manufacturer of Tongshu Capsule. This funder provided support in the form of salaries for author JW, but did not have any additional role in the study design, data collection and analysis, decision to publish, orpreparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. This study was also supported in part by National Nature Science Foundation of China (81120108019, U1132605, and 81325016), and a grant from the Yunnan Province High-Profile Scientist Program (2010CI114). These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALLEGRA JC, 1979, CANCER, V44, P228, DOI 10.1002/1097-0142(197907)44:1<228::AID-CNCR2820440137>3.0.CO;2-0; Altucci L, 1996, ONCOGENE, V12, P2315; Callige M, 2005, MOL CELL BIOL, V25, P4349, DOI 10.1128/MCB.25.11.4349-4358.2005; Chen J, 2011, HEBEI MED J, V33, P623; Cheng L, 2012, J CLIN INVEST, V122, P2857, DOI 10.1172/JCI62676; Chu I, 2005, CANCER RES, V65, P18; Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Key TJ, 2003, J NATL CANCER I, V95, P1218, DOI 10.1093/jnci/djg022; Kontostolis E, 1997, GYNECOL ENDOCRINOL, V11, P393, DOI 10.3109/09513599709152566; Lagiou P, 2013, ANN ONCOLOGY; Li X, 2006, GUIDE CHINA MED, V4; MADDOX PR, 1989, WORLD J SURG, V13, P699, DOI 10.1007/BF01658417; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Santen RJ, 2005, NEW ENGL J MED, V353, P275, DOI 10.1056/NEJMra035692; Sartippour MR, 2006, CARCINOGENESIS, V27, P2424, DOI 10.1093/carcin/bgl066; Sasaki Y, 2010, CANCER SCI, V101, P2286, DOI 10.1111/j.1349-7006.2010.01673.x; Shaw LE, 2006, J STEROID BIOCHEM, V99, P19, DOI 10.1016/j.jsbmb.2005.11.005	20	4	4	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 7	2014	9	8							e104261	10.1371/journal.pone.0104261	http://dx.doi.org/10.1371/journal.pone.0104261			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6SB	25101695	Green Submitted, gold, Green Published			2023-01-03	WOS:000339993900054
J	Forbes, SJ; Rosenthal, N				Forbes, Stuart J.; Rosenthal, Nadia			Preparing the ground for tissue regeneration: from mechanism to therapy	NATURE MEDICINE			English	Review							REGULATORY T-CELLS; IN-VITRO EXPANSION; LIVER-REGENERATION; PROGENITOR-CELLS; STEM-CELLS; SMALL-INTESTINE; SPINAL-CORD; ACTIVATED MACROPHAGES; PARTIAL-HEPATECTOMY; IMMUNE-SYSTEM	Chronic diseases confer tissue and organ damage that reduce quality of life and are largely refractory to therapy. Although stem cells hold promise for treating degenerative diseases by 'seeding' injured tissues, the regenerative capacity of stem cells is influenced by regulatory networks orchestrated by local immune responses to tissue damage, with macrophages being a central component of the injury response and coordinator of tissue repair. Recent research has turned to how cellular and signaling components of the local stromal microenvironment (the 'soil' to the stem cells' seed), such as local inflammatory reactions, contribute to successful tissue regeneration. This Review discusses the basic principles of tissue regeneration and the central role locally acting components may play in the process. Application of seed-and-soil concepts to regenerative medicine strengthens prospects for developing cell-based therapies or for promotion of endogenous repair.	[Forbes, Stuart J.] Univ Edinburgh, MRC Ctr Regenerat Med, Edinburgh, Midlothian, Scotland; [Rosenthal, Nadia] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Rosenthal, Nadia] Monash Univ, Australian Regenerat Med Inst, Melbourne, Vic 3004, Australia	University of Edinburgh; Imperial College London; Australian Regenerative Medicine Institute; Monash University	Forbes, SJ (corresponding author), Univ Edinburgh, MRC Ctr Regenerat Med, Edinburgh, Midlothian, Scotland.	stuart.forbes@ed.ac.uk; n.rosenthal@imperial.ac.uk	Rosenthal, Nadia/O-7009-2015	Rosenthal, Nadia/0000-0002-7599-7365; Forbes, Stuart/0000-0003-3715-2561	British Heart Foundation [PG/10/19/28218] Funding Source: Medline; Medical Research Council [G1000868, MR/K026666/1] Funding Source: Medline; MRC [MR/K026666/1, G1000868] Funding Source: UKRI	British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alikhan MA, 2011, AM J PATHOL, V179, P1243, DOI 10.1016/j.ajpath.2011.05.037; Anders HJ, 2014, NAT REV NEPHROL, V10, P347, DOI 10.1038/nrneph.2014.68; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Behfar A, 2014, NAT REV CARDIOL, V11, P232, DOI 10.1038/nrcardio.2014.9; Bird TG, 2008, CELL TISSUE RES, V331, P283, DOI 10.1007/s00441-007-0542-z; Bird TG, 2013, P NATL ACAD SCI USA, V110, P6542, DOI 10.1073/pnas.1302168110; Boulter L, 2012, NAT MED, V18, P572, DOI 10.1038/nm.2667; Boulton R, 1997, HEPATOLOGY, V26, P49; Boulton RA, 1998, J HEPATOL, V29, P271, DOI 10.1016/S0168-8278(98)80013-5; Burchfield JS, 2008, CIRC RES, V103, P203, DOI 10.1161/CIRCRESAHA.108.178475; Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054; Burzyn D, 2013, NAT IMMUNOL, V14, P1007, DOI 10.1038/ni.2683; Butovsky O, 2005, MOL CELL NEUROSCI, V29, P381, DOI 10.1016/j.mcn.2005.03.005; Cappellari O, 2013, DEV CELL, V24, P586, DOI 10.1016/j.devcel.2013.01.022; Carosio S, 2011, AGEING RES REV, V10, P35, DOI 10.1016/j.arr.2009.08.001; Chen CW, 2009, CYTOKINE GROWTH F R, V20, P429, DOI 10.1016/j.cytogfr.2009.10.014; Cheng K, 2013, HEART LUNG CIRC, V22, P887, DOI 10.1016/j.hlc.2013.04.112; Cho DI, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2013.135; Choi TY, 2014, GASTROENTEROLOGY, V146, P776, DOI 10.1053/j.gastro.2013.10.019; Corselli M, 2010, ARTERIOSCL THROM VAS, V30, P1104, DOI 10.1161/ATVBAHA.109.191643; Czopka T, 2013, DEV CELL, V25, P599, DOI 10.1016/j.devcel.2013.05.013; Davies LC, 2013, NAT IMMUNOL, V14, P986, DOI 10.1038/ni.2705; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; Dellavalle A, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1508; Ding BS, 2014, NATURE, V505, P97, DOI 10.1038/nature12681; Ding BS, 2010, NATURE, V468, P310, DOI 10.1038/nature09493; Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675; Dulauroy S, 2012, NAT MED, V18, P1262, DOI 10.1038/nm.2848; Egea L, 2013, J IMMUNOL, V190, P1702, DOI 10.4049/jimmunol.1202368; Ellis EL, 2012, J HEPATOL, V56, P1171, DOI 10.1016/j.jhep.2011.09.024; Epelman S, 2014, IMMUNITY, V40, P91, DOI 10.1016/j.immuni.2013.11.019; Espanol-Suner R, 2012, GASTROENTEROLOGY, V143, P1564, DOI 10.1053/j.gastro.2012.08.024; Fallowfield JA, 2007, J IMMUNOL, V178, P5288, DOI 10.4049/jimmunol.178.8.5288; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Gibbons MA, 2011, AM J RESP CRIT CARE, V184, P569, DOI 10.1164/rccm.201010-1719OC; Gibson EM, 2014, SCIENCE, V344, P487, DOI 10.1126/science.1252304; Goh YPS, 2013, P NATL ACAD SCI USA, V110, P9914, DOI 10.1073/pnas.1304046110; Goritz C, 2011, SCIENCE, V333, P238, DOI 10.1126/science.1203165; Gow DJ, 2010, J LEUKOCYTE BIOL, V88, P475, DOI 10.1189/jlb.0310158; Haubner BJ, 2012, AGING-US, V4, P966, DOI 10.18632/aging.100526; Hay DC, 2011, STEM CELL RES, V6, P92, DOI 10.1016/j.scr.2010.12.002; HAY ED, 1961, DEV BIOL, V3, P26, DOI 10.1016/0012-1606(61)90009-4; He J, 2014, GASTROENTEROLOGY, V146, P789; Henderson NC, 2013, NAT MED, V19, P1617, DOI 10.1038/nm.3282; Higgins GM, 1931, ARCH PATHOL, V12, P186; Hu JH, 2014, SCIENCE, V343, P416, DOI 10.1126/science.1244880; Huch M, 2013, NATURE, V494, P247, DOI 10.1038/nature11826; Iekushi K, 2012, CIRCULATION, V125, P1765, DOI 10.1161/CIRCULATIONAHA.111.079699; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; IREDALE JP, 1992, J CLIN INVEST, V90, P282, DOI 10.1172/JCI115850; Issa R, 2002, FASEB J, V16, P47, DOI 10.1096/fj.02-0494fje; Jenkins SJ, 2013, J EXP MED, V210, P2477, DOI 10.1084/jem.20121999; Jenkins SJ, 2011, SCIENCE, V332, P1284, DOI 10.1126/science.1204351; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Jung P, 2011, NAT MED, V17, P1225, DOI 10.1038/nm.2470; Kallis YN, 2011, GUT, V60, P525, DOI 10.1136/gut.2010.224436; Katare R, 2011, CIRC RES, V109, P894, DOI 10.1161/CIRCRESAHA.111.251546; Kikuchi K, 2012, ANNU REV CELL DEV BI, V28, P719, DOI 10.1146/annurev-cellbio-101011-155739; Kisseleva T, 2012, P NATL ACAD SCI USA, V109, P9448, DOI 10.1073/pnas.1201840109; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Lammers G, 2011, TISSUE ENG PART B-RE, V17, P33, DOI [10.1089/ten.teb.2010.0473, 10.1089/ten.TEB.2010.0473]; LeBleu VS, 2013, NAT MED, V19, P1047, DOI 10.1038/nm.3218; Leor J, 2006, CIRCULATION, V114, pI94, DOI 10.1161/CIRCULATIONAHA.105.000331; Li L, 2012, J BIOL CHEM, V287, P25353, DOI 10.1074/jbc.M112.349126; Lin SL, 2008, AM J PATHOL, V173, P1617, DOI 10.2353/ajpath.2008.080433; London A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00034; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Lu HY, 2011, FASEB J, V25, P358, DOI 10.1096/fj.10-171579; Lu N, 2014, J IMMUNOL, V192, P1013, DOI 10.4049/jimmunol.1300133; Lucas T, 2010, J IMMUNOL, V184, P3964, DOI 10.4049/jimmunol.0903356; MacDonald TT, 2011, GASTROENTEROLOGY, V140, P1768, DOI 10.1053/j.gastro.2011.02.047; Martinez F. O., 2014, F1000PRIME REP, V6, P13; Massimino ML, 1997, BIOCHEM BIOPH RES CO, V235, P754, DOI 10.1006/bbrc.1997.6823; Mccampbell KK, 2014, TRANSL RES, V163, P109, DOI 10.1016/j.trsl.2013.10.003; Meijer C, 2000, LIVER, V20, P66, DOI 10.1034/j.1600-0676.2000.020001066.x; Mendelson A, 2014, NAT MED, V20, P833, DOI 10.1038/nm.3647; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885; Nakamura T, 2007, GASTROENTEROLOGY, V133, P91, DOI 10.1053/j.gastro.2007.03.110; Niethammer P, 2009, NATURE, V459, P996, DOI 10.1038/nature08119; Ochoa B, 2010, HEPATOLOGY, V51, P1712, DOI 10.1002/hep.23525; Ochoa O, 2007, AM J PHYSIOL-REG I, V293, pR651, DOI 10.1152/ajpregu.00069.2007; Overturf K, 1997, AM J PATHOL, V151, P1273; Pase L, 2012, CURR BIOL, V22, P1818, DOI 10.1016/j.cub.2012.07.060; Passino MA, 2007, SCIENCE, V315, P1853, DOI 10.1126/science.1137603; Pellicoro A, 2014, NAT REV IMMUNOL, V14, P181, DOI 10.1038/nri3623; Pinto AR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036814; Porrello ER, 2013, P NATL ACAD SCI USA, V110, P187, DOI 10.1073/pnas.1208863110; Porrello ER, 2011, SCIENCE, V331, P1078, DOI 10.1126/science.1200708; Porta C, 2009, P NATL ACAD SCI USA, V106, P14978, DOI 10.1073/pnas.0809784106; Psaltis PJ, 2012, EUR J NUCL MED MOL I, V39, P165, DOI 10.1007/s00259-011-1925-7; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Rabelink TJ, 2013, NAT REV NEPHROL, V9, P747, DOI 10.1038/nrneph.2013.152; Ramachandran P, 2012, P NATL ACAD SCI USA, V109, pE3186, DOI 10.1073/pnas.1119964109; Ritsma L, 2014, NATURE, V507, P362, DOI 10.1038/nature12972; Romagnani P, 2013, NAT REV NEPHROL, V9, P137, DOI 10.1038/nrneph.2012.290; Rosado-de-Castro PH, 2013, STEM CELLS DEV, V22, P2095, DOI 10.1089/scd.2013.0089; Ruffell D, 2009, P NATL ACAD SCI USA, V106, P17475, DOI 10.1073/pnas.0908641106; Russell SE, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00246; Saclier M, 2013, STEM CELLS, V31, P384, DOI 10.1002/stem.1288; Sala FG, 2011, TISSUE ENG PT A, V17, P1841, DOI [10.1089/ten.TEA.2010.0564, 10.1089/ten.tea.2010.0564]; Santini MP, 2007, CIRC RES, V100, P1732, DOI 10.1161/CIRCRESAHA.107.148791; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Schwartz M, 2014, NEUROSCIENTIST, V20, P343, DOI 10.1177/1073858413516799; Seno H, 2009, P NATL ACAD SCI USA, V106, P256, DOI 10.1073/pnas.0803343106; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Shechter R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027969; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Skaper SD, 2014, IMMUNOLOGY, V141, P314, DOI 10.1111/imm.12170; Smart N, 2012, ANN NY ACAD SCI, V1269, P92, DOI 10.1111/j.1749-6632.2012.06708.x; Soltys KA, 2010, J HEPATOL, V53, P769, DOI 10.1016/j.jhep.2010.05.010; Stark K, 2013, NAT IMMUNOL, V14, P41, DOI 10.1038/ni.2477; Swirski FK, 2013, SCIENCE, V339, P161, DOI 10.1126/science.1230719; Taghavie-Moghadam PL, 2014, ANN NY ACAD SCI, V1319, P19, DOI 10.1111/nyas.12392; Takeda N, 2011, SCIENCE, V334, P1420, DOI 10.1126/science.1213214; Tang TT, 2012, BASIC RES CARDIOL, V107, DOI 10.1007/s00395-011-0232-6; Thomas JA, 2011, HEPATOLOGY, V53, P2003, DOI 10.1002/hep.24315; Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408; Tidball JG, 2010, AM J PHYSIOL-REG I, V298, pR1173, DOI 10.1152/ajpregu.00735.2009; Tsuchiya A, 2014, HEPATOLOGY, V60, P1727, DOI 10.1002/hep.27099; Turner M, 2013, CELL STEM CELL, V13, P382, DOI 10.1016/j.stem.2013.08.003; Villalta SA, 2011, HUM MOL GENET, V20, P790, DOI 10.1093/hmg/ddq523; Villalta SA, 2009, HUM MOL GENET, V18, P482, DOI 10.1093/hmg/ddn376; Wang L, 2012, J CLIN INVEST, V122, P1567, DOI 10.1172/JCI58789; Wang Y, 2007, KIDNEY INT, V72, P290, DOI 10.1038/sj.ki.5002275; Willenborg S, 2014, J DTSCH DERMATOL GES, V12, P214, DOI 10.1111/ddg.12290; Williams MJ, 2014, GASTROENTEROLOGY, V146, P349, DOI 10.1053/j.gastro.2013.11.034; Wing K, 2010, NAT IMMUNOL, V11, P7, DOI 10.1038/ni.1818; Wulff BC, 2013, EXP DERMATOL, V22, P507, DOI 10.1111/exd.12169; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; YAMANAKA N, 1993, HEPATOLOGY, V18, P79, DOI 10.1016/0270-9139(93)90510-T; Yanger K, 2013, GENE DEV, V27, P719, DOI 10.1101/gad.207803.112; Yimlamai D, 2014, CELL, V157, P1324, DOI 10.1016/j.cell.2014.03.060; Yui SR, 2012, NAT MED, V18, P618, DOI 10.1038/nm.2695; Zangi L, 2013, NAT BIOTECHNOL, V31, P898, DOI 10.1038/nbt.2682; Ziv Y, 2006, P NATL ACAD SCI USA, V103, P13174, DOI 10.1073/pnas.0603747103	142	356	376	7	156	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2014	20	8					857	869		10.1038/nm.3653	http://dx.doi.org/10.1038/nm.3653			13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	AM7UQ	25100531				2023-01-03	WOS:000340074600017
J	Komatsu, S; Nagai, Y; Naruse, K; Kimata, Y				Komatsu, Seiji; Nagai, Yusuke; Naruse, Keiji; Kimata, Yoshihiro			The Neutral Self-Assembling Peptide Hydrogel SPG-178 as a Topical Hemostatic Agent	PLOS ONE			English	Article							NANOFIBER SCAFFOLDS; COMPLEMENTARY OLIGOPEPTIDE; SPINAL-CORD; CULTURE; CELLS; PURAMATRIX; MORTALITY; EFFICACY; RELEASE	Conventional self-assembling peptide hydrogels are effective as topical hemostatic agents. However, there is a possibility to harm living tissues due to their low pH. The aim of the present study was to demonstrate the efficacy of SPG-178, a neutral self-assembling peptide hydrogel, as a topical hemostatic agent. First, we measured the bleeding duration of incisions made on rat livers after application of SPG-178 (1.0% w/v), SPG-178 (1.5% w/v), RADA16 (1.0% w/v), and saline (n = 12/group). Second, we observed the bleeding surfaces by transmission electron microscopy immediately after hemostasis. Third, we measured the elastic and viscous responses (G' and G '', respectively) of the hydrogels using a rheometer. Our results showed that bleeding duration was significantly shorter in the SPG-178 group than in the RADA16 group and that there were no significant differences in transmission electron microscopy findings between the groups. The greater the G' value of a hydrogel, the shorter was the bleeding duration. We concluded that SPG-178 is more effective and has several advantages: it is non-biological, transparent, nonadherent, and neutral and can be sterilized by autoclaving.	[Komatsu, Seiji] Okayama Saiseikai Gen Hosp, Dept Plast & Reconstruct Surg, Okayama, Japan; [Nagai, Yusuke; Naruse, Keiji] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Cardiovasc Physiol, Okayama 7008530, Japan; [Nagai, Yusuke] Menicon Co Ltd, Nagoya, Aichi, Japan; [Kimata, Yoshihiro] Okayama Univ, Dept Plast & Reconstruct Surg, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008530, Japan	Okayama University; Okayama University	Komatsu, S (corresponding author), Okayama Saiseikai Gen Hosp, Dept Plast & Reconstruct Surg, Okayama, Japan.	komats-s@cc.okayama-u.ac.jp	Sokabe, Masahiro/I-1565-2012; Komatsu, Seiji/H-7235-2013	Komatsu, Seiji/0000-0001-7625-7927; naruse, keiji/0000-0003-4100-6444	Ministry of Education, Culture, Sports, Sciences, and Technology of Japan [23792045, 40252233]; Grants-in-Aid for Scientific Research [26220203] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Sciences, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Financial support for this study was provided by Grant-in-Aid for Young Scientists (B) 23792045 provided by the Ministry of Education, Culture, Sports, Sciences, and Technology of Japan (to Seiji Komatsu), and Grant-in-Aid for Challenging Exploratory Research 40252233 provided by the Ministry of Education, Culture, Sports, Sciences, and Technology of Japan (to Keiji Naruse). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achneck HE, 2010, ANN SURG, V251, P217, DOI 10.1097/SLA.0b013e3181c3bcca; Akiyama N, 2013, INT J NANOMED, V8, P2629, DOI 10.2147/IJN.S47279; CARSON JL, 1988, LANCET, V1, P727; Cylwik D, 2004, J PHYSIOL PHARMACOL, V55, P563; Davis ME, 2005, CIRCULATION, V111, P442, DOI 10.1161/01.CIR.0000153847.47301.80; Degano IR, 2009, BIOMATERIALS, V30, P1156, DOI 10.1016/j.biomaterials.2008.11.021; Ellis-Behnke RG, 2006, NANOMED-NANOTECHNOL, V2, P207, DOI 10.1016/j.nano.2006.08.001; Emilia M, 2011, TRANSFUS APHER SCI, V45, P305, DOI 10.1016/j.transci.2011.10.013; Genove E, 2005, BIOMATERIALS, V26, P3341, DOI 10.1016/j.biomaterials.2004.08.012; Guo J, 2007, NANOMED-NANOTECHNOL, V3, P311, DOI 10.1016/j.nano.2007.09.003; Holmes TC, 2000, P NATL ACAD SCI USA, V97, P6728, DOI 10.1073/pnas.97.12.6728; Kim MS, 2007, BIOMED MICRODEVICES, V9, P25, DOI 10.1007/s10544-006-9016-4; Koutsopoulos S, 2009, P NATL ACAD SCI USA, V106, P4623, DOI 10.1073/pnas.0807506106; Lang CJG, 1998, J NEUROL SCI, V160, P128, DOI 10.1016/S0022-510X(98)00226-3; Leugn GKK, 2012, METHOD ENZYMOL, V508, P177; Liedmann A, 2012, JOVE-J VIS EXP, DOI 10.3791/3830; Luo ZL, 2011, BIOMATERIALS, V32, P2013, DOI 10.1016/j.biomaterials.2010.11.049; Masuhara H, 2012, ANN THORAC CARDIOVAS, V18, P444, DOI 10.5761/atcs.oa.12.01977; Meng H, 2009, J BIOMED MATER RES B, V89B, P379, DOI 10.1002/jbm.b.31226; Moradi F, 2012, J NEUROSCI RES, V90, P2335, DOI 10.1002/jnr.23120; Nagai Y, 2006, J CONTROL RELEASE, V115, P18, DOI 10.1016/j.jconrel.2006.06.031; Nagai Y, 2012, BIOMATERIALS, V33, P1044, DOI 10.1016/j.biomaterials.2011.10.049; Schneider A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001410; Semino CE, 2003, DIFFERENTIATION, V71, P262, DOI 10.1046/j.1432-0436.2003.7104503.x; Shivachar AC, 2008, TOPICS TISSUE ENG, V4; Song H, 2010, MACROMOL BIOSCI, V10, P33, DOI 10.1002/mabi.200900129; Um E, 2008, MICROFLUID NANOFLUID, V5, P541, DOI 10.1007/s10404-008-0268-6; Wu WC, 2012, ANN SURG, V255, P708, DOI 10.1097/SLA.0b013e31824a55b9; Yasunaga H, 2007, LANCET, V370, P2063, DOI 10.1016/S0140-6736(07)61867-4; Yokoi H, 2005, P NATL ACAD SCI USA, V102, P8414, DOI 10.1073/pnas.0407843102; ZHANG SG, 1993, P NATL ACAD SCI USA, V90, P3334, DOI 10.1073/pnas.90.8.3334; ZHANG SG, 1995, BIOMATERIALS, V16, P1385, DOI 10.1016/0142-9612(95)96874-Y; Zhao Y, 2008, BIOMACROMOLECULES, V9, P1511, DOI 10.1021/bm701143g	33	27	37	0	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2014	9	7							e102778	10.1371/journal.pone.0102778	http://dx.doi.org/10.1371/journal.pone.0102778			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM0SW	25047639	Green Submitted, Green Published, gold			2023-01-03	WOS:000339558100074
J	Kapoor, A				Kapoor, Akhil			PERSONAL VIEW A train offers hope to Punjab's patients with cancer but it isn't enough	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Sardar Patel Med Coll & Hosp, Acharya Tulsi Reg Canc Treatment & Res Ctr, Dept Radiat Oncol, Bikaner 334003, Rajasthan, India	Sardar Patel Medical College, Bikaner	Kapoor, A (corresponding author), Sardar Patel Med Coll & Hosp, Acharya Tulsi Reg Canc Treatment & Res Ctr, Dept Radiat Oncol, Bikaner 334003, Rajasthan, India.	kapoorakhil1987@gmail.com	Kapoor, Akhil/H-4224-2019	Kapoor, Akhil/0000-0001-6006-2631				Government of Punjab, 2013, STAT WID DOOR DOOR C; Indian Railways, CONC RUL; Kaur J., 2012, GOVERNANCE NOW  0420; Kaur Raminderjeet, 2011, Indian J Hum Genet, V17, P179, DOI 10.4103/0971-6866.92100; Mallath MK, 2014, LANCET ONCOL, V15, pE205, DOI 10.1016/S1470-2045(14)70115-9; Nayak R., 2013, HLTH SITE       0130; Sandhu K., 2009, TRIBUNE INDIA   1001; US Environmental Protection Agency, BANN SEV RESTR PEST; US Library of Congress, COUNTR STUD	9	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 8	2014	349								g4484	10.1136/bmj.g4484	http://dx.doi.org/10.1136/bmj.g4484			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AL2ZB	25005259				2023-01-03	WOS:000338993300010
J	Mostaghel, EA; Morgan, A; Zhang, XT; Marck, BT; Xia, J; Hunter-Merrill, R; Gulati, R; Plymate, S; Vessella, RL; Corey, E; Higano, CS; Matsumoto, AM; Montgomery, RB; Nelson, PS				Mostaghel, Elahe A.; Morgan, Andrew; Zhang, Xiaotun; Marck, Brett T.; Xia, Jing; Hunter-Merrill, Rachel; Gulati, Roman; Plymate, Stephen; Vessella, Robert L.; Corey, Eva; Higano, Celestia S.; Matsumoto, Alvin M.; Montgomery, R. Bruce; Nelson, Peter S.			Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis	PLOS ONE			English	Article							INCREASED SURVIVAL; HORMONAL-THERAPY; CARCINOMA; DIHYDROTESTOSTERONE; TESTOSTERONE; PROGRESSION; ABIRATERONE; RESISTANCE; ENZALUTAMIDE; INDEPENDENCE	Background: Factors influencing differential responses of prostate tumors to androgen receptor (AR) axis-directed therapeutics are poorly understood, and predictors of treatment efficacy are needed. We hypothesized that the efficacy of inhibiting DHT ligand synthesis would associate with intra-tumoral androgen ratios indicative of relative dependence on DHT-mediated growth. Methods: We characterized two androgen-sensitive prostate cancer xenograft models after androgen suppression by castration in combination with the SRD5A inhibitor, dutasteride, as well as a panel of castration resistant metastases obtained via rapid autopsy. Results: In LuCaP35 tumors (intra-tumoral T: DHT ratio 2: 1) dutasteride suppressed DHT to 0.02 ng/gm and prolonged survival vs. castration alone (337 vs. 152 days, HR 2.8, p = 0.0015). In LuCaP96 tumors (T: DHT 10: 1), survival was not improved despite similar DHT reduction (0.02 ng/gm). LuCaP35 demonstrated higher expression of steroid biosynthetic enzymes maintaining DHT levels (5-fold higher SRD5A1, 41 fold higher, 99-fold higher RL-HSD, p<0.0001 for both), reconstitution of intra-tumoral DHT (to similar to 30% of untreated tumors), and similar to 2 fold increased expression of full length AR. In contrast, LuCaP96 demonstrated higher levels of steroid catabolizing enzymes (6.9-fold higher AKR1C2, 3000-fold higher UGT2B15, p = 0.002 and p<0.0001 respectively), persistent suppression of intra-tumoral DHT, and 6-8 fold induction of full length AR and the ligand independent V7 AR splice variant. Human metastases demonstrated bio-active androgen levels and AR full length and AR splice-variant expression consistent with the range observed in xenografts. Conclusions: Intrinsic differences in basal steroidogenesis, as well as variable expression of full length and splice-variant AR, associate with response and resistance to pre-receptor AR ligand suppression. Expression of steroidogenic enzymes and AR isoforms may serve as potential biomarkers of sensitivity to potent AR-axis inhibition and should be validated in additional models.	[Mostaghel, Elahe A.; Morgan, Andrew; Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; [Mostaghel, Elahe A.; Marck, Brett T.; Plymate, Stephen; Higano, Celestia S.; Matsumoto, Alvin M.; Montgomery, R. Bruce; Nelson, Peter S.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; [Zhang, Xiaotun; Vessella, Robert L.; Corey, Eva] Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA; [Marck, Brett T.; Plymate, Stephen; Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA; [Xia, Jing; Hunter-Merrill, Rachel; Gulati, Roman] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Fred Hutchinson Cancer Center	Mostaghel, EA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.	emostagh@fhcrc.org	Gulati, Roman/AAE-4298-2019; Matsumoto, Alvin/AAH-6096-2020	Gulati, Roman/0000-0002-7592-6567; 	Prostate Cancer Foundation Career Development Award; Challenge Award; Damon Runyon Genentech-Clinical Investigator Award [C-40-08]; NIH grant [1K23 CA122820-01]; DOD New Investigator Award [W81XWH-10-1-0228]; GlaxoSmithKline; NIH/NCI Pacific Northwest Prostate Cancer SPORE [P50CA97186]; Department of Veterans Affairs;  [1RC1 CA146849];  [PC093509];  [PO1 CA 85859]; NATIONAL CANCER INSTITUTE [K23CA122820, RC1CA146849, P50CA097186, P01CA085859] Funding Source: NIH RePORTER	Prostate Cancer Foundation Career Development Award; Challenge Award; Damon Runyon Genentech-Clinical Investigator Award; NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD New Investigator Award; GlaxoSmithKline(GlaxoSmithKline); NIH/NCI Pacific Northwest Prostate Cancer SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs(US Department of Veterans Affairs); ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Prostate Cancer Foundation Career Development Award (E. A. M.) and Challenge Award (E. A. M., S. P., R. L. V., A. M. M., R. B. M., P.S.N.), Damon Runyon Genentech-Clinical Investigator Award C-40-08 (E. A. M.), NIH grant 1K23 CA122820-01 (E. A. M.), DOD New Investigator Award W81XWH-10-1-0228 (E. A. M.); GlaxoSmithKline (A. M. and P.S.N.); 1RC1 CA146849 (P.S.N.); PC093509 (P.S.N.); PO1 CA 85859 (J.X., R. G., R. V., P.S.N.); the NIH/NCI Pacific Northwest Prostate Cancer SPORE P50CA97186 (J.X., R. H., R. G., P.S.N., R. V.); and the Department of Veterans Affairs (B. T. M., S. P. and A. M. M.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; Andersen RJ, 2010, CANCER CELL, V17, P535, DOI 10.1016/j.ccr.2010.04.027; Andriole GL, 2010, NEW ENGL J MED, V362, P1192, DOI 10.1056/NEJMoa0908127; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Arnold JT, 2007, PROSTATE, V67, P1152, DOI 10.1002/pros.20585; Bohl CE, 2005, J BIOL CHEM, V280, P37747, DOI 10.1074/jbc.M507464200; Chang KH, 2011, P NATL ACAD SCI USA, V108, P13728, DOI 10.1073/pnas.1107898108; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Corey E, 2003, PROSTATE, V55, P239, DOI 10.1002/pros.10198; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dehm SM, 2011, ENDOCR-RELAT CANCER, V18, pR183, DOI 10.1530/ERC-11-0141; Efstathiou E, 2012, J CLIN ONCOL, V30, P637, DOI 10.1200/JCO.2010.33.7675; GELLER J, 1978, J CLIN ENDOCR METAB, V46, P440; Gregory CW, 2001, CANCER RES, V61, P4315; GRINO PB, 1990, ENDOCRINOLOGY, V126, P1165, DOI 10.1210/endo-126-2-1165; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Hobisch A, 1996, PROSTATE, V28, P129; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Hornberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019059; Hu R, 2011, PROSTATE; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Mohler JL, 1996, CLIN CANCER RES, V2, P889; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Mostaghel EA, 2011, CLIN CANC RES; Page ST, 2007, J ANDROL JANDROL, V107; Roudier MP, 2003, HUM PATHOL, V34, P646, DOI 10.1016/S0046-8177(03)00190-4; SADI MV, 1991, CANCER, V67, P3057, DOI 10.1002/1097-0142(19910615)67:12<3057::AID-CNCR2820671221>3.0.CO;2-S; Samson DJ, 2002, CANCER, V95, P361, DOI 10.1002/cncr.10647; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Taplin ME, 2009, CLIN CANCER RES, V15, P7099, DOI 10.1158/1078-0432.CCR-09-1722; Thomas LN, 2005, PROSTATE, V63, P231, DOI 10.1002/pros.20188; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Watson PA, 2010, P NATL ACAD SCI; Wright AS, 1996, J CLIN INVEST, V98, P2558, DOI 10.1172/JCI119074; Xu Y, 2006, CLIN CANCER RES, V12, P4072, DOI 10.1158/1078-0432.CCR-06-0184; Zhang XT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027970	39	3	4	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2014	9	10							e111545	10.1371/journal.pone.0111545	http://dx.doi.org/10.1371/journal.pone.0111545			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX2HU	25356728	Green Published, gold, Green Submitted			2023-01-03	WOS:000346765000069
J	Shah, S; McArthur, E; Farag, A; Nartey, M; Fleet, JL; Knoll, GA; Kim, SJ; Garg, AX; Jain, AK				Shah, Sachin; McArthur, Eric; Farag, Alexandra; Nartey, Michael; Fleet, Jamie L.; Knoll, Greg A.; Kim, S. Joseph; Garg, Amit X.; Jain, Arsh K.			Risk of Hospitalization for Community Acquired Pneumonia with Renin-Angiotensin Blockade in Elderly Patients: A Population-Based Study	PLOS ONE			English	Article							CONVERTING-ENZYME-INHIBITORS; RECEPTOR BLOCKERS; ACE-INHIBITOR; COUGH; METAANALYSIS; MORTALITY; REFLEX	Objective: To characterize the 90-day risk of hospitalization with pneumonia among patients treated with different antihypertensive drug classes. Design: Population based cohort study using five linked databases. Participants: Individuals over the age of 65 who filled a new outpatient prescription for one of four anti-hypertensive medications: ACE inhibitors (n = 86 775), ARBs (n = 33 953), calcium channel blockers (CCB, n = 34 240), beta blockers (BB, n = 35 331) and thiazide diuretics (n = 64 186). Primary Outcome: Hospitalization with pneumonia within 90 days of a qualifying prescription. We adjusted for ten a priori selected covariates, including age, sex, diabetes and number of visits to a family doctor. Results: Baseline characteristics of the groups were relatively well matched, except for age, sex, diabetes and frequency of family doctor visits. 128 of the 86 775 patients (0.15%) initiated on an ACE inhibitor and 43 of the 33953 patients (0.13%) of patients initiated on an ARB were hospitalized with pneumonia in the subsequent 90 days. 135 of 64 186 patients (0.21%) initiated on a thiazide, 112 of 35 331 patients (.32%) initiated on a BB, and 89 of 34 240 (0.26%) patients initiated on a CCB achieved the primary outcome. Compared to calcium channel blockers, ACE inhibitors (adjusted OR 0.61, 95% CI 0.46 to 0.81) and ARBs (adjusted OR 0.52, 95% CI 0.36 to 0.76) were associated with a lower risk of pneumonia. No benefit was seen with thiazides (adjusted OR 0.87, 95% CI 0.66 to 1.14) or beta blockers (adjusted OR 1.21, 95% CI 0.91 to 1.60). Conclusion: Initiating medications that block the renin angiotensin system, compared to other anti-hypertensive medications, is associated with a small absolute reduction in the 90 day risk of hospitalization with pneumonia.	[Shah, Sachin; Farag, Alexandra; Nartey, Michael; Fleet, Jamie L.; Garg, Amit X.; Jain, Arsh K.] Univ Western Ontario, Dept Med, Div Nephrol, London, ON, Canada; [Garg, Amit X.; Jain, Arsh K.] Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada; [McArthur, Eric; Garg, Amit X.; Jain, Arsh K.] Inst Clin Evaluat Sci, London, ON, Canada; [Knoll, Greg A.] Univ Ottawa, Ottawa Hosp Res Inst, Kidney Res Ctr, Div Nephrol, Ottawa, ON, Canada; [Kim, S. Joseph] Univ Toronto, Toronto Gen Hosp, Univ Hlth Network, Div Nephrol, Toronto, ON M5G 1L7, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Jain, AK (corresponding author), Univ Western Ontario, Dept Med, Div Nephrol, London, ON, Canada.	arsh.jain@lhsc.on.ca	Jain, Arsh/G-3308-2011; Fleet, Jamie L/GYJ-7373-2022; Garg, Amit X/G-3295-2011	Knoll, Greg/0000-0001-5442-9310; Fleet, Jamie/0000-0002-9468-0697	Ontario Ministry of Health and Long-term Care; Academic Medical Organization of Southwestern Ontario	Ontario Ministry of Health and Long-term Care(Ministry of Health and Long-Term Care, Ontario); Academic Medical Organization of Southwestern Ontario	This project was conducted at the Institute for Clinical Evaluative Sciences (ICES) Western Site. ICES is funded by an annual grant from the Ontario Ministry of Health and Long-term Care. ICES@Western is funded by an operating grant from the Academic Medical Organization of Southwestern Ontario. Dr. Jain receives unrestricted grant support from the Academic Medical Organization of Southwestern Ontario. The opinions, results and conclusions reported in this paper are those of the authors and are independent of the funding sources. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almirall J, 1999, EUR RESPIR J, V13, P349, DOI 10.1183/09031936.99.13234999; Arai T, 2001, CHEST, V119, P660, DOI 10.1378/chest.119.2.660; Asadi L, 2012, CLIN INFECT DIS, V55, P371, DOI 10.1093/cid/cis414; Austin PC, 2009, COMMUN STAT-SIMUL C, V38, P1228, DOI 10.1080/03610910902859574; Caldeira D, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4260; Etminan M, 2006, PHARMACOTHERAPY, V26, P479, DOI 10.1592/phco.26.4.479; Fox AJ, 1996, NAT MED, V2, P814, DOI 10.1038/nm0796-814; Gonzalez NC, 2007, AM J PHYSIOL-HEART C, V292, pH2285, DOI 10.1152/ajpheart.00981.2006; Hagiwara S, 2009, CRIT CARE MED, V37, P626, DOI 10.1097/CCM.0b013e3181958d91; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; Joffe MM, 1998, STAT MED, V17, P2233, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2233::AID-SIM922>3.0.CO;2-0; Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67; Mamdani M, 2005, BMJ-BRIT MED J, V330, P960, DOI 10.1136/bmj.330.7497.960; Marik PE, 2003, CHEST, V124, P328, DOI 10.1378/chest.124.1.328; Marrie TJ, 2000, CLIN INFECT DIS, V31, P1066, DOI 10.1086/318124; MORICE AH, 1987, LANCET, V2, P1116; Mukamal KJ, 2010, J HYPERTENS, V28, P401, DOI 10.1097/HJH.0b013e3283330948; Nahmod KA, 2013, CLIN INFECT DIS, V56, P1193, DOI 10.1093/cid/cit007; Nakayama K, 1998, CHEST, V113, P1425, DOI 10.1378/chest.113.5.1425; Ohkubo T, 2004, AM J RESP CRIT CARE, V169, P1041, DOI 10.1164/rccm.200309-1219OC; Okaishi K, 1999, AM J HYPERTENS, V12, P778, DOI 10.1016/S0895-7061(99)00035-7; Sekizawa K, 1998, LANCET, V352, P1069, DOI 10.1016/S0140-6736(05)60114-6; Tomaki M, 1996, THORAX, V51, P199, DOI 10.1136/thx.51.2.199; Vinogradova Y, 2009, BRIT J GEN PRACT, V59, P742, DOI 10.3399/bjgp09X472629; Yusuf S, 2000, NEW ENGL J MED, V342, P145	25	19	19	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2014	9	10							e110165	10.1371/journal.pone.0110165	http://dx.doi.org/10.1371/journal.pone.0110165			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8TG	25353172	gold, Green Published, Green Submitted			2023-01-03	WOS:000345204200016
J	Salerno, M; Avnet, S; Bonuccelli, G; Hosogi, S; Granchi, D; Baldini, N				Salerno, Manuela; Avnet, Sofia; Bonuccelli, Gloria; Hosogi, Shigekuni; Granchi, Donatella; Baldini, Nicola			Impairment of Lysosomal Activity as a Therapeutic Modality Targeting Cancer Stem Cells of Embryonal Rhabdomyosarcoma Cell Line RD	PLOS ONE			English	Article							SIDE POPULATION CELLS; ACRIDINE-ORANGE; V-ATPASE; ACIDIC VESICLES; P-GLYCOPROTEIN; IDENTIFICATION; EXPRESSION; RESISTANCE; TUMORS; AXIS	Rhabdomyosarcoma is the most frequent soft tissue sarcoma in children and adolescents, with a high rate of relapse that dramatically affects the clinical outcome. Multiagent chemotherapy, in combination with surgery and/or radiation therapy, is the treatment of choice. However, the relapse rate is disappointingly high and identification of new therapeutic tools is urgently needed. Under this respect, the selective block of key features of cancer stem cells (CSC) appears particularly promising. In this study, we isolated rhabdomyosarcoma CSC with stem-like features (high expression of NANOG and OCT3/4, self-renewal ability, multipotency). Rhabdomyosarcoma CSC showed higher invasive ability and a reduced cytotoxicity to doxorubicin in comparison to native cells, through a mechanism unrelated to the classical multidrug resistance process. This was dependent on a high level of lysosome acidity mediated by a high expression of vacuolar ATPase (V-ATPase). Since it was not associated with other paediatric cancers, like Ewing's sarcoma and neuroblastoma, V-ATPase higher expression in CSC was rhabdomyosarcoma specific. Inhibition of lysosomal acidification by the V-ATPase inhibitor omeprazole, or by specific siRNA silencing, significantly enhanced doxorubicin cytoxicity. Unexpectedly, lysosomal targeting also blocked cell growth and reduced the invasive potential of rhabdomyosarcoma CSC, even at very low doses of omeprazole (10 and 50 mu M, respectively). Based on these observations, we propose lysosome acidity as a valuable target to enhance chemosensitivity of rhabdomyosarcoma CSC, and suggest the use of anti-V-ATPase agents in combination with standard regimens as a promising tool for the eradication of minimal residual disease or the prevention of metastatic disease.	[Salerno, Manuela; Avnet, Sofia; Bonuccelli, Gloria; Hosogi, Shigekuni; Granchi, Donatella; Baldini, Nicola] Ist Ortoped Rizzoli, Orthopaed Pathophysiol & Regenerat Med Unit, Bologna, Italy; [Salerno, Manuela; Bonuccelli, Gloria; Baldini, Nicola] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy; [Hosogi, Shigekuni] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Cell Physiol, Kyoto, Japan	IRCCS Istituto Ortopedico Rizzoli; University of Bologna; Kyoto Prefectural University of Medicine	Salerno, M (corresponding author), Ist Ortoped Rizzoli, Orthopaed Pathophysiol & Regenerat Med Unit, Bologna, Italy.	manuela.salerno@ior.it	Baldini, Nicola/J-4806-2016; Granchi, Donatella/ABD-5402-2021; Granchi, Donatella/J-3647-2016; Avnet, Sofia/B-3220-2018	Baldini, Nicola/0000-0003-2228-3833; Granchi, Donatella/0000-0001-7225-0023; Avnet, Sofia/0000-0002-7843-0591; Bonuccelli, Gloria/0000-0001-7576-5508	FIRB from the Italian Ministry of Education, University and Research [RBAP10447J]; Italian Association for Cancer Research [AIRC 11426]; Italian Ministry of the Health	FIRB from the Italian Ministry of Education, University and Research; Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of the Health(Ministry of Health, Italy)	This work was supported by a FIRB grant (RBAP10447J to N.B.) from the Italian Ministry of Education, University and Research; from the Italian Association for Cancer Research (AIRC 11426 to N.B.); and by the Italian Ministry of the Health, Financial Support for Scientific Research "5 per mille 2010". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adhikari AS, 2010, CANCER RES, V70, P4602, DOI 10.1158/0008-5472.CAN-09-3463; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Avnet S, 2013, BBA-MOL BASIS DIS, V1832, P1105, DOI 10.1016/j.bbadis.2013.04.003; BALDINI N, 1995, NEW ENGL J MED, V333, P1380, DOI 10.1056/NEJM199511233332103; BALDINI N, 1992, J CANCER RES CLIN, V119, P121, DOI 10.1007/BF01209668; Bell C, 2013, CELL BIOCHEM BIOPHYS, V66, P499, DOI 10.1007/s12013-012-9497-0; Castino R, 2003, J MOL RECOGNIT, V16, P337, DOI 10.1002/jmr.643; Cyranoski D, 2014, NATURE, V505, P596, DOI 10.1038/505596a; De Milito A, 2007, CANCER RES, V67, P5408, DOI 10.1158/0008-5472.CAN-06-4095; Deleyrolle LP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015844; Domanska UM, 2013, EUR J CANCER, V49, P219, DOI 10.1016/j.ejca.2012.05.005; Ghiaur G, 2012, STEM CELLS, V30, P89, DOI 10.1002/stem.769; Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394; Glunde K, 2003, NEOPLASIA, V5, P533, DOI 10.1016/S1476-5586(03)80037-4; Guan JL, 2013, AUTOPHAGY, V9, P830, DOI 10.4161/auto.24132; Jefferies KC, 2008, ARCH BIOCHEM BIOPHYS, V476, P33, DOI 10.1016/j.abb.2008.03.025; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Komuro H, 2007, J PEDIATR SURG, V42, P2040, DOI 10.1016/j.jpedsurg.2007.08.026; Kusuzaki K, 2000, ANTICANCER RES, V20, P965; Kusuzaki K, 2007, IN VIVO, V21, P205; Kusuzaki K, 2012, CURR PHARM DESIGN, V18, P1414, DOI 10.2174/138161212799504812; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Libura J, 2002, BLOOD, V100, P2597, DOI 10.1182/blood-2002-01-0031; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Long HX, 2012, STEM CELLS, V30, P2309, DOI 10.1002/stem.1194; Luciani F, 2004, JNCI-J NATL CANCER I, V96, P1702, DOI 10.1093/jnci/djh305; Mahoney BP, 2003, BIOCHEM PHARMACOL, V66, P1207, DOI 10.1016/S0006-2952(03)00467-2; Millot C, 1997, J HISTOCHEM CYTOCHEM, V45, P1255, DOI 10.1177/002215549704500909; MORIYAMA Y, 1993, BIOCHEM BIOPH RES CO, V196, P699, DOI 10.1006/bbrc.1993.2306; Murase M, 2009, BRIT J CANCER, V101, P1425, DOI 10.1038/sj.bjc.6605330; Nakanishi H, 1997, J CANCER RES CLIN, V123, P352, DOI 10.1007/BF01438312; Ndolo RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049366; Ognjanovic S, 2009, CANCER-AM CANCER SOC, V115, P4218, DOI 10.1002/cncr.24465; Perut F, 2014, EXP CELL RES, V320, P21, DOI 10.1016/j.yexcr.2013.10.011; Raghunand N, 1999, BIOCHEM PHARMACOL, V57, P1047, DOI 10.1016/S0006-2952(99)00021-0; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Roncuzzi L, 2014, ONCOL REP, V32, P389, DOI 10.3892/or.2014.3181; Sakhrani NM, 2013, DRUG DES DEV THER, V7, P585, DOI 10.2147/DDDT.S45614; Salerno M, 2013, INT J ONCOL, V43, P95, DOI 10.3892/ijo.2013.1927; Singh SK, 2003, CANCER RES, V63, P5821; Spugnini EP, 2010, J EXP CLIN CANC RES, V8, P29; Stiller CA, 2004, ONCOGENE, V23, P6429, DOI 10.1038/sj.onc.1207717; Strahm B, 2008, CLIN EXP METASTAS, V25, P1, DOI 10.1007/s10585-007-9094-6; Suva ML, 2009, CANCER RES, V69, P1776, DOI 10.1158/0008-5472.CAN-08-2242; Swietach P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035949; Tirino V, 2011, FASEB J, V25, P2022, DOI 10.1096/fj.10-179036; Walter D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019506; Wang L, 2009, CANCER BIOL THER, V8, P543, DOI 10.4161/cbt.8.6.7695; You HY, 2009, CANCER LETT, V280, P110, DOI 10.1016/j.canlet.2009.02.023	50	40	42	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2014	9	10							e110340	10.1371/journal.pone.0110340	http://dx.doi.org/10.1371/journal.pone.0110340			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0AY	25329465	Green Published, Green Submitted, gold			2023-01-03	WOS:000343942100055
J	Fan, XG; Huang, R; Wang, J; Ye, HJ; Guo, QY; Yi, CY; Lin, JX; Zhou, Q; Shao, FM; Yu, XQ; Yang, X				Fan, Xiaoguang; Huang, Rong; Wang, Juan; Ye, Hongjian; Guo, Qunying; Yi, Chunyan; Lin, Jianxiong; Zhou, Qian; Shao, Fengmin; Yu, Xueqing; Yang, Xiao			Risk Factors for the First Episode of Peritonitis in Southern Chinese Continuous Ambulatory Peritoneal Dialysis Patients	PLOS ONE			English	Article							FAILURE; IMPACT; OUTCOMES; COHORT; RATES	Background: The first episode of peritonitis affects survival of the peritoneal membrane as a medium for dialysis as well as survival of patients. The aim of this study is to investigate risk factors associated with the first episode of peritonitis in Southern Chinese continuous ambulatory peritoneal dialysis (CAPD) patients. Methods: This is a single-center, retrospective, cohort study. All incident CAPD patients from 1 January 2006 to 31 December 2010 were recruited, and followed up until their first episode of peritonitis or 31 December, 2012. Baseline demographic, socioeconomic, clinical and laboratory data were collected. Cox proportional model was used to determine the factors associated with the first episode of peritonitis. Results: In a cumulative 30756.5 patient-months follow-up (the median vintage 26.1 months) of 1117 CAPD patients, 309(27.7%) patients presented the first episodes of peritonitis. The cumulative peritonitis-free survival was 86.2%, 78.1%, 71.4% and 57.8% at 1, 2, 3 and 5 year, respectively. The multivariate analysis showed that factors associated with risk for the first episode of peritonitis were elderly patients (>65 years) [hazard ratio (HR) = 1.427, 95% confidence interval (CI) = 1.051 to 1.938, P = 0.023], male(HR = 1.315, 95% CI = 1.028 to 1.684, P = 0.030), lower education level (HR = 1.446, 95% CI: 1.127 to 1.855, P = 0.004) and albumin <38g/L (HR = 1.425, 95% CI: 1.112 to 1.825, P = 0.005). Conclusions: Older age, male, lower educational level and hypoalbuminemia at the commencement of PD were the risk factors associated with the first episode of peritonitis in Southern Chinese CAPD patients.	[Fan, Xiaoguang; Huang, Rong; Wang, Juan; Ye, Hongjian; Guo, Qunying; Yi, Chunyan; Lin, Jianxiong; Zhou, Qian; Yu, Xueqing; Yang, Xiao] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Nephrol, Guangzhou 510275, Guangdong, Peoples R China; [Huang, Rong; Wang, Juan; Ye, Hongjian; Guo, Qunying; Zhou, Qian; Yu, Xueqing; Yang, Xiao] Minist Hlth, Key Lab Nephrol, Guangzhou, Guangdong, Peoples R China; [Fan, Xiaoguang; Shao, Fengmin] Zhengzhou Univ, Peoples Hosp, Dept Nephrol, Zhengzhou 450052, Peoples R China	Sun Yat Sen University; Zhengzhou University	Yang, X (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Nephrol, Guangzhou 510275, Guangdong, Peoples R China.	yangxsysu@126.com	ye, hongjian/ABE-3294-2021; Lin, Jianxiong/AAX-6379-2020	Qian, Zhou/0000-0003-3954-5449; Yang, Xiao/0000-0003-0437-2015	U.S Baxter's Renal Discoveries Extramural Grant Program, Key Clinical Program of the Ministry of Health of China [2010439]; National Basic Research Program of China [2011CB504000]; National Key Technology RD Program [2011BAI10B08]	U.S Baxter's Renal Discoveries Extramural Grant Program, Key Clinical Program of the Ministry of Health of China; National Basic Research Program of China(National Basic Research Program of China); National Key Technology RD Program(National Key Technology R&D Program)	This study is supported by the U.S Baxter's Renal Discoveries Extramural Grant Program, Key Clinical Program of the Ministry of Health of China (2010439); the National Basic Research Program of China (Grant No 2011CB504000) and the National Key Technology R&D Program (No. 2011BAI10B08). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bastos KD, 2011, CLIN J AM SOC NEPHRO, V6, P1676, DOI 10.2215/CJN.09041010; Brown MC, 2011, PERITON DIALYSIS INT, V31, P639, DOI 10.3747/pdi.2010.00185; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chern YB, 2013, PERITON DIALYSIS INT, V33, P552, DOI 10.3747/pdi.2012.00065; Chow KM, 2005, NEPHROL DIAL TRANSPL, V20, P2504, DOI 10.1093/ndt/gfi061; Chow KM, 2005, PERITON DIALYSIS INT, V25, P374; Guo QY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053294; Hsieh YP, 2014, PERITON DIALYSIS INT, V34, P85, DOI 10.3747/pdi.2012.00075; Kotsanas D, 2007, NEPHROLOGY, V12, P239, DOI 10.1111/j.1440-1797.2006.00756.x; Li PKT, 2010, PERITON DIALYSIS INT, V30, P393, DOI 10.3747/pdi.2010.00049; Lim WH, 2005, NEPHROLOGY, V10, P192, DOI 10.1111/j.1440-1797.2005.00374.x; Martin LC, 2011, CLIN J AM SOC NEPHRO, V6, P1944, DOI 10.2215/CJN.11431210; Oo TN, 2005, AM J KIDNEY DIS, V45, P372, DOI 10.1053/j.ajkd.2004.10.008; Portoles J, 2013, NEFROLOGIA, V33, P316, DOI 10.3265/Nefrologia.pre2013.Feb.11733; Remon C, 2006, NEFROLOGIA, V26, P45; Wang Q, 2003, AM J KIDNEY DIS, V41, P664, DOI 10.1053/ajkd.2003.50128; Woodrow G, 1997, PERITON DIALYSIS INT, V17, P360; Yang X, 2013, DIABETES RES CLIN PR, V100, P354, DOI 10.1016/j.diabres.2013.03.030	18	29	35	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2014	9	9							e107485	10.1371/journal.pone.0107485	http://dx.doi.org/10.1371/journal.pone.0107485			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AP0SR	25222609	Green Published, Green Submitted, gold			2023-01-03	WOS:000341774800075
J	Annas, GJ				Annas, George J.			Medical Marijuana, Physicians, and State Law	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA.							Annas GJ, 1997, NEW ENGL J MED, V337, P435, DOI 10.1056/NEJM199708073370621; [Anonymous], 2014, NY TIMES; Cole JM, 2013, GUIDANCE REGARDING M; Kassirer JP, 1997, NEW ENGL J MED, V336, P366, DOI 10.1056/NEJM199701303360509	4	19	20	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 11	2014	371	11					983	985		10.1056/NEJMp1408965	http://dx.doi.org/10.1056/NEJMp1408965			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AO5KD	25099473				2023-01-03	WOS:000341382800002
J	Eisenstein, M				Eisenstein, Michael			Special treatment	NATURE			English	Editorial Material							LUNG CANCERS; MUTATIONS											Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Drilon A, 2013, CANCER DISCOV, V3, P630, DOI 10.1158/2159-8290.CD-13-0035; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Shaw AT, 2014, NEW ENGL J MED, V370, P2537, DOI 10.1056/NEJMc1404894	8	13	13	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2014	513	7517					S8	S9		10.1038/513S8a	http://dx.doi.org/10.1038/513S8a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO5DP	25208073	Bronze			2023-01-03	WOS:000341362800005
J	Li, Q; Liu, M; Ma, F; Luo, Y; Cai, RG; Wang, LM; Xu, NZ; Xu, BH				Li, Qian; Liu, Mei; Ma, Fei; Luo, Yang; Cai, Ruigang; Wang, Liming; Xu, Ningzhi; Xu, Binghe			Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel	PLOS ONE			English	Article							MICRORNA EXPRESSION; PROGNOSTIC-SIGNIFICANCE; ADJUVANT CHEMOTHERAPY; IDENTIFICATION; RESISTANCE; CELLS; GENE; TRASTUZUMAB; PATHWAY; MARKERS	Background: The luminal A subtype of breast cancer has a good prognosis and is sensitive to endocrine therapy but is less sensitive to chemotherapy. It is necessary to identify biomarkers to predict chemosensitivity and avoid over-treatment. We hypothesized that miRNAs in the serum might be associated with chemosensitivity. Methods: Sixty-eight breast cancer patients received neoadjuvant chemotherapy with epirubicin plus paclitaxel. The serum of the patients was collected before chemotherapy and stored at -80 degrees C. The samples were classified into two groups in term of the chemosensitivity. We identified the differential expression patterns of miRNAs between the chemotherapy sensitive and resistant groups using microRNA profiling. Four miRNAs that were differentially expressed between the two groups were further validated in another 56 samples. We created a model fitting formula and a receiver operating characteristics (ROC) curve using logistic regression analysis to evaluate the prediction potency. Results: We identified 8 miRNAs differentially expressed between the two groups: 6 miRNAs were up-regulated, and 2 miRNAs were down-regulated in the resistant group compared with the sensitive group. The expression of miR-19a and miR-205 were determined to have significant differences between the two groups (P<0.05). A predictive model of these two miRNAs was created by the logistic regression analysis. The probability of this model was 89.71%. Based on the ROC curve, the specificity was 75.00%, and the sensitivity was 81.25%. Conclusions: The combination of miR-19a and miR-205 in the serum may predict the chemosensitivity of luminal A subtype of breast cancer to epirubicin plus paclitaxel neoadjuvant chemotherapy.	[Li, Qian; Ma, Fei; Luo, Yang; Cai, Ruigang; Xu, Binghe] Chinese Acad Med Sci, Inst Canc, Dept Med Oncol, Beijing 100021, Peoples R China; [Li, Qian; Liu, Mei; Ma, Fei; Luo, Yang; Cai, Ruigang; Wang, Liming; Xu, Ningzhi; Xu, Binghe] Chinese Acad Med Sci, Canc Hosp, Beijing 100021, Peoples R China; [Li, Qian; Liu, Mei; Ma, Fei; Luo, Yang; Cai, Ruigang; Wang, Liming; Xu, Ningzhi; Xu, Binghe] Peking Union Med Coll, Beijing 100021, Peoples R China; [Liu, Mei; Xu, Ningzhi] Chinese Acad Med Sci, Inst Canc, Lab Cell & Mol Biol, Beijing 100021, Peoples R China; [Liu, Mei; Xu, Ningzhi] Chinese Acad Med Sci, Inst Canc, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; [Wang, Liming] Chinese Acad Med Sci, Inst Canc, Dept Abdominal Surg, Beijing 100021, Peoples R China; [Li, Qian] Peking Univ, Hosp 3, Dept Tumor Chemotherapy & Radiat Sickness, Beijing 100871, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking University	Xu, BH (corresponding author), Chinese Acad Med Sci, Inst Canc, Dept Med Oncol, Beijing 100021, Peoples R China.	bhxu@hotmail.com	Wang, Liming/AAD-7697-2020; Cai, Rui/GRO-1869-2022	Ma, Fei/0000-0001-9432-1902; li, qian/0000-0002-7204-0429	National Natural Science Foundation [81372830]; Beijing Hope Run Special Fund [LC2013L09]; Capital Clinical Feature Applied Research Fund [Z141107002514010]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Beijing Hope Run Special Fund; Capital Clinical Feature Applied Research Fund	This work was supported by National Natural Science Foundation grant (81372830), Beijing Hope Run Special Fund (LC2013L09) and Capital Clinical Feature Applied Research Fund (Z141107002514010). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bhargava R, 2010, CANCER-AM CANCER SOC, V116, P1431, DOI 10.1002/cncr.24876; Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Choi BH, 2008, CANCER LETT, V259, P111, DOI 10.1016/j.canlet.2007.10.003; Coates AS, 2012, J CLIN ONCOL, V30, P1260, DOI 10.1200/JCO.2011.37.7879; Farazi TA, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-1-r9; Godfrey AC, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3428; Hayes DF, 2012, J CLIN ONCOL, V30, P1264, DOI 10.1200/JCO.2011.38.4529; Healy NA, 2012, INT J CANCER, V131, P2215, DOI 10.1002/ijc.27642; Hu XW, 2013, MOL CANCER RES, V11, P240, DOI 10.1158/1541-7786.MCR-12-0432; Hu ZB, 2012, CARCINOGENESIS, V33, P828, DOI 10.1093/carcin/bgs030; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jung EJ, 2012, CANCER-AM CANCER SOC, V118, P2603, DOI 10.1002/cncr.26565; Kutanzi KR, 2011, CLIN EPIGENETICS, V2, P171, DOI 10.1007/s13148-011-0040-8; Le Quesne J, 2012, J PATHOL, V227, P306, DOI 10.1002/path.3983; Lee JT, 2004, CANCER RES, V64, P8397, DOI 10.1158/0008-5472.CAN-04-1612; Liang ZX, 2011, PHARM RES-DORDR, V28, P3091, DOI 10.1007/s11095-011-0570-y; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Markou A, 2014, CLIN CHEM, V60, P197, DOI 10.1373/clinchem.2013.210542; Mo WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054775; Ogston KN, 2003, BREAST, V12, P320, DOI 10.1016/S0960-9776(03)00106-1; Peltier HJ, 2008, RNA, V14, P844, DOI 10.1261/rna.939908; Qi RQ, 2012, HEPATOLOGY, V55, P1640, DOI 10.1002/hep.25558; Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019; Sochor M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-448; Sun Y, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0032115, 10.1371/journal.pone.0047003]; Takada T, 2005, DRUG METAB DISPOS, V33, P905, DOI 10.1124/dmd.104.003228; von Minckwitz G, 2013, CURR OPIN OBSTET GYN, V25, P66, DOI 10.1097/GCO.0b013e32835c0889; von Minckwitz G, 2011, BREAST, V20, pS142, DOI 10.1016/S0960-9776(11)70312-5; Wang HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034210; Wu HL, 2009, CELL RES, V19, P439, DOI 10.1038/cr.2009.18; Yao YS, 2014, ONCOL LETT, V7, P541, DOI 10.3892/ol.2013.1697; Ye XM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-134	32	50	53	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2014	9	8							e104870	10.1371/journal.pone.0104870	http://dx.doi.org/10.1371/journal.pone.0104870			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN6XM	25137071	gold, Green Published, Green Submitted			2023-01-03	WOS:000340742100050
J	Bundela, S; Sharma, A; Bisen, PS				Bundela, Saurabh; Sharma, Anjana; Bisen, Prakash S.			Potential Therapeutic Targets for Oral Cancer: ADM, TP53, EGFR, LYN, CTLA4, SKIL, CTGF, CD70	PLOS ONE			English	Article							EXPRESSION; RESISTANCE; THERAPIES; GENES	In India, oral cancer has consistently ranked among top three causes of cancer-related deaths, and it has emerged as a top cause for the cancer-related deaths among men. Lack of effective therapeutic options is one of the main challenges in clinical management of oral cancer patients. We interrogated large pool of samples from oral cancer gene expression studies to identify potential therapeutic targets that are involved in multiple cancer hallmark events. Therapeutic strategies directed towards such targets can be expected to effectively control cancer cells. Datasets from different gene expression studies were integrated by removing batch-effects and was used for downstream analyses, including differential expression analysis. Dependency network analysis was done to identify genes that undergo marked topological changes in oral cancer samples when compared with control samples. Causal reasoning analysis was carried out to identify significant hypotheses, which can explain gene expression profiles observed in oral cancer samples. Text-mining based approach was used to detect cancer hallmarks associated with genes significantly expressed in oral cancer. In all, 2365 genes were detected to be differentially expressed genes, which includes some of the highly differentially expressed genes like matrix metalloproteinases (MMP-1/3/10/13), chemokine (C-X-C motif) ligands (IL8, CXCL-10/-11), PTHLH, SERPINE1, NELL2, S100A7A, MAL, CRNN, TGM3, CLCA4, keratins (KRT-3/4/13/76/78), SERPINB11 and serine peptidase inhibitors (SPINK-5/7). XIST, TCEAL2, NRAS and FGFR2 are some of the important genes detected by dependency and causal network analysis. Literature mining analysis annotated 1014 genes, out of which 841 genes were statistically significantly annotated. The integration of output of various analyses, resulted in the list of potential therapeutic targets for oral cancer, which included targets such as ADM, TP53, EGFR, LYN, CTLA4, SKIL, CTGF and CD70.	[Bundela, Saurabh; Bisen, Prakash S.] Govt India, Def Res Dev Estab, Def Res Dev Org, Minist Def, Gwalior, Madhya Pradesh, India; [Bundela, Saurabh; Sharma, Anjana] Rani Durgavati Univ, Dept Postgrad Studies & Res Biol Sci, Jabalpur 482001, Madhya Pradesh, India; [Bisen, Prakash S.] Jiwaji Univ, Sch Studies Biotechnol, Gwalior, Madhya Pradesh, India	Defence Research & Development Organisation (DRDO); Defence Research & Development Establishment (DRDE); Jiwaji University Gwalior	Bisen, PS (corresponding author), Govt India, Def Res Dev Estab, Def Res Dev Org, Minist Def, Gwalior, Madhya Pradesh, India.	psbisen@gmail.com	Bisen, Prakash S/H-3392-2019	Bisen, Prakash S/0000-0002-2818-7829	Council of Scientific and Industrial Research (CSIR), New Delhi under Emeritus Scientist scheme	Council of Scientific and Industrial Research (CSIR), New Delhi under Emeritus Scientist scheme	Financial assistance was awarded by the Council of Scientific and Industrial Research (CSIR), New Delhi under Emeritus Scientist scheme to Professor P.S. Bisen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambatipudi S, 2012, GENE CHROMOSOME CANC, V51, P161, DOI 10.1002/gcc.20940; Awada A, 2013, CURR OPIN ONCOL, V25, P296, DOI 10.1097/CCO.0b013e32835ff318; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bisen P.S., 2013, BIOL ORAL CANC KEY A; Bonferroni C.E., 1935, STUDI ONORE PROFESSO, P13; Bonferroni CE, 1936, PUBBLICAZIONI R I SU, V8, P3; Chen X, 2002, NUCLEIC ACIDS RES, V30, P412, DOI 10.1093/nar/30.1.412; Chindelevitch L, 2012, BIOINFORMATICS, V28, P1114, DOI 10.1093/bioinformatics/bts090; Dikshit R, 2012, LANCET, V379, P1807, DOI 10.1016/S0140-6736(12)60358-4; Ding J, 2002, Pac Symp Biocomput, P326; Ellis LM, 2009, CLIN CANCER RES, V15, P7471, DOI 10.1158/1078-0432.CCR-09-1070; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fisher R., 1970, STAT METHODS RES WOR; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hoaglin D. C., 2000, UNDERSTANDING ROBUST; Hubbell E, 2002, BIOINFORMATICS, V18, P1585, DOI 10.1093/bioinformatics/18.12.1585; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jeanmougin M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012336; Jenssen TK, 2001, NAT GENET, V28, P21, DOI 10.1038/88213; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Lackner MR, 2012, FUTURE ONCOL, V8, P999, DOI [10.2217/fon.12.86, 10.2217/FON.12.86]; Mittal AK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070352; Pearson H, 2001, NATURE, V411, P631, DOI 10.1038/35079694; Peng CH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023452; Pickering CR, 2013, CANCER DISCOV, V3, P770, DOI 10.1158/2159-8290.CD-12-0537; Raffoul F, 2010, AUTOPHAGY, V6, P955, DOI 10.4161/auto.6.7.13041; Ramasamy A, 2008, PLOS MED, V5, P1320, DOI 10.1371/journal.pmed.0050184; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Rudy J, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-467; Sayers E, 2014, NCBI SHORT COURSES; Schafer J, 2005, BIOINFORMATICS, V21, P754, DOI 10.1093/bioinformatics/bti062; Shabalin AA, 2008, BIOINFORMATICS, V24, P1154, DOI 10.1093/bioinformatics/btn083; Smyth GK., 2004, STAT APPL GENET MOL, V3, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Aoki Kiyoko F, 2005, Curr Protoc Bioinformatics, VChapter 1, DOI [10.1002/0471250953.bi0112s38, 10.1002/0471250953.bi0112s11]; Turnbull AK, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-35; Warnes GR, 2006, SAMPLE SIZE ESTIMATI; Wheeler SE, 2012, CLIN CANCER RES, V18, P2850, DOI 10.1158/1078-0432.CCR-11-2486; Xu C, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-143; Yildirim MA, 2007, NAT BIOTECHNOL, V25, P1119, DOI 10.1038/nbt1338	39	24	28	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2014	9	7							e102610	10.1371/journal.pone.0102610	http://dx.doi.org/10.1371/journal.pone.0102610			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4KM	25029526	Green Submitted, Green Published, gold			2023-01-03	WOS:000341306600087
J	Naude, CE; Schoonees, A; Senekal, M; Young, T; Garner, P; Volmink, J				Naude, Celeste E.; Schoonees, Anel; Senekal, Marjanne; Young, Taryn; Garner, Paul; Volmink, Jimmy			Low Carbohydrate versus Isoenergetic Balanced Diets for Reducing Weight and Cardiovascular Risk: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							LOW-FAT DIET; RANDOMIZED CONTROLLED-TRIAL; HIGH-MONOUNSATURATED-FAT; MEDITERRANEAN-STYLE DIET; ENERGY-RESTRICTED DIETS; CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; DENSITY-LIPOPROTEIN CHOLESTEROL; GLYCEMIC INDEX DIET; 2 HYPOCALORIC DIETS	Background: Some popular weight loss diets restricting carbohydrates (CHO) claim to be more effective, and have additional health benefits in preventing cardiovascular disease compared to balanced weight loss diets. Methods and Findings: We compared the effects of low CHO and isoenergetic balanced weight loss diets in overweight and obese adults assessed in randomised controlled trials (minimum follow-up of 12 weeks), and summarised the effects on weight, as well as cardiovascular and diabetes risk. Dietary criteria were derived from existing macronutrient recommendations. We searched Medline, EMBASE and CENTRAL (19 March 2014). Analysis was stratified by outcomes at 3-6 months and 1-2 years, and participants with diabetes were analysed separately. We evaluated dietary adherence and used GRADE to assess the quality of evidence. We calculated mean differences (MD) and performed random-effects meta-analysis. Nineteen trials were included (n = 3209); 3 had adequate allocation concealment. In non-diabetic participants, our analysis showed little or no difference in mean weight loss in the two groups at 3-6 months (MD 0.74 kg, 95% CI -1.49 to 0.01 kg; I-2 = 53%; n = 1745, 14 trials; moderate quality evidence) and 1-2 years (MD 0.48 kg, 95% CI -1.44 kg to 0.49 kg; I-2 = 12%; n = 1025; 7 trials, moderate quality evidence). Furthermore, little or no difference was detected at 3-6 months and 1-2 years for blood pressure, LDL, HDL and total cholesterol, triglycerides and fasting blood glucose (>914 participants). In diabetic participants, findings showed a similar pattern. Conclusions: Trials show weight loss in the short-term irrespective of whether the diet is low CHO or balanced. There is probably little or no difference in weight loss and changes in cardiovascular risk factors up to two years of follow-up when overweight and obese adults, with or without type 2 diabetes, are randomised to low CHO diets and isoenergetic balanced weight loss diets.	[Naude, Celeste E.; Schoonees, Anel; Young, Taryn; Volmink, Jimmy] Univ Stellenbosch, Fac Med & Hlth Sci, Ctr Evidence Based Hlth Care, Cape Town, South Africa; [Senekal, Marjanne] Univ Cape Town, Fac Hlth Sci, Dept Human Biol, Div Human Nutr, ZA-7925 Cape Town, South Africa; [Young, Taryn; Volmink, Jimmy] South African Med Res Council, South African Cochrane Ctr, Cape Town, South Africa; [Garner, Paul] Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Effect Hlth Care Res Consortium, Liverpool L3 5QA, Merseyside, England	Stellenbosch University; University of Cape Town; South African Medical Research Council; Liverpool School of Tropical Medicine; University of Liverpool	Naude, CE (corresponding author), Univ Stellenbosch, Fac Med & Hlth Sci, Ctr Evidence Based Hlth Care, Cape Town, South Africa.	cenaude@sun.ac.za	Garner, Paul/HII-5856-2022; Garner, Paul/Y-8385-2019; Senekal, Marjanne/ABG-1478-2021	Garner, Paul/0000-0002-0607-6941; Senekal, Marjanne/0000-0002-9427-2319; Young, Taryn/0000-0003-2406-081X; Schoonees, Anel/0000-0001-8989-6891; Naude, Celeste/0000-0002-9114-1452	Effective Health Care Research Consortium; South African Medical Research Council; Centre for Evidence-based Health Care (CEBHC); CEBHC; University of Cape Town; Stellenbosch University; South African Cochrane Centre; University of Liverpool; Evidence Building and Synthesis Research Consortium; Department for International Development (DFID) [201400] Funding Source: researchfish	Effective Health Care Research Consortium; South African Medical Research Council(South African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Centre for Evidence-based Health Care (CEBHC); CEBHC; University of Cape Town; Stellenbosch University; South African Cochrane Centre; University of Liverpool; Evidence Building and Synthesis Research Consortium; Department for International Development (DFID)	This review was funded by the Effective Health Care Research Consortium and the South African Medical Research Council. CN is funded by the Centre for Evidence-based Health Care (CEBHC) and the South African Medical Research Council. AS and TY are funded by CEBHC. MS is funded by University of Cape Town. JV is funded by Stellenbosch University and the South African Cochrane Centre. PG is funded by the University of Liverpool and the Evidence Building and Synthesis Research Consortium. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abegunde DO, 2007, LANCET, V370, P1929, DOI 10.1016/S0140-6736(07)61696-1; Abete I, 2009, INT J FOOD SCI NUTR, V60, P1, DOI 10.1080/09637480802232625; Al-Sarraj T, 2010, NUTR METAB CARDIOVAS, V20, P720, DOI 10.1016/j.numecd.2009.06.004; Al-Sarraj T, 2009, J NUTR, V139, P1667, DOI 10.3945/jn.109.109603; Alhassan S, 2008, INT J OBESITY, V32, P985, DOI 10.1038/ijo.2008.8; [Anonymous], 2012, CIRCULATION, V125, pAP306; de Luis DA, 2012, DIABETES-METAB RES, V28, P663, DOI 10.1002/dmrr.2323; Aquilani R, 1999, EUR HEART J, V20, P1020, DOI 10.1053/euhj.1999.1402; Ashton EL, 2000, J AM DIET ASSOC, V100, P537, DOI 10.1016/S0002-8223(00)00167-X; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Aude YW, 2004, ARCH INTERN MED, V164, P2141, DOI 10.1001/archinte.164.19.2141; Australian National Health and Medical Research Council (NHMRC), 2006, NUTR REF VAL AUSTR N; Avenell A, 2004, HEALTH TECHNOL ASSES, V8, P1; Baba NH, 1999, INT J OBESITY, V23, P1202, DOI 10.1038/sj.ijo.0801064; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Barnett J., 2009, ZONE DIET EXPLAINED; BARON JA, 1986, AM J PUBLIC HEALTH, V76, P1293, DOI 10.2105/AJPH.76.11.1293; Becker W., 2004, Scandinavian Journal of Nutrition, V48, P178, DOI 10.1080/1102680410003794; Belobrajdic DP, 2010, EUR J ENDOCRINOL, V162, P1075, DOI 10.1530/EJE-10-0062; Ben-Avraham S, 2009, DIABETES RES CLIN PR, V86, pS41, DOI 10.1016/S0168-8227(09)70008-7; Berglund L, 1999, AM J CLIN NUTR, V70, P992; Bowden RG, 2007, J AM COLL HEALTH, V56, P147, DOI 10.3200/JACH.56.2.147-152; Bradley U, 2009, DIABETES, V58, P2741, DOI 10.2337/db09-0098; Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480; Brehm BJ, 2009, DIABETES CARE, V32, P215, DOI 10.2337/dc08-0687; Brinkworth GD, 2004, DIABETOLOGIA, V47, P1677, DOI 10.1007/s00125-004-1511-7; Brinkworth GD, 2009, AM J CLIN NUTR, V90, P23, DOI 10.3945/ajcn.2008.27326; British Dietetic Association, 2013, WEIGHT WIS EAT WELL; Buscemi S, 2009, EUR J CLIN INVEST, V39, P339, DOI 10.1111/j.1365-2362.2009.02091.x; Camhi SM, 2010, OBESITY, V18, P548, DOI 10.1038/oby.2009.304; Campbell DD, 2012, BRIT J NUTR, V108, P1658, DOI 10.1017/S0007114511007215; Campbell WW, 2010, J GERONTOL A-BIOL, V65, P1115, DOI 10.1093/gerona/glq083; Carter JD, 2006, OSTEOPOROSIS INT, V17, P1398, DOI 10.1007/s00198-006-0134-x; Carty CL, 2011, AM J CLIN NUTR, V93, P516, DOI 10.3945/ajcn.110.006395; CHEN YDI, 1995, DIABETES CARE, V18, P10, DOI 10.2337/diacare.18.1.10; Clifton PM, 2008, AM J CLIN NUTR, V87, P23, DOI 10.1093/ajcn/87.1.23; Cohen JC, 2006, NEW ENGL J MED, V354, P1264, DOI 10.1056/NEJMoa054013; Daly ME, 2006, DIABETIC MED, V23, P15, DOI 10.1111/j.1464-5491.2005.01760.x; Dansinger ML, 2005, JAMA-J AM MED ASSOC, V293, P43, DOI 10.1001/jama.293.1.43; Das SK, 2007, AM J CLIN NUTR, V85, P1023, DOI 10.1093/ajcn/85.4.1023; Davis NJ, 2009, DIABETES CARE, V32, P1147, DOI 10.2337/dc08-2108; de Luis DA, 2007, HORM RES, V67, P296, DOI 10.1159/000099329; de Luis DA, 2009, J DIABETES COMPLICAT, V23, P239, DOI 10.1016/j.jdiacomp.2007.12.006; De Natale C, 2009, DIABETES CARE, V32, P2168, DOI 10.2337/dc09-0266; Delbridge EA, 2009, AM J CLIN NUTR, V90, P1203, DOI 10.3945/ajcn.2008.27209; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; Djuric Z, 2002, J AM COLL NUTR, V21, P38, DOI 10.1080/07315724.2002.10719192; Donnelly JE, 2008, OBESITY, V16, P107, DOI 10.1038/oby.2007.33; Douketis JD, 2005, INT J OBESITY, V29, P1153, DOI 10.1038/sj.ijo.0802982; Dreon DM, 1999, AM J CLIN NUTR, V69, P411; Due A, 2004, INT J OBESITY, V28, P1283, DOI 10.1038/sj.ijo.0802767; Due A, 2008, AM J CLIN NUTR, V87, P855, DOI 10.1093/ajcn/87.4.855; Dyson PA, 2007, DIABETIC MED, V24, P1430, DOI 10.1111/j.1464-5491.2007.02290.x; Dyson PA, 2010, DIABETIC MED, V27, P363, DOI 10.1111/j.1464-5491.2010.02926.x; Ebbeling CB, 2007, JAMA-J AM MED ASSOC, V297, P2092, DOI 10.1001/jama.297.19.2092; EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010, DIET REF VAL PARM; Egert S, 2011, EUR J NUTR, V50, P71, DOI 10.1007/s00394-010-0116-9; Elhayany A, 2010, DIABETES OBES METAB, V12, P204, DOI 10.1111/j.1463-1326.2009.01151.x; Erlinger TP, 2003, CIRCULATION, V108, P150, DOI 10.1161/01.CIR.0000080288.30567.86; Esposito K, 2004, JAMA-J AM MED ASSOC, V292, P1440, DOI 10.1001/jama.292.12.1440; Esposito K, 2009, ANN INTERN MED, V151, P306, DOI 10.7326/0003-4819-151-5-200909010-00004; Estruch R, 2009, J EPIDEMIOL COMMUN H, V63, P582, DOI 10.1136/jech.2008.082214; Estruch R, 2006, ANN INTERN MED, V145, P1, DOI 10.7326/0003-4819-145-1-200607040-00004; Evangelista LS, 2009, J CARDIOVASC NURS, V24, P207, DOI 10.1097/JCN.0b013e31819846b9; Fabricatore AN, 2011, DIABETES RES CLIN PR, V92, P37, DOI 10.1016/j.diabres.2010.12.016; Farnsworth E, 2003, AM J CLIN NUTR, V78, P31, DOI 10.1093/ajcn/78.1.31; Ference BA, 2012, J AM COLL CARDIOL, V60, P2631, DOI 10.1016/j.jacc.2012.09.017; Fito M, 2007, ARCH INTERN MED, V167, P1195, DOI 10.1001/archinte.167.11.1195; Flechtner-Mors M, 2010, DIABETES-METAB RES, V26, P393, DOI 10.1002/dmrr.1097; Fleming Richard M, 2002, Prev Cardiol, V5, P110, DOI 10.1111/j.1520-037X.2002.01231.x; Foster GD, 2010, ANN INTERN MED, V153, P147, DOI 10.7326/0003-4819-153-3-201008030-00005; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; Frisch S, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-36; Galani C, 2007, INT J PUBLIC HEALTH, V52, P348, DOI 10.1007/s00038-007-7015-8; Gardner CD, 2007, JAMA-J AM MED ASSOC, V297, P969, DOI 10.1001/jama.297.9.969; Gerhard GT, 2004, AM J CLIN NUTR, V80, P668; Glenton C, 2010, MED DECIS MAKING, V30, P566, DOI 10.1177/0272989X10375853; GRADE Working Group, 2004, GRADEPROFILER GRADEP; Greenberg I, 2009, J AM COLL NUTR, V28, P159, DOI 10.1080/07315724.2009.10719767; Groeneveld IF, 2010, SCAND J WORK ENV HEA, V36, P202, DOI 10.5271/sjweh.2891; Guay V, 2012, METABOLISM, V61, P76, DOI 10.1016/j.metabol.2011.06.002; Guldbrand H, 2012, DIABETOLOGIA, V55, P2118, DOI 10.1007/s00125-012-2567-4; Gulseth HL, 2010, BRIT J NUTR, V104, P160, DOI 10.1017/S0007114510000565; Hall KD, 2011, LANCET, V378, P826, DOI 10.1016/S0140-6736(11)60812-X; Halyburton AK, 2007, AM J CLIN NUTR, V86, P580, DOI 10.1093/ajcn/86.3.580; Hartwich J, 2009, CLIN NUTR, V28, P510, DOI 10.1016/j.clnu.2009.04.016; Haufe S, 2012, HYPERTENSION, V59, P70, DOI 10.1161/HYPERTENSIONAHA.111.178616; Haufe S, 2011, HEPATOLOGY, V53, P1504, DOI 10.1002/hep.24242; Hays NP, 2004, ARCH INTERN MED, V164, P210, DOI 10.1001/archinte.164.2.210; Higgins D, 2011, COCHRANE HDB SYSTEMA; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; HOCKADAY TDR, 1978, BRIT J NUTR, V39, P357, DOI 10.1079/BJN19780045; Hodson L, 2010, J HUM HYPERTENS, V24, P312, DOI 10.1038/jhh.2009.65; Holloway CJ, 2011, AM J CLIN NUTR, V93, P748, DOI 10.3945/ajcn.110.002758; Howard BV, 2010, AM J CLIN NUTR, V91, P860, DOI 10.3945/ajcn.2009.28034; Howard BV, 2006, JAMA-J AM MED ASSOC, V295, P655, DOI 10.1001/jama.295.6.655; Hoy MK, 2009, J AM DIET ASSOC, V109, P688, DOI 10.1016/j.jada.2008.12.016; Hu T, 2013, CIRCULATION, V127, pAP167; Hu T, 2013, CIRCULATION, V127, pAP166; Hu T, 2013, CIRCULATION, V127, pAP165; Institute of Medicine Food and Nutrition Board, 2002, DIET REF INT EN CARB; Iqbal N, 2005, Eur Rev Med Pharmacol Sci, V9, P161; Iqbal N, 2010, OBESITY, V18, P1733, DOI 10.1038/oby.2009.460; Jakobsen MU, 2010, AM J CLIN NUTR, V91, P1764, DOI 10.3945/ajcn.2009.29099; Jakobsen MU, 2009, AM J CLIN NUTR, V89, P1425, DOI 10.3945/ajcn.2008.27124; Jebb SA, 2010, AM J CLIN NUTR, V92, P748, DOI 10.3945/ajcn.2009.29096; Jenkins DJA, 2009, ARCH INTERN MED, V169, P1046, DOI 10.1001/archinternmed.2009.115; Jensen M.D., 2013, 2013 AHA ACC TOS GUI, V01; Jeppesen J, 1997, AM J CLIN NUTR, V65, P1027, DOI 10.1093/ajcn/65.4.1027; Jimenez-Gomez Y, 2010, J NUTR, V140, P1595, DOI 10.3945/jn.109.120816; Johnston CS, 2006, AM J CLIN NUTR, V83, P1055, DOI 10.1093/ajcn/83.5.1055; Johnston CS, 2004, J NUTR, V134, P586, DOI 10.1093/jn/134.3.586; Johnstone AM, 2011, BRIT J NUTR, V106, P282, DOI 10.1017/S0007114511000092; KASIM SE, 1993, AM J CLIN NUTR, V57, P146, DOI 10.1093/ajcn/57.2.146; Kasim-Karakas SE, 2009, FERTIL STERIL, V92, P262, DOI 10.1016/j.fertnstert.2008.05.065; Keogh JB, 2008, AM J CLIN NUTR, V87, P567, DOI 10.1093/ajcn/87.3.567; Keogh JB, 2007, BRIT J NUTR, V98, P852, DOI 10.1017/S0007114507747815; Kleiner Rima E, 2006, MedGenMed, V8, P39; Klemsdal TO, 2010, NUTR METAB CARDIOVAS, V20, P195, DOI 10.1016/j.numecd.2009.03.010; Knopp RH, 1997, JAMA-J AM MED ASSOC, V278, P1509, DOI 10.1001/jama.278.18.1509; Knopp RH, 2000, P SOC EXP BIOL MED, V225, P191, DOI 10.1046/j.1525-1373.2000.22524.x; KRAUSS RM, 1995, AM J CLIN NUTR, V62, p478S, DOI 10.1093/ajcn/62.2.478S; Krauss RM, 2006, AM J CLIN NUTR, V83, P1025, DOI 10.1093/ajcn/83.5.1025; Krebs JD, 2012, DIABETOLOGIA, V55, P905, DOI 10.1007/s00125-012-2461-0; Labayen Idoia, 2003, Forum Nutr, V56, P168; Lagiou P, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4026; Larsen RN, 2011, DIABETOLOGIA, V54, P731, DOI 10.1007/s00125-010-2027-y; Larsen TM, 2010, NEW ENGL J MED, V363, P2102, DOI 10.1056/NEJMoa1007137; Lasker DAW, 2008, NUTR METAB, V5, DOI 10.1186/1743-7075-5-30; Layman DK, 2005, J NUTR, V135, P1903, DOI 10.1093/jn/135.8.1903; Layman DK, 2003, J NUTR, V133, P411, DOI 10.1093/jn/133.2.411; Layman DK, 2009, J NUTR, V139, P514, DOI 10.3945/jn.108.099440; Lefevre M, 2005, AM J CLIN NUTR, V82, P957, DOI 10.1093/ajcn/82.5.957; Leidy HJ, 2007, OBESITY, V15, P421, DOI 10.1038/oby.2007.531; Lim SS, 2010, NUTR METAB CARDIOVAS, V20, P599, DOI 10.1016/j.numecd.2009.05.003; Lindeberg S, 2007, DIABETOLOGIA, V50, P1795, DOI 10.1007/s00125-007-0716-y; Louheranta AM, 2000, NUTR METAB CARDIOVAS, V10, P177; Luscombe ND, 2003, INT J OBESITY, V27, P582, DOI 10.1038/sj.ijo.0802270; Luscombe-Marsh ND, 2005, AM J CLIN NUTR, V81, P762, DOI 10.1093/ajcn/81.4.762; Mangravite LM, 2011, J NUTR, V141, P2180, DOI 10.3945/jn.111.139477; McAuley KA, 2006, INT J OBESITY, V30, P342, DOI 10.1038/sj.ijo.0803075; McAuley KA, 2005, DIABETOLOGIA, V48, P8, DOI 10.1007/s00125-004-1603-4; McClain AD, 2013, DIABETES OBES METAB, V15, P87, DOI 10.1111/j.1463-1326.2012.01668.x; McLaughlin T, 2007, DIABETES CARE, V30, P1877, DOI 10.2337/dc07-0301; McManus K, 2001, INT J OBESITY, V25, P1503, DOI 10.1038/sj.ijo.0801796; Meckling KA, 2004, J CLIN ENDOCR METAB, V89, P2717, DOI 10.1210/jc.2003-031606; Mensink RP, 2003, AM J CLIN NUTR, V77, P1146, DOI 10.1093/ajcn/77.5.1146; Miller M, 2009, J AM DIET ASSOC, V109, P713, DOI 10.1016/j.jada.2008.12.023; Mohler ER, 2013, OBESITY, V21, P504, DOI 10.1002/oby.20055; Monteiro CA, 2013, OBES REV, V14, P21, DOI 10.1111/obr.12107; Moodie R, 2013, LANCET, V381, P670, DOI 10.1016/S0140-6736(12)62089-3; Moore C, 2009, J NUTR, V139, P1534, DOI 10.3945/jn.108.103374; Moore SD, 2011, EAT BEHAV, V12, P60, DOI 10.1016/j.eatbeh.2010.08.007; Morenga LAT, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-40; Morgan LM, 2009, PUBLIC HEALTH NUTR, V12, P799, DOI 10.1017/S1368980008003236; Mozaffarian D, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000252; Mueller C, 2010, NUTR CLIN PRACT, V25, P542, DOI 10.1177/0884533610379854; Neter JE, 2003, HYPERTENSION, V42, P878, DOI 10.1161/01.HYP.0000094221.86888.AE; Nielsen JV, 2005, UPSALA J MED SCI, V110, P69, DOI 10.3109/2000-1967-182; NNR Project Group, 2004, NORD NUTR REC NNR 20; Noakes M, 2005, AM J CLIN NUTR, V81, P1298; Noakes M, 2006, NUTR METAB, V3, DOI 10.1186/1743-7075-3-7; Noakes TD, 2013, SAMJ S AFR MED J, V103, P826, DOI [10.7196/samj.7302, 10.7196/SAMJ.7302]; Noto H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055030; Paniagua JA, 2011, ATHEROSCLEROSIS, V218, P443, DOI 10.1016/j.atherosclerosis.2011.07.003; Papakonstantinou E, 2010, EUR J CLIN NUTR, V64, P595, DOI 10.1038/ejcn.2010.29; Parker B, 2002, DIABETES CARE, V25, P425, DOI 10.2337/diacare.25.3.425; PASCALE RW, 1995, DIABETES CARE, V18, P1241, DOI 10.2337/diacare.18.9.1241; Patterson RE, 2004, J AM DIET ASSOC, V104, P654, DOI 10.1016/j.jada.2004.01.014; Pereira MA, 2004, JAMA-J AM MED ASSOC, V292, P2482, DOI 10.1001/jama.292.20.2482; Petersen M, 2006, INT J OBESITY, V30, P552, DOI 10.1038/sj.ijo.0803186; Phillips SA, 2008, HYPERTENSION, V51, P376, DOI 10.1161/HYPERTENSIONAHA.107.101824; Raatz SK, 2005, J NUTR, V135, P2387, DOI 10.1093/jn/135.10.2387; Rencher AC, 2002, METHODS MULTIVARIATE, P43; Rodriguez-Hernandez H, 2009, BRIT J NUTR, V102, P1847, DOI 10.1017/S0007114509991231; Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Sebregts EH, 2003, INT J BEHAV MED, V10, P315, DOI 10.1207/S15327558IJBM1004_3; Segal-Isaacson CJ, 2004, OBES RES, V12, p130S, DOI 10.1038/oby.2004.278; Seshadri P, 2004, AM J MED, V117, P398, DOI 10.1016/j.amjmed.2004.04.009; Seshadri Prakash, 2005, Endocr Pract, V11, P234; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; Sharman MJ, 2004, J NUTR, V134, P880, DOI 10.1093/jn/134.4.880; Shaw DI, 2009, BRIT J NUTR, V101, P750, DOI 10.1017/S0007114508039962; SHEPPARD L, 1991, AM J CLIN NUTR, V54, P821, DOI 10.1093/ajcn/54.5.821; Shikany JM, 2011, AM J CLIN NUTR, V94, P75, DOI 10.3945/ajcn.110.010843; SIMKINSILVERMAN L, 1995, PREV MED, V24, P509, DOI 10.1006/pmed.1995.1081; Simons-Morton DG, 2006, JAMA-J AM MED ASSOC, V295, P826, DOI 10.1001/jama.295.7.826; Sjogren P, 2010, AM J CLIN NUTR, V92, P967, DOI 10.3945/ajcn.2010.29345; Skov AR, 1999, INT J OBESITY, V23, P528, DOI 10.1038/sj.ijo.0800867; Sloth B, 2009, BRIT J NUTR, V101, P1846, DOI 10.1017/S0007114508137710; Soenen S, 2012, PHYSIOL BEHAV, V107, P374, DOI 10.1016/j.physbeh.2012.08.004; Stamets K, 2004, FERTIL STERIL, V81, P630, DOI 10.1016/j.fertnstert.2003.08.023; Stoernell CK, 2008, NUTR RES, V28, P443, DOI 10.1016/j.nutres.2008.03.013; Summer SS, 2011, OBESITY, V19, P2198, DOI 10.1038/oby.2011.60; Swinburn BA, 1999, J AM DIET ASSOC, V99, P1400, DOI 10.1016/S0002-8223(99)00339-9; Swinburn BA, 2001, DIABETES CARE, V24, P619, DOI 10.2337/diacare.24.4.619; Swinburn BA, 2011, LANCET, V378, P804, DOI 10.1016/S0140-6736(11)60813-1; Tay J, 2008, J AM COLL CARDIOL, V51, P59, DOI 10.1016/j.jacc.2007.08.050; The Nordic Cochrane Centre The Cochrane Collaboration, 2011, REV MAN REVMAN 5 1; Tierney AC, 2011, INT J OBESITY, V35, P800, DOI 10.1038/ijo.2010.209; Torbay N, 2002, NUTR RES, V22, P587, DOI 10.1016/S0271-5317(02)00359-7; Treyzon L, 2008, NUTR J, V7, DOI 10.1186/1475-2891-7-23; Turley ML, 1998, EUR J CLIN NUTR, V52, P728, DOI 10.1038/sj.ejcn.1600634; Tuttle KR, 2008, AM J CARDIOL, V101, P1523, DOI 10.1016/j.amjcard.2008.01.038; Varady KA, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-8; Vartiainen E, 2010, INT J EPIDEMIOL, V39, P504, DOI 10.1093/ije/dyp330; Volek JS, 2009, METABOLISM, V58, P1769, DOI 10.1016/j.metabol.2009.06.005; Volek JS, 2003, J NUTR, V133, P2756, DOI 10.1093/jn/133.9.2756; WALKER KZ, 1995, DIABETES CARE, V18, P401, DOI 10.2337/diacare.18.3.401; Wang YF, 2008, J HUM HYPERTENS, V22, P745, DOI 10.1038/jhh.2008.64; WebMD, 2012, ATK DIET; Westman EC, 2006, INT J CARDIOL, V110, P212, DOI 10.1016/j.ijcard.2005.08.034; WHO, 2010, GLOB STAT REP NONC D; Wolever TMS, 2008, DIABETOLOGIA, V51, P1607, DOI 10.1007/s00125-008-1093-x; World Health Organization, 2008, GLOB BURD DIS 2004 U; World Health Organization, 1995, PHYS STAT US INT ANT; Wycherley TP, 2012, NUTR DIABETES, V2, DOI 10.1038/nutd.2012.11; Wycherley TP, 2010, J INTERN MED, V267, P452, DOI 10.1111/j.1365-2796.2009.02174.x; Wycherley TP, 2010, DIABETES CARE, V33, P969, DOI 10.2337/dc09-1974; Yancy WS, 2007, EUR J CLIN NUTR, V61, P1416, DOI 10.1038/sj.ejcn.1602661; Yancy WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006; Zatonski WA, 2005, BMJ-BRIT MED J, V331, P187, DOI 10.1136/bmj.331.7510.187	223	157	159	0	68	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2014	9	7							e100652	10.1371/journal.pone.0100652	http://dx.doi.org/10.1371/journal.pone.0100652			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AL3PK	25007189	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000339040600016
J	Vossius, C; Lotto, E; Lyanga, S; Mduma, E; Msemo, G; Perlman, J; Ersdal, HL				Vossius, Corinna; Lotto, Editha; Lyanga, Sara; Mduma, Estomih; Msemo, Georgina; Perlman, Jeffrey; Ersdal, Hege L.			Cost-Effectiveness of the "Helping Babies Breathe'' Program in a Missionary Hospital in Rural Tanzania	PLOS ONE			English	Article							CHILD-MORTALITY; COUNTRIES	Objective: The Helping Babies Breathe'' (HBB) program is an evidence-based curriculum in basic neonatal care and resuscitation, utilizing simulation-based training to educate large numbers of birth attendants in low-resource countries. We analyzed its cost-effectiveness at a faith-based Haydom Lutheran Hospital (HLH) in rural Tanzania. Methods: Data about early neonatal mortality and fresh stillbirth rates were drawn from a linked observational study during one year before and one year after full implementation of the HBB program. Cost data were provided by the Tanzanian Ministry of Health and Social Welfare (MOHSW), the research department at HLH, and the manufacturer of the training material Laerdal Global Health. Findings: Costs per life saved were USD 233, while they were USD 4.21 per life year gained. Costs for maintaining the program were USD 80 per life saved and USD 1.44 per life year gained. Costs per disease adjusted life year (DALY) averted ranged from International Dollars (ID; a virtual valuta corrected for purchasing power world-wide) 12 to 23, according to how DALYs were calculated. Conclusion: The HBB program is a low-cost intervention. Implementation in a very rural faith-based hospital like HLH has been highly cost-effective. To facilitate further global implementation of HBB a cost-effectiveness analysis including government owned institutions, urban hospitals and district facilities is desirable for a more diverse analysis to explore cost-driving factors and predictors of enhanced cost-effectiveness.	[Vossius, Corinna; Ersdal, Hege L.] Stavanger Univ Hosp, SAFER Stavanger Acute Med Fdn Educ & Res, Stavanger, Norway; [Lotto, Editha; Lyanga, Sara; Mduma, Estomih; Ersdal, Hege L.] Haydom Lutheran Hosp, Res Inst, Haydom, Tanzania; [Msemo, Georgina] Minist Hlth & Social Welf, Dar Es Salaam, Tanzania; [Perlman, Jeffrey] Weill Cornell Med Coll, Dept Pediat, New York, NY USA	Stavanger University Hospital; Cornell University	Vossius, C (corresponding author), Stavanger Univ Hosp, SAFER Stavanger Acute Med Fdn Educ & Res, Stavanger, Norway.	c.vossius@hotmail.com			Laerdal Foundation for Acute Medicine [40023]; municipaility of Stavanger, Norway; research department of Haydom Lutheran Hospital, Tanzania	Laerdal Foundation for Acute Medicine; municipaility of Stavanger, Norway; research department of Haydom Lutheran Hospital, Tanzania	The study was partly funded by the Laerdal Foundation for Acute Medicine (grant number 40023; http://www.laerdal.com/no/doc/311/Laerdals-Fond-for-Akuttmedisin), that provided travel expenses for Corinna Vossius and Hege L. Ersdal and a reserach grant for Hege L. Ersdal. Further, the research was funded by the municipaility of Stavanger, Norway and the research department of Haydom Lutheran Hospital, Tanzania. No funding bodies had any role in study design, data collection, decision or preparation of the manuscript.	Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Bryce J, 2008, LANCET, V371, P1247, DOI 10.1016/S0140-6736(08)60559-0; Ersdal HL, 2013, RESUSCITATION, V84, P1422, DOI 10.1016/j.resuscitation.2013.04.005; Ersdal HL, 2012, RESUSCITATION, V83, P869, DOI 10.1016/j.resuscitation.2011.12.011; Ersdal HL, 2012, PEDIATRICS, V129, pE1238, DOI 10.1542/peds.2011-3134; Ersdal HL, 2013, PAS 2013; Johns B, 2003, PROGRAMME COSTS EC E; Lozano R, 2011, LANCET, V378, P1139, DOI 10.1016/S0140-6736(11)61337-8; Manasyan A, 2011, PEDIATRICS, V127, pE1176, DOI 10.1542/peds.2010-2158; Mduma E, 2013, PAS 2013; Msemo G, 2013, PEDIATRICS, V131, pE353, DOI 10.1542/peds.2012-1795; Oestergaard MZ, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001080; Rajaratnam JK, 2010, LANCET, V375, P1988, DOI 10.1016/S0140-6736(10)60703-9; Save The Children, 2009, SIT AN NEWB HLTH TAN; UN, 1994, INT C POP DEV 5 13 S, P5; UNICEF, 2004, STAT WORLDS CHILDR R; UNICEF, 2011, UNICEF REP 2011 LEV; United Nations, 2013, BREAKTHR INN CAN SAV; United Nations Department of Economic and Social Affairs (UN DESA), 2011, POP DIV WORLD POP PR; WHO, 2009, NAT ROADM STRAT PLAN; World Health Organization, 2006, NEON PER MORT COUNTR; World Health Organization, 2005, CHOOS INT AR COST EF; World Health Organization, 2005, CHOSS INT ARE COST E; World Health Organization, 2006, WORK HLTH; World Health Organization, 2005, WORLD HLTH REPORT 20	25	28	28	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2014	9	7							e102080	10.1371/journal.pone.0102080	http://dx.doi.org/10.1371/journal.pone.0102080			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AL3PK	25006802	gold, Green Submitted, Green Published			2023-01-03	WOS:000339040600092
J	Yokota, M; Kobayashi, Y; Morita, J; Suzuki, H; Hashimoto, Y; Sasaki, Y; Akiyoshi, K; Moriyama, K				Yokota, Masako; Kobayashi, Yukiho; Morita, Jumpei; Suzuki, Hiroyuki; Hashimoto, Yoshihide; Sasaki, Yoshihiro; Akiyoshi, Kazunari; Moriyama, Keiji			Therapeutic Effect of Nanogel-Based Delivery of Soluble FGFR2 with S252W Mutation on Craniosynostosis	PLOS ONE			English	Article							FACTOR RECEPTOR-2 FGFR2; APERT-SYNDROME; MOUSE MODEL; SUSTAINED-RELEASE; IMMUNE-RESPONSES; BONE-DEVELOPMENT; CROUZON-SYNDROME; CALVARIAL BONE; GENE CAUSE; DIFFERENTIATION	Apert syndrome is an autosomal dominantly inherited disorder caused by missense mutations in fibroblast growth factor receptor 2 (FGFR2). Surgical procedures are frequently required to reduce morphological and functional defects in patients with Apert syndrome; therefore, the development of noninvasive procedures to treat Apert syndrome is critical. Here we aimed to clarify the etiological mechanisms of craniosynostosis in mouse models of Apert syndrome and verify the effects of purified soluble FGFR2 harboring the S252W mutation (sFGFR2IIIc(S252W)) on calvarial sutures in Apert syndrome mice in vitro. We observed increased expression of Fgf10, Esrp1, and Fgfr2IIIb, which are indispensable for epidermal development, in coronal sutures in Apert syndrome mice. Purified sFGFR2IIIc(S252W) exhibited binding affinity for fibroblast growth factor (Fgf)2 but also formed heterodimers with FGFR2IIIc, FGFR2IIIc(S252W), and FGFR2IIIb(S252W). Administration of sFGFR2IIIc(S252W) also inhibited Fgf2-dependent proliferation, phosphorylation of intracellular signaling molecules, and mineralization of FGFR2(S252W)-overexpressing MC3T3-E1 osteoblasts. sFGFR2IIIc(S252W) complexed with nanogels maintained the patency of coronal sutures, whereas synostosis was observed where the nanogel without sFGFR2(S252W) was applied. Thus, based on our current data, we suggest that increased Fgf10 and Fgfr2IIIb expression may induce the onset of craniosynostosis in patients with Apert syndrome and that the appropriate delivery of purified sFGFR2IIIc(S252W) could be effective for treating this disorder.	[Yokota, Masako; Kobayashi, Yukiho; Morita, Jumpei; Suzuki, Hiroyuki; Moriyama, Keiji] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Div Maxillofacial Neck Reconstruct, Dept Maxillofacial Reconstruct & Funct, Tokyo, Japan; [Kobayashi, Yukiho; Suzuki, Hiroyuki; Sasaki, Yoshihiro; Akiyoshi, Kazunari; Moriyama, Keiji] Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo, Japan; [Sasaki, Yoshihiro; Akiyoshi, Kazunari] Kyoto Univ, Grad Sch Engn, Dept Polymer Chem, Kyoto, Japan; [Hashimoto, Yoshihide; Akiyoshi, Kazunari] Japan Sci & Technol Agcy, ERATO, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Kyoto University; Japan Science & Technology Agency (JST)	Kobayashi, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Div Maxillofacial Neck Reconstruct, Dept Maxillofacial Reconstruct & Funct, Tokyo, Japan.	yukiho-kobayashi.mort@tmd.ac.jp	HASHIMOTO, YOSHIHIDE/S-3056-2017; Moriyama, Keiji/AAC-3193-2019	HASHIMOTO, YOSHIHIDE/0000-0003-0537-8291; Moriyama, Keiji/0000-0003-0580-4510	Japan Society for the Promotion of Science, as well as the Global Center of Excellence Program at the Tokyo Medical and Dental University (TMDU), Japan [23390471, 23792418]	Japan Society for the Promotion of Science, as well as the Global Center of Excellence Program at the Tokyo Medical and Dental University (TMDU), Japan	This study was financially supported by a Grant-in-aid for Scientific Research (No. 23390471 to KM, http://www.jsps.go.jp/english/index.html) and Young Scientists (No. 23792418 to YK, http://www.jsps.go.jp/english/index.html) from Japan Society for the Promotion of Science, as well as the Global Center of Excellence Program at the Tokyo Medical and Dental University (TMDU), Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Behr B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070240; Biechele TL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002274; Chen L, 2003, BONE, V33, P169, DOI 10.1016/S8756-3282(03)00222-9; Chevrel G, 2002, ANN RHEUM DIS, V61, P730, DOI 10.1136/ard.61.8.730; Fong KD, 2004, PLAST RECONSTR SURG, V113, P2037, DOI 10.1097/01.PRS.0000121182.01199.C1; Fragale A, 1999, AM J PATHOL, V154, P1465, DOI 10.1016/S0002-9440(10)65401-6; Fujioka-Kobayashi M, 2012, BIOMATERIALS, V33, P7613, DOI 10.1016/j.biomaterials.2012.06.075; Hajihosseini MK, 2001, P NATL ACAD SCI USA, V98, P3855, DOI 10.1073/pnas.071586898; Hayashi C, 2009, J CELL PHYSIOL, V220, P1, DOI 10.1002/jcp.21760; Holmes G, 2009, DEV BIOL, V328, P273, DOI 10.1016/j.ydbio.2009.01.026; Ikuta Y, 2002, BLOOD, V99, P3717, DOI 10.1182/blood.V99.10.3717; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; Johnson D, 2011, EUR J HUM GENET, V19, P369, DOI 10.1038/ejhg.2010.235; Kageyama S, 2008, CANCER SCI, V99, P601, DOI 10.1111/j.1349-7006.2007.00705.x; Kitano S, 2006, CLIN CANCER RES, V12, P7397, DOI 10.1158/1078-0432.CCR-06-1546; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Lamoureux F, 2008, MOL CANCER THER, V7, P3389, DOI 10.1158/1535-7163.MCT-08-0497; Lomri A, 1998, J CLIN INVEST, V101, P1310; Matsumoto K, 2002, SCAND J PLAST RECONS, V36, P368, DOI 10.1080/028443102321096375; Miralles F, 1999, P NATL ACAD SCI USA, V96, P6267, DOI 10.1073/pnas.96.11.6267; Miraoui H, 2009, J BIOL CHEM, V284, P4897, DOI 10.1074/jbc.M805432200; Morita J, 2014, DEV DYNAM, V243, P560, DOI 10.1002/dvdy.24099; Nochi T, 2010, NAT MATER, V9, P572, DOI [10.1038/NMAT2784, 10.1038/nmat2784]; Oldridge M, 1999, AM J HUM GENET, V64, P446, DOI 10.1086/302245; Przylepa KA, 1996, NAT GENET, V13, P492, DOI 10.1038/ng0896-492; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; Rice DPC, 1999, EUR J ORAL SCI, V107, P265, DOI 10.1046/j.0909-8836.1999.eos107406.x; Rice DPC, 2003, BONE, V33, P14, DOI 10.1016/S8756-3282(03)00163-7; Rice DPC, 2000, DEVELOPMENT, V127, P1845; RUTLAND P, 1995, NAT GENET, V9, P173, DOI 10.1038/ng0295-173; Sasaki Y, 2010, CHEM REC, V10, P366, DOI 10.1002/tcr.201000008; Shen K, 2009, ORTHOD CRANIOFAC RES, V12, P254, DOI 10.1111/j.1601-6343.2009.01460.x; Shimizu T, 2008, BIOCHEM BIOPH RES CO, V367, P330, DOI 10.1016/j.bbrc.2007.12.112; Shimoda A, 2012, COLLOID SURFACE B, V99, P38, DOI 10.1016/j.colsurfb.2011.09.025; Shukla V, 2007, NAT GENET, V39, P1145, DOI 10.1038/ng2096; Suzuki H, 2012, J CELL PHYSIOL, V227, P3267, DOI 10.1002/jcp.24021; Tanimoto Y, 2004, J BIOL CHEM, V279, P45926, DOI 10.1074/jbc.M404824200; TROWELL OA, 1954, EXP CELL RES, V6, P246, DOI 10.1016/0014-4827(54)90169-X; Veistinen L, 2009, J EXP ZOOL PART B, V312B, P351, DOI 10.1002/jez.b.21276; Wang YL, 2005, DEVELOPMENT, V132, P3537, DOI 10.1242/dev.01914; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Watanabe K, 2011, BIOMATERIALS, V32, P5900, DOI 10.1016/j.biomaterials.2011.04.058; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; Yang F, 2008, BONE, V43, P55, DOI 10.1016/j.bone.2008.02.008; Yin L, 2008, BONE, V42, P631, DOI 10.1016/j.bone.2007.11.019; Yu K, 2000, P NATL ACAD SCI USA, V97, P14536, DOI 10.1073/pnas.97.26.14536	46	17	19	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2014	9	7							e101693	10.1371/journal.pone.0101693	http://dx.doi.org/10.1371/journal.pone.0101693			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AL6KZ	25003957	gold, Green Published, Green Submitted			2023-01-03	WOS:000339242700054
J	Wu, HM; Fairley, JK; Steinberg, J; Kozarsky, P				Wu, Henry M.; Fairley, Jessica K.; Steinberg, James; Kozarsky, Phyllis			The Potential Ebola-Infected Patient in the Ambulatory Care Setting: Preparing for the Worst Without Compromising Care	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Wu, HM (corresponding author), 550 Peachtree St NE,Med Off Tower 7, Atlanta, GA 30308 USA.	hmwu@emory.edu	Fairley, Jessica K/W-2777-2019					[Anonymous], 2014, CAS DEF EB VIR DIS E; Center for Disease Control, 2014, 2014 EB OUTBR W AFR; Centers for Disease Control and Prevention, 2014, CAS EB DIAGN US; Centers for Disease Control and Prevention, 2014, INT GUID ENV INF CON; Centers for Disease Control and Prevention, 2014, GUID PERS PROT EQ BE; Centers for Disease Control and Prevention, 2014, INT GUID SPEC COLL T; Isakov A, 2014, ANN INTERN MED, V161, P829, DOI 10.7326/M14-2084; Mendelson M, 2014, EMERG INFECT DIS, V20, P532, DOI 10.3201/eid2004.131128; Siegel JD, 2007, AM J INFECT CONTROL, V35, pS65, DOI 10.1016/j.ajic.2007.10.007	9	10	10	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 6	2015	162	1					66	U109		10.7326/M14-2312	http://dx.doi.org/10.7326/M14-2312			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC1LU	25329137				2023-01-03	WOS:000350103000009
J	Long, GV; Stroyakovskiy, D; Gogas, H; Levchenko, E; de Braud, F; Larkin, J; Garbe, C; Jouary, T; Hauschild, A; Grob, JJ; Sileni, VC; Lebbe, C; Mandala, M; Millward, M; Arance, A; Bondarenko, I; Haanen, JBAG; Hansson, J; Utikal, J; Ferraresi, V; Kovalenko, N; Mohr, P; Probachai, V; Schadendorf, D; Nathan, P; Robert, C; Ribas, A; DeMarini, DJ; Irani, JG; Casey, M; Ouellet, D; Martin, AM; Le, N; Patel, K; Flaherty, K				Long, G. V.; Stroyakovskiy, D.; Gogas, H.; Levchenko, E.; de Braud, F.; Larkin, J.; Garbe, C.; Jouary, T.; Hauschild, A.; Grob, J. J.; Sileni, V. Chiarion; Lebbe, C.; Mandala, M.; Millward, M.; Arance, A.; Bondarenko, I.; Haanen, J. B. A. G.; Hansson, J.; Utikal, J.; Ferraresi, V.; Kovalenko, N.; Mohr, P.; Probachai, V.; Schadendorf, D.; Nathan, P.; Robert, C.; Ribas, A.; DeMarini, D. J.; Irani, J. G.; Casey, M.; Ouellet, D.; Martin, A. -M.; Le, N.; Patel, K.; Flaherty, K.			Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METASTATIC MELANOMA; RAF INHIBITORS; ACQUIRED-RESISTANCE; IMPROVED SURVIVAL; SOLID TUMORS; DABRAFENIB; MUTATIONS; TRIAL; VEMURAFENIB; PROGRESSION	BACKGROUND Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone, delays the emergence of resistance and reduces toxic effects in patients who have melanoma with BRAF V600E or V600K mutations. METHODS In this phase 3 trial, we randomly assigned 423 previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation to receive a combination of dabrafenib (150 mg orally twice daily) and trametinib (2 mg orally once daily) or dabrafenib and placebo. The primary end point was progression-free survival. Secondary end points included overall survival, response rate, response duration, and safety. A preplanned interim overall survival analysis was conducted. RESULTS The median progression-free survival was 9.3 months in the dabrafenib-trametinib group and 8.8 months in the dabrafenib-only group (hazard ratio for progression or death in the dabrafenib-trametinib group, 0.75; 95% confidence interval [CI], 0.57 to 0.99; P = 0.03). The overall response rate was 67% in the dabrafenib-trametinib group and 51% in the dabrafenib-only group (P = 0.002). At 6 months, the interim overall survival rate was 93% with dabrafenib-trametinib and 85% with dabrafenib alone (hazard ratio for death, 0.63; 95% CI, 0.42 to 0.94; P = 0.02). However, a specified efficacy-stopping boundary (two-sided P = 0.00028) was not crossed. Rates of adverse events were similar in the two groups, although more dose modifications occurred in the dabrafenib-trametinib group. The rate of cutaneous squamous-cell carcinoma was lower in the dabrafenib-trametinib group than in the dabrafenib-only group (2% vs. 9%), whereas pyrexia occurred in more patients (51% vs. 28%) and was more often severe (grade 3, 6% vs. 2%) in the dabrafenib-trametinib group. CONCLUSIONS A combination of dabrafenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic melanoma with BRAF V600E or V600K mutations.	[Long, G. V.] Univ Sydney, Melanoma Inst Australia, Mater Hosp, Sydney, NSW 2006, Australia; [Millward, M.] Sir Charles Gairdner Hosp, Perth, WA, Australia; [Stroyakovskiy, D.] Moscow City Oncol Hosp 62, Moscow, Russia; [Levchenko, E.] Petrov Res Inst Oncol, St Petersburg, Russia; [Kovalenko, N.] Volograd Reg Oncol Dispensary 3, Volzhsky, Russia; [Gogas, H.] Univ Athens, GR-10679 Athens, Greece; [de Braud, F.] Fdn IRCCS Ist Nazl Tumori, Milan, Italy; [Sileni, V. Chiarion] Veneto Oncol Inst IRCCS, Padua, Italy; [Mandala, M.] Papa Giovanni XXIII Hosp, Bergamo, Italy; [Ferraresi, V.] Regina Elena Inst Canc Res, Rome, Italy; [Larkin, J.] Royal Marsden NHS Fdn Trust, London, England; [Nathan, P.] Mt Vernon Canc Ctr, Northwood, Middx, England; [Garbe, C.] Univ Tubingen, Tubingen, Germany; [Hauschild, A.] Univ Hosp Schleswig Holstein, Kiel, Germany; [Utikal, J.] Heidelberg Univ, German Canc Res Ctr DKFZ, Mannheim, Germany; [Utikal, J.] Heidelberg Univ, Univ Med Ctr Mannheim, Mannheim, Germany; [Utikal, J.] Heidelberg Univ, German Canc Res Ctr DKFZ, Heidelberg, Germany; [Utikal, J.] Heidelberg Univ, Univ Med Ctr Mannheim, Heidelberg, Germany; [Mohr, P.] Elbe Kliniken Stade Buxtehude, Buxtehude, Germany; [Stroyakovskiy, D.] Univ Hosp Essen, Essen, Germany; [Jouary, T.] Hop Francois Mitterrand, Pau, France; [Grob, J. J.] Hop Enfants La Timone, Marseille, France; [Lebbe, C.] Hop St Louis, Paris, France; [Robert, C.] Inst Gustave Roussy, Villejuif, France; [Arance, A.] Hosp Clin Barcelona, Barcelona, Spain; [Bondarenko, I.] Dnipropetrovsk Med Acad, Clin Hosp 4, Dnepropetrovsk, Ukraine; [Probachai, V.] Dnipropetrovsk State Council, Dnipropetrovsk Clin Oncol Ctr, Dnepropetrovsk, Ukraine; [Haanen, J. B. A. G.] Netherlands Canc Inst, Amsterdam, Netherlands; [Hansson, J.] Karolinska Inst, Stockholm, Sweden; [Ribas, A.] Univ Calif Los Angeles, Los Angeles, CA USA; [DeMarini, D. J.; Irani, J. G.; Casey, M.; Martin, A. -M.; Le, N.; Patel, K.] GlaxoSmithKline, Collegeville, PA USA; [Ouellet, D.] GlaxoSmithKline, Res Triangle Pk, NC USA; [Flaherty, K.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA	Melanoma Institute Australia; University of Sydney; University of Western Australia; N.N. Petrov Research Institute of Oncology; National & Kapodistrian University of Athens; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Istituto Oncologico Veneto (IOV); ASST Papa Giovanni XXIII; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Royal Marsden NHS Foundation Trust; Mount Vernon Cancer Centre; Eberhard Karls University of Tubingen; University of Kiel; Schleswig Holstein University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Duisburg Essen; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy; University of Barcelona; Hospital Clinic de Barcelona; Dnipro State Medical University; Netherlands Cancer Institute; Karolinska Institutet; University of California System; University of California Los Angeles; GlaxoSmithKline; GlaxoSmithKline; Harvard University; Massachusetts General Hospital	Long, GV (corresponding author), Univ Sydney, Melanoma Inst Australia, 40 Rocklands Rd, Sydney, NSW 2060, Australia.	georgina.long@sydney.edu.au	Haanen, John/AAD-8534-2022; Bondarenko, Igor/U-5156-2017; Haanen, John/AAD-8578-2022; Schadendorf, Dirk/AAE-8206-2019; Ferraresi, Virginia/A-2075-2019; Robert, Caroline/G-6157-2018; mandala, mario/AAB-8637-2022; Levchenko, Evgeny/X-8697-2018; sileni, vanna chiarion/B-9042-2018; Mandala', Mario/AAA-4258-2019; Kovalenko, Nadezhda/AAG-6298-2021; Garbe, Claus/ABH-2128-2021; Bondarenko, Igor N/GQP-1497-2022; ferraresi, virginia/ABH-7898-2020; de Braud, Filippo/B-9997-2017; Bondarenko, Igor/W-9412-2019; Long, Georgina V/C-1771-2013	Haanen, John/0000-0001-5884-7704; Bondarenko, Igor/0000-0002-7071-2471; Robert, Caroline/0000-0002-9493-0238; Levchenko, Evgeny/0000-0003-3837-2515; sileni, vanna chiarion/0000-0001-9191-9124; Garbe, Claus/0000-0001-8530-780X; Bondarenko, Igor N/0000-0002-7071-2471; ferraresi, virginia/0000-0001-6419-1668; de Braud, Filippo/0000-0003-0103-730X; Bondarenko, Igor/0000-0002-7071-2471; Long, Georgina V/0000-0001-8894-3545; Utikal, Jochen/0000-0001-5316-0241; Larkin, James/0000-0001-5569-9523; Stroyakovskiy, Daniil/0000-0003-1973-1092; Nathan, Paul/0000-0002-2327-3250; Arance, Ana/0000-0003-2896-1957; Grob, Jean-Jacques/0000-0002-0667-153X	GlaxoSmithKline	GlaxoSmithKline(GlaxoSmithKline)	Supported by GlaxoSmithKline.	Ascierto PA, 2013, J CLIN ONCOL, V31, P3205, DOI 10.1200/JCO.2013.49.8691; Callahan MK, 2012, NEW ENGL J MED, V367, P2316, DOI 10.1056/NEJMoa1208958; Chapman PB, 2012, J CLIN ONCOL, V30; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5; Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Hauschild A, 2013, J CLIN ONCOL, V31; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Infante J.R., 2011, J CLIN ONCOL, V29, P8503; Lee CI, 2014, MELANOMA RES, V24, P468, DOI 10.1097/CMR.0000000000000110; National Cancer Institute, 2009, COMM TERM CRIT ADV E; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Oberholzer PA, 2012, J CLIN ONCOL, V30, P316, DOI 10.1200/JCO.2011.36.7680; Paraiso KHT, 2010, BRIT J CANCER, V102, P1724, DOI 10.1038/sj.bjc.6605714; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Shi HB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1727; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312	30	1191	1211	2	85	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2014	371	20					1877	1888		10.1056/NEJMoa1406037	http://dx.doi.org/10.1056/NEJMoa1406037			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AT1RB	25265492	Green Published			2023-01-03	WOS:000344709800005
J	David, AL; Holloway, A; Thomasson, L; Syngelaki, A; Nicolaides, K; Patel, RR; Sommerlad, B; Wilson, A; Martin, W; Chitty, LS				David, Anna L.; Holloway, Andrew; Thomasson, Louise; Syngelaki, Argyro; Nicolaides, Kypros; Patel, Roshni R.; Sommerlad, Brian; Wilson, Amie; Martin, William; Chitty, Lyn S.			A Case-Control Study of Maternal Periconceptual and Pregnancy Recreational Drug Use and Fetal Malformation Using Hair Analysis	PLOS ONE			English	Article							PRENATAL COCAINE EXPOSURE; BIRTH-DEFECTS; GASTROSCHISIS; ABUSE; ABNORMALITIES; INFANTS; GROWTH; RISKS; MODEL	Objective: Maternal recreational drug use may be associated with the development of fetal malformations such as gastroschisis, brain and limb defects, the aetiology due to vascular disruption during organogenesis. Using forensic hair analysis we reported evidence of recreational drug use in 18% of women with a fetal gastroschisis. Here we investigate this association in a variety of fetal malformations using the same method. Methods: In a multi-centre study, women with normal pregnancies (controls) and those with fetal abnormalities (cases) gave informed consent for hair analysis for recreational drug metabolites using mass spectrometry. Hair samples cut at the root were tested in sections corresponding to 3 month time periods (pre and periconceptual period). Results: Women whose fetus had gastroschisis, compared to women with a normal control fetus, were younger (mean age 23.78 +/- SD4.79 years, 18-37 vs 29.79 +/- SD6 years, 18-42, p = 0.00001), were more likely to have evidence of recreational drug use (15, 25.4% vs 21, 13%, OR2.27, 95th CI 1.08-4.78, p = 0.028), and were less likely to report periconceptual folic acid use (31, 53.4% vs 124, 77.5%, OR0.33, 95th CI 0.18-0.63, p = 0.001). Age-matched normal control women were no less likely to test positive for recreational drugs than women whose fetus had gastroschisis. After accounting for all significant factors, only young maternal age remained significantly associated with gastroschisis. Women with a fetus affected by a non-neural tube central nervous system (CNS) anomaly were more likely to test positive for recreational drugs when compared to women whose fetus was normal (7, 35% vs 21, 13%, OR3.59, 95th CI1.20-10.02, p = 0.01). Conclusions: We demonstrate a significant association between non neural tube CNS anomalies and recreational drug use in the periconceptual period, first or second trimesters, but we cannot confirm this association with gastroschisis. We confirm the association of gastroschisis with young maternal age.	[David, Anna L.; Holloway, Andrew; Thomasson, Louise; Nicolaides, Kypros] UCL, Inst Womens Hlth, London, England; [David, Anna L.; Holloway, Andrew; Thomasson, Louise; Chitty, Lyn S.] Univ Coll London Hosp NHS Fdn Trust, London, England; [Syngelaki, Argyro; Nicolaides, Kypros] Kings Coll Hosp London, Harris Birthright Ctr, London, England; [Patel, Roshni R.] St Michaels Hosp, Fetal Med Unit, Bristol, Avon, England; [Sommerlad, Brian] Great Ormond St Hosp Sick Children, North Thames Cleft Lip & Palate Unit, London, England; [Wilson, Amie] Brigham & Womens Hosp, Birmingham, W Midlands, England; [Chitty, Lyn S.] UCL Inst Child Hlth, Clin & Mol Genet Unit, London, England	University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Birmingham Women's Hospital; University of London; University College London	David, AL (corresponding author), UCL, Inst Womens Hlth, London, England.	a.david@ucl.ac.uk	Wilson, Amie/HHS-0117-2022; Sommerlad, Brian/AAG-3946-2020	Wilson, Amie/0000-0002-1015-3786; Syngelaki, Argyro/0000-0001-5856-6072; chitty, lyn/0000-0002-4857-7138; Patel, Roshni/0000-0002-1399-3131; David, Anna/0000-0002-0199-6140; Nicolaides, Kypros/0000-0003-1266-0711	BDF Newlife; UK Central and East London Comprehensive Local Research Network;  [06/29]; National Institute for Health Research [NF-SI-0513-10141] Funding Source: researchfish	BDF Newlife; UK Central and East London Comprehensive Local Research Network; ; National Institute for Health Research(National Institute for Health Research (NIHR))	This study was funded by a grant "Recreational drugs as aetiological factors in fetal malformations" from BDF Newlife (http://www.newlifecharity.co.uk/). Funding was used to support the cost of hair analysis for recreational drugs, and a salary for a research assistant to co-ordinate the study. Grant reference: 06/29. Recruitment was supported by funding from the UK Central and East London Comprehensive Local Research Network. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bays J, 1994, PEDIATRICS, V87, P416; Beaty TH, 2001, ANN EPIDEMIOL, V11, P434, DOI 10.1016/S1047-2797(01)00222-8; Bower C, 2006, AUST NZ J PUBL HEAL, V30, P258, DOI 10.1111/j.1467-842X.2006.tb00867.x; Chief Medical Officer's Annual Report, 2004, CHIEF MED OFF ANN RE; Colado MI, 1997, BRIT J PHARMACOL, V121, P827, DOI 10.1038/sj.bjp.0701201; DOMINGUEZ R, 1991, AM J DIS CHILD, V145, P688, DOI 10.1001/archpedi.1991.02160060106030; Draper ES, 2008, AM J EPIDEMIOL, V167, P485, DOI 10.1093/aje/kwm335; Godwin KA, 2008, CANADIAN J PUB HLTH, V99, P71; GRANT T, 1994, OBSTET GYNECOL, V83, P524, DOI 10.1097/00006250-199404000-00007; He N, 2004, NEUROTOXICOLOGY, V25, P419, DOI 10.1016/j.neuro.2003.10.002; Huestis MA, 2002, FORENSIC SCI INT, V128, P20, DOI 10.1016/S0379-0738(02)00160-3; Hume RF, 1997, FETAL DIAGN THER, V12, P292; HUME RF, 1994, FETAL DIAGN THER, V9, P239; Kashiwagi M, 2003, BIRTH DEFECTS RES A, V67, P951, DOI 10.1002/bdra.10101; Klein J, 2000, FORENSIC SCI INT, V107, P281, DOI 10.1016/S0379-0738(99)00171-1; Kline J, 1997, AM J PUBLIC HEALTH, V87, P352, DOI 10.2105/AJPH.87.3.352; LIPSHULTZ SE, 1991, J PEDIATR-US, V118, P44, DOI 10.1016/S0022-3476(05)81842-6; Markov D, 2003, Clin Exp Obstet Gynecol, V30, P109; MIYAZAWA N, 1992, THER DRUG MONIT, V14, P525, DOI 10.1097/00007691-199212000-00015; Morrison JJ, 2005, BJOG-INT J OBSTET GY, V112, P1022, DOI 10.1111/j.1471-0528.2005.00655.x; NAKAHARA Y, 1992, J ANAL TOXICOL, V16, P253, DOI 10.1093/jat/16.4.253; NORA JJ, 1970, LANCET, V1, P1290; Orrico A, 2002, EUR J NEUROL, V9, P679, DOI 10.1046/j.1468-1331.2002.00473.x; Paranjothy S, 2012, INT J EPIDEMIOL, V41, P1141, DOI 10.1093/ije/dys092; Plessinger MA, 1998, OBSTET GYN CLIN N AM, V25, P119, DOI 10.1016/S0889-8545(05)70361-2; Spiehler V, 2000, FORENSIC SCI INT, V107, P249, DOI 10.1016/S0379-0738(99)00168-1; Tan KH, 1996, BRIT MED J, V313, P903; TORFS CP, 1994, TERATOLOGY, V50, P44, DOI 10.1002/tera.1420500107; Villain M, 2004, CLIN CHEM LAB MED, V42, P1265, DOI 10.1515/CCLM.2004.247; WEBSTER WS, 1990, TERATOLOGY, V41, P689, DOI 10.1002/tera.1420410605; Werler MM, 2003, EPIDEMIOLOGY, V14, P349, DOI 10.1097/00001648-200305000-00016; Yamamoto Y, 1992, Nihon Hoigaku Zasshi, V46, P126	32	13	14	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2014	9	10							e111038	10.1371/journal.pone.0111038	http://dx.doi.org/10.1371/journal.pone.0111038			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0BN	25360669	Green Published, gold			2023-01-03	WOS:000343943700058
J	Qin, H; Pan, F; Li, JJ; Zhang, XL; Liang, HJ; Ruan, ZH				Qin, Hong; Pan, Feng; Li, Jianjun; Zhang, Xiaoli; Liang, Houjie; Ruan, Zhihua			Whole Brain Radiotherapy Plus Concurrent Chemotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: A Meta-Analysis	PLOS ONE			English	Article							PHASE-III TRIAL; RADIATION-THERAPY; CNS-METASTASES; TEMOZOLOMIDE; CARCINOMA; CARBOPLATIN; CISPLATIN	Objective: The aim of the present meta-analysis is to evaluate the response rate, median survival time (MST) and toxicity in patients with brain metastases (BM) originating from non-small cell lung cancer (NSCLC) and who were treated using either whole brain radiotherapy (WBRT) plus concurrent chemotherapy or WBRT alone. Methods: PubMed, EMBASE, Web of Science, The Cochrane Library, clinical trials and current controlled trials were searched to identify any relevant publications. After screening the literature and undertaking quality assessment and data extraction, the meta-analysis was performed using Stata11.0 software. Results: In total, six randomized controlled trials (RCT) involving 910 participants were included in the meta-analysis. The results of the analysis indicate that WBRT plus concurrent chemotherapy was more effective at improving response rate (RR = 2.06, 95% CI [1.13, 3.77]; P = 0.019) than WBRT alone. However, WBRT plus concurrent chemotherapy did not improve median survival time (MST) (HR = 1.09, 95% CI [0.94, 1.26]; P = 0.233) or time of neurological progression (CNS-TTP) (HR = 0.93, 95%CI [0.75, 1.16]; P = 0.543), and increased adverse events (Grade >= 3) (RR = 2.59, 95% CI [1.88, 3.58]; P = 0.000). There were no significant differences in Grade 3-5 neurological or hematological toxicity between two patient groups (RR = 1.08, 95%CI [0.23, 5.1]; P = 0.92). Conclusion: The combination of chemotherapy plus WBRT in patients with BM originating from NSCLC may increase treatment response rates of brain metastases with limited toxicity. Although the therapy schedule did not prolong MST or CNS-TTP, further assessment is warranted.	[Qin, Hong; Pan, Feng; Li, Jianjun; Zhang, Xiaoli; Liang, Houjie; Ruan, Zhihua] Third Mil Med Univ, Southwest Hosp, Dept Oncol, Chongqing, Peoples R China	Army Medical University	Liang, HJ (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Oncol, Chongqing, Peoples R China.	lianghoujie@sina.com; zhihuaruan@gmail.com						Addeo R, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-18; Addeo R, 2011, EXPERT OPIN INV DRUG, V20, P881, DOI 10.1517/13543784.2011.580736; Adonizio Christian S, 2002, Clin Lung Cancer, V3, P254, DOI 10.3816/CLC.2002.n.009; Bailon O, 2012, NEURO-ONCOLOGY, V14, P491, DOI 10.1093/neuonc/nos004; Barlesi F, 2011, ANN ONCOL, V22, P2466, DOI 10.1093/annonc/mdr003; Berger LA, 2013, LUNG CANCER, V80, P242, DOI 10.1016/j.lungcan.2013.02.004; Biswas G, 2006, J Cancer Res Ther, V2, P5; Chua D, 2010, CLIN LUNG CANCER, V11, P176, DOI 10.3816/CLC.2010.n.022; Ford AC, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3174; Gijtenbeek J M M Anja, 2011, Ned Tijdschr Geneeskd, V155, pA4141; Guerrieri M, 2004, LUNG CANCER, V46, P107, DOI 10.1016/j.lungcan.2004.02.019; Hassler MR, 2013, WIEN KLIN WOCHENSCHR, V125, P481, DOI 10.1007/s00508-013-0402-7; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Kaba SE, 1997, J CLIN ONCOL, V15, P1063, DOI 10.1200/JCO.1997.15.3.1063; Mehta MP, 2009, INT J RADIAT ONCOL, V73, P1069, DOI 10.1016/j.ijrobp.2008.05.068; Neuhaus T, 2009, BRIT J CANCER, V100, P291, DOI 10.1038/sj.bjc.6604835; Nieder C, 1999, CANCER, V86, P900, DOI 10.1002/(SICI)1097-0142(19990901)86:5<900::AID-CNCR30>3.0.CO;2-5; Seoane J, 2014, MOL ONCOL, V8, P1120, DOI 10.1016/j.molonc.2014.05.009; Siu TL, 2011, J CLIN NEUROSCI, V18, P1429, DOI 10.1016/j.jocn.2011.04.002; Sperduto PW, 2013, INT J RADIAT ONCOL, V85, P1312, DOI 10.1016/j.ijrobp.2012.11.042; Sperduto PW, 2012, J CLIN ONCOL, V30, P419, DOI 10.1200/JCO.2011.38.0527; USHIO Y, 1991, NEUROSURGERY, V28, P201, DOI 10.1227/00006123-199102000-00005; Verger E, 2005, INT J RADIAT ONCOL, V61, P185, DOI 10.1016/j.ijrobp.2004.04.061	23	18	19	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2014	9	10							e111475	10.1371/journal.pone.0111475	http://dx.doi.org/10.1371/journal.pone.0111475			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AZ1JF	25347291	Green Published, gold, Green Submitted			2023-01-03	WOS:000347994900079
J	Alves, JP; Nunes, RB; Stefani, GP; Dal Lago, P				Alves, Jadson P.; Nunes, Ramiro B.; Stefani, Giuseppe P.; Dal Lago, Pedro			Resistance Training Improves Hemodynamic Function, Collagen Deposition and Inflammatory Profiles: Experimental Model of Heart Failure	PLOS ONE			English	Article							SKELETAL-MUSCLE; MYOCARDIAL-INFARCTION; EXTRACELLULAR-MATRIX; VENTRICULAR-FUNCTION; EXERCISE; RATS; STRENGTH; CARDIOMYOPATHY; ASSOCIATION; DYSFUNCTION	The role of resistance training on collagen deposition, the inflammatory profile and muscle weakness in heart failure remains unclear. Therefore, this study evaluated the influence of a resistance training program on hemodynamic function, maximum strength gain, collagen deposition and inflammatory profile in chronic heart failure rats. Thirty-two male Wistar rats submitted to myocardial infarction by coronary artery ligation or sham surgery were assigned into four groups: sedentary sham (S-Sham, n = 8); trained sham (T-Sham, n = 8); sedentary chronic heart failure (S-CHF, n = 8) and trained chronic heart failure (T-CHF, n = 8). The maximum strength capacity was evaluated by the one maximum repetition test. Trained groups were submitted to an 8-week resistance training program (4 days/week, 4 sets of 10-12 repetitions/session, at 65% to 75% of one maximum repetition). After 8 weeks of the resistance training program, the T-CHF group showed lower left ventricular end diastolic pressure (P<0.001), higher left ventricular systolic pressure (P<0.05), higher systolic blood pressure (P<0.05), an improvement in the maximal positive derivative of ventricular pressure (P<0.05) and maximal negative derivative of ventricular pressure (P<0.05) when compared to the S-CHF group; no differences were observed when compared to Sham groups. In addition, resistance training was able to reduce myocardial hypertrophy (P<0.05), left ventricular total collagen volume fraction (P<0.01), IL-6 (P<0.05), and TNF-alpha/IL-10 ratio (P<0.05), as well as increasing IL-10 (P<0.05) in chronic heart failure rats when compared to the S-CHF group. Eight weeks of resistance training promotes an improvement of cardiac function, strength gain, collagen deposition and inflammatory profile in chronic heart failure rats.	[Alves, Jadson P.; Nunes, Ramiro B.; Stefani, Giuseppe P.; Dal Lago, Pedro] Univ Fed Ciencias Saude Porto Alegre, Physiol Lab, Porto Alegre, RS, Brazil; [Dal Lago, Pedro] Univ Fed Ciencias Saude Porto Alegre, Dept Phys Therapy, Porto Alegre, RS, Brazil	Universidade Federal de Ciencias da Saude de Porto Alegre; Universidade Federal de Ciencias da Saude de Porto Alegre	Dal Lago, P (corresponding author), Univ Fed Ciencias Saude Porto Alegre, Physiol Lab, Porto Alegre, RS, Brazil.	pdallago@ufcspa.edu.br	Dal Lago, Pedro/AAM-9136-2020; Alves, Jadson/R-1882-2016; Dal Lago, Pedro/K-4414-2013; Stefani, Giuseppe Potrick/D-4561-2014	Dal Lago, Pedro/0000-0001-9907-7689; Dal Lago, Pedro/0000-0001-9907-7689; Stefani, Giuseppe Potrick/0000-0001-5492-4530; Alves, Jadson/0000-0002-4131-6058	CAPES, Brasilia, Brazil; CNPq, Brasilia, Brazil; PROAP/UFCSPA, Porto Alegre, Brazil	CAPES, Brasilia, Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CNPq, Brasilia, Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); PROAP/UFCSPA, Porto Alegre, Brazil	This work was supported by grants from the following: CAPES and CNPq, Brasilia, Brazil, and PROAP/UFCSPA, Porto Alegre, Brazil (http://www.capes.gov.br/; http://www.ufcspa.edu.br/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamopoulos S, 2002, J AM COLL CARDIOL, V39, P653, DOI 10.1016/S0735-1097(01)01795-8; Anker SD, 2004, HEART, V90, P464, DOI 10.1136/hrt.2002.007005; Anker SD, 1997, LANCET, V349, P1050, DOI 10.1016/S0140-6736(96)07015-8; Barauna VG, 2007, CLIN MED RES, V5, P114, DOI 10.3121/cmr.2007.707; Batista ML, 2010, CYTOKINE, V49, P102, DOI 10.1016/j.cyto.2009.10.007; Cheetham C, 2002, J APPL PHYSIOL, V93, P175, DOI 10.1152/japplphysiol.01240.2001; de Cassia Cypriano Ervati Pinter R, 2008, EUROPEAN J APPL PHYS, V103, P605; de Leon EB, 2011, ACTA PHYSIOL, V201, P265, DOI 10.1111/j.1748-1716.2010.02176.x; Emter CA, 2010, AM J PHYSIOL-HEART C, V299, pH1348, DOI 10.1152/ajpheart.00578.2010; Francis J, 2001, AM J PHYSIOL-REG I, V281, pR1734, DOI 10.1152/ajpregu.2001.281.5.R1734; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Georgiadou Panagiota, 2012, Curr Heart Fail Rep, V9, P128, DOI 10.1007/s11897-012-0090-z; Gielen S, 2003, J AM COLL CARDIOL, V42, P861, DOI 10.1016/S0735-1097(03)00848-9; Goswami B, 2009, CLIN CHIM ACTA, V408, P14, DOI 10.1016/j.cca.2009.06.029; Gurtl B, 2009, INT J EXP PATHOL, V90, P338, DOI 10.1111/j.1365-2613.2009.00647.x; Houser SR, 2012, CIRC RES, V111, P131, DOI 10.1161/RES.0b013e3182582523; Hulsmann M, 2004, EUR J HEART FAIL, V6, P101, DOI 10.1016/j.ejheart.2003.07.008; Hunt SA, 2009, CIRCULATION, V119, pE391, DOI 10.1161/CIRCULATIONAHA.109.192065; Hutchinson KR, 2010, J MOL CELL CARDIOL, V48, P564, DOI 10.1016/j.yjmcc.2009.06.001; Jaenisch RB, 2011, J APPL PHYSL; Jankowska EA, 2008, INT J CARDIOL, V130, P36, DOI 10.1016/j.ijcard.2007.07.158; Jannig PR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085820; Krisan AD, 2004, J APPL PHYSIOL, V96, P1691, DOI 10.1152/japplphysiol.01054.2003; Kwan G, 2012, CIRCULATION, V125, pE369, DOI 10.1161/CIRCULATIONAHA.112.093310; Levinger I, 2005, INT J CARDIOL, V105, P159, DOI 10.1016/j.ijcard.2004.11.022; LINDPAINTNER K, 1993, J MOL CELL CARDIOL, V25, P133, DOI 10.1006/jmcc.1993.1017; Lunde PK, 2001, ACTA PHYSIOL SCAND, V171, P277, DOI 10.1046/j.1365-201x.2001.00830.x; Matsubara LS, 2000, AM J PHYSIOL-HEART C, V279, pH1534, DOI 10.1152/ajpheart.2000.279.4.H1534; MCKELVIE RS, 1995, AM J CARDIOL, V76, P977, DOI 10.1016/S0002-9149(99)80277-X; McMurray JJV, 2010, NEW ENGL J MED, V362, P228, DOI 10.1056/NEJMcp0909392; Mihl C, 2008, NETH HEART J, V16, P129, DOI 10.1007/BF03086131; Musch TI, 2002, J APPL PHYSIOL, V92, P2326, DOI 10.1152/japplphysiol.00686.2001; Nunes RB, 2008, J APPL PHYSIOL, V104, P1641, DOI 10.1152/japplphysiol.00062.2008; Palevo G, 2009, J CARDIOPULM REHABIL, V29, P294, DOI 10.1097/HCR.0b013e3181ac784b; PFEFFER MA, 1979, CIRC RES, V44, P503, DOI 10.1161/01.RES.44.4.503; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; Pfeifer PC, 2001, MED SCI SPORT EXER, V33, P542; Piepoli MF, 2001, ACTA PHYSIOL SCAND, V171, P295, DOI 10.1046/j.1365-201x.2001.00831.x; Savage PA, 2011, MED SCI SPORT EXER, V43, P1379, DOI 10.1249/MSS.0b013e31820eeea1; Smart NA, 2013, INT J CARDIOL, V166, P352, DOI 10.1016/j.ijcard.2011.10.075; Vanzelli AS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062452; Weber KT, 2008, J AM COLL CARDIOL, V52, P2029, DOI 10.1016/j.jacc.2008.09.012; WHITTAKER P, 1991, CIRCULATION, V84, P2123, DOI 10.1161/01.CIR.84.5.2123; WHITTAKER P, 1994, BASIC RES CARDIOL, V89, P397, DOI 10.1007/BF00788278; Xu XH, 2008, J MOL CELL CARDIOL, V44, P114, DOI 10.1016/j.yjmcc.2007.10.004; Yengo CM, 2012, MED SCI SPORT EXER, V44, P1005, DOI 10.1249/MSS.0b013e318244bc8a; Yu CM, 1996, EUR HEART J, V17, P1694	47	33	35	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2014	9	10							e110317	10.1371/journal.pone.0110317	http://dx.doi.org/10.1371/journal.pone.0110317			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR5ZY	25340545	Green Published, Green Submitted, gold			2023-01-03	WOS:000343662800030
J	Park, SH; Shin, D; Lim, SS; Lee, JY; Kang, YH				Park, Sin-Hye; Shin, Daekeun; Lim, Soon Sung; Lee, Jae-Yong; Kang, Young-Hee			Purple Perilla Extracts Allay ER Stress in Lipid-Laden Macrophages	PLOS ONE			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; METABOLIC DISEASES; SCAVENGER RECEPTOR; OXIDIZED LDL; CHEMICAL CHAPERONES; INDUCED APOPTOSIS; ATHEROSCLEROSIS; MECHANISMS; INFLAMMATION	There is a growing body of evidence that excess lipids, hypoxic stress and other inflammatory signals can stimulate endoplasmic reticulum (ER) stress in metabolic diseases. However, the pathophysiological importance and the underlying mechanisms of this phenomenon remain unknown. The current study investigated that 50 ng/ml oxidized LDL promoted unfolded protein response (UPR) and ER stress in J774A1 murine macrophages, which was blocked by extracts (PPE) of purple Perilla frutescens, a plant of the mint family Lamiaceae. The ER stressor tunicamycin was employed as a positive control. Treating 1-10 mu g/ml oxidized LDL for 24 h elicited lipotoxic apoptosis in macrophages with obvious nuclear condensation and DNA fragmentation, which was inhibited by PPE. Tunicamycin and oxidized LDL activated and induced the UPR components of activating transcription factor 6 and ER resident chaperone BiP/Grp78 in temporal manners and such effects were blocked by >= 5 mu g/ml PPE. In addition, PPE suppressed the enhanced mRNA transcription and splicing of X-box binding protein 1 (XBP1) by tunicamycin and oxidized LDL. The protein induction and nuclear translocation of XBP1 were deterred in PPE-treated macrophages under ER stress. The induction of ATP-binding cassette transporter A1 (ABCA1), scavenger receptor-B1 (SR-B1) and intracellular adhesion molecule-1 (ICAM-1) was abolished by the ER stressor in activated macrophages. The protein induction of ABCA1 and ICAM1 but not SR-B1 was retrieved by adding 10 mu g/ml PPE to cells. These results demonstrate that PPE inhibited lipotoxic apoptosis and demoted the induction and activation of UPR components in macrophages. PPE restored normal proteostasis in activated macrophages oxidized LDL. Therefore, PPE was a potent agent antagonizing macrophage ER stress due to lipotoxic signals associated with atherosclerosis.	[Park, Sin-Hye; Shin, Daekeun; Lim, Soon Sung; Kang, Young-Hee] Hallym Univ, Dept Food Sci & Nutr, Chunchon, Kangwon Do, South Korea; [Lee, Jae-Yong] Hallym Univ, Dept Biochem, Chunchon, Kangwon Do, South Korea	Hallym University; Hallym University	Kang, YH (corresponding author), Hallym Univ, Dept Food Sci & Nutr, Chunchon, Kangwon Do, South Korea.	yhkang@hallym.ac.kr			High Value-added Food Technology Development Program, Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries [112085-03-1-SB010]; National Research Foundation of Korea through the Human Resource Training Project for Regional Innovation [2012-01-A-05-003-12-010100]	High Value-added Food Technology Development Program, Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries; National Research Foundation of Korea through the Human Resource Training Project for Regional Innovation(National Research Foundation of Korea)	This study was supported by High Value-added Food Technology Development Program, Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries (112085-03-1-SB010) and by National Research Foundation of Korea through the Human Resource Training Project for Regional Innovation (2012-01-A-05-003-12-010100). The funders had no role in study design, data collection and analyses, decision to publish, or preparation of the manuscript.	Bernales S, 2012, FRONT AGING NEUROSCI, V4, DOI 10.3389/fnagi.2012.00005; Bravo R, 2013, INT REV CEL MOL BIO, V301, P215, DOI 10.1016/B978-0-12-407704-1.00005-1; Cao SS, 2013, EXPERT OPIN THER TAR, V17, P437, DOI 10.1517/14728222.2013.756471; Chuang CC, 2011, ANNU REV NUTR, V31, P155, DOI 10.1146/annurev-nutr-072610-145149; DeVries-Seimon T, 2005, J CELL BIOL, V171, P61, DOI 10.1083/jcb.200502078; Ding Y, 2013, MOL NUTR FOOD RES, V57, P365, DOI 10.1002/mnfr.201200463; Engin F, 2010, DIABETES OBES METAB, V12, P108, DOI 10.1111/j.1463-1326.2010.01282.x; Erbay E, 2009, NAT MED, V15, P1383, DOI 10.1038/nm.2067; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Iwawaki T, 2013, SEMIN IMMUNOPATHOL, V35, P333, DOI 10.1007/s00281-013-0369-5; Jeong YJ, 2005, BRIT J NUTR, V93, P581, DOI 10.1079/BJN20041397; Ji AL, 2011, ATHEROSCLEROSIS, V217, P106, DOI 10.1016/j.atherosclerosis.2011.03.017; Lee J, 2014, J BIOL CHEM, V289, P1203, DOI 10.1074/jbc.R113.534743; Li DY, 2005, CARDIOVASC RES, V68, P353, DOI 10.1016/j.cardiores.2005.09.009; Liu JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077458; Minamino T, 2010, CIRC RES, V107, P1071, DOI 10.1161/CIRCRESAHA.110.227819; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Paek JH, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/679463; Pagliassotti MJ, 2012, ANNU REV NUTR, V32, P17, DOI 10.1146/annurev-nutr-071811-150644; Park SH, 2011, J NUTR, V141, P1931, DOI 10.3945/jn.111.144816; Park S, 2010, J AGR FOOD CHEM, V58, P1551, DOI 10.1021/jf903432b; Ryno LM, 2013, CURR OPIN CHEM BIOL, V17, P346, DOI 10.1016/j.cbpa.2013.04.009; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Tabas I, 2009, ANN NY ACAD SCI, V1173, pE40, DOI 10.1111/j.1749-6632.2009.04957.x; Tabata Y, 2007, AM J PHYSIOL-CELL PH, V293, pC411, DOI 10.1152/ajpcell.00095.2007; Valacchi G, 2011, ANN NY ACAD SCI, V1229, pE1, DOI 10.1111/j.1749-6632.2011.06205.x; Vandewynckel YP, 2013, ANTICANCER RES, V33, P4683; Yao ST, 2012, EXP BIOL MED, V237, P822, DOI 10.1258/ebm.2012.012027; Yokoyama S, 2006, J ATHEROSCLER THROMB, V13, P1, DOI 10.5551/jat.13.1; Yoshiuchi K, 2009, ENDOCR J, V56, P1103, DOI 10.1507/endocrj.K09E-140; Zhao H, 2008, HYPERTENS RES, V31, P1977, DOI 10.1291/hypres.31.1977; Zhou AX, 2013, SEMIN IMMUNOPATHOL, V35, P321, DOI 10.1007/s00281-013-0372-x; Zingg JM, 2013, BIOFACTORS, V39, P101, DOI 10.1002/biof.1072	35	10	14	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2014	9	10							e110581	10.1371/journal.pone.0110581	http://dx.doi.org/10.1371/journal.pone.0110581			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX2IH	25333946	Green Submitted, Green Published, gold			2023-01-03	WOS:000346766200126
J	Li, L; Lin, M; Krassilnikova, M; Ostrow, K; Bader, A; Radbill, B; Uribarri, J; Tokita, J; Leisman, S; Lapsia, V; Albrecht, RA; Garcia-Sastre, A; Branch, AD; Heeger, PS; Mehrotra, A				Li, Lily; Lin, Marvin; Krassilnikova, Maria; Ostrow, Katya; Bader, Amanda; Radbill, Brian; Uribarri, Jaime; Tokita, Joji; Leisman, Staci; Lapsia, Vijay; Albrecht, Randy A.; Garcia-Sastre, Adolfo; Branch, Andrea D.; Heeger, Peter S.; Mehrotra, Anita			Effect of Cholecalciferol Supplementation on Inflammation and Cellular Alloimmunity in Hemodialysis Patients: Data from a Randomized Controlled Pilot Trial	PLOS ONE			English	Article							VITAMIN-D DEFICIENCY; T-CELL; ALLOGRAFT SURVIVAL; MINERAL METABOLISM; DIFFERENTIATION; POSTTRANSPLANT; MATURATION; REJECTION; IMMUNITY; BARRIER	Background: Memory T-cells are mediators of transplant injury, and no therapy is known to prevent the development of cross-reactive memory alloimmunity. Activated vitamin D is immunomodulatory, and vitamin D deficiency, common in hemodialysis patients awaiting transplantation, is associated with a heightened alloimmune response. Thus, we tested the hypothesis that vitamin D-3 supplementation would prevent alloreactive T-cell memory formation in vitamin D-deficient hemodialysis patients. Methods and Findings: We performed a 12-month single-center pilot randomized, controlled trial of 50,000 IU/week of cholecalciferol (D-3) versus no supplementation in 96 hemodialysis patients with serum 25(OH)D<25 ng/mL, measuring effects on serum 25(OH) D and phenotypic and functional properties of T-cells. Participants were randomized 2: 1 to active treatment versus control. D-3 supplementation increased serum 25(OH) D at 6 weeks (13.5 [ 11.2] ng/mL to 42.5 [ 18.5] ng/mL, p<0.001) and for the duration of the study. No episodes of sustained hypercalcemia occurred in either group. Results of IFN gamma ELISPOT-based panel of reactive T-cell assays (PRT), quantifying alloreactive memory, demonstrated greater increases in the controls over 1 year compared to the treatment group (delta PRT in treatment 104.8+/2330.8 vs 252.9+/2431.3 in control), but these changes in PRT between groups did not reach statistical significance (p = 0.25). Conclusions: D-3 supplements are safe, effective at treating vitamin D deficiency, and may prevent time-dependent increases in T-cell alloimmunity in hemodialysis patients, but their effects on alloimmunity need to be confirmed in larger studies. These findings support the routine supplementation of vitamin D-deficient transplant candidates on hemodialysis and highlight the need for large-scale prospective studies of vitamin D supplementation in transplant candidates and recipients.	[Li, Lily; Lin, Marvin; Krassilnikova, Maria; Ostrow, Katya; Bader, Amanda; Radbill, Brian; Uribarri, Jaime; Tokita, Joji; Leisman, Staci; Lapsia, Vijay; Heeger, Peter S.; Mehrotra, Anita] Icahn Sch Med Mt Sinai, Div Nephrol, New York, NY 10029 USA; [Li, Lily; Lin, Marvin; Krassilnikova, Maria; Ostrow, Katya; Bader, Amanda; Radbill, Brian; Uribarri, Jaime; Tokita, Joji; Leisman, Staci; Lapsia, Vijay; Garcia-Sastre, Adolfo; Branch, Andrea D.; Heeger, Peter S.; Mehrotra, Anita] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA; [Heeger, Peter S.] Icahn Sch Med Mt Sinai, Recanati Miller Transplantat Inst, New York, NY 10029 USA; [Heeger, Peter S.] Icahn Sch Med Mt Sinai, Inst Immunol, New York, NY 10029 USA; [Albrecht, Randy A.; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA; [Albrecht, Randy A.; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA; [Branch, Andrea D.] Icahn Sch Med Mt Sinai, Div Liver Dis, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Mehrotra, A (corresponding author), Icahn Sch Med Mt Sinai, Div Nephrol, New York, NY 10029 USA.	anita.mehrotra@mssm.edu	Li, Lily/AAN-6297-2020; Albrecht, Randy A./H-5119-2019	Li, Lily/0000-0002-9794-8468; Albrecht, Randy A./0000-0003-4008-503X; Garcia-Sastre, Adolfo/0000-0002-6551-1827	Doris Duke Charitable Foundation; National Kidney Foundation; American Heart Association; National Institute of Health from the National Center for Advancing Translational Sciences [DK090317, DA0301095, U01AI063594, U19AI089987, UL1TR000067]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI089987, U01AI063594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK090317] Funding Source: NIH RePORTER	Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); National Kidney Foundation; American Heart Association(American Heart Association); National Institute of Health from the National Center for Advancing Translational Sciences; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the Doris Duke Charitable Foundation (LL), National Kidney Foundation (PSH), American Heart Association (AM), and National Institute of Health: DK090317, DA0301095 (ADB), U01AI063594 (PSH), U19AI089987 (AG-S, RA), and UL1TR000067 from the National Center for Advancing Translational Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams AB, 2003, J CLIN INVEST, V111, P1887, DOI 10.1172/JCI200317477; Adorini L, 2001, TRANSPLANT P, V33, P58, DOI 10.1016/S0041-1345(00)02262-4; Augustine JF, 2007, J AM SOC NEPHROL, V18, P1602, DOI 10.1681/ASN.2006101105; BHALLA AK, 1984, J IMMUNOL, V133, P1748; Bienaime F, 2013, J AM SOC NEPHROLOGY; Bjelakovic G, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007470.pub2; Boonstra A, 2001, J IMMUNOL, V167, P4974, DOI 10.4049/jimmunol.167.9.4974; de Baey A, 2001, EUR J IMMUNOL, V31, P1646, DOI 10.1002/1521-4141(200106)31:6<1646::AID-IMMU1646>3.0.CO;2-X; Goodkin DA, 2003, J AM SOC NEPHROL, V14, P3270, DOI 10.1097/01.ASN.0000100127.54107.57; Heeger PS, 1999, J IMMUNOL, V163, P2267; Hewison M, 2007, J STEROID BIOCHEM, V103, P316, DOI 10.1016/j.jsbmb.2006.12.078; Hewison M, 2011, VITAM HORM, V86, P23, DOI 10.1016/B978-0-12-386960-9.00002-2; Hricik DE, 2003, AM J TRANSPLANT, V3, P878, DOI 10.1034/j.1600-6143.2003.00132.x; Jean G, 2008, NEPHROL DIAL TRANSPL, V23, P3670, DOI 10.1093/ndt/gfn339; Jeffery LE, 2012, J IMMUNOL, V189, P5155, DOI 10.4049/jimmunol.1200786; Kim H, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-22; Lavin PJ, 2007, RENAL FAILURE, V29, P785, DOI 10.1080/08860220701540417; Lee JR, 2014, TRANSPLANTATION, V98, P292, DOI 10.1097/TP.0000000000000055; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Looker Anne C, 2011, NCHS Data Brief, P1; Matias PJ, 2010, CLIN J AM SOC NEPHRO, V5, P905, DOI 10.2215/CJN.06510909; Nadazdin O, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002093; Nair V, 2012, CLIN TRANSPLANT, V26, pE261, DOI 10.1111/j.1399-0012.2012.01657.x; Penna G, 2000, J IMMUNOL, V164, P2405, DOI 10.4049/jimmunol.164.5.2405; Piemonti L, 2000, J IMMUNOL, V164, P4443, DOI 10.4049/jimmunol.164.9.4443; Poggio ED, 2007, TRANSPLANTATION, V83, P847, DOI 10.1097/01.tp.0000258730.75137.39; Pramyothin P, 2012, CURR OPIN GASTROEN, V28, P139, DOI 10.1097/MOG.0b013e32835004dc; Saab G, 2007, NEPHRON CLIN PRACT, V105, P132, DOI 10.1159/000098645; Saghaei Mahmood, 2004, BMC Med Res Methodol, V4, P26, DOI 10.1186/1471-2288-4-26; Sawinski D, 2010, AM J TRANSPLANT, V10, P2287, DOI 10.1111/j.1600-6143.2010.03264.x; Schenk AD, 2008, AM J TRANSPLANT, V8, P1652, DOI 10.1111/j.1600-6143.2008.02302.x; Valujskikh A, 2002, AM J TRANSPLANT, V2, P501, DOI 10.1034/j.1600-6143.2002.20603.x; Wasse H, 2012, AM J CLIN NUTR, V95, P522, DOI 10.3945/ajcn.111.025502; Wu ZH, 2004, NAT MED, V10, P87, DOI 10.1038/nm965; Zand MS, 2005, AM J TRANSPLANT, V5, P76, DOI 10.1111/j.1600-6143.2003.00637.x; Ziegler-Heitbrock L, 2007, J LEUKOCYTE BIOL, V81, P584, DOI 10.1189/jlb.0806510	36	12	14	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 8	2014	9	10							e109998	10.1371/journal.pone.0109998	http://dx.doi.org/10.1371/journal.pone.0109998			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8TE	25296334	Green Submitted, gold, Green Published			2023-01-03	WOS:000345204000109
J	Kilickaya, O; Schmickl, C; Ahmed, A; Pulido, J; Onigkeit, J; Kashani, K; Gajic, O; Herasevich, V; Pickering, B				Kilickaya, Oguz; Schmickl, Christopher; Ahmed, Adil; Pulido, Juan; Onigkeit, James; Kashani, Kianoush; Gajic, Ognjen; Herasevich, Vitaly; Pickering, Brian			Customized Reference Ranges for Laboratory Values Decrease False Positive Alerts in Intensive Care Unit Patients	PLOS ONE			English	Article							INFORMATION OVERLOAD; USER INTERFACES; ALARMS; ICU; THERAPY; RECORD; TESTS	Background: Traditional electronic medical record (EMR) interfaces mark laboratory tests as abnormal based on standard reference ranges derived from healthy, middle-aged adults. This yields many false positive alerts with subsequent alert-fatigue when applied to complex populations like hospitalized, critically ill patients. Novel EMR interfaces using adjusted reference ranges customized for specific patient populations may ameliorate this problem. Objective: To compare accuracy of abnormal laboratory value indicators in a novel vs traditional EMR interface. Methods: Laboratory data from intensive care unit (ICU) patients consecutively admitted during a two-day period were recorded. For each patient, available laboratory results and the problem list were sent to two mutually blinded critical care experts, who marked the values about which they would like to be alerted. All disagreements were resolved by an independent super-reviewer. Based on this gold standard, we calculated and compared the sensitivity, specificity, positive and negative predictive values (PPV, NPV) of customized vs traditional abnormal value indicators. Results: Thirty seven patients with a total of 1341 laboratory results were included. Experts' agreement was fair (kappa = 0.39). Compared to the traditional EMR, custom abnormal laboratory value indicators had similar sensitivity (77% vs 85%, P = 0.22) and NPV (97.1% vs 98.6%, P = 0.06) but higher specificity (79% vs 61%, P<0.001) and PPV (28% vs 11%, P<0.001). Conclusions: Reference ranges for laboratory values customized for an ICU population decrease false positive alerts. Disagreement among clinicians about which laboratory values should be indicated as abnormal limits the development of customized reference ranges.	[Kilickaya, Oguz; Schmickl, Christopher; Ahmed, Adil; Pulido, Juan; Onigkeit, James; Gajic, Ognjen; Herasevich, Vitaly; Pickering, Brian] Mayo Clin, Dept Med, Div Pulm & Crit Care Med, Multidisciplinary Epidemiol & Translat Res Intens, Rochester, MN 55905 USA; [Schmickl, Christopher] Univ Witten Herdecke, Witten, Germany; [Pulido, Juan; Onigkeit, James; Gajic, Ognjen; Herasevich, Vitaly; Pickering, Brian] Mayo Clin, Dept Anesthesiol, Div Crit Care, Rochester, MN USA; [Kashani, Kianoush] Mayo Clin, Dept Med, Div Pulm & Crit Care, Rochester, MN USA; [Kashani, Kianoush] Mayo Clin, Dept Med, Div Nephrol & Hypertens, Rochester, MN USA	Mayo Clinic; Witten Herdecke University; Mayo Clinic; Mayo Clinic; Mayo Clinic	Pickering, B (corresponding author), Mayo Clin, Dept Med, Div Pulm & Crit Care Med, Multidisciplinary Epidemiol & Translat Res Intens, Rochester, MN 55905 USA.	Pickering.Brian@mayo.edu	Herasevich, Vitaly/V-4000-2019	Herasevich, Vitaly/0000-0002-0214-0651; Schmickl, Christopher/0000-0001-5417-9980	Centers for Medicare and Medicaid Service, Center for Medicare and Medicaid Innovation, a component of the United States Department of Human Health and Services (HHS) [CMS-1C1-12-0001]; CTSA from National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1 TR000135]	Centers for Medicare and Medicaid Service, Center for Medicare and Medicaid Innovation, a component of the United States Department of Human Health and Services (HHS); CTSA from National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	The study was supported (VH, BP, OG) by Funding Opportunity Number CMS-1C1-12-0001 from the Centers for Medicare and Medicaid Service, Center for Medicare and Medicaid Innovation (http://www.cms.gov/), a component of the United States Department of Human Health and Services (HHS). This study was further supported (OK) in part by CTSA Grant Number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS, http://www.ncats.nih.gov/), a component of the National Institutes of Health (NIH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The contents of this report are solely the responsibility of the authors and do not necessarily represent the official view of HHS or any of its agencies (including NIH).	Ahmed A, 2011, CRIT CARE MED, V39, P1626, DOI 10.1097/CCM.0b013e31821858a0; Brigden ML, 2000, POSTGRAD MED, V107, P145; Carlsson L, 2010, GERONTOLOGY, V56, P259, DOI 10.1159/000251722; CARPENTER PC, 1994, INT J BIOMED COMPUT, V34, P159, DOI 10.1016/0020-7101(94)90019-1; Chambrin MC, 1999, INTENS CARE MED, V25, P1360, DOI 10.1007/s001340051082; Herasevich V, 2010, MAYO CLIN PROC, V85, P247, DOI 10.4065/mcp.2009.0479; Hwang MI, 1999, J INFORM SCI, V25, P213, DOI 10.1177/016555159902500305; LAWLESS ST, 1994, CRIT CARE MED, V22, P981, DOI 10.1097/00003246-199406000-00017; Lundberg, 1972, MED LAB OBSERV, V4, P47; OCARROLL TM, 1986, ANAESTHESIA, V41, P742, DOI 10.1111/j.1365-2044.1986.tb12844.x; Pickering BW, 2009, AM J RESP CRIT CARE, V179; Pickering BW, 2010, APPL CLIN INFORM, V1, P116, DOI 10.4338/ACI-2009-12-CR-0027; Pickering BW, 2013, CRIT CARE MED, V41, P1502, DOI 10.1097/CCM.0b013e318287f0c0; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; The Joint Commission on Accreditation of Healthcare Organizations, LAB SERV 2014 NAT PA	15	6	6	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2014	9	9							e107930	10.1371/journal.pone.0107930	http://dx.doi.org/10.1371/journal.pone.0107930			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ6KR	25233485	Green Published, Green Submitted, gold			2023-01-03	WOS:000342921200062
J	Amjad, MW; Amin, MCIM; Mahali, SM; Katas, H; Ismail, I; ul Hassan, MN; Chuang, VTG				Amjad, M. Wahab; Amin, Mohd Cairul I. Mohd; Mahali, Shalela M.; Katas, Haliza; Ismail, Ismanizan; ul Hassan, M. Naeem; Chuang, Victor T. Giam			Nanoscale Diblock Copolymer Micelles: Characterizations and Estimation of the Effective Diffusion Coefficients of Biomolecules Release through Cylindrical Diffusion Model	PLOS ONE			English	Article							CONTROLLED DRUG-DELIVERY; BIOMEDICAL APPLICATIONS; CHITOSAN NANOPARTICLES; BIODEGRADABLE POLYMERS; TARGETED DELIVERY; TAT PEPTIDE; BSA; THERAPEUTICS; STABILITY; BIOLOGY	Biomolecules have been widely investigated as potential therapeutics for various diseases. However their use is limited due to rapid degradation and poor cellular uptake in vitro and in vivo. To address this issue, we synthesized a new nano-carrier system comprising of cholic acid-polyethylenimine (CA-PEI) copolymer micelles, via carbodiimide-mediated coupling for the efficient delivery of small interfering ribonucleic acid (siRNA) and bovine serum albumin (BSA) as model protein. The mean particle size of siRNA- or BSA-loaded CA-PEI micelles ranged from 100-150 nm, with zeta potentials of +3-+11 mV, respectively. Atomic force, transmission electron and field emission scanning electron microscopy demonstrated that the micelles exhibited excellent spherical morphology. No significant morphology or size changes were observed in the CA-PEI micelles after siRNA and BSA loading. CA-PEI micelles exhibited sustained release profile, the effective diffusion coefficients were successfully estimated using a mathematically-derived cylindrical diffusion model and the release data of siRNA and BSA closely fitted into this model. High siRNA and BSA binding and loading efficiencies (95% and 70%, respectively) were observed for CA-PEI micelles. Stability studies demonstrated that siRNA and BSA integrity was maintained after loading and release. The CA-PEI micelles were non cytotoxic to V79 and DLD-1 cells, as shown by alamarBlue and LIVE/DEAD cell viability assays. RT-PCR study revealed that siRNA-loaded CA-PEI micelles suppressed the mRNA for ABCB1 gene. These results revealed the promising potential of CA-PEI micelles as a stable, safe, and versatile nano-carrier for siRNA and the model protein delivery.	[Amjad, M. Wahab; Amin, Mohd Cairul I. Mohd; Katas, Haliza] Univ Kebangsaan Malaysia, Fac Pharm, Ctr Drug Delivery Res, Kuala Lumpur, Fed Territory, Malaysia; [Mahali, Shalela M.] Univ Malaysia Terengganu, Sch Informat & Appl Math, Kuala Terengganu, Terengganu, Malaysia; [Ismail, Ismanizan; ul Hassan, M. Naeem] Univ Kebangsaan Malaysia, Inst Syst Biol, Bangi 43600, Selangor, Malaysia; [Chuang, Victor T. Giam] Curtin Univ, Fac Hlth Sci, Curtin Hlth Innovat Res Inst, Sch Pharm, Perth, WA 6845, Australia	Universiti Kebangsaan Malaysia; Universiti Malaysia Terengganu; Universiti Kebangsaan Malaysia; Curtin University	Mahali, SM (corresponding author), Univ Kebangsaan Malaysia, Fac Pharm, Ctr Drug Delivery Res, Kuala Lumpur, Fed Territory, Malaysia.	mciamin@pharmacy.ukm.my	Mohd Mahali, Shalela Mohd/AAX-7558-2021; Chuang, Victor/A-3644-2011; Naeem-ul-Hassan, Muhammad/K-8886-2019; Amjad, Muhammad Wahab/AHA-5553-2022; KATAS, HALIZA/I-6417-2016	Chuang, Victor/0000-0002-2141-630X; Naeem-ul-Hassan, Muhammad/0000-0003-3709-6248; KATAS, HALIZA/0000-0001-7249-1628; MAHALI, SHALELA/0000-0003-3458-991X; Amjad, Muhammad Wahab/0000-0002-5832-8602	Universiti Kebangsaan Malaysia (UKM) [UKM-GUP-SK-07-23-045]; Ministry of Science, Technology and Innovation, Malaysia [02-01-02-SF0738]	Universiti Kebangsaan Malaysia (UKM); Ministry of Science, Technology and Innovation, Malaysia(Ministry of Energy, Science, Technology, Environment and Climate Change (MESTECC), Malaysia)	This project was funded by a Research University Grant (UKM-GUP-SK-07-23-045) from Universiti Kebangsaan Malaysia (UKM) and Science Fund (02-01-02-SF0738) from the Ministry of Science, Technology and Innovation, Malaysia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali-Boucetta H, 2008, CHEM COMMUN, P459, DOI 10.1039/b712350g; Amjad MW, 2012, NANOSCALE RES LETT, V7, DOI 10.1186/1556-276X-7-687; Bowman K, 2006, INT J NANOMED, V1, P117, DOI 10.2147/nano.2006.1.2.117; Butt AM, 2012, J NANOMATER, V2012, DOI 10.1155/2012/916573; Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002; Chaudhuri P, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/2/025102; Check E, 2005, NAT MED, V11, P243, DOI 10.1038/nm0305-243; Dash S, 2010, ACTA POL PHARM, V67, P217; Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614; De M, 2008, ADV MATER, V20, P4225, DOI 10.1002/adma.200703183; Devalapally H, 2007, J PHARM SCI-US, V96, P2547, DOI 10.1002/jps.20875; DeVincenzo J, 2008, ANTIVIR RES, V77, P225, DOI 10.1016/j.antiviral.2007.11.009; Han XL, 2012, J PHOTOCH PHOTOBIO B, V109, P1, DOI 10.1016/j.jphotobiol.2011.12.010; Katas H, 2006, J CONTROL RELEASE, V115, P216, DOI 10.1016/j.jconrel.2006.07.021; Kirchhoff F, 2008, CELL, V134, P566, DOI 10.1016/j.cell.2008.08.004; Langer R, 2004, NATURE, V428, P487, DOI 10.1038/nature02388; Larsericsdotter H, 2005, J COLLOID INTERF SCI, V289, P26, DOI 10.1016/j.jcis.2005.03.064; Li YL, 2012, CHEM SOC REV, V41, P2193, DOI 10.1039/c1cs15203c; Liu HA, 2011, INVEST OPHTH VIS SCI, V52, P4789, DOI 10.1167/iovs.10-5891; Liu TY, 2005, J CONTROL RELEASE, V107, P112, DOI 10.1016/j.jconrel.2005.05.025; Luckachan GE, 2011, J POLYM ENVIRON, V19, P637, DOI 10.1007/s10924-011-0317-1; Maeda H, 2001, J CONTROL RELEASE, V74, P47, DOI 10.1016/S0168-3659(01)00309-1; Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5; Manosroi J, 2013, DRUG DEV IND PHARM, V39, P520, DOI 10.3109/03639045.2012.684388; Mora-Huertas CE, 2010, INT J PHARMACEUT, V385, P113, DOI 10.1016/j.ijpharm.2009.10.018; Narla SN, 2014, BIOCHEM BIOPH RES CO, V443, P562, DOI 10.1016/j.bbrc.2013.12.006; Sakai-Kato K, 2003, J PHARMACEUT BIOMED, V31, P299, DOI 10.1016/S0731-7085(02)00638-6; Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008; Ulery BD, 2011, J POLYM SCI POL PHYS, V49, P832, DOI 10.1002/polb.22259; Wang S, 2009, J IND MANAG OPTIM, V5, P127, DOI 10.3934/jimo.2009.5.127	30	2	2	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2014	9	8							e105234	10.1371/journal.pone.0105234	http://dx.doi.org/10.1371/journal.pone.0105234			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4JF	25133390	Green Published, Green Submitted, gold			2023-01-03	WOS:000341302700093
J	Davanco, MG; Aguiar, ACC; dos Santos, LA; Padilha, EC; Campos, ML; de Andrade, CR; da Fonseca, LM; dos Santos, JL; Chin, CM; Krettli, AU; Peccinini, RG				Davanco, Marcelo Gomes; Campos Aguiar, Anna Caroline; dos Santos, Leandro Alves; Padilha, Elias Carvalho; Campos, Michel Leandro; de Andrade, Cleverton Roberto; da Fonseca, Luiz Marcos; dos Santos, Jean Leandro; Chin, Chung Man; Krettli, Antoniana Ursine; Peccinini, Rosangela Goncalves			Evaluation of Antimalarial Activity and Toxicity of a New Primaquine Prodrug	PLOS ONE			English	Article							PLASMODIUM-GALLINACEUM; DIPEPTIDE DERIVATIVES; IN-VITRO; DRUGS; ERYTHROCYTES; DISCOVERY; MEMBRANE; SCREEN; RAT	Plasmodium vivax is the most prevalent of the five species causing malaria in humans. The current available treatment for P. vivax malaria is limited and unsatisfactory due to at least two drawbacks: the undesirable side effects of primaquine (PQ) and drug resistance to chloroquine. Phenylalanine-alanine-PQ (Phe-Ala-PQ) is a PQ prodrug with a more favorable pharmacokinetic profile compared to PQ. The toxicity of this prodrug was evaluated in in vitro assays using a human hepatoma cell line (HepG2), a monkey kidney cell line (BGM), and human red blood cells deficient in the enzyme glucose-6-phosphate-dehydrogenase (G6PD). In addition, in vivo toxicity assays were performed with rats that received multiple doses of Phe-Ala-PQ to evaluate biochemical, hematological, and histopathological parameters. The activity was assessed by the inhibition of the sporogonic cycle using a chicken malaria parasite. Phe-Ala-PQ blocked malaria transmission in Aedes mosquitoes. When compared with PQ, it was less cytotoxic to BGM and HepG2 cells and caused less hemolysis of G6PD-deficient red blood cells at similar concentrations. The prodrug caused less alteration in the biochemical parameters than did PQ. Histopathological analysis of the liver and kidney did show differences between the control and Phe-Ala-PQ-treated groups, but they were not statistically significant. Taken together, the results highlight the prodrug as a novel lead compound candidate for the treatment of P. vivax malaria and as a blocker of malaria transmission.	[Davanco, Marcelo Gomes; Padilha, Elias Carvalho; Campos, Michel Leandro; Peccinini, Rosangela Goncalves] Univ Estadual Paulista UNESP, Fac Ciencias Farm, Dept Principios Ativos Nat & Toxicol, Sao Paulo, Brazil; [Campos Aguiar, Anna Caroline; Krettli, Antoniana Ursine] Fiocruz MS, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil; [dos Santos, Leandro Alves; de Andrade, Cleverton Roberto] Univ Estadual Paulista UNESP, Fac Odontol Araraquara, Dept Fisiol & Patol, Sao Paulo, Brazil; [da Fonseca, Luiz Marcos] Univ Estadual Paulista UNESP, Fac Ciencias Farm, Dept Anal Clin, Sao Paulo, Brazil; [dos Santos, Jean Leandro; Chin, Chung Man] Univ Estadual Paulista UNESP, Fac Ciencias Farm, Lab Pesquisa & Desenvolvimento Farmacos Lapdesf, Sao Paulo, Brazil	Universidade Estadual Paulista; Fundacao Oswaldo Cruz; Universidade Estadual Paulista; Universidade Estadual Paulista; Universidade Estadual Paulista	Peccinini, RG (corresponding author), Univ Estadual Paulista UNESP, Fac Ciencias Farm, Dept Principios Ativos Nat & Toxicol, Sao Paulo, Brazil.	peccinin@fcfar.unesp.br	Chin, Chung Man/W-2762-2019; Davanço, Marcelo Gomes/A-7196-2015; Chung/AAP-8459-2021; de+Andrade, Cleverton Roberto/AAA-6683-2019; de Andrade, Cleverton Roberto Roberto/D-9138-2012; Peccinini, Rosangela/G-6068-2015; Dos Santos, Jean Leandro/O-9111-2019; Padilha, Elias Carvalho/J-5671-2015; Santos, Jean Leandro dos/E-8753-2016; de Campos, Michel Leandro/G-2855-2014; Aguiar, Anna Caroline/J-6970-2015; Man Chin, Chung/C-2259-2013	de+Andrade, Cleverton Roberto/0000-0001-7015-7175; de Andrade, Cleverton Roberto Roberto/0000-0001-7015-7175; Peccinini, Rosangela/0000-0002-2692-8101; Padilha, Elias Carvalho/0000-0002-3794-9389; Santos, Jean Leandro dos/0000-0002-2460-2829; de Campos, Michel Leandro/0000-0002-7147-7637; Aguiar, Anna Caroline/0000-0003-0139-8279; Alves dos Santos, Leandro/0000-0001-8088-5790; Man Chin, Chung/0000-0003-4141-0455	Sao Paulo Research Foundation - FAPESP [09/51075-5, 11/11239-9]; National Institute of Science and Technology - Pharmaceutical Innovation (INCT-if); Coordination for the Improvement of Higher Education Personnel - CAPES; National Council for Scientific and Technological Development - CNPq (Neglected Diseases); Minas Gerais State Research Foundation - FAPEMIG	Sao Paulo Research Foundation - FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); National Institute of Science and Technology - Pharmaceutical Innovation (INCT-if); Coordination for the Improvement of Higher Education Personnel - CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); National Council for Scientific and Technological Development - CNPq (Neglected Diseases)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Minas Gerais State Research Foundation - FAPEMIG(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG))	This work was supported by Sao Paulo Research Foundation - FAPESP (process 09/51075-5 and process 11/11239-9, http://www.bv.fapesp.br/5394 and http://www.bv.fapesp.br/5395); National Institute of Science and Technology - Pharmaceutical Innovation (INCT-if); Coordination for the Improvement of Higher Education Personnel - CAPES; National Council for Scientific and Technological Development - CNPq (Neglected Diseases, Project 2012-14); and Minas Gerais State Research Foundation - FAPEMIG. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	ALVING A S, 1960, Bull World Health Organ, V22, P621; Baird JK, 2004, CLIN INFECT DIS, V39, P1336, DOI 10.1086/424663; Bell A, 2005, FEMS MICROBIOL LETT, V253, P171, DOI 10.1016/j.femsle.2005.09.035; BREWER GJ, 1962, JAMA-J AM MED ASSOC, V180, P386, DOI 10.1001/jama.1962.03050180032008; CARVALHO LH, 1992, BRAZ J MED BIOL RES, V25, P247; Charman SA, 2011, P NATL ACAD SCI USA, V108, P4400, DOI 10.1073/pnas.1015762108; Chung MC, 1997, J PHARM SCI, V86, P1127, DOI 10.1021/js970006v; Cushion MT, 2009, CURR MED CHEM, V16, P2514, DOI 10.2174/092986709788682038; Davanco MG, 2012, BIOPHARM DRUG DISPOS, V33, P437, DOI 10.1002/bdd.1807; de Madureira MD, 2002, J ETHNOPHARMACOL, V81, P23, DOI 10.1016/S0378-8741(02)00005-3; Dembele L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018162; Deye GA, 2012, AM J TROP MED HYG, V86, P931, DOI 10.4269/ajtmh.2012.11-0552; FERRANTE A, 1984, PARASITE IMMUNOL, V6, P571, DOI 10.1111/j.1365-3024.1984.tb00826.x; FRASER IM, 1968, ANN NY ACAD SCI, V151, P777, DOI 10.1111/j.1749-6632.1968.tb48261.x; GINSBURG H, 1988, BIOCHEM PHARMACOL, V37, P2013, DOI 10.1016/0006-2952(88)90549-7; GWADZ RW, 1983, EXP PARASITOL, V55, P188, DOI 10.1016/0014-4894(83)90013-9; Heurtault B, 2001, ANN TROP MED PARASIT, V95, P529, DOI 10.1080/00034980120067226; Katsuragawa Tony H., 2004, Rev. Bras. Hematol. Hemoter., V26, P268, DOI 10.1590/S1516-84842004000400007; Kaur K, 2011, BIOORGAN MED CHEM, V19, P197, DOI 10.1016/j.bmc.2010.11.036; Kim T, 2009, J INFECT CHEMOTHER, V15, P343, DOI 10.1007/s10156-009-0710-z; LORKE D, 1983, ARCH TOXICOL, V54, P275, DOI 10.1007/BF01234480; Luzzatto L, 2014, BRIT J HAEMATOL, V164, P469, DOI 10.1111/bjh.12665; Mata G, 2012, BIOORGAN MED CHEM, V20, P886, DOI 10.1016/j.bmc.2011.11.059; MIHALY GW, 1984, BRIT J CLIN PHARMACO, V17, P441, DOI 10.1111/j.1365-2125.1984.tb02369.x; Na-Bangchang K, 2009, FUND CLIN PHARMACOL, V23, P387, DOI 10.1111/j.1472-8206.2009.00709.x; Naoum Paulo Cesar, 2004, Rev. Bras. Hematol. Hemoter., V26, P19, DOI 10.1590/S1516-84842004000100004; Noel S, 2007, TOXICOLOGY, V239, P96, DOI 10.1016/j.tox.2007.06.098; PHILIP A, 1988, J MED CHEM, V31, P870, DOI 10.1021/jm00399a032; Portela MJ, 1999, PHARM RES-DORDR, V16, P949, DOI 10.1023/A:1018922425551; Schiff U, 1866, CLIN TESTS HISTOPATH, P100; SCHLESINGER PH, 1988, ANTIMICROB AGENTS CH, V32, P793, DOI 10.1128/AAC.32.6.793; SCHMIDT LH, 1986, AM J TROP MED HYG, V35, P1077, DOI 10.4269/ajtmh.1986.35.1077; Sticova E, 2013, WORLD J GASTROENTERO, V19, P6398, DOI 10.3748/wjg.v19.i38.6398; Tekwani BL, 2006, CURR OPIN INFECT DIS, V19, P623, DOI 10.1097/QCO.0b013e328010b848; Thoolen B, 2010, TOXICOL PATHOL, V38, p5S, DOI 10.1177/0192623310386499; TROUET A, 1981, B WORLD HEALTH ORGAN, V59, P449; Vale N, 2009, J MED CHEM, V52, P7800, DOI 10.1021/jm900738c; Vale N, 2009, EUR J MED CHEM, V44, P2506, DOI 10.1016/j.ejmech.2009.01.018; Vale N, 2009, EUR J MED CHEM, V44, P937, DOI 10.1016/j.ejmech.2008.08.011; Vale-Costa S, 2012, ANTIMICROB AGENTS CH, V56, P5774, DOI 10.1128/AAC.00873-12; Walsh JJ, 2009, CURR PHARM DESIGN, V15, P2970, DOI 10.2174/138161209789058183; Wang C, 2010, BIOCHEM BIOPH RES CO, V402, P773, DOI 10.1016/j.bbrc.2010.10.108; Weerasinghe K. L., 2002, Ceylon Medical Journal, V47, P83; White NJ, 2014, LANCET, V383, P723, DOI 10.1016/S0140-6736(13)60024-0; WHO, 2010, WORLD MALARIA REPORT 2010, P1; Williams HD, 2013, PHARMACOL REV, V65, P315, DOI 10.1124/pr.112.005660; Yardley V, 2010, ANTIMICROB AGENTS CH, V54, P5356, DOI 10.1128/AAC.00985-10; Zeeman AM, 2014, ANTIMICROB AGENTS CH, V58, P1586, DOI 10.1128/AAC.01927-13	48	17	18	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2014	9	8							e105217	10.1371/journal.pone.0105217	http://dx.doi.org/10.1371/journal.pone.0105217			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4JF	25133630	Green Published, Green Submitted, gold			2023-01-03	WOS:000341302700089
J	Proclemer, A; Arenal, A; Lunati, M; Ferrer, JBM; Hersi, A; Manotta, L; Gasparini, M				Proclemer, Alessandro; Arenal, Angel; Lunati, Maurizio; Martnez Ferrer, Jose Bautista; Hersi, Ahmad; Manotta, Laura; Gasparini, Maurizio			Association of Long vs Standard Detection Intervals for Implantable Cardioverter-Defibrillators With Hospitalizations and Costs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							HEART-FAILURE; TRIAL; ICD		[Proclemer, Alessandro] Azienda Osped Univ S Maria Misericordia, Udine, Italy; [Arenal, Angel] Hosp Gen Univ Gregorio Maranon, Madrid, Spain; [Lunati, Maurizio] Azienda Osped Niguarda Ca Granda, Milan, Italy; [Martnez Ferrer, Jose Bautista] Hosp Txagorritxu C Jose Achotegui, Vitoria, Spain; [Hersi, Ahmad] King Saud Univ, Coll Med, Riyadh 11461, Saudi Arabia; [Manotta, Laura] Medtron Clin Res Inst, Sesto San Giovanni, Italy; [Gasparini, Maurizio] Humanitas Res Hosp, Rozzano, Italy	Hospital Santa Maria della Misericordia; General University Gregorio Maranon Hospital; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; King Saud University; IRCCS Humanitas Research Hospital	Gasparini, M (corresponding author), IRRCCS, Humanitas Res Hosp, Electrophysiol & Pacing Unit, Via Manzoni 56, I-20089 Rozzano, Italy.	maurizio.gasparini@humanitas.it	Gasparini, Maurizio/GZL-4963-2022; Hersi, Ahmad/ABC-9266-2020	Gasparini, Maurizio/0000-0002-1365-7357; Arenal Maiz, Angel/0000-0001-6636-5473				Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Gasparini M, 2013, JAMA-J AM MED ASSOC, V309, P1903, DOI 10.1001/jama.2013.4598; Gasparini M, 2009, EUR HEART J, V30, P2758, DOI 10.1093/eurheartj/ehp247; Moss AJ, 2012, NEW ENGL J MED, V367, P2275, DOI 10.1056/NEJMoa1211107; Schwab JO, 2009, J CARDIOVASC ELECTR, V20, P663, DOI 10.1111/j.1540-8167.2008.01415.x	5	6	6	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	2014	312	5					555	557		10.1001/jama.2014.4783	http://dx.doi.org/10.1001/jama.2014.4783			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AM4FL	25096697				2023-01-03	WOS:000339808600026
J	Ohashi, S; Kikuchi, O; Tsurumaki, M; Nakai, Y; Kasai, H; Horimatsu, T; Miyamoto, S; Shimizu, A; Chiba, T; Muto, M				Ohashi, Shinya; Kikuchi, Osamu; Tsurumaki, Mihoko; Nakai, Yukie; Kasai, Hiroi; Horimatsu, Takahiro; Miyamoto, Shin'ichi; Shimizu, Akira; Chiba, Tsutomu; Muto, Manabu			Preclinical Validation of Talaporfin Sodium-Mediated Photodynamic Therapy for Esophageal Squamous Cell Carcinoma	PLOS ONE			English	Article							ASPARTYL CHLORIN E(6); DIODE-LASER; PHASE-II; CANCER; DEATH; DIFFERENTIATION; PHOTORADIATION; TRANSFORMATION; METASTASIS; EXPRESSION	Photodynamic therapy (PDT) kills cancer cells via a photochemical reaction mediated by an oncotropic photosensitizer. Herein, we performed an experimental preclinical study to validate the anti-tumour effect of talaporfin sodium-mediated PDT (t-PDT) for esophageal squamous cell carcinoma (ESCC) cells. We used human ESCC cells derived from various differentiation grades or resistant to 5-fluorouracil (5-FU). The cytotoxic effect of t-PDT was determined by evaluating cell viability, apoptosis and generation of reactive oxygen species (ROS) and DNA double-strand breaks. Furthermore, the antitumour effect of t-PDT was assessed using an anchorage-independent cell-growth assay and xenograft transplantation models. t-PDT induced potent cytotoxicity in ESCC cells independent of their differentiation grade or 5-FU resistance. Moreover, t-PDT induced robust apoptosis, as indicated by cell shrinkage, perinuclear vacuolization, nuclear fragmentation and induction of annexin V-positive cells. This apoptotic response was accompanied by concurrent activation of ROS, and induction of DNA double-strand breakage. Importantly, t-PDT suppressed efficiently anchorage-independent cell growth as well as ESCC-xenografted tumor formation. In aggregate, t-PDT showed anti-tumor potential for ESCC cells with various histological grades or chemoresistance, providing a novel translational rationale of t-PDT for the treatment of ESCC.	[Ohashi, Shinya; Tsurumaki, Mihoko; Nakai, Yukie; Horimatsu, Takahiro; Muto, Manabu] Kyoto Univ, Grad Sch Med, Dept Therapeut Oncol, Sakyo Ku, Kyoto, Japan; [Kikuchi, Osamu; Miyamoto, Shin'ichi; Chiba, Tsutomu] Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Kyoto, Japan; [Kasai, Hiroi; Shimizu, Akira] Kyoto Univ Hosp, Inst Adv Clin & Translat Sci, Sakyo Ku, Kyoto 606, Japan	Kyoto University; Kyoto University; Kyoto University	Muto, M (corresponding author), Kyoto Univ, Grad Sch Med, Dept Therapeut Oncol, Sakyo Ku, Kawahara Cho, Kyoto, Japan.	mmuto@kuhp.kyoto-u.ac.jp	Ohashi, Shinya/AAD-8920-2022	Horimatsu, Takahiro/0000-0002-4188-9059; Kikuchi, Osamu/0000-0001-5012-5897	Health and Labor Sciences Research Grant, Research on Clinical Trial on Development of New Drugs and Medical Devices [H24-012]; Grants-in-Aid for Scientific Research [25293069] Funding Source: KAKEN	Health and Labor Sciences Research Grant, Research on Clinical Trial on Development of New Drugs and Medical Devices; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by a Health and Labor Sciences Research Grant, Research on Clinical Trial on Development of New Drugs and Medical Devices (H24-012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114; Allison RR, 2013, CLIN ENDOSC, V46, P24, DOI 10.5946/ce.2013.46.1.24; BIEL MA, 1994, LARYNGOSCOPE, V104, P399; CALAF G, 1993, CARCINOGENESIS, V14, P483, DOI 10.1093/carcin/14.3.483; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; DOUGHERTY TJ, 1979, J NATL CANCER I, V62, P231; DOUGHERTY TJ, 1978, CANCER RES, V38, P2628; EDELL ES, 1989, CHEST, V96, P919, DOI 10.1378/chest.96.4.919; Evans HH, 1997, PHOTOCHEM PHOTOBIOL, V66, P690, DOI 10.1111/j.1751-1097.1997.tb03208.x; Grosjean P, 1996, J Clin Laser Med Surg, V14, P281; Kato H, 2003, LUNG CANCER, V42, P103, DOI 10.1016/S0169-5002(03)00242-3; KATO H, 1993, JPN J CANCER RES, V84, P1209, DOI 10.1111/j.1349-7006.1993.tb02823.x; Katsumi TA, 1996, PHOTOCHEM PHOTOBIOL, V64, P671, DOI 10.1111/j.1751-1097.1996.tb03122.x; Kishi K, 2010, INT J ONCOL, V36, P313, DOI 10.3892/ijo_00000502; Liu L, 2011, FREE RADICAL BIO MED, V51, P53, DOI 10.1016/j.freeradbiomed.2011.03.042; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Luna MC, 2000, CANCER RES, V60, P1637; MCCORMICK JJ, 1990, PROG CLIN BIOL RES, V340, P195; MCMAHON KS, 1994, CANCER RES, V54, P5374; Miki Y, 2013, BIOL PHARM BULL, V36, P215, DOI 10.1248/bpb.b12-00567; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; Nozoe T, 2006, ONCOLOGY-BASEL, V71, P402, DOI 10.1159/000108611; Ohashi S, 2011, CANCER RES, V71, P6836, DOI 10.1158/0008-5472.CAN-11-0846; Overholt BF, 1999, GASTROINTEST ENDOSC, V49, P1, DOI 10.1016/S0016-5107(99)70437-2; Patel VA, 2006, J BIOL CHEM, V281, P4663, DOI 10.1074/jbc.M508342200; Saito K, 2000, JPN J CANCER RES, V91, P560, DOI 10.1111/j.1349-7006.2000.tb00981.x; Savary JF, 1998, ENDOSCOPY, V30, P258, DOI 10.1055/s-2007-1001252; SCHWEITZER VG, 1990, OTOLARYNG HEAD NECK, V102, P225, DOI 10.1177/019459989010200304; Taber SW, 1998, CLIN CANCER RES, V4, P2741; Tajima Y, 2000, CANCER, V88, P1285; TAPAROWSKY EJ, 1987, CANCER RES, V47, P4125; Toda Y, 1999, PATHOL INT, V49, P479, DOI 10.1046/j.1440-1827.1999.00875.x; Valdiglesias V, 2013, MUTAT RES-REV MUTAT, V753, P24, DOI 10.1016/j.mrrev.2013.02.001; Yano T, 2012, INT J CANCER, V131, P1228, DOI 10.1002/ijc.27320	34	21	22	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2014	9	8							e103126	10.1371/journal.pone.0103126	http://dx.doi.org/10.1371/journal.pone.0103126			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM4GX	25090101	Green Published, gold, Green Submitted			2023-01-03	WOS:000339812700017
J	Kim, TH; Kim, KH; Kang, JW; Lee, M; Kang, KW; Kim, JE; Kim, JH; Lee, S; Shin, MS; Jung, SY; Kim, AR; Park, HJ; Jung, HJ; Song, HS; Kim, HJ; Choi, JB; Hong, KE; Choi, SM				Kim, Tae-Hun; Kim, Kun Hyung; Kang, Jung Won; Lee, MinHee; Kang, Kyung-Won; Kim, Jung Eun; Kim, Joo-Hee; Lee, Seunghoon; Shin, Mi-Suk; Jung, So-Young; Kim, Ae-Ran; Park, Hyo-Ju; Jung, Hee-Jung; Song, Ho Sueb; Kim, Hyeong Jun; Choi, Jin-Bong; Hong, Kwon Eui; Choi, Sun-Mi			Moxibustion Treatment for Knee Osteoarthritis: A Multi-Centre, Non-Blinded, Randomised Controlled Trial on the Effectiveness and Safety of the Moxibustion Treatment versus Usual Care in Knee Osteoarthritis Patients	PLOS ONE			English	Article							ADVERSE EVENTS; CLINICAL-TRIAL; VALIDATION; ARTHRITIS; WOMAC	Introduction: This study tested the effectiveness of moxibustion on pain and function in chronic knee osteoarthritis (KOA) and evaluated safety. Methods: A multi-centre, non-blinded, parallel-group, randomised controlled trial compared moxibustion with usual care (UC) in KOA. 212 South Korean patients aged 40-70 were recruited from 2011-12, stratified by mild (Kellgren/Lawrence scale grades 0/1) and moderate-severe KOA (grades 2/3/4), and randomly allocated to moxibustion or UC for four weeks. Moxibustion involved burning mugwort devices over acupuncture and Ashi points in affected knee(s). UC was allowed. Korean Western Ontario and McMaster Universities Questionnaire (K-WOMAC), Short Form 36 Health Survey (SF-36v2), Beck Depression Inventory (BDI), physical performance test, pain numeric rating scale (NRS) and adverse events were evaluated at 5 and 13 weeks. K-WOMAC global score at 5 weeks was the primary outcome. Results: 102 patients (73 mild, 29 moderate-severe) were allocated to moxibustion, 110 (77 mild, 33 moderate-severe) to UC. K-WOMAC global score (moxibustion 25.42+/2SD 19.26, UC 33.60+/217.91, p < 0.01, effect size = 0.0477), NRS (moxibustion 44.77+/222.73, UC 56.23+/217.71, p < 0.01, effect size = 0.0073) and timed-stand test (moxibustion 24.79+/29.76, UC 25.24+/28.84, p = 0.0486, effect size = 0.0021) were improved by moxibustion at 5 weeks. The primary outcome improved for mild but not moderate-severe KOA. At 13 weeks, moxibustion significantly improved the K-WOMAC global score and NRS. Moxibustion improved SF-36 physical component summary (p = 0.0299), bodily pain (p = 0.0003), physical functioning (p = 0.0025) and social functioning (p = 0.0418) at 5 weeks, with no difference in mental component summary at 5 and 13 weeks. BDI showed no difference (p = 0.34) at 5 weeks. After 1158 moxibustion treatments, 121 adverse events included first (n = 6) and second degree (n = 113) burns, pruritus and fatigue (n = 2). Conclusions: Moxibustion may improve pain, function and quality of life in KOA patients, but adverse events are common. Limitations included no sham control or blinding.	[Kim, Tae-Hun; Kim, Kun Hyung; Lee, MinHee; Kang, Kyung-Won; Kim, Jung Eun; Kim, Joo-Hee; Lee, Seunghoon; Shin, Mi-Suk; Jung, So-Young; Kim, Ae-Ran; Park, Hyo-Ju; Jung, Hee-Jung; Choi, Sun-Mi] Korea Inst Oriental Med, Taejon, South Korea; [Kim, Tae-Hun] Gachon Univ, Coll Korean Med, Songnam, South Korea; [Kim, Kun Hyung] Pusan Natl Univ, Korean Med Hosp, Dept Acupuncture & Moxibust, Yangsan, South Korea; [Kang, Jung Won] Kyung Hee Univ, Dept Acupuncture & Moxibust, Coll Korean Med, Seoul, South Korea; [Song, Ho Sueb] Kyungwon Univ, Incheon Gill Oriental Med Hosp, Inchon, South Korea; [Kim, Hyeong Jun] Semyung Univ, Jecheon Oriental Med Hosp, Jecheon, South Korea; [Choi, Jin-Bong] Dongshin Univ, Gwangju Oriental Hosp, Kwangju, South Korea; [Hong, Kwon Eui] Daejeon Univ, Dept Acupuncture & Moxibust, Taejon, South Korea	Korea Institute of Oriental Medicine (KIOM); Gachon University; Pusan National University; Kyung Hee University; Gachon University; Semyung University; Dongshin University; Daejeon University	Choi, SM (corresponding author), Korea Inst Oriental Med, Taejon, South Korea.	smchoi@kiom.re.kr	Lee, Seunghoon/ABC-8506-2020; Kim, Tae-Hun/G-8728-2014	Kim, Tae-Hun/0000-0002-8448-3219	"Development of Acupuncture, Moxibustion and Meridian Standard Health Technology" project of the Korea Institute of Oriental Medicine [K12010]	"Development of Acupuncture, Moxibustion and Meridian Standard Health Technology" project of the Korea Institute of Oriental Medicine	This study was supported by the "Development of Acupuncture, Moxibustion and Meridian Standard Health Technology" project of the Korea Institute of Oriental Medicine (K12010). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905; Bae SC, 2001, OSTEOARTHR CARTILAGE, V9, P746, DOI 10.1053/joca.2001.0471; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Choi TY, 2012, RHEUMATOL INT, V32, P2969, DOI 10.1007/s00296-012-2367-7; Choi TY, 2011, CLIN RHEUMATOL, V30, P937, DOI 10.1007/s10067-011-1706-5; Conaghan PG, 2008, BRIT MED J, V336, P502, DOI 10.1136/bmj.39490.608009.AD; Dorfer L, 1998, SCIENCE, V282, P242; Ellis PD, 2010, ESSENTIAL GUIDE TO EFFECT SIZES: STATISTICAL POWER, META-ANALYSIS AND THE INTERPRETATION OF RESEARCH RESULTS, P1; Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003-4819-133-8-200010170-00016; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Lee J, 2013, INTEGR CANC THER; Lee S, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-59; Li Zhuo-Dong, 2009, Zhongguo Zhong Xi Yi Jie He Za Zhi, V29, P883; MARK DH, 1994, JAMA-J AM MED ASSOC, V271, P661, DOI 10.1001/jama.1994.03510330039025; Maruish ME, 2009, GUIDE DEV CERTIFIED; Niu J, 2009, ARTHRIT RHEUM-ARTHR, V61, P329, DOI 10.1002/art.24337; Park J. E., 2007, J KOREAN ORIENTAL ME, V13, P93; Park JE, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-124; Park JE, 2010, COMPLEMENT THER MED, V18, P215, DOI 10.1016/j.ctim.2010.07.001; Raisch DW, 2001, CLIN THER, V23, P2011, DOI 10.1016/S0149-2918(01)80153-3; Ren Xiu-Mei, 2011, Zhongguo Zhen Jiu, V31, P1057; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Son HM, 2013, ACUPUNCT MED, V31, P39, DOI 10.1136/acupmed-2012-010224; Spilker B., 1991, GUIDE CLIN TRIALS; Turk DC, 2003, PAIN, V106, P337, DOI 10.1016/j.pain.2003.08.001; Wang CC, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-108; Wasiak J, 2009, CLIN EVID; Williams ACD, 2000, PAIN, V85, P457, DOI 10.1016/S0304-3959(99)00299-7; Zhao BX, 2006, COMPLEMENT THER MED, V14, P53, DOI 10.1016/j.ctim.2005.06.003; Zhao Jing-Sheng, 2010, Zhen Ci Yan Jiu, V35, P388	32	39	43	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2014	9	7							e101973	10.1371/journal.pone.0101973	http://dx.doi.org/10.1371/journal.pone.0101973			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6RP	25061882	Green Published, gold, Green Submitted			2023-01-03	WOS:000339992600007
J	Connolly, F; Rae, MT; Butler, M; Klibanov, AL; Sboros, V; McNeilly, AS; Duncan, WC				Connolly, Fiona; Rae, Michael T.; Butler, Mairead; Klibanov, Alexander L.; Sboros, Vassilis; McNeilly, Alan S.; Duncan, W. Colin			The Local Effects of Ovarian Diathermy in an Ovine Model of Polycystic Ovary Syndrome	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; STROMAL BLOOD-FLOW; PRENATAL TESTOSTERONE EXCESS; INSULIN-SENSITIZING DRUGS; CORPUS-LUTEUM; CLOMIPHENE CITRATE; SYNDROME PCOS; ANDROGEN PRODUCTION; FOLLICULAR-GROWTH; INFERTILE WOMEN	In order to develop a medical alternative to surgical ovarian diathermy (OD) in polycystic ovary syndrome (PCOS) more mechanistic information is required about OD. We therefore studied the cellular, molecular and vascular effects of diathermy on the ovary using an established ovine model of PCOS. Pregnant sheep were treated twice weekly with testosterone propionate (100 mg) from day 30-100 gestation. Their female offspring (n = 12) were studied during their second breeding season when the PCOS-like phenotype, with anovulation, is fully manifest. In one group (n = 4) one ovary underwent diathermy and it was collected and compared to the contralateral ovary after 24 hours. In another group a treatment PCOS cohort underwent diathermy (n = 4) and the ovaries were collected and compared to the control PCOS cohort (n = 4) after 5 weeks. Ovarian vascular indices were measured using contrast-enhanced ultrasound and colour Doppler before, immediately after, 24 hours and five weeks after diathermy. Antral follicles were assessed by immunohistochemistry and ovarian stromal gene expression by quantitative RT-PCR 24 hours and 5 weeks after diathermy. Diathermy increased follicular atresia (P<0.05) and reduced antral follicle numbers after 5 weeks (P<0.05). There was an increase in stromal CCL2 expression 24 hours after diathermy (P<0.01) but no alteration in inflammatory indices at 5 weeks. Immediately after diathermy there was increased microbubble transit time in the ovarian microvasculature (P = 0.05) but this was not seen at 24 hours. However 24 hours after diathermy there was a reduction in the stromal Doppler blood flow signal (P<0.05) and an increased ovarian resistance index (P<0.05) both of which persisted at 5 weeks (P<0.01; P<0.05). In the ovine model of PCOS, OD causes a sustained reduction in ovarian stromal blood flow with an increased ovarian artery resistance index associated with atresia of antral follicles.	[Connolly, Fiona; McNeilly, Alan S.; Duncan, W. Colin] Univ Edinburgh, Ctr Reprod Hlth, MRC, Edinburgh, Midlothian, Scotland; [Rae, Michael T.] Edinburgh Napier Univ, Sch Hlth Life & Social Sci, Edinburgh, Midlothian, Scotland; [Butler, Mairead; Sboros, Vassilis] Heriot Watt Univ, Inst Biophys Biochem & Bioengn, Edinburgh, Midlothian, Scotland; [Klibanov, Alexander L.] Univ Virginia, Dept Biomed Engn, Charlottesville, VA USA	University of Edinburgh; Edinburgh Napier University; Heriot Watt University; University of Virginia	Duncan, WC (corresponding author), Univ Edinburgh, Ctr Reprod Hlth, MRC, Edinburgh, Midlothian, Scotland.	W.C.Duncan@ed.ac.uk		Sboros, Vassilis/0000-0002-9133-7252	Medical Research Council [G0901807]; Scottish Funding Council; MRC [G0800896, G0500717, G1002033, G0901807] Funding Source: UKRI; Medical Research Council [G1002033, G0500717] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Scottish Funding Council; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This research was funded by the Medical Research Council (G0901807) and WCD was supported by a Senior Clinical Fellowship from the Scottish Funding Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abramovich D, 2012, ENDOCRINOLOGY, V153, P3446, DOI 10.1210/en.2012-1105; Agrawal R, 1998, HUM REPROD, V13, P651, DOI 10.1093/humrep/13.3.651; Aleem FA, 1996, FERTIL STERIL, V65, P510, DOI 10.1016/S0015-0282(16)58145-X; Amer S, 2011, ACTA OBSTET GYN SCAN, V90, P338, DOI 10.1111/j.1600-0412.2010.01061.x; Amer SAKS, 2003, FERTIL STERIL, V79, P1211, DOI 10.1016/S0015-0282(02)04960-9; Amer SAKS, 2002, HUM REPROD, V17, P2851, DOI 10.1093/humrep/17.11.2851; Amin AF, 2003, FERTIL STERIL, V79, P938, DOI 10.1016/S0015-0282(02)04849-5; Anderson RA, 1998, CLIN ENDOCRINOL, V48, P577, DOI 10.1046/j.1365-2265.1998.00442.x; Averkiou M, 2010, ULTRASOUND MED BIOL, V36, P68, DOI 10.1016/j.ultrasmedbio.2009.07.005; Azziz R, 2004, J CLIN ENDOCR METAB, V89, P2745, DOI 10.1210/jc.2003-032046; Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; BATTAGLIA C, 1995, AM J OBSTET GYNECOL, V172, P108, DOI 10.1016/0002-9378(95)90094-2; Birch RA, 2003, ENDOCRINOLOGY, V144, P1426, DOI 10.1210/en.2002-220965; BRANNSTROM M, 1993, ENDOCRINOLOGY, V132, P399, DOI 10.1210/en.132.1.399; Connolly F, 2013, ENDOCRINOLOGY, V154, P1921, DOI 10.1210/en.2012-2153; Dale PO, 2004, GYNECOL ENDOCRINOL, V19, P182, DOI 10.1080/09513590400012093; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Dunaif A, 2008, NAT CLIN PRACT ENDOC, V4, P272, DOI 10.1038/ncpendmet0787; Duncan W. C., 2009, Animal Reproduction, V6, P34; Duncan WC, 2013, REPROD FERT DEVELOP, V25, P362, DOI 10.1071/RD12112; Duncan WC, 1998, HUM REPROD, V13, P2435, DOI 10.1093/humrep/13.9.2435; Duncan WC, 1994, CONT REV OBSTET GYNE, V6, P154; El Behery MM, 2011, INT J GYNECOL OBSTET, V112, P119, DOI 10.1016/j.ijgo.2010.08.018; FRANKS S, 1995, NEW ENGL J MED, V333, P853, DOI 10.1056/NEJM199509283331307; Fraser Hamish M., 2005, Angiogenesis, V8, P101, DOI 10.1007/s10456-005-9004-y; Fraser HM, 2009, REPROD FERT DEVELOP, V21, P277; GILLINGSMITH C, 1994, J CLIN ENDOCR METAB, V79, P1158, DOI 10.1210/jc.79.4.1158; GJONNAESS H, 1994, ACTA OBSTET GYN SCAN, V73, P407, DOI 10.3109/00016349409006253; GONEN Y, 1990, HUM REPROD, V5, P670, DOI 10.1093/oxfordjournals.humrep.a137165; Goodarzi MO, 2011, NAT REV ENDOCRINOL, V7, P219, DOI 10.1038/nrendo.2010.217; Hogg K, 2012, ENDOCRINOLOGY, V153, P450, DOI 10.1210/en.2011-1607; Hogg K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024877; Homburg R, 2005, HUM REPROD, V20, P2043, DOI 10.1093/humrep/dei042; Homburg R, 2012, HUM REPROD, V27, P468, DOI 10.1093/humrep/der401; Homburg R, 1998, J ENDOCRINOL INVEST, V21, P552, DOI 10.1007/BF03350780; KECKSTEIN J, 1989, BAILLIERE CLIN OB GY, V3, P563, DOI 10.1016/S0950-3552(89)80009-4; Klibanov AL, 2004, INVEST RADIOL, V39, P187, DOI 10.1097/01.rli.0000115926.96796.75; Li HWR, 2010, HUM FERTIL, V13, P35, DOI 10.3109/14647270903490765; Liguori G, 1996, GYNECOL ENDOCRINOL, V10, P257, DOI 10.3109/09513599609012317; Lopez E, 2004, REPROD BIOMED ONLINE, V9, P382, DOI 10.1016/S1472-6483(10)61273-4; Manikkam M, 2006, ENDOCRINOLOGY, V147, P1997, DOI 10.1210/en.2005-1338; Nelson VL, 1999, MOL ENDOCRINOL, V13, P946, DOI 10.1210/me.13.6.946; Nieuwenhuis-Ruifrok AE, 2009, HUM REPROD UPDATE, V15, P57, DOI 10.1093/humupd/dmn043; Ozkan S, 2007, J CLIN ULTRASOUND, V35, P305, DOI 10.1002/jcu.20358; Padmanabhan V, 2006, MOL CELL ENDOCRINOL, V246, P165, DOI 10.1016/j.mce.2005.11.016; Padmanabhan V, 2010, ENDOCRINOLOGY, V151, P595, DOI 10.1210/en.2009-1015; Padmanabhan V, 2013, MOL CELL ENDOCRINOL, V373, P8, DOI 10.1016/j.mce.2012.10.005; Palomba S, 2010, HUM REPROD, V25, P1005, DOI 10.1093/humrep/dep466; Pate JL, 2010, AM J REPROD IMMUNOL, V64, P275, DOI 10.1111/j.1600-0897.2010.00906.x; Peluffo MC, 2009, MOL REPROD DEV, V76, P367, DOI 10.1002/mrd.20970; Rae M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056263; Recabarren SE, 2005, AM J PHYSIOL-ENDOC M, V289, pE801, DOI 10.1152/ajpendo.00107.2005; Richards JS, 2002, ANNU REV PHYSIOL, V64, P69, DOI 10.1146/annurev.physiol.64.081501.131029; Sboros V, 2011, ULTRASOUND MED BIOL, V37, P59, DOI 10.1016/j.ultrasmedbio.2010.10.013; Schmidt J, 2014, MOL HUM REPROD, V20, P49, DOI 10.1093/molehr/gat051; Strouthos C, 2010, IEEE T ULTRASON FERR, V57, P1296, DOI 10.1109/TUFFC.2010.1550; Sunj M, 2013, HUM REPROD, V28, P2417, DOI 10.1093/humrep/det273; Takayama K, 1996, HUM REPROD, V11, P1387; Tan Seang Lin, 2002, Reprod Biomed Online, V4 Suppl 1, P18; TOZAWA H, 1995, HUM REPROD, V10, P544, DOI 10.1093/oxfordjournals.humrep.a135986; Tulandi T, 2000, FERTIL STERIL, V74, P585, DOI 10.1016/S0015-0282(00)00684-1; Tulandi T, 1997, INT J FERTIL WOMEN M, V42, P436; Veiga-Lopez A, 2008, BIOL REPROD, V78, P636, DOI 10.1095/biolreprod.107.065904; Veiga-Lopez A, 2010, ENDOCRINOLOGY, V151, P4007, DOI 10.1210/en.2010-0124; Vendola KA, 1998, J CLIN INVEST, V101, P2622, DOI 10.1172/JCI2081; Wulff C, 2002, ENDOCRINOLOGY, V143, P2797, DOI 10.1210/en.143.7.2797; Yoshioka S, 2012, MOL REPROD DEV, V79, P689, DOI 10.1002/mrd.22075; ZAIDI J, 1995, HUM REPROD, V10, P1992, DOI 10.1093/oxfordjournals.humrep.a136222	68	10	10	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2014	9	10							e111280	10.1371/journal.pone.0111280	http://dx.doi.org/10.1371/journal.pone.0111280			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0BL	25343339	gold, Green Published, Green Submitted			2023-01-03	WOS:000343943500093
J	Farooq, S; Shakeel-u-Rehman; Dangroo, NA; Priya, D; Banday, JA; Sangwan, PL; Qurishi, MA; Koul, S; Saxena, AK				Farooq, Saleem; Shakeel-u-Rehman; Dangroo, Nisar Ahmad; Priya, Dev; Banday, Javid Ahmad; Sangwan, Pyare Lal; Qurishi, Mushtaq Ahmad; Koul, Surrinder; Saxena, Ajit Kumar			Isolation, Cytotoxicity Evaluation and HPLC-Quantification of the Chemical Constituents from Prangos pabularia	PLOS ONE			English	Article							ESSENTIAL OIL; COUMARINS; DERIVATIVES; ANTIBACTERIAL; INHIBITION; OSTHOLE; PLANTS; BARK	Phytochemical analysis of the dichloromethane: methanol (1: 1) extract of root parts of Prangos pabularia led to the isolation of twelve cytotoxic constituents, viz., 6-hydroxycoumarin (1), 7-hydroxycoumarin (2), heraclenol-glycoside (3), xanthotoxol (4), heraclenol (5), oxypeucedanin hydrate (6), 8-((3,3-dimethyloxiran-2-yl) methyl)-7-methoxy-2H-chromen-2-one (7), oxypeucedanin hydrate monoacetate (8), xanthotoxin (9), 4-((2-hydroxy-3-methylbut-3-en-1-yl) oxy)-7H-furo[3,2-g]chromen-7-one (10), imperatorin (11) and osthol (12). The isolates were identified using spectral techniques in the light of literature. 3-(4,5-dimethyl thiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity screening of the isolated constituents was carried out against six human cancer cell lines including lung (A549 and NCI-H322), epidermoid carcinoma (A431), melanoma (A375), prostate (PC-3) and Colon (HCT-116) cell lines. Osthol (12) exhibited the highest cytotoxicity with IC50 values of 3.2, 6.2, 10.9, 14.5, 24.8, and 30.2 mu M against epidermoid carcinoma (A431), melanoma (A375), lung (NCI-H322), lung (A549), prostate (PC-3) and colon (HCT-116) cell lines respectively. Epidermoid carcinoma cell line A431 was sensitive to most of the compounds followed by lung (A549) cancer cell line. Finally a simple and reliable HPLC method was developed (RP-HPLC-DAD) and validated for the simultaneous quantification of these cytotoxic constituents in Prangos pabularia. The extract was analyzed using a reversed-phase Agilent ZORBAX eclipse plus column C-18 (4.6x250 mm, 5 mu m) at 250 nm wavelength using a gradient water-methanol solvent system at a flow rate of 0.8 ml/min. The RP-HPLC method is validated in terms of recovery, linearity, accuracy and precision (intra and inter-day validation). This method, because of shorter analysis time, makes it valuable for the commercial quality control of Prangos pabularia extracts and its future pharmaceutical preparations.	[Farooq, Saleem; Dangroo, Nisar Ahmad; Sangwan, Pyare Lal; Koul, Surrinder] CSIR, Indian Inst Integrat Med, Bioorgan Chem Sect, Jammu, India; [Shakeel-u-Rehman] CSIR, Indian Inst Integrat Med, Bioorgan Chem Sect, Srinagar, Jammu & Kashmir, India; [Shakeel-u-Rehman; Banday, Javid Ahmad; Qurishi, Mushtaq Ahmad] Univ Kashmir, Dept Chem, Srinagar 190006, Jammu & Kashmir, India; [Priya, Dev; Saxena, Ajit Kumar] CSIR, Indian Inst Integrat Med, Canc Pharmacol Div, Jammu, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Integrative Medicine (IIIM); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Integrative Medicine (IIIM); University of Kashmir; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Integrative Medicine (IIIM)	Farooq, S (corresponding author), CSIR, Indian Inst Integrat Med, Bioorgan Chem Sect, Jammu, India.	farooqprince100@yahoo.in; skoul@iiim.ac.in	Banday, Javid/ABB-7348-2020; Banday, Javid/AAT-4684-2020	Banday, Javid/0000-0003-0339-4781; Dangroo, Dr Nisar Ahmad/0000-0003-4880-1408	CSIR India	CSIR India(Council of Scientific & Industrial Research (CSIR) - India)	The authors have received fellowship/funding from CSIR India. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banday JA., 2012, AM J ANAL CHEM, V3, P204, DOI [10.4236/ajac.2012.33029, DOI 10.4236/AJAC.2012.33029]; Baser KHC, 2000, PLANTA MED, V66, P674, DOI 10.1055/s-2000-8627; Cao XW, 2010, J SEP SCI, V33, P1587, DOI 10.1002/jssc.200900866; CHATTERJEE A, 1972, TETRAHEDRON, V28, P5175, DOI 10.1016/S0040-4020(01)88937-7; Chopra R.N., 1986, GLOSSARY INDIAN MED; Ding Y, 2014, INT J CLIN PHARM TH, V52, P112, DOI 10.5414/CP201923; Dokovic DD, 2004, CHEM PHARM BULL, V52, P853, DOI 10.1248/cpb.52.853; Dongmo AB, 2007, J ETHNOPHARMACOL, V111, P329, DOI 10.1016/j.jep.2006.11.026; Farooq S, 2014, EUR J MED CHEM, V84, P545, DOI 10.1016/j.ejmech.2014.07.069; GUPTA BK, 1964, INDIAN J CHEM, V2, P464; Hata K, 1963, J PHARM SOC JPN, V83, P611; Iqbal PF, 2009, EUR J MED CHEM, V44, P2252, DOI 10.1016/j.ejmech.2008.06.003; JAMWAL KS, 1964, ARCH INT PHARMACOD T, V147, P351; Kawaii S, 2001, ANTICANCER RES, V21, P1905; KIRTIKAR KR, 1980, INDIAN MED PLANTS, V1; Kogure K, 2004, PHYTOMEDICINE, V11, P645, DOI 10.1016/j.phymed.2003.09.004; KOUL SK, 1979, PHYTOCHEMISTRY, V18, P1762, DOI 10.1016/0031-9422(79)80213-7; Koul SK, 1978, INDIAN PERFUMER, V22, P284; Lake B., 1999, FOOD CHEM TOXICOL, V3, P412; Mavi A, 2004, BIOL PHARM BULL, V27, P702, DOI 10.1248/bpb.27.702; Mazloomifar H, 2004, J ESSENT OIL RES, V16, P415, DOI 10.1080/10412905.2004.9698758; Nimisha S, 2012, J PHARMACOGN PHYTOCH, V1, P48; Okamoto T, 2007, MED CHEM, V3, P35, DOI 10.2174/157340607779317607; Piao XL, 2004, J ETHNOPHARMACOL, V93, P243, DOI 10.1016/j.jep.2004.03.054; Ramanitrahasimbola D, 2005, J ETHNOPHARMACOL, V102, P400, DOI 10.1016/j.jep.2005.06.037; Razavi SM, 2008, PHYTOCHEM LETT, V1, P159, DOI 10.1016/j.phytol.2008.07.009; Razavi SM, 2008, REV BRAS FARMACOGN, V18, P1, DOI 10.1590/S0102-695X2008000100002; Rosselli S, 2007, PLANTA MED, V73, P116, DOI 10.1055/s-2006-951772; Shakeel-u-Rehman, 2014, BIOORG MED CHEM LETT, V24, P4243, DOI 10.1016/j.bmcl.2014.07.031; Siskos EP, 2008, J AGR FOOD CHEM, V56, P5577, DOI 10.1021/jf800446t; Stein AC, 2006, J ETHNOPHARMACOL, V107, P95, DOI 10.1016/j.jep.2006.02.009; Tada Y, 2002, PHYTOCHEMISTRY, V59, P649, DOI 10.1016/S0031-9422(02)00023-7; Tawaha K., 2001, ALEX J PHARM SCI, V15, P89; Torres R, 2006, PHYTOCHEMISTRY, V67, P984, DOI 10.1016/j.phytochem.2006.03.016; Xu XM, 2012, MOL MED REP, V6, P1018, DOI 10.3892/mmr.2012.1044	35	18	20	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2014	9	10							e108713	10.1371/journal.pone.0108713	http://dx.doi.org/10.1371/journal.pone.0108713			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR5ZW	25314269	Green Published, Green Submitted, gold			2023-01-03	WOS:000343662500017
J	Morgan, DJ; Kaye, KS; Diekema, DJ				Morgan, Daniel J.; Kaye, Keith S.; Diekema, Daniel J.			Reconsidering Isolation Precautions for Endemic Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CONTACT PRECAUTIONS; INTENSIVE-CARE; TRANSMISSION; ACQUISITION; BACTERIA		[Morgan, Daniel J.] Univ Maryland, Sch Med, VA Maryland Healthcare Syst, Baltimore, MD 21201 USA; [Kaye, Keith S.] Detroit Med Ctr, Detroit, MI USA; [Kaye, Keith S.] Wayne State Univ, Detroit, MI USA; [Kaye, Keith S.] Univ Hlth Ctr, Detroit, MI USA; [Diekema, Daniel J.] Univ Iowa, Dept Internal Med, Div Infect Dis, Coll Med, Iowa City, IA 52242 USA	University System of Maryland; University of Maryland Baltimore; Detroit Medical Center; Wayne State University; University of Iowa	Morgan, DJ (corresponding author), Univ Maryland, Sch Med, VA Maryland Healthcare Syst, 10 S Pine St,MSTF 334, Baltimore, MD 21201 USA.	dmorgan@epi.umaryland.edu	Kaye, Keith/AAF-1048-2019	Diekema, Daniel/0000-0003-1273-0724				Dhar S, 2014, INFECT CONT HOSP EP, V35, P213, DOI 10.1086/675294; Haessler S, 2014, SUCCESS STORIES MRSA; Harris AD, 2013, JAMA-J AM MED ASSOC, V310, P1571, DOI 10.1001/jama.2013.277815; Huskins WC, 2011, NEW ENGL J MED, V364, P1407, DOI 10.1056/NEJMoa1000373; Magill SS, 2014, NEW ENGL J MED, V370, P1198, DOI 10.1056/NEJMoa1306801; Morgan DJ, 2009, AM J INFECT CONTROL, V37, P85, DOI 10.1016/j.ajic.2008.04.257; Price JR, 2014, CLIN INFECT DIS, V58, P609, DOI 10.1093/cid/cit807; Siegel JD, 2006, MANAGEMENT MULTIDRUG	8	25	26	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2014	312	14					1395	1396		10.1001/jama.2014.10142	http://dx.doi.org/10.1001/jama.2014.10142			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AQ2PQ	25291571				2023-01-03	WOS:000342630200010
J	Bazargani, YT; de Boer, A; Leufkens, HGM; Mantel-Teeuwisse, AK				Bazargani, Yaser T.; de Boer, Anthonius; Leufkens, Hubert G. M.; Mantel-Teeuwisse, Aukje K.			Selection of Essential Medicines for Diabetes in Low and Middle Income Countries: A Survey of 32 National Essential Medicines Lists	PLOS ONE			English	Article							CARE; MANAGEMENT; ACCESS; AVAILABILITY; INSULIN	Aim: Diabetes is a growing burden especially in low and middle income countries (LMICs). Inadequate access to diabetes care is of particular concern and selection of appropriate diabetes medicines on national essential medicines lists (NEMLs) is a first step in achieving adequate access. This selection was studied among LMICs and influences of various factors associated with selection decisions were assessed. Methods: Countries were studied if they employed NEMLs for reimbursement or procurement purposes. Presence and number of essential diabetes medicines from different classes, both insulins and oral blood glucose lowering medicines, were surveyed and calculated. Data were also analyzed by country income level, geographic region, year of last update of the NEML and purpose of NEML employment. The effect of prevalence and burden of disease on the number of essential diabetes medicines was also studied. Non parametric tests and univariate linear regression analysis were used. Results: Nearly all countries (n = 32) had chosen fast (97%) and intermediate acting insulin (93%), glibenclamide and metformin (100% both) as essential medicines. The median number of essential diabetes medicines was 6, equally divided between insulins and oral medicines. 20% of the countries had selected insulin analogues as essential medicines. Among all the studied factors, an increase in burden of diabetes and wealth of countries were associated with selection of higher numbers of essential diabetes medicines (p = 0.02 in both cases). Conclusions: Nearly all the studied LMICs had included the minimum required medicines for diabetes management in their NEMLs. Selection can still be improved (e. g. exclusion of insulin analogues and replacement of glibenclamide by gliclazide). Nevertheless, the known suboptimal and inconsistent availability of essential diabetes medicines in LMICs cannot be explained by inadequate selection of essential medicines. Countries should therefore be encouraged to give precedence to implementation of NEMLs to make essential diabetes medicines more accessible.	[Bazargani, Yaser T.; de Boer, Anthonius; Leufkens, Hubert G. M.; Mantel-Teeuwisse, Aukje K.] Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands	Utrecht University	Mantel-Teeuwisse, AK (corresponding author), Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands.	A.K.Mantel@uu.nl	Mantel-Teeuwisse, Aukje/I-8902-2016					Abbatecola AM, 2009, DRUG AGING, V26, P53, DOI 10.2165/11534660-000000000-00000; Ali S, 2012, EXPERT OPIN PHARMACO, V13, P1797, DOI 10.1517/14656566.2012.705829; [Anonymous], 2012, JEMDSA, V17, pS1, DOI 10.1080/22201009.2012.10872277; Bazargani YT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087576; BERAN D, 2012, HOW TO INVESTIGATE A; Beran D, 2008, B WORLD HEALTH ORGAN, V86, P648, DOI 10.2471/BLT.07.048710; Beran D, 2006, LANCET, V368, P1689, DOI 10.1016/S0140-6736(06)69704-3; Beran D, 2013, INT J HEALTH PLAN M, V28, pe121, DOI 10.1002/hpm.2145; Beran D, 2013, ASIA-PAC J PUBLIC HE, V25, P92, DOI 10.1177/1010539511412177; Beran D, 2010, DIABETES RES CLIN PR, V88, P217, DOI 10.1016/j.diabres.2010.03.029; Bhojani U, 2013, GLOBAL HEALTH ACTION, V6, DOI 10.3402/gha.v6i0.22258; Blonde L, 2010, AM J MED, V123, pS12, DOI 10.1016/j.amjmed.2009.12.005; Bo S, 2013, EUR J ENDOCRINOL, V169, P117, DOI 10.1530/EJE-13-0299; Cameron A, 2011, B WORLD HEALTH ORGAN, V89, P412, DOI 10.2471/BLT.10.084327; Cohen D, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5782; COLAGIURI S, 2012, GLOBAL GUIDELINE FOR; Erlich Deborah R, 2013, FP Essent, V408, P20; Gill GV, 2011, DIABETOLOGIA, V54, P19, DOI 10.1007/s00125-010-1897-3; Grant P, 2013, CLIN MED, V13, P27, DOI 10.7861/clinmedicine.13-1-27; *HLTH ACT INT, 2010, LIFE SAVING INSULIN; Holden SE, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000258; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; *IHME, 2013, GLOBAL BURDEN OF DIS; Imam K, 2013, ADV EXP MED BIOL, V771, P340; *INT DIAB FED, 2013, GLOBAL GUIDELINE FOR; *INT DIAB FED, 2013, TREATMENT ALGORITHM; International Diabetes Federation, 2009, DIABETES ATLAS; Inzucchi SE, 2012, DIABETES CARE, V35, P1364, DOI 10.2337/dc12-0413; *IQWIG, 2005, ANONYMOUS INSTITUTE; Krishna S, 2010, J RURAL HEALTH, V26, P3, DOI 10.1111/j.1748-0361.2009.00259.x; Lamos EM, 2012, EXPERT OPIN PHARMACO, V13, P2545, DOI 10.1517/14656566.2012.738196; *MAN SCI HLTH, 2012, INTERNATIONAL DRUG P; Marks Donald H, 2013, Int J Risk Saf Med, V25, P39, DOI 10.3233/JRS-120581; Mbanya JCN, 2010, LANCET, V375, P2254, DOI 10.1016/S0140-6736(10)60550-8; Mendis S, 2007, B WORLD HEALTH ORGAN, V85, P279, DOI 10.2471/BLT.06.033647; Nagpal J, 2006, DIABETES CARE, V29, P2341, DOI 10.2337/dc06-0783; *NICE, 2004, TYPE 1 DIABETES DIAG; *NORW I PUBL HLTH, 2012, ANATOMICAL THERAPEUT; Ramachandran A, 2008, J Assoc Physicians India, V56, P513; RICHTER B, HUMAN INSULIN VERSUS; Tahrani AA, 2011, LANCET, V378, P182, DOI 10.1016/S0140-6736(11)60207-9; United Nations, POLITICAL DECLARATIO; *WHO, 2013, DIABETES; *WHO, 2013, WHO REGIONS AND THE; *WHO, 2013, DIABETES PROGRAMME; *WHO, 2011, REVIEW OF THE EVIDEN; *WHO, 2013, SELECTION OF ESSENTI; *WHO, 2012, PHARMACEUTICAL COUNT; *WHO, 2013, DEVELOPMENT OF COUNT; *WHO, 2013, DIABETES FACTSHEETS; *WHO, 2013, WHO FRAMEWORK FOR AC; *WHO, 2013, NATIONAL MEDICINES L; *WORLD BANK, 2013, COUNTRY CLASSIFICATI; World Health Organization, 2013, GLOBAL ACTION PLAN F; World Health Organization, 2013, WHO MODEL LIST OF ES	55	19	19	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2014	9	9							e106072	10.1371/journal.pone.0106072	http://dx.doi.org/10.1371/journal.pone.0106072			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ3IP	25259517	Green Published, Green Submitted, gold			2023-01-03	WOS:000342685600005
J	Si, JW; Wang, N; Wang, H; Xie, J; Yang, J; Yi, H; Shi, ZX; Ma, J; Wang, W; Yang, LF; Yu, SG; Li, JC				Si, Jingwen; Wang, Ning; Wang, Huan; Xie, Juan; Yang, Jian; Yi, Hui; Shi, Zixuan; Ma, Jing; Wang, Wen; Yang, Lifang; Yu, Shigiang; Li, Junchang			HIF-1 alpha Signaling Activation by Post-Ischemia Treatment with Astragaloside IV Attenuates Myocardial Ischemia-Reperfusion Injury	PLOS ONE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; NITRIC-OXIDE SYNTHASE; CARDIOPROTECTION; ANGIOGENESIS; SUPPRESSION; INHIBITION; EXPRESSION; PROTECTION; MYOCYTES; HEART	In this study, we evaluated the effect of astragaloside IV (Ast IV) post-ischemia treatment on myocardial ischemia-reperfusion (IR) injury (IRI). We also examined whether hypoxia inducible factor-1 alpha (HIF-1 alpha) and its downstream geneinducible nitric oxide (NO) synthase (iNOS) play roles in the cardioprotective effect of Ast IV. Cultured cardiomyocytes and perfused isolated rat hearts were exposed to Ast IV during reperfusion in the presence or absence of the HIF-1 alpha inhibitor 2methoxyestradiol (2-MeOE2). The post-ischemia treatment with Ast IV protected cardiomyocytes from the apoptosis and death induced by simulated IRI (SIRI). Additionally, in cardiomyocytes, 2-MeOE2 and HIF-1 alpha siRNA treatment each not only abolished the anti-apoptotic effect of post-ischemia treatment with Ast IV but also reversed the upregulation of HIF-1 alpha and iNOS expression. Furthermore, after treatment with Ast IV, post-ischemic cardiac functional recovery and lactate dehydrogenase (LDH) release in the coronary flow (CF) were improved, and the myocardial infarct size was decreased. Moreover, the number of apoptotic cells was reduced, and the upregulation of the anti-apoptotic protein Bcl2 and downregulation of the pro-apoptotic protein Caspase3 were reversed. 2-MeOE2 reversed these effects of Ast IV on IRinjured hearts. These results suggest that post-ischemia treatment with Ast IV can attenuate IRI by upregulating HIF-1 alpha expression, which transmits a survival signal to the myocardium.	[Si, Jingwen; Xie, Juan; Shi, Zixuan; Ma, Jing; Wang, Wen; Li, Junchang] Fourth Mil Med Univ, Xijing Hosp, Dept Tradit Chinese Med, Xian 710032, Shaanxi Provinc, Peoples R China; [Wang, Ning; Yang, Jian; Yu, Shigiang] Fourth Mil Med Univ, Xijing Hosp, Dept Cardiovasc Surg, Xian 710032, Shaanxi Provinc, Peoples R China; [Wang, Huan] Fourth Mil Med Univ, Tangdu Hosp, Dept Dermatol, Xian 710032, Shaanxi Provinc, Peoples R China; [Yi, Hui] Gen Mil Hosp Beijing PLA, BaYi Childrens Hosp, Dept Nephropathy & Immunol, Beijing, Peoples R China; [Yang, Lifang] Fourth Mil Med Univ, Xijing Hosp, Dept Anesthesiol, Xian 710032, Shaanxi Provinc, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University	Yang, LF (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Anesthesiol, Xian 710032, Shaanxi Provinc, Peoples R China.	yangjian1212@hotmail.com; shigiangyu210@126.com; jingwensi111@126.com		Yu, Shiqiang/0000-0003-3519-0943; Yang, Lifang/0000-0002-4004-9883	12th National Five Years Supporting Project of China [2011BAI11B20]; National Natural Science Foundation of China [81072972, 81102687, 81270170, 81070198, 81170213, 81000938]; Academic Promotion Project of Xijing Hospital [XJZT10 M11]; Social Development Project of Shaanxi Province [2007043, 13-JC050, 2012JQ4001, 2012K15-02-01, 2012SF2-21-1]	12th National Five Years Supporting Project of China(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Academic Promotion Project of Xijing Hospital; Social Development Project of Shaanxi Province	This study was supported by grants from the 12th National Five Years Supporting Project of China (2011BAI11B20), the National Natural Science Foundation of China (81072972, 81102687, 81270170, 81070198, 81170213, and 81000938), the Academic Promotion Project of Xijing Hospital (XJZT10 M11), and the Social Development Project of Shaanxi Province (2007043, 13-JC050, 2012JQ4001, 2012K15-02-01, and 2012SF2-21-1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adluri RS, 2011, ANTIOXID REDOX SIGN, V15, P1789, DOI 10.1089/ars.2010.3769; Belaidi E, 2012, FUND CLIN PHARMACOL, V26, P454, DOI 10.1111/j.1472-8206.2011.00940.x; Brune B, 2007, CARDIOVASC RES, V75, P275, DOI 10.1016/j.cardiores.2007.03.005; Cai Z, 2008, CARDIOVASC RES, V77, P463, DOI 10.1093/cvr/cvm035; Chen X, 2012, J ETHNOPHARMACOL, V139, P721, DOI 10.1016/j.jep.2011.11.035; Cheng MX, 2011, TRANSPL P, V43, P1456, DOI 10.1016/j.transproceed.2011.02.066; Dang VC, 2006, AM J PHYSIOL-HEART C, V290, pH1808, DOI 10.1152/ajpheart.00772.2005; Dijkers PF, 2009, MOL BIOL CELL, V20, P4083, DOI 10.1091/mbc.E09-05-0362; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; ESUMI K, 1991, AM J PHYSIOL, V260, pH1743, DOI 10.1152/ajpheart.1991.260.6.H1743; Gui DK, 2013, APOPTOSIS, V18, P409, DOI 10.1007/s10495-013-0801-2; Gui DK, 2013, CYTOKINE, V61, P970, DOI 10.1016/j.cyto.2013.01.008; Hausenloy DJ, 2012, CARDIOVASC RES, V94, P253, DOI 10.1093/cvr/cvs131; Hausenloy DJ, 2010, BASIC RES CARDIOL, V105, P677, DOI 10.1007/s00395-010-0121-4; Hellwig-Burgel T, 2005, J INTERF CYTOK RES, V25, P297, DOI 10.1089/jir.2005.25.297; Heusch G, 2008, CIRCULATION, V118, P1915, DOI 10.1161/CIRCULATIONAHA.108.805242; Jones SP, 2006, J MOL CELL CARDIOL, V40, P16, DOI 10.1016/j.yjmcc.2005.09.011; Kim SR, 2010, EUR J IMMUNOL, V40, P2858, DOI 10.1002/eji.200939948; Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904; Lei J, 2013, NITRIC OXIDE-BIOL CH, V35, P175, DOI 10.1016/j.niox.2013.09.004; Li M, 2012, NEUROCHEM INT, V60, P458, DOI 10.1016/j.neuint.2012.01.026; Li QF, 2012, BRAIN RES, V1451, P1, DOI 10.1016/j.brainres.2012.02.055; Li ZP, 2002, ACTA PHARMACOL SIN, V23, P898; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Mewton N, 2013, CIRC J, V77, P1123, DOI 10.1253/circj.CJ-13-0385; Ovize M, 2010, CARDIOVASC RES, V87, P406, DOI 10.1093/cvr/cvq129; Punn A, 2000, BIOCHEM J, V350, P891, DOI 10.1042/0264-6021:3500891; Ren S, 2013, J TRADIT CHIN MED, V33, P413, DOI 10.1016/S0254-6272(13)60189-2; Salama SA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007356; Schwartz Longacre L, 2011, CIRCULATION, V124, P1172, DOI 10.1161/CIRCULATIONAHA.111.032698; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Skyschally A, 2009, BASIC RES CARDIOL, V104, P469, DOI 10.1007/s00395-009-0040-4; Smart N, 2006, CARDIOVASC RES, V69, P164, DOI 10.1016/j.cardiores.2005.08.017; Strijdom H, 2009, MOL CELL BIOCHEM, V321, P23, DOI 10.1007/s11010-008-9906-2; Wu XQ, 2013, AM J PATHOL, V182, P2005, DOI 10.1016/j.ajpath.2013.02.012; Yang Y, 2013, FREE RADICAL BIO MED, V65, P667, DOI 10.1016/j.freeradbiomed.2013.07.007; Yang Y, 2013, J PINEAL RES, V55, P275, DOI 10.1111/jpi.12070; Yellon DM, 2007, NEW ENGL J MED, V357, P2409; Zhang L, 2011, J PHARMACOL EXP THER, V338, P485, DOI 10.1124/jpet.111.180992; Zhang WD, 2006, PLANTA MED, V72, P4, DOI 10.1055/s-2005-873126; Zhao HX, 2010, BASIC RES CARDIOL, V105, P109, DOI 10.1007/s00395-009-0044-0; Zhao J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044938	42	38	43	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2014	9	9							e107832	10.1371/journal.pone.0107832	http://dx.doi.org/10.1371/journal.pone.0107832			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ0RY	25238237	Green Published, Green Submitted, gold			2023-01-03	WOS:000342491600055
J	Yang, J; Zheng, M; Chen, SQ; Ou, S; Zhang, J; Wang, N; Cao, YY; Wang, J				Yang, Juan; Zheng, Min; Chen, Shuqun; Ou, Shu; Zhang, Jie; Wang, Ni; Cao, Yingying; Wang, Jian			Knowledge of Thrombolytic Therapy for Acute Ischemic Stroke among Community Residents in Western Urban China	PLOS ONE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; AMERICAN-HEART-ASSOCIATION; RISK-FACTORS; MICHIGAN ADULTS; WARNING SIGNS; SYMPTOMS; DELAY; RECOGNITION; POPULATION; EDUCATION	Background and Purpose: Thrombolytic therapy rate for acute ischemic stroke remains low, and improving public awareness of thrombolytic therapy may be helpful to reduce delay and increase chances of thrombolytic therapy. Our purpose was to survey the level of knowledge about thrombolytic therapy for acute ischemic stroke among community residents in Yuzhong district, Chongqing, China. Methods: In 2011, a population-based face-to-face interview survey was conducted in Yuzhong district, Chongqing. A total of 1500 potential participants aged >= 18 years old were selected using a multi-stage sampling method. Results: A total of 1101 participants completed the survey. Only 23.3% (95% CI = 20.8 to 25.8) were aware of thrombolytic therapy for acute ischemic stroke, of whom 59.9% (95% CI = 53.9 to 65.9) knew the time window. Awareness of thrombolytic therapy was higher among young people, those with higher levels of education and household income, those with health insurance, and those who knew all 5 stroke warning signs, while awareness of the time window was higher among those aged 75 years or older. Multivariate logistic regression analysis showed that awareness of thrombolytic therapy was independently associated with age, education level, health insurance and knowledge of stroke warning signs (P<0.05). Conclusions: In this population-based survey the community residents have poor awareness of thrombolytic therapy for acute ischemic stroke.	[Yang, Juan; Wang, Jian] Second Peoples Hosp Chengdu, Dept Neurol, Chengdu, Peoples R China; [Zheng, Min] Chongqing Med Univ, Basic Med Coll, Chongqing, Peoples R China; [Chen, Shuqun] Chongqing Med Univ, Dept Prevent Med, Chongqing, Peoples R China; [Ou, Shu; Zhang, Jie; Wang, Ni; Cao, Yingying] Chongqing Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China	Chongqing Medical University; Chongqing Medical University; Chongqing Medical University	Wang, J (corresponding author), Second Peoples Hosp Chengdu, Dept Neurol, Chengdu, Peoples R China.	jian.wx@163.com						ALBERTS MJ, 1992, STROKE, V23, P352, DOI 10.1161/01.STR.23.3.352; Anderson BE, 2009, STROKE, V40, P2564, DOI 10.1161/STROKEAHA.108.545988; [Anonymous], WARN SIGNS; Barr J, 2006, NEUROEPIDEMIOLOGY, V26, P168, DOI 10.1159/000091659; BARSAN WG, 1994, STROKE, V25, P2132, DOI 10.1161/01.STR.25.11.2132; Becker KJ, 2001, CEREBROVASC DIS, V11, P34, DOI 10.1159/000047609; Billings-Gagliardi S, 2005, STROKE, V36, P1035, DOI 10.1161/01.STR.0000162716.82295.ac; California Acute Stroke Pilot Registry (CASPR) Investigators, 2005, NEUROLOGY, V64, P654; Chen SY, 2013, NEUROL RES, V35, P522, DOI 10.1179/1743132813Y.0000000203; Chen Z., 2008, 3 NATL SURVEY CAUSE, V1, P14; Deng YZ, 2006, NEUROLOGY, V66, P306, DOI 10.1212/01.wnl.0000196478.77152.fc; Ellis C, 2009, AM J MED SCI, V337, P5, DOI 10.1097/MAJ.0b013e318176abd1; Ferris A, 2005, CIRCULATION, V111, P1321, DOI 10.1161/01.CIR.0000157745.46344.A1; Fussman C, 2010, STROKE, V41, P1501, DOI 10.1161/STROKEAHA.110.578195; Jin HQ, 2012, STROKE, V43, P362, DOI 10.1161/STROKEAHA.111.623512; Jurkowski Janine M, 2008, Prev Chronic Dis, V5, pA41; Kleindorfer D, 2009, STROKE, V40, P2502, DOI 10.1161/STROKEAHA.109.551861; Liu M, 2007, LANCET NEUROL, V6, P456, DOI 10.1016/S1474-4422(07)70004-2; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Morgenstern LB, 2003, ARCH INTERN MED, V163, P2198, DOI 10.1001/archinte.163.18.2198; Morgenstern LB, 2002, STROKE, V33, P160, DOI 10.1161/hs0102.101990; Morgenstern LB, 2001, STROKE, V32, P1360, DOI 10.1161/01.STR.32.6.1360; Moser DK, 2007, J CARDIOVASC NURS, V22, P326, DOI 10.1097/01.JCN.0000278963.28619.4a; Reeves MJ, 2008, CEREBROVASC DIS, V25, P385, DOI 10.1159/000121338; Ritter MA, 2007, NEUROL RES, V29, P476, DOI 10.1179/016164107X163202; Rudd AG, 2011, J NEUROL NEUROSUR PS, V82, P14, DOI 10.1136/jnnp.2009.203174; Schroeder EB, 2000, STROKE, V31, P2591, DOI 10.1161/01.STR.31.11.2591; Sun HX, 2011, NEUROL RES, V33, P536, DOI 10.1179/016164111X13007856084368; Wang YL, 2009, CHINESE J STROKE, V4, P23, DOI DOI 10.3969/J.ISSN.1673-5765.2009.01.005; Williams LS, 1997, STROKE, V28, P912, DOI 10.1161/01.STR.28.5.912; Wojner AW, 2003, AM J CRIT CARE, V12, P411, DOI 10.4037/ajcc2003.12.5.411; Yang J, 2014, J STROKE CEREBROVASC, V23, P1216, DOI 10.1016/j.jstrokecerebrovasdis.2013.10.019; Yang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073578; Yoon SS, 2001, STROKE, V32, P1926, DOI 10.1161/01.STR.32.8.1926	35	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2014	9	9							e107892	10.1371/journal.pone.0107892	http://dx.doi.org/10.1371/journal.pone.0107892			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AP0SR	25222126	Green Published, gold, Green Submitted			2023-01-03	WOS:000341774800098
J	Felix-Silva, J; Souza, T; Menezes, YAS; Cabral, B; Camara, RBG; Silva, AA; Rocha, HAO; Rebecchi, IMM; Zucolotto, SM; Fernandes-Pedrosa, MF				Felix-Silva, Juliana; Souza, Thiago; Menezes, Yamara A. S.; Cabral, Barbara; Camara, Rafael B. G.; Silva-Junior, Arnobio A.; Rocha, Hugo A. O.; Rebecchi, Ivanise M. M.; Zucolotto, Silvana M.; Fernandes-Pedrosa, Matheus F.			Aqueous Leaf Extract of Jatropha gossypiifolia L. (Euphorbiaceae) Inhibits Enzymatic and Biological Actions of Bothrops jararaca Snake Venom	PLOS ONE			English	Article							ANTIINFLAMMATORY ACTIVITY; PHOSPHOLIPASE A(2); ETHANOLIC EXTRACT; GOSSYPIFOLIA L.; PAW EDEMA; METALLOPROTEINASES; CONSTITUENTS; LEAVES; ANTICOAGULANT; QUANTITATION	Snakebites are a serious public health problem due their high morbi-mortality. The main available specific treatment is the antivenom serum therapy, which has some disadvantages, such as poor neutralization of local effects, risk of immunological reactions, high cost and difficult access in some regions. In this context, the search for alternative therapies is relevant. Therefore, the aim of this study was to evaluate the antiophidic properties of Jatropha gossypiifolia, a medicinal plant used in folk medicine to treat snakebites. The aqueous leaf extract of the plant was prepared by decoction and phytochemical analysis revealed the presence of sugars, alkaloids, flavonoids, tannins, terpenes and/or steroids and proteins. The extract was able to inhibit enzymatic and biologic activities induced by Bothrops jararaca snake venom in vitro and in vivo. The blood incoagulability was efficiently inhibited by the extract by oral route. The hemorrhagic and edematogenic local effects were also inhibited, the former by up to 56% and the latter by 100%, in animals treated with extract by oral and intraperitoneal routes, respectively. The inhibition of myotoxic action of B. jararaca reached almost 100%. According to enzymatic tests performed, it is possible to suggest that the antiophidic activity may be due an inhibitory action upon snake venom metalloproteinases (SVMPs) and/or serine proteinases (SVSPs), including fibrinogenolytic enzymes, clotting factors activators and thrombin like enzymes (SVTLEs), as well upon catalytically inactive phospholipases A(2) (Lys49 PLA(2)). Anti-inflammatory activity, at least partially, could also be related to the inhibition of local effects. Additionally, protein precipitating and antioxidant activities may also be important features contributing to the activity presented. In conclusion, the results demonstrate the potential antiophidic activity of J. gossypiifolia extract, including its significant action upon local effects, suggesting that it may be used as a new source of bioactive molecules against bothropic venom.	[Felix-Silva, Juliana; Souza, Thiago; Menezes, Yamara A. S.; Silva-Junior, Arnobio A.; Fernandes-Pedrosa, Matheus F.] Univ Fed Rio Grande do Norte, Lab Tecnol & Biotecnol Farmaceut TecBioFar, Programa Posgrad Ciencias Farmaceut PPgCF, BR-59072970 Natal, RN, Brazil; [Cabral, Barbara; Zucolotto, Silvana M.] Univ Fed Rio Grande do Norte, Dept Farm, Lab Farmacognosia, BR-59072970 Natal, RN, Brazil; [Camara, Rafael B. G.; Rocha, Hugo A. O.] Univ Fed Rio Grande do Norte, Programa Posgrad Bioquim, Lab Biotecnol Polimeros Nat BIOPOL, BR-59072970 Natal, RN, Brazil; [Rebecchi, Ivanise M. M.] Univ Fed Rio Grande do Norte, Dept Anal Clin & Toxicol, Lab Hematol Clin, BR-59072970 Natal, RN, Brazil	Universidade Federal do Rio Grande do Norte; Universidade Federal do Rio Grande do Norte; Universidade Federal do Rio Grande do Norte; Universidade Federal do Rio Grande do Norte	Fernandes-Pedrosa, MF (corresponding author), Univ Fed Rio Grande do Norte, Lab Tecnol & Biotecnol Farmaceut TecBioFar, Programa Posgrad Ciencias Farmaceut PPgCF, BR-59072970 Natal, RN, Brazil.	mpedrosa@ufrnet.br	Félix-Silva, Juliana/K-7066-2012; Félix-Silva, Juliana/AAA-1737-2019; Câmara, Rafael Barros Gomes da/X-7416-2019; Zucolotto, Silvana Maria/A-8557-2014; Menezes, Yamara/K-1783-2016; de Oliveira Rocha, Hugo Alexandre/I-5130-2019; Fernandes-Pedrosa, Matheus/C-6398-2014; da Silva, Arnobio A/L-4252-2013; Rocha, Hugo Alexandre Oliveira/X-6410-2019; Silva, André/HHN-2071-2022; Rocha, Hugo Alexandre Oliveira/X-6411-2019	Félix-Silva, Juliana/0000-0003-3131-9025; Félix-Silva, Juliana/0000-0003-3131-9025; Zucolotto, Silvana Maria/0000-0002-2768-0793; Menezes, Yamara/0000-0002-3532-5273; Fernandes-Pedrosa, Matheus/0000-0003-4221-9580; da Silva, Arnobio A/0000-0002-7516-1787; Rocha, Hugo Alexandre Oliveira/0000-0003-2252-1221; 	CAPES [23038000814/2011-83]; CNPq [483842/2010-9]; BNB [ETENE/2010]; FAPERN [PRONEM/2011]	CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); BNB; FAPERN(Fundacao de Apoio a Pesquisa do Estado do Rio Grande do Norte (FAPERN))	This research was supported by grants from CAPES (23038000814/2011-83), CNPq (483842/2010-9), BNB (ETENE/2010) and FAPERN (PRONEM/2011). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambikabothy J, 2011, J ETHNOPHARMACOL, V137, P257, DOI 10.1016/j.jep.2011.05.013; Pereanez JA, 2013, TOXICON, V71, P41, DOI 10.1016/j.toxicon.2013.05.013; [Anonymous], 2014, INT J PHARM PHARM SC; Araujo SD, 2007, INFLAMM RES, V56, P409, DOI 10.1007/s00011-007-7054-x; Arni RK, 1996, TOXICON, V34, P827, DOI 10.1016/0041-0101(96)00036-0; Bhagat R, 2011, J SCI IND RES INDIA, V70, P289; BJARNASON JB, 1994, PHARMACOL THERAPEUT, V62, P325, DOI 10.1016/0163-7258(94)90049-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Brasil, 2011, REN REL NCAL PLANT M; CURY Y, 1994, TOXICON, V32, P1425, DOI 10.1016/0041-0101(94)90414-6; Dantas Jose Oliveira, 2006, Biologia Geral e Experimental, V6, P32; de Albuquerque UP, 2007, J ETHNOPHARMACOL, V110, P76, DOI 10.1016/j.jep.2006.09.010; De PRC, 2010, J VENOM ANIM TOXINS, V16, P311, DOI 10.1590/S1678-91992010000200012; de Paula RC, 2009, PROTEIN PEPTIDE LETT, V16, P899, DOI 10.2174/092986609788923365; de Roodt AR, 2000, TOXICON, V38, P865, DOI 10.1016/S0041-0101(99)00205-6; Devappa RK, 2010, J TOXICOL ENV HEAL B, V13, P476, DOI 10.1080/10937404.2010.499736; Dey A, 2012, INT J PHARMACOL, V8, P62, DOI 10.3923/ijp.2012.62.79; Di Stasi L.C., 2002, PLANTAS MED AMAZONIA; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Escalante T, 2011, J PROTEOMICS, V74, P1781, DOI 10.1016/j.jprot.2011.03.026; Feitosa L, 1998, TOXICON, V36, P1039, DOI 10.1016/S0041-0101(97)00083-4; Felix-Silva J, 2014, EVID-BASED COMPL ALT, V2014, P1; Franke K, 2004, BIOCHEM SYST ECOL, V32, P219, DOI 10.1016/S0305-1978(03)00140-6; Fuly, 2011, BIOMED PREV NUTR, V1, P61, DOI [10.1016/j.bionut.2010.09.003, DOI 10.1016/J.BIONUT.2010.09.003]; Gomes A, 2010, INDIAN J EXP BIOL, V48, P865; GUTIERREZ J M, 1989, Memorias do Instituto Butantan (Sao Paulo), V51, P211; GUTIERREZ JM, 1995, TOXICON, V33, P1405, DOI 10.1016/0041-0101(95)00085-Z; Gutierrez JM, 2000, BIOCHIMIE, V82, P841, DOI 10.1016/S0300-9084(00)01163-9; Gutierrez JM, 2006, PLOS MED, V3, P727, DOI 10.1371/journal.pmed.0030150; Gutierrez JM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002162; HABERMANN E, 1972, ANAL BIOCHEM, V50, P163, DOI 10.1016/0003-2697(72)90495-2; Kang TS, 2011, FEBS J, V278, P4544, DOI 10.1111/j.1742-4658.2011.08115.x; Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218; KORNALIK F, 1985, PHARMACOL THERAPEUT, V29, P353, DOI 10.1016/0163-7258(85)90008-7; KUPPUSAMY UR, 1993, PHARMACOL TOXICOL, V72, P290, DOI 10.1111/j.1600-0773.1993.tb01652.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maiorano VA, 2005, J ETHNOPHARMACOL, V102, P364, DOI 10.1016/j.jep.2005.06.039; Mao WJ, 2009, INT J BIOL MACROMOL, V44, P70, DOI 10.1016/j.ijbiomac.2008.10.003; Gutierrez JM, 2011, BIOLOGICALS, V39, P129, DOI 10.1016/j.biologicals.2011.02.005; Mariz SR, 2012, REV BRAS FARMACOGN, V22, P663, DOI 10.1590/S0102-695X2012005000024; MEBS D, 1983, TOXICON, V21, P393, DOI 10.1016/0041-0101(83)90096-X; Melo-Silveira RF, 2012, INT J MOL SCI, V13, P409, DOI 10.3390/ijms13010409; Ministerio da Saude, 2009, CADERNO 14; Mors WB, 2000, PHYTOCHEMISTRY, V55, P627, DOI 10.1016/S0031-9422(00)00229-6; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagaharika Y, 2013, J ACUTE DIS, V2, P156, DOI 10.1016/S2221-6189(13)60118-3; Nunez V, 2004, BRAZ J MED BIOL RES, V37, P969, DOI 10.1590/S0100-879X2004000700005; Ode O.J., 2010, INT J APPL BIOL PHAR, V1, P1330; Panda BB, 2009, GLOBAL J PHARM, V3, P1; Pilon AC, 2013, PHYTOCHEM ANALYSIS, V24, P401, DOI 10.1002/pca.2423; Ramos OHP, 2006, COMP BIOCHEM PHYS C, V142, P328, DOI 10.1016/j.cbpc.2005.11.005; Robert S, 2010, J ETHNOPHARMACOL, V128, P641, DOI 10.1016/j.jep.2010.02.007; Rodrigues VM, 2000, ARCH BIOCHEM BIOPHYS, V381, P213, DOI 10.1006/abbi.2000.1958; Sabandar CW, 2013, PHYTOCHEMISTRY, V85, P7, DOI 10.1016/j.phytochem.2012.10.009; Sajevic T, 2011, TOXICON, V57, P627, DOI 10.1016/j.toxicon.2011.01.006; Santhosh MS, 2013, MINI-REV MED CHEM, V13, P106; Shenoy PA, 2013, J ETHNOPHARMACOL, V147, P373, DOI 10.1016/j.jep.2013.03.022; STOCKER K, 1982, TOXICON, V20, P265, DOI 10.1016/0041-0101(82)90225-2; SUBRAMAN.SS, 1971, PHYTOCHEMISTRY, V10, P1690, DOI 10.1016/0031-9422(71)85055-0; Swenson S, 2005, TOXICON, V45, P1021, DOI 10.1016/j.toxicon.2005.02.027; Teixeira CFP, 2003, TOXICON, V42, P947, DOI 10.1016/j.toxicon.2003.11.006; Melo KRT, 2013, MOLECULES, V18, P14543, DOI 10.3390/molecules181214543; THEAKSTON RDG, 1983, B WORLD HEALTH ORGAN, V61, P949; TREBIEN HA, 1989, AGENTS ACTIONS, V26, P292, DOI 10.1007/BF01967293; Wagner H., 2001, PLANT DRUGS ANAL THI; Zhang XP, 2009, CHEM BIODIVERS, V6, P2166, DOI 10.1002/cbdv.200700461	67	33	34	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2014	9	8							e104952	10.1371/journal.pone.0104952	http://dx.doi.org/10.1371/journal.pone.0104952			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN8UD	25126759	Green Published, Green Submitted, gold			2023-01-03	WOS:000340879300063
J	Li, C; Wang, Y; Qiu, Q; Shi, TJ; Wu, Y; Han, J; Chai, XY; Wang, W				Li, Chun; Wang, Yong; Qiu, Qi; Shi, Tianjiao; Wu, Yan; Han, Jing; Chai, Xingyun; Wang, Wei			Qishenyiqi Protects Ligation-Induced Left Ventricular Remodeling by Attenuating Inflammation and Fibrosis via STAT3 and NF-kappa B Signaling Pathway	PLOS ONE			English	Article							CHRONIC HEART-FAILURE; INHIBITION; BIOMARKERS; CYTOKINES	Aim: Qi-shen-yi-qi (QSYQ), a formula used for the routine treatment of heart failure (HF) in China, has been demonstrated to improve cardiac function through down-regulating the activation of the Renin-Angiotensin-Aldosterone System (RAAS). However, the mechanisms governing its therapeutic effects are largely unknown. The present study aims to demonstrate that QSYQ treatment can prevent left ventricular remodeling in heart failure by attenuating oxidative stress and inhabiting inflammation. Methods: Sprague-Dawley (SD) rats were randomly divided into 6 groups: sham group, model group (LAD coronary artery ligation), QSYQ group with high dosage, middle dosage and low dosage (LAD ligation and treated with QSYQ), and captopril group (LAD ligation and treated with captopril as the positive drug). Indicators of fibrosis (Masson, MMPs, and collagens) and inflammation factors were detected 28 days after surgery. Results: Results of hemodynamic alterations (dp/dt value) in the model group as well as other ventricular remodeling (VR) markers, such as MMP-2, MMP-9, collagen I and III elevated compared with sham group. VR was accompanied by activation of RAAS (angiotensin II and NADPHoxidase). Levels of pro-inflammatory cytokines (TNF-alpha, IL-6) in myocardial tissue were also up-regulated. Treatment of QSYQ improved cardiac remodeling through counter-acting the aforementioned events. The improvement of QSYQ was accompanied with a restoration of angiotensin II-NADPHoxidase-ROS-MMPs pathways. In addition, "therapeutic'' QSYQ administration can reduce both TNF-alpha-NF-B and IL-6-STAT3 pathways, respectively, which further proves the beneficial effects of QSYQ. Conclusions: Our study demonstrated that QSYQ protected LAD ligation-induced left VR via attenuating AngII -NADPH oxidase pathway and inhabiting inflammation. These findings provide evidence as to the cardiac protective efficacy of QSYQ to HF and explain the beneficial effects of QSYQ in the clinical application for HF.	[Li, Chun; Chai, Xingyun] Beijing Univ Chinese Med, Modern Res Ctr Tradit Chinese Med, Beijing, Peoples R China; [Wang, Yong; Shi, Tianjiao; Wu, Yan; Han, Jing; Wang, Wei] Beijing Univ Chinese Med, Basic Med Coll, Beijing, Peoples R China; [Qiu, Qi] Capital Med Univ, Anzhen Hosp, Beijing, Peoples R China	Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Capital Medical University	Wang, W (corresponding author), Beijing Univ Chinese Med, Basic Med Coll, Beijing, Peoples R China.	wangwei26960@126.com			National Natural Science Foundation of China [81202788, 81302908]; National Science & Technology Pillar Program [2012BAI29B07]; Beijing Natural Science Foundation [7142099]; Creation for Significant New Drugs Project of China [2012ZX09103-201-011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science & Technology Pillar Program; Beijing Natural Science Foundation(Beijing Natural Science Foundation); Creation for Significant New Drugs Project of China	This study was financially supported, in part, by the Grants from the National Natural Science Foundation of China (No. 81202788 and 81302908), the National Science & Technology Pillar Program (No. 2012BAI29B07), Beijing Natural Science Foundation (7142099), and Creation for Significant New Drugs Project of China (No. 2012ZX09103-201-011). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal R, 2010, PHARMACOL RES, V61, P269, DOI 10.1016/j.phrs.2009.11.012; Ahmad T, 2012, NAT REV CARDIOL, V9, P347, DOI 10.1038/nrcardio.2012.37; Armstrong PC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020062; Bartunek J, 2012, BIOMARK MED, V6, P1, DOI [10.2217/BMM.12.3, 10.2217/bmm.12.3]; Dai Guo-hua, 2007, Zhongguo Zhong Xi Yi Jie He Za Zhi, V27, P653; Ferreira AS, 2011, CHIN J INTEGR MED, V17, P818, DOI 10.1007/s11655-011-0892-y; Fertin M, 2012, AM J CARDIOL, V110, P277, DOI 10.1016/j.amjcard.2012.02.069; Gullestad L, 2012, CARDIOLOGY, V122, P23, DOI 10.1159/000338166; Hamid T, 2009, CIRCULATION, V119, P1386, DOI 10.1161/CIRCULATIONAHA.108.802918; Hohensinner PJ, 2011, CURR OPIN INFECT DIS, V24, P259, DOI 10.1097/QCO.0b013e328344f50f; Hong Chengtao, 2009, Zhongguo Zhong Yao Za Zhi, V34, P1018; Houser SR, 2012, CIRC RES, V111, P131, DOI 10.1161/RES.0b013e3182582523; Kairouz V, 2012, ANN NY ACAD SCI, V1254, P42, DOI 10.1111/j.1749-6632.2012.06520.x; Khatib R, 2012, INT J CARDIOLOGY; Kirkpatrick James N, 2012, Curr Heart Fail Rep, V9, P328, DOI 10.1007/s11897-012-0116-6; Kurdi Mazen, 2010, Congest Heart Fail, V16, P234, DOI 10.1111/j.1751-7133.2010.00175.x; Lecour S, 2011, EUR HEART J, V32, P680, DOI 10.1093/eurheartj/ehq484; Li YW, 2006, CARDIOVASC RES, V71, P684, DOI 10.1016/j.cardiores.2006.06.003; Lin Yang, 2012, China Journal of Traditional Chinese Medicine and Pharmacy, V27, P1280; Mir SA, 2012, J BIOL CHEM, V287, P2666, DOI 10.1074/jbc.M111.246173; Mukhopadhyay P, 2007, J AM COLL CARDIOL, V50, P528, DOI 10.1016/j.jacc.2007.03.057; Pacher P, 2008, NAT PROTOC, V3, P1422, DOI 10.1038/nprot.2008.138; Rajesh M, 2010, J AM COLL CARDIOL, V56, P2115, DOI 10.1016/j.jacc.2010.07.033; Schroder K, 2012, CIRC RES, V110, P1217, DOI 10.1161/CIRCRESAHA.112.267054; Wang MJ, 2007, AM J PHYSIOL-HEART C, V293, pH2101, DOI 10.1152/ajpheart.00125.2007; Wang Y., 2012, EVIDENCE BASED COMPL; Wang Y, 2013, EVIDENCE BASED COMPL, V2013; Wysong A, 2011, AM J PATHOL, V178, P1059, DOI 10.1016/j.ajpath.2010.12.009; Zhang M, 2013, ANTIOXID REDOX SIGN, V18, P1024, DOI 10.1089/ars.2012.4550	29	52	58	1	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2014	9	8							e104255	10.1371/journal.pone.0104255	http://dx.doi.org/10.1371/journal.pone.0104255			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO0QT	25122164	gold, Green Submitted, Green Published			2023-01-03	WOS:000341017000033
J	Long, ZJ; Hu, YA; Li, XD; He, Y; Xiao, RZ; Fang, ZG; Wang, DN; Liu, JJ; Yan, JS; Huang, RW; Lin, DJ; Liu, QT				Long, Zi-Jie; Hu, Yuan; Li, Xu-Dong; He, Yi; Xiao, Ruo-Zhi; Fang, Zhi-Gang; Wang, Dong-Ning; Liu, Jia-Jun; Yan, Jin-Song; Huang, Ren-Wei; Lin, Dong-Jun; Liu, Quentin			ATO/ATRA/Anthracycline-Chemotherapy Sequential Consolidation Achieves Long-Term Efficacy in Primary Acute Promyelocytic Leukemia	PLOS ONE			English	Article							TRANS-RETINOIC ACID; ARSENIC TRIOXIDE AS2O3; REMISSION INDUCTION; INITIAL THERAPY; COMBINATION; SURVIVAL; DIFFERENTIATION; ANTHRACYCLINE; INTERGROUP; SAFETY	The combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3, ATO) has been effective in obtaining high clinical complete remission (CR) rates in acute promyelocytic leukemia (APL), but the long-term efficacy and safety among newly diagnosed APL patients are unclear. In this retrospective study, total 45 newly diagnosed APL patients received ATRA/chemotherapy combination regimen to induce remission. Among them, 43 patients (95.6%) achieved complete remission (CR) after induction therapy, followed by ATO/ATRA/anthracycline-based chemotherapy sequential consolidation treatment with a median follow-up of 55 months. In these patients, the estimated overall survival (OS) and the relapse-free survival (RFS) were 94.4%+/- 3.9% and 94.6 +/- 3.7%, respectively. The toxicity profile was mild and reversible. No secondary carcinoma was observed. These results demonstrated the high efficacy and minimal toxicity of ATO/ATRA/anthracycline-based chemotherapy sequential consolidation treatment for newly diagnosed APL in long-term follow-up, suggesting a potential frontline therapy for APL.	[Long, Zi-Jie; Hu, Yuan; Li, Xu-Dong; He, Yi; Xiao, Ruo-Zhi; Fang, Zhi-Gang; Wang, Dong-Ning; Liu, Jia-Jun; Huang, Ren-Wei; Lin, Dong-Jun; Liu, Quentin] Sun Yat Sen Univ, Sun Yat Sen Inst Hematol, Affiliated Hosp 3, Dept Hematol, Guangzhou, Guangdong, Peoples R China; [Liu, Quentin] Dalian Med Univ, Inst Canc Stem Cell, Dalian, Peoples R China; [Yan, Jin-Song] Dalian Med Univ, Affiliated Hosp 2, Dept Hematol, Dalian, Peoples R China	Sun Yat Sen University; Dalian Medical University; Dalian Medical University	Huang, RW (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Inst Hematol, Affiliated Hosp 3, Dept Hematol, Guangzhou, Guangdong, Peoples R China.	huangrw56@163.com; lindj@mail.sysu.edu.cn; liuq9@mail.sysu.edu.cn	Huang, Ren/HJG-5652-2022; Yan, Jinsong/ABC-6784-2020; liu, xiaoyun/GXV-0330-2022	Huang, Ren/0000-0002-3068-8331; Yan, Jinsong/0000-0003-4109-2602; liu, xiaoyun/0000-0002-5425-7456				Aribi A, 2007, CANCER, V109, P1355, DOI 10.1002/cncr.22524; Asou N, 2007, BLOOD, V110, P59, DOI 10.1182/blood-2006-08-043992; Au WY, 2002, BRIT J HAEMATOL, V117, P130, DOI 10.1046/j.1365-2141.2002.03409.x; Avvisati G, 2011, BLOOD, V117, P4716, DOI 10.1182/blood-2010-08-302950; Chen GQ, 1997, BLOOD, V89, P3345; Coutre SE, 2014, BRIT J HAEMATOL, V165, P497, DOI 10.1111/bjh.12775; CUNNINGHAM I, 1989, BLOOD, V73, P1116; Dai CW, 2009, ACTA HAEMATOL-BASEL, V121, P1, DOI 10.1159/000204472; dos Santos GA, 2013, J EXP MED, V210, P2793, DOI 10.1084/jem.20131121; Estey E, 2006, BLOOD, V107, P3469, DOI 10.1182/blood-2005-10-4006; Galimberti S, 1999, BONE MARROW TRANSPL, V24, P345, DOI 10.1038/sj.bmt.1701875; Ghavamzadeh A, 2006, ANN ONCOL, V17, P131, DOI 10.1093/annonc/mdj019; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Gore SD, 2010, J CLIN ONCOL, V28, P1047, DOI 10.1200/JCO.2009.25.5158; Grigg A, 2003, LEUKEMIA, V17, P1916, DOI 10.1038/sj.leu.2403050; Hu J, 2009, P NATL ACAD SCI USA, V106, P3342, DOI 10.1073/pnas.0813280106; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Iland HJ, 2012, BLOOD, V120, P1570, DOI 10.1182/blood-2012-02-410746; Jing YK, 2001, BLOOD, V97, P264, DOI 10.1182/blood.V97.1.264; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; Lengfelder E, 2009, LEUKEMIA, V23, P2248, DOI 10.1038/leu.2009.183; Li X, 2007, LEUKEMIA RES, V31, P765, DOI 10.1016/j.leukres.2006.07.028; Lo-Coco F, 2013, NEW ENGL J MED, V369, P111, DOI 10.1056/NEJMoa1300874; Mathews V, 2006, BLOOD, V107, P2627, DOI 10.1182/blood-2005-08-3532; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Powell BL, 2010, BLOOD, V116, P3751, DOI 10.1182/blood-2010-02-269621; Quezada G, 2008, PEDIATR BLOOD CANCER, V51, P133, DOI 10.1002/pbc.21529; Raffoux E, 2003, J CLIN ONCOL, V21, P2326, DOI 10.1200/JCO.2003.01.149; Rock N, 2014, PEDIATR HEMAT ONCOL, V31, P143, DOI 10.3109/08880018.2013.876470; SANZ MA, 1988, CANCER, V61, P7, DOI 10.1002/1097-0142(19880101)61:1<7::AID-CNCR2820610103>3.0.CO;2-6; Sanz MA, 2010, BLOOD, V115, P5137, DOI 10.1182/blood-2010-01-266007; Shen ZX, 2004, P NATL ACAD SCI USA, V101, P5328, DOI 10.1073/pnas.0400053101; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Shigeno K, 2005, INT J HEMATOL, V82, P224, DOI 10.1532/IJH97.05044; Soignet SL, 2001, J CLIN ONCOL, V19, P3852, DOI 10.1200/JCO.2001.19.18.3852; Sun H. D., 1992, CHIN J INTEGRAT CHIN, V12, P170; Tallman MS, 2007, BEST PRACT RES CL HA, V20, P57, DOI 10.1016/j.beha.2006.11.002; Tallman MS, 2002, BLOOD, V100, P4298, DOI 10.1182/blood-2002-02-0632; Wang GJ, 2004, HEMATOL ONCOL, V22, P63, DOI 10.1002/hon.728; Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182/blood-2007-07-102798; ZHANG P, 1996, CHIN J HEMATOL, V17, P58; Zhang YM, 2013, CANCER-AM CANCER SOC, V119, P115, DOI 10.1002/cncr.27650; Zheng PZ, 2005, P NATL ACAD SCI USA, V102, P7653, DOI 10.1073/pnas.0502825102	43	12	14	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2014	9	8							e104610	10.1371/journal.pone.0104610	http://dx.doi.org/10.1371/journal.pone.0104610			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO0QT	25122165	gold, Green Submitted, Green Published			2023-01-03	WOS:000341017000047
J	Kroenke, K; Krebs, EE; Wu, JW; Yu, ZS; Chumbler, NR; Bair, MJ				Kroenke, Kurt; Krebs, Erin E.; Wu, Jingwei; Yu, Zhangsheng; Chumbler, Neale R.; Bair, Matthew J.			Telecare Collaborative Management of Chronic Pain in Primary Care A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MUSCULOSKELETAL PAIN; COMPARATIVE RESPONSIVENESS; DEPRESSION; THERAPY; CANCER	IMPORTANCE Chronic musculoskeletal pain is among the most prevalent, costly, and disabling medical disorders. However, few clinical trials have examined interventions to improve chronic pain in primary care. OBJECTIVE To determine the effectiveness of a telecare intervention for chronic pain. DESIGN, SETTING, AND PARTICIPANTS The Stepped Care to Optimize Pain Care Effectiveness (SCOPE) study was a randomized trial comparing a telephone-delivered collaborative care management intervention vs usual care in 250 patients with chronic (>= 3 months) musculoskeletal pain of at least moderate intensity (Brief Pain Inventory [BPI] score >= 5). Patients were enrolled from 5 primary care clinics in a single Veterans Affairs medical center from June 2010 through May 2012, with 12-month follow-up completed by June 2013. INTERVENTIONS Patients were randomized either to an intervention group (n = 124) or to a usual care group whose members received all pain care as usual from their primary care physicians (n = 126). The intervention group received 12 months of telecare management that coupled automated symptom monitoring with an algorithm-guided stepped care approach to optimizing analgesics. MAIN OUTCOMES AND MEASURES Primary outcome was the BPI total score, which ranges from 0 ("no pain") to 10 ("pain as bad as you can imagine") and for which a 1-point change is considered clinically important. Secondary pain outcomes included BPI interference and severity, global pain improvement, treatment satisfaction, and use of opioids and other analgesics. RESULTS Overall, mean (SD) baseline BPI scores in the intervention and control groups were 5.31 (1.81) and 5.12 (1.80), respectively. Compared with usual care, the intervention group had a 1.02-point lower (95% CI, -1.58 to -0.47) BPI score at 12 months (3.57 vs 4.59). Patients in the intervention group were nearly twice as likely to report at least a 30% improvement in their pain score by 12 months (51.7% vs 27.1%; relative risk, 1.9 [95% CI, 1.4 to 2.7]), with a number needed to treat of 4.1 (95% CI, 3.0 to 6.4) for a 30% improvement. Secondary pain outcomes also improved. Few patients in either group required opioid initiation or dose escalation. CONCLUSIONS AND RELEVANCE Telecare collaborative management increased the proportion of primary care patients with improved chronic musculoskeletal pain. This was accomplished by optimizing nonopioid analgesic medications using a stepped care algorithm and monitoring. Copyright 2014 American Medical Association. All rights reserved.	[Kroenke, Kurt; Bair, Matthew J.] Roudebush VA Med Ctr, VA HSR&D Ctr Hlth Informat & Commun, Indianapolis, IN USA; [Kroenke, Kurt; Bair, Matthew J.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Kroenke, Kurt; Bair, Matthew J.] Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA; [Krebs, Erin E.] Minneapolis VA Hlth Care Syst, VA HSR&D Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Krebs, Erin E.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; [Wu, Jingwei; Yu, Zhangsheng] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA; [Chumbler, Neale R.] Univ Georgia, Coll Publ Hlth, Dept Hlth Policy & Management, Athens, GA 30602 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; Indiana University System; Indiana University Bloomington; University System of Georgia; University of Georgia	Kroenke, K (corresponding author), Regenstrief Inst Hlth Care, 1050 Wishard Blvd,Fifth Floor, Indianapolis, IN 46202 USA.	kkroenke@regenstrief.org	Wu, Jing/GZK-5063-2022	Krebs, Erin/0000-0003-0843-7410; Kroenke, Kurt/0000-0002-0114-4669	Department of Veterans Affairs (VA) Health Services Research and Development (VA HSR&D) Merit Review award [IIR 07-119]; VA Career Development Award [CDA 07-215]	Department of Veterans Affairs (VA) Health Services Research and Development (VA HSR&D) Merit Review award; VA Career Development Award	This work was supported by a Department of Veterans Affairs (VA) Health Services Research and Development (VA HSR&D) Merit Review award to Dr Kroenke (IIR 07-119) and a VA Career Development Award to Dr Krebs (CDA 07-215).	Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Curatolo M, 2001, CLIN J PAIN, V17, P25, DOI 10.1097/00002508-200103000-00005; Dobscha SK, 2009, JAMA-J AM MED ASSOC, V301, P1242, DOI 10.1001/jama.2009.377; Dowell D, 2013, JAMA-J AM MED ASSOC, V309, P2219, DOI 10.1001/jama.2013.5794; Du SZ, 2011, PATIENT EDUC COUNS, V85, pE299, DOI 10.1016/j.pec.2011.02.021; Dunn KM, 2008, PAIN, V135, P48, DOI 10.1016/j.pain.2007.05.001; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Gilbody S, 2008, CAN MED ASSOC J, V178, P997, DOI 10.1503/cmaj.070281; Jackson JL, 2006, CNS SPECTRUMS, V11, P212, DOI 10.1017/S1092852900014383; Joint Commission on Accreditation of Healthcare Organizations, 2000, PAIN ASS MAN ORG APP; Kamaleri Y, 2009, PAIN, V141, P25, DOI 10.1016/j.pain.2008.09.013; Katon W, 2010, GEN HOSP PSYCHIAT, V32, P456, DOI 10.1016/j.genhosppsych.2010.04.001; Krebs EE, 2010, MED CARE, V48, P1007, DOI 10.1097/MLR.0b013e3181eaf835; Krebs EE, 2009, J GEN INTERN MED, V24, P733, DOI 10.1007/s11606-009-0981-1; Kroenke K, 2003, INT J METH PSYCH RES, V12, P34, DOI 10.1002/mpr.140; Kroenke K, 2013, CONTEMP CLIN TRIALS, V34, P270, DOI 10.1016/j.cct.2012.11.008; Kroenke K, 2012, J PAIN, V13, P764, DOI 10.1016/j.jpain.2012.05.004; Kroenke K, 2010, GEN HOSP PSYCHIAT, V32, P345, DOI 10.1016/j.genhosppsych.2010.03.006; Kroenke K, 2010, JAMA-J AM MED ASSOC, V304, P163, DOI 10.1001/jama.2010.944; Kroenke K, 2009, GEN HOSP PSYCHIAT, V31, P206, DOI 10.1016/j.genhosppsych.2008.12.006; Kroenke K, 2009, JAMA-J AM MED ASSOC, V301, P2099, DOI 10.1001/jama.2009.723; Mallinckrodt CH, 2001, DRUG INF J, V35, P1215, DOI 10.1177/009286150103500418; McGeary DD, 2012, PAIN PRACT, V12, P570, DOI 10.1111/j.1533-2500.2012.00534.x; Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805; Panel on Musculoskeletal Disorders and the Workplace Institute of Medicine, 2000, MUSC DIS WORKPL LOW; Schappert S M, 1992, Vital Health Stat 13, P1; Smith BH, 2001, FAM PRACT, V18, P292, DOI 10.1093/fampra/18.3.292; Tan G, 2007, J REHABIL RES DEV, V44, P195, DOI 10.1682/JRRD.2006.06.0063; Trivedi MH, 2009, J CLIN PSYCHIAT, V70, P26, DOI 10.4088/JCP.8133su1c.04; Turk DC, 2002, CLIN J PAIN, V18, P355, DOI 10.1097/00002508-200211000-00003; Von Korff M, 2011, ANN INTERN MED, V155, P325, DOI 10.7326/0003-4819-155-5-201109060-00011	31	109	110	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	2014	312	3					240	248		10.1001/jama.2014.7689	http://dx.doi.org/10.1001/jama.2014.7689			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AL2FC	25027139	Bronze			2023-01-03	WOS:000338940300021
J	Ramos, P; Bentires-Alj, M				Ramos, P.; Bentires-Alj, M.			Mechanism-based cancer therapy: resistance to therapy, therapy for resistance	ONCOGENE			English	Review							METASTATIC BREAST-CANCER; PATIENTS RECEIVING IMATINIB; MEDIATED DRUG-RESISTANCE; CHRONIC MYELOID-LEUKEMIA; CELL LUNG-CANCER; TRASTUZUMAB RESISTANCE; ACQUIRED-RESISTANCE; TUMOR MICROENVIRONMENT; PI3K INHIBITORS; MEK INHIBITORS	The introduction of targeted therapy promised personalized and efficacious cancer treatments. However, although some targeted therapies have undoubtedly improved prognosis and outcome for specific cancer patients, the recurrent problem of therapeutic resistance subdues present revolutionary claims in this field. The plasticity of tumor cells leads to the development of drug resistance by distinct mechanisms: (1) mutations in the target, (2) reactivation of the targeted pathway, (3) hyperactivation of alternative pathways and (4) cross-talk with the microenvironment. Moreover, the intra-tumor heterogeneity of most tumors can also limit therapeutic response. Interestingly, the early identification of some mechanisms of resistance led to the use of alternative agents that improved clinical benefit, demonstrating that an understanding of the molecular mechanisms driving resistance to specific therapies is of paramount importance. Here we review the most generalized mechanisms of resistance to targeted therapies, together with some experimental strategies employed to identify such mechanisms. Therapeutic failure is not an option and we need to understand the dynamics of tumor adaptation in order to adequately adjust therapies; in essence 'to fight fire with fire'.	[Ramos, P.; Bentires-Alj, M.] Friedrich Miescher Inst Biomed Res FMI, Mechanisms Canc, Basel, Switzerland; [Ramos, P.] Novartis Inst Biomed Res, Oncol, Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Novartis	Bentires-Alj, M (corresponding author), Friedrich Miescher Inst Biomed Res, Mechanisms Canc, Maulbeerstr 66, CH-4058 Basel, Switzerland.	bentires@fmi.ch	Bentires-Alj, Mohamed/F-4484-2015	Bentires-Alj, Mohamed/0000-0001-6344-1127	Novartis Research Foundation; European Research Council (ERC) [243211-PTP5BDC]; Swiss Cancer League; Swiss national science foundation; Krebsliga Beider Basel; 'Novartis presidential postdoc fellowship'	Novartis Research Foundation; European Research Council (ERC)(European Research Council (ERC)European Commission); Swiss Cancer League; Swiss national science foundation(Swiss National Science Foundation (SNSF)European Commission); Krebsliga Beider Basel; 'Novartis presidential postdoc fellowship'	Research in the laboratory of MB-A is supported by the Novartis Research Foundation, the European Research Council (ERC starting grant 243211-PTP5BDC), the Swiss Cancer League, the Swiss national science foundation and the Krebsliga Beider Basel. PR recevied a 'Novartis presidential postdoc fellowship'.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Aftimos PG, 2013, INT J ONCOL, V43, P919, DOI 10.3892/ijo.2013.2008; Alba E, 2014, BRIT J CANCER, V110, P1139, DOI 10.1038/bjc.2013.831; Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Andre F, 2010, J CLIN ONCOL, V28, P5110, DOI 10.1200/JCO.2009.27.8549; Barok M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2868; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Beaver JA, 2012, FUTURE ONCOL, V8, P651, DOI [10.2217/fon.12.49, 10.2217/FON.12.49]; Bedard PL, 2013, NATURE, V501, P355, DOI 10.1038/nature12627; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Blencke S, 2004, CHEM BIOL, V11, P691, DOI 10.1016/j.chembiol.2004.02.029; Bousquet G, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3615; Britschgi A, 2013, DRUG RESIST UPDATE, V16, P68, DOI 10.1016/j.drup.2013.10.001; Britschgi A, 2012, CANCER CELL, V22, P796, DOI 10.1016/j.ccr.2012.10.023; Burris HA, 2013, CANCER CHEMOTH PHARM, V71, P829, DOI 10.1007/s00280-012-2043-3; Burris HA, 2011, J CLIN ONCOL, V29, P398, DOI 10.1200/JCO.2010.29.5865; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Chandarlapaty S, 2012, CLIN CANCER RES, V18, P6784, DOI 10.1158/1078-0432.CCR-12-1785; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen L, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-93; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; Cools J, 2004, CANCER RES, V64, P6385, DOI 10.1158/0008-5472.CAN-04-2148; Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Damiano JS, 2001, LEUKEMIA, V15, P1232, DOI 10.1038/sj.leu.2402179; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; De Luca A, 2012, EXPERT OPIN THER TAR, V16, pS17, DOI 10.1517/14728222.2011.639361; Dhillon S, 2013, DRUGS, V73, P475, DOI 10.1007/s40265-013-0034-2; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Ercan D, 2010, ONCOGENE, V29, P2346, DOI 10.1038/onc.2009.526; Esteva FJ, 2010, AM J PATHOL, V177, P1647, DOI 10.2353/ajpath.2010.090885; Fang H, 2013, CANCER RES, V73, P4965, DOI 10.1158/0008-5472.CAN-13-0661; Galizia G, 2007, ONCOGENE, V26, P3654, DOI 10.1038/sj.onc.1210381; Gallardo A, 2012, BRIT J CANCER, V106, P1367, DOI 10.1038/bjc.2012.85; Gambacorti-Passerini C, 2011, JNCI-J NATL CANCER I, V103, P553, DOI 10.1093/jnci/djr060; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gillies RJ, 2012, NAT REV CANCER, V12, P487, DOI 10.1038/nrc3298; Grant S, 2008, J CLIN INVEST, V118, P3003, DOI 10.1172/JCI36898; Gridelli C, 2007, ONCOLOGIST, V12, P840, DOI 10.1634/theoncologist.12-7-840; Haber DA, 2011, CELL, V145, P19, DOI 10.1016/j.cell.2011.03.026; Hafsi S, 2012, INT J ONCOL, V40, P639, DOI 10.3892/ijo.2011.1312; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harbinski F, 2012, CANCER DISCOV, V2, P948, DOI 10.1158/2159-8290.CD-12-0237; Hidalgo M, 2011, MOL CANCER THER, V10, P1311, DOI 10.1158/1535-7163.MCT-11-0233; Ho WJ, 2010, CANCER SCI, V101, P2637, DOI 10.1111/j.1349-7006.2010.01723.x; Hochhaus A, 2009, LEUKEMIA, V23, P1054, DOI 10.1038/leu.2009.38; Hoeflich KP, 2012, CANCER RES, V72, P210, DOI 10.1158/0008-5472.CAN-11-1515; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Hongisto V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077232; Huang C, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2936; Janne PA, 2009, NAT REV DRUG DISCOV, V8, P709, DOI 10.1038/nrd2871; Janku F, 2014, THER ADV MED ONCOL, V6, P43, DOI 10.1177/1758834013517414; Janku F, 2013, CANCER RES, V73, P276, DOI 10.1158/0008-5472.CAN-12-1726; Jin K, 2012, INT J ONCOL, V41, P583, DOI 10.3892/ijo.2012.1469; Joensuu H, 2006, NEW ENGL J MED, V354, P809, DOI 10.1056/NEJMoa053028; Jordan VC, 2008, EUR J CANCER, V44, P30, DOI 10.1016/j.ejca.2007.11.002; JORDAN VC, 1976, CANCER TREAT REP, V60, P1409; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Junttila TT, 2011, BREAST CANCER RES TR, V128, P347, DOI 10.1007/s10549-010-1090-x; Karvela M, 2012, EXPERT REV ANTICANC, V12, P381, DOI [10.1586/ERA.12.10, 10.1586/era.12.10]; Kinkade CW, 2008, J CLIN INVEST, V118, P3051, DOI 10.1172/JCI34764; Klein CA, 2013, NATURE, V501, P365, DOI 10.1038/nature12628; Krop IE, 2010, J CLIN ONCOL, V28, P2698, DOI 10.1200/JCO.2009.26.2071; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Legrier ME, 2007, CANCER RES, V67, P11300, DOI 10.1158/0008-5472.CAN-07-0702; Li FF, 2014, INT J CANCER, V134, P1257, DOI 10.1002/ijc.28261; Lin D, 2014, CANCER RES, V74, P1272, DOI 10.1158/0008-5472.CAN-13-2921-T; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Lu CH, 2007, CLIN CANCER RES, V13, P5883, DOI 10.1158/1078-0432.CCR-06-2837; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; McCubrey JA, 2012, ONCOTARGET, V3, P1068, DOI 10.18632/oncotarget.659; McCubrey JA, 2011, J CELL PHYSIOL, V226, P2762, DOI 10.1002/jcp.22647; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Miller TW, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3039; Mori Y, 2004, BLOOD, V104, P2149, DOI 10.1182/blood-2004-01-0236; Muellner MK, 2011, NAT CHEM BIOL, V7, P787, DOI 10.1038/nchembio.695; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509; Nardi V, 2004, CURR OPIN HEMATOL, V11, P35, DOI 10.1097/00062752-200401000-00006; Navin N, 2010, GENOME RES, V20, P68, DOI 10.1101/gr.099622.109; NICHOLSON RI, 1975, EUR J CANCER, V11, P571, DOI 10.1016/0014-2964(75)90129-2; Nielsen DL, 2013, BREAST, V22, P1, DOI 10.1016/j.breast.2012.09.008; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Park CC, 2008, CANCER RES, V68, P4398, DOI 10.1158/0008-5472.CAN-07-6390; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Quintas-Cardama A, 2013, LEUKEMIA RES, V37, P487, DOI 10.1016/j.leukres.2013.01.006; Rad R, 2010, SCIENCE, V330, P1104, DOI 10.1126/science.1193004; Rahrmann EP, 2013, NAT GENET, V45, P756, DOI 10.1038/ng.2641; Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schwartz MA, 2008, CLIN CANCER RES, V14, P6193, DOI 10.1158/1078-0432.CCR-08-1285; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sridhar SS, 2003, LANCET ONCOL, V4, P397, DOI 10.1016/S1470-2045(03)01137-9; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Swanton C, 2012, CANCER RES, V72, P4875, DOI 10.1158/0008-5472.CAN-12-2217; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Turajlic S, 2012, GENOME RES, V22, P196, DOI 10.1101/gr.125591.111; Vecchione L, 2011, EXP CELL RES, V317, P2765, DOI 10.1016/j.yexcr.2011.08.021; Vignot S, 2013, J CLIN ONCOL, V31, P2167, DOI 10.1200/JCO.2012.47.7737; Vignot S, 2012, CRIT REV ONCOL HEMAT, V84, P301, DOI 10.1016/j.critrevonc.2012.05.002; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang LP, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-248; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Will M, 2014, CANCER DISCOV, V4, P334, DOI 10.1158/2159-8290.CD-13-0611; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yauch RL, 2012, CURR OPIN GENET DEV, V22, P45, DOI 10.1016/j.gde.2012.01.003; Yu K, 2008, CANCER BIOL THER, V7, P307	128	156	162	1	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3617	3626		10.1038/onc.2014.314	http://dx.doi.org/10.1038/onc.2014.314			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25263438				2023-01-03	WOS:000357679100001
J	Lee, DW; Kochenderfer, JN; Stetler-Stevenson, M; Cui, YZK; Delbrook, C; Feldman, SA; Fry, TJ; Orentas, R; Sabatino, M; Shah, NN; Steinberg, SM; Stroncek, D; Tschemia, N; Yuan, C; Zhang, H; Zhang, L; Rosenberg, SA; Wayne, AS; Mackall, CL				Lee, Daniel W.; Kochenderfer, James N.; Stetler-Stevenson, Maryalice; Cui, Yongzhi K.; Delbrook, Cindy; Feldman, Steven A.; Fry, Terry J.; Orentas, Rimas; Sabatino, Marianna; Shah, Nirali N.; Steinberg, Seth M.; Stroncek, Dave; Tschemia, Nick; Yuan, Constance; Zhang, Hua; Zhang, Ling; Rosenberg, Steven A.; Wayne, Alan S.; Mackall, Crystal L.			T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial	LANCET			English	Article							C-REACTIVE PROTEIN; PEDIATRIC-PATIENTS; SURVIVAL; TRANSPLANTATION; CLOFARABINE; MANAGEMENT; CANCER	Background Chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown activity in case series of patients with acute and chronic lymphocytic leukaemia and B-cell lymphomas, but feasibility, toxicity, and response rates of consecutively enrolled patients treated with a consistent regimen and assessed on an intention-to-treat basis have not been reported. We aimed to define feasibility, toxicity, maximum tolerated dose, response rate, and biological correlates of response in children and young adults with refractory B-cell malignancies treated with CD19-CAR T cells. Methods This phase 1, dose-escalation trial consecutively enrolled children and young adults (aged 1-30 years) with relapsed or refractory acute lymphoblastic leukaemia or non-Hodgkin lymphoma. Autologous T cells were engineered via an 11-day manufacturing process to express a CD19-CAR incorporating an anti-CD19 single-chain variable fragment plus TCR zeta and CD28 signalling domains. All patients received fludarabine and cyclophosphamide before a single infusion of CD19-CAR T cells. Using a standard 3 + 3 design to establish the maximum tolerated dose, patients received either 1 x 106 CAR-transduced T cells per kg (dose 1), 3 x 106 CAR-transduced T cells per kg (dose 2), or the entire CAR T-cell product if sufficient numbers of cells to meet the assigned dose were not generated. After the dose-escalation phase, an expansion cohort was treated at the maximum tolerated dose. The trial is registered with ClinicalTrials.gov, number NCT01593696. Findings Between July 2, 2012, and June 20, 2014, 21 patients (including eight who had previously undergone allogeneic haematopoietic stem-cell transplantation) were enrolled and infused with CD19-CAR T cells. 19 received the prescribed dose of CD19-CAR T cells, whereas the assigned dose concentration could not be generated for two patients (90% feasible). All patients enrolled were assessed for response. The maximum tolerated dose was defi ned as 1 x 106 CD19-CAR T cells per kg. All toxicities were fully reversible, with the most severe being grade 4 cytokine release syndrome that occurred in three (14%) of 21 patients (95% CI 3.0-36.3). The most common non-haematological grade 3 adverse events were fever (nine [43%] of 21 patients), hypokalaemia (nine [43%] of 21 patients), fever and neutropenia (eight [38%] of 21 patients), and cytokine release syndrome (three [14%) of 21 patients). Interpretation CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukaemia. All toxicities were reversible and prolonged B-cell aplasia did not occur.	[Lee, Daniel W.; Cui, Yongzhi K.; Delbrook, Cindy; Fry, Terry J.; Orentas, Rimas; Shah, Nirali N.; Zhang, Hua; Zhang, Ling; Mackall, Crystal L.] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA; [Kochenderfer, James N.] NCI, Transplantat & Immunol Branch, Bethesda, MD 20892 USA; [Stetler-Stevenson, Maryalice; Yuan, Constance] NCI, Pathol Lab, Bethesda, MD 20892 USA; [Feldman, Steven A.; Rosenberg, Steven A.] NCI, Surg Branch, Bethesda, MD 20892 USA; [Steinberg, Seth M.] NCI, Off Clin Director, Biostat & Data Management Sect, Bethesda, MD 20892 USA; [Sabatino, Marianna; Stroncek, Dave] NIH, Dept Transfus Med, Cell Proc Sect, Bethesda, MD 20892 USA; [Tschemia, Nick] Univ Nevada, Sch Med, Med Student Training Program, NIH, Reno, NV 89557 USA; [Wayne, Alan S.] Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, Childrens Ctr Canc & Blood Dis,Div Hematol Oncol, Los Angeles, CA USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; Nevada System of Higher Education (NSHE); University of Nevada Reno; Children's Hospital Los Angeles; University of Southern California	Mackall, CL (corresponding author), NCI, Pediat Oncol Branch, Bldg 10,Rm 1W-3750,10 Ctr Dr MSC 1104, Bethesda, MD 20892 USA.	mackallc@mail.nih.gov	Kochenderfer, James/X-5231-2019; Stetler-Stevenson, Maryalice/AAV-7393-2020	Kochenderfer, James/0000-0002-4362-9875; Tschernia, Nicholas/0000-0002-2389-9974	Intramural Research Program of the National Cancer Institute; St Baldrick's Foundation Scholar Award; Stand Up To Cancer-St Baldrick's-National Cancer Institute Pediatric Dream Team Translational Cancer Research Gran; NATIONAL CANCER INSTITUTE [ZICBC011104, ZIABC011565, ZICSC009372, ZICBC011093] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL002120] Funding Source: NIH RePORTER	Intramural Research Program of the National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); St Baldrick's Foundation Scholar Award; Stand Up To Cancer-St Baldrick's-National Cancer Institute Pediatric Dream Team Translational Cancer Research Gran; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CLINICAL CENTER	This work was supported, in part, by the Intramural Research Program of the National Cancer Institute. DWL's work is also supported by a St Baldrick's Foundation Scholar Award. Research was also supported by a Stand Up To Cancer-St Baldrick's-National Cancer Institute Pediatric Dream Team Translational Cancer Research Grant. Stand Up To Cancer is a programme of the Entertainment Industry Foundation administered by the American Association for Cancer Research. We would like to thank Laurence Cooper for supplying the CD19-CAR anti-idiotype antibody, Mario Roederer, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, for assistance in design of T-cell subset panels and analysis, and Linda Weaver who worked on standardisation of methodology.	Brentjens RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005930; Brentjens RJ, 2011, BLOOD, V118, P4817, DOI 10.1182/blood-2011-04-348540; Burke MJ, 2013, BIOL BLOOD MARROW TR, V19, P138, DOI 10.1016/j.bbmt.2012.08.020; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Cruz CRY, 2013, BLOOD, V122, P2965, DOI 10.1182/blood-2013-06-506741; Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226; Forman SJ, 2013, BLOOD, V121, P1077, DOI 10.1182/blood-2012-08-234492; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Haso W, 2013, BLOOD, V121, P1165, DOI 10.1182/blood-2012-06-438002; Hegde M, 2013, MOL THER, V21, P2087, DOI 10.1038/mt.2013.185; Hunger SP, 2012, J CLIN ONCOL, V30, P1663, DOI 10.1200/JCO.2011.37.8018; Jeha S, 2006, J CLIN ONCOL, V24, P1917, DOI 10.1200/JCO.2005.03.8554; Jeha S, 2004, BLOOD, V103, P784, DOI 10.1182/blood-2003-06-2122; Jena B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057838; Kalos M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002842; Kochenderfer JN, 2013, NAT REV CLIN ONCOL, V10, P267, DOI 10.1038/nrclinonc.2013.46; Kochenderfer JN, 2012, BLOOD, V119, P2709, DOI 10.1182/blood-2011-10-384388; Kochenderfer JN, 2010, BLOOD, V116, P4099, DOI 10.1182/blood-2010-04-281931; Kochenderfer JN, 2009, J IMMUNOTHER, V32, P689, DOI 10.1097/CJI.0b013e3181ac6138; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Lee DW, 2012, CLIN CANCER RES, V18, P2780, DOI 10.1158/1078-0432.CCR-11-1920; Leung W, 2011, BLOOD, V118, P223, DOI 10.1182/blood-2011-01-333070; Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Pui CH, 2008, LANCET ONCOL, V9, P257, DOI 10.1016/S1470-2045(08)70070-6; Pulte D, 2009, BLOOD, V113, P1408, DOI 10.1182/blood-2008-06-164863; Pulte D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085554; Robison LL, 2011, HEMATOL-AM SOC HEMAT, P238, DOI 10.1182/asheducation-2011.1.238; SCHULTZ DR, 1990, SEMIN ARTHRITIS RHEU, V20, P129, DOI 10.1016/0049-0172(90)90055-K; Topp MS, 2012, BLOOD, V120, P5185, DOI 10.1182/blood-2012-07-441030; Tumaini B, 2013, CYTOTHERAPY, V15, P1406, DOI 10.1016/j.jcyt.2013.06.003; US Food and Drug Administration Guidance for industry: gene therapy clinical trialsobserving subjects for delayed adverse events, GUID IND GEN THER CL; WESTERMANN J, 1990, IMMUNOL TODAY, V11, P406, DOI 10.1016/0167-5699(90)90160-B	34	1900	2053	71	626	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	2015	385	9967					517	528		10.1016/S0140-6736(14)61403-3	http://dx.doi.org/10.1016/S0140-6736(14)61403-3			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CA9AV	25319501	Green Accepted			2023-01-03	WOS:000349213600030
J	Starmer, AJ; Spector, ND; Srivastava, R; West, DC; Rosenbluth, G; Allen, AD; Noble, EL; Tse, LL; Dalal, AK; Keohane, CA; Lipsitz, SR; Rothschild, JM; Wien, MF; Yoon, CS; Zigmont, KR; Wilson, KM; O'Toole, JK; Solan, LG; Aylor, M; Bismilla, Z; Coffey, M; Mahant, S; Blankenburg, RL; Destino, LA; Everhart, JL; Patel, SJ; Bale, JF; Spackman, JB; Stevenson, AT; Calaman, S; Cole, FS; Balmer, DF; Hepps, JH; Lopreiato, JO; Yu, CE; Sectish, TC; Landrigan, CP				Starmer, A. J.; Spector, N. D.; Srivastava, R.; West, D. C.; Rosenbluth, G.; Allen, A. D.; Noble, E. L.; Tse, L. L.; Dalal, A. K.; Keohane, C. A.; Lipsitz, S. R.; Rothschild, J. M.; Wien, M. F.; Yoon, C. S.; Zigmont, K. R.; Wilson, K. M.; O'Toole, J. K.; Solan, L. G.; Aylor, M.; Bismilla, Z.; Coffey, M.; Mahant, S.; Blankenburg, R. L.; Destino, L. A.; Everhart, J. L.; Patel, S. J.; Bale, J. F., Jr.; Spackman, J. B.; Stevenson, A. T.; Calaman, S.; Cole, F. S.; Balmer, D. F.; Hepps, J. H.; Lopreiato, J. O.; Yu, C. E.; Sectish, T. C.; Landrigan, C. P.		I-PASS Study Grp	Changes in Medical Errors after Implementation of a Handoff Program	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADVERSE DRUG EVENTS; I-PASS HANDOFF; INTENSIVE-CARE; DUTY HOURS; WORK HOURS; POPULATION; EDUCATION; SAFETY; INTERVENTION; RESIDENTS	BACKGROUND Miscommunications are a leading cause of serious medical errors. Data from multicenter studies assessing programs designed to improve handoff of information about patient care are lacking. METHODS We conducted a prospective intervention study of a resident handoff-improvement program in nine hospitals, measuring rates of medical errors, preventable adverse events, and miscommunications, as well as resident workflow. The intervention included a mnemonic to standardize oral and written handoffs, handoff and communication training, a faculty development and observation program, and a sustainability campaign. Error rates were measured through active surveillance. Handoffs were assessed by means of evaluation of printed handoff documents and audio recordings. Workflow was assessed through time-motion observations. The primary outcome had two components: medical errors and preventable adverse events. RESULTS In 10,740 patient admissions, the medical-error rate decreased by 23% from the preintervention period to the postintervention period (24.5 vs. 18.8 per 100 admissions, P<0.001), and the rate of preventable adverse events decreased by 30% (4.7 vs. 3.3 events per 100 admissions, P<0.001). The rate of nonpreventable adverse events did not change significantly (3.0 and 2.8 events per 100 admissions, P = 0.79). Site-level analyses showed significant error reductions at six of nine sites. Across sites, significant increases were observed in the inclusion of all prespecified key elements in written documents and oral communication during handoff (nine written and five oral elements; P<0.001 for all 14 comparisons). There were no significant changes from the preintervention period to the postintervention period in the duration of oral handoffs (2.4 and 2.5 minutes per patient, respectively; P = 0.55) or in resident workflow, including patient-family contact and computer time. CONCLUSIONS Implementation of the handoff program was associated with reductions in medical errors and in preventable adverse events and with improvements in communication, without a negative effect on workflow.	[Starmer, A. J.; Allen, A. D.; Noble, E. L.; Tse, L. L.; Sectish, T. C.; Landrigan, C. P.] Boston Childrens Hosp, Dept Med, Div Gen Pediat, Boston, MA 02115 USA; [Starmer, A. J.; Dalal, A. K.; Lipsitz, S. R.; Rothschild, J. M.; Sectish, T. C.; Landrigan, C. P.] Harvard Univ, Sch Med, Boston, MA USA; [Dalal, A. K.; Keohane, C. A.; Lipsitz, S. R.; Rothschild, J. M.; Sectish, T. C.; Landrigan, C. P.] Brigham & Womens Hosp, Ctr Patient Safety Res, Div Gen Med, Boston, MA 02115 USA; [Landrigan, C. P.] Brigham & Womens Hosp, Div Sleep Med, Boston, MA 02115 USA; [Keohane, C. A.] CRICO Risk Management Fdn, Boston, MA USA; [Starmer, A. J.; Aylor, M.] Oregon Hlth & Sci Univ, Doernbecher Childrens Hosp, Dept Pediat, Portland, OR 97201 USA; [Spector, N. D.] Drexel Univ, Coll Med, St Christophers Hosp Children, Dept Pediat,Sect Gen Pediat, Philadelphia, PA 19104 USA; [Calaman, S.] Drexel Univ, Coll Med, St Christophers Hosp Children, Sect Crit Care, Philadelphia, PA 19104 USA; [Srivastava, R.; Spackman, J. B.; Stevenson, A. T.] Univ Utah, Sch Med, Dept Pediat, Primary Childrens Hosp, Salt Lake City, UT USA; [Bale, J. F., Jr.] Univ Utah, Sch Med, Dept Neurol, Primary Childrens Hosp, Salt Lake City, UT USA; [Srivastava, R.] Intermt Healthcare, Inst Hlth Care Delivery Res, Salt Lake City, UT USA; [West, D. C.; Rosenbluth, G.] Univ Calif San Francisco, Benioff Childrens Hosp, Dept Pediat, San Francisco, CA 94143 USA; [Blankenburg, R. L.; Destino, L. A.; Everhart, J. L.; Patel, S. J.] Stanford Univ, Sch Med, Lucile Packard Childrens Hosp Stanford, Dept Pediat,Div Gen Pediat, Palo Alto, CA 94304 USA; [Wilson, K. M.] Univ Colorado, Sch Med, Childrens Hosp Colorado, Dept Pediat, Aurora, CO USA; [O'Toole, J. K.; Solan, L. G.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Bismilla, Z.; Coffey, M.; Mahant, S.] Hosp Sick Children, Dept Paediat, Toronto, ON M5G 1X8, Canada; [Coffey, M.] Hosp Sick Children, Ctr Qual Improvement & Patient Safety, Toronto, ON M5G 1X8, Canada; [Mahant, S.] Hosp Sick Children, Inst Hlth Policy Management & Evaluat, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada; [Patel, S. J.] Kapiolani Med Ctr Women & Children, Dept Pediat, Div Gen Pediat, Honolulu, HI USA; [Patel, S. J.] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA; [Cole, F. S.] St Louis Childrens Hosp, Edward Mallinckrodt Dept Pediat, St Louis, MO USA; [Cole, F. S.] Washington Univ, Sch Med, St Louis, MO 63130 USA; [Balmer, D. F.] Texas Childrens Hosp, Dept Pediat, Houston, TX 77030 USA; [Balmer, D. F.] Baylor Coll Med, Houston, TX 77030 USA; [Hepps, J. H.; Lopreiato, J. O.; Yu, C. E.] Uniformed Serv Univ Hlth Sci, Walter Reed Natl Mil Med Ctr, Dept Pediat, Bethesda, MD 20814 USA; [Lopreiato, J. O.] Uniformed Serv Univ Hlth Sci, Val G Hemming Simulat Ctr, Bethesda, MD 20814 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Oregon Health & Science University; Drexel University; Drexel University; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Intermountain Healthcare; Intermountain Medical Center; University of California System; University of California San Francisco; Lucile Packard Children's Hospital (LPCH); Stanford University; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Centre for Quality Improvement & Patient Safety; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Hawaii System; St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL); Baylor College of Medicine; Baylor College of Medicine; Uniformed Services University of the Health Sciences - USA; Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA	Starmer, AJ (corresponding author), Boston Childrens Hosp, Dept Med, Div Gen Pediat, 300 Longwood Ave, Boston, MA 02115 USA.	amy.starmer@childrens.harvard.edu	Satterwhite, Shannon/K-5004-2015; Balmer, Dorene/AAY-1185-2021; Hefner, Jennifer/P-5962-2014; West, Daniel/AAW-3111-2020; Ramotar, Matt W/K-2193-2019; West, Daniel/HJB-2778-2022	Satterwhite, Shannon/0000-0002-6351-2287; Hefner, Jennifer/0000-0001-8083-8038; West, Daniel/0000-0002-0909-4213; West, Daniel/0000-0002-0909-4213; Blankenburg, Rebecca/0000-0002-1938-6113; Balmer, Dorene/0000-0001-6805-4062; Hobson, Wendy/0000-0002-1918-1417; Landrigan, Christopher/0000-0001-8386-4100	Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K12HS019456] Funding Source: NIH RePORTER	Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Funded by the Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services, and others.	[Anonymous], 2014, SENT EV DAT ROOT CAU; Arnedt JT, 2005, JAMA-J AM MED ASSOC, V294, P1025, DOI 10.1001/jama.294.9.1025; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Berry JG, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001158; Berry JG, 2011, JAMA-J AM MED ASSOC, V305, P682, DOI 10.1001/jama.2011.122; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Calaman S., 2013, I PASS HANDOFF CURRI; Cohen E, 2011, PEDIATRICS, V127, P529, DOI 10.1542/peds.2010-0910; DeRienzo CM, 2012, ACAD MED, V87, P403, DOI 10.1097/ACM.0b013e318248e5c2; Desai SV, 2013, JAMA INTERN MED, V173, P649, DOI 10.1001/jamainternmed.2013.2973; Feudtner C, 2000, PEDIATRICS, V106, P205; Gordon M, 2011, MED EDUC, V45, P1081, DOI 10.1111/j.1365-2923.2011.04049.x; Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119; Kaushal R, 2002, AM J HEALTH-SYST PH, V59, P2323, DOI 10.1093/ajhp/59.23.2323; Landrigan CP, 2010, NEW ENGL J MED, V363, P2124, DOI 10.1056/NEJMsa1004404; Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406; Levine AC, 2010, SLEEP, V33, P1043, DOI 10.1093/sleep/33.8.1043; Lipsitz SR, 2000, BIOMETRICS, V56, P528, DOI 10.1111/j.0006-341X.2000.00528.x; Lockley SW, 2004, NEW ENGL J MED, V351, P1829, DOI 10.1056/NEJMoa041404; Nasca TJ, 2010, NEW ENGL J MED, V363, DOI 10.1056/NEJMsb1005800; O'Toole J. K., 2013, I PASS HANDOFF CURRI; O'Toole JK, 2014, ACAD PEDIATR, V14, P221, DOI 10.1016/j.acap.2014.02.013; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Resar R, 2005, JT COMM J QUAL PATIE, V31, P243, DOI 10.1016/S1553-7250(05)31031-2; Riesenberg LA, 2009, ACAD MED, V84, P1775, DOI 10.1097/ACM.0b013e3181bf51a6; Rosenbluth G., MEDEDPORTAL, V9, P9397, DOI [10.15766/mep_2374-8265.9397, DOI 10.15766/MEP_2374-8265.9397]; Rothschild JM, 2005, CRIT CARE MED, V33, P1694, DOI 10.1097/01.CCM.0000171609.91035.BD; Sectish TC, 2010, PEDIATRICS, V126, P619, DOI 10.1542/peds.2010-1793; Spector N, 2013, I PASS HAND CURR COR; Starmer A. J., 2013, I PASS HANDOFF CURRI; Starmer AJ, 2014, ACAD MED, V89, P876, DOI 10.1097/ACM.0000000000000264; Starmer AJ, 2013, JAMA-J AM MED ASSOC, V310, P2262, DOI 10.1001/jama.2013.281961; Starmer AJ, 2012, PEDIATRICS, V129, P201, DOI 10.1542/peds.2011-2966; TeamSTEPPS, NAT IMPL; The Joint Commission, 2007, IMPR AM HOSP JOINT C; Wang Y, 2014, NEW ENGL J MED, V370, P341, DOI 10.1056/NEJMsa1300991; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	37	453	459	2	72	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 6	2014	371	19					1803	1812		10.1056/NEJMsa1405556	http://dx.doi.org/10.1056/NEJMsa1405556			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AS3IH	25372088	Bronze			2023-01-03	WOS:000344170300009
J	Martin, AC; Johnston, E; Xing, CG; Hegeman, AD				Martin, Amanda C.; Johnston, Ed; Xing, Chengguo; Hegeman, Adrian D.			Measuring the Chemical and Cytotoxic Variability of Commercially Available Kava (Piper methysticum G. Forster)	PLOS ONE			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; LUNG TUMORIGENESIS; CANCER CELLS; EXTRACTS; CULTIVARS; HEPATOTOXICITY; IDENTIFICATION; CONSTITUENTS; FLAVOKAVINS; CHALCONE	Formerly used world-wide as a popular botanical medicine to reduce anxiety, reports of hepatotoxicity linked to consuming kava extracts in the late 1990s have resulted in global restrictions on kava use and have hindered kava-related research. Despite its presence on the United States Food and Drug Administration consumer advisory list for the past decade, export data from kava producing countries implies that US kava imports, which are not publicly reported, are both increasing and of a fairly high volume. We have measured the variability in extract chemical composition and cytotoxicity towards human lung adenocarcinoma A549 cancer cells of 25 commercially available kava products. Results reveal a high level of variation in chemical content and cytotoxicity of currently available kava products. As public interest and use of kava products continues to increase in the United States, efforts to characterize products and expedite research of this potentially useful botanical medicine are necessary.	[Martin, Amanda C.; Hegeman, Adrian D.] Univ Minnesota, Dept Hort Sci, Plant Biol Sci Grad Program, Dept Plant Biol, Minneapolis, MN USA; [Martin, Amanda C.; Hegeman, Adrian D.] Univ Minnesota, Microbial & Plant Genom Inst, Minneapolis, MN 55455 USA; [Johnston, Ed] Alia Point Awa Nursery, Pepeekeo, HI USA; [Xing, Chengguo] Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Xing, CG (corresponding author), Univ Minnesota, Coll Pharm, Minneapolis, MN 55455 USA.	xingx009@umn.edu; hegem007@umn.edu	; Hegeman, Adrian/D-5984-2013	Martin, Amanda C./0000-0002-6958-6332; Hegeman, Adrian/0000-0003-1008-6066	National Science Foundation Plant Genome Research Program [IOS-0923960, IOS-1238812]; National Science Foundation Graduate Research Fellowship [00006595]; National Cancer Institute, National Institutes of Health [R01 CA142649]; NATIONAL CANCER INSTITUTE [R01CA193278, R01CA142649] Funding Source: NIH RePORTER	National Science Foundation Plant Genome Research Program(National Science Foundation (NSF)NSF - Office of the Director (OD)); National Science Foundation Graduate Research Fellowship(National Science Foundation (NSF)); National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the National Science Foundation Plant Genome Research Program grants IOS-0923960 and IOS-1238812 (www.nsf.gov)(ACM,ADH), the National Science Foundation Graduate Research Fellowship Program 00006595 (www.nsf.gov) (ACM), and the National Cancer Institute, National Institutes of Health grant R01 CA142649 (www.cancer.gov) (CX). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anke J, 2004, J ETHNOPHARMACOL, V93, P153, DOI 10.1016/j.jep.2004.04.009; Behl M, 2011, FOOD CHEM TOXICOL, V49, P2820, DOI 10.1016/j.fct.2011.07.067; Dasgupta A., 2011, Herbal supplements: efficacy, toxicity, interactions with Western drugs, and effects on clinical laboratory tests, P155; Dinh LD, 2001, PLANTA MED, V67, P306, DOI 10.1055/s-2001-14334; Discussion paper on the development of a standard for kava products, 2012, DISC PAP DEV STAND K; Dragull K, 2003, PHYTOCHEMISTRY, V63, P193, DOI 10.1016/S0031-9422(03)00111-0; Fiji Bureau of Statistics, 2013, 2011 EXP STAT; He XG, 1997, PLANTA MED, V63, P70, DOI 10.1055/s-2006-957608; Hegeman AD, 2010, BRIEF FUNCT GENOMICS, V9, P139, DOI 10.1093/bfgp/elp053; Jhoo JW, 2006, J AGR FOOD CHEM, V54, P3157, DOI 10.1021/jf051853j; Johansen HN, 1996, J AGR FOOD CHEM, V44, P1470, DOI 10.1021/jf950482b; Johnson BM, 2003, CHEM RES TOXICOL, V16, P733, DOI 10.1021/tx020113r; Johnson TE, 2011, AM J CHINESE MED, V39, P727, DOI 10.1142/S0192415X11009202; Johnson TE, 2008, CANCER PREV RES, V1, P430, DOI 10.1158/1940-6207.CAPR-08-0027; Jokhan A., 2004, S PAC J NAT SCI, V22, P43; Lapornik B, 2005, J FOOD ENG, V71, P214, DOI 10.1016/j.jfoodeng.2004.10.036; Lebot V, 1999, ECON BOT, V53, P407, DOI 10.1007/BF02866720; Lebot V, 2014, FOOD CHEM, V151, P554, DOI 10.1016/j.foodchem.2013.11.120; Lebot V, 2004, ETHNOBOT RES APPL, V2, P19; Lebot V, 2006, HERBALGRAM, V71, P34; Leitzman P, 2014, CANCER PREV RES, V7, P86, DOI 10.1158/1940-6207.CAPR-13-0301; Meissner O, 2005, J CHROMATOGR B, V826, P46, DOI 10.1016/j.jchromb.2005.08.003; Olsen LR, 2011, CHEM RES TOXICOL, V24, P992, DOI 10.1021/tx100412m; Rogers H., 2006, HAWAIIAN AWA VIEWS E, P1; Sarris J, 2011, PLANTA MED, V77, P107, DOI 10.1055/s-0030-1250290; Shaik AA, 2009, BIOORG MED CHEM LETT, V19, P5732, DOI 10.1016/j.bmcl.2009.08.003; Shao Y, 1998, J CHROMATOGR A, V825, P1, DOI 10.1016/S0021-9673(98)00699-2; Simeoni P, 2002, BIOCHEM SYST ECOL, V30, P413, DOI 10.1016/S0305-1978(01)00093-X; SMITH RM, 1984, J CHROMATOGR, V283, P303, DOI 10.1016/S0021-9673(00)96265-4; Steiner G G, 2000, Hawaii Med J, V59, P420; Teschke R, 2003, PHYTOMEDICINE, V10, P440, DOI 10.1078/0944-7113-00314; Teschke R, 2011, AM HERB PROD ASS REP, V26, P8; Teschke R, 2011, PHYTOTHER RES, V25, P1263, DOI 10.1002/ptr.3464; Teschke R, 2011, FOOD CHEM TOXICOL, V49, P2503, DOI 10.1016/j.fct.2011.06.075; Teschke R, 2011, DIGEST LIVER DIS, V43, P676, DOI 10.1016/j.dld.2011.01.018; Teschke R, 2011, BRIT J CLIN PHARMACO, V71, P445, DOI 10.1111/j.1365-2125.2010.03775.x; Teschke R, 2011, PHYTOMEDICINE, V18, P96, DOI 10.1016/j.phymed.2010.10.002; Teschke R, 2009, J ETHNOPHARMACOL, V123, P378, DOI 10.1016/j.jep.2009.03.038; Tonga Statistics Department, 2008, KING TONG ANN FOR TR; U.S. Food and Drug Administration, 2002, US FDA PUBL; Vanuatu National Statistics Office, 2013, STAT UPD OV TRAD; Warmka JK, 2012, BIOCHEM BIOPH RES CO, V424, P488, DOI 10.1016/j.bbrc.2012.06.140; Whitton PA, 2003, PHYTOCHEMISTRY, V64, P673, DOI 10.1016/S0031-9422(03)00381-9; Yang X, 2011, PHYTOMEDICINE, V18, P592, DOI 10.1016/j.phymed.2011.02.006; Zhang LY, 2011, PHYTOTHER RES, V25, P629, DOI 10.1002/ptr.3301; Zhou P, 2010, FASEB J, V24, P4722, DOI 10.1096/fj.10-163311; Zi XL, 2005, CANCER RES, V65, P3479, DOI 10.1158/0008-5472.CAN-04-3803; Zou L, 2004, PHYTOMEDICINE, V11, P285, DOI 10.1078/0944711041495263	48	30	32	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2014	9	11							e111572	10.1371/journal.pone.0111572	http://dx.doi.org/10.1371/journal.pone.0111572			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU4DB	25365244	gold, Green Published, Green Submitted			2023-01-03	WOS:000345558100078
J	Fox, MP; Shearer, K; Maskew, M; Meyer-Rath, G; Clouse, K; Sanne, I				Fox, Matthew P.; Shearer, Kate; Maskew, Mhairi; Meyer-Rath, Gesine; Clouse, Kate; Sanne, Ian			Attrition through Multiple Stages of Pre-Treatment and ART HIV Care in South Africa	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; ANTIRETROVIRAL THERAPY; PREVENTION; INITIATION; INFECTION; RETENTION; OUTCOMES; COHORT	Introduction: While momentum for increasing treatment thresholds is growing, if patients cannot be retained in HIV care from the time of testing positive through long-term adherence to antiretroviral therapy (ART), such strategies may fall short of expected gains. While estimates of retention on ART exist, few cohorts have data on retention from testing positive through long-term ART care. Methods: We explored attrition (loss or death) at the Themba Lethu HIV clinic, Johannesburg, South Africa in 3 distinct cohorts enrolled at HIV testing, pre-ART initiation, and ART initiation. Results: Between March 2010 and August 2012 we enrolled 380 patients testing HIV+, 206 initiating pre-ART care, and 185 initiating ART. Of the 380 patients enrolled at testing HIV-positive, 38.7% (95% CI: 33.9-43.7%) returned for eligibility staging within <= 3 months of testing. Of the 206 enrolled at pre-ART care, 84.5% (95% CI: 79.0-88.9%) were ART eligible at their first CD4 count. Of those, 87.9% (95% CI: 82.4-92.2%) initiated ART within 6 months. Among patients not ART eligible at their first CD4 count, 50.0% (95% CI: 33.1-66.9%) repeated their CD4 count within one year of the first ineligible CD4. Among the 185 patients in the ART cohort, 22 transferred out and were excluded from further analysis. Of the remaining 163, 81.0% (95% CI: 74.4-86.5%) were retained in care through two years on treatment. Conclusions: Our findings from a well-resourced clinic demonstrate continual loss from all stages of HIV care and strategies to reduce attrition from all stages of care are urgently needed.	[Fox, Matthew P.; Meyer-Rath, Gesine] Boston Univ, Ctr Global Hlth & Dev, Boston, MA 02215 USA; [Fox, Matthew P.; Shearer, Kate; Maskew, Mhairi; Meyer-Rath, Gesine; Clouse, Kate; Sanne, Ian] Univ Witwatersrand, Fac Hlth Sci, Sch Clin Med, Dept Internal Med,Hlth Econ & Epidemiol Res Off, Johannesburg, South Africa; [Fox, Matthew P.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA; [Clouse, Kate] Vanderbilt Univ, Vanderbilt Inst Global Hlth, Nashville, TN 37235 USA; [Sanne, Ian] Univ Witwatersrand, Fac Hlth Sci, Sch Clin Med, Dept Internal Med,Clin HIV Res Unit, Johannesburg, South Africa	Boston University; University of Witwatersrand; Boston University; Vanderbilt University; University of Witwatersrand	Fox, MP (corresponding author), Boston Univ, Ctr Global Hlth & Dev, Boston, MA 02215 USA.	mfox@bu.edu	Sanne, Ian/ABH-2231-2020; Harding, Richard/G-9729-2012; Fox, Matthew/K-2004-2019	MASKEW, MHAIRI/0000-0003-4238-0200; Clouse, Kate/0000-0002-0190-7398	National Institute of Allergy And Infectious Diseases [K01AI083097]; United States Agency for International Development (USAID) [AID 674-A-12-00029]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K01AI083097, T32AI102623] Funding Source: NIH RePORTER	National Institute of Allergy And Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); United States Agency for International Development (USAID)(United States Agency for International Development (USAID)CGIAR); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The project described was also supported by Award Number K01AI083097 from the National Institute of Allergy And Infectious Diseases. This study is also made possible by the generous support of the American people through Cooperative Agreement AID 674-A-12-00029 from the United States Agency for International Development (USAID). The contents are the responsibility of the authors and do not necessarily reflect the views of the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, USAID or the United States Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barnighausen T, 2012, P NATL ACAD SCI USA, V109, P21271, DOI 10.1073/pnas.1209017110; Bendavid E, 2010, ARCH INTERN MED, V170, P1347, DOI 10.1001/archinternmed.2010.249; Cain LE, 2011, ANN INTERN MED, V154, P509, DOI 10.7326/0003-4819-154-8-201104190-00001; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Cohen MS, 2009, LANCET, V373, P1077, DOI 10.1016/S0140-6736(09)60640-1; Das M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011068; Donnell D, 2010, LANCET, V375, P2092, DOI 10.1016/S0140-6736(10)60705-2; Eaton JW, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001245; El-Sadr WM, 2010, JAIDS-J ACQ IMM DEF, V55, pS116, DOI 10.1097/QAI.0b013e3181fbca6e; Fox MP, 2010, AIDS, V24, P2041, DOI 10.1097/QAD.0b013e32833c703e; Fox MP, 2013, INT J EPIDEMIOL, V42, P430, DOI 10.1093/ije/dys029; Fox MP, 2012, AIDS, V26, P1823, DOI 10.1097/QAD.0b013e328357058a; Fox MP, 2012, TROP MED INT HEALTH, V17, P1235, DOI 10.1111/j.1365-3156.2012.03055.x; Fox MP, 2010, TROP MED INT HEALTH, V15, P1, DOI 10.1111/j.1365-3156.2010.02508.x; Govindasamy D, 2011, JAIDS-J ACQ IMM DEF, V58, P344, DOI 10.1097/QAI.0b013e31822e0c4c; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Hontelez JAC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001534; Hontelez JAC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021919; Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252; Klein DJ, 2014, AIDS, V28, pS47, DOI 10.1097/QAD.0000000000000081; Kranzer K, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17383; Kranzer K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013801; Montaner JSG, 2006, LANCET, V368, P531, DOI 10.1016/S0140-6736(06)69162-9; Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1; Mugglin C, 2012, TROP MED INT HEALTH, V17, P1509, DOI 10.1111/j.1365-3156.2012.03089.x; National Department of Health SA, 2004, NAT ANT TREATM GUID; National Department of Health South Africa, 2010, CLIN GUID MAN HIV AI; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Rosen S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001056; Severe P, 2010, NEW ENGL J MED, V363, P257, DOI 10.1056/NEJMoa0910370; Walensky RP, 2013, NEW ENGL J MED, V369, P1715, DOI 10.1056/NEJMsa1214720; World Health Organization, 2013, ANT THER HIV INF AD	32	49	49	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2014	9	10							e110252	10.1371/journal.pone.0110252	http://dx.doi.org/10.1371/journal.pone.0110252			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0AY	25330087	Green Submitted, Green Published, gold			2023-01-03	WOS:000343942100048
J	Bernard, JJ; Lou, YR; Peng, QY; Li, T; Lu, YP				Bernard, Jamie J.; Lou, You-Rong; Peng, Qing-Yun; Li, Tao; Lu, Yao-Ping			PDE2 Is a Novel Target for Attenuating Tumor Formation in a Mouse Model of UVB-Induced Skin Carcinogenesis	PLOS ONE			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; ULTRAVIOLET-B LIGHT; SKH-1 MICE; STIMULATED PHOSPHODIESTERASE; INDUCED APOPTOSIS; GREEN TEA; INHIBITORS; CAFFEINE; CANCER; CELLS	Our previous studies demonstrated that the topical application of caffeine is a potent inhibitor of UVB-induced carcinogenesis and selectively increases apoptosis in tumors but not in non-tumor areas of the epidermis in mice that are at a high risk for developing skin cancer. While this effect is mainly through a p53 independent pathway, the mechanism by which caffeine inhibits skin tumor formation has not been fully elucidated. Since caffeine is a non-specific phosphodiesterase inhibitor, we investigated the effects of several PDE inhibitors on the formation of sunburn cells in mouse skin after an acute exposure to ultraviolet light B (UVB). The topical application of a PDE2 inhibitor, erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA hydrochloride), stimulated epidermal apoptosis compared to control (P< 0.01) and to a greater extent than caffeine whereas a PDE4 inhibitor attenuated the epidermal apoptosis compared to control (P<0.01). Since PDE2 hydrolyzes cyclic nucleotides, mainly cGMP, the effects of EHNA hydrochloride on epidermal apoptosis following UVB exposure may be mediated, in part, by increased cGMP signaling. Data demonstrated that the topical application of dibutyryl cGMP stimulated epidermal apoptosis (P<0.01) following an acute exposure to UVB. Treating UVB-pretreated mice topically with 3.1 mu mole or 0.8 mu mole of EHNA hydrochloride attenuated tumor formation to a greater extent than treating with 6.2 mu mole caffeine when these compounds were applied once a day, five days a week for 18 weeks. These observations suggest a novel role for PDE2 in UVB-induced tumorigenesis and that PDE2 inhibitors that mediate cGMP signaling may be useful for the prevention and treatment of skin cancer.	[Bernard, Jamie J.; Lou, You-Rong; Peng, Qing-Yun; Li, Tao; Lu, Yao-Ping] Rutgers State Univ, Dept Biol Chem, Susan Lehman Cullman Lab Canc Res, Ernest Mario Sch Pharm, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Lu, YP (corresponding author), Rutgers State Univ, Dept Biol Chem, Susan Lehman Cullman Lab Canc Res, Ernest Mario Sch Pharm, Piscataway, NJ 08854 USA.	yaoping.lu@pharmacy.rutgers.edu		Bernard, Jamie/0000-0002-3800-2576	National Cancer Institute [R01CA128997, R01CA114442]; National Institute of Environmental Health Sciences (NIEHS) [ES007148, ES005022]; NATIONAL CANCER INSTITUTE [R01CA114442, R01CA128997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007148] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The project was supported by grants R01CA128997, R01CA114442 from the National Cancer Institute and in part, by Training Grant ES007148 and Center Grant ES005022 from the National Institute of Environmental Health Sciences (NIEHS). The content is solely the responsibility of the authors and does not necessary represent the official views of the National Cancer Institute or the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abadi AH, 2010, EUR J MED CHEM, V45, P1278, DOI 10.1016/j.ejmech.2009.10.046; Bender AT, 2006, PHARMACOL REV, V58, P488, DOI 10.1124/pr.58.3.5; Borland G, 2009, BRIT J PHARMACOL, V158, P70, DOI 10.1111/j.1476-5381.2008.00087.x; Camici M, 2008, BIOMED PHARMACOTHER, V62, P70, DOI 10.1016/j.biopha.2007.04.010; Caretta Antonio, 2011, Cancers (Basel), V3, P913, DOI 10.3390/cancers3010913; Chen HJ, 2008, J BIOL CHEM, V283, P4439, DOI 10.1074/jbc.M709439200; Cho ES, 2004, ARCH PHARM RES, V27, P1258, DOI 10.1007/BF02975891; Conti M, 2007, ANNU REV BIOCHEM, V76, P481, DOI 10.1146/annurev.biochem.76.060305.150444; DAVIES GE, 1973, INT ARCH ALLER A IMM, V45, P467, DOI 10.1159/000231064; Fajardo AM, 2014, CANCERS, V6, P436, DOI 10.3390/cancers6010436; Haynes J, 1996, J PHARMACOL EXP THER, V276, P752; Hirsh L, 2004, BIOCHEM PHARMACOL, V68, P981, DOI 10.1016/j.bcp.2004.05.026; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; Jedlitschky G, 2000, J BIOL CHEM, V275, P30069, DOI 10.1074/jbc.M005463200; Kool M, 1997, CANCER RES, V57, P3537; Lee IH, 2008, J UROLOGY, V179, P1072, DOI 10.1016/j.juro.2007.10.053; Li P, 2007, GASTROENTEROLOGY, V133, P599, DOI 10.1053/j.gastro.2007.05.052; Lou YR, 2011, CARCINOGENESIS, V32, P1078, DOI 10.1093/carcin/bgr074; Lou YR, 1999, NUTR CANCER, V33, P146, DOI 10.1207/S15327914NC330205; Lu YP, 2007, CARCINOGENESIS, V28, P199, DOI 10.1093/carcin/bgl112; Lu YP, 2006, P NATL ACAD SCI USA, V103, P16301, DOI 10.1073/pnas.0607789103; Lu YP, 2012, P NATL ACAD SCI USA, V109, P9065, DOI 10.1073/pnas.1205810109; Lu YP, 2004, CANCER RES, V64, P5020, DOI 10.1158/0008-5472.CAN-04-0760; Lu YP, 2002, P NATL ACAD SCI USA, V99, P12455, DOI 10.1073/pnas.182429899; Lu YP, 2000, CANCER RES, V60, P4785; Lu YP, 2001, ONCOL RES, V13, P61; Lu YP, 2001, CANCER RES, V61, P5002; MERY PF, 1995, MOL PHARMACOL, V48, P121; Moon EY, 2003, BLOOD, V101, P4122, DOI 10.1182/blood-2002-10-3208; Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Pitari GM, 2001, P NATL ACAD SCI USA, V98, P7846, DOI 10.1073/pnas.141124698; PODZUWEIT T, 1995, CELL SIGNAL, V7, P733, DOI 10.1016/0898-6568(95)00042-N; Savai R, 2010, EXPERT OPIN INV DRUG, V19, P117, DOI 10.1517/13543780903485642; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Slominski AT, 2012, ADV ANAT EMBRYOL CEL, V212, P1; Steinbrecher KA, 2002, AM J PATHOL, V161, P2169, DOI 10.1016/S0002-9440(10)64494-X; Verhoest PR, 2009, J MED CHEM, V52, P7946, DOI 10.1021/jm9015334; Zhu J, 2001, CNS DRUG REV, V7, P387	39	6	12	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2014	9	10							e109862	10.1371/journal.pone.0109862	http://dx.doi.org/10.1371/journal.pone.0109862			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ9XC	25330380	Green Submitted, Green Published, gold			2023-01-03	WOS:000343210800044
J	Dhalla, IA; O'Brien, T; Morra, D; Thorpe, KE; Wong, BM; Mehta, R; Frost, DW; Abrams, H; Ko, F; Van Rooyen, P; Bell, CM; Gruneir, A; Lewis, GH; Daub, S; Anderson, GM; Hawker, GA; Rochon, PA; Laupacis, A				Dhalla, Irfan A.; O'Brien, Tara; Morra, Dante; Thorpe, Kevin E.; Wong, Brian M.; Mehta, Rajin; Frost, David W.; Abrams, Howard; Ko, Francoise; Van Rooyen, Patrick; Bell, Chaim M.; Gruneir, Andrea; Lewis, Geraint H.; Daub, Stacey; Anderson, Geoff M.; Hawker, Gillian A.; Rochon, Paula A.; Laupacis, Andreas			Effect of a Postdischarge Virtual Ward on Readmission or Death for High-Risk Patients A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BOOST; CARE; REHOSPITALIZATION; INTERVENTIONS; ASSOCIATION; PROGRAM; SIZE	IMPORTANCE Hospital readmissions are common and costly, and no single intervention or bundle of interventions has reliably reduced readmissions. Virtual wards, which use elements of hospital care in the community, have the potential to reduce readmissions, but have not yet been rigorously evaluated. OBJECTIVE To determine whether a virtual ward-a model of care that uses some of the systems of a hospital ward to provide interprofessional care for community-dwelling patients-can reduce the risk of readmission in patients at high risk of readmission or death when being discharged from hospital. DESIGN, SETTING, AND PATIENTS High-risk adult hospital discharge patients in Toronto were randomly assigned to either the virtual ward or usual care. A total of 1923 patients were randomized during the course of the study: 960 to the usual care group and 963 to the virtual ward group. The first patient was enrolled on June 29, 2010, and follow-up was completed on June 2, 2014. INTERVENTIONS Patients assigned to the virtual ward received care coordination plus direct care provision (via a combination of telephone, home visits, or clinic visits) from an interprofessional team for several weeks after hospital discharge. The interprofessional team met daily at a central site to design and implement individualized management plans. Patients assigned to usual care typically received a typed, structured discharge summary, prescription for new medications if indicated, counseling from the resident physician, arrangements for home care as needed, and recommendations, appointments, or both for follow-up care with physicians as indicated. MAIN OUTCOMES AND MEASURES The primary outcome was a composite of hospital readmission or death within 30 days of discharge. Secondary outcomes included nursing home admission and emergency department visits, each of the components of the primary outcome at 30 days, as well as each of the outcomes (including the composite primary outcome) at 90 days, 6 months, and 1 year. RESULTS There were no statistically significant between-group differences in the primary or secondary outcomes at 30 or 90 days, 6 months, or 1 year. The primary outcome occurred in 203 of 959 (21.2%) of the virtual ward patients and 235 of 956 (24.6%) of the usual care patients (absolute difference, 3.4%; 95% CI, -0.3% to 7.2%; P = .09). There were no statistically significant interactions to indicate that the virtual ward model of care was more or less effective in any of the prespecified subgroups. CONCLUSIONS AND RELEVANCE In a diverse group of high-risk patients being discharged from the hospital, we found no statistically significant effect of a virtual ward model of care on readmissions or death at either 30 days or 90 days, 6 months, or 1 year after hospital discharge. Copyright 2014 American Medical Association. All rights reserved.	[Dhalla, Irfan A.; O'Brien, Tara; Morra, Dante; Wong, Brian M.; Mehta, Rajin; Frost, David W.; Abrams, Howard; Bell, Chaim M.; Hawker, Gillian A.; Rochon, Paula A.; Laupacis, Andreas] Univ Toronto, Dept Med, Toronto, ON M5B 1W8, Canada; [Dhalla, Irfan A.; Gruneir, Andrea; Anderson, Geoff M.; Rochon, Paula A.; Laupacis, Andreas] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON M5B 1W8, Canada; [Dhalla, Irfan A.] St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada; [Dhalla, Irfan A.; Thorpe, Kevin E.; Van Rooyen, Patrick; Laupacis, Andreas] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Dhalla, Irfan A.; Bell, Chaim M.; Gruneir, Andrea; Hawker, Gillian A.; Rochon, Paula A.; Laupacis, Andreas] Inst Clin Evaluat Sci, Toronto, ON, Canada; [O'Brien, Tara; Hawker, Gillian A.; Rochon, Paula A.] Womens Coll Hosp, Dept Med, Toronto, ON, Canada; [Morra, Dante] Trillium Hlth Partners, Mississauga, ON, Canada; [Thorpe, Kevin E.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON M5B 1W8, Canada; [Wong, Brian M.; Mehta, Rajin] Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON M4N 3M5, Canada; [Wong, Brian M.] Univ Toronto, Ctr Qual Improvement & Patient Safety, Toronto, ON M5B 1W8, Canada; [Frost, David W.; Abrams, Howard] Univ Hlth Network, Dept Med, Toronto, ON, Canada; [Ko, Francoise] Taddle Creek Family Hlth Team, Toronto, ON, Canada; [Bell, Chaim M.] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; [Gruneir, Andrea; Rochon, Paula A.] Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON, Canada; [Lewis, Geraint H.] NHS England, London, England; [Daub, Stacey] Toronto Cent Community Care Access Ctr, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; Trillium Health Partners; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Centre for Quality Improvement & Patient Safety; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Womens College Hospital	Dhalla, IA (corresponding author), Univ Toronto, Dept Med, 30 Bond St, Toronto, ON M5B 1W8, Canada.	dhallai@smh.ca	Bell, Chaim/C-4611-2015; Rochon, Paula A/J-2918-2016; Wong, Brian/AFT-0135-2022	Bell, Chaim/0000-0002-3778-9469; Rochon, Paula A/0000-0002-5973-4151; Abrams, Howard/0000-0002-4869-3913; Thorpe, Kevin/0000-0002-7586-3893; Frost, David William/0000-0002-4313-3802	Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care; Green Shield Canada Foundation; University of Toronto Department of Medicine; Academic Funding Plan Innovation Fund	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Health and Long-Term Care(Ministry of Health and Long-Term Care, Ontario); Green Shield Canada Foundation; University of Toronto Department of Medicine(University of Toronto); Academic Funding Plan Innovation Fund	This research was funded by the Canadian Institutes of Health Research, the Ontario Ministry of Health and Long-Term Care, the Green Shield Canada Foundation, the University of Toronto Department of Medicine, and the Academic Funding Plan Innovation Fund.	Auerbach A, 2013, J HOSP MED, V8, P468, DOI 10.1002/jhm.2065; Berenson RA, 2012, NEW ENGL J MED, V366, P1364, DOI 10.1056/NEJMp1201268; Chen YHJ, 2004, STAT MED, V23, P1023, DOI 10.1002/sim.1688; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Detsky AS, 2014, JAMA-J AM MED ASSOC, V311, P2169, DOI 10.1001/jama.2014.3695; Friedberg MW, 2014, JAMA-J AM MED ASSOC, V311, P815, DOI 10.1001/jama.2014.353; Gruneir Andrea, 2011, Open Med, V5, pe104; Hansen LO, 2013, J HOSP MED, V8, P421, DOI 10.1002/jhm.2054; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jha AK, 2013, J HOSP MED, V8, P470, DOI 10.1002/jhm.2069; Joynt KE, 2013, NEW ENGL J MED, V368, P1175, DOI 10.1056/NEJMp1300122; Larson EB, 2010, JAMA-J AM MED ASSOC, V303, P1644, DOI 10.1001/jama.2010.524; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; Leppin AL, 2014, JAMA INTERN MED, V174, P1095, DOI 10.1001/jamainternmed.2014.1608; Lewis G, 2013, INT J INTEGR CARE, V13; Lewis G, 2012, POPUL HEALTH MANAG, V15, P315, DOI 10.1089/pop.2011.0086; McAlister FA, 2013, CMAJ, V185, P681; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Reuben DB, 2014, NEW ENGL J MED, V370, P694, DOI 10.1056/NEJMp1315568; Schachter ME, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-33; Schwenk TL, 2014, JAMA-J AM MED ASSOC, V311, P802, DOI 10.1001/jama.2014.352; Smith PC, 2009, J GEN INTERN MED, V24, P783, DOI 10.1007/s11606-009-0928-6; van Walraven C, 2010, J EVAL CLIN PRACT, V16, P947, DOI 10.1111/j.1365-2753.2009.01235.x; van Walraven C, 2010, CAN MED ASSOC J, V182, P551, DOI 10.1503/cmaj.091117; vanWalraven C, 2011, CMAJ, V183, P1067	28	83	83	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2014	312	13					1305	1312		10.1001/jama.2014.11492	http://dx.doi.org/10.1001/jama.2014.11492			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AP8RB	25268437				2023-01-03	WOS:000342345400016
J	Cusso, L; Vaquero, JJ; Bacharach, S; Desco, M				Cusso, Lorena; Jose Vaquero, Juan; Bacharach, Stephen; Desco, Manuel			Comparison of Methods to Reduce Myocardial 18F-FDG Uptake in Mice: Calcium Channel Blockers versus High-Fat Diets	PLOS ONE			English	Article							LOW-CARBOHYDRATE-DIET; DUAL-TRACER PET; F-18-FDG UPTAKE; INFLAMMATION; SUPPRESSION; METABOLISM; GLUCOSE; F-18-FLUORODEOXYGLUCOSE; RESTRICTION; ARTERIES	Purpose: Besides its application in oncology, F-18-FDG PET-CT imaging is also useful in the diagnosis of certain lung infections, inflammatory diseases, and atherosclerotic plaques. Myocardial uptake of F-18-FDG may hamper visualization of the lesions caused by these diseases. Two approaches have been proposed for reducing myocardial uptake in preclinical studies, namely, calcium channel blockers (verapamil) and high-fat diets such as commercial ketogenic diets and sunflower seed diets. The objective of this study was to compare the efficacy of these approaches in reducing myocardial uptake of F-18-FDG in mice. Methods: We performed two experiments. In experiment A, each animal underwent four F-18-FDG PET/CT scans in the following order: baseline, after administration of verapamil, after two days on ketogenic diet and after two days on sunflower seeds. PET scans were performed 60 minutes after injection of 18.5 MBq of F-18-FDG. In experiment B, the best protocol of the three (ketogenic diet) was evaluated in a lung inflammation model to assess the efficacy of reducing myocardial uptake of F-18-FDG. Results: Compared with baseline (SUV 2.03 +/- 1.21); the greatest reduction in uptake of F-18-FDG was with ketogenic diet (SUV 0.79 +/- 0.16; p = 0.008), followed by sunflower seeds (SUV 0.91 +/- 0.13; p = 0.015); the reduction in myocardial uptake produced by verapamil was not statistically significant (SUV 1.78 +/- 0.79; p = NS). In experiment B, complete suppression of myocardial uptake noticeably improved the visualization of inflamed areas near the heart, while in the case of null or partial myocardial suppression, it was much harder to distinguish lung inflammation from myocardial spillover. Conclusion: A high-fat diet appeared to be the most effective method for decreasing myocardial uptake of F-18-FDG in healthy mice, outperforming verapamil. Our findings also demonstrate that ketogenic diet actually improves visualization of inflammatory lesions near the heart.	[Cusso, Lorena; Jose Vaquero, Juan; Desco, Manuel] Univ Carlos III Madrid, Dept Bioingn & Ingn Aeroespacial, Madrid, Spain; [Cusso, Lorena; Jose Vaquero, Juan; Desco, Manuel] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain; [Bacharach, Stephen] Univ Calif San Francisco, Dept Radiol, Nucl Med Sect, San Francisco, CA USA; [Desco, Manuel] Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain	Universidad Carlos III de Madrid; University of California System; University of California San Francisco; CIBER - Centro de Investigacion Biomedica en Red; CIBERSAM	Cusso, L (corresponding author), Univ Carlos III Madrid, Dept Bioingn & Ingn Aeroespacial, Madrid, Spain.	lcusso@hggm.es	cussó, lorena/R-6715-2019; Vaquero, Juan José/D-3033-2009; Desco, Manuel/AAD-7137-2019	cussó, lorena/0000-0001-9298-0015; Vaquero, Juan José/0000-0001-9200-361X; Desco, Manuel/0000-0003-0989-3231	Innovative Medicines Initiative Joint Undertaking [115337]; European Union; EFPIA companies; Spanish MICINN [CEN-20101014]; RIC-RETIC network, Spanish MINECO [RD12/0042/0057]	Innovative Medicines Initiative Joint Undertaking; European Union(European Commission); EFPIA companies; Spanish MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); RIC-RETIC network, Spanish MINECO	This research was funded in part by the Innovative Medicines Initiative Joint Undertaking under grant agreement no115337 (www.imi.europa.eu), resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution, and from the Spanish MICINN (CEN-20101014) and the RIC-RETIC network, Spanish MINECO (RD12/0042/0057). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abella M, 2012, COMPUT METH PROG BIO, V107, P218, DOI 10.1016/j.cmpb.2011.06.008; Altman DG, 1991, PRACTICAL STAT MED R; Bertagna F, 2013, CLIN TRANSL IMAGING, V1, P77, DOI 10.1007/s40336-013-0014-2; Bertagna F, 2012, INT J CARDIOVAS IMAG, V28, P1417, DOI 10.1007/s10554-011-9984-1; Cheng VY, 2010, J NUCL CARDIOL, V17, P286, DOI 10.1007/s12350-009-9179-5; DeFuria J, 2009, J NUTR, V139, P1510, DOI 10.3945/jn.109.105155; Dilsizian V, 2008, J NUCL MED, V49, P1909, DOI 10.2967/jnumed.108.053892; Erridge C, 2007, AM J CLIN NUTR, V86, P1286, DOI 10.1093/ajcn/86.5.1286; Fine EJ, 2009, NUCL MED COMMUN, V30, P675, DOI 10.1097/MNM.0b013e32832aa6e8; Fueger BJ, 2006, J NUCL MED, V47, P999; Gaeta C, 2011, EUR J NUCL MED MOL I, V38, P2018, DOI 10.1007/s00259-011-1873-2; Harisankar CNB, 2011, J NUCL CARDIOL, V18, P926, DOI 10.1007/s12350-011-9422-8; Ishimaru S, 2005, EUR HEART J, V26, P1538, DOI 10.1093/eurheartj/ehi180; Israel O, 2007, J NUCL MED, V48, P234; Khandani AH, 2005, NUCL MED COMMUN, V26, P787, DOI 10.1097/01.mnm.0000175264.33368.da; Kobayashi Y, 2013, J CARDIOL, V62, P314, DOI 10.1016/j.jjcc.2013.05.004; Li B, 2011, J CELL PHYSIOL, V226, P2398, DOI 10.1002/jcp.22577; Lum Darren P, 2002, Mol Imaging Biol, V4, P232, DOI 10.1016/S1095-0397(01)00062-0; McNulty PH, 2000, CIRCULATION, V101, P917, DOI 10.1161/01.CIR.101.8.917; Pifferi F, 2011, NUTR NEUROSCI, V14, P51, DOI 10.1179/1476830510Y.0000000001; Roy M, 2012, BRAIN RES, V1488, P14, DOI 10.1016/j.brainres.2012.10.008; Services USDoHaH, 2013, SERV USDOHAH; Shreve PD, 1999, RADIOGRAPHICS, V19, P61, DOI 10.1148/radiographics.19.1.g99ja0761; Stanley WC, 2005, PHYSIOL REV, V85, P1093, DOI 10.1152/physrev.00006.2004; Stanley WC, 2001, EUR HEART J SUPPL, V3, pO2, DOI 10.1016/S1520-765X(01)90147-6; Todoric J, 2006, DIABETOLOGIA, V49, P2109, DOI 10.1007/s00125-006-0300-x; Tupper T, 2011, WORLD MOL IM C WMIC; U.S. Department of Agriculture ARS, 2013, USDA NAT NUTR DAT ST; Vaquero JJ, 2008, IEEE T NUCL SCI, V55, P898, DOI 10.1109/TNS.2008.922814; Wang YC, 2006, J NUCL MED, V47, P1891; Williams G, 2008, AM J ROENTGENOL, V190, pW151, DOI 10.2214/AJR.07.2409; Wong KP, 2011, J NUCL MED, V52, P800, DOI 10.2967/jnumed.110.085092; Wykrzykowska J, 2009, J NUCL MED, V50, P563, DOI 10.2967/jnumed.108.055616; Yun MJ, 2001, CLIN NUCL MED, V26, P314, DOI 10.1097/00003072-200104000-00007; Zhao Y, 2008, J NUCL MED, V49, P1707, DOI 10.2967/jnumed.108.051847	35	9	10	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2014	9	9							e107999	10.1371/journal.pone.0107999	http://dx.doi.org/10.1371/journal.pone.0107999			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ0RY	25238619	Green Published, Green Submitted, gold			2023-01-03	WOS:000342491600074
J	Mayosi, BM; Ntsekhe, M; Bosch, J; Pandie, S; Jung, H; Gumedze, F; Pogue, J; Thabane, L; Smieja, M; Francis, V; Joldersma, L; Thomas, KM; Thomas, B; Awotedu, AA; Magula, NP; Naidoo, DP; Damasceno, A; Banda, AC; Brown, B; Manga, P; Kirenga, B; Mondo, C; Mntla, P; Tsitsi, JM; Peters, F; Essop, MR; Russell, JBW; Hakim, J; Matenga, J; Barasa, AF; Sani, MU; Olunuga, T; Ogah, O; Ansa, V; Aje, A; Danbauchi, S; Ojji, D; Yusuf, S				Mayosi, B. M.; Ntsekhe, M.; Bosch, J.; Pandie, S.; Jung, H.; Gumedze, F.; Pogue, J.; Thabane, L.; Smieja, M.; Francis, V.; Joldersma, L.; Thomas, K. M.; Thomas, B.; Awotedu, A. A.; Magula, N. P.; Naidoo, D. P.; Damasceno, A.; Banda, A. C.; Brown, B.; Manga, P.; Kirenga, B.; Mondo, C.; Mntla, P.; Tsitsi, J. M.; Peters, F.; Essop, M. R.; Russell, J. B. W.; Hakim, J.; Matenga, J.; Barasa, A. F.; Sani, M. U.; Olunuga, T.; Ogah, O.; Ansa, V.; Aje, A.; Danbauchi, S.; Ojji, D.; Yusuf, S.		IMPI Trial Investigators	Prednisolone and Mycobacterium indicus pranii in Tuberculous Pericarditis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ADJUNCTIVE PREDNISOLONE; CORTICOSTEROIDS; MANAGEMENT; VACCINE; IMMUNOTHERAPY; EFFUSIONS; MORTALITY; DIAGNOSIS	BACKGROUND Tuberculous pericarditis is associated with high morbidity and mortality even if antituberculosis therapy is administered. We evaluated the effects of adjunctive glucocorticoid therapy and Mycobacterium indicus pranii immunotherapy in patients with tuberculous pericarditis. METHODS Using a 2-by-2 factorial design, we randomly assigned 1400 adults with definite or probable tuberculous pericarditis to either prednisolone or placebo for 6 weeks and to either M. indicus pranii or placebo, administered in five injections over the course of 3 months. Two thirds of the participants had concomitant human immunodeficiency virus (HIV) infection. The primary efficacy outcome was a composite of death, cardiac tamponade requiring pericardiocentesis, or constrictive pericarditis. RESULTS There was no significant difference in the primary outcome between patients who received prednisolone and those who received placebo (23.8% and 24.5%, respectively; hazard ratio, 0.95; 95% confidence interval [CI], 0.77 to 1.18; P = 0.66) or between those who received M. indicus pranii immunotherapy and those who received placebo (25.0% and 24.3%, respectively; hazard ratio, 1.03; 95% CI, 0.82 to 1.29; P = 0.81). Prednisolone therapy, as compared with placebo, was associated with significant reductions in the incidence of constrictive pericarditis (4.4% vs. 7.8%; hazard ratio, 0.56; 95% CI, 0.36 to 0.87; P = 0.009) and hospitalization (20.7% vs. 25.2%; hazard ratio, 0.79; 95% CI, 0.63 to 0.99; P = 0.04). Both prednisolone and M. indicus pranii, each as compared with placebo, were associated with a significant increase in the incidence of cancer (1.8% vs. 0.6%; hazard ratio, 3.27; 95% CI, 1.07 to 10.03; P = 0.03, and 1.8% vs. 0.5%; hazard ratio, 3.69; 95% CI, 1.03 to 13.24; P = 0.03, respectively), owing mainly to an increase in HIV-associated cancer. CONCLUSIONS In patients with tuberculous pericarditis, neither prednisolone nor M. indicus pranii had a significant effect on the composite of death, cardiac tamponade requiring pericardiocentesis, or constrictive pericarditis.	[Mayosi, B. M.; Ntsekhe, M.; Pandie, S.; Francis, V.] Univ Cape Town, Dept Med, Groote Schuur Hosp, ZA-7925 Cape Town, South Africa; [Mayosi, B. M.; Ntsekhe, M.; Pandie, S.; Francis, V.] Univ Cape Town, ZA-7925 Cape Town, South Africa; [Gumedze, F.] Univ Cape Town, Dept Stat Sci, ZA-7925 Cape Town, South Africa; [Thomas, K. M.; Thomas, B.; Awotedu, A. A.] Nelson Mandela Acad Hosp, Dept Internal Med, Mthatha, South Africa; [Thomas, K. M.; Thomas, B.; Awotedu, A. A.] Walter Sisulu Univ, Mthanta, South Africa; [Magula, N. P.] King Edward VIII Hosp, Dept Med, Durban, South Africa; [Magula, N. P.] Univ KwaZulu Natal, Durban, South Africa; [Naidoo, D. P.] Inkosi Albert Luthuli Cent Hosp, Dept Cardiol, Durham, South Africa; [Naidoo, D. P.] Univ KwaZulu Natal, Durham, South Africa; [Brown, B.] Prov & Livingstone Hosp, Dept Cardiol, Port Elizabeth, South Africa; [Brown, B.] Walter Sisulu Univ, Port Elizabeth, South Africa; [Manga, P.] Charlotte Maxeke Johannesburg Acad Hosp, Div Cardiol, Johannesburg, South Africa; [Manga, P.] Univ Witwatersrand, Johannesburg, South Africa; [Mntla, P.] Dr George Mukhari Hosp, Div Cardiol, Pretoria, South Africa; [Mntla, P.] Univ Limpopo, Pretoria, South Africa; [Tsitsi, J. M.; Peters, F.; Essop, M. R.] Chris Hani Baragwanath Hosp, Div Cardiol, Soweto, South Africa; [Tsitsi, J. M.; Peters, F.; Essop, M. R.] Univ Witwatersrand, Soweto, South Africa; [Bosch, J.; Jung, H.; Pogue, J.; Thabane, L.; Smieja, M.; Joldersma, L.; Yusuf, S.] McMaster Univ, Hamilton, ON, Canada; [Bosch, J.; Jung, H.; Pogue, J.; Thabane, L.; Smieja, M.; Yusuf, S.] Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada; [Damasceno, A.] Hosp Cent Maputo, Maputo, Mozambique; [Banda, A. C.] Malawi Mil Hlth Serv, Lilongwe, Malawi; [Kirenga, B.; Mondo, C.] New Mulago Hosp, Kampala, Uganda; [Russell, J. B. W.] Connaught Hosp, Freetown, Sierra Leone; [Hakim, J.; Matenga, J.] Parirenyatwa Hosp, Harare, Zimbabwe; [Barasa, A. F.] Moi Hosp, Eldoret, Kenya; [Sani, M. U.] Aminu Kano Teaching Hosp, Kano, Nigeria; [Olunuga, T.; Ogah, O.] Fed Med Ctr, Abeokuta, Ogun State, Niger; [Ansa, V.] Univ Calabar, Teaching Hosp, Calabar, Nigeria; [Aje, A.] Univ Coll Hosp, Ibadan, Oyo State, Nigeria; [Danbauchi, S.] Ahmadu Bello Teaching Hosp, Zaria, Kaduna State, Nigeria; [Ojji, D.] Abuja Teaching Hosp, Abuja, Nigeria	University of Cape Town; University of Cape Town; University of Cape Town; University of Kwazulu Natal; Walter Sisulu University; University of Kwazulu Natal; University of Kwazulu Natal; Walter Sisulu University; University of Witwatersrand; University of Witwatersrand; University of Limpopo; University of Witwatersrand; McMaster University; McMaster University; Population Health Research Institute; Mulago National Referral Hospital; Connaught Hospital; University of Calabar; University of Ibadan; University College Hospital, Ibadan	Mayosi, BM (corresponding author), Old Groote Schuur Hosp, Dept Med, J Fl,Rm J46-53,Groote Schuur Dr, ZA-7925 Cape Town, South Africa.	bongani.mayosi@uct.ac.za	Maseeh, Arun/AAO-7868-2021; Bosch, Jacqueline/AAP-6910-2021; ntsekhe, mpiko/AAI-8001-2021; Tsabedze, Nqoba/U-5941-2017	Maseeh, Arun/0000-0002-5435-941X; Bosch, Jacqueline/0000-0001-6292-4207; ntsekhe, mpiko/0000-0002-0851-7675; Tsabedze, Nqoba/0000-0002-7210-1447; Esmail, Hanif/0000-0002-4278-9316; Kirenga, Bruce/0000-0002-2023-2840; Meintjes, Graeme/0000-0003-1196-4414; Gumedze, Freedom N/0000-0003-4387-8844; Mayosi, Bongani/0000-0001-6641-8950; Russell, James/0000-0003-4732-6588; Yusuf, Salim/0000-0003-4776-5601	Canadian Institutes of Health Research; Canadian Network and Centre for Trials Internationally; Population Health Research Institute; South African Medical Research Council; Lily and Ernst Hausmann Research Trust; Cadila Pharma, India	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Network and Centre for Trials Internationally; Population Health Research Institute; South African Medical Research Council(South African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Lily and Ernst Hausmann Research Trust; Cadila Pharma, India	Supported by grants from the Canadian Institutes of Health Research, the Canadian Network and Centre for Trials Internationally, the Population Health Research Institute, the South African Medical Research Council, the Lily and Ernst Hausmann Research Trust, and Cadila Pharma, India.	Cherian G, 2004, POSTGRAD MED J, V80, P262, DOI 10.1136/pgmj.2003.013664; Critchley JA, 2013, LANCET INFECT DIS, V13, P223, DOI 10.1016/S1473-3099(12)70321-3; Elliott AM, 2004, J INFECT DIS, V190, P869, DOI 10.1086/422257; ELLIOTT AM, 1992, Q J MED, V85, P855; Evans DJ, 2008, RESP MED, V102, P793, DOI 10.1016/j.rmed.2008.01.018; Gupta A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039215; Gupta S, 2008, J EUR ACAD DERMATOL, V22, P1089, DOI 10.1111/j.1468-3083.2008.02719.x; Hakim JG, 2000, HEART, V84, P183, DOI 10.1136/heart.84.2.183; International Diabetes Federation, 2013, IDF DIABETES ATLAS, V6th ed.; Kharkar Rajendra, 2002, J Indian Med Assoc, V100, P578; LEPPER MH, 1963, ANN NY ACAD SCI, V106, P106, DOI 10.1111/j.1749-6632.1963.tb16629.x; Maisch B, 2004, EUR HEART J, V25, P587, DOI 10.1016/j.ehj.2004.02.002; Mathur ML, 2006, CURR RESPIR MED REV, V2, P183, DOI 10.2174/157339806776843120; Mayosi B.M., 2002, COCHRANE DB SYST REV, V4), DOI [10.1002/14651858.CD000526, DOI 10.1002/14651858.CD000526]; Mayosi BM, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-2; Mayosi BM, 2005, CIRCULATION, V112, P3608, DOI 10.1161/CIRCULATIONAHA.105.543066; Mayosi BM, 2008, SAMJ S AFR MED J, V98, P36; Mayosi BM, 2013, AM HEART J, V165, P109, DOI 10.1016/j.ahj.2012.08.006; Mutyaba A, 1990, J THORAC CA IN PRESS; Nath I, 1998, NAT MED, V4, P548, DOI 10.1038/nm0598-548; Ntsekhe M, 2003, QJM-INT J MED, V96, P593, DOI 10.1093/qjmed/hcg100; Pandie S, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-101; Reuter H, 2006, QJM-INT J MED, V99, P827, DOI 10.1093/qjmed/hcl123; Reuter Helmuth, 2006, Cardiovasc J S Afr, V17, P233; Saini V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006263; SCHRIRE V., 1959, S AFRICAN MED JOUR, V33, P810; Sharma P, 2005, LEPROSY REV, V76, P127; STRANG JIG, 1994, J INFECTION, V28, P251, DOI 10.1016/S0163-4453(94)91593-8; STRANG JIG, 1988, LANCET, V2, P759; STRANG JIG, 1987, LANCET, V2, P1418; Talwar G P, 1999, Int Rev Immunol, V18, P229, DOI 10.3109/08830189909043027; Thwaites GE, 2004, NEW ENGL J MED, V351, P1741, DOI 10.1056/NEJMoa040573; Treatment of tuberculosis, 2003, MMWR RECOMM REP, V52, P1; WHO, 2010, TREATMENT OF TUBERCULOSIS: GUIDELINES, FOURTH EDITION, P1; WHO, 2010, ANT THER HIV INF AD; World Health Organization, 2006, ANT THER HIV INF AD; Zuhlke L, 2013, HEART, V99, P1554, DOI 10.1136/heartjnl-2013-303896	37	150	155	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2014	371	12					1121	1130		10.1056/NEJMoa1407380	http://dx.doi.org/10.1056/NEJMoa1407380			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AO9PI	25178809	Green Accepted, Bronze			2023-01-03	WOS:000341687300007
J	Sobczynski, DJ; Charoenphol, P; Heslinga, MJ; Onyskiw, PJ; Namdee, K; Thompson, AJ; Eniola-Adefeso, O				Sobczynski, Daniel J.; Charoenphol, Phapanin; Heslinga, Michael J.; Onyskiw, Peter J.; Namdee, Katawut; Thompson, Alex J.; Eniola-Adefeso, Omolola			Plasma Protein Corona Modulates the Vascular Wall Interaction of Drug Carriers in a Material and Donor Specific Manner	PLOS ONE			English	Article							PEG CHAIN-LENGTH; HUMAN BLOOD-FLOW; TARGETING THERAPEUTICS; MARGINATION PROPENSITY; CANCER-CELLS; NANOPARTICLES; PARTICLES; DELIVERY; SURFACE; NANOMATERIALS	The nanoscale plasma protein interaction with intravenously injected particulate carrier systems is known to modulate their organ distribution and clearance from the bloodstream. However, the role of this plasma protein interaction in prescribing the adhesion of carriers to the vascular wall remains relatively unknown. Here, we show that the adhesion of vascular-targeted poly(lactide-co-glycolic-acid) (PLGA) spheres to endothelial cells is significantly inhibited in human blood flow, with up to 90% reduction in adhesion observed relative to adhesion in simple buffer flow, depending on the particle size and the magnitude and pattern of blood flow. This reduced PLGA adhesion in blood flow is linked to the adsorption of certain high molecular weight plasma proteins on PLGA and is donor specific, where large reductions in particle adhesion in blood flow (> 80% relative to buffer) is seen with similar to 60% of unique donor bloods while others exhibit moderate to no reductions. The depletion of high molecular weight immunoglobulins from plasma is shown to successfully restore PLGA vascular wall adhesion. The observed plasma protein effect on PLGA is likely due to material characteristics since the effect is not replicated with polystyrene or silica spheres. These particles effectively adhere to the endothelium at a higher level in blood over buffer flow. Overall, understanding how distinct plasma proteins modulate the vascular wall interaction of vascular-targeted carriers of different material characteristics would allow for the design of highly functional delivery vehicles for the treatment of many serious human diseases.	[Sobczynski, Daniel J.; Charoenphol, Phapanin; Heslinga, Michael J.; Onyskiw, Peter J.; Thompson, Alex J.; Eniola-Adefeso, Omolola] Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA; [Namdee, Katawut; Eniola-Adefeso, Omolola] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Eniola-Adefeso, O (corresponding author), Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA.	lolaa@umich.edu		Thompson, Alex/0000-0002-2670-4626; Namdee, Katawut/0000-0003-3763-9388; Charoenphol, Phapanin/0000-0003-1328-9344	National Institutes of Health (NIH) Cellular Biotechnology Training grant at the University of Michigan; NIH [R01 (HL115138)]; STFC [ST/J001465/1] Funding Source: UKRI; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL115138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008353] Funding Source: NIH RePORTER	National Institutes of Health (NIH) Cellular Biotechnology Training grant at the University of Michigan; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the National Institutes of Health (NIH) Cellular Biotechnology Training grant at the University of Michigan to D.J.S. and a NIH R01 (HL115138) grant to O.E.A. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali M, 2004, FASEB J, V18, P152, DOI 10.1096/fj.03-0346fje; Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833; Boutry S, 2006, CONTRAST MEDIA MOL I, V1, P15, DOI 10.1002/cmmi.87; Burns AR, 1997, J IMMUNOL, V159, P2893; Caracciolo G, 2013, ACS APPL MATER INTER, V5, P13171, DOI 10.1021/am404171h; Charoenphol P, 2012, J BIOMECH, V45, P2822, DOI 10.1016/j.jbiomech.2012.08.035; Charoenphol P, 2011, ATHEROSCLEROSIS, V217, P364, DOI 10.1016/j.atherosclerosis.2011.04.016; Charoenphol P, 2010, BIOMATERIALS, V31, P1392, DOI 10.1016/j.biomaterials.2009.11.007; Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043; Decuzzi P, 2005, ANN BIOMED ENG, V33, P179, DOI 10.1007/s10439-005-8976-5; Deng ZJ, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/45/455101; Eniola AO, 2005, BIOMATERIALS, V26, P7136, DOI 10.1016/j.biomaterials.2005.05.005; Eniola AO, 2005, BIOMATERIALS, V26, P661, DOI 10.1016/j.biomaterials.2004.03.003; Fillafer C, 2009, LAB CHIP, V9, P2782, DOI 10.1039/b906006e; Fleischer CC, 2013, BIOMATER SCI-UK, V1, P975, DOI 10.1039/c3bm60121h; Galimard A, 2012, SMALL, V8, P2036, DOI 10.1002/smll.201102356; Gref R, 2000, COLLOID SURFACE B, V18, P301, DOI 10.1016/S0927-7765(99)00156-3; Hajitou A, 2006, TRENDS CARDIOVAS MED, V16, P80, DOI 10.1016/j.tcm.2006.01.003; Heslinga MJ, 2009, J CONTROL RELEASE, V138, P235, DOI 10.1016/j.jconrel.2009.05.020; Huang RB, 2013, BIOTECHNOL BIOENG, V110, P999, DOI 10.1002/bit.24746; Huang RB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031874; Kittler S, 2010, J MATER CHEM, V20, P512, DOI 10.1039/b914875b; Kona S, 2012, INT J PHARMACEUT, V423, P516, DOI 10.1016/j.ijpharm.2011.11.043; Kuo SC, 1997, BIOPHYS J, V73, P517, DOI 10.1016/S0006-3495(97)78090-1; Lee SY, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/49/495101; Lee SY, 2009, J BIOMECH, V42, P1885, DOI 10.1016/j.jbiomech.2009.05.012; Lee TR, 2013, SCI REP-UK, V3, DOI 10.1038/srep02079; Lundqvist M, 2008, P NATL ACAD SCI USA, V105, P14265, DOI 10.1073/pnas.0805135105; Medina SH, 2013, ADV HEALTHC MATER, V2, P1337, DOI 10.1002/adhm.201200406; Mirshafiee V, 2013, CHEM COMMUN, V49, P2557, DOI 10.1039/c3cc37307j; Mortimer GM, 2014, ACS NANO, V8, P3357, DOI 10.1021/nn405830g; Muro S, 2006, J PHARMACOL EXP THER, V317, P1161, DOI 10.1124/jpet.105.098970; Namdee K, 2013, LANGMUIR, V29, P2530, DOI 10.1021/la304746p; Onyskiw PJ, 2013, LANGMUIR, V29, P11127, DOI 10.1021/la402182j; Pozzi D, 2014, NANOSCALE, V6, P2782, DOI 10.1039/c3nr05559k; Safi M, 2011, BIOMATERIALS, V32, P9353, DOI 10.1016/j.biomaterials.2011.08.048; Sah H, 2013, INT J NANOMED, V8, P747, DOI 10.2147/IJN.S40579; Salvati A, 2013, NAT NANOTECHNOL, V8, P137, DOI [10.1038/nnano.2012.237, 10.1038/NNANO.2012.237]; Schwendeman SP, 2014, J CONTROL RELEASE; Sempf K, 2013, EUR J PHARM BIOPHARM, V85, P53, DOI 10.1016/j.ejpb.2012.11.030; Tenzer S, 2011, ACS NANO, V5, P7155, DOI 10.1021/nn201950e; Thompson AJ, 2013, BIOMATERIALS, V34, P5863, DOI 10.1016/j.biomaterials.2013.04.011; Unger RE, 2002, MICROVASC RES, V64, P384, DOI 10.1006/mvre.2002.2434; Van Langendonckt A, 2008, MOL HUM REPROD, V14, P259, DOI 10.1093/molehr/gan019; Walkey CD, 2012, CHEM SOC REV, V41, P2780, DOI 10.1039/c1cs15233e; WATTS PJ, 1990, CRIT REV THER DRUG, V7, P235; Xu H, 2013, J CARDIOVASC TRANSL, V6, P570, DOI 10.1007/s12265-013-9460-5; Yan Y, 2013, ACS NANO, V7, P10960, DOI 10.1021/nn404481f; Yovita H, 2004, Acta Med Indones, V36, P197; Zhang Wandong, 2002, Current Drug Targets - Inflammation and Allergy, V1, P151, DOI 10.2174/1568010023344689	50	28	28	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2014	9	9							e107408	10.1371/journal.pone.0107408	http://dx.doi.org/10.1371/journal.pone.0107408			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AP5MS	25229244	Green Published, gold, Green Submitted			2023-01-03	WOS:000342123900039
J	Shi, Y; Wang, JY; Wang, HM; Hu, YH; Chen, XM; Yang, ZM				Shi, Yang; Wang, Jingyu; Wang, Huaimin; Hu, Yanhui; Chen, Xuemei; Yang, Zhimou			Glutathione-Triggered Formation of a Fmoc-Protected Short Peptide-Based Supramolecular Hydrogel	PLOS ONE			English	Article							MOLECULAR HYDROGELS; DELIVERY SYSTEM; SELF; NANOFIBERS; PH; NANOSTRUCTURES; INHIBITION; MATRICES; GELATION; RELEASE	A biocompatible method of glutathione (GSH) catalyzed disulfide bond reduction was used to form Fmoc-short peptide-based supramolecular hydrogels. The hydrogels could form in both buffer solution and cell culture medium containing 10% of Fetal Bovine Serum (FBS) within minutes. The hydrogel was characterized by rheology, transmission electron microscopy, and fluorescence emission spectra. Their potential in three dimensional (3D) cell culture was evaluated and the results indicated that the gel with a low concentration of the peptide (0.1 wt%) was suitable for 3D cell culture of 3T3 cells. This study provides an alternative candidate of supramolecular hydrogel for 3D cell culture and cell delivery.	[Shi, Yang; Wang, Jingyu; Wang, Huaimin; Yang, Zhimou] Nankai Univ, Coll Life Sci, Key Lab Bioact Mat, State Key Lab Med Chem Biol,Minist Educ, Tianjin 300071, Peoples R China; [Shi, Yang; Wang, Jingyu; Wang, Huaimin; Yang, Zhimou] Nankai Univ, Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300071, Peoples R China; [Hu, Yanhui; Chen, Xuemei] Hubei Inst Technol, Sch Chem & Mat Engn, Huangshi, Hubei, Peoples R China	Nankai University; Nankai University	Yang, ZM (corresponding author), Nankai Univ, Coll Life Sci, Key Lab Bioact Mat, State Key Lab Med Chem Biol,Minist Educ, Tianjin 300071, Peoples R China.	yangzm@nankai.edu.cn	wang, huaimin/G-8722-2011; Yang, Zhimou/F-1798-2010; Wang, Huaimin/O-3260-2019	wang, huaimin/0000-0002-8796-0367; Yang, Zhimou/0000-0003-2967-6920; Wang, Huaimin/0000-0002-8796-0367	National Natural Science Foundation of China [51373079, 51173060]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	National Natural Science Foundation of China (51373079 and 51173060). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Behanna HA, 2005, J AM CHEM SOC, V127, P1193, DOI 10.1021/ja044863u; Beniash E, 2005, ACTA BIOMATER, V1, P387, DOI 10.1016/j.actbio.2005.04.002; Boekhoven J, 2013, NAT CHEM, V5, P433, DOI 10.1038/nchem.1617; Bowerman CJ, 2010, J AM CHEM SOC, V132, P9526, DOI 10.1021/ja1025535; Bremmer SC, 2012, CHEM COMMUN, V48, P5482, DOI 10.1039/c2cc31537h; Cai YB, 2014, ANAL CHEM, V86, P2193, DOI 10.1021/ac4038653; Cao H, 2013, ANGEW CHEM INT EDIT, V52, P4122, DOI 10.1002/anie.201300444; Channon KJ, 2008, J AM CHEM SOC, V130, P5487, DOI 10.1021/ja710310c; Collier JH, 2004, ADV MATER, V16, P907, DOI 10.1002/adma.200306379; Collier JH, 2003, BIOCONJUGATE CHEM, V14, P748, DOI 10.1021/bc034017t; Collier JH, 2010, CHEM SOC REV, V39, P3413, DOI 10.1039/b914337h; Debnath S, 2013, J AM CHEM SOC, V135, P16789, DOI 10.1021/ja4086353; Du X, 2013, RSC ADV, V3, P18259, DOI 10.1039/c3ra43457e; Duan PF, 2011, CHEM-EUR J, V17, P6389, DOI 10.1002/chem.201003049; Fu YT, 2013, LANGMUIR, V29, P6013, DOI 10.1021/la400910g; Gao Y, 2010, CHEM SOC REV, V39, P3425, DOI 10.1039/b919450a; Gelain F, 2010, J CONTROL RELEASE, V145, P231, DOI 10.1016/j.jconrel.2010.04.026; He MT, 2013, J AM CHEM SOC, V135, P18718, DOI 10.1021/ja409000b; Hirst AR, 2008, ANGEW CHEM INT EDIT, V47, P8002, DOI 10.1002/anie.200800022; Ikeda M, 2011, J AM CHEM SOC, V133, P1670, DOI 10.1021/ja109692z; Jayawarna V, 2006, ADV MATER, V18, P611, DOI 10.1002/adma.200501522; Jung JP, 2009, BIOMATERIALS, V30, P2400, DOI 10.1016/j.biomaterials.2009.01.033; Kuang Y, 2013, ANGEW CHEM INT EDIT, V52, P6944, DOI 10.1002/anie.201302658; Kuang Y, 2011, CHEM COMMUN, V47, P12625, DOI 10.1039/c1cc15577f; Kumar DK, 2014, CHEM SOC REV, V43, P2080, DOI 10.1039/c3cs60224a; Li XM, 2010, J AM CHEM SOC, V132, P17707, DOI 10.1021/ja109269v; Lin R, 2013, CHEM COMMUN, V49, P4968, DOI 10.1039/c3cc41896k; Lv LN, 2013, COLLOID SURFACE B, V108, P352, DOI 10.1016/j.colsurfb.2013.03.013; Mahler A, 2006, ADV MATER, V18, P1365, DOI 10.1002/adma.200501765; Marini DM, 2002, NANO LETT, V2, P295, DOI 10.1021/nl015697g; Miao XM, 2013, ANGEW CHEM INT EDIT, V52, P7781, DOI 10.1002/anie.201303199; Minkenberg CB, 2012, CHEM COMMUN, V48, P9837, DOI 10.1039/c2cc34863b; Piepenbrock MOM, 2010, CHEM REV, V110, P1960, DOI 10.1021/cr9003067; Qiu ZJ, 2009, CHEM COMMUN, P3342, DOI 10.1039/b822840j; Ren CH, 2011, CHEM COMMUN, V47, P1619, DOI 10.1039/c0cc04135a; Rudra JS, 2012, ACS NANO, V6, P1557, DOI 10.1021/nn204530r; Shah RN, 2010, P NATL ACAD SCI USA, V107, P3293, DOI 10.1073/pnas.0906501107; Smith AM, 2008, ADV MATER, V20, P37, DOI 10.1002/adma.200701221; Steed JW, 2010, CHEM SOC REV, V39, P3686, DOI 10.1039/b926219a; Sun ZF, 2013, J AM CHEM SOC, V135, P13379, DOI 10.1021/ja403345p; Toledano S, 2006, J AM CHEM SOC, V128, P1070, DOI 10.1021/ja056549l; Wang HM, 2012, MATER TODAY, V15, P500, DOI 10.1016/S1369-7021(12)70219-5; Wang HM, 2012, NANOSCALE, V4, P5259, DOI 10.1039/c2nr31149f; Wang HM, 2012, SOFT MATTER, V8, P2344, DOI 10.1039/c2sm06923g; Wang TY, 2010, LANGMUIR, V26, P18694, DOI 10.1021/la103435t; Wang ZH, 2011, CHEM COMMUN, V47, P8901, DOI 10.1039/c1cc11564b; Xu XD, 2012, MACROMOL RAPID COMM, V33, P426, DOI 10.1002/marc.201100689; Xu XD, 2010, ACS APPL MATER INTER, V2, P2663, DOI 10.1021/am100484c; Yang YG, 2007, J AM CHEM SOC, V129, P581, DOI 10.1021/ja064240b; Yang Z, 2008, ACCOUNTS CHEM RES, V41, P315, DOI 10.1021/ar7001914; Yokoi H, 2005, P NATL ACAD SCI USA, V102, P8414, DOI 10.1073/pnas.0407843102; Zhang X, 2012, ANGEW CHEM, V124, P4464, DOI DOI 10.1002/ANGE.201108612; Zhang Y, 2013, J AM CHEM SOC, V135, P5008, DOI 10.1021/ja402490j; Zhao Y, 2008, BIOMACROMOLECULES, V9, P1511, DOI 10.1021/bm701143g; Zheng C, 2012, J AM CHEM SOC, V134, P5026, DOI 10.1021/ja210846d	55	17	17	0	104	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2014	9	9							e106968	10.1371/journal.pone.0106968	http://dx.doi.org/10.1371/journal.pone.0106968			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AP0SR	25222132	Green Published, gold, Green Submitted			2023-01-03	WOS:000341774800034
J	Gerdin, M; Roy, N; Khajanchi, M; Kumar, V; Dharap, S; Fellander-Tsai, L; Petzold, M; Bhoi, S; Saha, ML; von Schreeb, J				Gerdin, Martin; Roy, Nobhojit; Khajanchi, Monty; Kumar, Vineet; Dharap, Satish; Fellander-Tsai, Li; Petzold, Max; Bhoi, Sanjeev; Saha, Makhan Lal; von Schreeb, Johan			Predicting Early Mortality in Adult Trauma Patients Admitted to Three Public University Hospitals in Urban India: A Prospective Multicentre Cohort Study	PLOS ONE			English	Article							PROGNOSTIC MODELS; SCORING SYSTEM; GLOBAL BURDEN; FIELD TRIAGE; MISSING DATA; CARE; PERFORMANCE; INJURIES; SERVICES; EVENTS	Background: In India alone, more than one million people die yearly due to trauma. Identification of patients at risk of early mortality is crucial to guide clinical management and explain prognosis. Prediction models can support clinical judgement, but existing models have methodological limitations. The aim of this study was to derive a vital sign based prediction model for early mortality among adult trauma patients admitted to three public university hospitals in urban India. Methods: We conducted a prospective cohort study of adult trauma patients admitted to three urban university hospitals in India between October 2013 and January 2014. The outcome measure was mortality within 24 hours. We used logistic regression with restricted cubic splines to derive our model. We assessed model performance in terms of discrimination, calibration, and optimism. Results: A total of 1629 patients were included. Median age was 35, 80% were males. Mortality between admission and 24 hours was 6%. Our final model included systolic blood pressure, heart rate, and Glasgow coma scale. Our model displayed good discrimination, with an area under the receiver operating characteristics curve (AUROCC) of 0.85. Predicted mortality corresponded well with observed mortality, indicating good calibration. Conclusion: This study showed that routinely recorded systolic blood pressure, heart rate, and Glasgow coma scale predicted early hospital mortality in trauma patients admitted to three public university hospitals in urban India. Our model needs to be externally validated before it can be applied in the clinical setting.	[Gerdin, Martin; Roy, Nobhojit; von Schreeb, Johan] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden; [Roy, Nobhojit] Bhabha Atom Res Ctr Hosp, Dept Surg, Mumbai, Maharashtra, India; [Roy, Nobhojit] Sch Habitat, Tata Inst Social Sci, Mumbai, Maharashtra, India; [Khajanchi, Monty] King Edward Mem Hosp, Dept Surg, Mumbai, Maharashtra, India; [Kumar, Vineet; Dharap, Satish] Lokmanya Tilak Municipal Med Coll & Gen Hosp, Dept Surg, Mumbai, Maharashtra, India; [Fellander-Tsai, Li] Karolinska Inst, Dept Clin Sci Intervent & Technol, Div Orthoped & Biotechnol, Stockholm, Sweden; [Petzold, Max] Univ Gothenburg, Sahlgrenska Acad, Ctr Appl Biostat Occupat & Environm Med, Gothenburg, Sweden; [Bhoi, Sanjeev] All India Inst Med Sci, Jai Prakash Narayan Apex Trauma Ctr, Dept Emergency Med, New Delhi, India; [Saha, Makhan Lal] Inst Post Grad Med Educ & Res, Dept Surg, Kolkata, India; [Saha, Makhan Lal] Seth Sukhlal Karnani Mem Hosp, Kolkata, India	Karolinska Institutet; Bhabha Atomic Research Center (BARC); Tata Institute of Social Sciences; Karolinska Institutet; University of Gothenburg; All India Institute of Medical Sciences (AIIMS) New Delhi; Jai Prakash Narayan Apex Trauma Center; Institute of Post Graduate Medical Education & Research (IPGMER), Kolkata; Institute of Post Graduate Medical Education & Research (IPGMER), Kolkata	Gerdin, M (corresponding author), Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden.	martin.gerdin@ki.se	Wärnberg, Martin Gerdin/D-7482-2019; Dharap, Satish/AAE-8565-2020	Wärnberg, Martin Gerdin/0000-0001-6069-4794; Dharap, Satish/0000-0002-9304-9617; Roy, Nobhojit/0000-0003-2022-7416; Fellander-Tsai, Li/0000-0003-0693-6080	Laerdal Foundation for Acute Medicine; Swedish National Board of Health and Welfare	Laerdal Foundation for Acute Medicine; Swedish National Board of Health and Welfare	This study was funded by grants from the Laerdal Foundation for Acute Medicine and the Swedish National Board of Health and Welfare. The funding bodies were not involved in the design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.	Austin S, 2014, INTENS CARE MED, V40, P342, DOI 10.1007/s00134-013-3174-7; Bodner TE, 2008, STRUCT EQU MODELING, V15, P651, DOI 10.1080/10705510802339072; Brockamp T, 2013, CRIT CARE, V17, DOI 10.1186/cc12813; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Chandran A, 2010, EPIDEMIOL REV, V32, P110, DOI 10.1093/epirev/mxq009; Clark TG, 2003, J CLIN EPIDEMIOL, V56, P28, DOI 10.1016/S0895-4356(02)00539-5; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; Gerdin M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090064; Global Burden of Disease Study 2010, 2013, IND GLOB BURD DIS ST; GORMICAN SP, 1982, ANN EMERG MED, V11, P132, DOI 10.1016/S0196-0644(82)80237-0; Gururaj G, 2005, NATL COMMISSION MACR, P325; Harrell Frank E., 2001, REGRESSION MODELING; Hsiao M, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002621; Husum H, 2003, J TRAUMA, V55, P466, DOI 10.1097/01.TA.0000044634.98189.DE; Joshipura MK, 2008, WORLD J SURG, V32, P1613, DOI 10.1007/s00268-008-9634-5; Ker K, 2012, BMC EMERG MED, V12, DOI 10.1186/1471-227X-12-3; Khajanchi MU, 2013, WORLD J SURG, V37, P705, DOI 10.1007/s00268-012-1785-8; Khan S, 2014, WORLD J SURG, V38, P281, DOI 10.1007/s00268-013-2308-y; Kimura A, 2012, WORLD J SURG, V36, P813, DOI 10.1007/s00268-012-1498-z; KOEHLER JJ, 1986, ANN EMERG MED, V15, P178, DOI 10.1016/S0196-0644(86)80016-6; Kondo Y, 2011, CRIT CARE, V15, DOI 10.1186/cc10348; Kumar S, 2009, INDIAN J SURG, V71, P133, DOI 10.1007/s12262-009-0037-0; Labarere J, 2014, INTENS CARE MED, V40, P513, DOI 10.1007/s00134-014-3227-6; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Marshall A, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-57; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel P, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5166; Pfeifer R, 2009, INJURY, V40, P907, DOI 10.1016/j.injury.2009.05.006; Rehn M, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-17; Roy N, 2010, PREHOSP DISASTER MED, V25, P145, DOI 10.1017/S1049023X00007883; StataCorp LP, 2013, MKSPLIN LIN RESTR CU; Steyerberg EW, 2001, STAT NEERL, V55, P76, DOI 10.1111/1467-9574.00157; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Subhan I, 2010, INT J EMERG MED, V3, P207, DOI 10.1007/s12245-010-0223-7; Trickey AW, 2013, J TRAUMA ACUTE CARE, V75, pS68, DOI 10.1097/TA.0b013e3182914530; Vergouwe Y, 2010, J CLIN EPIDEMIOL, V63, P205, DOI 10.1016/j.jclinepi.2009.03.017; Vittinghoff E, 2007, AM J EPIDEMIOL, V165, P710, DOI 10.1093/aje/kwk052; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Wood AM, 2008, STAT MED, V27, P3227, DOI 10.1002/sim.3177	41	19	19	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2014	9	9							e105606	10.1371/journal.pone.0105606	http://dx.doi.org/10.1371/journal.pone.0105606			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO3LR	25180494	gold, Green Published, Green Submitted			2023-01-03	WOS:000341231500028
J	Yu, JB; Shi, J; Gong, LR; Dong, SA; Xu, Y; Zhang, Y; Cao, XS; Wu, LL				Yu, Jian-bo; Shi, Jia; Gong, Li-rong; Dong, Shu-an; Xu, Yan; Zhang, Yuan; Cao, Xin-shun; Wu, Li-li			Role of Nrf2/ARE Pathway in Protective Effect of Electroacupuncture against Endotoxic Shock-Induced Acute Lung Injury in Rabbits	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; OXIDATIVE STRESS; ISCHEMIA-REPERFUSION; HEME OXYGENASE-1; MONOXIDE SYSTEM; LIPOIC ACID; OLEIC-ACID; RATS; EXPRESSION; ACTIVATION	NF-E2 related factor 2 (Nrf2) is a major transcription factor and acts as a key regulator of antioxidant genes to exogenous stimulations. The aim of current study was to determine whether Nrf2/ARE pathway is involved in the protective effect of electroacupuncture on the injured lung in a rabbit model of endotoxic shock. A dose of lipopolysaccharide (LPS) 5 mg/kg was administered intravenously to replicate the model of acute lung injury induced by endotoxic shock. Electroacupuncture pretreatment was handled bilaterally at Zusanli and Feishu acupoints for five consecutive days while sham electroacupuncture punctured at non-acupoints. Fourty anesthetized New England male rabbits were randomized into normal control group (group C), LPS group (group L), electroacupuncture + LPS group (group EL) and sham electroacupuncture + LPS (group SEL). At 6 h after LPS administration, the animals were sacrificed and the blood samples were collected for biochemical measurements. The lungs were removed for calculation of wet-to-dry weight ratios (W/D), histopathologic examination, determination of heme oxygenase (HO)-1 protein and mRNA, Nrf2 total and nucleoprotein, as well as Nrf2 mRNA expression, and evaluation of the intracellular distribution of Nrf2 nucleoprotein. LPS caused extensive morphologic lung damage, which was lessened by electroacupuncture treatment. Besides, lung W/D ratios were significantly decreased, the level of malondialdehyde was inhibited, plasma levels of TNF-alpha and interleukin-6 were decreased, while the activities of superoxide dismutase, glutathione peroxidase and catalase were enhanced in the electroacupucnture treated animals. In addition, electroacupuncture stimulation distinctly increased the expressions of HO-1 and Nrf2 protein including Nrf2 total protein and nucleoprotein as well as mRNA in lung tissue, while these effects were blunted in the sham electroacupuncture group. We concluded that electroacupuncture treatment at ST36 and BL13 effectively attenuates lung injury in a rabbit model of endotoxic shock through activation of Nrf2/ARE pathway and following up-regulation of HO-1 expression.	[Yu, Jian-bo; Shi, Jia; Gong, Li-rong; Dong, Shu-an; Xu, Yan; Zhang, Yuan; Cao, Xin-shun; Wu, Li-li] Tianjin Med Univ, Tianjin Nankai Hosp, Dept Anesthesiol, Tianjin, Peoples R China	Tianjin Medical University	Yu, JB (corresponding author), Tianjin Med Univ, Tianjin Nankai Hosp, Dept Anesthesiol, Tianjin, Peoples R China.	yujianbo11@126.com			National Natural Science Foundation of China, Beijing, China [81372096]; Key Project of Tianjin Science and Technology Support, Tianjin, China [12ZCZDSY03300]	National Natural Science Foundation of China, Beijing, China(National Natural Science Foundation of China (NSFC)); Key Project of Tianjin Science and Technology Support, Tianjin, China	This research was supported by grants No. 81372096 from the National Natural Science Foundation of China, Beijing, China, and grant 12ZCZDSY03300 from the Key Project of Tianjin Science and Technology Support, Tianjin, China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619; Bauer M, 2008, INTENS CARE MED, V34, P640, DOI 10.1007/s00134-008-1010-2; Chen HI, 2008, CRIT CARE MED, V36, P1214, DOI 10.1097/CCM.0b013e31816a0607; Chen HH, 2012, FREE RADICAL BIO MED, V52, P1054, DOI 10.1016/j.freeradbiomed.2011.12.012; Chen XJ, 2013, RESP PHYSIOL NEUROBI, V188, P214, DOI 10.1016/j.resp.2013.04.014; Chernyak GV, 2005, ANESTHESIOLOGY, V102, P1031, DOI 10.1097/00000542-200505000-00024; Di Filippo A, 2006, ANN CLIN LAB SCI, V36, P345; Fer ND, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-91; Ferreira Arthurde de Sa, 2009, Zhong Xi Yi Jie He Xue Bao, V7, P969, DOI 10.3736/jcim20091011; Francis RC, 2011, ANESTHESIOLOGY, V115, P1012, DOI 10.1097/ALN.0b013e31823306cf; GHOSH S, 1993, CRIT CARE MED, V21, pS19, DOI 10.1097/00003246-199302001-00005; Goraca A, 2007, J PHYSIOL PHARMACOL, V58, P541; Goraca A, 2009, J PHYSIOL PHARMACOL, V60, P61; Jian-Bo Y, 2008, CHINESE MED J-PEKING, V121, P49, DOI 10.1097/00029330-200801010-00010; Jung KA, 2010, MOLECULES, V15, P7266, DOI 10.3390/molecules15107266; Kilic U, 2013, NUTR METAB, V10, DOI 10.1186/1743-7075-10-7; Kim JH, 2012, FREE RADICAL BIO MED, V53, P629, DOI 10.1016/j.freeradbiomed.2012.04.019; LOEWENBERG J. R., 1967, ANAL BIOCHEM, V19, P95, DOI 10.1016/0003-2697(67)90138-8; Mikawa K, 2003, ANESTH ANALG, V97, P1751, DOI 10.1213/01.ANE.0000086896.90343.13; MIKAWA K, 1994, ANESTHESIOLOGY, V81, P689, DOI 10.1097/00000542-199409000-00023; Mikawa K, 1998, CRIT CARE MED, V26, P905, DOI 10.1097/00003246-199805000-00026; MISRA HP, 1971, J BIOL CHEM, V246, P6886; NISHINA K, 1995, ANESTHESIOLOGY, V83, P169, DOI 10.1097/00000542-199507000-00020; Nishina K, 1997, ANESTH ANALG, V84, P1097, DOI 10.1097/00000539-199705000-00026; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Pan P, 2010, EXP BIOL MED, V235, P642, DOI 10.1258/ebm.2010.009353; Sarkar S, 2013, CELL MOL BIOENG, V6, P130, DOI 10.1007/s12195-013-0272-0; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Song JG, 2012, ANESTHESIOLOGY, V116, P406, DOI 10.1097/ALN.0b013e3182426ebd; Takaki S, 2010, INTENS CARE MED, V36, P42, DOI 10.1007/s00134-009-1575-4; Takao Y, 2005, ANESTH ANALG, V100, P810, DOI 10.1213/01.ANE.0000144775.19385.8C; Tsai PS, 2006, ANESTHESIOLOGY, V105, P1201, DOI 10.1097/00000542-200612000-00020; Voigtsberger S, 2009, ANESTHESIOLOGY, V111, P1238, DOI 10.1097/ALN.0b013e3181bdf857; Wang C, 2011, CHINESE MED J-PEKING, V124, P3476, DOI 10.3760/cma.j.issn.0366-6999.2011.21.007; Wang K, 2009, ANESTH ANALG, V109, P1666, DOI 10.1213/ANE.0b013e3181b5a234; Xia JG, 2014, ANESTHESIOLOGY, V120, P1441, DOI 10.1097/ALN.0000000000000259; Yu JB, 2009, IRISH J MED SCI, V178, P491, DOI 10.1007/s11845-008-0260-x; Yu JB, 2009, TRANSL RES, V153, P283, DOI 10.1016/j.trsl.2009.01.002; Yu JB, 2013, EXP BIOL MED, V238, P705, DOI 10.1177/1535370213489487; Yu JB, 2013, ANESTH ANALG, V116, P239, DOI 10.1213/ANE.0b013e31826f0a4a; Yu M, 2013, REGUL TOXICOL PHARM, V66, P279, DOI 10.1016/j.yrtph.2013.04.005; Zhang HX, 2009, CAN J CARDIOL, V25, P359, DOI 10.1016/S0828-282X(09)70095-9; Zhang ZD, 2012, ANESTH ANALG, V114, P879, DOI 10.1213/ANE.0b013e318246536d; Zhao HD, 2010, WORLD J GASTROENTERO, V16, P3002, DOI 10.3748/wjg.v16.i24.3002	44	43	54	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2014	9	8							e104924	10.1371/journal.pone.0104924	http://dx.doi.org/10.1371/journal.pone.0104924			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO3LJ	25115759	gold, Green Submitted, Green Published			2023-01-03	WOS:000341230400107
J	Torres-Fuentes, C; Theeuwes, WF; McMullen, MK; McMullen, AK; Dinan, TG; Cryan, JF; Schellekens, H				Torres-Fuentes, Cristina; Theeuwes, Wessel F.; McMullen, Michael K.; McMullen, Anna K.; Dinan, Timothy G.; Cryan, John F.; Schellekens, Harriet			Devil's Claw to Suppress Appetite-Ghrelin Receptor Modulation Potential of a Harpagophytum procumbens Root Extract	PLOS ONE			English	Article							DIETARY FIBER; HORMONE; DESENSITIZATION; HARPAGOSIDE; ARRESTINS; PEPTIDES; PROTEINS; STOMACH; AGONIST; OBESITY	Ghrelin is a stomach-derived peptide that has been identified as the only circulating hunger hormone that exerts a potent orexigenic effect via activation of its receptor, the growth hormone secretagogue receptor (GHS-R1a). Hence, the ghrelinergic system represents a promising target to treat obesity and obesity-related diseases. In this study we analysed the GHS-R1a receptor activating potential of Harpagophytum procumbens, popularly known as Devil's Claw, and its effect on food intake in vivo. H. procumbens is an important traditional medicinal plant from Southern Africa with potent anti-inflammatory and analgesic effects. This plant has been also used as an appetite modulator but most evidences are anecdotal and to our knowledge, no clear scientific studies relating to appetite modulation have been done to this date. The ghrelin receptor activation potential of an extract derived from the dried tuberous roots of H. procumbens was analysed by calcium mobilization and receptor internalization assays in human embryonic kidney cells (Hek) stably expressing the GHS-R1a receptor. Food intake was investigated in male C57BL/6 mice following intraperitoneal administration of H. procumbens root extract in ad libitum and food restricted conditions. Exposure to H. procumbens extract demonstrated a significant increased cellular calcium influx but did not induce subsequent GHS-R1a receptor internalization, which is a characteristic for full receptor activation. A significant anorexigenic effect was observed in male C57BL/6 mice following peripheral administration of H. procumbens extract. We conclude that H. procumbens root extract is a potential novel source for potent anti-obesity bioactives. These results reinforce the promising potential of natural bioactives to be developed into functional foods with weight-loss and weight maintenance benefits.	[Torres-Fuentes, Cristina; Dinan, Timothy G.; Cryan, John F.; Schellekens, Harriet] Natl Univ Ireland Univ Coll Cork, Alimentary Pharmabiot Ctr, Cork, Ireland; [Theeuwes, Wessel F.; Cryan, John F.; Schellekens, Harriet] Natl Univ Ireland Univ Coll Cork, Dept Anat & Neurosci, Cork, Ireland; [McMullen, Michael K.; McMullen, Anna K.] Life Force Res, Ljungskile, Sweden; [McMullen, Michael K.] Univ Westminster, Sch Biosci, London W1R 8AL, England; [Dinan, Timothy G.] Natl Univ Ireland Univ Coll Cork, Dept Psychiat, Cork, Ireland	University College Cork; University College Cork; University of Westminster; University College Cork	Schellekens, H (corresponding author), Natl Univ Ireland Univ Coll Cork, Alimentary Pharmabiot Ctr, Cork, Ireland.	h.schellekens@ucc.ie	Torres-Fuentes, Cristina/J-5551-2019; Cryan, John F./A-6950-2013; Dinan, Timothy/ABA-8284-2020	Torres-Fuentes, Cristina/0000-0002-2917-6910; Cryan, John F./0000-0001-5887-2723; Dinan, Timothy/0000-0002-2316-7220; Schellekens, Harriet/0000-0002-6065-3797	Enterprise Ireland [CC20080001]; Science Foundation Ireland (SFI) in the form of a centre grant (Alimentary Pharmabiotic Centre); SFI [02/CE/B124, 07/CE/B1368]	Enterprise Ireland; Science Foundation Ireland (SFI) in the form of a centre grant (Alimentary Pharmabiotic Centre)(Science Foundation Ireland); SFI(Science Foundation Ireland)	This work was supported by Enterprise Ireland under Grant Number CC20080001. JFC and TGD are also supported in part by Science Foundation Ireland (SFI) in the form of a centre grant (Alimentary Pharmabiotic Centre) through the Irish Government's National Development Plan. The authors and their work were supported by SFI (grant nos. 02/CE/B124 and 07/CE/B1368). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2009, OILS DET OIL CONT RE; Asakawa A, 2001, GASTROENTEROLOGY, V120, P337, DOI 10.1053/gast.2001.22158; Beck B, 2004, LIFE SCI, V76, P473, DOI 10.1016/j.lfs.2004.09.001; Brendler Thomas, 2006, Journal of Herbal Pharmacotherapy, V6, P89, DOI 10.1300/J157v06n01_09; Camina JP, 2004, ENDOCRINOLOGY, V145, P930, DOI 10.1210/en.2003-0974; Costantino L, 2012, EXPERT OPIN THER PAT, V22, P697, DOI 10.1517/13543776.2012.684946; Depoortere I, 2009, REGUL PEPTIDES, V156, P13, DOI 10.1016/j.regpep.2009.04.002; Derosa G, 2012, EXPERT OPIN DRUG SAF, V11, P459, DOI 10.1517/14740338.2012.675326; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Els S, 2010, METHOD ENZYMOL, V485, P103, DOI [10.1016/S0076-6879(10)85006-2, 10.1016/B978-0-12-381296-4.00006-3]; Ferguson SSG, 2007, TRENDS PHARMACOL SCI, V28, P173, DOI 10.1016/j.tips.2007.02.008; Finger BC, 2011, PSYCHOPHARMACOLOGY, V216, P421, DOI 10.1007/s00213-011-2234-3; Georgiev MI, 2013, PHYTOCHEMISTRY, V92, P8, DOI 10.1016/j.phytochem.2013.04.009; Grant L, 2007, PHYTOTHER RES, V21, P199, DOI 10.1002/ptr.2029; Gunther M, 2006, PHYTOCHEM ANALYSIS, V17, P1, DOI 10.1002/pca.822; Helrich K., 1990, ASS OFFICIAL ANAL CH; Hidalgo FJ, 2001, ANAL CHEM, V73, P698, DOI 10.1021/ac000876o; Holst B, 2003, MOL ENDOCRINOL, V17, P2201, DOI 10.1210/me.2003-0069; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; Howarth NC, 2001, NUTR REV, V59, P129, DOI 10.1111/j.1753-4887.2001.tb07001.x; Kang JG, 2012, DIABETES METAB J, V36, P13, DOI 10.4093/dmj.2012.36.1.13; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; LEE SC, 1992, J AOAC INT, V75, P395; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Liu G, 2007, J PHARMACOL EXP THER, V322, P1036, DOI 10.1124/jpet.107.123141; Mear Y, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00087; Mncwangi N, 2012, J ETHNOPHARMACOL, V143, P755, DOI 10.1016/j.jep.2012.08.013; Moore CAC, 2007, ANNU REV PHYSIOL, V69, P451, DOI 10.1146/annurev.physiol.69.022405.154712; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x; Patterson M, 2011, PEPTIDES, V32, P2290, DOI 10.1016/j.peptides.2011.07.021; Petersen PS, 2009, ENDOCRINOLOGY, V150, P4920, DOI 10.1210/en.2008-1638; Qi J, 2006, PHYTOCHEMISTRY, V67, P1372, DOI 10.1016/j.phytochem.2006.05.029; Reiter E, 2012, ANNU REV PHARMACOL, V52, P179, DOI 10.1146/annurev.pharmtox.010909.105800; Ritter SL, 2009, NAT REV MOL CELL BIO, V10, P819, DOI 10.1038/nrm2803; Rolland Y, 2011, CURR OPIN CLIN NUTR, V14, P15, DOI 10.1097/MCO.0b013e328340c2c2; Schellekens H, 2012, J PHARM PHARM; Schellekens H, 2013, J PHARM PHARMACOL, V65, P528, DOI 10.1111/jphp.12010; Schellekens H, 2013, J BIOL CHEM, V288, P181, DOI 10.1074/jbc.M112.382473; Schellekens H, 2012, PHARMACOL THERAPEUT, V135, P316, DOI 10.1016/j.pharmthera.2012.06.004; Schellekens H, 2010, NEUROPHARMACOLOGY, V58, P2, DOI 10.1016/j.neuropharm.2009.06.024; Singleton VL, 1999, METHOD ENZYMOL, V299, P152; Soares JB, 2008, PEPTIDES, V29, P1255, DOI 10.1016/j.peptides.2008.02.018; Stewart KM, 2005, J ETHNOPHARMACOL, V100, P225, DOI 10.1016/j.jep.2005.07.004; Torres-Fuentes C, 2014, NUTR NEUROSCI; Torres-Fuentes C, 2011, FOOD CHEM, V129, P485, DOI 10.1016/j.foodchem.2011.04.103; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Vermaak I, 2011, NAT PROD REP, V28, P1493, DOI 10.1039/c1np00035g; World Health Organization, 2013, OB OV, P311; Yi CX, 2011, MOL CELL ENDOCRINOL, V340, P29, DOI 10.1016/j.mce.2011.03.001; Yun JW, 2010, PHYTOCHEMISTRY, V71, P1625, DOI 10.1016/j.phytochem.2010.07.011	51	14	14	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2014	9	7							e103118	10.1371/journal.pone.0103118	http://dx.doi.org/10.1371/journal.pone.0103118			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6RZ	25068823	Green Published, Green Submitted, gold			2023-01-03	WOS:000339993700036
J	Zhang, Y; Peng, L; Kan, HD; Xu, JM; Chen, RJ; Liu, Y; Wang, WB				Zhang, Yue; Peng, Li; Kan, Haidong; Xu, Jianming; Chen, Renjie; Liu, Yuan; Wang, Weibing			Effects of Meteorological Factors on Daily Hospital Admissions for Asthma in Adults: A Time-Series Analysis	PLOS ONE			English	Article							DIURNAL TEMPERATURE-RANGE; CLIMATE-CHANGE; AIR-POLLUTION; CHILDHOOD ASTHMA; COLD TEMPERATURE; HEAT WAVES; MORTALITY; PREVALENCE; SYMPTOMS; DISEASE	Background: There is limited evidence for the impacts of meteorological changes on asthma hospital admissions in adults in Shanghai, China. Objectives: To quantitatively evaluate the short-term effects of daily mean temperature on asthma hospital admissions. Methods: Daily hospital admissions for asthma and daily mean temperatures between January 2005 and December 2012 were analyzed. After controlling for secular and seasonal trends, weather, air pollution and other confounding factors, a Poisson generalized additive model (GAM) combined with a distributed lag non-linear model were used to explore the associations between temperature and hospital admissions for asthma. Results: During the study periods, there were 15,678 hospital admissions for asthma by residents of Shanghai, an average 5.6 per day. Pearson correlation analysis found a significant negative correlation (r = -0.174, P<0.001) between asthma hospitalizations and daily mean temperature (DMT). The DMT effect on asthma increased below the median DMT, with lower temperatures associated with a higher risk of hospital admission for asthma. Generally, the cold effect appeared to be relatively acute, with duration lasting several weeks, while the hot effect was short-term. The relative risk of asthma hospital admissions associated with cold temperature (the 25th percentile of temperature relative to the median temperature) was 1.20 (95% confidence interval [CI], 1.01 similar to 1.41) at lag0-14. However, warmer temperatures were not associated with asthma hospital admissions. Conclusions: Cold temperatures may trigger asthmatic attacks. Effective strategies are needed to protect populations at risk from the effects of cold.	[Zhang, Yue; Kan, Haidong; Chen, Renjie; Liu, Yuan; Wang, Weibing] Fudan Univ, Minist Educ, Sch Publ Hlth, Dept Epidemiol, Shanghai 200433, Peoples R China; [Zhang, Yue; Kan, Haidong; Chen, Renjie; Liu, Yuan; Wang, Weibing] Fudan Univ, Minist Educ, Key Lab Publ Hlth Safety, Shanghai 200433, Peoples R China; [Kan, Haidong; Wang, Weibing] Fudan Univ, Fudan Tyndall Ctr, Shanghai 200433, Peoples R China; [Peng, Li; Xu, Jianming] Shanghai Ctr Urban Environm Meteorol, Shanghai, Peoples R China; [Peng, Li; Xu, Jianming] Shanghai Key Lab Meteorol & Hlth, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University	Wang, WB (corresponding author), Fudan Univ, Minist Educ, Sch Publ Hlth, Dept Epidemiol, Shanghai 200433, Peoples R China.	wwb@fudan.edu.cn	Kan, Haidong/AGU-0328-2022		Global Environment Change Research in Fudan University [EZH1829007/003]; Chinese Meteorological Administration [GYHY201206027]; Chinese National Science Foundation [30800937]; program of Key Discipline Construction of Public Health of Shanghai [12GWZX0101]	Global Environment Change Research in Fudan University; Chinese Meteorological Administration; Chinese National Science Foundation(National Natural Science Foundation of China (NSFC)); program of Key Discipline Construction of Public Health of Shanghai	This study was funded by the Global Environment Change Research in Fudan University (Grant No. EZH1829007/003), the Chinese Meteorological Administration (Grant No. GYHY201206027), Chinese National Science Foundation (30800937) and the program of Key Discipline Construction of Public Health of Shanghai (Grant No. 12GWZX0101). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe T, 2009, AM J EMERG MED, V27, P153, DOI 10.1016/j.ajem.2008.01.013; Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x; Amoah A S, 2012, Ghana Med J, V46, P23; Anderson BG, 2009, EPIDEMIOLOGY, V20, P205, DOI 10.1097/EDE.0b013e318190ee08; Anderson GB, 2011, ENVIRON HEALTH PERSP, V119, P210, DOI 10.1289/ehp.1002313; Basu R, 2002, EPIDEMIOL REV, V24, P190, DOI 10.1093/epirev/mxf007; Beggs PJ, 2010, INT J ENV RES PUB HE, V7, P3006, DOI 10.3390/ijerph7083006; Bertin RI, 2008, J TORREY BOT SOC, V135, P126, DOI 10.3159/07-RP-035R.1; Buckley JP, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-55; Cao JS, 2009, SCI TOTAL ENVIRON, V407, P5531, DOI 10.1016/j.scitotenv.2009.07.021; Chan-Yeung M, 2002, EUR RESPIR J, V19, P853, DOI 10.1183/09031936.02.00250602; Chen RJ, 2010, J HAZARD MATER, V181, P234, DOI 10.1016/j.jhazmat.2010.05.002; D'Amato G, 2013, MULTIDISCIP RESP MED, V8, DOI 10.1186/2049-6958-8-12; D'Amato G, 2011, MULTIDISCIP RESP MED, V6, P28, DOI 10.1186/2049-6958-6-1-28; Donaldson GC, 1999, EUR RESPIR J, V13, P844, DOI 10.1034/j.1399-3003.1999.13d25.x; Epton MJ, 1997, THORAX, V52, P528, DOI 10.1136/thx.52.6.528; Europe WHOROf, 2006, AIR QUAL GUID GLOB U; Gasparrini A, 2010, STAT MED, V29, P2224, DOI 10.1002/sim.3940; Gasparrini A, 2011, J STAT SOFTW, V43, P1, DOI 10.18637/jss.v043.i08; Goodman PG, 2004, ENVIRON HEALTH PERSP, V112, P179, DOI 10.1289/ehp.6451; Grineski SE, 2011, ENVIRON RES, V111, P1148, DOI 10.1016/j.envres.2011.06.007; Guo YM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042232; Guo YM, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-36; Guo YM, 2011, ENVIRON HEALTH PERSP, V119, P1719, DOI 10.1289/ehp.1103598; Guo YM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016511; Hajat S, 2002, INT J EPIDEMIOL, V31, P825, DOI 10.1093/ije/31.4.825; Hales S, 1998, ENVIRON HEALTH PERSP, V106, P607, DOI 10.2307/3434236; Larsson K, 1998, EUR RESPIR J, V12, P825, DOI 10.1183/09031936.98.12040825; Li MC, 2011, J ALLERGY CLIN IMMUN, V128, P626, DOI 10.1016/j.jaci.2011.04.032; Lim YH, 2012, SCI TOTAL ENVIRON, V417, P55, DOI 10.1016/j.scitotenv.2011.12.048; Lin S, 2009, EPIDEMIOLOGY, V20, P738, DOI 10.1097/EDE.0b013e3181ad5522; Makinen TM, 2009, RESP MED, V103, P456, DOI 10.1016/j.rmed.2008.09.011; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; McMichael AJ, 2008, INT J EPIDEMIOL, V37, P1121, DOI 10.1093/ije/dyn086; Michelozzi P, 2006, J EPIDEMIOL COMMUN H, V60, P417, DOI 10.1136/jech.2005.040857; Reid CE, 2009, ECOHEALTH, V6, P458, DOI 10.1007/s10393-009-0261-x; Shi ZM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051567; Son J-Y, 2014, INT J BIOMETEOROL, P1; To T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-204; Vutcovici M, 2014, INT J BIOMETEOROL, V58, P843, DOI 10.1007/s00484-013-0664-9; Wang MZ, 2013, SCI TOTAL ENVIRON, V456, P370, DOI 10.1016/j.scitotenv.2013.03.023; WHO, 2005, AIR QUAL GUID GLOB U; Xu ZW, 2013, OCCUP ENVIRON MED, V70, P730, DOI 10.1136/oemed-2013-101538; Xu ZW, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-12; Yang J, 2012, ENV HLTH, V11, P1; Zanobetti A, 2000, Biostatistics, V1, P279, DOI 10.1093/biostatistics/1.3.279	46	52	54	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2014	9	7							e102475	10.1371/journal.pone.0102475	http://dx.doi.org/10.1371/journal.pone.0102475			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM1PC	25019158	gold, Green Submitted, Green Published			2023-01-03	WOS:000339618600085
J	Bowen, AC; Tong, SYC; Andrews, RM; O'Meara, IM; McDonald, MI; Chatfield, MD; Currie, BJ; Carapetis, JR				Bowen, Asha C.; Tong, Steven Y. C.; Andrews, Ross M.; O'Meara, Irene M.; McDonald, Malcolm I.; Chatfield, Mark D.; Currie, Bart J.; Carapetis, Jonathan R.			Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled, non-inferiority trial	LANCET			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; NORTHERN-TERRITORY; ABORIGINAL CHILDREN; SKIN INFECTIONS; RHEUMATIC-FEVER; GLOBAL BURDEN; PENICILLIN-G; COMMUNITY; PYODERMA; DISEASES	Background Impetigo affects more than 110 million children worldwide at any one time. The major burden of disease is in developing and tropical settings where topical antibiotics are impractical and lead to rapid emergence of antimicrobial resistance. Few trials of systemic antibiotics are available to guide management of extensive impetigo. As such, we aimed to compare short-course oral co-trimoxazole with standard treatment with intramuscular benzathine benzylpenicillin in children with impetigo in a highly endemic setting. Methods In this randomised, controlled, non-inferiority trial, Indigenous Australian children aged 3 months to 13 years with purulent or crusted non-bullous impetigo were randomly assigned (1:1:1) to receive benzathine benzylpenicillin (weight-banded injection), twice-daily co-trimoxazole for 3 days (4 mg/kg plus 20 mg/kg per dose), or once-daily co-trimoxazole for 5 days (8 mg/kg plus 40 mg/kg per dose). At every visit, participants were randomised in blocks of six and 12, stratified by disease severity. Randomisation was done by research nurses and codes were in sealed, sequentially numbered, opaque envelopes. Independent reviewers masked to treatment allocation compared digital images of sores from days 0 and 7. The primary outcome was treatment success at day 7 in a modified intention-to-treat analysis. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12609000858291. Findings Between Nov 26, 2009, and Nov 20, 2012, 508 patients were randomly assigned to receive benzathine benzylpenicillin (n=165 [156 analysed]), twice-daily co-trimoxazole for 3 days (n=175 [173 analysed]), or once-daily co-trimoxazole for 5 days (n=168 [161 analysed]). Treatment was successful in 133 (85%) children who received benzathine benzylpenicillin and 283 (85%) who received pooled co-trimoxazole (absolute difference 0.5%; 95% CI -6.2 to 7.3), showing non-inferiority of co-trimoxazole (10% margin). Results for twice-daily co-trimoxazole for 3 days and once-daily co-trimoxazole for 5 days were similar. Adverse events occurred in 54 participants, 49 (90%) of whom received benzathine benzylpenicillin. Interpretation Short-course co-trimoxazole is a non-inferior, alternative treatment to benzathine benzylpenicillin for impetigo; it is palatable, pain-free, practical, and easily administered.	[Bowen, Asha C.; Tong, Steven Y. C.; Andrews, Ross M.; O'Meara, Irene M.; Chatfield, Mark D.; Currie, Bart J.] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT 0909, Australia; [McDonald, Malcolm I.] James Cook Univ, Townsville, Qld 4811, Australia; [Carapetis, Jonathan R.] Univ Western Australia, Telethon Kids Inst, Perth, WA 6009, Australia	Charles Darwin University; Menzies School of Health Research; James Cook University; Telethon Kids Institute; University of Western Australia	Bowen, AC (corresponding author), Menzies Sch Hlth Res, Casuarina, NT 0811, Australia.	asha.bowen@menzies.edu.au	Chatfield, Mark D/N-2278-2013; Tong, Steven/N-2353-2013; Bowen, Asha Clare/X-5221-2018; Carapetis, Jonathan R/H-8933-2014	Chatfield, Mark D/0000-0002-0004-6274; Tong, Steven/0000-0002-1368-8356; Bowen, Asha Clare/0000-0002-3242-1155; Carapetis, Jonathan R/0000-0002-1182-9792	Australian National Health and Medical Research Council	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	Australian National Health and Medical Research Council.	Andrews RM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000554; Antibiotic Expert Group, 2010, THER GUID ANT; Bowen AC, 2013, T ROY SOC TROP MED H, V107, P384, DOI 10.1093/trstmh/trt032; Bowen AC, 2012, J CLIN MICROBIOL, V50, P4067, DOI 10.1128/JCM.02195-12; Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X; Carapetis JR, 1999, EPIDEMIOL INFECT, V122, P59, DOI 10.1017/S0950268898001952; CARPA, 2009, CARPA STAND TREATM M; Currie B J, 2000, Australas J Dermatol, V41, P139, DOI 10.1046/j.1440-0960.2000.00417.x; Currie BJ, 1996, PEDIATRICS, V97, P989; DERRICK CW, 1970, J PEDIATR-US, V77, P696, DOI 10.1016/S0022-3476(70)80218-9; DILLON HC, 1970, J PEDIATR, V76, P676, DOI 10.1016/S0022-3476(70)80284-0; ESTERLY NB, 1970, J AMER MED ASSOC, V212, P1667, DOI 10.1001/jama.212.10.1667; Faye O, 2007, INT J DERMATOL, V46, P19, DOI 10.1111/j.1365-4632.2007.03364.x; Kearns T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058231; Kemp K NT, 1994, AUST J RURAL HEALTH, V2, P25; Koning S, 2004, BMJ-BRIT MED J, V329, P695, DOI 10.1136/bmj.329.7468.695; Koning S, 2004, COCHRANE DB SYST REV, V2; Koning S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003261.pub3; Krolicki A, 2004, POL J PHARMACOL, V56, P257; Kumar R, 2012, INDIAN J MED RES, V135, P133, DOI 10.4103/0971-5916.93437; Liu C, 2011, CLIN INFECT DIS, V53, P319, DOI [10.1093/cid/ciq146, 10.1093/cid/cir353]; Mahe AH, 2005, EPIDEMIOLOGY MANAGEM; Marshall CS, 2011, AM J TROP MED HYG, V85, P703, DOI 10.4269/ajtmh.2011.11-0185; McDonald M, 2004, LANCET INFECT DIS, V4, P240, DOI 10.1016/S1473-3099(04)00975-2; Menzies School of Health Research Cooperative Research Centre for Aborginal Health, REC TREAT SKIN COND; Parks T, 2012, CURR OPIN INFECT DIS, V25, P145, DOI 10.1097/QCO.0b013e3283511d27; Parnaby MG, 2010, J PAEDIATR CHILD H, V46, P527, DOI 10.1111/j.1440-1754.2010.01841.x; Skull SA, 1999, AUST NZ J MED, V29, P66, DOI 10.1111/j.1445-5994.1999.tb01590.x; Steer AC, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000467; Tong SYC, 2011, DERMATOL CLIN, V29, P21, DOI 10.1016/j.det.2010.09.005; Tong SYC, 2010, J PAEDIATR CHILD H, V46, P131, DOI 10.1111/j.1440-1754.2010.01697.x; Turnidge J., 2010, KUCERS USE ANTIBIOTI; UDO EE, 1994, J HOSP INFECT, V26, P157, DOI 10.1016/0195-6701(94)90038-8; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Wyber R, 2013, GLOB HEART, V8, P227, DOI 10.1016/j.gheart.2013.08.011	35	68	69	1	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 13	2014	384	9960					2132	2140		10.1016/S0140-6736(14)60841-2	http://dx.doi.org/10.1016/S0140-6736(14)60841-2			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW6BK	25172376	Green Submitted			2023-01-03	WOS:000346354300029
J	Tiffin-Richards, FE; Costa, AS; Holschbach, B; Frank, RD; Vassiliadou, A; Kruger, T; Kuckuck, K; Gross, T; Eitner, F; Floege, J; Schulz, JB; Reetz, K				Tiffin-Richards, Frances E.; Costa, Ana S.; Holschbach, Bernhard; Frank, Rolf D.; Vassiliadou, Athina; Krueger, Thilo; Kuckuck, Karl; Gross, Theresa; Eitner, Frank; Floege, Juergen; Schulz, Joerg B.; Reetz, Kathrin			The Montreal Cognitive Assessment (MoCA) - A Sensitive Screening Instrument for Detecting Cognitive Impairment in Chronic Hemodialysis Patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; MINI-MENTAL-STATE; RELIABILITY; DEMENTIA; PERFORMANCE; PREVALENCE; DIALYSIS; VALIDITY; ADULTS; TIME	Background: Chronic kidney disease (CKD) patients undergoing hemodialysis (HD) therapy have an increased risk of developing cognitive impairment and dementia, which are known relevant factors in disease prognosis and therapeutic success, but still lack adequate screening in clinical routine. We evaluated the Montreal Cognitive Assessment (MoCA) for suitability in assessing cognitive performance in HD patients in comparison to the commonly used Mini-Mental State Examination (MMSE) and a detailed neuropsychological test battery, used as gold standard. Methods: 43 HD patients and 42 healthy controls with an average age of 58 years, were assessed with the MoCA, the MMSE and a detailed neuropsychological test battery, covering the domains of memory, attention, language, visuospatial and executive functions. Composite scores were created for comparison of cognitive domains and test results were analyzed using Spearman's correlation and linear regression. Cognitive dysfunction was defined using z-score values and predictive values were calculated. Sensitivity and specificity of the MoCA were determined using receiver operating characteristic (ROC) analysis. Results: HD patients performed worse in all cognitive domains, especially in memory recall and executive functions. The MoCA correlated well with the detailed test battery and identified patients with cognitive impairment with a sensitivity of 76.7% and specificity of 78.6% for a cut-off value of <= 24 out of 30 points. In the detailed assessment executive functions accounted significantly for performance in the MoCA. The MMSE only discriminated weakly between groups. Conclusions: The MoCA represents a suitable cognitive screening tool for hemodialysis patients, demonstrating good sensitivity and specificity levels, and covering executive functions, which appear to play an important role in cognitive performance of HD patients.	[Tiffin-Richards, Frances E.; Costa, Ana S.; Kuckuck, Karl; Schulz, Joerg B.; Reetz, Kathrin] RWTH Aachen Univ Hosp, Dept Neurol, Aachen, Germany; [Tiffin-Richards, Frances E.; Costa, Ana S.; Kuckuck, Karl; Schulz, Joerg B.; Reetz, Kathrin] Julich Aachen Res Alliance JARA, Translat Brain Med, Aachen, Germany; [Tiffin-Richards, Frances E.; Costa, Ana S.; Kuckuck, Karl; Schulz, Joerg B.; Reetz, Kathrin] Julich Aachen Res Alliance JARA, Translat Brain Med, Julich, Germany; [Holschbach, Bernhard] KfH Nephrol Ctr, KfH Curatorship Dialysis & Kidney Transplant EV, Stolberg, Germany; [Frank, Rolf D.] St Antonius Hosp Eschweiler, Dept Internal Med, Eschweiler, Germany; [Vassiliadou, Athina] Dialysis Ctr Aachen, Dialysis Ctr, Aachen, Germany; [Krueger, Thilo; Gross, Theresa; Eitner, Frank; Floege, Juergen] Rhein Westfal TH Aachen, Div Nephrol & Clin Immunol, Aachen, Germany; [Gross, Theresa] Dresden Friedreichstadt Hosp, Dept Internal Med, Dresden, Germany; [Eitner, Frank] Bayer Pharma AG, Wuppertal, Germany; [Reetz, Kathrin] Res Ctr Julich GmbH, Inst Neurosci & Med INM 4, Julich, Germany	RWTH Aachen University; RWTH Aachen University Hospital; Saint Antonius Hospital; RWTH Aachen University; Bayer AG; Bayer Healthcare Pharmaceuticals; Helmholtz Association; Research Center Julich	Reetz, K (corresponding author), RWTH Aachen Univ Hosp, Dept Neurol, Aachen, Germany.	kreetz@ukaachen.de	Costa, Ana Sofia/O-3913-2017; Schulz, Jörg B/D-9786-2012; Reetz, Kathrin/H-9510-2012	Costa, Ana Sofia/0000-0002-1999-6616; Schulz, Jörg B/0000-0002-8903-0593; Reetz, Kathrin/0000-0002-9730-9228	Fundacao para a Ciencia e Tecnologia (FCT, Portugal) [SFRH/BD/65743/2009]; Excellence Initiative of the German federal and state governments (DFG) [ZUK32/1]; Helmholtz Alliance ICEMED - Imaging and Curing Environmental Metabolic Diseases, through the Initiative and Network Fund of the Helmholtz Association; POPH - QREN Program	Fundacao para a Ciencia e Tecnologia (FCT, Portugal)(Portuguese Foundation for Science and Technology); Excellence Initiative of the German federal and state governments (DFG)(German Research Foundation (DFG)); Helmholtz Alliance ICEMED - Imaging and Curing Environmental Metabolic Diseases, through the Initiative and Network Fund of the Helmholtz Association; POPH - QREN Program	Ana S. Costa was supported by a PhD fellowship (SFRH/BD/65743/2009) from Fundacao para a Ciencia e Tecnologia (FCT, Portugal) and financed by the POPH - QREN Program. Kathrin Reetz was funded by the Excellence Initiative of the German federal and state governments (DFG ZUK32/1). Jorg B. Schulz was in part funded by the Helmholtz Alliance ICEMED - Imaging and Curing Environmental Metabolic Diseases, through the Initiative and Network Fund of the Helmholtz Association. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aebi C, 2002, VALIEDIRUNG NEUROPSY; Agganis BT, 2010, AM J KIDNEY DIS, V56, P704, DOI 10.1053/j.ajkd.2010.04.018; Ahmed S, 2011, NEUROCASE; Aschenbrenner S., 2000, REGENSBURGER WORTFLU; Beddhu S, 2000, AM J MED, V108, P609, DOI 10.1016/S0002-9343(00)00371-5; Bossola M, 2011, J PSYCHOSOM RES, V71, P50, DOI 10.1016/j.jpsychores.2011.01.001; Bossola Maurizio, 2009, Blood Purif, V28, P245, DOI 10.1159/000231985; Bugnicourt JM, 2013, J AM SOC NEPHROL, V24, P353, DOI 10.1681/ASN.2012050536; Buumler G., 1985, FARBE WORT INTERFERE; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cohen J., 2013, STAT POWER ANAL BEHA; Costa AS, 2012, DEMENT GERIATR COGN, V33, P379, DOI 10.1159/000340006; Costa AS, 2014, AM J KIDNEY DIS, pS0272; Elias MF, 2009, NEPHROL DIAL TRANSPL, V24, P2446, DOI 10.1093/ndt/gfp107; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Freitas S, 2011, ALZ DIS ASSOC DIS, V00, P1; Gill DJ, 2008, MOVEMENT DISORD, V23, P1043, DOI 10.1002/mds.22017; Griva K, 2010, AM J KIDNEY DIS, V56, P693, DOI 10.1053/j.ajkd.2010.07.003; Helmer C, 2011, NEUROLOGY, V77, P2043, DOI 10.1212/WNL.0b013e31823b4765; Herrmann-Lingen C., 1995, HOSP ANXIETY DEPRESS; Ingram F, 1997, NEUROPSY NEUROPSY BE, V10, P144; Johns M, 1991, SLEEP; Kessler J, 2000, MINIMENTALSTATUSTEST; Kurella M, 2004, J AM GERIATR SOC, V52, P1863, DOI 10.1111/j.1532-5415.2004.52508.x; Lessig S, 2012, MOVEMENT DISORD, V27, P1125, DOI 10.1002/mds.25070; Luis CA, 2009, INT J GERIATR PSYCHI; Madero M, SEMIN DIAL, V21, P29; McLennan SN, 2011, J GERIATR PSYCH NEUR, V24, P33, DOI 10.1177/0891988710390813; Murray AM, 2006, NEUROLOGY, V67, P216, DOI 10.1212/01.wnl.0000225182.15532.40; Murray AM, 2010, AM J KIDNEY DIS, V56, P615, DOI 10.1053/j.ajkd.2010.08.003; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Niemann H., 2008, CALIFORNIA VERBAL LE; Pereira Arema A, 2007, Hemodial Int, V11, P309, DOI 10.1111/j.1542-4758.2007.00185.x; Perk J, 2012, EUR HEART J, V33, P2126, DOI 10.1093/eurheartj/ehs254; Post JB, 2010, NEPHRON CLIN PRACT, V116, pC247, DOI 10.1159/000317206; Radbruch L, 2003, J PAIN SYMPTOM MANAG, V25, P449, DOI 10.1016/S0885-3924(03)00073-3; Sanchez-Roman S, 2011, J INT NEUROPSYCH SOC, V17, P80, DOI 10.1017/S1355617710001219; Sarnak MJ, 2013, NEUROLOGY, V80, P471, DOI 10.1212/WNL.0b013e31827f0f7f; Sehgal AR, 1997, AM J KIDNEY DIS, V30, P41, DOI 10.1016/S0272-6386(97)90563-1; Sorensen EP, 2012, AM J KIDNEY DIS, P1; Tamura MK, 2008, AM J KIDNEY DIS, V52, P227, DOI 10.1053/j.ajkd.2008.05.004; Tamura MK, 2011, KIDNEY INT, V79, P14, DOI 10.1038/ki.2010.336; Tholen S, 2014, DEMENT GERIATR COGN, V38, P31, DOI 10.1159/000357803; Von Aste M, 2006, WECHSLER INTELLIGENZ; Wagner S, 2011, ARCH CLIN NEUROPSYCH, V26, P314, DOI 10.1093/arclin/acr024; Wang F, 2010, AM J NEPHROL, V32, P117, DOI 10.1159/000315618; Warrington E, 1992, TESTBATTERIE VISUELL; Watnick S, 2003, AM J KIDNEY DIS, V41, P105, DOI 10.1053/ajkd.2003.50029; Williams MA, 2004, AM J KIDNEY DIS, V43, P705, DOI 10.1053/j.ajkd.2003.12.031; Wong A, 2009, DEMENT GERIATR COGN, V28, P81, DOI 10.1159/000232589; Yaffe K, 2010, J AM GERIATR SOC, V58, P338, DOI 10.1111/j.1532-5415.2009.02670.x; Zadikoff C, 2008, MOVEMENT DISORD, V23, P297, DOI 10.1002/mds.21837; Zhao J, 2012, METAB BRAIN DIS, V27, P17, DOI 10.1007/s11011-011-9275-5; Zimmermann PFB, 2012, TESTBATTERIE AUFMERK	54	103	111	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2014	9	10							e106700	10.1371/journal.pone.0106700	http://dx.doi.org/10.1371/journal.pone.0106700			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AZ1JF	25347578	gold, Green Submitted, Green Published			2023-01-03	WOS:000347994900002
J	De Vuyst, H; Mugo, NR; Franceschi, S; McKenzie, K; Tenet, V; Njoroge, J; Rana, FS; Sakr, SR; Snijders, PJF; Chung, MH				De Vuyst, Hugo; Mugo, Nelly R.; Franceschi, Silvia; McKenzie, Kevin; Tenet, Vanessa; Njoroge, Julia; Rana, Farzana S.; Sakr, Samah R.; Snijders, Peter J. F.; Chung, Michael H.			Residual Disease and HPV Persistence after Cryotherapy for Cervical Intraepithelial Neoplasia Grade 2/3 in HIV-Positive Women in Kenya	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN-PAPILLOMAVIRUS; HIGH-RISK; INFECTED WOMEN; FOLLOW-UP; RESIDUAL/RECURRENT DISEASE; ANTIRETROVIRAL THERAPY; RECURRENCE; CYTOLOGY; DYSPLASIA	Objective: To assess residual cervical intraepithelial neoplasia (CIN) 2/3 disease and clearance of high-risk (hr) human papillomavirus (HPV) infections at 6 months after cryotherapy among HIV-positive women. Design: Follow-up study. Methods: 79 HIV-positive women received cryotherapy for CIN2/3 in Nairobi, Kenya, and underwent conventional cytology 6 months later. Biopsies were performed on high grade cytological lesions and hrHPV was assessed before (cervical cells and biopsy) and after cryotherapy (cells). Results: At 6 months after cryotherapy CIN2/3 had been eliminated in 61 women (77.2%; 95% Confidence Interval, (CI): 66.4-85.9). 18 women (22.8%) had residual CIN2/3, and all these women had hrHPV at baseline. CD4 count and duration of combination antiretroviral therapy (cART) were not associated with residual CIN2/3. CIN3 instead of CIN2 was the only significant risk factor for residual disease (odds ratio, OR vs CIN2 = 4.3; 95% CI: 1.2-15.0) among hrHPV-positive women after adjustment for age and HPV16 infection. Persistence of hrHPV types previously detected in biopsies was found in 77.5% of women and was associated with residual CIN2/3 (OR = 8.1, 95% CI: 0.9-70). The sensitivity, specificity, and negative predictive value of hrHPV test in detecting residual CIN2/3 were 0.94, 0.36, and 0.96 respectively. Conclusions: Nearly one quarter of HIV-positive women had residual CIN2/3 disease at 6 months after cryotherapy, and the majority had persistent hrHPV. CD4 count and cART use were not associated with residual disease or hrHPV persistence. The value of hrHPV testing in the detection of residual CIN2/3 was hampered by a low specificity.	[De Vuyst, Hugo; Franceschi, Silvia; Tenet, Vanessa] Int Agcy Res Canc, F-69372 Lyon, France; [Mugo, Nelly R.] Kenyatta Natl Hosp, Dept Obstet & Gynecol, Nairobi, Kenya; [McKenzie, Kevin; Njoroge, Julia; Chung, Michael H.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Rana, Farzana S.] Aga Khan Univ Hosp, Nairobi, Kenya; [Sakr, Samah R.] Coptic Hosp, Coptic Hope Ctr, Nairobi, Kenya; [Snijders, Peter J. F.] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands; [Chung, Michael H.] Univ Washington, Dept Med, Seattle, WA USA; [Chung, Michael H.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA	World Health Organization; International Agency for Research on Cancer (IARC); Kenyatta National Hospital; University of Washington; University of Washington Seattle; Vrije Universiteit Amsterdam; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	De Vuyst, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	devuysth@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071	Washington Global Health Alliance; National Institutes of Health [5K23AI065222-04]; Fondation de France [00016673]; Bill & Melinda Gates Foundation [35537]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI065222] Funding Source: NIH RePORTER	Washington Global Health Alliance; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fondation de France(Fondation de France); Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded by the Washington Global Health Alliance, the National Institutes of Health (grant number 5K23AI065222-04), the Fondation de France (grant number 00016673), and the Bill & Melinda Gates Foundation (grant number 35537). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alonso I, 2006, GYNECOL ONCOL, V103, P631, DOI 10.1016/j.ygyno.2006.04.016; Bais AG, 2009, INT J CANCER, V124, P889, DOI 10.1002/ijc.23824; Cejtin HE, 2011, J LOW GENIT TRACT DI, V15, P37, DOI 10.1097/LGT.0b013e3181eb3115; Chirenje Z M, 2003, J Low Genit Tract Dis, V7, P16, DOI 10.1097/00128360-200301000-00005; Chung MH, 2013, AIDS, V27, P2909, DOI 10.1097/01.aids.0000432472.92120.1b; Chung MH, 2011, AIDS, V25, P1915, DOI 10.1097/QAD.0b013e32834a3654; Clifford GM, 2006, AIDS, V20, P2337, DOI 10.1097/01.aids.0000253361.63578.14; De Vuyst H, 2012, BRIT J CANCER, V107, P1624, DOI 10.1038/bjc.2012.441; De Vuyst H, 2008, EUR J CANCER PREV, V17, P545, DOI 10.1097/CEJ.0b013e3282f75ea1; De Vuyst H, 2013, INT J CANCER, V133, P1441, DOI 10.1002/ijc.28131; Elfgren K, 2002, OBSTET GYNECOL, V100, P965, DOI 10.1016/S0029-7844(02)02280-9; Foulot H, 2008, EUR J OBSTET GYN R B, V141, P153, DOI 10.1016/j.ejogrb.2008.07.015; Fruchter RG, 1996, OBSTET GYNECOL, V87, P338, DOI 10.1016/0029-7844(95)00408-4; Gilles C, 2005, GYNECOL ONCOL, V96, P112, DOI 10.1016/j.ygyno.2004.10.003; Gingelmaier A, 2007, ANTICANCER RES, V27, P1795; Heard I, 2005, JAIDS-J ACQ IMM DEF, V39, P412, DOI 10.1097/01.qai.0000167157.83098.60; Holcomb K, 1999, GYNECOL ONCOL, V74, P428, DOI 10.1006/gyno.1999.5479; Jacobs MV, 2000, INT J CANCER, V87, P221, DOI 10.1002/1097-0215(20000715)87:2&lt;221::AID-IJC11&gt;3.0.CO;2-2; Jones J, 2011, J CLIN VIROL, V52, P88, DOI 10.1016/j.jcv.2011.06.021; Kitchener HC, 2008, BJOG-INT J OBSTET GY, V115, P1001, DOI 10.1111/j.1471-0528.2008.01748.x; Kocken M, 2012, BRIT J CANCER, V106, P817, DOI 10.1038/bjc.2012.5; Kocken M, 2012, GYNECOL ONCOL, V125, P500, DOI 10.1016/j.ygyno.2012.01.015; Kocken M, 2011, LANCET ONCOL, V12, P441, DOI 10.1016/S1470-2045(11)70078-X; Kreimer AR, 2006, CANCER EPIDEM BIOMAR, V15, P908, DOI 10.1158/1055-9965.EPI-05-0845; Lehtovirta P, 2008, INT J STD AIDS, V19, P37, DOI 10.1258/ijsa.2007.005672; LUFF RD, 1992, AM J CLIN PATHOL, V98, P152, DOI 10.1093/ajcp/98.2.152; Martin-Hirsch PPL, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001421.pub3; Massad L Stewart, 2007, J Low Genit Tract Dis, V11, P90, DOI 10.1097/01.lgt.0000245038.06977.a7; Nene BM, 2008, INT J GYNECOL OBSTET, V103, P232, DOI 10.1016/j.ijgo.2008.07.016; Nobbenhuis MAE, 2001, BRIT J CANCER, V84, P796, DOI 10.1054/bjoc.2000.1689; Ojoo S, 2007, KENYA NATL CLIN MANU; Quint W, 2012, J PATHOL, V227, P62, DOI 10.1002/path.3970; Reimers LL, 2010, GYNECOL ONCOL, V119, P92, DOI 10.1016/j.ygyno.2010.06.012; Rijkaart DC, 2012, LANCET ONCOL, V13, P78, DOI 10.1016/S1470-2045(11)70296-0; Sankaranarayanan R, 2007, BRIT J CANCER, V96, P738, DOI 10.1038/sj.bjc.6603633; Santesso N, 2012, INT J GYNECOL OBSTET, V118, P97, DOI 10.1016/j.ijgo.2012.01.029; Schiffman Mark, 2009, Infect Agent Cancer, V4, P8, DOI 10.1186/1750-9378-4-8; Sellors J. W., 2003, COLPOSCOPY TREATMENT; Strander B, 2007, EUR J CANCER, V43, P1849, DOI 10.1016/j.ejca.2007.05.016; Tate DR, 2002, AM J OBSTET GYNECOL, V186, P880, DOI 10.1067/mob.2002.123607; Tebeu PM, 2006, INT J STD AIDS, V17, P507, DOI 10.1258/095646206778145703; Valasoulis G, 2011, GYNECOL ONCOL, V121, P43, DOI 10.1016/j.ygyno.2010.12.003; van den Brule AJC, 2002, J CLIN MICROBIOL, V40, P779, DOI 10.1128/JCM.40.3.779-787.2002; van der Marel J, 2012, INT J CANCER, V131, pE946, DOI 10.1002/ijc.27532; Zielinski GD, 2003, GYNECOL ONCOL, V91, P67, DOI 10.1016/S0090-8258(03)00415-3	45	18	18	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2014	9	10							e111037	10.1371/journal.pone.0111037	http://dx.doi.org/10.1371/journal.pone.0111037			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0BL	25343563	Green Published, gold, Green Submitted			2023-01-03	WOS:000343943500078
J	Pak, Y; Pastan, I; Kreitman, RJ; Lee, B				Pak, Youngshang; Pastan, Ira; Kreitman, Robert J.; Lee, Byungkook			Effect of Antigen Shedding on Targeted Delivery of Immunotoxins in Solid Tumors from a Mathematical Model	PLOS ONE			English	Article							RECOMBINANT IMMUNOTOXIN; ANTITUMOR-ACTIVITY; ANIMAL TOXICITY; CANCER; CELL; MESOTHELIN; THERAPY; PENETRATION; BINDING; IMMUNOTHERAPY	Most cancer-specific antigens used as targets of antibody-drug conjugates and immunotoxins are shed from the cell surface (Zhang & Pastan (2008) Clin. Cancer Res. 14: 7981-7986), although at widely varying rates and by different mechanisms (Dello Sbarba & Rovida (2002) Biol. Chem. 383: 69-83). Why many cancer-specific antigens are shed and how the shedding affects delivery efficiency of antibody-based protein drugs are poorly understood questions at present. Before a detailed numerical study, it was assumed that antigen shedding would reduce the efficacy of antibody-drug conjugates and immunotoxins. However, our previous study using a comprehensive mathematical model showed that antigen shedding can significantly improve the efficacy of the mesothelin-binding immunotoxin, SS1P (anti-mesothelin-Fv-PE38), and suggested that receptor shedding can be a general mechanism for enhancing the effect of inter-cellular signaling molecules. Here, we improved this model and applied it to both SS1P and another recombinant immunotoxin, LMB-2, which targets CD25. We show that the effect of antigen shedding is influenced by a number of factors including the number of antigen molecules on the cell surface and the endocytosis rate. The high shedding rate of mesothelin is beneficial for SS1P, for which the antigen is large in number and endocytosed rapidly. On the other hand, the slow shedding of CD25 is beneficial for LMB-2, for which the antigen is small in number and endocytosed slowly.	[Pak, Youngshang] Pusan Natl Univ, Dept Chem, Pusan, South Korea; [Pak, Youngshang] Pusan Natl Univ, Inst Funct Mat, Pusan, South Korea; [Pak, Youngshang; Pastan, Ira; Kreitman, Robert J.; Lee, Byungkook] NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	Pusan National University; Pusan National University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pak, Y (corresponding author), Pusan Natl Univ, Dept Chem, Pusan, South Korea.	ypak@pusan.ac.kr; bk@nih.gov	pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270	NCI; Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC011233] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by an appointment to the ORISE Research Participation Program at NCI. This program is administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US department of Energy and the National Cancer Institute. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackerman ME, 2008, MOL CANCER THER, V7, P2233, DOI 10.1158/1535-7163.MCT-08-0067; Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; Cheever MA, 2009, CLIN CANCER RES, V15, P5323, DOI 10.1158/1078-0432.CCR-09-0737; Chen KC, 2008, ANN BIOMED ENG, V36, P486, DOI 10.1007/s10439-007-9425-4; Dello Sbarba P, 2002, BIOL CHEM, V383, P69; Dosio F, 2014, RECENT PAT ANTI-CANC, V9, P35; Dreher MR, 2006, JNCI-J NATL CANCER I, V98, P335, DOI 10.1093/jnci/djj070; FUJIMORI K, 1990, J NUCL MED, V31, P1191; GREENE WC, 1986, ANN INTERN MED, V105, P560, DOI 10.7326/0003-4819-105-4-560; Hassan R, 2004, CLIN CANCER RES, V10, P3937, DOI 10.1158/1078-0432.CCR-03-0801; Hassan R, 2008, EUR J CANCER, V44, P46, DOI 10.1016/j.ejca.2007.08.028; HONDA M, 1990, J IMMUNOL, V145, P4131; Jain RK, 2001, ADV DRUG DELIVER REV, V46, P149, DOI 10.1016/S0169-409X(00)00131-9; Junghans RP, 1996, J EXP MED, V183, P1587, DOI 10.1084/jem.183.4.1587; Kobayashi H, 2000, J NUCL MED, V41, P755; Kreitman RJ, 1998, CANCER RES, V58, P968; KREITMAN RJ, 1994, BLOOD, V83, P426; Kulasingam V, 2008, NAT CLIN PRACT ONCOL, V5, P588, DOI 10.1038/ncponc1187; LAIRD AK, 1964, BRIT J CANCER, V18, P490, DOI 10.1038/bjc.1964.55; LAUK S, 1989, CANCER RES, V49, P4557; Michaelis L, 1913, BIOCHEM Z, V49, P333; Onda M, 2001, CANCER RES, V61, P5070; Pak Y, 2012, CANCER RES, V72, P3143, DOI 10.1158/0008-5472.CAN-11-3925; Pastan I, 2006, NAT REV CANCER, V6, P559, DOI 10.1038/nrc1891; Reiter Y, 1996, NAT BIOTECHNOL, V14, P1239, DOI 10.1038/nbt1096-1239; Rippe B, 1985, Microvasc Res, V30, P246, DOI 10.1016/0026-2862(85)90055-X; Schmidt MM, 2009, MOL CANCER THER, V8, P2861, DOI 10.1158/1535-7163.MCT-09-0195; Singh R, 2012, CLIN CANCER RES, V18, P152, DOI 10.1158/1078-0432.CCR-11-1839; Thurber GM, 2008, ADV DRUG DELIVER REV, V60, P1421, DOI 10.1016/j.addr.2008.04.012; Tsutsumi Y, 2000, P NATL ACAD SCI USA, V97, P8548, DOI 10.1073/pnas.140210597; Zhang YJ, 2008, CLIN CANCER RES, V14, P7981, DOI 10.1158/1078-0432.CCR-08-0324; Zhang YJ, 2007, P NATL ACAD SCI USA, V104, P17099, DOI 10.1073/pnas.0708101104; Zhang YJ, 2011, CANCER RES, V71, P5915, DOI 10.1158/0008-5472.CAN-11-0466; Zhang YJ, 2010, CANCER RES, V70, P1082, DOI 10.1158/0008-5472.CAN-09-2405	35	9	11	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2014	9	10							e110716	10.1371/journal.pone.0110716	http://dx.doi.org/10.1371/journal.pone.0110716			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0BL	25343405	Green Published, Green Submitted, gold			2023-01-03	WOS:000343943500051
J	Su, YY; Zhang, FJ; Liu, HX; Smith, MK; Zhu, L; Wu, J; Wang, N				Su, Yingying; Zhang, Fujie; Liu, Huixin; Smith, M. Kumi; Zhu, Lin; Wu, Jing; Wang, Ning			The Prevalence of HIV-1 Drug Resistance among Antiretroviral Treatment Naive Individuals in Mainland China: A Meta-Analysis	PLOS ONE			English	Article							MUTATIONS; SEX; MEN; SURVEILLANCE; HETEROGENEITY; DIVERSITY; HIV/AIDS; SUBTYPES; THERAPY; TRENDS	Background: Surveillance of drug resistance in antiretroviral treatment-naive patients in China is needed to ensure optimal treatment outcomes and control of the human immunodeficiency virus (HIV) epidemic. Methods: A systematic literature search was conducted in English and Chinese through PubMed (English), China National Knowledge Infrastructure (Chinese), Chinese Biomedical Literature Database (Chinese), and Wanfang (Chinese). Random effects models were used to calculate the pooled prevalence of transmitted drug resistance and subgroup analyses examined prevalence estimates across time periods, study locations, and study populations. Results: Analysis of data from 71 studies (47 in Chinese and 24 in English) yielded a pooled prevalence of transmitted HIV drug resistance to any antiretroviral drug class of 3.64% (95% confidence interval [CI]: 3.00%-4.32%). Rates were significantly high at initial stage of free ART program from 2003 to 2005 (5.18%, 95% CI: 3.13%-7.63%), and were much lower among studies conducted in 2006-2008 (3.02%, 95% CI: 2.03%-4.16%). A slight increase was observed again in the most recent study period from 2009 to 2012 (3.68%, 95% CI: 2.78%-4.69%). Subgroup analysis revealed highest prevalence levels of transmitted drug resistance in Beijing city, and Henan and Hubei provinces (above 5%), and although differences in prevalence rates among risk groups were negligible, men who have sex with men were unique in their relatively large portion of protease inhibitor resistance, a second-line drug of limited availability in China. Conclusions: Overall prevalence of transmitted HIV drug resistance in China is classified as "low'' by the World Health Organization. However regional and temporal variability suggest a more complex epidemic for which closer HIV drug resistance surveillance is needed. A nationwide HIV drug resistance surveillance system to monitor both treatment-experienced and treatment-naive patients will be a cornerstone to ensure the effectiveness of treatment scale-up, particularly as China seeks to expand a national policy of antiretroviral treatment as prevention.	[Su, Yingying; Zhang, Fujie; Liu, Huixin; Zhu, Lin; Wu, Jing; Wang, Ning] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China; [Smith, M. Kumi] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA	Chinese Center for Disease Control & Prevention; National Center for AIDS/STD Control & Prevention, Chinese Center for Disease Control & Prevention; University of North Carolina; University of North Carolina Chapel Hill	Wang, N (corresponding author), Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China.	wangnbj@163.com		Smith, M. Kumi/0000-0001-5861-8100	Mega-projects of national science research for the 12th Five-Year Plan of China [2012ZX10001-001]	Mega-projects of national science research for the 12th Five-Year Plan of China	This work was supported by funding from the Mega-projects of national science research for the 12th Five-Year Plan (2012ZX10001-001) of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2008, MANUAL NATL FREE HIV; [Anonymous], 2005, MANUAL NATL FREE HIV; Avila-Rios S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027812; Bennett DE, 2008, ANTIVIR THER, V13, P25; Bennett DE, 2008, ANTIVIR THER, V13, P1; Bennett DE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004724; Chen M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087033; Dou ZH, 2010, INT J EPIDEMIOL, V39, pII56, DOI 10.1093/ije/dyq215; Gupta RK, 2012, LANCET, V380, P1250, DOI 10.1016/S0140-6736(12)61038-1; [韩晓旭 Han Xiaoxu], 2012, [中国公共卫生, China Public Health], V28, P810; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; Kuang JQ, 2007, GENOTYPIC HIV 1 DRUG; Li L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075777; Li L, 2013, AIDS RES HUM RETROV, V29, P633, DOI [10.1089/AID.2012.0281, 10.1089/aid.2012.0281]; Li L, 2011, INFECT GENET EVOL, V11, P1487, DOI 10.1016/j.meegid.2011.05.017; Li TS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003918; Li WJ, 2012, CHIN J VIRAL DIS, V2, P40; Liao LJ, 2007, AIDS RES HUM RETROV, V23, P1062, DOI 10.1089/aid.2007.0050; Liao LJ, 2013, AIDS, V27, P1815, DOI 10.1097/QAD.0b013e3283611931; Liao LJ, 2010, JAIDS-J ACQ IMM DEF, V53, pS10, DOI 10.1097/QAI.0b013e3181c7d363; Little SJ, 2000, ANTIVIR THER, V5, P33; Ministry of Health People's Republic of China Joint United Nations Programme on HIV/AIDS World Health Organization, 2011, 2011 EST HIV AIDS EP; National Health and Family Planning Commission of the People's Republic of China, 2013, BACKGR HIV AIDS PREV; Qiu LJ, 2013, CHIN J AIDS STD, V19, P6; R Core Team, 2021, R LANG ENV STAT COMP; Si Xue-feng, 2004, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, V18, P308; Vercauteren J, 2009, J INFECT DIS, V200, P1503, DOI 10.1086/644505; Wang X, 2012, AIDS RES HUM RETROV, V28, P1637, DOI [10.1089/aid.2012.0164, 10.1089/AID.2012.0164]; Wheeler WH, 2010, AIDS, V24, P1203, DOI 10.1097/QAD.0b013e3283388742; WHO, 2012, WHO HIV DRUG RES REP; Wittkop L, 2011, LANCET INFECT DIS, V11, P363, DOI 10.1016/S1473-3099(11)70032-9; Wu YS, 2011, CHIN MED ASS 5 NAT A; Xing H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062408; [羊海涛 Yang Haitao], 2012, [南京医科大学学报. 自然科学版, Acta Universitatis Medicinalis Nanjing], V32, P1; Yang J, 2013, ARCH VIROL, V158, P839, DOI 10.1007/s00705-012-1557-7; Yin CY, 2011, CHIN J CLIN INFECT D, V4, P201; Zeng PB, 2012, TRANSFUSION, V52, P1041, DOI 10.1111/j.1537-2995.2011.03415.x; Zhang FJ, 2005, CELL RES, V15, P877, DOI 10.1038/sj.cr.7290362; Zhang FJ, 2006, CHINESE MED J-PEKING, V119, P1999, DOI 10.1097/00029330-200612010-00010; Zhang FJ, 2007, AIDS, V21, pS143, DOI 10.1097/01.aids.0000304710.10036.2b; Zhang FJ, 2011, LANCET INFECT DIS, V11, P516, DOI 10.1016/S1473-3099(11)70097-4; Zhang L, 2013, LANCET INFECT DIS, V13, P955, DOI 10.1016/S1473-3099(13)70245-7; Zhang XY, 2007, AIDS, V21, pS59, DOI 10.1097/01.aids.0000304698.47261.b1; Zhao B, 2011, AIDS RES HUM RETROV, V27, P1047, DOI [10.1089/aid.2010.0119, 10.1089/AID.2010.0119]; Zhao DC, 2012, CHINESE MED J-PEKING, V125, P3514, DOI 10.3760/cma.j.issn.0366-6999.2012.19.028; Zhao GL, 2009, CHIN J AIDS STD, V15, P589; Zhao Y, 2012, CHINESE MED J-PEKING, V125, P1331, DOI 10.3760/cma.j.issn.0366-6999.2012.07.025	48	8	17	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2014	9	10							e110652	10.1371/journal.pone.0110652	http://dx.doi.org/10.1371/journal.pone.0110652			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0BL	25343483	gold, Green Published, Green Submitted			2023-01-03	WOS:000343943500041
J	Zanchi, A; Tappy, L; Le, KA; Bortolotti, M; Theumann, N; Halabi, G; Gauthier, T; Mathieu, C; Tremblay, S; Bertrand, PC; Burnier, M; Teta, D				Zanchi, Anne; Tappy, Luc; Le, Kim-Anne; Bortolotti, Murielle; Theumann, Nicolas; Halabi, Georges; Gauthier, Thierry; Mathieu, Claudine; Tremblay, Sylvie; Bertrand, Pauline Coti; Burnier, Michel; Teta, Daniel			Pioglitazone Improves Fat Distribution, the Adipokine Profile and Hepatic Insulin Sensitivity in Non-Diabetic End-Stage Renal Disease Subjects on Maintenance Dialysis: A Randomized Cross-Over Pilot Study	PLOS ONE			English	Article							TYPE-2 DIABETIC-PATIENTS; CHRONIC-HEMODIALYSIS PATIENTS; PERITONEAL-DIALYSIS; ADIPONECTIN RATIO; CARDIOVASCULAR MORTALITY; INDEPENDENT PREDICTOR; LEPTIN; RESISTANCE; GLUCOSE; ROSIGLITAZONE	Background: Fat redistribution, increased inflammation and insulin resistance are prevalent in non-diabetic subjects treated with maintenance dialysis. The aim of this study was to test whether pioglitazone, a powerful insulin sensitizer, alters body fat distribution and adipokine secretion in these subjects and whether it is associated with improved insulin sensitivity. Trial Design: This was a double blind cross-over study with 16 weeks of pioglitazone 45 mg vs placebo involving 12 subjects. Methods: At the end of each phase, body composition (anthropometric measurements, dual energy X-ray absorptometry (DEXA), abdominal CT), hepatic and muscle insulin sensitivity (2-step hyperinsulinemic euglycemic clamp with 2H2-glucose) were measured and fasting blood adipokines and cardiometabolic risk markers were monitored. Results: Four months treatment with pioglitazone had no effect on total body weight or total fat but decreased the visceral/sub-cutaneous adipose tissue ratio by 16% and decreased the leptin/adiponectin (L/A) ratio from 3.63x10(-3) to 0.76x10(-3). This was associated with a 20% increase in hepatic insulin sensitivity without changes in muscle insulin sensitivity, a 12% increase in HDL cholesterol and a 50% decrease in CRP. Conclusions/Limitations: Pioglitazone significantly changes the visceral-subcutaneous fat distribution and plasma L/A ratio in non diabetic subjects on maintenance dialysis. This was associated with improved hepatic insulin sensitivity and a reduction of cardio-metabolic risk markers. Whether these effects may improve the outcome of non diabetic end-stage renal disease subjects on maintenance dialysis still needs further evaluation.	[Zanchi, Anne; Halabi, Georges; Gauthier, Thierry; Mathieu, Claudine; Tremblay, Sylvie; Burnier, Michel; Teta, Daniel] CHU Vaudois, Serv Nephrol, Dept Med, Univ Lausanne Hosp, CH-1011 Lausanne, Switzerland; [Tappy, Luc; Le, Kim-Anne; Bortolotti, Murielle] Univ Lausanne, Dept Physiol, Lausanne, Switzerland; [Zanchi, Anne; Tappy, Luc; Bertrand, Pauline Coti] CHU Vaudois, Univ Lausanne Hosp, Dept Med, Serv Endocrinol Diabet & Metab, CH-1011 Lausanne, Switzerland; [Theumann, Nicolas] CHU Vaudois, Dept Radiol, Univ Lausanne Hosp, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Zanchi, A (corresponding author), CHU Vaudois, Serv Nephrol, Dept Med, Univ Lausanne Hosp, CH-1011 Lausanne, Switzerland.	Anne.Zanchi@chuv.ch	Tappy, Luc/A-8911-2017	Tappy, Luc/0000-0001-8469-4692	Service of Nephrology at the Lausanne University Hospital	Service of Nephrology at the Lausanne University Hospital	Funding of this study was internal to the Service of Nephrology at the Lausanne University Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Investigators performed completely the study design, data collection and analysis and prepared the manuscript.	Abe M, 2010, EXPERT OPIN PHARMACO, V11, P1611, DOI 10.1517/14656566.2010.495119; Axelsson J, 2004, AM J CLIN NUTR, V80, P1222, DOI 10.1093/ajcn/80.5.1222; Bajaj M, 2004, J CLIN ENDOCR METAB, V89, P200, DOI 10.1210/jc.2003-031315; Barazzoni R, 2008, CLIN NUTR, V27, P142, DOI 10.1016/j.clnu.2007.06.013; Basu R, 2008, DIABETES, V57, P24, DOI 10.2337/db07-0827; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; DEBODO RC, 1963, RECENT PROG HORM RES, V19, P445; DEFRONZO RA, 1978, J CLIN INVEST, V62, P425, DOI 10.1172/JCI109144; Diez JJ, 2009, AM J NEPHROL, V30, P244, DOI 10.1159/000221147; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; Hung AM, 2011, CONTRIB NEPHROL, V171, P127, DOI 10.1159/000327177; Hung AM, 2011, CLIN J AM SOC NEPHRO, V6, P767, DOI 10.2215/CJN.08070910; JALLUT D, 1990, JPEN-PARENTER ENTER, V14, P563, DOI 10.1177/0148607190014006563; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Kobayashi S, 2005, AM J KIDNEY DIS, V45, P275, DOI 10.1053/j.ajkd.2004.09.034; Koenen TB, 2009, J CLIN ENDOCR METAB, V94, P4453, DOI 10.1210/jc.2009-0517; Li Y, 2012, PERITON DIALYSIS INT, V32, P507, DOI 10.3747/pdi.2011.00116; Lin SH, 2003, AM J KIDNEY DIS, V42, P774, DOI 10.1016/S0272-6386(03)00844-8; LIVESEY G, 1988, AM J CLIN NUTR, V47, P608, DOI 10.1093/ajcn/47.4.608; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; Manley HJ, 2003, PHARMACOTHERAPY, V23, P861, DOI 10.1592/phco.23.7.861.32727; Miyazaki Y, 2004, J CLIN ENDOCR METAB, V89, P4312, DOI 10.1210/jc.2004-0190; Miyazaki Y, 2002, J CLIN ENDOCR METAB, V87, P2784, DOI 10.1210/jc.87.6.2784; Nolan JJ, 1996, DIABETES, V45, P1276, DOI 10.2337/diabetes.45.9.1276; Norata GD, 2007, STROKE, V38, P2844, DOI 10.1161/STROKEAHA.107.485540; Odamaki M, 1999, NEPHROL DIAL TRANSPL, V14, P2427, DOI 10.1093/ndt/14.10.2427; Postorino M, 2009, J AM COLL CARDIOL, V53, P1265, DOI 10.1016/j.jacc.2008.12.040; Saraf N, 2012, J PHARM PHARMACOL, V64, P161, DOI 10.1111/j.2042-7158.2011.01366.x; Satoh N, 2004, DIABETES CARE, V27, P2488, DOI 10.2337/diacare.27.10.2488; Schneiter P, 1999, METABOLISM, V48, P1260, DOI 10.1016/S0026-0495(99)90265-2; Shinohara K, 2002, J AM SOC NEPHROL, V13, P1894, DOI 10.1097/01.ASN.0000019900.87535.43; Stenvinkel P, 2004, KIDNEY INT, V65, P274, DOI 10.1111/j.1523-1755.2004.00370.x; Teta D, 2008, KIDNEY INT, V73, pS112, DOI 10.1038/sj.ki.5002611; Teta D, 2012, J RENAL NUTR, V22, P81, DOI 10.1053/j.jrn.2011.10.029; Tonelli J, 2004, DIABETES, V53, P1621, DOI 10.2337/diabetes.53.6.1621; van Wijk JPH, 2005, ANN INTERN MED, V143, P337, DOI 10.7326/0003-4819-143-5-200509060-00009; Weigle DS, 1997, J CLIN ENDOCR METAB, V82, P561, DOI 10.1210/jc.82.2.561; Wong TYH, 2005, AM J KIDNEY DIS, V46, P713, DOI 10.1053/j.ajkd.2005.06.020; Yun JE, 2011, ENDOCR J, V58, P807, DOI 10.1507/endocrj.K11E-084; Zanchi A, 2004, J CLIN ENDOCR METAB, V89, P1140, DOI 10.1210/jc.2003-031526; Zanchi A, 2010, DIABETOLOGIA, V53, P1568, DOI 10.1007/s00125-010-1756-2	41	8	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2014	9	10							e109134	10.1371/journal.pone.0109134	http://dx.doi.org/10.1371/journal.pone.0109134			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ9XC	25330088	Green Published, Green Submitted, gold			2023-01-03	WOS:000343210800015
J	Trembley, JH; Unger, GM; Korman, VL; Abedin, MJ; Nacusi, LP; Vogel, RI; Slaton, JW; Kren, BT; Ahmed, K				Trembley, Janeen H.; Unger, Gretchen M.; Korman, Vicci L.; Abedin, Md. Joynal; Nacusi, Lucas P.; Vogel, Rachel I.; Slaton, Joel W.; Kren, Betsy T.; Ahmed, Khalil			Tenfibgen Ligand Nanoencapsulation Delivers Bi-Functional Anti-CK2 RNAi Oligomer to Key Sites for Prostate Cancer Targeting Using Human Xenograft Tumors in Mice	PLOS ONE			English	Article							PROTEIN-KINASE CK2; SQUAMOUS-CELL CARCINOMA; TENASCIN-C; IN-VIVO; SIRNA; CK2-ALPHA; SUBUNIT; HEAD; PROGRESSION; ASSOCIATION	Protected and specific delivery of nucleic acids to malignant cells remains a highly desirable approach for cancer therapy. Here we present data on the physical and chemical characteristics, mechanism of action, and pilot therapeutic efficacy of a tenfibgen (TBG)-shell nanocapsule technology for tumor-directed delivery of single stranded DNA/RNA chimeric oligomers targeting CK2 alpha alpha' to xenograft tumors in mice. The sub-50 nm size TBG nanocapsule (s50-TBG) is a slightly negatively charged, uniform particle of 15 - 20 nm size which confers protection to the nucleic acid cargo. The DNA/RNA chimeric oligomer (RNAi-CK2) functions to decrease CK2 alpha alpha' expression levels via both siRNA and antisense mechanisms. Systemic delivery of s50-TBG-RNAi-CK2 specifically targets malignant cells, including tumor cells in bone, and at low doses reduces size and CK2-related signals in orthotopic primary and metastatic xenograft prostate cancer tumors. In conclusion, the s50-TBG nanoencapsulation technology together with the chimeric oligomer targeting CK2aa' offer significant promise for systemic treatment of prostate malignancy.	[Trembley, Janeen H.; Abedin, Md. Joynal; Kren, Betsy T.; Ahmed, Khalil] Minneapolis VA Hlth Care Syst, Res Serv, Minneapolis, MN 55417 USA; [Trembley, Janeen H.; Abedin, Md. Joynal; Ahmed, Khalil] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [Trembley, Janeen H.; Vogel, Rachel I.; Kren, Betsy T.; Ahmed, Khalil] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA; [Unger, Gretchen M.; Korman, Vicci L.; Nacusi, Lucas P.] GeneSegues Inc, Chaska, MN USA; [Kren, Betsy T.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Slaton, Joel W.; Ahmed, Khalil] Univ Minnesota, Dept Urol, Minneapolis, MN USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Ahmed, K (corresponding author), Minneapolis VA Hlth Care Syst, Res Serv, Minneapolis, MN 55417 USA.	ahmedk@umn.edu		Trembley, Janeen/0000-0003-3597-2611; Vogel, Rachel/0000-0003-0149-8464	Department of Veterans Affairs [1IO1B001731]; National Cancer Institute, National Institutes of Health, Department of Health and Human Services [CA150182, HHS-N261-2008-00027/N42CM-2008-00027C, CA99366, CA119556]; National Cancer Institute [CA158730, DK067436-05]; National Institute of Diabetes, Digestive Diseases and Kidney Diseases, National Institutes of Health, Department of Health and Human Services; NATIONAL CANCER INSTITUTE [R01CA150182, R43CA099366, R43CA119556, R21CA158730, P30CA077598] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000114] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067436] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); National Cancer Institute, National Institutes of Health, Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Diabetes, Digestive Diseases and Kidney Diseases, National Institutes of Health, Department of Health and Human Services; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Merit review research funds (1IO1B001731) awarded by the Department of Veterans Affairs www.va.gov (KA). Research grant CA150182 awarded by National Cancer Institute, National Institutes of Health, Department of Health and Human Services www.nih.gov (KA). Research grants CA158730 and DK067436-05 awarded by National Cancer Institute and National Institute of Diabetes, Digestive Diseases and Kidney Diseases, National Institutes of Health, Department of Health and Human Services www.nih.gov (BTK). Research grants HHS-N261-2008-00027/N42CM-2008-00027C, CA99366, and CA119556 awarded by National Cancer Institute, National Institutes of Health, Department of Health and Human Services www.nih.gov (GMU). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the United States Department of Veterans Affairs or the United States government.	Ahmad KA, 2005, ANTI-CANCER DRUG, V16, P1037, DOI 10.1097/00001813-200511000-00001; Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Alam MR, 2010, OLIGONUCLEOTIDES, V20, P103, DOI 10.1089/oli.2009.0211; AUKHIL I, 1993, J BIOL CHEM, V268, P2542; Bertrand N, 2014, ADV DRUG DELIVER REV, V66, P2, DOI 10.1016/j.addr.2013.11.009; Brown MS, 2010, CLIN CANCER RES, V16, P2295, DOI 10.1158/1078-0432.CCR-09-3200; Buchou T, 2003, MOL CELL BIOL, V23, P908, DOI 10.1128/MCB.23.3.908-915.2003; Burnett JC, 2012, CHEM BIOL, V19, P60, DOI 10.1016/j.chembiol.2011.12.008; CROOKE ST, 1995, BIOCHEM J, V312, P599, DOI 10.1042/bj3120599; Dassie JP, 2009, NAT BIOTECHNOL, V27, P839, DOI 10.1038/nbt.1560; Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Di Maira G, 2005, CELL DEATH DIFFER, V12, P668, DOI 10.1038/sj.cdd.4401604; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; FDA-CDER, 2002, PHARM TOX; GAPANY M, 1995, MOL MED, V1, P659, DOI 10.1007/BF03401606; Giusiano S, 2011, EUR J CANCER, V47, P792, DOI 10.1016/j.ejca.2010.11.028; Guerra B, 2008, CURR MED CHEM, V15, P1870, DOI 10.2174/092986708785132933; Juliano RL, 2012, BIOCONJUGATE CHEM, V23, P147, DOI 10.1021/bc200377d; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Kim JS, 2007, CLIN CANCER RES, V13, P1019, DOI 10.1158/1078-0432.CCR-06-1602; Kren BT, 2009, J CLIN INVEST, V119, P2086, DOI 10.1172/JCI34332; Laramas M, 2007, EUR J CANCER, V43, P928, DOI 10.1016/j.ejca.2006.11.021; Lightfoot HL, 2012, NUCLEIC ACIDS RES, V40, P10585, DOI 10.1093/nar/gks861; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Liu J, 2013, NUCLEIC ACIDS RES, V41, P9570, DOI 10.1093/nar/gkt693; Love KT, 2010, P NATL ACAD SCI USA, V107, P1864, DOI 10.1073/pnas.0910603106; Martinez J, 2004, GENE DEV, V18, P975, DOI 10.1101/gad.1187904; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; O-charoenrat P, 2004, CLIN CANCER RES, V10, P5792, DOI 10.1158/1078-0432.CCR-03-0317; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Sanhai WR, 2008, NAT NANOTECHNOL, V3, P242, DOI 10.1038/nnano.2008.114; Schellekens H, 2005, NEPHROL DIAL TRANSPL, V20, P3, DOI 10.1093/ndt/gfh1092; Schrecengost R, 2013, SEMIN ONCOL, V40, P244, DOI 10.1053/j.seminoncol.2013.04.001; Seldin DC, 2008, MOL CELL BIOCHEM, V316, P141, DOI 10.1007/s11010-008-9811-8; Tabernero J, 2013, CANCER DISCOV, V3, P406, DOI 10.1158/2159-8290.CD-12-0429; Tawfic S, 2001, HISTOL HISTOPATHOL, V16, P573, DOI 10.14670/HH-16.573; Tousignant JD, 2000, HUM GENE THER, V11, P2493, DOI 10.1089/10430340050207984; Trembley JH, 2009, CELL MOL LIFE SCI, V66, P1858, DOI 10.1007/s00018-009-9154-y; Trembley JH, 2012, CANCER LETT, V315, P48, DOI 10.1016/j.canlet.2011.10.007; Trembley JH, 2011, MOL CELL BIOCHEM, V356, P21, DOI 10.1007/s11010-011-0943-x; Trembley JH, 2010, BIOFACTORS, V36, P187, DOI 10.1002/biof.96; Ui-Tei K, 2008, NUCLEIC ACIDS RES, V36, P2136, DOI 10.1093/nar/gkn042; Unger GM, 2004, CURR CANCER DRUG TAR, V4, P77, DOI 10.2174/1568009043481687; Unger GM, 2014, MOL CANCER THER, V13, P2018, DOI 10.1158/1535-7163.MCT-14-0166; Van Obberghen-Schilling E, 2011, INT J DEV BIOL, V55, P511, DOI 10.1387/ijdb.103243eo; Wang GX, 2005, MOL CELL BIOCHEM, V274, P77, DOI 10.1007/s11010-005-3077-1; Yao YD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003601; Yokoyama K, 2000, J BIOL CHEM, V275, P16891, DOI 10.1074/jbc.M000610200	52	14	15	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2014	9	10							e109970	10.1371/journal.pone.0109970	http://dx.doi.org/10.1371/journal.pone.0109970			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX2IH	25333839	Green Published, gold, Green Submitted			2023-01-03	WOS:000346766200070
J	Chao, CT; Lee, SY; Yang, WS; Chen, HW; Fang, CC; Yen, CJ; Chiang, CK; Hung, KY; Huang, JW				Chao, Chia-Ter; Lee, Szu-Ying; Yang, Wei-Shun; Chen, Huei-Wen; Fang, Cheng-Chung; Yen, Chung-Jen; Chiang, Chih-Kang; Hung, Kuan-Yu; Huang, Jenq-Wen			Acinetobacter Peritoneal Dialysis Peritonitis: A Changing Landscape over Time	PLOS ONE			English	Article							INFECTIONS RECOMMENDATIONS; MATCHED COHORT; BAUMANNII; MORTALITY; RISK	Background: Acinetobacter species are assuming an increasingly important role in modern medicine, with their persistent presence in health-care settings and antibiotic resistance. However, clinical reports addressing this issue in patients with peritoneal dialysis (PD) peritonitis are rare. Methods: All PD peritonitis episodes caused by Acinetobacter that occurred between 1985 and 2012 at a single centre were retrospectively reviewed. Clinical features, microbiological data, and outcomes were analysed, with stratifications based upon temporal periods (before and after 2000). Results: Acinetobacter species were responsible for 26 PD peritonitis episodes (3.5% of all episodes) in 25 patients. A. baumannii was the most common pathogen (54%), followed by A. iwoffii (35%), with the former being predominant after 2000. Significantly more episodes resulted from breaks in exchange sterility after 2000, while those from exit site infections decreased (P=0.01). The interval between the last and current peritonitis episodes lengthened significantly after 2000 (5 vs. 13.6 months; P=0.05). All the isolates were susceptible to cefepime, fluoroquinolone, and aminoglycosides, with a low ceftazidime resistance rate (16%). Nearly half of the patients (46%) required hospitalisation for their Acinetobacter PD-associated peritonitis, and 27% required an antibiotic switch. The overall outcome was fair, with no mortality and a 12% technique failure rate, without obvious interval differences. Conclusions: The temporal change in the microbiology and origin of Acinetobacter PD-associated peritonitis in our cohort suggested an important evolutional trend. Appropriate measures, including technique re-education and sterility maintenance, should be taken to decrease the Acinetobacter peritonitis incidence in PD patients.	[Chao, Chia-Ter] Natl Taiwan Univ Hosp, Dept Internal Med, Jin Shan Branch, Div Nephrol, New Taipei City, Taiwan; [Chao, Chia-Ter] Natl Taiwan Univ, Grad Inst Toxicol, Taipei 10764, Taiwan; [Lee, Szu-Ying] Natl Taiwan Univ Hosp, Dept Internal Med, Div Nephrol, Yun Lin Branch, Taipei, Taiwan; [Yang, Wei-Shun] Natl Taiwan Univ Hosp, Dept Internal Med, Div Nephrol, Hsin Chu Branch, Taipei, Hsin Chu County, Taiwan; [Chen, Huei-Wen; Hung, Kuan-Yu; Huang, Jenq-Wen] Natl Taiwan Univ Hosp, Dept Internal Med, Div Nephrol, Taipei 100, Taiwan; [Fang, Cheng-Chung] Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei 100, Taiwan; [Yen, Chung-Jen] Natl Taiwan Univ Hosp, Dept Geriatr & Gerontol, Taipei 100, Taiwan; [Chiang, Chih-Kang] Natl Taiwan Univ Hosp, Dept Integrat Diagnost & Therapeut, Taipei 100, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Huang, JW (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, Div Nephrol, Taipei 100, Taiwan.	007378@ntuh.gov.tw	Yang, Weishun/AAR-6218-2020; Chao, Chia-Ter/H-7994-2019	Yang, Weishun/0000-0002-3249-280X; Chao, Chia-Ter/0000-0003-2892-7986; HUNG, KUAN-YU/0000-0003-3472-5512; CHIANG, CHIH-KANG/0000-0001-9021-4616; YEN, CHUNG-JEN/0000-0001-5372-3657; FANG, CHENG-CHUNG/0000-0001-5386-6674; CHEN, HUEI-WEN/0000-0001-5051-9896; HUANG, JENQ-WEN/0000-0001-8011-2317	National Taiwan University Hospital intramural fund [102-N2249]	National Taiwan University Hospital intramural fund	This study is financially supported by National Taiwan University Hospital intramural fund (project NO. 102-N2249). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbo A, 2007, EUR J CLIN MICROBIOL, V26, P793, DOI 10.1007/s10096-007-0371-8; Baboolal K, 2008, NEPHROL DIAL TRANSPL, V23, P1982, DOI 10.1093/ndt/gfm870; Barraclough K, 2010, AM J KIDNEY DIS, V55, P121, DOI 10.1053/j.ajkd.2009.08.020; Chao CT, 2013, J AM COLL SURGEONS, V217, P240, DOI 10.1016/j.jamcollsurg.2013.03.024; Chao CT, 2013, INT J MED SCI, V10, P1092, DOI 10.7150/ijms.6251; Chao CT, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-111; Chao CT, 2012, KIDNEY INT, V82, P920, DOI 10.1038/ki.2012.237; Falagas ME, 2006, CRIT CARE, V10, DOI [10.1186/cc4910, 10.1186/cc4869]; Falagas ME, 2006, J ANTIMICROB CHEMOTH, V57, P1251, DOI 10.1093/jac/dkl130; Friedman O, 2008, PERITON DIALYSIS INT, V28, P195; GALVAO C, 1989, AM J KIDNEY DIS, V14, P101, DOI 10.1016/S0272-6386(89)80184-2; GERNERSMIDT P, 1991, J CLIN MICROBIOL, V29, P277, DOI 10.1128/JCM.29.2.277-282.1991; Jarvis EM, 2010, KIDNEY INT, V78, P408, DOI 10.1038/ki.2010.149; Keane WF, 2000, PERITON DIALYSIS INT, V20, P396; Kern EO, 2002, PERITON DIALYSIS INT, V22, P323; Lafrance JP, 2012, CLIN J AM SOC NEPHRO, V7, P1598, DOI 10.2215/CJN.00440112; Li PKT, 2013, AM J KIDNEY DIS, V62, P993, DOI 10.1053/j.ajkd.2013.03.038; Li PKT, 2010, PERITON DIALYSIS INT, V30, P393, DOI 10.3747/pdi.2010.00049; LYE WC, 1991, ADV PERIT D, V7, P176; LYE WC, 1994, PERITON DIALYSIS INT, V14, P174; McConnell MJ, 2013, FEMS MICROBIOL REV, V37, P130, DOI 10.1111/j.1574-6976.2012.00344.x; Najafi I, 2013, PERIT DIAL INT; Piraino B, 2005, PERITON DIALYSIS INT, V25, P107; PROWANT B, 1986, NEPHRON, V43, P105, DOI 10.1159/000183807; Szeto CC, 2005, CLIN MICROBIOL INFEC, V11, P837, DOI 10.1111/j.1469-0691.2005.01222.x; Towner KJ, 2009, J HOSP INFECT, V73, P355, DOI 10.1016/j.jhin.2009.03.032; Zarrilli R, 2013, INT J ANTIMICROB AG, V41, P11, DOI 10.1016/j.ijantimicag.2012.09.008; Zelenitsky S, 2000, AM J KIDNEY DIS, V36, P1009, DOI 10.1053/ajkd.2000.19103	28	10	10	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2014	9	10							e110315	10.1371/journal.pone.0110315	http://dx.doi.org/10.1371/journal.pone.0110315			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR5ZW	25314341	gold, Green Published, Green Submitted			2023-01-03	WOS:000343662500107
J	Huang, RJ; Zhang, YL; Bozzetti, C; Ho, KF; Cao, JJ; Han, YM; Daellenbach, KR; Slowik, JG; Platt, SM; Canonaco, F; Zotter, P; Wolf, R; Pieber, SM; Bruns, EA; Crippa, M; Ciarelli, G; Piazzalunga, A; Schwikowski, M; Abbaszade, G; Schnelle-Kreis, J; Zimmermann, R; An, ZS; Szidat, S; Baltensperger, U; El Haddad, I; Prevot, ASH				Huang, Ru-Jin; Zhang, Yanlin; Bozzetti, Carlo; Ho, Kin-Fai; Cao, Jun-Ji; Han, Yongming; Daellenbach, Kaspar R.; Slowik, Jay G.; Platt, Stephen M.; Canonaco, Francesco; Zotter, Peter; Wolf, Robert; Pieber, Simone M.; Bruns, Emily A.; Crippa, Monica; Ciarelli, Giancarlo; Piazzalunga, Andrea; Schwikowski, Margit; Abbaszade, Guelcin; Schnelle-Kreis, Juergen; Zimmermann, Ralf; An, Zhisheng; Szidat, Soenke; Baltensperger, Urs; El Haddad, Imad; Prevot, Andre S. H.			High secondary aerosol contribution to particulate pollution during haze events in China	NATURE			English	Article							ORGANIC AEROSOLS; SOURCE APPORTIONMENT; PM2.5; EMISSIONS; FIELD	Rapid industrialization and urbanization in developing countries has led to an increase in air pollution, along a similar trajectory to that previously experienced by the developed nations(1). In China, particulate pollution is a serious environmental problem that is influencing air quality, regional and global climates, and human health(2,3). In response to the extremely severe and persistent haze pollution experienced by about 800 million people during the first quarter of 2013 (refs 4, 5), the Chinese State Council announced its aim to reduce concentrations of PM2.5 (particulate matter with an aerodynamic diameter less than 2.5 micrometres) by up to 25 per cent relative to 2012 levels by 2017 (ref. 6). Such efforts however require elucidation of the factors governing the abundance and composition of PM2.5, which remain poorly constrained in China(3,7,8). Here we combine a comprehensive set of novel and state-of-the-art offline analytical approaches and statistical techniques to investigate the chemical nature and sources of particulate matter at urban locations in Beijing, Shanghai, Guangzhou and Xi'an during January 2013. We find that the severe haze pollution event was driven to a large extent by secondary aerosol formation, which contributed 30-77 per cent and 44-71 per cent (average for all four cities) of PM2.5 and of organic aerosol, respectively. On average, the contribution of secondary organic aerosol (SOA) and secondary inorganic aerosol (SIA) are found to be of similar importance (SOA/SIA ratios range from 0.6 to 1.4). Our results suggest that, in addition to mitigating primary particulate emissions, reducing the emissions of secondary aerosol precursors from, for example, fossil fuel combustion and biomass burning is likely to be important for controlling China's PM2.5 levels and for reducing the environmental, economic and health impacts resulting from particulate pollution.	[Huang, Ru-Jin; Bozzetti, Carlo; Daellenbach, Kaspar R.; Slowik, Jay G.; Platt, Stephen M.; Canonaco, Francesco; Zotter, Peter; Wolf, Robert; Pieber, Simone M.; Bruns, Emily A.; Crippa, Monica; Ciarelli, Giancarlo; Baltensperger, Urs; El Haddad, Imad; Prevot, Andre S. H.] PSI, Lab Atmospher Chem, CH-5232 Villigen, Switzerland; [Huang, Ru-Jin; Cao, Jun-Ji; Han, Yongming; An, Zhisheng] Chinese Acad Sci, Inst Earth Environm, SKLLQG, Xian 710075, Peoples R China; [Huang, Ru-Jin; Cao, Jun-Ji; Han, Yongming; An, Zhisheng] Chinese Acad Sci, Inst Earth Environm, Key Lab Aerosol Chem & Phys, Xian 710075, Peoples R China; [Zhang, Yanlin; Schwikowski, Margit; Szidat, Soenke] Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; [Zhang, Yanlin; Schwikowski, Margit; Szidat, Soenke] Univ Bern, Oeschger Ctr Climate Change Res, CH-3012 Bern, Switzerland; [Zhang, Yanlin; Schwikowski, Margit] PSI, Lab Radiochem & Environm Chem, CH-5232 Villigen, Switzerland; [Ho, Kin-Fai] Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Hong Kong, Hong Kong, Peoples R China; [Piazzalunga, Andrea] Univ Milano Bicocca, Dept Earth & Environm Sci, I-20126 Milan, Italy; [Abbaszade, Guelcin; Schnelle-Kreis, Juergen; Zimmermann, Ralf] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth GmbH, Joint Mass Spectrometry Ctr, Cooperat Grp Comprehens Mol Analyt, D-85764 Neuherberg, Germany; [Abbaszade, Guelcin; Schnelle-Kreis, Juergen; Zimmermann, Ralf] Helmholtz Virtual Inst Complex Mol Syst Environm, D-85764 Neuherberg, Germany; [Zimmermann, Ralf] Univ Rostock, Joint Mass Spectrometry Ctr, Inst Chem, D-18015 Rostock, Germany	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Chinese Academy of Sciences; Institute of Earth Environment, CAS; Chinese Academy of Sciences; Institute of Earth Environment, CAS; University of Bern; University of Bern; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Chinese University of Hong Kong; University of Milano-Bicocca; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Rostock	Cao, JJ (corresponding author), Chinese Acad Sci, Inst Earth Environm, SKLLQG, Xian 710075, Peoples R China.	jjcao@ieecas.cn; andre.prevot@psi.ch	Zhang, Yanlin/AAH-7770-2021; AN, Zhisheng/F-8834-2012; Schnelle-Kreis, Jürgen/M-9845-2014; Dällenbach, Kaspar Rudolf/ABB-4630-2020; Junji, Cao/D-3259-2014; Zhang, Yan-Lin/I-3875-2012; Platt, Stephen M/G-1678-2019; Haddad, Imad El/B-8073-2011; bruns, emily/A-4558-2013; Huang, Ru-Jin/K-5022-2018; Szidat, Sönke/D-6706-2011; Crippa, Monica/ABD-8045-2021; Prevot, Andre S. H./C-6677-2008; Ho, Kin Fai/E-6131-2011; Daellenbach, Kaspar/AAY-4521-2020; Francesco, Canonaco/GZN-0838-2022; Slowik, Jay G/F-4894-2011	Schnelle-Kreis, Jürgen/0000-0003-4846-2303; Dällenbach, Kaspar Rudolf/0000-0003-1246-6396; Junji, Cao/0000-0003-1000-7241; Zhang, Yan-Lin/0000-0002-8722-8635; Platt, Stephen M/0000-0002-8439-6633; Haddad, Imad El/0000-0002-2461-7238; Huang, Ru-Jin/0000-0002-4907-9616; Szidat, Sönke/0000-0002-1824-6207; Prevot, Andre S. H./0000-0002-9243-8194; Ho, Kin Fai/0000-0001-7464-3437; Slowik, Jay G/0000-0001-5682-850X; Pieber, Simone M./0000-0002-5674-6640; an, zhi sheng/0000-0002-9538-9826; Schwikowski, Margit/0000-0002-0856-5183	European Community [290605]; Swiss National Science Foundation (SAPMAV) [200021_13016]; Swiss National Science Foundation (WOOSHI) [200021L_140590]; Swiss National Science Foundation (Ambizione) [PZ00P2_131673]; Swiss Competence Center Environment and Sustainability; Swiss Competence Center Energy and Mobility under project OPTIWARES; National Science Foundation of China [40925009]; "Strategic Priority Research Program'' of the Chinese Academy of Sciences [XDA05100402]; Helmholtz Virtual Institute of Complex Molecular Systems in Environmental Health - Aerosol and Health (HICE)	European Community(European Commission); Swiss National Science Foundation (SAPMAV)(Swiss National Science Foundation (SNSF)); Swiss National Science Foundation (WOOSHI)(Swiss National Science Foundation (SNSF)); Swiss National Science Foundation (Ambizione)(Swiss National Science Foundation (SNSF)); Swiss Competence Center Environment and Sustainability; Swiss Competence Center Energy and Mobility under project OPTIWARES; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); "Strategic Priority Research Program'' of the Chinese Academy of Sciences(Chinese Academy of Sciences); Helmholtz Virtual Institute of Complex Molecular Systems in Environmental Health - Aerosol and Health (HICE)	The research leading to these results received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 290605, the Swiss National Science Foundation (SAPMAV, no. 200021_13016, WOOSHI, no. 200021L_140590, and Ambizione, PZ00P2_131673), the Swiss Competence Centers Environment and Sustainability as well as Energy and Mobility under project OPTIWARES, the National Science Foundation of China (no. 40925009), the "Strategic Priority Research Program'' of the Chinese Academy of Sciences (XDA05100402), and the Helmholtz Virtual Institute of Complex Molecular Systems in Environmental Health - Aerosol and Health (HICE). The help of G. Salazar (University of Bern) during <SUP>14</SUP>C analysis is acknowledged.	[Anonymous], 1998, CMB8 APPL VALIDATION; Atkinson R, 2003, CHEM REV, V103, P4605, DOI 10.1021/cr0206420; Canonaco F, 2013, ATMOS MEAS TECH, V6, P3649, DOI 10.5194/amt-6-3649-2013; Cao J., 2012, J EARTH ENV, V3, P1030; Cao JJ, 2013, J GEOPHYS RES-ATMOS, V118, P4834, DOI 10.1002/jgrd.50381; Chen RJ, 2013, AM J RESP CRIT CARE, V188, P1170, DOI 10.1164/rccm.201304-0678LE; China National Environmental Monitoring Centre, AIR QUAL REP 74 CHIN; Chinese State Council, ATM POLL PREV CONTR; DeCarlo PF, 2006, ANAL CHEM, V78, P8281, DOI 10.1021/ac061249n; Ervens B, 2011, ATMOS CHEM PHYS, V11, P11069, DOI 10.5194/acp-11-11069-2011; Hallquist M, 2009, ATMOS CHEM PHYS, V9, P5155, DOI 10.5194/acp-9-5155-2009; Jimenez JL, 2009, SCIENCE, V326, P1525, DOI 10.1126/science.1180353; Orasche J, 2011, ATMOS CHEM PHYS, V11, P8977, DOI 10.5194/acp-11-8977-2011; Pandis S. N., 2006, ATMOSPHERIC CHEM PHY; Robinson AL, 2007, SCIENCE, V315, P1259, DOI 10.1126/science.1133061; Saravanan R., 2014, NATURE COMMUN, P5; Seinfeld JH, 2004, AICHE J, V50, P1096, DOI 10.1002/aic.10102; Tiwari S, 2013, ATMOS RES, V125, P50, DOI 10.1016/j.atmosres.2013.01.011; UNEP, 2013, AFR ENV OUTL 3 OUR E; Wang GH, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL027624; Wang X, 2013, ATMOS CHEM PHYS, V13, P10919, DOI 10.5194/acp-13-10919-2013; Wang XF, 2012, ATMOS ENVIRON, V63, P68, DOI 10.1016/j.atmosenv.2012.09.029; Wang Y, 2013, ATMOS CHEM PHYS, V13, P2635, DOI 10.5194/acp-13-2635-2013; World Health Organization, 7 MILL PREM DEATHS A; Wuebbles DJ, 2007, ENVIRON POLLUT, V150, P65, DOI 10.1016/j.envpol.2007.06.066; Xing J, 2011, ATMOS CHEM PHYS, V11, P3119, DOI 10.5194/acp-11-3119-2011; Yang F, 2011, ATMOS CHEM PHYS, V11, P5207, DOI 10.5194/acp-11-5207-2011; Zhang Q, 2012, NATURE, V484, P161, DOI 10.1038/484161a; Zhang YL, 2012, ATMOS CHEM PHYS, V12, P10841, DOI 10.5194/acp-12-10841-2012; Zheng M, 2005, ATMOS ENVIRON, V39, P3967, DOI 10.1016/j.atmosenv.2005.03.036	30	2863	3206	306	4685	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 9	2014	514	7521					218	222		10.1038/nature13774	http://dx.doi.org/10.1038/nature13774			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ3BG	25231863	Green Accepted			2023-01-03	WOS:000342663100040
J	Hinman, RS; McCrory, P; Pirotta, M; Relf, I; Forbes, A; Crossley, KM; Williamson, E; Kyriakides, M; Novy, K; Metcalf, BR; Harris, A; Reddy, P; Conaghan, PG; Bennell, KL				Hinman, Rana S.; McCrory, Paul; Pirotta, Marie; Relf, Ian; Forbes, Andrew; Crossley, Kay M.; Williamson, Elizabeth; Kyriakides, Mary; Novy, Kitty; Metcalf, Ben R.; Harris, Anthony; Reddy, Prasuna; Conaghan, Philip G.; Bennell, Kim L.			Acupuncture for Chronic Knee Pain A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OSTEOARTHRITIS; HIP; OUTCOMES; LASER; RECOMMENDATIONS; INTERVENTION; MANAGEMENT; THERAPY; WOMAC	IMPORTANCE There is debate about benefits of acupuncture for knee pain. OBJECTIVE To determine the efficacy of laser and needle acupuncture for chronic knee pain. DESIGN, SETTING, AND PARTICIPANTS Zelen-design clinical trial (randomization occurred before informed consent), in Victoria, Australia (February 2010-December 2012). Community volunteers (282 patients aged >= 50 years with chronic knee pain) were treated by family physician acupuncturists. INTERVENTIONS No acupuncture (control group, n = 71) and needle (n = 70), laser (n = 71), and sham laser (n = 70) acupuncture. Treatments were delivered for 12 weeks. Participants and acupuncturists were blinded to laser and sham laser acupuncture. Control participants were unaware of the trial. MAIN OUTCOMES AND MEASURES Primary outcomes were average knee pain (numeric rating scale, 0 [no pain] to 10 [worst pain possible]; minimal clinically important difference [MCID], 1.8 units) and physical function (Western Ontario and McMaster Universities Osteoarthritis Index, 0 [no difficulty] to 68 [extreme difficulty]; MCID, 6 units) at 12 weeks. Secondary outcomes included other pain and function measures, quality of life, global change, and 1-year follow-up. Analyses were by intention-to-treat using multiple imputation for missing outcome data. RESULTS At 12 weeks and 1 year, 26 (9%) and 50 (18%) participants were lost to follow-up, respectively. Analyses showed neither needle nor laser acupuncture significantly improved pain (mean difference; -0.4 units; 95% CI, -1.2 to 0.4, and -0.1; 95% CI, -0.9 to 0.7, respectively) or function (-1.7; 95% CI, -6.1 to 2.6, and 0.5; 95% CI, -3.4 to 4.4, respectively) compared with sham at 12 weeks. Compared with control, needle and laser acupuncture resulted in modest improvements in pain (-1.1; 95% CI, -1.8 to -0.4, and -0.8; 95% CI, -1.5 to -0.1, respectively) at 12 weeks, but not at 1 year. Needle acupuncture resulted in modest improvement in function compared with control at 12 weeks (-3.9; 95% CI, -7.7 to -0.2) but was not significantly different from sham (-1.7; 95% CI, -6.1 to 2.6) and was not maintained at 1 year. There were no differences for most secondary outcomes and no serious adverse events. CONCLUSIONS AND RELEVANCE In patients older than 50 years with moderate or severe chronic knee pain, neither laser nor needle acupuncture conferred benefit over sham for pain or function. Our findings do not support acupuncture for these patients. Copyright 2014 American Medical Association. All rights reserved.	[Hinman, Rana S.; McCrory, Paul; Metcalf, Ben R.; Bennell, Kim L.] Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Physiotherapy, Ctr Hlth Exercise & Sports Med,Sch Hlth Sci, Melbourne, Vic 3010, Australia; [McCrory, Paul] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Pirotta, Marie; Relf, Ian; Kyriakides, Mary; Novy, Kitty] Univ Melbourne, Fac Med Dent & Hlth Sci, Sch Med, Dept Gen Practice, Melbourne, Vic 3010, Australia; [Forbes, Andrew] Monash Univ, Fac Med Nursing & Hlth Sci, Melbourne, Vic 3004, Australia; [Crossley, Kay M.] Univ Queensland, Sch Hlth & Rehabil Sci, Div Physiotherapy, Brisbane, Qld, Australia; [Williamson, Elizabeth] Farr Inst Hlth Informat Res, London, England; [Williamson, Elizabeth] London Sch Hyg & Trop Med, Dept Med Stat, London WC1, England; [Harris, Anthony] Monash Univ, Fac Business & Econ, Ctr Hlth Econ, Melbourne, Vic 3004, Australia; [Reddy, Prasuna] Univ Newcastle, Fac Hlth & Med, Sch Med & Publ Hlth, Newcastle, NSW 2300, Australia; [Conaghan, Philip G.] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England; [Conaghan, Philip G.] NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England	University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Monash University; University of Queensland; University of London; London School of Hygiene & Tropical Medicine; Monash University; University of Newcastle; University of Leeds; Leeds Biomedical Research Centre	Hinman, RS (corresponding author), Univ Melbourne, Sch Hlth Sci, Dept Physiotherapy, Ctr Hlth Exercise & Sports Med, Melbourne, Vic 3010, Australia.	ranash@unimelb.edu.au	McCrory, Paul/Q-8688-2019; Crossley, Kay M/G-4436-2010; Bennell, Kim/C-7022-2014	Harris, Anthony/0000-0003-1641-3320; Metcalf, Ben/0000-0002-4945-3217; Crossley, Kay/0000-0001-5892-129X; Forbes, Andrew/0000-0003-4269-914X; McCrory, Paul/0000-0003-4850-0568; Bennell, Kim/0000-0003-4982-5639; Reddy, Prasuna/0000-0002-0709-9352; Hinman, Rana/0000-0001-6368-9456; Conaghan, Philip/0000-0002-3478-5665; Relf, Ian/0000-0002-9708-5906	National Health and Medical Research Council [566783, 1026383, 1050830, 1004233]; Australian Research Council Future Fellowships [FT130100175, FT0991413]	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council Future Fellowships(Australian Research Council)	This trial was funded by the National Health and Medical Research Council (project 566783). Drs Hinman and Bennell are both funded in part by Australian Research Council Future Fellowships (FT130100175 and FT0991413, respectively). Dr McCrory is funded in part by a National Health and Medical Research Council Practitioner Fellowship (1026383). Dr Pirotta is funded in part by a National Health and Medical Research Council Career Development Fellowship (1050830). Dr Williamson was funded in part by a National Health and Medical Research Council grant (1004233).	Abhishek A, 2013, OSTEOARTHR CARTILAGE, V21, P1229, DOI 10.1016/j.joca.2013.04.018; Adamson J, 2006, CONTEMP CLIN TRIALS, V27, P305, DOI 10.1016/j.cct.2005.11.003; American Academy of Orthopaedic Surgeons, TREATM OST KNEE EV B; Angst F, 2001, ARTHRIT RHEUM-ARTHR, V45, P384, DOI 10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0; [Anonymous], 1984, LANCET, V1, P1445; Barnes Patricia M, 2008, Natl Health Stat Report, P1; Baxter GD, 2008, J ACUPUNCT MERIDIAN, V1, P65, DOI 10.1016/S2005-2901(09)60026-1; BELLAMY N, 1992, J RHEUMATOL, V19, P451; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bishop FL, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-102; CHANG RW, 1990, J BONE JOINT SURG AM, V72A, P1451, DOI 10.2106/00004623-199072100-00004; Chow RT, 2009, LANCET, V374, P1897, DOI 10.1016/S0140-6736(09)61522-1; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Fernandes L, 2013, ANN RHEUM DIS, V72, P1125, DOI 10.1136/annrheumdis-2012-202745; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Hawthorne G, 2005, AUST NZ J PUBL HEAL, V29, P136, DOI 10.1111/j.1467-842X.2005.tb00063.x; Hinman RS, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-161; Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596; Huang WJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032960; Ilbuldu E, 2004, PHOTOMED LASER SURG, V22, P306; Irnich D, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq009; Jinks C, 2004, RHEUMATOLOGY, V43, P55, DOI 10.1093/rheumatology/keg438; Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006; Lund Irene, 2006, Acupunct Med, V24, P13; MacPherson Hugh, 2010, J Evid Based Med, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x; MacPherson H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077438; Mantyselka P, 2001, PAIN, V89, P175, DOI 10.1016/S0304-3959(00)00361-4; McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003; Quilty B, 2003, J RHEUMATOL, V30, P1311; Relf I, 2008, EVID-BASED COMPL ALT, V5, P383, DOI 10.1093/ecam/nem085; Sherman KJ, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-114; Stuart E, 2008, PREV SCI, V9, P288, DOI 10.1007/s11121-008-0104-y; Tubach F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ard.2004.022905; Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654; Witt CM, 2013, COMPLEMENT THER MED, V21, P112, DOI 10.1016/j.ctim.2012.12.005; Yousefi-Nooraie R, 2007, COCHRANE DB SYST REV, V2; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; Zhang W, 2008, ANN RHEUM DIS, V67, P1716, DOI 10.1136/ard.2008.092015	38	150	189	7	94	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2014	312	13					1313	1322		10.1001/jama.2014.12660	http://dx.doi.org/10.1001/jama.2014.12660			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AP8RB	25268438	Green Published, Green Accepted			2023-01-03	WOS:000342345400017
J	Shigehiro, T; Kasai, T; Murakami, M; Sekhar, SC; Tominaga, Y; Okada, M; Kudoh, T; Mizutani, A; Murakami, H; Salomon, DS; Mikuni, K; Mandai, T; Hamada, H; Seno, M				Shigehiro, Tsukasa; Kasai, Tomonari; Murakami, Masaharu; Sekhar, Sreeja C.; Tominaga, Yuki; Okada, Masashi; Kudoh, Takayuki; Mizutani, Akifumi; Murakami, Hiroshi; Salomon, David S.; Mikuni, Katsuhiko; Mandai, Tadakatsu; Hamada, Hiroki; Seno, Masaharu			Efficient Drug Delivery of Paclitaxel Glycoside: A Novel Solubility Gradient Encapsulation into Liposomes Coupled with Immunoliposomes Preparation	PLOS ONE			English	Article							BREAST-CANCER CELLS; ANTI-HER2 IMMUNOLIPOSOMES; FORMULATIONS; NANOPARTICLES; EFFICACY; TAXOIDS; TUMORS; EGFR	Although the encapsulation of paclitaxel into liposomes has been extensively studied, its significant hydrophobic and uncharged character has generated substantial difficulties concerning its efficient encapsulation into the inner water core of liposomes. We found that a more hydrophilic paclitaxel molecule, 7-glucosyloxyacetylpaclitaxel, retained tubulin polymerization stabilization activity. The hydrophilic nature of 7-glucosyloxyacetylpaclitaxel allowed its efficient encapsulation into the inner water core of liposomes, which was successfully accomplished using a remote loading method with a solubility gradient between 40% ethylene glycol and Cremophor EL/ethanol in PBS. Trastuzumab was then conjugated onto the surface of liposomes as immunoliposomes to selectively target human epidermal growth factor receptor-2 (HER2)-overexpressing cancer cells. In vitro cytotoxicity assays revealed that the immunoliposomes enhanced the toxicity of 7-glucosyloxyacetylpaclitaxel in HER2-overexpressing cancer cells and showed more rapid suppression of cell growth. The immunoliposomes strongly inhibited the tumor growth of HT-29 cells xenografted in nude mice. Notably, mice survived when treated with the immunoliposomes formulation, even when administered at a lethal dose of 7glucosyloxyacetylpaclitaxel in vivo. This data successfully demonstrates immunoliposomes as a promising candidate for the efficient delivery of paclitaxel glycoside.	[Shigehiro, Tsukasa; Kasai, Tomonari; Murakami, Masaharu; Sekhar, Sreeja C.; Tominaga, Yuki; Okada, Masashi; Kudoh, Takayuki; Mizutani, Akifumi; Murakami, Hiroshi; Seno, Masaharu] Okayama Univ, Grad Sch Nat Sci & Technol, Dept Biotechnol, Okayama 7008530, Japan; [Salomon, David S.] NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21701 USA; [Mikuni, Katsuhiko] Ensuiko Sugar Refining Co Ltd, Tokyo, Japan; [Mandai, Tadakatsu] Kurashiki Univ Sci & Arts, Fac Life Sci, Kurashiki, Okayama, Japan; [Hamada, Hiroki] Okayama Univ Sci, Fac Sci, Okayama, Japan	Okayama University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Okayama University of Science	Hamada, H (corresponding author), Okayama Univ Sci, Fac Sci, Okayama, Japan.	hamada@dls.ous.ac.jp; mseno@okayama-u.ac.jp	Shigehiro, Tsukasa/AHA-5978-2022; Shigehiro, Tsukasa/R-5805-2019; hamada, hiroki/A-4276-2009; SENO, Masaharu/B-2092-2011	Shigehiro, Tsukasa/0000-0002-5286-5108; SENO, Masaharu/0000-0001-8547-6259; sekhar, sreeja/0000-0002-9827-5349	Ministry of Education, Culture, Sports, Science and Technology of Japan [23650598, 25242045, 26640079, 24510151, 24501315]; Japan Society for the Promotion of Science; Ensuiko Sugar Refining Co., Ltd. (Tokyo, Japan); Grants-in-Aid for Scientific Research [24510151] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ensuiko Sugar Refining Co., Ltd. (Tokyo, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was partly supported by Grant-in-Aid for Challenging Exploratory Research No. 23650598 (MS), 25242045 (MS), and 26640079 (MS); Grant-in-Aid for Scientific Research (C) Nos. 24510151 (T. Kasai) and 24501315 (AM) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (http://www.mext.go.jp); and from the Japan Society for the Promotion of Science (http://www.jsps.go.jp). This research was funded by a commercial company, Ensuiko Sugar Refining Co., Ltd. (Tokyo, Japan). Ensuiko Sugar Refining Co., Ltd. had a role in the study design. The other funders had no role in study design. All funders had no role in data collection and analysis, decision to publish, or preparation of the manuscript in this study.	Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037; Barenholz Y, 2012, J CONTROL RELEASE, V160, P117, DOI 10.1016/j.jconrel.2012.03.020; Crosasso P, 2000, J CONTROL RELEASE, V63, P19, DOI 10.1016/S0168-3659(99)00166-2; Desai N, 2006, CLIN CANCER RES, V12, P1317, DOI 10.1158/1078-0432.CCR-05-1634; Fetterly GJ, 2003, AAPS PHARMSCI, V5; Gao J, 2011, BIOMATERIALS, V32, P3459, DOI 10.1016/j.biomaterials.2011.01.034; Gelderblom H, 2001, EUR J CANCER, V37, P1590, DOI 10.1016/S0959-8049(01)00171-X; Kan P, 2011, J DRUG DELIV, V2011, DOI 10.1155/2011/629234; Kirpotin DB, 2006, CANCER RES, V66, P6732, DOI 10.1158/0008-5472.CAN-05-4199; Koudelka S, 2012, J CONTROL RELEASE, V163, P322, DOI 10.1016/j.jconrel.2012.09.006; Koudelka S, 2010, J PHARM SCI-US, V99, P2309, DOI 10.1002/jps.21992; Ma P, 2013, J NANOMED NANOTECHNO, V4, DOI DOI 10.4172/2157-7439.1000164; Mandai T, 2001, HETEROCYCLES, V54, P561, DOI 10.3987/COM-00-S(I)34; Maruyama K, 2011, ADV DRUG DELIVER REV, V63, P161, DOI 10.1016/j.addr.2010.09.003; Park JW, 1997, CANCER LETT, V118, P153, DOI 10.1016/S0304-3835(97)00326-1; Park JW, 2002, CLIN CANCER RES, V8, P1172; Park JW, 2001, J CONTROL RELEASE, V74, P95, DOI 10.1016/S0168-3659(01)00315-7; PAZDUR R, 1993, CANCER TREAT REV, V19, P351, DOI 10.1016/0305-7372(93)90010-O; Rusnak DW, 2007, CELL PROLIFERAT, V40, P580, DOI 10.1111/j.1365-2184.2007.00455.x; Sharma A, 1997, INT J CANCER, V71, P103, DOI 10.1002/(SICI)1097-0215(19970328)71:1<103::AID-IJC17>3.0.CO;2-J; Singla AK, 2002, INT J PHARMACEUT, V235, P179, DOI 10.1016/S0378-5173(01)00986-3; Sparreboom A, 1997, P NATL ACAD SCI USA, V94, P2031, DOI 10.1073/pnas.94.5.2031; Spratlin J, 2007, CRIT REV ONCOL HEMAT, V61, P222, DOI 10.1016/j.critrevonc.2006.09.006; Steinhauser I, 2006, BIOMATERIALS, V27, P4975, DOI 10.1016/j.biomaterials.2006.05.016; Tai WY, 2010, J CONTROL RELEASE, V146, P264, DOI 10.1016/j.jconrel.2010.04.009; Vaidyanath A, 2011, J CELL MOL MED, V15, P2525, DOI 10.1111/j.1582-4934.2011.01277.x; Wang HB, 2013, MOL MED REP, V7, P947, DOI 10.3892/mmr.2013.1264; Xu H, 2005, MOL CANCER THER, V4, P435; Yang T, 2007, PHARM RES-DORDR, V24, P2402, DOI 10.1007/s11095-007-9425-y; Yang T, 2007, J CONTROL RELEASE, V120, P169, DOI 10.1016/j.jconrel.2007.05.011; Yang T, 2007, INT J PHARMACEUT, V338, P317, DOI 10.1016/j.ijpharm.2007.02.011; Yoshizawa Y, 2011, INT J PHARMACEUT, V412, P132, DOI 10.1016/j.ijpharm.2011.04.008; Zhigaltsev IV, 2010, J CONTROL RELEASE, V144, P332, DOI 10.1016/j.jconrel.2010.02.029	33	26	26	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2014	9	9							e107976	10.1371/journal.pone.0107976	http://dx.doi.org/10.1371/journal.pone.0107976			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU6XR	25264848	Green Published, Green Submitted, gold			2023-01-03	WOS:000345745400036
J	Heath, B				Heath, Bob			The art of medicine "Hello it's me...why aren't you there?"	LANCET			English	Editorial Material												Bob.heath.therapy@gmail.com							0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 13	2014	384	9947					948	949		10.1016/S0140-6736(14)61618-4	http://dx.doi.org/10.1016/S0140-6736(14)61618-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AO9ML	25225702				2023-01-03	WOS:000341679700013
J	D'Souza, DV; Jonckers, E; Bruns, A; Kunnecke, B; von Kienlin, M; Van der Linden, A; Mueggler, T; Verhoye, M				D'Souza, Dany V.; Jonckers, Elisabeth; Bruns, Andreas; Kuennecke, Basil; von Kienlin, Markus; Van der Linden, Annemie; Mueggler, Thomas; Verhoye, Marleen			Preserved Modular Network Organization in the Sedated Rat Brain	PLOS ONE			English	Article							STATE FUNCTIONAL CONNECTIVITY; RESTING-STATE; DEFAULT-MODE; SPONTANEOUS FLUCTUATIONS; ANESTHESIA; CORRELATE; SIGNALS; CORTEX; FMRI	Translation of resting-state functional connectivity (FC) magnetic resonance imaging (rs-fMRI) applications from human to rodents has experienced growing interest, and bears a great potential in pre-clinical imaging as it enables assessing non-invasively the topological organization of complex FC networks (FCNs) in rodent models under normal and various pathophysiological conditions. However, to date, little is known about the organizational architecture of FCNs in rodents in a mentally healthy state, although an understanding of the same is of paramount importance before investigating networks under compromised states. In this study, we characterized the properties of resting-state FCN in an extensive number of Sprague-Dawley rats (n = 40) under medetomidine sedation by evaluating its modular organization and centrality of brain regions and tested for reproducibility. Fully-connected large-scale complex networks of positively and negatively weighted connections were constructed based on Pearson partial correlation analysis between the time courses of 36 brain regions encompassing almost the entire brain. Applying recently proposed complex network analysis measures, we show that the rat FCN exhibits a modular architecture, comprising six modules with a high between subject reproducibility. In addition, we identified network hubs with strong connections to diverse brain regions. Overall our results obtained under a straight medetomidine protocol show for the first time that the community structure of the rat brain is preserved under pharmacologically induced sedation with a network modularity contrasting from the one reported for deep anesthesia but closely resembles the organization described for the rat in conscious state.	[D'Souza, Dany V.; Bruns, Andreas; Kuennecke, Basil; von Kienlin, Markus; Mueggler, Thomas] F Hoffmann La Roche & Co Ltd, Neurosci Discovery, CH-4002 Basel, Switzerland; [Jonckers, Elisabeth; Van der Linden, Annemie; Verhoye, Marleen] Univ Antwerp, Bio Imaging Lab, B-2020 Antwerp, Belgium	Roche Holding; University of Antwerp	Jonckers, E (corresponding author), Univ Antwerp, Bio Imaging Lab, B-2020 Antwerp, Belgium.	elisabeth.jonckers@uantwerpen.be	Bruns, Andreas/B-7330-2015; Van der Linden, Annemie/L-7855-2017; Mueggler, Thomas/AAC-7998-2020	Bruns, Andreas/0000-0001-6965-641X; Van der Linden, Annemie/0000-0003-2941-6520; Verhoye, Marleen/0000-0002-6267-0611; von Kienlin, Markus/0000-0002-7972-3003	Roche Postdoctoral Fellowship (RPF), Switzerland	Roche Postdoctoral Fellowship (RPF), Switzerland	This work was funded by the Roche Postdoctoral Fellowship (RPF), Switzerland. The funder provided support in the form of salaries for authors DVD, AB, BK, MvK and TM, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017; Anderson JS, 2011, CEREB CORTEX, V21, P1134, DOI 10.1093/cercor/bhq190; Anderson JS, 2011, HUM BRAIN MAPP, V32, P919, DOI 10.1002/hbm.21079; Becerra L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025701; Bifone A, 2010, MAGN RESON IMAGING, V28, P1200, DOI 10.1016/j.mri.2010.07.001; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Chang C, 2009, NEUROIMAGE, V47, P1381, DOI 10.1016/j.neuroimage.2009.04.048; Chhatwal JP, 2013, NEUROLOGY, V81, P736, DOI 10.1212/WNL.0b013e3182a1aafe; De Groof G, 2013, BEHAV BRAIN RES, V239, P43, DOI 10.1016/j.bbr.2012.10.044; Dougan L, 2011, P NATL ACAD SCI USA, V108, P9759, DOI [10.1073/pnas.1101934108, 10.1073/pnas.1200506109]; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Fox MD, 2006, P NATL ACAD SCI USA, V103, P10046, DOI 10.1073/pnas.0604187103; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Hampson M, 2002, HUM BRAIN MAPP, V15, P247, DOI 10.1002/hbm.10022; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Hutchison RM, 2010, J NEUROPHYSIOL, V103, P3398, DOI 10.1152/jn.00141.2010; Jiang TZ, 2004, HUM BRAIN MAPP, V22, P63, DOI 10.1002/hbm.20012; Jonckers E, 2014, MAGN RESON MED, V72, P1103, DOI 10.1002/mrm.24990; Jonckers E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018876; Kalthoff D, 2013, NMR BIOMED, V26, P638, DOI 10.1002/nbm.2908; Kalthoff D, 2011, NEUROIMAGE, V54, P2828, DOI 10.1016/j.neuroimage.2010.10.053; Kannurpatti SS, 2008, NEUROIMAGE, V40, P1738, DOI 10.1016/j.neuroimage.2007.05.061; Keilholz S, 2012, BRAIN CONNECT; Liang ZF, 2012, J NEUROSCI, V32, P10183, DOI 10.1523/JNEUROSCI.1020-12.2012; Liang ZF, 2012, NEUROIMAGE, V59, P1190, DOI 10.1016/j.neuroimage.2011.08.009; Liang ZF, 2011, J NEUROSCI, V31, P3776, DOI 10.1523/JNEUROSCI.4557-10.2011; Liu WC, 2008, BRAIN RES, V1223, P42, DOI 10.1016/j.brainres.2008.05.054; Lu H, 2007, P NATL ACAD SCI USA, V104, P18265, DOI 10.1073/pnas.0705791104; Majeed W, 2009, J MAGN RESON IMAGING, V30, P384, DOI 10.1002/jmri.21848; Mishra AM, 2013, EPILEPSIA, V54, P1214, DOI 10.1111/epi.12227; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Nallasamy N, 2011, NEUROSCIENTIST, V17, P94, DOI 10.1177/1073858410374126; Nasrallah FA, 2012, NEUROIMAGE, V60, P436, DOI 10.1016/j.neuroimage.2011.12.026; Nelson LE, 2003, ANESTHESIOLOGY, V98, P428, DOI 10.1097/00000542-200302000-00024; Orliac F, 2013, SCHIZOPHR RES; Pan WJ, 2011, BRAIN CONNECT, V1, P119, DOI 10.1089/brain.2011.0014; Pawela CP, 2008, MAGN RESON MED, V59, P1021, DOI 10.1002/mrm.21524; Pawela CP, 2010, NEUROIMAGE, V49, P2467, DOI 10.1016/j.neuroimage.2009.09.054; Pawela CP, 2009, NEUROIMAGE, V46, P1137, DOI 10.1016/j.neuroimage.2009.03.004; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rubinov M, 2011, NEUROIMAGE, V56, P2068, DOI 10.1016/j.neuroimage.2011.03.069; Sakoglu U, 2011, BIOCHEM PHARMACOL, V81, P1374, DOI 10.1016/j.bcp.2010.12.029; Schwarz AJ, 2013, BRAIN CONNECT, V3, P503, DOI 10.1089/brain.2013.0168; Schwarz AJ, 2009, NEUROIMAGE, V47, P302, DOI 10.1016/j.neuroimage.2009.03.064; Seminowicz DA, 2012, J NEUROSCI, V32, P15843, DOI 10.1523/JNEUROSCI.2927-12.2012; Shah D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084241; Shim WH, 2013, J NEUROPHYSIOL, V109, P238, DOI 10.1152/jn.00332.2012; Stam Cornelis J, 2007, Nonlinear Biomed Phys, V1, P3, DOI 10.1186/1753-4631-1-3; Supekar K, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000100; van den Heuvel MP, 2008, NEUROIMAGE, V43, P528, DOI 10.1016/j.neuroimage.2008.08.010; van den Heuvel MP, 2013, TRENDS COGN SCI, V17, P683, DOI 10.1016/j.tics.2013.09.012; van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008; van Meer MPA, 2012, J NEUROSCI, V32, P4495, DOI 10.1523/JNEUROSCI.3662-11.2012; van Zijl P. C., 2013, SCHIZOPHR B; Wang JH, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00016; Watson C, 2006, RAT BRAIN STEREOTAXI; Williams KA, 2010, MAGN RESON IMAGING, V28, P995, DOI 10.1016/j.mri.2010.03.007; Yu QB, 2011, FRONT SYST NEUROSCI, V5, DOI [10.3389/fnsys.2011.00007, 10.3389/fnsys.2011.00103]; Zhao FQ, 2008, NEUROIMAGE, V39, P248, DOI 10.1016/j.neuroimage.2007.07.063	61	25	25	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2014	9	9							e106156	10.1371/journal.pone.0106156	http://dx.doi.org/10.1371/journal.pone.0106156			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO3LR	25181007	Green Submitted, Green Published, gold			2023-01-03	WOS:000341231500053
J	Mazumder, S; Taneja, S; Bahl, R; Mohan, P; Strand, TA; Sommerfelt, H; Kirkwood, BR; Goyal, N; Van Den Hombergh, H; Martines, J; Bhandari, N				Mazumder, Sarmila; Taneja, Sunita; Bahl, Rajiv; Mohan, Pavitra; Strand, Tor A.; Sommerfelt, Halvor; Kirkwood, Betty R.; Goyal, Nidhi; Van Den Hombergh, Henri; Martines, Jose; Bhandari, Nita		Integrated Management Neonatal	Effect of implementation of Integrated Management of Neonatal and Childhood Illness programme on treatment seeking practices for morbidities in infants: cluster randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARE PRACTICES; IMNCI PROGRAM; HEALTH-CARE; MORTALITY; BEHAVIOR; WORKERS; INTERVENTION; BANGLADESH; NUTRITION; DISTRICT	Objective To determine the effect of implementation of the Integrated Management of Neonatal and Childhood Illness strategy on treatment seeking practices and on neonatal and infant morbidity. Design Cluster randomised trial. Setting Haryana, India. Participants 29 667 births in nine intervention clusters and 30 813 births in nine control clusters. Main outcome measures The pre-specified outcome was the effect on treatment seeking practices. Post hoc exploratory analyses assessed morbidity, hospital admission, post-neonatal infant care, and nutritional status outcomes. Interventions The Integrated Management of Neonatal and Childhood Illness intervention included home visits by community health workers, improved case management of sick children, and strengthening of health systems. Outcomes were ascertained through interviews with randomly selected caregivers: 6204, 3073, and 2045 in intervention clusters and 6163, 3048, and 2017 in control clusters at ages 29 days, 6 months, and 12 months, respectively. Results In the intervention cluster, treatment was sought more often from an appropriate provider for severe neonatal illness (risk ratio 1.76, 95% confidence interval 1.38 to 2.24), for local neonatal infection (4.86, 3.80 to 6.21), and for diarrhoea at 6 months (1.96, 1.38 to 2.79) and 12 months (1.22, 1.06 to 1.42) and pneumonia at 6 months (2.09, 1.31 to 3.33) and 12 months (1.44, 1.00 to 2.08). Intervention mothers reported fewer episodes of severe neonatal illness (risk ratio 0.82, 0.67 to 0.99) and lower prevalence of diarrhoea (0.71, 0.60 to 0.83) and pneumonia (0.73, 0.52 to 1.04) in the two weeks preceding the 6 month interview and of diarrhoea (0.63, 0.49 to 0.80) and pneumonia (0.60, 0.46 to 0.78) in the two weeks preceding the 12 month interview. Infants in the intervention clusters were more likely to still be exclusively breast fed in the sixth month of life (risk ratio 3.19, 2.67 to 3.81). Conclusion Implementation of the Integrated Management of Neonatal and Childhood Illness programme was associated with timely treatment seeking from appropriate providers and reduced morbidity, a likely explanation for the reduction in mortality observed following implementation of the programme in this study.	[Mazumder, Sarmila; Taneja, Sunita; Goyal, Nidhi; Bhandari, Nita] Soc Appl Studies, Ctr Hlth Res & Dev, New Delhi 110016, India; [Bahl, Rajiv] WHO, Dept Maternal Newborn Child & Adolescent Hlth, CH-1211 Geneva, Switzerland; [Mohan, Pavitra] UNICEF India Country Off, New Delhi, India; [Van Den Hombergh, Henri] UNICEF India Country Off, Hlth Sect, New Delhi, India; [Strand, Tor A.] Univ Bergen, Ctr Int Hlth, N-5020 Bergen, Norway; [Sommerfelt, Halvor] Univ Bergen, Ctr Int Hlth, Ctr Intervent Sci Maternal & Child Hlth, N-5020 Bergen, Norway; [Kirkwood, Betty R.] London Sch Hyg & Trop Med, London WC1, England	World Health Organization; University of Bergen; University of Bergen; University of London; London School of Hygiene & Tropical Medicine	Bhandari, N (corresponding author), Soc Appl Studies, Ctr Hlth Res & Dev, New Delhi 110016, India.	CHRD@sas.org.in	Strand, Tor/D-9836-2016; Mazumder, Sarmila/AAD-8952-2020; Sommerfelt, Halvor/ABD-3552-2020	Strand, Tor/0000-0002-4038-151X; Mazumder, Sarmila/0000-0003-4200-6112; Sommerfelt, Halvor/0000-0002-5670-9786; Kirkwood, Betty/0000-0001-5274-6072	World Health Organization, Geneva; United States Agency for International Development; United Nations Children's Fund, New Delhi; Programme for Global Health and Vaccination Research of the Research Council of Norway [183722]	World Health Organization, Geneva(World Health Organization); United States Agency for International Development(United States Agency for International Development (USAID)); United Nations Children's Fund, New Delhi; Programme for Global Health and Vaccination Research of the Research Council of Norway	The study was funded by the World Health Organization, Geneva (through umbrella grant from United States Agency for International Development); the United Nations Children's Fund, New Delhi; and the Programme for Global Health and Vaccination Research of the Research Council of Norway through grant No 183722. Individual scientists at WHO and UNICEF contributed importantly to the planning, analysis, and reporting of this study. However, the central bodies of these agencies and the Research Council of Norway had no influence on how the data were collected, analysed, or presented.	Arifeen SE, 2009, LANCET, V374, P393, DOI 10.1016/S0140-6736(09)60828-X; Bahl R, 2005, B WORLD HEALTH ORGAN, V83, P418; Bang Abhay T, 2005, J Perinatol, V25 Suppl 1, pS108, DOI 10.1038/sj.jp.7211278; Baqui AH, 2008, B WORLD HEALTH ORGAN, V86, P796, DOI 10.2471/BLT.07.042226; Baqui AH, 2008, LANCET, V371, P1936, DOI 10.1016/S0140-6736(08)60835-1; Bhandari N, 2003, LANCET, V361, P1418, DOI 10.1016/S0140-6736(03)13134-0; Bhandari N, 2008, PEDIATRICS, V121, pE1279, DOI 10.1542/peds.2007-1939; Bhandari N, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1634; Bhattacharyya Agnihotri, 2012, Indian J Community Med, V37, P174, DOI 10.4103/0970-0218.99923; Bhutta ZA, 2011, LANCET, V377, P403, DOI 10.1016/S0140-6736(10)62274-X; Biswas AB, 2011, J TROP PEDIATRICS, V57, P352, DOI 10.1093/tropej/fmq106; Black RE, 2013, LANCET, V382, P427, DOI 10.1016/S0140-6736(13)60937-X; D'Souza RM, 2003, J BIOSOC SCI, V35, P131, DOI 10.1017/S0021932003001317; Darmstadt GL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009696; de Silva MWA, 2001, SOC SCI MED, V53, P1363, DOI 10.1016/S0277-9536(00)00425-1; de Souza ACT, 2000, SOC SCI MED, V51, P1675, DOI 10.1016/S0277-9536(00)00100-3; De Zoysa I, 1998, SOC SCI MED, V47, P2101, DOI 10.1016/S0277-9536(98)00275-5; Edmond KM, 2006, PEDIATRICS, V117, pE380, DOI 10.1542/peds.2005-1496; Goldman N, 2000, TROP MED INT HEALTH, V5, P145, DOI 10.1046/j.1365-3156.2000.00527.x; Hill Z, 2004, FAMILY AND COMMUNITY; International Institute for Population Sciences (IIPS), 2007, NATIONAL FAMILY HEAL; Kesterton AJ, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-20; Kirkwood BR, 2013, LANCET, V381, P2184, DOI 10.1016/S0140-6736(13)60095-1; Kumar V, 2008, LANCET, V372, P1151, DOI 10.1016/S0140-6736(08)61483-X; Lahariya Chandrakant, 2009, Indian J Community Med, V34, P15, DOI 10.4103/0970-0218.45370; Lassi Z, 2010, COCHRANE DB SYST REV, V11; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Localio AR, 2007, J CLIN EPIDEMIOL, V60, P874, DOI 10.1016/j.jclinepi.2006.12.001; Ministry of Health and Family Welfare, NATIONAL RURAL HEALT; Ministry of Health and Family Welfare, 2003, IMNCI TRAINING MODUL; Ministry of Health and Family Welfare, IMNCI WALL CHART ASS; Ministry of Health and Family Welfare, 2003, INTEGRATED MANAGEMEN; Mittal K, 2014, INDIAN J PEDIATR, V81, P797, DOI 10.1007/s12098-013-1225-2; Mohan P, 2011, J HEALTH POPUL NUTR, V29, P629; National Rural Health Mission, MEETING PEOPLES HEAL; Prinja S, 2013, J TROP PEDIATRICS, V59, P489, DOI 10.1093/tropej/fmt057; Shewade HD, 2013, INDIAN J PEDIATR, V80, P448, DOI 10.1007/s12098-012-0835-4; Sreeramareddy Chandrashekhar T, 2006, BMC Int Health Hum Rights, V6, P7, DOI 10.1186/1472-698X-6-7; Tsion A, 2008, ETHIOP J HEALTH SCI, V18, P87; UNICEF World Health Organization World Bank United Nations, 2013, LEVEL AND TRENDS IN; Upadhyay RP, 2012, J TROP PEDIATRICS, V58, P406, DOI 10.1093/tropej/fmr113; World Health Organization, 2003, INTEGRATED MANAGEMEN; World Health Organization, 1998, IMCI ADAPTATION GUID; World Health Organization, 2013, CHILDREN REDUCING MO; World Health Organization, 2008, INDICATORS FOR ASSES	45	22	23	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 29	2014	349								g4988	10.1136/bmj.g4988	http://dx.doi.org/10.1136/bmj.g4988			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AO2SA	25172514	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000341174500001
J	Wang, ZS; Ren, S; Huang, N				Wang, Zhengshi; Ren, Shan; Huang, Ning			Saltation of Non-Spherical Sand Particles	PLOS ONE			English	Article							GRAINS; CLOUD; SHAPE; FLOW; DRAG; AIR	Saltation is an important geological process and the primary source of atmospheric mineral dust aerosols. Unfortunately, no studies to date have been able to precisely reproduce the saltation process because of the simplified theoretical models used. For example, sand particles in most of the existing wind sand movement models are considered to be spherical, the effects of the sand shape on the structure of the wind sand flow are rarely studied, and the effect of mid-air collision is usually neglected. In fact, sand grains are rarely round in natural environments. In this paper, we first analyzed the drag coefficients, drag forces, and starting friction wind speeds of sand grains with different shapes in the saltation process, then established a sand saltation model that considers the coupling effect between wind and the sand grains, the effect of the mid-air collision of sand grains, and the effect of the sand grain shape. Based on this model, the saltation process and sand transport rate of non-spherical sand particles were simulated. The results show that the sand shape has a significant impact on the saltation process; for the same wind speed, the sand transport rates varied for different shapes of sand grains by as much as several-fold. Therefore, sand shape is one of the important factors affecting wind-sand movement.	[Wang, Zhengshi; Huang, Ning] Lanzhou Univ, Key Lab Mech Disaster & Environm Western China, Minist Educ China, Lanzhou 730000, Peoples R China; [Wang, Zhengshi; Ren, Shan; Huang, Ning] Lanzhou Univ, Sch Civil Engn & Mech, Dept Mech, Lanzhou 730000, Peoples R China	Lanzhou University; Ministry of Education, China; Lanzhou University	Huang, N (corresponding author), Lanzhou Univ, Key Lab Mech Disaster & Environm Western China, Minist Educ China, Lanzhou 730000, Peoples R China.	huangn@lzu.edu.cn			National Key Basic Research and Development Program ("973'' Program) [2009CB421304]; Innovative Research Groups of the National Natural Science Foundation of China [11121202]; National Natural Science Foundation of China [11172118, 41371034, 91325203]; National Key Technologies R & D Program of China [2013BAC07B01]	National Key Basic Research and Development Program ("973'' Program)(National Basic Research Program of China); Innovative Research Groups of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Technologies R & D Program of China(National Key Technology R&D Program)	This work is supported by the National Key Basic Research and Development Program ("973'' Program) (2009CB421304), the Innovative Research Groups of the National Natural Science Foundation of China (11121202), the National Natural Science Foundation of China (11172118, 41371034, 91325203), and the National Key Technologies R & D Program of China (2013BAC07B01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeida MP, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.018001; Anderson R.S., 1991, WIND MODIFICATION BE, V1, P21, DOI DOI 10.1007/978-3-7091-6706-9_2; Bagnold R., 1941, PHYS BLOWN SAND DESE; Barton ED, 1973, J AEROSOL SCI, V4, P139; Blott SJ, 2006, SEDIMENTOLOGY, V53, P671, DOI 10.1111/j.1365-3091.2006.00786.x; Carneiro MV, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.058001; [程旭 Cheng Xu], 2003, [工程热物理学报, Journal of Engineering Thermophysics], V24, P437; Clift R., 1978, BUBBLES DROPS PARTIC; Dong Q S, 1997, CHIN J RADIO SCI, V12, P15; Dong ZB, 2002, EARTH SURF PROC LAND, V27, P641, DOI 10.1002/esp.341; Dupont S, 2013, J GEOPHYS RES-ATMOS, V118, P7109, DOI 10.1002/jgrd.50528; Duran O, 2006, J STAT MECH-THEORY E, V2006, pP0711; Gao D, 1983, WORLD DESERT STUDY, V4, P47; Gavze E, 1997, INT J MULTIPHAS FLOW, V23, P155, DOI 10.1016/S0301-9322(96)00054-7; Huang N, 2010, J GEOPHYS RES-ATMOS, V115, DOI 10.1029/2009JD013593; Juan JKZ, 2009, B SOC GEOL MEX, V61, P1; Kok JF, 2012, REP PROG PHYS, V75, DOI 10.1088/0034-4885/75/10/106901; Kok JF, 2009, J GEOPHYS RES-ATMOS, V114, DOI 10.1029/2009JD011702; Liu XP, 2004, GEOMORPHOLOGY, V60, P371, DOI 10.1016/j.geomorph.2003.08.009; Loth E, 2008, POWDER TECHNOL, V182, P342, DOI 10.1016/j.powtec.2007.06.001; McTainsh G., 2013, TREATISE GEOMORPHOLO, V11, P23; OWEN PR, 1964, J FLUID MECH, V20, P225, DOI 10.1017/S0022112064001173; Ren S, 2010, EUR PHYS J E, V33, P351, DOI 10.1140/epje/i2010-10681-4; SAGGA AMS, 1993, SEDIMENT GEOL, V87, P63, DOI 10.1016/0037-0738(93)90036-5; UNGAR JE, 1987, SEDIMENTOLOGY, V34, P289, DOI 10.1111/j.1365-3091.1987.tb00778.x; Wu Z., 1987, AEOLIAN GEOMORPHOLOG; Xu Weijiang, 2006, Journal of Xi'an Jiaotong University, V40, P298; Yin CG, 2003, CHEM ENG SCI, V58, P3489, DOI 10.1016/S0009-2509(03)00214-8; Zastawny M, 2012, INT J MULTIPHAS FLOW, V39, P227, DOI 10.1016/j.ijmultiphaseflow.2011.09.004; Zheng XJ, 2009, ENVIRON SCI-GER, P1, DOI 10.1007/978-3-540-88254-1_1; Zhou YH, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.021305; 黄宁, 2008, [中国科学. G辑, 物理学，力学，天文学, Science in China. Series G, Physics, Mechanics & Astronomy], V38, P260	32	4	5	2	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2014	9	8							e105208	10.1371/journal.pone.0105208	http://dx.doi.org/10.1371/journal.pone.0105208			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO2EE	25170614	Green Published, gold, Green Submitted			2023-01-03	WOS:000341127500035
J	Xie, SS; Li, M; Zhou, CC; Song, XL; Wang, CH				Xie, Shuan-shuan; Li, Ming; Zhou, Cai-cun; Song, Xiao-lian; Wang, Chang-hui			Prophylactic Cranial Irradiation May Impose a Detrimental Effect on Overall Survival of Patients with Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							TERM-FOLLOW-UP; NEOADJUVANT CHEMOTHERAPY; RADIATION-THERAPY; BRAIN METASTASES; RADIOTHERAPY; CARCINOMA; SURGERY; CHEMORADIOTHERAPY; BIAS	Purpose: To determine the role of brain metastases (BM) and overall survival (OS) in patients with non-small cell lung cancer (NSCLC) by performing a meta-analysis of the RCTs (randomized controlled clinical trials) and non-RCTs (non-randomized controlled clinical trials) published in the literature. Methods: A meta-analysis was performed using trials identified through PubMed, EMBASE and Cochrane databases. Two investigators independently assessed the quality of the trials and extracted data. The outcomes included BM, OS, median survival (MS), response rate (RR), Hazard ratios (HRs) and odds ratios (ORs), and their 95% confidence intervals (CIs) were pooled using ReMan software. Results: Twelve trials (6 RCTs and 6 non-RCTs) involving 1,718 NSCLC patients met the inclusion criteria. They were grouped on the basis of study design for separate Meta-analyses. The results showed that prophylactic cranial irradiation (PCI) reduced the risk of BM as compared with non-PCI in NSCLC patients (OR = 0.30, 95% [CI]: 0.21-0.43, p < 0.00001). However, HRs for OS favored non-PCI (HR = 1.19, 95% [CI]: 1.06-1.33, p = 0.004), without evidence of heterogeneity between the studies. Conclusion: Our results suggest that although PCI decreased the risk of BM, it may impose a detrimental effect on OS of NSCLC patients.	[Xie, Shuan-shuan; Li, Ming; Song, Xiao-lian; Wang, Chang-hui] Tongji Univ, Shanghai Peoples Hosp 10, Dept Resp Med, Shanghai 200092, Peoples R China; [Zhou, Cai-cun] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Inst Canc,Dept Oncol, Shanghai 200092, Peoples R China	Tongji University; Tongji University	Song, XL (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Dept Resp Med, Shanghai 200092, Peoples R China.	song-xiao-lian@hotmail.com; wang-chang-hui@hotmail.com			National Natural Science Foundation of China [81172229, 81100018]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was funded by the National Natural Science Foundation of China (No. 81172229, 81100018). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahles TA, 1998, J CLIN ONCOL, V16, P1954, DOI 10.1200/JCO.1998.16.5.1954; ALBAIN KS, 1995, J CLIN ONCOL, V13, P1880, DOI 10.1200/JCO.1995.13.8.1880; Andre F, 2001, CANCER, V91, P2394, DOI 10.1002/1097-0142(20010615)91:12<2394::AID-CNCR1273>3.3.CO;2-Y; ARRIAGADA R, 1995, JNCI-J NATL CANCER I, V87, P183, DOI 10.1093/jnci/87.3.183; Auperin A, 1999, NEW ENGL J MED, V341, P476, DOI 10.1056/NEJM199908123410703; Budach W, 2003, P AN M AM SOC CLIN, V22, P637; CARMICHAEL J, 1988, INT J RADIAT ONCOL, V14, P455, DOI 10.1016/0360-3016(88)90260-X; Corradetti MN, 2012, INT J RADIAT ONCOL, V84, pS599, DOI 10.1016/j.ijrobp.2012.07.1599; COX JD, 1981, JAMA-J AM MED ASSOC, V245, P469, DOI 10.1001/jama.245.5.469; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Gore EM, 2012, INT J RADIAT ONCOL, V84, pS103, DOI 10.1016/j.ijrobp.2012.07.169; Gore EM, 2011, J CLIN ONCOL, V29, P272, DOI 10.1200/JCO.2010.29.1609; Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859; Grosshans DR, 2008, CANCER, V112, P589, DOI 10.1002/cncr.23222; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; JACOBS RH, 1987, CANCER, V59, P2016, DOI 10.1002/1097-0142(19870615)59:12<2016::AID-CNCR2820591208>3.0.CO;2-4; KOMAKI R, 1995, INT J RADIAT ONCOL, V33, P179, DOI 10.1016/0360-3016(95)00026-U; Langer CJ, 2005, J CLIN ONCOL, V23, P6207, DOI 10.1200/JCO.2005.03.145; Le Pechoux C, 2009, LANCET ONCOL, V10, P467, DOI 10.1016/S1470-2045(09)70101-9; Meert AP, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-5; MIRA J G, 1990, International Journal of Radiation Oncology, Biology, Physics, V19, P145, DOI 10.1016/0360-3016(90)90693-E; MIRA JG, 1988, INT J RADIAT ONCOL, V15, P757, DOI 10.1016/0360-3016(88)90323-9; Nussbaum ES, 1996, CANCER-AM CANCER SOC, V78, P1781, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1781::AID-CNCR19>3.3.CO;2-Z; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Pottgen C, 2007, J CLIN ONCOL, V25, P4987, DOI 10.1200/JCO.2007.12.5468; RUSSELL AH, 1991, INT J RADIAT ONCOL, V21, P637, DOI 10.1016/0360-3016(91)90681-S; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SHAW EG, 1994, J CLIN ONCOL, V12, P2327, DOI 10.1200/JCO.1994.12.11.2327; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; SKARIN A, 1989, J SURG ONCOL, V40, P266, DOI 10.1002/jso.2930400413; STRAUSS GM, 1992, J CLIN ONCOL, V10, P1237, DOI 10.1200/JCO.1992.10.8.1237; Stuschke M, 1999, J CLIN ONCOL, V17, P2700, DOI 10.1200/JCO.1999.17.9.2700; Sun A, 2011, J CLIN ONCOL, V29, P279, DOI 10.1200/JCO.2010.29.6053; UMSAWASDI T, 1984, J NEURO-ONCOL, V2, P253; VanOosterhout AGM, 1996, INT J RADIAT ONCOL, V34, P1037, DOI 10.1016/0360-3016(95)02257-0; WALLING J, 1994, RESP MED, V88, P649, DOI 10.1016/S0954-6111(05)80061-7	37	18	20	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2014	9	7							e103431	10.1371/journal.pone.0103431	http://dx.doi.org/10.1371/journal.pone.0103431			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4KU	25072281	Green Published, gold, Green Submitted			2023-01-03	WOS:000341307600049
J	Bilcke, J; Coenen, S; Beutels, P				Bilcke, Joke; Coenen, Samuel; Beutels, Philippe			Influenza-Like-Illness and Clinically Diagnosed Flu: Disease Burden, Costs and Quality of Life for Patients Seeking Ambulatory Care or No Professional Care at All	PLOS ONE			English	Article							HEALTHY-CHILDREN; VACCINATION; IMPACT	This is one of the first studies to (1) describe the out-of-hospital burden of influenza-like-illness (ILI) and clinically diagnosed flu, also for patients not seeking professional medical care, (2) assess influential background characteristics, and (3) formally compare the burden of ILI in patients with and without a clinical diagnosis of flu. A general population sample with recent ILI experience was recruited during the 2011-2012 influenza season in Belgium. Half of the 2250 respondents sought professional medical care, reported more symptoms (especially more often fever), a longer duration of illness, more use of medication (especially antibiotics) and a higher direct medical cost than patients not seeking medical care. The disease and economic burden were similar for ambulatory ILI patients, irrespective of whether they received a clinical diagnosis of flu. On average, they experienced 5-6 symptoms over a 6-day period; required 1.6 physician visits and 86-91% took medication. An average episode amounted to is an element of 51-is an element of 53 in direct medical costs, 4 days of absence from work or school and the loss of 0.005 quality-adjusted life-years. Underlying illness led to greater costs and lower quality-of-life. The costs of ILI patients with clinically diagnosed flu tended to increase, while those of ILI patients without clinically diagnosed flu tended to decrease with age. Recently vaccinated persons experienced lower costs and a higher quality-of-life, but this was only the case for patients not seeking professional medical care. This information can be used directly to evaluate the implementation of cost-effective prevention and control measures for influenza. In particular to inform the evaluation of more widespread seasonal influenza vaccination, including in children, which is currently considered by many countries.	[Bilcke, Joke; Beutels, Philippe] Univ Antwerp, Fac Med & Hlth Sci, Ctr Hlth Econ Res & Modelling Infect Dis, Vaccine & Infect Dis Inst VAXINFECTIO,WHO Collabo, B-2020 Antwerp, Belgium; [Coenen, Samuel] Univ Antwerp, Fac Med & Hlth Sci, Ctr Gen Practice Primary & Interdisciplinary Care, B-2020 Antwerp, Belgium; [Coenen, Samuel] Univ Antwerp, Fac Med & Hlth Sci, Vaccine & Infect Dis Inst VAXINFECTIO, Lab Med Microbiol,WHO Collaborating Ctr, B-2020 Antwerp, Belgium; [Beutels, Philippe] Sch Publ Hlth & Community Med, Sydney, NSW, Australia	University of Antwerp; University of Antwerp; University of Antwerp; World Health Organization	Bilcke, J (corresponding author), Univ Antwerp, Fac Med & Hlth Sci, Ctr Hlth Econ Res & Modelling Infect Dis, Vaccine & Infect Dis Inst VAXINFECTIO,WHO Collabo, B-2020 Antwerp, Belgium.	joke.bilcke@uantwerp.be	Bilcke, Joke/AAC-8932-2019; Geurts, José W/O-3673-2014; Beutels, Philippe/A-1919-2010; Coenen, Samuel JA/A-6410-2011	Bilcke, Joke/0000-0001-5720-5291; Beutels, Philippe/0000-0001-5034-3595; Coenen, Samuel JA/0000-0002-1238-8052	Belgian Health Care Knowledge Centre; Research Foundation - Flanders (FWO) [G.0274.08N]; European Commission Framework Programme 6	Belgian Health Care Knowledge Centre; Research Foundation - Flanders (FWO)(FWO); European Commission Framework Programme 6(European Commission)	This study was funded by the Belgian Health Care Knowledge Centre. JB is supported by a postdoctoral grant from the Research Foundation - Flanders (FWO). GRACE is funded via European Commission Framework Programme 6 and Research Foundation - Flanders (FWO G.0274.08N). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antonova EN, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-968; Beutels P, 2013, SEASONAL INFLUENZA 2; Butler CC, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b2242; Cleemput I, 2012, HLTH TECHNOLOGY ASSE, V2nd; Esposito S, 2011, J INFECTION, V62, P379, DOI 10.1016/j.jinf.2011.02.015; Grigoryan L, 2006, EMERG INFECT DIS, V12, P452, DOI 10.3201/eid1203.050992; Hollmann M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060477; Jit M, 2013, HUM VACC IMMUNOTHER, V9, P834, DOI 10.4161/hv.23637; Little P, 2013, LANCET INFECT DIS, V13, P123, DOI 10.1016/S1473-3099(12)70300-6; Michiels B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060348; Michiels B, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-4; Newall AT, 2013, PHARMACOECONOMICS, V31, P693, DOI 10.1007/s40273-013-0060-7; Nicholson K G, 1992, Semin Respir Infect, V7, P26; O'Brien BJ, 2003, VALUE HEALTH, V6, P116, DOI 10.1046/j.1524-4733.2003.00213.x; Ortega-Sanchez IR, 2012, VACCINE, V30, P4175, DOI 10.1016/j.vaccine.2012.04.057; Payne L, 2005, Euro Surveill, V10, P241; Pitman RJ, 2013, VACCINE, V31, P927, DOI 10.1016/j.vaccine.2012.12.010; Ploin D, 2003, PEDIATR INFECT DIS J, V22, pS218, DOI 10.1097/01.inf.0000092191.78339.1a; Ploin D, 2007, PEDIATR INFECT DIS J, V26, P142, DOI 10.1097/01.inf.0000253062.41648.60; Principi N, 2004, ARCH DIS CHILD, V89, P1002, DOI 10.1136/adc.2003.045401; Sander B, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000256; Savy V, 2013, INFLUENZA OTHER RESP, V7, P1017, DOI 10.1111/irv.12036; van Hoek AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017030; Yin JK, 2013, INFLUENZA OTHER RESP, V7, P1103, DOI 10.1111/irv.12138; Zhou L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063788	25	30	32	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2014	9	7							e102634	10.1371/journal.pone.0102634	http://dx.doi.org/10.1371/journal.pone.0102634			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AL8VR	25032688	Green Submitted, gold, Green Published			2023-01-03	WOS:000339418300071
J	Michalowska, M; Winiarczyk, S; Adaszek, L; Lopuszynski, W; Gradzki, Z; Salmons, B; Gunzburg, WH				Michalowska, Monika; Winiarczyk, Stanislaw; Adaszek, Lukasz; Lopuszynski, Wojciech; Gradzki, Zbigniew; Salmons, Brian; Guenzburg, Walter H.			Phase I/II Clinical Trial of Encapsulated, Cytochrome P450 Expressing Cells as Local Activators of Cyclophosphamide to Treat Spontaneous Canine Tumours	PLOS ONE			English	Article							PROGESTERONE-RECEPTOR EXPRESSION; MAMMARY-TUMORS; PANCREATIC-CARCINOMA; IFOSFAMIDE; CHEMOTHERAPY; RECURRENCE; INJECTION; ESTROGEN; PROTOCOL; THERAPY	Based upon promising preclinical studies, a clinical trial was performed in which encapsulated cells overexpressing cytochrome P450 enzyme isoform 2B1 were implanted around malignant mammary tumours arising spontaneously in dogs. The dogs were then given cyclophosphamide, one of the standard chemotherapeutic agents used for the treatment of mammary tumours. The dogs were assessed for a number of clinical parameters as well as for reduction in tumour size. The treatment was well tolerated with no evidence of adverse reactions or side effects being associated with the administration of the encapsulated cells. Reductions in tumour size of more than 50% were observed for 6 out of the 11 tumours analysed while 5 tumours showing minor responses, i.e. stable disease. In contrast, the tumours that received cyclophosphamide alone showed only stable disease. Taken together, this data suggests that encapsulated cytochrome P450 expressing cells combined with chemotherapy may be useful in the local treatment of a number of dog mammary tumours and support the performance of further clinical studies to evaluate this new treatment.	[Michalowska, Monika; Winiarczyk, Stanislaw; Adaszek, Lukasz; Gradzki, Zbigniew] Univ Life Sci, Fac Vet Med, Dept Epizootiol & Clin Infect Dis, Lublin, Poland; [Lopuszynski, Wojciech] Univ Life Sci, Fac Vet Med, Dept Pathol Anat, Lublin, Poland; [Salmons, Brian] Austrianova, Centros, Singapore; [Guenzburg, Walter H.] Univ Vet Med, Inst Virol, Dept Pathobiol, Vienna, Austria	University of Veterinary Medicine Vienna	Adaszek, L (corresponding author), Univ Life Sci, Fac Vet Med, Dept Epizootiol & Clin Infect Dis, Lublin, Poland.	ukaszek0@wp.pl	Salmons, Brian/E-3001-2010; Gunzburg, Walter/ABI-6076-2020; Grądzki, Zbigniew/R-6589-2018	Salmons, Brian/0000-0002-9490-9447; Gunzburg, Walter/0000-0001-8907-1021; Grądzki, Zbigniew/0000-0002-5390-3225; Adaszek, Lukasz/0000-0003-0261-2695; Lopuszynski, Wojciech/0000-0002-9875-5449				Alenza MDP, 2001, J AM VET MED ASSOC, V219, P1110, DOI 10.2460/javma.2001.219.1110; Armeanu S, 2001, J MICROENCAPSUL, V18, P491; BRODEY RS, 1983, J AM ANIM HOSP ASSOC, V19, P61; Cassali GD, 2007, CYTOPATHOLOGY, V18, P191, DOI 10.1111/j.1365-2303.2007.00412.x; Chen L, 1996, CANCER RES, V56, P1331; Dautzenberg H, 1999, ANN NY ACAD SCI, V875, P46, DOI 10.1111/j.1749-6632.1999.tb08493.x; de las Mulas JM, 2005, VET PATHOL, V42, P200, DOI 10.1354/vp.42-2-200; DONNAY I, 1995, AM J VET RES, V56, P1188; Elmslie RE, 2008, J VET INTERN MED, V22, P1373, DOI 10.1111/j.1939-1676.2008.0179.x; Gordon A, 1997, Clin Oncol (R Coll Radiol), V9, P338, DOI 10.1016/S0936-6555(05)80069-X; Gunzburg WH, 1999, ANN NY ACAD SCI, V880, P326, DOI 10.1111/j.1749-6632.1999.tb09536.x; Kammertoens T, 2000, CANCER GENE THER, V7, P629, DOI 10.1038/sj.cgt.7700139; Karayannopoulou M, 2001, J VET MED A, V48, P85, DOI 10.1046/j.1439-0442.2001.00336.x; Karle P, 2001, CANCER GENE THER, V8, P220, DOI 10.1038/sj.cgt.7700290; Karle P, 1998, ADV EXP MED BIOL, V451, P97; Kroger JC, 2003, PANCREATOLOGY, V3, P55, DOI 10.1159/000069147; Lohr M, 2005, NEOPLASIA, V7, P17, DOI 10.1593/neo.04445; Lohr M, 2002, CANCER CHEMOTH PHARM, V49, pS21, DOI 10.1007/s00280-002-0448-0; Lohr M, 1998, GENE THER, V5, P1070, DOI 10.1038/sj.gt.3300671; Lohr M, 2001, LANCET, V357, P1591, DOI 10.1016/S0140-6736(00)04749-8; Lohr M, 1999, J MOL MED, V77, P393, DOI 10.1007/s001090050366; Loscher W, 1994, GRUNDLAGEN PHARMAKOT, P398; Marconato L, 2008, VET COMP ONCOL, V6, P90, DOI 10.1111/j.1476-5829.2007.00143.x; Merlo DF, 2008, J VET INTERN MED, V22, P976, DOI 10.1111/j.1939-1676.2008.0133.x; Misdorp W, 1999, WHO INT HISTOLOGICAL, P18; Munson Linda, 2007, Breast Dis, V28, P7; NEMOTO K, 1994, BRIT J HAEMATOL, V87, P572, DOI 10.1111/j.1365-2141.1994.tb08314.x; Novosad CA, 2003, CLIN TECH SMALL AN P, V18, P107, DOI 10.1053/svms.2003.36625; OWEN LN, 1979, INVEST CELL PATHOL, V2, P257; Pelegrin M, 2000, HUM GENE THER, V11, P1407, DOI 10.1089/10430340050057486; Pelegrin M, 1998, HUM GENE THER, V9, P2165, DOI 10.1089/hum.1998.9.15-2165; Saller RM, 2002, J GENE MED, V4, P150, DOI 10.1002/jgm.257; Salmons B, 2003, J GASTROENTEROL, V38, P78; Salmons B, 2010, ADV EXP MED BIOL, V670, P92; Sorenmo K, 2003, VET CLIN N AM-SMALL, V33, P573, DOI 10.1016/S0195-5616(03)00020-2; STANGE J, 1993, BIOMAT ARTIF CELL IM, V21, P343, DOI 10.3109/10731199309117372; Stratmann N, 2008, VET SURG, V37, P82, DOI 10.1111/j.1532-950X.2007.00351.x; UCKERT W, 2003, METH MOLEC MED, V90, P345; Winiarczyk S, 2002, J MOL MED-JMM, V80, P610, DOI 10.1007/s00109-002-0356-0; Zenker I, 2010, VET REC, V167, P744, DOI 10.1136/vr.c5081	40	2	2	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2014	9	7							e102061	10.1371/journal.pone.0102061	http://dx.doi.org/10.1371/journal.pone.0102061			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4KM	25028963	gold, Green Published, Green Submitted			2023-01-03	WOS:000341306600033
J	Al-khattawi, A; Alyami, H; Townsend, B; Ma, XH; Mohammed, AR				Al-khattawi, Ali; Alyami, Hamad; Townsend, Bill; Ma, Xianghong; Mohammed, Afzal R.			Evidence-Based Nanoscopic and Molecular Framework for Excipient Functionality in Compressed Orally Disintegrating Tablets	PLOS ONE			English	Article							ATOMIC-FORCE MICROSCOPY; MICROCRYSTALLINE CELLULOSE; PARTICLE-SIZE; SOLID-STATE; COMPACTION PROPERTIES; PUNCH VELOCITY; CRYSTAL HABIT; THEOPHYLLINE; ADHESION; BEHAVIOR	The work investigates the adhesive/cohesive molecular and physical interactions together with nanoscopic features of commonly used orally disintegrating tablet (ODT) excipients microcrystalline cellulose (MCC) and D-mannitol. This helps to elucidate the underlying physico-chemical and mechanical mechanisms responsible for powder densification and optimum product functionality. Atomic force microscopy (AFM) contact mode analysis was performed to measure nano-adhesion forces and surface energies between excipient-drug particles (6-10 different particles per each pair). Moreover, surface topography images (100 nm(2)-10 mu m(2)) and roughness data were acquired from AFM tapping mode. AFM data were related to ODT macro/microscopic properties obtained from SEM, FTIR, XRD, thermal analysis using DSC and TGA, disintegration testing, Heckel and tabletability profiles. The study results showed a good association between the adhesive molecular and physical forces of paired particles and the resultant densification mechanisms responsible for mechanical strength of tablets. MCC micro roughness was 3 times that of D-mannitol which explains the high hardness of MCC ODTs due to mechanical interlocking. Hydrogen bonding between MCC particles could not be established from both AFM and FTIR solid state investigation. On the contrary, D-mannitol produced fragile ODTs due to fragmentation of surface crystallites during compression attained from its weak crystal structure. Furthermore, AFM analysis has shown the presence of extensive micro fibril structures inhabiting nano pores which further supports the use of MCC as a disintegrant. Overall, excipients (and model drugs) showed mechanistic behaviour on the nano/micro scale that could be related to the functionality of materials on the macro scale.	[Al-khattawi, Ali; Alyami, Hamad; Mohammed, Afzal R.] Aston Univ, Aston Sch Pharm, Birmingham B4 7ET, W Midlands, England; [Townsend, Bill; Ma, Xianghong] Aston Univ, Sch Engn & Appl Sci, Birmingham B4 7ET, W Midlands, England; [Al-khattawi, Ali; Townsend, Bill; Ma, Xianghong; Mohammed, Afzal R.] Aston Univ, Aston Res Ctr Hlth Ageing, Birmingham B4 7ET, W Midlands, England	Aston University; Aston University; Aston University	Mohammed, AR (corresponding author), Aston Univ, Aston Sch Pharm, Birmingham B4 7ET, W Midlands, England.	a.u.r.mohammed@aston.ac.uk		Ma, Xianghong/0000-0003-4957-2942; Al-khattawi, Ali/0000-0002-2498-2817; Mohammed, Afzal-Ur-Rahman/0000-0002-5212-3040; Alyami, Hamad/0000-0003-3513-4976	Aston University through a Post graduate overseas bursary awarded	Aston University through a Post graduate overseas bursary awarded	The work was funded by Aston University through a Post graduate overseas bursary awarded to Ali Al-Khattawi. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adolfsson A, 1999, DRUG DEV IND PHARM, V25, P753, DOI 10.1081/DDC-100102235; Al-Khattawi A, 2014, CURR DRUG DELIV, V11, P486, DOI 10.2174/1567201811666140323201650; Al-khattawi A, 2013, EXPERT OPIN DRUG DEL, V10, P651, DOI 10.1517/17425247.2013.769955; ALDERBORN G, 1988, ACTA PHARM SUEC, V25, P31; ALDERBORN G, 2008, PHARM POWDER COMPACT, V1; AMIDON GE, 1995, PHARMACEUT RES, V12, P923, DOI 10.1023/A:1016233725612; Burger A, 2000, J PHARM SCI-US, V89, P457, DOI 10.1002/(SICI)1520-6017(200004)89:4<457::AID-JPS3>3.0.CO;2-G; Busignies V, 2006, EUR J PHARM BIOPHARM, V64, P66, DOI 10.1016/j.ejpb.2006.03.004; BUTT HJ, 1991, BIOPHYS J, V60, P1438, DOI 10.1016/S0006-3495(91)82180-4; Camesano TA, 2000, ENVIRON SCI TECHNOL, V34, P3354, DOI 10.1021/es9913176; Chattoraj S, 2010, CRYSTENGCOMM, V12, P2466, DOI 10.1039/c000614a; Chaw KC, 2005, ANTIMICROB AGENTS CH, V49, P4853, DOI 10.1128/AAC.49.12.4853-4859.2005; Convention USP, 2005, DISINTEGRATION, V701; Davies MJ, 2011, INT J PHARMACEUT, V421, P1, DOI 10.1016/j.ijpharm.2011.09.004; Di Martino P, 2002, J CRYST GROWTH, V243, P345, DOI 10.1016/S0022-0248(02)01523-3; Eve JK, 2002, INT J PHARMACEUT, V238, P17, DOI 10.1016/S0378-5173(02)00055-8; Fox CD, 1963, DRUG COSMET IND, V92, P161; Garekani HA, 2001, DRUG DEV IND PHARM, V27, P803, DOI 10.1081/DDC-100107243; Gohel MC., 2007, AAPS PHARMSCITECH, V8, pE94, DOI [10.1208/pt0801013, DOI 10.1208/PT0801013]; Gonnissen Y, 2007, EUR J PHARM BIOPHARM, V67, P220, DOI 10.1016/j.ejpb.2006.12.021; Grierson DS, 2005, J ADHES SCI TECHNOL, V19, P291, DOI 10.1163/1568561054352685; Hancock BC, 1997, J PHARM SCI, V86, P1, DOI 10.1021/js9601896; HECKEL RW, 1961, T METALL SOC AIME, V221, P671; Herting MG, 2007, INT J PHARM, V338, P110, DOI 10.1016/j.ijpharm.2007.01.035; Hinterstoisser B, 2003, BIOMACROMOLECULES, V4, P1232, DOI 10.1021/bm030017k; HUTTENRA.R, 1971, PHARMAZIE, V26, P645; Inghelbrecht S, 1998, INT J PHARM, V161, P215, DOI 10.1016/S0378-5173(97)00356-6; Janardhnan S, 2011, INT J POLYM SCI, V2011, DOI 10.1155/2011/279610; JOHNSON KL, 1971, PROC R SOC LON SER-A, V324, P301, DOI 10.1098/rspa.1971.0141; Kaialy W, 2010, COLLOID SURFACE B, V79, P345, DOI 10.1016/j.colsurfb.2010.04.016; KAREHILL PG, 1990, INT J PHARM, V64, P35, DOI 10.1016/0378-5173(90)90176-5; KAREHILL PG, 1990, INT J PHARM, V61, P251, DOI 10.1016/0378-5173(90)90216-Q; LAM KK, 1992, POWDER TECHNOL, V73, P117, DOI 10.1016/0032-5910(92)80072-5; LIANG CY, 1959, J POLYM SCI, V37, P385, DOI 10.1002/pol.1959.1203713209; MARSHALL PV, 1993, POWDER TECHNOL, V74, P171, DOI 10.1016/0032-5910(93)87009-D; NESIC M, 1990, ACTA PHARM JUGOSL, V40, P545; Oh SY, 2005, CARBOHYD RES, V340, P2376, DOI 10.1016/j.carres.2005.08.007; Pather SI, 1998, INT J PHARM, V164, P1, DOI 10.1016/S0378-5173(97)00348-7; Picker KM, 1999, EUR J PHARM BIOPHARM, V48, P27, DOI 10.1016/S0939-6411(99)00009-0; Picker KM, 2002, J PHARM SCI-US, V91, P342, DOI 10.1002/jps.10018; Pifferi G, 1999, FARMACO, V54, P1, DOI 10.1016/S0014-827X(98)00101-3; RICHMAN MD, 1965, J PHARM SCI, V54, P447, DOI 10.1002/jps.2600540323; Roberts CJ, 2005, EUR J PHARM SCI, V24, P153, DOI 10.1016/j.ejps.2004.11.002; ROBERTS RJ, 1985, J PHARM PHARMACOL, V37, P377, DOI 10.1111/j.2042-7158.1985.tb03019.x; ROBERTS RJ, 1987, INT J PHARM, V36, P205, DOI 10.1016/0378-5173(87)90157-8; ROMERO AJ, 1993, INT J PHARMACEUT, V99, P125, DOI 10.1016/0378-5173(93)90354-I; Seton L, 2010, CRYST GROWTH DES, V10, P3879, DOI 10.1021/cg100165t; Soh JLP, 2013, PHARM DEV TECHNOL, V18, P172, DOI 10.3109/10837450.2012.685658; Sonnergaard JM, 1999, INT J PHARM, V193, P63, DOI 10.1016/S0378-5173(99)00319-1; Suihko E, 2001, INT J PHARM, V217, P225, DOI 10.1016/S0378-5173(01)00607-X; Suihko E, 1997, INT J PHARM, V158, P47, DOI 10.1016/S0378-5173(97)00239-1; SUZUKI E, 1989, CHEM PHARM BULL, V37, P493; Szczesniak L, 2008, CELLULOSE, V15, P445, DOI 10.1007/s10570-007-9192-2; van Veen B, 2000, INT J PHARM, V203, P71, DOI 10.1016/S0378-5173(00)00450-6; Whelan MR, 2002, J PHARMACEUT BIOMED, V30, P1355, DOI 10.1016/S0731-7085(02)00394-1; YORK P, 1983, INT J PHARMACEUT, V14, P1, DOI 10.1016/0378-5173(83)90111-4; Yoshinari T, 2003, INT J PHARM, V258, P121, DOI 10.1016/S0378-5173(03)00157-1; Yvonne P., 2012, DRUG DELIV LETT, V2, P195	58	10	11	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2014	9	7							e101369	10.1371/journal.pone.0101369	http://dx.doi.org/10.1371/journal.pone.0101369			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6RN	25025427	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000339992400013
J	Noratto, GD; Garcia-Mazcorro, JF; Markel, M; Martino, HS; Minamoto, Y; Steiner, JM; Byrne, D; Suchodolski, JS; Mertens-Talcott, SU				Noratto, Giuliana D.; Garcia-Mazcorro, Jose F.; Markel, Melissa; Martino, Hercia S.; Minamoto, Yasushi; Steiner, Joerg M.; Byrne, David; Suchodolski, Jan S.; Mertens-Talcott, Susanne U.			Carbohydrate-Free Peach (Prunus persica) and Plum (Prunus domestica) Juice Affects Fecal Microbial Ecology in an Obese Animal Model	PLOS ONE			English	Article							EUTERPE-OLERACEA MART.; DIET-INDUCED OBESITY; GUT MICROBIOTA; IN-VITRO; INTESTINAL MICROBIOTA; BACTERIAL MICROBIOTA; TEA POLYPHENOLS; METABOLIC-FATE; RIBOSOMAL-RNA; RED WINE	Background: Growing evidence shows the potential of nutritional interventions to treat obesity but most investigations have utilized non-digestible carbohydrates only. Peach and plum contain high amounts of polyphenols, compounds with demonstrated anti-obesity effects. The underlying process of successfully treating obesity using polyphenols may involve an alteration of the intestinal microbiota. However, this phenomenon is not well understood. Methodology/Principal Findings: Obese Zucker rats were assigned to three groups (peach, plum, and control, n = 10 each), wild-type group was named lean (n = 10). Carbohydrates in the fruit juices were eliminated using enzymatic hydrolysis. Fecal samples were obtained after 11 weeks of fruit or control juice administration. Real-time PCR and 454-pyrosequencing were used to evaluate changes in fecal microbiota. Over 1,500 different Operational Taxonomic Units at 97% similarity were detected in all rats. Several bacterial groups (e. g. Lactobacillus and members of Ruminococcacea) were found to be more abundant in the peach but especially in the plum group (plum juice contained 3 times more total polyphenolics compared to peach juice). Principal coordinate analysis based on Unifrac-based unweighted distance matrices revealed a distinct separation between the microbiota of control and treatment groups. These changes in fecal microbiota occurred simultaneously with differences in fecal short-chain acids concentrations between the control and treatment groups as well as a significant decrease in body weight in the plum group. Conclusions: This study suggests that consumption of carbohydrate-free peach and plum juice has the potential to modify fecal microbial ecology in an obese animal model. The separate contribution of polyphenols and non-polyphenols compounds (vitamins and minerals) to the observed changes is unknown.	[Noratto, Giuliana D.; Martino, Hercia S.; Mertens-Talcott, Susanne U.] Texas A&M Univ, Dept Nutr & Food Sci, College Stn, TX 77843 USA; [Garcia-Mazcorro, Jose F.] Univ Autonoma Nuevo Leon, Fac Med Vet & Zootecnia, Nuevo Leon, Mexico; [Markel, Melissa; Minamoto, Yasushi; Steiner, Joerg M.; Suchodolski, Jan S.] Texas A&M Univ, Gastrointestinal Lab, College Stn, TX USA; [Byrne, David] Texas A&M Univ, Dept Hort Sci, College Stn, TX 77843 USA; [Mertens-Talcott, Susanne U.] Texas A&M Univ, College Stn, TX USA	Texas A&M University System; Texas A&M University College Station; Universidad Autonoma de Nuevo Leon; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Mertens-Talcott, SU (corresponding author), Texas A&M Univ, Dept Nutr & Food Sci, College Stn, TX 77843 USA.	SMTalcott@tamu.edu	Noratto, Giuliana/AAS-8959-2020; Byrne, David/AAF-6262-2021; Garcia-Mazcorro, Jose F./O-5799-2018	Garcia-Mazcorro, Jose F./0000-0001-6047-4361; Stampini Duarte Martino, Hercia/0000-0002-8565-8439; Noratto, Giuliana/0000-0003-1831-7172; Suchodolski, Jan/0000-0002-2176-6932; Mertens-Talcott, Susanne/0000-0003-2828-4044	Vegetable and Fruit Improvement Center at Texas AM University; National Counsel of Technological and Scientific Development (CNPq-Brazil) [200382/2011-0]; CONACYT (Mexico) through the National System of Researchers program	Vegetable and Fruit Improvement Center at Texas AM University; National Counsel of Technological and Scientific Development (CNPq-Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CONACYT (Mexico) through the National System of Researchers program	This research was supported by the Vegetable and Fruit Improvement Center (http://vfic.tamu.edu/) at Texas A&M University. Hercia S. Martino thanks the National Counsel of Technological and Scientific Development (CNPq-Brazil) for the scholarship (reference number: 200382/2011-0). Jose F Garcia-Mazcorro is financially supported by CONACYT (Mexico) through the National System of Researchers (SNI, for initials in Spanish) program (http://www.conacyt.mx/index.php/el-conacyt/sistema-nacional-de-investigadores). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn YJ, 1998, J APPL MICROBIOL, V84, P439, DOI 10.1046/j.1365-2672.1998.00363.x; Albrecht M, 2004, J MED FOOD, V7, P274, DOI 10.1089/1096620041938704; Bialonska D, 2010, INT J FOOD MICROBIOL, V140, P175, DOI 10.1016/j.ijfoodmicro.2010.03.038; Bolca S, 2013, CURR OPIN BIOTECH, V24, P220, DOI 10.1016/j.copbio.2012.09.009; Bravo L, 1998, NUTR REV, V56, P317, DOI 10.1111/j.1753-4887.1998.tb01670.x; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Chiva-Blanch G, 2012, J BERRY RES, V2, P63, DOI 10.3233/JBR-2012-028; Coccia A, 2012, INT J FOOD SCI TECH, V47, P1620, DOI 10.1111/j.1365-2621.2012.03012.x; Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879; Crozier A, 2009, NAT PROD REP, V26, P1001, DOI 10.1039/b802662a; Cueva C, 2013, FEMS MICROBIOL ECOL, V83, P792, DOI 10.1111/1574-6941.12037; Delzenne NM, 2011, ANNU REV NUTR, V31, P15, DOI 10.1146/annurev-nutr-072610-145146; Duncan SH, 2008, INT J OBESITY, V32, P1720, DOI 10.1038/ijo.2008.155; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Everard A, 2013, P NATL ACAD SCI USA, V110, P9066, DOI 10.1073/pnas.1219451110; Gallagher EJ, 2010, MT SINAI J MED, V77, P511, DOI 10.1002/msj.20212; Garcia-Mazcorro JF, 2012, FEMS MICROBIOL ECOL, V80, P624, DOI 10.1111/j.1574-6941.2012.01331.x; LeBlanc JG, 2013, CURR OPIN BIOTECH, V24, P160, DOI 10.1016/j.copbio.2012.08.005; Hammer Oyvind, 2001, Palaeontologia Electronica, V4, pUnpaginated; Hidalgo M, 2012, J AGR FOOD CHEM, V60, P3882, DOI 10.1021/jf3002153; Holvoet P, 2008, Verh K Acad Geneeskd Belg, V70, P193; Hunter DC, 2012, PHYTOCHEMICALS NUTRA, P225; Ikeda I, 2005, J NUTR, V135, P155, DOI 10.1093/jn/135.2.155; Queipo-Ortuno MI, 2012, AM J CLIN NUTR, V95, P1323, DOI 10.3945/ajcn.111.027847; Jellinger Paul S, 2007, Clin Cornerstone, V8 Suppl 7, pS30, DOI 10.1016/S1098-3597(07)80019-6; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926; Lacombe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067497; Lee HC, 2006, RES MICROBIOL, V157, P876, DOI 10.1016/j.resmic.2006.07.004; Lei F, 2007, INT J OBESITY, V31, P1023, DOI 10.1038/sj.ijo.0803502; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Ley RE, 2008, SCIENCE, V320, P1647, DOI 10.1126/science.1155725; Lin JK, 2006, MOL NUTR FOOD RES, V50, P211, DOI 10.1002/mnfr.200500138; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Ly NP, 2011, J ALLERGY CLIN IMMUN, V127, P1087, DOI 10.1016/j.jaci.2011.02.015; Malinen E, 2005, AM J GASTROENTEROL, V100, P373, DOI 10.1111/j.1572-0241.2005.40312.x; Mertens-Talcott SU, 2008, J AGR FOOD CHEM, V56, P7796, DOI 10.1021/jf8007037; Meydani M, 2010, NUTRIENTS, V2, P737, DOI 10.3390/nu2070737; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; Moreau NM, 2003, J CHROMATOGR B, V784, P395, DOI 10.1016/S1570-0232(02)00827-9; Muhling M, 2008, ISME J, V2, P379; MUYZER G, 1993, APPL ENVIRON MICROB, V59, P695, DOI 10.1128/AEM.59.3.695-700.1993; Nakai M, 2005, J AGR FOOD CHEM, V53, P4593, DOI 10.1021/jf047814+; Niswender KD, 2011, POSTGRAD MED, V123, P27, DOI 10.3810/pgm.2011.07.2301; Pacheco-Palencia LA, 2008, J AGR FOOD CHEM, V56, P3593, DOI 10.1021/jf8001608; Parkar SG, 2008, INT J FOOD MICROBIOL, V124, P295, DOI 10.1016/j.ijfoodmicro.2008.03.017; Png CW, 2010, AM J GASTROENTEROL, V105, P2420, DOI 10.1038/ajg.2010.281; Presley LL, 2010, APPL ENVIRON MICROB, V76, P936, DOI 10.1128/AEM.01561-09; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Suchodolski JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051907; Suchodolski JS, 2010, VET MICROBIOL, V142, P394, DOI 10.1016/j.vetmic.2009.11.002; SWAIN T., 1959, Journal of the Science of Food and Agriculture, V10, P63, DOI 10.1002/jsfa.2740100110; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Tzounis X, 2008, BRIT J NUTR, V99, P782, DOI 10.1017/S0007114507853384; Tzounis X, 2011, AM J CLIN NUTR, V93, P62, DOI 10.3945/ajcn.110.000075; van Baarlen P, 2011, P NATL ACAD SCI USA, V108, P4562, DOI 10.1073/pnas.1000079107; van Dorsten FA, 2010, MOL NUTR FOOD RES, V54, P897, DOI 10.1002/mnfr.200900212; van Duynhoven J, 2011, P NATL ACAD SCI USA, V108, P4531, DOI 10.1073/pnas.1000098107; Waldram A, 2009, J PROTEOME RES, V8, P2361, DOI 10.1021/pr8009885	61	32	34	1	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2014	9	7							e101723	10.1371/journal.pone.0101723	http://dx.doi.org/10.1371/journal.pone.0101723			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AL3PK	25007331	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000339040600061
J	Decker, BK; Sevransky, JE; Barrett, K; Davey, RT; Chertow, DS				Decker, Brooke K.; Sevransky, Jonathan E.; Barrett, Kevin; Davey, Richard T.; Chertow, Daniel S.			Preparing for Critical Care Services to Patients With Ebola	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							VIRUS TRANSMISSION		NIH, Bethesda, MD 20892 USA; Emory Univ Hosp, Med Intens Care Unit, Atlanta, GA 30322 USA	National Institutes of Health (NIH) - USA; Emory University	Decker, BK (corresponding author), NIH, Ctr Clin, 10 Ctr Dr,Room 2C145, Bethesda, MD 20892 USA.	brooke.decker@nih.gov		Decker M.D., Brooke K/0000-0002-3404-9115				Bausch DG, 2007, J INFECT DIS, V196, pS142, DOI 10.1086/520545; Centers for Disease Control and Prevention, 2014, INF PREV CONTR REC H; Eckmanns T, 2006, INFECT CONT HOSP EP, V27, P931, DOI 10.1086/507294; Fischer WA, 2014, ANN INTERN MED, V161, P753, DOI 10.7326/M14-1953; Franz DR, 1997, JAMA-J AM MED ASSOC, V278, P399, DOI 10.1001/jama.278.5.399; Kerstiens B, 1999, J INFECT DIS, V179, pS263, DOI 10.1086/514320; Klompas M, 2014, ANN INTERN MED, V161, P751, DOI 10.7326/M14-1918	7	24	24	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 2	2014	161	11					831	U124		10.7326/M14-2141	http://dx.doi.org/10.7326/M14-2141			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AX9UJ	25244048				2023-01-03	WOS:000347247200014
J	d'Ettorre, G; Baroncelli, S; Micci, L; Ceccarelli, G; Andreotti, M; Sharma, P; Fanello, G; Fiocca, F; Cavallari, EN; Giustini, N; Mallano, A; Galluzzo, CM; Vella, S; Mastroianni, CM; Silvestri, G; Paiardini, M; Vullo, V				d'Ettorre, Gabriella; Baroncelli, Silvia; Micci, Luca; Ceccarelli, Giancarlo; Andreotti, Mauro; Sharma, Prachi; Fanello, Gianfranco; Fiocca, Fausto; Cavallari, Eugenio Nelson; Giustini, Noemi; Mallano, Alessandra; Galluzzo, Clementina M.; Vella, Stefano; Mastroianni, Claudio M.; Silvestri, Guido; Paiardini, Mirko; Vullo, Vincenzo			Reconstitution of Intestinal CD4 and Th17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects: Implication for Residual Immune Activation from the Results of a Clinical Trial	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NATURAL SIV HOSTS; MICROBIAL TRANSLOCATION; LYMPHOID-TISSUE; HIV-1-INFECTED PATIENTS; POSITIVE PATIENTS; GUT MUCOSA; RESTORATION; AIDS; DEPLETION	Introduction: During HIV infection the severe depletion of intestinal CD4(+) T-cells is associated with microbial translocation, systemic immune activation, and disease progression. This study examined intestinal and peripheral CD4(+) T-cell subsets reconstitution under combined antiretroviral therapy (cART), and systemic immune activation markers. Methods: This longitudinal single-arm pilot study evaluates CD4(+) T cells, including Th1 and Th17, in gut and blood and soluble markers for inflammation in HIV-infected individuals before (M0) and after eight (M8) months of cART. From January 2010 to December 2011, 10 HIV-1 naive patients were screened and 9 enrolled. Blood and gut CD4(+) T-cells subsets and cellular immune activation were determined by flow-cytometry and plasma soluble CD14 by ELISA. CD4(+) Th17 cells were detected in gut biopsies by immunohistochemistry. Microbial translocation was measured by limulus-amebocyte-lysate assay to detect bacterial lipopolysaccharide (LPS) and PCR Real Time to detect plasma bacterial 16S rDNA. Results: Eight months of cART increased intestinal CD4(+) and Th17 cells and reduced levels of T-cell activation and proliferation. The magnitude of intestinal CD4(+) T-cell reconstitution correlated with the reduction of plasma LPS. Importantly, the magnitude of Th17 cells reconstitution correlated directly with blood CD4(+) T-cell recovery. Conclusion: Short-term antiretroviral therapy resulted in a significant increase in the levels of total and Th17 CD4(+) T-cells in the gut mucosa and in decline of T-cell activation. The observation that pre-treatment levels of CD4(+) and of CD8(+) T-cell activation are predictors of the magnitude of Th17 cell reconstitution following cART provides further rationale for an early initiation of cART in HIV-infected individuals.	[d'Ettorre, Gabriella; Ceccarelli, Giancarlo; Cavallari, Eugenio Nelson; Giustini, Noemi; Vullo, Vincenzo] Univ Roma La Sapienza, Dept Publ Hlth & Infect Dis, Ist Pasteur Fdn Cenci Bolognetti, I-00185 Rome, Italy; [Baroncelli, Silvia; Andreotti, Mauro; Mallano, Alessandra; Galluzzo, Clementina M.; Vella, Stefano] Ist Super Sanita, Dept Therapeut Res & Med Evaluat, I-00161 Rome, Italy; [Micci, Luca; Silvestri, Guido; Paiardini, Mirko] Yerkes Natl Primate Res Ctr, Div Microbiol & Immunol, Atlanta, GA USA; [Sharma, Prachi] Yerkes Natl Primate Res Ctr, Div Pathol, Atlanta, GA USA; [Fanello, Gianfranco; Fiocca, Fausto] Univ Roma La Sapienza, Policlin Umberto I, Dept Emergency Surg, Emergency Endoscop Unit, I-00185 Rome, Italy; [Mastroianni, Claudio M.] Sapienza Univ, Infect Dis Unit, Fdn Eleonora Lorillard Spencer Cenci, Latina, Italy; [Silvestri, Guido; Paiardini, Mirko] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Fondazione Cenci Bolognetti; Sapienza University Rome; Istituto Superiore di Sanita (ISS); Sapienza University Rome; University Hospital Sapienza Rome; Sapienza University Rome; Emory University	d'Ettorre, G (corresponding author), Univ Roma La Sapienza, Dept Publ Hlth & Infect Dis, Ist Pasteur Fdn Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	gabriella.dettorre@uniroma1.it	MASTROIANNI, Claudio Maria/O-9741-2019; Ceccarelli, Giancarlo/K-6454-2016; Sharma, Prachi/HGD-0637-2022; andreotti, mauro/K-1436-2016; Ceccarelli, Giancarlo/ABD-8347-2020; Cavallari, Eugenio Nelson/ABF-1968-2020; VELLA, STEFANO/ABI-3368-2020; MALLANO, ALESSANDRA/D-7959-2016; andreotti, mauro/ABA-8513-2021; Vella, Stefano/GZM-0519-2022; d'Ettorre, Gabriella/K-4511-2016; Fiocca, Fausto/AAI-4702-2020; galluzzo, clementina maria/M-8912-2017	MASTROIANNI, Claudio Maria/0000-0002-1286-467X; Ceccarelli, Giancarlo/0000-0001-5921-3180; andreotti, mauro/0000-0001-5168-8624; Ceccarelli, Giancarlo/0000-0001-5921-3180; Cavallari, Eugenio Nelson/0000-0002-6021-484X; MALLANO, ALESSANDRA/0000-0003-2392-0769; andreotti, mauro/0000-0001-5168-8624; d'Ettorre, Gabriella/0000-0002-3571-5677; galluzzo, clementina maria/0000-0003-1392-6569; Fiocca, Fausto/0000-0002-7787-1766	ISS "Programma Italia Usa"; National Institutes of Health [R01-AI-084836]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI084836] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P51OD011132] Funding Source: NIH RePORTER	ISS "Programma Italia Usa"; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by ISS "Programma Italia Usa" (to AM) and by National Institutes of Health grant R01-AI-084836 (to MP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ancuta P, 2010, CURR OPIN HIV AIDS, V5, P158, DOI 10.1097/COH.0b013e3283364733; Baroncelli S, 2009, J CLIN VIROL, V46, P367, DOI 10.1016/j.jcv.2009.09.011; Bhaskaran K, 2008, JAMA-J AM MED ASSOC, V300, P51, DOI 10.1001/jama.300.1.51; Brandt L, 2011, JAIDS-J ACQ IMM DEF, V57, P101, DOI 10.1097/QAI.0b013e318215a991; Brenchley JM, 2008, BLOOD, V112, P2826, DOI 10.1182/blood-2008-05-159301; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Brenchley JM, 2006, NAT IMMUNOL, V7, P235, DOI 10.1038/ni1316; Cassol E, 2013, J INFECT DIS, V208, P1113, DOI 10.1093/infdis/jit249; Cecchinato V, 2008, MUCOSAL IMMUNOL, V1, P279, DOI 10.1038/mi.2008.14; Chahroudi A, 2012, SCIENCE, V335, P1188, DOI 10.1126/science.1217550; Chege D, 2011, AIDS, V25, P741, DOI 10.1097/QAD.0b013e328344cefb; Ciccone EJ, 2010, MUCOSAL IMMUNOL, V3, P172, DOI 10.1038/mi.2009.129; Ciccone EJ, 2011, J VIROL, V85, P5880, DOI 10.1128/JVI.02643-10; Costiniuk CT, 2012, MUCOSAL IMMUNOL, V5, P596, DOI 10.1038/mi.2012.82; d'Ettorre G, 2011, AIDS RES HUM RETROV, V27, P355, DOI 10.1089/aid.2010.0342; d'Ettorre G, 2011, CURR HIV RES, V9, P148, DOI 10.2174/157016211795945296; Dandekar S, 2010, CURR OPIN HIV AIDS, V5, P173, DOI 10.1097/COH.0b013e328335eda3; Deeks SG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3172; El Hed A, 2010, J INFECT DIS, V201, P843, DOI 10.1086/651021; Estes JD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001052; Favre D, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000295; Gaardbo JC, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/670957; George MD, 2005, J VIROL, V79, P2709, DOI 10.1128/JVI.79.5.2709-2719.2005; Gordon SN, 2010, J IMMUNOL, V185, P5169, DOI 10.4049/jimmunol.1001801; Guadalupe M, 2003, J VIROL, V77, P11708, DOI 10.1128/JVI.77.21.11708-11717.2003; Guadalupe M, 2006, J VIROL, V80, P8236, DOI 10.1128/JVI.00120-06; Guglani L, 2010, CURR OPIN HIV AIDS, V5, P120, DOI 10.1097/COH.0b013e328335c2f6; Hartigan-O'Connor DJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003941; Hartigan-O'Connor DJ, 2011, CURR OPIN HIV AIDS, V6, P221, DOI 10.1097/COH.0b013e32834577b3; Hayes TL, 2013, AIDS, V27, P867, DOI 10.1097/QAD.0b013e32835d85b4; Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7; Hunt PW, 2010, CURR OPIN HIV AIDS, V5, P189, DOI 10.1097/COH.0b013e32833647d9; Jain V, 2013, J INFECT DIS, V208, P1202, DOI 10.1093/infdis/jit311; Jiang W, 2009, J INFECT DIS, V199, P1177, DOI 10.1086/597476; Kanwar B, 2010, CURR OPIN HIV AIDS, V5, P151, DOI 10.1097/COH.0b013e328335c0c1; Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203; Lambotte O, 2006, PATHOL BIOL, V54, P566, DOI 10.1016/j.patbio.2006.07.035; Lok JJ, 2012, BIOMETRICS, V68, P745, DOI 10.1111/j.1541-0420.2011.01738.x; Macal M, 2008, MUCOSAL IMMUNOL, V1, P475, DOI 10.1038/mi.2008.35; Marchetti G, 2013, CLIN MICROBIOL REV, V26, P2, DOI 10.1128/CMR.00050-12; Mavigner M, 2012, J CLIN INVEST, V122, P62, DOI 10.1172/JCI59011; Mehandru S, 2006, PLOS MED, V3, P2335, DOI 10.1371/journal.pmed.0030484; Merlini E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018580; Micci L, 2012, BLOOD, V120, P3925, DOI 10.1182/blood-2012-04-420240; Noma Takeshi, 2010, Nihon Rinsho Meneki Gakkai Kaishi, V33, P262; Paiardini M, 2010, CURR OPIN HIV AIDS, V5, P166, DOI 10.1097/COH.0b013e328335c161; Papasavvas E, 2009, AIDS, V23, P369, DOI 10.1097/QAD.0b013e32831e9c76; Pelletier M, 2010, BLOOD, V115, P335, DOI 10.1182/blood-2009-04-216085; Piconi S, 2010, AIDS, V24, P1991, DOI 10.1097/QAD.0b013e32833c93ce; Pinzone MR, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/515962; Prendergast A, 2010, AIDS, V24, P491, DOI 10.1097/QAD.0b013e3283344895; Raffatellu M, 2008, NAT MED, V14, P421, DOI 10.1038/nm1743; Salgado M, 2011, CLIN IMMUNOL, V139, P110, DOI 10.1016/j.clim.2011.02.008; Sheth PM, 2008, MUCOSAL IMMUNOL, V1, P382, DOI 10.1038/mi.2008.23; Stockinger B, 2007, CURR OPIN IMMUNOL, V19, P281, DOI 10.1016/j.coi.2007.04.005; Tesmer LA, 2008, IMMUNOL REV, V223, P87, DOI 10.1111/j.1600-065X.2008.00628.x; Tincati C, 2009, ANTIVIR THER, V14, P321; Wallet MA, 2010, AIDS, V24, P1281, DOI 10.1097/QAD.0b013e328339e228; Westrop SJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005474; Yukl SA, 2010, J INFECT DIS, V202, P1553, DOI 10.1086/656722	60	26	26	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2014	9	10							e109791	10.1371/journal.pone.0109791	http://dx.doi.org/10.1371/journal.pone.0109791			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR5ZY	25340778	Green Published, gold, Green Submitted			2023-01-03	WOS:000343662800017
J	Feizpour, A; Boskabady, MH; Ghorbani, A				Feizpour, Azadeh; Boskabady, Mohammad Hossein; Ghorbani, Ahmad			Adipose-Derived Stromal Cell Therapy Affects Lung Inflammation and Tracheal Responsiveness in Guinea Pig Model of COPD	PLOS ONE			English	Article							MESENCHYMAL STEM-CELLS; CIGARETTE-SMOKE; AIRWAY HYPERRESPONSIVENESS; EMPHYSEMA; INJURY	The effects of adipose derived stromal cells (ASCs) were evaluated on tracheal responsiveness and biochemical parameters in guinea pigs model of chronic obstructive pulmonary disease (COPD). Thirty six guinea pigs were divided into 6 groups including: Control, COPD, COPD+intratracheal delivery of PBS (COPD+ITPBS), COPD+intravenous delivery of PBS (COPD+IVPBS), COPD+intratracheal delivery of ASCs (COPD+ITASC) and COPD+intravenous injection of ASCs (COPD+IVASC). COPD was induced by exposing animals to cigarette smoke for 3 months. Cell therapy was then performed and after 14 days, tracheal responsiveness, concentration of interleukin-8 (IL-8) in serum and broncho-alveolar lavage fluid (BALF), as well as total and differential white blood cells (WBC) counts were evaluated. Tracheal responsiveness, total WBC counts, neutrophil and eosinophil percentage in BALF as well as concentration of IL-8 in serum and BALF significantly increased but lymphocyte percentage decreased in COPD compared to the control group (P<0.05 to p<0.001). Cell therapy was able to restore the tracheal hyper-responsiveness and the increased IL-8 concentration in serum and BALF of COPD-ITASC but not COPD-IVASC animals (P<0.05 for all cases). Total WBC in BALF also showed a significant decrease in both treated groups and the percentages of eosinophils, neutrophils and lymphocytes in BALF were reversed in COPD-ITASC compared to COPD-ITPBS animals (P<0.05 to P<0.001). Therefore, intratracheal cell therapy with ASC can decrease tracheal hyperresponsiveness and lung inflammation in cigarette smoke induced-COPD which may be helpful in attenuation of the severity of disease in patients suffering from COPD.	[Feizpour, Azadeh; Boskabady, Mohammad Hossein] Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad, Iran; [Feizpour, Azadeh; Boskabady, Mohammad Hossein] Mashhad Univ Med Sci, Sch Med, Dept Physiol, Mashhad, Iran; [Ghorbani, Ahmad] Mashhad Univ Med Sci, Pharmacol Res Ctr Med Plants, Sch Med, Mashhad, Iran	Mashhad University Medical Science; Mashhad University Medical Science; Mashhad University Medical Science	Boskabady, MH (corresponding author), Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad, Iran.	boskabadymh@mums.ac.ir	Ghorbani, Ahmad/S-8164-2016; Boskabady, Mohammad Hossein/AAR-5552-2021	Ghorbani, Ahmad/0000-0002-1603-2619; naseri, shahrokh/0000-0001-8974-2120; Feizpour, Azadeh/0000-0003-0826-4011	Research Council of Mashhad University of Medical Sciences	Research Council of Mashhad University of Medical Sciences	This study was financially supported by the Research Council of Mashhad University of Medical Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abboud RT, 2008, INT J TUBERC LUNG D, V12, P361; Barrett EG, 2002, AM J RESP CRIT CARE, V165, P1410, DOI 10.1164/rccm.2106029; Boskabady MH, 2010, PHARMAZIE, V65, P300, DOI 10.1691/ph.2010.9760; Boskabady M H, 2007, Pathophysiology, V14, P97, DOI 10.1016/j.pathophys.2007.06.003; Boskabady MH, 2005, MED SCI MONITOR, V11, pCR344; Boskabady MH, 2003, RESPIROLOGY, V8, P473, DOI 10.1046/j.1440-1843.2003.00511.x; Boskabady MH, 2006, RESPIROLOGY, V11, P572, DOI 10.1111/j.1440-1843.2005.00893.x; Boskabady Morteza, 2010, Indian J Med Sci, V64, P363; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; Clark J.D., 1996, GUIDE CARE USE LAB A; Cruz FF, 2012, RESP PHYSIOL NEUROBI, V182, P26, DOI 10.1016/j.resp.2012.01.002; Drost EM, 2005, THORAX, V60, P293, DOI 10.1136/thx.2004.027946; DUSSER DJ, 1989, J CLIN INVEST, V84, P900, DOI 10.1172/JCI114251; Ghorbani A, 2010, EXP CLIN ENDOCR DIAB, V118, P442, DOI 10.1055/s-0030-1247566; Ghorbani A, 2013, PAK J BIOL SCI, V7, P1; Ghorbani Ahmad, 2013, ISRN Endocrinol, V2013, P205385, DOI 10.1155/2013/205385; Ghorbani A, 2014, DARU, V22, DOI 10.1186/2008-2231-22-26; Ghorbani A, 2014, TISSUE CELL, V46, P54, DOI 10.1016/j.tice.2013.11.002; Gladysheva Ekaterina S, 2010, Int J Chron Obstruct Pulmon Dis, V5, P153; Gupta N, 2007, J IMMUNOL, V179, P1855, DOI 10.4049/jimmunol.179.3.1855; Iyer SS, 2008, EXPERT OPIN BIOL TH, V8, P569, DOI 10.1517/14712598.8.5.569 ; Katsha AM, 2011, MOL THER, V19, P196, DOI 10.1038/mt.2010.192; Krampera M, 2006, CURR OPIN PHARMACOL, V6, P435, DOI 10.1016/j.coph.2006.02.008; Kubo S, 2005, EUR RESPIR J, V26, P993, DOI 10.1183/09031936.05.00042405; Kwong K, 2001, AM J RESP CELL MOL, V25, P299, DOI 10.1165/ajrcmb.25.3.4557; LEE LY, 1995, RESP PHYSIOL, V99, P173, DOI 10.1016/0034-5687(94)00088-H; Ortiz LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI 10.1073/pnas.0704421104; Pauwels R A, 2001, Respir Care, V46, P798; Raynaud CM, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/658356; Sakai Hiroyasu, 2011, Journal of Smooth Muscle Research, V47, P1; Schweitzer KS, 2011, AM J RESP CRIT CARE, V183, P215, DOI 10.1164/rccm.201001-0126OC; Shigemura N, 2006, AM J RESP CRIT CARE, V174, P1199, DOI 10.1164/rccm.200603-406OC; Wright JL, 2002, CHEST, V122, p301S, DOI 10.1378/chest.122.6_suppl.301S; WRIGHT JL, 1990, AM REV RESPIR DIS, V142, P1422, DOI 10.1164/ajrccm/142.6_Pt_1.1422; Wu ZX, 1999, J APPL PHYSIOL, V87, P1621, DOI 10.1152/jappl.1999.87.5.1621; XU LJ, 1993, LUNG, V171, P95, DOI 10.1007/BF00542337	36	22	22	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2014	9	10							e108974	10.1371/journal.pone.0108974	http://dx.doi.org/10.1371/journal.pone.0108974			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0AY	25330334	Green Published, Green Submitted, gold			2023-01-03	WOS:000343942100015
J	Tramer, MR				Tramer, Martin R.			Do we need to know whether nitrous oxide harms patients?	LANCET			English	Editorial Material							ANESTHESIA; HOMOCYSTEINE		Univ Hosp Geneva, Dept Anaesthesiol Clin Pharmacol & Intens Care Me, Div Anaesthesiol, CH-1211 Geneva, Switzerland	University of Geneva	Tramer, MR (corresponding author), Univ Hosp Geneva, Dept Anaesthesiol Clin Pharmacol & Intens Care Me, Div Anaesthesiol, CH-1211 Geneva, Switzerland.	martin.tramer@hcuge.ch						Badner NH, 1998, ANESTH ANALG, V87, P711, DOI 10.1097/00000539-199809000-00041; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; DEACON R, 1980, EUR J BIOCHEM, V104, P419, DOI 10.1111/j.1432-1033.1980.tb04443.x; Herff H, 2007, ANAESTHESIA, V62, P1202, DOI 10.1111/j.1365-2044.2007.05193.x; Jevtovic-Todorovic V, 2003, NEUROSCIENCE, V122, P609, DOI 10.1016/j.neuroscience.2003.07.012; Myles PS, 2014, LANCET; Nagele P, 2008, ANESTHESIOLOGY, V109, P36, DOI 10.1097/ALN.0b013e318178820b; Tramer M, 1996, BRIT J ANAESTH, V76, P186, DOI 10.1093/bja/76.2.186; Viterbo JF, 2012, EUR J ANAESTH, V29, P477, DOI 10.1097/EJA.0b013e3283542421; WHO Expert Committee on Selection and Use of Essential Medicines, 2013, WHO MOD LISTS ESS ME	10	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	2014	384	9952					1407	1409		10.1016/S0140-6736(14)61061-8	http://dx.doi.org/10.1016/S0140-6736(14)61061-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AQ8TV	25142709				2023-01-03	WOS:000343107000006
J	Abate, M; Assefa, N; Alemayehu, T				Abate, Meskerem; Assefa, Nega; Alemayehu, Tadesse			Knowledge, Attitude, Practice, and Determinants Emergency Contraceptive Use among Women Seeking Abortion Services in Dire Dawa, Ethiopia	PLOS ONE			English	Article								Background: Unplanned pregnancy from casual sex, unplanned sexual activity, and sexual violence are increasing. Emergency Contraceptives (EC) are used to prevent unplanned pregnancies thereby preventing the occurrence and consequences of unplanned pregnancy. Emergency contraception is widely available in Ethiopia particularly in major cities. Yet the use of EC is very low and abortion rate in cities is high compared to the national average. Objectives: To assess knowledge, attitude and practice and determinants on the use of emergency contraception among women obtaining abortion service at selected health institutions in Dire Dawa, Eastern Ethiopia. Methods: A facility based cross-sectional study was conducted on 390 women selected by multi-stage random sampling technique. The samples were generated from government and private for non profit health facilities. Participant's knowledge and attitude towards emergency contraception were measured using composite index based on 7 and 9 questions, respectively and analyzed using mean score to classify them as knowledgeable or not, and have positive attitude or not. Practice was assessed if the women reported ever use of emergency contraception. Determinants of use of emergency contraception were analyzed using logistic regression. Result: Out of 390 women interviewed, 162 women (41.5%) heard about EC, only 133 (34.1%) had good knowledge, and 200 (51.3%) of the respondents had positive attitudes towards to EC. Ever use of EC was reported by 38 (9.7%). Age, living arrangement, education, marital status, religion were found to be significantly associated with the use of emergency contraceptives. Women with poor knowledge were less likely to use EC compared to the knowledgeable ones [AOR = 0.027, 95% CI (0.007, 0.105)]. Conclusion: The study identified that most respondents lack adequate knowledge on the method of EC. In addition ever use of EC is very low. Recommendations: Health professions should give attention in increasing knowledge and uptake of Emergency Contraception.	[Abate, Meskerem] Dire Dawa Hlth Off, Sabian Hlth Ctr, Dire Dawa, Ethiopia; [Assefa, Nega; Alemayehu, Tadesse] Haramaya Univ, Coll Hlth & Med Sci, East Harerge, Ethiopia	Haramaya University	Assefa, N (corresponding author), Haramaya Univ, Coll Hlth & Med Sci, East Harerge, Ethiopia.	negaassefa@yahoo.com		Assefa, Nega/0000-0003-0341-2329; Alemayehu, Tadesse/0000-0002-1560-7636	Haramaya University	Haramaya University	Haramaya University supported the study. The study was part of masters thesis. The university has no role in the design and conduct of the study. One of the author is Haramaya University Employee, this does not have any influence on affecting the design, and implementation of the study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Admasu A, 2009, ETHIOPIAN J REPROD H, V3; Babaee G, 2003, J SEX MARITAL THER, V29, P269, DOI 10.1080/00926230390195506; Chavuma N, 2010, MED J ZAMBIA LUSAKA, V37; Cheng L, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001324.pub3, 10.1002/14651858.CD001324.pub4]; Dire Dawa City Administration, 2010, DIR DAW PROF; Margaret OE, 2006, INT FAMILY PLANNING, V32, P89; Merchant RC, 2007, J EMERG MED, V33, P367, DOI 10.1016/j.jemermed.2007.02.031; Myer L, 2007, BMC WOMENS HEALTH, V7, P14, DOI DOI 10.1186/1472-6874-7-14; Neinstein LS., 2008, ADOLESCENT HLTH CARE, P533; Schwarz EB, 2007, CONTRACEPTION, V75, P285, DOI 10.1016/j.contraception.2006.11.002; Seife M, 2007, THESIS ADDIS ABABA U; Singh S, 2010, INT PERSPECT SEX R H, V36, P16, DOI 10.1363/ipsrh.36.016.10; Stella K, 2011, KNOWLEDGE ATTITUDES; Wegene T, 2007, ETHIOP J HEALTH DEV, V21, P112; WHO Gutmacher Institute, 2007, FACTS IND AB WORLDW; Worku A, 2011, ETHIOP J HEALTH DEV, V25, P176	16	5	5	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2014	9	10							e110008	10.1371/journal.pone.0110008	http://dx.doi.org/10.1371/journal.pone.0110008			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8TF	25330229	Green Published, gold, Green Submitted			2023-01-03	WOS:000345204100038
J	Adams, BD; Benger, J				Adams, Bruce D.; Benger, Jonathan			Should we take patients to hospital in cardiac arrest?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CLINICAL-PREDICTION RULE; LIFE-SUPPORT TERMINATION; CARDIOPULMONARY-RESUSCITATION; SURVIVAL; IMPLEMENTATION; GUIDELINES; DERIVATION		[Adams, Bruce D.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Benger, Jonathan] Univ W England, Bristol BS16 1QY, Avon, England; [Benger, Jonathan] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England	University of Texas System; University of Texas Health San Antonio; University of West England; University of Bristol	Adams, BD (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr,Mail Code 7736, San Antonio, TX 78229 USA.	adamsb@uthscsa.edu; Jonathan.Benger@uwe.ac.uk						Arlt M, 2011, RESUSCITATION, V82, P1243, DOI 10.1016/j.resuscitation.2011.03.022; Berdowski J, 2010, RESUSCITATION, V81, P1479, DOI 10.1016/j.resuscitation.2010.08.006; BONNIN MJ, 1993, JAMA-J AM MED ASSOC, V270, P1457, DOI 10.1001/jama.270.12.1457; Chiang WC, 2015, EMERG MED J, V32, P318, DOI 10.1136/emermed-2013-203289; Eckstein M, 2005, ANN EMERG MED, V45, P504, DOI 10.1016/j.annemergmed.2004.11.024; Edbrooke DL, 2011, CRIT CARE, V15, DOI 10.1186/cc10029; Gilbert M, 2000, LANCET, V355, P375, DOI 10.1016/S0140-6736(00)01021-7; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; Herlitz J, 2008, RESUSCITATION, V76, P31, DOI 10.1016/j.resuscitation.2007.06.027; Jacobs IG, 2011, RESUSCITATION, V82, P1138, DOI 10.1016/j.resuscitation.2011.06.029; Kajino K, 2013, RESUSCITATION, V84, P54, DOI 10.1016/j.resuscitation.2012.05.027; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1433, DOI 10.1001/jama.270.12.1433; Millin MG, 2011, PREHOSP EMERG CARE, V15, P547, DOI 10.3109/10903127.2011.608872; Morrison LJ, 2007, RESUSCITATION, V74, P266, DOI 10.1016/j.resuscitation.2007.01.009; Morrison LJ, 2007, RESUSCITATION, V74, P150, DOI 10.1016/j.resuscitation.2006.10.030; Morrison LJ, 2006, NEW ENGL J MED, V355, P478, DOI 10.1056/NEJMoa052620; Morrison LJ, 2014, RESUSCITATION, V85, P486, DOI 10.1016/j.resuscitation.2013.12.013; Morrison LJ, 2009, RESUSCITATION, V80, P324, DOI 10.1016/j.resuscitation.2008.11.014; Muller T, 2013, RESUSCITATION, V84, P1463, DOI 10.1016/j.resuscitation.2013.08.004; Naess AC, 2004, RESUSCITATION, V60, P57, DOI 10.1016/S0300-9572(03)00262-4; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Nichol G, 2010, CIRCULATION, V122, pE439, DOI 10.1161/CIR.0b013e3181efa990; Nolan JP, 2010, RESUSCITATION, V81, pE1, DOI 10.1016/j.resuscitation.2010.08.002; Ong MEH, 2007, RESUSCITATION, V75, P244, DOI 10.1016/j.resuscitation.2007.04.013; Orioles A, 2013, CRIT CARE MED, V41, P2794, DOI 10.1097/CCM.0b013e31829a7202; Perkins GD, 2012, EMERG MED J, V29, P3, DOI 10.1136/emermed-2011-200758; Sherbino J, 2010, J EMERG MED, V38, P80, DOI 10.1016/j.jemermed.2009.08.002; Stiell IG, 2004, NEW ENGL J MED, V351, P647, DOI 10.1056/NEJMoa040325; Suchard JR, 1999, J EMERG MED, V17, P801, DOI 10.1016/S0736-4679(99)00086-4; Tagami T, 2012, CIRCULATION, V126, P589, DOI 10.1161/CIRCULATIONAHA.111.086173; Verbeek PR, 2002, ACAD EMERG MED, V9, P671, DOI 10.1197/aemj.9.7.671; ZOLL PM, 1956, NEW ENGL J MED, V254, P727, DOI 10.1056/NEJM195604192541601	32	8	8	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 23	2014	349								g5659	10.1136/bmj.g5659	http://dx.doi.org/10.1136/bmj.g5659			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AP9UL	25249357	Green Published			2023-01-03	WOS:000342425700004
J	Shiraishi, N; Nishida, A; Shimodera, S; Sasaki, T; Oshima, N; Watanabe, N; Akechi, T; Furukawa, TA; Okazaki, Y				Shiraishi, Nao; Nishida, Atsushi; Shimodera, Shinji; Sasaki, Tsukasa; Oshima, Norihito; Watanabe, Norio; Akechi, Tatsuo; Furukawa, Toshiaki A.; Okazaki, Yuji			Relationship between Violent Behavior and Repeated Weight-Loss Dieting among Female Adolescents in Japan	PLOS ONE			English	Article							ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; MENTAL-HEALTH STATUS; EATING-DISORDERS; CHILDHOOD ABUSE; RISK-FACTORS; BODY-IMAGE; OBESITY; ASSOCIATIONS; QUESTIONNAIRE; CONSEQUENCES	Purpose: To examine whether interpersonal violence perpetration and violence toward objects are associated with body mass index (BMI), body weight perception (BWP), and repeated weight-loss dieting in female adolescents. Methods: A cross-sectional survey using a self-report questionnaire was performed evaluating interpersonal violence perpetration, violence toward objects, the number of diets, BMI, BWP, the 12-item General Health Questionnaire (GHQ-12), victimization, substance use, and other psychosocial variables among 9,112 Japanese females aged between 12-18 years. Logistic regression analysis was conducted to analyze the contribution of BMI, BWP, and weight-control behavior to the incidence of violent behavior, while controlling for potential confounding factors. Results: The number of diets was associated with both interpersonal violence perpetration (OR = 1.18, 95% CI 1.08-1.29, p<0.001) and violence toward objects (OR = 1.34, 95% CI 1.24-1.45, p<0.001), after adjusting for age, BMI, BWP, the GHQ-12 total score, victimization, and substance use. In terms of BMI and BWP, the "overweight'' BWP was associated with violence toward objects (OR = 1.29, 95% CI 1.07-1.54, p<0.05). On the other hand, the "Underweight'' and "Slightly underweight'' BMI were related to violence toward objects [(OR = 1.28, 95% CI 1.01-1.62, p<0.05) and (OR = 1.27, 95% CI 1.07-1.51, p<0.05), respectively]. The "Underweight'' BWP was related to interpersonal violence perpetration (OR = 2.30, 95% CI 1.38-3.84, p<0.05). Conclusions: The cumulative number of diets is associated with violent behavior in female adolescents. In addition, underweight BMI and extreme BWP are associated with violent behavior.	[Shiraishi, Nao; Akechi, Tatsuo] Nagoya City Univ, Grad Sch Med Sci, Dept Psychiat & Cognit Behav Med, Mizuho Ku, Nagoya, Aichi, Japan; [Nishida, Atsushi] Tokyo Metropolitan Inst Med Sci, Dept Psychiat & Behav Sci, Setagaya Ku, Tokyo 113, Japan; [Shimodera, Shinji] Kochi Univ, Kochi Med Sch, Dept Neuropsychiat, Nanngoku, Kohchi, Japan; [Sasaki, Tsukasa] Univ Tokyo, Grad Sch Educ, Lab Hlth Educ, Bunkyo Ku, Tokyo, Japan; [Oshima, Norihito] Univ Tokyo, Div Counseling & Support, Off Mental Hlth Support, Bunkyo Ku, Tokyo, Japan; [Watanabe, Norio] Natl Ctr Neurol & Psychiat, Translat Med Ctr, Dept Clin Epidemiol, Kodaira, Tokyo, Japan; [Furukawa, Toshiaki A.] Kyoto Univ, Grad Sch Med, Sch Publ Hlth, Dept Hlth Promot & Human Behav,Sakyo Ku, Kyoto, Japan; [Okazaki, Yuji] Tokyo Metropolitan Matsuzawa Hosp, Setagaya Ku, Tokyo, Japan	Nagoya City University; Tokyo Metropolitan Institute of Medical Science; Kochi University; University of Tokyo; University of Tokyo; National Center for Neurology & Psychiatry - Japan; Kyoto University	Shimodera, S (corresponding author), Kochi Univ, Kochi Med Sch, Dept Neuropsychiat, Nanngoku, Kohchi, Japan.	shimodes@kochi-u.ac.jp	Andoh, Akira/AAB-9303-2022; Furukawa, Toshi A./B-9259-2011	Furukawa, Toshi A./0000-0003-2159-3776	Ministry of Health, Labor, and Welfare of Japan [H19-kokoro-ippan-012]; Research Group for Schizophrenia in Japan	Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Research Group for Schizophrenia in Japan	This study was funded by a grant-in-aid for scientific research (#H19-kokoro-ippan-012) from the Ministry of Health, Labor, and Welfare of Japan and a grant-in-aid from the Research Group for Schizophrenia in Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackard DM, 2002, J PSYCHOSOM RES, V52, P129, DOI 10.1016/S0022-3999(01)00269-0; Baksheev GN, 2011, PSYCHIAT RES, V187, P291, DOI 10.1016/j.psychres.2010.10.010; BALLIN A, 1992, AM J DIS CHILD, V146, P803, DOI 10.1001/archpedi.1992.02160190035015; Blaine B, 2008, J HEALTH PSYCHOL, V13, P1190, DOI 10.1177/1359105308095977; Blitstein JL, 2005, HEALTH EDUC BEHAV, V32, P175, DOI 10.1177/1090198104269516; Chang JJ, 2003, J ADOLESCENT HEALTH, V32, P272, DOI 10.1016/S1054-139X(02)00564-5; Cortese S, 2008, CRIT REV FOOD SCI, V48, P524, DOI 10.1080/10408390701540124; Crow S, 2006, J ADOLESCENT HEALTH, V38, P569, DOI 10.1016/j.jadohealth.2005.05.019; Daee A, 2002, SOUTH MED J, V95, P1032, DOI 10.1097/00007611-200209000-00021; Devaud C, 1998, INT J EAT DISORDER, V24, P207, DOI 10.1002/(SICI)1098-108X(199809)24:2&lt;207::AID-EAT10&gt;3.0.CO;2-W; Doi Y, 2003, PSYCHIAT CLIN NEUROS, V57, P379, DOI 10.1046/j.1440-1819.2003.01135.x; Eaton Danice K., 2012, Morbidity and Mortality Weekly Report, V61, P1; Ellickson PL, 2001, J ADOLESCENT HEALTH, V28, P465, DOI 10.1016/S1054-139X(00)00202-0; Fang XM, 2010, ARCH GEN PSYCHIAT, V67, P1179, DOI 10.1001/archgenpsychiatry.2010.137; Favaro A, 2010, PSYCHOL MED, V40, P657, DOI 10.1017/S0033291709990973; FRENCH SA, 1995, AM J PUBLIC HEALTH, V85, P695, DOI 10.2105/AJPH.85.5.695; FRENCH SA, 1994, HEALTH PSYCHOL, V13, P195, DOI 10.1037/0278-6133.13.3.195; GOLDBERG DP, 1976, BRIT J PSYCHIAT, V129, P61, DOI 10.1192/bjp.129.1.61; Herrenkohl TI, 2000, J ADOLESCENT HEALTH, V26, P176, DOI 10.1016/S1054-139X(99)00065-8; Himes JH, 2005, ANN EPIDEMIOL, V15, P272, DOI 10.1016/j.annepidem.2004.08.010; Kaneita Y, 2007, J CLIN PSYCHIAT, V68, P1426, DOI 10.4088/JCP.v68n0916; Kaneko K, 1999, PSYCHIAT CLIN NEUROS, V53, P365, DOI 10.1046/j.1440-1819.1999.00559.x; Kato N., 2009, J JAPAN ASS HUM AUXO, V15, P37; Krug Etienne G, 2002, Biomedica, V22 Suppl 2, P327; Laufer Avital, 2003, Int J Adolesc Med Health, V15, P235; Maeda M, 1999, INT J HEMATOL, V69, P75; Mansson J, 2005, SCAND J PRIM HEALTH, V23, P28, DOI 10.1080/02813430510018428; Neumark-Sztainer D, 2006, J AM DIET ASSOC, V106, P559, DOI 10.1016/j.jada.2006.01.003; Neumark-Sztainer D, 2000, ARCH PEDIAT ADOL MED, V154, P569, DOI 10.1001/archpedi.154.6.569; Neumark-Sztainer D, 2004, J AM DIET ASSOC, V104, P913, DOI 10.1016/j.jada.2004.03.021; Neumark-Sztainer D, 2006, J ADOLESCENT HEALTH, V39, P244, DOI 10.1016/j.jadohealth.2005.12.001; Nishida A, 2008, SCHIZOPHR RES, V99, P125, DOI 10.1016/j.schres.2007.11.038; Ojala K, 2007, INT J BEHAV NUTR PHY, V4, DOI 10.1186/1479-5868-4-50; Polivy J, 1996, J AM DIET ASSOC, V96, P589, DOI 10.1016/S0002-8223(96)00161-7; PUGLIESE MT, 1983, NEW ENGL J MED, V309, P513, DOI 10.1056/NEJM198309013090901; Rayworth BB, 2004, EPIDEMIOLOGY, V15, P271, DOI 10.1097/01.ede.0000120047.07140.9d; RESNICK MD, 2004, J HLTH EC, V0035; Smith-Khuri E, 2004, ARCH PEDIAT ADOL MED, V158, P539, DOI 10.1001/archpedi.158.6.539; Smolak L, 2002, INT J EAT DISORDER, V31, P136, DOI 10.1002/eat.10008; Stice E, 2000, J ABNORM PSYCHOL, V109, P438, DOI 10.1037/0021-843X.109.3.438; STORY M, 1991, AM J DIS CHILD, V145, P994, DOI 10.1001/archpedi.1991.02160090046020; Suka Machi, 2005, Environmental Health and Preventive Medicine, V10, P324, DOI 10.1007/BF02898192; Swahn MH, 2004, J ADOLESCENT HEALTH, V34, P480, DOI 10.1016/S1054-139X(03)00368-9; WHO Regional Office for Europe, HLTH BEH SCH AG CHIL; Yoshimasu K, 2012, J CHILD PSYCHOL PSYC, V53, P1036, DOI 10.1111/j.1469-7610.2012.02567.x	45	3	3	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2014	9	9							e107744	10.1371/journal.pone.0107744	http://dx.doi.org/10.1371/journal.pone.0107744			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AP1UA	25210854	Green Submitted, Green Published, gold			2023-01-03	WOS:000341855900092
J	Schmiedl, S; Fischer, R; Ibanez, L; Fortuny, J; Klungel, OH; Reynolds, R; Gerlach, R; Tauscher, M; Thurmann, P; Hasford, J; Rottenkolber, M				Schmiedl, Sven; Fischer, Rainald; Ibanez, Luisa; Fortuny, Joan; Klungel, Olaf H.; Reynolds, Robert; Gerlach, Roman; Tauscher, Martin; Thuermann, Petra; Hasford, Joerg; Rottenkolber, Marietta			Utilisation and Off-Label Prescriptions of Respiratory Drugs in Children	PLOS ONE			English	Article							ACUTE BRONCHIOLITIS; PEDIATRIC ASTHMA; MANAGEMENT; POPULATION; MEDICATION; LIFE	Respiratory drugs are widely used in children to treat labeled and non-labeled indications but only some data are available quantifying comprehensively off-label usage. Thus, we aim to analyse drug utilisation and off-label prescribing of respiratory drugs focusing on age- and indication-related off-label use. Patients aged <= 18 years documented in the Bavarian Association of Statutory Health Insurance Physicians database approx. 2 million children) between 2004 and 2008 were included in our study. Annual period prevalence rates PPRs) per 10,000 children and the proportion of age- and indication-related off-label prescriptions were calculated and stratified by age and gender. Within the study period, highest PPRs were found for the fixed combination of clenbuterol/ambroxol between 374-575 per 10,000 children) and the inhaled short acting beta-2-agonist salbutamol between 378-527 per 10,000 children). Highest relative PPR increase was found for oral salbutamol approx. 39-fold) whereas the most distinct decrease was found for oral long-acting beta-2-agonist clenbuterol -97%). Compound classes most frequently involved in off-label prescribing were inhaled bronchodilative compounds 91,402; 37.3%) and oral beta-2-agonists 26,850; 22.5%). The highest absolute number of off-label prescriptions were found for inhaled salbutamol n = 67,084; 42.0%) and oral clenbuterol/ambroxol fixed combination, n = 18,897; 20.7%). Off-label prescribing due to indication was of much greater relevance than age-related off-label use. Most frequently, bronchodilative compounds were used off-label to treat respiratory tract infections. Highest off-label prescription rates were found in the youngest patients without relevant gender-related differences. Off-label prescribing of respiratory drugs is common especially in young children. Bronchodilative drugs were most frequently used off-label for treating acute bronchitis or upper respiratory tract infections underlining the essential need for a more rational prescribing in this area.	[Schmiedl, Sven; Thuermann, Petra] Univ Witten Herdecke, Sch Med, Fac Hlth, Dept Clin Pharmacol, Witten, Germany; [Schmiedl, Sven; Thuermann, Petra] HELIOS Clin Wuppertal, Philipp Klee Inst Clin Pharmacol, Wuppertal, Germany; [Fischer, Rainald] Pneumolog Praxis Munchen Pasing, Munich, Germany; [Ibanez, Luisa] Hosp Univ Vall Hebron, Fdn Inst Catalia Farmacol, Barcelona, Spain; [Ibanez, Luisa] Univ Autonoma Barcelona, Dept Farmacol Terapeut & Toxicol, E-08193 Barcelona, Spain; [Fortuny, Joan] Novartis Farmaceut SA, Barcelona, Spain; [Klungel, Olaf H.] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands; [Reynolds, Robert] Pfizer, Epidemiol, New York, NY USA; [Gerlach, Roman; Tauscher, Martin] Natl Assoc Statutory Hlth Insurance Phys Bavaria, Munich, Germany; [Hasford, Joerg; Rottenkolber, Marietta] Univ Munich, Inst Med Informat Sci Biometry & Epidemiol, Munich, Germany	Witten Herdecke University; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Novartis; Utrecht University; Pfizer; University of Munich	Schmiedl, S (corresponding author), Univ Witten Herdecke, Sch Med, Fac Hlth, Dept Clin Pharmacol, Witten, Germany.	sven.schmiedl@helios-kliniken.de	Ibanez, Luisa/M-2986-2013	Ibanez, Luisa/0000-0002-1175-0574; Fortuny, Joan/0000-0001-9401-5243; Thurmann, Petra/0000-0001-9724-1422	Innovative Medicines Initiative Joint Undertaking [115004]; European Union's Seventh Framework Programme (FP7); EFPIA; IMI JU; Utrecht University from Pfizer	Innovative Medicines Initiative Joint Undertaking; European Union's Seventh Framework Programme (FP7); EFPIA; IMI JU; Utrecht University from Pfizer	The PROTECT project has received support from the Innovative Medicines Initiative Joint Undertaking (www.imi.europa.eu) under Grant Agreement nu 115004, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution. In addition, as a special form of the IMI JU grant, Utrecht University received a direct financial contribution from Pfizer. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baiardi P, 2010, ACTA PAEDIATR, V99, P544, DOI 10.1111/j.1651-2227.2009.01668.x; Barben J, 2008, THORAX, V63, P1103, DOI 10.1136/thx.2007.094706; Bayerisches Landesamt fur Statistik und Datenverarbeitung, 2013, BEV BAYERN; Bianchi M, 2012, RESP MED, V106, P1383, DOI 10.1016/j.rmed.2012.06.005; Bianchi M, 2010, EUR J CLIN PHARMACOL, V66, P929, DOI 10.1007/s00228-010-0845-y; Choonara I, 2013, ARCH DIS CHILD, V98, P720, DOI 10.1136/archdischild-2013-304559; Conroy S, 2011, ARCH DIS CHILD, V96, P305, DOI 10.1136/adc.2010.191940; De Brasi D, 2010, ITAL J PEDIATR, V36, DOI 10.1186/1824-7288-36-67; Deutsches Institut fur Medizinische Dokumentation und Information, 2013, AMIS OFF TEIL; Elkout H, 2012, ARCH DIS CHILD, V97, P521, DOI 10.1136/adc.2010.206268; Fernandes RM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004878.pub4; Gadomski AM, 2010, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001266.pub2, 10.1002/14651858.CD001266.pub3]; Global Initiative for Asthma (GINA), 2012, GLOB STRAT ASTHM MAN; Graubner B, 2008, ICD 10 GM INT STAT K; Hartling L, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1714; Lieberthal AS, 2006, PEDIATRICS, V118, P1774, DOI 10.1542/peds.2006-2223; McCowan C, 2007, BRIT J GEN PRACT, V57, P220; Neubert A, 2004, DRUG SAFETY, V27, P1059, DOI 10.2165/00002018-200427130-00006; Sangrador CO, 2012, EUR J PEDIATR, V171, P1109, DOI 10.1007/s00431-012-1683-y; Parikh K, 2014, PEDIATRICS, V133, pE1, DOI 10.1542/peds.2013-2005; Rote Liste Service GmbH, 2013, ROT LIST ARZN DEUTSC; Rote Liste Service GmbH, 2013, FACHINFO SERV FACH D; Sen EF, 2011, EUR J PEDIATR, V170, P81, DOI 10.1007/s00431-010-1275-7; Teoh L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003797.pub2; Ufer M, 2004, PHARMACOEPIDEM DR S, V13, P147, DOI 10.1002/pds.858; WHO, 1992, AN THER CHEM ATC CLA; Zuidgeest MGP, 2010, J ASTHMA, V47, P209, DOI 10.3109/02770900903483790; Zuidgeest MG, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-16	28	11	11	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2014	9	9							e105110	10.1371/journal.pone.0105110	http://dx.doi.org/10.1371/journal.pone.0105110			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO3LR	25180704	Green Published, gold			2023-01-03	WOS:000341231500020
J	Fujiwara, Y; Toyoda, M; Chayahara, N; Kiyota, N; Shimada, T; Imamura, Y; Mukohara, T; Minami, H				Fujiwara, Yutaka; Toyoda, Masanori; Chayahara, Naoko; Kiyota, Naomi; Shimada, Takanobu; Imamura, Yoshinori; Mukohara, Toru; Minami, Hironobu			Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients	PLOS ONE			English	Article							RECEPTOR ANTAGONIST APREPITANT; CYTOCHROME-P450 3A4; PHARMACODYNAMICS; METABOLISM; DEXAMETHASONE	Purpose: Oxycodone is a m-opioid receptor agonist widely used in the treatment of cancer pain. The predominant metabolic pathway of oxycodone is CYP3A4-mediated N-demethylation to noroxycodone, while a minor proportion undergoes 3-O-demethylation to oxymorphone by CYP2D6. The aim of this study was to investigate the effects of the mild CYP3A4 inhibitor aprepitant on the pharmacokinetics of orally administered controlled-release (CR) oxycodone. Method: This study design was an open-label, single-sequence with two phases in cancer patients with pain who continued to be administered orally with multiple doses of CR oxycodone every 8 or 12 hours. Plasma concentration of oxycodone and its metabolites were measured up to 8 hours after administration as follows: on day 1, CR oxycodone was administered alone; on day 2, CR oxycodone was administered with aprepitant (125 mg, at the same time of oxycodone dosing in the morning). The steady-state trough concentrations (Css) were measured from day 1 to day 3. Results: Aprepitant increased the area under the plasma concentration-time curve (AUC(0-8)) of oxycodone by 25% (p<0.001) and of oxymorphone by 34% (p, 0.001), as well as decreased the AUC(0-8) of noroxycodone by 14% (p<0.001). Moreover, aprepitant increased Css of oxycodone by 57% (p = 0.001) and of oxymorphone by 36% (p<0.001) and decreased Css of noroxycodone by 24% (p = 0.02) at day 3 compared to day 1. Conclusions: The clinical use of aprepitant in patients receiving multiple doses of CR oxycodone for cancer pain significantly altered plasma concentration levels, but would not appear to need modification of the CR oxycodone dose.	[Fujiwara, Yutaka; Toyoda, Masanori; Chayahara, Naoko; Kiyota, Naomi; Shimada, Takanobu; Imamura, Yoshinori; Mukohara, Toru; Minami, Hironobu] Kobe Univ, Grad Sch Med, Div Med Oncol Hematol, Kobe, Hyogo 657, Japan; [Mukohara, Toru; Minami, Hironobu] Kobe Univ, Grad Sch Med, Ctr Canc, Kobe, Hyogo 657, Japan; [Fujiwara, Yutaka] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Invest Canc Therapeut, Chiba, Japan	Kobe University; Kobe University; National Cancer Center - Japan	Fujiwara, Y (corresponding author), Kobe Univ, Grad Sch Med, Div Med Oncol Hematol, Kobe, Hyogo 657, Japan.	yutakafu@ncc.go.jp	Imamura, Yoshinori/ABD-4175-2021; Kiyota, Naomi/K-3226-2016; Fujiwara, Yutaka/ABB-4863-2020	Kiyota, Naomi/0000-0001-8021-6116; Fujiwara, Yutaka/0000-0001-6981-0800; Imamura, Yoshinori/0000-0002-5202-531X; Minami, Hironobu/0000-0001-8630-9145	Research on Applying Health Technology from the Ministry of Health, Labour, and Welfare of Japan; Yokoyama-Rinsyo foundation	Research on Applying Health Technology from the Ministry of Health, Labour, and Welfare of Japan; Yokoyama-Rinsyo foundation	This study was supported by a grant for Research on Applying Health Technology from the Ministry of Health, Labour, and Welfare of Japan and Yokoyama-Rinsyo foundation. However, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Kalso E, 2005, J PAIN SYMPTOM MANAG, V29, pS47, DOI 10.1016/j.jpainsymman.2005.01.010; Kalso E, 2007, PAIN, V132, P227, DOI 10.1016/j.pain.2007.09.027; Lalovic B, 2004, DRUG METAB DISPOS, V32, P447, DOI 10.1124/dmd.32.4.447; Lalovic B, 2006, CLIN PHARMACOL THER, V79, P461, DOI 10.1016/j.clpt.2006.01.009; LEOW KP, 1992, CLIN PHARMACOL THER, V52, P487, DOI 10.1038/clpt.1992.176; LEOW KP, 1995, ANESTH ANALG, V80, P296, DOI 10.1097/00000539-199502000-00016; Loos WJ, 2007, CANCER CHEMOTH PHARM, V59, P407, DOI 10.1007/s00280-006-0359-6; Majumdar AK, 2003, CLIN PHARMACOL THER, V74, P150, DOI 10.1016/S0009-9236(03)00123-1; McCrea JB, 2003, CLIN PHARMACOL THER, V74, P17, DOI 10.1016/S0009-9236(03)00066-3; Merck, 2003, EMEND APR CAPS OR US; National Cancer Center, CANC STAT JAP 2010; Nygren P, 2005, CANCER CHEMOTH PHARM, V55, P609, DOI 10.1007/s00280-004-0946-3; POYHIA R, 1992, BRIT J CLIN PHARMACO, V33, P617, DOI 10.1111/j.1365-2125.1992.tb04090.x; Sanchez RI, 2004, DRUG METAB DISPOS, V32, P1287, DOI 10.1124/dmd.104.000216	14	4	4	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2014	9	8							e104215	10.1371/journal.pone.0104215	http://dx.doi.org/10.1371/journal.pone.0104215			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO0QT	25121773	Green Published, gold, Green Submitted			2023-01-03	WOS:000341017000031
J	Morris, S; Hunter, RM; Ramsay, AIG; Boaden, R; McKevitt, C; Perry, C; Pursani, N; Rudd, AG; Schwamm, LH; Turner, SJ; Tyrrell, PJ; Wolfe, CDA; Fulop, NJ				Morris, Stephen; Hunter, Rachael M.; Ramsay, Angus I. G.; Boaden, Ruth; McKevitt, Christopher; Perry, Catherine; Pursani, Nanik; Rudd, Anthony G.; Schwamm, Lee H.; Turner, Simon J.; Tyrrell, Pippa J.; Wolfe, Charles D. A.; Fulop, Naomi J.			Impact of centralising acute stroke services in English metropolitan areas on mortality and length of hospital stay: difference-in-differences analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE ISCHEMIC-STROKE; UNIT CARE; IMPLEMENTATION; PERFORMANCE; ENGLAND; MODELS	Objective To investigate whether centralisation of acute stroke services in two metropolitan areas of England was associated with changes in mortality and length of hospital stay. Design Analysis of difference-in-differences between regions with patient level data from the hospital episode statistics database linked to mortality data supplied by the Office for National Statistics. Setting Acute stroke services in Greater Manchester and London, England. Participants 258 915 patients with stroke living in urban areas and admitted to hospital in January 2008 to March 2012. Interventions "Hub and spoke" model for acute stroke care. In London hyperacute care was provided to all patients with stroke. In Greater Manchester hyperacute care was provided to patients presenting within four hours of developing symptoms of stroke. Main outcome measures Mortality from any cause and at any place at 3, 30, and 90 days after hospital admission; length of hospital stay. Results In London there was a significant decline in risk adjusted mortality at 3, 30, and 90 days after admission. At 90 days the absolute reduction was -1.1% (95% confidence interval -2.1 to -0.1; relative reduction 5%), indicating 168 fewer deaths (95% confidence interval 19 to 316) during the 21 month period after reconfiguration in London. In both areas there was a significant decline in risk adjusted length of hospital stay: -2.0 days in Greater Manchester (95% confidence interval -2.8 to -1.2; 9%) and -1.4 days in London (-2.3 to -0.5; 7%). Reductions in mortality and length of hospital stay were largely seen among patients with ischaemic stroke. Conclusions A centralised model of acute stroke care, in which hyperacute care is provided to all patients with stroke across an entire metropolitan area, can reduce mortality and length of hospital stay.	[Morris, Stephen; Ramsay, Angus I. G.; Turner, Simon J.; Fulop, Naomi J.] UCL, Dept Appl Hlth Res, London WC1E 7HB, England; [Hunter, Rachael M.] UCL, Res Dept Primary Care & Populat Hlth, London NW3 2PF, England; [Boaden, Ruth; Perry, Catherine] Univ Manchester, Manchester Business Sch, Manchester M15 6PB, Lancs, England; [McKevitt, Christopher; Wolfe, Charles D. A.] Kings Coll London, Div Hlth & Social Care Res, Sch Med, London SE1 3QD, England; [Pursani, Nanik] Kings Coll London, Stroke Res Patients & Family Grp, Sch Med, Div Hlth & Social Care Res, London SE1 3QD, England; [Rudd, Anthony G.] Guys & St Thomas NHS Fdn Trust, St Thomas Hosp, London SE1 7EH, England; [Schwamm, Lee H.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Tyrrell, Pippa J.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Salford Royal Hosp NHS Fdn Trust, Stroke & Vasc Ctr, Salford M6 8HD, Lancs, England; [Wolfe, Charles D. A.] Guys & St Thomas NHS Fdn Trust, Natl Inst Hlth, Res Comprehens Biomed Res Ctr, London SE1 7EH, England; [Wolfe, Charles D. A.] Kings Coll London, London SE1 3QD, England	University of London; University College London; University of London; University College London; University of Manchester; University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; Harvard University; Harvard Medical School; Massachusetts General Hospital; Salford Royal NHS Foundation Trust; Salford Royal Hospital; University of Manchester; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Morris, S (corresponding author), UCL, Dept Appl Hlth Res, London WC1E 7HB, England.	steve.morris@ucl.ac.uk	Boaden, Ruth/L-3443-2016; mckevitt, christopher/AAN-7271-2021; Hunter, Rachael Maree/H-7846-2019	Boaden, Ruth/0000-0003-1927-6405; Hunter, Rachael Maree/0000-0002-7447-8934; MCKEVITT, CHRISTOPHER/0000-0002-5290-4613; Perry, Catherine/0000-0002-8496-6923; Ramsay, Angus/0000-0002-4446-6916; Tyrrell, Pippa/0000-0001-9609-1231; Schwamm, Lee/0000-0003-0592-9145; Morris, Stephen/0000-0002-5828-3563; Fulop, Naomi/0000-0001-5306-6140	Department of Health [10/1009/09]; NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust; NIHR Biomedical Research Centre at King's College London; NIHR Collaboration for Leadership in Applied Health Research and Care Funding scheme; National Institute for Health Research [10/1009/09, NF-SI-0510-10060, RP-PG-0407-10184] Funding Source: researchfish	Department of Health; NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust; NIHR Biomedical Research Centre at King's College London; NIHR Collaboration for Leadership in Applied Health Research and Care Funding scheme; National Institute for Health Research(National Institute for Health Research (NIHR))	This paper presents independent research commissioned by the health services and delivery research programme of the National Institute for Health Research (NIHR), funded by the Department of Health (study reference 10/1009/09). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. CDAW was supported by the NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, and also by the NIHR Collaboration for Leadership in Applied Health Research and Care Funding scheme.	Audebert Heinrich J, 2009, Cerebrovasc Dis, V27 Suppl 4, P15, DOI 10.1159/000213054; Barber Julie, 2004, J Health Serv Res Policy, V9, P197, DOI 10.1258/1355819042250249; Bray BD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2827; Cadilhac DA, 2013, STROKE, V44, P2848, DOI 10.1161/STROKEAHA.113.001258; Craig P, 2012, J EPIDEMIOL COMMUNIT; Data.gov.uk, IND MULT DEPR 2004; Demaerschalk BM, 2009, MAYO CLIN PROC, V84, P53, DOI 10.1016/S0025-6196(11)60808-2; Department of Health, 2007, NAT STROK STRAT; Fonarow GC, 2012, JAMA-J AM MED ASSOC, V308, P257, DOI 10.1001/jama.2012.7870; Fosbol EL, 2013, CIRCULATION, V127, P604, DOI 10.1161/CIRCULATIONAHA.112.118463; Fulop N, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-5; Gabbe BJ, 2012, ANN SURG, V255, P1009, DOI 10.1097/SLA.0b013e31824c4b91; Greater Manchester and Cheshire Cardiac and Stroke Network Support Team, 2011, DEV STROK SERV GREAT; Health and Social Care Information Centre, HOS EP STAT; Health and Social Care Information Centre, LINK HES ONS MORT DA; Higashida R, 2013, STROKE, V44, P2961, DOI 10.1161/STR.0b013e3182a6d2b2; Hunter RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070420; Imbens GW, 2008, RECENT DEV ECONOMETR; Intercollegiate Stroke Working Party, 2012, NAT CLIN GUID STROK; Lahr MMH, 2013, J NEUROL, V260, P960, DOI 10.1007/s00415-012-6647-7; Lahr MMH, 2012, STROKE, V43, P1336, DOI 10.1161/STROKEAHA.111.641795; Langhorne P, 2013, STROKE, V44, P3044, DOI 10.1161/STROKEAHA.113.001564; Langhorne P, 2010, J NEUROL NEUROSUR PS, V81, P1301, DOI 10.1136/jnnp.2009.195131; Mackay J, 2004, ATLAS HEART DIS STRO; Mohan KM, 2011, STROKE, V42, P1489, DOI 10.1161/STROKEAHA.110.602615; National Audit Office, 2010, 291 HC NAT AUD OFF C; Office for National Statistics, 2012, 2011 CENS US RES POP; Office for National Statistics, 2001 URB CLASS; Prabhakaran S, 2013, JAMA NEUROL, V70, P1126, DOI 10.1001/jamaneurol.2013.293; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Ramelyte M, 2012, STROKE ANN REPORT 20; Royal College of Physicians, 2013, SINAP LAT RES; Sacco S, 2009, STROKE, V40, P394, DOI 10.1161/STROKEAHA.108.523209; Silva GS, 2012, STROKE, V43, P2078, DOI 10.1161/STROKEAHA.111.645861; Slot KB, 2009, ACTA NEUROL SCAND, V120, P270, DOI 10.1111/j.1600-0404.2009.01162.x; Smith Eric E, 2008, Crit Pathw Cardiol, V7, P173, DOI 10.1097/HPC.0b013e318184e2bc; Sudlow C, 2009, BMJ, V338; Sutton M, 2012, NEW ENGL J MED, V367, P1821, DOI 10.1056/NEJMsa1114951; Townsend N, 2012, CORONARY HEART DIS S; Weir NU, 2005, J NEUROL NEUROSUR PS, V76, P863, DOI 10.1136/jnnp.2004.053462; Williams D., 2011, MAJOR RECONFIGURATIO; Woo YL, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007945.pub2	42	136	138	4	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 5	2014	349								g4757	10.1136/bmj.g4757	http://dx.doi.org/10.1136/bmj.g4757			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AM9MP	25098169	Green Published, hybrid			2023-01-03	WOS:000340206000004
J	Cheung, KC; van den Bemt, PMLA; Bouvy, ML; Wensing, M; De Smet, PAGM				Cheung, Ka-Chun; van den Bemt, Patricia M. L. A.; Bouvy, Marcel L.; Wensing, Michel; De Smet, Peter A. G. M.			Medication Incidents Related to Automated Dose Dispensing in Community Pharmacies and Hospitals - A Reporting System Study	PLOS ONE			English	Article							OLDER PATIENTS; ADHERENCE; ERRORS; CARE	Introduction: Automated dose dispensing (ADD) is being introduced in several countries and the use of this technology is expected to increase as a growing number of elderly people need to manage their medication at home. ADD aims to improve medication safety and treatment adherence, but it may introduce new safety issues. This descriptive study provides insight into the nature and consequences of medication incidents related to ADD, as reported by healthcare professionals in community pharmacies and hospitals. Methods: The medication incidents that were submitted to the Dutch Central Medication incidents Registration (CMR) reporting system were selected and characterized independently by two researchers. Main Outcome Measures: Person discovering the incident, phase of the medication process in which the incident occurred, immediate cause of the incident, nature of incident from the healthcare provider's perspective, nature of incident from the patient's perspective, and consequent harm to the patient caused by the incident. Results: From January 2012 to February 2013 the CMR received 15,113 incidents: 3,685 (24.4%) incidents from community pharmacies and 11,428 (75.6%) incidents from hospitals. Eventually 1 of 50 reported incidents (268/15,113 = 1.8%) were related to ADD; in community pharmacies more incidents (227/3,685 = 6.2%) were related to ADD than in hospitals (41/11,428 = 0.4%). The immediate cause of an incident was often a change in the patient's medicine regimen or relocation. Most reported incidents occurred in two phases: entering the prescription into the pharmacy information system and filling the ADD bag. Conclusion: A proportion of incidents was related to ADD and is reported regularly, especially by community pharmacies. In two phases, entering the prescription into the pharmacy information system and filling the ADD bag, most incidents occurred. A change in the patient's medicine regimen or relocation was the immediate causes of an incident.	[Cheung, Ka-Chun; Wensing, Michel; De Smet, Peter A. G. M.] Radboud Univ Nijmegen Med Ctr, Sci Inst Qual Healthcare, Nijmegen, Netherlands; [Cheung, Ka-Chun; De Smet, Peter A. G. M.] Royal Dutch Pharmacists Assoc KNMP, The Hague, Netherlands; [van den Bemt, Patricia M. L. A.] Erasmus MC, Dept Hosp Pharm, Rotterdam, Netherlands; [Bouvy, Marcel L.] Univ Utrecht, UIPS, Dept Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands; [De Smet, Peter A. G. M.] Radboud Univ Nijmegen Med Ctr, Dept Clin Pharm, Nijmegen, Netherlands	Radboud University Nijmegen; Erasmus University Rotterdam; Erasmus MC; Utrecht University; Radboud University Nijmegen	Cheung, KC (corresponding author), Radboud Univ Nijmegen Med Ctr, Sci Inst Qual Healthcare, Nijmegen, Netherlands.	k.c.cheung@knmp.nl	Wensing, Michel/H-8113-2014; Bouvy, Marcel/M-4233-2016; Smet, P.A.G.M./L-4654-2015	Wensing, Michel/0000-0001-6569-8137; Bouvy, Marcel/0000-0002-4596-0684; Van den Bemt, Patricia/0000-0003-1418-5520				Bell JS, 2007, ANN PHARMACOTHER, V41, P1039, DOI 10.1345/aph.1H638; Cheung KC, 2011, J AM MED INFORM ASSN, V18, P799, DOI 10.1136/amiajnl-2011-000191; Fontan JE, 2003, PHARM WORLD SCI, V25, P112, DOI 10.1023/A:1024053514359; Foundation for Pharmaceutical Statistics, 2012, FACTS FIG 2012 PHARM; Johnell K, 2008, SCAND J PRIM HEALTH, V26, P86, DOI 10.1080/02813430802022196; Jones D G, 1989, Hosp Pharm, V24, P606; Jones DG, 1989, HOSP PHARM, P610; KLEIN EG, 1994, AM J HOSP PHARM, V51, P1193, DOI 10.1093/ajhp/51.9.1193; Kratz K, 1992, Hosp Pharm, V27, P19; Kratz K, 1992, HOSP PHARM, V27, P22; Kwint HF, 2013, AGE AGEING, V42, P620, DOI 10.1093/ageing/aft083; Kwint HF, 2011, DRUG AGING, V28, P305, DOI 10.2165/11586850-000000000-00000; Larsen Anna Bira, 2007, Res Social Adm Pharm, V3, P265, DOI 10.1016/j.sapharm.2006.10.002; Lee JK, 2006, JAMA-J AM MED ASSOC, V296, P2563, DOI 10.1001/jama.296.21.joc60162; Mehuys E, 2012, J NUTR HEALTH AGING, V16, P721, DOI 10.1007/s12603-012-0028-x; Oswald S, 2007, AM J HEALTH-SYST PH, V64, P1427, DOI 10.2146/ajhp060313; Palttala I, 2013, DRUG DEV IND PHARM, V39, P489, DOI 10.3109/03639045.2012.670860; Sinnemaki J, 2013, SYST REV-LONDON, V2, DOI 10.1186/2046-4053-2-1; Sjoberg C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026574; Statistics Netherlands, 2013, MED CONT HOSP MED SE; Stricker BHC, 2004, BRIT MED J, V329, P44, DOI 10.1136/bmj.329.7456.44; The Association of Finnish Pharmacies, 2004, ANN REV 2003 MED PRE, P6; van den Bemt PMLA, 2009, J AM MED INFORM ASSN, V16, P486, DOI 10.1197/jamia.M2959; van der Veen W, 2013, INT J CLIN PHARM-NET, V35, P195, DOI 10.1007/s11096-012-9727-y; Wekre LJ, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2009.038745; WHO, 2011, NIH PUBL	26	9	9	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2014	9	7							e101686	10.1371/journal.pone.0101686	http://dx.doi.org/10.1371/journal.pone.0101686			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO5BG	25058321	Green Published, gold, Green Submitted			2023-01-03	WOS:000341354800006
J	van der Wouden, JC; Koning, S				van der Wouden, Johannes C.; Koning, Sander			Treatment of impetigo in resource-limited settings	LANCET			English	Editorial Material							PREVALENCE; BURDEN		[van der Wouden, Johannes C.] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Dept Gen Practice & Elderly Care Med, NL-1007 MB Amsterdam, Netherlands; [Koning, Sander] Univ Med Ctr Rotterdam, Dept Gen Practice, Erasmus MC, Rotterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Erasmus University Rotterdam; Erasmus MC	van der Wouden, JC (corresponding author), Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Dept Gen Practice & Elderly Care Med, NL-1007 MB Amsterdam, Netherlands.	j.vanderwouden@vumc.nl	van der Wouden, Johannes C/O-5109-2019	van der Wouden, Johannes C/0000-0001-6639-6050				Bigger JW, 1944, LANCET, V2, P78; Bowen AC, 2014, LANCET, V384, P2132, DOI 10.1016/S0140-6736(14)60841-2; Carapetis JR, 1999, EPIDEMIOL INFECT, V122, P59, DOI 10.1017/S0950268898001952; Currie B J, 2000, Australas J Dermatol, V41, P139, DOI 10.1046/j.1440-0960.2000.00417.x; Faye O, 2007, INT J DERMATOL, V46, P19, DOI 10.1111/j.1365-4632.2007.03364.x; Fleming DM, 2005, BRIT J GEN PRACT, V55, P589; Harvey F, 1917, LANCET, V2, P582; Hay RJ, 2014, J INVEST DERMATOL, V134, P1527, DOI 10.1038/jid.2013.446; Koning S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003261.pub3; MACKENNA RMB, 1945, LANCET, V249, P357; Mohammedamin RS, 2006, BMC DERMATOL, V6, DOI 10.1186/1471-5945-6-4; Steer AC, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000467	12	2	2	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 13	2014	384	9960					2090	2091		10.1016/S0140-6736(14)61395-7	http://dx.doi.org/10.1016/S0140-6736(14)61395-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW6BK	25172375				2023-01-03	WOS:000346354300008
J	Wang, SL; Lei, T; Zhang, K; Zhao, WX; Fang, L; Lai, BC; Han, J; Xiao, L; Wang, NP				Wang, Shaolan; Lei, Ting; Zhang, Kang; Zhao, Wenxiang; Fang, Li; Lai, Baochang; Han, Jie; Xiao, Lei; Wang, Nanping			Xenobiotic Pregnane X Receptor (PXR) Regulates Innate Immunity via Activation of NLRP3 Inflammasome in Vascular Endothelial Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						Cellular Immune Response; Endothelial Cell; Innate Immunity; Nod-like Receptor (NLR); Pattern Recognition Receptor (PRR); Toll-like Receptor (TLR); Transcription Factor; Xenobiotic	DRUG-METABOLISM; MACULAR DEGENERATION; STRESS; INFECTIONS; DEFENSES; PROMOTER; DISEASE; ELEMENT; BINDING; HEALTH	Background: Xenobiotics activate nuclear receptor PXR for detoxification and clearance. However, a role of PXR in regulating innate immunity remains unknown. Results: PXR induced NLRP3 expression and triggered inflammasome activation in vascular ECs. Conclusion: PXR plays an important role in the activation of NLRP3 inflammasome in response to xenobiotics. Significance: Our findings revealed a novel mechanism of innate immunity. Pregnane X receptor (PXR) is a member of nuclear receptor superfamily and responsible for the detoxification of xenobiotics. Our previously study demonstrated that PXR is expressed in endothelial cells (ECs) and acts as a master regulator of detoxification genes to protect ECs against xenobiotics. Vascular endothelial cells are key sentinel cells to sense the pathogens and xenobiotics. In this study, we examined the potential function of PXR in the regulation of innate immunity in vasculatures. Treatments with PXR agonists or overexpression of a constitutively active PXR in cultured ECs increased gene expression of the key pattern recognition receptors, including Toll-like receptors (TLR-2, -4, -9) and NOD-like receptors (NOD-1 and -2 and NLRP3). In particular, PXR agonism triggered the activation of NLRP3 inflammasome and the ensuing cleavage and maturation of caspase-1 and interleukin-1 (IL-1). Conversely, selective antagonism or gene silencing of PXR abrogated NLRP3 inflammasome activation. In addition, we identified NLRP3 as a transcriptional target of PXR by using the promoter-reporter and ChIP assays. In summary, our findings revealed a novel regulatory mechanism of innate immune by PXR, which may act as a master transcription factor controlling the convergence between the detoxification of xenobiotics and the innate immunity against them.	[Wang, Shaolan; Lei, Ting; Zhang, Kang; Zhao, Wenxiang; Lai, Baochang; Han, Jie; Xiao, Lei; Wang, Nanping] Xi An Jiao Tong Univ, Cardiovasc Res Ctr, Sch Med, Xian 710061, Peoples R China; [Fang, Li; Wang, Nanping] Peking Univ, Inst Cardiovasc Sci, Beijing 100191, Peoples R China	Xi'an Jiaotong University; Peking University	Wang, NP (corresponding author), Xi An Jiao Tong Univ, Cardiovasc Res Ctr, Sch Med, 76 W Yanta Rd, Xian 710061, Peoples R China.	nanpingwang2003@yahoo.com	Wang, Nanping/G-1818-2011	Wang, Nanping/0000-0002-8528-8132	National Science Foundation of China [81220108005, 31430045]; Ministry of Science and Technology [2010CB912502]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	This work was supported by grants from the National Science Foundation of China (81220108005 and 31430045) and the Ministry of Science and Technology (2010CB912502).	Anderson JP, 2008, GENES IMMUN, V9, P721, DOI 10.1038/gene.2008.66; Cunha A, 2012, NAT REV IMMUNOL, V12, DOI 10.1038/nri3237; Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717; Gao J, 2012, TRENDS PHARMACOL SCI, V33, P552, DOI 10.1016/j.tips.2012.07.003; Hariparsad N, 2009, NUCLEIC ACIDS RES, V37, P1160, DOI 10.1093/nar/gkn1047; Jacobs MN, 2005, TOXICOL APPL PHARM, V209, P123, DOI 10.1016/j.taap.2005.03.015; Mai JT, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-61; Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002; Melo JA, 2012, CELL, V149, P452, DOI 10.1016/j.cell.2012.02.050; Mitchell JA, 2007, BIOCHEM SOC T, V35, P1449, DOI 10.1042/BST0351449; Ogura Y, 2006, CELL, V126, P659, DOI 10.1016/j.cell.2006.08.002; Opitz B, 2009, THROMB HAEMOSTASIS, V102, P1103, DOI 10.1160/TH09-05-0323; Qiao Y, 2012, FEBS LETT, V586, P1022, DOI 10.1016/j.febslet.2012.02.045; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Schuetz EG, 1998, MOL PHARMACOL, V54, P1113, DOI 10.1124/mol.54.6.1113; Sonoda J, 2003, CURR DRUG METAB, V4, P59, DOI 10.2174/1389200033336739; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Swales KE, 2012, CARDIOVASC RES, V93, P674, DOI 10.1093/cvr/cvr330; Vladimer GI, 2013, CURR OPIN MICROBIOL, V16, P23, DOI 10.1016/j.mib.2012.11.008; Wang XH, 2013, P NATL ACAD SCI USA, V110, P13174, DOI 10.1073/pnas.1312065110; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; Xia M, 2014, AM J PATHOL, V184, P1617, DOI 10.1016/j.ajpath.2014.01.032; Xiao H, 2013, CIRCULATION, V128, P632, DOI 10.1161/CIRCULATIONAHA.113.002714; Xiao L, 2014, AM J PHYSIOL-HEART C, V306, pH317, DOI 10.1152/ajpheart.00182.2013; Yin Y, 2009, INT J IMMUNOPATH PH, V22, P311, DOI 10.1177/039463200902200208; Zhou C, 2006, J CLIN INVEST, V116, P2280, DOI 10.1172/JCI26283	26	37	41	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2014	289	43					30075	30081		10.1074/jbc.M114.578781	http://dx.doi.org/10.1074/jbc.M114.578781			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	AS6JU	25202020	Green Published, hybrid			2023-01-03	WOS:000344370800047
J	Holst, LB; Haase, N; Wetterslev, J; Wernerman, J; Guttormsen, AB; Karlsson, S; Johansson, PI; Aneman, A; Vang, ML; Winding, R; Nebrich, L; Nibro, HL; Rasmussen, BS; Lauridsen, JRM; Nielsen, JS; Oldner, A; Pettila, V; Cronhjort, MB; Andersen, LH; Pedersen, UG; Reiter, N; Wiis, J; White, JO; Russell, L; Thornberg, KJ; Hjortrup, PB; Muller, RG; Moller, MH; Steensen, M; Tjader, I; Kilsand, K; Odeberg-Wernerman, S; Sjobo, B; Bundgaard, H; Thyo, MA; Lodahl, D; Maerkedahl, R; Albeck, C; Illum, D; Kruse, M; Winkel, P; Perner, A				Holst, Lars B.; Haase, Nicolai; Wetterslev, Jorn; Wernerman, Jan; Guttormsen, Anne B.; Karlsson, Sari; Johansson, Par I.; Aneman, Anders; Vang, Marianne L.; Winding, Robert; Nebrich, Lars; Nibro, Helle L.; Rasmussen, Bodil S.; Lauridsen, Johnny R. M.; Nielsen, Jane S.; Oldner, Anders; Pettila, Ville; Cronhjort, Maria B.; Andersen, Lasse H.; Pedersen, Ulf G.; Reiter, Nanna; Wiis, Jorgen; White, Jonathan O.; Russell, Lene; Thornberg, Klaus J.; Hjortrup, Peter B.; Muller, Rasmus G.; Moller, Morten H.; Steensen, Morten; Tjader, Inga; Kilsand, Kristina; Odeberg-Wernerman, Suzanne; Sjobo, Brit; Bundgaard, Helle; Thyo, Maria A.; Lodahl, David; Maerkedahl, Rikke; Albeck, Carsten; Illum, Dorte; Kruse, Mary; Winkel, Per; Perner, Anders		TRISS Trial Grp; Scandinavian Critical Care Trials	Lower versus Higher Hemoglobin Threshold for Transfusion in Septic Shock	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-CELL TRANSFUSION; SEVERE SEPSIS; CLINICAL CHARACTERISTICS; HYDROXYETHYL STARCH; UNSELECTED PATIENTS; CRITICALLY-ILL; MORTALITY; MULTICENTER; RISK; REQUIREMENTS	BACKGROUND Blood transfusions are frequently given to patients with septic shock. However, the benefits and harms of different hemoglobin thresholds for transfusion have not been established. METHODS In this multicenter, parallel-group trial, we randomly assigned patients in the intensive care unit (ICU) who had septic shock and a hemoglobin concentration of 9 g per deciliter or less to receive 1 unit of leukoreduced red cells when the hemoglobin level was 7 g per deciliter or less (lower threshold) or when the level was 9 g per deciliter or less (higher threshold) during the ICU stay. The primary outcome measure was death by 90 days after randomization. RESULTS We analyzed data from 998 of 1005 patients (99.3%) who underwent randomization. The two intervention groups had similar baseline characteristics. In the ICU, the lower-threshold group received a median of 1 unit of blood (interquartile range, 0 to 3) and the higher-threshold group received a median of 4 units (interquartile range, 2 to 7). At 90 days after randomization, 216 of 502 patients (43.0%) assigned to the lower-threshold group, as compared with 223 of 496 (45.0%) assigned to the higher-threshold group, had died (relative risk, 0.94; 95% confidence interval, 0.78 to 1.09; P = 0.44). The results were similar in analyses adjusted for risk factors at baseline and in analyses of the per-protocol populations. The numbers of patients who had ischemic events, who had severe adverse reactions, and who required life support were similar in the two intervention groups. CONCLUSIONS Among patients with septic shock, mortality at 90 days and rates of ischemic events and use of life support were similar among those assigned to blood transfusion at a higher hemoglobin threshold and those assigned to blood transfusion at a lower threshold; the latter group received fewer transfusions.	[Holst, Lars B.; Haase, Nicolai; Andersen, Lasse H.; Pedersen, Ulf G.; Reiter, Nanna; Wiis, Jorgen; White, Jonathan O.; Russell, Lene; Thornberg, Klaus J.; Hjortrup, Peter B.; Muller, Rasmus G.; Moller, Morten H.; Steensen, Morten; Perner, Anders] Rigshosp, Dept Intens Care, Blegdamsvej 9, DK-2100 Copenhagen, Denmark; [Wetterslev, Jorn; Winkel, Per] Rigshosp, Ctr Clin Intervent Res, Copenhagen Trial Unit, DK-2100 Copenhagen, Denmark; [Johansson, Par I.] Rigshosp, Transfus Med Sect, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Copenhagen, Denmark; [Vang, Marianne L.; Bundgaard, Helle; Thyo, Maria A.] Randers Cent Hosp, Randers, Denmark; [Winding, Robert; Lodahl, David; Maerkedahl, Rikke] Herning Hosp, Herning, Denmark; [Nebrich, Lars; Albeck, Carsten] Univ Copenhagen, Hvidovre Hosp, DK-2650 Hvidovre, Denmark; [Nibro, Helle L.; Illum, Dorte] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark; [Rasmussen, Bodil S.] Aalborg Univ Hosp, Aalborg, Denmark; [Lauridsen, Johnny R. M.] Holbaek Cent Hosp, Holbaek, Denmark; [Nielsen, Jane S.] Kolding Cty Hosp, Kolding, Denmark; [Kruse, Mary] Hjorring Hosp, Hjorring, Denmark; [Wernerman, Jan; Tjader, Inga; Kilsand, Kristina; Odeberg-Wernerman, Suzanne] Karolinska Univ Hosp, Stockholm, Sweden; [Oldner, Anders] Karolinska Univ Hosp, Solna, Sweden; [Cronhjort, Maria B.] Soder Sjukhuset, S-10064 Stockholm, Sweden; [Guttormsen, Anne B.; Sjobo, Brit] Haukeland Hosp, N-5021 Bergen, Norway; [Guttormsen, Anne B.; Sjobo, Brit] Univ Bergen, Bergen, Norway; [Karlsson, Sari] Tampere Univ Hosp, Tampere, Finland; [Pettila, Ville] Univ Helsinki Hosp, Helsinki, Finland; [Pettila, Ville] Univ Helsinki, Helsinki, Finland; [Aneman, Anders] Liverpool Hosp, Sydney, NSW, Australia	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen; Aarhus University; Aarhus University; University of Copenhagen; Aarhus University; Aalborg University; Aalborg University Hospital; Holbaek Hospital; Kolding Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Sodersjukhuset Hospital; University of Bergen; Tampere University; Tampere University Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Liverpool Hospital	Perner, A (corresponding author), Rigshosp, Dept Intens Care, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	anders.perner@regionh.dk	Reiter, Nanna/AAW-8322-2021; Oldner, Anders/Q-4353-2018; Møller, Morten Hylander/AAQ-6891-2020; Krammel, Vera/N-4826-2014; Johansson, Pär/GQB-1032-2022; Russell, Lene/I-8743-2019; Wetterslev, Jørn/ABF-1251-2020; Cronhjort, Maria/AAH-8819-2021; Johansson, Pär I/P-9283-2015; Thorsen-Meyer, Hans-Christian/ABA-6959-2021	Oldner, Anders/0000-0003-1600-9221; Møller, Morten Hylander/0000-0002-6378-9673; Krammel, Vera/0000-0002-8273-8396; Johansson, Pär/0000-0001-9778-5964; Russell, Lene/0000-0001-7352-8728; Wetterslev, Jørn/0000-0001-7778-1771; Johansson, Pär I/0000-0001-9778-5964; Thorsen-Meyer, Hans-Christian/0000-0001-7002-3089; Rasmussen, Bodil Steen/0000-0003-2190-145X; Dyrskog, Stig/0000-0002-1903-1742; Rowan, Kathryn/0000-0001-8217-5602; Aneman, Anders/0000-0003-2096-5304; Buhl Hjortrup, Peter/0000-0002-3847-3247; Poulsen, Lone Musaeus/0000-0002-7030-3395; Perner, Anders/0000-0002-4668-0123; Cronhjort, Maria/0000-0002-0444-8553	Danish Strategic Research Council	Danish Strategic Research Council(Danske Strategiske Forskningsrad (DSF))	Funded by the Danish Strategic Research Council and others; TRISS ClinicalTrials.gov number, NCT01485315.	Asfar P, 2014, NEW ENGL J MED, V370, P1583, DOI 10.1056/NEJMoa1312173; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Caironi P, 2014, NEW ENGL J MED, V370, P1412, DOI 10.1056/NEJMoa1305727; Carlsen S, 2011, ACTA ANAESTH SCAND, V55, P394, DOI 10.1111/j.1399-6576.2011.02399.x; Carson Jeffrey L, 2012, Cochrane Database Syst Rev, pCD002042, DOI 10.1002/14651858.CD002042.pub3; Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452; Chatterjee S, 2013, JAMA INTERN MED, V173, P132, DOI 10.1001/2013.jamainternmed.1001; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Fergusson D, 2004, CAN J ANAESTH, V51, P417, DOI 10.1007/BF03018302; Haase N, 2013, INTENS CARE MED, V39, P2126, DOI 10.1007/s00134-013-3111-9; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Heyland DK, 2011, CRIT CARE, V15, DOI 10.1186/cc10110; Holst LB, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-150; ICH Steering Committee, 1998, ICH HARM TRIP GUID S; Kahan BC, 2012, STAT MED, V31, P328, DOI 10.1002/sim.4431; Labelle A, 2012, CRIT CARE MED, V40, P2016, DOI 10.1097/CCM.0b013e318250aa72; Marik PE, 2008, CRIT CARE MED, V36, P2667, DOI 10.1097/CCM.0b013e3181844677; Park DW, 2012, CRIT CARE MED, V40, P3140, DOI 10.1097/CCM.0b013e3182657b75; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; Reade MC, 2010, EMERG MED J, V27, P110, DOI 10.1136/emj.2008.070912; Reinikainen M, 2010, INTENS CARE MED, V36, P673, DOI 10.1007/s00134-009-1688-9; Rohde JM, 2014, JAMA-J AM MED ASSOC, V311, P1317, DOI 10.1001/jama.2014.2726; Rosland RG, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/1757-7241-22-14; Smith SH, 2012, CRIT CARE, V16, DOI 10.1186/cc11333; Villanueva C, 2013, NEW ENGL J MED, V368, P11, DOI 10.1056/NEJMoa1211801; Vincent JL, 2008, ANESTHESIOLOGY, V108, P31, DOI 10.1097/01.anes.0000296070.75956.40; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Walsh TS, 2013, CRIT CARE MED, V41, P2354, DOI 10.1097/CCM.0b013e318291cce4; Yealy DM, 2014, NEW ENGL J MED, V370, P1683, DOI 10.1056/NEJMoa1401602; Zarychanski R, 2008, CRIT CARE MED, V36, P2973, DOI 10.1097/CCM.0b013e31818b8c6b; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	32	535	555	0	55	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 9	2014	371	15					1381	1391		10.1056/NEJMoa1406617	http://dx.doi.org/10.1056/NEJMoa1406617			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AQ3FJ	25270275	Bronze			2023-01-03	WOS:000342674800007
J	Chae, Y; Lee, IS; Jung, WM; Chang, DS; Napadow, V; Lee, H; Park, HJ; Wallraven, C				Chae, Younbyoung; Lee, In-Seon; Jung, Won-Mo; Chang, Dong-Seon; Napadow, Vitaly; Lee, Hyejung; Park, Hi-Joon; Wallraven, Christian			Decreased Peripheral and Central Responses to Acupuncture Stimulation following Modification of Body Ownership	PLOS ONE			English	Article							SHAM ACUPUNCTURE; PREMOTOR CORTEX; RUBBER HAND; BRAIN; NEEDLE; PAIN; SENSATION; FEEL; FMRI; INTEROCEPTION	Acupuncture stimulation increases local blood flow around the site of stimulation and induces signal changes in brain regions related to the body matrix. The rubber hand illusion (RHI) is an experimental paradigm that manipulates important aspects of bodily self-awareness. The present study aimed to investigate how modifications of body ownership using the RHI affect local blood flow and cerebral responses during acupuncture needle stimulation. During the RHI, acupuncture needle stimulation was applied to the real left hand while measuring blood microcirculation with a LASER Doppler imager (Experiment 1, N = 28) and concurrent brain signal changes using functional magnetic resonance imaging (fMRI; Experiment 2, N = 17). When the body ownership of participants was altered by the RHI, acupuncture stimulation resulted in a significantly lower increase in local blood flow (Experiment 1), and significantly less brain activation was detected in the right insula (Experiment 2). This study found changes in both local blood flow and brain responses during acupuncture needle stimulation following modification of body ownership. These findings suggest that physiological responses during acupuncture stimulation can be influenced by the modification of body ownership.	[Chae, Younbyoung; Jung, Won-Mo; Wallraven, Christian] Korea Univ, Dept Brain & Cognit Engn, Seoul, South Korea; [Chae, Younbyoung; Lee, In-Seon; Lee, Hyejung; Park, Hi-Joon] Kyung Hee Univ, Acupuncture & Meridian Sci Res Ctr, Coll Korean Med, Seoul, South Korea; [Chang, Dong-Seon] Max Planck Inst Biol Cybernet, Dept Human Percept Cognit & Act, D-72076 Tubingen, Germany; [Napadow, Vitaly] Harvard Univ, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Sch Med, Charlestown, MA USA; [Napadow, Vitaly] Kyung Hee Univ, Dept Biomed Engn, Yongin, South Korea	Korea University; Kyung Hee University; Max Planck Society; Harvard University; Massachusetts General Hospital; Kyung Hee University	Chae, Y (corresponding author), Korea Univ, Dept Brain & Cognit Engn, Seoul, South Korea.	ybchae@khu.ac.kr; wallraven@korea.ac.kr	Lee, In-Seon/AAM-1252-2020; Chae, Younbyoung/AAM-1243-2020; Park, Hi-Joon/AAG-1196-2021	Lee, In-Seon/0000-0001-9275-3111; Park, Hi-Joon/0000-0002-0538-2664; Wallraven, Christian/0000-0002-2604-9115; Napadow, Vitaly/0000-0003-1941-1750; Chae, Younbyoung/0000-0001-6787-2215; Chang, Dong-Seon/0000-0003-4562-1321	NCCIH NIH HHS [P01-AT006663,, R01-AT007550, P01 AT006663, R01 AT005280, R01-AT005280, R01 AT007550] Funding Source: Medline; NIAMS NIH HHS [R01-AR064367, R01 AR064367] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [R01AT005280] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT007550, P01AT006663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR064367] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Asghar AU, 2010, BRAIN RES, V1315, P111, DOI 10.1016/j.brainres.2009.12.019; Barnsley N, 2011, CURR BIOL, V21, pR945, DOI 10.1016/j.cub.2011.10.039; Botvinick M, 1998, NATURE, V391, P756, DOI 10.1038/35784; Chae Y, 2013, J PAIN, V14, P215, DOI 10.1016/j.jpain.2012.11.011; Chae Y, 2009, MOVEMENT DISORD, V24, P1794, DOI 10.1002/mds.22673; Chae Y, 2009, NEUROSCI LETT, V450, P80, DOI 10.1016/j.neulet.2008.11.048; Chang DS, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/849602; Choi YJ, 2013, COMPLEMENT THER MED, V21, P207, DOI 10.1016/j.ctim.2012.12.009; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; Craig AD, 2003, CURR OPIN NEUROBIOL, V13, P500, DOI 10.1016/S0959-4388(03)00090-4; Davis RT, 2012, ACUPUNCT MED, V30, P113, DOI 10.1136/acupmed-2011-010111; Dhond RP, 2007, J ALTERN COMPLEM MED, V13, P603, DOI 10.1089/acm.2007.7040; Dincer F, 2003, COMPLEMENT THER MED, V11, P235, DOI 10.1016/S0965-2299(03)00124-9; Dougherty DD, 2008, BEHAV BRAIN RES, V193, P63, DOI 10.1016/j.bbr.2008.04.020; Ehrsson HH, 2007, P NATL ACAD SCI USA, V104, P9828, DOI 10.1073/pnas.0610011104; Ehrsson HH, 2004, SCIENCE, V305, P875, DOI 10.1126/science.1097011; Fang JL, 2009, HUM BRAIN MAPP, V30, P1196, DOI 10.1002/hbm.20583; Folegatti A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006920; Gallagher S, 2000, TRENDS COGN SCI, V4, P14, DOI 10.1016/S1364-6613(99)01417-5; Harris RE, 2009, NEUROIMAGE, V47, P1077, DOI 10.1016/j.neuroimage.2009.05.083; Herbert BM, 2012, TOP COGN SCI, V4, P692, DOI 10.1111/j.1756-8765.2012.01189.x; Hsiu H, 2011, EVID-BASED COMPL ALT, V2011, P435928, DOI [10.1093/ecam/neq.073, DOI 10.1093/ECAM/NEQ.073]; Huang WJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032960; Hui KKS, 2010, AUTON NEUROSCI-BASIC, V157, P81, DOI 10.1016/j.autneu.2010.03.022; Hui Kathleen K S, 2007, BMC Complement Altern Med, V7, P33, DOI 10.1186/1472-6882-7-33; Kang OS, 2011, AUTON NEUROSCI-BASIC, V159, P127, DOI 10.1016/j.autneu.2010.07.027; Kong J, 2009, NEUROIMAGE, V47, P1066, DOI 10.1016/j.neuroimage.2009.05.087; Kong J, 2009, NEUROIMAGE, V45, P940, DOI 10.1016/j.neuroimage.2008.12.025; Kong J, 2009, HUM BRAIN MAPP, V30, P38, DOI 10.1002/hbm.20481; Langevin HM, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1155/2011/180805; Lee J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104582; Liu H, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/932581; Liu T, 2009, EVID-BASED COMPL ALT, V6, P185, DOI 10.1093/ecam/nen002; Lopez C, 2008, NEUROPHYSIOL CLIN, V38, P149, DOI 10.1016/j.neucli.2007.12.006; Makin TR, 2008, BEHAV BRAIN RES, V191, P1, DOI 10.1016/j.bbr.2008.02.041; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Mehling WE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005614; Mohan R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052400; Moseley GL, 2008, P NATL ACAD SCI USA, V105, P13169, DOI 10.1073/pnas.0803768105; Moseley GL, 2012, NEUROSCI BIOBEHAV R, V36, P34, DOI 10.1016/j.neubiorev.2011.03.013; Napadow V, 2010, ARTHRITIS RHEUM-US, V62, P2545, DOI 10.1002/art.27497; Napadow V, 2009, NEUROIMAGE, V47, P1055, DOI 10.1016/j.neuroimage.2009.05.079; Newport R, 2010, EXP BRAIN RES, V204, P385, DOI 10.1007/s00221-009-2104-y; Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016; Park H, 2002, AM J CHINESE MED, V30, P45, DOI 10.1142/S0192415X02000053; Tsakiris M, 2007, CEREB CORTEX, V17, P2235, DOI 10.1093/cercor/bhl131; Tsakiris M, 2010, NEUROPSYCHOLOGIA, V48, P703, DOI 10.1016/j.neuropsychologia.2009.09.034; Tsukayama H, 2006, CLIN J PAIN, V22, P346, DOI 10.1097/01.ajp.0000176359.94644.mL; Uchida S, 2008, EVID-BASED COMPL ALT, V5, P145, DOI 10.1093/ecam/nem051; Zeller D, 2011, J NEUROSCI, V31, P4852, DOI 10.1523/JNEUROSCI.5154-10.2011; Zhang WT, 2003, NEUROREPORT, V14, P1591, DOI 10.1097/00001756-200308260-00010	51	13	13	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2014	9	10							e109489	10.1371/journal.pone.0109489	http://dx.doi.org/10.1371/journal.pone.0109489			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU6XC	25285620	Green Published, gold, Green Submitted			2023-01-03	WOS:000345743700069
J	DeLoughery, TG				DeLoughery, Thomas G.			Microcytic Anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONHEME-IRON-ABSORPTION; INTRAVENOUS IRON; DEFICIENCY ANEMIA; CONTROLLED-TRIAL; CHRONIC DISEASE; WOMEN; SUPPLEMENTATION; DIAGNOSIS; FERRITIN; THERAPY	THE MICROCYTIC ANEMIAS ARE THOSE CHARACTERIZED BY THE PRODUCTION of red cells that are smaller than normal. The small size of these cells is due to decreased production of hemoglobin, the predominant constituent of red cells (Fig. 1). The causes of microcytic anemia are a lack of globin product (thalassemia), restricted iron delivery to the heme group of hemoglobin (anemia of inflammation), a lack of iron delivery to the heme group (iron-deficiency anemia), and defects in the synthesis of the heme group (sideroblastic anemias). This review highlights new aspects of the most common microcytic anemias: thalassemia, anemia of inflammation, and iron-deficiency anemia.	[DeLoughery, Thomas G.] Oregon Hlth & Sci Univ, Hematol Sect, Knight Canc Inst, Portland, OR 97239 USA; [DeLoughery, Thomas G.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA; [DeLoughery, Thomas G.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA; [DeLoughery, Thomas G.] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	DeLoughery, TG (corresponding author), Oregon Hlth & Sci Univ, Div Hematol Med Oncol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	delought@ohsu.edu			Alexion	Alexion	Dr. DeLoughery reports receiving grant support from Alexion. No other potential conflict of interest relevant to this article was reported.	An P, 2012, HUM MOL GENET, V21, P2124, DOI 10.1093/hmg/dds028; [Anonymous], 2008, PHARM LETT PRESCRIBE; Auerbach M, 2011, AM J HEMATOL, V86, P860, DOI 10.1002/ajh.22153; Chertow GM, 2006, NEPHROL DIAL TRANSPL, V21, P378, DOI 10.1093/ndt/gfi253; COOK JD, 1976, AM J CLIN NUTR, V29, P859, DOI 10.1093/ajcn/29.8.859; Ganz T, 2011, ANNU REV MED, V62, P347, DOI 10.1146/annurev-med-050109-142444; GUYATT GH, 1992, J GEN INTERN MED, V7, P145, DOI 10.1007/BF02598003; Guyatt GH, 1992, J GEN INTERN MED, V7, P423; Hunt JR, 2009, AM J CLIN NUTR, V89, P1792, DOI 10.3945/ajcn.2009.27439; Hurrell RF, 1999, BRIT J NUTR, V81, P289, DOI 10.1017/S0007114599000537; Hurrell R, 2010, AM J CLIN NUTR, V91, p1461S, DOI 10.3945/ajcn.2010.28674F; Krayenbuehl PA, 2011, BLOOD, V118, P3222, DOI 10.1182/blood-2011-04-346304; Love AL, 2008, AM J HEMATOL, V83, P403, DOI 10.1002/ajh.21106; Lu M, 2010, AM J HEMATOL, V85, P315, DOI 10.1002/ajh.21656; Mei ZG, 2005, J NUTR, V135, P1974, DOI 10.1093/jn/135.8.1974; Okam MM, 2012, AM J HEMATOL, V87, pE123, DOI 10.1002/ajh.23322; ONEILCUTTING MA, 1987, ARCH INTERN MED, V147, P489, DOI 10.1001/archinte.147.3.489; Pantopoulos K, 2012, BIOCHEMISTRY-US, V51, P5705, DOI 10.1021/bi300752r; Pasricha SR, 2014, J NUTR, V144, P906, DOI 10.3945/jn.113.189589; Passarello C, 2012, HAEMATOL-HEMATOL J, V97, P472, DOI 10.3324/haematol.2011.052357; Pavord S, 2012, BRIT J HAEMATOL, V156, P588, DOI 10.1111/j.1365-2141.2011.09012.x; Payen E, 2012, HEMATOL-AM SOC HEMAT, P276, DOI 10.1182/asheducation-2012.1.276; Peeling P, 2008, EUR J APPL PHYSIOL, V103, P381, DOI 10.1007/s00421-008-0726-6; Rimon E, 2005, AM J MED, V118, P1142, DOI 10.1016/j.amjmed.2005.01.065; ROBERTSON JD, 1987, BRIT MED J, V295, P303, DOI 10.1136/bmj.295.6593.303; Ruz M, 2012, AM J CLIN NUTR, V96, P810, DOI 10.3945/ajcn.112.039255; Ryan K, 2010, BRIT J HAEMATOL, V149, P35, DOI 10.1111/j.1365-2141.2009.08054.x; SCOTT DE, 1967, J AMER MED ASSOC, V199, P897, DOI 10.1001/jama.199.12.897; Sun CC, 2012, AM J HEMATOL, V87, P392, DOI 10.1002/ajh.23110; Vaucher P, 2012, CAN MED ASSOC J, V184, P1247, DOI 10.1503/cmaj.110950; Verdon F, 2003, BRIT MED J, V326, P1124, DOI 10.1136/bmj.326.7399.1124; Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809; Zhou SJ, 2009, EUR J CLIN NUTR, V63, P183, DOI 10.1038/sj.ejcn.1602926; Zhu A, 2010, DIGEST DIS SCI, V55, P548, DOI 10.1007/s10620-009-1108-6; Zimmermann MB, 2007, LANCET, V370, P511, DOI 10.1016/S0140-6736(07)61235-5	35	85	92	2	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 2	2014	371	14					1324	1331		10.1056/NEJMra1215361	http://dx.doi.org/10.1056/NEJMra1215361			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AP9VS	25271605				2023-01-03	WOS:000342429800009
J	Navratilova, E; Porreca, F				Navratilova, Edita; Porreca, Frank			Reward and motivation in pain and pain relief	NATURE NEUROSCIENCE			English	Review							ANTERIOR CINGULATE CORTEX; PLACE PREFERENCE PARADIGM; VENTRAL TEGMENTAL AREA; NUCLEUS-ACCUMBENS; ONGOING PAIN; SPINAL-CORD; NEGATIVE REINFORCEMENT; CENTRAL SENSITIZATION; ANIMAL-MODEL; DOPAMINE	Pain is fundamentally unpleasant, a feature that protects the organism by promoting motivation and learning. Relief of aversive states, including pain, is rewarding. The aversiveness of pain, as well as the reward from relief of pain, is encoded by brain reward/motivational mesocorticolimbic circuitry. In this Review, we describe current knowledge of the impact of acute and chronic pain on reward/motivation circuits gained from preclinical models and from human neuroimaging. We highlight emerging clinical evidence suggesting that anatomical and functional changes in these circuits contribute to the transition from acute to chronic pain. We propose that assessing activity in these conserved circuits can offer new outcome measures for preclinical evaluation of analgesic efficacy to improve translation and speed drug discovery. We further suggest that targeting reward/motivation circuits may provide a path for normalizing the consequences of chronic pain to the brain, surpassing symptomatic management to promote recovery from chronic pain.	[Navratilova, Edita; Porreca, Frank] Univ Arizona, Hlth Sci Ctr, Dept Pharmacol, Tucson, AZ 85721 USA	University of Arizona; University of Arizona Health Sciences	Porreca, F (corresponding author), Univ Arizona, Hlth Sci Ctr, Dept Pharmacol, Tucson, AZ 85721 USA.	frankp@email.arizona.edu			US National Institutes of Health [NS066958, DA034975]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS066958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA034975] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We gratefully acknowledge comments and suggestions from I. Tracey and H. Fields. We thank P. Navratilova for help with illustrations. This work was funded by grants NS066958 and DA034975 from the US National Institutes of Health.	Altier N, 1999, LIFE SCI, V65, P2269, DOI 10.1016/S0024-3205(99)00298-2; Anderson EM, 2013, JOVE-J VIS EXP, DOI 10.3791/50336; Andreatta M, 2012, LEARN MEMORY, V19, P518, DOI 10.1101/lm.026864.112; Apkarian AV, 2011, PAIN MANAG, V1, P577, DOI 10.2217/PMT.11.53; Apkarian AV, 2013, CURR OPIN NEUROL, V26, P360, DOI 10.1097/WCO.0b013e32836336ad; Apkarian AV, 2011, PAIN, V152, pS49, DOI 10.1016/j.pain.2010.11.010; Apkarian AV, 2009, PROG NEUROBIOL, V87, P81, DOI 10.1016/j.pneurobio.2008.09.018; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Atlas LY, 2012, NEUROSCI LETT, V520, P140, DOI 10.1016/j.neulet.2012.03.039; Baliki MN, 2012, NAT NEUROSCI, V15, P1117, DOI 10.1038/nn.3153; Baliki MN, 2010, NEURON, V66, P149, DOI 10.1016/j.neuron.2010.03.002; Becerra L, 2013, J NEUROPHYSIOL, V110, P1221, DOI 10.1152/jn.00284.2013; Becerra L, 2008, EUR J PAIN, V12, P866, DOI 10.1016/j.ejpain.2007.12.007; Berger JV, 2011, BRAIN RES REV, V67, P282, DOI 10.1016/j.brainresrev.2011.03.003; Brischoux F, 2009, P NATL ACAD SCI USA, V106, P4894, DOI 10.1073/pnas.0811507106; Brotis AG, 2009, STEREOT FUNCT NEUROS, V87, P271, DOI 10.1159/000226669; Budygin EA, 2012, NEUROSCIENCE, V201, P331, DOI 10.1016/j.neuroscience.2011.10.056; Burgess G, 2010, J CLIN INVEST, V120, P3753, DOI 10.1172/JCI43195; BURSTEIN R, 1989, BRAIN RES, V497, P149, DOI 10.1016/0006-8993(89)90981-5; Bushnell MC, 2013, NAT REV NEUROSCI, V14, P502, DOI 10.1038/nrn3516; Chapin H, 2012, NEUROSCI LETT, V520, P174, DOI 10.1016/j.neulet.2012.02.076; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; Davoody L, 2011, J PAIN, V12, P868, DOI 10.1016/j.jpain.2011.01.010; DeFelice M, 2013, ANN NEUROL, V74, P257, DOI 10.1002/ana.23922; Denk F, 2014, NAT NEUROSCI, V17, P192, DOI 10.1038/nn.3628; Denton DA, 2009, CONSCIOUS COGN, V18, P500, DOI 10.1016/j.concog.2008.06.009; Dodick DW, 2014, LANCET NEUROL, V13, P885, DOI 10.1016/S1474-4422(14)70128-0; Eippert F, 2009, SCIENCE, V326, P404, DOI 10.1126/science.1180142; Ewan EE, 2013, NEUROSCI LETT, V557, P60, DOI 10.1016/j.neulet.2013.08.018; Fields H, 2004, NAT REV NEUROSCI, V5, P565, DOI 10.1038/nrn1431; Fields HL, 1999, PAIN, pS61, DOI 10.1016/S0304-3959(99)00139-6; Fields HL., 2006, P 11 WORLD C PAIN, P449; FOLTZ EL, 1962, J NEUROSURG, V19, P89, DOI 10.3171/jns.1962.19.2.0089; Gear RW, 2011, EXP NEUROL, V229, P502, DOI 10.1016/j.expneurol.2011.03.021; Geha PY, 2008, NEURON, V60, P570, DOI 10.1016/j.neuron.2008.08.022; Gerber B, 2014, LEARN MEMORY, V21, P232, DOI 10.1101/lm.032995.113; Gjerstad AC, 2008, PEDIATRICS, V122, pE848, DOI 10.1542/peds.2007-2545; Gold MS, 2010, NAT MED, V16, P1248, DOI 10.1038/nm.2235; Harris RE, 2007, J NEUROSCI, V27, P10000, DOI 10.1523/JNEUROSCI.2849-07.2007; He Y, 2012, J PAIN, V13, P598, DOI 10.1016/j.jpain.2012.03.011; Johannes CB, 2010, J PAIN, V11, P1230, DOI 10.1016/j.jpain.2010.07.002; Johansen JP, 2001, P NATL ACAD SCI USA, V98, P8077, DOI 10.1073/pnas.141218998; Johansen JP, 2004, NAT NEUROSCI, V7, P398, DOI 10.1038/nn1207; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Kender RG, 2008, J PAIN, V9, P597, DOI 10.1016/j.jpain.2008.01.334; King CD, 2007, NEUROSCIENCE, V147, P174, DOI 10.1016/j.neuroscience.2007.04.012; King T, 2009, NAT NEUROSCI, V12, P1364, DOI 10.1038/nn.2407; LaBuda CJ, 2000, EXP NEUROL, V163, P490, DOI 10.1006/exnr.2000.7395; LaGraize SC, 2004, EXP NEUROL, V188, P139, DOI 10.1016/j.expneurol.2004.04.003; Lanz S, 2011, J NEURAL TRANSM, V118, P1139, DOI 10.1007/s00702-011-0606-9; Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012; Lee MC, 2013, BRIT J ANAESTH, V111, P64, DOI 10.1093/bja/aet174; Lee MC, 2010, CURR PAIN HEADACHE R, V14, P124, DOI 10.1007/s11916-010-0103-0; Leknes S, 2008, EUR J NEUROSCI, V28, P794, DOI 10.1111/j.1460-9568.2008.06380.x; Leknes S, 2008, NAT REV NEUROSCI, V9, P314, DOI 10.1038/nrn2333; Leknes S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017870; Levenson RW, 2011, EMOT REV, V3, P379, DOI 10.1177/1754073911410743; Lim SL, 2011, J NEUROSCI, V31, P13214, DOI 10.1523/JNEUROSCI.1246-11.2011; Lorenz J, 2002, NEURON, V35, P383, DOI 10.1016/S0896-6273(02)00767-5; Martin TJ, 2006, PAIN, V125, P257, DOI 10.1016/j.pain.2006.05.027; May A, 2008, PAIN, V137, P7, DOI 10.1016/j.pain.2008.02.034; Mohseni HR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037993; Narita M, 2010, ADDICT BIOL, V15, P434, DOI 10.1111/j.1369-1600.2010.00249.x; Navratilova E, 2013, ANN NY ACAD SCI, V1282, P1, DOI 10.1111/nyas.12095; Navratilova E, 2012, P NATL ACAD SCI USA, V109, P20709, DOI 10.1073/pnas.1214605109; Neugebauer V, 2009, BRAIN RES REV, V60, P226, DOI 10.1016/j.brainresrev.2008.12.014; Noonan MP, 2010, P NATL ACAD SCI USA, V107, P20547, DOI 10.1073/pnas.1012246107; Okun A, 2012, PAIN, V153, P924, DOI 10.1016/j.pain.2012.01.022; Okun A, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-4; Park HJ, 2013, ANESTH ANALG, V116, P224, DOI 10.1213/ANE.0b013e31826e1007; Porreca F, 2002, TRENDS NEUROSCI, V25, P319, DOI 10.1016/S0166-2236(02)02157-4; Qu CL, 2011, PAIN, V152, P1641, DOI 10.1016/j.pain.2011.03.002; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; Redgrave P, 2008, BRAIN RES REV, V58, P322, DOI 10.1016/j.brainresrev.2007.10.007; Rodriguez-Raecke R, 2009, J NEUROSCI, V29, P13746, DOI 10.1523/JNEUROSCI.3687-09.2009; Rushworth MFS, 2008, NAT NEUROSCI, V11, P389, DOI 10.1038/nn2066; Rushworth MFS, 2011, NEURON, V70, P1054, DOI 10.1016/j.neuron.2011.05.014; Schultz W, 2013, CURR OPIN NEUROBIOL, V23, P229, DOI 10.1016/j.conb.2012.11.012; Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34; Scott DJ, 2007, NEURON, V55, P325, DOI 10.1016/j.neuron.2007.06.028; Scott DJ, 2006, J NEUROSCI, V26, P10789, DOI 10.1523/JNEUROSCI.2577-06.2006; Seminowicz DA, 2011, J NEUROSCI, V31, P7540, DOI 10.1523/JNEUROSCI.5280-10.2011; Seminowicz DA, 2009, NEUROIMAGE, V47, P1007, DOI 10.1016/j.neuroimage.2009.05.068; Seymour B, 2005, NAT NEUROSCI, V8, P1234, DOI 10.1038/nn1527; Simons LE, 2014, NEUROSCI BIOBEHAV R, V39, P61, DOI 10.1016/j.neubiorev.2013.12.006; Singh Gurkirpal, 1998, American Journal of Medicine, V105, p31S, DOI 10.1016/S0002-9343(98)00072-2; Sotocinal SG, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-55; Sprenger C, 2012, CURR BIOL, V22, P1019, DOI 10.1016/j.cub.2012.04.006; SUFKA KJ, 1994, PAIN, V58, P355, DOI 10.1016/0304-3959(94)90130-9; Tracey I, 2010, NAT MED, V16, P1277, DOI 10.1038/nm.2229; Tracey I, 2009, J PAIN, V10, P1113, DOI 10.1016/j.jpain.2009.09.001; van Hecke O, 2013, BRIT J ANAESTH, V111, P13, DOI 10.1093/bja/aet123; Villemure C, 2012, PAIN RES MANAG, V17, P69, DOI 10.1155/2012/371362; Villemure C, 2009, J NEUROSCI, V29, P705, DOI 10.1523/JNEUROSCI.3822-08.2009; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Wager TD, 2008, NEURON, V59, P1037, DOI 10.1016/j.neuron.2008.09.006; Wager TD, 2013, NEW ENGL J MED, V368, P1388, DOI 10.1056/NEJMoa1204471; Wang JY, 2003, BRAIN RES, V992, P263, DOI 10.1016/j.brainres.2003.08.059; Wanigasekera V, 2012, P NATL ACAD SCI USA, V109, P17705, DOI 10.1073/pnas.1120201109; Watson A, 2009, PAIN, V145, P24, DOI 10.1016/j.pain.2009.04.003; Wiech K, 2005, NEUROIMAGE, V27, P59, DOI 10.1016/j.neuroimage.2005.03.044; Wiech K, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00046; Wiech K, 2009, NEUROIMAGE, V47, P987, DOI 10.1016/j.neuroimage.2009.05.059; Wood PB, 2007, J PAIN, V8, P51, DOI 10.1016/j.jpain.2006.05.014; Woolf CJ, 2007, NEURON, V55, P353, DOI 10.1016/j.neuron.2007.07.016; Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030; Xie JY, 2014, PAIN, V155, P1659, DOI 10.1016/j.pain.2014.05.018; Yen CP, 2005, J CLIN NEUROSCI, V12, P886, DOI 10.1016/j.jocn.2004.11.018; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005	109	274	285	9	155	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	OCT	2014	17	10					1304	1312		10.1038/nn.3811	http://dx.doi.org/10.1038/nn.3811			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	AP8KD	25254980	Green Accepted			2023-01-03	WOS:000342327000008
J	Sato, H; Suzuki, Y; Ide, M; Katoh, T; Noda, S; Ando, K; Oike, T; Yoshimoto, Y; Okonogi, N; Mimura, K; Asao, T; Kuwano, H; Nakano, T				Sato, Hiro; Suzuki, Yoshiyuki; Ide, Munenori; Katoh, Toshihide; Noda, Shin-ei; Ando, Ken; Oike, Takahiro; Yoshimoto, Yuya; Okonogi, Noriyuki; Mimura, Kousaku; Asao, Takayuki; Kuwano, Hiroyuki; Nakano, Takashi			HLA Class I Expression and Its Alteration by Preoperative Hyperthermo-Chemoradiotherapy in Patients with Rectal Cancer	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMA; MHC CLASS-I; ANTIGEN DOWN-REGULATION; COLORECTAL-CANCER; TUMOR; RADIATION; SURVIVAL; LESIONS; IMMUNOSURVEILLANCE; ASSOCIATION	Objective: Enhancing immunologic responses, including human leukocyte antigen (HLA) class I expression on tumor cells and recognition and elimination of tumor cells by tumor-specific cytotoxic T lymphocyte (CTL), is considered a novel concept of radiotherapy. The present study examined patients who underwent preoperative hyperthermo-chemoradiotherapy (HCRT) for locally advanced rectal cancer to assess the correlation between HLA class I expression and clinical outcome. Materials and Methods: Seventy-eight patients with locally advanced rectal adenocarcinoma who received preoperative HCRT were enrolled. The median age of the patients was 64 years (range, 33-85 years) and 4, 18, and 56 patients had clinical stage I, II and III disease, respectively. Formalin-fixed and paraffin-embedded tissues excised before and after HCRT were subjected to immunohistochemical analysis with an anti-HLA class I-A, B, C antibody. HLA class I expression was graded according to tumor cell positivity. Results: In pre-HCRT, the number of specimens categorized as Grade 0 and 1 were 19 (24%) and 58 (74%), respectively. Only 1 patient (1%) showed Grade 2 expression. However, 6 (8%), 27 (35%), 7 (9%), and 12 (15%) post-HCRT specimens were graded as Grade 0, 1, 2, and 3, respectively. There was a significant increase in HLA class I expression in post-HCRT specimens (p<0.01). However, neither pre- nor post-HCRT HLA class I expression affected overall survival and distant metastasis-free survival in clinical stage III patients. Univariate analysis revealed that Post-HCRT HLA class I expression showed a significant negative relationship with LC (p<0.05). Nevertheless, multivariate analysis showed that there was no correlation between HLA class I expression and clinical outcome. Conclusion: HCRT increased HLA class I expression in rectal cancer patients. However, multivariate analysis failed to show any correlation between the level of HLA class I expression and prognosis.	[Sato, Hiro; Suzuki, Yoshiyuki; Noda, Shin-ei; Ando, Ken; Oike, Takahiro; Yoshimoto, Yuya; Okonogi, Noriyuki; Nakano, Takashi] Gunma Univ, Grad Sch Med, Dept Radiat Oncol, Maebashi, Gunma 371, Japan; [Ide, Munenori] Gunma Univ, Grad Sch Med, Dept Human Pathol, Maebashi, Gunma 371, Japan; [Katoh, Toshihide; Kuwano, Hiroyuki] Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, Maebashi, Gunma 371, Japan; [Mimura, Kousaku] Natl Univ Singapore, Dept Surg, Singapore 117548, Singapore; [Asao, Takayuki] Gunma Univ, Grad Sch Med, Dept Oncol Clin Dev, Maebashi, Gunma 371, Japan	Gunma University; Gunma University; Gunma University; National University of Singapore; Gunma University	Suzuki, Y (corresponding author), Gunma Univ, Grad Sch Med, Dept Radiat Oncol, Maebashi, Gunma 371, Japan.	syoshi@gunma-u.ac.jp	/CAH-2060-2022; Sato, Hiro/GWU-7659-2022	Okonogi, Noriyuki/0000-0002-9486-1922	Grants-in-Aid for Scientific Research [24591834] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		AbdelWahab Z, 1996, CELL IMMUNOL, V171, P246, DOI 10.1006/cimm.1996.0200; Bandoh N, 2010, ONCOL REP, V23, P933, DOI 10.3892/or_00000717; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Gameiro SR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070417; Garnett CT, 2004, CANCER RES, V64, P7985, DOI 10.1158/0008-5472.CAN-04-1525; Homma I, 2009, CANCER SCI, V100, P2331, DOI 10.1111/j.1349-7006.2009.01329.x; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kikuchi E, 2007, CANCER SCI, V98, P1424, DOI 10.1111/j.1349-7006.2007.00558.x; Lee YJ, 2009, BLOOD, V114, P589, DOI 10.1182/blood-2009-02-206870; Mizukami Y, 2008, BRIT J CANCER, V99, P1462, DOI 10.1038/sj.bjc.6604715; Naito Y, 1998, CANCER RES, V58, P3491; Newcomb EW, 2006, CLIN CANCER RES, V12, P4730, DOI 10.1158/1078-0432.CCR-06-0593; Ogino T, 2003, CLIN CANCER RES, V9, P4043; Ogino T, 2006, CANCER RES, V66, P9281, DOI 10.1158/0008-5472.CAN-06-0488; Ohtsukasa S, 2003, J CANCER RES CLIN, V129, P719, DOI 10.1007/s00432-003-0492-0; Reits EA, 2006, J EXP MED, V203, P1259, DOI 10.1084/jem.20052494; Shioya M, 2011, J RADIAT RES, V52, P821, DOI 10.1269/jrr.11117; Speetjens FM, 2008, CANCER IMMUNOL IMMUN, V57, P601, DOI 10.1007/s00262-007-0396-y; Suzuki Y, 2012, CANCER RES, V72, P3967, DOI 10.1158/0008-5472.CAN-12-0851; Takeshima T, 2010, CANCER RES, V70, P2697, DOI 10.1158/0008-5472.CAN-09-2982; Tsukahara T, 2006, CANCER SCI, V97, P1374, DOI 10.1111/j.1349-7006.2006.00317.x; Tsutsumi S, 2011, ANTICANCER RES, V31, P3963; Watson NFS, 2006, INT J CANCER, V118, P6, DOI 10.1002/ijc.21303	23	10	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2014	9	9							e108122	10.1371/journal.pone.0108122	http://dx.doi.org/10.1371/journal.pone.0108122			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ3IP	25259797	gold, Green Published, Green Submitted			2023-01-03	WOS:000342685600049
J	Fang, P; Zhou, L; Zhou, YQ; Kolls, JK; Zheng, T; Zhu, Z				Fang, Ping; Zhou, Li; Zhou, Yuqi; Kolls, Jay K.; Zheng, Tao; Zhu, Zhou			Immune Modulatory Effects of IL-22 on Allergen-Induced Pulmonary Inflammation	PLOS ONE			English	Article							EOSINOPHILIC AIRWAY INFLAMMATION; INNATE LYMPHOID-CELLS; MOUSE MODEL; IFN-GAMMA; T-CELLS; ASTHMA; LUNG; IL-17; INTERLEUKIN-22; T(H)17	IL-22 is a Th17/Th22 cytokine that is increased in asthma. However, recent animal studies showed controversial findings in the effects of IL-22 in allergic asthma. To determine the role of IL-22 in ovalbumin-induced allergic inflammation we generated inducible lung-specific IL-22 transgenic mice. Transgenic IL-22 expression and signaling activity in the lung were determined. Ovalbumin (OVA)-induced pulmonary inflammation, immune responses, and airway hyperresponsiveness (AHR) were examined and compared between IL-22 transgenic mice and wild type controls. Following doxycycline (Dox) induction, IL-22 protein was readily detected in the large (CC10 promoter) and small (SPC promoter) airway epithelial cells. IL-22 signaling was evidenced by phosphorylated STAT3. After OVA sensitization and challenge, compared to wild type littermates, IL-22 transgenic mice showed decreased eosinophils in the bronchoalveolar lavage (BAL), and in lung tissue, decreased mucus metaplasia in the airways, and reduced AHR. Among the cytokines and chemokines examined, IL-13 levels were reduced in the BAL fluid as well as in lymphocytes from local draining lymph nodes of IL-22 transgenic mice. No effect was seen on the levels of serum total or OVA-specific IgE or IgG. These findings indicate that IL-22 has immune modulatory effects on pulmonary inflammatory responses in allergen-induced asthma.	[Fang, Ping] Xi An Jiao Tong Univ, Resp Dept, Affiliated Hosp 2, Sch Med, Xian 710049, Shaanxi, Peoples R China; [Fang, Ping; Zhou, Li; Zhou, Yuqi; Zheng, Tao; Zhu, Zhou] Johns Hopkins Univ, Sch Med, Dept Internal Med, Div Allergy & Clin Immunol, Baltimore, MD USA; [Kolls, Jay K.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Div Pediat Rheumatol, Pittsburgh, PA USA	Xi'an Jiaotong University; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhu, Z (corresponding author), Yale Univ, Sch Med, New Haven, CT 06520 USA.	zhou.zhu@yale.edu	Kolls, Jay/AAH-1829-2019	Kolls, Jay/0000-0001-5151-6304	NIH [AI075025, AI07502, HL079349, HL107151]; National Natural Science Foundation of China [81000009]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079349, P01HL107151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI075025] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The work was supported by the following: NIH grants HL079349 and HL107151 to ZZ; NIH grants AI075025 and AI07502 to TZ; and National Natural Science Foundation of China 81000009 to PF. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akdis M, 2012, J ALLERGY CLIN IMMUN, V129, P1438, DOI 10.1016/j.jaci.2012.05.003; Akeson AL, 2003, DEV BIOL, V264, P443, DOI 10.1016/j.ydbio.2003.09.004; Atarashi K, 2010, BENEF MICROBES, V1, P327, DOI 10.3920/BM2010.0026; Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710; Besnard AG, 2011, AM J RESP CRIT CARE, V183, P1153, DOI 10.1164/rccm.201008-1383OC; Bonneville M, 2010, NAT REV IMMUNOL, V10, P467, DOI 10.1038/nri2781; Cannon MJ, 2011, EXPERT OPIN BIOL TH, V11, P441, DOI 10.1517/14712598.2011.554812; Chang Y, 2012, FASEB J, V26, P5152, DOI 10.1096/fj.12-208033; Cobleigh MA, 2013, AM J PATHOL, V182, P21, DOI 10.1016/j.ajpath.2012.08.043; Dumoutier L, 2000, GENES IMMUN, V1, P488, DOI 10.1038/sj.gene.6363716; Goto M, 2009, CELL IMMUNOL, V254, P81, DOI 10.1016/j.cellimm.2008.10.002; Hellings PW, 2003, AM J RESP CELL MOL, V28, P42, DOI 10.1165/rcmb.4832; Hirose K, 2013, J ALLERGY CAIRO, V2013; Kim KW, 2012, ARTHRITIS RHEUM-US, V64, P1015, DOI 10.1002/art.33446; Laurence A, 2008, NAT MED, V14, P247, DOI 10.1038/nm0308-247; Lecart S, 2002, INT IMMUNOL, V14, P1351, DOI 10.1093/intimm/dxf096; Lee YC, 2001, J ASTHMA, V38, P665, DOI 10.1081/JAS-100107544; Liang MR, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/209179; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Middleton GW, 2012, CANCER IMMUNOL IMMUN, V61, P1, DOI 10.1007/s00262-011-1151-y; Mjosberg J, 2012, EUR J IMMUNOL, V42, P1093, DOI 10.1002/eji.201242549; Nakagome K, 2011, J IMMUNOL, V187, P5077, DOI 10.4049/jimmunol.1001560; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Oh SY, 2009, AM J RESP CELL MOL, V40, P568, DOI 10.1165/rcmb.2008-0225OC; Park O, 2011, HEPATOLOGY, V54, P252, DOI 10.1002/hep.24339; Pociask DA, 2013, AM J PATHOL, V182, P1286, DOI 10.1016/j.ajpath.2012.12.007; Res PCM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014108; Scanlon ST, 2012, CURR OPIN IMMUNOL, V24, P707, DOI 10.1016/j.coi.2012.08.009; Simonian PL, 2010, J EXP MED, V207, P2239, DOI 10.1084/jem.20100061; Sonnenberg GF, 2010, J EXP MED, V207, P1293, DOI 10.1084/jem.20092054; Souwer Y, 2010, CURR OPIN IMMUNOL, V22, P821, DOI 10.1016/j.coi.2010.10.013; Stirling RG, 2000, BRIT MED BULL, V56, P1037, DOI 10.1258/0007142001903526; Sugimoto K, 2008, J CLIN INVEST, V118, P534, DOI [10.1172/JC133194, 10.1172/JCI33194]; Takahashi K, 2011, J ALLERGY CLIN IMMUN, V128, P1067, DOI 10.1016/j.jaci.2011.06.018; Takatori H, 2009, J EXP MED, V206, P35, DOI 10.1084/jem.20072713; Taube C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021799; Tichelaar JW, 2000, J BIOL CHEM, V275, P11858, DOI 10.1074/jbc.275.16.11858; Witte E, 2010, CYTOKINE GROWTH F R, V21, P365, DOI 10.1016/j.cytogfr.2010.08.002; Wolk K, 2009, J MOL MED, V87, P523, DOI 10.1007/s00109-009-0457-0; Wong CK, 2001, CLIN EXP IMMUNOL, V125, P177, DOI 10.1046/j.1365-2249.2001.01602.x; Zenewicz LA, 2011, INT IMMUNOL, V23, P159, DOI 10.1093/intimm/dxr001; Zenewicz LA, 2008, EUR J IMMUNOL, V38, P3265, DOI 10.1002/eji.200838655; Zhao J, 2013, MUCOSAL IMMUNOL, V6, P335, DOI 10.1038/mi.2012.76; Zhao Y, 2010, INT ARCH ALLERGY IMM, V151, P297, DOI 10.1159/000250438; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhu Z, 2001, J BIOL CHEM, V276, P25222, DOI 10.1074/jbc.M101512200; Zhu Z, 2011, SCI REP-UK, V1, DOI 10.1038/srep00023	47	21	22	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2014	9	9							e107454	10.1371/journal.pone.0107454	http://dx.doi.org/10.1371/journal.pone.0107454			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT3UZ	25254361	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000344862300024
J	Nonnekes, J; Arrogi, A; Munneke, MAM; van Asseldonk, EHF; Nijhuis, LBO; Geurts, AC; Weerdesteyn, V				Nonnekes, Jorik; Arrogi, Anass; Munneke, Moniek A. M.; van Asseldonk, Edwin H. F.; Nijhuis, Lars B. Oude; Geurts, Alexander C.; Weerdesteyn, Vivian			Subcortical Structures in Humans Can Be Facilitated by Transcranial Direct Current Stimulation	PLOS ONE			English	Article							POPULATION-DYNAMICS; SPATIAL HETEROGENEITY; HABITAT QUALITY; EFFECT SIZE; DISPERSAL; AUTOCORRELATION; VARIABILITY; PERSISTENCE; MODELS; FRAGMENTATION	Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation technique that alters cortical excitability. Interestingly, in recent animal studies facilitatory effects of tDCS have also been observed on subcortical structures. Here, we sought to provide evidence for the potential of tDCS to facilitate subcortical structures in humans as well. Subjects received anodal-tDCS and sham-tDCS on two separate testing days in a counterbalanced order. After stimulation, we assessed the effect of tDCS on two responses that arise from subcortical structures; (1) wrist and ankle responses to an imperative stimulus combined with a startling acoustic stimulus (SAS), and (2) automatic postural responses to external balance perturbations with and without a concurrent SAS. During all tasks, response onsets were significantly faster following anodal-tDCS compared to sham-tDCS, both in trials with and without a SAS. The effect of tDCS was similar for the dominant and non-dominant leg. The SAS accelerated the onsets of ankle and wrist movements and the responses to backward, but not forward perturbations. The faster onsets of SAS-induced wrist and ankle movements and automatic postural responses following stimulation provide strong evidence that, in humans, subcortical structures - in particular the reticular formation can be facilitated by tDCS. This effect may be explained by two mechanisms that are not mutually exclusive. First, subcortical facilitation may have resulted from enhanced cortico-reticular drive. Second, the applied current may have directly stimulated the reticular formation. Strengthening reticulospinal output by tDCS may be of interest to neurorehabilitation, as there is evidence for reticulospinal compensation after corticospinal lesions.	[Nonnekes, Jorik; Arrogi, Anass; Geurts, Alexander C.; Weerdesteyn, Vivian] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Rehabil, NL-6525 ED Nijmegen, Netherlands; [Munneke, Moniek A. M.; Nijhuis, Lars B. Oude] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Neurol Clin Neurophysiol, NL-6525 ED Nijmegen, Netherlands; [van Asseldonk, Edwin H. F.] Univ Twente, MIRA, Dept Biomech Engn, NL-7500 AE Enschede, Netherlands; [Geurts, Alexander C.; Weerdesteyn, Vivian] Sint Maartensklin Res Dev & Educ, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; University of Twente; Sint Maartens Clinic	Nonnekes, J (corresponding author), Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Rehabil, NL-6525 ED Nijmegen, Netherlands.	jorik.nonnekes@radboudumc.nl	Weerdesteyn, Vivian/A-9599-2014; Nonnekes, Jorik/P-6648-2015; Munneke, Moniek/D-4723-2009; Geurts, Alexander/H-8032-2014	Weerdesteyn, Vivian/0000-0003-4327-7600; Munneke, Moniek/0000-0002-5542-8034; Geurts, Alexander/0000-0001-7478-1119; van Asseldonk, Edwin/0000-0003-1534-2348; Nonnekes, Jorik/0000-0003-2434-1427	Radboud University Nijmegen Medical Centre Research Grant; Netherlands Organization for Scientific Research Veni Research Grants [916.10.106, 916.10.143]	Radboud University Nijmegen Medical Centre Research Grant; Netherlands Organization for Scientific Research Veni Research Grants	This research was funded by a Radboud University Nijmegen Medical Centre Research Grant to Jorik Nonnekes, and Netherlands Organization for Scientific Research Veni Research Grants to Vivian Weerdesteyn (916.10.106) and Edwin van Asseldonk (916.10.143). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armsworth PR, 2009, THEOR ECOL-NETH, V2, P105, DOI 10.1007/s12080-008-0032-2; Bakeman R, 2005, BEHAV RES METHODS, V37, P379, DOI 10.3758/BF03192707; Boeye J, 2014, LANDSCAPE ECOL, V29, P593, DOI 10.1007/s10980-014-0010-6; Bolker BM, 2003, THEOR POPUL BIOL, V64, P255, DOI 10.1016/S0040-5809(03)00090-X; Bowler DE, 2005, BIOL REV, V80, P205, DOI 10.1017/S1464793104006645; Brachet S, 1999, J THEOR BIOL, V198, P479, DOI 10.1006/jtbi.1999.0926; Burgess MD, 2011, J ANIM ECOL, V80, P688, DOI 10.1111/j.1365-2656.2011.01816.x; Chipperfield JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017040; Clarke RT, 1997, P ROY SOC B-BIOL SCI, V264, P347, DOI 10.1098/rspb.1997.0050; Cohen J., 2013, STAT POWER ANAL BEHA; DHONDT AA, 1992, J ANIM ECOL, V61, P643, DOI 10.2307/5619; DUTILLEUL P, 1993, OIKOS, V66, P152, DOI 10.2307/3545210; Fahrig L, 1998, ECOL MODEL, V105, P273, DOI 10.1016/S0304-3800(97)00163-4; Fleishman E, 2002, CONSERV BIOL, V16, P706, DOI 10.1046/j.1523-1739.2002.00539.x; Getz WM, 2008, P NATL ACAD SCI USA, V105, P19066, DOI 10.1073/pnas.0801732105; Gilbert B, 2004, P NATL ACAD SCI USA, V101, P7651, DOI 10.1073/pnas.0400814101; Gonzalez A, 2002, P NATL ACAD SCI USA, V99, P14872, DOI 10.1073/pnas.232589299; Grimm V, 2006, ECOL MODEL, V198, P115, DOI 10.1016/j.ecolmodel.2006.04.023; Grimm V, 2010, ECOL MODEL, V221, P2760, DOI 10.1016/j.ecolmodel.2010.08.019; HAEFNER JW, 1991, ECOL MODEL, V56, P221, DOI 10.1016/0304-3800(91)90201-B; Harrison S, 1999, ECOGRAPHY, V22, P225, DOI 10.1111/j.1600-0587.1999.tb00496.x; HASSELL MP, 1975, J ANIM ECOL, V44, P283, DOI 10.2307/3863; Hiebeler D, 2004, THEOR POPUL BIOL, V66, P205, DOI 10.1016/j.tpb.2004.06.004; Humphries NE, 2013, METHODS ECOL EVOL, V4, P930, DOI 10.1111/2041-210X.12096; Itakura J, 2010, BIOSYSTEMS, V99, P70, DOI 10.1016/j.biosystems.2009.09.001; Jacobson B, 2010, LANDSCAPE ECOL, V25, P495, DOI 10.1007/s10980-009-9442-9; Jager HI, 2001, ECOL MODEL, V144, P61, DOI 10.1016/S0304-3800(01)00362-3; Jonsen ID, 1997, LANDSCAPE ECOL, V12, P185, DOI 10.1023/A:1007961006232; Kendall BE, 1998, THEOR POPUL BIOL, V54, P11, DOI 10.1006/tpbi.1998.1365; Kolasa J, 2003, P ROY SOC B-BIOL SCI, V270, pS198, DOI 10.1098/rsbl.2003.0059; Lawrence M. A., 2011, EZ EASY ANAL VISUALI; LEGENDRE P, 1993, ECOLOGY, V74, P1659, DOI 10.2307/1939924; Lou Y, 2006, J DIFFER EQUATIONS, V223, P400, DOI 10.1016/j.jde.2005.05.010; Lovett GM, 2005, Ecosystem Function in Heterogeneous Landscapes, P1, DOI 10.1007/0-387-24091-8_1; Mortelliti A, 2010, OECOLOGIA, V163, P535, DOI 10.1007/s00442-010-1623-3; Nevoux M, 2010, P ROYAL SOC B, V278, P2173; Olejnik S, 2003, PSYCHOL METHODS, V8, P434, DOI 10.1037/1082-989X.8.4.434; Parrott L, 2000, COMPLEXITY INT, V7; Pearson SM, 2011, SOURCES SINKS SUSTAI; Petchey OL, 1997, P ROY SOC B-BIOL SCI, V264, P1841, DOI 10.1098/rspb.1997.0254; Pigliucci M, 2001, ENV HETEROGENEITY TE; Pike N, 2004, P ROY SOC B-BIOL SCI, V271, P2143, DOI 10.1098/rspb.2004.2834; Pinto SM, 2010, AM NAT, V175, P675, DOI 10.1086/652467; PULLIAM HR, 1988, AM NAT, V132, P652, DOI 10.1086/284880; PULLIAM HR, 1991, AM NAT, V137, pS50, DOI 10.1086/285139; PULLIAM HR, 1992, ECOL APPL, V2, P165, DOI 10.2307/1941773; R Core Team, 2021, R LANG ENV STAT COMP; Ries L, 2004, ANNU REV ECOL EVOL S, V35, P491, DOI 10.1146/annurev.ecolsys.35.112202.130148; Rodenhouse NL, 1997, ECOLOGY, V78, P2025, DOI 10.1890/0012-9658(1997)078[2025:SDROPS]2.0.CO;2; Ruel JJ, 1999, TRENDS ECOL EVOL, V14, P361, DOI 10.1016/S0169-5347(99)01664-X; Schiegg K, 2003, TRENDS ECOL EVOL, V18, P212, DOI 10.1016/S0169-5347(03)00074-0; Schooley RL, 2007, ECOSYSTEMS, V10, P846, DOI 10.1007/s10021-007-9062-7; Skelsey P, 2013, THEOR ECOL-NETH, V6, P203, DOI 10.1007/s12080-012-0171-3; Snyder RE, 2003, ECOL LETT, V6, P301, DOI 10.1046/j.1461-0248.2003.00434.x; Stoddard ST, 2010, ECOL MODEL, V221, P2409, DOI 10.1016/j.ecolmodel.2010.06.024; White JW, 2014, OIKOS, V123, P385, DOI 10.1111/j.1600-0706.2013.01073.x; Wiegand T, 1999, AM NAT, V154, P605, DOI 10.1086/303272; WIENS JA, 1993, OIKOS, V66, P369, DOI 10.2307/3544931; With KA, 1999, CONSERV BIOL, V13, P314, DOI 10.1046/j.1523-1739.1999.013002314.x; Wu J., 2007, KEY TOPICS LANDSCAPE; Wu JG, 2002, LANDSCAPE ECOL, V17, P355, DOI 10.1023/A:1020561630963; Ye XP, 2013, ECOL RES, V28, P949, DOI 10.1007/s11284-013-1077-2; Zajac T, 2008, J AVIAN BIOL, V39, P206, DOI 10.1111/j.0908-8857.2008.04183.x	63	38	38	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2014	9	9							e107731	10.1371/journal.pone.0107731	http://dx.doi.org/10.1371/journal.pone.0107731			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ6KR	25233458	Green Submitted, gold, Green Published			2023-01-03	WOS:000342921200049
J	Na, KS; Jee, DH; Han, K; Park, YG; Kim, MS; Kim, EC				Na, Kyung-Sun; Jee, Dong Hyun; Han, Kyungdo; Park, Yong-Gyu; Kim, Man Soo; Kim, Eun Chul			The Ocular Benefits of Estrogen Replacement Therapy: A Population-Based Study in Postmenopausal Korean Women	PLOS ONE			English	Article							AGE-RELATED MACULOPATHY; BLUE MOUNTAINS EYE; BEAVER DAM EYE; INTRAOCULAR-PRESSURE; HORMONE-THERAPY; REPRODUCTIVE FACTORS; PTERYGIUM; PREVALENCE; EXPOSURES; CATARACT	Purpose: To elucidate the prevalence of cataract, glaucoma, pterygia, and diabetic retinopathy among Korean postmenopausal women with or without estrogen replacement therapy (ERT). Methods: A cross-sectional, nationally representative sample from the 4th Korea National Health and Nutrition Examination Survey (KNHANES IV) (2007-2009) was used. Participants were interviewed for the determination of socioeconomic and gynecologic factors. Each woman also underwent an ophthalmologic examination and provided a blood sample for risk factor assessment. Results: Of 3968 postmenopausal women enrolled, 3390 had never received estrogen, and 578 were undergoing estrogen treatment. After adjusting for age, diabetes, hypertension, high cholesterol levels, and high low-density lipoprotein levels, the prevalence of anterior polar cataract, retinal nerve fiber layer (RNFL) defect, and flesh pterygium was higher in the non-ERT group (OR, 3.24; 95% CI, 1.12-9.35, OR 1.70; 95% CI, 1.04-2.78, OR 3.725; 95% CI, 1.21-11.45, respectively). Further, the prevalence of atrophic pterygium was lower in the non-ERT group compared to that in the ERT group (OR, 0.21, 95% CI, 0.07-0.63). Conclusions: These data suggest that ERT has a protective effect against the development of anterior polar cataract, flesh pterygium, and RNFL defect.	[Na, Kyung-Sun; Jee, Dong Hyun; Kim, Man Soo; Kim, Eun Chul] Catholic Univ Korea, Coll Med, Dept Ophthalmol, Seoul, South Korea; [Han, Kyungdo; Park, Yong-Gyu] Catholic Univ Korea, Dept Biostat, Seoul, South Korea	Catholic University of Korea; Catholic University of Korea	Kim, EC (corresponding author), Catholic Univ Korea, Coll Med, Dept Ophthalmol, Seoul, South Korea.	eunchol@hanmail.net		Park, Yong Gyu/0000-0002-8721-3230	National Research Foundation of Korea Grant [201238648]	National Research Foundation of Korea Grant(National Research Foundation of Korea)	This study is supported by National Research Foundation of Korea Grant founded by the Korean Government (201238648). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abramov Y, 2005, J GLAUCOMA, V14, P271, DOI 10.1097/01.ijg.0000169390.17427.b7; Abramov Y, 2004, MENOPAUSE, V11, P62, DOI 10.1097/01.GME.0000074701.19603.11; Ang M, 2012, OPHTHALMOLOGY, V119, P1509, DOI 10.1016/j.ophtha.2012.02.009; Craig MC, 2010, ANN NY ACAD SCI, V1205, P245, DOI 10.1111/j.1749-6632.2010.05673.x; Cumming RG, 1997, AM J EPIDEMIOL, V145, P242; Dahlman-Wright K, 2006, PHARMACOL REV, V58, P773, DOI 10.1124/pr.58.4.8; Deschenes MC, 2010, INVEST OPHTH VIS SCI, V51, P2587, DOI 10.1167/iovs.09-3710; Gabriel SR, 2005, COCHRANE DB SYST REV, V18; Gagliano C, 2014, BRIT J OPHTHALMOL, V98, P371, DOI 10.1136/bjophthalmol-2012-302705; GERHARD M, 1995, CIRCULATION, V92, P5, DOI 10.1161/01.CIR.92.1.5; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Hayashi T, 2011, NITRIC OXIDE-BIOL CH, V24, P199, DOI 10.1016/j.niox.2011.04.002; Kanthan GL, 2010, ACTA OPHTHALMOL, V88, P773, DOI 10.1111/j.1755-3768.2009.01565.x; Khurana RN, 2006, AM J OPHTHALMOL, V142, P494, DOI 10.1016/j.ajo.2006.04.018; Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8; KLEIN BEK, 1994, ARCH OPHTHALMOL-CHIC, V112, P85, DOI 10.1001/archopht.1994.01090130095025; Klein BEK, 1999, DIABETES CARE, V22, P1984, DOI 10.2337/diacare.22.12.1984; Li ZJ, 2013, CORNEA, V32, P806, DOI 10.1097/ICO.0b013e31826dff30; Maki PM, 2012, CLIMACTERIC, V15, P256, DOI 10.3109/13697137.2012.660613; Ogueta SB, 1999, INVEST OPHTH VIS SCI, V40, P1906; Pasquale LR, 2013, MOL VIS, V19, P1471; Rosano G, 2012, CLIMACTERIC, V15, P299, DOI 10.3109/13697137.2012.658899; Sator MO, 1998, MATURITAS, V29, P93, DOI 10.1016/S0378-5122(97)00091-1; Sator MO, 1997, MATURITAS, V28, P55, DOI 10.1016/S0378-5122(97)00060-1; Saw S M, 1999, Ophthalmic Epidemiol, V6, P219, DOI 10.1076/opep.6.3.219.1504; Schaumberg DA, 2001, JAMA-J AM MED ASSOC, V286, P2114, DOI 10.1001/jama.286.17.2114; Tan DTH, 1997, ARCH OPHTHALMOL-CHIC, V115, P1235, DOI 10.1001/archopht.1997.01100160405001; Tint NL, 2010, MENOPAUSE, V17, P157, DOI 10.1097/gme.0b013e3181b82fb4; Tostes RC, 2003, BRAZ J MED BIOL RES, V36, P1143, DOI 10.1590/S0100-879X2003000900002; Uncu G, 2006, GYNECOL ENDOCRINOL, V22, P501, DOI 10.1080/09513590600917919	30	23	22	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2014	9	9							e106473	10.1371/journal.pone.0106473	http://dx.doi.org/10.1371/journal.pone.0106473			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AP1UA	25210892	gold, Green Published, Green Submitted			2023-01-03	WOS:000341855900012
J	MacPherson, H; Newbronner, L; Chamberlain, R; Richmond, SJ; Lansdown, H; Perren, S; Hopton, A; Spilsbury, K				MacPherson, Hugh; Newbronner, Liz; Chamberlain, Ruth; Richmond, Stewart J.; Lansdown, Harriet; Perren, Sara; Hopton, Ann; Spilsbury, Karen			Practitioner Perspectives on Strategies to Promote Longer-Term Benefits of Acupuncture or Counselling for Depression: A Qualitative Study	PLOS ONE			English	Article							SYMPTOMS; CARE	Background: Non-pharmacological interventions for depression may help patients manage their condition. Evidence from a recent large-scale trial (ACUDep) suggests that acupuncture and counselling can provide longer-term benefits for many patients with depression. This paper describes the strategies practitioners reported using to promote longer-term benefits for their patients. Methods: A qualitative sub-study of practitioners (acupuncturists and counsellors) embedded in a randomised controlled trial. Using topic guides, data was collected from telephone interviews and a focus group, altogether involving 19 counsellors and 17 acupuncturists. Data were audio recorded, transcribed verbatim and analysed using thematic content analysis. Results: For longer-term impact, both acupuncturists and counsellors encouraged insight into root causes of depression on an individual basis and saw small incremental changes as precursors to sustained benefit. Acupuncturists stressed the importance of addressing concurrent physical symptoms, for example helping patients relax or sleep better in order to be more receptive to change, and highlighted the importance of Chinese medicine theory-based lifestyle change for lasting benefit. Counsellors more often highlighted the importance of the therapeutic relationship, emphasising the need for careful "pacing'' such that the process and tools employed were tailored and timed for each individual, depending on the "readiness'' to change. Our data is limited to acupuncture practitioners using the principles of traditional Chinese medicine, and counsellors using a humanistic, non-directive and person-centred approach. Conclusions: Long-term change appears to be an important focus within the practices of both acupuncturists and counsellors. To achieve this, practitioners stressed the need for an individualised approach with a focus on root causes.	[MacPherson, Hugh; Newbronner, Liz; Richmond, Stewart J.; Lansdown, Harriet; Perren, Sara; Hopton, Ann; Spilsbury, Karen] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; [Newbronner, Liz; Chamberlain, Ruth] Firefly Res & Evaluat, Malton, N Yorkshire, England	University of York - UK	MacPherson, H (corresponding author), Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England.	hugh.macpherson@york.ac.uk		Spilsbury, Karen/0000-0002-6908-0032; MacPherson, Hugh/0000-0003-4255-4768	National Institute for Health Research (NIHR) under Programme Grants for Applied Research [RP-PG-0707-10186]; National Institute for Health Research [RP-PG-0707-10186] Funding Source: researchfish	National Institute for Health Research (NIHR) under Programme Grants for Applied Research(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	This research is supported by the National Institute for Health Research (NIHR) under Programme Grants for Applied Research (Grant No. RP-PG-0707-10186). The views expressed in this presentation are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2013, BERG GARF HDB PSYCH, P495; Bower P, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001025.pub3; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Centre for Outcomes Research & Effectiveness (CORE), HUM PSYCH THER COMP; Hannes K, 2011, GUIDANCE INCLUSION S; Katona C, 2005, CLIN MED, V5, P390, DOI 10.7861/clinmedicine.5-4-390; Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045; MacPherson H, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/286048; MacPherson H, 2006, J ALTERN COMPLEM MED, V12, P873, DOI 10.1089/acm.2006.12.873; MacPherson H, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001518; MacPherson H, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-209; Mind, 2002, MY CHOIC SURV; Parker G, 2009, BRIT J PSYCHIAT, V194, P1, DOI 10.1192/bjp.bp.108.054767; Perren S, 2009, COUNS PSYCHOTHER RES, V9, P241, DOI 10.1080/14733140903150745; Ritchie J., 2003, GUIDE SOCIAL SCI STU, V1, P77; Roth A.D., 2009, COMPETENCES REQUIRED; Simon GE, 1999, NEW ENGL J MED, V341, P1329, DOI 10.1056/NEJM199910283411801; Smith CA, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004046.pub3	18	8	8	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2014	9	9							e104077	10.1371/journal.pone.0104077	http://dx.doi.org/10.1371/journal.pone.0104077			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4JX	25198108	Green Published, Green Submitted, gold			2023-01-03	WOS:000341304700007
J	Seneviratne, CJ; Leung, KCF; Wong, CH; Lee, SF; Li, X; Leung, PC; Lau, CBS; Wat, E; Jin, LJ				Seneviratne, Chaminda Jayampath; Leung, Ken Cham-Fai; Wong, Chi-Hin; Lee, Siu-Fung; Li, Xuan; Leung, Ping Chung; Lau, Clara Bik San; Wat, Elaine; Jin, Lijian			Nanoparticle-Encapsulated Chlorhexidine against Oral Bacterial Biofilms	PLOS ONE			English	Article							IRON-OXIDE NANOPARTICLES; PORPHYROMONAS-GINGIVALIS; RESISTANCE; EFFICACY; FLUORIDE; DISEASE; MUTANS	Background: Chlorhexidine (CHX) is a widely used antimicrobial agent in dentistry. Herein, we report the synthesis of a novel mesoporous silica nanoparticle-encapsulated pure CHX (Nano-CHX), and its mechanical profile and antimicrobial properties against oral biofilms. Methodology/Principal Findings: The release of CHX from the Nano-CHX was characterized by UV/visible absorption spectroscopy. The antimicrobial properties of Nano-CHX were evaluated in both planktonic and biofilm modes of representative oral pathogenic bacteria. The Nano-CHX demonstrated potent antibacterial effects on planktonic bacteria and mono-species biofilms at the concentrations of 50-200 mu g/mL against Streptococcus mutans, Streptococcus sobrinus, Fusobacterium nucleatum, Aggregatibacter actinomycetemcomitans and Enterococccus faecalis. Moreover, Nano-CHX effectively suppressed multi-species biofilms such as S. mutans, F. nucleatum, A. actinomycetemcomitans and Porphyromonas gingivalis up to 72 h. Conclusions/Significance: This pioneering study demonstrates the potent antibacterial effects of the Nano-CHX on oral biofilms, and it may be developed as a novel and promising anti-biofilm agent for clinical use.	[Seneviratne, Chaminda Jayampath; Li, Xuan; Jin, Lijian] Univ Hong Kong, Fac Dent, Hong Kong, Hong Kong, Peoples R China; [Seneviratne, Chaminda Jayampath] Natl Univ Singapore, Fac Dent, Singapore 117548, Singapore; [Leung, Ken Cham-Fai; Wong, Chi-Hin] Hong Kong Baptist Univ, Inst Creat, Dept Chem, Hong Kong, Hong Kong, Peoples R China; [Leung, Ken Cham-Fai; Wong, Chi-Hin] Hong Kong Baptist Univ, Partner State Key Lab Environm & Biol Anal, Hong Kong, Hong Kong, Peoples R China; [Lee, Siu-Fung] Chinese Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China; [Leung, Ping Chung; Lau, Clara Bik San; Wat, Elaine] Chinese Univ Hong Kong, Inst Chinese Med, Hong Kong, Hong Kong, Peoples R China; [Leung, Ping Chung; Lau, Clara Bik San; Wat, Elaine] Chinese Univ Hong Kong, Partner State Key Lab Phytochem & Plant Resources, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; National University of Singapore; Hong Kong Baptist University; Hong Kong Baptist University; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Jin, LJ (corresponding author), Univ Hong Kong, Fac Dent, Hong Kong, Hong Kong, Peoples R China.	ljjin@hku.hk	Leung, Ken Cham-Fai/B-1764-2009; Li, Xuan/Y-5295-2019; Wong, Kristy/C-8748-2015; Lau, Clara Bik-San/AAF-3989-2020	Leung, Ken Cham-Fai/0000-0002-0349-0418; Li, Xuan/0000-0003-3785-5507; Lau, Clara Bik-San/0000-0002-7409-1270; /0000-0003-0816-538X	Hong Kong Research Grants Council [HKU767512M, 768713M]; Modern Dental Laboratory/HKU Endowment Fund	Hong Kong Research Grants Council(Hong Kong Research Grants Council); Modern Dental Laboratory/HKU Endowment Fund	This study has been supported by the General Research Fund (GRF) from the Hong Kong Research Grants Council (HKU767512M and 768713M) and the Modern Dental Laboratory/HKU Endowment Fund to LJJ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barbour Michele E, 2013, Int J Nanomedicine, V8, P3507, DOI 10.2147/IJN.S50140; Cheng L, 2012, DENT MATER, V28, P573, DOI 10.1016/j.dental.2012.01.006; Chu CH, 2012, INT J PAEDIATR DENT, V22, P2, DOI 10.1111/j.1365-263X.2011.01149.x; Cousido MC, 2010, CLIN ORAL INVEST, V14, P397, DOI 10.1007/s00784-009-0320-2; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; Darveau RP, 2012, J DENT RES, V91, P816, DOI 10.1177/0022034512453589; Garcia-Caballero L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083522; Goutham Bala Subramanya, 2013, J Int Oral Health, V5, P56; Hajishengallis G, 2011, CELL HOST MICROBE, V10, P497, DOI 10.1016/j.chom.2011.10.006; Hench LL, 1999, CERAMIC T, V101; Herath TDK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058496; Lee SF, 2013, ACS APPL MATER INTER, V5, P1566, DOI 10.1021/am4004705; Li L, 2008, J MATER CHEM, V18, P4079, DOI 10.1039/b806090h; Marsh PD, 2011, PERIODONTOL 2000, V55, P16, DOI 10.1111/j.1600-0757.2009.00339.x; Milstone AM, 2008, CLIN INFECT DIS, V46, P274, DOI 10.1086/524736; Nguyen TD, 2007, J AM CHEM SOC, V129, P626, DOI 10.1021/ja065485r; Papas AS, 2012, J DENT RES, V91, P150, DOI 10.1177/0022034511424154; SANDHAM HJ, 1992, J DENT RES, V71, P32, DOI 10.1177/00220345920710010501; Seneviratne CJ, 2013, ARCH ORAL BIOL, V58, P1327, DOI 10.1016/j.archoralbio.2013.06.017; Seneviratne CJ, 2012, PROTEOMICS, V12, P651, DOI 10.1002/pmic.201100356; Seneviratne CJ, 2011, CHIN J DENT RES, V14, P87; Shen Y, 2011, J ENDODONT, V37, P657, DOI 10.1016/j.joen.2011.02.007; Sreenivasan P, 2002, J CLIN PERIODONTOL, V29, P965, DOI 10.1034/j.1600-051X.2002.291101.x; Tomas I, 2013, J PERIODONTOL, V84, P1662, DOI 10.1902/jop.2013.120475; Varoni E, 2012, Minerva Stomatol, V61, P399; Wang DW, 2013, J MATER CHEM B, V1, P2934, DOI 10.1039/c3tb20090f; Wang HH, 2009, CHEM-EUR J, V15, P12417, DOI 10.1002/chem.200901548; Wang YXJ, 2011, MATERIALS, V4, P703, DOI 10.3390/ma4040703; Wilson M, 1996, J MED MICROBIOL, V44, P79, DOI 10.1099/00222615-44-2-79; Xuan SH, 2012, ACS APPL MATER INTER, V4, P2033, DOI 10.1021/am300008x; Xuan SH, 2011, CHEM COMMUN, V47, P2514, DOI 10.1039/c0cc05390b; Yamaguchi M, 2013, EUR J ORAL SCI, V121, P162, DOI 10.1111/eos.12050; Zhu XM, 2012, INT J NANOMED, V7, P953, DOI 10.2147/IJN.S28316	33	47	50	5	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2014	9	8							e103234	10.1371/journal.pone.0103234	http://dx.doi.org/10.1371/journal.pone.0103234			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO2EE	25170958	Green Published, Green Submitted, gold			2023-01-03	WOS:000341127500010
J	Wang, SM; Lai, MN; Wei, A; Chen, YY; Pu, YS; Chen, PC; Wang, JD				Wang, Shuo-Meng; Lai, Ming-Nan; Wei, Alan; Chen, Ya-Yin; Pu, Yeong-Shiau; Chen, Pau-Chung; Wang, Jung-Der			Increased Risk of Urinary Tract Cancer in ESRD Patients Associated with Usage of Chinese Herbal Products Suspected of Containing Aristolochic Acid	PLOS ONE			English	Article							TRANSITIONAL-CELL-CARCINOMA; DISEASE ENDEMIC AREA; BLADDER-CANCER; UROTHELIAL CARCINOMA; MALIGNANT NEOPLASMS; DIALYSIS PATIENTS; TAIWAN; NEPHROPATHY; ANALGESICS; RESIDENTS	Introduction: Both end-stage renal disease (ESRD) and urothelial cancer (UC) are associated with the consumption of Chinese herbal products containing aristolochic acid (AA) by the general population. The objective of this study was to determine the risk of UC associated with AA-related Chinese herbal products among ESRD patients. Methods: We conducted a cohort study using the National Health Insurance reimbursement database to enroll all ESRD patients in Taiwan from 1998-2002. Cox regression models were constructed and hazard ratios and confidence intervals were estimated after controlling for potential confounders, including age, sex, residence in region with endemic black foot disease, urinary tract infection, and use of non-steroidal anti-inflammatory drugs and acetaminophen. Results: A total of 38,995 ESRD patients were included in the final analysis, and 320 patients developed UC after ESRD. Having been prescribed Mu Tong that was adulterated with Guan Mu Tong (Aristolochia manshuriensis) before 2004, or an estimated consumption of more than 1-100 mg of aristolochic acid, were both associated with an increased risk of UC in the multivariable analyses. Analgesic consumption of more than 150 pills was also associated with an increased risk of UC, although there was little correlation between the two risk factors. Conclusion: Consumption of aristolochic acid-related Chinese herbal products was associated with an increased risk of developing UC in ESRD patients. Regular follow-up screening for UC in ESRD patients who have consumed Chinese herbal products is thus necessary.	[Wang, Shuo-Meng; Chen, Ya-Yin; Pu, Yeong-Shiau] Natl Taiwan Univ Hosp, Dept Urol, Taipei, Taiwan; [Lai, Ming-Nan; Chen, Ya-Yin] Feng Chia Univ, Dept Stat, Taichung 40724, Taiwan; [Wei, Alan] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA; [Wang, Shuo-Meng; Chen, Pau-Chung] Natl Taiwan Univ, Coll Publ Hlth, Inst Occupat Med & Ind Hyg, Taipei 10764, Taiwan; [Wang, Jung-Der] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan 70101, Taiwan; [Wang, Jung-Der] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan 70428, Taiwan; [Wang, Jung-Der] Natl Cheng Kung Univ Hosp, Dept Occupat & Environm Med, Tainan 70428, Taiwan	National Taiwan University; National Taiwan University Hospital; Feng Chia University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; National Taiwan University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital	Wang, JD (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan 70101, Taiwan.	jdwang121@gmail.com	Chen, Pau-Chung/H-5686-2011	Chen, Pau-Chung/0000-0002-6242-5974; WANG, SHUO-MENG/0000-0003-2090-1757; PU, YEONG-SHIAU/0000-0002-2859-3966	National Health Research Institutes of Taiwan [EO-100-EO-PP04]; Headquarters of University Advancement at the National Cheng Kung University	National Health Research Institutes of Taiwan(National Health Research Institutes - Taiwan); Headquarters of University Advancement at the National Cheng Kung University	This study was supported by the National Health Research Institutes of Taiwan (intramural project EO-100-EO-PP04), and a grant from the Headquarters of University Advancement at the National Cheng Kung University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achenbach H, 1997, PLANTA MED, V63, P579, DOI 10.1055/s-2006-957777; [Anonymous], 2008, CANC INCIDENCE RATE; [Anonymous], 2009, TAIWANYEARBOOK; Arlt VM, 2002, MUTAGENESIS, V17, P265, DOI 10.1093/mutage/17.4.265; Centers for Disease Control and Prevention, 2009, INT CLASS DIS; Chang CH, 2007, CANCER-AM CANCER SOC, V109, P1487, DOI 10.1002/cncr.22557; CHEN CJ, 1986, BRIT J CANCER, V53, P399, DOI 10.1038/bjc.1986.65; CHEN CJ, 1985, CANCER RES, V45, P5895; CHEN KS, 1995, AM J KIDNEY DIS, V25, P694, DOI 10.1016/0272-6386(95)90544-8; CHIANG HS, 1993, BRIT J UROL, V71, P274, DOI 10.1111/j.1464-410X.1993.tb15942.x; Chiou HY, 2001, AM J EPIDEMIOL, V153, P411, DOI 10.1093/aje/153.5.411; Chuang CH, 2002, ACTA NEPHROLOGICA, V16, P19; Chuang MS, 2002, ANN REPT NLFD TAIWAN, V20, P104; Committee Chinese Medicine and Pharmacy DOH-T, 2002, UN FORM; Cosyns JP, 2003, DRUG SAFETY, V26, P33, DOI 10.2165/00002018-200326010-00004; Cosyns JP, 1999, AM J KIDNEY DIS, V33, P1011, DOI 10.1016/S0272-6386(99)70136-8; DENG JS, 2002, THESIS CHINA MED U T, P75; Gago-Dominguez M, 1999, BRIT J CANCER, V81, P542, DOI 10.1038/sj.bjc.6690728; GONWA TA, 1980, ANN INTERN MED, V93, P249, DOI 10.7326/0003-4819-93-2-249; Groah SL, 2002, ARCH PHYS MED REHAB, V83, P346, DOI 10.1053/apmr.2002.29653; Hsieh SC, 2008, PHARMACOEPIDEM DR S, V17, P609, DOI 10.1002/pds.1611; Hsu YH, 2003, ANN REPT NLFD TAIWAN, V21, P153; Hsu YH, 1997, ANN REPT NLFD TAIWAN, V15, P136; Jiang X, 2009, BRIT J CANCER, V100, P834, DOI 10.1038/sj.bjc.6604889; Johansson SL, 1997, SEMIN SURG ONCOL, V13, P291; Jong TT, 2003, J PHARMACEUT BIOMED, V33, P831, DOI 10.1016/S0731-7085(03)00310-8; KJELLSTRAND CM, 1979, NEPHRON, V23, P159, DOI 10.1159/000181627; Kliem V, 1996, TRANSPLANT INT, V9, P231, DOI 10.1111/j.1432-2277.1996.tb00885.x; Lai MN, 2010, JNCI-J NATL CANCER I, V102, P179, DOI 10.1093/jnci/djp467; Maisonneuve P, 1999, LANCET, V354, P93, DOI 10.1016/S0140-6736(99)06154-1; MATAS AJ, 1975, LANCET, V1, P883; NHRI-Taiwan, 2003, NAT HLTH RES DAT; Nortier JL, 2000, NEW ENGL J MED, V342, P1686, DOI 10.1056/NEJM200006083422301; Ou JH, 2000, EUR UROL, V37, P90, DOI 10.1159/000020106; PERNEGER TV, 1994, NEW ENGL J MED, V331, P1675, DOI 10.1056/NEJM199412223312502; PORT FK, 1989, AM J KIDNEY DIS, V14, P119, DOI 10.1016/S0272-6386(89)80187-8; Swindle P, 1998, BRIT J UROL, V81, P229; TaiwanCancerRegistry, 2009, CANC INC RAT TAIW 19; Tung C, 1999, CHIN MED COLL J, P35; VANHAELEN M, 1994, LANCET, V343, P174, DOI 10.1016/S0140-6736(94)90964-4; Vanherweghem JL, 1998, J ALTERN COMPLEM MED, V4, P9, DOI 10.1089/acm.1998.4.1-9; VANHERWEGHEM JL, 1993, LANCET, V341, P387, DOI 10.1016/0140-6736(93)92984-2; Wiessler M., 1994, V125, P165	43	18	18	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2014	9	8							e105218	10.1371/journal.pone.0105218	http://dx.doi.org/10.1371/journal.pone.0105218			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO2EE	25170766	Green Published, gold, Green Submitted			2023-01-03	WOS:000341127500036
J	Mccoy, SI; Buzdugan, R; Ralph, LJ; Mushavi, A; Mahomva, A; Hakobyan, A; Watadzaushe, C; Dirawo, J; Cowan, FM; Padian, NS				McCoy, Sandra I.; Buzdugan, Raluca; Ralph, Lauren J.; Mushavi, Angela; Mahomva, Agnes; Hakobyan, Anna; Watadzaushe, Constancia; Dirawo, Jeffrey; Cowan, Frances M.; Padian, Nancy S.			Unmet Need for Family Planning, Contraceptive Failure, and Unintended Pregnancy among HIV-Infected and HIV-Uninfected Women in Zimbabwe	PLOS ONE			English	Article							TRANSMISSION; FERTILITY	Background: Prevention of unintended pregnancies among women living with HIV infection is a strategy recommended by the World Health Organization for prevention of mother-to-child transmission of HIV (PMTCT). We assessed pregnancy intentions and contraceptive use among HIV-positive and HIV-negative women with a recent pregnancy in Zimbabwe. Methods: We analyzed baseline data from the evaluation of Zimbabwe's Accelerated National PMTCT Program. Eligible women were randomly sampled from the catchment areas of 157 health facilities offering PMTCT services in five provinces. Eligible women were >= 16 years old and mothers of infants (alive or deceased) born 9 to 18 months prior to the interview. Participants were interviewed about their HIV status, intendedness of the birth, and contraceptive use. Results: Of 8,797 women, the mean age was 26.7 years, 92.8% were married or had a regular sexual partner, and they had an average of 2.7 lifetime births. Overall, 3,090 (35.1%) reported that their births were unintended; of these women, 1,477 (47.8%) and 1,613 (52.2%) were and were not using a contraceptive method prior to learning that they were pregnant, respectively. Twelve percent of women reported that they were HIV-positive at the time of the survey; women who reported that they were HIV-infected were significantly more likely to report that their pregnancy was unintended compared to women who reported that they were HIV-uninfected (44.9% vs. 33.8%, p<0.01). After adjustment for covariates, among women with unintended births, there was no association between self-reported HIV status and lack of contraception use prior to pregnancy. Conclusions: Unmet need for family planning and contraceptive failure contribute to unintended pregnancies among women in Zimbabwe. Both HIV-infected and HIV-uninfected women reported unintended pregnancies despite intending to avoid or delay pregnancy, highlighting the need for effective contraceptive methods that align with pregnancy intentions.	[McCoy, Sandra I.; Buzdugan, Raluca; Ralph, Lauren J.; Padian, Nancy S.] Univ Calif Berkeley, Berkeley, CA 94720 USA; [Mushavi, Angela] Minist Hlth & Child Care, Harare, Zimbabwe; [Mahomva, Agnes] Elizabeth Glaser Pediat AIDS Fdn, Harare, Zimbabwe; [Hakobyan, Anna] Childrens Investment Fund Fdn, London, England; [Watadzaushe, Constancia; Dirawo, Jeffrey; Cowan, Frances M.] Ctr Sexual Hlth & HIV Res, Harare, Zimbabwe; [Cowan, Frances M.] UCL, London, England	University of California System; University of California Berkeley; University of London; University College London	Mccoy, SI (corresponding author), Univ Calif Berkeley, Berkeley, CA 94720 USA.	smccoy@berkeley.edu		Cowan, Frances/0000-0003-3087-4422	Children's Investment Fund Foundation (CIFF); National Institute of Mental Health [K01MH094246]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD080492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K01MH094246] Funding Source: NIH RePORTER	Children's Investment Fund Foundation (CIFF); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The evaluation of Zimbabwe's Accelerated National PMTCT Program was supported by the Children's Investment Fund Foundation (CIFF, www.ciff.org) in a grant to NSP. AH (from CIFF) contributed to the study and is included as a co-author. SIM is supported by Award Number K01MH094246 from the National Institute of Mental Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health. The funders had no role in data collection and analysis or the decision to publish. AH (from CIFF) participated in designing the impact evaluation and preparation of this manuscript.	AHPRA, 2012, 201112 ANN REP AHPR; [Anonymous], 2020, HIGH POSS COST COVID; Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21; Brown S.S., 1995, BEST INTENTIONS UNIN; Buzdugan R, 2013, 7 IAS C HIV PATH TRE; Espey E, 2011, OBSTET GYNECOL, V117, P705, DOI 10.1097/AOG.0b013e31820ce2f0; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; GREENLAND S, 1987, AM J EPIDEMIOL, V125, P761, DOI 10.1093/oxfordjournals.aje.a114593; Grieser M, 2001, J S AFR STUD, V27, P225, DOI 10.1080/03057070120049949; Hayford SR, 2012, STUD FAMILY PLANN, V43, P191, DOI 10.1111/j.1728-4465.2012.00317.x; Hladik W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007691; Hubacher D, 2008, CONTRACEPTION, V78, P73, DOI 10.1016/j.contraception.2008.03.002; Inter-agency task team for prevention and treatment of HIV infection in preg-nant women m and their children, 2012, PREV HIV UN PREGN ST; Jhangri GS, 2012, J FAM PLAN REPROD H, V38, P23, DOI 10.1136/jfprhc-2011-0108; Koenig MA, 2006, POP STUD-J DEMOG, V60, P243, DOI 10.1080/00324720600895819; Kolenikov S, 2004, USE DISCRETE DATA PR; Kutner M.H., 2005, APPL LINEAR STAT MOD; Mahy M, 2010, SEX TRANSM INFECT, V86, pI48, DOI 10.1136/sti.2010.045989; Petruney Tricia, 2008, Bull World Health Organ, V86, pb; Policar M., 2011, CONTRACEPTIVE TECHNO; Reynolds HW, 2008, SEX TRANSM INFECT, V84, pII49, DOI 10.1136/sti.2008.030049; Reynolds HW, 2006, SEX TRANSM DIS, V33, P350, DOI 10.1097/01.olq.0000194602.01058.e1; Reynolds HW, 2005, SEX TRANSM INFECT, V81, P184, DOI 10.1136/sti.2004.012013; Robinson Jennifer A, 2012, Infect Dis Obstet Gynecol, V2012, P890160, DOI 10.1155/2012/890160; Santelli J, 2003, PERSPECT SEX REPRO H, V35, P94, DOI 10.1363/3509403; Schaan MM, 2012, AIDS CARE, V24, P1120, DOI 10.1080/09540121.2012.672814; Schwartz SR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036039; Singh S, 2012, ADDING IT COSTS BENE; Sweat MD, 2004, AIDS, V18, P1661, DOI 10.1097/01.aids.0000131353.06784.8f; Trinitapoli J, 2011, AM SOCIOL REV, V76, P935, DOI 10.1177/0003122411427672; Trussell J, 2007, CONTRACEPTIVE TECHNO, P221; UNAIDS, 2012, REP GLOB AIDS EP; UNAIDS, 2010, REP GLOB AIDS EP; United Nations Department of Economic and Social Affairs Population Division, 2011, WORLD CONTR US 2011; Vyas S, 2006, HEALTH POLICY PLANN, V21, P459, DOI 10.1093/heapol/czl029; Wanyenze RK, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-98; *WHO, 2009, RAP ADV US ANT DRUGS; WHO UNAIDS Unicef, 2011, GLOB HIV AIDS RESP E; Wilcher R, 2008, SEX TRANSM INFECT, V84, pII54, DOI 10.1136/sti.2008.030098; World Health Organization, 2011, WHO UNICEF EST NAT I; World Health Organization, 2012, PROGR UPD US ANT DRU; World Health Organization, 2007, GUID GLOB SCAL UP PR; World Health Organization, 2021, ANT DRUGS TREAT PREG; World Health Organization (WHO), 2012, TRENDS MAT MORT 1990; Yamey G, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e4160; Zimbabwe Ministry of Health and Child Welfare, 2012, NAT SEX REPR HLTH PO; Zimbabwe National Family Planning Council (ZNFPC), ZIMB NAT FAM PLANN S; Zocchetti C, 1997, INT J EPIDEMIOL, V26, P220, DOI 10.1093/ije/26.1.220	48	52	52	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2014	9	8							e105320	10.1371/journal.pone.0105320	http://dx.doi.org/10.1371/journal.pone.0105320			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AO1WL	25144229	Green Published, Green Submitted, gold			2023-01-03	WOS:000341106100052
J	Nunes, JC; Braz, JRC; Oliveira, TS; de Carvalho, LR; Castiglia, YMM; Braz, LG				Nunes, Juscimar C.; Braz, Jose R. C.; Oliveira, Thais S.; de Carvalho, Lidia R.; Castiglia, Yara M. M.; Braz, Leandro G.			Intraoperative and Anesthesia-Related Cardiac Arrest and Its Mortality in Older Patients: A 15-Year Survey in a Tertiary Teaching Hospital	PLOS ONE			English	Article							THAI; DEATH	Background: Little information is known about factors that influence perioperative and anesthesia-related cardiac arrest (CA) in older patients. This study evaluated the incidence, causes and outcome of intraoperative and anesthesia-related CA in older patients in a Brazilian teaching hospital between 1996 and 2010. Methods: During the study, older patients received 18,367 anesthetics. Data collected included patient characteristics, surgical procedures, American Society of Anesthesiologists (ASA) physical status, anesthesia type, medical specialty team and outcome. All CAs were categorized by cause into one of four groups: patient's disease/condition-related, surgery-related, totally anesthesia-related or partially anesthesia-related. Results: All intraoperative CAs and deaths rates are shown per 10,000 anesthetics. There were 100 CAs (54.44; 95% confidence intervals [CI]: 44.68-64.20) and 68 deaths (37.02; 95% CI: 27.56-46.48). The majority of CAs were patient's disease-/condition-related (43.5; 95% CI: 13.44-73.68). There were six anesthesia-related CAs (3.26; 95% CI: 0.65-5.87) -1 totally and 5 partially anesthesia-related, and three deaths, all partially anesthesia-related (1.63; 95% CI: 0.0-3.47). ASA I-II physical status patients presented no anesthesia-related CA. Anesthesia-related CA, absent in the last five years of the study, was due to medication-/airway-related causes. ASA physical status was the most important predictor of CA (odds ratio: 14.52; 95% CI: 4.48-47.08; P<0.001) followed by emergency surgery (odds ratio: 8.07; 95% CI: 5.14-12.68; P<0.001). Conclusions: The study identified high incidence of intraoperative CAs with high mortality in older patients. The large majority of CAs were caused by factors not anesthesia-related. Anesthesia-related CA and mortality rates were 3.26 and 1.63 per 10,000 anesthetics, with no anesthesia-related CA in the last five years of the study. Major predictors of intraoperative CAs were poorer ASA physical status and emergency surgery. All anesthesia-related CAs were medication-related or airway-related, which is important for prevention strategies.	[Nunes, Juscimar C.; Braz, Jose R. C.; Oliveira, Thais S.; Castiglia, Yara M. M.; Braz, Leandro G.] Univ Estadual Paulista, Botucatu Med Sch, Dept Anesthesiol, Botucatu, SP, Brazil; [de Carvalho, Lidia R.] Univ Estadual Paulista, Inst Biosci, Dept Biostat, Botucatu, SP, Brazil	Universidade Estadual Paulista; Universidade Estadual Paulista	Braz, LG (corresponding author), Univ Estadual Paulista, Botucatu Med Sch, Dept Anesthesiol, Botucatu, SP, Brazil.	lbraz@fmb.unesp.br	Carvalho, L.R./C-2973-2013; Braz, Leandro/AAK-8378-2021; Braz, Leandro Gobbo/W-4445-2019	Carvalho, L.R./0000-0003-0575-2263; Braz, Leandro Gobbo/0000-0002-1927-8729	CAPES/DINTER; PIBIC/CNPq	CAPES/DINTER; PIBIC/CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	J.C. Nunes was granted a scholarship from CAPES/DINTER and T.S. Oliveira was granted a scholarship from PIBIC/CNPq. CAPES and CNPq are Brazilian governmental agencies dedicated to promoting scientific research.	AUBAS S, 1991, ANN FR ANESTH, V10, P436, DOI 10.1016/S0750-7658(05)80846-9; Bainbridge D, 2012, LANCET, V380, P1075, DOI 10.1016/S0140-6736(12)60990-8; Biboulet P, 2001, CAN J ANAESTH, V48, P326, DOI 10.1007/BF03014958; Bishop MJ, 2008, ANESTH ANALG, V107, P1924, DOI 10.1213/ane.0b013e31818af8f3; Braz LG, 2009, CLINICS, V64, P999, DOI 10.1590/S1807-59322009001000011; Braz LG, 2006, BRIT J ANAESTH, V96, P569, DOI 10.1093/bja/ael065; Deshpande JK, 2011, ANESTH ANALG, V112, P1259, DOI 10.1213/ANE.0b013e3182182199; Ellis SJ, 2014, ANESTHESIOLOGY, V120, P829, DOI 10.1097/ALN.0000000000000153; Goswami S, 2012, ANESTHESIOLOGY, V117, P1018, DOI 10.1097/ALN.0b013e31827005e9; Kawashima Yasuo, 2002, J Anesth, V16, P319; Kehlet H, 2008, ANN SURG, V248, P189, DOI 10.1097/SLA.0b013e31817f2c1a; KUBOTA Y, 1994, J CLIN ANESTH, V6, P227, DOI 10.1016/0952-8180(94)90064-7; MARX GF, 1973, ANESTHESIOLOGY, V39, P54, DOI 10.1097/00000542-197307000-00010; MOLLER IW, 1984, BRIT J ANAESTH, V56, P1191, DOI 10.1093/bja/56.11.1191; Morray JP, 2011, PEDIATR ANESTH, V21, P722, DOI 10.1111/j.1460-9592.2010.03440.x; OLSSON GL, 1988, ACTA ANAESTH SCAND, V32, P653, DOI 10.1111/j.1399-6576.1988.tb02804.x; Pearse RM, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5759; Rodanant Oraluxna, 2007, Journal of the Medical Association of Thailand, V90, P1375; Rooke GA, 2003, J CARDIOTHOR VASC AN, V17, P512, DOI 10.1016/S1053-0770(03)00161-7; Silva E, 2012, MINERVA ANESTESIOL, V78, P1215; Story DA, 2010, ANAESTHESIA, V65, P1022, DOI 10.1111/j.1365-2044.2010.06478.x; Tamdee Decha, 2009, Journal of the Medical Association of Thailand, V92, P198; Tuchinda Lawan, 2010, Journal of the Medical Association of Thailand, V93, P698; Ward SA, 2011, BEST PRACT RES-CLIN, V25, P305, DOI 10.1016/j.bpa.2011.05.002	24	37	40	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2014	9	8							e104041	10.1371/journal.pone.0104041	http://dx.doi.org/10.1371/journal.pone.0104041			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO3LJ	25117481	Green Published, gold, Green Submitted			2023-01-03	WOS:000341230400028
J	Schachter, B				Schachter, Beth			Therapies of the state	NATURE BIOTECHNOLOGY			English	Article								What can governmental agencies do to lower the risk of cell therapies and the enterprises commercializing them?										Alliance for Regenerative Medicine, 2014, 2014 REG MED ANN IND; Giebel LB, 2005, NAT BIOTECHNOL, V23, P798, DOI 10.1038/nbt0705-798	2	14	14	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2014	32	8					736	741		10.1038/nbt.2984	http://dx.doi.org/10.1038/nbt.2984			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	AW7PF	25093881				2023-01-03	WOS:000346455900012
J	Vilela, FMP; Syed, DN; Chamcheu, JC; Calvo-Castro, LA; Fortes, VS; Fonseca, MJV; Mukhtar, H				Pinto Vilela, Fernanda Maria; Syed, Deeba N.; Chamcheu, Jean Christopher; Calvo-Castro, Laura A.; Fortes, Vanessa Silveira; Vieira Fonseca, Maria Jose; Mukhtar, Hasan			Biotransformed Soybean Extract (BSE) Inhibits Melanoma Cell Growth and Viability In Vitro: Involvement of Nuclear Factor-Kappa B Signaling	PLOS ONE			English	Article							CANCER CHEMOPREVENTION; BETA-GLUCOSIDASE; INDUCED APOPTOSIS; SKIN-CANCER; ISOFLAVONES; ACTIVATION; PATHWAY; KERATINOCYTES; FISETIN; TRAIL	Melanoma is recognized as one of the most aggressive cancers with a relatively high propensity for metastasis. The prognosis of melanoma remains poor in spite of treatment advances, emphasizing the importance of additional preventive measures. Isoflavonoids have become not only potential chemopreventive, but also important therapeutic natural agents. We evaluated the antiproliferative and proapoptotic properties of biotransformed soybean extract (BSE) in A375 melanoma cells. Previous analyses demonstrated that the concentration of daidzein, genistein and aminoacids/peptides present in BSE, fermented by Aspergillus awamori is much higher than in the non biotransformed extract (NBSE). Experiments comparing the efficacy of the extracts in preventing cancer cell growth showed that treatment (24 h) of aggressive melanoma cells (A375 and 451Lu) with BSE resulted in a dose-dependent inhibition of growth and viability. In contrast, treatment with similar doses of NBSE failed to inhibit melanoma cell viability. Further studies in A375 cells showed that decrease in cell viability with BSE treatment (1.5-1.9 mg/ml; 24 h) was associated with induction of apoptosis. Immunoblot analysis revealed that BSE treatment resulted in induction of PARP cleavage, activation of caspase-3, -7, and -8 and increased expression of TRAIL and its receptor DR4. BSE did not activate the intrinsic apoptotic pathway in A375 cells, as no change was observed in caspase-9 expression. The expression of Bcl-2 apoptotic proteins such as Bid and Bax remained unaffected with BSE treated cells. Interestingly, we also showed that BSE treatment increased the phosphorylation and activation of IKK, I kappa B alpha degradation and p65/NF-kappa B translocation to the nucleus, and that stimulation of the NF-??? B pathway was required for BSE-induced apoptosis of A375 cells. Our findings indicate that the biotransformation of soybean plays a crucial role in the extract anti-cancer effect observed in melanoma cells. However, further studies are warranted to define the active anticancer agent(s) present in BSE.	[Pinto Vilela, Fernanda Maria; Fortes, Vanessa Silveira; Vieira Fonseca, Maria Jose] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil; [Pinto Vilela, Fernanda Maria; Syed, Deeba N.; Chamcheu, Jean Christopher; Mukhtar, Hasan] Univ Wisconsin, Dept Dermatol, Madison, WI USA; [Calvo-Castro, Laura A.] Inst Tecnol Costa Rica, Ctr Invest Biotecnol, Cartago, Costa Rica	Universidade de Sao Paulo; University of Wisconsin System; University of Wisconsin Madison; Instituto Tecnologico de Costa Rica	Mukhtar, H (corresponding author), Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil.	hmukhtar@wisc.edu	Vilela, Fernanda/P-3538-2015; Chamcheu, Jean Christopher/J-5451-2018	Chamcheu, Jean Christopher/0000-0002-3927-5664; Calvo-Castro, Laura A./0000-0001-5101-9105	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES, Brazil); CNPQ [200450/2012-3]; NATIONAL CANCER INSTITUTE [P30CA014520] Funding Source: NIH RePORTER	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES, Brazil)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CNPQ(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors are grateful to Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil), and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES, Brazil) for the research fellowship. F. M. P. Vilela was the recipient of a CNPQ fellowship (process # 200450/2012-3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AFAQ F, 2005, MUTAT RES, V57, P1153; Afaq F, 2007, J INVEST DERMATOL, V127, P222, DOI 10.1038/sj.jid.5700510; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Calvo-Castro L, 2013, PHOTOCHEM PHOTOBIOL, V89, P1199, DOI 10.1111/php.12104; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Chen F, 2003, J CELL BIOCHEM, V90, P732, DOI 10.1002/jcb.10668; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Einspahr JG, 2003, RECENT RESULTS CANC, V163, P151; F'guyer S, 2003, PHOTODERMATOL PHOTO, V19, P56, DOI 10.1034/j.1600-0781.2003.00019.x; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Georgetti SR, 2009, J APPL MICROBIOL, V106, P459, DOI 10.1111/j.1365-2672.2008.03978.x; Hsieh MC, 2001, PHYTOCHEMISTRY, V58, P995, DOI 10.1016/S0031-9422(01)00380-6; Huang Y, 2000, CANCER RES, V60, P4426; Khan N, 2008, CARCINOGENESIS, V29, P1049, DOI 10.1093/carcin/bgn078; Kim SB, 2006, FEBS LETT, V580, P311, DOI 10.1016/j.febslet.2005.12.012; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Kurbanov BM, 2007, ONCOGENE, V26, P3364, DOI 10.1038/sj.onc.1210134; Lens MB, 2004, BRIT J DERMATOL, V150, P179, DOI 10.1111/j.1365-2133.2004.05708.x; Lin JK, 2002, ARCH PHARM RES, V25, P561, DOI 10.1007/BF02976924; McCue P., 2004, Innovative Food Science & Emerging Technologies, V5, P385, DOI 10.1016/j.ifset.2004.05.003; Otieno DO, 2006, FOOD RES INT, V39, P394, DOI 10.1016/j.foodres.2005.08.010; Sarkar FH, 2004, FRONT BIOSCI-LANDMRK, V9, P2714, DOI 10.2741/1430; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Stark LA, 2001, FASEB J, V15, P1273, DOI 10.1096/fj.00-0529fje; Stark LA, 2007, CARCINOGENESIS, V28, P968, DOI 10.1093/carcin/bgl220; Syed DN, 2007, ONCOGENE, V26, P673, DOI 10.1038/sj.onc.1209829; Syed DN, 2011, J INVEST DERMATOL, V131, P1291, DOI 10.1038/jid.2011.6; Szliszka E, 2011, ONCOL REP, V26, P533, DOI 10.3892/or.2011.1332; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Wang HZ, 2002, J NUTR BIOCHEM, V13, P421, DOI 10.1016/S0955-2863(02)00184-5; Waters JP, 2013, J PATHOL, V230, P241, DOI 10.1002/path.4188; Yin LJ, 2005, BIOSCI BIOTECH BIOCH, V69, P267, DOI 10.1271/bbb.69.267	32	6	6	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2014	9	7							e103248	10.1371/journal.pone.0103248	http://dx.doi.org/10.1371/journal.pone.0103248			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4KU	25072850	gold, Green Published, Green Submitted			2023-01-03	WOS:000341307600035
J	Kim, Y; Lee, HG; Dmitrieva, N; Kim, J; Kaur, B; Friedman, A				Kim, Yangjin; Lee, Hyun Geun; Dmitrieva, Nina; Kim, Junseok; Kaur, Balveen; Friedman, Avner			Choindroitinase ABC I-Mediated Enhancement of Oncolytic Virus Spread and Anti Tumor Efficacy: A Mathematical Model	PLOS ONE			English	Article							CHONDROITIN-SULFATE PROTEOGLYCANS; VESICULAR STOMATITIS-VIRUS; EXTRACELLULAR-MATRIX; INTRATUMORAL SPREAD; CELL-PROLIFERATION; MALIGNANT GLIOMAS; HYALURONIC-ACID; VIRAL THERAPY; HYBRID MODEL; BRAIN	Oncolytic viruses are genetically engineered viruses that are designed to kill cancer cells while doing minimal damage to normal healthy tissue. After being injected into a tumor, they infect cancer cells, multiply inside them, and when a cancer cell is killed they move on to spread and infect other cancer cells. Chondroitinase ABC (Chase-ABC) is a bacterial enzyme that can remove a major glioma ECM component, chondroitin sulfate glycosoamino glycans from proteoglycans without any deleterious effects in vivo. It has been shown that Chase-ABC treatment is able to promote the spread of the viruses, increasing the efficacy of the viral treatment. In this paper we develop a mathematical model to investigate the effect of the Chase-ABC on the treatment of glioma by oncolytic viruses (OV). We show that the model's predictions agree with experimental results for a spherical glioma. We then use the model to test various treatment options in the heterogeneous microenvironment of the brain. The model predicts that separate injections of OV, one into the center of the tumor and another outside the tumor will result in better outcome than if the total injection is outside the tumor. In particular, the injection of the ECM-degrading enzyme (Chase-ABC) on the periphery of the main tumor core need to be administered in an optimal strategy in order to infect and eradicate the infiltrating glioma cells outside the tumor core in addition to proliferative cells in the bulk of tumor core. The model also predicts that the size of tumor satellites and distance between the primary tumor and multifocal/satellite lesions may be an important factor for the efficacy of the viral therapy with Chase treatment.	[Kim, Yangjin; Friedman, Avner] Ohio State Univ, Dept Math, Columbus, OH 43210 USA; [Dmitrieva, Nina; Kaur, Balveen] Ohio State Univ, Dept Neurol Surg, Columbus, OH 43210 USA; [Friedman, Avner] Ohio State Univ, Math Biosci Inst, Columbus, OH 43210 USA; [Kim, Junseok] Korea Univ, Dept Math, Seoul, South Korea; [Kim, Yangjin] Konkuk Univ, Dept Math, Seoul, South Korea	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Korea University; Konkuk University	Kim, Y (corresponding author), Ohio State Univ, Dept Math, 231 W 18th Ave, Columbus, OH 43210 USA.	ahyouhappy@gmail.com	Kim, Junseok/AAH-5349-2019; Kim, Yangjin/C-9681-2014; kaur, Balveen/E-3355-2011	Kim, Yangjin/0000-0002-8905-8481; Kim, Junseok/0000-0002-0484-9189	Konkuk University; NATIONAL CANCER INSTITUTE [R01CA150153, P01CA163205] Funding Source: NIH RePORTER	Konkuk University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the faculty research fund of Konkuk University in 2013. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ananthanarayanan B, 2011, BIOMATERIALS, V32, P7913, DOI 10.1016/j.biomaterials.2011.07.005; Arslan F, 2007, BRIT J CANCER, V96, P1560, DOI 10.1038/sj.bjc.6603766; Aubert M, 2006, PHYS BIOL, V3, P93, DOI 10.1088/1478-3975/3/2/001; Badoual M, 2010, PHYS BIOL, V7, DOI 10.1088/1478-3975/7/4/046013; Balachandran S, 2001, J VIROL, V75, P3474, DOI 10.1128/JVI.75.7.3474-3479.2001; Barcellos-Hoff MH, 2009, SEMIN RADIAT ONCOL, V19, P163, DOI 10.1016/j.semradonc.2009.02.004; Beadle C, 2008, MOL BIOL CELL, V19, P3357, DOI 10.1091/mbc.E08-03-0319; Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; BIGNAMI A, 1993, ANAT EMBRYOL, V188, P419; Black PC, 2007, UROL ONCOL-SEMIN ORI, V25, P433, DOI 10.1016/j.urolonc.2007.05.011; Bruckner G, 1998, EXP BRAIN RES, V121, P300, DOI 10.1007/s002210050463; Chauviere A, 2010, MATH MED BIOL, V27, P255, DOI 10.1093/imammb/dqp021; Cheema TA, 2013, P NATL ACAD SCI USA, V110, P12006, DOI 10.1073/pnas.1307935110; Choi IK, 2010, GENE THER, V17, P190, DOI 10.1038/gt.2009.142; CHOUCAIR AK, 1986, J NEUROSURG, V65, P654, DOI 10.3171/jns.1986.65.5.0654; Connor JH, 2004, J VIROL, V78, P8960, DOI 10.1128/JVI.78.17.8960-8970.2004; Corwin D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079115; Daginakatte GC, 2007, HUM MOL GENET, V16, P1098, DOI 10.1093/hmg/ddm059; DAHL D, 1982, J HISTOCHEM CYTOCHEM, V30, P912, DOI 10.1177/30.9.6182187; Davis F G, 2001, Expert Rev Anticancer Ther, V1, P395, DOI 10.1586/14737140.1.3.395; DELPECH B, 1993, EUR J CANCER, V29A, P1012, DOI 10.1016/S0959-8049(05)80214-X; Dmitrieva N, 2011, CLIN CANCER RES, V17, P1362, DOI 10.1158/1078-0432.CCR-10-2213; Dutt S, 2006, J BIOL CHEM, V281, P12123, DOI 10.1074/jbc.M510834200; Dutt S, 2006, THESCIENTIFICWORLDJO, V6, P1114, DOI 10.1100/tsw.2006.219; Dwyer CA, 2011, MOL TARGETS CNS TUMO, P239; Eikenes L, 2004, CANCER RES, V64, P4768, DOI 10.1158/0008-5472.CAN-03-1472; Friedman A, 2006, CANCER RES, V66, P2314, DOI 10.1158/0008-5472.CAN-05-2661; FRYER HJL, 1992, J BIOL CHEM, V267, P9874; Gerin C, 2012, CELL PROLIFERAT, V45, P76, DOI 10.1111/j.1365-2184.2011.00790.x; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Gladson CL, 1999, J NEUROPATH EXP NEUR, V58, P1029, DOI 10.1097/00005072-199910000-00001; Glasgow JN, 2006, CANCER GENE THER, V13, P830, DOI 10.1038/sj.cgt.7700928; Gotoh N, 2008, CANCER SCI, V99, P1319, DOI 10.1111/j.1349-7006.2008.00840.x; Green NK, 2008, J GENE MED, V10, P280, DOI 10.1002/jgm.1121; Grumet M, 1996, PERSPECT DEV NEUROBI, V3, P319; Gu WL, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-128; Guedan S, 2010, MOL THER, V18, P1275, DOI 10.1038/mt.2010.79; Harpold HLP, 2007, J NEUROPATH EXP NEUR, V66, P1, DOI 10.1097/nen.0b013e31802d9000; Harsh GR, 2000, J NEUROSURG, V92, P804, DOI 10.3171/jns.2000.92.5.0804; Haseley A, 2012, CANCER RES, V72, P1353, DOI 10.1158/0008-5472.CAN-11-2526; Haseley Amy, 2009, Recent Pat CNS Drug Discov, V4, P1; Hatzikirou H, 2010, MATH MED BIOL, V27, P255; HEINEGARD D, 1981, BIOCHEM J, V197, P355, DOI 10.1042/bj1970355; Hong CS, 2010, GENE THER, V17, P1200, DOI 10.1038/gt.2010.66; Jacobs VL, 2011, ASN NEURO, V3, DOI 10.1042/AN20110014; Kaur B, 2012, CURR PHARM BIOTECHNO, V13, P1842, DOI 10.2174/138920112800958814; Kaur B, 2009, CURR GENE THER, V9, P341, DOI 10.2174/156652309789753329; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kim J, 2012, BIOMATERIALS, V33, P1838, DOI 10.1016/j.biomaterials.2011.11.020; Kim JH, 2006, JNCI-J NATL CANCER I, V98, P1482, DOI 10.1093/jnci/djj397; Kim Y, 2007, MATH MOD METH APPL S, V17, P1773, DOI 10.1142/S0218202507002479; Kim Y, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00053; Kim Y, 2013, DISCRETE CONT DYN-B, V18, P969, DOI 10.3934/dcdsb.2013.18.969; Kim Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028293; Kim Y, 2011, PROG BIOPHYS MOL BIO, V106, P353, DOI 10.1016/j.pbiomolbio.2011.06.006; Kim Y, 2010, B MATH BIOL, V72, P1029, DOI 10.1007/s11538-009-9481-z; Kim Y, 2009, J THEOR BIOL, V260, P359, DOI 10.1016/j.jtbi.2009.06.025; Klekner A, 2013, EVOLUTION MOL BIOL B, P3; Kuriyama N, 2000, HUM GENE THER, V11, P2219, DOI 10.1089/104303400750035744; Lin R, 2008, J NEUROCHEM, V104, P400, DOI 10.1111/j.1471-4159.2007.05066.x; Lowengrub JS, 2010, NONLINEARITY, V23, pR1, DOI 10.1088/0951-7715/23/1/R01; Lun X, 2006, JNCI-J NATL CANCER I, V98, P1546, DOI 10.1093/jnci/djj413; Markert JM, 2009, MOL THER, V17, P199, DOI 10.1038/mt.2008.228; Mok W, 2009, CLIN CANCER RES, V15, P2352, DOI 10.1158/1078-0432.CCR-08-2082; Mok W, 2007, CANCER RES, V67, P10664, DOI 10.1158/0008-5472.CAN-07-3107; Moon LDF, 2003, J NEUROSCI RES, V71, P23, DOI 10.1002/jnr.10449; Morrison J, 2008, MOL THER, V16, P244, DOI 10.1038/sj.mt.6300363; Msaouel P, 2009, CURR OPIN MOL THER, V11, P43; Muir EM, 2010, J BIOTECHNOL, V145, P103, DOI 10.1016/j.jbiotec.2009.11.002; Netti PA, 2000, CANCER RES, V60, P2497; Nicklin SA, 2005, MOL THER, V12, P384, DOI 10.1016/j.ymthe.2005.05.008; ODONOGHUE JA, 1995, J NUCL MED, V36, P1902; Ozduman K, 2008, J NEUROSCI, V28, P1882, DOI 10.1523/JNEUROSCI.4905-07.2008; Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013; Pardridge WM, 2006, CURR OPIN PHARMACOL, V6, P494, DOI 10.1016/j.coph.2006.06.001; Pardridge WM, 2002, NEURON, V36, P555, DOI 10.1016/S0896-6273(02)01054-1; Parker JN, 2009, NEUROTHERAPEUTICS, V6, P558, DOI 10.1016/j.nurt.2009.04.011; PASQUIER B, 1980, CANCER, V45, P112, DOI 10.1002/1097-0142(19800101)45:1<112::AID-CNCR2820450121>3.0.CO;2-9; Patan S, 2004, CANC TREAT, V117, P3; Pham K, 2012, J BIOL DYNAM, V6, P54, DOI 10.1080/17513758.2011.590610; Pope WB, 2005, AM J NEURORADIOL, V26, P2466; Pulkkanen KJ, 2005, MOL THER, V12, P585, DOI 10.1016/j.ymthe.2005.07.357; Puumalainen AM, 1998, HUM GENE THER, V9, P1769, DOI 10.1089/hum.1998.9.12-1769; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; Ramanujan S, 2002, BIOPHYS J, V83, P1650, DOI 10.1016/S0006-3495(02)73933-7; Rejniak KA, 2011, WIRES SYST BIOL MED, V3, P115, DOI 10.1002/wsbm.102; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Silver DJ, 2013, J NEUROSCI, V33, P15603, DOI 10.1523/JNEUROSCI.3004-12.2013; Stolarska MA, 2009, PHILOS T R SOC A, V367, P3525, DOI 10.1098/rsta.2009.0095; Swanson KR, 2003, MATH COMPUT MODEL, V37, P1177, DOI 10.1016/S0895-7177(03)00129-8; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Verheije MH, 2009, J VIROL, V83, P7507, DOI 10.1128/JVI.00495-09; Viapiano M., 2009, GLIOMA INVASION MECH; Viapiano MS, 2006, TRENDS MOL MED, V12, P488, DOI 10.1016/j.molmed.2006.08.007; Viapiano MS, 2008, J NEURO-ONCOL, V88, P261, DOI 10.1007/s11060-008-9575-8; Viapiano MS, 2005, CANCER RES, V65, P6726, DOI 10.1158/0008-5472.CAN-05-0585; Wang C., 2014, MOL PHARM; Wang Y, 2008, CELL MOL LIFE SCI, V65, P237, DOI 10.1007/s00018-007-7288-3; Whitley RJ, 2013, P NATL ACAD SCI USA, V110, P11672, DOI 10.1073/pnas.1310253110; Wollmann G, 2005, J VIROL, V79, P6005, DOI 10.1128/JVI.79.10.6005-6022.2005; Zimmermann DR, 2008, HISTOCHEM CELL BIOL, V130, P635, DOI 10.1007/s00418-008-0485-9	101	22	22	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2014	9	7							e102499	10.1371/journal.pone.0102499	http://dx.doi.org/10.1371/journal.pone.0102499			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM0SW	25047810	Green Submitted, Green Published, gold			2023-01-03	WOS:000339558100036
J	Jiang, Y; Li, LL; Liu, B; Zhang, YH; Chen, Q; Li, CQ				Jiang, Ying; Li, Longling; Liu, Bin; Zhang, Yanhong; Chen, Qian; Li, Changqing			Vagus Nerve Stimulation Attenuates Cerebral Ischemia and Reperfusion Injury via Endogenous Cholinergic Pathway in Rat	PLOS ONE			English	Article							INFLAMMATORY RESPONSE; ISCHEMIA/REPERFUSION INJURY; ANTIINFLAMMATORY PATHWAY; VAGAL-STIMULATION; ARTERY OCCLUSION; HEME OXYGENASE-1; INFARCT SIZE; BLOOD-FLOW; STROKE; ACETYLCHOLINE	Inflammation and apoptosis play critical roles in the acute progression of ischemic injury pathology. Emerging evidence indicates that vagus nerve stimulation (VNS) following focal cerebral ischemia and reperfusion (I/R) may be neuroprotective by limiting infarct size. However, the underlying molecular mechanisms remain unclear. In this study, we investigated whether the protective effects of VNS in acute cerebral I/R injury were associated with anti-inflammatory and anti-apoptotic processes. Male Sprague-Dawley (SD) rats underwent VNS at 30 min after focal cerebral I/R surgery. Twenty-four h after reperfusion, neurological deficit scores, infarct volume, and neuronal apoptosis were evaluated. In addition, the levels of pro-inflammatory cytokines were detected using enzyme-linked immune sorbent assay (ELISA), and immunofluorescence staining for the endogenous "cholinergic anti-inflammatory pathway" was also performed. The protein expression of a7 nicotinic acetylcholine receptor (a7nAchR), phosphorylated Akt (p-Akt), and cleaved caspase 3 in ischemic penumbra were determined with Western blot analysis. I/R rats treated with VNS (I/R+VNS) had significantly better neurological deficit scores, reduced cerebral infarct volume, and decreased number of TdT mediated dUTP nick end labeling (TUNEL) positive cells. Furthermore, in the ischemic penumbra of the I/R+ VNS group, the levels of pro-inflammatory cytokines and cleaved caspase 3 protein were significantly decreased, and the levels of a7nAchR and phosphorylated Akt were significantly increased relative to the I/R alone group. These results indicate that VNS is neuroprotective in acute cerebral I/R injury by suppressing inflammation and apoptosis via activation of cholinergic and a7nAchR/Akt pathways.	[Jiang, Ying; Li, Longling; Liu, Bin; Zhang, Yanhong; Chen, Qian; Li, Changqing] Chongqing Med Univ, Affiliated Hosp 2, Dept Neurol, Chongqing, Peoples R China	Chongqing Medical University	Li, CQ (corresponding author), Chongqing Med Univ, Affiliated Hosp 2, Dept Neurol, Chongqing, Peoples R China.	licq9217@cqmu.edu.cn			National Nature and Science Foundation of China [81271306]	National Nature and Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Nature and Science Foundation of China (Grant NO. 81271306). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ay I, 2011, BRAIN RES, V1392, P110, DOI 10.1016/j.brainres.2011.03.060; Ay I, 2009, NEUROSCI LETT, V459, P147, DOI 10.1016/j.neulet.2009.05.018; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Boon P, 2006, SEIZURE-EUR J EPILEP, V15, P259, DOI 10.1016/j.seizure.2006.02.014; Borckardt Jeffrey J, 2005, Pain Res Manag, V10, P9; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Brouns R, 2009, CLIN NEUROL NEUROSUR, V111, P483, DOI 10.1016/j.clineuro.2009.04.001; Burneo JG, 2002, NEUROLOGY, V59, P463, DOI 10.1212/WNL.59.3.463; Calvillo L, 2011, J CARDIOVASC PHARM, V58, P500, DOI 10.1097/FJC.0b013e31822b7204; Chong ZZ, 2005, HISTOL HISTOPATHOL, V20, P299, DOI 10.14670/HH-20.299; Conway CR, 2012, BRAIN STIMUL, V5, P163, DOI 10.1016/j.brs.2011.03.001; Duris K, 2011, STROKE, V42, P3530, DOI 10.1161/STROKEAHA.111.619965; Fanselow MS, 2013, BIOL PSYCHIAT, V73, P1043, DOI 10.1016/j.biopsych.2013.03.025; Fu SH, 2014, N-S ARCH PHARMACOL, V387, P87, DOI 10.1007/s00210-013-0922-8; Furmaga H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034844; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Hiraki T, 2012, J NEUROSCI RES, V90, P887, DOI 10.1002/jnr.22812; Kakinuma Y, 2005, FEBS LETT, V579, P2111, DOI 10.1016/j.febslet.2005.02.065; Kakinuma Y, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.112.004887; Khodaparast N, 2013, NEUROBIOL DIS, V60, P80, DOI 10.1016/j.nbd.2013.08.002; Kong YH, 2013, NEUROCHEM RES, V38, P815, DOI 10.1007/s11064-013-0984-5; Krafft PR, 2012, STROKE, V43, P844, DOI 10.1161/STROKEAHA.111.639989; Marrero MB, 2009, BRAIN RES, V1256, P1, DOI 10.1016/j.brainres.2008.11.053; Morris GL, 2013, EPILEPSY CURR, V13, P297, DOI 10.5698/1535-7597-13.6.297; Mravec B, 2010, AUTON NEUROSCI-BASIC, V158, P8, DOI 10.1016/j.autneu.2010.08.009; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Parada E, 2013, ANTIOXID REDOX SIGN, V19, P1135, DOI 10.1089/ars.2012.4671; Park J, 2013, EUR J PHARMACOL, V707, P61, DOI 10.1016/j.ejphar.2013.03.026; Rosas-Ballina M, 2008, P NATL ACAD SCI USA, V105, P11008, DOI 10.1073/pnas.0803237105; Schabitz WR, 1996, J NEUROL SCI, V138, P21, DOI 10.1016/0022-510X(95)00341-X; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Sun ZH, 2012, BRAIN STIMUL, V5, P1, DOI 10.1016/j.brs.2011.01.009; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; Van Westerloo DJ, 2006, GASTROENTEROLOGY, V130, P1822, DOI 10.1053/j.gastro.2006.02.022; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wang JY, 2008, STROKE, V39, P983, DOI 10.1161/STROKEAHA.107.499079; Wang QA, 2011, STROKE, V42, P389, DOI 10.1161/STROKEAHA.110.597336; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; You SJ, 2007, J KOREAN MED SCI, V22, P442, DOI 10.3346/jkms.2007.22.3.442; Zhang L, 2010, BRAIN RES, V1357, P157, DOI 10.1016/j.brainres.2010.08.007	40	68	76	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2014	9	7							e102342	10.1371/journal.pone.0102342	http://dx.doi.org/10.1371/journal.pone.0102342			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM1OC	25036185	Green Published, Green Submitted, gold			2023-01-03	WOS:000339615200047
J	Piszczek, J; Mamdani, M; Antoniou, T; Juurlink, DN; Gomes, T				Piszczek, Jolanta; Mamdani, Muhammad; Antoniou, Tony; Juurlink, David N.; Gomes, Tara			The Impact of Drug Reimbursement Policy on Rates of Testosterone Replacement Therapy among Older Men	PLOS ONE			English	Article							MIDDLE-AGED MEN; BODY-COMPOSITION; TIME-SERIES; TRENDS; ENDOCRINE; AUSTRALIA; MORTALITY; STRENGTH	Background: Despite a lack of data describing the long-term efficacy and safety of testosterone replacement therapy (TRT), prescribing of testosterone to older men has increased with the availability of topical formulations. The magnitude of this increase and the impact of formulary restrictions on testosterone prescribing are poorly characterized. Methods: We conducted a time series analysis using the linked health administrative records of men aged 66 years or older in Ontario, Canada between January 1, 1997 and March 31, 2012. We used interventional autoregressive integrated moving average models to examine the impact of a restrictive drug reimbursement policy on testosterone prescribing and examined the demographic profile of men initiating testosterone in the final 2 years of the study period. Results: A total of 28,477 men were dispensed testosterone over the study period. Overall testosterone prescribing declined 27.9% in the 6 months following the implementation of the restriction policy (9.5 to 6.9 men per 1000 eligible; p<0.01). However, the overall decrease was temporary and testosterone use exceeded pre-policy levels by the end of the study period (11.0 men per 1000 eligible), largely driven by prescriptions for topical testosterone (4.8 men per 1000 eligible). Only 6.3% of men who initiated testosterone had a documented diagnosis of hypogonadism, the main criteria for TRT reimbursement according to the new policy. Conclusion: Government-imposed restrictions did not influence long-term prescribing of testosterone to older men. By 2012, approximately 1 in every 90 men aged 66 or older was being treated with TRT, most with topical formulations.	[Piszczek, Jolanta; Mamdani, Muhammad; Antoniou, Tony; Gomes, Tara] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada; [Mamdani, Muhammad; Juurlink, David N.; Gomes, Tara] ICES, Toronto, ON, Canada; [Antoniou, Tony] St Michaels Hosp, Dept Family & Community Med, Toronto, ON M5B 1W8, Canada; [Juurlink, David N.] Sunnybrook Hlth Sci Ctr, Dept Med, Div Clin Pharmacol & Toxicol, Toronto, ON M4N 3M5, Canada; [Mamdani, Muhammad] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Mamdani, Muhammad; Gomes, Tara] St Michaels Hosp, Li Ka Shing Knowledge Inst, Appl Hlth Res Ctr, Toronto, ON M5B 1W8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Hospital for Sick Children (SickKids); Sunnybrook Health Science Center; University of Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Gomes, T (corresponding author), Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada.	gomest@smh.ca		Gomes, Tara/0000-0002-1468-1965	Ontario Ministry of Health and Long-Term Care (MOHLTC) Drug Innovation Fund; Institute for Clinical Evaluative Sciences (ICES) - Ontario MOHLTC; Ontario HIV Treatment Network	Ontario Ministry of Health and Long-Term Care (MOHLTC) Drug Innovation Fund; Institute for Clinical Evaluative Sciences (ICES) - Ontario MOHLTC; Ontario HIV Treatment Network	This study was supported by a grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC) Drug Innovation Fund and the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario MOHLTC. Tony Antoniou is funded by a post-doctoral fellowship from the Ontario HIV Treatment Network. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The opinions, results, and conclusions are those of the authors, and no endorsement by Ontario's Ministry of Health and Long-term Care or by the Institute for Clinical Evaluative Sciences is intended or should be inferred.	Baillargeon J, 2013, JAMA INTERN MED, V173, P1465, DOI 10.1001/jamainternmed.2013.6895; Basaria S, 2010, NEW ENGL J MED, V363, P109, DOI 10.1056/NEJMoa1000485; Bhasin S, 2010, J CLIN ENDOCR METAB, V95, P2536, DOI 10.1210/jc.2009-2354; Braun SR, 2013, JAMA INTERN MED, V173, P1458, DOI 10.1001/jamainternmed.2013.6892; DICKEY DA, 1979, J AM STAT ASSOC, V74, P427, DOI 10.2307/2286348; Dobs AS, 1990, J CLIN ENDOCR METAB, V84, P3469; Edelstein Daniel, 2006, Expert Opin Emerg Drugs, V11, P685, DOI 10.1517/14728214.11.4.685; Eggertson L, 2011, CAN MED ASSOC J, V183, pE1161, DOI 10.1503/cmaj.109-4000; Feldman HA, 2002, J CLIN ENDOCR METAB, V87, P589, DOI 10.1210/jc.87.2.589; Gomes Tara, 2011, Open Med, V5, pe13; Handelsman DJ, 2013, MED J AUSTRALIA, V199, P548, DOI 10.5694/mja13.10111; Handelsman DJ, 2012, MED J AUSTRALIA, V196, P642, DOI 10.5694/mja11.11277; Handelsman DJ, 2004, MED J AUSTRALIA, V181, P419, DOI 10.5694/j.1326-5377.2004.tb06364.x; Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724; Helfenstein U, 1996, Stat Methods Med Res, V5, P3, DOI 10.1177/096228029600500102; Isidori AM, 2005, CLIN ENDOCRINOL, V63, P280, DOI 10.1111/j.1365-2265.2005.02339.x; Kenny AM, 2002, J GERONTOL A-BIOL, V57, pM321, DOI 10.1093/gerona/57.5.M321; Kermode-Scott B, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d5501; Liverman KT, 2004, TESTOSTERONE AGING C; LJUNG GM, 1978, BIOMETRIKA, V65, P297, DOI 10.2307/2335207; Mamdani M, 2007, AM J MED, V120, P893, DOI 10.1016/j.amjmed.2007.02.028; Marshall BL, 2009, MED STUDIES, V1, P249, DOI DOI 10.1007/S12376-009-0019-3; Fernandez-Balsells MM, 2010, J CLIN ENDOCR METAB, V95, P2560, DOI 10.1210/jc.2009-2575; Page ST, 2005, J CLIN ENDOCR METAB, V90, P1502, DOI 10.1210/jc.2004-1933; Quail JM, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-146; Schoenfeld MJ, 2013, J SEX MED, V10, P1401, DOI 10.1111/jsm.12114; Schwartz L, 2013, JAMA INTERN MED, V173, P1; Shores MM, 2009, J CLIN PSYCHIAT, V70, P1009, DOI 10.4088/JCP.08m04478; Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P2647, DOI 10.1210/jc.84.8.2647; Snyder PJ, 2000, J CLIN ENDOCR METAB, V85, P2670, DOI 10.1210/jc.85.8.2670; Szeinbach SL, 2012, PATIENT PREFER ADHER, V6, P631, DOI 10.2147/PPA.S35840; Vigen R, 2013, JAMA-J AM MED ASSOC, V310, P1829, DOI 10.1001/jama.2013.280386; Wang C, 2008, EUR J ENDOCRINOL, V159, P507, DOI 10.1530/EJE-08-0601; Weeks C., 2012, GLOBE MAIL; Weir MA, 2012, J ONCOL PRACT, V8, P179, DOI 10.1200/JOP.2011.000287	35	23	23	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2014	9	7							e98003	10.1371/journal.pone.0098003	http://dx.doi.org/10.1371/journal.pone.0098003			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4KM	25029014	gold, Green Submitted, Green Published			2023-01-03	WOS:000341306600002
J	McCartney, M				McCartney, Margaret			NO HOLDS BARRED The BMJ is wrong: doctor assisted dying would overmedicalise death	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Bingham J., 2014, DAILY TELEGRAPH, DOI [10674267/Family-breakdowncouldcost-taxpayers-46bn.htmlhttp://www.telegraph.co.uk/women/sex/divorce/10674267/Familybreakdown-could-cost-taxpayers-46bn.html, DOI 10674267/FAMILY-BREAKDOWNCOULDCOST-TAXPAYERS-46BN.HTMLHTTP://WWW.TELEGRAPH.CO.UK/WOMEN/SEX/DIVORCE/10674267/FAMILYBREAKDOWN-COULD-COST-TAXPAYERS-46BN.HTML]; Delamothe T, 2014, BMJ-BRIT MED J, V348, pg4094; Heath I, 2013, JAMA INTERN MED, V173, P956, DOI 10.1001/jamainternmed.2013.970; Marmot, 2010, FAIR SOC HLTH LIVES; McPherson K, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c3106; The Royal College of Midwives, CAMP NORM BIRTH	6	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 8	2014	349								g4502	10.1136/bmj.g4502	http://dx.doi.org/10.1136/bmj.g4502			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AL2ZB	25005033	Bronze, Green Published			2023-01-03	WOS:000338993300013
J	Razali, FN; Ismail, A; Abidin, NZ; Shuib, AS				Razali, Faizan Naeem; Ismail, Amirah; Abidin, Nurhayati Zainal; Shuib, Adawiyah Suriza			Stimulatory Effects of Polysaccharide Fraction from Solanum nigrum on RAW 264.7 Murine Macrophage Cells	PLOS ONE			English	Article							PHENOLIC-COMPOUNDS; ANTITUMOR-ACTIVITY; NITRIC-OXIDE; IMMUNOMODULATION; ACTIVATION; PLANTS; INOS	The polysaccharide fraction from Solanum nigrum Linne has been shown to have antitumor activity by enhancing the CD4(+)/CD8(+) ratio of the T-lymphocyte subpopulation. In this study, we analyzed a polysaccharide extract of S. nigrum to determine its modulating effects on RAW 264.7 murine macrophage cells since macrophages play a key role in inducing both innate and adaptive immune responses. Crude polysaccharide was extracted from the stem of S. nigrum and subjected to ion-exchange chromatography to partially purify the extract. Five polysaccharide fractions were then subjected to a cytotoxicity assay and a nitric oxide production assay. To further analyze the ability of the fractionated polysaccharide extract to activate macrophages, the phagocytosis activity and cytokine production were also measured. The polysaccharide fractions were not cytotoxic, but all of the fractions induced nitric oxide in RAW 264.7 cells. Of the five fractions tested, SN-ppF3 was the least toxic and also induced the greatest amount of nitric oxide, which was comparable to the inducible nitric oxide synthase expression detected in the cell lysate. This fraction also significantly induced phagocytosis activity and stimulated the production of tumor necrosis factor-alpha and interleukin-6. Our study showed that fraction SN-ppF3 could classically activate macrophages. Macrophage induction may be the manner in which polysaccharides from S. nigrum are able to prevent tumor growth.	[Razali, Faizan Naeem; Ismail, Amirah; Abidin, Nurhayati Zainal; Shuib, Adawiyah Suriza] Univ Malaya, Fac Sci, Inst Biol Sci, Kuala Lumpur, Malaysia; [Shuib, Adawiyah Suriza] Univ Malaya, Fac Med, Ctr Prote Res, Kuala Lumpur, Malaysia	Universiti Malaya; Universiti Malaya	Shuib, AS (corresponding author), Univ Malaya, Fac Sci, Inst Biol Sci, Kuala Lumpur, Malaysia.	adawiyah@um.edu.my	SHUIB, ADAWIYAH SURIZA/B-8136-2010; ABIDIN, NURHAYATI ZAINAL/B-9429-2010; ISMAIL, AMIRAH/A-1801-2019	Shuib, Adawiyah Suriza/0000-0001-5525-2713; RAZALI, FAIZAN NAEEM/0000-0002-6458-6915	Ministry of Higher Education, Malaysia [FRGS FP001/2011A]; University Malaya Postgraduate Research Grant [PPP PG057-2012B]	Ministry of Higher Education, Malaysia(Ministry of Education, Malaysia); University Malaya Postgraduate Research Grant	This work was funded by the Ministry of Higher Education, Malaysia (FRGS FP001/2011A) and University Malaya Postgraduate Research Grant (PPP PG057-2012B). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdullah-Soheimi SS, 2010, PROTEOME SCI, V8, DOI 10.1186/1477-5956-8-58; AKHTAR MS, 1989, J ETHNOPHARMACOL, V27, P163, DOI 10.1016/0378-8741(89)90088-3; Bae IY, 2013, FOOD RES INT, V51, P195, DOI 10.1016/j.foodres.2012.12.008; Batovska DI, 2008, NAT PROD RES, V22, P1237, DOI 10.1080/14786410701725865; Byeon SE, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/732860; Cartea ME, 2011, MOLECULES, V16, P251, DOI 10.3390/molecules16010251; Chen HX, 2013, TEA IN HEALTH AND DISEASE PREVENTION, P225, DOI 10.1016/B978-0-12-384937-3.00019-7; Chen JN, 2010, J AGR FOOD CHEM, V58, P12117, DOI 10.1021/jf103576r; Chen RZ, 2010, CARBOHYD POLYM, V80, P845, DOI 10.1016/j.carbpol.2009.12.042; Edmonds J.M., 1997, BLACK NIGHTSHADES SO, DOI DOI 10.1016/j.bcab.2020.101524; Fan YJ, 2011, AFR J PHARM PHARMACO, V5, P415, DOI 10.5897/AJPP11.089; Farah Adriana, 2006, Braz. J. Plant Physiol., V18, P23, DOI 10.1590/S1677-04202006000100003; Fujihara M, 2003, PHARMACOL THERAPEUT, V100, P171, DOI 10.1016/j.pharmthera.2003.08.003; Han SB, 2001, INT IMMUNOPHARMACOL, V1, P1969, DOI 10.1016/S1567-5769(01)00124-2; Heo KS, 2004, TOXICOL IN VITRO, V18, P755, DOI 10.1016/j.tiv.2004.03.003; Houghton RA, 1998, LAB HDB FRACTIONATIO; Hu K, 1999, PLANTA MED, V65, P35, DOI 10.1055/s-1999-13958; Jain R, 2011, ALTERN MED REV, V16, P78; Khoo LT, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/614273; Klimp AH, 2002, CRIT REV ONCOL HEMAT, V44, P143, DOI 10.1016/S1040-8428(01)00203-7; Lechner M, 2005, SEMIN CANCER BIOL, V15, P277, DOI 10.1016/j.semcancer.2005.04.004; Lee CC, 2005, J ETHNOPHARMACOL, V100, P237, DOI 10.1016/j.jep.2005.01.064; Li JA, 2010, J ETHNOPHARMACOL, V129, P350, DOI 10.1016/j.jep.2010.03.033; Lowenstein CJ, 2004, J CELL SCI, V117, P2865, DOI 10.1242/jcs.01166; Masuko T, 2005, ANAL BIOCHEM, V339, P69, DOI 10.1016/j.ab.2004.12.001; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Ooi VEC, 2000, CURR MED CHEM, V7, P715; Park HY, 2012, FASEB J, V26, P323; Schepetkin IA, 2006, INT IMMUNOPHARMACOL, V6, P317, DOI 10.1016/j.intimp.2005.10.005; Shin KS, 1996, PROGR BIOTECHNOL, V14, P623, DOI 10.1016/S0921-0423(96)80295-4; SULTANA S, 1995, J ETHNOPHARMACOL, V45, P189, DOI 10.1016/0378-8741(94)01214-K; Sun X B, 1994, Phytomedicine, V1, P225, DOI 10.1016/S0944-7113(11)80069-3; Thakur M, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq012; Xu HS, 2009, CARBOHYD POLYM, V78, P316, DOI 10.1016/j.carbpol.2009.04.007; Yu MY, 2009, EUR FOOD RES TECHNOL, V228, P477, DOI 10.1007/s00217-008-0955-2	35	26	27	3	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2014	9	10							e108988	10.1371/journal.pone.0108988	http://dx.doi.org/10.1371/journal.pone.0108988			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0AP	25299340	Green Published, gold, Green Submitted			2023-01-03	WOS:000343941200029
J	Chan, K; Shah, K; Lien, K; Coyle, D; Lam, H; Ko, YJ				Chan, Kelvin; Shah, Keya; Lien, Kelly; Coyle, Doug; Lam, Henry; Ko, Yoo-Joung			A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer	PLOS ONE			English	Article							RANDOMIZED PHASE-III; ONCOLOGY-GROUP; GEMCITABINE; TRIAL; COMBINATION; CAPECITABINE; OXALIPLATIN; MULTICENTER; CARCINOMA; CISPLATIN	Background: For advanced pancreatic cancer, many regimens have been compared with gemcitabine (G) as the standard arm in randomized controlled trials. Few regimens have been directly compared with each other in randomized controlled trials and the relative efficacy and safety among them remains unclear. Methods: A systematic review was performed through MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and ASCO meeting abstracts up to May 2013 to identify randomized controlled trials that included advanced pancreatic cancer comparing the following regimens: G, G+5-fluorouracil, G+ capecitabine, G+S1, G+ cisplatin, G+oxaliplatin, G+ erlotinib, G+ nab-paclitaxel, and FOLFIRINOX. Overall survival and progression-free survival with 95% credible regions were extracted using the Parmar method. A Bayesian multiple treatment comparisons was performed to compare all regimens simultaneously. Results: Twenty-two studies were identified and 16 were included in the meta-analysis. Median overall survival, progression free survival, and response rates for G arms from all trials were similar, suggesting no significant clinical heterogeneity. For overall survival, the mixed treatment comparisons found that the probability that FOLFIRINOX was the best regimen was 83%, while it was 11% for G+ nab-paclitaxel and 3% for G+S1 and G+ erlotinib, respectively. The overall survival hazard ratio for FOLFIRINOX versus G+ nab-paclitaxel was 0.79 [0.50-1.24], with no obvious difference in toxicities. The hazard ratios from direct pairwise comparisons were consistent with the mixed treatment comparisons results. Conclusions: FOLFIRINOX appeared to be the best regimen for advanced pancreatic cancer probabilistically, with a trend towards improvement in survival when compared with other regimens by indirect comparisons.	[Chan, Kelvin; Shah, Keya; Lien, Kelly; Lam, Henry; Ko, Yoo-Joung] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada; [Chan, Kelvin] Univ Toronto, Div Biostat, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Coyle, Doug] Univ Ottawa, Ottawa, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Ottawa	Chan, K (corresponding author), Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.	kelvin.chan@sunnybrook.ca		Lien, Kelly/0000-0002-9494-3776; Coyle, Doug/0000-0003-3492-2268				Altman DG, 1999, BRIT MED J, V319, P1492, DOI 10.1136/bmj.319.7223.1492; American Cancer Society, 2013, CANC FACTS FIG 2013; [Anonymous], 2008, ERL TREATM NONSM CEL; Berlin JD, 2002, J CLIN ONCOL, V20, P3270, DOI 10.1200/JCO.2002.11.149; Boeck S, 2008, ANN ONCOL, V19, P340, DOI 10.1093/annonc/mdm467; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Colucci G, 2002, CANCER, V94, P902, DOI 10.1002/cncr.10323.abs; Colucci G, 2010, J CLIN ONCOL, V28, P1645, DOI 10.1200/JCO.2009.25.4433; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446; Di Costanzo F, 2005, BRIT J CANCER, V93, P185, DOI 10.1038/sj.bjc.6602640; Heinemann V, 2006, J CLIN ONCOL, V24, P3946, DOI 10.1200/JCO.2005.05.1490; Herrmann R, 2007, J CLIN ONCOL, V25, P2212, DOI 10.1200/JCO.2006.09.0886; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hoaglin DC, 2011, VALUE HEALTH, V14, P429, DOI 10.1016/j.jval.2011.01.011; Kulke MH, 2009, J CLIN ONCOL, V27, P5506, DOI 10.1200/JCO.2009.22.1309; Li CP, 2004, J CLIN ONCOL, V22, p349S; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Li TJ, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-79; Louvet C, 2005, J CLIN ONCOL, V23, P3509, DOI 10.1200/JCO.2005.06.023; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Nakai Y, 2012, BRIT J CANCER, V106, P1934, DOI 10.1038/bjc.2012.183; Ntzoufras I., 2009, BAYESIAN MODELING US; Office for National Statistics, 2011, CANC SURV ENGL PAT D; Ozaka M, 2012, CANCER CHEMOTH PHARM, V69, P1197, DOI 10.1007/s00280-012-1822-1; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Peddi PF, 2012, J PANCREAS, V13, P497, DOI 10.6092/1590-8577/913; Philip PA, 2009, J CLIN ONCOL, V27, P5660, DOI 10.1200/JCO.2009.21.9022; Poplin E, 2009, J CLIN ONCOL, V27, P3778, DOI 10.1200/JCO.2008.20.9007; Riess A, 2005, J CLIN ONCOL, V23; Scheithauer W, 2003, ANN ONCOL, V14, P97, DOI 10.1093/annonc/mdg029; Sutton AJ, 2001, STAT METHODS MED RES, V10, P277, DOI 10.1191/096228001678227794; Ueno H, 2013, J CLIN ONCOL, V31, P1640, DOI 10.1200/JCO.2012.43.3680; Viret F, 2004, J CLIN ONCOL, V22, p342S; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Von Hoff DD, 2012, J CLIN ONCOL S, V34; Wang Xingyuan, 2002, Zhonghua Zhongliu Zazhi, V24, P404; Warsame R, 2012, EXPERT REV ANTICANC, V12, P1327, DOI [10.1586/ERA.12.115, 10.1586/era.12.115]; Wells GA, 2009, INDIRECT EVIDENCE IN	40	40	40	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2014	9	10							e108749	10.1371/journal.pone.0108749	http://dx.doi.org/10.1371/journal.pone.0108749			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU6XC	25286060	Green Published, gold, Green Submitted			2023-01-03	WOS:000345743700033
J	Zhang, L; Wu, CY; Zhang, Y; Liu, F; Wang, XE; Zhao, M; Hoffman, RM				Zhang, Lei; Wu, Chengyu; Zhang, Yong; Liu, Fang; Wang, Xiaoen; Zhao, Ming; Hoffman, Robert M.			Comparison of Efficacy and Toxicity of Traditional Chinese Medicine (TCM) Herbal Mixture LQ and Conventional Chemotherapy on Lung Cancer Metastasis and Survival in Mouse Models	PLOS ONE			English	Article							FLUORESCENT-PROTEIN EXPRESSION; NUDE-MOUSE; CELLULAR-DYNAMICS; PANCREATIC-CANCER; BREAST-CANCER; IN-VIVO; CELLS; MICE; CARCINOMA; ADENOCARCINOMA	Unlike Western medicine that generally uses purified compounds and aims to target a single molecule or pathway, traditional Chinese medicine (TCM) compositions usually comprise multiple herbs and components that are necessary for efficacy. Despite the very long-time and wide-spread use of TCM, there are very few direct comparisons of TCM and standard cytotoxic chemotherapy. In the present report, we compared the efficacy of the TCM herbal mixture LQ against lung cancer in mouse models with doxorubicin (DOX) and cyclophosphamide (CTX). LQ inhibited tumor size and weight measured directly as well as by fluorescent-protein imaging in subcutaneous, orthotopic, spontaneous experimental metastasis and angiogenesis mouse models of lung cancer. LQ was efficacious against primary and metastatic lung cancer without weight loss and organ toxicity. In contrast, CTX and DOX, although efficacious in the lung cancer models caused significant weight loss, and organ toxicity. LQ also had anti-angiogenic activity as observed in lung tumors growing in nestin-driven green fluorescent protein (ND-GFP) transgenic nude mice, which selectively express GFP in nascent blood vessels. Survival of tumor-bearing mice was also prolonged by LQ, comparable to DOX. In vitro, lung cancer cells were killed by LQ as observed by time-lapse imaging, comparable to cisplatinum. LQ was more potent to induce cell death on cancer cell lines than normal cell lines unlike cytotoxic chemotherapy. The results indicate that LQ has non-toxic efficacy against metastatic lung cancer.	[Zhang, Lei; Zhang, Yong; Liu, Fang; Wang, Xiaoen; Zhao, Ming; Hoffman, Robert M.] AntiCancer Inc, San Diego, CA USA; [Wu, Chengyu] Nanjing Univ Chinese Med, Dept Tradit Chinese Med Diagnost, Nanjing, Jiangsu, Peoples R China; [Zhang, Lei; Hoffman, Robert M.] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; [Liu, Fang] Second Mil Med Univ, Dept Anat, Shanghai, Peoples R China	Anti Cancer Inc; Nanjing University of Chinese Medicine; University of California System; University of California San Diego; Naval Medical University	Wu, CY (corresponding author), Nanjing Univ Chinese Med, Dept Tradit Chinese Med Diagnost, Nanjing, Jiangsu, Peoples R China.	chengyu720@163.com; all@anticancer.com			National Cancer Institute [CA132971]; Jiangsu Science and Technology Achievements Transformation Thematic Special Funds, China [BA2011019]; NATIONAL CANCER INSTITUTE [R01CA132971] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Jiangsu Science and Technology Achievements Transformation Thematic Special Funds, China; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by National Cancer Institute grant CA132971 and grant BA2011019 from the Jiangsu Science and Technology Achievements Transformation Thematic Special Funds, China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amoh Y, 2004, P NATL ACAD SCI USA, V101, P13291, DOI 10.1073/pnas.0405250101; Amoh Y, 2005, CANCER RES, V65, P5352, DOI 10.1158/0008-5472.CAN-05-0821; ASTOUL P, 1994, J CELL BIOCHEM, V56, P9, DOI 10.1002/jcb.240560104; ASTOUL P, 1994, ANTICANCER RES, V14, P85; ASTOUL P, 1993, ANTICANCER RES, V13, P1999; Gai RY, 2008, DRUG DISCOV THER, V2, P2; Hayashi K, 2009, CELL PROLIFERAT, V42, P75, DOI 10.1111/j.1365-2184.2008.00574.x; Hoffman RM, 1999, INVEST NEW DRUG, V17, P343, DOI 10.1023/A:1006326203858; Hoffman RM, 2005, NAT REV CANCER, V5, P796, DOI 10.1038/nrc1717; Hoffman RM, 2006, NAT PROTOC, V1, P1429, DOI 10.1038/nprot.2006.223; Hoffman RM, 2006, NAT PROTOC, V1, P775, DOI 10.1038/nprot.2006.109; Hoffman RM, 2006, NAT PROTOC, V1, P928, DOI 10.1038/nprot.2006.119; Hu MX, 2012, ANTICANCER RES, V32, P2509; Jiang P, 2006, CELL CYCLE, V5, P1198, DOI 10.4161/cc.5.11.2795; Katz MH, 2003, J SURG RES, V113, P151, DOI 10.1016/S0022-4804(03)00234-8; Kimura H, 2010, J CELL BIOCHEM, V109, P58, DOI 10.1002/jcb.22379; Li LN, 2003, P NATL ACAD SCI USA, V100, P9958, DOI 10.1073/pnas.1733025100; Liu F, 2010, CELL CYCLE, V9, P4518, DOI 10.4161/cc.9.22.13744; Martinez-Gutierrez M, 2011, INTERVIROLOGY, V54, P202, DOI 10.1159/000321892; Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s; Ottewell PD, 2008, JNCI-J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240; Qi FH, 2010, BIOSCI TRENDS, V4, P297; Rashidi B, 2000, CLIN EXP METASTAS, V18, P57, DOI 10.1023/A:1026596131504; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Unger RE, 2014, BIOMATERIALS, DOI [10.1016/j.biomaterials.2013.12.059, DOI 10.1016/J.BIOMATERIALS.2013.12.059.]; Wang MR, 2012, ANTICANCER RES, V32, P1213; WANG XE, 1992, ANTICANCER RES, V12, P1399; Wong R, 2001, CANCER TREAT REV, V27, P235, DOI 10.1053/ctrv.2001.0227; Yamamoto N, 2004, CANCER RES, V64, P4251, DOI 10.1158/0008-5472.CAN-04-0643; Yamauchi K, 2006, CANCER RES, V66, P4208, DOI 10.1158/0008-5472.CAN-05-3927; Yang M, 1998, CANCER RES, V58, P4217; Zhang L, 2013, J CELL BIOCHEM, V114, P2131, DOI 10.1002/jcb.24561; Zhang Qing-yuan, 2005, Zhongguo Zhong Xi Yi Jie He Za Zhi, V25, P1074; Zhao M, 2012, CELL CYCLE, V11, P187, DOI 10.4161/cc.11.1.18667; Zou Yu-he, 2003, Zhongguo Zhong Xi Yi Jie He Za Zhi, V23, P733	35	25	28	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2014	9	10							e109814	10.1371/journal.pone.0109814	http://dx.doi.org/10.1371/journal.pone.0109814			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU6XC	25286158	Green Submitted, Green Published, gold			2023-01-03	WOS:000345743700093
J	Rose, SJ; Neville, ME; Gupta, R; Bermudez, LE				Rose, Sasha J.; Neville, Mary E.; Gupta, Renu; Bermudez, Luiz E.			Delivery of Aerosolized Liposomal Amikacin as a Novel Approach for the Treatment of Nontuberculous Mycobacteria in an Experimental Model of Pulmonary Infection	PLOS ONE			English	Article							AVIUM COMPLEX INFECTION; MOUSE MODEL; GUINEA-PIG; ABSCESSUS; TUBERCULOSIS; MICE; AMINOGLYCOSIDES; CAPREOMYCIN; RESISTANCE; EFFICACY	Pulmonary infections caused by nontuberculous mycobacteria (NTM) are an increasing problem in individuals with chronic lung conditions and current therapies are lacking. We investigated the activity of liposomal amikacin for inhalation (LAI) against NTM in vitro as well as in a murine model of respiratory infection. Macrophage monolayers were infected with three strains of Mycobacterium avium, two strains of Mycobacterium abscessus, and exposed to LAI or free amikacin for 4 days before enumerating bacterial survival. Respiratory infection was established in mice by intranasal inoculation with M. avium and allowing three weeks for the infection to progress. Three different regimens of inhaled LAI were compared to inhaled saline and parenterally administered free amikacin over a 28 day period. Bacteria recovered from the mice were analyzed for acquired resistance to amikacin. In vitro, liposomal amikacin for inhalation was more effective than free amikacin in eliminating both intracellular M. avium and M. abscessus. In vivo, inhaled LAI demonstrated similar effectiveness to a similar to 25% higher total dose of parenterally administered amikacin at reducing M. avium in the lungs when compared to inhaled saline. Additionally, there was no acquired resistance to amikacin observed after the treatment regimen. The data suggest that LAI has the potential to be an effective therapy against NTM respiratory infections in humans.	[Rose, Sasha J.; Bermudez, Luiz E.] Oregon State Univ, Dept Biomed Sci, Corvallis, OR 97331 USA; [Rose, Sasha J.; Bermudez, Luiz E.] Oregon State Univ, Dept Microbiol, Corvallis, OR 97331 USA; [Neville, Mary E.; Gupta, Renu] Insmed Inc, Monmouth Jct, NJ USA	Oregon State University; Oregon State University	Bermudez, LE (corresponding author), Oregon State Univ, Dept Biomed Sci, Corvallis, OR 97331 USA.	Luiz.Bermudez@oregonstate.edu			Insmed	Insmed	This study was funded by Insmed. Co-authors MEN and RG are employed by Insmed. The funder provided support in the form of salaries for authors MEN and RG, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Bermudez LE, 2001, ANTIMICROB AGENTS CH, V45, P2210, DOI 10.1128/AAC.45.8.2210-2214.2001; BERMUDEZ LE, 1990, J INFECT DIS, V161, P1262, DOI 10.1093/infdis/161.6.1262; Bermudez LE, 2008, J INFECT DIS, V197, P1506, DOI 10.1086/587906; Briones E, 2008, J CONTROL RELEASE, V125, P210, DOI 10.1016/j.jconrel.2007.10.027; Carter G, 2003, J MED MICROBIOL, V52, P747, DOI 10.1099/jmm.0.05224-0; Clancy JP, 2013, THORAX, V68, P818, DOI 10.1136/thoraxjnl-2012-202230; Dharmadhikari AS, 2013, ANTIMICROB AGENTS CH, V57, P2613, DOI 10.1128/AAC.02346-12; Garcia-Contreras L, 2007, ANTIMICROB AGENTS CH, V51, P2830, DOI 10.1128/AAC.01164-06; Garcia-Contreras L, 2006, J ANTIMICROB CHEMOTH, V58, P980, DOI 10.1093/jac/dkl369; Gonzalez-Juarrero M, 2012, ANTIMICROB AGENTS CH, V56, P3957, DOI 10.1128/AAC.00464-12; Greendyke R, 2008, ANTIMICROB AGENTS CH, V52, P2019, DOI 10.1128/AAC.00986-07; Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST; Griffith DE, 2011, CLIN INFECT DIS, V52, P572, DOI 10.1093/cid/ciq252; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; ISEMAN MD, 1989, NEW ENGL J MED, V321, P896, DOI 10.1056/NEJM198909283211310; Johnson MM, 2014, J THORAC DIS, V6, P210, DOI 10.3978/j.issn.2072-1439.2013.12.24; KILBY JM, 1992, CHEST, V102, P70, DOI 10.1378/chest.102.1.70; Laugero KD, 2000, AM J PHYSIOL-ENDOC M, V279, pE33, DOI 10.1152/ajpendo.2000.279.1.E33; Luedtke NW, 2003, J AM CHEM SOC, V125, P12374, DOI 10.1021/ja0360135; Meers P, 2008, J ANTIMICROB CHEMOTH, V61, P859, DOI 10.1093/jac/dkn059; Nash KA, 2009, ANTIMICROB AGENTS CH, V53, P1367, DOI 10.1128/AAC.01275-08; Teng SH, 2013, J CLIN MICROBIOL, V51, P3113, DOI 10.1128/JCM.01239-13; WOLFF RK, 1993, CRIT REV TOXICOL, V23, P343, DOI 10.3109/10408449309104076; Yamazaki Y, 2006, CELL MICROBIOL, V8, P806, DOI 10.1111/j.1462-5822.2005.00667.x	24	56	62	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2014	9	9							e108703	10.1371/journal.pone.0108703	http://dx.doi.org/10.1371/journal.pone.0108703			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU6XR	25264757	gold, Green Submitted, Green Published			2023-01-03	WOS:000345745400107
J	Bronfort, G; Hondras, MA; Schulz, CA; Evans, RL; Long, CR; Grimm, R				Bronfort, Gert; Hondras, Maria A.; Schulz, Craig A.; Evans, Roni L.; Long, Cynthia R.; Grimm, Richard			Spinal Manipulation and Home Exercise With Advice for Subacute and Chronic Back-Related Leg Pain A Trial With Adaptive Allocation	ANNALS OF INTERNAL MEDICINE			English	Article							LUMBAR-DISK HERNIATION; QUALITY-OF-LIFE; NECK PAIN; CONSERVATIVE TREATMENTS; NONOPERATIVE TREATMENT; EPIDURAL INJECTIONS; NATURAL-HISTORY; CLINICAL-TRIALS; MIXED-METHODS; HEALTH SURVEY	Background: Back-related leg pain (BRLP) is often disabling and costly, and there is a paucity of research to guide its management. Objective: To determine whether spinal manipulative therapy (SMT) plus home exercise and advice (HEA) compared with HEA alone reduces leg pain in the short and long term in adults with BRLP. Design: Controlled pragmatic trial with allocation by minimization conducted from 2007 to 2011. (ClinicalTrials.gov: NCT00494065) Setting: 2 research centers (Minnesota and Iowa). Patients: Persons aged 21 years or older with BRLP for least 4 weeks. Intervention: 12 weeks of SMT plus HEA or HEA alone. Measurements: The primary outcome was patient-rated BRLP at 12 and 52 weeks. Secondary outcomes were self-reported low back pain, disability, global improvement, satisfaction, medication use, and general health status at 12 and 52 weeks. Blinded objective tests were done at 12 weeks. Results: Of the 192 enrolled patients, 191 (99%) provided follow-up data at 12 weeks and 179 (93%) at 52 weeks. For leg pain, SMT plus HEA had a clinically important advantage over HEA (difference, 10 percentage points [95% CI, 2 to 19]; P = 0.008) at 12 weeks but not at 52 weeks (difference, 7 percentage points [CI, -2 to 15]; P = 0.146). Nearly all secondary outcomes improved more with SMT plus HEA at 12 weeks, but only global improvement, satisfaction, and medication use had sustained improvements at 52 weeks. No serious treatment-related adverse events or deaths occurred. Limitation: Patients and providers could not be blinded. Conclusion: For patients with BRLP, SMT plus HEA was more effective than HEA alone after 12 weeks, but the benefit was sustained only for some secondary outcomes at 52 weeks.	Univ Minnesota, Minneapolis, MN 55455 USA; Northwestern Hlth Sci Univ, Minneapolis, MN 55431 USA; Minneapolis Med Res Fdn Inc, Berman Ctr Outcomes & Clin Res, Minneapolis, MN 55404 USA; Palmer Ctr Chiropract Res, Davenport, IA 52803 USA	University of Minnesota System; University of Minnesota Twin Cities; Minneapolis Medical Research Foundation	Bronfort, G (corresponding author), Univ Minnesota, Ctr Spiritual & Healing, MMC 505,425 Delaware St Southeast, Minneapolis, MN 55455 USA.	bronf003@umn.edu	Hondras, Maria/AAW-1979-2021	Schulz, Craig/0000-0002-4019-1521	Health Resources and Services Administration, U.S. Department of Health and Human Services [R18HP07638]	Health Resources and Services Administration, U.S. Department of Health and Human Services(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA))	By the Health Resources and Services Administration, U.S. Department of Health and Human Services (grant R18HP07638).	Albert HB, 2012, SPINE, V37, P531, DOI 10.1097/BRS.0b013e31821ace7f; Andersson Gunnar B. J., 1997, P93; [Anonymous], 1987, Spine (Phila Pa 1976), V12, pS1; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Bombardier C, 2001, J RHEUMATOL, V28, P431; Bronfort G, 2000, J MANIP PHYSIOL THER, V23, P536, DOI 10.1067/mmt.2000.109678; Bronfort G, 2004, J MANIP PHYSIOL THER, V27, P503, DOI 10.1016/j.jmpt.2004.08.002; Bronfort G, 2012, ANN INTERN MED, V156, P1, DOI 10.7326/0003-4819-156-1-201201030-00002; Bronfort G, 2011, SPINE J, V11, P585, DOI 10.1016/j.spinee.2011.01.036; Burton AK, 1999, SPINE, V24, P2484, DOI 10.1097/00007632-199912010-00010; Cherkin DC, 1996, SPINE, V21, P345, DOI 10.1097/00007632-199602010-00019; Cohen J., 2013, STAT POWER ANAL BEHA; Delitto A, 2012, J ORTHOP SPORT PHYS, V42, pA1, DOI 10.2519/jospt.2012.42.4.A1; Deshpande A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004959.pub3; Deyo RA, 2009, J AM BOARD FAM MED, V22, P62, DOI 10.3122/jabfm.2009.01.080102; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; Dworkin RH, 2009, PAIN, V146, P238, DOI 10.1016/j.pain.2009.08.019; Engers A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004057.pub3; Evans RL, 2003, J MANIP PHYSIOL THER, V26, P502, DOI 10.1016/S0161-4754(03)00107-6; Evans R, 2014, EUR SPINE J, V23, P888, DOI 10.1007/s00586-013-3149-y; Fritz JM, 2011, SPINE, V36, P1772, DOI 10.1097/BRS.0b013e318216337d; Fritz JM, 2009, SPINE, V34, P2803, DOI 10.1097/BRS.0b013e3181ae2bd4; Gore M, 2012, SPINE, V37, pE668, DOI 10.1097/BRS.0b013e318241e5de; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Hahne AJ, 2010, SPINE, V35, pE488, DOI 10.1097/BRS.0b013e3181cc3f56; Hill JC, 2011, SPINE, V36, P2168, DOI 10.1097/BRS.0b013e31820712bb; Jacobs WCH, 2011, EUR SPINE J, V20, P513, DOI 10.1007/s00586-010-1603-7; JAESCHKE R, 1990, CONTROL CLIN TRIALS, V11, P43, DOI 10.1016/0197-2456(90)90031-V; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; Kent PM, 2008, MANUAL THER, V13, P12, DOI 10.1016/j.math.2007.05.009; Kongsted A, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-236; Konstantinou K, 2013, CLIN J PAIN, V29, P644, DOI 10.1097/AJP.0b013e31826f9a52; Lawrence DJ, 2008, J MANIP PHYSIOL THER, V31, P659, DOI 10.1016/j.jmpt.2008.10.007; Leininger B, 2011, PHYS MED REH CLIN N, V22, P105, DOI 10.1016/j.pmr.2010.11.002; Lequin MB, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002534; Lin CWC, 2014, EUR J PAIN, V18, P455, DOI 10.1002/j.1532-2149.2013.00384.x; Luijsterburg PAJ, 2007, EUR SPINE J, V16, P881, DOI 10.1007/s00586-007-0367-1; Manchikanti L, 2010, PAIN PHYSICIAN, V13, P199; Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006; McGill S, 2002, LOW BACK DISORDERS E, P205; McGill SM, 2002, LOW BACK DISORDERS E, P239; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Mckenzie RA, 1990, TREAT YOUR OWN BACK, P37; McMorland G, 2010, J MANIP PHYSIOL THER, V33, P576, DOI 10.1016/j.jmpt.2010.08.013; National Health and Family Planning Commission of the People's Republic of China, 2010, PRACT GUID PREC ULTR, P1; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Nyiendo J, 2001, J MANIP PHYSIOL THER, V24, P433, DOI 10.1016/S0161-4754(01)77689-0; hm A, 2012, PATIENT SAF SURG, V6, DOI 10.1186/1754-9493-6-2; Oliveira VC, 2012, ARTHRIT CARE RES, V64, P1739, DOI 10.1002/acr.21737; Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10; PATRICK DL, 1995, SPINE, V20, P1899, DOI 10.1097/00007632-199509000-00011; Paulozzi Leonard, 2012, Morbidity and Mortality Weekly Report, V61, P10; Petersen T, 2011, SPINE, V36, P1999, DOI 10.1097/BRS.0b013e318201ee8e; Pickar JG, 2012, J ELECTROMYOGR KINES, V22, P785, DOI 10.1016/j.jelekin.2012.01.015; Pinto RZ, 2012, ANN INTERN MED, V157, P865, DOI 10.7326/0003-4819-157-12-201212180-00564; Pinto RZ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e497; ROLAND M, 1983, SPINE, V8, P145, DOI 10.1097/00007632-198303000-00005; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Schulz CA, 2011, CHIROPR MAN THER, V19, DOI 10.1186/2045-709X-19-8; Seffinger MA, 2004, SPINE, V29, pE413, DOI 10.1097/01.brs.0000141178.98157.8e; Selim AJ, 1998, SPINE, V23, P470, DOI 10.1097/00007632-199802150-00013; TAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; Thorpe KE, 2009, J CLIN EPIDEMIOL, V62, P464, DOI [10.1503/cmaj.090523, 10.1016/j.jclinepi.2008.12.011]; Ware JE, 1998, J CLIN EPIDEMIOL, V51, P903, DOI 10.1016/S0895-4356(98)00081-X; Weinstein JN, 2006, JAMA-J AM MED ASSOC, V296, P2441, DOI 10.1001/jama.296.20.2441	66	39	41	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2014	161	6					381	U38		10.7326/M14-0006	http://dx.doi.org/10.7326/M14-0006			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AR9LF	25222385				2023-01-03	WOS:000343894400013
J	Kascakova, S; Hofland, LJ; De Bruijn, HS; Ye, YP; Achilefu, S; van der Wansem, K; van der Ploeg-van den Heuvel, A; van Koetsveld, PM; Brugts, MP; van der Lelij, AJ; Sterenborg, HJCM; ten Hagen, TLM; Robinson, DJ; van Hagen, MP				Kascakova, Slavka; Hofland, Leo J.; De Bruijn, Henriette S.; Ye, Yunpeng; Achilefu, Samuel; van der Wansem, Katy; van der Ploeg-van den Heuvel, Angelique; van Koetsveld, Peter M.; Brugts, Michael P.; van der Lelij, Aart-Jan; Sterenborg, Henricus J. C. M.; ten Hagen, Timo L. M.; Robinson, Dominic J.; van Hagen, Martin P.			Somatostatin Analogues for Receptor Targeted Photodynamic Therapy	PLOS ONE			English	Article							TUMOR-CELLS; SINGLET OXYGEN; CHLORIN E(6); CANCER; PHOTOSENSITIZERS; GROWTH; PHOTOIMMUNOTHERAPY; PHOTODESTRUCTION; DERIVATIVES; SENSITIZERS	Photodynamic therapy (PDT) is an established treatment modality, used mainly for anticancer therapy that relies on the interaction of photosensitizer, light and oxygen. For the treatment of pathologies in certain anatomical sites, improved targeting of the photosensitizer is necessary to prevent damage to healthy tissue. We report on a novel dual approach of targeted PDT (vascular and cellular targeting) utilizing the expression of neuropeptide somatostatin receptor (sst(2)) on tumor and neovascular-endothelial cells. We synthesized two conjugates containing the somatostatin analogue [Tyr3]-octreotate and Chlorin e6 (Ce6): Ce6-K-3-[Tyr3]-octreotate (1) and Ce6-[Tyr3]-octreotate-K-3-[Tyr3]-octreotate (2). Investigation of the uptake and photodynamic activity of conjugates in-vitro in human erythroleukemic K562 cells showed that conjugation of [Tyr3]-octreotate with Ce6 in conjugate 1 enhances uptake (by a factor 2) in cells over-expressing sst(2) compared to wildtype cells. Co-treatment with excess free Octreotide abrogated the phototoxicity of conjugate 1 indicative of a specific sst(2)-mediated effect. In contrast conjugate 2 showed no receptor-mediated effect due to its high hydrophobicity. When compared with un-conjugated Ce6, the PDT activity of conjugate 1 was lower. However, it showed higher photostability which may compensate for its lower phototoxicity. Intra-vital fluorescence pharmacokinetic studies of conjugate 1 in rat skin-fold observation chambers transplanted with sst(2)(+) AR42J acinar pancreas tumors showed significantly different uptake profiles compared to free Ce6. Co-treatment with free Octreotide significantly reduced conjugate uptake in tumor tissue (by a factor 4) as well as in the chamber neo-vasculature. These results show that conjugate 1 might have potential as an in-vivo sst(2) targeting photosensitizer conjugate.	[Kascakova, Slavka; van der Ploeg-van den Heuvel, Angelique; Sterenborg, Henricus J. C. M.] Erasmus MC, Ctr Opt Diagnost & Therapy, Dept Radiat Oncol, Rotterdam, Netherlands; [Hofland, Leo J.; van der Wansem, Katy; van Koetsveld, Peter M.; van der Lelij, Aart-Jan; van Hagen, Martin P.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands; [De Bruijn, Henriette S.; Robinson, Dominic J.] Erasmus MC, Dept Otolaryngol & Head & Neck Surg, Rotterdam, Netherlands; [Ye, Yunpeng; Achilefu, Samuel] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA; [Brugts, Michael P.; van Hagen, Martin P.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [ten Hagen, Timo L. M.] Erasmus MC, Dept Surg Oncol, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Washington University (WUSTL); Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	van Hagen, MP (corresponding author), Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.	p.m.vanhagen@erasmusmc.nl	Achilefu, Samuel/AAC-2401-2019; Sterenborg, Henricus J.C.M./H-9401-2013; Kascakova, Slavka/V-1844-2018; Sterenborg, HJCM/O-7195-2019	Sterenborg, Henricus J.C.M./0000-0002-6007-2992; Sterenborg, HJCM/0000-0002-6007-2992; Achilefu, Samuel/0000-0002-3133-6717	National Institutes of Health [R01 EB001430]; Erasmus MC; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB001430] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Erasmus MC; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This study was supported in part by the National Institutes of Health grant (R01 EB001430) to SA and by an Erasmus MC Grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AKHLYNINA TV, 1995, CANCER RES, V55, P1014; [Anonymous], 1985, SINGLET O2; Cavanaugh PG, 2002, BREAST CANCER RES TR, V72, P117, DOI 10.1023/A:1014811915564; Chen B, 2006, CRIT REV EUKAR GENE, V16, P279, DOI 10.1615/CritRevEukarGeneExpr.v16.i4.10; Cunderlikova B, 1999, J PHOTOCH PHOTOBIO B, V53, P81, DOI 10.1016/s1011-1344(99)00130-x; de la Torre NG, 2002, CLIN ENDOCRINOL, V57, P425, DOI 10.1046/j.1365-2265.2002.01619.x; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; Del Governatore M, 2000, BRIT J CANCER, V82, P56; Del Governatore M, 2000, CANCER RES, V60, P4200; Delhanty PJD, 2007, AM J PHYSIOL-ENDOC M, V293, pE302, DOI 10.1152/ajpendo.00377.2006; Denzler B, 1999, CANCER, V85, P188, DOI 10.1002/(SICI)1097-0142(19990101)85:1<188::AID-CNCR26>3.0.CO;2-3; Dougherty TJ, 2002, J CLIN LASER MED SUR, V20, P3, DOI 10.1089/104454702753474931; Dutour A, 1998, INT J CANCER, V76, P620, DOI 10.1002/(SICI)1097-0215(19980529)76:5<620::AID-IJC2>3.3.CO;2-X; Ferone D, 1999, ENDOCRINOLOGY, V140, P373, DOI 10.1210/en.140.1.373; Gibril F, 1996, ANN INTERN MED, V125, P26, DOI 10.7326/0003-4819-125-1-199607010-00005; Hasan T., 2006, CANC MED, P537; HOFLAND LJ, 1990, EUR J CANCER, V26, P37, DOI 10.1016/0277-5379(90)90254-Q; Hongying Y, 1999, DYES PIGMENTS, V43, P109, DOI DOI 10.1016/S0143-7208(99)00049-2; Isakau HA, 2008, J PHOTOCH PHOTOBIO B, V92, P165, DOI 10.1016/j.jphotobiol.2008.06.004; Jordan M, 2004, METHODS, V33, P136, DOI 10.1016/j.ymeth.2003.11.011; Kelbauskas L, 2002, PHOTOCHEM PHOTOBIOL, V76, P686, DOI 10.1562/0031-8655(2002)076<0686:IOAPBT>2.0.CO;2; Kessel D, 2004, J PORPHYR PHTHALOCYA, V8, P1009, DOI 10.1142/S1088424604000374; KOSTENICH GA, 1994, J PHOTOCH PHOTOBIO B, V22, P211, DOI 10.1016/1011-1344(93)06974-8; Kruijt B, 2009, LASER SURG MED, V41, P653, DOI 10.1002/lsm.20845; Kwekkeboom DJ, 2010, ENDOCR-RELAT CANCER, V17, pR53, DOI 10.1677/ERC-09-0078; Lakowicz J.R., 2006, PRINCIPLES FLUORESCE, V3rd, DOI [10.1007/978-0-387-46312-4, DOI 10.1007/978-0-387-46312-4]; Li L, 2010, J CONTROL RELEASE, V143, P274, DOI 10.1016/j.jconrel.2010.01.006; Lobel J, 2001, LASER SURG MED, V29, P397, DOI 10.1002/lsm.10001; MICHAELI A, 1994, PHOTOCHEM PHOTOBIOL, V59, P284, DOI 10.1111/j.1751-1097.1994.tb05035.x; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; Molecular Probes, 2004, PROD INF; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OSEROFF AR, 1986, P NATL ACAD SCI USA, V83, P8744, DOI 10.1073/pnas.83.22.8744; Parkhots M. V., 2003, Journal of Applied Spectroscopy, V70, P921, DOI 10.1023/B:JAPS.0000016312.04644.c7; Redmond RW, 1999, PHOTOCHEM PHOTOBIOL, V70, P391, DOI 10.1111/j.1751-1097.1999.tb08240.x; Reubi JC, 2003, ENDOCR REV, V24, P389, DOI 10.1210/er.2002-0007; Reubi Jean Claude, 2004, Neuroendocrinology, V80 Suppl 1, P51, DOI 10.1159/000080742; Rosenkranz AA, 2000, IMMUNOL CELL BIOL, V78, P452, DOI 10.1046/j.1440-1711.2000.00925.x; Rotomskis R, 1997, J PHOTOCH PHOTOBIO B, V39, P167, DOI 10.1016/S1011-1344(96)00015-2; SAHAI D, 1993, PHOTOCHEM PHOTOBIOL, V58, P803, DOI 10.1111/j.1751-1097.1993.tb04973.x; Sharman WM, 2004, ADV DRUG DELIVER REV, V56, P53, DOI 10.1016/j.addr.2003.08.015; Soukos NS, 2001, CANCER RES, V61, P4490; Starkey JR, 2008, CLIN CANCER RES, V14, P6564, DOI 10.1158/1078-0432.CCR-07-4162; ten Bokum AMC, 2000, EUR CYTOKINE NETW, V11, P161; van Veen RLP, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2338009; Waldherr C, 2001, ANN ONCOL, V12, P941, DOI 10.1023/A:1011160913619; Watson JC, 2001, BRIT J CANCER, V85, P266, DOI 10.1054/bjoc.2001.1881; WILKINSON F, 1993, J PHYS CHEM REF DATA, V22, P113, DOI 10.1063/1.555934; Zenkevich E, 1996, J PHOTOCH PHOTOBIO B, V33, P171, DOI 10.1016/1011-1344(95)07241-1; Zhu TC, 2005, J PHOTOCH PHOTOBIO B, V79, P231, DOI 10.1016/j.jphotobiol.2004.09.013	51	13	13	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 11	2014	9	8							e104448	10.1371/journal.pone.0104448	http://dx.doi.org/10.1371/journal.pone.0104448			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO1WB	25111655	Green Published, gold, Green Submitted			2023-01-03	WOS:000341105100060
J	Laviano, A				Laviano, Alessandro			Young Blood	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ERYTHROPOIESIS		Univ Roma La Sapienza, Dept Clin Med, I-00185 Rome, Italy	Sapienza University Rome	Laviano, A (corresponding author), Univ Roma La Sapienza, Dept Clin Med, Piazzale Aldo Moro 5, I-00185 Rome, Italy.							Dussiot M, 2014, NAT MED, V20, P398, DOI 10.1038/nm.3468; Katsimpardi L, 2014, SCIENCE, V344, P630, DOI 10.1126/science.1251141; Loffredo FS, 2013, CELL, V153, P828, DOI 10.1016/j.cell.2013.04.015; Sinha M, 2014, SCIENCE, V344, P649, DOI 10.1126/science.1251152; Suragani RNVS, 2014, NAT MED, V20, P408, DOI 10.1038/nm.3512; Villeda SA, 2014, NAT MED, V20, P659, DOI 10.1038/nm.3569	6	21	24	0	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 7	2014	371	6					573	575		10.1056/NEJMcibr1407158	http://dx.doi.org/10.1056/NEJMcibr1407158			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AM5LE	25099584				2023-01-03	WOS:000339899100016
J	Soh, SX; Lim, JYS; Huang, JWJ; Jiang, N; Yeoh, AEJ; Ong, ST				Soh, Sheila Xinxuan; Lim, Joshua Yew Suang; Huang, John W. J.; Jiang, Nan; Yeoh, Allen Eng Juh; Ong, S. Tiong			Multi-Agent Chemotherapy Overcomes Glucocorticoid Resistance Conferred by a BIM Deletion Polymorphism in Pediatric Acute Lymphoblastic Leukemia	PLOS ONE			English	Article							CHRONIC MYELOID-LEUKEMIA; GERMLINE GENETIC-VARIATION; CELLULAR-DRUG RESISTANCE; INDUCED APOPTOSIS; KINASE INHIBITORS; CHILDREN; CELLS; EXPRESSION; PREDICTION; CANCER	A broad range of anti-cancer agents, including glucocorticoids (GCs) and tyrosine kinase inhibitors (TKIs), kill cells by upregulating the pro-apoptotic BCL2 family member, BIM. A common germline deletion in the BIM gene was recently shown to favor the production of non-apoptotic BIM isoforms, and to predict inferior responses in TKI-treated chronic myeloid leukemia (CML) and EGFR-driven lung cancer patients. Given that both in vitro and in vivo GC resistance are predictive of adverse outcomes in acute lymphoblastic leukemia (ALL), we hypothesized that this polymorphism would mediate GC resistance, and serve as a biomarker of poor response in ALL. Accordingly, we used zinc finger nucleases to generate ALL cell lines with the BIM deletion, and confirmed the ability of the deletion to mediate GC resistance in vitro. In contrast to CML and lung cancer, the BIM deletion did not predict for poorer clinical outcome in a retrospective analysis of 411 pediatric ALL patients who were uniformly treated with GCs and chemotherapy. Underlying the lack of prognostic significance, we found that the chemotherapy agents used in our cohort (vincristine, L-asparaginase, and methotrexate) were each able to induce ALL cell death in a BIM-independent fashion, and resensitize BIM deletion-containing cells to GCs. Together, our work demonstrates how effective therapy can overcome intrinsic resistance in ALL patients, and suggests the potential of using combinations of drugs that work via divergent mechanisms of cell killing to surmount BIM deletion-mediated drug resistance in other cancers.	[Soh, Sheila Xinxuan; Huang, John W. J.; Ong, S. Tiong] Duke NUS Grad Med Sch, Canc & Stem Cell Biol Program, Singapore, Singapore; [Lim, Joshua Yew Suang; Jiang, Nan; Yeoh, Allen Eng Juh] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Paediat, Singapore 117595, Singapore; [Yeoh, Allen Eng Juh] Natl Univ Hlth Syst, Natl Univ Canc Inst, Singapore, Singapore; [Yeoh, Allen Eng Juh] Viva Univ, Natl Univ Hlth Syst, Univ Childrens Med Inst, Childrens Canc Ctr, Singapore, Singapore; [Yeoh, Allen Eng Juh] Natl Univ Singapore, Canc Sci Inst, Singapore 117548, Singapore; [Ong, S. Tiong] Singapore Gen Hosp, Dept Haematol, Singapore, Singapore; [Ong, S. Tiong] Natl Canc Ctr, Dept Med Oncol, Singapore, Singapore; [Ong, S. Tiong] Duke Univ, Med Ctr, Div Med Oncol, Durham, NC USA	National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; Singapore General Hospital; National Cancer Centre Singapore (NCCS); Duke University	Ong, ST (corresponding author), Duke NUS Grad Med Sch, Canc & Stem Cell Biol Program, Singapore, Singapore.	sintiong.ong@duke-nus.edu.sg	Yeoh, Allen EJ/D-9663-2015	Yeoh, Allen EJ/0000-0002-6454-976X; Jiang, Nan/0000-0002-7661-5728; Ong, S. Tiong/0000-0001-9460-3483	Leukemia & Lymphoma Society Translational Research Program [R913-302-026-597]; Singapore National Medical Research Council [NMRC/0582/2001, NMRC/CSA/003/2008]; A*STAR [SCS-POU98, NMRC/CSI/004/2005]; Children's Cancer Foundation, Singapore; VIVA Foundation for Children with Cancer, Singapore	Leukemia & Lymphoma Society Translational Research Program(Leukemia and Lymphoma Society); Singapore National Medical Research Council(National Medical Research Council, Singapore); A*STAR(Agency for Science Technology & Research (A*STAR)); Children's Cancer Foundation, Singapore; VIVA Foundation for Children with Cancer, Singapore	STO was supported by the Leukemia & Lymphoma Society Translational Research Program Grant (R913-302-026-597) www.lls.org. AEY was supported by the Singapore National Medical Research Council (NMRC/0582/2001, NMRC/CSA/003/2008). www.nmrc.gov.sg, and by A*STAR (SCS-POU98, NMRC/CSI/004/2005). www.a-star.edu.sg, and by Children's Cancer Foundation, Singapore. www.ccf.org.sg, and by VIVA Foundation for Children with Cancer, Singapore. www.viva.sg. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrams MT, 2004, J BIOL CHEM, V279, P55809, DOI 10.1074/jbc.M411767200; Aichberger KJ, 2005, CANCER RES, V65, P9436, DOI 10.1158/0008-5472.CAN-05-0972; Augis V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078582; Bachmann PS, 2010, BLOOD, V116, P3013, DOI 10.1182/blood-2010-05-284968; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Coate L, 2010, J CLIN ONCOL, V28, P4029, DOI 10.1200/JCO.2009.27.2336; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Den Boer ML, 2003, J CLIN ONCOL, V21, P3262, DOI 10.1200/JCO.2003.11.031; DeVita Jr VT, 2008, DEVITA HELLMAN ROSEN, p[427, 451, 490]; Dordelmann M, 1999, BLOOD, V94, P1209, DOI 10.1182/blood.V94.4.1209.416k05_1209_1217; Erlacher M, 2005, BLOOD, V106, P4131, DOI 10.1182/blood-2005-04-1595; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; Gagne V, 2013, CLIN CANCER RES, V19, P5240, DOI 10.1158/1078-0432.CCR-13-1215; Gaj T, 2013, TRENDS BIOTECHNOL, V31, P397, DOI 10.1016/j.tibtech.2013.04.004; Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294; Jabbour E, 2009, MAYO CLIN PROC, V84, P161, DOI 10.1016/S0025-6196(11)60824-0; Jiang N, 2011, EXP HEMATOL, V39, P321, DOI 10.1016/j.exphem.2010.11.009; Juan WC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095210; Kaspers GJL, 1998, BLOOD, V92, P259, DOI 10.1182/blood.V92.1.259.413k21_259_266; KASPERS GJL, 1995, LEUKEMIA LYMPHOMA, V19, P407, DOI 10.3109/10428199509112198; Kuribara R, 2004, MOL CELL BIOL, V24, P6172, DOI 10.1128/MCB.24.14.6172-6183.2004; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Lauten M, 2012, HAEMATOL-HEMATOL J, V97, P1048, DOI 10.3324/haematol.2011.047613; Locatelli F, 2012, BLOOD, V120, P2807, DOI 10.1182/blood-2012-02-265884; Martinelli G, 2009, J CLIN ONCOL, V27, P5202, DOI 10.1200/JCO.2008.21.6408; McLeod HL, 2013, SCIENCE, V339, P1563, DOI 10.1126/science.1234139; MIYAGI T, 1993, INT J CANCER, V53, P457, DOI 10.1002/ijc.2910530318; Morel F, 2003, LEUKEMIA LYMPHOMA, V44, P1333, DOI 10.1080/1042819031000097384; Mullighan CG, 2012, HEMATOL-AM SOC HEMAT, P389, DOI 10.1182/asheducation-2012.1.389; Ng KP, 2012, NAT MED, V18, P521, DOI 10.1038/nm.2713; Perez-Andreu V, 2013, NAT GENET, V45, P1494, DOI 10.1038/ng.2803; PIETERS R, 1993, LEUKEMIA, V7, P392; Ploner C, 2008, LEUKEMIA, V22, P370, DOI 10.1038/sj.leu.2405039; Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603; Radtke S, 2013, BLOOD, V121, P5145, DOI 10.1182/blood-2013-01-480335; Roberts KG, 2012, CANCER CELL, V22, P153, DOI 10.1016/j.ccr.2012.06.005; Rocha JCC, 2005, BLOOD, V105, P4752, DOI 10.1182/blood-2004-11-4544; Sanchez R, 2014, HAEMATOLOGICA, V99, P314, DOI 10.3324/haematol.2013.085340; Schmidt S, 2006, BLOOD, V107, P2061, DOI 10.1182/blood-2005-07-2853; Schrappe M, 1998, BLOOD, V92, P2730; STONG RC, 1985, BLOOD, V65, P21, DOI 10.1182/blood.V65.1.21.21; Trevin LR, 2009, J CLIN ONCOL, V27, P5972, DOI 10.1200/JCO.2008.20.4156; Wang ZQ, 2003, J BIOL CHEM, V278, P23861, DOI 10.1074/jbc.M301843200; Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Xu H, 2012, J CLIN ONCOL, V30, P751, DOI 10.1200/JCO.2011.38.0345; Yang JJ, 2012, BLOOD, V120, P4197, DOI 10.1182/blood-2012-07-440107; Yang JJ, 2009, JAMA-J AM MED ASSOC, V301, P393, DOI 10.1001/jama.2009.7; Yeoh AEJ, 2012, J CLIN ONCOL, V30, P2384, DOI 10.1200/JCO.2011.40.5936; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	50	8	10	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2014	9	8							e103435	10.1371/journal.pone.0103435	http://dx.doi.org/10.1371/journal.pone.0103435			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM4GX	25090024	Green Published, gold, Green Submitted			2023-01-03	WOS:000339812700027
J	Tsai, MJ; Fu, YS; Lin, YH; Huang, YB; Wu, PC				Tsai, Ming-Jun; Fu, Yaw-Syan; Lin, Yu-Hsuan; Huang, Yaw-Bin; Wu, Pao-Chu			The Effect of Nanoemulsion as a Carrier of Hydrophilic Compound for Transdermal Delivery	PLOS ONE			English	Article							DRUG-DELIVERY; PARKINSONS-DISEASE; SUBMICRON EMULSIONS; TOPICAL DELIVERY; SKIN PERMEATION; MICROEMULSIONS; DESIGN; FORMULATION; ROPINIROLE; LIPOSOMES	The purpose of the present study was to investigate the effect of nanoemulsions as a carrier vehicle of hydrophilic drug for transdermal delivery. The response surface methodology with a mixture design was used to evaluate the effect of ingredient levels of nanoemulsion formulations including cosurfactant (isopropyl alcohol, 20 similar to 30%), surfactant (mixed of Brij 30 and Brij 35, 20 similar to 30%), and distilled-water (34.5 similar to 50.0%) on properties of the drug-loaded nanoemulsions including physicochemical characters and drug permeability through rat skin. The result showed that the hydrophilic drug in aqueous solution with or without penetration enhancer could not transport across rat skin after 12 h of application. Used nanoemulsions as carrier vehicle, the permeation rate of drug was significantly increased from 0 to 63.23 mu g/cm(2)/h and the lag time was shortened from more than 12 h to about 2.7 similar to 4.0 h. Moreover, the drug-loaded nanoemulsion formulation also showed physicochemical stability after 3 month storage at 25 degrees C and 40 degrees C.	[Tsai, Ming-Jun] China Med Univ, Coll Med, Sch Med, Dept Neurol,China Med Univ Hosp, Taichung, Taiwan; [Tsai, Ming-Jun] Tainan Municipal An Nan Hosp, Dept Neurol, Tainan, Taiwan; [Fu, Yaw-Syan] Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol, Kaohsiung, Taiwan; [Lin, Yu-Hsuan; Huang, Yaw-Bin; Wu, Pao-Chu] Kaohsiung Med Univ, Sch Pharm, Kaohsiung, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; Kaohsiung Medical University; Kaohsiung Medical University	Wu, PC (corresponding author), Kaohsiung Med Univ, Sch Pharm, Kaohsiung, Taiwan.	pachwu@kmu.edu.tw		Fu, Yaw-Syan/0000-0001-8715-9644; Huang, Yaw-Bin/0000-0002-6024-0108	National Science Council of Taiwan [NSC 102-2320-B-037-006-MY2, NSC101-2320-B-037-33]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by a Grant from the National Science Council of Taiwan (NSC 102-2320-B-037-006-MY2 and NSC101-2320-B-037-33). The funders had no role in study design, data collection and analysis to publish, or preparation of the manuscript.	Alonso Canovas A, 2011, NEUROLOGIA; Aydogmus Z, 2008, SPECTROCHIM ACTA A, V70, P69, DOI 10.1016/j.saa.2007.07.012; Azeem A, 2009, AAPS PHARMSCITECH, V10, P1093, DOI 10.1208/s12249-009-9306-2; Azeem A, 2009, DRUG DEV IND PHARM, V35, P525, DOI 10.1080/03639040802448646; Azeem A, 2009, AAPS PHARMSCITECH, V10, P69, DOI 10.1208/s12249-008-9178-x; Brown MB, 2006, DRUG DELIV, V13, P175, DOI 10.1080/10717540500455975; Cevc G, 2004, ADV DRUG DELIVER REV, V56, P675, DOI 10.1016/j.addr.2003.10.028; Chen Y, 2012, MOLECULES, V17, P5972, DOI 10.3390/molecules17055972; El Maghraby GM, 2008, INT J PHARMACEUT, V355, P285, DOI 10.1016/j.ijpharm.2007.12.022; El Maghraby GM, 2013, DRUG DEV IND PHARM; Fang YP, 2009, EUR J PHARM BIOPHARM, V73, P391, DOI 10.1016/j.ejpb.2009.07.011; Fouad SA, 2013, INT J PHARMACEUT, V453, P569, DOI 10.1016/j.ijpharm.2013.06.009; Fuh JL, 1997, CLIN NEUROL NEUROSUR, V99, P106, DOI 10.1016/S0303-8467(97)00606-9; Heuschkel S, 2008, J PHARM SCI-US, V97, P603, DOI 10.1002/jps.20995; Kaye CM, 2000, CLIN PHARMACOKINET, V39, P243, DOI 10.2165/00003088-200039040-00001; Kim HM, 2012, INT J DERMATOL, V51, P859, DOI 10.1111/j.1365-4632.2011.05343.x; Kimura C, 2007, EUR J PHARM BIOPHARM, V67, P420, DOI 10.1016/j.ejpb.2007.02.022; Kogan A, 2006, ADV COLLOID INTERFAC, V123, P369, DOI 10.1016/j.cis.2006.05.014; Makraduli L, 2013, J MICROENCAPSUL, V30, P81, DOI 10.3109/02652048.2012.700957; Matheson AJ, 2000, DRUGS, V60, P115, DOI 10.2165/00003495-200060010-00007; Mostafa DM, 2014, DRUG DELIV, V21, P130, DOI 10.3109/10717544.2013.834419; Nair A, 2011, DRUG DELIV, V18, P19, DOI 10.3109/10717544.2010.509361; OSBORNE DW, 1991, J PHARM PHARMACOL, V43, P451, DOI 10.1111/j.2042-7158.1991.tb03511.x; Pabari RM, 2012, INT J PHARMACEUT, V430, P18, DOI 10.1016/j.ijpharm.2012.03.021; Peltola S, 2003, INT J PHARMACEUT, V254, P99, DOI 10.1016/S0378-5173(02)00632-4; Piemi MPY, 1999, J CONTROL RELEASE, V58, P177, DOI 10.1016/S0168-3659(98)00156-4; Raza K, 2011, J MICROENCAPSUL, V28, P190, DOI 10.3109/02652048.2010.546435; Ryan E, 2012, EUR J PHARM SCI, V47, P297, DOI 10.1016/j.ejps.2012.06.012; SCHREIER H, 1994, J CONTROL RELEASE, V30, P1, DOI 10.1016/0168-3659(94)90039-6; Shi J, 2012, J LIPOSOME RES, V22, P270, DOI 10.3109/08982104.2012.690159; Teichmann A, 2007, EUR J PHARM BIOPHARM, V67, P699, DOI 10.1016/j.ejpb.2007.04.006; Tompson DJ, 2007, CLIN THER, V29, P2654, DOI 10.1016/j.clinthera.2007.12.010; Tsai PJ, 2013, THESCIENTIFICWORLDJO, V2013, DOI [10.1155/2013/856967, DOI 10.1155/2013/856967]; Tsai YH, 2012, J FOOD DRUG ANAL, V20, P22; Wang LJ, 2009, J COLLOID INTERF SCI, V330, P443, DOI 10.1016/j.jcis.2008.10.077; Wu HL, 2001, INT J PHARM, V220, P63, DOI 10.1016/S0378-5173(01)00671-8; Zidan AS, 2007, J PHARM SCI-US, V96, P2409, DOI 10.1002/jps.20824	37	26	26	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2014	9	7							e102850	10.1371/journal.pone.0102850	http://dx.doi.org/10.1371/journal.pone.0102850			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6RZ	25068531	Green Published, Green Submitted, gold			2023-01-03	WOS:000339993700022
J	Olsen, MF; Abdissa, A; Kaestel, P; Tesfaye, M; Yilma, D; Girma, T; Wells, JCK; Ritz, C; Molgaard, C; Michaelsen, KF; Zerfu, D; Brage, S; Andersen, AB; Friis, H				Olsen, Mette F.; Abdissa, Alemseged; Kaestel, Pernille; Tesfaye, Markos; Yilma, Daniel; Girma, Tsinuel; Wells, Jonathan C. K.; Ritz, Christian; Molgaard, Christian; Michaelsen, Kim F.; Zerfu, Dilnesaw; Brage, Soren; Andersen, Ase B.; Friis, Henrik			Effects of nutritional supplementation for HIV patients starting antiretroviral treatment: randomised controlled trial in Ethiopia	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BIOELECTRICAL-IMPEDANCE ANALYSIS; PLASMA GLUTATHIONE LEVELS; BODY CELL MASS; WEIGHT-LOSS; WHEY PROTEINS; RESISTANCE EXERCISE; PHYSICAL-ACTIVITY; INFECTED PATIENTS; MUSCLE STRENGTH; DOUBLE-BLIND	Objectives To determine the effects of lipid based nutritional supplements with either whey or soy protein in patients with HIV during the first three months of antiretroviral treatment (ART) and to explore effects of timing by comparing supplementation at the start of ART and after three months delay. Design Randomised controlled trial. Setting Three public ART facilities in Jimma, Oromia region, Ethiopia. Participants Adults with HIV eligible for ART with body mass index (BMI) >16. Intervention Daily supplementation with 200 g (4600 kJ) of supplement containing whey or soy during either the first three or the subsequent three months of ART. Outcome measures Primary: lean body mass assessed with deuterium dilution, grip strength measured with dynamometers, and physical activity measured with accelerometer and heart rate monitors. Secondary: viral load and CD4 counts. Auxiliary: weight and CD3 and CD8 counts. Results Of 318 patients enrolled, 210 (66%) were women, mean age was 33 (SD 9), and mean BMI was 19.5 (SD 2.4). At three months, participants receiving the supplements containing whey or soy had increased their lean body mass by 0.85 kg (95% confidence interval 0.16 kg to 1.53 kg) and 0.97 kg (0.29 kg to 1.64 kg), respectively, more than controls. This was accompanied by an increased gain of grip strength of 0.68 kg (-0.11 kg to 1.46 kg) for the whey supplement group and 0.93 kg (0.16 kg to 1.70 kg) for the soy supplement group. There were no effects on physical activity. Total weight gain increased by 2.05 kg (1.12 kg to 2.99 kg) and 2.06 kg (1.14 kg to 2.97 kg) for the whey and soy groups, respectively. In addition, in the whey supplement group overall CD3 counts improved by 150 cells/mu L (24 to 275 cells/mu L), of which 112 cells/mu L (15 to 209 cells/mu L) were CD8 and 25 cells/mu L (-2 to 53 cells/mu L) were CD4. Effects of the soy containing supplement on immune recovery were not significant. The effects of the two supplements, however, were not significantly different in direct comparison. Exploratory analysis showed that relatively more lean body mass was gained by patients with undetectable viral load at three months. Patients receiving delayed supplementation had higher weight gain but lower gains in functional outcomes. Conclusions Lipid based nutritional supplements improved gain of weight, lean body mass, and grip strength in patients with HIV starting ART. Supplements containing whey were associated with improved immune recovery.	[Olsen, Mette F.; Kaestel, Pernille; Ritz, Christian; Molgaard, Christian; Michaelsen, Kim F.; Friis, Henrik] Univ Copenhagen, Dept Nutr Exercise & Sports, DK-1958 Frederiksberg C, Denmark; [Abdissa, Alemseged] Jimma Univ, Dept Lab Sci & Pathol, Jimma, Ethiopia; [Tesfaye, Markos] Jimma Univ, Coll Publ Hlth & Med Sci, Dept Psychiat, Jimma, Ethiopia; [Yilma, Daniel] Jimma Univ Specialized Hosp, Dept Internal Med, Jimma, Ethiopia; [Girma, Tsinuel] Jimma Univ Specialized Hosp, Dept Paediat & Child Hlth, Jimma, Ethiopia; [Wells, Jonathan C. K.] UCL Inst Child Hlth, Childhood Nutr Res Ctr, London, England; [Zerfu, Dilnesaw] Ethiopian Hlth & Nutr Res Inst, Addis Ababa, Ethiopia; [Brage, Soren] Univ Cambridge, MRC Epidemiol Unit, Cambridge, England; [Andersen, Ase B.] Odense Univ Hosp, Dept Infect Dis, DK-5000 Odense, Denmark	University of Copenhagen; Jimma University; Jimma University; University of London; University College London; Ethiopian Health & Nutrition Research Institute; University of Cambridge; University of Southern Denmark; Odense University Hospital	Olsen, MF (corresponding author), Univ Copenhagen, Dept Nutr Exercise & Sports, Rolighedsvej 30, DK-1958 Frederiksberg C, Denmark.	mette.frahm.olsen@gmail.com	Brage, Soren/C-6415-2013; Wells, Jonathan/A-4604-2009; Olsen, Mette F/S-6119-2016; Mølgaard, Christian/D-2052-2014; Tesfaye, Markos/H-9297-2019; Friis, Henrik/N-2047-2014; Friis, Henrik/P-2891-2019; Yilma, Daniel/AAJ-2072-2021; Ritz, Christian/P-6159-2014	Brage, Soren/0000-0002-1265-7355; Wells, Jonathan/0000-0003-0411-8025; Olsen, Mette F/0000-0002-5742-6403; Mølgaard, Christian/0000-0002-5311-9457; Friis, Henrik/0000-0002-2848-2940; Friis, Henrik/0000-0002-2848-2940; Yilma, Daniel/0000-0001-6058-2696; Abdissa, Alemseged/0000-0003-3798-5037; Tesfaye, Markos/0000-0002-3351-701X; Michaelsen, Kim F/0000-0003-0449-0839; Ritz, Christian/0000-0002-5095-0624; Abdissa, Alemseged/0000-0001-6871-1958; Kaestel, Pernille/0000-0003-2769-4666	US Dairy Export Council; International Atomic Energy Agency (IAEA); Ministry of Foreign Affairs of Denmark (DANIDA); MRC [MC_U106179473, MC_UU_12015/3] Funding Source: UKRI; Medical Research Council [MC_UU_12015/3, MC_U106179473] Funding Source: researchfish	US Dairy Export Council; International Atomic Energy Agency (IAEA)(International Atomic Energy Agency); Ministry of Foreign Affairs of Denmark (DANIDA); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The study was funded by US Dairy Export Council, International Atomic Energy Agency (IAEA), and Ministry of Foreign Affairs of Denmark (DANIDA). Nutriset developed the supplements and partially covered transportation expenses. The funders had no role in study design, data collection, and analysis, the decision to publish or preparation of the manuscript	Agin D, 2001, AIDS, V15, P2431, DOI 10.1097/00002030-200112070-00011; Agin D, 2000, ANN NY ACAD SCI, V904, P607, DOI 10.1111/j.1749-6632.2000.tb06523.x; Anema A, 2012, PUBLIC HEALTH NUTR, V15, P938, DOI 10.1017/S136898001100125X; [Anonymous], 2008, GUID MAN OPP INF ANT; BOUNOUS G, 1993, CLIN INVEST MED, V16, P204; Brage S, 2005, EUR J CLIN NUTR, V59, P561, DOI 10.1038/sj.ejcn.1602118; Brage S, 2004, J APPL PHYSIOL, V96, P343, DOI 10.1152/japplphysiol.00703.2003; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Christensen DL, 2012, AM J HUM BIOL, V24, P723, DOI 10.1002/ajhb.22303; Desquilbet L, 2007, J GERONTOL A-BIOL, V62, P1279, DOI 10.1093/gerona/62.11.1279; EHNRI, 1998, FOOD COMPOSITION TAB; Ethiopian Nutrition Institute, 1980, ETH TRAD REC; Fao/Who, 2001, HUM VIT MIN REQ; Federal Ministry of Health, 2011, NAT GUID NUTR CAR SU; Gillespie S. R., 2006, AIDS POVERTY HUNGER; Grobler L, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004536.pub3; Gupta A, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0022730, 10.1371/journal.pone.0028691]; Heimburger DC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010687; Hoppe C, 2008, J NUTR, V138, p145S, DOI 10.1093/jn/138.1.145S; IAEA human health series, 2010, INTR BOD COMP ASS US; Koethe JR, 2010, AM J CLIN NUTR, V91, p1138S, DOI 10.3945/ajcn.2010.28608D; Koethe JR, 2010, JAIDS-J ACQ IMM DEF, V53, P507, DOI 10.1097/QAI.0b013e3181b32baf; KOTLER DP, 1990, JPEN-PARENTER ENTER, V14, P454, DOI 10.1177/0148607190014005454; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; Kusko RL, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-10; Lamb MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038443; Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd; Lugassy DM, 2010, EMERG MED CLIN N AM, V28, P409, DOI 10.1016/j.emc.2010.01.011; Madec Y, 2009, AIDS, V23, P853, DOI 10.1097/QAD.0b013e32832913ee; Malvy D, 2001, J AM COLL NUTR, V20, P609, DOI 10.1080/07315724.2001.10719065; May M, 2010, LANCET, V376, P449, DOI 10.1016/S0140-6736(10)60666-6; Melchior JC, 1999, NUTRITION, V15, P865, DOI 10.1016/S0899-9007(99)00210-5; Micke P, 2001, EUR J CLIN INVEST, V31, P171, DOI 10.1046/j.1365-2362.2001.00781.x; Micke P, 2002, EUR J NUTR, V41, P12, DOI 10.1007/s003940200001; Ndekha MJ, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1867; Olsen MF, 2013, PATIENT PREFER ADHER, V7, P481, DOI 10.2147/PPA.S44413; OTT M, 1995, J ACQ IMMUN DEF SYND, V9, P20; Paton NIJ, 1997, J ACQ IMMUN DEF SYND, V14, P119, DOI 10.1097/00042560-199702010-00004; Raso V, 2013, JAIDS-J ACQ IMM DEF, V63, pE30, DOI 10.1097/QAI.0b013e31828c42bb; Sadler K, 2012, MEASURING IMPACT COS, P29; Sattler FR, 2008, AM J CLIN NUTR, V88, P1313, DOI 10.3945/ajcn.2006.23583; Schwenk A, 2000, AM J CLIN NUTR, V72, P496; Shabert JK, 1996, MED HYPOTHESES, V46, P252, DOI 10.1016/S0306-9877(96)90251-0; Shabert JK, 1999, NUTRITION, V15, P860, DOI 10.1016/S0899-9007(99)00213-0; Sudfeld CR, 2013, AM J CLIN NUTR, V97, P1278, DOI 10.3945/ajcn.112.053728; SUTTMANN U, 1995, J ACQ IMMUN DEF SYND, V8, P239, DOI 10.1097/00042560-199503010-00004; Tang AM, 2005, JAIDS-J ACQ IMM DEF, V40, P70, DOI 10.1097/01.qai.0000159627.54149.2e; Wanke C, 2002, AIDS PATIENT CARE ST, V16, P375, DOI 10.1089/10872910260196404; WELBOURNE TC, 1995, AM J CLIN NUTR, V61, P1058, DOI 10.1093/ajcn/61.5.1058	49	42	43	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	2014	348								g3187	10.1136/bmj.g3187	http://dx.doi.org/10.1136/bmj.g3187			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AH5GP	25134117	Green Published, hybrid			2023-01-03	WOS:000336156800003
J	Pawlotsky, JM				Pawlotsky, Jean-Michel			Hepatitis E screening for blood donations: an urgent need?	LANCET			English	Editorial Material							E VIRUS-INFECTION; AGENTS		[Pawlotsky, Jean-Michel] Univ Paris Est, Natl Reference Ctr Viral Hepatitis B C & D, Dept Virol, Hop Henri Mondor, F-94010 Creteil, France; [Pawlotsky, Jean-Michel] Hop Henri Mondor, INSERM, U955, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Pawlotsky, JM (corresponding author), Univ Paris Est, Natl Reference Ctr Viral Hepatitis B C & D, Dept Virol, Hop Henri Mondor, F-94010 Creteil, France.	jean-michel.pawlotsky@hmn.aphp.fr	Pawlotsky, Jean-Michel/R-8159-2018	Pawlotsky, Jean-Michel/0000-0003-0745-7559				Coilly A, 2013, TRANSPLANTATION, V96, pE4, DOI 10.1097/TP.0b013e318296c9f7; Coste J, 2005, VOX SANG, V88, P289, DOI 10.1111/j.1423-0410.2005.00636_1.x; Dalton HR, 2009, NEW ENGL J MED, V361, P1025, DOI 10.1056/NEJMc0903778; Feray C, 2014, LANCET, V383, P218, DOI 10.1016/S0140-6736(14)60072-6; Hewitt EP, 2014, LANCET; Hogema BM, 2014, TRANSFUSION, V54, P3092, DOI 10.1111/trf.12733; Kamar N, 2008, NEW ENGL J MED, V358, P811, DOI 10.1056/NEJMoa0706992; Kamar N, 2014, CLIN MICROBIOL REV, V27, P116, DOI 10.1128/CMR.00057-13; Kamar N, 2011, GASTROENTEROLOGY, V140, P1481, DOI 10.1053/j.gastro.2011.02.050; Khuroo MS, 2004, J GASTROEN HEPATOL, V19, P778, DOI 10.1111/j.1440-1746.2004.03437.x; Ollier L, 2009, ANN INTERN MED, V150, P430, DOI 10.7326/0003-4819-150-6-200903170-00026; Peron JM, 2007, J VIRAL HEPATITIS, V14, P298, DOI 10.1111/j.1365-2893.2007.00858.x; Stramer SL, 2000, CURR OPIN HEMATOL, V7, P387, DOI 10.1097/00062752-200011000-00011; Vollmer T, 2012, J CLIN MICROBIOL, V50, P2708, DOI 10.1128/JCM.01119-12	14	38	38	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	2014	384	9956					1729	1730		10.1016/S0140-6736(14)61187-9	http://dx.doi.org/10.1016/S0140-6736(14)61187-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AT7KX	25078305	hybrid			2023-01-03	WOS:000345116400008
J	Wani, KD; Kadu, BS; Mansara, P; Gupta, P; Deore, AV; Chikate, RC; Poddar, P; Dhole, SD; Kaul-Ghanekar, R				Wani, Kirtee D.; Kadu, Brijesh S.; Mansara, Prakash; Gupta, Preeti; Deore, Avinash V.; Chikate, Rajeev C.; Poddar, Pankaj; Dhole, Sanjay D.; Kaul-Ghanekar, Ruchika			Synthesis, Characterization and In Vitro Study of Biocompatible Cinnamaldehyde Functionalized Magnetite Nanoparticles (CPGF Nps) For Hyperthermia and Drug Delivery Applications in Breast Cancer	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; IRON-OXIDE NANOPARTICLES; ESTROGEN-RECEPTOR STATUS; FE3O4 NANOPARTICLES; CHEMOTHERAPY; CELLS; CYTOTOXICITY; EXPRESSION; CARCINOMA	Cinnamaldehyde, the bioactive component of the spice cinnamon, and its derivatives have been shown to possess anticancer activity against various cancer cell lines. However, its hydrophobic nature invites attention for efficient drug delivery systems that would enhance the bioavailability of cinnamaldehyde without affecting its bioactivity. Here, we report the synthesis of stable aqueous suspension of cinnamaldehyde tagged Fe3O4 nanoparticles capped with glycine and pluronic polymer (CPGF NPs) for their potential application in drug delivery and hyperthermia in breast cancer. The monodispersed superparamagnetic NPs had an average particulate size of similar to 20 nm. TGA data revealed the drug payload of similar to 18%. Compared to the free cinnamaldehyde, CPGF NPs reduced the viability of breast cancer cell lines, MCF7 and MDAMB231, at lower doses of cinnamaldehyde suggesting its increased bioavailability and in turn its therapeutic efficacy in the cells. Interestingly, the NPs were non-toxic to the non-cancerous HEK293 and MCF10A cell lines compared to the free cinnamaldehyde. The novelty of CPGF nanoparticulate system was that it could induce cytotoxicity in both ER/PRpositive/Her2 negative (MCF7) and ER/PRnegative/Her2 negative (MDAMB231) breast cancer cells, the latter being insensitive to most of the chemotherapeutic drugs. The NPs decreased the growth of the breast cancer cells in a dose-dependent manner and altered their migration through reduction in MMP-2 expression. CPGF NPs also decreased the expression of VEGF, an important oncomarker of tumor angiogenesis. They induced apoptosis in breast cancer cells through loss of mitochondrial membrane potential and activation of caspase-3. Interestingly, upon exposure to the radiofrequency waves, the NPs heated up to 41.6 degrees C within 1 min, suggesting their promise as a magnetic hyperthermia agent. All these findings indicate that CPGF NPs prove to be potential nano-chemotherapeutic agents in breast cancer.	[Wani, Kirtee D.; Mansara, Prakash; Kaul-Ghanekar, Ruchika] Interact Res Sch Hlth Affairs, Cell & Translat Res Lab, Pune, Maharashtra, India; [Kadu, Brijesh S.; Chikate, Rajeev C.] MES Abasaheb Garware Coll, Postgrad & Res Ctr, Dept Chem, Nanosci Grp, Pune, Maharashtra, India; [Gupta, Preeti; Poddar, Pankaj] CSIR, Natl Chem Lab, Phys & Mat Chem Div, Pune, Maharashtra, India; [Deore, Avinash V.; Dhole, Sanjay D.] Univ Pune, Dept Phys, Pune, Maharashtra, India	Bharati Vidyapeeth Deemed University; Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Chemical Laboratory (NCL); Savitribai Phule Pune University	Kaul-Ghanekar, R (corresponding author), Interact Res Sch Hlth Affairs, Cell & Translat Res Lab, Bharati Vidyapeeth Univ Med Coll Campus, Pune, Maharashtra, India.	ruchika.kaulghanekar@gmail.com	Chikate, Rajeev/AAJ-9613-2020	Chikate, Rajeev/0000-0002-6312-0582; Chikate, Rajeev/0000-0003-3777-9196; MANSARA, PRAKASH/0000-0002-2851-448X; Deore, Avinash/0000-0003-2412-4617	Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth University	Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth University	This work was supported by the Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggarwal BB, 2009, EXP BIOL MED, V234, P825, DOI 10.3181/0902-MR-78; Ahmed M, 2013, OPEN ACCESS SCI REPO, V2, P641, DOI DOI 10.2174/1381612826666200515132218; Akbarzadeh A, 2012, NANOTECHNOL SCI APPL, V5, P13, DOI 10.2147/NSA.S24328; Aljarrah K, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-62; Asin L, 2012, PHARM RES-DORDR, V29, P1319, DOI 10.1007/s11095-012-0710-z; Bentzon N, 2008, INT J CANCER, V122, P1089, DOI 10.1002/ijc.22892; Berry CC, 2003, J PHYS D APPL PHYS, V36, pR198, DOI 10.1088/0022-3727/36/13/203; Bhadoriya S. S., 2011, J CURR PHARM RES, V8, P1; Bhattaram VA, 2002, PHYTOMEDICINE, V9, P1; Binkley JM, 2012, CANCER-AM CANCER SOC, V118, P2207, DOI 10.1002/cncr.27469; Choudhari AS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070127; CLARK GM, 1983, NEW ENGL J MED, V309, P1343, DOI 10.1056/NEJM198312013092240; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dent R, 2009, BREAST CANCER RES TR, V115, P423, DOI 10.1007/s10549-008-0086-2; Ganta S, 2008, J CONTROL RELEASE, V126, P187, DOI 10.1016/j.jconrel.2007.12.017; Gonzales M, 2007, J MAGN MAGN MATER, V311, P59, DOI 10.1016/j.jmmm.2006.10.1150; Haffty BG, 2006, J CLIN ONCOL, V24, P5652, DOI 10.1200/JCO.2006.06.5664; Hasany S. F., 2012, NANOSCI NANOTECHNOL, V2, P148, DOI [DOI 10.5923/J.NN.20120206.01, 10.5923/J.NN.20120206.01]; Hilger I, 2012, NANOMEDICINE-UK, V7, P1443, DOI 10.2217/NNM.12.112; Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3; Ismail IA, 2012, BIOL PHARM BULL, V35, P895; Jain TK, 2005, MOL PHARMACEUT, V2, P194, DOI 10.1021/mp0500014; Kale SN, 2012, NANOMED-NANOTECHNOL, V8, P452, DOI 10.1016/j.nano.2011.07.010; Kareparamban J. A., 2012, International Journal of Research in Pharmacy and Chemistry, V2, P299; Kikumori T, 2009, BREAST CANCER RES TR, V113, P435, DOI 10.1007/s10549-008-9948-x; Kong G, 2000, CANCER RES, V60, P4440; Koppikar SJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-210; Kwon BM, 1998, ARCH PHARM RES, V21, P147, DOI 10.1007/BF02974019; Liao GS, 2013, EVID-BASED COMPL ALT, V2013, P1; Mauri FA, 1999, INT J ONCOL, V15, P1137; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; PAONE JF, 1981, SURG GYNECOL OBSTET, V152, P70; Patnaik JL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2901; Petri-Fink A, 2008, EUR J PHARM BIOPHARM, V68, P129, DOI 10.1016/j.ejpb.2007.02.024; Poddar P, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.060403; Quaranta M, 2007, ANTICANCER RES, V27, P3593; Ren YY, 2012, INT J NANOMED, V7, P2261, DOI 10.2147/IJN.S29357; Rose DP, 2009, EXPERT REV ANTICANC, V9, P1091, DOI 10.1586/ERA.09.71; Sadeghi-Aliabadi Hojjat, 2013, Avicenna Journal of Medical Biotechnology, V5, P96; Schott AF, 2012, J CLIN ONCOL, V30, P1747, DOI 10.1200/JCO.2011.41.3161; Shafi KVPM, 2002, CHEM MATER, V14, P1778, DOI [10.1021/cm011535+, 10.1021/cm011535]; Shieh DB, 2006, NANOTECHNOLOGY, V17, P4174, DOI 10.1088/0957-4484/17/16/030; Singh R, 2009, PHARM BIOL, V47, P1174, DOI 10.3109/13880200903019242; SONG CW, 1984, CANCER RES, V44, P4721; Stammati A, 1999, FOOD CHEM TOXICOL, V37, P813, DOI 10.1016/S0278-6915(99)00075-7; UNEMORI EN, 1992, J CELL PHYSIOL, V153, P557, DOI 10.1002/jcp.1041530317; VERONESI U, 1995, J NATL CANCER I, V87, P19, DOI 10.1093/jnci/87.1.19; Wani K. D., 2011, Journal of Bionanoscience, V5, P59, DOI 10.1166/jbns.2011.1041; WILLIAMS CH, 1988, BIOCHEM J, V256, P911, DOI 10.1042/bj2560911; Yin SY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/302426	50	51	52	2	54	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2014	9	9							e107315	10.1371/journal.pone.0107315	http://dx.doi.org/10.1371/journal.pone.0107315			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR6CW	25268975	Green Submitted, Green Published, gold			2023-01-03	WOS:000343671700036
J	Jaouadi, NZ; Jaouadi, B; Ben Hlima, H; Rekik, H; Belhoul, M; Hmidi, M; Ben Aicha, HS; Hila, CG; Toumi, A; Aghajari, N; Bejar, S				Jaouadi, Nadia Zarai; Jaouadi, Bassem; Ben Hlima, Hajer; Rekik, Hatem; Belhoul, Mouna; Hmidi, Maher; Ben Aicha, Houda Slimene; Hila, Chiraz Gorgi; Toumi, Abdessatar; Aghajari, Nushin; Bejar, Samir			Probing the Crucial Role of Leu31 and Thr33 of the Bacillus pumilus CBS Alkaline Protease in Substrate Recognition and Enzymatic Depilation of Animal Hide	PLOS ONE			English	Article							MOLECULAR CHARACTERIZATION; SERINE-PROTEASE; PURIFICATION; SPECIFICITY; SKINS	The sapB gene, encoding Bacillus pumilus CBS protease, and seven mutated genes (sapB-L31I, sapB-T33S, sapB-N99Y, sapB-L31I/T33S, sapB-L31I/N99Y, sapB-T33S/N99Y, and sapB-L31I/T33S/N99Y) were overexpressed in protease-deficient Bacillus subtilis DB430 and purified to homogeneity. SAPB-N99Y and rSAPB displayed the highest levels of keratinolytic activity, hydrolysis efficiency, and enzymatic depilation. Interestingly, and at the semi-industrial scale, rSAPB efficiently removed the hair of goat hides within a short time interval of 8 h, thus offering a promising opportunity for the attainment of a lime and sulphide-free depilation process. The efficacy of the process was supported by submitting depilated pelts and dyed crusts to scanning electron microscopic analysis, and the results showed well opened fibre bundles and no apparent damage to the collagen layer. The findings also revealed better physico-chemical properties and less effluent loads, which further confirmed the potential candidacy of the rSAPB enzyme for application in the leather industry to attain an ecofriendly process of animal hide depilation. More interestingly, the findings on the substrate specificity and kinetic properties of the enzyme using the synthetic peptide para-nitroanilide revealed strong preferences for an aliphatic amino-acid (valine) at position P1 for keratinases and an aromatic amino-acid (phenylalanine) at positions P1/P4 for subtilisins. Molecular modeling suggested the potential involvement of a Leu31 residue in a network of hydrophobic interactions, which could have shaped the S4 substrate binding site. The latter could be enlarged by mutating L31I, fitting more easily in position P4 than a phenylalanine residue. The molecular modeling of SAPB-T33S showed a potential S2 subside widening by a T33S mutation, thus suggesting its importance in substrate specificity.	[Jaouadi, Nadia Zarai; Jaouadi, Bassem; Ben Hlima, Hajer; Rekik, Hatem; Belhoul, Mouna; Hmidi, Maher; Bejar, Samir] Univ Sfax, CBS, Lab Microorganisms & Biomol, Sfax, Tunisia; [Ben Aicha, Houda Slimene; Hila, Chiraz Gorgi; Toumi, Abdessatar] Natl Leather & Shoe Ctr CNCC, Megrine, Ben Arous, Tunisia; [Aghajari, Nushin] UMR 5086 CNRS Univ Lyon 1, IBCP, Lab Biocrystallog & Struct Biol Therapeut Targets, FR3302, Lyon, France	Centre de Biotechnologie de Sfax; Universite de Sfax; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Jaouadi, B (corresponding author), Univ Sfax, CBS, Lab Microorganisms & Biomol, Sfax, Tunisia.	bassem.jaouadi@cbs.rnrt.tn; samir.bejar@cbs.rnrt.tn	Aghajari, Nushin B.H./P-1906-2016; JAOUADI, Bassem/AAN-8106-2021	Aghajari, Nushin B.H./0000-0002-2245-2679; Bassem, JAOUADI/0000-0002-5182-7353	Tunisian Ministry of Higher Education, Scientific Research and Information and Communication Technologies Higher Education and Scientific Research sector under the "Contract Program LMB-CBS" [LR10CBS04 2010-2013]; Tunisian Ministry of Industry, Energy and Mines [PNRI-ENZYMES 2012-2015]	Tunisian Ministry of Higher Education, Scientific Research and Information and Communication Technologies Higher Education and Scientific Research sector under the "Contract Program LMB-CBS"; Tunisian Ministry of Industry, Energy and Mines	This work was funded by the Tunisian Ministry of Higher Education, Scientific Research and Information and Communication Technologies Higher Education and Scientific Research sector under the "Contract Program LMB-CBS, grant no. LR10CBS04 2010-2013" and the Tunisian Ministry of Industry, Energy and Mines under the "National Programme for the Promotion of Technological Innovation, grant no. PNRI-ENZYMES 2012-2015." The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Public Health Association, 1995, STANDARD METHODS EXA; [Anonymous], 2018, 40482018 ISO; [Anonymous], 53971984 ISO; Benkiar A, 2013, INT BIODETER BIODEGR, V83, P129, DOI 10.1016/j.ibiod.2013.05.014; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Colmenares JC, 2014, APPL CATAL B-ENVIRON, V150, P432, DOI 10.1016/j.apcatb.2013.12.038; Dayanandan A, 2003, J CLEAN PROD, V11, P533, DOI 10.1016/S0959-6526(02)00056-2; Gamble M, 2012, FEBS OPEN BIO, V2, P209, DOI 10.1016/j.fob.2012.07.001; Gupta R, 2006, APPL MICROBIOL BIOT, V70, P21, DOI 10.1007/s00253-005-0239-8; Gupta R, 2002, APPL MICROBIOL BIOT, V59, P15, DOI 10.1007/s00253-002-0975-y; Huang Q, 2003, CURR MICROBIOL, V46, P169, DOI 10.1007/s00284-002-3850-2; IUP, 2000, S J SOC LEATHER TECH, V84, P327; IUP 6, 2000, J SOC LEATHER TECHNO, V84, P312; Jain SC, 1998, J MOL BIOL, V284, P137, DOI 10.1006/jmbi.1998.2161; Jaouadi B, 2008, BIOCHIMIE, V90, P1291, DOI 10.1016/j.biochi.2008.03.004; Jaouadi B, 2010, BIORESOURCE TECHNOL, V101, P8361, DOI 10.1016/j.biortech.2010.05.066; Jaouadi B, 2010, BIOCHIMIE, V92, P360, DOI 10.1016/j.biochi.2010.01.008; Jaouadi NZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076722; Jaouadi NZ, 2012, BIORESOURCE TECHNOL, V105, P142, DOI 10.1016/j.biortech.2011.11.115; Kumar AG, 2008, J APPL MICROBIOL, V104, P411, DOI 10.1111/j.1365-2672.2007.03564.x; Kumar EV, 2011, BIOPROC BIOSYST ENG, V34, P403, DOI 10.1007/s00449-010-0483-x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Najafi MF, 2005, ELECTRON J BIOTECHN, V8, P197, DOI 10.2225/vol8-issue2-fulltext-5; Nilegaonkar SS, 2007, BIORESOURCE TECHNOL, V98, P1238, DOI 10.1016/j.biortech.2006.05.003; Pandeeti EVP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016742; Pillai P, 2008, APPL MICROBIOL BIOT, V78, P643, DOI 10.1007/s00253-008-1355-z; Rao MB, 1998, MICROBIOL MOL BIOL R, V62, P597, DOI 10.1128/MMBR.62.3.597-635.1998; Sambrook J., 1989, MOL CLONING LAB MANU, P23; SCHECHTER I, 1968, BIOCHEM BIOPH RES CO, V32, P898, DOI 10.1016/0006-291X(68)90326-4; Siezen RJ, 1997, PROTEIN SCI, V6, P501; Sivasubramanian S, 2008, CHEMOSPHERE, V70, P1025, DOI 10.1016/j.chemosphere.2007.07.084; Sivasubramanian S, 2008, CHEMOSPHERE, V70, P1015, DOI 10.1016/j.chemosphere.2007.09.036; Sundararajan S, 2011, J BIOSCI BIOENG, V111, P128, DOI 10.1016/j.jbiosc.2010.09.009; Takagi H, 1996, FEBS LETT, V395, P127, DOI 10.1016/0014-5793(96)01014-9; Thanikaivelan P, 2004, TRENDS BIOTECHNOL, V22, P181, DOI 10.1016/j.tibtech.2004.02.008; Thanikaivelan P, 2003, ENVIRON SCI TECHNOL, V37, P2609, DOI 10.1021/es026474a; Thanikaivelan P, 2002, ENVIRON SCI TECHNOL, V36, P4187, DOI 10.1021/es025618i; Wang HY, 2007, LETT APPL MICROBIOL, V44, P1, DOI 10.1111/j.1472-765X.2006.02039.x	38	30	31	2	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2014	9	9							e108367	10.1371/journal.pone.0108367	http://dx.doi.org/10.1371/journal.pone.0108367			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU6XR	25264614	Green Published, gold, Green Submitted			2023-01-03	WOS:000345745400070
J	Fennell, DA; Myrand, SP; Nguyen, TS; Ferry, D; Kerr, KM; Maxwell, P; Moore, SD; Visseren-Grul, C; Das, M; Nicolson, MC				Fennell, Dean A.; Myrand, Scott P.; Nguyen, Tuan S.; Ferry, David; Kerr, Keith M.; Maxwell, Perry; Moore, Stephen D.; Visseren-Grul, Carla; Das, Mayukh; Nicolson, Marianne C.			Association between Gene Expression Profiles and Clinical Outcome of Pemetrexed-Based Treatment in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Exploratory Results from a Phase II Study	PLOS ONE			English	Article							THYROID TRANSCRIPTION FACTOR-1; THYMIDYLATE SYNTHASE; MESSENGER-RNA; ADENOCARCINOMA; CHEMOTHERAPY; GEMCITABINE; INHIBITION; MICROARRAY; INDUCTION; CARCINOMA	Introduction: We report exploratory gene-expression profiling data from a single-arm Phase-II-study in patients with non-squamous (ns) NSCLC treated with pemetrexed and cisplatin. Previously disclosed results indicated a significant association of low thymidylate-synthase (TS)-expression with longer progression-free and overall survival (PFS/OS). Methods: Treatment-naive nsNSCLC patients (IIIB/IV) received 4 cycles of pemetrexed/cisplatin; non-progressing patients continued on pemetrexed-maintenance. Diagnostic tissue-samples were used to assess TS-expression by immunohistochemistry (IHC) and mRNA-expression array-profiling (1,030 lung cancer-specific genes). Cox proportional-hazard models were applied to explore the association between each gene and PFS/OS. Genes significantly correlated with PFS/OS were further correlated with TS-protein expression (Spearman-rank). Unsupervised clustering was applied to all evaluable samples (n = 51) for all 1,030 genes and an overlapping 870-gene subset associated with adenocarcinoma (ADC, n = 47). Results: 51/70 tissue-samples (72.9%) were evaluable; 9 of 1,030 genes were significantly associated with PFS/OS (unadjusted p<0.01, genes: Chromosome 16 open reading frame 89, napsin A, surfactant protein B, aquaporin 4, TRAF2- and Nck-interacting kinase, Lysophosphatidylcholine acyltransferase 1, Interleukin 1 receptor type II, NK2 homeobox 1, ABO glycosyl-transferase); expression for all except IL1R2 correlated negatively with nuclear TS-expression (statistically significant for 5/8 genes, unadjusted p<0.01). Cluster-analysis based on 1,030 genes revealed no clear trend regarding PFS/OS; the ADC-based cluster analysis identified 3 groups (n = 21/11/15) with median (95%CI) PFS of 8.1(6.9,NE)/2.4(1.2,NE)/4.4(1.2, NE) months and OS of 20.3(17.5,NE)/4.3(1.4,NE)/8.3(3.9,NE) months, respectively. Conclusions: These exploratory gene-expression profiling results describe genes potentially linked to low TS-expression. Nine genes were significantly associated with PFS/OS but could not be differentiated as prognostic or predictive as this was a single-arm study. Although these hypotheses-generating results are interesting, they provide no evidence to change the current histology-based treatment approach with pemetrexed.	[Fennell, Dean A.] Leicester Univ Hosp, Leicester, Leics, England; [Myrand, Scott P.; Nguyen, Tuan S.] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Ferry, David] New Cross Hosp, Wolverhampton, W Midlands, England; [Kerr, Keith M.; Nicolson, Marianne C.] Univ Aberdeen, Aberdeen Royal Infirm, Aberdeen, Scotland; [Maxwell, Perry] Queens Univ, Belfast, Antrim, North Ireland; [Moore, Stephen D.] Almac Diagnost, Craigavon, North Ireland; [Visseren-Grul, Carla] Eli Lilly & Co, Houten, Netherlands; [Das, Mayukh] Eli Lilly & Co, Basingstoke, Hants, England	University Hospitals of Leicester NHS Trust; Eli Lilly; New Cross Hospital; University of Aberdeen; Queens University Belfast; Eli Lilly; Eli Lilly	Fennell, DA (corresponding author), Leicester Univ Hosp, Leicester, Leics, England.	df132@leicester.ac.uk			Eli Lilly and company	Eli Lilly and company(Eli Lilly)	This study was funded by Eli Lilly and company. The funder was involved in study design, data collection and analysis, decision to publish, and preparation of the manuscript.	Afink GB, 2010, THYROID, V20, P811, DOI 10.1089/thy.2009.0366; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Ceppi P, 2006, CANCER-AM CANCER SOC, V107, P1589, DOI 10.1002/cncr.22208; Chen CY, 2011, LUNG CANCER, V74, P132, DOI 10.1016/j.lungcan.2011.01.024; Christoph DC, 2013, J THORAC ONCOL, V8, P19, DOI 10.1097/JTO.0b013e31827628ff; Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417; Ellis Bryon, 2012, World J Biol Chem, V3, P159, DOI 10.4331/wjbc.v3.i7.159; Fu CA, 1999, J BIOL CHEM, V274, P30729, DOI 10.1074/jbc.274.43.30729; Giovannetti E, 2005, MOL PHARMACOL, V68, P110, DOI 10.1124/mol.104.009373; Hayes DN, 2006, J CLIN ONCOL, V24, P5079, DOI 10.1200/JCO.2005.05.1748; Katz S, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-464; Khoor A, 1997, MODERN PATHOL, V10, P62; Lee JG, 2012, LUNG CANCER, V77, P156, DOI 10.1016/j.lungcan.2012.02.013; Mendelsohn LG, 1999, SEMIN ONCOL, V26, P42; Moldvay J, 2004, PATHOL ONCOL RES, V10, P85, DOI 10.1007/BF02893461; Nicolson MC, 2013, J THORAC ONCOL, V8, P930, DOI 10.1097/JTO.0b013e318292c500; Olsson ML, 2001, TRANSFUSION MED, V11, P295, DOI 10.1046/j.1365-3148.2001.00320.x; Paz-Ares LG, 2013, J CLIN ONCOL, V31, P2895, DOI 10.1200/JCO.2012.47.1102; Re F, 1996, J EXP MED, V183, P1841, DOI 10.1084/jem.183.4.1841; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Shitashige M, 2010, CANCER RES, V70, P5024, DOI 10.1158/0008-5472.CAN-10-0306; Sigmond J, 2003, BIOCHEM PHARMACOL, V66, P431, DOI 10.1016/S0006-2952(03)00287-9; Sun JM, 2011, J THORAC ONCOL, V6, P1392, DOI 10.1097/JTO.0b013e3182208ea8; Tang XM, 2011, CLIN CANCER RES, V17, P2434, DOI 10.1158/1078-0432.CCR-10-1412; Tanney A, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-20; Turner BM, 2012, ARCH PATHOL LAB MED, V136, P163, DOI 10.5858/arpa.2011-0320-OA; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; Warth A, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-161; Wilkerson MD, 2013, J MOL DIAGN, V15, P485, DOI 10.1016/j.jmoldx.2013.03.007; Wilkerson MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036530; Xie YP, 2012, CLIN LAB, V58, P75; Yang L, 2012, J ZHEJIANG UNIV-SC B, V13, P855, DOI 10.1631/jzus.B1100382	33	8	9	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2014	9	9							e107455	10.1371/journal.pone.0107455	http://dx.doi.org/10.1371/journal.pone.0107455			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ0SJ	25250715	Green Published, gold, Green Submitted			2023-01-03	WOS:000342492700032
J	Luo, HY; Zeng, CQ; Fang, C; Seeruttun, SR; Lv, L; Wang, W				Luo, Huiyan; Zeng, Changqing; Fang, Cheng; Seeruttun, Sharvesh Raj; Lv, Lin; Wang, Wei			A New Strategy Using ALDH(high)-CD8+T Cells to Inhibit Tumorigenesis	PLOS ONE			English	Article							CANCER STEM-CELLS; PULSED DENDRITIC CELLS; LUNG-CANCER; INITIATING CELLS; PROSTATE-CANCER; HETEROGENEITY; VACCINATION; MARKER; MODEL; TRIAL	Background: Currently, many studies suggest that cancer stem cells (CSCs) are responsible for tumor initiation, tumorigenesis, metastasis and recurrence. CSCs have been identified from various human and murine tumors. The identification of CSCs allows us to develop strategies to target the CSCs. Methods and Results: In this study, we used ALDEFLUOR as a single marker to isolate the CSCs from the human lung cancer cell line H460. We then characterized the CSCs by testing their sphere formation ability and tumorigenicity. Furthermore, we used CSC lysate-pulsed dendritic cells to stimulate CD8+T cells as a treatment strategy. Our study demonstrated that ALDEFLUOR could be used as a single marker to identify CSCs from the human lung cancer cell line H460. The ALDH(high) cells could form more spheres and were more tumorigenic than the ALDH(low) cells. Further study demonstrated that ALDH(high)-CD8+T cells conferred more significant antitumor effects, resulting in the inhibition of tumor growth and prolonged survival. And the ALDH(high)-CD8+ T cells-mediated anti-tumor immunity might be due to the directly targeting against ALDH(high) cancer stem cells (CSCs). Conclusions: This study shows that ALDH(high)-CD8+ T cells mediate anti-tumor immunity by selectively targeting cancer stem cells, which result in inhibiting tumor growth and prolonging the survival of tumor-bearing mice, which provides a new strategy using ALDH(high)-CD8+ T cells to treat tumors.	[Luo, Huiyan] Third Peoples Hosp Chongqing, Dept Oncol, Chongqing, Peoples R China; [Zeng, Changqing] Fujian Prov Hosp, Dept Gastrointestinal Surg, Fuzhou, Peoples R China; [Zeng, Changqing] Fujian Med Univ, Prov Clin Med Coll, Fuzhou, Peoples R China; [Fang, Cheng; Seeruttun, Sharvesh Raj; Wang, Wei] Sun Yat Sen Univ, Dept Gastr & Pancreat Surg, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China; [Luo, Huiyan; Fang, Cheng; Seeruttun, Sharvesh Raj; Lv, Lin; Wang, Wei] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Luo, Huiyan; Fang, Cheng; Seeruttun, Sharvesh Raj; Lv, Lin; Wang, Wei] Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [Lv, Lin] Guangzhou First Peoples Hosp, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China	Fujian Provincial Hospital; Fujian Medical University; Sun Yat Sen University; State Key Lab Oncology South China; South China University of Technology	Lv, L (corresponding author), State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China.	lvlin@sysucc.org.cn; wangwei@sysucc.org.cn			National Natural Science Foundation of China [81201773]; Specialized Research Fund for the Doctoral Program of Higher Education of China [20120171120114]; Science and technology project of Fujian Province [2014J01284]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Specialized Research Fund for the Doctoral Program of Higher Education of China(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Science and technology project of Fujian Province	This project was supported by the National Natural Science Foundation of China (grant no. 81201773), the Specialized Research Fund for the Doctoral Program of Higher Education of China (grant no. 20120171120114), and the Science and technology project of Fujian Province (2014J01284). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alamgeer M, 2013, RESPIROLOGY, V18, P757, DOI 10.1111/resp.12094; Carpentino JE, 2009, CANCER RES, V69, P8208, DOI 10.1158/0008-5472.CAN-09-1132; Chang AE, 2003, J CLIN ONCOL, V21, P884, DOI 10.1200/JCO.2003.08.023; Chang AE, 2002, CLIN CANCER RES, V8, P1021; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Dougan M, 2009, ANNU REV IMMUNOL, V27, P83, DOI 10.1146/annurev.immunol.021908.132544; Duarte S, 2013, STEM CELLS, V31, P423, DOI 10.1002/stem.1292; Garcia-Hernandez MD, 2008, CANCER RES, V68, P861, DOI 10.1158/0008-5472.CAN-07-0445; Geissler C, 2012, IN VIVO, V26, P593; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Huang CP, 2013, CANCER LETT, V328, P144, DOI 10.1016/j.canlet.2012.08.021; Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418; Laga AC, 2010, ARCH PATHOL LAB MED, V134, P1750, DOI 10.1043/2009-0394-RAR.1; Liang D, 2012, MED ONCOL, V29, P633, DOI 10.1007/s12032-011-9933-9; Lu L, 2013, J IMMUNOTHER, V36, P451, DOI 10.1097/CJI.0b013e3182a802cf; Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584; Ning N, 2012, CANCER RES, V72, P1853, DOI 10.1158/0008-5472.CAN-11-1400; OLDHAM RK, 1986, J CELL PHYSIOL, P91; Park SY, 2010, CLIN CANCER RES, V16, P876, DOI 10.1158/1078-0432.CCR-09-1532; Redman BG, 2008, J IMMUNOTHER, V31, P591, DOI 10.1097/CJI.0b013e31817fd90b; Shafee N, 2008, CANCER RES, V68, P3243, DOI 10.1158/0008-5472.CAN-07-5480; Sottoriva A, 2010, CANCER RES, V70, P46, DOI 10.1158/0008-5472.CAN-09-3663; Valent P, 2013, CANCER RES, V73, P1037, DOI 10.1158/0008-5472.CAN-12-3678; van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806; Visus C, 2011, CLIN CANCER RES, V17, P6174, DOI 10.1158/1078-0432.CCR-11-1111; Yang Ping, 2009, V471, P469, DOI 10.1007/978-1-59745-416-2_24	26	22	22	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2014	9	8							e103193	10.1371/journal.pone.0103193	http://dx.doi.org/10.1371/journal.pone.0103193			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR0CG	25105957	gold, Green Published, Green Submitted			2023-01-03	WOS:000343231900010
J	Le Floc'h, N; Deblanc, C; Cariolet, R; Gautier-Bouchardon, AV; Merlot, E; Simon, G				Le Floc'h, Nathalie; Deblanc, Celine; Cariolet, Roland; Gautier-Bouchardon, Anne V.; Merlot, Elodie; Simon, Gaelle			Effect of Feed Restriction on Performance and Postprandial Nutrient Metabolism in Pigs Co-Infected with Mycoplasma hyopneumoniae and Swine Influenza Virus	PLOS ONE			English	Article							AMINO-ACID; IMMUNE-SYSTEM; GLUCOSE-METABOLISM; MUCIN SYNTHESIS; PRE-INFECTION; PROTEIN; PLASMA; INFLAMMATION; THREONINE; DISEASE	As nutritional status and inflammation are strongly connected, feeding and nutritional strategies could be effective to improve the ability of pigs to cope with disease. The aims of this study were to investigate the impact of a feed restriction on the ability of pigs to resist and be tolerant to a coinfection with Mycoplasma hyopneumoniae (Mhp) and the European H1N1 swine influenza virus, and the consequences for nutrient metabolism, with a focus on amino acids. Two groups of specific pathogen-free pigs were inoculated with Mhp and H1N1 21 days apart. One group was fed ad libitum, the other group was subjected to a two-week 40% feed restriction starting one week before H1N1 infection. The two respective mock control groups were included. Three days post-H1N1 infection, 200 g of feed was given to pigs previously fasted overnight and serial blood samples were taken over 4 hours to measure plasma nutrient concentrations. Throughout the study, clinical signs were observed and pathogens were detected in nasal swabs and lung tissues. Feed-restricted pigs presented shorter hyperthermia and a positive mean weight gain over the 3 days post-H1N1 infection whereas animals fed ad libitum lost weight. Both infection and feed restriction reduced postprandial glucose concentrations, indicating changes in glucose metabolism. Post-prandial plasma concentrations of the essential amino acids histidine, arginine and threonine were lower in co-infected pigs suggesting a greater use of those amino acids for metabolic purposes associated with the immune response. Altogether, these results indicate that modifying feeding practices could help to prepare animals to overcome an influenza infection. Connections with metabolism changes are discussed.	[Le Floc'h, Nathalie; Merlot, Elodie] INRA, PEGASE UMR1348, St Gilles, France; [Le Floc'h, Nathalie; Merlot, Elodie] Agrocampus Ouest, PEGASE UMR1348, Rennes, France; [Deblanc, Celine; Simon, Gaelle] Anses, Ploufragan Plouzane Lab, Swine Virol Immunol Unit, BP53, Ploufragan, France; [Deblanc, Celine; Cariolet, Roland; Gautier-Bouchardon, Anne V.; Simon, Gaelle] European Univ Brittany, Rennes, France; [Cariolet, Roland] Anses, Ploufragan Plouzane Lab, Prod Decontaminated Pigs & Testing, BP53, Ploufragan, France; [Gautier-Bouchardon, Anne V.] Anses, Ploufragan Plouzane Lab, Mycoplasmol Bacteriol Unit, BP53, Ploufragan, France	INRAE; Institut Agro; Agrocampus Ouest; Agence Nationale de Securite Sanitaire de l'Alimentation, de l'Environnement du Travail (ANSES); Agence Nationale de Securite Sanitaire de l'Alimentation, de l'Environnement du Travail (ANSES); Agence Nationale de Securite Sanitaire de l'Alimentation, de l'Environnement du Travail (ANSES)	Deblanc, C (corresponding author), Anses, Ploufragan Plouzane Lab, Swine Virol Immunol Unit, BP53, Ploufragan, France.	celine.deblanc@anses.fr	le floc'h, nathalie/L-6049-2018; Simon, Gaelle/ABI-1479-2020; Merlot, Elodie/AAQ-8761-2020	Simon, Gaelle/0000-0003-1099-5075; Merlot, Elodie/0000-0003-2300-0970; Le Floch, Nathalie/0000-0001-9858-1584	FARM'APRO; Conseil General des Cotes d'Armor	FARM'APRO; Conseil General des Cotes d'Armor(Region BretagneRegion Pays de la Loire)	This work received financial support from FARM'APRO. FARM'APRO participated in the study design but had no role in the data collection and analysis, decision to publish, or preparation of the manuscript. Remuneration of the Anses' personnel from the unit "Production of decontaminated pigs and testing'' was partially supported by the Conseil General des Cotes d'Armor. This funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BECHT H, 1971, J VIROL, V7, P204, DOI 10.1128/JVI.7.2.204-207.1971; Bruins MJ, 2003, CLIN SCI, V104, P127, DOI 10.1042/CS20020275; CALDER PC, 1995, P NUTR SOC, V54, P65, DOI 10.1079/PNS19950038; Calder PC, 2007, CURR OPIN CLIN NUTR, V10, P531, DOI 10.1097/MCO.0b013e3281e72ad4; CUARON JA, 1984, J ANIM SCI, V58, P631, DOI 10.2527/jas1984.583631x; Deblanc C, 2013, VET MICROBIOL, V162, P643, DOI 10.1016/j.vetmic.2012.11.028; Deblanc C, 2012, VET MICROBIOL, V157, P96, DOI 10.1016/j.vetmic.2011.12.027; Detilleux JC, 2011, GENET SEL EVOL, V43, DOI 10.1186/1297-9686-43-9; Fablet C, 2012, VET MICROBIOL, V157, P152, DOI 10.1016/j.vetmic.2011.12.015; Grimble RF, 1998, NUTRITION, V14, P634, DOI 10.1016/S0899-9007(98)00010-0; Heyer A, 2007, J ANIM SCI, V85, P769, DOI 10.2527/jas.2006-164; IMAMURA M, 1975, SURGERY, V77, P868; Jahoor F, 1999, J NUTR, V129, P693, DOI 10.1093/jn/129.3.693; Jonasson R, 2007, RES VET SCI, V82, P323, DOI 10.1016/j.rvsc.2006.08.005; Kagemann G, 2005, BIOL CHEM, V386, P1055, DOI 10.1515/BC.2005.121; Kaore SN, 2013, FUND CLIN PHARMACOL, V27, P35, DOI 10.1111/j.1472-8206.2012.01059.x; Kim CH, 2012, VET J, V192, P120, DOI 10.1016/j.tvjl.2011.04.023; Klasing KC, 1999, EAAP PUBLIC, P253; Konsman JP, 2001, NUTRITION, V17, P664, DOI 10.1016/S0899-9007(01)00602-5; KOONG LJ, 1982, J NUTR, V112, P1638, DOI 10.1093/jn/112.8.1638; Kuntz-Simon G, 2009, ZOONOSES PUBLIC HLTH, V56, P310, DOI 10.1111/j.1863-2378.2009.01236.x; Kuntz -Simon G., 2010, INFECT PARASITIC DIS, V1, P273; Le Floc'h N, 2005, BRIT J NUTR, V93, P447, DOI 10.1079/BJN20051375; Le Floc'h N, 2004, LIVEST PROD SCI, V87, P37, DOI 10.1016/j.livprodsci.2003.09.005; Le Floc'h N, 2011, AMINO ACIDS, V41, P1195, DOI 10.1007/s00726-010-0752-7; Li DF, 1999, ANIM FEED SCI TECH, V78, P179, DOI 10.1016/S0377-8401(99)00005-X; Lien KA, 1997, Z ERNAHRUNGSWISS, V36, P182, DOI 10.1007/BF01611398; Lkhagvadorj S, 2010, AM J PHYSIOL-REG I, V298, P25; LLOYD C, 1984, IN VITRO CELL DEV B, V20, P416, DOI 10.1007/BF02619588; Madec F, 1982, J RECH PORCINE FRANC, V14, P405; Marois C, 2010, J APPL MICROBIOL, V108, P1523, DOI 10.1111/j.1365-2672.2009.04556.x; Mata M, 2011, BIOCHEM PHARMACOL, V82, P548, DOI 10.1016/j.bcp.2011.05.014; Matsuzaki J, 2001, J NUTR, V131, P2139, DOI 10.1093/jn/131.8.2139; Melchior D, 2004, J ANIM SCI, V82, P1091; Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378; Nafikov RA, 2007, J NUTR, V137, P702, DOI 10.1093/jn/137.3.702; Newsholme P, 2001, J NUTR, V131, p2515S, DOI 10.1093/jn/131.9.2515S; Noah L, 2000, AM J PHYSIOL-ENDOC M, V278, pE181, DOI 10.1152/ajpendo.2000.278.2.E181; Obled C, 2002, CAN J ANIM SCI, V82, P55; Opriessnig T., 2011, Animal Health Research Reviews, V12, P133, DOI 10.1017/S1466252311000120; Perrone LA, 2013, J INFECT DIS, V207, P1576, DOI 10.1093/infdis/jit062; Pithon-Curi TC, 2004, CELL BIOCHEM FUNCT, V22, P321, DOI 10.1002/cbf.1109; Pol F, 2011, J VIROL METHODS, V171, P241, DOI 10.1016/j.jviromet.2010.11.007; Rantzer D, 1996, ACTA AGR SCAND A-AN, V46, P219, DOI 10.1080/09064709609415874; REEDS PJ, 1994, J NUTR, V124, P906, DOI 10.1093/jn/124.6.906; Reeds PJ, 2001, CLIN NUTR, V20, P15, DOI 10.1054/clnu.2001.0402; Reeth VK, 2012, DIS SWINE, V10th, P557; Remond D, 2009, J NUTR, V139, P720, DOI 10.3945/jn.108.101675; Rose N, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-72; WANNEMACHER RW, 1977, AM J CLIN NUTR, V30, P1269, DOI 10.1093/ajcn/30.8.1269; Yoo SS, 1997, J NUTR, V127, P2253, DOI 10.1093/jn/127.11.2253; Zervas S, 2002, J ANIM SCI, V80, P3238	52	19	19	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 7	2014	9	8							e104605	10.1371/journal.pone.0104605	http://dx.doi.org/10.1371/journal.pone.0104605			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6SB	25101681	Green Published, Green Submitted, gold			2023-01-03	WOS:000339993900078
J	Oh, YT; Cho, HJ; Kim, JK; Lee, JH; Rho, K; Seo, YJ; Choi, YS; Jung, HJ; Song, HS; Kong, DS; Seol, HJ; Lee, JI; Yoon, Y; Kim, SH; Nam, DH; Joo, KM				Oh, Young Taek; Cho, Hee Jin; Kim, Jinkuk; Lee, Ji-Hyun; Rho, Kyoohyoung; Seo, Yun-Jee; Choi, Yeon-Sook; Jung, Hye Jin; Song, Hyeon Suk; Kong, Doo-Sik; Seol, Ho Jun; Lee, Jung-Il; Yoon, Yeup; Kim, Sunghoon; Nam, Do-Hyun; Joo, Kyeung Min			Translational Validation of Personalized Treatment Strategy Based on Genetic Characteristics of Glioblastoma	PLOS ONE			English	Article							RECURSIVE PARTITIONING ANALYSIS; CENTRAL-NERVOUS-SYSTEM; NUDE-MOUSE MODEL; TUMOR MICROENVIRONMENT; PANCREATIC-CANCER; DRUG DEVELOPMENT; MULTIFORME; TEMOZOLOMIDE; XENOGRAFT; BRAIN	Glioblastoma (GBM) heterogeneity in the genomic and phenotypic properties has potentiated personalized approach against specific therapeutic targets of each GBM patient. The Cancer Genome Atlas (TCGA) Research Network has been established the comprehensive genomic abnormalities of GBM, which sub-classified GBMs into 4 different molecular subtypes. The molecular subtypes could be utilized to develop personalized treatment strategy for each subtype. We applied a classifying method, NTP (Nearest Template Prediction) method to determine molecular subtype of each GBM patient and corresponding orthotopic xenograft animal model. The models were derived from GBM cells dissociated from patient's surgical sample. Specific drug candidates for each subtype were selected using an integrated pharmacological network database (PharmDB), which link drugs with subtype specific genes. Treatment effects of the drug candidates were determined by in vitro limiting dilution assay using patient-derived GBM cells primarily cultured from orthotopic xenograft tumors. The consistent identification of molecular subtype by the NTP method was validated using TCGA database. When subtypes were determined by the NTP method, orthotopic xenograft animal models faithfully maintained the molecular subtypes of parental tumors. Subtype specific drugs not only showed significant inhibition effects on the in vitro clonogenicity of patient-derived GBM cells but also synergistically reversed temozolomide resistance of MGMT-unmethylated patient-derived GBM cells. However, inhibitory effects on the clonogenicity were not totally subtype-specific. Personalized treatment approach based on genetic characteristics of each GBM could make better treatment outcomes of GBMs, although more sophisticated classifying techniques and subtype specific drugs need to be further elucidated.	[Oh, Young Taek; Cho, Hee Jin; Kim, Jinkuk; Seo, Yun-Jee; Choi, Yeon-Sook; Jung, Hye Jin; Song, Hyeon Suk; Kong, Doo-Sik; Seol, Ho Jun; Lee, Jung-Il; Yoon, Yeup; Nam, Do-Hyun; Joo, Kyeung Min] Samsung Med Ctr, Samsung Biomed Res Inst, Seoul, South Korea; [Oh, Young Taek; Cho, Hee Jin; Kim, Jinkuk; Seo, Yun-Jee; Choi, Yeon-Sook; Jung, Hye Jin; Song, Hyeon Suk; Kong, Doo-Sik; Seol, Ho Jun; Lee, Jung-Il; Yoon, Yeup; Nam, Do-Hyun; Joo, Kyeung Min] Samsung Med Ctr, Inst Refractory Canc Res, Seoul, South Korea; [Oh, Young Taek; Cho, Hee Jin; Yoon, Yeup; Nam, Do-Hyun; Joo, Kyeung Min] Sungkyunkwan Univ, SAIHST, Seoul, South Korea; [Kong, Doo-Sik; Seol, Ho Jun; Lee, Jung-Il; Nam, Do-Hyun] Sungkyunkwan Univ, Sch Med, Dept Neurosurg, Seoul, South Korea; [Joo, Kyeung Min] Sungkyunkwan Univ, Sch Med, Dept Anat & Cell Biol, Seoul, South Korea; [Kim, Jinkuk] Samsung Elect Co Ltd, Samsung Adv Inst Technol, Seoul, South Korea; [Lee, Ji-Hyun; Rho, Kyoohyoung; Kim, Sunghoon] Seoul Natl Univ, Coll Pharm, Med Bioconvergence Res Ctr, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Samsung; Seoul National University (SNU)	Kim, SH (corresponding author), Seoul Natl Univ, Coll Pharm, Med Bioconvergence Res Ctr, Seoul, South Korea.	sungkim@snu.ac.kr; nsnam@skku.edu; kmjoo@skku.edu	Kim, Jinkuk/AAJ-1999-2020; Kim, Sunghoon/AAE-8314-2020; Oh, Michael/AAO-8026-2020	Oh, Michael/0000-0001-8356-2428; kim, sunghoon/0000-0002-1570-3230	Korea Health Technology R & D Project through the Korea Health Industry Development Institute (KHIDI); Ministry of Health & Welfare, Republic of Korea [H109C1552]	Korea Health Technology R & D Project through the Korea Health Industry Development Institute (KHIDI)(Korea Health Industry Development Institute (KHIDI)); Ministry of Health & Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	This research was supported by a grant of the Korea Health Technology R & D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (H109C1552). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamson C, 2009, EXPERT OPIN INV DRUG, V18, P1061, DOI 10.1517/13543780903052764; Charles NA, 2011, GLIA, V59, P1169, DOI 10.1002/glia.21136; CURRAN WJ, 1993, J NATL CANCER I, V85, P704, DOI 10.1093/jnci/85.9.704; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218; FU XY, 1992, P NATL ACAD SCI USA, V89, P5645, DOI 10.1073/pnas.89.12.5645; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Groves MD, 2002, J CLIN ONCOL, V20, P1383, DOI 10.1200/JCO.20.5.1383; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; HORTEN BC, 1981, J NEUROPATH EXP NEUR, V40, P493, DOI 10.1097/00005072-198109000-00002; Hoshida Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015543; Hoshida Y, 2010, SEMIN LIVER DIS, V30, P35, DOI 10.1055/s-0030-1247131; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Joo KM, 2008, LAB INVEST, V88, P808, DOI 10.1038/labinvest.2008.57; Joo KM, 2013, CELL REP, V3, P260, DOI 10.1016/j.celrep.2012.12.013; Karam JA, 2011, EUR UROL, V59, P619, DOI 10.1016/j.eururo.2010.11.043; Kreth FW, 1999, CANCER, V86, P2117, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2117::AID-CNCR33>3.3.CO;2-#; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Lathia JD, 2011, CELL STEM CELL, V8, P482, DOI 10.1016/j.stem.2011.04.013; Lee HS, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-80; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; Martens T, 2008, CLIN CANCER RES, V14, P5447, DOI 10.1158/1078-0432.CCR-08-0147; Rubio-Viqueira B, 2006, CLIN CANCER RES, V12, P4652, DOI 10.1158/1078-0432.CCR-06-0113; Sausville EA, 2006, CANCER RES, V66, P3351, DOI 10.1158/0008-5472.CAN-05-3627; Scott CB, 1998, INT J RADIAT ONCOL, V40, P51, DOI 10.1016/S0360-3016(97)00485-9; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Taillandier L, 2003, J NEUROSCI METH, V125, P147, DOI 10.1016/S0165-0270(03)00043-8; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-465; Xie Q, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-77; Zhuo Ying, 2010, Zhongguo Fei Ai Za Zhi, V13, P568, DOI 10.3779/j.issn.1009-3419.2010.06.020	32	19	20	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2014	9	8							e103327	10.1371/journal.pone.0103327	http://dx.doi.org/10.1371/journal.pone.0103327			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM4JL	25084005	Green Submitted, Green Published, gold			2023-01-03	WOS:000339819800032
J	Kesselheim, AS; Bykov, K; Avorn, J; Tong, A; Doherty, M; Choudhry, NK				Kesselheim, Aaron S.; Bykov, Katsiaryna; Avorn, Jerry; Tong, Angela; Doherty, Michael; Choudhry, Niteesh K.			Burden of Changes in Pill Appearance for Patients Receiving Generic Cardiovascular Medications After Myocardial Infarction Cohort and Nested Case-Control Studies	ANNALS OF INTERNAL MEDICINE			English	Article							BRAND-NAME DRUGS; STATIN THERAPY; ADHERENCE; NONADHERENCE; EQUIVALENCE; PREVENTION; MORTALITY; DISEASE; RISK	Background: Generic prescription drugs made by different manufacturers may vary in color or shape, and switching among these drug products may interrupt medication use. Objective: To determine whether nonpersistent use of generic drugs among patients with cardiovascular disease after myocardial infarction (MI) is associated with inconsistent appearance of their medications. Design: Cohort and nested case-control studies. Setting: Claims from a commercial health insurance database in the United States. Patients: Patients discharged after hospitalization for MI between 2006 and 2011 who initiated treatment with a generic beta-blocker, angiotensin-converting enzyme inhibitor, angiotensin II-receptor blocker, or statin. Case patients discontinued their index medication for at least 1 month; control patients continued treatment. Control patients were matched to case patients on therapeutic class, number of dispensings before nonpersistence, sex, and age. Measurements: Rates of changes in pill color and shape during the year after MI were calculated. Next, 2 refills preceding nonpersistence were evaluated to determine whether pill color or shape had changed. Odds of discordance among case and control patients were compared using conditional logistic regression. Results: A total of 29% of patients (3286 of 11 513) had a change in pill shape or color during the study. Statins had the most changes in appearance, whereas beta-blockers had the fewest. A total of 4573 episodes of nonpersistence was matched to 19 881 control episodes. The odds of nonpersistence in case patients increased by 34% after a change in pill color (adjusted odds ratio, 1.34 [95% CI, 1.12 to 1.59]) and 66% after a change in pill shape (adjusted odds ratio, 1.66 [CI, 1.43 to 1.94]). Limitation: Only 3 categories of drugs indicated after MI were evaluated, and clinical outcomes were not addressed. Conclusion: Variation in the appearance of generic pills is associated with nonpersistent use of these essential drugs after MI among patients with cardiovascular disease.	Brigham & Womens Hosp, Boston, MA 02120 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Kesselheim, AS (corresponding author), Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	akesselheim@partners.org	Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666; Bykov, Katsiaryna/0000-0003-3336-5412	Agency for Healthcare Research and Quality [K08HS18465-01]; Greenwall Faculty Scholars Program in Bioethics; Harvard Program in Therapeutic Science; Robert Wood Johnson Foundation Investigator Award in Health Policy Research; FDA Office of Generic Drugs; CVS Caremark; Commonwealth Fund; Robert Wood Johnson Foundation; Aetna	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Greenwall Faculty Scholars Program in Bioethics; Harvard Program in Therapeutic Science; Robert Wood Johnson Foundation Investigator Award in Health Policy Research(Robert Wood Johnson Foundation (RWJF)); FDA Office of Generic Drugs; CVS Caremark; Commonwealth Fund; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); Aetna	Dr. Kesselheim was supported by a career development award from the Agency for Healthcare Research and Quality (K08HS18465-01), the Greenwall Faculty Scholars Program in Bioethics, the Harvard Program in Therapeutic Science, and a Robert Wood Johnson Foundation Investigator Award in Health Policy Research. Dr. Kesselheim and Dr. Avorn receive research support from the FDA Office of Generic Drugs. Dr. Choudhry was supported by unrestricted research grants from CVS Caremark, Aetna, The Commonwealth Fund, and the Robert Wood Johnson Foundation.	Akincigil A, 2008, J GEN INTERN MED, V23, P115, DOI 10.1007/s11606-007-0351-9; [Anonymous], 2010, CBS NEWS; [Anonymous], 2003, ADHERENCE LONG TERM; [Anonymous], 2011, CLOS LOOK PRESCR BOT; BIRON P, 1974, CAN MED ASSOC J, V110, P1346; Boh M, 2011, INT ANGIOL, V30, P366; Brookhart MA, 2007, ARCH INTERN MED, V167, P847, DOI 10.1001/archinte.167.8.847; Center for Drug Evaluation and Research, 2013, GUID IND SI IN PRESS; Choudhry NK, 2011, NEW ENGL J MED, V365, P2088, DOI 10.1056/NEJMsa1107913; Choudhry NK, 2011, ARCH INTERN MED, V171, P814, DOI 10.1001/archinternmed.2010.495; Cohen M, 2011, PHILLY COM      0808; Colivicchi F, 2007, STROKE, V38, P2652, DOI 10.1161/STROKEAHA.107.487017; Cramer JA, 2008, VALUE HEALTH, V11, P44, DOI 10.1111/j.1524-4733.2007.00213.x; Cutler C, 2011, BIOL BLOOD MARROW TR, V17, P285, DOI 10.1016/j.bbmt.2010.11.006; Cutler DM, 2010, NEW ENGL J MED, V362, P1553, DOI 10.1056/NEJMp1002305; Dicken JE, 2012, GAO12371R; Engelberg AB, 2011, J MANAGE CARE PHARM, V17, P321, DOI 10.18553/jmcp.2011.17.4.321; Faasse K, 2013, PSYCHOSOM MED, V75, P90, DOI 10.1097/PSY.0b013e3182738826; Fischer MA, 2011, AM J MED, V124, DOI 10.1016/j.amjmed.2011.05.028; Gagne JJ, 2011, J CLIN EPIDEMIOL, V64, P749, DOI 10.1016/j.jclinepi.2010.10.004; Goldman DP, 2007, JAMA-J AM MED ASSOC, V298, P61, DOI 10.1001/jama.298.1.61; Green JB, 2013, JAMA INTERN MED, V173, P229, DOI 10.1001/jamainternmed.2013.1529; Greene JA, 2011, NEW ENGL J MED, V365, P83, DOI 10.1056/NEJMhle1101722; Haas JS, 2005, ANN INTERN MED, V142, P891, DOI 10.7326/0003-4819-142-11-200506070-00006; Ho PM, 2006, ARCH INTERN MED, V166, P1836, DOI 10.1001/archinte.166.17.1836; Ho PM, 2008, AM HEART J, V155, P772, DOI 10.1016/j.ahj.2007.12.011; Ho P Michael, 2006, BMC Cardiovasc Disord, V6, P48, DOI 10.1186/1471-2261-6-48; Kenagy JW, 2001, AM J HEALTH-SYST PH, V58, P2033, DOI 10.1093/ajhp/58.21.2033; Kesselheim AS, 2008, JAMA-J AM MED ASSOC, V300, P2514, DOI 10.1001/jama.2008.758; Kesselheim AS, 2013, JAMA INTERN MED, V173, P202, DOI 10.1001/2013.jamainternmed.997; Kronish IM, 2013, PROG CARDIOVASC DIS, V55, P590, DOI 10.1016/j.pcad.2013.02.001; Nightingale SL, 1998, THERAPEUTIC EQUIVALE; Petersen LA, 1999, J GEN INTERN MED, V14, P555, DOI 10.1046/j.1525-1497.1999.10198.x; Rasmussen JN, 2007, JAMA-J AM MED ASSOC, V297, P177, DOI 10.1001/jama.297.2.177; Roullet B, 2005, ADV CONSUM RES, V32, P164; Shah ND, 2009, AM J MED, V122, DOI 10.1016/j.amjmed.2008.12.021; Shrank WH, 2011, HEALTH AFFAIR, V30, P1351, DOI 10.1377/hlthaff.2010.0431; Smith DH, 2008, ARCH INTERN MED, V168, P477, DOI 10.1001/archinternmed.2007.132; Sundar RP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038819; Yu LX, 2013, JAMA INTERN MED, V173, P208, DOI 10.1001/jamainternmed.2013.2283; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487	41	63	63	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	2014	161	2					96	+		10.7326/M13-2381	http://dx.doi.org/10.7326/M13-2381			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AM3PJ	25023248				2023-01-03	WOS:000339764600018
J	Tran, NM; Dufresne, M; Helle, F; Hoffmann, TW; Francois, C; Brochot, E; Paullier, P; Legallais, C; Duverlie, G; Castelain, S				Tran, Nhu-Mai; Dufresne, Murielle; Helle, Francois; Hoffmann, Thomas Walter; Francois, Catherine; Brochot, Etienne; Paullier, Patrick; Legallais, Cecile; Duverlie, Gilles; Castelain, Sandrine			Alginate Hydrogel Protects Encapsulated Hepatic HuH-7 Cells against Hepatitis C Virus and Other Viral Infections	PLOS ONE			English	Article							SULFATED POLYSACCHARIDES; ANTIVIRAL ACTIVITY; LIVER-FAILURE; STEM-CELLS; HEPATOCYTES; CULTURE; SYSTEM; REPLICATION; TRANSPLANTATION; COENCAPSULATION	Cell microencapsulation in alginate hydrogel has shown interesting applications in regenerative medicine and the biomedical field through implantation of encapsulated tissue or for bioartificial organ development. Although alginate solution is known to have low antiviral activity, the same property regarding alginate gel has not yet been studied. The aim of this work is to investigate the potential protective effect of alginate encapsulation against hepatitis C virus (HCV) infection for a hepatic cell line (HuH-7) normally permissive to the virus. Our results showed that alginate hydrogel protects HuH-7 cells against HCV when the supernatant was loaded with HCV. In addition, alginate hydrogel blocked HCV particle release out of the beads when the HuH-7 cells were previously infected and encapsulated. There was evidence of interaction between the molecules of alginate hydrogel and HCV, which was dose-and incubation time-dependent. The protective efficiency of alginate hydrogel towards HCV infection was confirmed against a variety of viruses, whether or not they were enveloped. This promising interaction between an alginate matrix and viruses, whose chemical mechanisms are discussed, is of great interest for further medical therapeutic applications based on tissue engineering.	[Tran, Nhu-Mai; Dufresne, Murielle; Paullier, Patrick; Legallais, Cecile] Univ Technol, UMR CNRS Biomech & Bioingn 7338, Compiegne, France; [Helle, Francois; Hoffmann, Thomas Walter; Francois, Catherine; Brochot, Etienne; Duverlie, Gilles; Castelain, Sandrine] Univ Picardie Jules Verne, Dept Fundamental & Clin Virol, EA4294, Amiens, France	Picardie Universites; Universite de Picardie Jules Verne (UPJV)	Dufresne, M (corresponding author), Univ Technol, UMR CNRS Biomech & Bioingn 7338, Compiegne, France.	murielle.dufresne@utc.fr	CASTELAIN, SANDRINE/AAJ-7506-2020; HELLE, Francois/G-7427-2011; BROCHOT, ETIENNE/I-5318-2012; Castelain, Sandrine/AAA-6344-2019; FRANCOIS, Catherine/AAJ-8289-2020	CASTELAIN, SANDRINE/0000-0002-2670-3148; HELLE, Francois/0000-0001-6884-2456; BROCHOT, ETIENNE/0000-0002-8677-6349; Legallais, Cecile/0000-0002-8061-906X; FRANCOIS, Catherine/0000-0002-1797-4253	FEDER Program; Picardy Region, France	FEDER Program(European Commission); Picardy Region, France(Region Hauts-de-France)	The authors would like to thank the FEDER Program and the Picardy Region, France for providing financial support for this project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abouna GM, 2008, TRANSPL P, V40, P34, DOI 10.1016/j.transproceed.2007.11.067; Ananthanarayanan A, 2014, MOL PHARMACEUT, V11, P2106, DOI 10.1021/mp500063y; Aoki T, 2005, TRANSPLANTATION, V79, P783, DOI 10.1097/01.TP.0000156319.47645.3B; Araya N, 2011, ANTIVIR THER, V16, P89, DOI 10.3851/IMP1699; Bandyopadhyaya SS, 2011, PHYTOCHEMISTRY, V72, P276, DOI 10.1016/j.phytochem.2010.11.006; Blandino A, 1999, J BIOSCI BIOENG, V88, P686, DOI 10.1016/S1389-1723(00)87103-0; Buck CB, 2006, PLOS PATHOG, V2, P671, DOI 10.1371/journal.ppat.0020069; Calafiore R, 2014, ADV DRUG DELIVER REV, V67-68, P84, DOI 10.1016/j.addr.2013.09.020; Capone SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062032; Castelain S, 2004, J CLIN VIROL, V31, P227, DOI 10.1016/j.jcv.2004.03.009; Cermelli C, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-141; David B, 2004, BIOTECHNOL PROGR, V20, P1204, DOI 10.1021/bp034301z; de Vos P, 2006, BIOMATERIALS, V27, P5603, DOI 10.1016/j.biomaterials.2006.07.010; Delgrange D, 2007, J GEN VIROL, V88, P2495, DOI 10.1099/vir.0.82872-0; Fitton JH, 2011, MAR DRUGS, V9, P1731, DOI 10.3390/md9101731; Gandhi NS, 2008, CHEM BIOL DRUG DES, V72, P455, DOI 10.1111/j.1747-0285.2008.00741.x; Ghosh T, 2009, GLYCOBIOLOGY, V19, P2, DOI 10.1093/glycob/cwn092; GIROND S, 1991, RES VIROLOGY, V142, P261, DOI 10.1016/0923-2516(91)90011-Q; Helle F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070809; Jones CT, 2010, NAT BIOTECHNOL, V28, P167, DOI 10.1038/nbt.1604; Kam N, 2011, CAN J MICROBIOL, V57, P1032, DOI [10.1139/w11-106, 10.1139/W11-106]; KIM JH, 2009, BEIH Z ALTTEST WISS, V394, P1; Kurosaki T, 2009, BIOMATERIALS, V30, P4427, DOI 10.1016/j.biomaterials.2009.04.041; LaBarre DD, 2001, J VIROL METHODS, V96, P107, DOI 10.1016/S0166-0934(01)00316-0; Mei J, 2009, CELL TRANSPLANT, V18, P101, DOI 10.3727/096368909788237168; Miao BC, 2004, BIOCHEM PHARMACOL, V68, P641, DOI 10.1016/j.bcp.2004.04.009; Molina-Jimenez F, 2012, VIROLOGY, V425, P31, DOI 10.1016/j.virol.2011.12.021; Ngo DH, 2013, INT J BIOL MACROMOL, V62, P70, DOI 10.1016/j.ijbiomac.2013.08.036; Tran NM, 2013, TISSUE ENG PT A, V19, P103, DOI [10.1089/ten.TEA.2012.0139, 10.1089/ten.tea.2012.0139]; Nimtrakul P, 2015, DRUG DEV IND PHARM, V41, P423, DOI 10.3109/03639045.2013.873448; Opara Emmanuel C, 2013, Methods Mol Biol, V1001, P261, DOI 10.1007/978-1-62703-363-3_21; Orive G, 2006, BIOMATERIALS, V27, P3691, DOI 10.1016/j.biomaterials.2006.02.048; Queiroz KCS, 2008, BIOMED PHARMACOTHER, V62, P303, DOI 10.1016/j.biopha.2008.03.006; Revie D, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-346; Sainz B, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-103; Saitoh S, 2000, Dent Mater J, V19, P396; Shi XL, 2009, TRANSPLANTATION, V88, P1178, DOI 10.1097/TP.0b013e3181bc288b; Sinha S, 2010, PHYTOCHEMISTRY, V71, P235, DOI 10.1016/j.phytochem.2009.10.014; Steele JAM, 2014, ADV DRUG DELIVER REV, V67-68, P74, DOI 10.1016/j.addr.2013.09.015; STEENSON LR, 1987, J DAIRY SCI, V70, P1121, DOI 10.3168/jds.S0022-0302(87)80121-2; Sun JC, 2013, MATERIALS, V6, P1285, DOI 10.3390/ma6041285; Talarico LB, 2007, VIROLOGY, V363, P473, DOI 10.1016/j.virol.2007.01.043; Tengdelius M, 2014, BIOMACROMOLECULES, V15, P2359, DOI 10.1021/bm5002312; Tonnesen HH, 2002, DRUG DEV IND PHARM, V28, P621, DOI 10.1081/DDC-120003853; Vo TS, 2010, MAR DRUGS, V8, P2871, DOI 10.3390/md8122871; Wang W, 2012, MAR DRUGS, V10, P2795, DOI 10.3390/md10122795; Wilson GK, 2012, INT J HEPATOL, V2012, DOI 10.1155/2012/292591; Zhang Y, 2014, INT J ARTIF ORGANS, V37, P133, DOI 10.5301/ijao.5000284	48	30	30	2	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2014	9	10							e109969	10.1371/journal.pone.0109969	http://dx.doi.org/10.1371/journal.pone.0109969			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ9WZ	25310111	gold, Green Published, Green Submitted			2023-01-03	WOS:000343210300082
J	Chiang, TC; Lu, RB; Hsieh, S; Chang, YH; Yang, YK				Chiang, Tzu-Ching; Lu, Ru-Band; Hsieh, Shulan; Chang, Yun-Hsuan; Yang, Yen-Kuang			Stimulation in the Dorsolateral Prefrontal Cortex Changes Subjective Evaluation of Percepts	PLOS ONE			English	Article							EXECUTIVE ATTENTION; METAMEMORY; BLINDSIGHT	Nelson and Narens have proposed a metacognition model that dissociates the objective processing of information (object-level) and the subjective evaluation of the performance (i.e., the metalevel). Neurophysiological evidence also indicates that the prefrontal cortices (PFC) are the brain areas which perform the metalevel function [1-3]. A corresponding neural mechanism of Nelson and Narens's model, called dynamic filtering theory [4,5], indicates that object-level processing is distributed in the posterior cortices and regulated by the prefrontal cortices with a filtering or gating mechanism to select appropriate signals and suppress inappropriate signals and noise. Based on this model, a hypothesis can be developed that, in the case of uncertainty or overloading of object-level processing, the prefrontal cortices will become more active in order to modulate signals and noise. This hypothesis is supported by a recent fMRI study [6] showing that the PFC (Brodmann area 9, BA9) was activated when subjects were overloaded in a bimodal attentional task, compared to a unimodal task. Here, we report a study showing that applying repetitive transmagnetic stimulation (rTMS) over the BA9 in order to interfere with its functional activity resulted in significant increas in guessed responses, compared to three other control conditions (i.e., no-TMS, sham TMS on BA9, and rTMS on Cz). The results are compatible with the dynamic filtering theory and suggest that a malfunction of the PFC would weaken the quality of meta-cognitive percepts and increase the number of guessed responses.	[Chiang, Tzu-Ching] Univ Western Ontario, Brain & Mind Inst, London, ON, Canada; [Chiang, Tzu-Ching] Natl Chung Cheng Univ, Dept Psychol, Chiayi, Taiwan; [Lu, Ru-Band; Yang, Yen-Kuang] Natl Cheng Kung Univ & Hosp, Coll Med, Dept Psychiat, Tainan, Taiwan; [Lu, Ru-Band; Yang, Yen-Kuang] Natl Cheng Kung Univ, Coll Med, Inst Behav Med, Tainan 70101, Taiwan; [Lu, Ru-Band; Hsieh, Shulan; Chang, Yun-Hsuan] Natl Cheng Kung Univ, Coll Med, Inst Allied Hlth Sci, Tainan 70101, Taiwan; [Hsieh, Shulan] Natl Cheng Kung Univ, Dept Psychol, Tainan 70101, Taiwan	Western University (University of Western Ontario); National Chung Cheng University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University	Chiang, TC (corresponding author), Univ Western Ontario, Brain & Mind Inst, London, ON, Canada.	tchiang5@uwo.ca		Hsieh, Shulan/0000-0001-6247-244X	Ministry of Science and Technology [MOST100-2410-H-194-047]; National Cheng Kung University Hospital [NCKUH-9902022]; Headquarters of University Advancement at the National Cheng Kung University; Ministry of Education, Taiwan, R.O.C.	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); National Cheng Kung University Hospital; Headquarters of University Advancement at the National Cheng Kung University; Ministry of Education, Taiwan, R.O.C.(Ministry of Education, Taiwan)	The research was made possible by the following funding from Ministry of Science and Technology (MOST100-2410-H-194-047) and National Cheng Kung University Hospital (NCKUH-9902022). In addition, this research received funding from the Headquarters of University Advancement at the National Cheng Kung University, which is sponsored by the Ministry of Education, Taiwan, R.O.C. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284; Chiang TC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077408; Dienes Z, 2008, PROG BRAIN RES, V168, P49, DOI 10.1016/S0079-6123(07)68005-4; Dienes Z, 2013, CORTEX, V49, P386, DOI 10.1016/j.cortex.2012.07.009; Fernandez-Duque D, 2000, CONSCIOUS COGN, V9, P288, DOI 10.1006/ccog.2000.0447; Fleck MS, 2006, CEREB CORTEX, V16, P1623, DOI 10.1093/cercor/bhj097; Fleming SM, 2012, J NEUROSCI, V32, P6117, DOI 10.1523/JNEUROSCI.6489-11.2012; Fleming SM, 2012, PHILOS T R SOC B, V367, P1338, DOI 10.1098/rstb.2011.0417; Galvin SJ, 2003, PSYCHON B REV, V10, P843, DOI 10.3758/BF03196546; Gelfand SA, 2010, HEARING INTRO PSYCH; Jaeger TF, 2008, J MEM LANG, V59, P434, DOI 10.1016/j.jml.2007.11.007; JANOWSKY JS, 1989, BEHAV NEUROSCI, V103, P548, DOI 10.1037/0735-7044.103.3.548; Kaiser P.K., 1991, LIMITS VISION, P171; KOLB FC, 1995, NATURE, V377, P336, DOI 10.1038/377336a0; Macmillan N., 2005, DETECTION THEORY, V2; Maniscalco B, 2012, CONSCIOUS COGN, V21, P422, DOI 10.1016/j.concog.2011.09.021; McGuire JT, 2010, P NATL ACAD SCI USA, V107, P7922, DOI 10.1073/pnas.0910662107; Morgan MJ, 1997, NATURE, V385, P401, DOI 10.1038/385401b0; Naccache L, 2005, NEUROPSYCHOLOGIA, V43, P1318, DOI 10.1016/j.neuropsychologia.2004.11.024; Nelson T.O., 1994, METACOGNITION KNOWIN, P1, DOI [10.7551/mitpress/4561.001.0001, DOI 10.1080/01443410.2013.860217]; Nelson T. O., 1990, PSYCHOL LEARNING MOT, V26, P125, DOI DOI 10.1016/S0079-7421(08)60053-5; Pannu JK, 2005, NEUROPSYCHOL REV, V15, P105, DOI 10.1007/s11065-005-7091-6; Pannu JK, 2005, J INT NEUROPSYCH SOC, V11, P668, DOI 10.1017/S13556177050873; RABBITT P, 1977, Q J EXP PSYCHOL, V29, P727, DOI 10.1080/14640747708400645; Rahnev D, 2011, NAT NEUROSCI, V14, P1513, DOI 10.1038/nn.2948; Rounis E, 2010, COGN NEUROSCI-UK, V1, P165, DOI 10.1080/17588921003632529; Shimamura A. P., 2008, HDB METAMEMORY MEMOR, P373; Shimamura AP, 2000, PSYCHOBIOLOGY, V28, P207; Shimamura AP, 1996, METACOGNITION IMPLIC, P210; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; Turatto M, 2004, NEUROREPORT, V15, P2549, DOI 10.1097/00001756-200411150-00024	31	8	8	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2014	9	9							e106943	10.1371/journal.pone.0106943	http://dx.doi.org/10.1371/journal.pone.0106943			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ3IP	25259586	Green Published, gold, Green Submitted			2023-01-03	WOS:000342685600014
J	Perazzo, KKNC; Conceicao, ACD; dos Santos, JCP; Assis, DD; Souza, CO; Druzian, JI				Carneiro Lins Perazzo, Katya Karine Nery; de Vasconcelos Conceicao, Anderson Carlos; Pires dos Santos, Juliana Caribe; Assis, Denilson de Jesus; Souza, Carolina Oliveira; Druzian, Janice Izabel			Properties and Antioxidant Action of Actives Cassava Starch Films Incorporated with Green Tea and Palm Oil Extracts	PLOS ONE			English	Article							BARRIER PROPERTIES; CAMELLIA-SINENSIS; GELATIN FILMS; EDIBLE FILMS; MODEL; FLAVONOIDS; STABILITY; CATECHINS; COATINGS; CHITOSAN	There is an interest in the development of an antioxidant packaging fully biodegradable to increase the shelf life of food products. An active film from cassava starch bio-based, incorporated with aqueous green tea extract and oil palm colorant was developed packaging. The effects of additives on the film properties were determined by measuring mechanical, barrier and thermal properties using a response surface methodology design experiment. The bio-based films were used to pack butter (maintained for 45 days) under accelerated oxidation conditions. The antioxidant action of the active films was evaluated by analyzing the peroxide index, total carotenoids, and total polyphenol. The same analysis also evaluated unpacked butter, packed in films without additives and butter packed in LDPE films, as controls. The results suggested that incorporation of the antioxidants extracts tensile strength and water vapor barrier properties (15 times lower) compared to control without additives. A lower peroxide index (231.57%), which was significantly different from that of the control (p<0.05), was detected in products packed in film formulations containing average concentration of green tea extracts and high concentration of colorant. However, it was found that the high content of polyphenols in green tea extract can be acted as a pro-oxidant agent, which suggests that the use of high concentration should be avoided as additives for films. These results support the applicability of a green tea extract and oil palm carotenoics colorant in starch films totally biodegradable and the use of these materials in active packaging of the fatty products.	[Carneiro Lins Perazzo, Katya Karine Nery; de Vasconcelos Conceicao, Anderson Carlos; Pires dos Santos, Juliana Caribe; Souza, Carolina Oliveira; Druzian, Janice Izabel] Univ Fed Bahia, Coll Pharm, Dept Food Sci, Salvador, BA, Brazil; [Assis, Denilson de Jesus] Univ Fed Bahia, Dept Chem Engn Federacao, Salvador, BA, Brazil	Universidade Federal da Bahia; Universidade Federal da Bahia	Perazzo, KKNC (corresponding author), Univ Fed Bahia, Coll Pharm, Dept Food Sci, Salvador, BA, Brazil.	katyanery@gmail.com	Druzian, Janice Izabel/G-6884-2015; Souza, Carolina O/G-8869-2015; de Jesus Assis, Denilson/E-1586-2014	de Jesus Assis, Denilson/0000-0002-9226-4155; Oliveira de Souza, Carolina/0000-0002-8028-5418; Druzian, Janice Izabel/0000-0001-8940-6098	Brazilian Committee for Postgraduate Courses in Higher Education (FAPESB); The National Council for Scientific and Technological Development [CNPq 505831/2008-2]	Brazilian Committee for Postgraduate Courses in Higher Education (FAPESB); The National Council for Scientific and Technological Development(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	Funding was provided by the Brazilian Committee for Postgraduate Courses in Higher Education (FAPESB) for graduate scholarships for KP for this study. The National Council for Scientific and Technological Development funded this technology research - CNPq 505831/2008-2, with a financial incentive to acquisition of laboratory supplies and equipment for the laboratory, and also scholarships for scientific initiation and post-graduate levels MA and PhD, for other researchers working on the same study. The funders had the role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Vieira MGA, 2011, EUR POLYM J, V47, P254, DOI 10.1016/j.eurpolymj.2010.12.011; Anesini C, 2008, J AGR FOOD CHEM, V56, P9225, DOI 10.1021/jf8022782; Association of Official Analytical Chemists, 2000, OFF METH AN CD 8B 90; ASTM, 1995, ANN BOOK ASTM STAND; ASTM Standards, 1989, E9680 ASTM; Averous L, 2001, STARCH-STARKE, V53, P368, DOI 10.1002/1521-379X(200108)53:8<368::AID-STAR368>3.0.CO;2-W; Azeredo HMC, 2009, J FOOD SCI, V74, pN31, DOI 10.1111/j.1750-3841.2009.01186.x; Bonilla J, 2013, J FOOD ENG, V114, P303, DOI 10.1016/j.jfoodeng.2012.08.005; Boon CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055908; Cao GH, 1997, FREE RADICAL BIO MED, V22, P749, DOI 10.1016/S0891-5849(96)00351-6; Curcio M, 2009, J AGR FOOD CHEM, V57, P5933, DOI 10.1021/jf900778u; Falguera V, 2011, TRENDS FOOD SCI TECH, V22, P292, DOI 10.1016/j.tifs.2011.02.004; FINLEY JW, 1986, FOOD CHEM TOXICOL, V24, P999, DOI 10.1016/0278-6915(86)90280-2; Gimenez B, 2013, LWT-FOOD SCI TECHNOL, V53, P445, DOI 10.1016/j.lwt.2013.03.020; Gimenez B, 2013, FOOD HYDROCOLLOID, V30, P264, DOI 10.1016/j.foodhyd.2012.05.014; GONTARD N, 1993, J FOOD SCI, V58, P206, DOI 10.1111/j.1365-2621.1993.tb03246.x; Gramza A, 2006, EUR J LIPID SCI TECH, V108, P351, DOI 10.1002/ejlt.200500330; GRISI C.V.B., 2008, FOOD CHEM RES DEV, V1, P1; Gumel AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045214; Haugaard VK, 2001, STARCH-STARKE, V53, P189, DOI 10.1002/1521-379X(200105)53:5<189::AID-STAR189>3.0.CO;2-3; He YH, 1997, J AGR FOOD CHEM, V45, P4262, DOI 10.1021/jf9706134; Heim KE, 2002, J NUTR BIOCHEM, V13, P572, DOI 10.1016/S0955-2863(02)00208-5; Heumann BF, 1990, INFORM, V1; Immel S, 2000, STARCH-STARKE, V52, P1; Jansson A, 2004, CARBOHYD POLYM, V56, P499, DOI 10.1016/j.carbpol.2004.03.019; Khwaldia K, 2010, COMPR REV FOOD SCI F, V9, P82, DOI 10.1111/j.1541-4337.2009.00095.x; Lee ES, 2003, J PHARM PHARMACOL, V55, P1169, DOI 10.1211/0022357021396; Martin-Diana AB, 2008, INNOV FOOD SCI EMERG, V9, P593, DOI 10.1016/j.ifset.2008.04.001; Miller KS, 1997, TRENDS FOOD SCI TECH, V8, P228, DOI 10.1016/S0924-2244(97)01051-0; Montenegro MA, 2004, J AGR FOOD CHEM, V52, P367, DOI 10.1021/jf0349026; Montenegro MA, 2007, J AGR FOOD CHEM, V55, P323, DOI 10.1021/jf0622883; Moradi M, 2012, LWT-FOOD SCI TECHNOL, V46, P477, DOI 10.1016/j.lwt.2011.11.020; Munoz-Munoz JL, 2008, J AGR FOOD CHEM, V56, P9215, DOI 10.1021/jf8012162; Nerin C, 2008, J FOOD ENG, V84, P313, DOI 10.1016/j.jfoodeng.2007.05.027; Nishiyama MF, 2010, CIENCIA TECNOL ALIME, V30, P191, DOI 10.1590/S0101-20612010000500029; Passoto JA, 1998, FOOD SCI TECHNOL, V18, P624; Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3; RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9; Schlemmer D, J THERMAL ANAL CALOR, V87, P635; Silva JBA, 2012, J FOOD SCI, V77, P14; Silva S. R. da, 2002, Ciencia e Tecnologia de Alimentos, V22, P254, DOI 10.1590/S0101-20612002000300010; Singh A., 2011, WORLD APPL SCI J, V14, P1703; Siracusa V, 2012, INT J POLYM SCI, V2012, DOI 10.1155/2012/302029; Siripatrawan U, 2010, FOOD HYDROCOLLOID, V24, P770, DOI 10.1016/j.foodhyd.2010.04.003; Song Hyeun Sung, 2013, Prev Nutr Food Sci, V18, P80, DOI 10.3746/pnf.2013.18.1.080; Souza CO, 2011, J AGR FOOD CHEM, V59, P2248, DOI 10.1021/jf1040405; Veiga-Santos P, 2005, FOOD HYDROCOLLOID, V19, P1064, DOI 10.1016/j.foodhyd.2005.02.007; Vermeiren L, 1999, TRENDS FOOD SCI TECH, V10, P77, DOI 10.1016/S0924-2244(99)00032-1; Wanasundara UN, 1998, FOOD CHEM, V63, P335, DOI 10.1016/S0308-8146(98)00025-9; Wei BX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086024; Wessling C, 2000, PACKAG TECHNOL SCI, V13, P19, DOI 10.1002/(SICI)1099-1522(200001/02)13:1<19::AID-PTS492>3.0.CO;2-B; Xiao XS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022934; Xiong HG, 2008, CARBOHYD POLYM, V71, P263, DOI 10.1016/j.carbpol.2007.05.035; Zhu F, 2009, FOOD CHEM, V112, P919, DOI 10.1016/j.foodchem.2008.06.079	54	54	55	1	84	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2014	9	9							e105199	10.1371/journal.pone.0105199	http://dx.doi.org/10.1371/journal.pone.0105199			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ0SJ	25251437	gold, Green Submitted, Green Published			2023-01-03	WOS:000342492700007
J	van der Horst, G; Bos, L; van der Mark, M; Cheung, H; Heckmann, B; Clement-Lacroix, P; Lorenzon, G; Pelger, RCM; Bevers, RFM; van der Pluijm, G				van der Horst, Geertje; Bos, Lieke; van der Mark, Maaike; Cheung, Henry; Heckmann, Bertrand; Clement-Lacroix, Philippe; Lorenzon, Giocondo; Pelger, Rob C. M.; Bevers, Rob F. M.; van der Pluijm, Gabri			Targeting of Alpha-V Integrins Reduces Malignancy of Bladder Carcinoma	PLOS ONE			English	Article							CANCER STEM-CELLS; SIDE POPULATION CELLS; MESENCHYMAL TRANSITION; THERAPEUTIC TARGET; TUMOR PROGRESSION; INITIATING CELLS; SELF-RENEWAL; EXPRESSION; METASTASIS; DIFFERENTIATION	Low survival rates of metastatic cancers emphasize the need for a drug that can prevent and/or treat metastatic cancer. alpha v integrins are involved in essential processes for tumor growth and metastasis and targeting of av integrins has been shown to decrease angiogenesis, tumor growth and metastasis. In this study, the role of av integrin and its potential as a drug target in bladder cancer was investigated. Treatment with an av integrin antagonist as well as knockdown of alpha v integrin in the bladder carcinoma cell lines, resulted in reduced malignancy in vitro, as illustrated by decreased proliferative, migratory and clonogenic capacity. The CDH1/CDH2 ratio increased, indicating a shift towards a more epithelial phenotype. This shift appeared to be associated with downregulation of EMT-inducing transcription factors including SNAI2. The expression levels of the self-renewal genes NANOG and BMI1 decreased as well as the number of cells with high Aldehyde Dehydrogenase activity. In addition, self-renewal ability decreased as measured with the urosphere assay. In line with these observations, knockdown or treatment of av integrins resulted in decreased metastatic growth in preclinical in vivo models as assessed by bioluminescence imaging. In conclusion, we show that av integrins are involved in migration, EMT and maintenance of Aldehyde Dehydrogenase activity in bladder cancer cells. Targeting of alpha v integrins might be a promising approach for treatment and/or prevention of metastatic bladder cancer.	[van der Horst, Geertje; Bos, Lieke; van der Mark, Maaike; Cheung, Henry; Pelger, Rob C. M.; Bevers, Rob F. M.; van der Pluijm, Gabri] Leiden Univ, Med Ctr, Dept Urol, Leiden, Netherlands; [Heckmann, Bertrand; Clement-Lacroix, Philippe; Lorenzon, Giocondo] Galapagos SASU, Romainville, France	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Galapagos NV	van der Horst, G (corresponding author), Leiden Univ, Med Ctr, Dept Urol, Leiden, Netherlands.	G.van_der_Horst@lumc.nl	Pelger, Rob/ABF-9029-2021	Pelger, Rob/0000-0001-6328-6462; van der Pluijm, Gabri/0000-0002-1351-1884; van der Horst, Geertje/0000-0003-1696-160X	Dutch Cancer Society [UL 2011-4930]	Dutch Cancer Society(KWF Kankerbestrijding)	This work is supported by a grant from the Dutch Cancer Society UL 2011-4930. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alison MR, 2011, J PATHOL, V223, P147, DOI 10.1002/path.2793; Atlasi Y, 2007, INT J CANCER, V120, P1598, DOI 10.1002/ijc.22508; Bentivegna A, 2010, CANCER SCI, V101, P416, DOI 10.1111/j.1349-7006.2009.01414.x; Bisson I, 2009, CELL RES, V19, P683, DOI 10.1038/cr.2009.43; Bonnomet A, 2010, J MAMMARY GLAND BIOL, V15, P261, DOI 10.1007/s10911-010-9174-0; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Cavaleri F, 2003, CELL, V113, P551, DOI 10.1016/S0092-8674(03)00394-5; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chan KS, 2009, P NATL ACAD SCI USA, V106, P14016, DOI 10.1073/pnas.0906549106; Chang CC, 2008, CANCER RES, V68, P6281, DOI 10.1158/0008-5472.CAN-08-0094; Chang JT, 2013, CANCER LETT, V341, P16, DOI 10.1016/j.canlet.2013.03.004; Chen QM, 2008, CLIN EXP METASTAS, V25, P139, DOI 10.1007/s10585-007-9132-4; Coghlin C, 2010, J PATHOL, V222, P1, DOI 10.1002/path.2727; ElShamy WM, 2013, CANCER LETT, V341, P2, DOI 10.1016/j.canlet.2013.06.020; Floor S, 2011, ONCOGENE, V30, P4609, DOI 10.1038/onc.2011.184; Fondrevelle ME, 2009, UROL ONCOL-SEMIN ORI, V27, P268, DOI 10.1016/j.urolonc.2007.12.012; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He XB, 2009, STEM CELLS, V27, P1487, DOI 10.1002/stem.92; Hong H, 2010, CURR TOP MED CHEM, V10, P1237, DOI 10.2174/156802610791384234; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Huang P, 2012, MED ONCOL, V29, P829, DOI 10.1007/s12032-011-9962-4; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kong Dejuan, 2011, Cancers (Basel), V3, P716, DOI 10.3390/cancers30100716; Kryczek I, 2012, INT J CANCER, V130, P29, DOI 10.1002/ijc.25967; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marshall JF, 1996, SEMIN CANCER BIOL, V7, P129, DOI 10.1006/scbi.1996.0018; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Nemeth JA, 2007, CANCER INVEST, V25, P632, DOI 10.1080/07357900701522638; Ning ZF, 2009, J INT MED RES, V37, P621, DOI 10.1177/147323000903700304; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; O'Day SJ, 2012, INVEST NEW DRUG, V30, P1074, DOI 10.1007/s10637-011-9639-z; Oates JE, 2009, STEM CELLS DEV, V18, P1515, DOI 10.1089/scd.2008.0302; Overdevest JB, 2011, CANCER RES, V71, P3802, DOI 10.1158/0008-5472.CAN-11-0519; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Sachs MD, 2002, UROLOGY, V60, P531, DOI 10.1016/S0090-4295(02)01748-X; She JJ, 2008, CANCER BIOL THER, V7, P1663, DOI 10.4161/cbt.7.10.6637; Su Y, 2010, CANCER EPIDEM BIOMAR, V19, P327, DOI 10.1158/1055-9965.EPI-09-0865; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Trikha M, 2004, INT J CANCER, V110, P326, DOI 10.1002/ijc.20116; van den Hoogen C, 2011, AM J PATHOL, V179, P2559, DOI 10.1016/j.ajpath.2011.07.011; van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806; van der Horst G, 2012, MOL CANCER RES, V10, P995, DOI 10.1158/1541-7786.MCR-12-0274; van der Horst G, 2011, EUR UROL, V60, P337, DOI 10.1016/j.eururo.2011.05.005; van der Horst G, 2011, NEOPLASIA, V13, P516, DOI 10.1593/neo.11122; van der Pluijm G, 2011, BONE, V48, P37, DOI 10.1016/j.bone.2010.07.023; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wallerand H, 2010, UROL ONCOL-SEMIN ORI, V28, P473, DOI 10.1016/j.urolonc.2008.12.018; Wang X, 2010, MED ONCOL S, V1, pS413; Yu QC, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-119; Zhang Z, 2007, HUM PATHOL, V38, P598, DOI 10.1016/j.humpath.2006.10.004; Zhao YS, 2007, CANCER RES, V67, P5821, DOI 10.1158/0008-5472.CAN-06-4499	56	30	31	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2014	9	9							e108464	10.1371/journal.pone.0108464	http://dx.doi.org/10.1371/journal.pone.0108464			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AP8TL	25247809	gold, Green Published, Green Submitted			2023-01-03	WOS:000342351800087
J	Chisti, MJ; Graham, SM; Duke, T; Ahmed, T; Faruque, AG; Ashraf, H; Bardhan, PK; Shahid, AMSB; Shahunja, KM; Salam, MA				Chisti, Mohammod Jobayer; Graham, Stephen M.; Duke, Trevor; Ahmed, Tahmeed; Faruque, Abu Syed Golam; Ashraf, Hasan; Bardhan, Pradip Kumar; Shahid, Abu S. M. S. B.; Shahunja, K. M.; Salam, Mohammed Abdus			Post-Discharge Mortality in Children with Severe Malnutrition and Pneumonia in Bangladesh	PLOS ONE			English	Article							MALNOURISHED CHILDREN; RISK-FACTORS; FOLLOW-UP; DIARRHEA; TRIAL; REHABILITATION; MANAGEMENT; DISCHARGE; DISEASE; MALAWI	Background: Post-discharge mortality among children with severe illness in resource-limited settings is under-recognized and there are limited data. We evaluated post-discharge mortality in a recently reported cohort of children with severe malnutrition and pneumonia, and identified characteristics associated with an increased risk of death. Methods: Young children (< 5 years of age) with severe malnutrition (WHO criteria) and radiographic pneumonia on admission to Dhaka Hospital of icddr, b over a 15-month period were managed according to standard protocols. Those discharged were followed-up and survival status at 12 weeks post-discharge was determined. Verbal autopsy was requested from families of those that died. Results: Of 405 children hospitalized with severe malnutrition and pneumonia, 369 (median age, 10 months) were discharged alive with a follow-up plan. Of these, 32 (8.7%) died in the community within 3 months of discharge: median 22 (IQR 9-35) days from discharge to death. Most deaths were reportedly associated with acute onset of new respiratory or gastrointestinal symptoms. Those that died following discharge were significantly younger (median 6 [IQR 3,12] months) and more severely malnourished, on admission and on discharge, than those that survived. Bivariate analysis found that severe wasting on admission (OR 3.64, 95% CI 1.66-7.97) and age,12 months (OR 2.54, 95% CI 1.1-8.8) were significantly associated with post-discharge death. Of those that died in the community, none had attended a scheduled follow-up and care-seeking from a traditional healer was more common (p, 0.001) compared to those who survived. Conclusion and Significance: Post-discharge mortality was common in Bangladeshi children following inpatient care for severe malnutrition and pneumonia. The underlying contributing factors require a better understanding to inform the potential of interventions that could improve survival.	[Chisti, Mohammod Jobayer; Ahmed, Tahmeed; Faruque, Abu Syed Golam; Ashraf, Hasan; Bardhan, Pradip Kumar; Shahid, Abu S. M. S. B.; Shahunja, K. M.; Salam, Mohammed Abdus] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh; [Chisti, Mohammod Jobayer; Graham, Stephen M.; Duke, Trevor] Univ Melbourne, Dept Paediat, Ctr Int Child Hlth, Melbourne, Vic, Australia; [Chisti, Mohammod Jobayer; Graham, Stephen M.; Duke, Trevor] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Graham, Stephen M.] Int Union TB & Lung Dis, Paris, France	International Centre for Diarrhoeal Disease Research (ICDDR); University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Graham, SM (corresponding author), Univ Melbourne, Dept Paediat, Ctr Int Child Hlth, Melbourne, Vic, Australia.	steve.graham@rch.org.au	Chisti, Mohammod J/A-7216-2018; Shahunja, K M/AAR-6229-2020	Shahunja, K M/0000-0002-9345-206X; Graham, Stephen/0000-0003-3525-2294	Dhaka Hospital of International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B) [Gr-00233]	Dhaka Hospital of International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B)	This research study was funded by the Dhaka Hospital of International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B; grant no Gr-00233) and its donors, which provide unrestricted support to ICDDR, B for its operations and research. Current donors providing unrestricted support include: Australian Agency for International Development, Government of the People's Republic of Bangladesh, Canadian International Development Agency, Swedish International Development Cooperation Agency, and the Department for International Development, United Kingdom. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed T, 1999, LANCET, V353, P1919, DOI 10.1016/S0140-6736(98)07499-6; Ashraf H, 2012, J TROP PEDIATRICS, V58, P253, DOI 10.1093/tropej/fmr083; Bejon P, 2008, AM J CLIN NUTR, V88, P1626, DOI 10.3945/ajcn.2008.26510; Brewster DR, 1997, EUR J CLIN NUTR, V51, P139, DOI 10.1038/sj.ejcn.1600367; Chang AB, 2008, PEDIATR PULM, V43, P519, DOI 10.1002/ppul.20821; Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353; Chintu C, 2004, LANCET, V364, P1865, DOI 10.1016/S0140-6736(04)17442-4; Chisti MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093776; Chisti MJ, 2009, TROP MED INT HEALTH, V14, P1173, DOI 10.1111/j.1365-3156.2009.02364.x; Ciliberto MA, 2005, AM J CLIN NUTR, V81, P864, DOI 10.1093/ajcn/81.4.864; D'Souza RM, 2003, J BIOSOC SCI, V35, P131, DOI 10.1017/S0021932003001317; HENNART P, 1987, J TROP PEDIATRICS, V33, P10, DOI 10.1093/tropej/33.1.10; Islam MA, 1996, J TROP PEDIATRICS, V42, P342, DOI 10.1093/tropej/42.6.342; Kerac M, 2009, LANCET, V374, P136, DOI 10.1016/S0140-6736(09)60884-9; Marais BJ, 2010, AM J RESP CRIT CARE, V181, P195, DOI 10.1164/ajrccm.181.2.195a; Mercer A, 2006, HEALTH POLICY PLANN, V21, P432, DOI 10.1093/heapol/czl024; Qureshi JS, 2014, TROP MED INT HLTH; Reneman L, 1997, J TROP PEDIATRICS, V43, P293, DOI 10.1093/tropej/43.5.293; Roy SK, 2011, J HEALTH POPUL NUTR, V29, P229, DOI 10.3329/jhpn.v29i3.7870; ROY SK, 1983, BRIT MED J, V287, P1097, DOI 10.1136/bmj.287.6399.1097; Veirum JE, 2007, ACTA PAEDIATR, V96, P1832, DOI 10.1111/j.1651-2227.2007.00562.x; Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6; Waterlow J C, 1971, Adv Protein Chem, V25, P117, DOI 10.1016/S0065-3233(08)60280-6; Wiens MO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066698; World Health Organization, 2006, GUID COTR PROH HIV R; World Health Organization, 2007, 2007 WHO VERB AUT IN, P20; World Health Organization, 2013, POCK BOOK HOSP CAR C; Zurovac D, 2011, LANCET, V378, P795, DOI 10.1016/S0140-6736(11)60783-6	28	42	42	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2014	9	9							e107663	10.1371/journal.pone.0107663	http://dx.doi.org/10.1371/journal.pone.0107663			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS5NP	25225798	Green Published, Green Submitted, gold			2023-01-03	WOS:000344317700072
J	Glass-Kaastra, SK; Finley, R; Hutchinson, J; Patrick, DM; Weiss, K; Conly, J				Glass-Kaastra, Shiona K.; Finley, Rita; Hutchinson, Jim; Patrick, David M.; Weiss, Karl; Conly, John			Does Variation among Provincial Drug Formulary Antimicrobial Listings in Canada Influence Prescribing Rates?	PLOS ONE			English	Article							IMPACT	Background: The financial accessibility of antimicrobial drugs to the outpatient community in Canada is governed at the provincial level through formularies. Each province may choose to list particular drugs or impose restriction criteria on products in order to guide prescribing and/or curtail costs. Although changes to formularies have been shown to change patterns in the use of individual products and alter costs, no comparison has been made among the provincial antimicrobial formularies with regards to flexibility/stringency, or an assessment of how these formularies impact overall antimicrobial use in the provinces. Objectives: To summarize provincial antimicrobial formularies and assess whether their relative flexibility/stringency had a statistical impact upon provincial prescription volume during a one year period. Methods: Provincial drug plan formularies were accessed and summarized for all prescribed antimicrobials in Canada during 2010. The number of general and restricted benefits for each plan was compiled by antimicrobial classification. Population-adjusted prescription rates for all individual antimicrobials and by antimicrobial class were obtained from the Canadian Integrated Program for Antimicrobial Resistance Surveillance. Correlations between the number of general benefits, restricted benefits, and total benefits with the prescription rate in the provinces were assessed by Spearman rank correlation coefficients. Results: Formularies varied considerably among the Canadian provinces. Quebec had the most flexible formulary, offering the greatest number of general benefits and fewest restrictions. In contrast, Saskatchewan's formulary displayed the lowest number of general benefits and most restrictions. Correlation analyses detected a single significant result; macrolide prescription rates decreased as the number of general macrolide benefits increased. All other rates of provincial antimicrobial prescribing and measures of flexibility/stringency revealed no significant correlations. Conclusions: Although antimicrobial formulary listings are used to guide prescribing rates within a province, our analysis of one year's data of the impact of the antimicrobial formulary structure did not correlate with antimicrobial prescribing rates, and other factors are likely to be at play.	[Glass-Kaastra, Shiona K.; Finley, Rita] Publ Hlth Agcy Canada, Ctr Food Borne Environm & Zoonot Infect Dis, Guelph, ON, Canada; [Hutchinson, Jim] Univ British Columbia, Div Med Microbiol, Isl Med Program, Victoria, BC, Canada; [Patrick, David M.] British Columbia Ctr Dis Control, Vancouver, BC, Canada; [Patrick, David M.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada; [Weiss, Karl] Univ Montreal, Hop Maison Neuve Rosemont, Dept Infect Dis & Microbiol, Montreal, PQ, Canada; [Conly, John] Univ Calgary, Dept Med, Calgary, AB, Canada; [Conly, John] Univ Calgary, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada; [Conly, John] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada; [Conly, John] Univ Calgary, Synder Inst Chron Dis, Calgary, AB, Canada	Public Health Agency of Canada; University of British Columbia; University of British Columbia; Universite de Montreal; University of Calgary; University of Calgary; University of Calgary; University of Calgary	Finley, R (corresponding author), Publ Hlth Agcy Canada, Ctr Food Borne Environm & Zoonot Infect Dis, Guelph, ON, Canada.	Rita.Finley@phac-aspc.gc.ca			Abbott; Bayer; Gilead; Merck; Pfizer; Optimer Pharma; Roche; Vertex; Alberta Heritage Foundation for Medical Research; Canadian Institutes for Health Research; PHAC; NCCID; Alberta Advanced Education Technology	Abbott(Abbott Laboratories); Bayer(Bayer AG); Gilead(Gilead Sciences); Merck(Merck & Company); Pfizer(Pfizer); Optimer Pharma; Roche(Roche Holding); Vertex(Vertex Pharmaceuticals); Alberta Heritage Foundation for Medical Research(Alberta Heritage Foundation for Medical ResearchGeneral Electric); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); PHAC; NCCID; Alberta Advanced Education Technology	The authors have read the journal's policy and have identified the following conflicts: KW has received research funds and/or has been on the advisory board from Abbott, Bayer, Gilead, Merck, Pfizer, Optimer Pharma, Roche, Vertex. JC has received honoraria from the Canadian Agency for Drugs and Technologies in Health for work as an expert reviewer and clinical expert, respectively, for projects on the role of rapid PCR testing for MRSA in hospitalized patients and the use of vancomycin or metronidazole for treatment of Clostridium difficile colitis within the last 3 years. He has also received speaker's honoraria related to new anti-bacterial agents from Janssen-Ortho and Pfizer within the past 3 years. He has received financial support for research activities from the Alberta Heritage Foundation for Medical Research, the Canadian Institutes for Health Research, PHAC, NCCID, Alberta Advanced Education & Technology and Pfizer. RF, SGK, DP and JH do not have any conflict of interest. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data or materials.	Alberta Health and Wellness, 2012, ALB HLTH WELLN DRUG; Anis AH, 2001, MED CARE, V39, P315, DOI 10.1097/00005650-200104000-00003; [Anonymous], ATC DDD IND; British Columbia Ministry of Health, 2011, LTD COV DRUG PLAN CR; British Columbia Ministry of Health Services, 2011, PHARMACARE FORM SEAR; Burke JP, 1998, JAMA-J AM MED ASSOC, V280, P1270, DOI 10.1001/jama.280.14.1270; Canadian Agency for Drugs and Technologies in Health (CADTH), 2012, COMM DRUG REV; Finley R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076398; Glass-Kaastra SK, 2014, CAN J INFECT DIS MED, V25, P95, DOI 10.1155/2014/703898; Government of Alberta Health and Wellness, 2011, ALB HLTH WELLN DRUG; Government of Manitoba, 2012, MAN DRUG BEN INT F 3; Health PEI, 2011, FORMULARY; Health Prince Edward Island, 2012, P E I PHARM FORM; Mamdani M, 2007, AM J MED, V120, P893, DOI 10.1016/j.amjmed.2007.02.028; Manitoba Health, 2011, MAN PHARM PROGR DRUG; Marshall DA, 2006, CAN J PUBLIC HEALTH, V97, P126, DOI 10.1007/BF03405330; Mckay RM, 2011, CAN J INFECT DIS MED, V22, P19, DOI 10.1155/2011/745090; New Brunswick Department of Health, 2012, PRESCR DRUG PROGR SP; New Brunswick Department of Health, 2011, PRESCR DRUG PROGR FO; Newfoundland and Labrador Department of Health and Community Services, 2011, PRESCR DRUG PROGR NL; Newfoundland and Labrador Department of Health and Community Services, 2012, NEWF LABR PRESCR DRU; Nova Scotia Pharmacare, 2011, DRUG FORM; Nova Scotia Pharmacare, 2012, CRIT EXC STAT COV; Ontario Ministry of Health and Long-Term Care, 2011, ONT DRUG BEN FORM CO; Ontario Ministry of Health and Long-Term Care, 2011, ONT DRUG BEN PROGR L; Pomey MP, 2020, J HLTH POLIT POLICY, V35, P705; Quebec Regie de L'assurance maladie, 2011, DEM AUT PAIEM MED EX; Regie de l'assurance maladie Quebec, 2011, LIST MED; Sabuncu E, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000084; Saskatchewan Ministry of Health, 2011, DRUG PLAN FORM; Weiss K, 2011, CLIN INFECT DIS, V53, P433, DOI 10.1093/cid/cir409	31	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2014	9	9							e107515	10.1371/journal.pone.0107515	http://dx.doi.org/10.1371/journal.pone.0107515			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ3IF	25203557	Green Published, gold, Green Submitted			2023-01-03	WOS:000342684500105
J	Bazzano, LA; Hu, T; Reynolds, K; Yao, L; Bunol, C; Liu, YX; Chen, CS; Klag, MJ; Whelton, PK; He, J				Bazzano, Lydia A.; Hu, Tian; Reynolds, Kristi; Yao, Lu; Bunol, Calynn; Liu, Yanxi; Chen, Chung-Shiuan; Klag, Michael J.; Whelton, Paul K.; He, Jiang			Effects of Low-Carbohydrate and Low-Fat Diets A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; WEIGHT-LOSS DIETS; RISK-FACTORS; PROTEIN; PLASMA; ATKINS; ORNISH; ZONE	Background: Low-carbohydrate diets are popular for weight loss, but their cardiovascular effects have not been well-studied, particularly in diverse populations. Objective: To examine the effects of a low-carbohydrate diet compared with a low-fat diet on body weight and cardiovascular risk factors. Design: A randomized, parallel-group trial. (ClinicalTrials.gov:NCT00609271) Setting: A large academic medical center. Participants: 148 men and women without clinical cardiovascular disease and diabetes. Intervention: A low-carbohydrate (<40 g/d) or low-fat (<30% of daily energy intake from total fat [<7% saturated fat]) diet. Both groups received dietary counseling at regular intervals throughout the trial. Measurements: Data on weight, cardiovascular risk factors, and dietary composition were collected at 0, 3, 6, and 12 months. Results: Sixty participants (82%) in the low-fat group and 59 (79%) in the low-carbohydrate group completed the intervention. At 12 months, participants on the low-carbohydrate diet had greater decreases in weight (mean difference in change, -3.5 kg [95% CI, -5.6 to -1.4 kg]; P = 0.002), fat mass (mean difference in change, -1.5% [CI, -2.6% to -0.4%]; P = 0.011), ratio of total-high-density lipoprotein (HDL) cholesterol (mean difference in change, -0.44 [CI, -0.71 to -0.16]; P = 0.002), and triglyceride level (mean difference in change, -0.16 mmol/L [-14.1 mg/dL] [CI, -0.31 to -0.01 mmol/L {-27.4 to -0.8 mg/dL}]; P = 0.038) and greater increases in HDL cholesterol level (mean difference in change, 0.18 mmol/L [7.0 mg/dL] [CI, 0.08 to 0.28 mmol/L {3.0 to 11.0 mg/dL}]; P = 0.001) than those on the low-fat diet. Limitation: Lack of clinical cardiovascular disease end points. Conclusion: The low-carbohydrate diet was more effective for weight loss and cardiovascular risk factor reduction than the low-fat diet. Restricting carbohydrate may be an option for persons seeking to lose weight and reduce cardiovascular risk factors.	[Bazzano, Lydia A.] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA 70112 USA; Kaiser Permanente So Calif, Pasadena, CA 91101 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA	Tulane University; Kaiser Permanente; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bazzano, LA (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, 1440 Canal St,SL-18,Suite 2000, New Orleans, LA 70112 USA.	lbazzano@tulane.edu	He, Jiang/AAF-5303-2020; Reynolds, Kristi/AAN-1434-2021	He, Jiang/0000-0002-8286-9652; Reynolds, Kristi/0000-0001-7619-1649	National Institutes of Health; National Center for Research Resources of the National Institutes of Health [NIH/NCRR P20-RR017659]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103337] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	National Institutes of Health.; From the National Center for Research Resources of the National Institutes of Health (NIH/NCRR P20-RR017659) to the Tulane University Hypertension and Renal Center of Excellence.	ALLAIN CC, 1974, CLIN CHEM, V20, P470; Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480; Brinkworth GD, 2009, AM J CLIN NUTR, V90, P23, DOI 10.3945/ajcn.2008.27326; Calonge N, 2009, ANN INTERN MED, V150, P396; Cardillo S, 2006, Eur Rev Med Pharmacol Sci, V10, P99; Dansinger ML, 2005, JAMA-J AM MED ASSOC, V293, P43, DOI 10.1001/jama.293.1.43; Davis NJ, 2009, DIABETES CARE, V32, P1147, DOI 10.2337/dc08-2108; Ebbeling CB, 2012, JAMA-J AM MED ASSOC, V307, P2627, DOI 10.1001/jama.2012.6607; Foster GD, 2010, ANN INTERN MED, V153, P147, DOI 10.7326/0003-4819-153-3-201008030-00005; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gardner CD, 1996, JAMA-J AM MED ASSOC, V276, P875, DOI 10.1001/jama.276.11.875; Gardner CD, 2007, JAMA-J AM MED ASSOC, V297, P969, DOI 10.1001/jama.297.9.969; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Halton TL, 2006, NEW ENGL J MED, V355, P1991, DOI 10.1056/NEJMoa055317; Hu T, 2012, AM J EPIDEMIOL, V176, pS44, DOI 10.1093/aje/kws264; Krauss RM, 2000, CIRCULATION, V102, P2284; Lagiou P, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4026; LAROSA JC, 1980, J AM DIET ASSOC, V77, P264; Liuzzo G, 2001, Rays, V26, P221; Molenberghs G., 2007, MISSING DATA CLIN ST; Nutrition Data System for Research, 2005, MINN NUTR DAT SYST; Pickering Thomas G., 2005, Hypertension (Baltimore), V45, P142; Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Seshadri P, 2004, AM J MED, V117, P398, DOI 10.1016/j.amjmed.2004.04.009; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; Stern L, 2004, ANN INTERN MED, V140, P778, DOI 10.7326/0003-4819-140-10-200405180-00007; Stone Neil J, 2002, Curr Atheroscler Rep, V4, P433, DOI 10.1007/s11883-002-0047-x; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837	31	191	195	3	145	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2014	161	5					309	+		10.7326/M14-0180	http://dx.doi.org/10.7326/M14-0180			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AO7VT	25178568	Green Accepted			2023-01-03	WOS:000341561400001
J	Fox, IJ; Daley, GQ; Goldman, SA; Huard, J; Kamp, TJ; Trucco, M				Fox, Ira J.; Daley, George Q.; Goldman, Steven A.; Huard, Johnny; Kamp, Timothy J.; Trucco, Massimo			Use of differentiated pluripotent stem cells in replacement therapy for treating disease	SCIENCE			English	Review							DUCHENNE MUSCULAR-DYSTROPHY; RED-BLOOD-CELLS; HEPATOCYTE TRANSPLANTATION; PROGENITOR CELLS; SKELETAL-MUSCLE; HUMAN ES; MYOBLAST TRANSPLANTATION; ANIMAL-MODELS; MOUSE MODEL; HEPATOCELLULAR TRANSPLANTATION	Pluripotent stem cells (PSCs) directed to various cell fates holds promise as source material for treating numerous disorders. The availability of precisely differentiated PSC-derived cells will dramatically affect blood component and hematopoietic stem cell therapies and should facilitate treatment of diabetes, some forms of liver disease and neurologic disorders, retinal diseases, and possibly heart disease. Although an unlimited supply of specific cell types is needed, other barriers must be overcome. This review of the state of cell therapies highlights important challenges. Successful cell transplantation will require optimizing the best cell type and site for engraftment, overcoming limitations to cell migration and tissue integration, and occasionally needing to control immunologic reactivity, as well as a number of other challenges. Collaboration among scientists, clinicians, and industry is critical for generating new stem cell-based therapies.	[Fox, Ira J.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA; [Fox, Ira J.] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA USA; [Daley, George Q.] Boston Childrens Hosp, Boston, MA USA; [Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Daley, George Q.] Harvard Univ, Sch Med, Broad Inst, Dept Biol Chem & Mol Pharmacol, Cambridge, MA 02138 USA; [Daley, George Q.] Howard Hughes Med Inst, Chevy Chase, MD USA; [Goldman, Steven A.] Univ Rochester, Med Ctr, Ctr Translat Neuromed, Rochester, NY 14642 USA; [Goldman, Steven A.] Univ Copenhagen, Ctr Basic & Translat Neurosci, DK-1168 Copenhagen, Denmark; [Huard, Johnny] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, Stem Cell Res Ctr, Pittsburgh, PA 15261 USA; [Kamp, Timothy J.] Univ Wisconsin, Dept Med, Stem Cell & Regenerat Med Ctr, Cellular & Mol Arrhythmia Res Program,Sch Med & P, Madison, WI USA; [Trucco, Massimo] Univ Pittsburgh, Childrens Hosp Pittsburgh, Div Immunogenet, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Howard Hughes Medical Institute; University of Rochester; University of Copenhagen; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Fox, IJ (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA.	foxi@upmc.edu	Kamp, Timothy/ABD-1343-2020	Kamp, Timothy/0000-0003-2103-7876	NIH [R01DK48794, P01DK096990, R01DK099320, 1P01AG043376, U01HL099773]; National Institute of Neurological Disorders and Stroke; National Institute of Mental Health; Mathers Charitable Foundation; National Multiple Sclerosis Society; Adelson Medical Research Foundation; Child Health and Development Institute; New York Stem Cell Research Program; DOD [W81XWH-10-1-1055]; Novo Nordisk Fonden [NNF13OC0004260] Funding Source: researchfish; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL099773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK096990, R01DK099320, R01DK048794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH104701, R01MH099578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS075345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG043376] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Mathers Charitable Foundation; National Multiple Sclerosis Society(National Multiple Sclerosis Society); Adelson Medical Research Foundation; Child Health and Development Institute; New York Stem Cell Research Program; DOD(United States Department of Defense); Novo Nordisk Fonden(Novo Nordisk Foundation); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank E. Tafaleng, N. Giannoukakis, and J. H. Cummins for providing figures and for text editing. This work was supported in part by NIH R01DK48794, P01DK096990, and R01DK099320 (I.J.F.); National Institute of Neurological Disorders and Stroke, National Institute of Mental Health, the Mathers Charitable Foundation, the National Multiple Sclerosis Society, the Adelson Medical Research Foundation, Child Health and Development Institute, and the New York Stem Cell Research Program (S.A.G.); NIH 1P01AG043376 (J. H.); U01HL099773 (T.J.K.); and DOD W81XWH-10-1-1055 (M.T.). I.J.F. is a member of the Scientific Advisory Board of Regenerative Medicine Solutions, Inc.; G.Q.D. is a member of the Senior Advisory Board of MPM Capital, Inc.; S.A.G. is a consultant for Biogen Idec; T.J.K. is a founding shareholder in Cellular Dynamics International; and J. H. is a consultant for Cook Myosite. S.A.G. is an inventor on patents owned by the University of Rochester and Cornell University concerning the use of tissue-and iPSC-derived glial progenitor cells.	ALEJANDRO R, 1986, J CLIN INVEST, V78, P1339, DOI 10.1172/JCI112720; Alipio Z, 2010, P NATL ACAD SCI USA, V107, P13426, DOI 10.1073/pnas.1007884107; ARAHATA K, 1988, NATURE, V333, P861, DOI 10.1038/333861a0; Archer DR, 1997, NAT MED, V3, P54, DOI 10.1038/nm0197-54; Bachrach E, 2004, P NATL ACAD SCI USA, V101, P3581, DOI 10.1073/pnas.0400373101; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Barberi T, 2007, NAT MED, V13, P642, DOI 10.1038/nm1533; Barton FB, 2012, DIABETES CARE, V35, P1436, DOI 10.2337/dc12-0063; Beauchamp JR, 1999, J CELL BIOL, V144, P1113, DOI 10.1083/jcb.144.6.1113; Benraiss A, 2013, CELL STEM CELL, V12, P787, DOI 10.1016/j.stem.2013.04.014; Benraiss A, 2011, NEUROTHERAPEUTICS, V8, P577, DOI 10.1007/s13311-011-0075-8; Bilir BM, 2000, LIVER TRANSPLANT, V6, P32, DOI 10.1016/S1527-6465(00)80030-1; BISCHOFF R, 1986, DEV BIOL, V115, P129, DOI 10.1016/0012-1606(86)90234-4; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Blin G, 2010, J CLIN INVEST, V120, P1125, DOI 10.1172/JCI40120; Bottino R, 2002, BEST PRACT RES CL GA, V16, P457, DOI 10.1053/bega.2002.0318; Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163; Carr LK, 2008, INT UROGYNECOL J, V19, P881, DOI 10.1007/s00192-007-0553-z; Carri AD, 2013, DEVELOPMENT, V140, P301, DOI 10.1242/dev.084608; Caspi O, 2007, J AM COLL CARDIOL, V50, P1884, DOI 10.1016/j.jacc.2007.07.054; Chong JJH, 2014, NATURE, V510, P273, DOI 10.1038/nature13233; Christoforou N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011536; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Creusot RJ, 2014, DIABETES, V63, P20, DOI 10.2337/db13-0886; Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003; Darabi R, 2012, CELL STEM CELL, V10, P610, DOI 10.1016/j.stem.2012.02.015; De Angelis L, 1999, J CELL BIOL, V147, P869, DOI 10.1083/jcb.147.4.869; De Vree JML, 2000, GASTROENTEROLOGY, V119, P1720, DOI 10.1053/gast.2000.20222; Dellavalle A, 2007, NAT CELL BIOL, V9, P255, DOI 10.1038/ncb1542; DEMETRIOU AA, 1988, HEPATOLOGY, V8, P1006, DOI 10.1002/hep.1840080505; DEPAEPE ME, 1995, HEPATOLOGY, V21, P1144, DOI 10.1016/0270-9139(95)90267-8; Dhawan A, 2010, NAT REV GASTRO HEPAT, V7, P288, DOI 10.1038/nrgastro.2010.44; Dubois NC, 2011, NAT BIOTECHNOL, V29, P1011, DOI 10.1038/nbt.2005; Echeverria GJ, 2009, AM J TRANSPLANT, V9, P2485, DOI 10.1111/j.1600-6143.2009.02815.x; Fan Y, 1996, MUSCLE NERVE, V19, P853, DOI 10.1002/(SICI)1097-4598(199607)19:7<853::AID-MUS7>3.0.CO;2-8; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Ferreira LS, 2007, CIRC RES, V101, P286, DOI 10.1161/CIRCRESAHA.107.150201; Filareto A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2550; Fisher SA, 2014, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD007888.PUB2; Fox IJ, 1998, NEW ENGL J MED, V338, P1422, DOI 10.1056/NEJM199805143382004; Gagandeep S, 2000, J PATHOL, V191, P78, DOI 10.1002/(SICI)1096-9896(200005)191:1<78::AID-PATH587>3.0.CO;2-P; Galli R, 2000, NAT NEUROSCI, V3, P986, DOI 10.1038/79924; Goldman SA, 2012, SCIENCE, V338, P491, DOI 10.1126/science.1218071; Goldman SA, 2011, ARCH NEUROL-CHICAGO, V68, P848, DOI 10.1001/archneurol.2011.46; Goudenege S, 2012, MOL THER, V20, P2153, DOI 10.1038/mt.2012.188; GROTH CG, 1977, TRANSPLANT P, V9, P313; Guha C, 2002, HEPATOLOGY, V36, P354, DOI 10.1053/jhep.2002.34516; Gupta N, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004373; Gupta S, 1999, HEPATOLOGY, V29, P509, DOI 10.1002/hep.510290213; GUSSONI E, 1992, NATURE, V356, P435, DOI 10.1038/356435a0; HABIBULLAH CM, 1994, TRANSPLANTATION, V58, P951, DOI 10.1097/00007890-199410270-00016; Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092; HD iPSC Consortium, 2012, CELL STEM CELL, V11, P264, DOI 10.1016/j.stem.2012.04.027; He JQ, 2003, CIRC RES, V93, P32, DOI 10.1161/01.RES.0000080317.92718.99; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Hoppo T, 2011, GASTROENTEROLOGY, V140, P656, DOI 10.1053/j.gastro.2010.11.006; Horslen SP, 2003, PEDIATRICS, V111, P1262, DOI 10.1542/peds.111.6.1262; HUARD J, 1992, MUSCLE NERVE, V15, P550, DOI 10.1002/mus.880150504; JASMIN G, 1984, LAB INVEST, V50, P197; Kallestad KM, 2011, EXP CELL RES, V317, P873, DOI 10.1016/j.yexcr.2011.01.018; KARPATI G, 1989, AM J PATHOL, V135, P27; Karumbayaram S, 2009, STEM CELLS, V27, P806, DOI 10.1002/stem.31; Kawamura M, 2012, CIRCULATION, V126, pS29, DOI 10.1161/CIRCULATIONAHA.111.084343; KEMP CB, 1973, NATURE, V244, P447, DOI 10.1038/244447a0; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; Kobayashi N, 2000, HEPATOLOGY, V31, P851, DOI 10.1053/he.2000.5636; Kriks S, 2011, NATURE, V480, P547, DOI 10.1038/nature10648; Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3; Lacotte S, 2011, EXPERT OPIN BIOL TH, V11, P55, DOI 10.1517/14712598.2011.536530; Laflamme MA, 2007, NAT BIOTECHNOL, V25, P1015, DOI 10.1038/nbt1327; Ledran MH, 2008, CELL STEM CELL, V3, P85, DOI 10.1016/j.stem.2008.06.001; Leobon B, 2003, P NATL ACAD SCI USA, V100, P7808, DOI 10.1073/pnas.1232447100; Lepore AC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025968; Li M, 2014, J BIOL CHEM, V289, P4594, DOI 10.1074/jbc.R113.488247; Li XJ, 2005, NAT BIOTECHNOL, V23, P215, DOI 10.1038/nbt1063; Liao SW, 2013, BIOMATERIALS, V34, P3984, DOI 10.1016/j.biomaterials.2013.02.007; LIECHTIGALLATI S, 1981, PEDIATR RES, V15, P1411, DOI 10.1203/00006450-198111000-00004; Lindvall O, 2012, NAT BIOTECHNOL, V30, P56, DOI 10.1038/nbt.2077; Liu Y, 2013, NAT BIOTECHNOL, V31, P440, DOI 10.1038/nbt.2565; MATAS AJ, 1976, SCIENCE, V192, P892, DOI 10.1126/science.818706; Mazurier C, 2011, CURR OPIN HEMATOL, V18, P249, DOI 10.1097/MOH.0b013e3283476129; McKinney-Freeman SL, 2009, BLOOD, V114, P268, DOI 10.1182/blood-2008-12-193888; Menasche P, 2008, CIRCULATION, V117, P1189, DOI 10.1161/CIRCULATIONAHA.107.734103; MENDELL JR, 1995, NEW ENGL J MED, V333, P832, DOI 10.1056/NEJM199509283331303; MITO M, 1979, TRANSPLANTATION, V28, P499, DOI 10.1097/00007890-197912000-00013; MITO M, 1992, TRANSPLANT P, V24, P3052; Moretti A, 2006, CELL, V127, P1151, DOI 10.1016/j.cell.2006.10.029; MORGAN JE, 1990, J CELL BIOL, V111, P2437, DOI 10.1083/jcb.111.6.2437; Muller M, 2000, FASEB J, V14, P2540, DOI 10.1096/fj.00-0002com; Mummery CL, 2012, CIRC RES, V111, P344, DOI 10.1161/CIRCRESAHA.110.227512; Muraca M, 2002, LANCET, V359, P317, DOI 10.1016/S0140-6736(02)07529-3; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Nakamura S, 2014, CELL STEM CELL, V14, P535, DOI 10.1016/j.stem.2014.01.011; Newsome PN, 2000, LIVER TRANSPLANT, V6, P21, DOI 10.1016/S1527-6465(00)80029-5; Nguyen PK, 2011, CIRC RES, V109, P962, DOI 10.1161/CIRCRESAHA.111.242909; Nicholas CR, 2013, CELL STEM CELL, V12, P573, DOI 10.1016/j.stem.2013.04.005; Nilsson B, 2011, CURR OPIN ORGAN TRAN, V16, P620, DOI 10.1097/MOT.0b013e32834c2393; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Peault B, 2007, MOL THER, V15, P867, DOI 10.1038/mt.sj.6300145; PIPELEERS DG, 1991, DIABETES, V40, P908, DOI 10.2337/diabetes.40.7.908; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; PONDER KP, 1991, P NATL ACAD SCI USA, V88, P1217, DOI 10.1073/pnas.88.4.1217; Qu ZQ, 1998, J CELL BIOL, V142, P1257, DOI 10.1083/jcb.142.5.1257; RIBEIRO J, 1992, HEPATOLOGY, V15, P12, DOI 10.1002/hep.1840150104; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; Rideout WM, 2002, CELL, V109, P17, DOI 10.1016/S0092-8674(02)00681-5; Rinaldi F, 2014, TRANSL RES, V163, P409, DOI 10.1016/j.trsl.2013.11.006; ROHWEDEL J, 1994, DEV BIOL, V164, P87, DOI 10.1006/dbio.1994.1182; Rousseau GF, 2014, BIOTECHNOL J, V9, P28, DOI 10.1002/biot.201200368; Roy NS, 2006, NAT MED, V12, P1259, DOI 10.1038/nm1495; Roy NS, 2005, EXP NEUROL, V196, P224, DOI 10.1016/j.expneurol.2005.06.021; RUGSTAD JE, 1970, SCIENCE, V170, P553; Ryan EA, 2005, DIABETES, V54, P2060, DOI 10.2337/diabetes.54.7.2060; Sacco A, 2010, CELL, V143, P1059, DOI 10.1016/j.cell.2010.11.039; Sampaolesi M, 2006, NATURE, V444, P574, DOI 10.1038/nature05282; Sanganalmath SK, 2013, CIRC RES, V113, P810, DOI 10.1161/CIRCRESAHA.113.300219; Schulz TC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037004; Schumacher IK, 1996, HEPATOLOGY, V24, P337; Sharma V, 2006, NEW ENGL J MED, V355, P1397; Shiba Y, 2012, NATURE, V489, P322, DOI 10.1038/nature11317; Sokal EM, 2003, TRANSPLANTATION, V76, P735, DOI 10.1097/01.TP.0000077420.81365.53; Soltys KA, 2010, J HEPATOL, V53, P769, DOI 10.1016/j.jhep.2010.05.010; Stern JH, 2011, NEUROTHERAPEUTICS, V8, P736, DOI 10.1007/s13311-011-0077-6; Sutherland DER, 2012, J AM COLL SURGEONS, V214, P409, DOI 10.1016/j.jamcollsurg.2011.12.040; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tedesco FS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003541; TERBLANCHE J, 1991, DIGEST DIS SCI, V36, P770, DOI 10.1007/BF01311235; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tian XH, 2006, STEM CELLS, V24, P1370, DOI 10.1634/stemcells.2005-0340; Tohyama S, 2013, CELL STEM CELL, V12, P127, DOI 10.1016/j.stem.2012.09.013; Torrente Y, 2000, CELL TRANSPLANT, V9, P539, DOI 10.1177/096368970000900410; Tuszynski MH, 2014, CELL, V156, P388, DOI 10.1016/j.cell.2014.01.016; Uygun BE, 2010, NAT MED, V16, P814, DOI 10.1038/nm.2170; van der Windt DJ, 2009, AM J TRANSPLANT, V9, P2716, DOI 10.1111/j.1600-6143.2009.02850.x; VILQUIN JT, 1995, J CELL BIOL, V131, P975, DOI 10.1083/jcb.131.4.975; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; Wang L, 2005, EXP HEMATOL, V33, P987, DOI 10.1016/j.exphem.2005.06.002; Wang S, 2013, CELL STEM CELL, V12, P252, DOI 10.1016/j.stem.2012.12.002; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; Westermark GT, 2008, NEW ENGL J MED, V359, P977, DOI 10.1056/NEJMc0802893; WIEDERKEHR JC, 1990, TRANSPLANTATION, V50, P466, DOI 10.1097/00007890-199009000-00021; Windrem MS, 2008, CELL STEM CELL, V2, P553, DOI 10.1016/j.stem.2008.03.020; Windrem MS, 2004, NAT MED, V10, P93, DOI 10.1038/nm974; Xiong Q, 2013, CIRCULATION, V127, P997, DOI 10.1161/CIRCULATIONAHA.112.000641; Yang L, 2008, NATURE, V453, P524, DOI 10.1038/nature06894; Yoshida Y, 1996, GASTROENTEROLOGY, V111, P1654, DOI 10.1016/S0016-5085(96)70029-X; Zheng B, 2007, NAT BIOTECHNOL, V25, P1025, DOI 10.1038/nbt1334; Zhou HC, 2009, HEPATOLOGY, V50, p303A; ZUBRZYCKAGAARN EF, 1988, NATURE, V333, P466, DOI 10.1038/333466a0	150	202	210	10	156	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2014	345	6199					889	+	1247391	10.1126/science.1247391	http://dx.doi.org/10.1126/science.1247391			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB6ZO	25146295	Green Accepted			2023-01-03	WOS:000349775800001
J	Abd-El-Maeboud, KHI; Kortam, MAMF; Ali, MS; Ibrahim, MI; Mohamed, RMMZ				Abd-El-Maeboud, Karim H. I.; Kortam, Mohamed A. M. F.; Ali, Mohamed S.; Ibrahim, Mostafa I.; Mohamed, Radwa M. M. Z.			A Preliminary Pilot Randomized Crossover Study of Uzara (Xysmalobium undulatum) versus Ibuprofen in the Treatment of Primary Dysmenorrhea	PLOS ONE			English	Article							PAIN; ISOXSUPRINE; TERBUTALINE	Objective: Preliminary evaluation of efficacy and safety of uzara use in treatment of moderate and severe primary dysmenorrhea in comparison to ibuprofen. Materials and Methods: This randomized, comparative two way cross-over study comprised 60 single female students at Faculty of Medicine, Ain Shams University, Egypt, aged 19-28 years with moderate (n = 46) or severe (n = 14) primary dysmenorrhea. Participants were randomized to take either uzara (80 mg/8 hours for two doses, then 40 mg/8 hours) then ibuprofen (400 mg/6 hours) in two subsequent cycles or vice versa. The pain intensity, using VAS, was recorded immediately before taking the medication (0 hour) and after 4, 12, 24, 48-60, 96-120 hours. Main outcome measures included effectiveness of pain relief defined as drop of VAS to 3 or less, patient's global evaluation of the drug, absence from school, the use of a rescue medication, and, in those who continued the treatment, the pain intensity difference (PID) at different points after start of medication and its sum (SPID). Results: Uzara was comparably effective to ibuprofen (78.3% vs. 86.7% of cycles; respectively), with comparable rates of effectiveness on global evaluation (being around 50% for either drug), and rates of school absences (11.7% vs. 13.3%; respectively). The need for rescue medication was different (18.3% and 10%; respectively), albeit with no statistical significance. The means of PID at different time points and SPID were comparable, with significantly lower average mean of VAS scores compared to that felt with no medication (1.6 vs. 6.8, p<0.001). Side effects were less with uzara than ibuprofen (0% vs. 8.3%, p<0.05). Conclusions: Uzara might be as effective as ibuprofen in management of primary dysmenorrhea but with less side effects. These findings need to be confirmed by a properly designed trial with a larger sample size.	[Abd-El-Maeboud, Karim H. I.; Kortam, Mohamed A. M. F.; Ali, Mohamed S.; Ibrahim, Mostafa I.; Mohamed, Radwa M. M. Z.] Ain Shams Univ, Fac Med, Dept Obstet & Gynecol, Cairo, Egypt	Egyptian Knowledge Bank (EKB); Ain Shams University	Abd-El-Maeboud, KHI (corresponding author), Ain Shams Univ, Fac Med, Dept Obstet & Gynecol, Cairo, Egypt.	Kabdelmaeboud@yahoo.com	Ibrahim, Moustafa/E-8112-2015	Ibrahim, Moustafa/0000-0003-4614-7182				AKERLUND M, 1976, BRIT J OBSTET GYNAEC, V83, P673, DOI 10.1111/j.1471-0528.1976.tb00911.x; Blumenthal M, 1998, COMPLETE GERMAN COMM, P226; Coco AS, 1999, AM FAM PHYSICIAN, V60, P489; Dawood MY, 2006, OBSTET GYNECOL, V108, P428, DOI 10.1097/01.AOG.0000230214.26638.0c; Fedorowicz Z, 2012, BETA2 ANDRENOCEPTOR; GALLEGOSTORRES J, 1975, J INT MED RES, V3, P194, DOI 10.1177/030006057500300309; Ganon L, 1986, WOMEN HLTH, V14, P105; HANSEN MK, 1975, AM J OBSTET GYNECOL, V121, P566, DOI 10.1016/0002-9378(75)90096-4; Harlow SD, 1996, BRIT J OBSTET GYNAEC, V103, P1134, DOI 10.1111/j.1471-0528.1996.tb09597.x; Kraft K, 2004, POCKET GUIDE HERBAL, P124; KULLANDER S, 1981, ACTA OBSTET GYN SCAN, V60, P425, DOI 10.3109/00016348109154139; Lara-Munoz C, 2004, ARCH MED RES, V35, P43, DOI 10.1016/j.arcmed.2003.07.007; Lee JS, 2003, ACAD EMERG MED, V10, P1128, DOI 10.1197/S1069-6563(03)00372-5; Marjoribanks J, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001751.pub2; Nejad V. Modaress, 2006, Eastern Mediterranean Health Journal, V12, P423; NESHEIM BI, 1976, ACTA OBSTET GYN SCAN, V55, P315, DOI 10.3109/00016347609158504; Novak J, 1913, BR MED J        0307, P39; Proctor M, 2005, COCHRANE DB SYST REV; Proctor M, 2007, COCHRANE DB SYST REV; Proctor M, 2006, COCHRANE DB SYST REV; Proctor ML., 2002, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD002123; Proctor ML, 2001, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD002124; Rahnama P, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-92; Schmelzer GH, 2011, PROTA 11 2 MED PLANT, V2; Schmiedl S, 2012, INT J CLIN PHARM TH, V50, P729, DOI 10.5414/CP201712; Schulz V, 2004, RATIONAL PHYTOTHERAP, P264; Schulzke JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018107; Smith CA, 2011, COCHRANE DB SYST REV; Thurmann PA, 2004, INT J CLIN PHARM TH, V42, P281; WILLIAMS LT, 1977, J CLIN INVEST, V60, P815, DOI 10.1172/JCI108835; Wong CL, 2009, COCHRANE DB SYST REV	31	10	10	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2014	9	8							e104473	10.1371/journal.pone.0104473	http://dx.doi.org/10.1371/journal.pone.0104473			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN9BM	25119571	Green Published, Green Submitted, gold			2023-01-03	WOS:000340900600059
J	Ronat, JB; Kakol, J; Khoury, MN; Berthelot, M; Yun, O; Brown, V; Murphy, RA				Ronat, Jean-Baptiste; Kakol, Jabar; Khoury, Marwan N.; Berthelot, Mathilde; Yun, Oliver; Brown, Vincent; Murphy, Richard A.			Highly Drug-Resistant Pathogens Implicated in Burn-Associated Bacteremia in an Iraqi Burn Care Unit	PLOS ONE			English	Article								Objective: In low-and middle-income countries, bloodstream infections are an important cause of mortality in patients with burns. Increasingly implicated in burn-associated infections are highly drug-resistant pathogens with limited treatment options. We describe the epidemiology of bloodstream infections in patients with burns in a humanitarian surgery project in Iraq. Methods: We performed a retrospective, descriptive study of blood culture isolates identified between July 2008 and September 2009 among patients with burns in a single hospital in Iraq who developed sepsis. Results: In 1169 inpatients admitted to the burn unit during the study period, 212 (18%) had suspected sepsis, and 65 (6%) had confirmed bacteremia. Sepsis was considered the primary cause of death in 198 patients (65%; 95% CI 65-70) of the 304 patients that died. The most commonly isolated organisms were Pseudomonas aeruginosa (22 isolates [34%]), Staphylococcus aureus (17 [26%]), Klebsiella pneumoniae (8 [12%]), Staphylococcus epidermidis (7 [11%]), Acinetobacter baumannii (6 [9%]), and Enterobacter cloacae (5 [8%]). A high proportion of Enterobacteriaceae strains produced extended-spectrum beta-lactamase and S. aureus isolates were uniformly methicillin-resistant. For gram-negative bacteria, the most reliably active antibiotics were imipenen and amikacin. Conclusions: Burn patients with sepsis in Iraq were commonly found to have bloodstream pathogens resistant to most antibiotics available locally. Effective empirical therapy of burn sepsis in this region of Iraq would consist of vancomycin or teicoplanin and a carbapenem-class antibiotic with antipseudomonal activity.	[Ronat, Jean-Baptiste; Berthelot, Mathilde; Yun, Oliver; Brown, Vincent; Murphy, Richard A.] Med Sans Frontieres Doctors Without Borders, Paris, France; [Kakol, Jabar] Dept Hlth, Sulaymaniyah, Iraq; [Khoury, Marwan N.] Ibn Al Haytham Hosp, Amman, Jordan; [Murphy, Richard A.] Albert Einstein Coll Med, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine	Ronat, JB (corresponding author), Med Sans Frontieres Doctors Without Borders, Paris, France.	jean-baptiste.ronat@paris.msf.org		Murphy, Richard/0000-0003-2249-7452	Medecins Sans Frontiers/Doctors Without Borders	Medecins Sans Frontiers/Doctors Without Borders	This work was supported by Medecins Sans Frontiers/Doctors Without Borders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ainaud P, 2007, RECOMMANDATIONS RELA; [Anonymous], 2008, M100S18 CLIN LAB STA; Bekeris LG, 2005, ARCH PATHOL LAB MED, V129, P1222; Broadhead J M, 2001, Crit Care Nurs Q, V24, P20; *CLIN LAB STAND I, 2006, M2A9 CLIN LAB STAND, V26; Forbes BA., 2007, BAILEY SCOTTS DIAGNO, V12th ed., P216; Kumarasamy KK, 2010, LANCET INFECT DIS, V10, P597, DOI 10.1016/S1473-3099(10)70143-2; Lari Abdolaziz Rastegar, 2002, Journal of Burn Care & Rehabilitation, V23, P39; Lari AR, 2013, BURNS, V39, P174, DOI 10.1016/j.burns.2012.02.025; Magiorakos AP, 2012, CLIN MICROBIOL INFEC, V18, P268, DOI 10.1111/j.1469-0691.2011.03570.x; MANSON WL, 1992, J HOSP INFECT, V22, P55, DOI 10.1016/0195-6701(92)90130-E; Martin M A, 1993, New Horiz, V1, P162; O'Brien TF, 2001, CLIN INFECT DIS, V33, pS118, DOI 10.1086/321836; Othman N, 2010, THESIS U NOTTINGHAM; Ressner RA, 2008, J AM COLL SURGEONS, V206, P439, DOI 10.1016/j.jamcollsurg.2007.09.017	15	43	47	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 11	2014	9	8							e101017	10.1371/journal.pone.0101017	http://dx.doi.org/10.1371/journal.pone.0101017			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO1WB	25111170	Green Submitted, gold, Green Published			2023-01-03	WOS:000341105100003
J	Clague, J; Reynolds, P; Henderson, KD; Sullivan-Halley, J; Ma, HY; Lacey, JV; Chang, SN; Delclos, GL; Du, XLL; Forman, MR; Bernstein, L				Clague, Jessica; Reynolds, Peggy; Henderson, Katherine D.; Sullivan-Halley, Jane; Ma, Huiyan; Lacey, James V., Jr.; Chang, Shine; Delclos, George L.; Du, Xianglin L.; Forman, Michele R.; Bernstein, Leslie			Menopausal Hormone Therapy and Lung Cancer-Specific Mortality Following Diagnosis: The California Teachers Study	PLOS ONE			English	Article							REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; NEVER SMOKERS; ESTROGEN; SURVIVAL; INFLAMMATION; OUTCOMES; RISK; BETA	Previous results from research on menopausal hormone therapy (MHT) and lung cancer survival have been mixed and most have not studied women who used estrogen therapy (ET) exclusively. We examined the associations between MHT use reported at baseline and lung cancer-specific mortality in the prospective California Teachers Study cohort. Among 727 postmenopausal women diagnosed with lung cancer from 1995 through 2007, 441 women died before January 1, 2008. Hazard Ratios (HR) and 95% Confidence Intervals (CI) for lung-cancer-specific mortality were obtained by fitting multivariable Cox proportional hazards regression models using age in days as the timescale. Among women who used ET exclusively, decreases in lung cancer mortality were observed (HR, 0.69; 95% CI, 0.52-0.93). No association was observed for estrogen plus progestin therapy use. Among former users, shorter duration (<5 years) of exclusive ET use was associated with a decreased risk of lung cancer mortality (HR, 0.56; 95% CI, 0.35-0.89), whereas among recent users, longer duration (>15 years) was associated with a decreased risk (HR, 0.60; 95% CI, 0.38-0.95). Smoking status modified the associations with deceases in lung cancer mortality observed only among current smokers. Exclusive ET use was associated with decreased lung cancer mortality.	[Clague, Jessica; Henderson, Katherine D.; Sullivan-Halley, Jane; Ma, Huiyan; Lacey, James V., Jr.; Bernstein, Leslie] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Div Canc Etiol, Duarte, CA 91010 USA; [Reynolds, Peggy] Canc Prevent Inst Calif, Fremont, CA USA; [Chang, Shine] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; [Delclos, George L.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Dept Environm & Occupat Hlth Sci, Houston, TX 77030 USA; [Du, Xianglin L.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Dept Epidemiol, Houston, TX 77030 USA; [Forman, Michele R.] Coll Nat Sci, Dell Pediat Res Inst, Dept Nutr Sci, Austin, TX USA	City of Hope; Beckman Research Institute of City of Hope; Cancer Prevention Institute of California; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health	Bernstein, L (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Div Canc Etiol, Duarte, CA 91010 USA.	lbernstein@coh.org		Chang, Shine/0000-0003-3804-9697	National Cancer Institute [R01 CA77398, K05 CA 136967, R25T CA57730]; National Cancer Institute's Surveillance, Epidemiology and End Results Program [N01-PC-35136]; Northern California Cancer Center [N01-PC-35139]; University of Southern California [N01-PC-35139]; Public Health Institute [N02-PC-15105]; Centers for Disease Control and Prevention's National Program of Cancer Registries [U55/CCR921930-02]; NATIONAL CANCER INSTITUTE [R01CA077398, K05CA136967, R25CA057730] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute's Surveillance, Epidemiology and End Results Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Northern California Cancer Center; University of Southern California; Public Health Institute; Centers for Disease Control and Prevention's National Program of Cancer Registries(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work reported here was supported by National Cancer Institute grants R01 CA77398, K05 CA 136967 and R25T CA57730. The collection of cancer incidence data used in this study was supported by the California Department of Health Services as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract N01-PC-35136 awarded to the Northern California Cancer Center (now known as the Cancer Prevention Institute of California), contract N01-PC-35139 awarded to the University of Southern California, and contract N02-PC-15105 awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement #U55/CCR921930-02 awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the authors. Endorsement by the State of California, Department of Health Services, the National Cancer Institute, and the Centers for Disease Control and Prevention or their contractors and subcontractors is not intended nor should be inferred. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ayeni O, 2009, CURR ONCOL, V16, P162; Bernstein L, 2002, CANCER CAUSE CONTROL, V13, P625, DOI 10.1023/A:1019552126105; Chlebowski RT, 2010, JNCI-J NATL CANCER I, V102, P1413, DOI 10.1093/jnci/djq285; Chlebowski RT, 2009, LANCET, V374, P1243, DOI 10.1016/S0140-6736(09)61526-9; Ettinger B, 1996, OBSTET GYNECOL, V87, P6, DOI 10.1016/0029-7844(95)00358-4; Flototto T, 2001, HORM METAB RES, V33, P451, DOI 10.1055/s-2001-16936; Ganti AK, 2006, J CLIN ONCOL, V24, P59, DOI 10.1200/JCO.2005.02.9827; Henschke CI, 2006, JAMA-J AM MED ASSOC, V296, P180; Horn-Ross PL, 2004, CANCER EPIDEM BIOMAR, V13, P405; Huang B, 2009, CANCER, V115, P4167, DOI 10.1002/cncr.24475; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kovacs EJ, 2005, EXP GERONTOL, V40, P549, DOI 10.1016/j.exger.2005.04.009; Meireles SI, 2010, CANCER PREV RES, V3, P707, DOI 10.1158/1940-6207.CAPR-09-0162; Niikawa H, 2008, CLIN CANCER RES, V14, P4417, DOI 10.1158/1078-0432.CCR-07-1950; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Schabath MB, 2004, CLIN CANCER RES, V10, P113, DOI 10.1158/1078-0432.CCR-0911-3; Sekine I, 2009, JPN J CLIN ONCOL, V39, P707, DOI 10.1093/jjco/hyp095; Siegfried JM, 2001, LANCET ONCOL, V2, P506, DOI 10.1016/S1470-2045(01)00457-0; Subramanian J, 2007, J CLIN ONCOL, V25, P561, DOI 10.1200/JCO.2006.06.8015; Takahashi H, 2010, CANCER CELL, V17, P89, DOI 10.1016/j.ccr.2009.12.008; Thomas L, 2005, CHEST, V128, P370, DOI 10.1378/chest.128.1.370; Wakelee HA, 2007, J CLIN ONCOL, V25, P472, DOI 10.1200/JCO.2006.07.2983	24	23	26	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2014	9	7							e103735	10.1371/journal.pone.0103735	http://dx.doi.org/10.1371/journal.pone.0103735			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6EF	25079077	Green Submitted, Green Published, gold			2023-01-03	WOS:000339954800074
J	Lawrence, BJ; Gasson, N; Kane, R; Bucks, RS; Loftus, AM				Lawrence, Blake J.; Gasson, Natalie; Kane, Robert; Bucks, Romola S.; Loftus, Andrea M.			Activities of Daily Living, Depression, and Quality of Life in Parkinson's Disease	PLOS ONE			English	Article							BRAZILIAN PATIENTS; DETERMINANTS; CRITIQUE; THERAPY; ANXIETY; SCALES	This study examined whether activities of daily living (ADL) mediate the relationship between depression and health-related quality of life (HR-QOL) in people with Parkinson's disease (PD). A cross-sectional, correlational research design examined data from 174 participants who completed the Geriatric Depression Scale (GDS-15), Parkinson's Disease Questionnaire-39 (PDQ-39), and Unified Parkinson's Disease Rating Scale-section 2 (UPDRS-section 2 [ADL]). Multiple Regression Analysis (MRA) was used to examine the mediator model. Depression and ADL significantly (p<.001) predicted HR-QOL, and depression significantly (p<.001) predicted ADL. Whilst ADL did not impact on the relationship between depression and HR-QOL, there was a significant (p<.001) indirect effect of depression on HR-QOL via ADL, suggesting both direct and indirect (via ADL) effects of depression on HR-QOL. The magnitude of this effect was moderate (R-2=.13). People with PD who report depression also experience greater difficulty completing ADL, which impacts upon their HR-QOL. It is recommended that clinicians adopt a multidisciplinary approach to care by combining pharmacological treatments with psycho/occupational therapy, thereby alleviating the heterogeneous impact of motor and non-motor symptoms on HR-QOL in people with PD.	[Lawrence, Blake J.; Gasson, Natalie; Kane, Robert; Loftus, Andrea M.] Curtin Univ, Sch Psychol & Speech Pathol, Curtin Neurosci Lab, Perth, WA 6845, Australia; [Gasson, Natalie; Bucks, Romola S.; Loftus, Andrea M.] Curtin Univ, Parkinsons Ctr ParkC, Perth, WA 6845, Australia; [Bucks, Romola S.] Univ Western Australia, Sch Psychol, Perth, WA 6009, Australia	Curtin University; Curtin University; University of Western Australia	Lawrence, BJ (corresponding author), Curtin Univ, Sch Psychol & Speech Pathol, Curtin Neurosci Lab, Perth, WA 6845, Australia.	blake.lawrence@postgrad.curtin.edu.au	Lawrence, Blake/C-6069-2016; Bucks, Romola Starr/B-9164-2011	Lawrence, Blake/0000-0002-8772-8226; Bucks, Romola Starr/0000-0002-4207-4724; Gasson, Natalie/0000-0001-6265-9095; Loftus, Andrea/0000-0001-8782-7024	Australian Research Council; Edith Cowan University's Office of Research and Innovation; Parkinson's Association of WA; McCusker Charitable Foundation; Parkinson's Young Onset Support Group (WA); Royal Freshwater Bay Yacht Club	Australian Research Council(Australian Research Council); Edith Cowan University's Office of Research and Innovation; Parkinson's Association of WA; McCusker Charitable Foundation; Parkinson's Young Onset Support Group (WA); Royal Freshwater Bay Yacht Club	All funding for ParkC has been received from the Australian Research Council, Edith Cowan University's Office of Research and Innovation, Parkinson's Association of WA, The McCusker Charitable Foundation, Parkinson's Young Onset Support Group (WA) and the Royal Freshwater Bay Yacht Club. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Carod-Artal FJ, 2008, PARKINSONISM RELAT D, V14, P102, DOI 10.1016/j.parkreldis.2007.06.011; Carod-Artal FJ, 2007, MOVEMENT DISORD, V22, P1408, DOI 10.1002/mds.21408; Cohen J., 2013, STAT POWER ANAL BEHA; Dissanayaka NNW, 2011, J AFFECT DISORDERS, V132, P82, DOI 10.1016/j.jad.2011.01.021; Dobkin Roseanne DeFronzo, 2008, Expert Rev Neurother, V8, P27, DOI 10.1586/14737175.8.1.27; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frazier PA, 2004, J COUNS PSYCHOL, V51, P115, DOI 10.1037/0022-0167.51.1.115; Goetz CG, 2008, MOVEMENT DISORD, V23, P2129, DOI 10.1002/mds.22340; Ishihara L, 2006, ACTA NEUROL SCAND, V113, P211, DOI 10.1111/j.1600-0404.2006.00579.x; Keus SHJ, 2007, MOVEMENT DISORD, V22, P451, DOI 10.1002/mds.21244; Kleiner-Fisman G, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-91; Lewis SJG, 2005, J NEUROL NEUROSUR PS, V76, P343, DOI 10.1136/jnnp.2003.033530; Martinez-Martin P, 2003, MOVEMENT DISORD, V18, P985, DOI 10.1002/mds.10479; Martinez-Martin P, 2011, MOVEMENT DISORD, V26, P2371, DOI 10.1002/mds.23834; Meek C, 2010, BRIT J OCCUP THER, V73, P178, DOI 10.4276/030802210X12706313444027; Pagonabarraga J, 2010, ENCYCLOPEDIA OF MOVEMENT DISORDERS, VOL 2: H-P, P405; Papapetropoulos S, 2006, CLIN NEUROL NEUROSUR, V108, P465, DOI 10.1016/j.clineuro.2005.08.002; Peto V, 1998, J NEUROL, V245, pS10, DOI 10.1007/PL00007730; Piccinni A, 2012, COMPR PSYCHIAT, V53, P727, DOI 10.1016/j.comppsych.2011.11.002; Qin ZH, 2009, PARKINSONISM RELAT D, V15, P767, DOI 10.1016/j.parkreldis.2009.05.011; Quelhas R, 2009, J NEUROPSYCH CLIN N, V21, P413, DOI 10.1176/appi.neuropsych.21.4.413; Rahman S, 2008, MOVEMENT DISORD, V23, P1428, DOI 10.1002/mds.21667; Reijnders JSAM, 2008, MOVEMENT DISORD, V23, P183, DOI 10.1002/mds.21803; Schrag A, 2000, J NEUROL NEUROSUR PS, V69, P308, DOI 10.1136/jnnp.69.3.308; Schrag A, 2006, J NEUROL SCI, V248, P151, DOI 10.1016/j.jns.2006.05.030; Schrag A, 2007, MOVEMENT DISORD, V22, P1077, DOI 10.1002/mds.21333; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; Soh SE, 2011, PARKINSONISM RELAT D, V17, P1, DOI 10.1016/j.parkreldis.2010.08.012; Wichowicz HM, 2006, EUR PSYCHIAT, V21, P516, DOI 10.1016/j.eurpsy.2006.01.012	30	48	49	1	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2014	9	7							e102294	10.1371/journal.pone.0102294	http://dx.doi.org/10.1371/journal.pone.0102294			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AM6RN	25025280	Green Submitted, gold, Green Published			2023-01-03	WOS:000339992400061
J	Yu, M; Bardia, A; Aceto, N; Bersani, F; Madden, MW; Donaldson, MC; Desai, R; Zhu, HL; Comaills, V; Zheng, ZL; Wittner, BS; Stojanov, P; Brachtel, E; Sgroi, D; Kapur, R; Shioda, T; Ting, DT; Ramaswamy, S; Getz, G; Iafrate, AJ; Benes, C; Toner, M; Maheswaran, S; Haber, DA				Yu, Min; Bardia, Aditya; Aceto, Nicola; Bersani, Francesca; Madden, Marissa W.; Donaldson, Maria C.; Desai, Rushil; Zhu, Huili; Comaills, Valentine; Zheng, Zongli; Wittner, Ben S.; Stojanov, Petar; Brachtel, Elena; Sgroi, Dennis; Kapur, Ravi; Shioda, Toshihiro; Ting, David T.; Ramaswamy, Sridhar; Getz, Gad; Iafrate, A. John; Benes, Cyril; Toner, Mehmet; Maheswaran, Shyamala; Haber, Daniel A.			Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility	SCIENCE			English	Article							CANCER; INHIBITOR; IDENTIFICATION; MUTATIONS; DISCOVERY; FAMILY; POTENT; DOMAIN; ALPHA	Circulating tumor cells (CTCs) are present at low concentrations in the peripheral blood of patients with solid tumors. It has been proposed that the isolation, ex vivo culture, and characterization of CTCs may provide an opportunity to noninvasively monitor the changing patterns of drug susceptibility in individual patients as their tumors acquire new mutations. In a proof-of-concept study, we established CTC cultures from six patients with estrogen receptor-positive breast cancer. Three of five CTC lines tested were tumorigenic in mice. Genome sequencing of the CTC lines revealed preexisting mutations in the PIK3CA gene and newly acquired mutations in the estrogen receptor gene (ESR1), PIK3CA gene, and fibroblast growth factor receptor gene (FGFR2), among others. Drug sensitivity testing of CTC lines with multiple mutations revealed potential new therapeutic targets. With optimization of CTC culture conditions, this strategy may help identify the best therapies for individual cancer patients over the course of their disease.	[Yu, Min; Bardia, Aditya; Aceto, Nicola; Bersani, Francesca; Madden, Marissa W.; Donaldson, Maria C.; Desai, Rushil; Zhu, Huili; Comaills, Valentine; Zheng, Zongli; Wittner, Ben S.; Sgroi, Dennis; Shioda, Toshihiro; Ting, David T.; Ramaswamy, Sridhar; Getz, Gad; Iafrate, A. John; Benes, Cyril; Maheswaran, Shyamala; Haber, Daniel A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; [Yu, Min; Haber, Daniel A.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA; [Bardia, Aditya; Shioda, Toshihiro; Ting, David T.; Ramaswamy, Sridhar; Benes, Cyril; Haber, Daniel A.] Harvard Univ, Sch Med, Dept Med, Charlestown, MA 02129 USA; [Zheng, Zongli; Brachtel, Elena; Sgroi, Dennis; Getz, Gad; Iafrate, A. John] Harvard Univ, Sch Med, Dept Pathol, Charlestown, MA 02129 USA; [Zheng, Zongli] Karolinska Insitutet, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Stojanov, Petar; Getz, Gad] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA; [Kapur, Ravi; Toner, Mehmet] Harvard Univ, Sch Med, Ctr Bioengn Med, Charlestown, MA 02129 USA; [Toner, Mehmet; Maheswaran, Shyamala] Harvard Univ, Sch Med, Dept Surg, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Harvard University; Karolinska Institutet; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard University	Maheswaran, S (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.	maheswaran@helix.mgh.harvard.edu; haber@helix.mgh.harvard.edu	zheng, zongli/C-7309-2008; Sgroi, Dennis/AAV-2487-2021; COMAILLS, VALENTINE/AAX-1697-2021; zheng, zongli/B-2917-2011; Stojanov, Petar/GQI-4462-2022; Ting, David/F-4389-2017; Aceto, Nicola/O-2484-2014	COMAILLS, VALENTINE/0000-0001-8857-6976; zheng, zongli/0000-0003-4849-4903; Stojanov, Petar/0000-0001-7815-776X; Donaldson Collier, Maria/0000-0001-6403-6713; Yu, Min/0000-0002-3969-8720; Ting, David/0000-0002-3261-2322; Bersani, Francesca/0000-0002-0343-7078; Aceto, Nicola/0000-0001-9579-6918	Breast Cancer Research Foundation; Stand Up to Cancer; Wellcome TrustNational Foundation for Cancer Research; NIH [CA129933]; NIBIB [EB008047]; Susan G. Komen for the Cure [KG09042]; National Cancer Institute-MGH Proton Federal Share Program; MGH-Johnson and Johnson Center for Excellence in CTCs; Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [R01CA129933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [U01EB012493, R01EB008047, P41EB002503] Funding Source: NIH RePORTER	Breast Cancer Research Foundation; Stand Up to Cancer; Wellcome TrustNational Foundation for Cancer Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIBIB(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); Susan G. Komen for the Cure(Susan G. Komen Breast Cancer Foundation); National Cancer Institute-MGH Proton Federal Share Program; MGH-Johnson and Johnson Center for Excellence in CTCs; Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	We are grateful to all the patients who participated in this study. We thank Dr. Lecia Sequist for coordinating the clinical studies, A. McGovern, C. Hart, and the Massachusetts General Hospital (MGH) clinical research coordinators P. Spuhler, A. Shah, J. Ciciliano, and V. Pai for bioengineering technical support; R. Milano, K. Lynch, H. Robinson, and M. Liebers for technical support; L. Collins (Beth Israel Deaconess Medical Center) for providing pathological specimens; and L. Libby for mouse studies. N. Aceto is a fellow of the Human Frontiers Science Program, the Swiss National Science Foundation, and the Swiss Foundation for Grants in Biology and Medicine. This work was supported by grants from the Breast Cancer Research Foundation (D. A. H), Stand Up to Cancer (D. A. H., M. T., S. M.), the Wellcome Trust (D. A. H., C. B.), National Foundation for Cancer Research (D. A. H.), NIH CA129933 (D. A. H.), NIBIB EB008047 (M. T., D. A. H.), Susan G. Komen for the Cure KG09042 (S. M.), National Cancer Institute-MGH Proton Federal Share Program (S. M.), the MGH-Johnson and Johnson Center for Excellence in CTCs (M. T., S. M.), and the Howard Hughes Medical Institute (M.Y., D. A. H.). A. J. I. holds equity in, and is a paid consultant for, Enzymatics, Inc. M. T., D. A. H., and the Massachusetts General Hospital have filed for patent protection for the CTC-iChip technology. RNA-Seq reads have been deposited into Gene Expression Omnibus: uncultured CTCs (accession no. GSE51827); the six cultured CTC lines (accession no. GSE55807).	Baccelli I, 2013, NAT BIOTECHNOL, V31, P539, DOI 10.1038/nbt.2576; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dias-Santagata D, 2010, EMBO MOL MED, V2, P146, DOI 10.1002/emmm.201000070; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Furet P, 2013, BIOORG MED CHEM LETT, V23, P3741, DOI 10.1016/j.bmcl.2013.05.007; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gavine PR, 2012, CANCER RES, V72, P2045, DOI 10.1158/0008-5472.CAN-11-3034; Haber DA, 2011, CELL, V145, P19, DOI 10.1016/j.cell.2011.03.026; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036; Merenbakh-Lamin K, 2013, CANCER RES, V73, P6856, DOI 10.1158/0008-5472.CAN-13-1197; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; Ozkumur E, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005616; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Sato Toshiro, 2013, Methods Mol Biol, V945, P319, DOI 10.1007/978-1-62703-125-7_19; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Wang YS, 2010, CURR OPIN INVEST DR, V11, P1466; Weis KE, 1996, MOL ENDOCRINOL, V10, P1388, DOI 10.1210/me.10.11.1388; Yu M, 2011, J CELL BIOL, V192, P373, DOI 10.1083/jcb.201010021; Zhang LX, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005109; Zhang QX, 1997, CANCER RES, V57, P1244	26	663	722	9	345	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	2014	345	6193					216	220		10.1126/science.1253533	http://dx.doi.org/10.1126/science.1253533			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AL8SS	25013076	Green Submitted, Green Accepted			2023-01-03	WOS:000339409900054
J	Azzopardi, D; Strohm, B; Marlow, N; Brocklehurst, P; Deierl, A; Eddama, O; Goodwin, J; Halliday, HL; Juszczak, E; Kapellou, O; Levene, M; Linsell, L; Omar, O; Thoresen, M; Tusor, N; Whitelaw, A; Edwards, AD				Azzopardi, Denis; Strohm, Brenda; Marlow, Neil; Brocklehurst, Peter; Deierl, Aniko; Eddama, Oya; Goodwin, Julia; Halliday, Henry L.; Juszczak, Edmund; Kapellou, Olga; Levene, Malcolm; Linsell, Louise; Omar, Omar; Thoresen, Marianne; Tusor, Nora; Whitelaw, Andrew; Edwards, A. David		TOBY Study Grp	Effects of Hypothermia for Perinatal Asphyxia on Childhood Outcomes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEONATAL ENCEPHALOPATHY; CEREBRAL-PALSY; CLASSIFICATION-SYSTEM; SCALES	Background In the Total Body Hypothermia for Neonatal Encephalopathy Trial (TOBY), newborns with asphyxial encephalopathy who received hypothermic therapy had improved neurologic outcomes at 18 months of age, but it is uncertain whether such therapy results in longer-term neurocognitive benefits. Methods We randomly assigned 325 newborns with asphyxial encephalopathy who were born at a gestational age of 36 weeks or more to receive standard care alone (control) or standard care with hypothermia to a rectal temperature of 33 to 34 degrees C for 72 hours within 6 hours after birth. We evaluated the neurocognitive function of these children at 6 to 7 years of age. The primary outcome of this analysis was the frequency of survival with an IQ score of 85 or higher. Results A total of 75 of 145 children (52%) in the hypothermia group versus 52 of 132 (39%) in the control group survived with an IQ score of 85 or more (relative risk, 1.31; P = 0.04). The proportions of children who died were similar in the hypothermia group and the control group (29% and 30%, respectively). More children in the hypothermia group than in the control group survived without neurologic abnormalities (65 of 145 [45%] vs. 37 of 132 [28%]; relative risk, 1.60; 95% confidence interval, 1.15 to 2.22). Among survivors, children in the hypothermia group, as compared with those in the control group, had significant reductions in the risk of cerebral palsy (21% vs. 36%, P = 0.03) and the risk of moderate or severe disability (22% vs. 37%, P = 0.03); they also had significantly better motor-function scores. There was no significant between-group difference in parental assessments of children's health status and in results on 10 of 11 psychometric tests. Conclusions Moderate hypothermia after perinatal asphyxia resulted in improved neurocognitive outcomes in middle childhood.	[Azzopardi, Denis; Tusor, Nora; Edwards, A. David] Kings Coll London, Ctr Dev Brain, London WC2R 2LS, England; [Marlow, Neil; Brocklehurst, Peter] UCL, Inst Womens Hlth, London, England; [Azzopardi, Denis; Deierl, Aniko] Univ London Imperial Coll Sci Technol & Med, Inst Clin Sci, London, England; [Kapellou, Olga] Homerton Univ Hosp, London, England; [Strohm, Brenda; Eddama, Oya; Goodwin, Julia; Juszczak, Edmund; Linsell, Louise; Omar, Omar] Univ Oxford, Natl Perinatal Epidemiol Unit, Clin Trials Unit, Oxford, England; [Halliday, Henry L.] Royal Matern Hosp, Belfast, Antrim, North Ireland; [Levene, Malcolm] Univ Leeds, Leeds, W Yorkshire, England; [Thoresen, Marianne; Whitelaw, Andrew] Univ Bristol, Bristol, Avon, England	University of London; King's College London; University of London; University College London; Imperial College London; University of London; Queen Mary University London; University of Oxford; University of Leeds; University of Bristol	Azzopardi, D (corresponding author), St Thomas Hosp, Dept Perinatal Imaging, Kings Coll London, Ctr Dev Brain, Westminster Bridge Rd, London SE1 7EH, England.	denis.azzopardi@kcl.ac.uk	Marlow, Neil/D-2918-2009; Edwards, Anthony/HCI-9626-2022; Hemingway, Harry/C-1219-2009	Marlow, Neil/0000-0001-5890-2953; Tusor, Nora/0000-0002-3664-7397; Hemingway, Harry/0000-0003-2279-0624; Edwards, Anthony David/0000-0003-4801-7066; Blennow, Mats/0000-0001-9517-0261; Halliday, Henry/0000-0001-7978-4992	United Kingdom Medical Research Council; National Institute for Health Research Biomedical Research Centres at Imperial College London; University of Oxford; King's College London; Medical Research Council [G0801320, MC_PC_13041, G0100126, MR/K006584/1] Funding Source: researchfish; National Institute for Health Research [NF-SI-0512-10034] Funding Source: researchfish; MRC [G0100126, G0801320] Funding Source: UKRI	United Kingdom Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research Biomedical Research Centres at Imperial College London; University of Oxford; King's College London(General Electric); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the United Kingdom Medical Research Council and the National Institute for Health Research Biomedical Research Centres at Imperial College London, the University of Oxford, and King's College London.	Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Barnett AL, 2004, ARCH DIS CHILD, V89, P637, DOI 10.1136/adc.2002.019349; Cans C, 2000, DEV MED CHILD NEUROL, V42, P816, DOI 10.1111/j.1469-8749.2000.tb00695.x; de Haan M, 2006, TRENDS NEUROSCI, V29, P374, DOI 10.1016/j.tins.2006.05.008; Drummond M, 2001, ANN MED, V33, P344, DOI 10.3109/07853890109002088; Eliasson AC, 2006, DEV MED CHILD NEUROL, V48, P549, DOI 10.1017/S0012162206001162; Guillet R, 2012, PEDIATR RES, V71, P205, DOI 10.1038/pr.2011.30; Horsman John, 2003, Health Qual Life Outcomes, V1, P54, DOI 10.1186/1477-7525-1-54; Jacobs S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub2; Korkman M., 2007, NEPSY 2 BATERIA NEUR; Marlow N, 2005, ARCH DIS CHILD-FETAL, V90, pF380, DOI 10.1136/adc.2004.067520; Pickering S., 2001, WORKING MEMORY TEST; Reid R, 1998, J ABNORM CHILD PSYCH, V26, P187, DOI 10.1023/A:1022620217886; Rosenbaum PL, 2008, DEV MED CHILD NEUROL, V50, P249, DOI 10.1111/j.1469-8749.2008.02045.x; Rutherford M, 2010, LANCET NEUROL, V9, P39, DOI 10.1016/S1474-4422(09)70295-9; Schmidt B, 2012, JAMA-J AM MED ASSOC, V307, P275, DOI 10.1001/jama.2011.2024; Shankaran S, 2012, NEW ENGL J MED, V366, P2085, DOI 10.1056/NEJMoa1112066; Touwen B. C. L, 1979, EXAMINATION CHILD MI; WECHSLER D, 2004, WECHSLER PRESCHOOL P; Wolke D, 2002, PEDIATRICS, V109, P1054, DOI 10.1542/peds.109.6.1054	20	388	404	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2014	371	2					140	149		10.1056/NEJMoa1315788	http://dx.doi.org/10.1056/NEJMoa1315788			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AK7YZ	25006720	Green Submitted, Green Published			2023-01-03	WOS:000338645500010
J	Bishop, FL; Aizlewood, L; Adams, AEM				Bishop, Felicity L.; Aizlewood, Lizzi; Adams, Alison E. M.			When and Why Placebo-Prescribing Is Acceptable and Unacceptable: A Focus Group Study of Patients' Views	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; CLINICAL-PRACTICE; QUALITATIVE RESEARCH; INTERVENTIONS; ETHICS; OSTEOARTHRITIS; PARTICIPANTS; PHYSICIANS; ATTITUDES; COMMUNICATION	Background: Surveys of doctors suggest that they use placebos and placebo effects clinically to help patients. However, patients' views are not well-understood. We aimed to identify when and why placebo-prescribing in primary care might be acceptable and unacceptable to patients. Methods: A purposive diverse sample of 58 English-speaking adults (18 men; aged 19-80 years) participated in 11 focus groups. Vignettes describing doctors prescribing placebos in primary care were used to initiate discussions. Data were analyzed inductively. Results: Participants discussed diverse harms and benefits of placebo-prescribing for individual patients, carers, healthcare providers, and society. Two perspectives on placebo-prescribing were identified. First, the "consequentialist'' perspective focused on the potential for beneficial outcomes of placebo-prescribing. Here, some participants thought placebos are beneficial and should be used clinically; they often invoked the power of the mind or mind-body interactions. Others saw placebos as ineffective and therefore a waste of time and money. Second, the "respecting autonomy'' perspective emphasized the harms caused by the deceptive processes thought necessary for placebo-prescribing. Here, participants judged placebo-prescribing unacceptable because placebo-prescribers deceive patients, thus a doctor who prescribes placebos cannot be trusted and patients' autonomy is compromised. They also saw placebo-responders as gullible, which deterred them from trying placebos themselves. Overall, the word "placebo'' was often thought to imply "ineffective''; some participants suggested alternative carefully chosen language that could enable doctors to prescribe placebos without directly lying to patients. Conclusions: Negative views of placebos derive from beliefs that placebos do not work and/or that they require deception by the doctor. Positive views are pragmatic in that if placebos work then any associated processes (e.g. mechanisms, deception) are deemed unimportant. Public education about placebos and their effects is warranted and research to identify optimal ways of harnessing placebo effects in clinical practice is needed.	[Bishop, Felicity L.; Aizlewood, Lizzi] Univ Southampton, Ctr Applicat Hlth Psychol, Southampton, Hants, England; [Adams, Alison E. M.] No Arizona Univ, Dept Biol, Flagstaff, AZ 86011 USA	University of Southampton; Northern Arizona University	Bishop, FL (corresponding author), Univ Southampton, Ctr Applicat Hlth Psychol, Southampton, Hants, England.	F.L.Bishop@southampton.ac.uk		Bishop, Felicity/0000-0002-8737-6662	Primary Care and Population Sciences, University of Southampton	Primary Care and Population Sciences, University of Southampton	This study was supported by an internal grant from Primary Care and Population Sciences, University of Southampton. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asai A, 2013, BIOETHICS, V27, P186, DOI 10.1111/j.1467-8519.2011.01943.x; Barrett B, 2011, ANN FAM MED, V9, P312, DOI 10.1370/afm.1250; Benedetti F, 2011, PATIENT EDUC COUNS, V84, P413, DOI 10.1016/j.pec.2011.04.034; Benedetti F, 2008, ANNU REV PHARMACOL, V48, P33, DOI 10.1146/annurev.pharmtox.48.113006.094711; Berthelot JM, 2001, JOINT BONE SPINE, V68, P65, DOI 10.1016/S1297-319X(00)00225-6; Bishop FL, 2012, QUAL HEALTH RES, V22, P1138, DOI 10.1177/1049732312448544; Bishop FL, 2012, SOC SCI MED, V74, P767, DOI 10.1016/j.socscimed.2011.11.020; BOK S, 1974, SCI AM, V231, P17, DOI 10.1038/scientificamerican1174-17; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Brody H, 2000, J FAM PRACTICE, V49, P649; BRODY H, 1982, ANN INTERN MED, V97, P112, DOI 10.7326/0003-4819-97-1-112; Chassany O, 2006, J RHEUMATOL, V33, P1827; Chen GF, 2009, NEW ZEAL MED J, V122, P35; COMAROFF J, 1976, SOCIOL REV, V24, P79, DOI 10.1111/j.1467-954X.1976.tb00574.x; Fassler M, 2011, BRIT J GEN PRACT, V61, P101, DOI 10.3399/bjgp11X556209; Fassler M, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-15; Fassler M, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-144; Golomb BA, 2010, ANN INTERN MED, V153, P532, DOI 10.7326/0003-4819-153-8-201010190-00010; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Howick J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058247; Hull SC, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f3757; Jonas WB, 2011, PHILOS T R SOC B, V366, P1896, DOI 10.1098/rstb.2010.0405; Kaptchuk TJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015591; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; Kelley JM, 2012, PSYCHOTHER PSYCHOSOM, V81, P312, DOI 10.1159/000337053; Kirsch I., 1998, PREVENTION TREATMENT, V1, DOI 10.1037/1522-3736.1.1.12a; Kisaalita NR, 2012, J PAIN, V13, P891, DOI 10.1016/j.jpain.2012.06.003; Kisaalita NR, 2011, J PAIN, V12, P920, DOI 10.1016/j.jpain.2011.02.353; KITZINGER J, 1994, SOCIOL HEALTH ILL, V16, P103, DOI 10.1111/1467-9566.ep11347023; KITZINGER J, 1995, BRIT MED J, V311, P299, DOI 10.1136/bmj.311.7000.299; Lichtenberg P, 2004, J MED ETHICS, V30, P551, DOI 10.1136/jme.2002.002832; Linde K, 2013, COMPLEMENT THER MED, V21, P109, DOI 10.1016/j.ctim.2012.11.010; Linde K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092938; Linde K, 2011, PHILOS T R SOC B, V366, P1905, DOI 10.1098/rstb.2010.0383; LYNOE N, 1993, SOC SCI MED, V36, P767, DOI 10.1016/0277-9536(93)90037-5; Mays N, 2000, BMJ-BRIT MED J, V320, P50, DOI 10.1136/bmj.320.7226.50; Meissner K, 2012, FAM PRACT, V29, P79, DOI 10.1093/fampra/cmr045; Moerman DE, 2002, ANN INTERN MED, V136, P471, DOI 10.7326/0003-4819-136-6-200203190-00011; Patel SM, 2005, NEUROGASTROENT MOTIL, V17, P332, DOI 10.1111/j.1365-2982.2005.00650.x; Patton M. Q., 2001, QUALITATIVE RES EVAL; Suarez-Almazor ME, 2010, ARTHRIT CARE RES, V62, P1229, DOI 10.1002/acr.20225; Thomas DR, 2006, AM J EVAL, V27, P237, DOI 10.1177/1098214005283748; Tilburt JC, 2008, BMJ-BRIT MED J, V337, P1097, DOI DOI 10.1136/BMJ.A1938; Vase L, 2011, PHILOS T R SOC B, V366, P1913, DOI 10.1098/rstb.2010.0402; Verheul W, 2010, PATIENT EDUC COUNS, V80, P300, DOI 10.1016/j.pec.2010.06.017; White P, 2012, PAIN, V153, P455, DOI 10.1016/j.pain.2011.11.007; Yardley L., 1999, PSYCHOL HEALTH, V15, P1; Zhang W, 2008, ANN RHEUM DIS, V67, P1716, DOI 10.1136/ard.2008.092015	48	29	29	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2014	9	7							e101822	10.1371/journal.pone.0101822	http://dx.doi.org/10.1371/journal.pone.0101822			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AL3PK	25006673	Green Submitted, Green Accepted, Green Published, gold			2023-01-03	WOS:000339040600069
J	Poddighe, S; De Rose, F; Marotta, R; Ruffilli, R; Fanti, M; Secci, PP; Mostallino, MC; Setzu, MD; Zuncheddu, MA; Collu, I; Solla, P; Marrosu, F; Kasture, S; Acquas, E; Liscia, A				Poddighe, Simone; De Rose, Francescaelena; Marotta, Roberto; Ruffilli, Roberta; Fanti, Maura; Secci, Pietro Paolo; Mostallino, Maria Cristina; Setzu, Maria Dolores; Zuncheddu, Maria Antonietta; Collu, Ignazio; Solla, Paolo; Marrosu, Francesco; Kasture, Sanjay; Acquas, Elio; Liscia, Anna			Mucuna pruriens (Velvet bean) Rescues Motor, Olfactory, Mitochondrial and Synaptic Impairment in PINK1(B9) Drosophila melanogaster Genetic Model of Parkinson's Disease (Publication with Expression of Concern. See vol. 15, 2020)	PLOS ONE			English	Article; Publication with Expression of Concern							ANTIPARKINSON DRUG; DYSFUNCTION; NEURODEGENERATION; PATHOLOGY; DOPAMINE; EXTRACT; FRUIT	The fruit fly Drosophila melanogaster (Dm) mutant for PTEN-induced putative kinase 1 (PINK1(B9)) gene is a powerful tool to investigate physiopathology of Parkinson's disease (PD). Using PINK1(B9) mutant Dm we sought to explore the effects of Mucuna pruriens methanolic extract (Mpe), a L-Dopa-containing herbal remedy of PD. The effects of Mpe on PINK1(B9) mutants, supplied with standard diet to larvae and adults, were assayed on 3-6 (I), 10-15 (II) and 20-25 (III) days old flies. Mpe 0.1% significantly extended lifespan of PINK1(B9) and fully rescued olfactory response to 1-hexanol and improved climbing behavior of PINK1(B9) of all ages; in contrast, L-Dopa (0.01%, percentage at which it is present in Mpe 0.1%) ameliorated climbing of only PINK1(B9) flies of age step II. Transmission electron microscopy analysis of antennal lobes and thoracic ganglia of PINK1(B9) revealed that Mpe restored to wild type (WT) levels both T-bars and damaged mitochondria. Western blot analysis of whole brain showed that Mpe, but not L-Dopa on its own, restored bruchpilot (BRP) and tyrosine hydroxylase (TH) expression to age-matched WT control levels. These results highlight multiple sites of action of Mpe, suggesting that its effects cannot only depend upon its L-Dopa content and support the clinical observation of Mpe as an effective medication with intrinsic ability of delaying the onset of chronic L-Dopa-induced long-term motor complications. Overall, this study strengthens the relevance of using PINK1(B9) Dm as a translational model to study the properties of Mucuna pruriens for PD treatment.	[Poddighe, Simone; Fanti, Maura; Setzu, Maria Dolores] Univ Cagliari, Dept Biomed Sci, Cagliari, Italy; [De Rose, Francescaelena; Zuncheddu, Maria Antonietta; Collu, Ignazio; Acquas, Elio; Liscia, Anna] Univ Cagliari, Dept Life & Environm Sci, Cagliari, Italy; [Marotta, Roberto; Ruffilli, Roberta] Ist Italiano Tecnol, Nanochem Dept, Electron Microscopy Lab, Genoa, Italy; [Secci, Pietro Paolo; Mostallino, Maria Cristina] CNR, Inst Neurosci, Cagliari, Italy; [Solla, Paolo; Marrosu, Francesco] Univ Cagliari, Dept Publ Hlth Clin & Mol Med, Cagliari, Italy; [Kasture, Sanjay] Sanjivani Coll Pharmaceut Educ & Res, Ahmednagar, Maharashtra, India; [Acquas, Elio] Univ Cagliari, Ctr Excellence Study Neurobiol Addict, Cagliari, Italy; [Acquas, Elio] Univ Cagliari, Natl Inst Neurosci INN, Cagliari, Italy	University of Cagliari; University of Cagliari; Istituto Italiano di Tecnologia - IIT; Consiglio Nazionale delle Ricerche (CNR); University of Cagliari; University of Cagliari; University of Cagliari	Liscia, A (corresponding author), Univ Cagliari, Dept Life & Environm Sci, Cagliari, Italy.	liscia@unica.it	Marotta, Roberto/B-5382-2014; Solla, Paolo/AAL-9671-2020; Marotta, Roberto/HGV-1599-2022; Solla, Paolo/R-5366-2016; Solla, Paolo/GQZ-7556-2022	Solla, Paolo/0000-0002-2982-0665; Setzu, Maria Dolores/0000-0002-6934-4042; Liscia, Anna/0000-0002-1629-2090; Acquas, Elio/0000-0002-4783-9319; Marotta, Roberto/0000-0003-0634-5483; Poddighe, Simone/0000-0002-7244-9240				Bjorklund A, 2010, PROG BRAIN RES, V184, P3, DOI 10.1016/S0079-6123(10)84001-4; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Brooks David J, 2008, Neuropsychiatr Dis Treat, V4, P39; Celotto AM, 2005, MOL INTERV, V5, P292, DOI 10.1124/mi.5.5.9; Chambers RP, 2013, BEHAV BRAIN RES, V253, P95, DOI 10.1016/j.bbr.2013.07.020; Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779; Coulom H, 2004, J NEUROSCI, V24, P10993, DOI 10.1523/JNEUROSCI.2993-04.2004; Dekker T, 2006, CURR BIOL, V16, P101, DOI 10.1016/j.cub.2005.11.075; Dhanasekaran M, 2008, PHYTOTHER RES, V22, P6, DOI 10.1002/ptr.2109; Ferraris A, 2009, MOVEMENT DISORD, V24, P2350, DOI 10.1002/mds.22816; Fishilevich E, 2005, CURR BIOL, V15, P1548, DOI 10.1016/j.cub.2005.07.066; Fox SH, 2013, DRUGS, V73, P1405, DOI 10.1007/s40265-013-0105-4; Gil S, 2010, CELL MOL NEUROBIOL, V30, P817, DOI 10.1007/s10571-010-9509-9; Haehner A, 2011, PARKINSONS DIS-US, V2011, DOI 10.4061/2011/450939; Humphrey DM, 2012, HUM MOL GENET, V21, P2698, DOI 10.1093/hmg/dds096; Kasture S, 2013, ORIENTAL PHARM EXP M, V13, P165, DOI 10.1007/s13596-013-0126-2; Katzenschlager R, 2004, J NEUROL NEUROSUR PS, V75, P1672, DOI 10.1136/jnnp.2003.028761; Katzenschlager R, 2004, CURR OPIN NEUROL, V17, P417, DOI 10.1097/01.wco.0000137531.76491.c2; Katzenschlager Regina, 2002, J Neurol, V249 Suppl 2, pII19; Kittel RJ, 2006, SCIENCE, V312, P1051, DOI 10.1126/science.1126308; Knott A, 2009, ANN NY ACAD SCI, V1147, P283; Lieu CA, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/840247; Lieu CA, 2010, PARKINSONISM RELAT D, V16, P458, DOI 10.1016/j.parkreldis.2010.04.015; Liu Z, 2008, P NATL ACAD SCI USA, V105, P2693, DOI 10.1073/pnas.0708452105; Liu ZH, 2011, PHARMACOL RES, V63, P439, DOI 10.1016/j.phrs.2011.01.004; Manyam BV, 2004, PHYTOTHER RES, V18, P706, DOI 10.1002/ptr.1514; Mercuri NB, 2005, TRENDS PHARMACOL SCI, V26, P341, DOI 10.1016/j.tips.2005.05.002; Moisoi N, 2014, NEUROPHARMACOLOGY, V77, P350, DOI 10.1016/j.neuropharm.2013.10.009; Monastirioti M, 1999, MICROSC RES TECHNIQ, V45, P106, DOI 10.1002/(SICI)1097-0029(19990415)45:2<106::AID-JEMT5>3.3.CO;2-V; Morais VA, 2009, EMBO MOL MED, V1, P99, DOI 10.1002/emmm.200900006; Morelli Micaela, 2009, Handb Exp Pharmacol, P589, DOI 10.1007/978-3-540-89615-9_18; Obata T, 2001, BRAIN RES, V906, P170, DOI 10.1016/S0006-8993(01)02238-7; Park J, 2006, NATURE, V441, P1157, DOI 10.1038/nature04788; Poddighe S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073156; Porras G, 2014, SCI REP-UK, V4, DOI 10.1038/srep03730; Sayeed O, 1996, P NATL ACAD SCI USA, V93, P6079, DOI 10.1073/pnas.93.12.6079; Schwaerzel M, 2003, J NEUROSCI, V23, P10495, DOI 10.1523/jneurosci.23-33-10495.2003; Sharot T, 2009, CURR BIOL, V19, P2077, DOI 10.1016/j.cub.2009.10.025; Takao-Rikitsu E, 2004, J CELL BIOL, V164, P301, DOI 10.1083/jcb.200307101; Tufi R, 2014, NAT CELL BIOL, V16, P157, DOI 10.1038/ncb2901; Wagh DA, 2006, BRUCHPILOT PROTEIN; Wang J, 2011, AM J NEURORADIOL, V32, P677, DOI 10.3174/ajnr.A2350; Yadav SK, 2014, NEUROCHEM INT, V65, P1, DOI 10.1016/j.neuint.2013.12.001; Yadav SK, 2013, NEUROCHEM INT, V62, P1039, DOI 10.1016/j.neuint.2013.03.015; Yang YF, 2006, P NATL ACAD SCI USA, V103, P10793, DOI 10.1073/pnas.0602493103; Yellman C, 1997, P NATL ACAD SCI USA, V94, P4131, DOI 10.1073/pnas.94.8.4131	46	26	28	3	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2014	9	10							e110802	10.1371/journal.pone.0110802	http://dx.doi.org/10.1371/journal.pone.0110802			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR5ZY	25340511	Green Submitted, Green Published, gold			2023-01-03	WOS:000343662800057
J	Bais, L; Vercammen, A; Stewart, R; van Es, F; Visser, B; Aleman, A; Knegtering, H				Bais, Leonie; Vercammen, Ans; Stewart, Roy; van Es, Frank; Visser, Bert; Aleman, Andre; Knegtering, Henderikus			Short and Long Term Effects of Left and Bilateral Repetitive Transcranial Magnetic Stimulation in Schizophrenia Patients with Auditory Verbal Hallucinations: A Randomized Controlled Trial	PLOS ONE			English	Article							SHAM-CONTROLLED TRIAL; LEFT TEMPOROPARIETAL CORTEX; RTMS; EFFICACY; BRAIN; DEPOTENTIATION; SYMPTOMS; FMRI	Background: Repetitive transcranial magnetic stimulation of the left temporo-parietal junction area has been studied as a treatment option for auditory verbal hallucinations. Although the right temporo-parietal junction area has also shown involvement in the genesis of auditory verbal hallucinations, no studies have used bilateral stimulation. Moreover, little is known about durability effects. We studied the short and long term effects of 1 Hz treatment of the left temporo-parietal junction area in schizophrenia patients with persistent auditory verbal hallucinations, compared to sham stimulation, and added an extra treatment arm of bilateral TPJ area stimulation. Methods: In this randomized controlled trial, 51 patients diagnosed with schizophrenia and persistent auditory verbal hallucinations were randomly allocated to treatment of the left or bilateral temporo-parietal junction area or sham treatment. Patients were treated for six days, twice daily for 20 minutes. Short term efficacy was measured with the Positive and Negative Syndrome Scale (PANSS), the Auditory Hallucinations Rating Scale (AHRS), and the Positive and Negative Affect Scale (PANAS). We included follow-up measures with the AHRS and PANAS at four weeks and three months. Results: The interaction between time and treatment for Hallucination item P3 of the PANSS showed a trend for significance, caused by a small reduction of scores in the left group. Although self-reported hallucination scores, as measured with the AHRS and PANAS, decreased significantly during the trial period, there were no differences between the three treatment groups. Conclusion: We did not find convincing evidence for the efficacy of left-sided rTMS, compared to sham rTMS. Moreover, bilateral rTMS was not superior over left rTMS or sham in improving AVH. Optimizing treatment parameters may result in stronger evidence for the efficacy of rTMS treatment of AVH. Moreover, future research should consider investigating factors predicting individual response.	[Bais, Leonie; Aleman, Andre; Knegtering, Henderikus] Univ Groningen, Univ Med Ctr Groningen, Dept Neurosci, Groningen, Netherlands; [Bais, Leonie; Aleman, Andre; Knegtering, Henderikus] Univ Groningen, Univ Med Ctr Groningen, BCN Neuroimaging Ctr, Groningen, Netherlands; [Bais, Leonie; Knegtering, Henderikus] Lentis Psychiat Inst, Groningen, Netherlands; [Vercammen, Ans] Australian Catholic Univ, Strathfield, Australia; [Stewart, Roy] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci Community & Occupat Med, Groningen, Netherlands; [van Es, Frank; Visser, Bert] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, Groningen, Netherlands; [Aleman, Andre] Univ Groningen, Dept Psychol, NL-9712 TS Groningen, Netherlands; [Knegtering, Henderikus] Univ Groningen, Univ Med Ctr Groningen, Rob Giel Res Ctr, Groningen, Netherlands	University of Groningen; University of Groningen; Australian Catholic University; University of Groningen; University of Groningen; University of Groningen; University of Groningen	Bais, L (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurosci, Groningen, Netherlands.	l.bais@umcg.nl		Vercammen, Ans/0000-0003-1229-9401; Stewart, Roy/0000-0001-9227-433X	University of Groningen	University of Groningen	This project was supported by the University of Groningen (www.rug.nl). The University of Groningen had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aleman A, 2007, J CLIN PSYCHIAT, V68, P416, DOI 10.4088/JCP.v68n0310; Allen P, 2008, NEUROSCI BIOBEHAV R, V32, P175, DOI 10.1016/j.neubiorev.2007.07.012; ANDREASEN NC, 1991, SCHIZOPHRENIA BULL, V17, P27, DOI 10.1093/schbul/17.1.27; Blumberger DM, 2012, BRAIN STIMUL, V5, P577, DOI 10.1016/j.brs.2011.12.002; Brunelin J, 2006, SCHIZOPHR RES, V81, P41, DOI 10.1016/j.schres.2005.10.009; Brunelin J, 2012, AM J PSYCHIAT, V169, P719, DOI 10.1176/appi.ajp.2012.11071091; Chibbaro G, 2005, NEUROSCI LETT, V383, P54, DOI 10.1016/j.neulet.2005.03.052; Costanzo F, 2012, NEUROPSYCHOLOGIA, V50, P2645, DOI 10.1016/j.neuropsychologia.2012.07.017; Curcic-Blake B, 2013, SCHIZOPHRENIA BULL, V39, P1087, DOI 10.1093/schbul/sbs107; Daalman K, 2011, J CLIN PSYCHIAT, V72, P320, DOI 10.4088/JCP.09m05797yel; de Jesus DR, 2011, PSYCHIAT RES, V188, P203, DOI 10.1016/j.psychres.2010.11.022; Di Lazzaro V, 2002, EXP BRAIN RES, V147, P108, DOI 10.1007/s00221-002-1223-5; Fitzgerald PB, 2006, CLIN NEUROPHYSIOL, V117, P2584, DOI 10.1016/j.clinph.2006.06.712; Fitzgerald PB, 2007, PSYCHIAT RES-NEUROIM, V155, P83, DOI 10.1016/j.pscychresns.2006.12.011; Fitzgerald PB, 2005, J CLIN PSYCHOPHARM, V25, P358, DOI 10.1097/01.jcp.0000168487.22140.7f; Froc DJ, 2000, J NEUROSCI, V20, P438, DOI 10.1523/JNEUROSCI.20-01-00438.2000; Giel R., 1996, SCAN 2 1 SCHEDULES C; Heller W, 1998, CURR DIR PSYCHOL SCI, V7, P26, DOI 10.1111/1467-8721.ep11521823; Herwig U, 2003, BRAIN TOPOGR, V16, P95, DOI 10.1023/B:BRAT.0000006333.93597.9d; Hoffman RE, 2007, CEREB CORTEX, V17, P2733, DOI 10.1093/cercor/bhl183; Hoffman RE, 2013, BIOL PSYCHIAT, V73, P1008, DOI 10.1016/j.biopsych.2013.01.016; Hoffman RE, 2003, ARCH GEN PSYCHIAT, V60, P49, DOI 10.1001/archpsyc.60.1.49; Hoffman RE, 1999, BIOL PSYCHIAT, V46, P130, DOI 10.1016/S0006-3223(98)00358-8; Hoffman RE, 2005, BIOL PSYCHIAT, V58, P97, DOI 10.1016/j.biopsych.2005.03.041; Hoffman RE, 2000, LANCET, V355, P1073, DOI 10.1016/S0140-6736(00)02043-2; Hoffman RE, 2002, AM J PSYCHIAT, V159, P1093, DOI 10.1176/appi.ajp.159.7.1093; Homan P, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.114; Homan P, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00304; Honig A, 1998, J NERV MENT DIS, V186, P646, DOI 10.1097/00005053-199810000-00009; Jandl M, 2006, NEUROPSYCHOBIOLOGY, V53, P63, DOI 10.1159/000091721; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Kindler J, 2013, BIOL PSYCHIAT, V73, P518, DOI 10.1016/j.biopsych.2012.06.019; Klirova M, 2013, EUR ARCH PSY CLIN N, V263, P475, DOI 10.1007/s00406-012-0368-x; Lee SH, 2005, NEUROSCI LETT, V376, P177, DOI 10.1016/j.neulet.2004.11.048; Lennox BR, 2000, PSYCHIAT RES-NEUROIM, V100, P13, DOI 10.1016/S0925-4927(00)00068-8; Loo CK, 2010, PSYCHOL MED, V40, P541, DOI 10.1017/S0033291709990900; Maiza O, 2013, BRAIN SCI, V3, P728, DOI 10.3390/brainsci3020728; McIntosh AM, 2004, PSYCHIAT RES, V127, P9, DOI 10.1016/j.psychres.2004.03.005; Montagne-Larmurier A, 2009, SCHIZOPHR RES, V113, P77, DOI 10.1016/j.schres.2009.05.006; Moseley P, 2013, NEUROSCI BIOBEHAV R, V37, P2794, DOI 10.1016/j.neubiorev.2013.10.001; Pascual-Leone A., 2002, HDB TRANSCRANIAL MAG; POST RM, 1997, CNS SPECTRUMS, V2, P54; Poulet E, 2005, BIOL PSYCHIAT, V57, P188, DOI 10.1016/j.biopsych.2004.10.007; Rosa MO, 2007, J CLIN PSYCHIAT, V68, P1528, DOI 10.4088/JCP.v68n1009; Saba G, 2006, J PSYCHIATR RES, V40, P147, DOI 10.1016/j.jpsychires.2005.02.008; Schutter DJLG, 2006, J ECT, V22, P176, DOI 10.1097/01.yct.0000235924.60364.27; Seok JH, 2007, PSYCHIAT RES-NEUROIM, V156, P93, DOI 10.1016/j.pscychresns.2007.02.002; Shergill SS, 1998, SCHIZOPHR RES, V32, P137, DOI 10.1016/S0920-9964(98)00052-8; Shergill SS, 2000, ARCH GEN PSYCHIAT, V57, P1033, DOI 10.1001/archpsyc.57.11.1033; SILBERMAN EK, 1986, BRAIN COGNITION, V5, P322, DOI 10.1016/0278-2626(86)90035-7; Slotema CW, 2012, SCHIZOPHR RES, V142, P40, DOI 10.1016/j.schres.2012.08.025; Slotema CW, 2014, BIOL PSYCHIAT, V76, P101, DOI 10.1016/j.biopsych.2013.09.038; Slotema CW, 2011, BIOL PSYCHIAT, V69, P450, DOI 10.1016/j.biopsych.2010.09.051; Sommer IEC, 2007, SCHIZOPHR RES, V93, P406, DOI 10.1016/j.schres.2007.03.020; Sommer IE, 2012, AM J PSYCHIAT, V169, P1211, DOI 10.1176/appi.ajp.2012.12060741; Sommer IEC, 2008, BRAIN, V131, P3169, DOI 10.1093/brain/awn251; Spalletta G, 2003, SCHIZOPHR RES, V64, P15, DOI 10.1016/S0920-9964(03)00010-0; Vercammen A, 2010, J PSYCHIATR RES, V44, P725, DOI 10.1016/j.jpsychires.2009.12.011; Vercammen A, 2009, SCHIZOPHR RES, V114, P172, DOI 10.1016/j.schres.2009.07.013; Wang Carol Sheei-Meei, 2003, Kaohsiung Journal of Medical Sciences, V19, P464; Waters F, 2012, SCHIZOPHRENIA BULL, V38, P683, DOI 10.1093/schbul/sbs045; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; WEINBERGER DR, 1988, ARCH GEN PSYCHIAT, V45, P609	63	32	32	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2014	9	10							e108828	10.1371/journal.pone.0108828	http://dx.doi.org/10.1371/journal.pone.0108828			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0AY	25329799	Green Published, Green Submitted, gold			2023-01-03	WOS:000343942100013
J	Yen, ZH; Dai, CL; Feng, HS; Liu, YF; Wang, SL				Yen, Zhihu; Dai, Caili; Feng, Haishun; Liu, Yifei; Wang, Shilu			Study of the Formation and Solution Properties of Worm-Like Micelles Formed Using Both N-Hexadecyl-N-Methylpiperidinium Bromide-Based Cationic Surfactant and Anionic Surfactant	PLOS ONE			English	Article							IONIC LIQUID; LIVING POLYMERS; DYNAMICS; SYSTEMS; MIXTURES; RHEOLOGY; CRYSTALS; ENERGY	The viscoelastic properties of worm-like micelles formed by mixing the cationic surfactant N-hexadecyl-N-methylpiperidinium bromide (C16MDB) with the anionic surfactant sodium laurate (SL) in aqueous solutions were investigated using rheological measurements. The effects of sodium laurate and temperature on the worm-like micelles and the mechanism of the observed shear thinning phenomenon and pseudoplastic behavior were systematically investigated. Additionally, cryogenic transmission electron microscopy images further ascertained existence of entangled worm-like micelles.	[Yen, Zhihu; Dai, Caili; Feng, Haishun; Liu, Yifei; Wang, Shilu] China Univ Petr Huadong, Sch Petr Engn, Qingdao, Peoples R China	China University of Petroleum	Yen, ZH (corresponding author), China Univ Petr Huadong, Sch Petr Engn, Qingdao, Peoples R China.	zhihuyan@126.com; daicl306@163.com		Dai, Cai li/0000-0002-7477-8865	National Natural Science Foundation of China [51174221, 21303268]; Program for New Century Excellent Talents in University [20110226]; China Postdoctoral Science Foundation [2013T60689]; National Ministry of Education [20120133110010]; Fundamental Research Funds for the Central Universities [14CX02041A]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); National Ministry of Education; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	The work was supported by National Natural Science Foundation of China (51174221, 21303268), the Program for New Century Excellent Talents in University (20110226), China Postdoctoral Science Foundation funded project (2013T60689), Doctoral Fund from National Ministry of Education (No. 20120133110010) and the Fundamental Research Funds for the Central Universities (14CX02041A). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Araos MU, 2005, J PHYS CHEM B, V109, P14275, DOI 10.1021/jp052862y; CANDAU SJ, 1988, J COLLOID INTERF SCI, V122, P430, DOI 10.1016/0021-9797(88)90377-3; Cates ME, 2006, ADV PHYS, V55, P799, DOI 10.1080/00018730601082029; CATES ME, 1990, J PHYS-CONDENS MAT, V2, P6869, DOI 10.1088/0953-8984/2/33/001; CATES ME, 1988, J PHYS-PARIS, V49, P1593, DOI 10.1051/jphys:019880049090159300; Couillet I, 2004, LANGMUIR, V20, P9541, DOI 10.1021/la049046m; Dreiss CA, 2007, SOFT MATTER, V3, P956, DOI 10.1039/b705775j; Forster S, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.017803; Gonzalez YI, 2005, CURR OPIN COLLOID IN, V10, P256, DOI 10.1016/j.cocis.2005.09.007; GRANEK R, 1992, J CHEM PHYS, V96, P4758, DOI 10.1063/1.462787; Lava K, 2009, J PHYS CHEM B, V113, P9506, DOI 10.1021/jp903667e; Lin Z, 1996, LANGMUIR, V12, P1729, DOI 10.1021/la950570q; Lu JM, 2009, PROG POLYM SCI, V34, P431, DOI 10.1016/j.progpolymsci.2008.12.001; Manero O, 2002, J NON-NEWTON FLUID, V106, P1, DOI 10.1016/S0377-0257(02)00082-4; Peters JE, 2008, MACROMOLECULES, V41, P7274, DOI 10.1021/ma8011569; Raghavan SR, 2002, LANGMUIR, V18, P3797, DOI 10.1021/la0115583; Razak NA, 2013, RHEOL ACTA, V52, P927, DOI 10.1007/s00397-013-0731-5; REHAGE H, 1988, J PHYS CHEM-US, V92, P4712, DOI 10.1021/j100327a031; Samuel MM, 1999, SPE DRILL COMPLETION, V14, P240, DOI 10.2118/59478-PA; SHINODA K, 1987, LANGMUIR, V3, P135, DOI 10.1021/la00074a001; Snyder SA, 2003, ENVIRON ENG SCI, V20, P449, DOI 10.1089/109287503768335931; UCHEGBU IF, 1995, ADV COLLOID INTERFAC, V58, P1, DOI 10.1016/0001-8686(95)00242-I; Varade D, 2005, COLLOID SURFACE A, V259, P95, DOI 10.1016/j.colsurfa.2005.02.018; Zhao GX, 1996, J COLLOID INTERF SCI, V177, P513, DOI 10.1006/jcis.1996.0065; Zhao MW, 2011, PHYS CHEM CHEM PHYS, V13, P1332, DOI 10.1039/c0cp00342e; Zhao YR, 2009, J PHYS CHEM B, V113, P983, DOI 10.1021/jp809048u	26	1	1	2	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 8	2014	9	10							e110155	10.1371/journal.pone.0110155	http://dx.doi.org/10.1371/journal.pone.0110155			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8TE	25296131	Green Published, Green Submitted, gold			2023-01-03	WOS:000345204000115
J	Liu, M; Liu, JB; Wang, LM; Wu, HY; Zhou, CC; Zhu, HX; Xu, NZ; Xie, YF				Liu, Mei; Liu, Jibing; Wang, Liming; Wu, Huiyong; Zhou, Changchun; Zhu, Hongxia; Xu, Ningzhi; Xie, Yinfa			Association of Serum MicroRNA Expression in Hepatocellular Carcinomas Treated with Transarterial Chemoembolization and Patient Survival	PLOS ONE			English	Article							CIRCULATING MICRORNAS; ALPHA-FETOPROTEIN; CANCER; MIR-122; MARKERS; MIR-21	Background and Aim: Hepatocellular carcinoma (HCC) is one of the most deadly tumors. Transarterial chemoembolization (TACE) is effective for unresectable HCC. In recent years, miRNAs have been proposed as novel diagnostic and prognostic tools for HCC. This study aimed to identify whether microRNAs (miRNAs) can serve as biomarkers to reliably predict outcome before HCC patients are treated with TACE. Methods: Eleven miRNAs (miR-, miR-19a, miR-101-3p, miR-199a-5p, miR-200a, miR-21, miR-214, miR-221, miR-222, miR-223 and miR-, -5p) were quantified by quantitative real-time PCR (qRT-PCR) in 136 HCC patients' serum before they received TACE therapy. Univariate and multivariate analysis were used to identify the prognostic value of clinical parameters and miRNAs. Area under the receiver operating characteristic curve (AUC) was used to evaluate the prediction potency. Results: The levels of some miRNAs were dramatically associated with clinicopathologic features regarding Child-Puge class, AFP, tumor size and satellite nodules. Univariate analysis revealed that miR-200a, miR-21, miR-122 and miR-224-5p were significantly associated with patients' survival. Multivariate analysis demonstrated that AFP, satellite nodules and miR-200a were the independent prognostic factors associated with survival in this cohort (p = 0.000, 0.001, 0.000, respectively). The probability of the prognostic accuracy of miR-200a was 81.64% (74.47% specificity and 88.76% sensitivity), which was higher than the classifier established by combination of AFP and satellite nodules (76.87% probability, 70.21% specificity and 69.66% sensitivity). Furthermore, the combination of AFP, satellite nodules and miR-200a demonstrated as a classifier for HCC prognosis, yielding a ROC curve area of 88.19% (93.62% specificity and 68.54% sensitivity). Conclusions: Our study indicated that serum miR-200a may prognosticate disease outcome in HCC patients with TACE therapy. Therefore, miR-200a can potentially guide individualized treatment for HCC patients with a high risk of TACE treatment failures.	[Liu, Mei; Zhu, Hongxia; Xu, Ningzhi] Chinese Acad Med Sci, Lab Cell & Mol Biol, Beijing 100730, Peoples R China; [Liu, Mei; Zhu, Hongxia; Xu, Ningzhi] Chinese Acad Med Sci, Inst Canc, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; [Liu, Mei; Wang, Liming; Zhu, Hongxia; Xu, Ningzhi] Chinese Acad Med Sci, Canc Hosp, Beijing 100730, Peoples R China; [Liu, Mei; Wang, Liming; Zhu, Hongxia; Xu, Ningzhi] Peking Union Med Coll, Beijing 100021, Peoples R China; [Liu, Jibing; Wu, Huiyong; Xie, Yinfa] Shandong Acad Med Sci, Canc Hosp Shandong Prov, Dept Intervent Surg Oncol, Jinan, Shandong, Peoples R China; [Wang, Liming] Chinese Acad Med Sci, Inst Canc, Dept Abdominal Surg, Beijing 100021, Peoples R China; [Zhou, Changchun] Shandong Acad Med Sci, Canc Hosp Shandong Prov, Clin Lab, Jinan, Shandong, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; Chinese Academy of Medical Sciences - Peking Union Medical College; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan	Xu, NZ (corresponding author), Chinese Acad Med Sci, Lab Cell & Mol Biol, Beijing 100730, Peoples R China.	xningzhi@public.bta.net.cn; Laoxie6996@163.com	Wang, Liming/AAD-7697-2020; , CC. Zhou/AGI-1229-2022		State Key Laboratory of Molecular Oncology program [SKL-2013-14]; Development projects of Shandong province science and technology [2012GSF11837]; Beijing Hope Run Special Fund, PR China [LC2012B19]	State Key Laboratory of Molecular Oncology program; Development projects of Shandong province science and technology; Beijing Hope Run Special Fund, PR China	This work was supported by State Key Laboratory of Molecular Oncology program (SKL-2013-14), Development projects of Shandong province science and technology (2012GSF11837) and Beijing Hope Run Special Fund (LC2012B19), PR China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Au V, 2014, BIOSCI TRENDS, V8, P101, DOI 10.5582/bst.8.101; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Buscaglia Lindsey E Becker, 2011, Chin J Cancer, V30, P371; Callegari Elisa, 2013, Onco Targets Ther, V6, P1167, DOI 10.2147/OTT.S36161; Coulouarn C, 2009, ONCOGENE, V28, P3526, DOI 10.1038/onc.2009.211; Dhayat SA, 2014, J SURG ONCOL, V110, P430, DOI 10.1002/jso.23668; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Farinati F, 2006, AM J GASTROENTEROL, V101, P524, DOI 10.1111/j.1572-0241.2006.00443.x; Ferracin M, 2010, EXPERT REV MOL DIAGN, V10, P297, DOI 10.1586/ERM.10.11; Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; Gramantieri L, 2009, CLIN CANCER RES, V15, P5073, DOI 10.1158/1078-0432.CCR-09-0092; Han ZB, 2012, MOL ONCOL, V6, P445, DOI 10.1016/j.molonc.2012.04.001; Hung CS, 2013, ANN SURG ONCOL, V20, pS360, DOI 10.1245/s10434-012-2482-4; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jiang J, 2008, CLIN CANCER RES, V14, P419, DOI 10.1158/1078-0432.CCR-07-0523; Kojima K, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1345; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Li Q, 2013, J GASTROENTEROL HEPA; Li Q, 2010, J GASTROEN HEPATOL, V25, P164, DOI 10.1111/j.1440-1746.2009.05971.x; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Minguez B, 2011, DIS MARKERS, V31, P181, DOI [10.1155/2011/310675, 10.3233/DMA-2011-0841]; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; Negrini M, 2011, ANTI-CANCER AGENT ME, V11, P500, DOI 10.2174/187152011796011037; Park JK, 2011, CANCER RES, V71, P7608, DOI 10.1158/0008-5472.CAN-11-1144; Petrelli A, 2014, HEPATOLOGY, V59, P228, DOI 10.1002/hep.26616; Riaz A, 2009, J CLIN ONCOL, V27, P5734, DOI 10.1200/JCO.2009.23.1282; Tsai WC, 2009, HEPATOLOGY, V49, P1571, DOI 10.1002/hep.22806; Wang K, 2009, P NATL ACAD SCI USA, V106, P4402, DOI 10.1073/pnas.0813371106; Wang Y, 2012, ANN SURG ONCOL, V19, P3540, DOI 10.1245/s10434-012-2368-5; Wang Y, 2014, GENE, V533, P389, DOI 10.1016/j.gene.2013.09.038; Xu JA, 2011, MOL CARCINOGEN, V50, P136, DOI 10.1002/mc.20712; Zhang Y, 2010, CLIN CHEM, V56, P1830, DOI 10.1373/clinchem.2010.147850	35	56	57	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2014	9	10							e109347	10.1371/journal.pone.0109347	http://dx.doi.org/10.1371/journal.pone.0109347			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ2BX	25275448	Green Published, Green Submitted, gold			2023-01-03	WOS:000342591500097
J	McCartney, M				McCartney, Margaret			Margaret McCartney: Don't blame us	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							INTRATHECAL VINCRISTINE					margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Gilbar Peter, 2012, J Oncol Pharm Pract, V18, P377, DOI 10.1177/1078155212453752; Gilbar Peter, 2012, J Oncol Pharm Pract, V18, P155, DOI 10.1177/1078155210396396; Reddy GK, 2011, CLIN NEUROL NEUROSUR, V113, P68, DOI 10.1016/j.clineuro.2010.08.008; SCHOCHE SS, 1968, J NEUROPATH EXP NEUR, V27, P645; The National Advisory Group on the Safety of Patients in England, 2013, PROMISE LEARN COMMIT; Toft B, 2001, EXT ENQ ADV INC OCC	6	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 30	2014	349								g5884	10.1136/bmj.g5884	http://dx.doi.org/10.1136/bmj.g5884			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AQ3CA	25269697	Bronze, Green Published			2023-01-03	WOS:000342665100011
J	Yang, T; Li, XM; Zhu, W; Chen, C; Sun, ZH; Tan, ZL; Kang, JH				Yang, Tan; Li, Xiaomin; Zhu, Wang; Chen, Cheng; Sun, Zhihong; Tan, Zhiliang; Kang, Jinghe			Alteration of Antioxidant Enzymes and Associated Genes Induced by Grape Seed Extracts in the Primary Muscle Cells of Goats In Vitro	PLOS ONE			English	Article							SKELETAL-MUSCLE; OXIDATIVE STRESS; PROANTHOCYANIDIN EXTRACT; TEA CATECHINS; GLUTATHIONE; ACTIVATION; EXPRESSION; PREVENTS; RAT; POLYPHENOLS	This study was conducted to investigate how the activity and expression of certain paramount antioxidant enzymes respond to grape seed extract (GSE) addition in primary muscle cells of goats. Gluteal primary muscle cells (PMCs) isolated from a 3-week old goat were cultivated as an unstressed cell model, or they were exposed to 100 mu M H2O2 to establish a H2O2-stimulated cell model. The activities of catalase (CAT), superoxide dismutases (SOD) and glutathione peroxidases (GPx) in combination with other relevant antioxidant indexes [i.e., reduced glutathione (GSH) and total antioxidant capacity (TAOC)] in response to GSE addition were tested in the unstressed and H2O2-stimulated cell models, and the relative mRNA levels of the CAT, GuZu-SOD, and GPx-1 genes were measured by qPCR. In unstressed PMCs, GSE addition at the dose of 10 mu g/ml strikingly attenuated the expression levels of CAT and CuZn-SOD as well as the corresponding enzyme activities. By contrast, in cells pretreated with 100 mu M H2O2, the expression and activity levels of these two antioxidant enzymes were enhanced by GSE addition at 10 mu g/ml. GSE addition promoted GPx activity in both unstressed and stressed PMCs, while the expression of the GPx 1 gene displayed partial divergence with GPx activity, which was mitigated by GSE addition at 10 mu g/ml in unstressed PMCs. GSH remained comparatively stable except for GSE addition to H2O2-stimulated PMCs at 60 mu g/ml, in which a dramatic depletion of GSH occurred. Moreover, GSE addition enhanced TAOC in unstressed (but not H2O2-stimulated) PMCs. GSE addition exerted a bidirectional modulating effect on the mRNA levels and activities of CAT and SOD in unstressed and stressed PMCs at a moderate dose, and it only exhibited a unidirectional effect on the promotion of GPx activity, reflecting its potential to improve antioxidant protection in ruminants.	[Yang, Tan; Li, Xiaomin; Zhu, Wang; Chen, Cheng; Sun, Zhihong] Southwest Univ, Key Lab Biofeed & Mol Nutr, Chongqing, Peoples R China; [Yang, Tan; Tan, Zhiliang; Kang, Jinghe] Chinese Acad Sci, Key Lab Agroecol Proc Subtrop Reg,Inst Subtrop Ag, Hunan Res Ctr Livestock & Poultry Sci,Minist Agr, South Cent Expt Stn Anim Nutr & Feed Sci, Changsha, Hunan, Peoples R China	Southwest University - China; Chinese Academy of Sciences; Ministry of Agriculture & Rural Affairs	Sun, ZH (corresponding author), Southwest Univ, Key Lab Biofeed & Mol Nutr, Chongqing, Peoples R China.	sunzh2002cn@aliyun.com; zltan@isa.ac.cn			National Program on Key Basic Research Project of China [2013CB127303, 2013CB127304]; CAS; Natural Science Foundation Project of CQ CSTC [cstc2013jjB0112, cstc2012jjA80001]; National Science & Technology Pillar Program [2012BAD14B18, 2014BAD08B11]; Fundamental Research Funds for the Central Universities [XDJK2011C030, XDJK2011B011]; National Natural Science Foundation of China [30600436, 31201826]	National Program on Key Basic Research Project of China(National Basic Research Program of China); CAS(Chinese Academy of Sciences); Natural Science Foundation Project of CQ CSTC(Natural Science Foundation Project of CQ CSTC); National Science & Technology Pillar Program; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was financially supported by the National Program on Key Basic Research Project of China (2013CB127303 and 2013CB127304), the CAS Presidential Scholarship (Excellence Award), the Natural Science Foundation Project of CQ CSTC (cstc2013jjB0112 and cstc2012jjA80001), the National Science & Technology Pillar Program (2012BAD14B18 and 2014BAD08B11), the Fundamental Research Funds for the Central Universities (XDJK2011C030 and XDJK2011B011), and the National Natural Science Foundation of China (30600436 and 31201826). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Martin MA, 2010, J NUTR BIOCHEM, V21, P196, DOI 10.1016/j.jnutbio.2008.10.009; Aoi Wataru, 2011, Curr Aging Sci, V4, P101; Baud O, 2004, J NEUROSCI, V24, P1531, DOI 10.1523/JNEUROSCI.3989-03.2004; Bonnard C, 2008, J CLIN INVEST, V118, P789, DOI 10.1172/JCI32601; Brenes A, 2010, SPAN J AGRIC RES, V8, P326, DOI 10.5424/sjar/2010082-1199; Cheah KY, 2009, CANCER BIOL THER, V8, P382, DOI 10.4161/cbt.8.4.7453; Chen LJ, 2004, CHEM RES TOXICOL, V17, P922, DOI 10.1021/tx0499315; Chen T, 2012, FREE RADICAL BIO MED, V53, P208, DOI 10.1016/j.freeradbiomed.2012.05.014; Ding Y, 2013, MOL NUTR FOOD RES, V57, P365, DOI 10.1002/mnfr.201200463; Du Y, 2007, J AGR FOOD CHEM, V55, P1695, DOI 10.1021/jf063071b; Duthie G, 2012, OXID MED CELL LONGEV, V2012, P165; El-Ashmawy IM, 2006, BASIC CLIN PHARMACOL, V99, P230, DOI 10.1111/j.1742-7843.2006.pto_497.x; Gilliam LAA, 2012, AM J PHYSIOL-CELL PH, V302, pC195, DOI 10.1152/ajpcell.00217.2011; Girnun GD, 2002, MOL ENDOCRINOL, V16, P2793, DOI 10.1210/me.2002-0020; Gong P, 2012, BIOMED RES-INDIA, V23, P551; Guler A, 2011, MED SCI MONITOR, V17, pBR326, DOI 10.12659/MSM.882042; Hanhineva K, 2010, INT J MOL SCI, V11, P1365, DOI 10.3390/ijms11041365; Hotta M, 2010, J LIPID RES, V51, P132, DOI 10.1194/jlr.M900255-JLR200; Kaur M, 2011, MOL CARCINOGEN, V50, P553, DOI 10.1002/mc.20739; Khan N, 2008, MOL MED REP, V1, P813, DOI 10.3892/mmr_00000033; Khoo NKH, 2013, REDOX BIOL, V1, P70, DOI 10.1016/j.redox.2012.12.006; Kim MJ, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/510212; Kusano C., 2008, J CELL MOL BIOL, V7, P1; Li XL, 2010, INT J MOL MED, V25, P237, DOI 10.3892/ijmm_00000336; Lynge J, 2001, J PHYSIOL-LONDON, V537, P597, DOI 10.1111/j.1469-7793.2001.00597.x; Mandic AI, 2009, APTEFF, V40, P1; Masella R, 2005, J NUTR BIOCHEM, V16, P577, DOI 10.1016/j.jnutbio.2005.05.013; McClung JM, 2010, AM J PHYSIOL-CELL PH, V298, pC542, DOI 10.1152/ajpcell.00192.2009; McClung JM, 2009, AM J PHYSIOL-CELL PH, V296, pC363, DOI 10.1152/ajpcell.00497.2008; Mellen PB, 2010, J AM COLL NUTR, V29, P469, DOI 10.1080/07315724.2010.10719883; Molina MF, 2003, BIOL PHARM BULL, V26, P1398, DOI 10.1248/bpb.26.1398; Myburgh KH, 2012, J NUTR BIOCHEM, V23, P1072, DOI 10.1016/j.jnutbio.2011.05.014; Nannelli A, 2009, TOXICOLOGY, V265, P69, DOI 10.1016/j.tox.2009.09.010; Ohta Y, 2011, AM J PHYSIOL-HEART C, V300, pH1637, DOI 10.1152/ajpheart.01185.2009; Ozkan G, 2012, RENAL FAILURE, V34, P460, DOI 10.3109/0886022X.2012.656563; Satyam SM, 2014, J NUTR HEALTH AGING, V18, P524, DOI 10.1007/s12603-014-0020-8; Shao ZH, 2003, PHARMACOL RES, V47, P463, DOI 10.1016/S1043-6618(03)00041-0; Silva LA, 2011, CELL BIOCHEM FUNCT, V29, P43, DOI 10.1002/cbf.1716; Tonon J, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-39; Ulusoy S, 2012, NEPHROLOGY, V17, P372, DOI 10.1111/j.1440-1797.2012.01565.x; Wang ZF, 2009, FREE RADICAL BIO MED, V47, P1221, DOI 10.1016/j.freeradbiomed.2009.08.001; Yang HB, 2012, BIOL TRACE ELEM RES, V147, P156, DOI 10.1007/s12011-011-9272-x; Yang WW, 2011, MOL CELL BIOCHEM, V358, P21, DOI 10.1007/s11010-011-0915-1; Yano CL, 2005, FREE RADICAL BIO MED, V39, P1378, DOI 10.1016/j.freeradbiomed.2005.07.001; Yokota T, 2009, AM J PHYSIOL-HEART C, V297, pH1069, DOI 10.1152/ajpheart.00267.2009; Zhong RZ, 2011, J AGR FOOD CHEM, V59, P11338, DOI 10.1021/jf202839t; Zhou DY, 2011, PLANTA MED, V77, P1575, DOI 10.1055/s-0030-1270957; Zhu H, 2005, FEBS LETT, V579, P3029, DOI 10.1016/j.febslet.2005.04.058	48	20	22	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2014	9	9							e107670	10.1371/journal.pone.0107670	http://dx.doi.org/10.1371/journal.pone.0107670			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ0RY	25238394	Green Submitted, Green Published, gold			2023-01-03	WOS:000342491600040
J	Riaz, MK; Hashmi, FK; Bukhari, NI; Riaz, M; Hussain, K				Riaz, Muhammad Kashif; Hashmi, Furqan Khurshid; Bukhari, Nadeem Irfan; Riaz, Mohammad; Hussain, Khalid			Occurrence of Medication Errors and Comparison of Manual and Computerized Prescription Systems in Public Sector Hospitals in Lahore, Pakistan	PLOS ONE			English	Article							HEALTH; IMPACT; CARE	The knowledge of medication errors is an essential prerequisite for better healthcare delivery. The present study investigated prescribing errors in prescriptions from outpatient departments (OPDs) and emergency wards of two public sector hospitals in Lahore, Pakistan. A manual prescription system was followed in Hospital A. Hospital B was running a semi-computerised prescription system in the OPD and a fully computerised prescription system in the emergency ward. A total of 510 prescriptions from both departments of these two hospitals were evaluated for patient characteristics, demographics and medication errors. The data was analysed using a chi square test for comparison of errors between both the hospitals. The medical departments in OPDs of both hospitals were the highest prescribers at 45%-60%. The age group receiving the most treatment in emergency wards of both the hospitals was 21-30 years (21%-24%). A trend of omitting patient addresses and diagnoses was observed in almost all prescriptions from both of the hospitals. Nevertheless, patient information such as name, age, gender and legibility of the prescriber's signature were found in almost 100% of the electronic-prescriptions. In addition, no prescribing error was found pertaining to drug concentrations, quantity and rate of administration in e-prescriptions. The total prescribing errors in the OPD and emergency ward of Hospital A were found to be 44% and 60%, respectively. In hospital B, the OPD had 39% medication errors and the emergency department had 73.5% errors; this unexpected difference between the emergency ward and OPD of hospital B was mainly due to the inclusion of 69.4% omissions of route of administration in the prescriptions. The incidence of prescription overdose was approximately 7%-19% in the manual system and approximately 8% in semi and fully electronic system. The omission of information and incomplete information are contributors of prescribing errors in both manual and electronic prescriptions.	[Riaz, Muhammad Kashif; Hashmi, Furqan Khurshid; Bukhari, Nadeem Irfan; Riaz, Mohammad; Hussain, Khalid] Univ Punjab, Univ Coll Pharm, Lahore, Pakistan	University of Punjab	Riaz, MK (corresponding author), Univ Punjab, Univ Coll Pharm, Lahore, Pakistan.	kashifriaz22@yahoo.com	Hashmi, Furqan/ABG-5594-2020; Bukhari, Nadeem Irfan/F-2030-2016	Hashmi, Furqan/0000-0003-4921-3739; Bukhari, Nadeem Irfan/0000-0001-5710-9574; RIAZ, M. Kashif/0000-0001-7833-4631				Agalu A, 2011, J MULTIDISCIP HEALTH, V4, P377, DOI 10.2147/JMDH.S24671; [Anonymous], 1993, Am J Hosp Pharm, V50, P305; [Anonymous], DRUG OV; Calligaris Laura, 2009, BMC Clin Pharmacol, V9, P9, DOI 10.1186/1472-6904-9-9; Camire E, 2009, CAN MED ASSOC J, V180, P936, DOI 10.1503/cmaj.080869; Devine EB, 2010, J AM MED INFORM ASSN, V17, P78, DOI 10.1197/jamia.M3285; GLADSTONE J, 1995, J ADV NURS, V22, P628, DOI 10.1046/j.1365-2648.1995.22040628.x; Holmstrom AR, 2012, J PATIENT SAF, V8, P165, DOI 10.1097/PTS.0b013e3182676cf3; Hyman D, 2012, PEDIATRICS, V130, pE211, DOI 10.1542/peds.2011-2984; Katzung BG, 2006, BASIC CLIN PHARM, P1063; Lisby M, 2005, INT J QUAL HEALTH C, V17, P15, DOI 10.1093/intqhc/mzi015; Mayo AM, 2004, J NURS CARE QUAL, V19, P209, DOI 10.1097/00001786-200407000-00007; Mitka M, 2009, JAMA-J AM MED ASSOC, V301, P587, DOI 10.1001/jama.2009.37; National Coordinating Council for Medication Error Reporting and Prevention, 2014, CONS INF SAF MED US; SCHNEIDER PJ, 1995, AM J HEALTH-SYST PH, V52, P2415, DOI 10.1093/ajhp/52.21.2415; Shawahna R, 2013, J CLIN NURS, V22, P550, DOI 10.1111/j.1365-2702.2012.04076.x; Starfield B, 2000, JAMA-J AM MED ASSOC, V284, P483, DOI 10.1001/jama.284.4.483; van Doormaal JE, 2009, J AM MED INFORM ASSN, V16, P816, DOI 10.1197/jamia.M3099; Villamanan E, 2011, ARCH BRONCONEUMOL, V47, P138, DOI 10.1016/j.arbres.2010.11.004	19	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2014	9	8							e106080	10.1371/journal.pone.0106080	http://dx.doi.org/10.1371/journal.pone.0106080			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AO4JP	25165851	Green Published, gold, Green Submitted			2023-01-03	WOS:000341303700071
J	DeBaun, MR; Gordon, M; McKinstry, RC; Noetzel, MJ; White, DA; Sarnaik, SA; Meier, ER; Howard, TH; Majumdar, S; Inusa, BPD; Telfer, PT; Kirby-Allen, M; McCavit, TL; Kamdem, A; Airewele, G; Woods, GM; Berman, B; Panepinto, JA; Fuh, BR; Kwiatkowski, JL; King, AA; Fixler, JM; Rhodes, MM; Thompson, AA; Heiny, ME; Redding-Lallinger, RC; Kirkham, FJ; Dixon, N; Gonzalez, CE; Kalinyak, KA; Quinn, CT; Strouse, JJ; Miller, JP; Lehmann, H; Kraut, MA; Ball, WS; Hirtz, D; Casella, JF				DeBaun, M. R.; Gordon, M.; McKinstry, R. C.; Noetzel, M. J.; White, D. A.; Sarnaik, S. A.; Meier, E. R.; Howard, T. H.; Majumdar, S.; Inusa, B. P. D.; Telfer, P. T.; Kirby-Allen, M.; McCavit, T. L.; Kamdem, A.; Airewele, G.; Woods, G. M.; Berman, B.; Panepinto, J. A.; Fuh, B. R.; Kwiatkowski, J. L.; King, A. A.; Fixler, J. M.; Rhodes, M. M.; Thompson, A. A.; Heiny, M. E.; Redding-Lallinger, R. C.; Kirkham, F. J.; Dixon, N.; Gonzalez, C. E.; Kalinyak, K. A.; Quinn, C. T.; Strouse, J. J.; Miller, J. P.; Lehmann, H.; Kraut, M. A.; Ball, W. S., Jr.; Hirtz, D.; Casella, J. F.			Controlled Trial of Transfusions for Silent Cerebral Infarcts in Sickle Cell Anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILDREN; DISEASE; STROKE; BRAIN; HEMOGLOBINOPATHY; PREVENTION; STATE; BLOOD; RISK	BACKGROUND Silent cerebral infarcts are the most common neurologic injury in children with sickle cell anemia and are associated with the recurrence of an infarct (stroke or silent cerebral infarct). We tested the hypothesis that the incidence of the recurrence of an infarct would be lower among children who underwent regular blood transfusion therapy than among those who received standard care. METHODS In this randomized, single-blind clinical trial, we randomly assigned children with sickle cell anemia to receive regular blood transfusions (transfusion group) or standard care (observation group). Participants were between 5 and 15 years of age, with no history of stroke and with one or more silent cerebral infarcts on magnetic resonance imaging and a neurologic examination showing no abnormalities corresponding to these lesions. The primary end point was the recurrence of an infarct, defined as a stroke or a new or enlarged silent cerebral infarct. RESULTS A total of 196 children (mean age, 10 years) were randomly assigned to the observation or transfusion group and were followed for a median of 3 years. In the transfusion group, 6 of 99 children (6%) had an end-point event (1 had a stroke, and 5 had new or enlarged silent cerebral infarcts). In the observation group, 14 of 97 children (14%) had an end-point event (7 had strokes, and 7 had new or enlarged silent cerebral infarcts). The incidence of the primary end point in the transfusion and observation groups was 2.0 and 4.8 events, respectively, per 100 years at risk, corresponding to an incidence rate ratio of 0.41 (95% confidence interval, 0.12 to 0.99; P = 0.04). CONCLUSIONS Regular blood-transfusion therapy significantly reduced the incidence of the recurrence of cerebral infarct in children with sickle cell anemia. (Funded by the National Institute of Neurological Disorders and Stroke and others; Silent Cerebral Infarct Multi-Center Clinical Trial ClinicalTrials.gov number, NCT00072761, and Current Controlled Trials number, ISRCTN52713285.)	[DeBaun, M. R.] Vanderbilt Univ, Sch Med, Vanderbilt Meharry Ctr Excellence Sickle Cell Dis, Dept Pediat,Div Hematol Oncol, Nashville, TN 37212 USA; [Gordon, M.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, Div Biostat, St Louis, MO 63130 USA; [McKinstry, R. C.] Washington Univ, Sch Med, Dept Radiol & Pediat, St Louis, MO 63130 USA; [Noetzel, M. J.] Washington Univ, Sch Med, Dept Neurol & Pediat, St Louis, MO 63130 USA; [White, D. A.] Washington Univ, Sch Med, Dept Psychol, St Louis, MO 63130 USA; [King, A. A.] Washington Univ, Sch Med, Program Occupat Therapy, St Louis, MO 63130 USA; [King, A. A.] Washington Univ, Sch Med, Dept Pediat Hematol Oncol, St Louis, MO 63130 USA; [Miller, J. P.] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63130 USA; [Miller, J. P.] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63130 USA; [Sarnaik, S. A.] Wayne State Univ, Dept Pediat, Div Hematol Oncol, Detroit, MI 48202 USA; [Meier, E. R.] George Washington Univ, Dept Pediat, Med Ctr, Ctr Canc & Blood Disorders,Childrens Natl Med Ctr, Washington, DC 20052 USA; [Gonzalez, C. E.] Georgetown Univ Hosp, Dept Pediat, Div Hematol Oncol, Washington, DC 20007 USA; [Howard, T. H.] Univ Alabama Birmingham, Dept Pediat, Div Hematol Oncol, Birmingham, W Midlands, England; [Majumdar, S.] Univ Mississippi, Med Ctr, Dept Pediat, Div Hematol Oncol, Jackson, MS USA; [Inusa, B. P. D.] St Thomas Hosp NHS Trust, Evelina Childrens Hosp, Dept Paediat, London, England; [Telfer, P. T.] Barts Hlth NHS Trust, Royal London Hosp, Dept Pediat Hematol, London, England; [Kirkham, F. J.] UCL, Inst Child Hlth, Neurosci Unit, London WC1E 6BT, England; [Kirby-Allen, M.] Univ Toronto, Dept Paediat, Hosp Sick Children, Toronto, ON M5S 1A1, Canada; [McCavit, T. L.] UT Southwestern Med Ctr, Dept Pediat, Div Hematol Oncol, Dallas, TX USA; [Kamdem, A.] Hop Intercommunal Creteil, Dept Pediat, Creteil, France; [Airewele, G.] Baylor Coll Med, Dept Pediat, Div Hematol Oncol, Houston, TX 77030 USA; [Woods, G. M.] Univ Missouri Kansas City, Dept Pediat, Kansas City, MO USA; [Berman, B.] Case Western Reserve Univ, Dept Pediat, Div Hematol Oncol, Cleveland, OH 44106 USA; [Rhodes, M. M.] Ohio State Univ, Dept Pediat, Div Hematol Oncol, Columbus, OH 43210 USA; [Kalinyak, K. A.; Quinn, C. T.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Hematol, Cincinnati, OH 45229 USA; [Ball, W. S., Jr.] Cincinnati Childrens Hosp Med Ctr, Dept Radiol, Cincinnati, OH 45229 USA; [Panepinto, J. A.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; [Fuh, B. R.] Brody Sch Med, Dept Pediat, Greenville, NC USA; [Redding-Lallinger, R. C.] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; [Dixon, N.] Wake Forest Univ Hlth Sci, Dept Pediat, Winston Salem, NC USA; [Kwiatkowski, J. L.] Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA; [Kwiatkowski, J. L.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Fixler, J. M.] Johns Hopkins Univ, Sch Med, Dept Pediat, Sinai Hosp, Baltimore, MD 21205 USA; [Strouse, J. J.] Johns Hopkins Univ, Sch Med, Dept Pediat & Med, Div Pediat Hematol, Baltimore, MD USA; [Casella, J. F.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Hematol, Baltimore, MD 21205 USA; [Kraut, M. A.] Johns Hopkins Univ, Sch Med, Dept Radiol, Div Neuroradiol, Baltimore, MD 21205 USA; [Lehmann, H.] Johns Hopkins Bloomberg Sch Publ Hlth, Div Hlth Sci Informat, Baltimore, MD USA; [Hirtz, D.] NINDS, NIH, Bethesda, MD 20892 USA; [Thompson, A. A.] Northwestern Univ, Dept Pediat, Ann & Robert H Lurie Childrens Hosp Chicago, Div Hematol Oncol, Chicago, IL 60611 USA; [Heiny, M. E.] Indiana Univ Purdue Univ, Dept Pediat, Indianapolis, IN 46202 USA	Meharry Medical College; Vanderbilt University; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Wayne State University; Children's National Health System; George Washington University; Georgetown University; University of Mississippi; University of Mississippi Medical Center; Guy's & St Thomas' NHS Foundation Trust; Barts Health NHS Trust; Royal London Hospital; University of London; University College London; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Texas System; University of Texas Southwestern Medical Center Dallas; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Baylor College of Medicine; University of Missouri System; University of Missouri Kansas City; Case Western Reserve University; University System of Ohio; Ohio State University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Medical College of Wisconsin; University of North Carolina; University of North Carolina Chapel Hill; Wake Forest University; Wake Forest University School of Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Johns Hopkins University; Sinai Hospital of Baltimore; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Indiana University System; Indiana University-Purdue University Indianapolis	DeBaun, MR (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Meharry Ctr Excellence Sickle Cell Dis, Dept Pediat,Div Hematol Oncol, Nashville, TN 37212 USA.	m.debaun@vanderbilt.edu	Miller, John J/GZG-5663-2022; Strouse, J/A-2690-2008; Quinn, Charles T./J-6842-2012; Kirkham, Fenella/C-2442-2009; Inusa, Baba/R-7447-2017	Strouse, J/0000-0003-0341-1457; Quinn, Charles T./0000-0002-2372-2175; Kirkham, Fenella/0000-0002-2443-7958; Lehmann, Harold/0000-0002-7698-219X; White, Desiree/0000-0001-9439-9574; King, Allison/0000-0002-1951-6176; Inusa, Baba/0000-0003-2643-765X	National Institute of Neurological Disorders and Stroke; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000003, UL1TR001079, UL1TR000448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS042804] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Funded by the National Institute of Neurological Disorders and Stroke and others; Silent Cerebral Infarct Multi-Center Clinical Trial ClinicalTrials.gov number, NCT00072761, and Current Controlled Trials number, ISRCTN52713285.	Adams RJ, 2004, BLOOD, V103, P3689, DOI 10.1182/blood-2003-08-2733; Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; Armstrong FD, 1996, PEDIATRICS, V97, P864; Bernaudin F, 2000, J CHILD NEUROL, V15, P333, DOI 10.1177/088307380001500510; Bernaudin F, 2011, BLOOD, V117, P1130, DOI 10.1182/blood-2010-06-293514; Brousseau DC, 2010, AM J HEMATOL, V85, P77, DOI 10.1002/ajh.21570; Casella JF, 2010, PEDIATR HEMAT ONCOL, V27, P69, DOI 10.3109/08880010903360367; DeBaun MR, 2012, BLOOD, V119, P3684, DOI 10.1182/blood-2011-05-349621; Dowling MM, 2012, BLOOD, V120, P3891, DOI 10.1182/blood-2012-01-406314; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; GLAUSER TA, 1995, J CHILD NEUROL, V10, P88, DOI 10.1177/088307389501000203; Hassell KL, 2010, AM J PREV MED, V38, pS512, DOI 10.1016/j.amepre.2009.12.022; King AA, 2008, PEDIATR BLOOD CANCER, V50, P599, DOI 10.1002/pbc.21338; King AA, 2014, AM J HEMATOL, V89, P162, DOI 10.1002/ajh.23604; Kwiatkowski JL, 2009, BRIT J HAEMATOL, V146, P300, DOI 10.1111/j.1365-2141.2009.07753.x; Lorey FW, 1996, GENET EPIDEMIOL, V13, P501, DOI 10.1002/(SICI)1098-2272(1996)13:5<501::AID-GEPI6>3.0.CO;2-4; Miller ST, 2001, J PEDIATR-US, V139, P385, DOI 10.1067/mpd.2001.117580; Pegelow CH, 2002, BLOOD, V99, P3014, DOI 10.1182/blood.V99.8.3014; PROHOVNIK I, 1989, NEUROLOGY, V39, P344, DOI 10.1212/WNL.39.3.344; Quinn CT, 2013, JAMA NEUROL, V70, P58, DOI 10.1001/jamaneurol.2013.576; Schatz J, 2001, NEUROLOGY, V56, P1109, DOI 10.1212/WNL.56.8.1109; VICHINSKY EP, 1990, NEW ENGL J MED, V322, P1617, DOI 10.1056/NEJM199006073222301; Vichinsky EP, 2001, TRANSFUSION, V41, P1086, DOI 10.1046/j.1537-2995.2001.41091086.x; Wang WC, 2008, PEDIATR BLOOD CANCER, V51, P643, DOI 10.1002/pbc.21612; Wechsler D., 1967, WPPSI MANUAL WECHSLE; Wechsler D., 1999, WECHSLER ABBREVIATED; Zagorsky JL, 2007, INTELLIGENCE, V35, P489, DOI 10.1016/j.intell.2007.02.003	27	323	327	1	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2014	371	8					699	710		10.1056/NEJMoa1401731	http://dx.doi.org/10.1056/NEJMoa1401731			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AN3SV	25140956	Green Accepted, Green Published			2023-01-03	WOS:000340509900005
J	de Rezende, LFM; Lopes, MR; Rey-Lopez, JP; Matsudo, VKR; Luiz, OD				Machado de Rezende, Leandro Fornias; Lopes, Mauricio Rodrigues; Rey-Lopez, Juan Pablo; Rodrigues Matsudo, Victor Keihan; Luiz, Olinda do Carmo			Sedentary Behavior and Health Outcomes: An Overview of Systematic Reviews	PLOS ONE			English	Review							TELEVISION VIEWING TIME; ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE; CHILDHOOD OBESITY; LIFE-STYLE; CHILDREN; ADULTS; INDICATORS; ADOLESCENTS	Objective: 1) To synthesize the current observational evidence for the association between sedentary behavior and health outcomes using information from systematic reviews. 2) To assess the methodological quality of the systematic reviews found. Methodology/Principal Findings: Medline; Excerpta Medica (Embase); PsycINFO; and Web of Science were searched for reviews published up to September 2013. Additional publications were provided by Sedentary Behaviour Research Network members. The methodological quality of the systematic reviews was evaluated using recommended standard criteria from AMSTAR. For each review, improper use of causal language in the description of their main results/conclusion was evaluated. Altogether, 1,044 review titles were identified, 144 were read in their entirety, and 27 were included. Based on the systematic reviews with the best methodological quality, we found in children and adolescents, strong evidence of a relationship between time spent in sedentary behavior and obesity. Moreover, moderate evidence was observed for blood pressure and total cholesterol, self-esteem, social behavior problems, physical fitness and academic achievement. In adults, we found strong evidence of a relationship between sedentary behavior and all-cause mortality, fatal and non-fatal cardiovascular disease, type 2 diabetes and metabolic syndrome. In addition, there is moderate evidence for incidence rates of ovarian, colon and endometrial cancers. Conclusions: This overview based on the best available systematics reviews, shows that sedentary behavior may be an important determinant of health, independently of physical activity. However, the relationship is complex because it depends on the type of sedentary behavior and the age group studied. The relationship between sedentary behavior and many health outcomes remains uncertain; thus, further studies are warranted.	[Machado de Rezende, Leandro Fornias; Lopes, Mauricio Rodrigues; Rey-Lopez, Juan Pablo; Luiz, Olinda do Carmo] Univ Sao Paulo, Fac Med, Dept Prevent Med, Sao Paulo, Brazil; [Machado de Rezende, Leandro Fornias; Rodrigues Matsudo, Victor Keihan] Ctr Estudos Lab Aptidao Fis Sao Caetano do Sul, Sao Caetano do Sul, Brazil	Universidade de Sao Paulo	de Rezende, LFM (corresponding author), Univ Sao Paulo, Fac Med, Dept Prevent Med, Sao Paulo, Brazil.	lerezende@usp.br	Rezende, Leandro F. M./C-1724-2012; Luiz, Olinda do Carmo/C-6075-2012	Rezende, Leandro F. M./0000-0002-7469-1399; Luiz, Olinda do Carmo/0000-0002-2596-3626; Rey Lopez, Juan Pablo/0000-0002-7201-2006	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo Research Foundation) [2012/07314-8]; FAPESP, Sao Paulo Research Foundation [2012/057238]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo Research Foundation)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); FAPESP, Sao Paulo Research Foundation(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This study received financial support from the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo Research Foundation; Grant no. 2012/07314-8). JPRL received financial support from the FAPESP, Sao Paulo Research Foundation: Grant no. 2012/057238. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atkin AJ, 2012, INT J EPIDEMIOL, V41, P1460, DOI 10.1093/ije/dys118; Boyle T, 2012, AM J LIFESTYLE MED, V6, P204, DOI 10.1177/1559827612436932; Brown AW, 2013, AM J CLIN NUTR, V98, P1298, DOI 10.3945/ajcn.113.064410; Cerimele JM, 2013, GEN HOSP PSYCHIAT, V35, P16, DOI 10.1016/j.genhosppsych.2012.08.001; Chen SM, 2009, INT ARCH OCC ENV HEA, V82, P797, DOI 10.1007/s00420-009-0410-0; Chinapaw MJM, 2011, OBES REV, V12, pE621, DOI 10.1111/j.1467-789X.2011.00865.x; Costigan SA, 2013, J ADOLESCENT HEALTH, V52, P382, DOI 10.1016/j.jadohealth.2012.07.018; Davis MG, 2011, MED SCI SPORT EXER, V43, P647, DOI 10.1249/MSS.0b013e3181f36196; Dunstan DW, 2010, CIRCULATION, V121, P384, DOI 10.1161/CIRCULATIONAHA.109.894824; Edwardson CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034916; Egger M, 1998, BRIT MED J, V316, P140; Ford ES, 2012, INT J EPIDEMIOL, V41, P1338, DOI 10.1093/ije/dys078; Gabriel KKP, 2012, J PHYS ACT HEALTH, V9, pS11, DOI 10.1123/jpah.9.s1.s11; Grontved A, 2011, JAMA-J AM MED ASSOC, V305, P2448, DOI 10.1001/jama.2011.812; Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI [10.1249/mss.0b013e3180616b27, 10.1161/CIRCULATIONAHA.107.185649]; Hoare E, 2014, OBES REV, V15, P40, DOI 10.1111/obr.12069; Hu J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028696; Hutcheon JA, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2289; IARC Working Group on the Evaluation of Cancer-Preventive Agents, 2002, IARC HDB CANC PREV, V6; IJmker S, 2007, OCCUP ENVIRON MED, V64, P211, DOI 10.1136/oem.2006.026468; Katzmarzyk PT, 2010, DIABETES, V59, P2717, DOI 10.2337/db10-0822; Katzmarzyk PT, 2009, MED SCI SPORT EXER, V41, P998, DOI 10.1249/MSS.0b013e3181930355; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; LeBlanc AG, 2012, APPL PHYSIOL NUTR ME, V37, P753, DOI [10.1139/h2012-063, 10.1139/H2012-063]; LEE IM, 1995, JAMA-J AM MED ASSOC, V273, P1179, DOI 10.1001/jama.273.15.1179; Leung MM, 2012, J OBES, V2012, DOI 10.1155/2012/685430; Lynch BM, 2010, CANCER EPIDEM BIOMAR, V19, P2691, DOI 10.1158/1055-9965.EPI-10-0815; MacMillan F, 2014, PEDIATR DIABETES, V15, P175, DOI 10.1111/pedi.12060; Marshall SJ, 2004, INT J OBESITY, V28, P1238, DOI 10.1038/sj.ijo.0802706; Matthews CE, 2008, AM J EPIDEMIOL, V167, P875, DOI 10.1093/aje/kwm390; Mitrofan O, 2009, CHILD CARE HLTH DEV, V35, P5, DOI 10.1111/j.1365-2214.2008.00912.x; MORRIS JN, 1953, LANCET, V265, P1053; Owen N, 2011, AM J PREV MED, V41, P189, DOI 10.1016/j.amepre.2011.05.013; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; Pate RR, 2008, EXERC SPORT SCI REV, V36, P173, DOI 10.1097/JES.0b013e3181877d1a; Pearson N, 2011, AM J PREV MED, V41, P178, DOI 10.1016/j.amepre.2011.05.002; Prentice-Dunn H, 2012, PSYCHOL HEALTH MED, V17, P255, DOI 10.1080/13548506.2011.608806; Proper KI, 2011, AM J PREV MED, V40, P174, DOI 10.1016/j.amepre.2010.10.015; Rey-Lopez JP, 2008, NUTR METAB CARDIOVAS, V18, P242, DOI 10.1016/j.numecd.2007.07.008; Rossi CE, 2010, REV NUTR, V23, P607, DOI 10.1590/S1415-52732010000400011; Salmon J, 2011, AM J PREV MED, V41, P197, DOI 10.1016/j.amepre.2011.05.001; Schulze MB, 2004, JAMA-J AM MED ASSOC, V292, P927, DOI 10.1001/jama.292.8.927; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; Shea BJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001350; Sheehan NA, 2008, PLOS MED, V5, P1205, DOI 10.1371/journal.pmed.0050177; Stubbe JH, 2007, PREV MED, V44, P148, DOI 10.1016/j.ypmed.2006.09.002; Sugiyama T, 2008, ANN BEHAV MED, V35, P245, DOI 10.1007/s12160-008-9017-z; Teychenne M, 2013, AM J PREV MED, V45, P217, DOI 10.1016/j.amepre.2013.04.004; Teychenne M, 2011, INT J BEHAV MED, V17, P246, DOI 10.1007/s12529-010-9075-z; Thorp AA, 2011, AM J PREV MED, V41, P207, DOI 10.1016/j.amepre.2011.05.004; Tremblay MS, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-98; van Holten TC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062080; van Uffelen JGZ, 2010, AM J PREV MED, V39, P379, DOI 10.1016/j.amepre.2010.05.024; Velde SJT, 2012, OBES REV, V13, P56, DOI 10.1111/j.1467-789X.2011.00960.x; Waersted M, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-79; Wilmot EG, 2012, DIABETOLOGIA, V55, P2895, DOI 10.1007/s00125-012-2677-z	56	512	530	19	165	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2014	9	8							e105620	10.1371/journal.pone.0105620	http://dx.doi.org/10.1371/journal.pone.0105620			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AO1WL	25144686	Green Submitted, gold, Green Published			2023-01-03	WOS:000341106100098
J	Rigotti, NA; Regan, S; Levy, DE; Japuntich, S; Chang, YC; Park, ER; Viana, JC; Kelley, JHI; Reyen, M; Singer, DE				Rigotti, Nancy A.; Regan, Susan; Levy, Douglas E.; Japuntich, Sandra; Chang, Yuchiao; Park, Elyse R.; Viana, Joseph C.; Kelley, Jennifer H. I.; Reyen, Michele; Singer, Daniel E.			Sustained Care Intervention and Postdischarge Smoking Cessation Among Hospitalized Adults A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NICOTINE DEPENDENCE; FOLLOW-UP; SMOKERS; OUTCOMES; SYSTEM; HEALTH	IMPORTANCE Health care systems need effective models to manage chronic diseases like tobacco dependence across transitions in care. Hospitalizations provide opportunities for smokers to quit, but research suggests that hospital-delivered interventions are effective only if treatment continues after discharge. OBJECTIVE To determine whether an intervention to sustain tobacco treatment after hospital discharge increases smoking cessation rates compared with standard care. DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial compared sustained care (a postdischarge tobacco cessation intervention) with standard care among 397 hospitalized daily smokers (mean age, 53 years; 48% were males; 81% were non-Hispanic whites) who wanted to quit smoking after discharge and received a tobacco dependence intervention in the hospital; 92% of eligible patients and 44% of screened patients enrolled. The study was conducted from August 2010 through November 2012 at Massachusetts General Hospital. INTERVENTIONS Sustained care participants received automated interactive voice response telephone calls and their choice of free smoking cessation medication (any type approved by the US Food and Drug Administration) for up to 90 days. The automated telephone calls promoted cessation, provided medication management, and triaged smokers for additional counseling. Standard care participants received recommendations for postdischarge pharmacotherapy and counseling. MAIN OUTCOMES AND MEASURES The primary outcome was biochemically confirmed past 7-day tobacco abstinence at 6-month follow-up after discharge from the hospital; secondary outcomes included self-reported tobacco abstinence. RESULTS Smokers randomly assigned to sustained care (n = 198) used more counseling and more pharmacotherapy at each follow-up assessment than those assigned to standard care (n = 199). Biochemically validated 7-day tobacco abstinence at 6 months was higher with sustained care (26%) than with standard care (15%) (relative risk [RR], 1.71 [95% CI, 1.14-2.56], P = .009; number needed to treat, 9.4 [95% CI, 5.4-35.5]). Using multiple imputation for missing outcomes, the RR for 7-day tobacco abstinence was 1.55 (95% CI, 1.03-2.21; P = .04). Sustained care also resulted in higher self-reported continuous abstinence rates for 6 months after discharge (27% vs 16% for standard care; RR, 1.70 [95% CI, 1.15-2.51]; P = .007). CONCLUSIONS AND RELEVANCE Among hospitalized adult smokers who wanted to quit smoking, a postdischarge intervention providing automated telephone calls and free medication resulted in higher rates of smoking cessation at 6 months compared with a standard recommendation to use counseling and medication after discharge. These findings, if replicated, suggest an approach to help achieve sustained smoking cessation after a hospital stay.	[Rigotti, Nancy A.; Regan, Susan; Levy, Douglas E.; Japuntich, Sandra; Park, Elyse R.; Viana, Joseph C.; Kelley, Jennifer H. I.; Reyen, Michele] Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA; [Rigotti, Nancy A.; Regan, Susan; Chang, Yuchiao; Reyen, Michele; Singer, Daniel E.] Massachusetts Gen Hosp, Div Gen Internal Med, Med Serv, Boston, MA 02114 USA; [Rigotti, Nancy A.; Levy, Douglas E.; Park, Elyse R.; Kelley, Jennifer H. I.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA; [Rigotti, Nancy A.; Levy, Douglas E.; Park, Elyse R.; Kelley, Jennifer H. I.] Partners HealthCare, Boston, MA USA; [Rigotti, Nancy A.; Regan, Susan; Levy, Douglas E.; Chang, Yuchiao; Singer, Daniel E.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Japuntich, Sandra] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA; [Japuntich, Sandra] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Park, Elyse R.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Viana, Joseph C.] Univ Calif Los Angeles, Dept Hlth Policy & Management, Los Angeles, CA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Partners Healthcare System; Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Boston University; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles	Rigotti, NA (corresponding author), Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, 50 Staniford St, Boston, MA 02114 USA.	nrigotti@partners.org	Levy, Douglas/W-1516-2019	Levy, Douglas/0000-0001-9446-7899	National Institutes of Health/National Heart, Lung, and Blood Institute [RC1 HL099668, K24 HL004440]; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institute on Drug Abuse; National Institutes of Health Office of Behavioral and Social Science Research; US Department of Veterans Affairs Clinical Sciences Research and Development Service [11K2CX000918-01A1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL004440, RC1HL099668] Funding Source: NIH RePORTER	National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Institutes of Health Office of Behavioral and Social Science Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Veterans Affairs Clinical Sciences Research and Development Service(US Department of Veterans Affairs); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by grants RC1 HL099668 and K24 HL004440 from the National Institutes of Health/National Heart, Lung, and Blood Institute. This study is part of the Consortium of Hospitals Advancing Research on Tobacco initiative, jointly sponsored by the National Heart, Lung, and Blood Institute, the National Cancer Institute, the National Institute on Drug Abuse, and the National Institutes of Health Office of Behavioral and Social Science Research. TelAsk Technologies (Ottawa, Ontario, Canada) developed and provided the interactive voice response services and was compensated for this work by the National Heart, Lung, and Blood Institute grants that funded the project. This work was supported in part by career development award 11K2CX000918-01A1 (Dr Japuntich) from the US Department of Veterans Affairs Clinical Sciences Research and Development Service.	Bodenheimer T, 2008, NEW ENGL J MED, V358, P1064, DOI 10.1056/NEJMhpr0706165; Brendryen H, 2008, ADDICTION, V103, P478, DOI 10.1111/j.1360-0443.2007.02119.x; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Carlini BH, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-507; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Fiore M. C., 2008, TREATING TOBACCO USE; Fiore MC, 2012, NEW ENGL J MED, V366, P1172, DOI 10.1056/NEJMp1115176; Forster AJ, 2009, J GEN INTERN MED, V24, P520, DOI 10.1007/s11606-009-0910-3; Gourevitch MN, 2014, ACAD MED, V89, P544, DOI 10.1097/ACM.0000000000000171; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Hedeker D, 2007, ADDICTION, V102, P1564, DOI 10.1111/j.1360-0443.2007.01946.x; Hughes JR, 2003, NICOTINE TOB RES, V5, P13, DOI 10.1080/1462220031000070552; Japuntich SJ, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-124; Kindig D, 2003, AM J PUBLIC HEALTH, V93, P380, DOI 10.2105/AJPH.93.3.380; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; McDaniel AM, 2005, NICOTINE TOB RES, V7, pS57, DOI 10.1080/14622200500078139; McDonough JE, 2014, JAMA-J AM MED ASSOC, V311, P569, DOI 10.1001/jama.2013.286067; MELCHIOR LA, 1993, EDUC PSYCHOL MEAS, V53, P1117, DOI 10.1177/0013164493053004024; National Center for Chronic Disease P, 2014, HLTH CONSMOK 50 YE; Oake N, 2009, AM J MANAG CARE, V15, P383; Papadakis S, 2013, PREV MED, V56, P390, DOI 10.1016/j.ypmed.2013.02.018; Piette JD, 2000, MED CARE, V38, P218, DOI 10.1097/00005650-200002000-00011; Regan S, 2012, NICOTINE TOB RES, V14, P885, DOI 10.1093/ntr/ntr244; Regan S, 2011, NICOTINE TOB RES, V13, P255, DOI 10.1093/ntr/ntq248; Reid RD, 2007, PATIENT EDUC COUNS, V66, P319, DOI 10.1016/j.pec.2007.01.005; Reid RD, 2010, NICOTINE TOB RES, V12, P11, DOI 10.1093/ntr/ntp165; Rigotti NA, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001837.pub3; Rutten LJF, 2011, J CANCER EDUC, V26, P79, DOI 10.1007/s13187-010-0163-1; SRNT Subcommittee on Biochemical Verification, 2002, Nicotine Tob Res, V4, P149, DOI 10.1080/14622200210123581; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3; Stead LF, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008286.pub2; US Department of Labor, FAQS AFF CAR ACT IMP	32	93	95	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2014	312	7					719	728		10.1001/jama.2014.9237	http://dx.doi.org/10.1001/jama.2014.9237			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AN2TR	25138333	Green Accepted, Bronze			2023-01-03	WOS:000340438700020
J	den Uil, CA; Lagrand, WK; van der Ent, MD; Nieman, K; Struijs, A; Jewbali, LSD; Constantinescu, AA; Spronk, PE; Simoons, ML				den Uil, Corstiaan A.; Lagrand, Wim K.; van der Ent, Martin; Nieman, Koen; Struijs, Ard; Jewbali, Lucia S. D.; Constantinescu, Alina A.; Spronk, Peter E.; Simoons, Maarten L.			Conventional Hemodynamic Resuscitation May Fail to Optimize Tissue Perfusion: An Observational Study on the Effects of Dobutamine, Enoximone, and Norepinephrine in Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock	PLOS ONE			English	Article							SEVERE HEART-FAILURE; SEPTIC SHOCK; BLOOD-FLOW; MICROCIRCULATION; NITROGLYCERIN; ASSOCIATION; INHIBITORS; SUPPORT	Aim: To investigate the effects of inotropic agents on parameters of tissue perfusion in patients with cardiogenic shock. Methods and Results: Thirty patients with cardiogenic shock were included. Patients received dobutamine, enoximone, or norepinephrine. We performed hemodynamic measurements at baseline and after titration of the inotropic agent until cardiac index (CI) >= 2.5 L.min(-1).m(-2) or mixed-venous oxygen saturation (SvO(2)) >= 70% (dobutamine or enoximone), and mean arterial pressure (MAP) >= 70 mmHg (norepinephrine). As parameters of tissue perfusion, we measured central-peripheral temperature gradient (delta-T) and sublingual perfused capillary density (PCD). All patients reached predefined therapeutic targets. The inotropes did not significantly change delta-T. Dobutamine did not change PCD. Enoximone increased PCD (9.1 [8.9-10.2] vs. 11.4 [8.4-13.9] mm.mm(-2); p<0.05), and norepinephrine tended to decrease PCD (9.8 [8.5-11.9] vs. 8.8 [8.2-9.6] mm.mm(-2), p = 0.08). Fifteen patients (50%) died within 30 days after admission. Patients who had low final PCD (<= 10.3 mm.mm(-2); 64%) were more likely to die than patients who had preserved PCD (>10.3 mm.mm(-2); mortality 72% vs. 17%, p = 0.003). Conclusion: This study demonstrates the effects of commonly used inotropic agents on parameters of tissue perfusion in patients with cardiogenic shock. Despite hemodynamic optimization, tissue perfusion was not sufficiently restored in most patients. In these patients, mortality was high. Interventions directed at improving microcirculation may eventually help bridging the gap between improved hemodynamics and dismal patient outcome in cardiogenic shock.	[den Uil, Corstiaan A.; Nieman, Koen; Struijs, Ard; Jewbali, Lucia S. D.; Constantinescu, Alina A.; Simoons, Maarten L.] Erasmus MC, Thoraxctr, Dept Cardiol & Intens Care Med, Rotterdam, Netherlands; [Lagrand, Wim K.] Univ Amsterdam, Acad Med Ctr, Dept Intens Care Med, NL-1105 AZ Amsterdam, Netherlands; [van der Ent, Martin] Maasstad Hosp, Dept Cardiol, Rotterdam, Netherlands; [Spronk, Peter E.] Gelre Hosp, Dept Intens Care Med, Apeldoorn, Netherlands	Erasmus University Rotterdam; Erasmus MC; University of Amsterdam; Academic Medical Center Amsterdam; Maasstad Hospital; Gelre Hospitals	den Uil, CA (corresponding author), Erasmus MC, Thoraxctr, Dept Cardiol & Intens Care Med, Rotterdam, Netherlands.	c.denuil@erasmusmc.nl	Struijs, Ard/A-5597-2016	Struijs, Ard/0000-0002-5531-4969				Bezemer R, 2011, MED BIOL ENG COMPUT, V49, P1269, DOI 10.1007/s11517-011-0824-1; BOLDT J, 1993, BRIT J CLIN PHARMACO, V36, P309, DOI 10.1111/j.1365-2125.1993.tb00369.x; CALDICOTT LD, 1993, EUR HEART J, V14, P696, DOI 10.1093/eurheartj/14.5.696; Cuschieri J, 2005, INTENS CARE MED, V31, P818, DOI 10.1007/s00134-005-2602-8; De Backer D, 2006, CRIT CARE MED, V34, P403, DOI 10.1097/01.CCM.0000198107.61493.5A; De Backer D, 2004, AM HEART J, V147, P91, DOI 10.1016/j.ahj.2003.07.006; De Backer D, 2007, CRIT CARE, V11, DOI 10.1186/cc6118; den Uil CA, 2008, J THORAC CARDIOV SUR, V136, P129, DOI 10.1016/j.jtcvs.2007.10.046; den Uil CA, 2010, EUR HEART J, V31, P3032, DOI 10.1093/eurheartj/ehq324; den Uil CA, 2009, INTENS CARE MED, V35, P1893, DOI 10.1007/s00134-009-1591-4; den Uil CA, 2009, CARDIOLOGY, V114, P42, DOI 10.1159/000212060; den Uil CA, 2009, J HEART LUNG TRANSPL, V28, P906, DOI 10.1016/j.healun.2009.05.010; den Uil CA, 2009, EUR J HEART FAIL, V11, P386, DOI 10.1093/eurjhf/hfp021; den Uil CA, 2008, PROG CARDIOVASC DIS, V51, P161, DOI 10.1016/j.pcad.2008.07.002; Dobbe JGG, 2008, MED BIOL ENG COMPUT, V46, P659, DOI 10.1007/s11517-008-0349-4; Goedhart PT, 2007, OPT EXPRESS, V15, P15101, DOI 10.1364/OE.15.015101; Hollenberg SM, 2013, CHEST, V143, P1480, DOI 10.1378/chest.12-1901; Hubble SMA, 2009, MICROCIRCULATION, V16, P183, DOI 10.1080/10739680802461935; Jhanji S, 2009, CRIT CARE MED, V37, P1961, DOI 10.1097/CCM.0b013e3181a00a1c; Jolly S, 2005, AM J CARDIOL, V96, P1617, DOI 10.1016/j.amjcard.2005.07.076; JOLY HR, 1969, CIRCULATION, V39, P131, DOI 10.1161/01.CIR.39.1.131; Kaluski E, 2009, CARDIOLOGY, V114, P39, DOI 10.1159/000212059; Kern H, 2001, CRIT CARE MED, V29, P1519, DOI 10.1097/00003246-200108000-00004; Lauten A, 2011, EUR J HEART FAIL, V13, P711, DOI 10.1093/eurjhf/hfr043; Lima A, 2009, CRIT CARE MED, V37, P934, DOI 10.1097/CCM.0b013e31819869db; Maier S, 2009, BRIT J ANAESTH, V102, P485, DOI 10.1093/bja/aep018; McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104; MUELLER H, 1970, J CLIN INVEST, V49, P1885, DOI 10.1172/JCI106408; Petersen John W, 2008, Crit Care Med, V36, pS106, DOI 10.1097/01.CCM.0000296273.72952.39; Pirracchio R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071659; Salgado DR, 2013, CLIN HEMORHEOL MICRO, V54, P87, DOI 10.3233/CH-2012-1569; SAXENA PR, 1985, PFLUG ARCH EUR J PHY, V403, P128, DOI 10.1007/BF00584089; Shah MR, 2001, J CARD FAIL, V7, P105, DOI 10.1054/jcaf.2001.24131; Stevenson LW, 2005, JAMA-J AM MED ASSOC, V294, P1625; Struijker-Boudier HAJ, 2007, EUR HEART J, V28, P2834, DOI 10.1093/eurheartj/ehm448; Trzeciak S, 2008, INTENS CARE MED, V34, P2210, DOI 10.1007/s00134-008-1193-6; Woolsey CA, 2006, CURR OPIN CRIT CARE, V12, P155, DOI 10.1097/01.ccx.0000216584.72427.e4	37	28	28	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2014	9	8							e103978	10.1371/journal.pone.0103978	http://dx.doi.org/10.1371/journal.pone.0103978			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM4JL	25084171	Green Published, Green Submitted, gold			2023-01-03	WOS:000339819800114
J	Chang, MC; Chen, YJ; Chang, HH; Chan, CP; Yeh, CY; Wang, YL; Cheng, RH; Hahn, LJ; Jeng, JH				Chang, Mei-Chi; Chen, Yi-Jane; Chang, Hsiao-Hua; Chan, Chiu-Po; Yeh, Chien-Yang; Wang, Yin-Lin; Cheng, Ru-Hsiu; Hahn, Liang-Jiunn; Jeng, Jiiang-Huei			Areca Nut Components Affect COX-2, Cyclin B1/cdc25C and Keratin Expression, PGE2 Production in Keratinocyte Is Related to Reactive Oxygen Species, CYP1A1, Src, EGFR and Ras Signaling	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMA; HUMAN ORAL KERATINOCYTE; GROWTH-FACTOR RECEPTOR; EPITHELIAL-CELLS; CHEMICAL CARCINOGENESIS; PLATELET-AGGREGATION; KAPPA-B; CANCER; CYTOTOXICITY; ACTIVATION	Aims: Chewing of betel quid (BQ) increases the risk of oral cancer and oral submucous fibrosis (OSF), possibly by BQ-induced toxicity and induction of inflammatory response in oral mucosa. Methods: Primary gingival keratinocytes (GK cells) were exposed to areca nut (AN) components with/without inhibitors. Cytotoxicity was measured by 3-(4,5-dimethyl- thiazol- 2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. mRNA and protein expression was evaluated by reverse transcriptase-polymerase chain reaction (RT-PCR) and western blotting. PGE(2)/PGF(2 alpha) production was measured by enzyme-linked immunosorbent assays. Results: Areca nut extract (ANE) stimulated PGE(2)/PGF(2 alpha) production, and upregulated the expression of cyclooxygenase-2 (COX-2), cytochrome P450 1A1 (CYP1A1) and hemeoxygenase-1 (HO-1), but inhibited expression of keratin 5/14, cyclinB1 and cdc25C in GK cells. ANE also activated epidermal growth factor receptor (EGFR), Src and Ras signaling pathways. ANE-induced COX-2, keratin 5, keratin 14 and cdc25C expression as well as PGE(2) production were differentially regulated by alpha-naphthoflavone (a CYP 1A1/1A2 inhibitor), PD153035 (EGFR inhibitor), pp2 (Src inhibitor), and manumycin A (a Ras inhibitor). ANE-induced PGE(2) production was suppressed by piper betle leaf (PBL) extract and hydroxychavicol (two major BQ components), dicoumarol (a NAD(P)H:Quinone Oxidoreductase - NQO1 inhibitor) and curcumin. ANE-induced cytotoxicity was inhibited by catalase and enhanced by dicoumarol, suggesting that AN components may contribute to the pathogenesis of OSF and oral cancer via induction of aberrant differentiation, cytotoxicity, COX-2 expression, and PGE(2)/PGF(2 alpha)production. Conclusions: CYP4501A1, reactive oxygen species (ROS), EGFR, Src and Ras signaling pathways could all play a role in ANE-induced pathogenesis of oral cancer. Addition of PBL into BQ and curcumin consumption could inhibit the ANE-induced inflammatory response.	[Chang, Mei-Chi; Cheng, Ru-Hsiu] Chang Gung Univ Sci & Technol, Team Biomed Sci, Taoyuan, Taiwan; [Chen, Yi-Jane; Chang, Hsiao-Hua; Yeh, Chien-Yang; Wang, Yin-Lin; Hahn, Liang-Jiunn; Jeng, Jiiang-Huei] Natl Taiwan Univ Hosp, Sch Dent, Lab Pharmacol Toxicol & Chem Carcinogenesis, Taipei, Taiwan; [Chen, Yi-Jane; Chang, Hsiao-Hua; Yeh, Chien-Yang; Wang, Yin-Lin; Hahn, Liang-Jiunn; Jeng, Jiiang-Huei] Natl Taiwan Univ Hosp, Dept Dent, Taipei, Taiwan; [Chen, Yi-Jane; Chang, Hsiao-Hua; Yeh, Chien-Yang; Wang, Yin-Lin; Hahn, Liang-Jiunn; Jeng, Jiiang-Huei] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan; [Chan, Chiu-Po] Chang Gung Mem Hosp, Dept Dent, Taipei 10591, Taiwan	Chang Gung University of Science & Technology; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; Chang Gung Memorial Hospital	Jeng, JH (corresponding author), Natl Taiwan Univ Hosp, Sch Dent, Lab Pharmacol Toxicol & Chem Carcinogenesis, Taipei, Taiwan.	jhjeng@ntu.edu.tw		CHEN, YI-JANE/0000-0002-9178-8379; WANG, YIN-LIN/0000-0001-6790-1311; CHANG, HSIAO-HUA/0000-0002-8417-8847; Jeng, Jiiang-Huei/0000-0002-2068-5380	National Science Council, Taiwan, R.O.C. [NSC102-2314-B-255-003-MY2, NSC102-2628-B-255-001-MY3, NSC101-2320-B-255-002, NSC-100-2314-B-002-094, NSC-101-2320-B-255-002]; Chang Gung Memorial Hospital [NMRPF3C0061, NMRPF3C0091, NMRPF3B0071]	National Science Council, Taiwan, R.O.C.(Ministry of Science and Technology, Taiwan); Chang Gung Memorial Hospital(Chang Gung Memorial Hospital)	This study is supported by grants from National Science Council, Taiwan, R.O.C. (NSC102-2314-B-255-003-MY2, NSC102-2628-B-255-001-MY3, NSC101-2320-B-255-002, NSC-100-2314-B-002-094 and NSC-101-2320-B-255-002) and Chang Gung Memorial Hospital (NMRPF3C0061, NMRPF3C0091, NMRPF3B0071). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alam H, 2011, MOL BIOL CELL, V22, P4068, DOI 10.1091/mbc.E10-08-0703; Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; BROWN LJ, 1994, J INVEST DERMATOL, V102, P886, DOI 10.1111/1523-1747.ep12382905; Buranrat B, 2010, WORLD J GASTROENTERO, V16, P2362, DOI 10.3748/wjg.v16.i19.2362; Chan CP, 2008, J PERIODONTOL, V79, P1248, DOI [10.1902/jop.2008.070523, 10.1902/jop.2008.070523 ]; Chang EE, 2007, J HAZARD MATER, V146, P356, DOI 10.1016/j.jhazmat.2006.12.035; Chang MC, 2007, BRIT J PHARMACOL, V152, P73, DOI 10.1038/sj.bjp.0707367; Chang MC, 2004, J BIOL CHEM, V279, P50676, DOI 10.1074/jbc.M404465200; Chang MC, 2001, CARCINOGENESIS, V22, P1527, DOI 10.1093/carcin/22.9.1527; Chang MC, 2013, HEAD NECK IN PRESS; Chang MC, 2010, BIOMATERIALS, V31, P8164, DOI 10.1016/j.biomaterials.2010.07.049; Chen JYF, 2008, NEOPLASIA, V10, P1393, DOI 10.1593/neo.08854; Chiang WF, 2008, ORAL ONCOL, V44, P270, DOI 10.1016/j.oraloncology.2007.02.008; El-Abaseri TB, 2006, CARCINOGENESIS, V27, P225, DOI 10.1093/carcin/bgi220; Endres M, 2005, EUR ARCH OTO-RHINO-L, V262, P390, DOI 10.1007/s00405-004-0842-9; Villamil SHF, 2012, CHEM-BIOL INTERACT, V200, P84, DOI 10.1016/j.cbi.2012.09.011; GIMENEZCONTI IB, 1990, CANCER RES, V50, P4441; Hakkola J, 1996, BIOCHEM PHARMACOL, V51, P403, DOI 10.1016/0006-2952(95)02184-1; Hernando-Rodriguez M, 2012, J ORAL PATHOL MED, V41, P1, DOI 10.1111/j.1600-0714.2011.01067.x; Huang PL, 2010, FOOD CHEM TOXICOL, V48, P306, DOI 10.1016/j.fct.2009.10.014; Huang SF, 2009, HEAD NECK-J SCI SPEC, V31, P1068, DOI 10.1002/hed.21067; Husvik C, 2009, EUR J ORAL SCI, V117, P528, DOI 10.1111/j.1600-0722.2009.00669.x; Jeng JH, 2002, FREE RADICAL BIO MED, V32, P860, DOI 10.1016/S0891-5849(02)00749-9; Jeng JH, 2001, ORAL ONCOL, V37, P477, DOI 10.1016/S1368-8375(01)00003-3; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; KUO MYP, 1995, J ORAL PATHOL MED, V24, P255, DOI 10.1111/j.1600-0714.1995.tb01178.x; KUO MYP, 1994, J ORAL PATHOL MED, V23, P70, DOI 10.1111/j.1600-0714.1994.tb00259.x; Leonard SS, 2004, FREE RADICAL BIO MED, V37, P1921, DOI 10.1016/j.freeradbiomed.2004.09.010; Li N, 2011, MED HYPOTHESES, V77, P834, DOI 10.1016/j.mehy.2011.07.049; Lin SC, 2005, INT J CANCER, V116, P526, DOI 10.1002/ijc.21104; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; Lu SY, 2006, CARCINOGENESIS, V27, P1273, DOI 10.1093/carcin/bgi357; Marks F, 2000, EUR J CANCER, V36, P314, DOI 10.1016/S0959-8049(99)00318-4; Meng B, 2013, CURR PHARM DESIGN, V19, P2101; Miyazaki M, 2005, MUTAT RES-GEN TOX EN, V581, P165, DOI 10.1016/j.mrgentox.2004.12.002; Murugan AK, 2012, ORAL ONCOL, V48, P383, DOI 10.1016/j.oraloncology.2011.12.006; NAIR UJ, 1990, CARCINOGENESIS, V11, P2145, DOI 10.1093/carcin/11.12.2145; Nemekaite-Ceniene A, 2005, ARCH BIOCHEM BIOPHYS, V441, P182, DOI 10.1016/j.abb.2005.07.002; Pae Hyun-Ock, 2009, Immune Netw, V9, P12, DOI 10.4110/in.2009.9.1.12; Pandey M, 2008, INT J ORAL MAX SURG, V37, P379, DOI 10.1016/j.ijom.2008.01.004; PARKE DV, 1994, ENVIRON HEALTH PERSP, V102, P852, DOI 10.2307/3432116; Sharan RN, 2010, ENVIRONMENTAL FACTORS, GENES, AND THE DEVELOPMENT OF HUMAN CANCERS, P401, DOI 10.1007/978-1-4419-6752-7_15; SINGH A, 1995, CANCER LETT, V92, P175, DOI 10.1016/0304-3835(95)03776-S; Sparfel L, 2002, TOXICOL LETT, V129, P245, DOI 10.1016/S0378-4274(02)00015-2; SUNDQVIST K, 1992, INT J CANCER, V52, P305, DOI 10.1002/ijc.2910520225; Topcu Z, 2002, CARCINOGENESIS, V23, P595, DOI 10.1093/carcin/23.4.595; Tseng YH, 2007, ORAL ONCOL, V43, P670, DOI 10.1016/j.oraloncology.2006.08.003; Tu CL, 2008, J BIOL CHEM, V283, P3519, DOI 10.1074/jbc.M708318200; Vendramini-Costa DB, 2012, CURR PHARM DESIGN, V18, P3831; Warnakulasuriya S, 2002, BMJ-BRIT MED J, V324, P799, DOI 10.1136/bmj.324.7341.799	50	23	29	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2014	9	7							e101959	10.1371/journal.pone.0101959	http://dx.doi.org/10.1371/journal.pone.0101959			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM0QO	25051199	Green Submitted, Green Published, gold			2023-01-03	WOS:000339551100018
J	Hodgson, I; Plummer, ML; Konopka, SN; Colvin, CJ; Jonas, E; Albertini, J; Amzel, A; Fogg, KP				Hodgson, Ian; Plummer, Mary L.; Konopka, Sarah N.; Colvin, Christopher J.; Jonas, Edna; Albertini, Jennifer; Amzel, Anouk; Fogg, Karen P.			A Systematic Review of Individual and Contextual Factors Affecting ART Initiation, Adherence, and Retention for HIV-Infected Pregnant and Postpartum Women	PLOS ONE			English	Article							TO-CHILD TRANSMISSION; ACTIVE ANTIRETROVIRAL THERAPY; SUB-SAHARAN AFRICA; COMMUNITY-HEALTH WORKERS; DOSE NEVIRAPINE REGIMEN; IMPROVE ADHERENCE; POSITIVE WOMEN; FOLLOW-UP; CAPE-TOWN; PREVENTION	Background: Despite progress reducing maternal mortality, HIV-related maternal deaths remain high, accounting, for example, for up to 24 percent of all pregnancy-related deaths in sub-Saharan Africa. Antiretroviral therapy (ART) is effective in improving outcomes among HIV-infected pregnant and postpartum women, yet rates of initiation, adherence, and retention remain low. This systematic literature review synthesized evidence about individual and contextual factors affecting ART use among HIV-infected pregnant and postpartum women. Methods: Searches were conducted for studies addressing the population (HIV-infected pregnant and postpartum women), intervention (ART), and outcomes of interest (initiation, adherence, and retention). Quantitative and qualitative studies published in English since January 2008 were included. Individual and contextual enablers and barriers to ART use were extracted and organized thematically within a framework of individual, interpersonal, community, and structural categories. Results: Thirty-four studies were included in the review. Individual-level factors included both those within and outside a woman's awareness and control (e.g., commitment to child's health or age). Individual-level barriers included poor understanding of HIV, ART, and prevention of mother-to-child transmission, and difficulty managing practical demands of ART. At an interpersonal level, disclosure to a spouse and spousal involvement in treatment were associated with improved initiation, adherence, and retention. Fear of negative consequences was a barrier to disclosure. At a community level, stigma was a major barrier. Key structural barriers and enablers were related to health system use and engagement, including access to services and health worker attitudes. Conclusions: To be successful, programs seeking to expand access to and continued use of ART by integrating maternal health and HIV services must identify and address the relevant barriers and enablers in their own context that are described in this review. Further research on this population, including those who drop out of or never access health services, is needed to inform effective implementation.	[Konopka, Sarah N.; Jonas, Edna] Ctr Hlth Serv Management Sci Hlth, Arlington, VA 22203 USA; [Colvin, Christopher J.] Univ Cape Town, Sch Publ Hlth & Family Med, CIDER, Div Social & Behav Sci, ZA-7925 Cape Town, South Africa; [Albertini, Jennifer] USAID, Africa Bur, Washington, DC USA; [Amzel, Anouk] USAID, Bur Global Hlth, Off HIV AIDS, Washington, DC USA; [Fogg, Karen P.] USAID, BGH, Off Hlth Infect Dis & Nutr, Washington, DC USA	University of Cape Town; United States Agency for International Development (USAID); United States Agency for International Development (USAID); United States Agency for International Development (USAID)	Konopka, SN (corresponding author), Ctr Hlth Serv Management Sci Hlth, Arlington, VA 22203 USA.	skonopka@msh.org	Colvin, Christopher/AAQ-1607-2021; Colvin, Christopher/AAB-8276-2019; Harding, Richard/G-9729-2012	Colvin, Christopher/0000-0002-8930-7863; Plummer, Mary Louisa/0000-0002-6816-8235	Africa Bureau of USAID	Africa Bureau of USAID(United States Agency for International Development (USAID))	This review was supported by funding from the Africa Bureau of USAID. Three coauthors on the paper are from USAID. They played a role in designing the review questions and methods, and contributed to revisions of the manuscript. They were not involved in data collection and analysis or drafting of the initial manuscript.	Abdool Karim Q, 2010, LANCET, V375, P1948, DOI 10.1016/S0140-6736(10)60747-7; Awiti-Ujiji O, 2011, AJAR-AFR J AIDS RES, V10, P157, DOI 10.2989/16085906.2011.593378; Ayuo P, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.17994; Aziz SA, 2011, SEX TRANSM INFECT, V87, pA356, DOI 10.1136/sextrans-2011-050119.17; Barnighausen T, 2011, LANCET INFECT DIS, V11, P942, DOI 10.1016/S1473-3099(11)70181-5; Bandura A, 2004, HEALTH EDUC BEHAV, V31, P143, DOI 10.1177/1090198104263660; Bardeguez AD, 2008, JAIDS-J ACQ IMM DEF, V48, P408, DOI 10.1097/QAI.0b013e31817bbe80; Boateng D, 2013, BMC WOMENS HEALTH, V13, DOI 10.1186/1472-6874-13-2; Burton J, 2010, AIDS BEHAV, V14, P1, DOI 10.1007/s10461-008-9471-4; Bwirire LD, 2008, T ROY SOC TROP MED H, V102, P1195, DOI 10.1016/j.trstmh.2008.04.002; Calvert C, 2013, AIDS; Chalker J, 2010, JAIDS-J ACQ IMM DEF, V53, P159, DOI 10.1097/QAI.0b013e3181befa12; Chinkonde JR, 2009, REPROD HEALTH MATTER, V17, P143, DOI 10.1016/S0968-8080(09)33440-0; Coates TJ, 2008, LANCET, V372, P669, DOI 10.1016/S0140-6736(08)60886-7; Cohn SE, 2008, AIDS PATIENT CARE ST, V22, P29, DOI 10.1089/apc.2007.0053; Colvin C, PLOS ONE IN PRESS; Coutsoudis A, 2013, LANCET, V381, P269, DOI 10.1016/S0140-6736(12)61807-8; Dean AL, 2012, J TELEMED TELECARE, V18, P399, DOI 10.1258/jtt.2012.120118; Delvaux T, 2009, JAIDS-J ACQ IMM DEF, V50, P223, DOI 10.1097/QAI.0b013e31819001a3; Dourado I, 2014, AIDS CARE; Duff P, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-37; Ekama SO, 2012, JOURNAL, V2012; Ferguson L, 2012, JAIDS-J ACQ IMM DEF, V60, pE90, DOI 10.1097/QAI.0b013e318253258a; Finocchario-Kessler S, 2012, PATIENT EDUC COUNS, V89, P163, DOI 10.1016/j.pec.2012.03.020; Higa DH, 2012, CURR HIV-AIDS REP, V9, P313, DOI 10.1007/s11904-012-0136-6; Hoffman RM, 2010, JAIDS-J ACQ IMM DEF, V54, P35, DOI 10.1097/QAI.0b013e3181cf9979; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Jasseron C, 2013, AIDS BEHAV, V17, P488, DOI 10.1007/s10461-011-0084-y; Jerome JS, 2012, AIDS CARE, V24, P491, DOI 10.1080/09540121.2011.613906; Kanjipite W, 2012, J INT AIDS SOC, V15, P132; Kasenga F, 2010, GLOBAL HEALTH ACTION, V3, DOI 10.3402/gha.v3i0.1882; Kenya S, 2011, HIV MED, V12, P525, DOI 10.1111/j.1468-1293.2011.00921.x; Kim MH, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.4.17389; Kirsten I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021020; Kohler P, 2012, J INT AIDS SOC, V15, P131; Kreitchmann R, 2012, AIDS PATIENT CARE ST, V26, P486, DOI 10.1089/apc.2012.0013; Kuonza LR, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-218; Lewin S, 2013, 21 COCHR C QUEB CAN; Lincoln Y.S., 1985, NATURALISTIC INQUIRY; Liotta G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071653; Lozano R, 2011, LANCET, V378, P1139, DOI 10.1016/S0140-6736(11)61337-8; McDonald K, 2011, AIDS CARE, V23, P578, DOI 10.1080/09540121.2010.482124; McIntyre J, 2003, BRIT MED BULL, V67, P127, DOI 10.1093/bmb/ldg012; MCLEROY KR, 1988, HEALTH EDUC QUART, V15, P351, DOI 10.1177/109019818801500401; Mellins CA, 2008, AIDS CARE, V20, P958, DOI 10.1080/09540120701767208; Mepham S, 2011, AIDS CARE, V23, P741, DOI 10.1080/09540121.2010.516341; Moodley J, 2011, BJOG-INT J OBSTET GY, V118, P219, DOI 10.1111/j.1471-0528.2010.02726.x; Muchedzi A, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-38; Myer L, 2012, AIDS CARE, V24, P986, DOI 10.1080/09540121.2012.668173; Nassali M, 2009, AIDS CARE, V21, P1124, DOI 10.1080/09540120802707467; O'Gorman DA, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-354; Pellowski JA, 2012, CURR HIV-AIDS REP, V9, P326, DOI 10.1007/s11904-012-0133-9; Peltzer K, 2011, ACTA PAEDIATR, V100, P1253, DOI 10.1111/j.1651-2227.2011.02253.x; Peltzer K, 2009, AFR J TRADIT COMPLEM, V6, P175; Richard L, 2011, ANNU REV PUBL HEALTH, V32, P307, DOI 10.1146/annurev-publhealth-031210-101141; Rosen S, 2010, TROP MED INT HEALTH, V15, P98, DOI 10.1111/j.1365-3156.2010.02512.x; Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X; Schutz Alfred., 1962, COLLECTED PAPERS; Sengupta S, 2011, AIDS BEHAV, V15, P1075, DOI 10.1007/s10461-010-9847-0; Skevington SM, 2013, AIDS BEHAV, V17, P1025, DOI 10.1007/s10461-012-0327-6; Stinson K, 2012, AJAR-AFR J AIDS RES, V11, P65, DOI 10.2989/16085906.2012.671263; SURE Collaboration, 2011, ID ADDR BARR IMPL PO; Sword W, 1999, J ADV NURS, V29, P1170, DOI 10.1046/j.1365-2648.1999.00986.x; Thetard R, 2014, SYSTEMATIC REV INTER; Turan JM, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001295; Ujiji OA, 2011, CULT HEALTH SEX, V13, P829, DOI 10.1080/13691058.2011.583682; UNAIDS, 2010, UNAIDS REP GLOB AIDS; UNICEF, 2012, OPT B B KEY CONS COU; Varga C, 2008, QUAL HEALTH RES, V18, P786, DOI 10.1177/1049732308318449; Watson-Jones D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040091; WHO and UNICEF, 2014, TRENDS MAT MORT 1990; WHO UNICEF UNFPA & Bank T. W, 2010, TRENDS MAT MORT 1990; Wise J, 2008, AIDS PATIENT CARE ST, V22, P495, DOI 10.1089/apc.2007.0180; World Health Organization, 2012, PROGR UPD US ANT DRU; World Health Organization, 2007, EVERYBODYS BUSINESS; World Health Organization, 2021, ANT DRUGS TREAT PREG; Zaba B, 2013, LANCET, V381, P1763, DOI 10.1016/S0140-6736(13)60803-X	77	191	193	1	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2014	9	11							e111421	10.1371/journal.pone.0111421	http://dx.doi.org/10.1371/journal.pone.0111421			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AS9IQ	25372479	Green Submitted, gold, Green Published			2023-01-03	WOS:000344556900047
J	Martin-Fernandez, B; de las Heras, N; Valero-Munoz, M; Ballesteros, S; Yao, YZ; Stanton, PG; Fuller, PJ; Lahera, V				Martin-Fernandez, Beatriz; de las Heras, Natalia; Valero-Munoz, Maria; Ballesteros, Sandra; Yao, Yi-Zhou; Stanton, Peter G.; Fuller, Peter J.; Lahera, Vicente			Beneficial Effects of Proanthocyanidins in the Cardiac Alterations Induced by Aldosterone in Rat Heart through Mineralocorticoid Receptor Blockade	PLOS ONE			English	Article							MYOCARDIAL-INFARCTION; ANGIOTENSIN-II; POSSIBLE INVOLVEMENT; DIETARY-SODIUM; PROTEIN-KINASE; EXPRESSION; PROCYANIDINS; INFLAMMATION; FIBROSIS; FAILURE	Aldosterone administration in rats results in several cardiac alterations. Previous studies have demonstrated that proanthocyanidins, phenolic bioactive compounds, have cardioprotective effects. We studied the potential beneficial effects of the proanthocyanidin-rich almond skin extract (PASE) on the cardiac alterations induced by aldosterone-salt treatment, their effects in mineralocorticoid receptor activity and we sought to confirm proanthocyanidins as the specific component of the extract involved in the beneficial cardiac effects. Male Wistar rats received aldosterone (1 mg/Kg/day) + 1% NaCl for 3 weeks. Half of the animals in each group were simultaneously treated with either PASE (100 mg/Kg/day) or spironolactone (200 mg/Kg/day). The ability of PASE to act as an antagonist of the mineralocorticoid receptor was examined using a transactivation assay. High performance liquid chromatography was used to identify and to isolate proanthocyanidins. Hypertension and diastolic dysfunction induced by aldosterone were abolished by treatment with PASE. Expression of the aldosterone mediator SGK-1, together with fibrotic, inflammatory and oxidative mediators were increased by aldosteronesalt treatment; these were reduced by PASE. Aldosterone-salt induced transcriptional activity of the mineralocorticoid receptor was reduced by PASE. HPLC confirmed proanthocyanidins as the compound responsible for the beneficial effects of PASE. The effects of PASE were comparable to those seen with the mineralocorticoid antagonist, spironolactone. The observed responses in the aldosterone-salt treated rats together with the antagonism of transactivation at the mineralocorticoid receptor by PASE provides evidence that the beneficial effect of this proanthocyanidin-rich almond skin extract is via as a mineralocorticoid receptor antagonist with proanthocyanidins identified as the compounds responsible for the beneficial effects of PASE.	[Martin-Fernandez, Beatriz; de las Heras, Natalia; Valero-Munoz, Maria; Ballesteros, Sandra; Lahera, Vicente] Univ Complutense, Sch Med, Dept Physiol, E-28040 Madrid, Spain; [Martin-Fernandez, Beatriz; Yao, Yi-Zhou; Stanton, Peter G.; Fuller, Peter J.] Prince Henrys Inst Med Res, Clayton, Vic, Australia	Complutense University of Madrid; Prince Henry's Institute of Medical Research	Lahera, V (corresponding author), Univ Complutense, Sch Med, Dept Physiol, E-28040 Madrid, Spain.	vlahera@med.ucm.es	Martín Fernández, Beatriz/ABG-8713-2021	Fuller, Peter/0000-0002-0948-2072; Martin-Fernandez, Beatriz/0000-0002-1904-6194; Lahera, Vicente/0000-0002-9688-4503; DE LAS HERAS, NATALIA/0000-0002-2960-6175	VI Programa Nacional de Investigacion Cientifica, Desarrollo e Innovacion Tecnologica de Espana [SAF2011-30396]; National Health and Medical Research Council of Australia [1002559, 1002575]; Victorian Government's Operational Infrastructure Program	VI Programa Nacional de Investigacion Cientifica, Desarrollo e Innovacion Tecnologica de Espana; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government's Operational Infrastructure Program	This work was supported by grants from VI Programa Nacional de Investigacion Cientifica, Desarrollo e Innovacion Tecnologica de Espana (SAF2011-30396) and the National Health and Medical Research Council of Australia through a Fellowship (#1002559) and Project Grant (#1002575) support to PJF. Prince Henry's Institute is supported by the Victorian Government's Operational Infrastructure Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afman L, 2014, MOL NUTR FOOD RES, V58, P1708, DOI 10.1002/mnfr.201300559; Anderson RA, 2004, J AGR FOOD CHEM, V52, P65, DOI 10.1021/jf034916b; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Barreiros ALBS, 2000, PHYTOCHEMISTRY, V55, P805, DOI 10.1016/S0031-9422(00)00297-1; Bauersachs J, 2008, PHARMACOL REP, V60, P119; Belleville J, 2002, NUTRITION, V18, P173, DOI 10.1016/S0899-9007(01)00721-3; Blade C, 2010, MOL NUTR FOOD RES, V54, P37, DOI 10.1002/mnfr.200900476; BRILLA CG, 1992, J LAB CLIN MED, V120, P893; BRILLA CG, 1990, CIRC RES, V67, P1355, DOI 10.1161/01.RES.67.6.1355; Brown AL, 2009, BRIT J NUTR, V101, P886, DOI 10.1017/S0007114508047727; Chanet A, 2013, BRIT J NUTR, V110, P587, DOI 10.1017/S0007114512005454; Coban D, 2012, MOL NUTR FOOD RES, V56, P1270, DOI 10.1002/mnfr.201100818; Dietz JD, 2008, HYPERTENSION, V51, P742, DOI 10.1161/HYPERTENSIONAHA.107.103580; Fagart J, 2010, J BIOL CHEM, V285, P29932, DOI 10.1074/jbc.M110.131342; Fraga CG, 2011, FREE RADICAL BIO MED, V51, P813, DOI 10.1016/j.freeradbiomed.2011.06.002; Funder JW, 2007, AM J CARDIOVASC DRUG, V7, P151, DOI 10.2165/00129784-200707030-00001; Garcia-Conesa MT, 2009, MOL NUTR FOOD RES, V53, P266, DOI 10.1002/mnfr.200800134; Goto T, 2012, BRIT J NUTR, V107, P769, DOI 10.1017/S0007114511003758; Guler A, 2011, MED SCI MONITOR, V17, pBR326, DOI 10.12659/MSM.882042; Hamalainen M, 2007, MEDIAT INFLAMM, V2007, DOI 10.1155/2007/45673; Jiang R, 2006, AM J EPIDEMIOL, V163, P222, DOI 10.1093/aje/kwj033; Kwak CJ, 2009, J HYPERTENS, V27, P92, DOI 10.1097/HJH.0b013e3283186994; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mano A, 2004, CIRCULATION, V110, P317, DOI 10.1161/01.CIR.0000135599.33787.CA; Martin-Fernandez B, 2011, J CARDIOVASC PHARM, V57, P114, DOI 10.1097/FJC.0b013e31820088ca; Martin-Fernandez B, 2009, EXP PHYSIOL, V94, P675, DOI 10.1113/expphysiol.2009.047688; Matsuyama T, 2008, OBESITY, V16, P1338, DOI 10.1038/oby.2008.60; Merx MW, 2004, CIRCULATION, V109, P2560, DOI 10.1161/01.CIR.0000129774.09737.5B; Milenkovic D, 2013, FREE RADICAL BIO MED, V64, P40, DOI 10.1016/j.freeradbiomed.2013.05.046; Mill JG, 2003, CLIN EXP PHARMACOL P, V30, P739, DOI 10.1046/j.1440-1681.2003.03906.x; Monagas M, 2007, J AGR FOOD CHEM, V55, P8498, DOI 10.1021/jf071780z; Murphy KJ, 2003, AM J CLIN NUTR, V77, P1466, DOI 10.1093/ajcn/77.6.1466; Nishiyama A, 2004, HYPERTENSION, V43, P841, DOI 10.1161/01.HYP.0000118519.66430.22; Nocun M, 2008, BIOMED PHARMACOTHER, V62, P168, DOI 10.1016/j.biopha.2007.07.002; Palfi A, 2009, J NUTR BIOCHEM, V20, P418, DOI 10.1016/j.jnutbio.2008.04.009; Pitt B, 2005, J AM COLL CARDIOL, V46, P425, DOI 10.1016/j.jacc.2005.04.038; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Pitt B, 2013, EUR HEART J, V34, P2453, DOI 10.1093/eurheartj/eht187; Ricchiuti V, 2011, J ENDOCRINOL, V211, P47, DOI 10.1530/JOE-10-0458; Rocha R, 2000, ENDOCRINOLOGY, V141, P3871, DOI 10.1210/endo.141.10.7711; Rocha R, 2002, ENDOCRINOLOGY, V143, P4828, DOI 10.1210/en.2002-220120; Rogerson FM, 1999, J BIOL CHEM, V274, P36305, DOI 10.1074/jbc.274.51.36305; Rogerson FM, 2007, MOL ENDOCRINOL, V21, P817, DOI 10.1210/me.2006-0246; Rossi GP, 2005, TRENDS ENDOCRIN MET, V16, P104, DOI 10.1016/j.tem.2005.02.010; Sano T, 2005, THROMB RES, V115, P115, DOI 10.1016/j.thromres.2004.07.015; Satoh M, 2002, CLIN SCI, V102, P381, DOI 10.1042/CS20010219; Schafer A, 2006, BIOMED PHARMACOTHER, V60, P5, DOI 10.1016/j.biopha.2005.08.006; Schafer A, 2003, THROMB HAEMOSTASIS, V89, P1024, DOI 10.1055/s-0037-1613404; Scherrer-Crosbie M, 2001, CIRCULATION, V104, P1286, DOI 10.1161/hc3601.094298; SCOTT BC, 1993, FREE RADICAL RES COM, V19, P241, DOI 10.3109/10715769309056512; Sheng R, 2007, ACTA PHARMACOL SIN, V28, P191, DOI 10.1111/j.1745-7254.2007.00495.x; Spencer JPE, 2010, BRIT J NUTR, V104, pS40, DOI 10.1017/S0007114510003934; Spencer JPE, 2009, GENES NUTR, V4, P243, DOI 10.1007/s12263-009-0136-3; Spiller GA, 2003, J AM COLL NUTR, V22, P195, DOI 10.1080/07315724.2003.10719293; Spiller GA, 1998, J AM COLL NUTR, V17, P285, DOI 10.1080/07315724.1998.10718761; Struthers AD, 2004, CARDIOVASC RES, V61, P663, DOI 10.1016/j.cardiores.2003.11.037; Struthers AD, 2004, EUR J HEART FAIL, V6, P539, DOI 10.1016/j.ejheart.2004.04.013; Sun Y, 1997, CARDIOVASC RES, V35, P138, DOI 10.1016/S0008-6363(97)00097-7; SWEDBERG K, 1990, CIRCULATION, V82, P1730, DOI 10.1161/01.CIR.82.5.1730; Takeda Y, 2000, ENDOCRINOLOGY, V141, P1901, DOI 10.1210/en.141.5.1901; Terra X, 2009, J NUTR BIOCHEM, V20, P210, DOI 10.1016/j.jnutbio.2008.02.005; Toufektsian MC, 2008, J NUTR, V138, P747, DOI 10.1093/jn/138.4.747; Wilke A, 1996, BASIC RES CARDIOL, V91, P79, DOI 10.1007/BF00795367; Young M, 2004, ENDOCRINOLOGY, V145, P3153, DOI 10.1210/en.2004-0005; Young MJ, 1996, STEROIDS, V61, P233, DOI 10.1016/0039-128X(96)00020-7; Zhao XH, 2006, PHYSIOL MEAS, V27, pN27, DOI 10.1088/0967-3334/27/6/N01	67	9	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2014	9	10							e111104	10.1371/journal.pone.0111104	http://dx.doi.org/10.1371/journal.pone.0111104			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8TG	25353961	Green Submitted, gold, Green Published			2023-01-03	WOS:000345204200055
J	Magrini, N; Formoso, G; Capelli, O; Maestri, E; Nonino, F; Paltrinieri, B; Del Giovane, C; Voci, C; Magnano, L; Daya, L; Marata, AM				Magrini, Nicola; Formoso, Giulio; Capelli, Oreste; Maestri, Emilio; Nonino, Francesco; Paltrinieri, Barbara; Del Giovane, Cinzia; Voci, Claudio; Magnano, Lucia; Daya, Lisa; Marata, Anna Maria		INDRA-NET Study Grp	Long Term Effectiveness on Prescribing of Two Multifaceted Educational Interventions: Results of Two Large Scale Randomized Cluster Trials	PLOS ONE			English	Article							PHARMACEUTICAL-INDUSTRY; INFORMATION; OUTREACH; IMPROVE	Introduction: Information on benefits and risks of drugs is a key element affecting doctors' prescribing decisions. Outreach visits promoting independent information have proved moderately effective in changing prescribing behaviours. Objectives: Testing the short and long-term effectiveness on general practitioners' prescribing of small groups meetings led by pharmacists. Methods: Two cluster open randomised controlled trials (RCTs) were carried out in a large scale NHS setting. Ad hoc prepared evidence based material were used considering a therapeutic area approach - TEA, with information materials on osteoporosis or prostatic hyperplasia -and a single drug oriented approach - SIDRO, with information materials on me-too drugs of 2 different classes: barnidipine or prulifloxacin. In each study, all 115 Primary Care Groups in a Northern Italy area (2.2 million inhabitants, 1737 general practitioners) were randomised to educational small groups meetings, in which available evidence was provided together with drug utilization data and clinical scenarios. Main outcomes were changes in the six-months prescription of targeted drugs. Longer term results (24 and 48 months) were also evaluated. Results: In the TEA trial, one of the four primary outcomes showed a reduction (prescription of alfuzosin compared to tamsulosin and terazosin in benign prostatic hyperplasia: prescribing ratio -8.5%, p = 0.03). Another primary outcome (prescription of risedronate) showed a reduction at 24 and 48 months (-7.6%, p = 0.02; and -9,8%, p = 0.03), but not at six months (-5.1%, p = 0.36). In the SIDRO trial both primary outcomes showed a statistically significant reduction (prescription of barnidipine 29.8%, p = 0.02; prescription of prulifloxacin -11.1%, p = 0.04), which persisted or increased over time. Interpretation: These two cluster RCTs showed the large scale feasibility of a complex educational program in a NHS setting, and its potentially relevant long-term impact on prescribing habits, in particular when focusing on a single drug. National Health systems should invest in independent drug information programs.	[Magrini, Nicola; Formoso, Giulio; Maestri, Emilio; Nonino, Francesco; Paltrinieri, Barbara; Voci, Claudio; Magnano, Lucia; Marata, Anna Maria] Emilia Romagna Reg Agcy Hlth & Social Care, Drug Evaluat Area, Bologna, Italy; [Capelli, Oreste; Daya, Lisa] Local Hlth Author, Modena, Italy; [Del Giovane, Cinzia] Univ Modena & Reggio Emilia, Dept Clin & Diagnost Med & Publ Hlth, Modena, Italy	Universita di Modena e Reggio Emilia	Magrini, N (corresponding author), Emilia Romagna Reg Agcy Hlth & Social Care, Drug Evaluat Area, Bologna, Italy.	nmagrini@regione.emilia-romagna.it	Formoso, Giulio/H-9350-2018; Nonino, Francesco/AAK-3260-2020; voci, claudio/AAA-6516-2020	Formoso, Giulio/0000-0002-1819-6887; , claudio/0000-0002-0385-666X; Del Giovane, Cinzia/0000-0002-5028-932X; Nonino, Francesco/0000-0003-3601-6381	Agenzia Italiana del Farmaco; NHS	Agenzia Italiana del Farmaco; NHS	Funding was provided by Agenzia Italiana del Farmaco, 2005 NHS fund for independent research on drugs. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; Chan AW, 2008, PLOS MED, V5, P1533, DOI 10.1371/journal.pmed.0050230; Collier J, 2002, LANCET, V360, P1405, DOI 10.1016/S0140-6736(02)11394-8; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Dickersin K, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P11; Donner A, 1996, J CLIN EPIDEMIOL, V49, P435, DOI 10.1016/0895-4356(95)00511-0; Dukes MNG, 2002, LANCET, V360, P1682, DOI 10.1016/S0140-6736(02)11599-6; Formoso G, 2001, ARCH INTERN MED, V161, P2037, DOI 10.1001/archinte.161.16.2037; Formoso G, 2007, SOC SCI MED, V64, P949, DOI 10.1016/j.socscimed.2006.09.022; Garattini S, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1025; Godwin Marshall, 2003, BMC Med Res Methodol, V3, P28, DOI 10.1186/1471-2288-3-28; Grimshaw JM, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8060; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Ivers N, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000259.pub3; Liberati A, 2010, EUR J CLIN INVEST, V40, P69, DOI 10.1111/j.1365-2362.2009.02226.x; Light DW, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4348; Magrini N, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-158; Melander H, 2003, BMJ-BRIT MED J, V326, P1171, DOI 10.1136/bmj.326.7400.1171; Nkansah N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000336.pub2; Norman G, 2002, BMJ-BRIT MED J, V324, P1560, DOI 10.1136/bmj.324.7353.1560; O'Brien MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000409.pub2; Ridker PM, 2006, JAMA-J AM MED ASSOC, V295, P2270, DOI 10.1001/jama.295.19.2270; Schwartz LM, 2009, NEW ENGL J MED, V361, P1717, DOI 10.1056/NEJMp0907708; Simon SR, 2005, AM J MED, V118, P521, DOI 10.1016/j.amjmed.2004.12.023; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; The Congress of the United States - Congressional Budget Office, 2006, RES DEV PHARM IND; Woloshin S, 2008, KNOW YOUR CHANCES UN; Woloshin S, 2011, ANN INTERN MED, V155, P87, DOI 10.7326/0003-4819-155-2-201107190-00004	28	8	8	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2014	9	10							e109915	10.1371/journal.pone.0109915	http://dx.doi.org/10.1371/journal.pone.0109915			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8TF	25329386	Green Published, gold			2023-01-03	WOS:000345204100035
J	Wang, X; Tang, YQ; Zhang, XP; Yin, X; Du, X; Zhang, XP				Wang, Xuan; Tang, Yuqing; Zhang, Xiaopeng; Yin, Xi; Du, Xin; Zhang, Xinping			Effect of Publicly Reporting Performance Data of Medicine Use on Injection Use: A Quasi-Experimental Study	PLOS ONE			English	Article							HEALTH-CARE; INTERACTIONAL GROUP; QUALITY; INTERVENTION; POLICY; IMPACT; CHINA	Background: Inappropriate use of prescribing pharmaceuticals, particularly injections, not only affects the quality of medical care, but also leads to an increase in medical expenses. Publicly reporting performance data of medical care is becoming a common health policy tool adopted to supervise medical quality. To our knowledge, few studies about public reporting applied to medicine use have been reported. This study intended to introduce public reporting in the field of medicine use, and evaluate the effect of publicly reporting performance data of medicine use on the use of injections. Methods: The research sites were 20 primary healthcare institutions in Q City, Hubei. By matching, the institutions were divided into the intervention group and control group. A quasi-experimental design was applied in this study. In the intervention group, the performance data of medicine use were publicly reported. The injection prescribing rates of the two groups before and after intervention were measured and compared. Difference-in-difference method and logistic regression were employed to estimate the effect of public reporting on injection use. Results: Public reporting led to a reduction of approximately 4% in the injection prescribing rate four months after intervention (OR = 0.96; 95% CI: 0.94, 0.97). The intervention effect was inconsistent in each month after intervention, and it was most positive in the second month after intervention (OR = 0.90; 95% CI: 0.89, 0.92). Conclusions: In general, publicly reporting performance data of medicine use may have positive effects on injection use to some extent. Further research is needed to investigate the mechanism by which public reporting influences injection use. Comprehensive measures are also necessary to promote the rational use of injections.	[Wang, Xuan; Tang, Yuqing; Zhang, Xiaopeng; Yin, Xi; Du, Xin; Zhang, Xinping] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Med & Hlth Management, Wuhan 430074, Hubei Province, Peoples R China	Huazhong University of Science & Technology	Zhang, XP (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Med & Hlth Management, Wuhan 430074, Hubei Province, Peoples R China.	xpzhang602@163.com		Zhang, Xinping/0000-0002-1579-1306; Zhang, Xinping/0000-0002-0688-2417	National Natural Science Foundation of China [71373092]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This research is supported by the National Natural Science Foundation of China (71373092, http://www.nsfc.gov.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berwick DM, 2003, MED CARE, V41, pI30; Bhunia R, 2010, INDIAN PEDIATR, V47, P409, DOI 10.1007/s13312-010-0076-4; Blumenthal D, 1996, NEW ENGL J MED, V335, P1328, DOI 10.1056/NEJM199610243351721; BROOMBERG J, 1990, S AFR MED J, V78, P130; Dong LF, 2011, J PUBLIC HEALTH-UK, V33, P565, DOI 10.1093/pubmed/fdr019; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; Espeland WN, 2007, AM J SOCIOL, V113, P1, DOI 10.1086/517897; Faber M, 2009, MED CARE, V47, P1, DOI 10.1097/MLR.0b013e3181808bb5; Finkelstein JA, 2001, PEDIATRICS, V108, pU113; Fung CH, 2008, ANN INTERN MED, V148, P111, DOI 10.7326/0003-4819-148-2-200801150-00006; Gerber JS, 2013, JAMA-J AM MED ASSOC, V309, P2345, DOI 10.1001/jama.2013.6287; Hadiyono JEP, 1996, SOC SCI MED, V42, P1177, DOI 10.1016/0277-9536(95)00391-6; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; Hibbard JH, 2003, HEALTH AFFAIR, V22, P84, DOI 10.1377/hlthaff.22.2.84; Hu SL, 2001, HEALTH POLICY PLANN, V16, P4, DOI 10.1093/heapol/16.suppl_2.4; Ivers N, 2012, COCHRANE DB SYST REV, V6, pD259; Jin C, 2012, CHINESE HLTH EC, V31, P79; Lansky D, 2002, HEALTH AFFAIR, V21, P52, DOI 10.1377/hlthaff.21.4.52; Le Grand A, 1999, HEALTH POLICY PLANN, V14, P89, DOI 10.1093/heapol/14.2.89; Li LM, 2010, EPIDEMIOLOGY, V6th; Li YB, 2012, HEALTH AFFAIR, V31, P1075, DOI 10.1377/hlthaff.2010.0965; Lindenauer PK, 2007, NEW ENGL J MED, V356, P486, DOI 10.1056/NEJMsa064964; Mainz J, 2004, INT J QUAL HEALTH C, V16, pI45, DOI 10.1093/intqhc/mzh031; Marshall MN, 2003, HEALTH AFFAIR, V22, P134, DOI 10.1377/hlthaff.22.3.134; Marshall MN, 2000, JAMA-J AM MED ASSOC, V283, P1866, DOI 10.1001/jama.283.14.1866; Meeker D, 2014, JAMA INTERN MED, V174, P425, DOI 10.1001/jamainternmed.2013.14191; Reynolds L, 2009, HEALTH POLICY, V90, P32, DOI 10.1016/j.healthpol.2008.09.002; Shen J, 2004, MED CARE, V42, P297, DOI 10.1097/01.mlr.0000114918.50088.1c; Snelling Iain, 2003, J Health Organ Manag, V17, P210, DOI 10.1108/14777260310480758; [孙奕 Sun Yi], 2005, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V5, P394; Tang YQ, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-183; Tu JV, 2003, INT J QUAL HEALTH C, V15, P131, DOI 10.1093/intqhc/mzg015; Wang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063225; WHO, INJECTION SAFETY; WHO, 1993, ACT PROGR ESS DRUGS, P1; WHO, 2009, MED US PRIM CAR DEV; WHO Website, MED RAT US MED; WHO. World Health Organization, 1993, INVESTIGATE DRUG USE; World Health Organization, 2002, ANTITB OTHER MED PRE; Xiang XX, 2012, J HUAZHONG U SCI-MED, V32, P626, DOI 10.1007/s11596-012-1008-4; Yang LP, 2013, HEALTH POLICY PLANN, V28, P750, DOI 10.1093/heapol/czs116	41	7	7	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2014	9	10							e109594	10.1371/journal.pone.0109594	http://dx.doi.org/10.1371/journal.pone.0109594			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AR5ZW	25313853	Green Published, Green Submitted, gold			2023-01-03	WOS:000343662500059
J	Jin, S; Deng, Y; Hao, JW; Li, Y; Liu, B; Yu, Y; Shi, FD; Zhou, QH				Jin, Shi; Deng, Yi; Hao, Jun-Wei; Li, Yang; Liu, Bin; Yu, Yan; Shi, Fu-Dong; Zhou, Qing-Hua			NK Cell Phenotypic Modulation in Lung Cancer Environment	PLOS ONE			English	Article							NATURAL-KILLER-CELLS; MOLONEY LEUKEMIA-CELLS; PROGNOSTIC-SIGNIFICANCE; IMMUNE SURVEILLANCE; CYTOTOXIC-CELLS; T-CELLS; STATISTICS; NKG2D; SPECIFICITY; RECEPTORS	Background: Nature killer (NK) cells play an important role in anti-tumor immunotherapy. But it indicated that tumor cells impacted possibly on NK cell normal functions through some molecules mechanisms in tumor microenvironment. Materials and methods: Our study analyzed the change about NK cells surface markers (NK cells receptors) through immunofluorescence, flow cytometry and real-time PCR, the killed function from mouse spleen NK cell and human high/low lung cancer cell line by co-culture. Furthermore we certificated the above result on the lung cancer model of SCID mouse. Results: We showed that the infiltration of NK cells in tumor periphery was related with lung cancer patients' prognosis. And the number of NK cell infiltrating in lung cancer tissue is closely related to the pathological types, size of the primary cancer, smoking history and prognosis of the patients with lung cancer. The expression of NK cells inhibitor receptors increased remarkably in tumor micro-environment, in opposite, the expression of NK cells activated receptors decrease magnificently. Conclusions: The survival time of lung cancer patient was positively related to NK cell infiltration degree in lung cancer. Thus, the down-regulation of NKG2D, Ly49I and the up-regulation of NKG2A may indicate immune tolerance mechanism and facilitate metastasis in tumor environment. Our research will offer more theory for clinical strategy about tumor immunotherapy.	[Jin, Shi; Deng, Yi; Li, Yang; Liu, Bin; Zhou, Qing-Hua] Tianjin Med Univ, Gen Hosp, Tianjin Lung Canc Inst, Tianjin Key Lab Lung Canc Metastasis & Tumor Micr, Tianjin, Peoples R China; [Jin, Shi; Yu, Yan] Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin, Peoples R China; [Deng, Yi] Third Mil Med Univ, Res Inst Surg & Daping Hosp, Ctr Canc, Chongqing, Peoples R China; [Shi, Fu-Dong] Tianjin Med Univ, Gen Hosp, Dept Neurol, Tianjin, Peoples R China	Tianjin Medical University; Harbin Medical University; Army Medical University; Tianjin Medical University	Zhou, QH (corresponding author), Tianjin Med Univ, Gen Hosp, Tianjin Lung Canc Inst, Tianjin Key Lab Lung Canc Metastasis & Tumor Micr, Tianjin, Peoples R China.	zhouqh135@163.com		Hao, Junwei/0000-0002-3075-5434	Young People Research Fund from the National Eleventh-Five-Year Key Task Projects of China [2006BAI02A01]; National 973 Program [2010CB529405]; Tianjin Scientific Innovation System Program [07SYSYSF05000, 07SYSYJC27900]; China-Sweden Cooperative Foundation [09ZCZDSF04100]; grant National Natural Scientific Foundation of China [81201828]; Young People Foundation of Heilongjiang Provincial of China [QC2012C013]; Health Department of Heilongjiang Provincial of China [2011-124]; Harbin Medical University Cancer Hospital major project Foundation [JJZ-2010-01]	Young People Research Fund from the National Eleventh-Five-Year Key Task Projects of China; National 973 Program(National Basic Research Program of China); Tianjin Scientific Innovation System Program; China-Sweden Cooperative Foundation; grant National Natural Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); Young People Foundation of Heilongjiang Provincial of China; Health Department of Heilongjiang Provincial of China; Harbin Medical University Cancer Hospital major project Foundation	This work was supported by Young People Research Fund from the grants the National Eleventh-Five-Year Key Task Projects of China (No. 2006BAI02A01), the National 973 Program (No. 2010CB529405), Tianjin Scientific Innovation System Program (No. 07SYSYSF05000, 07SYSYJC27900), the China-Sweden Cooperative Foundation (No. 09ZCZDSF04100), the grant National Natural Scientific Foundation of China (No 81201828), Young People Foundation of Heilongjiang Provincial of China (No QC2012C013), Health Department of Heilongjiang Provincial of China (No 2011-124) and Harbin Medical University Cancer Hospital major project Foundation (No: JJZ-2010-01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Campoli M, 2008, TISSUE ANTIGENS, V72, P321, DOI 10.1111/j.1399-0039.2008.01106.x; Carlsten M, 2009, J IMMUNOL, V183, P4921, DOI 10.4049/jimmunol.0901226; Castriconi R, 2003, P NATL ACAD SCI USA, V100, P4120, DOI 10.1073/pnas.0730640100; Coca S, 1997, CANCER-AM CANCER SOC, V79, P2320, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P; Cooper MA, 2001, BLOOD, V97, P3146, DOI 10.1182/blood.V97.10.3146; Dasgupta S, 2005, J IMMUNOL, V175, P5541, DOI 10.4049/jimmunol.175.8.5541; Esendagli G, 2008, LUNG CANCER, V59, P32, DOI 10.1016/j.lungcan.2007.07.022; Farag SS, 2006, BLOOD REV, V20, P123, DOI 10.1016/j.blre.2005.10.001; Glasner A, 2012, J IMMUNOL, V188, P2509, DOI 10.4049/jimmunol.1102461; Hayakawa Y, 2002, J IMMUNOL, V169, P5377, DOI 10.4049/jimmunol.169.10.5377; Ishigami S, 2000, CANCER LETT, V159, P103, DOI 10.1016/S0304-3835(00)00542-5; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Karre K, 2002, SCAND J IMMUNOL, V55, P221, DOI 10.1046/j.1365-3083.2002.01053.x; KIESSLING R, 1975, EUR J IMMUNOL, V5, P117, DOI 10.1002/eji.1830050209; KIESSLING R, 1975, EUR J IMMUNOL, V5, P112, DOI 10.1002/eji.1830050208; Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x; LeMaoult J, 2005, FASEB J, V19, P662, DOI 10.1096/fj.04-1617fje; Levy EM, 2008, INT J ONCOL, V32, P633, DOI 10.3892/ijo.32.3.633; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Peng Hong, 2011, Zhongguo Fei Ai Za Zhi, V14, P362, DOI 10.3779/j.issn.1009-3419.2011.04.11; Peng YM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083913; Ren Yuanrong, 2008, Zhongguo Fei Ai Za Zhi, V11, P321, DOI 10.3779/j.issn.1009-3419.2008.03.012; Richards JO, 2006, BLOOD, V108, P246, DOI 10.1182/blood-2005-11-4535; Salazar-Onfray F, 2007, CYTOKINE GROWTH F R, V18, P171, DOI 10.1016/j.cytogfr.2007.01.015; Schleypen JS, 2006, CLIN CANCER RES, V12, P718, DOI 10.1158/1078-0432.CCR-05-0857; Schleypen JS, 2003, INT J CANCER, V106, P905, DOI 10.1002/ijc.11321; Sullivan LC, 2008, TISSUE ANTIGENS, V72, P415, DOI 10.1111/j.1399-0039.2008.01138.x; Urosevic M, 2008, CANCER RES, V68, P627, DOI 10.1158/0008-5472.CAN-07-2704; Villegas FR, 2002, LUNG CANCER-J IASLC, V35, P23, DOI 10.1016/S0169-5002(01)00292-6; Vivier E, 2012, NAT REV IMMUNOL, V12, P239, DOI 10.1038/nri3174; Yang L, 2005, EUR J CANCER PREV, V14, P329, DOI 10.1097/00008469-200508000-00004; Yoshimi I, 2004, JPN J CLIN ONCOL, V34, P759, DOI 10.1093/jjco/hyh144; Zhou Qinghua, 2003, Zhongguo Fei Ai Za Zhi, V6, P464, DOI 10.3779/j.issn.1009-3419.2003.06.13; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	36	49	51	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2014	9	10							e109976	10.1371/journal.pone.0109976	http://dx.doi.org/10.1371/journal.pone.0109976			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0AP	25299645	Green Submitted, Green Published, gold			2023-01-03	WOS:000343941200088
J	Fu, R; Wang, YP; Bao, H; Wang, ZQ; Li, YQ; Su, SF; Liu, MN				Fu, Rong; Wang, Yupeng; Bao, Han; Wang, Zhiqiang; Li, Yongquan; Su, Shaofei; Liu, Meina			Trend of Urban-Rural Disparities in Hospital Admissions and Medical Expenditure in China from 2003 to 2011	PLOS ONE			English	Article							HEALTH SYSTEM REFORM; INSURANCE; SERVICES; COVERAGE; CHALLENGES; SCHEME; EQUITY; ACCESS; CARE	Objectives: To assess the trend of urban-rural disparities in hospital admissions and medical expenditure between 2003 and 2011 in the context of Chinese health-care system reform. Methods: The data were from three different national surveys: the Third National Health Services Survey in 2003, the Fourth National Health Services Survey in 2008 and the national health-care reform phased assessment survey in 2011. There were 151421, 143380 and 48356 respondents aged 15 years or older in 2003, 2008 and 2011, respectively. Results: The health insurance coverage expanded considerably from 27.7% in 2003 to 96.4% in 2011 among respondents aged 15 years or older. Hospitalization rate increased rapidly from 4.1% in 2003 to 9.6% in 2011. Urban respondents had higher hospital admissions than rural respondents, and the RR (95% CI) of hospitalization was 1.23 (1.17-1.30), 1.06 (1.02-1.10) and 1.16 (1.10-1.23) in 2003, 2008 and 2011, respectively. The urban-rural disparity in hospital admissions significantly narrowed over time. Urban respondents had a higher admission rate if insured and a lower admission if not insured than their rural counterparts. Of the six medical expenditure measures, the disparities in reimbursement rate and the proportion of hospitalization direct cost to the total consumer spending significantly narrowed. Conclusions: The health insurance coverage has been continually expanding and health service utilization has been substantially improved. Urban-rural disparities have been narrowed but still exist. Therefore, policy-makers should focus on increasing investment and reimbursement levels, developing a uniform standard health insurance system for urban and rural residents and improving the medical assistance system.	[Fu, Rong; Wang, Yupeng; Bao, Han; Su, Shaofei; Liu, Meina] Harbin Med Univ, Coll Publ Hlth, Dept Biostat, Harbin, Peoples R China; [Wang, Zhiqiang] Univ Queensland, Royal Brisbane & Womens Hosp, Sch Med, Herston, Qld, Australia; [Li, Yongquan] Harbin Med Univ, Grad Sch, Harbin, Peoples R China	Harbin Medical University; Royal Brisbane & Women's Hospital; University of Queensland; Harbin Medical University	Liu, MN (corresponding author), Harbin Med Univ, Coll Publ Hlth, Dept Biostat, Harbin, Peoples R China.	liumeina369@163.com	Wang, Zhiqiang/A-5835-2010	Wang, Zhiqiang/0000-0002-5839-743X	National Natural Science Foundation of China [81273183]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China [81273183 to Meina Liu, http://www.nsfc.gov.cn/Portal0/default152.htm]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Center for Health Statistics and Information National Health and Family Planning Commission, 2009, AN REP NAT HLTH SERV; Centre for Health Statistics and Information, 2004, RES NAT HLTH SERV AN; Cheng LW, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-713; China National Health Economics Institute, 2003, CHIN NAT HLTH ACC RE; Department of Disease Control and Prevention Ministry of Health, 2006, REP CHRON DIS CHIN; Dong KY, 2009, CHINA ECON REV, V20, P591, DOI 10.1016/j.chieco.2009.05.011; General Office of the State Council (GOSC), 1998, ZHONG ZHENG JIJ ORG; Hong LJ, 2011, ANAL REGIONAL BALANC; Hu SL, 2008, LANCET, V372, P1846, DOI 10.1016/S0140-6736(08)61368-9; Lei XY, 2009, HEALTH ECON, V18, pS25, DOI 10.1002/hec.1501; Liang QJ, 2010, HLTH EC RES, V5, P26; Lin WC, 2009, HEALTH ECON, V18, pS83, DOI 10.1002/hec.1500; Liu MN, 2007, MED CARE, V45, P767, DOI 10.1097/MLR.0b013e3180618b9a; Liu YL, 2002, HEALTH POLICY, V60, P133, DOI 10.1016/S0168-8510(01)00207-X; Meng Q, 2012, LANCET, V379, P805, DOI 10.1016/S0140-6736(12)60278-5; Ministry of Health, 2009, CHIN HLTH STAT YB 20; [顾东风 Gu Dong feng], 2003, [中华心血管病杂志, Chinese Journal of Cardiology], V31, P3; Shaw K, 2006, PUBLIC HEALTH, V120, P8, DOI 10.1016/j.puhe.2005.10.002; Spiegelman D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/aje/kwi188; State Statistics Bureau, 2012, CHIN STAT YB 2012; Sun HP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028411; Sun YL, 2007, CHINESE HLTH SERVICE, V23, P584; Tang SL, 2008, LANCET, V372, P1493, DOI 10.1016/S0140-6736(08)61364-1; Wu B, 2007, J PUBLIC HEALTH DENT, V67, P185, DOI 10.1111/j.1752-7325.2007.00038.x; Xu L, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-37; Yang GH, 2008, LANCET, V372, P1697, DOI 10.1016/S0140-6736(08)61366-5; Yang W, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-20; You XD, 2009, HEALTH POLICY, V91, P1, DOI 10.1016/j.healthpol.2008.11.012; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zhang ZG, 2011, REFORMATION STRATEGY, V27, P176	30	35	35	2	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2014	9	9							e108571	10.1371/journal.pone.0108571	http://dx.doi.org/10.1371/journal.pone.0108571			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AQ0SJ	25251367	Green Published, Green Submitted, gold			2023-01-03	WOS:000342492700143
J	Du, X; Wang, JY; Diao, WT; Wang, L; Long, JF; Zhou, H				Du, Xiao; Wang, Jingyu; Diao, Wentao; Wang, Ling; Long, Jiafu; Zhou, Hao			A Genetically Modified Protein-Based Hydrogel for 3D Culture of AD293 Cells	PLOS ONE			English	Article							MOLECULAR HYDROGELS; DESIGN; ENCAPSULATION; SCAFFOLDS; BIOMATERIALS; RELEASE	Hydrogels have strong application prospects for drug delivery, tissue engineering and cell therapy because of their excellent biocompatibility and abundant availability as scaffolds for drugs and cells. In this study, we created hybrid hydrogels based on a genetically modified tax interactive protein-1 (TIP1) by introducing two or four cysteine residues in the primary structure of TIP1. The introduced cysteine residues were crosslinked with a four-armed poly (ethylene glycol) having their arm ends capped with maleimide residues (4-armed-PEG-Mal) to form hydrogels. In one form of the genetically modification, we incorporated a peptide sequence 'GRGDSP' to introduce bioactivity to the protein, and the resultant hydrogel could provide an excellent environment for a three dimensional cell culture of AD293 cells. The AD293 cells continued to divide and displayed a polyhedron or spindle-shape during the 3-day culture period. Besides, AD293 cells could be easily separated from the cell-gel constructs for future large-scale culture after being cultured for 3 days and treating hydrogel with trypsinase. This work significantly expands the toolbox of recombinant proteins for hydrogel formation, and we believe that our hydrogel will be of considerable interest to those working in cell therapy and controlled drug delivery.	[Du, Xiao; Wang, Jingyu; Diao, Wentao; Wang, Ling; Long, Jiafu; Zhou, Hao] Nankai Univ, State Key Lab Med Chem Biol, Tianjin 300071, Peoples R China; [Du, Xiao; Wang, Jingyu; Diao, Wentao; Long, Jiafu; Zhou, Hao] Nankai Univ, Coll Life Sci, Tianjin 300071, Peoples R China; [Wang, Ling] Nankai Univ, Coll Pharm, Tianjin 300071, Peoples R China	Nankai University; Nankai University; Nankai University	Long, JF (corresponding author), Nankai Univ, State Key Lab Med Chem Biol, Tianjin 300071, Peoples R China.	jflong@nankai.edu.cn; haozhou@nankai.edu.cn	Long, Jiafu/B-7420-2012; Zhou, Hao/G-9693-2019	Long, Jiafu/0000-0002-6625-0147; Zhou, Hao/0000-0001-6813-648X	National Natural Science Foundation of China [31370964, 31270815, 31100527]; State Key Laboratory of Medicinal Chemical Biology [20140211]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Laboratory of Medicinal Chemical Biology	This work was partially supported by the National Natural Science Foundation of China (31370964 to LW, 31270815 to JL and 31100527 to HZ) and the Open Fund of State Key Laboratory of Medicinal Chemical Biology (20140211 to HZ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almany L, 2005, BIOMATERIALS, V26, P2467, DOI 10.1016/j.biomaterials.2004.06.047; Bahney CS, 2011, FASEB J, V25, P1486, DOI 10.1096/fj.10-165514; Branco MC, 2010, BIOMATERIALS, V31, P9527, DOI 10.1016/j.biomaterials.2010.08.047; Chien HW, 2012, BIOMATERIALS, V33, P5706, DOI 10.1016/j.biomaterials.2012.04.031; DiMarco RL, 2012, ADV MATER, V24, P3923, DOI 10.1002/adma.201200051; Drury JL, 2003, BIOMATERIALS, V24, P4337, DOI 10.1016/S0142-9612(03)00340-5; Esser-Kahn AP, 2008, ANGEW CHEM INT EDIT, V47, P3751, DOI 10.1002/anie.200705564; Esser-Kahn AP, 2008, J AM CHEM SOC, V130, P15820, DOI 10.1021/ja807095r; Foo CTSWP, 2009, P NATL ACAD SCI USA, V106, P22067, DOI 10.1073/pnas.0904851106; Gonen-Wadmany M, 2007, BIOMATERIALS, V28, P3876, DOI 10.1016/j.biomaterials.2007.05.005; Grove TZ, 2010, J AM CHEM SOC, V132, P14024, DOI 10.1021/ja106619w; Gu Z, 2011, ANAL CHEM, V83, P2324, DOI 10.1021/ac103236g; Hoyle CE, 2010, ANGEW CHEM INT EDIT, V49, P1540, DOI 10.1002/anie.200903924; Kopecek J, 2007, BIOMATERIALS, V28, P5185, DOI 10.1016/j.biomaterials.2007.07.044; Lim DW, 2007, BIOMACROMOLECULES, V8, P1463, DOI 10.1021/bm061059m; Liu JC, 2004, BIOMACROMOLECULES, V5, P497, DOI 10.1021/bm034340z; Lutolf MP, 2003, P NATL ACAD SCI USA, V100, P5413, DOI 10.1073/pnas.0737381100; Lv LN, 2013, COLLOID SURFACE B, V108, P352, DOI 10.1016/j.colsurfb.2013.03.013; Mather BD, 2006, PROG POLYM SCI, V31, P487, DOI 10.1016/j.progpolymsci.2006.03.001; Mosiewicz KA, 2010, J AM CHEM SOC, V132, P5972, DOI 10.1021/ja9098164; Nicodemus GD, 2008, TISSUE ENG PT B-REV, V14, P149, DOI 10.1089/ten.teb.2007.0332; Sengupta D, 2010, TISSUE ENG PART B-RE, V16, P285, DOI 10.1089/ten.teb.2009.0591; Straley KS, 2009, SOFT MATTER, V5, P114, DOI 10.1039/b808504h; Sui ZJ, 2007, ADV MATER, V19, P3377, DOI 10.1002/adma.200700092; Wang HM, 2014, ACS NANO, V8, P1475, DOI 10.1021/nn4054914; Wang HM, 2013, CHEM COMMUN, V49, P7448, DOI 10.1039/c3cc43711f; Wang HM, 2012, NANOSCALE, V4, P5259, DOI 10.1039/c2nr31149f; Wang JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075727; Yamaguchi N, 2007, J AM CHEM SOC, V129, P3040, DOI 10.1021/ja0680358; Yan XJ, 2009, J MOL BIOL, V392, P967, DOI 10.1016/j.jmb.2009.07.060; Yang CB, 2013, ORG BIOMOL CHEM, V11, P6946, DOI 10.1039/c3ob40969d; Yang CH, 2012, J PHYS CHEM B, V116, P633, DOI 10.1021/jp209441r; Yu Donghyeon, 2013, Genomics & Informatics, V11, P200, DOI 10.5808/GI.2013.11.4.200; Yuan WW, 2008, J AM CHEM SOC, V130, P15760, DOI 10.1021/ja805634x; Zhang XL, 2012, ANGEW CHEM INT EDIT, V51, P4388, DOI 10.1002/anie.201108612; Zhu JM, 2012, BIOMACROMOLECULES, V13, P706, DOI 10.1021/bm201596w	36	4	4	3	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2014	9	9							e107949	10.1371/journal.pone.0107949	http://dx.doi.org/10.1371/journal.pone.0107949			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ6KR	25233088	Green Published, Green Submitted, gold			2023-01-03	WOS:000342921200066
J	Weaver, ERN; Pane, M; Wandra, T; Windiyaningsih, C; Samaan, HG				Weaver, Emma Rosamond Nony; Pane, Masdalina; Wandra, Toni; Windiyaningsih, Cicilia; Samaan, Herlina Gina			Factors that Influence Adherence to Antiretroviral Treatment in an Urban Population, Jakarta, Indonesia	PLOS ONE			English	Article							THERAPY; PREDICTORS; HIV/AIDS; PROTEASE	Introduction: Although the number of people receiving antiretroviral therapy (ART) in Indonesia has increased in recent years, little is known about the specific characteristics affecting adherence in this population. Indonesia is different from most of its neighbors given that it is a geographically and culturally diverse country, with a large Muslim population. We aimed to identify the current rate of adherence and explore factors that influence ART adherence. Methods: Data were collected from ART-prescribed outpatients on an HIV registry at a North Jakarta hospital in 2012. Sociodemographic and behavioral characteristics were explored as factors associated with adherence using logistics regression analyses. Chi squared test was used to compare the difference between proportions. Reasons for missing medication were analyzed descriptively. Results: Two hundred and sixty-one patients participated, of whom 77% reported ART adherence in the last 3 months. The level of social support experienced was independently associated with adherence where some social support (p = 0.018) and good social support (p = 0.039) improved adherence compared to poor social support. Frequently cited reasons for not taking ART medication included forgetting to take medication (67%), busy with something else (63%) and asleep at medication time (60%). Discussion: This study identified that an increase in the level of social support experienced by ART-prescribed patients was positively associated with adherence. Social support may minimize the impact of stigma among ART prescribed patients. Based on these findings, if social support is not available, alternative support through community-based organizations is recommended to maximize treatment success.	[Pane, Masdalina; Wandra, Toni; Windiyaningsih, Cicilia] Minist Hlth Republ Indonesia, Sulianti Saroso Infect Dis Hosp, North Jakarta, Jakarta Provinc, Indonesia; [Samaan, Herlina Gina] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia	Ministry of Health - Indonesia; Australian National University	Pane, M (corresponding author), Minist Hlth Republ Indonesia, Sulianti Saroso Infect Dis Hosp, North Jakarta, Jakarta Provinc, Indonesia.	masdalina.pane@gmail.com	WANDRA, TONI/AAD-5736-2021; Pane, M/AGP-8366-2022	Pane, M/0000-0002-3697-4945; Wandra, Toni/0000-0002-4606-5411; cicilia, windiyaningsih/0000-0003-2193-2627				Ammassari A, 2002, JAIDS, V31, pS123, DOI 10.1097/00126334-200212153-00007; Bangsberg D, 2000, AIDS PATIENT CARE ST, V14; Bangsberg DR, 2006, AIDS, V20, P223, DOI 10.1097/01.aids.0000199825.34241.49; Chesney MA, 2000, CLIN INFECT DIS, V30, pS171, DOI 10.1086/313849; Habib AG, 2009, AIDS BEHAV, V13, P42, DOI 10.1007/s10461-008-9412-2; Hardon A., 2006, ACCESS ADHERENCE CHA; Kimmerling M, 2003, INT J STD AIDS, V14, P281, DOI 10.1258/095646203321264917; Kleeberger CA, 2001, J ACQ IMMUN DEF SYND, V26, P82, DOI 10.1097/00126334-200101010-00012; Konkle-Parker DJ, 2008, J ASSOC NURSE AIDS C, V19, P98, DOI 10.1016/j.jana.2007.09.005; Kranzer K, 2011, TROP MED INT HEALTH, V16, P1297, DOI 10.1111/j.1365-3156.2011.02828.x; Li L, 2010, NURS HEALTH SCI, V12, P212, DOI 10.1111/j.1442-2018.2010.00521.x; Mills EJ, 2006, PLOS MED, V3, P2039, DOI 10.1371/journal.pmed.0030438; Murphy DA, 2004, AIDS CARE, V16, P471, DOI 10.1080/09540120410001683402; National AIDS Commision, 2012, REP IND COUNTR REP F; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Paxton S, 2007, ASIA-PAC J PUBLIC HE, V19, P8, DOI 10.1177/10105395070190010301; Reidpath DD, 2005, AIDS CARE, V17, pS117, DOI 10.1080/09540120500120195; Reynolds NR, 2004, CURR HIV RES, V2, P207, DOI 10.2174/1570162043351309; Shah B, 2007, CLIN INFECT DIS, V44, P1235, DOI 10.1086/513429; StataCorp, 2019, STATA STAT SOFTWARE; Trzynka E, 2007, PSYCHOL PHYSL PREDIC; Wang HH, 2008, AIDS PATIENT CARE ST, V22, P71, DOI 10.1089/apc.2007.0047; Wasti SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035547; Wasti SP, 2012, TROP MED INT HEALTH, V17, P71, DOI 10.1111/j.1365-3156.2011.02888.x; WHO, 2013, DAT HIV AIDS RESP AN; World Health Organization, 2003, SCAL ANT THER RES LT	26	15	16	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2014	9	9							e107543	10.1371/journal.pone.0107543	http://dx.doi.org/10.1371/journal.pone.0107543			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AP5MS	25229671	Green Published, Green Submitted, gold			2023-01-03	WOS:000342123900047
J	Charles, R; Jackson, R; Dodman, J				Charles, Robert; Jackson, Robert; Dodman, James			A 20 year old man with a high pressure steam burn	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CARE		[Charles, Robert; Jackson, Robert; Dodman, James] Pinderfields Gen Hosp, Wakefield WF1 4DG, W Yorkshire, England	Pinderfields Hospital	Charles, R (corresponding author), Pinderfields Gen Hosp, Wakefield WF1 4DG, W Yorkshire, England.	robcharles@doctors.org.uk						American College of Surgeons, 2012, ADV TRAUM LIF SUPP S, P230; Bishop S, 2012, BJA EDUC, V12, P118, DOI 10.1093/bjaceaccp/mks001; British Burn Association, 2001, NAT BURN CAR REV 200; Brusselaers N, 2010, CRIT CARE, V14, DOI 10.1186/cc9300; Edgar D, 2004, BMJ-BRIT MED J, V329, P343, DOI 10.1136/bmj.329.7461.343; Endorf FW, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-69; Latenser BA, 2009, CRIT CARE MED, V37, P2819, DOI 10.1097/CCM.0b013e3181b3a08f; Mitchell CJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2856; National Network for Burn Care, 2011, NAT BURN CAR REF GUI; Norman AT., 2004, CONTIN ED ANAESTHESI, V4, P57; Procter Fiona, 2010, Indian J Plast Surg, V43, pS101, DOI 10.4103/0970-0358.70730; Singer A, 2000, EMERG MED PRACT, V2, P1; Spanholtz TA, 2009, DTSCH ARZTEBL INT, V106, P607, DOI 10.3238/arztebl.2009.0607	13	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 1	2014	349								g5278	10.1136/bmj.g5278	http://dx.doi.org/10.1136/bmj.g5278			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AO5LH	25179860				2023-01-03	WOS:000341385800002
J	Jho, HJ; Kim, Y; Kong, KA; Kim, DH; Choi, JY; Nam, EJ; Choi, JY; Koh, S; Hwang, KO; Baek, SK; Park, EJ				Jho, Hyun Jung; Kim, Yeol; Kong, Kyung Ae; Kim, Dae Hyun; Choi, Jin Young; Nam, Eun Jeong; Choi, Jin Young; Koh, Sujin; Hwang, Kwan Ok; Baek, Sun Kyung; Park, Eun Jung			Knowledge, Practices, and Perceived Barriers Regarding Cancer Pain Management among Physicians and Nurses in Korea: A Nationwide Multicenter Survey	PLOS ONE			English	Article							HEALTH-CARE PROVIDERS; ATTITUDES; PREVALENCE; EDUCATION; DOCTORS; MODEL	Purpose: Medical professionals' practices and knowledge regarding cancer pain management have often been cited as inadequate. This study aimed to evaluate knowledge, practices and perceived barriers regarding cancer pain management among physicians and nurses in Korea. Methods: A nationwide questionnaire survey was administered to physicians and nurses involved in the care of cancer patients. Questionnaire items covered pain assessment and documentation practices, knowledge regarding cancer pain management, the perceived barriers to cancer pain control, and processes perceived as the major causes of delay in opioid administration. Results: A total of 333 questionnaires (149 physicians and 284 nurses) were analyzed. Nurses performed pain assessment and documentation more regularly than physicians did. Although physicians had better knowledge of pain management than did nurses, both groups lacked knowledge regarding the side effects and pharmacology of opioids. Physicians working in the palliative care ward and nurses who had received pain management education obtained higher scores on knowledge. Physicians perceived patients' reluctance to take opioids as a barrier to pain control, more so than did nurses, while nurses perceived patients' tendency to under-report of pain as a barrier, more so than did physicians. Physicians and nurses held different perceptions regarding major cause of delay during opioid administration. Conclusions: There were differences between physicians and nurses in knowledge and practices for cancer pain management. An effective educational strategy for cancer pain management is needed in order to improve medical professionals' knowledge and clinical practices.	[Jho, Hyun Jung; Choi, Jin Young; Park, Eun Jung] Natl Canc Ctr, Natl Canc Control Inst, Hosp & Palliat Care Branch, Goyang, South Korea; [Kim, Yeol] Natl Canc Ctr, Natl Canc Control Inst, Div Canc Management & Policy, Goyang, South Korea; [Kong, Kyung Ae] Ewha Womans Univ, Med Ctr, Clin Trial Ctr, Seoul, South Korea; [Kim, Dae Hyun] Natl Canc Ctr, Dept Pain & Anesthesiol, Goyang, South Korea; [Nam, Eun Jeong; Choi, Jin Young] Natl Canc Ctr, Dept Nursing, Goyang, South Korea; [Koh, Sujin] Ulsan Univ Hosp, Dept Hematol & Oncol, Ulsan, South Korea; [Hwang, Kwan Ok] Korean Hosp & Palliat Nurse Assoc, Taejon, South Korea; [Baek, Sun Kyung] Kyung Hee Univ, Med Ctr, Dept Med Oncol & Hematol, Seoul, South Korea	National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); Ewha Womans University; National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); University of Ulsan; Ulsan University Hospital; Kyung Hee University	Kim, Y (corresponding author), Natl Canc Ctr, Natl Canc Control Inst, Div Canc Management & Policy, Goyang, South Korea.	drheat@ncc.re.kr			National Cancer Center [1032040-1]	National Cancer Center	This research was funded by National Cancer Center grant number 1032040-1. URL of funder http://ncc.re.kr/english/index.jsp. YK received the funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bernardi M, 2007, EUR J ONCOL NURS, V11, P272, DOI 10.1016/j.ejon.2006.09.003; Bookbinder M, 1996, J PAIN SYMPTOM MANAG, V12, P334, DOI 10.1016/S0885-3924(96)00204-7; Breuer B, 2011, J CLIN ONCOL, V29, P4769, DOI 10.1200/JCO.2011.35.0561; Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419; Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056; Furstenberg CT, 1998, J PAIN SYMPTOM MANAG, V15, P335, DOI 10.1016/S0885-3924(98)00023-2; Gallagher R, 2004, Pain Res Manag, V9, P188; Ger LP, 2000, J PAIN SYMPTOM MANAG, V20, P335, DOI 10.1016/S0885-3924(00)00207-4; Gunnarsdottir S, 2002, PAIN, V99, P385, DOI 10.1016/S0304-3959(02)00243-9; International Associations for the Study of Pain, 2008, BARR CANC PAIN TREAT; Jeon YS, 2007, SUPPORT CARE CANCER, V15, P463, DOI 10.1007/s00520-006-0183-x; Jung KW, 2013, CANCER RES TREAT, V45, P15, DOI 10.4143/crt.2013.45.1.15; Kim HJ, 2012, ASIAN ONCOL NURS, V12, P147, DOI 10.5388/aon.2012.12.2.147; Kim MH, 2011, JPN J CLIN ONCOL, V41, P783, DOI 10.1093/jjco/hyr043; Lebovits AH, 1997, CLIN J PAIN, V13, P237, DOI 10.1097/00002508-199709000-00009; Lui LYY, 2008, J CLIN NURS, V17, P2014, DOI 10.1111/j.1365-2702.2007.02183.x; Meuser T, 2001, PAIN, V93, P247, DOI 10.1016/S0304-3959(01)00324-4; Pargeon KL, 1999, J PAIN SYMPTOM MANAG, V18, P358, DOI 10.1016/S0885-3924(99)00097-4; Sapir R, 1999, J PAIN SYMPTOM MANAG, V17, P266, DOI 10.1016/S0885-3924(98)00156-0; Su YJ, 2010, SUPPORT CARE CANCER, V18, P1455, DOI 10.1007/s00520-009-0768-2; Sun VCY, 2007, J PAIN SYMPTOM MANAG, V34, P359, DOI 10.1016/j.jpainsymman.2006.12.011; Visentin M, 2001, J PAIN SYMPTOM MANAG, V22, P925, DOI 10.1016/S0885-3924(01)00355-4; Weissman DE, 1996, J PAIN SYMPTOM MANAG, V12, P364, DOI 10.1016/S0885-3924(96)00185-6; WEISSMAN DE, 1995, J PAIN SYMPTOM MANAG, V10, P292, DOI 10.1016/0885-3924(95)00006-K; World Health Organization, 1996, CANC PAIN REL GUID O; Xue Ying, 2007, Clin J Oncol Nurs, V11, P687; Yun YH, 2003, J PAIN SYMPTOM MANAG, V25, P430, DOI 10.1016/S0885-3924(03)00103-9; 전명희, 2006, [The Journal of Korean Academic Society of Nursing Education, 한국간호교육학회지], V12, P115; 박현애, 2003, [Korean Journal of Adult Nursing, 성인간호학회지], V15, P205	29	44	46	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2014	9	8							e105900	10.1371/journal.pone.0105900	http://dx.doi.org/10.1371/journal.pone.0105900			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO1WL	25144641	Green Submitted, Green Published, gold			2023-01-03	WOS:000341106100127
J	Kalikaki, A; Politaki, H; Souglakos, J; Apostolaki, S; Papadimitraki, E; Georgoulia, N; Tzardi, M; Mavroudis, D; Georgoulias, V; Voutsina, A				Kalikaki, Aristea; Politaki, Helen; Souglakos, John; Apostolaki, Stella; Papadimitraki, Elisavet; Georgoulia, Nefeli; Tzardi, Maria; Mavroudis, Dimitris; Georgoulias, Vassilis; Voutsina, Alexandra			KRAS Genotypic Changes of Circulating Tumor Cells during Treatment of Patients with Metastatic Colorectal Cancer	PLOS ONE			English	Article							ACQUIRED-RESISTANCE; PROGRESSION-FREE; MUTATIONS; EGFR; DNA; HETEROGENEITY; SURVIVAL; THERAPY; PREDICT; BRAF	Introduction: Circulating tumor cells (CTCs) could represent a non-invasive source of cancer cells used for longitudinal monitoring of the tumoral mutation status throughout the course of the disease. The aims of the present study were to investigate the detection of KRAS mutations in CTCs from patients with metastatic colorectal cancer (mCRC) and to compare their mutation status during treatment or disease progression with that of the corresponding primary tumors. Materials and Methods: Identification of the seven most common KRAS mutations on codons 12 and 13 was performed by Peptide Nucleic Acid (PNA)-based qPCR method. The sensitivity of the assay was determined after isolation of KRAS mutant cancer cells spiked into healthy donors' blood, using the CellSearch Epithelial Cell kit. Consistent detection of KRAS mutations was achieved in samples containing at least 10 tumor cells/7.5 ml of blood. Results: The clinical utility of the assay was assessed in 48 blood samples drawn from 31 patients with mCRC. All patients had PIK3CA and BRAF wild type primary tumors and 14 KRAS mutant tumors. CTCs were detected in 65% of specimens obtained from 74% of patients. KRAS mutation analysis in CTC-enriched specimens showed that 45% and 16.7% of patients with mutant and wild type primary tumors, respectively, had detectable mutations in their CTCs. Assessing KRAS mutations in serial blood samples revealed that individual patient's CTCs exhibited different mutational status of KRAS during treatment. Conclusions: The current findings support the rationale for using the CTCs as a dynamic source of tumor cells which, by re-evaluating their KRAS mutation status, could predict, perhaps more accurately, the response of mCRC patients to targeted therapy.	[Kalikaki, Aristea; Politaki, Helen; Souglakos, John; Apostolaki, Stella; Georgoulia, Nefeli; Mavroudis, Dimitris; Georgoulias, Vassilis; Voutsina, Alexandra] Univ Crete, Sch Med, Tumor Cell Biol Lab, Iraklion, Crete, Greece; [Souglakos, John; Papadimitraki, Elisavet; Mavroudis, Dimitris; Georgoulias, Vassilis] Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion, Crete, Greece; [Tzardi, Maria] Univ Gen Hosp Heraklion, Dept Pathol, Iraklion, Crete, Greece	University of Crete; University Hospital of Heraklion; University Hospital of Heraklion	Voutsina, A (corresponding author), Univ Crete, Sch Med, Tumor Cell Biol Lab, Iraklion, Crete, Greece.	voutsina@med.uoc.gr			Cretan Association for Biomedical Research (CABR); Hellenic Society of Medical Oncology (HeSMO); Operational Programme "Competitiveness & Entrepreneurship", National Strategic Reference Framework; National Action: "Cooperation", OncoSeed Diagnostics: Biology of Circulating Tumour Cells, Distant Metastasis & Development of Liquid Biopsy Methods; General Secretariat of Research and Technology of Greece	Cretan Association for Biomedical Research (CABR); Hellenic Society of Medical Oncology (HeSMO); Operational Programme "Competitiveness & Entrepreneurship", National Strategic Reference Framework; National Action: "Cooperation", OncoSeed Diagnostics: Biology of Circulating Tumour Cells, Distant Metastasis & Development of Liquid Biopsy Methods; General Secretariat of Research and Technology of Greece	This work was supported by research grants from the Cretan Association for Biomedical Research (CABR), the Hellenic Society of Medical Oncology (HeSMO) and the Operational Programme "Competitiveness & Entrepreneurship", National Strategic Reference Framework 2007-2013, National Action: "Cooperation", OncoSeed Diagnostics: Biology of Circulating Tumour Cells, Distant Metastasis & Development of Liquid Biopsy Methods; General Secretariat of Research and Technology of Greece. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggarwal C, 2013, ANN ONCOL, V24, P420, DOI 10.1093/annonc/mds336; Allen JE, 2010, CURR COLORECT CANC R, V6, P212, DOI 10.1007/s11888-010-0069-7; Baldus SE, 2010, CLIN CANCER RES, V16, P790, DOI 10.1158/1078-0432.CCR-09-2446; Cohen SJ, 2008, J CLIN ONCOL, V26, P3213, DOI 10.1200/JCO.2007.15.8923; Coumans FAW, 2010, ANN ONCOL, V21, P1851, DOI 10.1093/annonc/mdq030; Danila DC, 2011, CLIN CANCER RES, V17, P3903, DOI 10.1158/1078-0432.CCR-10-2650; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Di Fiore F, 2008, BRIT J CANCER, V99, P551, DOI 10.1038/sj.bjc.6604451; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789; Flores LM, 2010, BRIT J CANCER, V102, P1495, DOI 10.1038/sj.bjc.6605676; Garrigos N, 2010, CLIN TRANSL ONCOL, V12, P142, DOI 10.1007/S12094-010-0479-7; Gasch C, 2013, CLIN CHEM, V59, P252, DOI 10.1373/clinchem.2012.188557; Harb W, 2013, TRANSL ONCOL, V6, P528, DOI 10.1593/tlo.13367; Hayes DF, 2006, CLIN CANCER RES, V12, P4218, DOI 10.1158/1078-0432.CCR-05-2821; Heitzer E, 2013, CANCER RES, V73, P2965, DOI 10.1158/0008-5472.CAN-12-4140; Hodgkinson CL, 2014, NAT MED; Jiang YQ, 2010, CLIN CHEM, V56, P1492, DOI 10.1373/clinchem.2010.143297; Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834; Krebs MG, 2011, J CLIN ONCOL, V29, P1556, DOI 10.1200/JCO.2010.28.7045; Luo JD, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj008; Magbanua MJM, 2013, CANCER RES, V73, P30, DOI 10.1158/0008-5472.CAN-11-3017; Magbanua MJM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-78; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; McShane LM, 2005, J CLIN ONCOL, V23, P9067, DOI 10.1200/JCO.2004.01.0454; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Mostert B, 2013, INT J CANCER, V133, P130, DOI 10.1002/ijc.27987; Ni XH, 2013, P NATL ACAD SCI USA, V110, P21083, DOI 10.1073/pnas.1320659110; Parkinson DR, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-138; Punnoose EA, 2012, CLIN CANCER RES, V18, P2391, DOI 10.1158/1078-0432.CCR-11-3148; Sastre J, 2012, ONCOLOGIST, V17, P947, DOI 10.1634/theoncologist.2012-0048; Schneck H, 2013, MOL ONCOL; Fernandez MJS, 2009, CLIN TRANSL ONCOL, V11, P659, DOI 10.1007/s12094-009-0421-z; Sieuwerts AM, 2009, BREAST CANCER RES TR, V118, P455, DOI 10.1007/s10549-008-0290-0; Skvortsova TE, 2006, BRIT J CANCER, V94, P1492, DOI 10.1038/sj.bjc.6603117; Stoecklein NH, 2010, INT J CANCER, V126, P589, DOI 10.1002/ijc.24916; Stott SL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000403; Tol J, 2009, ANN ONCOL, V20, P24; Vermaat JS, 2012, CLIN CANCER RES, V18, P688, DOI 10.1158/1078-0432.CCR-11-1965; Voutsina A, 2012, MOD PATHOL; Voutsina A, 2013, MODERN PATHOL, V26, P302, DOI 10.1038/modpathol.2012.150; Watanabe T, 2011, DIS COLON RECTUM, V54, P1170, DOI 10.1097/DCR.0b013e31821d37a3	42	36	37	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2014	9	8							e104902	10.1371/journal.pone.0104902	http://dx.doi.org/10.1371/journal.pone.0104902			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN6XM	25137394	gold, Green Submitted, Green Published			2023-01-03	WOS:000340742100053
J	Zhang, P; Xi, M; Zhao, L; Shen, JX; Li, QQ; He, LR; Liu, SL; Liu, MZ				Zhang, Peng; Xi, Mian; Zhao, Lei; Shen, Jing-Xian; Li, Qiao-Qiao; He, Li-Ru; Liu, Shi-Liang; Liu, Meng-Zhong			Is There a Benefit in Receiving Concurrent Chemoradiotherapy for Elderly Patients with Inoperable Thoracic Esophageal Squamous Cell Carcinoma?	PLOS ONE			English	Article							DEFINITIVE CHEMORADIOTHERAPY; PROGNOSTIC-FACTORS; CANCER; CHEMORADIATION; OLDER; OUTCOMES; ADENOCARCINOMA; COMPLICATIONS; CHEMOTHERAPY; RADIOTHERAPY	Background and purpose: The benefit of concurrent chemoradiotherapy (CCRT) in elderly patients with inoperable esophageal squamous cell carcinoma (SCC) is controversial. This study aimed to assess the efficiency and safety of CCRT in elderly thoracic esophageal cancer patients. Methods and materials: Between January 2002 and December 2011, 128 patients aged 65 years or older treated with CCRT or radiotherapy (RT) alone for inoperable thoracic esophageal SCC were analyzed retrospectively (RT alone, n = 55; CCRT, n = 73). Results: No treatment-related deaths occurred and no patients experienced any acute grade 4 non-hematologic toxicities. Patients treated with CCRT developed more severe acute toxicities than patients who received RT alone. The 3-year overall survival (OS) rate was 36.1% for CCRT compared with 28.5% following RT alone (p = 0.008). Multivariate analysis identified T stage and treatment modality as independent prognostic factors for survival. Further analysis revealed that survival was significantly better in the CCRT group than in the RT alone group for patients <= 72 years. Nevertheless, the CCRT group had a similar OS to the RT group for patients > 72 years. Conclusion: Our results suggest that elderly patients with inoperable thoracic esophageal SCC could benefit from CCRT, without major toxicities. However, for patients older than 72 years, CCRT is not superior to RT alone in terms of survival benefit.	[Zhang, Peng; Xi, Mian; Zhao, Lei; Li, Qiao-Qiao; He, Li-Ru; Liu, Shi-Liang; Liu, Meng-Zhong] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol,State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China; [Shen, Jing-Xian] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Imaging Diag & Intervent Ctr,State Key Lab Oncol, Guangzhou 510275, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Liu, MZ (corresponding author), Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol,State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China.	liumengzhong@126.com			Sci-Tech Project Foundation of Guangdong Province [42012B031800287]	Sci-Tech Project Foundation of Guangdong Province	This work was supported by the grant from the Sci-Tech Project Foundation of Guangdong Province (No.42012B031800287). Website: http://www.gdstc.gov.cn. PZ and MX received the funding. The funders provided help in data collection and analysis.	Anderson SE, 2007, BRIT J CANCER, V96, P1823, DOI 10.1038/sj.bjc.6603821; Eloubeidi MA, 2002, CANCER-AM CANCER SOC, V95, P1434, DOI 10.1002/cncr.10868; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Go SI, 2012, TUMORI, V98, P225, DOI 10.1700/1088.11934; Gockel I, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-114; HERSKOVIC A, 1992, NEW ENGL J MED, V326, P1593, DOI 10.1056/NEJM199206113262403; HISHIKAWA Y, 1991, INT J RADIAT ONCOL, V20, P685, DOI 10.1016/0360-3016(91)90009-S; Hsu FM, 2008, J SURG ONCOL, V98, P34, DOI 10.1002/jso.21063; Kinugasa S, 2001, ANN THORAC SURG, V71, P414, DOI 10.1016/S0003-4975(00)02333-X; Lagarde SM, 2006, J CLIN ONCOL, V24, P4347, DOI 10.1200/JCO.2005.04.9445; Law S, 2004, ANN SURG, V240, P791, DOI 10.1097/01.sla.0000143123.24556.1c; Li QQ, 2010, DIS ESOPHAGUS, V23, P253, DOI 10.1111/j.1442-2050.2009.01003.x; Liu H, 2011, RADIOTHER ONCOL, V99, P181, DOI 10.1016/j.radonc.2011.05.011; Mak RH, 2010, DIS ESOPHAGUS, V23, P316, DOI 10.1111/j.1442-2050.2009.01014.x; Morota M, 2009, INT J RADIAT ONCOL, V75, P122, DOI 10.1016/j.ijrobp.2008.10.075; Nallapareddy S, 2005, ANTICANCER RES, V25, P3055; Reid BC, 2001, CANCER, V92, P2109, DOI 10.1002/1097-0142(20011015)92:8<2109::AID-CNCR1552>3.0.CO;2-M; Sabel MS, 2002, ANN SURG ONCOL, V9, P210, DOI 10.1007/BF02557376; Semrau R, 2012, STRAHLENTHER ONKOL, V188, P226, DOI 10.1007/s00066-011-0039-2; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Steyerberg EW, 2007, J CLIN ONCOL, V25, P2389, DOI 10.1200/JCO.2006.09.7931; Takeuchi S, 2007, AM J CLIN ONCOL-CANC, V30, P607, DOI 10.1097/COC.0b013e3180ca7c84; Tougeron D, 2008, BRIT J CANCER, V99, P1586, DOI 10.1038/sj.bjc.6604749; Tougeron D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-510; Trumper M, 2006, EUR J CANCER, V42, P827, DOI 10.1016/j.ejca.2005.08.044; Wu Sen, 2012, Zhonghua Zhong Liu Za Zhi, V34, P873, DOI 10.3760/cma.j.issn.0253-3766.2012.11.017; Xu HY, 2014, ONCOL LETT, V7, P260, DOI 10.3892/ol.2013.1694; YAMAKAWA M, 1994, INT J RADIAT ONCOL, V30, P1225, DOI 10.1016/0360-3016(94)90333-6	28	25	30	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2014	9	8							e105270	10.1371/journal.pone.0105270	http://dx.doi.org/10.1371/journal.pone.0105270			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4JF	25133495	Green Submitted, gold, Green Published			2023-01-03	WOS:000341302700094
J	Galanter, WL; Bryson, ML; Falck, S; Rosenfield, R; Laragh, M; Shrestha, N; Schiff, GD; Lambert, BL				Galanter, William L.; Bryson, Michelle L.; Falck, Suzanne; Rosenfield, Rachel; Laragh, Marci; Shrestha, Neeha; Schiff, Gordon D.; Lambert, Bruce L.			Indication Alerts Intercept Drug Name Confusion Errors during Computerized Entry of Medication Orders	PLOS ONE			English	Article							VISUAL-PERCEPTION; TRIAL	Background: Confusion between similar drug names is a common cause of potentially harmful medication errors. Interventions to prevent these errors at the point of prescribing have had limited success. The purpose of this study is to measure whether indication alerts at the time of computerized physician order entry (CPOE) can intercept drug name confusion errors. Methods and Findings: A retrospective observational study of alerts provided to prescribers in a public, tertiary hospital and ambulatory practice with medication orders placed using CPOE. Consecutive patients seen from April 2006 through February 2012 were eligible if a clinician received an indication alert during ordering. A total of 54,499 unique patients were included. The computerized decision support system prompted prescribers to enter indications when certain medications were ordered without a coded indication in the electronic problem list. Alerts required prescribers either to ignore them by clicking OK, to place a problem in the problem list, or to cancel the order. Main outcome was the proportion of indication alerts resulting in the interception of drug name confusion errors. Error interception was determined using an algorithm to identify instances in which an alert triggered, the initial medication order was not completed, and the same prescriber ordered a similar-sounding medication on the same patient within 5 minutes. Similarity was defined using standard text similarity measures. Two clinicians performed chart review of all cases to determine whether the first, non-completed medication order had a documented or non-documented, plausible indication for use. If either reviewer found a plausible indication, the case was not considered an error. We analyzed 127,458 alerts and identified 176 intercepted drug name confusion errors, an interception rate of 0.14+/-6.01%. Conclusions: Indication alerts intercepted 1.4 drug name confusion errors per 1000 alerts. Institutions with CPOE should consider using indication prompts to intercept drug name confusion errors.	[Galanter, William L.; Falck, Suzanne; Laragh, Marci] UIC, Dept Med, Chicago, IL 60607 USA; [Galanter, William L.; Bryson, Michelle L.] UIC, Dept Pharm Practice, Chicago, IL USA; [Rosenfield, Rachel] Univ Illinois, Coll Med, Chicago, IL USA; [Shrestha, Neeha] UIC, Dept Pharm Adm, Chicago, IL USA; [Schiff, Gordon D.] Harvard Univ, Dept Med, Boston, MA 02115 USA; [Lambert, Bruce L.] Northwestern Univ, Dept Commun Studies, Chicago, IL 60611 USA; [Lambert, Bruce L.] Northwestern Univ, Ctr Commun & Hlth, Chicago, IL 60611 USA	University of Illinois System; University of Illinois Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; Harvard University; Northwestern University; Northwestern University	Galanter, WL (corresponding author), UIC, Dept Med, Chicago, IL 60607 USA.	BillG@uic.edu		Galanter, William/0000-0001-7811-5391	Agency for Healthcare Research and Quality [U19HS021093]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U19HS021093] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This study was supported by grant number U19HS021093 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aspden P, 2007, PREVENTING MED ERROR; Barker KN, 2002, ARCH INTERN MED, V162, P1897, DOI 10.1001/archinte.162.16.1897; Cina JL, 2006, JT COMM J QUAL PATIE, V32, P73, DOI 10.1016/S1553-7250(06)32010-7; Cohen M.R., 2007, MED ERRORS; Darker IT, 2011, ERGONOMICS, V54, P21, DOI 10.1080/00140139.2010.535022; Falck S, INT J MED I IN PRESS; Filik R, 2010, DRUG SAFETY, V33, P677, DOI 10.2165/11532360-000000000-00000; Flynn Elizabeth Allan, 2003, J Am Pharm Assoc (Wash), V43, P191; Galanter W, 2013, J AM MED INFORM ASSN, V20, P477, DOI 10.1136/amiajnl-2012-001555; Galanter WL, 2010, INT J MED INFORM, V79, P332, DOI 10.1016/j.ijmedinf.2008.05.005; Galanter WL, 2005, J AM MED INFORM ASSN, V12, P269, DOI 10.1197/jamia.M1727; HICKS RW, 2008, MEDMARX DATA REPORT; Institute for Safe Medication Practices (ISMP), 2010, ISMPS LIST CONF DRUG; Irwin A, 2013, HUM FACTORS, V55, P253, DOI 10.1177/0018720812457565; Kondrak G, 2006, ARTIF INTELL MED, V36, P29, DOI 10.1016/j.artmed.2005.07.005; Lambert BL, 2005, DRUG SAFETY, V28, P495, DOI 10.2165/00002018-200528060-00003; Lambert BL, 1999, MED CARE, V37, P1214, DOI 10.1097/00005650-199912000-00005; Lambert BL, 2008, MEDMARX DATA REPORT, P10; Poon EG, 2010, NEW ENGL J MED, V362, P1698, DOI 10.1056/NEJMsa0907115; Raschke RA, 1998, JAMA-J AM MED ASSOC, V280, P1317, DOI 10.1001/jama.280.15.1317; US FDA, 2014, GUID IND BEST PRACT; Walton SM, 2011, APPL CLIN INFORM, V2, P94, DOI 10.4338/ACI-2010-11-RA-0072	22	38	38	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2014	9	7							e101977	10.1371/journal.pone.0101977	http://dx.doi.org/10.1371/journal.pone.0101977			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AM6RN	25025346	Green Published, gold, Green Submitted			2023-01-03	WOS:000339992400032
J	Brazil, R				Brazil, Rachel			FOOD SCIENCE Fat chance	NATURE			English	Editorial Material							KETOGENIC DIET; EPILEPSY; EFFICACY											Chang PS, 2013, NEUROPHARMACOLOGY, V69, P105, DOI 10.1016/j.neuropharm.2012.11.004; Gimenez-Cassina A, 2012, NEURON, V74, P719, DOI 10.1016/j.neuron.2012.03.032; Hallbook T, 2012, EPILEPSY RES, V100, P304, DOI 10.1016/j.eplepsyres.2011.04.017; Hughes SD, 2014, J NEUROCHEM, V129, P426, DOI 10.1111/jnc.12646; Kobow K, 2013, ACTA NEUROPATHOL, V126, P741, DOI 10.1007/s00401-013-1168-8; Kossoff EH, 2003, NEUROLOGY, V61, P1789, DOI 10.1212/01.WNL.0000098889.35155.72; Kossoff EH, 2009, EPILEPSIA, V50, P304, DOI 10.1111/j.1528-1167.2008.01765.x; Levy RG, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001903.pub2, 10.1002/14651858.CD001903.pub3]; McNally MA, 2012, J NEUROCHEM, V121, P28, DOI 10.1111/j.1471-4159.2012.07670.x; Muzykewicz DA, 2009, EPILEPSIA, V50, P1118, DOI 10.1111/j.1528-1167.2008.01959.x	10	1	1	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 10	2014	511	7508					S14	S15		10.1038/511S14a	http://dx.doi.org/10.1038/511S14a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AK8AP	25019130				2023-01-03	WOS:000338649800007
J	Detry, MA; Lewis, RJ				Detry, Michelle A.; Lewis, Roger J.			The Intention-to-Treat Principle How to Assess the True Effect of Choosing a Medical Treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							NONINFERIORITY		[Detry, Michelle A.; Lewis, Roger J.] Berry Consultants LLC, Austin, TX USA; [Lewis, Roger J.] Harbor UCLA Med Ctr, Dept Emergency Med, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA; [Lewis, Roger J.] UCLA, David Geffen Sch Med, Torrance, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lewis, RJ (corresponding author), Harbor UCLA Med Ctr, Dept Emergency, Bldg D9,1000 W Carson St, Torrance, CA 90509 USA.	roger@emedharbor.edu						Cook T, 2008, INTRO STAT METHODS C; Food and Drug Administration, 1998, GUID IND E9 STAT PRI; Le Henanff A, 2006, JAMA-J AM MED ASSOC, V295, P1147, DOI 10.1001/jama.295.10.1147; Montedori A, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-58; Mulla SM, 2012, JAMA-J AM MED ASSOC, V308, P2605, DOI 10.1001/2012.jama.11235; Piaggio G, 2012, JAMA-J AM MED ASSOC, V308, P2594, DOI 10.1001/jama.2012.87802; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232	8	76	77	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2014	312	1					85	86		10.1001/jama.2014.7523	http://dx.doi.org/10.1001/jama.2014.7523			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AK0UK	25058221				2023-01-03	WOS:000338131100024
J	Anderson, RJ; Tang, CW; Daniels, NJ; Compton, BJ; Hayman, CM; Johnston, KA; Knight, DA; Gasser, O; Poyntz, HC; Ferguson, PM; Larsen, DS; Ronchese, F; Painter, GF; Hermans, IF				Anderson, Regan J.; Tang, Ching-wen; Daniels, Naomi J.; Compton, Benjamin J.; Hayman, Colin M.; Johnston, Karen A.; Knight, Deborah A.; Gasser, Olivier; Poyntz, Hazel C.; Ferguson, Peter M.; Larsen, David S.; Ronchese, Franca; Painter, Gavin F.; Hermans, Ian F.			A self-adjuvanting vaccine induces cytotoxic T lymphocytes that suppress allergy	NATURE CHEMICAL BIOLOGY			English	Article							ALPHA-GALACTOSYLCERAMIDE; DENDRITIC CELLS; NKT CELLS; IN-VIVO; AIRWAY INFLAMMATION; TLR7 AGONIST; ANTIGEN; LIGAND; HELP; ACTIVATION	Epitope-based peptide vaccines encompass minimal immunogenic regions of protein antigens to allow stimulation of precisely targeted adaptive immune responses. However, because efficacy is largely determined by the functional status of antigen-presenting cells (APCs) that acquire and present peptides to cells of the adaptive immune system, adjuvant compounds are needed to enhance immunogenicity. We present here a vaccine consisting of an allergen-derived peptide conjugated to a pro-drug of the natural killer-like T (NKT) cell agonist a-galactosylceramide, which is highly effective in reducing inflammation in a mouse model of allergic airway inflammation. Unlike other peptide-adjuvant conjugates that directly activate APCs through pattern recognition pathways, this vaccine encourages third-party interactions with NKT cells to enhance APC function. Therapeutic efficacy was correlated with marked increases in the number and functional activity of allergen-specific cytotoxic T lymphocytes (CTLs), leading to suppression of immune infiltration into the lungs after allergen challenge in sensitized hosts.	[Anderson, Regan J.; Compton, Benjamin J.; Hayman, Colin M.; Johnston, Karen A.; Painter, Gavin F.] Victoria Univ Wellington, Ferrier Res Inst, Wellington, New Zealand; [Tang, Ching-wen; Daniels, Naomi J.; Knight, Deborah A.; Gasser, Olivier; Poyntz, Hazel C.; Ronchese, Franca; Hermans, Ian F.] Malaghan Inst Med Res, Wellington, New Zealand; [Daniels, Naomi J.] Wellington Sch Med & Hlth Sci, Dept Pathol & Mol Med, Wellington, New Zealand; [Ferguson, Peter M.] Capital & Coast Dist Hlth Board, Wellington, New Zealand; [Larsen, David S.] Univ Otago, Dept Chem, Dunedin, New Zealand; [Hermans, Ian F.] Victoria Univ Wellington, Sch Biol Sci, Wellington, New Zealand	Victoria University Wellington; Malaghan Institute; Victoria University Wellington; University of Otago; University of Otago; Victoria University Wellington	Anderson, RJ (corresponding author), Victoria Univ Wellington, Ferrier Res Inst, Wellington, New Zealand.	gavin.painter@vuw.ac.nz; ihermans@malaghan.org.nz	Ronchese, Franca/M-9618-2019; Hermans, Ian/I-3961-2013; Larsen, David S/A-6367-2014	Ronchese, Franca/0000-0001-5835-8230; Larsen, David S/0000-0002-3563-1086; Ferguson, Peter M./0000-0002-8335-0406; Gasser, Olivier/0000-0002-8235-2274; Compton, Benjamin/0000-0002-5245-9767; Hermans, Ian/0000-0002-7584-887X; Anderson, Regan/0000-0003-3467-9202	New Zealand Ministry of Science and Innovation [C08X0808]; research grant from the New Zealand Health Research Council; Rotary Club of Wellington; University of Otago; US National Institutes of Health Tetramer Core Facility [HHSN272201300006C]	New Zealand Ministry of Science and Innovation; research grant from the New Zealand Health Research Council; Rotary Club of Wellington; University of Otago; US National Institutes of Health Tetramer Core Facility	We thank the personnel of the Biomedical Research Unit of the Malaghan Institute of Medical Research for animal husbandry, K. Price for flow cytometry support, and the US National Institutes of Health Tetramer Core Facility (contract HHSN272201300006C) for provision of CD1d monomers. This research was supported by the New Zealand Ministry of Science and Innovation (C08X0808) and a research grant from the New Zealand Health Research Council to ER. N.J.D. was supported by the Rotary Club of Wellington and the University of Otago.	Aguilar-Pimentel JA, 2010, AM J RESP CRIT CARE, V181, P7, DOI 10.1164/rccm.200902-0190OC; ALEXANDER J, 1988, J MED CHEM, V31, P318, DOI 10.1021/jm00397a008; ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Cui JQ, 1999, J EXP MED, V190, P783, DOI 10.1084/jem.190.6.783; Elewaut D, 2003, J EXP MED, V198, P1133, DOI 10.1084/jem.20030143; Enomoto N, 2012, J IMMUNOL, V188, P1734, DOI 10.4049/jimmunol.1102699; ERARD F, 1993, SCIENCE, V260, P1802, DOI 10.1126/science.8511588; Farrand KJ, 2009, J IMMUNOL, V183, P7732, DOI 10.4049/jimmunol.0902707; Flechtner JB, 2006, J IMMUNOL, V177, P1017, DOI 10.4049/jimmunol.177.2.1017; Freigang S, 2012, J CLIN INVEST, V122, P3943, DOI 10.1172/JCI62267; Fujii S, 2003, J EXP MED, V198, P267, DOI 10.1084/jem.20030324; Galli G, 2003, J EXP MED, V197, P1051, DOI 10.1084/jem.20021616; Gonzalez-Aseguinolaza G, 2002, J EXP MED, V195, P617, DOI 10.1084/jem.20011889; Hachem P, 2005, EUR J IMMUNOL, V35, P2793, DOI 10.1002/eji.200535268; Hermans IF, 2003, J IMMUNOL, V171, P5140, DOI 10.4049/jimmunol.171.10.5140; Hunn MK, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23789; Ingale S, 2007, NAT CHEM BIOL, V3, P663, DOI 10.1038/nchembio.2007.25; Jackson DC, 2004, P NATL ACAD SCI USA, V101, P15440, DOI 10.1073/pnas.0406740101; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Khan S, 2007, J BIOL CHEM, V282, P21145, DOI 10.1074/jbc.M701705200; Kim JO, 2004, J ALLERGY CLIN IMMUN, V114, P1332, DOI 10.1016/j.jaci.2004.09.004; Kitamura H, 2000, CELL IMMUNOL, V199, P37, DOI 10.1006/cimm.1999.1602; Lang GA, 2006, IMMUNOLOGY, V119, P116, DOI 10.1111/j.1365-2567.2006.02413.x; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; Matsuda H, 2005, AM J RESP CELL MOL, V33, P22, DOI 10.1165/rcmb.2004-0010OC; Meyer EH, 2006, P NATL ACAD SCI USA, V103, P2782, DOI 10.1073/pnas.0510282103; Miyahara N, 2004, NAT MED, V10, P865, DOI 10.1038/nm1081; Morishima Y, 2005, EUR J IMMUNOL, V35, P2803, DOI 10.1002/eji.200525994; Mustapa MFM, 2009, BIOCONJUGATE CHEM, V20, P518, DOI 10.1021/bc800450r; Oh JZ, 2010, J IMMUNOL, V185, P4602, DOI 10.4049/jimmunol.1001892; Parekh VV, 2005, J CLIN INVEST, V115, P2572, DOI 10.1172/JCI24762; Pellicci DG, 2009, IMMUNITY, V31, P47, DOI 10.1016/j.immuni.2009.04.018; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Semmling V, 2010, NAT IMMUNOL, V11, P313, DOI 10.1038/ni.1848; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Stober D, 2003, J IMMUNOL, V170, P2540, DOI 10.4049/jimmunol.170.5.2540; Tighe H, 2000, EUR J IMMUNOL, V30, P1939, DOI 10.1002/1521-4141(200007)30:7<1939::AID-IMMU1939>3.0.CO;2-#; van den Elzen P, 2005, NATURE, V437, P906, DOI 10.1038/nature04001; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Vecchi S, 2014, EUR J PHARM BIOPHARM, V87, P310, DOI 10.1016/j.ejpb.2014.01.002; Wells JW, 2007, J ALLERGY CLIN IMMUN, V119, P226, DOI 10.1016/j.jaci.2006.09.004; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255	46	56	59	0	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	NOV	2014	10	11					943	949		10.1038/NCHEMBIO.1640	http://dx.doi.org/10.1038/NCHEMBIO.1640			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	AR5JP	25282504				2023-01-03	WOS:000343621500017
J	Zhou, ZW; Zhang, BC; Guo, K; Li, W; Zhang, R; Zhang, PP; Li, YG				Zhou, Zhi-Wen; Zhang, Bu-Chun; Guo, Kai; Li, Wei; Zhang, Rui; Zhang, Peng-Pai; Li, Yi-Gang			Acute Impact of Pacing at Different Cardiac Sites on Left Ventricular Rotation and Twist in Dogs	PLOS ONE			English	Article							HEART-FAILURE; RESYNCHRONIZATION THERAPY; TISSUE-DOPPLER; SYNCHRONY; DYSSYNCHRONY; ACTIVATION; DURATION; TORSION; MODEL; APEX	Objectives: We evaluated the acute impact of different cardiac pacing sites on two-dimensional speckle-tracking echocardiography (STE) derived left ventricular (LV) rotation and twist in healthy dogs. Methods: Twelve dogs were used in this study. The steerable pacing electrodes were positioned into right heart through the superior or inferior vena cava, into LV through aorta across the aortic valve. The steerable pacing electrodes were positioned individually in the right atrium (RA), right ventricular apex (RVA), RV outflow tract (RVOT), His bundle (HB), LV apex (LVA) and LV high septum (LVS), individual pacing mode was applied at 10 minutes interval for at least 5 minutes from each position under fluoroscopy and ultrasound guidance and at stabilized hemodynamic conditions. LV short-axis images at the apical and basal levels were obtained during sinus rhythm and pacing. Offline STE analysis was performed. Rotation, twist, time to peak rotation (TPR), time to peak twist (TPT), and apical-basal rotation delay (rotational synchronization index, RSI) values were compared at various conditions. LV pressure was monitored simultaneously. Results: Anesthetic death occurred in 1 dog, and another dog was excluded because of bad imaging quality. Data from 10 dogs were analyzed. RVA, RVOT, HB, LVA, LVS, RARV (RA+RVA) pacing resulted in significantly reduced apical and basal rotation and twist, significantly prolonged apical TPR, TPT and RSI compared to pre-pacing and RA pacing (all P<0.05). The apical and basal rotation and twist values were significantly higher during HB pacing than during pacing at ventricular sites (all P<0.05, except basal rotation at RVA pacing). The apical TPR during HB pacing was significantly shorter than during RVOT and RVA pacing (both P<0.05). The LV end systolic pressure (LVESP) was significantly lower during ventricular pacing than during pre-pacing and RA pacing. Conclusions: Our results show that RA and HB pacing results in less acute reduction on LV twist, rotation and LVESP compared to ventricular pacing.	[Zhou, Zhi-Wen; Guo, Kai; Li, Wei; Zhang, Rui; Zhang, Peng-Pai; Li, Yi-Gang] Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Dept Cardiol, Shanghai 200030, Peoples R China; [Zhou, Zhi-Wen] Shanghai Xuhui Cent Hosp, Dept Cardiol, Shanghai, Peoples R China; [Zhang, Bu-Chun] Xuzhou Med Coll, Affiliated Hosp, Dept Cardiol, Xuzhou, Jiangsu, Peoples R China	Shanghai Jiao Tong University; Xuzhou Medical University	Li, YG (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Dept Cardiol, Shanghai 200030, Peoples R China.	drliyigang@outlook.com			China Postdoctoral Science Foundation [2012M511114]; National Natural Science Foundation of China [81070154, 81270258]; Shanghai Committee of Science and Technology [11JC1408200]	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee)	This work was supported by China Postdoctoral Science Foundation (NO: 2012M511114), the National Natural Science Foundation of China (No: 81070154 and 81270258), and the Shanghai Committee of Science and Technology (NO: 11JC1408200). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albertsen AE, 2008, EUROPACE, V10, P127, DOI 10.1093/europace/eum279; Barba-Pichardo R, 2008, REV ESP CARDIOL, V61, P1096; Barba-Pichardo R, 2013, EUROPACE, V15, P83, DOI 10.1093/europace/eus228; Barba-Pichardo R, 2010, EUROPACE, V12, P527, DOI 10.1093/europace/euq038; Burns AT, 2008, HEART, V94, P978, DOI 10.1136/hrt.2007.120410; Burns AT, 2009, JACC-CARDIOVASC IMAG, V2, P709, DOI 10.1016/j.jcmg.2009.01.015; Burns KV, 2011, J CARD FAIL, V17, P495, DOI 10.1016/j.cardfail.2011.02.011; Catanzariti D, 2013, EUROPACE, V15, P546, DOI 10.1093/europace/eus313; Delgado V, 2009, CIRC-ARRHYTHMIA ELEC, V2, P135, DOI 10.1161/CIRCEP.108.814608; Deshmukh PM, 2004, PACE, V27, P862, DOI 10.1111/j.1540-8159.2004.00548.x; Domenichini G, 2012, EUR J INTERN MED, V23, P621, DOI 10.1016/j.ejim.2012.03.012; Friedberg MK, 2006, AM J CARDIOL, V97, P101, DOI 10.1016/j.amjcard.2005.07.127; Hara M, 2011, ECHOCARDIOGR-J CARD, V28, P69, DOI 10.1111/j.1540-8175.2010.01257.x; Hu K, 1998, CARDIOVASC RES, V39, P401, DOI 10.1016/S0008-6363(98)00090-X; Hu K, 2013, EUR HEART J-CARD IMG, V14, P205, DOI 10.1093/ehjci/jes240; Ji L, 2010, ECHOCARDIOGR-J CARD, V27, P1219, DOI 10.1111/j.1540-8175.2010.01221.x; Johnson L, 2007, AM J PHYSIOL-HEART C, V293, pH3046, DOI 10.1152/ajpheart.00728.2007; Kavanagh KM, 2008, CARDIOVASC RES, V77, P81, DOI 10.1093/cvr/cvm036; Kim WJ, 2009, CIRC-CARDIOVASC IMAG, V2, P123, DOI 10.1161/CIRCIMAGING.108.794719; Manolis AS, 2006, PACE, V29, P298, DOI 10.1111/j.1540-8159.2006.00338.x; Matsuoka K, 2009, J AM SOC ECHOCARDIOG, V22, P914, DOI 10.1016/j.echo.2009.05.001; Neilan TG, 2008, AM J PHYSIOL-HEART C, V294, pH2106, DOI 10.1152/ajpheart.01128.2007; Nielsen JC, 2011, EUR HEART J, V32, P686, DOI 10.1093/eurheartj/ehr022; Occhetta Eraldo, 2007, Indian Pacing Electrophysiol J, V7, P110; Padeletti L, 2007, AM J CARDIOL, V100, P1556, DOI 10.1016/j.amjcard.2007.06.055; Peschar M, 2003, J AM COLL CARDIOL, V41, P1218, DOI 10.1016/S0735-1097(03)00091-3; Poerner TC, 2007, ULTRASOUND MED BIOL, V33, P699, DOI 10.1016/j.ultrasmedbio.2006.11.014; RADEMAKERS FE, 1992, CIRCULATION, V85, P1572, DOI 10.1161/01.CIR.85.4.1572; Russel IK, 2009, JACC-CARDIOVASC IMAG, V2, P648, DOI 10.1016/j.jcmg.2009.03.001; Sade LE, 2008, AM J CARDIOL, V101, P1163, DOI 10.1016/j.amjcard.2007.11.069; Simantirakis EN, 2009, EUROPACE, V11, P77, DOI 10.1093/europace/eup277; Smith JJ, 1990, CIRCULATORY PHYSL ES, P40; Sweeney MO, 2003, CIRCULATION, V107, P2932, DOI 10.1161/01.CIR.0000072769.17295.B1; Takeuchi M, 2007, EUR HEART J, V28, P2756, DOI 10.1093/eurheartj/ehm440; Tanabe M, 2008, J AM SOC ECHOCARDIOG, V21, P1382, DOI 10.1016/j.echo.2008.09.012; van Deursen C, 2009, CIRC-ARRHYTHMIA ELEC, V2, P580, DOI 10.1161/CIRCEP.108.846022; Vanerio G, 2008, J INTERV CARD ELECTR, V21, P195, DOI 10.1007/s10840-008-9238-x; Varma N, 2012, J ELECTROCARDIOL, V45, P660, DOI 10.1016/j.jelectrocard.2012.07.003; Yoon HJ, 2009, ECHOCARDIOGR-J CARD, V26, P665, DOI 10.1111/j.1540-8175.2008.00855.x	39	1	1	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2014	9	10							e111231	10.1371/journal.pone.0111231	http://dx.doi.org/10.1371/journal.pone.0111231			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR5ZY	25340769	gold, Green Published, Green Submitted			2023-01-03	WOS:000343662800096
J	Tincati, C; Basilissi, M; Sinigaglia, E; Merlini, E; Carpani, G; Monforte, AD; Marchetti, G				Tincati, Camilla; Basilissi, Matteo; Sinigaglia, Elisabetta; Merlini, Esther; Carpani, Giovanni; Monforte, Antonella d'Arminio; Marchetti, Giulia			Invariant Natural Killer T (iNKT) Cells in HAART-Treated, HIV-Positive Patients with Bone and Cardiovascular Impairment	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; CD1D-RESTRICTED NKT CELLS; CAROTID-ARTERY-DISEASE; IMMUNE ACTIVATION; ANTIRETROVIRAL THERAPY; HUMAN ATHEROSCLEROSIS; TYPE-1 INFECTION; EXPRESSION; INFLAMMATION; MARKERS	Background: Invariant Natural Killer T (iNKT) cells represent a determinant in the course of infections and diseases, however, their role in the pathogenesis of non-infectious co-morbidities in HIV-positive patients is unknown. Methods: Flow cytometry was used to investigate iNKT cell frequency, phenotype and function in HIV-infected patients on HAART with bone and/or cardiovascular disorders and in HIV-positive controls free from co-morbidities. Results: iNKT cells from subjects with bone and cardiovascular impairment expressed high levels of CD161 and predominantly secreted TNF. iNKT cells from individuals with bone disease alone did not show any distinctive phenotypical or functional characteristics. The functional capacity of iNKT cells in patients with cardiovascular disorder was impaired with no cytokine release upon stimulation. Conclusion: iNKT cells may have a role in non-infectious co-morbidities in treated HIV disease, possibly through the exacerbation of inflammation. Further studies are needed to investigate iNKT cells in the pathogenesis of non-communicable disorders in HIV infection.	[Tincati, Camilla; Basilissi, Matteo; Merlini, Esther; Monforte, Antonella d'Arminio; Marchetti, Giulia] Univ Milan, Dept Hlth Sci, Clin Infect Dis & Trop Med, San Paolo Hosp, Milan, Italy; [Sinigaglia, Elisabetta; Carpani, Giovanni] San Paolo Hosp, Blood Transfus Unit, Milan, Italy	San Paolo-Polo Universitaria Hospital; University of Milan; San Paolo-Polo Universitaria Hospital	Marchetti, G (corresponding author), Univ Milan, Dept Hlth Sci, Clin Infect Dis & Trop Med, San Paolo Hosp, Milan, Italy.	giulia.marchetti@unimi.it	Marchetti, Giulia/GPX-7655-2022; Gori, Andrea/AAC-6078-2022; MARCHETTI, GIULIA CARLA/K-4384-2018; TINCATI, CAMILLA/K-4501-2018	MARCHETTI, GIULIA CARLA/0000-0002-4498-4828; TINCATI, CAMILLA/0000-0002-3083-2962	Italian Ministry of Health [GR-2009-1592029, 9Ab87b2822]	Italian Ministry of Health(Ministry of Health, Italy)	Grants from Italian Ministry of Health (GR-2009-1592029) and the Fellowship Program 2012 (9Ab87b2822). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andoh Y, 2006, CORONARY ARTERY DIS, V17, P523, DOI 10.1097/00019501-200609000-00005; Aslanian AM, 2005, ARTERIOSCL THROM VAS, V25, P628, DOI 10.1161/01.ATV.0000153046.59370.13; Baker J, 2010, J INFECT DIS, V201, P285, DOI 10.1086/649560; BENDELAC A, 1995, SCIENCE, V269, P185, DOI 10.1126/science.7542402; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Berzins SP, 2005, EUR J IMMUNOL, V35, P1399, DOI 10.1002/eji.200425958; Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302; Chan WL, 2005, CIRC RES, V96, P675, DOI 10.1161/01.RES.0000160543.84254.f1; de Lalla C, 2004, J IMMUNOL, V173, P1417, DOI 10.4049/jimmunol.173.2.1417; Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7; Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756; Desai Seema, 2010, Curr HIV/AIDS Rep, V7, P4, DOI 10.1007/s11904-009-0038-4; Desquilbet L, 2009, JAIDS-J ACQ IMM DEF, V50, P299, DOI 10.1097/QAI.0b013e3181945eb0; Fernandez CS, 2014, IMMUNOL CELL BIOL, V92, P578, DOI 10.1038/icb.2014.25; Fleuridor R, 2003, IMMUNOLOGY, V108, P3, DOI 10.1046/j.1365-2567.2003.01560.x; Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016; Funderburg NT, 2010, BLOOD, V115, P161, DOI 10.1182/blood-2009-03-210179; Gazzola L, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-51; GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904; Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660; Hu M, 2011, J IMMUNOL, V186, P2910, DOI 10.4049/jimmunol.1002353; Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786; Ibarrondo FJ, 2013, MUCOSAL IMMUNOL, V6, P591, DOI 10.1038/mi.2012.101; Joyee AG, 2007, J IMMUNOL, V178, P1048, DOI 10.4049/jimmunol.178.2.1048; Juno JA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002838; Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140-6736(02)08761-5; Kaplan RC, 2011, ATHEROSCLEROSIS, V217, P207, DOI 10.1016/j.atherosclerosis.2011.03.011; Kaplan RC, 2011, J INFECT DIS, V203, P452, DOI 10.1093/infdis/jiq071; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Kyriakakis E, 2010, EUR J IMMUNOL, V40, P3268, DOI 10.1002/eji.201040619; Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83, DOI 10.1097/00042560-199710010-00003; Longenecker CT, 2013, HIV MED, V14, P385, DOI 10.1111/hiv.12013; Major AS, 2004, ARTERIOSCL THROM VAS, V24, P2351, DOI 10.1161/01.ATV.0000147112.84168.87; Melian A, 1999, AM J PATHOL, V155, P775, DOI 10.1016/S0002-9440(10)65176-0; Merlini E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046073; Moll M, 2009, EUR J IMMUNOL, V39, P902, DOI 10.1002/eji.200838780; Motsinger A, 2002, J EXP MED, V195, P869, DOI 10.1084/jem.20011712; Nakai Y, 2004, BLOOD, V104, P2051, DOI 10.1182/blood-2003-10-3485; Neuhaus J, 2010, J INFECT DIS, V201, P1788, DOI 10.1086/652749; Ostos MA, 2002, FEBS LETT, V519, P23, DOI 10.1016/S0014-5793(02)02692-3; Reilly EC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037991; SALONEN JT, 1993, CIRCULATION, V87, P56; Sandberg JK, 2004, P NATL ACAD SCI USA, V101, P7058, DOI 10.1073/pnas.0305986101; Sandberg JK, 2002, J VIROL, V76, P7528, DOI 10.1128/JVI.76.15.7528-7534.2002; Smyth MJ, 2000, J EXP MED, V191, P661, DOI 10.1084/jem.191.4.661; Snyder-Cappione JE, 2007, J INFECT DIS, V195, P1361, DOI 10.1086/513567; Snyder-Cappione JE, 2013, EUR J IMMUNOL, V43, P2194, DOI 10.1002/eji.201243185; Snyder-Cappione JE, 2009, AIDS, V23, P1965, DOI 10.1097/QAD.0b013e32832b5134; Subleski JJ, 2011, IMMUNOTHERAPY-UK, V3, P1167, DOI [10.2217/IMT.11.117, 10.2217/imt.11.117]; Tarazona R, 2000, MECH AGEING DEV, V121, P77; Terabe M, 2000, NAT IMMUNOL, V1, P515, DOI 10.1038/82771; Tincati C, 2009, JAIDS-J ACQ IMM DEF, V51, P642, DOI 10.1097/QAI.0b013e3181add695; To K, 2009, ARTERIOSCL THROM VAS, V29, P671, DOI 10.1161/ATVBAHA.108.182592; Tupin E, 2004, J EXP MED, V199, P417, DOI 10.1084/jem.20030997; van der Vliet HJJ, 2006, J IMMUNOL, V177, P5775, DOI 10.4049/jimmunol.177.9.5775; van der Vliet HJJ, 2002, J IMMUNOL, V168, P1490, DOI 10.4049/jimmunol.168.3.1490; VanderLaan PA, 2007, AM J PATHOL, V170, P1100, DOI 10.2353/ajpath.2007.060188; Vasan S, 2007, INT IMMUNOL, V19, P943, DOI 10.1093/intimm/dxm055; Yang OO, 2007, AIDS RES HUM RETROV, V23, P913, DOI 10.1089/aid.2006.0253	59	6	7	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2014	9	10							e110287	10.1371/journal.pone.0110287	http://dx.doi.org/10.1371/journal.pone.0110287			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8TF	25329381	Green Published, Green Submitted, gold			2023-01-03	WOS:000345204100056
J	Wade, TJ; Lin, CJ; Jagai, JS; Hilborn, ED				Wade, Timothy J.; Lin, Cynthia J.; Jagai, Jyotsna S.; Hilborn, Elizabeth D.			Flooding and Emergency Room Visits for Gastrointestinal Illness in Massachusetts: A Case-Crossover Study	PLOS ONE			English	Article							UNITED-STATES; RISK; EVENTS; DESIGN; HEALTH; STRATEGIES; OUTBREAKS; EXPOSURE; ENGLAND; DISEASE	Introduction: Floods and other severe weather events are anticipated to increase as a result of global climate change. Floods can lead to outbreaks of gastroenteritis and other infectious diseases due to disruption of sewage and water infrastructure and impacts on sanitation and hygiene. Floods have also been indirectly associated with outbreaks through population displacement and crowding. Methods: We conducted a case-crossover study to investigate the association between flooding and emergency room visits for gastrointestinal illness (ER-GI) in Massachusetts for the years 2003 through 2007. We obtained ER-GI visits from the State of Massachusetts and records of floods from the National Oceanic and Atmospheric Association's Storm Events Database. ER-GI visits were considered exposed if a flood occurred in the town of residence within three hazard periods of the visit: 04 days; 5-9 days; and 10-14 days. A time-stratified bi-directional design was used for control selection, matching on day of the week with two weeks lead or lag time from the ER-GI visit. Fixed effect logistic regression models were used to estimate the risk of ER-GI visits following the flood. Results and Conclusions: A total of 270,457 ER-GI visits and 129 floods occurred in Massachusetts over the study period. Across all counties, flooding was associated with an increased risk for ER-GI in the 0-4 day period after flooding (Odds Ratio: 1.08; 95% Confidence Interval: 1.03-1.12); but not the 5-9 days (Odds Ratio: 0.995; 95% Confidence Interval: 0.955-1.04) or the 10-14 days after (Odds Ratio: 0.966, 95% Confidence Interval: 0.927-1.01). Similar results were observed for different definitions of ER-GI. The effect differed across counties, suggesting local differences in the risk and impact of flooding. Statewide, across the study period, an estimated 7% of ER-GI visits in the 0-4 days after a flood event were attributable to flooding.	[Wade, Timothy J.; Hilborn, Elizabeth D.] United States Environm Protect Agcy, Natl Hlth & Environm Effects Res Lab, Environm Publ Hlth Div, Chapel Hill, NC 27514 USA; [Lin, Cynthia J.] United States Environm Protect Agcy, ORISE, Res Participat Program, Chapel Hill, NC USA; [Lin, Cynthia J.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA; [Jagai, Jyotsna S.] Univ Illinois, Sch Publ Hlth, Div Environm & Occupat Hlth Sci, Chicago, IL USA	United States Environmental Protection Agency; Oak Ridge Associated Universities; United States Department of Energy (DOE); Oak Ridge Institute for Science & Education; United States Environmental Protection Agency; University of North Carolina; University of North Carolina Chapel Hill; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Wade, TJ (corresponding author), United States Environm Protect Agcy, Natl Hlth & Environm Effects Res Lab, Environm Publ Hlth Div, Chapel Hill, NC 27514 USA.	wade.tim@epa.gov		Hilborn, Elizabeth/0000-0002-3035-3101	United States Environmental Protection Agency	United States Environmental Protection Agency(United States Environmental Protection Agency)	This work was funded by the United States Environmental Protection Agency. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashley WS, 2005, B AM METEOROL SOC, V86, P1577, DOI 10.1175/BAMS-86-11-1577; Bouza E, 2012, CLIN MICROBIOL INFEC, V18, P5, DOI 10.1111/1469-0691.12064; Curriero FC, 2001, AM J PUBLIC HEALTH, V91, P1194, DOI 10.2105/AJPH.91.8.1194; de Man H, 2014, WATER RES, V48, P90, DOI 10.1016/j.watres.2013.09.022; Ding GY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065112; Greenough G, 2001, ENVIRON HEALTH PERSP, V109, P191, DOI 10.2307/3435009; Hanley JA, 2001, J EPIDEMIOL COMMUN H, V55, P508, DOI 10.1136/jech.55.7.508; Harder-Lauridsen NM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078371; Janes H, 2005, STAT MED, V24, P285, DOI 10.1002/sim.1889; Janes H, 2005, EPIDEMIOLOGY, V16, P717, DOI 10.1097/01.ede.0000181315.18836.9d; Maclure M, 2000, ANNU REV PUBL HEALTH, V21, P193, DOI 10.1146/annurev.publhealth.21.1.193; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; Malilay JF, 1997, PUBLIC HLTH CONSEQUE, P287; McMichael AJ, 2006, LANCET, V367, P859, DOI 10.1016/S0140-6736(06)68079-3; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; MITTLEMAN MA, 1995, AM J EPIDEMIOL, V142, P91, DOI 10.1093/oxfordjournals.aje.a117550; Natarajan S, 2007, STAT MED, V26, P3229, DOI 10.1002/sim.2779; Nichols G, 2009, J WATER HEALTH, V7, P1, DOI 10.2166/wh.2009.143; Pall P, 2011, NATURE, V470, P382, DOI 10.1038/nature09762; R Core Team, 2011, R LANG ENV STAT COMP; Reacher M, 2004, Commun Dis Public Health, V7, P39; Schmid D., 2005, EUROSURVEILLANCE, V10; Schumacher RS, 2006, WEATHER FORECAST, V21, P69, DOI 10.1175/WAF900.1; Schwartz BS, 2006, AM J TROP MED HYG, V74, P1067, DOI 10.4269/ajtmh.2006.74.1067; Stata Corporation, 2012, STAT SE VERS 12 1 WI; Toole M.J., 1997, PUBLIC HLTH CONSEQUE; Wade TJ, 2004, AM J EPIDEMIOL, V159, P398, DOI 10.1093/aje/kwh050; Waring Stephen C, 2002, Disaster Manag Response, P3; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wojcik OP, 2013, EPIDEMIOL INFECT, V141, P1756, DOI 10.1017/S0950268812002038	30	33	33	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2014	9	10							e110474	10.1371/journal.pone.0110474	http://dx.doi.org/10.1371/journal.pone.0110474			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8TF	25329916	Green Published, gold, Green Submitted			2023-01-03	WOS:000345204100079
J	Martens, EA; Gatta-Cherifi, B; Gonnissen, HK; Westerterp-Plantenga, MS				Martens, Eveline A.; Gatta-Cherifi, Blandine; Gonnissen, Hanne K.; Westerterp-Plantenga, Margriet S.			The Potential of a High Protein-Low Carbohydrate Diet to Preserve Intrahepatic Triglyceride Content in Healthy Humans	PLOS ONE			English	Article							FATTY-ACID SYNTHESIS; INSULIN-RESISTANCE; ENERGY-EXPENDITURE; PHYSICAL-ACTIVITY; SKELETAL-MUSCLE; QUESTIONNAIRE; METABOLISM; OBESITY; LIVER	Background: Protein supplementation has been shown to reduce the increases in intrahepatic triglyceride (IHTG) content induced by acute hypercaloric high-fat and high-fructose diets in humans. Objective: To assess the effect of a 12-wk iso-energetic high protein-low carbohydrate (HPLC) diet compared with an iso-energetic high carbohydrate-low protein (HCLP) diet on IHTG content in healthy non-obese subjects, at a constant body weight. Design: Seven men and nine women [mean +/- SD age: 24 +/- 5 y; BMI: 22.9 +/- 2.1 kg/m(2)] were randomly allocated to a HPLC [30/35/35% of energy (En%) from protein/carbohydrate/fat] or a HCLP (5/60/35 En%) diet by stratification on sex, age and BMI. Dietary guidelines were prescribed based on individual daily energy requirements. IHTG content was measured by H-1-magnetic resonance spectroscopy before and after the dietary intervention. Results: IHTG content changed in different directions with the HPLC (CH2H2O: 0.23 +/- 0.17 to 0.20 +/- 0.10; IHTG%: 0.25 +/- 0.20% to 0.22 +/- 0.11%) compared with the HCLP diet (CH2H2O: 0.34 +/- 0.20 vs. 0.38 +/- 0.21; IHTG%: 0.38 +/- 0.22% vs. 0.43 +/- 0.24%), which resulted in a lower IHTG content in the HPLC compared with the HCLP diet group after 12 weeks, which almost reached statistical significance (P=0.055). Conclusions: A HPLC vs. a HCLP diet has the potential to preserve vs. enlarge IHTG content in healthy non-obese subjects at a constant body weight.	[Martens, Eveline A.; Gatta-Cherifi, Blandine; Gonnissen, Hanne K.; Westerterp-Plantenga, Margriet S.] Maastricht Univ, Dept Human Biol, Maastricht, Netherlands	Maastricht University	Martens, EA (corresponding author), Maastricht Univ, Dept Human Biol, Maastricht, Netherlands.	eap.martens@maastrichtuniversity.nl		Cherifi, Blandine/0000-0002-7399-1330	European Union [266408]; French Society of Endocrinology	European Union(European Commission); French Society of Endocrinology	This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no 266408. BG-C was supported by grants from the French Society of Endocrinology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acheson KJ, 2013, EUR J CLIN NUTR, V67, P462, DOI 10.1038/ejcn.2012.194; Agius L, 2013, BIOCHEM PHARMACOL, V85, P306, DOI 10.1016/j.bcp.2012.09.019; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; Boesch C, 1997, MAGN RESON MED, V37, P484, DOI 10.1002/mrm.1910370403; Bortolotti M, 2011, CLIN NUTR, V30, P494, DOI 10.1016/j.clnu.2011.01.006; Bortolotti M, 2009, AM J CLIN NUTR, V90, P1002, DOI 10.3945/ajcn.2008.27296; Despres JP, 2006, NATURE, V444, P881, DOI 10.1038/nature05488; Fabbrini E, 2009, P NATL ACAD SCI USA, V106, P15430, DOI 10.1073/pnas.0904944106; Gannon MC, 2001, J CLIN ENDOCR METAB, V86, P1040, DOI 10.1210/jc.86.3.1040; Hamilton G, 2011, NMR BIOMED, V24, P784, DOI 10.1002/nbm.1622; Harris JA, 1918, P NATL ACAD SCI USA, V4, P370, DOI 10.1073/pnas.4.12.370; Hudgins LC, 2000, J LIPID RES, V41, P595; Hudgins LC, 1996, J CLIN INVEST, V97, P2081, DOI 10.1172/JCI118645; Lettner A, 2008, CURR DIABETES REP, V8, P185, DOI 10.1007/s11892-008-0032-z; Magkos F, 2010, OBESITY, V18, P1510, DOI 10.1038/oby.2010.90; Naressi A, 2001, MAGN RESON MATER PHY, V12, P141, DOI 10.1007/BF02668096; Parks EJ, 2000, AM J CLIN NUTR, V71, P412; Philippaerts RM, 2006, INT J SPORTS MED, V27, P131, DOI 10.1055/s-2005-837619; SCHICK F, 1993, MAGN RESON MED, V29, P158, DOI 10.1007/BF01769418; Schrauwen-Hinderling VB, 2003, J APPL PHYSIOL, V95, P2328, DOI 10.1152/japplphysiol.00304.2003; Schwarz JM, 1995, J CLIN INVEST, V96, P2735, DOI 10.1172/JCI118342; Stubbs RJ, 2001, J NUTR, V131, p2775S, DOI 10.1093/jn/131.10.2775S; Szczepaniak LS, 2005, AM J PHYSIOL-ENDOC M, V288, pE462, DOI 10.1152/ajpendo.00064.2004; Theytaz F, 2012, AM J CLIN NUTR, V96, P1008, DOI 10.3945/ajcn.112.035139; Torres N, 2007, NUTR REV, V65, pS64, DOI 10.1301/nr.2007.jun.S64-S68; Vanhamme L, 1997, J MAGN RESON, V129, P35, DOI 10.1006/jmre.1997.1244; Veldhorst MAB, 2009, AM J CLIN NUTR, V90, P519, DOI 10.3945/ajcn.2009.27834; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025; Westerterp KR, 2006, PHYSIOL BEHAV, V89, P62, DOI 10.1016/j.physbeh.2005.12.014; Westerterp KR, 1996, INT J OBESITY, V20, P1022; WESTERTERP KR, 1995, OBES RES, V3, P49, DOI 10.1002/j.1550-8528.1995.tb00007.x; Westerterp-Plantenga MS, 2012, BRIT J NUTR, V108, pS105, DOI 10.1017/S0007114512002589; Wycherley TP, 2012, AM J CLIN NUTR, V96, P1281, DOI 10.3945/ajcn.112.044321	33	13	14	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2014	9	10							e109617	10.1371/journal.pone.0109617	http://dx.doi.org/10.1371/journal.pone.0109617			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ9XC	25330327	Green Submitted, Green Published, gold			2023-01-03	WOS:000343210800030
J	Lee, YK; Lee, HW; Choi, KH; Kim, BS				Lee, Yong Kyu; Lee, Hae Won; Choi, Kyu Hun; Kim, Beom Seok			Ability of Nafamostat Mesilate to Prolong Filter Patency during Continuous Renal Replacement Therapy in Patients at High Risk of Bleeding: A Randomized Controlled Study	PLOS ONE			English	Article							CONTINUOUS VENOVENOUS HEMOFILTRATION; REGIONAL CITRATE ANTICOAGULATION; MOLECULAR-WEIGHT HEPARIN; PROTEASE INHIBITOR; SYSTEMIC HEPARIN; HEMODIALYSIS; PHARMACOKINETICS; COAGULATION; MECHANISMS; PROTAMINE	Continuous renal replacement therapy (CRRT) is considered as an effective modality for renal replacement therapy in hemodynamically unstable patients within intensive care units (ICUs). However, the role of heparin anticoagulation, which is used to maintain circuit patency, is equivocal due to the risk of bleeding and morbidity. Among various alternative anticoagulants, nafamostat mesilate has been shown to be an effective anticoagulant in patients prone to bleeding. Hence, we conducted a prospective, randomized controlled study investigating the effect of nafamostat mesilate on mortality, CRRT filter life span and adverse events in patients with bleeding tendency. Seventy-three Patients were randomized into either the futhan or no-anticoagulation group. Thirty-six subjects in the futhan group received nafamostat mesilate, while thirty seven subjects in the no-anticoagulation group received no anticoagulants. Baseline characteristics and appropriate laboratory tests were taken from each group. The mortality between the two groups was not significantly different. Nevertheless, between the futhan group and the no-anticoagulation group, the overall number of filters used during CRRT (2.71 +/- 2.12 vs. 4.50 +/- 3.25; p = 0.042) and the number of filters changed due to clots per 24 hours (1.15 +/- 0.81 vs. 1.74 +/- 1.62; p = 0.040) were significantly different. When filter life span was subdivided into below and over 12 hours, the number of filters functioning over 12 hours was significantly higher in the futhan group than in the no-anticoagulation group (p = 0.037, odds ratio 1.84). There were no significant differences in transfusion, mortality, or survival between the two groups, and no adverse events related to nafamostat mesilate were noted. Hence, nafamostat mesilate may be used as an effective and safe anticoagulant, without increasing the risk of major bleeding complications, in patients prone to bleeding.	[Lee, Yong Kyu] Ilsan Hosp, Natl Hlth Inst Corp, Dept Internal Med, Div Nephrol, Goyang, South Korea; [Lee, Hae Won; Choi, Kyu Hun; Kim, Beom Seok] Yonsei Univ, Coll Med, Dept Internal Med, Div Nephrol, Seoul, South Korea	NHIS Ilsan Hospital; Yonsei University; Yonsei University Health System	Kim, BS (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, Div Nephrol, Seoul, South Korea.	docbsk@yuhs.ac		Kim, Beom Seok/0000-0002-5732-2583; Choi, Kyu Hun/0000-0003-0095-9011	SK chemical, Seoul, Republic of Korea [NCT01761994]; faculty research grant of Yonsei University College of Medicine [2012(6-2012-0161)]	SK chemical, Seoul, Republic of Korea; faculty research grant of Yonsei University College of Medicine	This work was financially supported by SK chemical, Seoul, Republic of Korea (NCT01761994) and faculty research grant of Yonsei University College of Medicine for 2012(6-2012-0161). However, SK chemical and Yonsei University College of Medicine had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AKIZAWA T, 1993, NEPHRON, V64, P376, DOI 10.1159/000187357; Baek NN, 2012, RENAL FAILURE, V34, P279, DOI 10.3109/0886022X.2011.647293; Hetzel GR, 2011, NEPHROL DIAL TRANSPL, V26, P232, DOI 10.1093/ndt/gfq575; Higuchi N, 2000, NEPHRON, V86, P400, DOI 10.1159/000045822; Hirsh J, 2001, CHEST, V119, p64S, DOI 10.1378/chest.119.1_suppl.64S; HITOMI Y, 1985, HAEMOSTASIS, V15, P164; HORROW JC, 1985, ANESTH ANALG, V64, P348; Hwang SD, 2013, INT J ARTIF ORGANS, V36, P208, DOI [10.5301/IJAO.5000191, 10.5301/ijao.5000191]; JOURNOIS D, 1990, ANN FR ANESTH, V9, P331, DOI 10.1016/S0750-7658(05)80244-8; Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789; Kutsogiannis DJ, 2005, KIDNEY INT, V67, P2361, DOI 10.1111/j.1523-1755.2005.00342.x; Lindquist M, 2000, DRUG SAFETY, V23, P533, DOI 10.2165/00002018-200023060-00004; Maruyama Y, 2011, INT J ARTIF ORGANS, V34, P571, DOI 10.5301/IJAO.2011.8535; Meier-Kriesche H U, 1999, Am J Kidney Dis, V33, pe8, DOI 10.1016/S0272-6386(99)70249-0; Meier-Kriesche HU, 2001, CRIT CARE MED, V29, P748, DOI 10.1097/00003246-200104000-00010; Monchi M, 2004, INTENS CARE MED, V30, P260, DOI 10.1007/s00134-003-2047-x; Morabito S, 2012, CRIT CARE, V16, DOI 10.1186/cc11403; Nakae H, 2003, THER APHER DIAL, V7, P483, DOI 10.1046/j.1526-0968.2003.00088.x; National Cancer Institute NIoH, US DEP HLTH HUM SERV; OHTAKE Y, 1991, CONTRIB NEPHROL, V93, P215; OKADA H, 1992, NEPHROL DIAL TRANSPL, V7, P980, DOI 10.1093/ndt/7.9.980a; Ookawara S, 1996, EUR J CLIN PHARMACOL, V51, P149, DOI 10.1007/s002280050176; Oudemans-van Straaten HM, 2012, CRIT CARE, V16, DOI 10.1186/cc11645; Oudemans-van Straaten HM, 2009, CRIT CARE MED, V37, P545, DOI 10.1097/CCM.0b013e3181953c5e; Reeves JH, 1999, CRIT CARE MED, V27, P2224, DOI 10.1097/00003246-199910000-00026; SCHETZ M, 1989, INTENS CARE MED, V15, P349; Tolwani A, 2012, AM J KIDNEY DIS, V59, P745, DOI 10.1053/j.ajkd.2012.03.003; Tolwani AJ, 2009, SEMIN DIALYSIS, V22, P141, DOI 10.1111/j.1525-139X.2008.00545.x; van der Voort PHJ, 2005, BLOOD PURIFICAT, V23, P175, DOI 10.1159/000083938; vandeWetering J, 1996, J AM SOC NEPHROL, V7, P145; Wu MY, 2012, AM J KIDNEY DIS, V59, P810, DOI 10.1053/j.ajkd.2011.11.030	31	28	28	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2014	9	10							e108737	10.1371/journal.pone.0108737	http://dx.doi.org/10.1371/journal.pone.0108737			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR6ZS	25302581	gold, Green Published, Green Submitted			2023-01-03	WOS:000343730400024
J	Johnston, BC; Kanters, S; Bandayrel, K; Wu, P; Naji, F; Siemieniuk, RA; Ball, GDC; Busse, JW; Thorlund, K; Guyatt, G; Jansen, JP; Mills, EJ				Johnston, Bradley C.; Kanters, Steve; Bandayrel, Kristofer; Wu, Ping; Naji, Faysal; Siemieniuk, Reed A.; Ball, Geoff D. C.; Busse, Jason W.; Thorlund, Kristian; Guyatt, Gordon; Jansen, Jeroen P.; Mills, Edward J.			Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults A Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-FAT DIET; LOW-CARBOHYDRATE-DIET; RANDOMIZED CONTROLLED-TRIAL; STRUCTURED COMMERCIAL PROGRAM; ENERGY-RESTRICTED DIETS; HIGH-PROTEIN; BODY-COMPOSITION; GLYCEMIC CONTROL; KETOGENIC DIET; CLINICAL-TRIALS	IMPORTANCE Many claims have been made regarding the superiority of one diet or another for inducing weight loss. Which diet is best remains unclear. OBJECTIVE To determine weight loss outcomes for popular diets based on diet class (macronutrient composition) and named diet. DATA SOURCES Search of 6 electronic databases: AMED, CDSR, CENTRAL, CINAHL, EMBASE, and MEDLINE from inception of each database to April 2014. STUDY SELECTION Overweight or obese adults (body mass index >= 25) randomized to a popular self-administered named diet and reporting weight or body mass index data at 3-month follow-up or longer. DATA EXTRACTION AND SYNTHESIS Two reviewers independently extracted data on populations, interventions, outcomes, risk of bias, and quality of evidence. A Bayesian framework was used to perform a series of random-effects network meta-analyses with meta-regression to estimate the relative effectiveness of diet classes and programs for change in weight and body mass index from baseline. Our analyses adjusted for behavioral support and exercise. MAIN OUTCOMES AND MEASURES Weight loss and body mass index at 6- and 12-month follow-up (+/- 3 months for both periods). RESULTS Among 59 eligible articles reporting 48 unique randomized trials (including 7286 individuals) and compared with no diet, the largest weight loss was associated with low-carbohydrate diets (8.73 kg [95% credible interval {CI}, 7.27 to 10.20 kg] at 6-month follow-up and 7.25 kg [95% CI, 5.33 to 9.25 kg] at 12-month follow-up) and low-fat diets (7.99 kg [95% CI, 6.01 to 9.92 kg] at 6-month follow-up and 7.27 kg [95% CI, 5.26 to 9.34 kg] at 12-month follow-up). Weight loss differences between individual diets were minimal. For example, the Atkins diet resulted in a 1.71 kg greater weight loss than the Zone diet at 6-month follow-up. Between 6-and 12-month follow-up, the influence of behavioral support (3.23 kg [95% CI, 2.23 to 4.23 kg] at 6-month follow-up vs 1.08 kg [95% CI, -1.82 to 3.96 kg] at 12-month follow-up) and exercise (0.64 kg [95% CI, -0.35 to 1.66 kg] vs 2.13 kg [95% CI, 0.43 to 3.85 kg], respectively) on weight loss differed. CONCLUSIONS AND RELEVANCE Significant weight loss was observed with any low-carbohydrate or low-fat diet. Weight loss differences between individual named diets were small. This supports the practice of recommending any diet that a patient will adhere to in order to lose weight.	[Johnston, Bradley C.; Bandayrel, Kristofer] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; [Johnston, Bradley C.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Johnston, Bradley C.; Busse, Jason W.; Thorlund, Kristian; Guyatt, Gordon] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Johnston, Bradley C.; Bandayrel, Kristofer] Univ Toronto, Hosp Sick Children, Dept Anesthesia & Pain Med, Toronto, ON M5G 1X8, Canada; [Kanters, Steve] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada; [Kanters, Steve; Wu, Ping] Univ Ottawa, Fac Hlth Sci, Ottawa, ON, Canada; [Kanters, Steve; Thorlund, Kristian; Jansen, Jeroen P.; Mills, Edward J.] Redwood Outcomes, Vancouver, BC, Canada; [Naji, Faysal] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON, Canada; [Siemieniuk, Reed A.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Ball, Geoff D. C.] Univ Alberta, Dept Pediat, Edmonton, AB, Canada; [Ball, Geoff D. C.] Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB, Canada; [Busse, Jason W.] McMaster Univ, Michael G DeGroote Inst Pain Res & Care, Hamilton, ON, Canada; [Busse, Jason W.] McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada; [Thorlund, Kristian; Mills, Edward J.] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA; [Jansen, Jeroen P.] Tufts Univ, Dept Publ Hlth & Community Med, Boston, MA 02111 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; McMaster University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of British Columbia; University of Ottawa; McMaster University; University of Toronto; University of Alberta; University of Alberta; McMaster University; McMaster University; Stanford University; Massachusetts Department of Public Health; Tufts University	Mills, EJ (corresponding author), Stanford Univ, Sch Med, 1265 Welch Rd, Stanford, CA 94305 USA.	millsej@stanford.edu	Busse, Jason/CAH-3696-2022; Ball, Geoff/AAH-4741-2019	Busse, Jason/0000-0002-0178-8712; Jansen, Jeroen Paul/0000-0003-2686-9217	Canadian Institute of Health research via the Public Health Agency of Canada [201104]; Canadian Institute of Health Research	Canadian Institute of Health research via the Public Health Agency of Canada(Canadian Institutes of Health Research (CIHR)); Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by a Canadian Institute of Health research knowledge synthesis grant 201104 via the Public Health Agency of Canada. Dr Busse holds a Canadian Institute of Health Research new investigator award. Dr Mills holds a Canada Research Chair in global health.	Aldana SG, 2007, AM J HEALTH PROMOT, V21, P510, DOI 10.4278/0890-1171-21.6.510; [Anonymous], 2004, AM J NURS, V104, P94; Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; Blumenthal JA, 2000, ARCH INTERN MED, V160, P1947, DOI 10.1001/archinte.160.13.1947; Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480; Brehm BJ, 2005, J CLIN ENDOCR METAB, V90, P1475, DOI 10.1210/jc.2004-1540; Brinkworth GD, 2004, DIABETOLOGIA, V47, P1677, DOI 10.1007/s00125-004-1511-7; Brinkworth GD, 2004, INT J OBESITY, V28, P661, DOI 10.1038/sj.ijo.0802617; Brinkworth GD, 2009, ARCH INTERN MED, V169, P1873, DOI 10.1001/archinternmed.2009.329; Brinkworth GD, 2009, OBESITY, V17, P1916, DOI 10.1038/oby.2009.134; Brownell K, 2004, LEARN PROGRAM WEIGHT; Collins CE, 2012, J MED INTERNET RES, V14, DOI 10.2196/jmir.1980; Curioni CC, 2005, INT J OBESITY, V29, P1168, DOI 10.1038/sj.ijo.0803015; Daly ME, 2006, DIABETIC MED, V23, P15, DOI 10.1111/j.1464-5491.2005.01760.x; Dansinger ML, 2005, JAMA-J AM MED ASSOC, V293, P43, DOI 10.1001/jama.293.1.43; Das SK, 2007, AM J CLIN NUTR, V85, P1023, DOI 10.1093/ajcn/85.4.1023; Davis NJ, 2009, DIABETES CARE, V32, P1147, DOI 10.2337/dc08-2108; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Djuric Z, 2002, OBES RES, V10, P657, DOI 10.1038/oby.2002.89; Ebbeling CB, 2007, JAMA-J AM MED ASSOC, V297, P2092, DOI 10.1001/jama.297.19.2092; Ello-Martin JA, 2007, AM J CLIN NUTR, V85, P1465, DOI 10.1093/ajcn/85.6.1465; Farnsworth E, 2003, AM J CLIN NUTR, V78, P31, DOI 10.1093/ajcn/78.1.31; Figueroa A, 2013, MENOPAUSE, V20, P967, DOI [10.1097/GME.0b013e3182831ee4, 10.1097/gme.0b013e3182831ee4]; Foster GD, 2010, ANN INTERN MED, V153, P147, DOI 10.7326/0003-4819-153-3-201008030-00005; Foster GD, 2009, POSTGRAD MED, V121, P113, DOI 10.3810/pgm.2009.09.2046; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; Franz MJ, 2007, J AM DIET ASSOC, V107, P1755, DOI 10.1016/j.jada.2007.07.017; Freedman MR, 2001, OBES RES, V9, p1S, DOI 10.1038/oby.2001.113; Galletly C, 2007, APPETITE, V49, P590, DOI 10.1016/j.appet.2007.03.222; Gardner CD, 2007, JAMA-J AM MED ASSOC, V297, P969, DOI 10.1001/jama.297.9.969; Goodrick GK, 1998, J CONSULT CLIN PSYCH, V66, P363, DOI 10.1037/0022-006X.66.2.363; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P407, DOI 10.1016/j.jclinepi.2010.07.017; Hernan MA, 2013, ANN INTERN MED, V159, P560, DOI 10.7326/0003-4819-159-8-201310150-00709; Heshka S, 2000, AM J MED, V109, P282, DOI 10.1016/S0002-9343(00)00494-0; Heshka S, 2003, JAMA-J AM MED ASSOC, V289, P1792, DOI 10.1001/jama.289.14.1792; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Iqbal N, 2010, OBESITY, V18, P1733, DOI 10.1038/oby.2009.460; Jebb SA, 2011, LANCET, V378, P1485, DOI 10.1016/S0140-6736(11)61344-5; Jensen MD, 2014, J AM COLL CARDIOL, V63, P2985, DOI 10.1016/j.jacc.2013.11.004; Johnston B, BRANDED DIETS WEIGHT; Jolly K, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6500; Lasker DAW, 2008, NUTR METAB, V5, DOI 10.1186/1743-7075-5-30; Layman DK, 2005, J NUTR, V135, P1903, DOI 10.1093/jn/135.8.1903; Layman DK, 2003, J NUTR, V133, P411, DOI 10.1093/jn/133.2.411; Layman DK, 2009, J NUTR, V139, P514, DOI 10.3945/jn.108.099440; Lu GB, 2006, J AM STAT ASSOC, V101, P447, DOI 10.1198/016214505000001302; Luscombe ND, 2003, INT J OBESITY, V27, P582, DOI 10.1038/sj.ijo.0802270; Luscombe ND, 2002, DIABETES CARE, V25, P652, DOI 10.2337/diacare.25.4.652; Marketdata Enterprises, 2009, US WEIGHT LOSS DIET; McAlister FA, 1999, JAMA-J AM MED ASSOC, V282, P1371, DOI 10.1001/jama.282.14.1371; McAuley KA, 2005, DIABETOLOGIA, V48, P8, DOI 10.1007/s00125-004-1603-4; Mills EJ, 2012, JAMA-J AM MED ASSOC, V308, P1246, DOI 10.1001/2012.jama.11228; Morgan LM, 2009, PUBLIC HEALTH NUTR, V12, P799, DOI 10.1017/S1368980008003236; Pagoto SL, 2013, JAMA-J AM MED ASSOC, V310, P687, DOI 10.1001/jama.2013.8601; Parker B, 2002, DIABETES CARE, V25, P425, DOI 10.2337/diacare.25.3.425; Pinto AM, 2013, OBESITY, V21, P673, DOI 10.1002/oby.20044; Porrini M, 1997, PHYSIOL BEHAV, V62, P563, DOI 10.1016/S0031-9384(97)00162-5; Qi QB, 2012, AM J CLIN NUTR, V95, P506, DOI 10.3945/ajcn.111.025270; Rippe JM, 1998, OBES RES, V6, P208, DOI 10.1002/j.1550-8528.1998.tb00339.x; Rock CL, 2007, OBESITY, V15, P939, DOI 10.1038/oby.2007.614; Rock CL, 2010, JAMA-J AM MED ASSOC, V304, P1803, DOI 10.1001/jama.2010.1503; Ruth MR, 2013, METABOLISM, V62, P1779, DOI 10.1016/j.metabol.2013.07.006; Ryan DH, 2010, JAMA-J AM MED ASSOC, V304, P1835, DOI 10.1001/jama.2010.1531; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Savovic J, 2012, ANN INTERN MED, V157, P429, DOI 10.7326/0003-4819-157-6-201209180-00537; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; Stern L, 2004, ANN INTERN MED, V140, P778, DOI 10.7326/0003-4819-140-10-200405180-00007; Swenson BR, 2007, J SURG RES, V142, P308, DOI 10.1016/j.jss.2007.02.052; Tay J, 2008, J AM COLL CARDIOL, V51, P59, DOI 10.1016/j.jacc.2007.08.050; Thomson CA, 2010, NUTR CANCER, V62, P1142, DOI 10.1080/01635581.2010.513803; Truby H, 2006, BMJ-BRIT MED J, V332, P1309, DOI 10.1136/bmj.38833.411204.80; Tsai AG, 2005, ANN INTERN MED, V142, P56, DOI 10.7326/0003-4819-142-1-200501040-00012; US Department of Agriculture US Department of Health and Human Services, 2011, DIET GUID AM 2010; USPSTF, 2004, AM J NURS, V104, P97; USPSTF, 2004, AM J NURS, V104, P100; Volek JS, 2009, METABOLISM, V58, P1769, DOI 10.1016/j.metabol.2009.06.005; Volek JS, 2009, LIPIDS, V44, P297, DOI 10.1007/s11745-008-3274-2; Wadden TA, 2004, AM J CLIN NUTR, V80, P560; Westman EC, 2006, INT J CARDIOL, V110, P212, DOI 10.1016/j.ijcard.2005.08.034; Westman EC, 2008, NUTR METAB, V5, DOI 10.1186/1743-7075-5-36; Wing RR, 2006, NEW ENGL J MED, V355, P1563, DOI 10.1056/NEJMoa061883; Wing RR, 1998, DIABETES CARE, V21, P350, DOI 10.2337/diacare.21.3.350; Womble LG, 2004, OBES RES, V12, P1011, DOI 10.1038/oby.2004.124; Yancy WS, 2009, QUAL LIFE RES, V18, P281, DOI 10.1007/s11136-009-9444-8; Yancy WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006	88	344	350	6	125	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2014	312	9					923	933		10.1001/jama.2014.10397	http://dx.doi.org/10.1001/jama.2014.10397			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AO9IE	25182101	Bronze			2023-01-03	WOS:000341668600021
J	Rochwerg, B; Alhazzani, W; Sindi, A; Heels-Ansdell, D; Thabane, L; Fox-Robichaud, A; Mbuagbaw, L; Szczeklik, W; Alshamsi, F; Altayyar, S; Ip, WC; Li, GW; Wang, M; Wludarczyk, A; Zhou, Q; Guyatt, GH; Cook, DJ; Jaeschke, R; Annane, D				Rochwerg, Bram; Alhazzani, Waleed; Sindi, Anees; Heels-Ansdell, Diane; Thabane, Lehana; Fox-Robichaud, Alison; Mbuagbaw, Lawrence; Szczeklik, Wojciech; Alshamsi, Fayez; Altayyar, Sultan; Ip, Wang-Chun; Li, Guowei; Wang, Michael; Wludarczyk, Anna; Zhou, Qi; Guyatt, Gordon H.; Cook, Deborah J.; Jaeschke, Roman; Annane, Djillali		Fluids Sepsis Septic Shock Grp	Fluid Resuscitation in Sepsis A Systematic Review and Network Meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Review							HYDROXYETHYL STARCH 130/0.4; ACUTE KIDNEY INJURY; SEPTIC SHOCK; ILL PATIENTS; INTENSIVE-CARE; ALBUMIN; SALINE; MORTALITY; PENTASTARCH; ASSOCIATION	Background: Fluid resuscitation is the cornerstone of sepsis treatment. However, whether balanced or unbalanced crystalloids or natural or synthetic colloids confer a survival advantage is unclear. Purpose: To examine the effect of different resuscitative fluids on mortality in patients with sepsis. Data Sources: MEDLINE, EMBASE, ACP Journal Club, CINAHL, HealthSTAR, the Allied and Complementary Medicine Database, and the Cochrane Central Register of Controlled Trials through March 2014. Study Selection: Randomized trials that evaluated different resuscitative fluids in adult patients with sepsis or septic shock and death. No language restrictions were applied. Data Extraction: Two reviewers extracted data on study characteristics, methods, and outcomes. Risk of bias for individual studies and quality of evidence were assessed. Data Synthesis: 14 studies (18 916 patients) were included with 15 direct comparisons. Network meta-analysis at the 4-node level showed higher mortality with starches than with crystalloids (high confidence) and lower mortality with albumin than with crystalloids (moderate confidence) or starches (moderate confidence). Network meta-analysis at the 6-node level showed lower mortality with albumin than with saline (moderate confidence) and low-molecular-weight starch (low confidence) and with balanced crystalloids than with saline (low confidence) and low-and high-molecular-weight starches (moderate confidence). Limitations: These trials were heterogeneous in case mix, fluids evaluated, duration of fluid exposure, and risk of bias. Imprecise estimates for several comparisons in this network meta-analysis contribute to low confidence in most estimates of effect. Conclusion: Among patients with sepsis, resuscitation with balanced crystalloids or albumin compared with other fluids seems to be associated with reduced mortality.	McMaster Univ, Hamilton, ON L8N 3Z5, Canada; Prince Sultan Mil Med City, Riyadh, Saudi Arabia; King Abdulaziz Univ, Jeddah 21413, Saudi Arabia; Jagiellonian Univ, Coll Med, PL-31066 Krakow, Poland; Univ Versailles St Quentin En Yvelines, F-92380 Garches, France	McMaster University; Prince Sultan Military Medical City; King Abdulaziz University; Jagiellonian University; Collegium Medicum Jagiellonian University; UDICE-French Research Universities; Universite Paris Saclay	Cook, DJ (corresponding author), St Josephs Healthcare, Crit Care Med, Room D176,50 Charlton Ave East, Hamilton, ON L8N 3A5, Canada.	debcook@mcmaster.ca	Rochwerg, Bram/AAE-7606-2020; Alshamsi, Fayez/AAZ-5713-2021; Wludarczyk, Anna/AAP-4012-2021; Sindi, Anees A/D-6037-2019; Szczeklik, Wojciech/N-8096-2014; Li, Guowei/HCH-8923-2022; Mbuagbaw, Lawrence/D-9381-2015; Zhou, Qi/GSM-9583-2022; Annane, Djillali/R-7947-2019	Alshamsi, Fayez/0000-0002-9121-4279; Szczeklik, Wojciech/0000-0002-1349-1123; Mbuagbaw, Lawrence/0000-0001-5855-5461; Sindi, Anees/0000-0002-5854-6298	Hamilton Chapter of the Canadian Intensive Care Foundation; Critical Care Medicine Residency Program; Critical Care Division Alternate Funding Plan at McMaster University; Critical Care Medicine Residency Program at McMaster University; Canadian Institutes of Health Research	Hamilton Chapter of the Canadian Intensive Care Foundation; Critical Care Medicine Residency Program; Critical Care Division Alternate Funding Plan at McMaster University; Critical Care Medicine Residency Program at McMaster University; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	The Hamilton Chapter of the Canadian Intensive Care Foundation and the Critical Care Medicine Residency Program and Critical Care Division Alternate Funding Plan at McMaster University.; By the Hamilton Chapter of the Canadian Intensive Care Foundation and the Critical Care Medicine Residency Program and Critical Care Division Alternate Funding Plan, both at McMaster University. Dr. Cook is supported by the Canadian Institutes of Health Research.	Annane D, 2013, JAMA-J AM MED ASSOC, V310, P1809, DOI 10.1001/jama.2013.280502; [Anonymous], BASES TRIAL BAS STAR; Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; Bansal M, 2013, CURR DRUG SAF, V8, P236, DOI 10.2174/15748863113089990046; Bellomo R, 2010, CONTRIB NEPHROL, V165, P206, DOI 10.1159/000313760; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Bunn F, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001319.pub5; Caironi P, 2014, NEW ENGL J MED, V370, P1412, DOI 10.1056/NEJMoa1305727; Delaney AP, 2011, CRIT CARE MED, V39, P386, DOI 10.1097/CCM.0b013e3181ffe217; Dubin Arnaldo, 2010, J Crit Care, V25, DOI 10.1016/j.jcrc.2010.04.007; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finfer S, 2011, INTENS CARE MED, V37, P86, DOI 10.1007/s00134-010-2039-6; Gattas DJ, 2012, ANESTH ANALG, V114, P159, DOI 10.1213/ANE.0b013e318236b4d6; Guidet B, 2012, CRIT CARE, V16, DOI 10.1186/cc11358; GUYAT GH, 1993, JAMA-J AM MED ASSOC, V270, P2096, DOI 10.1001/jama.270.17.2096; Guyatt G, 2011, METHODS COMMENTARY R; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Haase N, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f839; Haase N, 2013, CURR OPIN CRIT CARE, V19, P321, DOI 10.1097/MCC.0b013e3283632de6; HAUPT MT, 1982, CRIT CARE MED, V10, P159, DOI 10.1097/00003246-198203000-00004; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Jansen JP, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-159; Jansen JP, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-152; Jiwaji Z, 2014, EMERG MED J, V31, P1000, DOI 10.1136/emermed-2013-202883; Jones D, 2010, ANAESTH INTENS CARE, V38, P266, DOI 10.1177/0310057X1003800207; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Li Feng, 2008, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V20, P472; Lobo DN, 2012, ANN SURG, V255, P830, DOI 10.1097/SLA.0b013e318250766c; Lv Jie, 2012, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V24, P38; McIntyre LA, 2008, CAN J ANAESTH, V55, P819, DOI 10.1007/BF03034053; Miller DR, 2011, CAN J ANESTH, V58, P777, DOI 10.1007/s12630-011-9558-7; Mills EJ, 2012, JAMA-J AM MED ASSOC, V308, P1246, DOI 10.1001/2012.jama.11228; Morgan TJ, 2013, CURR OPIN CRIT CARE, V19, P299, DOI 10.1097/MCC.0b013e3283632d46; Myburgh JA, 2013, NEW ENGL J MED, V369, P1243, DOI 10.1056/NEJMra1208627; Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759; Perel P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub6; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; RACKOW EC, 1989, CRIT CARE MED, V17, P394, DOI 10.1097/00003246-198905000-00003; Reilly Charles, 2011, Br J Anaesth, V107, P116, DOI 10.1093/bja/aer068; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Rochwerg B, 2013, POL ARCH MED WEWN, V123, P603, DOI 10.20452/pamw.1972; Rubin D. B., 1992, STAT SCI, V7, P457, DOI DOI 10.1111/j.1469-8137.2011.03796.x; Schortgen F, 2001, LANCET, V357, P911, DOI 10.1016/S0140-6736(00)04211-2; U.S. Food and Drug Administration, 2013, FDA SAF COMM BOX WAR; Wilkes MM, 2001, ANN INTERN MED, V135, P149, DOI 10.7326/0003-4819-135-3-200108070-00007; Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356; Zarychanski R, 2013, JAMA-J AM MED ASSOC, V309, P678, DOI 10.1001/jama.2013.430	47	179	193	1	39	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2014	161	5					347	+		10.7326/M14-0178	http://dx.doi.org/10.7326/M14-0178			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AO7VT	25047428				2023-01-03	WOS:000341561400005
J	Rojas-Villarraga, A; Torres-Gonzalez, JV; Ruiz-Sternberg, AM				Rojas-Villarraga, Adriana; Torres-Gonzalez, July-Vianneth; Ruiz-Sternberg, Angela-Maria			Safety of Hormonal Replacement Therapy and Oral Contraceptives in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							PREMATURE OVARIAN FAILURE; ESTROGEN PLUS PROGESTIN; RISK-FACTORS; SEX-HORMONES; T-CELL; CARDIOVASCULAR EVENTS; POSTMENOPAUSAL WOMEN; SJOGRENS-SYNDROME; DISEASE-ACTIVITY; GLOMERULONEPHRITIS	Background: There is conflicting data regarding exogenous sex hormones [oral contraceptives (OC) and hormonal replacement therapy (HRT)] exposure and different outcomes on Systemic Lupus Erythematosus (SLE). The aim of this work is to determine, through a systematic review and meta-analysis the risks associated with estrogen use for women with SLE as well as the association of estrogen with developing SLE. Methods and Findings: MEDLINE, EMBASE, SciElo, BIREME and the Cochrane library (1982 to July 2012), were databases from which were selected and reviewed (PRISMA guidelines) randomized controlled trials, cross-sectional, case-control and prospective or retrospective nonrandomized, comparative studies without language restrictions. Those were evaluated by two investigators who extracted information on study characteristics, outcomes of interest, risk of bias and summarized strength of evidence. A total of 6,879 articles were identified; 20 full-text articles were included. Thirty-two meta-analyses were developed. A significant association between HRT exposure (Random model) and an increased risk of developing SLE was found (Rate Ratio: 1.96; 95%-CI: 1.51-2.56; P-value < 0.001). One of eleven meta-analyses evaluating the risk for SLE associated with OC exposure had a marginally significant result. There were no associations between HRT or OC exposure and specific outcomes of SLE. It was not always possible to Meta-analyze all the available data. There was a wide heterogeneity of SLE outcome measurements and estrogen therapy administration. Conclusion: An association between HRT exposure and SLE causality was observed. No association was found when analyzing the risk for SLE among OC users, however since women with high disease activity/Thromboses or antiphospholipid-antibodies were excluded from most of the studies, caution should be exercised in interpreting the present results. To identify risk factors that predispose healthy individuals to the development of SLE who are planning to start HRT or OC is suggested.	[Rojas-Villarraga, Adriana] Univ Rosario, Sch Med & Hlth Sci, Ctr Autoimmune Dis Res CREA, Bogota, Colombia; [Torres-Gonzalez, July-Vianneth] Univ Rosario, Sch Med & Hlth Sci, Med Social Serv Provis Mandatory, Bogota, Colombia; [Ruiz-Sternberg, Angela-Maria] Univ Rosario, Sch Med & Hlth Sci, Dept Invest Grp Invest Clin, Bogota, Colombia	Universidad del Rosario; Universidad del Rosario; Universidad del Rosario	Rojas-Villarraga, A (corresponding author), Univ Rosario, Sch Med & Hlth Sci, Ctr Autoimmune Dis Res CREA, Bogota, Colombia.	adrirojas@gmail.com	Ruiz-Sternberg, Angela María/J-1073-2016; Rojas-Villarraga, Adriana/T-7070-2018; Rojas-Villarraga, Adriana/J-2404-2016	Ruiz-Sternberg, Angela María/0000-0002-4651-4635; Rojas-Villarraga, Adriana/0000-0003-3145-2440; Rojas-Villarraga, Adriana/0000-0003-3145-2440; Torres-Gonzalez, July/0000-0001-7311-2132				Ackerman LS, 2006, ARCH DERMATOL, V142, P371, DOI 10.1001/archderm.142.3.371; ALEKBEROVA ZS, 1990, TERAPEVT ARKH, V62, P17; Anaya JM, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3175; ARDEN NK, 1994, LUPUS, V3, P11, DOI 10.1177/096120339400300104; Beretta L, 2006, SCAND J RHEUMATOL, V35, P468, DOI 10.1080/03009740600844498; Bernier MO, 2009, ARTHRIT RHEUM-ARTHR, V61, P476, DOI 10.1002/art.24398; Bhatia SS, 2007, ANN RHEUM DIS, V66, P267, DOI 10.1136/ard.2006.060004; Blockeel C, 2012, REPROD BIOMED ONLINE, V24, P272, DOI 10.1016/j.rbmo.2011.11.012; Borenstein M., 2009, INTRO METAANALYSIS, V(1st), DOI [https://doi.org/10.1002/9780470743386, DOI 10.1002/9780470743386]; Buyon J P, 1995, J Clin Rheumatol, V1, P205, DOI 10.1097/00124743-199508000-00002; Buyon JP, 2005, ANN INTERN MED, V142, P953, DOI 10.7326/0003-4819-142-12_Part_1-200506210-00004; Capellino S, 2008, CLIN EXP RHEUMATOL, V26, P903; CARLSTEN H, 1991, J AUTOIMMUN, V4, P845, DOI 10.1016/0896-8411(91)90048-H; Choojitarom K, 2008, CLIN RHEUMATOL, V27, P345, DOI 10.1007/s10067-007-0721-z; Cooper GS, 2002, ARTHRITIS RHEUM, V46, P1830, DOI 10.1002/art.10365; Costenbader KH, 2007, ARTHRITIS RHEUM-US, V56, P1251, DOI 10.1002/art.22510; Cravioto MD, 2011, ARTHRIT CARE RES, V63, P1654, DOI 10.1002/acr.20608; Culwell KR, 2009, OBSTET GYNECOL, V114, P341, DOI 10.1097/AOG.0b013e3181ae9c64; Cutolo M, 2008, RHEUMATOLOGY, V47, P2, DOI 10.1093/rheumatology/ken150; D'Onofrio F, 2006, INT J IMMUNOPATH PH, V19, P445, DOI 10.1177/039463200601900222; Darroch JE, 2013, CONTRACEPTION, V87, P259, DOI 10.1016/j.contraception.2012.08.029; Fernandez M, 2007, JCR-J CLIN RHEUMATOL, V13, P261, DOI 10.1097/RHU.0b013e318156bbf5; Gompel A, 2007, Menopause Int, V13, P65, DOI 10.1258/175404507780796433; GRIMES DA, 1985, AM J OBSTET GYNECOL, V153, P179, DOI 10.1016/0002-9378(85)90108-5; Han SZ, 2009, HUM MOL GENET, V18, P1171, DOI 10.1093/hmg/ddp007; Herrington DM, 2002, CIRCULATION, V105, P2962, DOI 10.1161/01.CIR.0000019406.74017.B2; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hochman J, 2009, LUPUS, V18, P313, DOI 10.1177/0961203308097475; Hodis HN, 2012, CLIMACTERIC, V15, P217, DOI 10.3109/13697137.2012.656401; Howick J, 2011, 2011 OXFORD CEBM LEV; Jiang B, 2008, IMMUNOL INVEST, V37, P227, DOI 10.1080/08820130801973328; Julkunen H, 2000, SCAND J RHEUMATOL, V29, P146, DOI 10.1080/030097400750002003; JULKUNEN HA, 1993, BRIT J RHEUMATOL, V32, P227; Kiani AN, 2010, J RHEUMATOL, V37, P579, DOI 10.3899/jrheum.090824; Kipp M, 2012, FRONT NEUROENDOCRIN, V33, P1, DOI 10.1016/j.yfrne.2012.01.001; Kreidstein S, 1997, J RHEUMATOL, V24, P2149; Lakasing L, 2001, J FAM PLAN REPROD H, V27, P7, DOI 10.1783/147118901101195029; Li Raymond H. W., 2011, Hong Kong Medical Journal, V17, P487; Li Y, 2010, INTERNAL MED, V49, P611, DOI 10.2169/internalmedicine.49.2737; Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006; MASI AT, 1978, ARTHRITIS RHEUM-US, V21, P480, DOI 10.1002/art.1780210413; McMurray RW, 2003, ARTHRITIS RHEUM-US, V48, P2100, DOI 10.1002/art.11105; Medeiros PB, 2009, LUPUS, V18, P38, DOI 10.1177/0961203308094652; Meier CR, 1998, J RHEUMATOL, V25, P1515; Mok CC, 1999, ARTHRITIS RHEUM, V42, P1274, DOI 10.1002/1529-0131(199906)42:6<1274::AID-ANR26>3.0.CO;2-B; Mok CC, 1998, SCAND J RHEUMATOL, V27, P342, DOI 10.1080/03009749850154357; Mostafa S, 2012, EXP EYE RES, V96, P88, DOI 10.1016/j.exer.2011.12.016; Nagy G, 2005, CRIT REV IMMUNOL, V25, P123, DOI 10.1615/CritRevImmunol.v25.i2.30; Onel K, 2004, J THROMB HAEMOST, V2, P670, DOI 10.1111/j.1538-7836.2004.00644.x; Panay Nick, 2012, Menopause Int, V18, P90, DOI 10.1258/mi.2012.012019; Petri M, 2005, NEW ENGL J MED, V353, P2550, DOI 10.1056/NEJMoa051135; Quintero OL, 2012, J AUTOIMMUN, V38, pJ109, DOI 10.1016/j.jaut.2011.10.003; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; ROUBINIAN JR, 1978, J EXP MED, V147, P1568, DOI 10.1084/jem.147.6.1568; Salpeter SR, 2006, DIABETES OBES METAB, V8, P538, DOI 10.1111/j.1463-1326.2005.00545.x; Salpeter SR, 2009, AM J MED, V122, P1016, DOI 10.1016/j.amjmed.2009.05.021; Sanchez-Guerrero J, 2005, NEW ENGL J MED, V353, P2539, DOI 10.1056/NEJMoa050817; Sanchez-Guerrero J, 1999, ARTHRITIS RHEUM, V42, pS71, DOI [10.1002/art.1780422107, DOI 10.1002/ART.1780422107]; Sanchez-Guerrero J, 2007, ARTHRITIS RHEUM-US, V56, P3070, DOI 10.1002/art.22855; SanchezGuerrero J, 1997, ARTHRITIS RHEUM, V40, P804, DOI 10.1002/art.1780400505; SANCHEZGUERRERO J, 1995, ANN INTERN MED, V122, P430, DOI 10.7326/0003-4819-122-6-199503150-00005; Santen RJ, 2010, J CLIN ENDOCR METAB, V95, pS7, DOI 10.1210/jc.2009-2509; Schierbeck LL, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6409; Schwartzman-Morris J, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/604892; Schwarz EB, 2006, NEW ENGL J MED, V354, P1203; Shabanova SS, 2008, CLIN EXP RHEUMATOL, V26, P436; Silva CAA, 2007, LUPUS, V16, P531, DOI 10.1177/0961203307079300; Somers EC, 2005, ARTHRITIS RHEUM-US, V52, P2761, DOI 10.1002/art.21263; Somogyi A, 1998, ADVERSE DRUG REACT T, V17, P63; Steinberg A D, 1978, Arthritis Rheum, V21, pS190, DOI 10.1002/art.1780210932; Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001; STROM BL, 1994, AM J EPIDEMIOL, V140, P632, DOI 10.1093/oxfordjournals.aje.a117302; TALAL N, 1987, J RHEUMATOL, V14, P21; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Tartagni M, 2011, MENOPAUSE, V18, P932, DOI 10.1097/gme.0b013e31820dc48d; Vinet E, 2010, INT J CLIN RHEUMTOL, V5, P169; Yang DZ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054495, 10.1371/journal.pone.0059020, 10.1371/journal.pone.0062329]; Zonana-Nacach A, 2002, SALUD PUBLICA MEXICO, V44, P213, DOI 10.1590/S0036-36342002000300004	80	25	27	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2014	9	8							e104303	10.1371/journal.pone.0104303	http://dx.doi.org/10.1371/journal.pone.0104303			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN6XM	25137236	Green Published, gold, Green Submitted			2023-01-03	WOS:000340742100025
J	DosSantos, MF; Martikainen, IK; Nascimento, TD; Love, TM; DeBoer, MD; Schambra, HM; Bikson, M; Zubieta, JK; DaSilva, AF				DosSantos, Marcos F.; Martikainen, Ilkka K.; Nascimento, Thiago D.; Love, Tiffany M.; DeBoer, Misty D.; Schambra, Heidi M.; Bikson, Marom; Zubieta, Jon-Kar; DaSilva, Alexandre F.			Building up Analgesia in Humans via the Endogenous mu-Opioid System by Combining Placebo and Active tDCS: A Preliminary Report	PLOS ONE			English	Article							DIRECT-CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; MEDIAL PREFRONTAL CORTEX; MOTOR CORTEX; PERIAQUEDUCTAL GRAY; NEUROPATHIC PAIN; BACK-PAIN; BRAIN; MODULATION; ANTICIPATION	Transcranial Direct Current Stimulation (tDCS) is a method of non-invasive brain stimulation that has been frequently used in experimental and clinical pain studies. However, the molecular mechanisms underlying tDCS-mediated pain control, and most important its placebo component, are not completely established. In this pilot study, we investigated in vivo the involvement of the endogenous mu-opioid system in the global tDCS-analgesia experience. Nine healthy volunteers went through positron emission tomography (PET) scans with [C-11] carfentanil, a selective m-opioid receptor (MOR) radiotracer, to measure the central MOR activity during tDCS in vivo (non-displaceable binding potential, BPND) - one of the main analgesic mechanisms in the brain. Placebo and real anodal primary motor cortex (M1/2mA) tDCS were delivered sequentially for 20 minutes each during the PET scan. The initial placebo tDCS phase induced a decrease in MOR BPND in the periaqueductal gray matter (PAG), precuneus, and thalamus, indicating activation of endogenous mu-opioid neurotransmission, even before the active tDCS. The subsequent real tDCS also induced MOR activation in the PAG and precuneus, which were positively correlated to the changes observed with placebo tDCS. Nonetheless, real tDCS had an additional MOR activation in the left prefrontal cortex. Although significant changes in the MOR BPND occurred with both placebo and real tDCS, significant analgesic effects, measured by improvements in the heat and cold pain thresholds, were only observed after real tDCS, not the placebo tDCS. This study gives preliminary evidence that the analgesic effects reported with M1-tDCS, can be in part related to the recruitment of the same endogenous MOR mechanisms induced by placebo, and that such effects can be purposely optimized by real tDCS.	[DosSantos, Marcos F.; Martikainen, Ilkka K.; Nascimento, Thiago D.; DeBoer, Misty D.; DaSilva, Alexandre F.] Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; [DosSantos, Marcos F.; Martikainen, Ilkka K.; Nascimento, Thiago D.; DeBoer, Misty D.; DaSilva, Alexandre F.] Univ Michigan, Sch Dent, MCOHR, Ann Arbor, MI 48109 USA; [Martikainen, Ilkka K.; Love, Tiffany M.; Zubieta, Jon-Kar; DaSilva, Alexandre F.] Univ Michigan, Translat Neuroimaging Lab, MBNI, Ann Arbor, MI 48109 USA; [Schambra, Heidi M.] Columbia Univ, Dept Neurol, New York, NY USA; [Schambra, Heidi M.] Columbia Univ, Dept Rehabil & Regenerat Med, New York, NY USA; [Bikson, Marom] CUNY City Coll, Dept Biomed Engn, New York, NY 10031 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Columbia University; Columbia University; City University of New York (CUNY) System; City College of New York (CUNY)	DaSilva, AF (corresponding author), Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.	adasilva@umich.edu	DosSantos, Marcos/AAR-7308-2020; Zubieta, Jon-Kar/AAB-5565-2022; Nascimento, Thiago/GNH-3833-2022; Love, Tiffany/W-8427-2019; DosSantos, Marcos/E-8913-2014	DosSantos, Marcos/0000-0002-5997-9693; Nascimento, Thiago/0000-0003-0910-9005; Love, Tiffany/0000-0001-9299-3190; DosSantos, Marcos/0000-0002-5997-9693	Michigan Institute for Clinical & Health Research Clinical Trial Planning Program/CTSA, University of Michigan [UL1RR024986]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazil; University of Michigan, Ann Arbor, United States of America; Swedish Cultural Foundation in Finland, Helsinki, Finland; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024986] Funding Source: NIH RePORTER	Michigan Institute for Clinical & Health Research Clinical Trial Planning Program/CTSA, University of Michigan; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); University of Michigan, Ann Arbor, United States of America; Swedish Cultural Foundation in Finland, Helsinki, Finland; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by the following grants: Dr. DaSilva, the principal investigator of the study, was supported by Michigan Institute for Clinical & Health Research Clinical Trial Planning Program/CTSA high-tech funding UL1RR024986, University of Michigan. Dr. Santos was also supported by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazil, and by the University of Michigan, Ann Arbor, United States of America. Dr. Martikainen was supported by the Swedish Cultural Foundation in Finland, Helsinki, Finland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amanzio M, 1999, J NEUROSCI, V19, P484, DOI 10.1523/JNEUROSCI.19-01-00484.1999; Amer Assoc Electrodiagnost Med, 2004, MUSCLE NERVE, V29, P734, DOI 10.1002/mus.20053; Antal A, 2011, NEUROIMAGE, V55, P590, DOI 10.1016/j.neuroimage.2010.11.085; Apkarian AV, 2004, J NEUROSCI, V24, P10410, DOI 10.1523/JNEUROSCI.2541-04.2004; Bachmann CG, 2010, CLIN NEUROPHYSIOL, V121, P2083, DOI 10.1016/j.clinph.2010.05.005; Bingel U, 2006, PAIN, V120, P8, DOI 10.1016/j.pain.2005.08.027; Boggio PS, 2009, NEUROPSYCHOLOGIA, V47, P212, DOI 10.1016/j.neuropsychologia.2008.07.022; DANNALS RF, 1985, INT J APPL RADIAT IS, V36, P303, DOI 10.1016/0020-708X(85)90089-4; DaSilva AF, 2012, HEADACHE; DaSilva AF, 2011, JOVE-J VIS EXP, DOI 10.3791/2744; DaSilva AF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003396; DaSilva AFM, 2007, NEUROREPORT, V18, P301, DOI 10.1097/WNR.0b013e32801776bb; de Andrade DC, 2011, PAIN, V152, P320, DOI 10.1016/j.pain.2010.10.032; DosSantos Marcos Fabio, 2012, Front Psychiatry, V3, P93, DOI 10.3389/fpsyt.2012.00093; Essick GK, 2004, J OROFAC PAIN, V18, P345; Fregni F, 2006, ARTHRITIS RHEUM-US, V54, P3988, DOI 10.1002/art.22195; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Garcia-Larrea L, 1999, PAIN, V83, P259, DOI 10.1016/S0304-3959(99)00114-1; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Hansson P, 2007, PAIN, V129, P256, DOI 10.1016/j.pain.2007.03.030; Harris RE, 2009, NEUROIMAGE, V47, P1077, DOI 10.1016/j.neuroimage.2009.05.083; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; Jin CW, 2013, NMR BIOMED, V26, P58, DOI 10.1002/nbm.2819; Johnson S, 2006, PAIN, V123, P187, DOI 10.1016/j.pain.2006.02.030; Jurgens TP, 2012, EUR J PAIN, V16, P1251, DOI 10.1002/j.1532-2149.2012.00135.x; Kano M, 2013, AM J PHYSL GASTROINT; Kuchinad A, 2007, J NEUROSCI, V27, P4004, DOI 10.1523/JNEUROSCI.0098-07.2007; Leppa M, 2006, NEUROIMAGE, V31, P661, DOI 10.1016/j.neuroimage.2005.12.019; LEVINE JD, 1978, LANCET, V2, P654, DOI 10.1016/S0140-6736(78)92762-9; Linnman C, 2012, NEUROIMAGE, V60, P505, DOI 10.1016/j.neuroimage.2011.11.095; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Lorenz J, 2002, NEURON, V35, P383, DOI 10.1016/S0896-6273(02)00767-5; Luedtke K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048857; Maarrawi J, 2007, NEUROLOGY, V69, P827, DOI 10.1212/01.wnl.0000269783.86997.37; Mainero C, 2011, ANN NEUROL, V70, P838, DOI 10.1002/ana.22537; Maleki N, 2013, NMR BIOMED; Metz AE, 2009, P NATL ACAD SCI USA, V106, P2423, DOI 10.1073/pnas.0809897106; MINOSHIMA S, 1993, J NUCL MED, V34, P322; Moloney TM, 2013, NEUROSCI LETT, V534, P289, DOI 10.1016/j.neulet.2012.11.049; Mylius V, 2012, PAIN, V153, P1350, DOI 10.1016/j.pain.2012.04.009; Nahmias F, 2009, PAIN, V147, P224, DOI 10.1016/j.pain.2009.09.016; Nitsche MA, 2003, SUPPL CLIN NEUROPHYS, V56, P255; O'Connell NE, 2013, CLIN J PAIN, V29, P26, DOI 10.1097/AJP.0b013e318247ec09; O'Connell NE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047514; O'Connell NE, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008208.pub2; Ossipov MH, 2010, J CLIN INVEST, V120, P3779, DOI 10.1172/JCI43766; Phelps EA, 2004, NEURON, V43, P897, DOI 10.1016/j.neuron.2004.08.042; Porro CA, 2002, J NEUROSCI, V22, P3206, DOI 10.1523/JNEUROSCI.22-08-03206.2002; Rolke R, 2006, PAIN, V123, P231, DOI 10.1016/j.pain.2006.01.041; Schestatsky P, 2011, ARQ NEURO-PSIQUIAT, V69, P943, DOI 10.1590/S0004-282X2011000700019; Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34; Stagg CJ, 2013, J NEUROSCI, V33, P11425, DOI 10.1523/JNEUROSCI.3887-12.2013; Summers J, 2004, NEUROSCI LETT, V368, P197, DOI 10.1016/j.neulet.2004.07.008; Taylor JJ, 2013, NEUROPSYCHOPHARMACOL; Taylor JJ, 2012, PAIN, V153, P1219, DOI 10.1016/j.pain.2012.02.030; Villamar MF, 2013, JOVE-J VIS EXP, DOI 10.3791/50309; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Wager TD, 2007, P NATL ACAD SCI USA, V104, P11056, DOI 10.1073/pnas.0702413104; Wagner T, 2007, NEUROIMAGE, V35, P1113, DOI 10.1016/j.neuroimage.2007.01.027; Watson A, 2009, PAIN, V145, P24, DOI 10.1016/j.pain.2009.04.003; Wrigley PJ, 2013, PAIN, V154, P2178, DOI 10.1016/j.pain.2013.06.045; Wu D, 2013, EXP BRAIN RES; YARNITSKY D, 1994, J NEUROL SCI, V125, P39, DOI 10.1016/0022-510X(94)90239-9; Youssef AM, 2013, PAIN; Zheng X, 2011, NEUROIMAGE, V58, P26, DOI 10.1016/j.neuroimage.2011.06.018; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005; Zubieta JK, 2009, ANN NY ACAD SCI, V1156, P198, DOI 10.1111/j.1749-6632.2009.04424.x; Zyloney CE, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-80	69	52	54	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2014	9	7							e102350	10.1371/journal.pone.0102350	http://dx.doi.org/10.1371/journal.pone.0102350			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4KM	25029273	Green Published, gold			2023-01-03	WOS:000341306600068
J	Dai, CL; Yan, ZH; You, Q; Du, MY; Zhao, MW				Dai, Caili; Yan, Zhihu; You, Qing; Du, Mingyong; Zhao, Mingwei			Formation of Worm-Like Micelles in Mixed N-Hexadecyl-N-Methylpyrrolidinium Bromide-Based Cationic Surfactant and Anionic Surfactant Systems	PLOS ONE			English	Article							CETYLTRIMETHYLAMMONIUM BROMIDE; VISCOELASTIC PROPERTIES; RHEOLOGICAL BEHAVIOR; NMR-SPECTROSCOPY; IONIC LIQUIDS; BICELLES; DYNAMICS	Through the descriptive and rheological characterization of worm-like micelles formed by N-hexadecyl-N-methylpyrrolidinium bromide and sodium laurate, the formation and properties of the worm-like micelles were affected by the concentrations of sodium laurate and temperature. Additionally, cryogenic transmission electron microscopy images further validated the formation of worm-like micelles.	[Dai, Caili; Yan, Zhihu; Du, Mingyong; Zhao, Mingwei] China Univ Petr Huadong, Sch Petr Engn, Qingdao, Shandong, Peoples R China; [You, Qing] China Univ Geosci, Sch Energy Resources, Beijing, Peoples R China	China University of Petroleum; China University of Geosciences	Zhao, MW (corresponding author), China Univ Petr Huadong, Sch Petr Engn, Qingdao, Shandong, Peoples R China.	zhaomingwei@upc.edu.cn	Du, Mingyong/O-6384-2017	Dai, Cai li/0000-0002-7477-8865; Du, Mingyong/0000-0001-7006-2125	National Natural Science Foundation of China [51174221, 21303268]; Program for New Century Excellent Talents in University [20110226]; China Postdoctoral Science Foundation [2013T60689]; National Ministry of Education [20120133110010]; Fundamental Research Funds for the Central Universities [14CX02041A]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); National Ministry of Education; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was sponsored by the National Natural Science Foundation of China (number 51174221, 21303268), the Program for New Century Excellent Talents in University (number 20110226), China Postdoctoral Science Foundation funded project (number 2013T60689), Doctoral Fund from National Ministry of Education (number 20120133110010) and the Fundamental Research Funds for the Central Universities (number 14CX02041A). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acharya DP, 2004, PHYS CHEM CHEM PHYS, V6, P1627, DOI 10.1039/b312940c; Ali AA, 1999, COLLOID POLYM SCI, V277, P270; Anderson VJ, 2006, RHEOLOGY REV, V2006, P217; CANDAU SJ, 1988, J COLLOID INTERF SCI, V122, P430, DOI 10.1016/0021-9797(88)90377-3; CANDAU SJ, 1985, J COLLOID INTERF SCI, V105, P521, DOI 10.1016/0021-9797(85)90327-3; Cates ME, 2006, ADV PHYS, V55, P799, DOI 10.1080/00018730601082029; CATES ME, 1990, J PHYS-CONDENS MAT, V2, P6869, DOI 10.1088/0953-8984/2/33/001; Chu ZL, 2013, CHEM SOC REV, V42, P7174, DOI 10.1039/c3cs35490c; Davies TS, 2006, J AM CHEM SOC, V128, P6669, DOI 10.1021/ja060021e; Dong B, 2008, COLLOID SURFACE A, V317, P666, DOI 10.1016/j.colsurfa.2007.12.001; Dong B, 2007, LANGMUIR, V23, P4178, DOI 10.1021/la0633029; Dvinskikh S, 2006, J AM CHEM SOC, V128, P6326, DOI 10.1021/ja061153a; Dvinskikh SV, 2007, J AM CHEM SOC, V129, P794, DOI 10.1021/ja065536k; Dvinskikh SV, 2007, J MAGN RESON, V184, P228, DOI 10.1016/j.jmr.2006.10.004; Geng F, 2010, PROCESS BIOCHEM, V45, P306, DOI 10.1016/j.procbio.2009.10.001; GRANEK R, 1992, J CHEM PHYS, V96, P4758, DOI 10.1063/1.462787; HOFFMANN H, 1992, LANGMUIR, V8, P2140, DOI 10.1021/la00045a013; Israelachvili JN, 2011, INTERMOLECULAR AND SURFACE FORCES, 3RD EDITION, P1; Kumar R, 2007, LANGMUIR, V23, P12849, DOI 10.1021/la7028559; Li J, 2012, COLLOID SURFACE A, V396, P16, DOI 10.1016/j.colsurfa.2011.12.019; Lin Z, 1996, LANGMUIR, V12, P1729, DOI 10.1021/la950570q; Lu T, 2008, J PHYS CHEM B, V112, P2909, DOI 10.1021/jp0766205; Magid LJ, 1998, J PHYS CHEM B, V102, P4064, DOI 10.1021/jp9730961; Moitzi C, 2005, J PHYS CHEM B, V109, P16161, DOI 10.1021/jp0441691; Pei XM, 2011, J COLLOID INTERF SCI, V356, P176, DOI 10.1016/j.jcis.2010.12.065; REHAGE H, 1988, J PHYS CHEM-US, V92, P4712, DOI 10.1021/j100327a031; REHAGE H, 1991, MOL PHYS, V74, P933, DOI 10.1080/00268979100102721; Shi LJ, 2012, RSC ADV, V2, P11922, DOI 10.1039/c2ra21467a; SHIKATA T, 1987, LANGMUIR, V3, P1081, DOI 10.1021/la00078a035; Shrestha RG, 2007, J COLLOID INTERF SCI, V311, P276, DOI 10.1016/j.jcis.2007.02.050; Shrestha RG, 2009, COLLOID SURFACE A, V332, P103, DOI 10.1016/j.colsurfa.2008.09.002; Welton T, 1999, CHEM REV, V99, P2071, DOI 10.1021/cr980032t; Xu J, 2008, ANGEW CHEM, V120, P7982; Yamamoto K, 2009, LANGMUIR, V25, P7010, DOI 10.1021/la900200s; Zhao MW, 2011, PHYS CHEM CHEM PHYS, V13, P1332, DOI 10.1039/c0cp00342e	35	10	10	2	53	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2014	9	7							e102539	10.1371/journal.pone.0102539	http://dx.doi.org/10.1371/journal.pone.0102539			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM1PC	25019152	Green Published, Green Submitted, gold			2023-01-03	WOS:000339618600093
J	Shen, YC; Weng, SF; Wang, JJ; Tien, KJ				Shen, Yuan-Chi; Weng, Shih-Feng; Wang, Jhi-Joung; Tien, Kai-Jen			Erectile Dysfunction and Risk of End Stage Renal Disease Requiring Dialysis: A Nationwide Population-Based Study	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; CORONARY-HEART-DISEASE; SEXUAL DYSFUNCTION; CARDIOVASCULAR-DISEASE; PREVALENCE; MEN; HYPERTENSION; PREDICTOR; SEVERITY	Background: Previous studies have suggested that erectile dysfunction (ED) is an independent risk factor for macrovascular disease. Very few studies have evaluated the relationship between ED and risk of end stage renal disease (ESRD) requiring dialysis. Methods: A random sample of 1,000,000 individuals from Taiwan's National Health Insurance database was collected. We selected the control group by matching the subjects and controls by age, diabetes, hypertension, coronary heart disease, hyperlipidemia, area of residence, monthly income and index date. We identified 3985 patients with newly-diagnosed ED between 2000 and 2008 and compared them with a matched cohort of 23910 patients without ED. All patients were tracked from the index date to identify which patients subsequently developed a need for dialysis. Results: The incidence rates of dialysis in the ED cohort and comparison groups were 10.85 and 9.06 per 10000 person-years, respectively. Stratified by age, the incidence rate ratio for dialysis was greater in ED patients aged <50 years (3.16, 95% CI: 1.62-6.19, p = 0.0008) but not in aged 50-64 (0.94, 95% CI: 0.52-1.69, p = 0.8397) and those aged >= 65 (0.69, 95% CI: 0.32-1.52, p = 0.3594). After adjustment for patient characteristics and medial comorbidities, the adjusted HR for dialysis remained greater in ED patients aged <50 years (adjusted HR: 2.08, 95% CI: 1.05-4.11, p<0.05). The log-rank test revealed that ED patients <50-years-old had significantly higher cumulative incidence rates of dialysis than those without (p = 0.0004). Conclusion: Patients with ED, especially younger patients, are at an increased risk for ESRD requiring dialysis later in life.	[Shen, Yuan-Chi] Kaohsiung Chang Gung Mem Hosp, Dept Urol, Kaohsiung, Taiwan; [Shen, Yuan-Chi] Cheng Shiu Univ, Kaohsiung, Taiwan; [Weng, Shih-Feng; Wang, Jhi-Joung] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Weng, Shih-Feng] Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm, Tainan, Taiwan; [Tien, Kai-Jen] Chi Mei Med Ctr, Dept Internal Med, Div Endocrinol & Metab, Tainan, Taiwan; [Tien, Kai-Jen] Chia Nan Univ Pharm & Sci, Ctr Gen Educ, Tainan, Taiwan	Chang Gung Memorial Hospital; Cheng Shiu University; Chi Mei Hospital; Chia Nan University of Pharmacy & Science; Chi Mei Hospital; Chia Nan University of Pharmacy & Science	Tien, KJ (corresponding author), Chi Mei Med Ctr, Dept Internal Med, Div Endocrinol & Metab, Tainan, Taiwan.	cmmctkj@gmail.com		Weng, Shih-Feng/0000-0001-8684-3487				Aversa A, 2010, INT J UROL, V17, P38, DOI 10.1111/j.1442-2042.2009.02426.x; Bellinghieri G, 2008, J NEPHROL, V21, pS113; Blumentals W A, 2003, Aging Male, V6, P217, DOI 10.1080/13685530312331309752; Chew KK, 2010, J SEX MED, V7, P192, DOI 10.1111/j.1743-6109.2009.01576.x; Chuang YC, 2012, J SEX MED, V9, P1055, DOI 10.1111/j.1743-6109.2011.02586.x; Hermans MP, 2009, DIABETES METAB, V35, P484, DOI 10.1016/j.diabet.2009.06.003; Hwang TIS, 2010, J SEX MED, V7, P2817, DOI 10.1111/j.1743-6109.2010.01837.x; Lewis RW, 2010, J SEX MED, V7, P1598, DOI 10.1111/j.1743-6109.2010.01778.x; Ma RCW, 2008, J AM COLL CARDIOL, V51, P2045, DOI 10.1016/j.jacc.2008.02.051; Marumo K, 2001, INT J UROL, V8, P53, DOI 10.1046/j.1442-2042.2001.00258.x; McKinlay JB, 2000, INT J IMPOT RES, V12, pS6, DOI 10.1038/sj.ijir.3900567; Navaneethan SD, 2010, AM J KIDNEY DIS, V56, P670, DOI 10.1053/j.ajkd.2010.06.016; O'Leary MP, 2006, J UROLOGY, V175, P1058, DOI 10.1016/S0022-5347(05)00418-0; Ponholzer A, 2005, EUR UROL, V48, P512, DOI 10.1016/j.eururo.2005.05.014; Ravani P, 2005, J AM SOC NEPHROL, V16, P2449, DOI 10.1681/ASN.2005010076; RECKELHOFF JF, 1993, AM J PHYSIOL, V265, pR1126, DOI 10.1152/ajpregu.1993.265.5.R1126; Salem S, 2009, J SEX MED, V6, P3425, DOI 10.1111/j.1743-6109.2009.01515.x; Seftel AD, 2004, J UROLOGY, V171, P2341, DOI 10.1097/01.ju.0000125198.32936.38; Shamloul R, 2013, LANCET, V381, P153, DOI 10.1016/S0140-6736(12)60520-0; Shankar A, 2011, KIDNEY INT, V80, P1231, DOI 10.1038/ki.2011.283; Siu SC, 2001, DIABETIC MED, V18, P732, DOI 10.1046/j.0742-3071.2001.00557.x; Stenvinkel P, 2010, J INTERN MED, V268, P456, DOI 10.1111/j.1365-2796.2010.02269.x; Thompson IM, 2005, JAMA-J AM MED ASSOC, V294, P2996, DOI 10.1001/jama.294.23.2996; Uhlig K, 2002, TRADITIONAL CARDIAC, P118; Viigimaa M, 2011, J HYPERTENS, V29, P403, DOI 10.1097/HJH.0b013e328342c659; Weinberg AE, 2013, J SEX MED, V10, P3102, DOI 10.1111/jsm.12318; Yamasaki H, 2004, DIABETES RES CLIN PR, V66, pS173, DOI 10.1016/j.diabres.2003.09.019; Zoccali C, 2011, KIDNEY INT SUPPL, V1, P2, DOI 10.1038/kisup.2011.4	28	7	7	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2014	9	7							e102055	10.1371/journal.pone.0102055	http://dx.doi.org/10.1371/journal.pone.0102055			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AL8HH	25013905	Green Submitted, gold, Green Published			2023-01-03	WOS:000339378400059
J	Ryskina, KL; Korenstein, D; Weissman, A; Masters, P; Alguire, P; Smith, CD				Ryskina, Kira L.; Korenstein, Deborah; Weissman, Arlene; Masters, Philip; Alguire, Patrick; Smith, Cynthia D.			Development of a High-Value Care Subscore on the Internal Medicine In-Training Examination	ANNALS OF INTERNAL MEDICINE			English	Article							COST-CONSCIOUS CARE; TEACHING HIGH-VALUE; RESIDENTS; COMPETENCE; PHYSICIANS; VIGNETTES	Background: Although high-value care (HVC) that balances benefits of tests or treatments against potential harms and costs has been a recently emphasized competency for internal medicine (IM) residents, few tools to assess residents' knowledge of HVC are available. Objective: To describe the development and initial results of an HVC subscore of the Internal Medicine In-Training Examination (IM-ITE). Design: The HVC concepts were introduced to IM-ITE authors during question development. Three physicians independently reviewed each examination question for selection in the HVC subscore according to 6 HVC principles. The final subscore was determined by consensus. Data from the IM-ITE administered in October 2012 were analyzed at the program level. Setting: U.S. IM residency programs. Participants: 362 U.S. IM residency programs with IM-ITE data for at least 10 residents. Measurements: Program-level performance on the HVC subscore was compared with performance on the overall IM-ITE, the Dartmouth Atlas hospital care intensity (HCI) index of the program's primary training hospital, and residents' attitudes about HVC assessed with a voluntary survey. Results: The HVC subscore comprised 38 questions, including 21 (55%) on managing conservatively when appropriate and 14 (37%) on identifying low-value care. Of the 362 U.S. IM programs in the sample, 41% were in a different quartile when ranked based on the HVC subscore compared with overall IM-ITE performance. Rankings by HVC subscore and HCI index were modestly inversely associated, with 30% of programs ranked in the same quartile based on both measures. Limitation: Knowledge of HVC assessed from examination vignettes may not reflect practice of HVC. Conclusion: Although the HVC subscore has face validity and can contribute to evaluation of residents' HVC knowledge, additional tools are needed to accurately measure residents' proficiency in HVC.	[Ryskina, Kira L.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA; Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; Amer Coll Physicians, Philadelphia, PA USA	University of Pennsylvania; University of Pennsylvania; American College of Physicians	Ryskina, KL (corresponding author), Univ Penn, Div Gen Internal Med, 13-30B4,13th Floor,Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	ryskina@mail.med.upenn.edu			National Research Service Award	National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Dr. Ryskina is supported by a National Research Service Award. Drs. Korenstein, Weissman, Masters, Alguire, and Smith are employees of the ACP.	American College of Physicians Alliance for Academic Internal Medicine, 2014, ACP INT MED INTR EX; [Anonymous], 2014, DARTMOUTH ATLAS HLTH; Arora A, 2012, DARTMOUTH ATLAS HLTH; Asch DA, 2009, JAMA-J AM MED ASSOC, V302, P1277, DOI 10.1001/jama.2009.1356; Bach PB, 2010, NEW ENGL J MED, V362, P569, DOI 10.1056/NEJMp0909947; Bernabeo EC, 2013, ADV HEALTH SCI EDUC, V18, P463, DOI 10.1007/s10459-012-9384-x; Caverzagie KJ, 2013, ANN INTERN MED, V158, P557, DOI 10.7326/0003-4819-158-7-201304020-00593; Moriates C, 2013, JAMA INTERN MED, V173, P308, DOI 10.1001/jamainternmed.2013.2286; Owens DK, 2011, ANN INTERN MED, V154, P174, DOI 10.7326/0003-4819-154-3-201102010-00007; Peabody JW, 2004, ANN INTERN MED, V141, P771, DOI 10.7326/0003-4819-141-10-200411160-00008; Post J, 2013, AM J MED, V126, P838, DOI 10.1016/j.amjmed.2013.05.015; Skinner J, 2010, NEW ENGL J MED, V362, P569, DOI 10.1056/NEJMp1000448; Smith CD, 2012, ANN INTERN MED, V157, P284, DOI 10.7326/0003-4819-157-4-201208210-00496; Wallenstein J, 2010, ACAD EMERG MED, V17, pS67, DOI 10.1111/j.1553-2712.2010.00894.x; Weinberger SE, 2011, ANN INTERN MED, V155, P386, DOI 10.7326/0003-4819-155-6-201109200-00007	15	11	11	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 18	2014	161	10					733	U187		10.7326/M14-0444	http://dx.doi.org/10.7326/M14-0444			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AX9TT	25321871				2023-01-03	WOS:000347245600030
J	Gaillard, S; Lo Re, L; Mantilleri, A; Hepp, R; Urien, L; Malapert, P; Alonso, S; Deage, M; Kambrun, C; Landry, M; Low, SA; Alloui, A; Lambolez, B; Scherrer, G; Le Feuvre, Y; Bourinet, E; Moqrich, A				Gaillard, Stephane; Lo Re, Laure; Mantilleri, Annabelle; Hepp, Regine; Urien, Louise; Malapert, Pascale; Alonso, Serge; Deage, Michael; Kambrun, Charline; Landry, Marc; Low, Sarah A.; Alloui, Abdelkrim; Lambolez, Bertrand; Scherrer, Gregory; Le Feuvre, Yves; Bourinet, Emmanuel; Moqrich, Aziz			GINIP, a G(alpha i)-Interacting Protein, Functions as a Key Modulator of Peripheral GABA(B) Receptor-Mediated Analgesia	NEURON			English	Article							DORSAL-ROOT GANGLIA; SUBSTANTIA-GELATINOSA NEURONS; RAT SPINAL-CORD; NERVE INJURY; PAIN HYPERSENSITIVITY; ADULT-RAT; INFLAMMATORY PAIN; DISTINCT SUBSETS; ANIMAL-MODEL; IN-VIVO	One feature of neuropathic pain is a reduced GABAergic inhibitory function. Nociceptors have been suggested to play a key role in this process. However, the mechanisms behind nociceptor-mediated modulation of GABA signaling remain to be elucidated. Here we describe the identification of GINIP, a G(alpha i)-interacting protein expressed in two distinct subsets of nonpeptidergic nociceptors. GINIP null mice develop a selective and prolonged mechanical hypersensitivity in models of inflammation and neuropathy. GINIP null mice show impaired responsiveness to GABA(B), but not to delta or mu opioid receptor agonist-mediated analgesia specifically in the spared nerve injury (SNI) model. Consistently, GINIP-deficient dorsal root ganglia neurons had lower baclofen-evoked inhibition of high-voltage-activated calcium channels and a defective presynaptic inhibition of lamina IIi interneurons. These results further support the role of unmyelinated C fibers in injury-induced modulation of spinal GABAergic inhibition and identify GINIP as a key modulator of peripherally evoked GABA(B)-receptors signaling.	[Gaillard, Stephane; Lo Re, Laure; Mantilleri, Annabelle; Urien, Louise; Malapert, Pascale; Alonso, Serge; Moqrich, Aziz] Aix Marseille Univ, CNRS, Inst Biol Dev Marseille, UMR 7288, F-13288 Marseille 09, France; [Hepp, Regine; Lambolez, Bertrand] Univ Paris 06, Sorbonne Univ, UM CR 18, Neurosci Paris Seine, F-75005 Paris, France; [Hepp, Regine; Lambolez, Bertrand] CNRS, UMR 8246, Paris, France; [Hepp, Regine; Lambolez, Bertrand] INSERM, UMR S 1130, Paris, France; [Deage, Michael; Bourinet, Emmanuel] Univ Montpellier I, Labs Excellence Ion Channel Sci & Therapeut, Inst Genom Fonct, UMR5203,CNRS,U661,INSERM, F-34094 Montpellier 05, France; [Deage, Michael; Bourinet, Emmanuel] Univ Montpellier 2, Labs Excellence Ion Channel Sci & Therapeut, Inst Genom Fonct, CNRS,UMR5203,INSERM,U661, F-34094 Montpellier 05, France; [Kambrun, Charline; Landry, Marc; Le Feuvre, Yves] Univ Bordeaux, Interdisciplinary Inst Neurosci, UMR 5297, F-33000 Bordeaux, France; [Kambrun, Charline; Landry, Marc; Le Feuvre, Yves] CNRS, Interdisciplinary Inst Neurosci, UMR 5297, F-33000 Bordeaux, France; [Low, Sarah A.; Scherrer, Gregory] Stanford Univ, Dept Anesthesiol Perioperat & Pain Med, Dept Mol & Cellular Physiol, Stanford Neurosci Inst, Palo Alto, CA 94304 USA; [Alloui, Abdelkrim] Fac Med Pharm, Lab Pharmacol Med, UMR INSERM 766, F-63001 Clermont Ferrand 1, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Stanford University; Institut National de la Sante et de la Recherche Medicale (Inserm)	Moqrich, A (corresponding author), Aix Marseille Univ, CNRS, Inst Biol Dev Marseille, UMR 7288, Case 907, F-13288 Marseille 09, France.	aziz.moqrich@univ-amu.fr	Alloui, Abdelkrim/L-9861-2015	Urien, Louise/0000-0002-8284-9395; LOW, SARAH/0000-0002-3847-2965; Landry, Marc/0000-0003-3936-324X; HEPP, regine/0000-0002-7683-7451; Le Feuvre, Yves/0000-0002-2646-4028; moqrich, aziz/0000-0002-1937-1675; Gaillard, Stephane/0000-0001-9326-5363; Scherrer, Gregory/0000-0002-1983-5126; lambolez, bertrand/0000-0002-0653-480X	NIH [DA031777]; HHMI; ERC [260435]; NATIONAL INSTITUTE ON DRUG ABUSE [K99DA031777, R00DA031777] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); HHMI(Howard Hughes Medical Institute); ERC(European Research Council (ERC)European Commission); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We would like to thank Robert Kelly for his comments on the manuscript. We also thank members of the laboratory for scientific discussions, the IBDM imaging, and animal facilities for assistance. Thanks to the ARPEGE Pharmacology core facility at IGF and to Sebastien Leulier for his assistance with the BRET experiments. We are grateful to L. F. Reichardt for providing anti-TrkA antibody. G. S. is supported by NIH grant DA031777, and S. A. L. is supported by an HHMI Medical Research fellowship. This work has been funded by the ERC-starting grant, paineurons 260435. The authors declare that they have no competing financial interests.	Abrahamsen B, 2008, SCIENCE, V321, P702, DOI 10.1126/science.1156916; Agarwal N, 2007, NAT NEUROSCI, V10, P870, DOI 10.1038/nn1916; Ataka T, 2000, PAIN, V86, P273, DOI 10.1016/S0304-3959(00)00255-4; Barak LS, 2008, MOL PHARMACOL, V74, P585, DOI 10.1124/mol.108.048884; Bardoni R, 2014, NEURON, V81, P1312, DOI 10.1016/j.neuron.2014.01.044; CAMPBELL JN, 1988, PAIN, V32, P89, DOI 10.1016/0304-3959(88)90027-9; Castro AR, 2004, BRAIN RES, V1003, P77, DOI 10.1016/j.brainres.2003.12.027; Cavanaugh DJ, 2009, P NATL ACAD SCI USA, V106, P9075, DOI 10.1073/pnas.0901507106; Charles KJ, 2001, NEUROSCIENCE, V106, P447, DOI 10.1016/S0306-4522(01)00296-2; Decosterd I, 2000, PAIN, V87, P149, DOI 10.1016/S0304-3959(00)00276-1; Delfini MC, 2013, CELL REP, V5, P378, DOI 10.1016/j.celrep.2013.09.013; Descoeur J, 2011, EMBO MOL MED, V3, P266, DOI 10.1002/emmm.201100134; DIRIG DM, 1995, J PHARMACOL EXP THER, V275, P219; Engle MP, 2012, J COMP NEUROL, V520, P1663, DOI 10.1002/cne.23005; Gangadharan V, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-68; Gassmann M, 2004, J NEUROSCI, V24, P6086, DOI 10.1523/JNEUROSCI.5635-03.2004; Gervasi N, 2007, J NEUROSCI, V27, P2744, DOI 10.1523/JNEUROSCI.5352-06.2007; Han L, 2013, NAT NEUROSCI, V16, P174, DOI 10.1038/nn.3289; Hepp R, 2007, J NEUROCHEM, V102, P1875, DOI 10.1111/j.1471-4159.2007.04657.x; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Ibuki T, 1997, NEUROSCIENCE, V76, P845, DOI 10.1016/S0306-4522(96)00341-7; Iyadomi M, 2000, PAIN, V85, P385, DOI 10.1016/S0304-3959(99)00285-7; Janson W., 2003, Current Pharmaceutical Biotechnology, V4, P270, DOI 10.2174/1389201033489766; Jasmin L, 2003, NATURE, V424, P316, DOI 10.1038/nature01808; Laffray S, 2012, EMBO J, V31, P3239, DOI 10.1038/emboj.2012.161; Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012; Legha W, 2010, GENE EXPR PATTERNS, V10, P368, DOI 10.1016/j.gep.2010.08.003; Li LS, 2011, CELL, V147, P1615, DOI 10.1016/j.cell.2011.11.027; Luscher C, 2010, NAT REV NEUROSCI, V11, P301, DOI 10.1038/nrn2834; McGlone F, 2014, NEURON, V82, P737, DOI 10.1016/j.neuron.2014.05.001; Moore KA, 2002, J NEUROSCI, V22, P6724, DOI 10.1523/jneurosci.22-15-06724.2002; Moqrich A, 2004, NAT NEUROSCI, V7, P812, DOI 10.1038/nn1283; Nockemann D, 2013, EMBO MOL MED, V5, P1263, DOI 10.1002/emmm.201201980; Patel S, 2001, PAIN, V90, P217, DOI 10.1016/S0304-3959(00)00404-8; Polito M, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00211; PRICE GW, 1987, SYNAPSE, V1, P530, DOI 10.1002/syn.890010605; Remondes M, 2003, LEARN MEMORY, V10, P247, DOI 10.1101/lm.59103; Scherrer G, 2009, CELL, V137, P1148, DOI 10.1016/j.cell.2009.04.019; Schuler V, 2001, NEURON, V31, P47, DOI 10.1016/S0896-6273(01)00345-2; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Seal RP, 2009, NATURE, V462, P651, DOI 10.1038/nature08505; Shields SD, 2010, PAIN, V151, P422, DOI 10.1016/j.pain.2010.08.001; SMITH GD, 1994, NEUROPHARMACOLOGY, V33, P1103, DOI 10.1016/0028-3908(94)90149-X; Takeda M, 2004, NEUROSCIENCE, V123, P491, DOI 10.1016/j.neuroscience.2003.09.022; TATEBAYASHI H, 1992, J PHYSIOL-LONDON, V447, P391, DOI 10.1113/jphysiol.1992.sp019008; Tedford HW, 2006, PHARMACOL REV, V58, P837, DOI 10.1124/pr.58.4.11; Towers S, 2000, EUR J NEUROSCI, V12, P3201, DOI 10.1046/j.1460-9568.2000.00237.x; Vilar B, 2013, J NEUROSCI, V33, P18951, DOI 10.1523/JNEUROSCI.1221-13.2013; Vrontou S, 2013, NATURE, V493, P669, DOI 10.1038/nature11810; Wang XL, 2007, J PHYSIOL-LONDON, V579, P849, DOI 10.1113/jphysiol.2006.126102; Yang K, 2001, BRAIN RES BULL, V55, P479, DOI 10.1016/S0361-9230(01)00546-9; Zotterman Y, 1939, J PHYSIOL-LONDON, V95, P1; Zylka MJ, 2005, NEURON, V45, P17, DOI 10.1016/j.neuron.2004.12.015	53	32	32	3	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	OCT 1	2014	84	1					123	136		10.1016/j.neuron.2014.08.056	http://dx.doi.org/10.1016/j.neuron.2014.08.056			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AQ0WG	25242222	Bronze, Green Published, Green Accepted			2023-01-03	WOS:000342502800015
J	Sacks, CA; Jarcho, JA; Curfman, GD				Sacks, Chana A.; Jarcho, John A.; Curfman, Gregory D.			Paradigm Shifts in Heart-Failure Therapy - A Timeline	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	74	75	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 11	2014	371	11					989	991		10.1056/NEJMp1410241	http://dx.doi.org/10.1056/NEJMp1410241			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AO5KD	25184412				2023-01-03	WOS:000341382800004
J	Oberoi, S; Zamperlini-Netto, G; Beyene, J; Treister, NS; Sung, L				Oberoi, Sapna; Zamperlini-Netto, Gabriele; Beyene, Joseph; Treister, Nathaniel S.; Sung, Lillian			Effect of Prophylactic Low Level Laser Therapy on Oral Mucositis: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							NECK-CANCER-PATIENTS; BONE-MARROW-TRANSPLANTATION; BEAM-CONDITIONING CHEMOTHERAPY; RADIATION-INDUCED MUCOSITIS; HIGH-DOSE MELPHALAN; HELIUM-NEON LASER; LOW-POWER LASER; CONCURRENT CHEMORADIOTHERAPY; ASSESSMENT SCALE; CLINICAL-TRIAL	Background: Objective was to determine whether prophylactic low level laser therapy (LLLT) reduces the risk of severe mucositis as compared to placebo or no therapy. Methods: MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials were searched until February 2014 for randomized controlled trials (RCTs) comparing prophylactic LLLT with placebo or no therapy in patients with cancer or undergoing hematopoietic stem cell transplantation (HSCT). All analyses used random effects models. Results: Eighteen RCTs (1144 patients) were included. Prophylactic LLLT reduced the overall risk of severe mucositis (risk ratio (RR) 0.37, 95% confidence interval (CI) 0.20 to 0.67; P = 0.001). LLLT also reduced the following outcomes when compared to placebo/no therapy: severe mucositis at the time of anticipated maximal mucositis (RR 0.34, 95% CI 0.20 to 0.59), overall mean grade of mucositis (standardized mean difference -1.49, 95% CI -2.02 to -0.95), duration of severe mucositis (weighted mean difference -5.32, 95% CI -9.45 to -1.19) and incidence of severe pain (RR 0.26, 95% CI 0.18 to 0.37). Conclusion: Prophylactic LLLT reduced severe mucositis and pain in patients with cancer and HSCT recipients. Future research should identify the optimal characteristics of LLLT and determine feasibility in the clinical setting.	[Oberoi, Sapna; Zamperlini-Netto, Gabriele; Sung, Lillian] Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada; [Beyene, Joseph; Sung, Lillian] Hosp Sick Children, Program Child Hlth Evaluat Sci, Peter Gilgan Ctr Res & Learning, Toronto, ON M5G 1X8, Canada; [Beyene, Joseph] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Treister, Nathaniel S.] Brigham & Womens Hosp, Div Oral Med & Dent, Boston, MA 02115 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McMaster University; Harvard University; Brigham & Women's Hospital	Sung, L (corresponding author), Hosp Sick Children, Div Haematol Oncol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	lillian.sung@sickkids.ca		Treister, Nathaniel/0000-0002-5596-7222				Antunes HS, 2013, RADIOTHER ONCOL, V109, P297, DOI 10.1016/j.radonc.2013.08.010; Antunes HS, 2007, BLOOD, V109, P2250, DOI 10.1182/blood-2006-07-035022; Antunes HS, 2013, SUPPORT CARE CANCER, V21, pS199; Arbabi-Kalati Farshid, 2013, Acta Med Iran, V51, P157; Bensadoun RJ, 1999, SUPPORT CARE CANCER, V7, P244, DOI 10.1007/s005200050256; Bensadoun RJ, 2002, J ORAL LASER APPL, P115; Bjordal JM, 2011, SUPPORT CARE CANCER, V19, P1069, DOI 10.1007/s00520-011-1202-0; Blijlevens N, 2008, J CLIN ONCOL, V26, P1519, DOI 10.1200/JCO.2007.13.6028; Bowen JM, 2013, SUPPORT CARE CANCER, V21, P303, DOI 10.1007/s00520-012-1592-7; Chor A, 2010, EUR J HAEMATOL, V84, P178, DOI 10.1111/j.1600-0609.2009.01336.x; Collins JJ, 2002, J PAIN SYMPTOM MANAG, V23, P10, DOI 10.1016/S0885-3924(01)00375-X; Collins JJ, 2000, J PAIN SYMPTOM MANAG, V19, P363, DOI 10.1016/S0885-3924(00)00127-5; Collins SL, 1997, PAIN, V72, P95, DOI 10.1016/S0304-3959(97)00005-5; Cowen D, 1997, INT J RADIAT ONCOL, V38, P697, DOI 10.1016/S0360-3016(97)00076-X; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; Cruz LB, 2007, PEDIATR BLOOD CANCER, V48, P435, DOI 10.1002/pbc.20943; de Lima AG, 2012, INT J RADIAT ONCOL, V82, P270, DOI 10.1016/j.ijrobp.2010.10.012; Elting LS, 2003, CANCER, V98, P1531, DOI 10.1002/cncr.11671; Enwemeka CS, 2006, PHOTOMED LASER SURG, V24, P457, DOI 10.1089/pho.2006.24.457; Enwemeka CS, 2001, LASER THER, V13, P95; Epstein JB, 2007, CANCER-AM CANCER SOC, V109, P1914, DOI 10.1002/cncr.22620; Gautam AP, 2013, SUPPORT CARE CANCER, V21, P1421, DOI 10.1007/s00520-012-1684-4; Gautam AP, 2012, RADIOTHER ONCOL, V104, P349, DOI 10.1016/j.radonc.2012.06.011; Gautam AP, 2012, ORAL ONCOL, V48, P893, DOI 10.1016/j.oraloncology.2012.03.008; Henry DH, 2008, SUPPORT CARE CANCER, V16, P791, DOI 10.1007/s00520-007-0380-2; Higginson IJ, 2004, FATIGUE CANC, pxvii; Hode L, 2005, PHOTOMED LASER SURG, V23, P431, DOI 10.1089/pho.2005.23.431; Hodgson BD, 2012, SUPPORT CARE CANCER, V20, P1405, DOI 10.1007/s00520-011-1223-8; Khouri Vivian Youssef, 2009, Braz. Dent. J., V20, P215, DOI 10.1590/S0103-64402009000300008; Lalla RV, 2014, CANCER; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Silva GBL, 2011, PHOTOMED LASER SURG, V29, P27, DOI 10.1089/pho.2009.2699; Lopes Carlos de Oliveira, 2006, Radiol Bras, V39, P131, DOI 10.1590/S0100-39842006000200012; Maiya GA, 2006, INDIAN J MED RES, V124, P399; McCann S, 2009, BONE MARROW TRANSPL, V43, P141, DOI 10.1038/bmt.2008.299; Migliorati C, 2013, SUPPORT CARE CANCER, V21, P333, DOI 10.1007/s00520-012-1605-6; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Oton-Leite AF, 2013, SPEC CARE DENT, V33, P294, DOI 10.1111/j.1754-4505.2012.00303.x; Oton-Leite AF, 2012, HEAD NECK-J SCI SPEC, V34, P398, DOI 10.1002/hed.21737; Peterman A, 2001, J Natl Cancer Inst Monogr, P45; Pires-Santos GM, 2012, MED ORAL PATOL ORAL, V17, pS252; Schubert MM, 2007, SUPPORT CARE CANCER, V15, P1145, DOI 10.1007/s00520-007-0238-7; SCHUBERT MM, 1992, CANCER, V69, P2469, DOI 10.1002/1097-0142(19920515)69:10<2469::AID-CNCR2820691015>3.0.CO;2-W; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Sonis ST, 2004, CANCER-AM CANCER SOC, V100, P1995, DOI 10.1002/cncr.20162; Sonis ST, 1999, CANCER-AM CANCER SOC, V85, P2103, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2103::AID-CNCR2>3.0.CO;2-0; Stolik S, 2000, J PHOTOCH PHOTOBIO B, V57, P90, DOI 10.1016/S1011-1344(00)00082-8; Tardieu C, 1996, ORAL ONCOL, V32B, P381, DOI 10.1016/S0964-1955(96)00026-7; Trotti A, 2003, RADIOTHER ONCOL, V66, P253, DOI 10.1016/S0167-8140(02)00404-8; Vera-Llonch M, 2006, CANCER-AM CANCER SOC, V106, P329, DOI 10.1002/cncr.21622; Vera-Llonch M, 2007, SUPPORT CARE CANCER, V15, P491, DOI 10.1007/s00520-006-0176-9; Vogelzang NJ, 1997, SEMIN HEMATOL, V34, P4; WOO SB, 1993, CANCER, V72, P1612, DOI 10.1002/1097-0142(19930901)72:5<1612::AID-CNCR2820720520>3.0.CO;2-Q; World Health Organization, 1979, WHO HDB REP RES CANC; Worthington HV, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000978.pub5	55	102	107	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2014	9	9							e107418	10.1371/journal.pone.0107418	http://dx.doi.org/10.1371/journal.pone.0107418			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4JX	25198431	Green Published, gold, Green Submitted			2023-01-03	WOS:000341304700110
J	Benboubker, L; Dimopoulos, MA; Dispenzieri, A; Catalano, J; Belch, AR; Cavo, M; Pinto, A; Weisel, K; Ludwig, H; Bahlis, N; Banos, A; Tiab, M; Delforge, M; Cavenagh, J; Geraldes, C; Lee, JJ; Chen, C; Oriol, A; de la Rubia, J; Qiu, LG; White, DJ; Binder, D; Anderson, K; Fermand, JP; Moreau, P; Attal, M; Knight, R; Chen, G; Van Oostendorp, J; Jacques, C; Ervin-Haynes, A; Avet-Loiseau, H; Hulin, C; Facon, T				Benboubker, Lotfi; Dimopoulos, Meletios A.; Dispenzieri, Angela; Catalano, John; Belch, Andrew R.; Cavo, Michele; Pinto, Antonello; Weisel, Katja; Ludwig, Heinz; Bahlis, Nizar; Banos, Anne; Tiab, Mourad; Delforge, Michel; Cavenagh, Jamie; Geraldes, Catarina; Lee, Je-Jung; Chen, Christine; Oriol, Albert; de la Rubia, Javier; Qiu, Lugui; White, Darrell J.; Binder, Daniel; Anderson, Kenneth; Fermand, Jean-Paul; Moreau, Philippe; Attal, Michel; Knight, Robert; Chen, Guang; Van Oostendorp, Jason; Jacques, Christian; Ervin-Haynes, Annette; Avet-Loiseau, Herve; Hulin, Cyrille; Facon, Thierry		FIRST Trial Team	Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREDNISONE PLUS THALIDOMIDE; STEM-CELL TRANSPLANTATION; BORTEZOMIB-MELPHALAN-PREDNISONE; DIAGNOSED MULTIPLE-MYELOMA; QUALITY-OF-LIFE; ELDERLY-PATIENTS; RESPONSE CRITERIA; INITIAL TREATMENT; ORAL MELPHALAN; PHASE-III	BACKGROUND The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. METHODS We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. RESULTS The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P<0.001 for both comparisons). Continuous lenalidomide-dexamethasone was superior to MPT for all secondary efficacy end points, including overall survival (at the interim analysis). Overall survival at 4 years was 59% with continuous lenalidomide-dexamethasone, 56% with 18 cycles of lenalidomide-dexamethasone, and 51% with MPT. Grade 3 or 4 adverse events were somewhat less frequent with continuous lenalidomide-dexamethasone than with MPT (70% vs. 78%). As compared with MPT, continuous lenalidomide-dexamethasone was associated with fewer hematologic and neurologic toxic events, a moderate increase in infections, and fewer second primary hematologic cancers. CONCLUSIONS As compared with MPT, continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation.	[Benboubker, Lotfi] CHRU, Serv Hematol & Therapie Cellulaire, Hop Bretonneau, Tours, France; [Banos, Anne] Ctr Hosp Cote Basque, Bayonne, France; [Tiab, Mourad] Ctr Hosp Dept Oudairies, La Roche Sur Yon, France; [Fermand, Jean-Paul] Hop St Louis, Paris, France; [Moreau, Philippe] CHU Nantes, Serv Hematol, F-44035 Nantes 01, France; [Attal, Michel; Avet-Loiseau, Herve] CHRU Hop Purpan, Toulouse, France; [Hulin, Cyrille] CHU Nancy Brabois, Vandoeuvre Les Nancy, France; [Facon, Thierry] Ctr Hosp Reg Univ, Serv Malad Sang, Hop Claude Huriez, F-59037 Lille, France; [Dimopoulos, Meletios A.] Univ Athens, Sch Med, Athens, Greece; [Dispenzieri, Angela] Mayo Clin, Ctr Canc, Rochester, MN USA; [Catalano, John] Monash Univ, Frankston Hosp, Frankston, Vic, Australia; [Belch, Andrew R.] Univ Alberta, Edmonton, AB, Canada; [Belch, Andrew R.] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; [Bahlis, Nizar] Univ Calgary, Calgary, AB, Canada; [Chen, Christine] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada; [White, Darrell J.] Dalhousie Univ, Halifax, NS, Canada; [White, Darrell J.] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada; [Cavo, Michele] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy; [Pinto, Antonello] Ist Ricovero & Cura Carattere Sci, Unita Operat Complessa Ematol Oncol, Ist Nazl Tumori Fdn G Pascale, Naples, Italy; [Weisel, Katja] Univ Tubingen, Tubingen, Germany; [Ludwig, Heinz] Wilhelminenspital Stadt Wien, Dept Internal Med 1, Ctr Oncol & Hematol, Vienna, Austria; [Delforge, Michel] Univ Hosp Leuven, Leuven, Belgium; [Cavenagh, Jamie] Barts Hlth NHS Trust, Dept Haematol, St Bartholomews Hosp, London, England; [Geraldes, Catarina] Coimbra Univ Hosp, Dept Clin Hematol, Coimbra, Portugal; [Lee, Je-Jung] Chonnam Natl Univ, Hwasun Hosp, Dept Hematol & Oncol, Hwasun, Jeollanamdo, South Korea; [Oriol, Albert] Inst Josep Carreras, Dept Clin Hematol, Inst Catal Oncol Hosp Germans Trias & Pujol, Barcelona, Spain; [de la Rubia, Javier] Hosp Univ La Fe, Valencia, Spain; [de la Rubia, Javier] Univ Catolica Valencia San Vicente Martir, Valencia, Spain; [Qiu, Lugui] Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China; [Qiu, Lugui] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China; [Qiu, Lugui] Peking Union Med Coll, Tianjin, Peoples R China; [Binder, Daniel] Kantonsspital Winterthur, Winterthur, Switzerland; [Anderson, Kenneth] Dana Farber Canc Inst, Boston, MA 02115 USA; [Knight, Robert; Chen, Guang; Van Oostendorp, Jason; Jacques, Christian; Ervin-Haynes, Annette] Celgene, Summit, NJ USA	CHU Tours; CHD Vendee; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Nantes Universite; CHU de Nantes; CHU de Toulouse; CHU de Nancy; Universite de Lille - ISITE; CHU Lille; Athens Medical School; National & Kapodistrian University of Athens; Mayo Clinic; Frankston Hospital; Monash University; University of Alberta; University of Alberta; University of Calgary; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Dalhousie University; Queen Elizabeth II Health Sciences Centre; University of Bologna; IRCCS Fondazione Pascale; IRCCS Istituto di Ricerca Diagnostica e Nucleare (SDN); Eberhard Karls University of Tubingen; Wilhelminenspital; KU Leuven; University Hospital Leuven; Barts Health NHS Trust; University of London; Queen Mary University London; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Chonnam National University; Catalan Institute of Oncology; Institut de Recerca Contra la Leucemia Josep Carreras (IJC); Hospital Universitari i Politecnic La Fe; Universidad Catolica de Valencia San Vicente Martir; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Harvard University; Dana-Farber Cancer Institute; Bristol-Myers Squibb; Celgene Corporation	Facon, T (corresponding author), Ctr Hosp Reg Univ, Serv Malad Sang, Hop Claude Huriez, F-59037 Lille, France.	thierry.facon@chru-lille.fr	Avet-Loiseau, Herve/P-8872-2014; Salles, Gilles/Z-2336-2019; CAVO, MICHELE/AAK-8274-2020; Dimopoulos, Meletios Athanasios/AAD-4130-2019; Pisani, Francesco/ABH-8545-2020; Greil, Richard F/C-7673-2017; Kovacs, Michael/G-3315-2011; Oriol, Albert/K-9923-2017; Ottmann, Oliver/D-5007-2016	Avet-Loiseau, Herve/0000-0002-3050-0140; Salles, Gilles/0000-0002-9541-8666; CAVO, MICHELE/0000-0003-4514-3227; Pisani, Francesco/0000-0002-6853-5605; Greil, Richard F/0000-0002-4462-3694; Oriol, Albert/0000-0001-6804-2221; Ottmann, Oliver/0000-0001-9559-1330; moreau, philippe/0000-0003-1780-8746; de la Rubia, Javier/0000-0002-8354-768X; Bouscary, Didier/0000-0003-3654-5064; Gonzalez, Marta Sonia/0000-0001-5494-9009; pierre, philippe/0000-0003-0863-8255; nahi, hareth/0000-0003-4711-5094; Geraldes, Catarina/0000-0001-8627-6187; Dispenzieri, Angela/0000-0001-8780-9512; Dimopoulos, Meletios/0000-0001-8990-3254; Reu, Frederic/0000-0003-1160-8030	Intergroupe Francophone du Myelome; Celgene; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Intergroupe Francophone du Myelome; Celgene(Bristol-Myers SquibbCelgene Corporation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Intergroupe Francophone du Myelome and Celgene.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Attal M, 2012, NEW ENGL J MED, V366, P1782, DOI 10.1056/NEJMoa1114138; Beksac M, 2011, EUR J HAEMATOL, V86, P16, DOI 10.1111/j.1600-0609.2010.01524.x; Cheung K, 2009, EQ 5D USER GUIDE BAS; Cocks K, 2007, EUR J CANCER, V43, P1670, DOI 10.1016/j.ejca.2007.04.022; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; Dimopoulos MA, 2009, LEUKEMIA, V23, P2147, DOI 10.1038/leu.2009.147; Dimopoulos M, 2007, NEW ENGL J MED, V357, P2123, DOI 10.1056/NEJMoa070594; Dimopoulos MA, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.405.405; Dimopoulos MA, 2012, BLOOD, V119, P2764, DOI 10.1182/blood-2011-08-373514; Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284; Durie Brian G M, 2003, Hematol J, V4, P379; Facon T, 2007, LANCET, V370, P1209, DOI 10.1016/S0140-6736(07)61537-2; Fayers PM, 2011, BLOOD, V118, P1239, DOI 10.1182/blood-2011-03-341669; Gay F, 2011, BLOOD, V117, P3025, DOI 10.1182/blood-2010-09-307645; Hulin C, 2009, J CLIN ONCOL, V27, P3664, DOI 10.1200/JCO.2008.21.0948; Kapoor P, 2011, LEUKEMIA, V25, P689, DOI 10.1038/leu.2010.313; Ludwig H, 2014, LEUKEMIA, V28, P981, DOI 10.1038/leu.2013.293; Mateos MV, 2010, LANCET ONCOL, V11, P934, DOI 10.1016/S1470-2045(10)70187-X; McCarthy PL, 2012, NEW ENGL J MED, V366, P1770, DOI 10.1056/NEJMoa1114083; Moreau P, 2013, ANN ONCOL, V24, P133, DOI 10.1093/annonc/mdt297; National Cancer Institute, 2006, COMM TERM CRIT ADV E; NCCN, 2020, ANT; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Palumbo A, 2006, LANCET, V367, P825, DOI 10.1016/S0140-6736(06)68338-4; Palumbo A, 2008, BLOOD, V112, P3107, DOI 10.1182/blood-2008-04-149427; Palumbo A, 2014, J CLIN ONCOL, V32, P634, DOI 10.1200/JCO.2013.52.0023; Palumbo A, 2014, LANCET ONCOL, V15, P333, DOI 10.1016/S1470-2045(13)70609-0; Palumbo A, 2012, NEW ENGL J MED, V366, P1759, DOI 10.1056/NEJMoa1112704; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191; Rajkumar SV, 2010, LANCET ONCOL, V11, P29, DOI 10.1016/S1470-2045(09)70284-0; San Miguel JF, 2008, NEW ENGL J MED, V359, P906, DOI 10.1056/NEJMoa0801479; San Miguel JF, 2013, J CLIN ONCOL, V31, P448, DOI 10.1200/JCO.2012.41.6180; Waage A, 2010, BLOOD, V116, P1405, DOI 10.1182/blood-2009-08-237974; Weber DM, 2007, NEW ENGL J MED, V357, P2133, DOI 10.1056/NEJMoa070596; Wijermans P, 2010, J CLIN ONCOL, V28, P3160, DOI 10.1200/JCO.2009.26.1610	38	564	575	0	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2014	371	10					906	917		10.1056/NEJMoa1402551	http://dx.doi.org/10.1056/NEJMoa1402551			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AO5NB	25184863	Green Published			2023-01-03	WOS:000341390600008
J	Janssens, X; Decuman, S; De Keyser, F				Janssens, Xavier; Decuman, Saskia; De Keyser, Filip		Belgian Rheumatoid Arthrit	Assessment of Activity Limitations with the Health Assessment Questionnaire Predicts the Need for Support Measures in Patients with Rheumatoid Arthritis: A Multicenter Observational Study	PLOS ONE			English	Article							ASSOCIATION; BENEFITS; PEOPLE; HAQ	Objective: This study investigated whether the Health Assessment Questionnaire (HAQ) can be used as an instrument to assess the need for social support measures that address activity limitations and participation issues in patients with rheumatoid arthritis (RA). Methods: This multicenter observational study included patients with RA and disease duration of at least one year, consulting their rheumatologist for routine evaluation of disease activity. In the single study visit data on demographics, disease history and current treatment were collected. DAS28 values were collected to evaluate current RA disease activity. Patients were asked to fill out the HAQ and SF-36 questionnaires. Receiver Operator Characteristics (ROC) curves were constructed to evaluate the performance of the HAQ, SF-36 and DAS28 in predicting the need for nine supporting measures available for chronically ill patients in the Belgian social security system. The expert opinion of the treating rheumatologist was used as a reference. Results: The study included 316 patients with a mean age of 59.8 +/- 12.6 years, disease duration of 11.4 +/- 9.3 years, mean DAS28 values of 2.83 +/- 1.17. Mean HAQ score was 0.95 +/- 0.73, mean SF-36 score 56.5 +/- 21.3. HAQ scores >1 were observed in 39.4% of patients. The area under the HAQ ROC curve was consistently >0.7 and higher for the HAQ than for SF-36 or DAS28 for all support measures. Rheumatologists on average recommended 3.67 support measures. Conclusion: The HAQ score was found to be a good predictor of the need for social support measures in patients with RA.	[Janssens, Xavier; Decuman, Saskia; De Keyser, Filip] Ghent Univ Hosp, Dept Rheumatol, Ghent, Belgium; [Decuman, Saskia] Univ Ghent, Dept Internal Med, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University	Janssens, X (corresponding author), Ghent Univ Hosp, Dept Rheumatol, Ghent, Belgium.	janssens.reuma@skynet.be	Verschueren, Patrick/L-6397-2019	Verschueren, Patrick/0000-0002-0340-3580; durez, patrick/0000-0002-7156-2356	Roche; Fonds de la Recherche de l'Association Polyarthrite-FRAP; Fonds voor Wetenschappelijk Reuma Onderzoek/Fonds pour la Recherche Scientifique en Rhumatologie	Roche(Roche Holding); Fonds de la Recherche de l'Association Polyarthrite-FRAP; Fonds voor Wetenschappelijk Reuma Onderzoek/Fonds pour la Recherche Scientifique en Rhumatologie	This work was supported by an unrestricted educational grant from Roche, by the 'Fonds de la Recherche de l'Association Polyarthrite-FRAP' and by the 'Fonds voor Wetenschappelijk Reuma Onderzoek/Fonds pour la Recherche Scientifique en Rhumatologie'. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bendtsen P, DISABIL REHABIL, V17, P94; Bewick V, 2004, CRIT CARE, V8, P508, DOI 10.1186/cc3000; Bruce B, 2003, J RHEUMATOL, V30, P167; Bruce B, 2005, CLIN EXP RHEUMATOL, V23, pS14; Bruce Bonnie, 2003, Health Qual Life Outcomes, V1, P20, DOI 10.1186/1477-7525-1-20; Fruin C, 2008, MUSCULOSKELET CARE, V6, P211, DOI 10.1002/msc.133; Harrison MJ, 2009, ARTHRIT CARE RES, V61, P1297, DOI 10.1002/art.24830; Huscher D, 2006, ANN RHEUM DIS, V65, P1175, DOI 10.1136/ard.2005.046367; Langley C, 2004, RHEUMATOLOGY, V43, P863, DOI 10.1093/rheumatology/keh184; Linde L, 2008, J RHEUMATOL, V35, P1528; Massardo L, 2012, ARTHRIT CARE RES, V64, P1135, DOI 10.1002/acr.21680; Memel DS, 2002, RHEUMATOLOGY, V41, P100, DOI 10.1093/rheumatology/41.1.100; Pincus T, 2006, J RHEUMATOL, V33, P834; Sokka T, 2006, ARTHRITIS RHEUM-US, V54, P3113, DOI 10.1002/art.22130; WOLFE F, 1988, J RHEUMATOL, V15, P1480; Yelin E, 1999, ARTHRITIS RHEUM, V42, P1209, DOI 10.1002/1529-0131(199906)42:6<1209::AID-ANR18>3.0.CO;2-M; YOUDEN W. J., 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Zandbelt MM, 2001, ANN RHEUM DIS, V60, P841	19	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2014	9	9							e106749	10.1371/journal.pone.0106749	http://dx.doi.org/10.1371/journal.pone.0106749			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO3XV	25188388	gold, Green Published, Green Submitted			2023-01-03	WOS:000341271500082
J	Lohr, JM				Lohr, J-Matthias			PERSONAL VIEW Pancreatic cancer should be treated as a medical emergency	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ADENOCARCINOMA; SURGERY		[Lohr, J-Matthias] Karolinska Inst, Stockholm, Sweden; [Lohr, J-Matthias] Karolinska Univ Hosp, Gastroctr, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Lohr, JM (corresponding author), Karolinska Inst, Stockholm, Sweden.	matthias.lohr@ki.se	Löhr, Matthias/A-3692-2012	Löhr, Matthias/0000-0002-7647-198X				Aveyard E, 2013, WAITING TIMES SUSPEC; Balzano G, 2008, BRIT J SURG, V95, P1387, DOI 10.1002/bjs.6324; Birk D, 1998, J Hepatobiliary Pancreat Surg, V5, P450, DOI 10.1007/s005340050071; Bond-Smith G, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e2476; Christians KK, 2014, ONCOLOGIST, V19, P266, DOI 10.1634/theoncologist.2013-0273; Hall TC, 2012, ANN ROY COLL SURG, V94, P318, DOI 10.1308/003588412X13171221592410; Lohr M, 2006, NAT CLIN PRACT GASTR, V3, P236, DOI 10.1038/ncpgasthep0469; Luebeck EG, 2010, NATURE, V467, P1053, DOI 10.1038/4671053a; Malvezzi M, 2014, ANN ONCOL, V25, P1650, DOI 10.1093/annonc/mdu138; McPherson T, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e4007; NHS, 2013, CANC WAIT TIM GUID V; Pancreatic Cancer UK, POL BRIEF EV LIF MAT; Valle JW, 2014, J CLIN ONCOL, V32, P504, DOI 10.1200/JCO.2013.50.7657; WILLIAMSON RCN, 1988, BRIT MED J, V296, P445, DOI 10.1136/bmj.296.6620.445	14	19	19	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 4	2014	349								g5261	10.1136/bmj.g5261	http://dx.doi.org/10.1136/bmj.g5261			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AO5MK	25189693				2023-01-03	WOS:000341388800003
J	Fan, YH; Chen, M; Meng, J; Yu, L; Tu, YF; Wan, L; Fang, K; Zhu, WL				Fan, Yuhua; Chen, Meng; Meng, Jia; Yu, Lei; Tu, Yingfeng; Wan, Lin; Fang, Kun; Zhu, Wenliang			Arsenic Trioxide and Resveratrol Show Synergistic Anti-Leukemia Activity and Neutralized Cardiotoxicity	PLOS ONE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; OXIDATIVE STRESS; CELL-DEATH; CANCER-CELLS; QT INTERVAL; APOPTOSIS; AUTOPHAGY; DRUG; GENISTEIN; PATHWAY	Cardiotoxicity is an aggravating side effect of many clinical antineoplastic agents such as arsenic trioxide (As2O3), which is the first-line treatment for acute promyelocytic leukemia (APL). Clinically, drug combination strategies are widely applied for complex disease management. Here, an optimized, cardiac-friendly therapeutic strategy for APL was investigated using a combination of As2O3 and genistein or resveratrol. Potential combinations were explored with respect to their effects on mitochondrial membrane potential, reactive oxygen species, superoxide dismutase activity, autophagy, and apoptosis in both NB4 cells and neonatal rat left ventricular myocytes. All experiments consistently suggested that 5 mu M resveratrol remarkably alleviates As2O3-induced cardiotoxicity. To achieve an equivalent effect, a 10-fold dosage of genistein was required, thus highlighting the dose advantage of resveratrol, as poor bioavailability is a common concern for its clinical application. Co-administration of resveratrol substantially amplified the anticancer effect of As2O3 in NB4 cells. Furthermore, resveratrol exacerbated oxidative stress, mitochondrial damage, and apoptosis, thereby reflecting its full range of synergism with As2O3. Addition of 5 mM resveratrol to the single drug formula of As2O3 also further increased the expression of LC3, a marker of cellular autophagy activity, indicating an involvement of autophagy-mediated tumor cell death in the synergistic action. Our results suggest a possible application of an As2O3 and resveratrol combination to treat APL in order to achieve superior therapeutics effects and prevent cardiotoxicity.	[Fan, Yuhua; Yu, Lei; Fang, Kun] Harbin Med Univ Daqing, Coll Pharm, Daqing, Peoples R China; [Chen, Meng] Harbin Med Univ, Dept Resp Med, Hosp 4, Harbin, Peoples R China; [Meng, Jia] Harbin Med Univ, Affiliated Hosp 2, Dept Geriatr, Harbin, Peoples R China; [Tu, Yingfeng] Harbin Med Univ, Dept Cardiol, Hosp 4, Harbin, Peoples R China; [Wan, Lin] Harbin Med Univ, Hosp 4, Dept Radiol, Harbin, Peoples R China; [Wan, Lin] Harbin Med Univ, Hosp 4, Key Lab Mol Imaging, Harbin, Peoples R China; [Zhu, Wenliang] Harbin Med Univ, Affiliated Hosp 2, Inst Clin Pharmacol, Harbin, Peoples R China	Harbin Medical University; Harbin Medical University; Harbin Medical University; Harbin Medical University; Harbin Medical University; Harbin Medical University; Harbin Medical University	Zhu, WL (corresponding author), Harbin Med Univ, Affiliated Hosp 2, Inst Clin Pharmacol, Harbin, Peoples R China.	wenzwl@yeah.net			National Natural Science Foundation of China [31301136]; Foundation of Health Department of Heilongjiang Province of China [2011-233]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation of Health Department of Heilongjiang Province of China	This work was supported by National Natural Science Foundation of China (No. 31301136) and Foundation of Health Department of Heilongjiang Province of China (No. 2011-233). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barbey JT, 2003, J CLIN ONCOL, V21, P3609, DOI 10.1200/JCO.2003.10.009; Cesselli D, 2001, CIRC RES, V89, P279, DOI 10.1161/hh1501.094115; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Chu WF, 2012, CARDIOVASC RES, V96, P90, DOI 10.1093/cvr/cvs230; Drolet B, 2004, CIRCULATION, V109, P26, DOI 10.1161/01.CIR.0000109484.00668.CE; Ducas RA, 2011, J ROY COLL PHYS EDIN, V41, P117, DOI 10.4997/JRCPE.2011.204; Fan YH, 2013, CELL PHYSIOL BIOCHEM, V31, P80, DOI 10.1159/000343351; Fox E, 2008, BLOOD, V111, P566, DOI 10.1182/blood-2007-08-107839; Gao F, 2004, CELL RES, V14, P81, DOI 10.1038/sj.cr.7290206; Ghaffari SH, 2012, TUMOR BIOL, V33, P157, DOI 10.1007/s13277-011-0259-1; Heiss EH, 2007, J BIOL CHEM, V282, P26759, DOI 10.1074/jbc.M703229200; Hirano S, 2003, ARCH TOXICOL, V77, P305, DOI 10.1007/s00204-003-0447-x; Hollman PCH, 1999, FOOD CHEM TOXICOL, V37, P937, DOI 10.1016/S0278-6915(99)00079-4; Hwang JT, 2008, GENES NUTR, V2, P323, DOI 10.1007/s12263-007-0069-7; Jeanne M, 2010, CANCER CELL, V18, P88, DOI 10.1016/j.ccr.2010.06.003; Jiang SG, 2008, INT J ONCOL, V33, P103; Kanamori H, 2013, AM J PATHOL, V182, P701, DOI 10.1016/j.ajpath.2012.11.009; LANOTTE M, 1991, BLOOD, V77, P1080; Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451; Leonard SS, 2003, BIOCHEM BIOPH RES CO, V309, P1017, DOI 10.1016/j.bbrc.2003.08.105; Li Yan, 2002, Cardiovasc Toxicol, V2, P63, DOI 10.1385/CT:2:1:63; Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554; Manna P, 2008, ARCH TOXICOL, V82, P137, DOI 10.1007/s00204-007-0272-8; Mathews V, 2011, MEDITERR J HEMATOL I, V3, DOI 10.4084/MJHID.2011.056; Mumford JL, 2007, ENVIRON HEALTH PERSP, V115, P690, DOI 10.1289/ehp.9686; Nadal-Serrano M, 2013, INT J BIOCHEM CELL B, V45, P2045, DOI 10.1016/j.biocel.2013.07.002; Nencioni A, 2013, HAEMATOLOGICA, V98, P1335, DOI 10.3324/haematol.2012.079061; Park SY, 2011, N-S ARCH PHARMACOL, V383, P191, DOI 10.1007/s00210-010-0594-6; Pereira GC, 2011, CURR PHARM DESIGN, V17, P2113; Qian WB, 2007, LEUKEMIA RES, V31, P329, DOI 10.1016/j.leukres.2006.06.021; Ravindranath MH, 2004, ADV EXP MED BIOL, V546, P121; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Sun WM, 2008, ADV EXP MED BIOL, V614, P179, DOI 10.1007/978-0-387-74911-2_21; Ullah MF, 2011, MOL NUTR FOOD RES, V55, P553, DOI 10.1002/mnfr.201000329; Vizzardi E, 2008, CARDIOVASC TOXICOL, V8, P41, DOI 10.1007/s12012-007-9009-4; Xuan WL, 2012, CRIT CARE MED, V40, P3026, DOI 10.1097/CCM.0b013e31825fd7da; Zhang WQ, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/407839; Zhang XW, 2010, SCIENCE, V328, P240, DOI 10.1126/science.1183424	39	27	29	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2014	9	8							e105890	10.1371/journal.pone.0105890	http://dx.doi.org/10.1371/journal.pone.0105890			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO1WL	25144547	Green Published, Green Submitted, gold			2023-01-03	WOS:000341106100126
J	Marshall, JC				Marshall, John C.			Selective digestive decontamination reduces mortality more than chlorhexidine in general ICU patients	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RESISTANCE		Univ Toronto, St Michaels Hosp, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Marshall, JC (corresponding author), Univ Toronto, St Michaels Hosp, Toronto, ON, Canada.							Daneman N, 2013, LANCET INFECT DIS, V13, P328, DOI 10.1016/S1473-3099(12)70322-5; VANDERWAAIJ D, 1971, J HYG-CAMB, V69, P405, DOI 10.1017/S0022172400021653	2	0	0	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 19	2014	161	4							JC9	10.7326/0003-4819-161-4-201408190-02009	http://dx.doi.org/10.7326/0003-4819-161-4-201408190-02009			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AP8RU	25133388				2023-01-03	WOS:000342347300008
J	Fukuhara, T; Aoi, M; Namba, Y				Fukuhara, Toru; Aoi, Mizuho; Namba, Yoichiro			Mechanical Ventilation for Comatose Patients with Inoperative Acute Intracerebral Hemorrhage: Possible Futility of Treatment	PLOS ONE			English	Article							MINIMALLY CONSCIOUS STATE; BRAIN-DEATH; PREDICTION; MANAGEMENT; CONSENSUS; STROKE	Background: Comatose patients with acute intracerebral hemorrhage (ICH) diagnosed as inoperative due to their severe comorbidity will be treated differently between countries. In certain countries including Japan, aggressive medical care may be performed according to the patients' family requests although the effects on the outcome are obscure. For respiratory distress in comatose patients with inoperative acute ICH, the role of mechanical ventilation on the outcome is unknown. We speculated that the efficacy of a ventilator in such a specific condition is limited and possibly futile. Methods: We retrospectively evaluated the in-hospital mortality and further outcome of 65 comatose patients with inoperative ICH. Among the patients, 56 manifested respiratory distress, and the effect of the ventilator was evaluated by comparing the patients treated with and without the ventilator. Results: The in-hospital mortality was calculated as 80%. A statistically significant parameter affecting the mortality independently was the motor subset on the Glasgow Coma Scale (P = 0.015). Among the patients who manifested respiratory distress, 77% of patients treated with a ventilator and 14.0% of patients not treated with a ventilator survived; an outcome is not significantly different. The mean survival duration of patients treated with a ventilator was significantly longer than the mean survival duration of patients not treated with a ventilator (P = 0.021). Among the surviving 13 patients, 7 patients died 5 to 29 months after onset without significant consciousness recovery. Another 6 patients suffered continuous disablement due to prolonged severe consciousness disturbances. Conclusion: The current results indicate that treating comatose patients resulting from inoperative acute ICH may be futile. In particular, treating these patients with a ventilator only has the effect of prolonging unresponsive life, and the treatment may be criticized from the perspective of the appropriate use of public medical resources.	[Fukuhara, Toru; Aoi, Mizuho; Namba, Yoichiro] Okayama Med Ctr, Natl Hosp Org, Dept Neurol Surg, Okayama, Japan		Aoi, M (corresponding author), Okayama Med Ctr, Natl Hosp Org, Dept Neurol Surg, Okayama, Japan.	torufk@ninus.ocn.ne.jp						Andaluz N, 2009, J NEUROSURG, V110, P403, DOI 10.3171/2008.5.17559; Applbaum AI, 2008, JAMA-J AM MED ASSOC, V299, P2188, DOI 10.1001/jama.299.18.2188; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Burkle CM, 2011, NEUROLOGY, V76, P837, DOI 10.1212/WNL.0b013e31820e7bbe; Caulfield AF, 2010, NEUROLOGY, V74, P1096, DOI 10.1212/WNL.0b013e3181d8197f; Cruse D, 2012, NEUROLOGY, V78, P816, DOI 10.1212/WNL.0b013e318249f764; Edlow BL, 2013, NEUROCRIT CARE, V19, P364, DOI 10.1007/s12028-013-9870-x; Elliott J, 2010, ANESTH ANALG, V110, P1419, DOI 10.1213/ANE.0b013e3181d568c8; Elmer J, 2013, CRIT CARE MED, V41, P1992, DOI 10.1097/CCM.0b013e31828a3f4d; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gujjar AR, 1998, NEUROLOGY, V51, P447, DOI 10.1212/WNL.51.2.447; Helft PR, 2000, NEW ENGL J MED, V343, P293, DOI 10.1056/NEJM200007273430411; Hemphill JC, 2009, NEUROLOGY, V73, P1088, DOI 10.1212/WNL.0b013e3181b8b332; Hemphill JC, 2004, STROKE, V35, P1130, DOI 10.1161/01.STR.0000125858.71051.ca; Honeybul S, 2013, NEUROSURGERY, V73, P917, DOI 10.1227/NEU.0000000000000014; Jain A, 2013, NEUROCRIT CARE, V19, P342, DOI 10.1007/s12028-013-9878-2; Kelly ML, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.2.FOCUS1319; Maruya J, 2008, NEUROL MED-CHIR, V48, P114, DOI 10.2176/nmc.48.114; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Posner JB, 2007, DIAGNOSIS STUPOR COM, P377; Rost NS, 2008, STROKE, V39, P2304, DOI 10.1161/STROKEAHA.107.512202; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Tindall S. C., 1990, CLIN METHODS HIST PH, P296; Wijdicks EFM, 2002, NEUROLOGY, V58, P20, DOI 10.1212/WNL.58.1.20; YOUNGNER SJ, 1990, CLIN CHEM, V36, P1617; Zahuranec DB, 2007, NEUROLOGY, V68, P1651, DOI 10.1212/01.wnl.0000261906.93238.72; Zhang HT, 2013, CLIN NEUROL NEUROSUR, V115, P1602, DOI 10.1016/j.clineuro.2013.02.005	27	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2014	9	7							e103531	10.1371/journal.pone.0103531	http://dx.doi.org/10.1371/journal.pone.0103531			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6RP	25062014	gold, Green Submitted, Green Published			2023-01-03	WOS:000339992600080
J	Amihai, I; Kozhevnikov, M				Amihai, Ido; Kozhevnikov, Maria			Arousal vs. Relaxation: A Comparison of the Neurophysiological and Cognitive Correlates of Vajrayana and Theravada Meditative Practices	PLOS ONE			English	Article							HEART-RATE-VARIABILITY; POWER SPECTRUM ANALYSIS; ARTERIAL-PRESSURE; STRESS-MANAGEMENT; HUMAN EEG; SLEEP; ATTENTION; STATES; ELECTROCARDIOGRAM; OSCILLATIONS	Based on evidence of parasympathetic activation, early studies defined meditation as a relaxation response. Later research attempted to categorize meditation as either involving focused or distributed attentional systems. Neither of these hypotheses received strong empirical support, and most of the studies investigated Theravada style meditative practices. In this study, we compared neurophysiological (EEG, EKG) and cognitive correlates of meditative practices that are thought to utilize either focused or distributed attention, from both Theravada and Vajrayana traditions. The results of Study 1 show that both focused (Shamatha) and distributed (Vipassana) attention meditations of the Theravada tradition produced enhanced parasympathetic activation indicative of a relaxation response. In contrast, both focused (Deity) and distributed (Rig-pa) meditations of the Vajrayana tradition produced sympathetic activation, indicative of arousal. Additionally, the results of Study 2 demonstrated an immediate dramatic increase in performance on cognitive tasks following only Vajrayana styles of meditation, indicating enhanced phasic alertness due to arousal. Furthermore, our EEG results showed qualitatively different patterns of activation between Theravada and Vajrayana meditations, albeit highly similar activity between meditations within the same tradition. In conclusion, consistent with Tibetan scriptures that described Shamatha and Vipassana techniques as those that calm and relax the mind, and Vajrayana techniques as those that require 'an awake quality' of the mind, we show that Theravada and Vajrayana meditations are based on different neurophysiological mechanisms, which give rise to either a relaxation or arousal response. Hence, it may be more appropriate to categorize meditations in terms of relaxation vs. arousal, whereas classification methods that rely on the focused vs. distributed attention dichotomy may need to be reexamined.	[Amihai, Ido; Kozhevnikov, Maria] Natl Univ Singapore, Dept Psychol, Singapore 117548, Singapore; [Kozhevnikov, Maria] MGH, Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Kozhevnikov, Maria] Harvard Univ, Sch Med, Charlestown, MA USA	National University of Singapore; Harvard University	Kozhevnikov, M (corresponding author), Natl Univ Singapore, Dept Psychol, Singapore 117548, Singapore.	psymaria@nus.edu.sg			National University of Singapore	National University of Singapore(National University of Singapore)	This research is funded by the National University of Singapore. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aftanas LI, 2002, NEUROSCI LETT, V330, P143, DOI 10.1016/S0304-3940(02)00745-0; Agee JD, 2009, EXPLORE-NY, V5, P104, DOI 10.1016/j.explore.2008.12.004; AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; [Anonymous], 1994, J Clin Neurophysiol, V11, P111; [Anonymous], 2005, TIP PAL CAN; APPEL ML, 1989, J AM COLL CARDIOL, V14, P1139, DOI 10.1016/0735-1097(89)90408-7; Awasthi B, 2013, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00613; Bader K, 2013, J CLIN NEUROPHYSIOL, V30, P188, DOI 10.1097/WNP.0b013e3182767c4a; Baijal S, 2010, COGN PROCESS, V11, P31, DOI 10.1007/s10339-009-0272-0; Barnett Kylie J., 2008, Journal of Integrative Neuroscience, V7, P405, DOI 10.1142/S0219635208001903; BENSON H, 1990, BEHAV MED, V16, P90, DOI 10.1080/08964289.1990.9934596; Benson H., 1975, RELAXATION RESPONSE; Berntson GG, 1997, PSYCHOPHYSIOLOGY, V34, P623, DOI 10.1111/j.1469-8986.1997.tb02140.x; Beyer S, 1978, REF MIS; Bhasin MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062817; BIGGER JT, 1992, AM J CARDIOL, V69, P718, DOI 10.1016/0002-9149(92)90493-I; Billman GE, 2013, FRONT PHYSIOL, V4, DOI [10.3389/fphys.2013.00222, 10.3389/fphys.2013.00026]; Bodhi B, 2012, NUMERICAL DISCOURSES, P1287; Bolduc C, 2003, BRAIN COGNITION, V53, P193, DOI 10.1016/S0278-2626(03)00108-8; BOSWELL PC, 1979, J CONSULT CLIN PSYCH, V47, P606, DOI 10.1037/0022-006X.47.3.606; Boucsein W., 2012, ELECTRODERMAL ACTIVI, P1; Brefczynski-Lewis JA, 2007, P NATL ACAD SCI USA, V104, P11483, DOI 10.1073/pnas.0606552104; Britton WB, 2014, ANN NY ACAD SCI, V1307, P64, DOI 10.1111/nyas.12279; Buddhaghosa Bhadant?cariya., 2010, VISUDDHIMAGGA PATH P; Cahn BR, 2010, COGN PROCESS, V11, P39, DOI 10.1007/s10339-009-0352-1; Cahn BR, 2006, PSYCHOL BULL, V132, P180, DOI 10.1037/0033-2909.132.2.180; Camm AJ, 1996, CIRCULATION, V93, P1043; Cantero JL, 1999, NEUROSCI LETT, V271, P167, DOI 10.1016/S0304-3940(99)00565-0; CAUTHEN NR, 1977, J CONSULT CLIN PSYCH, V45, P496, DOI 10.1037/0022-006X.45.3.496; CHESS GF, 1975, AM J PHYSIOL, V228, P775, DOI 10.1152/ajplegacy.1975.228.3.775; Chiesa A, 2009, J ALTERN COMPLEM MED, V15, P593, DOI 10.1089/acm.2008.0495; CORBY JC, 1978, ARCH GEN PSYCHIAT, V35, P571; Daskalov I, 1997, MED ENG PHYS, V19, P375, DOI 10.1016/S1350-4533(96)00067-7; Design MMVirtual L, 2004, IMAGERY TESTING BATT; Dunn BR, 1999, APPL PSYCHOPHYS BIOF, V24, P147, DOI 10.1023/A:1023498629385; ECKBERG DL, 1984, J PHYSIOL-LONDON, V347, P75, DOI 10.1113/jphysiol.1984.sp015054; Engel AK, 2010, CURR OPIN NEUROBIOL, V20, P156, DOI 10.1016/j.conb.2010.02.015; Fell J, 2010, MED HYPOTHESES, V75, P218, DOI 10.1016/j.mehy.2010.02.025; Goleman D., 1996, MEDITATIVE MIND VARI; Grossman P., 2010, FOCUS ALTERN COMPLEM, V8, P500, DOI [10.1111/j.2042-7166.2003.tb04008.x, DOI 10.1111/J.2042-7166.2003.TB04008.X]; Gruber T, 2005, CEREB CORTEX, V15, P109, DOI 10.1093/cercor/bhh113; Gyatrul R, 1996, GENERATING DEITY; Hall Martica, 2007, Behav Sleep Med, V5, P178; Hasegawa RP, 2000, SCIENCE, V290, P1786, DOI 10.1126/science.290.5497.1786; Hassler U, 2011, NEUROIMAGE, V57, P1411, DOI 10.1016/j.neuroimage.2011.05.062; Huang H. -Y., 2009, Journal of Medical Engineering & Technology, V33, P314, DOI 10.1080/03091900802602677; Jain S, 2007, ANN BEHAV MED, V33, P11, DOI 10.1207/s15324796abm3301_2; KAMATH MV, 1993, CRIT REV BIOMED ENG, V21, P245; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Kozhevnikov M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058244; Kozhevnikov M, 2009, PSYCHOL SCI, V20, P645, DOI 10.1111/j.1467-9280.2009.02345.x; Lama D., 2008, EMOTIONAL AWARENESS; LEVY MN, 1971, CIRC RES, V29, P437, DOI 10.1161/01.RES.29.5.437; Lipsman N, 2014, NEUROIMAGE, V85, P769, DOI 10.1016/j.neuroimage.2013.05.104; Lohman DF, 1990, LEARN INDIVID DIFFER, V2, P67, DOI DOI 10.1016/1041-6080(90)90017-B; Lutz A, 2004, P NATL ACAD SCI USA, V101, P16369, DOI 10.1073/pnas.0407401101; Lutz A, 2008, TRENDS COGN SCI, V12, P163, DOI 10.1016/j.tics.2008.01.005; Lutz A, 2007, CAMB HANDB PSYCHOL, P499; MacLean KA, 2010, PSYCHOL SCI, V21, P829, DOI 10.1177/0956797610371339; MALLIANI A, 1991, CIRCULATION, V84, P482, DOI 10.1161/01.CIR.84.2.482; Manna A, 2010, BRAIN RES BULL, V82, P46, DOI 10.1016/j.brainresbull.2010.03.001; MERRI M, 1990, IEEE T BIO-MED ENG, V37, P99, DOI 10.1109/10.43621; MOLGAARD H, 1994, EUR HEART J, V15, P1174, DOI 10.1093/oxfordjournals.eurheartj.a060650; MONTANO N, 1994, CIRCULATION, V90, P1826, DOI 10.1161/01.CIR.90.4.1826; MORADY F, 1988, CIRCULATION, V77, P289, DOI 10.1161/01.CIR.77.2.289; MORSE DR, 1977, PSYCHOSOM MED, V39, P304, DOI 10.1097/00006842-197709000-00004; PAGANI M, 1986, CIRC RES, V59, P178, DOI 10.1161/01.RES.59.2.178; Petersen SE, 2012, ANNU REV NEUROSCI, V35, P73, DOI 10.1146/annurev-neuro-062111-150525; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151, DOI 10.1152/ajpheart.1985.248.1.H151; Powers J, 1995, WISDOM BUDDHA SAMDHI, P153; RIMOLDI O, 1990, AM J PHYSIOL, V258, pH967, DOI 10.1152/ajpheart.1990.258.4.H967; Rinpoche S., 1990, DZOGCHEN PADMASAMBHA; Robbins TW, 2005, J COMP NEUROL, V493, P140, DOI 10.1002/cne.20717; Robbins TW, 1997, BIOL PSYCHOL, V45, P57, DOI 10.1016/S0301-0511(96)05222-2; Schulte-Mecklenbeck M, 2011, HDB PROCESS TRACING, P272; Silber MH, 2007, J CLIN SLEEP MED, V3, P121; Snellgrove D, 2003, INDO TIBETAN BUDDHIS; STEIN KM, 1993, CIRCULATION, V88, P127, DOI 10.1161/01.CIR.88.1.127; Strijkstra AM, 2003, NEUROSCI LETT, V340, P17, DOI 10.1016/S0304-3940(03)00033-8; Sturm W, 1999, NEUROPSYCHOLOGIA, V37, P797, DOI 10.1016/S0028-3932(98)00141-9; Stutchbury E, 1998, EMBODIMENT MIND E W, P103; Tallon-Baudry C, 1999, TRENDS COGN SCI, V3, P151, DOI 10.1016/S1364-6613(99)01299-1; Tang YY, 2012, P NATL ACAD SCI USA, V109, P10570, DOI 10.1073/pnas.1207817109; Travis F, 1999, CONSCIOUS COGN, V8, P302, DOI 10.1006/ccog.1999.0403; TRAVIS TA, 1976, BIOFEEDBACK SELF-REG, V1, P387, DOI 10.1007/BF00998771; Tulku Urgyen Rinpoche, 1999, DROP, P85; Tulku Urgyen Rinpoche, 1999, AS IT IS, P118; Tulku Urgyen Rinpoche, 1999, AS IT IS, P88; Tulku Urgyen Rinpoche, 1999, AS IT IS; Valentine E.R., 1999, MENTAL HLTH RELIG CU, V2, P59, DOI DOI 10.1080/13674679908406332; van Dijk AE, 2013, JOVE-J VIS EXP, DOI 10.3791/50073; VANDEBORNE P, 1994, AM J PHYSIOL, V266, pH548, DOI 10.1152/ajpheart.1994.266.2.H548; Wallace A, 2006, ATTENTION REVOLUTION; WALRATH L C, 1975, American Journal of Clinical Hypnosis, V17, P190; Walshe M, 1995, LONG DISCOURSES BUDD, P152; Walter C., 1932, WISDOM BODY; Wangyal T., 1993, WONDERS NATURAL MIND; Weinbach N, 2011, COGNITION, V121, P454, DOI 10.1016/j.cognition.2011.08.010; WELCH PD, 1967, IEEE T ACOUST SPEECH, VAU15, P70, DOI 10.1109/TAU.1967.1161901; Young JDE, 1998, NEWS PHYSIOL SCI, V13, P149; Yuval-Greenberg S, 2008, NEURON, V58, P429, DOI 10.1016/j.neuron.2008.03.027; Zion-Golumbic E, 2007, CEREB CORTEX, V17, P1741, DOI 10.1093/cercor/bhl100	102	72	72	1	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2014	9	7							e102990	10.1371/journal.pone.0102990	http://dx.doi.org/10.1371/journal.pone.0102990			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AM0QO	25051268	Green Published, gold, Green Submitted			2023-01-03	WOS:000339551100074
J	Sakthivel, P; Gereke, M; Breithaupt, A; Fuchs, D; Gigliotti, L; Gruber, AD; Dianzani, U; Bruder, D				Sakthivel, Priya; Gereke, Marcus; Breithaupt, Angele; Fuchs, Dietmar; Gigliotti, Luca; Gruber, Achim D.; Dianzani, Umberto; Bruder, Dunja			Attenuation of Immune-Mediated Influenza Pneumonia by Targeting the Inducible Co-Stimulator (ICOS) Molecule on T Cells	PLOS ONE			English	Article							INDOLEAMINE 2,3-DIOXYGENASE; REGULATORY-CELLS; IL-10 PRODUCTION; CO-STIMULATION; CUTTING EDGE; VIRUS; RESPONSES; ACTIVATION; CD4(+); LIGAND	Inducible Co-stimulator (ICOS) plays a critical role in mediating T cell differentiation and function and is considered a key player in balancing T effector and T regulatory (T-reg) cell responses. Here we show that activation of the ICOS signalling pathway during acute influenza A virus (IAV) infection by application of an agonistic ICOS antibody reduced the frequency of CD8(+) T cells in the respiratory tract of IAV infected animals and delayed pathogen elimination. In line with this, immune-mediated influenza pneumonia was significantly ameliorated in mice that received ICOS agonist as indicated by significantly reduced alveolar infiltrations and bronchointerstitial pneumonia, while at the same time virus-related pathology remained unaffected. Importantly, ICOS agonist treatment resulted in expansion of CD4(+)Foxp3(+) T-regs in IAV infected mice, which was associated with elevated levels of the immunosuppressive cytokine IL-10 in the alveolar space. Together, our findings suggest a prominent role of ICOS signaling during acute IAV infection by increasing the T-reg/CD8(+) T cell ratio with beneficial outcome on immune-mediated pneumonia and underline the suitability of ICOS as potential therapeutic target for immune intervention in those infectious conditions characterized by strong immunopathology rather than virus-mediated cytopathic effects.	[Sakthivel, Priya; Gereke, Marcus; Bruder, Dunja] Helmholtz Ctr Infect Res, Immune Regulat Grp, Braunschweig, Germany; [Gereke, Marcus; Bruder, Dunja] Otto Von Guericke Univ, Inst Med Microbiol Infect Control & Prevent, Infect Immunol Grp, Magdeburg, Germany; [Breithaupt, Angele; Gruber, Achim D.] Free Univ Berlin, Inst Vet Pathol, Dept Vet Med, Berlin, Germany; [Fuchs, Dietmar] Med Univ Innsbruck, Div Biol Chem, A-6020 Innsbruck, Austria; [Gigliotti, Luca; Dianzani, Umberto] A Avogadro Univ Eastern Piedmont, Dept Hlth Sci, Novara, Italy; [Gigliotti, Luca; Dianzani, Umberto] A Avogadro Univ Eastern Piedmont, Interdisciplinary Res Ctr Autoimmune Dis, Novara, Italy	Helmholtz Association; Helmholtz-Center for Infection Research; Otto von Guericke University; Free University of Berlin; Medical University of Innsbruck; University of Eastern Piedmont Amedeo Avogadro; University of Eastern Piedmont Amedeo Avogadro	Bruder, D (corresponding author), Helmholtz Ctr Infect Res, Immune Regulat Grp, Braunschweig, Germany.	dunja.bruder@med.ovgu.de	Breithaupt, Angele/B-6155-2013; Dianzani, Umberto/K-1952-2016; Gruber, Achim D./ABA-4514-2021; Breithaupt, Angele/GON-7227-2022; Fuchs, Dietmar/AAL-8011-2021; Gigliotti, Casimiro Luca/H-8809-2016	Breithaupt, Angele/0000-0002-6373-5923; Fuchs, Dietmar/0000-0003-1627-9563; Gigliotti, Casimiro Luca/0000-0002-3127-5686; DIANZANI, Umberto/0000-0001-6723-3931	Alexander-von-Humboldt Foundation; President's Initiative and Networking Fund of the Helmholtz Association of German Research Centers (HGF) [W2/W3-029]; Centre of Dynamic Systems (CDS), Magdeburg; Associazione Italiana Ricerca sul Cancro (Milano); Fondazione Amici di Jean (Torino)	Alexander-von-Humboldt Foundation(Alexander von Humboldt Foundation); President's Initiative and Networking Fund of the Helmholtz Association of German Research Centers (HGF); Centre of Dynamic Systems (CDS), Magdeburg; Associazione Italiana Ricerca sul Cancro (Milano)(Fondazione AIRC per la ricerca sul cancro); Fondazione Amici di Jean (Torino)	This study was funded by the Alexander-von-Humboldt Foundation providing a postdoctoral fellowship to Priya Sakthivel. Dunja Bruder received financial support from the President's Initiative and Networking Fund of the Helmholtz Association of German Research Centers (HGF) under contract number W2/W3-029 and from the Centre of Dynamic Systems (CDS), Magdeburg. Umberto Dianzani and Luca Gigliotti received financial support from the Associazione Italiana Ricerca sul Cancro (Milano) and Fondazione Amici di Jean (Torino). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Bertram EM, 2004, SEMIN IMMUNOL, V16, P185, DOI 10.1016/j.smim.2004.02.006; Bertram EM, 2002, EUR J IMMUNOL, V32, P3376, DOI 10.1002/1521-4141(2002012)32:12<3376::AID-IMMU3376>3.0.CO;2-G; Betts RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027849; Busse M, 2012, J IMMUNOL, V189, P1975, DOI 10.4049/jimmunol.1103581; Doherty PC, 1997, IMMUNOL REV, V159, P105, DOI 10.1111/j.1600-065X.1997.tb01010.x; Dong C, 2001, J IMMUNOL, V166, P3659, DOI 10.4049/jimmunol.166.6.3659; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; Fox JM, 2013, J GEN VIROL, V94, P1451, DOI 10.1099/vir.0.053124-0; Fu TH, 2011, CANCER RES, V71, P5445, DOI 10.1158/0008-5472.CAN-11-1138; FUCHS D, 1990, J ACQ IMMUN DEF SYND, V3, P873; Gao XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052657; Gereke M, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-47; Gotsman I, 2006, CIRCULATION, V114, P2047, DOI 10.1161/CIRCULATIONAHA.106.633263; Greenwald RJ, 2002, J IMMUNOL, V168, P991, DOI 10.4049/jimmunol.168.3.991; Herman AE, 2004, J EXP MED, V199, P1479, DOI 10.1084/jem.20040179; Honkanen J, 2008, DIABETES-METAB RES, V24, P635, DOI 10.1002/dmrr.904; Humphreys IR, 2006, EUR J IMMUNOL, V36, P2928, DOI 10.1002/eji.200636155; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; Ito T, 2008, IMMUNITY, V28, P870, DOI 10.1016/j.immuni.2008.03.018; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Khayyamian S, 2002, P NATL ACAD SCI USA, V99, P6198, DOI 10.1073/pnas.092576699; Klingenberg R, 2005, EUR J IMMUNOL, V35, P1712, DOI 10.1002/eji.200425727; Kohyama M, 2004, P NATL ACAD SCI USA, V101, P4192, DOI 10.1073/pnas.0400214101; Kopf M, 2000, J EXP MED, V192, P53, DOI 10.1084/jem.192.1.53; Kornete M, 2012, J IMMUNOL, V188, P1064, DOI 10.4049/jimmunol.1101303; Laich A, 2002, CLIN CHEM, V48, P579; Liu XS, 2006, J IMMUNOL, V177, P2873, DOI 10.4049/jimmunol.177.5.2873; Liu XL, 2001, J EXP MED, V194, P1339, DOI 10.1084/jem.194.9.1339; Liu XS, 2003, J IMMUNOL, V171, P4765, DOI 10.4049/jimmunol.171.9.4765; Marks E, 2007, INFECT IMMUN, V75, P4638, DOI 10.1128/IAI.00465-07; Mcgee HS, 2010, AM J RESP CELL MOL, V42, P331, DOI 10.1165/rcmb.2008-0397OC; Mesturini R, 2013, CYTOKINE, V64, P322, DOI 10.1016/j.cyto.2013.05.021; Mittrucker HW, 2002, J IMMUNOL, V169, P5813, DOI 10.4049/jimmunol.169.10.5813; Nouailles G, 2011, EUR J IMMUNOL, V41, P981, DOI 10.1002/eji.201040608; Nurieva RI, 2003, J CLIN INVEST, V111, P701, DOI 10.1172/JCI200317321; O'Garra A, 2013, ANNU REV IMMUNOL, V31, P475, DOI 10.1146/annurev-immunol-032712-095939; Paulos CM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000448; Pfaff AW, 2008, INT J PARASITOL, V38, P249, DOI 10.1016/j.ijpara.2007.07.007; Quiroga MF, 2006, J IMMUNOL, V176, P5965, DOI 10.4049/jimmunol.176.10.5965; Redoglia V, 1996, EUR J IMMUNOL, V26, P2781, DOI 10.1002/eji.1830261134; Redpath SA, 2013, EUR J IMMUNOL, V43, P705, DOI 10.1002/eji.201242794; Scott BG, 2004, J NEUROIMMUNOL, V153, P16, DOI 10.1016/j.jneuroim.2004.04.019; Suvas S, 2003, J EXP MED, V198, P889, DOI 10.1084/jem.20030171; Telieps T, 2013, EUR J IMMUNOL, V43, P1499, DOI 10.1002/eji.201242819; Turner DL, 2013, J VIROL, V87, P4496, DOI 10.1128/JVI.03413-12; Vidric M, 2006, INFECT IMMUN, V74, P1050, DOI 10.1128/IAI.74.2.1050-1061.2006; Wallin JJ, 2001, J IMMUNOL, V167, P132, DOI 10.4049/jimmunol.167.1.132; Wang SD, 2000, BLOOD, V96, P2808; Wilson EH, 2006, J IMMUNOL, V177, P2365, DOI 10.4049/jimmunol.177.4.2365; Wong SC, 2003, BLOOD, V102, P1381, DOI 10.1182/blood-2002-08-2416; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582; Yu XZ, 2006, J IMMUNOL, V176, P7394, DOI 10.4049/jimmunol.176.12.7394	53	10	16	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2014	9	7							e100970	10.1371/journal.pone.0100970	http://dx.doi.org/10.1371/journal.pone.0100970			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4KM	25029240	Green Published, Green Submitted, gold			2023-01-03	WOS:000341306600011
J	Zhang, SC; Gremer, L; Heise, H; Janning, P; Shymanets, A; Cirstea, IC; Krause, E; Nurnberg, B; Ahmadian, MR				Zhang, Si-Cai; Gremer, Lothar; Heise, Henrike; Janning, Petra; Shymanets, Aliaksei; Cirstea, Ion C.; Krause, Eberhard; Nuernberg, Bernd; Ahmadian, Mohammad Reza			Liposome Reconstitution and Modulation of Recombinant Prenylated Human Rac1 by GEFs, GDI1 and Pak1	PLOS ONE			English	Article							GDP-DISSOCIATION INHIBITOR; GTPASE-ACTIVATING PROTEINS; NUCLEOTIDE EXCHANGE FACTOR; RHO-FAMILY GTPASES; NADPH OXIDASE; MEMBRANE TRANSLOCATION; STRUCTURAL BASIS; IN-VIVO; COMPLEX; BINDING	Small Rho GTPases are well known to regulate a variety of cellular processes by acting as molecular switches. The regulatory function of Rho GTPases is critically dependent on their posttranslational modification at the carboxyl terminus by isoprenylation and association with proper cellular membranes. Despite numerous studies, the mechanisms of recycling and functional integration of Rho GTPases at the biological membranes are largely unclear. In this study, prenylated human Rac1, a prominent member of the Rho family, was purified in large amount from baculovirus-infected Spodoptera frugiperda insect cells using a systematic detergent screening. In contrast to non-prenylated human Rac1 purified from Escherichia coli, prenylated Rac1 from insect cells was able to associate with synthetic liposomes and to bind Rho-specific guanine nucleotide dissociation inhibitor 1 (GDI1). Subsequent liposome reconstitution experiments revealed that GDI1 efficiently extracts Rac1 from liposomes preferentially in the inactive GDP-bound state. The extraction was prevented when Rac1 was activated to its GTP-bound state by Rac-specific guanine nucleotide exchange factors (GEFs), such as Vav2, Dbl, Tiam1, P-Rex1 and TrioN, and bound by the downstream effector Pak1. We found that dissociation of Rac1-GDP from its complex with GDI1 strongly correlated with two distinct activities of especially Dbl and Tiam1, including liposome association and the GDP/GTP exchange. Taken together, our results provided first detailed insights into the advantages of the in vitro liposome-based reconstitution system to study both the integration of the signal transducing protein complexes and the mechanisms of regulation and signaling of small GTPases at biological membranes.	[Zhang, Si-Cai; Gremer, Lothar; Cirstea, Ion C.; Ahmadian, Mohammad Reza] Univ Dusseldorf, Fac Med, Inst Biochem & Mol Biol 2, Dusseldorf, Germany; [Gremer, Lothar; Heise, Henrike] Univ Dusseldorf, Inst Phys Biol, Dusseldorf, Germany; [Gremer, Lothar; Heise, Henrike] Res Ctr Julich GmbH, ICS 6, Inst Complex Syst, Julich, Germany; [Janning, Petra] Max Planck Inst Mol Physiol, Dept Biol Chem, D-44139 Dortmund, Germany; [Shymanets, Aliaksei; Nuernberg, Bernd] Tubingen Med Sch, Inst Expt & Clin Pharmacol & Toxicol, Tubingen, Germany; [Cirstea, Ion C.] Leibniz Inst Age Res, Jena, Germany; [Krause, Eberhard] Leibniz Inst Mol Pharmacol, Lab Mass Spectrometry, Berlin, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Helmholtz Association; Research Center Julich; Max Planck Society; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Leibniz Forschungsinstitut furr Molekulare Pharmakologie (FMP)	Ahmadian, MR (corresponding author), Univ Dusseldorf, Fac Med, Inst Biochem & Mol Biol 2, Dusseldorf, Germany.	reza.ahmadian@uni-duesseldorf.de	Cirstea, Ion Cristian/AAQ-7670-2020; Gremer, Lothar/H-9128-2013; Heise, Henrike/A-7703-2010	Cirstea, Ion Cristian/0000-0003-3204-1598; Gremer, Lothar/0000-0001-7065-5027; Heise, Henrike/0000-0002-9081-3894; Nurnberg, Bernd/0000-0002-5995-6555	German Research Foundation (Deutsche Forschungsgemeinschaft or DFG) through the Collaborative Research Center 974 [SFB 974]; International NRW Research School BioStruct - Ministry of Innovation, Science and Research of the State North Rhine-Westphalia; Heinrich-Heine-University of Dusseldorf; Entrepreneur Foundation at the Heinrich-Heine-University of Dusseldorf	German Research Foundation (Deutsche Forschungsgemeinschaft or DFG) through the Collaborative Research Center 974; International NRW Research School BioStruct - Ministry of Innovation, Science and Research of the State North Rhine-Westphalia; Heinrich-Heine-University of Dusseldorf; Entrepreneur Foundation at the Heinrich-Heine-University of Dusseldorf	This research was gratefully supported in part by the German Research Foundation (Deutsche Forschungsgemeinschaft or DFG) through the Collaborative Research Center 974 (SFB 974) "Communication and Systems Relevance during Liver Injury and Regeneration'', and the International NRW Research School BioStruct, granted by the Ministry of Innovation, Science and Research of the State North Rhine-Westphalia, the Heinrich-Heine-University of Dusseldorf, and the Entrepreneur Foundation at the Heinrich-Heine-University of Dusseldorf. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexander M, 2009, CHEMBIOCHEM, V10, P98, DOI 10.1002/cbic.200800275; Barber MA, 2007, J BIOL CHEM, V282, P29967, DOI 10.1074/jbc.M701877200; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; Boissier P, 2014, CELL SIGNAL, V26, P483, DOI 10.1016/j.cellsig.2013.11.034; Boissier P, 2013, TRAFFIC, V14, P1255, DOI 10.1111/tra.12123; Boura E, 2012, P NATL ACAD SCI USA, V109, P1901, DOI 10.1073/pnas.1117597109; Brunsveld L, 2009, BBA-BIOMEMBRANES, V1788, P273, DOI 10.1016/j.bbamem.2008.08.006; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chae YC, 2008, MOL BIOL CELL, V19, P3111, DOI 10.1091/mbc.E07-04-0337; Contreras-Gomez A, 2013, BIOTECHNOL PROG; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; Dvorsky R, 2004, EMBO REP, V5, P1130, DOI 10.1038/sj.embor.7400293; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fansa EK, 2013, BIOCHEM BIOPH RES CO, V434, P785, DOI 10.1016/j.bbrc.2013.04.012; Faure J, 1999, EUR J BIOCHEM, V262, P879, DOI 10.1046/j.1432-1327.1999.00458.x; FUCHS A, 1994, EUR J BIOCHEM, V226, P587, DOI 10.1111/j.1432-1033.1994.tb20084.x; Garcia-Mata R, 2011, NAT REV MOL CELL BIO, V12, P493, DOI 10.1038/nrm3153; Gizachew D, 2000, BIOCHEMISTRY-US, V39, P3963, DOI 10.1021/bi992646d; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; Grizot S, 2001, BIOCHEMISTRY-US, V40, P10007, DOI 10.1021/bi010288k; Guo Z, 2008, EMBO J, V27, P2444, DOI 10.1038/emboj.2008.164; Gureasko J, 2008, NAT STRUCT MOL BIOL, V15, P452, DOI 10.1038/nsmb.1418; Haeusler LC, 2003, FEBS LETT, V555, P556, DOI 10.1016/S0014-5793(03)01351-6; Hall A, 2012, BIOCHEM SOC T, V40, P1378, DOI 10.1042/BST20120103; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Hemsath L, 2005, MOL CELL, V20, P313, DOI 10.1016/j.molcel.2005.08.036; Herbrand U, 2006, BIOL CHEM, V387, P311, DOI 10.1515/BC.2006.041; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Ismail SA, 2011, NAT CHEM BIOL, V7, P942, DOI [10.1038/nchembio.686, 10.1038/NCHEMBIO.686]; Jaiswal M, 2014, J BIOL CHEM, V289, P6839, DOI 10.1074/jbc.M113.527655; Jaiswal M, 2013, J BIOL CHEM, V288, P4486, DOI 10.1074/jbc.M112.429746; Jaiswal M, 2013, BIOL CHEM, V394, P89, DOI 10.1515/hsz-2012-0207; Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221; Lam B Daniel, 2013, Small GTPases, V4, P78, DOI 10.4161/sgtp.23310; LEONARD D, 1992, J BIOL CHEM, V267, P22860; Marrari Y, 2007, BIOCHEMISTRY-US, V46, P7665, DOI 10.1021/bi700338m; Mena JA, 2003, BIOTECHNIQUES, V34, P260, DOI 10.2144/03342bm05; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Moissoglu K, 2006, MOL BIOL CELL, V17, P2770, DOI 10.1091/mbc.E06-01-0005; Molnar G, 2001, BIOCHEMISTRY-US, V40, P10542, DOI 10.1021/bi011158e; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Navarro-Lerida I, 2012, EMBO J, V31, P534, DOI 10.1038/emboj.2011.446; Nomanbhoy TK, 1999, BIOCHEMISTRY-US, V38, P1744, DOI 10.1021/bi982198u; Ognibene M, 2014, GENE, V537, P220, DOI 10.1016/j.gene.2013.12.064; Parrini MC, 2005, BIOCHEM SOC T, V33, P646, DOI 10.1042/BST0330646; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; Philips MR, 2007, J CLIN INVEST, V117, P1223, DOI 10.1172/JCI32108; Rapley J, 2008, EMBO REP, V9, P655, DOI 10.1038/embor.2008.80; REED L. J., 1938, AMER JOUR HYG, V27, P493; Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200; Roberts PJ, 2008, J BIOL CHEM, V283, P25150, DOI 10.1074/jbc.M800882200; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Saci A, 2011, MOL CELL, V42, P50, DOI 10.1016/j.molcel.2011.03.017; SASAKI T, 1993, J BIOL CHEM, V268, P23959; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; Shymanets A, 2012, BIOCHEM J, V441, P851, DOI 10.1042/BJ20111664; Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086; Ten Klooster JP, 2006, BIOCHEM J, V397, P39, DOI 10.1042/BJ20051957; Tnimov Z, 2012, J BIOL CHEM, V287, P26549, DOI 10.1074/jbc.M112.371294; Triola G, 2012, ACS CHEM BIOL, V7, P87, DOI 10.1021/cb200460u; Ugolev Y, 2008, J BIOL CHEM, V283, P22257, DOI 10.1074/jbc.M800734200; van Hennik PB, 2003, J BIOL CHEM, V278, P39166, DOI 10.1074/jbc.M307001200; Viaud Julien, 2012, Advances in Biological Regulation, V52, P303, DOI 10.1016/j.jbior.2012.04.001; Weise K, 2012, J AM CHEM SOC, V134, P11503, DOI 10.1021/ja305518h; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Wu YW, 2007, P NATL ACAD SCI USA, V104, P12294, DOI 10.1073/pnas.0701817104; Wu YW, 2010, NAT CHEM BIOL, V6, P534, DOI [10.1038/NCHEMBIO.386, 10.1038/nchembio.386]; Zhang BL, 1998, J BIOL CHEM, V273, P8776, DOI 10.1074/jbc.273.15.8776	72	7	7	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2014	9	7							e102425	10.1371/journal.pone.0102425	http://dx.doi.org/10.1371/journal.pone.0102425			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AL8HH	25014207	Green Published, Green Submitted, gold			2023-01-03	WOS:000339378400096
J	Knikou, M				Knikou, Maria			Transpinal and Transcortical Stimulation Alter Corticospinal Excitability and Increase Spinal Output	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; MOTOR CORTEX EXCITABILITY; ELECTRICAL-STIMULATION; TIBIALIS ANTERIOR; REFLEX RESPONSES; CORD STIMULATION; BASIC PRINCIPLES; H-REFLEX; POTENTIALS; ACTIVATION	The objective of this study was to assess changes in corticospinal excitability and spinal output following noninvasive transpinal and transcortical stimulation in humans. The size of the motor evoked potentials (MEPs), induced by transcranial magnetic stimulation (TMS) and recorded from the right plantar flexor and extensor muscles, was assessed following transcutaneous electric stimulation of the spine (tsESS) over the thoracolumbar region at conditioning-test (C-T) intervals that ranged from negative 50 to positive 50 ms. The size of the transpinal evoked potentials (TEPs), induced by tsESS and recorded from the right and left plantar flexor and extensor muscles, was assessed following TMS over the left primary motor cortex at 0.7 and at 1.1 x MEP resting threshold at C-T intervals that ranged from negative 50 to positive 50 ms. The recruitment curves of MEPs and TEPs had a similar shape, and statistically significant differences between the sigmoid function parameters of MEPs and TEPs were not found. Anodal tsESS resulted in early MEP depression followed by long-latency MEP facilitation of both ankle plantar flexors and extensors. TEPs of ankle plantar flexors and extensors were increased regardless TMS intensity level. Subthreshold and suprathreshold TMS induced short-latency TEP facilitation that was larger in the TEPs ipsilateral to TMS. Noninvasive transpinal stimulation affected ipsilateral and contralateral actions of corticospinal neurons, while corticocortical and corticospinal descending volleys increased TEPs in both limbs. Transpinal and transcortical stimulation is a noninvasive neuromodulation method that alters corticospinal excitability and increases motor output of multiple spinal segments in humans.	[Knikou, Maria] CUNY, Grad Ctr, New York, NY 10021 USA; [Knikou, Maria] CUNY, Coll Staten Isl, Dept Phys Therapy, Staten Isl, NY USA; [Knikou, Maria] CUNY, Coll Staten Isl, Dept Neurosci, Staten Isl, NY USA; [Knikou, Maria] Rehabil Inst Chicago, Sensory Motor Performance Program, Chicago, IL 60611 USA; [Knikou, Maria] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA	City University of New York (CUNY) System; City University of New York (CUNY) System; College of Staten Island (CUNY); City University of New York (CUNY) System; College of Staten Island (CUNY); Shirley Ryan AbilityLab; Northwestern University; Feinberg School of Medicine	Knikou, M (corresponding author), CUNY, Grad Ctr, New York, NY 10021 USA.	Maria.Knikou@csi.cuny.edu	Knikou, Maria/E-5568-2015	Knikou, Maria/0000-0002-6277-236X				Aguilar J, 2011, J PHYSIOL-LONDON, V589, P4981, DOI 10.1113/jphysiol.2011.214189; BARKER AT, 1991, J CLIN NEUROPHYSIOL, V8, P26, DOI 10.1097/00004691-199101000-00005; BERARDELLI A, 1990, NEUROSCI LETT, V112, P54, DOI 10.1016/0304-3940(90)90321-Y; Brinkworth RSA, 2003, J NEUROSCI METH, V122, P179, DOI 10.1016/S0165-0270(02)00321-7; BURKE D, 1993, J PHYSIOL-LONDON, V470, P383, DOI 10.1113/jphysiol.1993.sp019864; Capaday C, 1997, J NEUROSCI METH, V74, P201, DOI 10.1016/S0165-0270(97)02250-4; Carroll TJ, 2001, J NEUROSCI METH, V112, P193, DOI 10.1016/S0165-0270(01)00468-X; Courtine GG, 2007, J PHYSIOL-LONDON, V582, P1125, DOI 10.1113/jphysiol.2007.128447; CRAYTON JW, 1981, J NEUROL NEUROSUR PS, V44, P239, DOI 10.1136/jnnp.44.3.239; DAVEY NJ, 1994, J PHYSIOL-LONDON, V477, P223, DOI 10.1113/jphysiol.1994.sp020186; DAY BL, 1989, J PHYSIOL-LONDON, V412, P449, DOI 10.1113/jphysiol.1989.sp017626; Dechent P, 2003, HUM BRAIN MAPP, V18, P272, DOI 10.1002/hbm.10084; Deng ZD, 2014, CLIN NEUROPHYSIOL, V125, P1202, DOI 10.1016/j.clinph.2013.11.038; DENOORDHOUT AM, 1988, J NEUROL NEUROSUR PS, V51, P174, DOI 10.1136/jnnp.51.2.174; Devanne H, 1997, EXP BRAIN RES, V114, P329, DOI 10.1007/PL00005641; Devanne H, 2009, EUR J NEUROSCI, V30, P439, DOI 10.1111/j.1460-9568.2009.06815.x; Di Lazzaro V, 2012, BRAIN STIMUL, V5, P512, DOI 10.1016/j.brs.2011.07.008; Di Lazzaro V, 1998, ELECTROMYOGR MOTOR C, V109, P397, DOI 10.1016/S0924-980X(98)00038-1; Di Lazzaro V, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00018; Duclay J, 2011, J PHYSIOL-LONDON, V589, P2901, DOI 10.1113/jphysiol.2011.207472; Einhorn J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076940; ELLAWAY PH, 1978, ELECTROEN CLIN NEURO, V45, P302, DOI 10.1016/0013-4694(78)90017-2; Geertsen SS, 2010, J PHYSIOL-LONDON, V588, P2391, DOI 10.1113/jphysiol.2010.190678; Gerasimenko YP, 2006, J NEUROSCI METH, V157, P253, DOI 10.1016/j.jneumeth.2006.05.004; HENNEMAN E, 1957, SCIENCE, V126, P1345, DOI 10.1126/science.126.3287.1345; Hofstoetter US, 2008, ARTIF ORGANS, V32, P644, DOI 10.1111/j.1525-1594.2008.00616.x; HUNTER JP, 1994, J PHYSIOL-LONDON, V474, P407, DOI 10.1113/jphysiol.1994.sp020032; INGHILLERI M, 1989, J NEUROL NEUROSUR PS, V52, P970, DOI 10.1136/jnnp.52.8.970; Jackson A, 2006, J PHYSIOL-LONDON, V573, P107, DOI 10.1113/jphysiol.2005.100537; Kaneko K, 1996, MUSCLE NERVE, V19, P659, DOI 10.1002/(SICI)1097-4598(199605)19:5<659::AID-MUS17>3.3.CO;2-B; Kaneko K, 1997, J NEUROL SCI, V151, P217, DOI 10.1016/S0022-510X(97)00135-4; KATZ R, 1977, J NEUROL NEUROSUR PS, V40, P575, DOI 10.1136/jnnp.40.6.575; Khaslavskaia S, 2002, EXP BRAIN RES, V145, P309, DOI 10.1007/s00221-002-1094-9; Kleinschmidt A, 1997, EUR J NEUROSCI, V9, P2178, DOI 10.1111/j.1460-9568.1997.tb01384.x; Klimstra M, 2008, EXP BRAIN RES, V186, P93, DOI 10.1007/s00221-007-1207-6; Knikou M, 2008, J NEUROSCI METH, V171, P1, DOI 10.1016/j.jneumeth.2008.02.012; Knikou M, 2013, CLIN NEUROPHYSIOL, V124, P2431, DOI 10.1016/j.clinph.2013.06.004; Knikou M, 2013, BIOELECTROMAGNETICS, V34, P630, DOI 10.1002/bem.21808; Knikou M, 2013, BIOELECTROMAGNETICS, V34, P200, DOI 10.1002/bem.21768; Knikou M, 2010, CLIN NEUROPHYSIOL, V121, P1655, DOI 10.1016/j.clinph.2010.01.039; KONRAD PE, 1994, SPINE, V19, P2812, DOI 10.1097/00007632-199412150-00014; Ladenbauer J, 2010, IEEE T NEUR SYS REH, V18, P637, DOI 10.1109/TNSRE.2010.2054112; Lamy JC, 2005, EXP BRAIN RES, V166, P248, DOI 10.1007/s00221-005-2360-4; Lemon RN, 2008, ANNU REV NEUROSCI, V31, P195, DOI 10.1146/annurev.neuro.31.060407.125547; Lontis ER, 2006, J CLIN NEUROPHYSIOL, V23, P462; MILLS KR, 1986, ELECTROEN CLIN NEURO, V63, P582, DOI 10.1016/0013-4694(86)90145-8; Minassian K, 2007, MUSCLE NERVE, V35, P327, DOI 10.1002/mus.20700; Miranda PC, 2003, IEEE T BIO-MED ENG, V50, P1074, DOI 10.1109/TBME.2003.816079; Mrachacz-Kersting N, 2007, J NEUROPHYSIOL, V97, P1951, DOI 10.1152/jn.01176.2006; Nielsen J, 1999, EEG CL N SU, P93; NIELSEN J, 1994, J PHYSIOL-LONDON, V477, P47, DOI 10.1113/jphysiol.1994.sp020170; PATTON HD, 1954, J NEUROPHYSIOL, V17, P345, DOI 10.1152/jn.1954.17.4.345; Petersen N, 1998, J PHYSIOL-LONDON, V512, P267, DOI 10.1111/j.1469-7793.1998.267bf.x; Petersen NT, 2001, J PHYSIOL-LONDON, V537, P651, DOI 10.1111/j.1469-7793.2001.00651.x; Pierrot-Deseilligny E., 2012, SPINAL CORTICOSPINAL; Poon DE, 2008, EXP BRAIN RES, V188, P13, DOI 10.1007/s00221-008-1334-8; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Rothwell J C, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P97; Roy FD, 2008, J PHYSIOL-LONDON, V586, P4091, DOI 10.1113/jphysiol.2008.153726; Roy FD, 2014, EXP BRAIN RES, V232, P1717, DOI 10.1007/s00221-014-3864-6; Roy FD, 2012, EXP BRAIN RES, V223, P281, DOI 10.1007/s00221-012-3258-6; Schneider C, 2004, J APPL PHYSIOL, V97, P2220, DOI 10.1152/japplphysiol.00542.2004; Sharpe AN, 2014, J NEURAL ENG, V11, DOI 10.1088/1741-2560/11/1/016005; Toschi N, 2008, J PSYCHIATR RES, V43, P255, DOI 10.1016/j.jpsychires.2008.04.008; Wagner TA, 2004, IEEE T BIO-MED ENG, V51, P1586, DOI 10.1109/TBME.2004.827925; Wagner T, 2009, CORTEX, V45, P1025, DOI 10.1016/j.cortex.2008.10.002	66	38	38	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2014	9	7							e102313	10.1371/journal.pone.0102313	http://dx.doi.org/10.1371/journal.pone.0102313			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AL3PK	25007330	gold, Green Published			2023-01-03	WOS:000339040600111
J	Ensrud, KE; Taylor, BC; Peters, KW; Gourlay, ML; Donaldson, MG; Leslie, WD; Blackwell, TL; Fink, HA; Orwoll, ES; Schousboe, J				Ensrud, Kristine E.; Taylor, Brent C.; Peters, Katherine W.; Gourlay, Margaret L.; Donaldson, Meghan G.; Leslie, William D.; Blackwell, Terri L.; Fink, Howard A.; Orwoll, Eric S.; Schousboe, John		Osteoporotic Fractures Men MrOS St	Implications of expanding indications for drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analysis of prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BONE-MINERAL DENSITY; OSTEOPOROTIC FRACTURES; POSTMENOPAUSAL WOMEN; CLINICAL-PRACTICE; DOUBLE-BLIND; US ADULTS; VERTEBRAL FRACTURES; ZOLEDRONIC ACID; ELDERLY-WOMEN; HIP FRACTURE	Objectives To quantify incremental effects of applying different criteria to identify men who are candidates for drug treatment to prevent fracture and to examine the extent to which fracture probabilities vary across distinct categories of men defined by these criteria. Design Cross sectional and longitudinal analysis of a prospective cohort study. Setting Multicenter Osteoporotic Fractures in Men (MrOS) study in the United States. Participants 5880 untreated community dwelling men aged 65 years or over classified into four distinct groups: osteoporosis by World Health Organization criteria alone; osteoporosis by National Osteoporosis Foundation (NOF) but not WHO criteria; no osteoporosis but at high fracture risk (at or above NOF derived FRAX intervention thresholds recommended for US); and no osteoporosis and at low fracture risk (below NOF derived FRAX intervention thresholds recommended for US). Main outcome measures Proportion of men identified for drug treatment; predicted 10 year probabilities of hip and major osteoporotic fracture calculated using FRAX algorithm with femoral neck bone mineral density; observed 10 year probabilities for confirmed incident hip and major osteoporotic (hip, clinical vertebral, wrist, or humerus) fracture events calculated using cumulative incidence estimation, accounting for competing risk of mortality. Results 130 (2.2%) men were identified as having osteoporosis by using the WHO definition, and an additional 422 were identified by applying the NOF definition (total osteoporosis prevalence 9.4%). Application of NOF derived FRAX intervention thresholds led to 936 (15.9%) additional men without osteoporosis being identified as at high fracture risk, raising the total prevalence of men potentially eligible for drug treatment to 25.3%. Observed 10 year hip fracture probabilities were 20.6% for men with osteoporosis by WHO criteria alone, 6.8% for men with osteoporosis by NOF (but not WHO) criteria, 6.4% for men without osteoporosis but classified as at high fracture risk, and 1.5% for men without osteoporosis and classified as at low fracture risk. A similar pattern was noted in observed fracture probabilities for major osteoporotic fracture. Among men with osteoporosis by WHO criteria, observed fracture probabilities were greater than FRAX predicted probabilities (20.6% v 9.5% for hip fracture and 30.0% v 17.4% for major osteoporotic fracture). Conclusions and relevance Choice of definition of osteoporosis and use of NOF derived FRAX intervention thresholds have major effects on the proportion of older men identified as warranting drug treatment to prevent fracture. Among men identified with osteoporosis by WHO criteria, who comprised 2% of the study population, actual observed fracture probabilities during 10 years of follow-up were highest and exceeded FRAX predicted fracture probabilities. On the basis of findings from randomized trials in women, these men are most likely to benefit from treatment. Expanding indications for treatment beyond this small group has uncertain value owing to lower observed fracture probabilities and uncertain benefits of treatment among men not selected on the basis of WHO criteria.	[Ensrud, Kristine E.; Taylor, Brent C.; Fink, Howard A.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Ensrud, Kristine E.; Taylor, Brent C.; Fink, Howard A.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA; [Ensrud, Kristine E.; Taylor, Brent C.; Fink, Howard A.] VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Peters, Katherine W.; Blackwell, Terri L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA; [Gourlay, Margaret L.] Univ N Carolina, Dept Family Med, Chapel Hill, NC 27514 USA; [Donaldson, Meghan G.] Univ British Columbia, Ctr Clin Epidemiol & Evaluat, Vancouver, BC V5Z 1M9, Canada; [Leslie, William D.] Univ Manitoba, Dept Med, Winnipeg, MB, Canada; [Orwoll, Eric S.] Oregon Hlth & Sci Univ, Bone & Mineral Unit, Portland, OR 97201 USA; [Schousboe, John] Pk Nicollet Clin, St Louis Pk, MN USA; [Schousboe, John] Univ Minnesota, Div Hlth Policy & Management, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; California Pacific Medical Center; California Pacific Medical Center Research Institute; University of North Carolina; University of North Carolina Chapel Hill; University of British Columbia; University of Manitoba; Oregon Health & Science University; University of Minnesota System; University of Minnesota Twin Cities	Ensrud, KE (corresponding author), One Vet Dr 111-0, Minneapolis, MN 55417 USA.	ensru001@umn.edu	Taylor, Brent C/A-8069-2009	Taylor, Brent C/0000-0002-2140-8377; Leslie, William/0000-0002-1056-1691; Ensrud, Kristine/0000-0002-9069-3036	National Institutes of Health (NIH); National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Aging; National Center for Research Resources; NIH Roadmap for Medical Research [U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01 AG027810, UL1 TR000128]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U01AR045583, U01AR045632, U01AR045654, U01AR066160, U01AR045647, U01AR045614, U01AR045580] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG018197, U01AG027810, U01AG042145, U01AG042168, U01AG042124, U01AG042139] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health (NIH) funding. The following institutes provide support: the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Institute on Aging, the National Center for Research Resources, and NIH Roadmap for Medical Research under the following grant numbers: U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01 AG027810, and UL1 TR000128. The funding agencies had no direct role in the conduct of the study; the collection, management, analyses, and interpretation of the data; or the preparation or approval of the manuscript.	ALEXEEVA L, 1994, WHO TECH REP SER, V843, P1; [Anonymous], 2010, CLIN GUID PREV TREAT; [Anonymous], 2011, FRAX WHO FRACTURE RI; Berry SD, 2010, OSTEOPOROSIS INT, V21, P53, DOI 10.1007/s00198-009-1127-3; Binkley Neil C, 2002, J Clin Densitom, V5 Suppl, pS19, DOI 10.1385/JCD:5:3S:S19; Blank JB, 2005, CONTEMP CLIN TRIALS, V26, P557, DOI 10.1016/j.cct.2005.05.005; Boonen S, 2012, NEW ENGL J MED, V367, P1714, DOI 10.1056/NEJMoa1204061; Boonen S, 2009, J BONE MINER RES, V24, P719, DOI 10.1359/JBMR.081214; Burge R, 2007, J BONE MINER RES, V22, P465, DOI 10.1359/JBMR.061113; Cawthon PM, 2009, J BONE MINER RES, V24, P1728, DOI [10.1359/JBMR.090419, 10.1359/jbmr.090419]; Compston J, 2013, MATURITAS, V75, P392, DOI 10.1016/j.maturitas.2013.05.013; Compston J, 2009, MATURITAS, V62, P105, DOI 10.1016/j.maturitas.2008.11.022; Coviello V, 2004, STATA J, V4, P103, DOI 10.1177/1536867X0400400201; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; Donaldson MG, 2012, J BONE MINER RES, V27, P1804, DOI 10.1002/jbmr.1625; Donaldson MG, 2010, J BONE MINER RES, V25, P1506, DOI 10.1002/jbmr.55; Douglas F, 2012, OSTEOPOROSIS INT, V23, P2135, DOI 10.1007/s00198-011-1823-7; Ebeling PR, 2008, NEW ENGL J MED, V358, P1474, DOI 10.1056/NEJMcp0707217; Endocrine Society, 2009, END SOC STAT IND REL; Ensrud KE, 2011, NEW ENGL J MED, V364, P1634, DOI 10.1056/NEJMcp1009697; Ettinger B, 2013, OSTEOPOROSIS INT, V24, P1185, DOI 10.1007/s00198-012-2215-3; Faulkner KG, 2002, J CLIN DENSITOM, V5, P87, DOI 10.1385/JCD:5:1:087; Hans DB, 2011, J CLIN DENSITOM, V14, P171, DOI 10.1016/j.jocd.2011.05.007; International Osteoporosis Foundation, 2013, ANN REP 2012 INT OST; International Society for Clinical Densitometry, 2007, 2007 ISCD OFF POS AD; International Society for Clinical Densitometry, 2013, 2013 ISCD OFF POS AD; Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304; Johnell O, 2005, OSTEOPOROSIS INT, V16, pS3, DOI 10.1007/s00198-004-1702-6; Jorgensen EB, 2008, KAIS, V2021, P1, DOI [DOI 10.1002/14651858.CD001155.PUB2, 10.1002/mp.15257]; Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198-007-0543-5; Kanis JA, 2011, OSTEOPOROSIS INT, V22, P2789, DOI 10.1007/s00198-011-1632-z; Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140-6736(02)08761-5; Kanis JA, 2007, ASSESSMENT OSTEOPORO; Kanis JA, 2008, BONE, V42, P467, DOI 10.1016/j.bone.2007.11.001; Kanis JA, 2010, BONE, V47, P729, DOI 10.1016/j.bone.2010.06.009; Kanis JA, 2009, BONE, V44, P734, DOI 10.1016/j.bone.2009.01.373; Kelly TL., 1990, J BONE MIN RES, V5, pS249; Looker AC, 2012, OSTEOPOROSIS INT, V23, P1351, DOI 10.1007/s00198-011-1693-z; Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761; Looker AC, 1998, OSTEOPOROSIS INT, V8, P468, DOI 10.1007/s001980050093; Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941; MacLean C, 2008, ANN INTERN MED, V148, P197, DOI 10.7326/0003-4819-148-3-200802050-00198; McCloskey EV, 2009, OSTEOPOROSIS INT, V20, P811, DOI 10.1007/s00198-008-0786-9; McCloskey EV, 2012, J BONE MINER RES, V27, P1480, DOI 10.1002/jbmr.1606; McCloskey EV, 2007, J BONE MINER RES, V22, P135, DOI 10.1359/JBMR.061008; McClung MR, 2012, J BONE MINER RES, V27, P211, DOI 10.1002/jbmr.536; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; National Osteoporosis Foundation, 2013, 2012 ANN REP NAT OST; National Osteoporosis Foundation, 2014, CLIN GUID PREV TREAT; Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9; Orwoll E, 2005, CONTEMP CLIN TRIALS, V26, P569, DOI 10.1016/j.cct.2005.05.006; Orwoll E, 2000, NEW ENGL J MED, V343, P604, DOI 10.1056/NEJM200008313430902; Orwoll E, 2012, J CLIN ENDOCR METAB, V97, P3161, DOI 10.1210/jc.2012-1569; PAHOR M, 1994, EUR J EPIDEMIOL, V10, P405, DOI 10.1007/BF01719664; Papaioannou A, 2010, CAN MED ASSOC J, V182, P1864, DOI 10.1503/cmaj.100771; Richy F, 2004, J CLIN DENSITOM, V7, P127, DOI 10.1385/JCD:7:2:127; Rubin KH, 2013, J BONE MINER RES, V28, P1701, DOI 10.1002/jbmr.1956; Stone KL, 2003, J BONE MINER RES, V18, P1947, DOI 10.1359/jbmr.2003.18.11.1947; Tosteson ANA, 2008, OSTEOPOROSIS INT, V19, P437, DOI 10.1007/s00198-007-0550-6; Watts NB, 2012, J CLIN ENDOCR METAB, V97, P1802, DOI 10.1210/jc.2011-3045	60	22	22	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	2014	349								g4120	10.1136/bmj.g4120	http://dx.doi.org/10.1136/bmj.g4120			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AK7ZE	24994809	Green Published, hybrid			2023-01-03	WOS:000338646100003
J	Jin, ZC; Berthiaume, JM; Li, QL; Henry, F; Huang, Z; Sadhukhan, S; Gao, P; Tochtrop, GP; Puchowicz, MA; Zhang, GF				Jin, Zhicheng; Berthiaume, Jessica M.; Li, Qingling; Henry, Fabrice; Huang, Zhong; Sadhukhan, Sushabhan; Gao, Peng; Tochtrop, Gregory P.; Puchowicz, Michelle A.; Zhang, Guo-Fang			Catabolism of (2E)-4-Hydroxy-2-nonenal via omega- and omega-1-Oxidation Stimulated by Ketogenic Diet	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						beta-Oxidation; Coenzyme A (CoA); Cytochrome P450; Diet; Fatty Acid Oxidation; Isotopic Tracer; Lipid Peroxidation; Mass Spectrometry (MS); Metabolism; Metabolomics	POLYMERASE-CHAIN-REACTION; HIGH-FAT DIET; RAT-LIVER; GAMMA-HYDROXYBUTYRATE; ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; MASS-SPECTROMETRY; LAURIC ACID; METABOLISM; MICROSOMES	Oxidative stress triggers the peroxidation of -6-polyunsaturated fatty acids to reactive lipid fragments, including (2E)-4-hydroxy-2-nonenal (HNE). We previously reported two parallel catabolic pathways of HNE. In this study, we report a novel metabolite that accumulates in rat liver perfused with HNE or 4-hydroxynonanoic acid (HNA), identified as 3-(5-oxotetrahydro-2-furanyl)propanoyl-CoA. In experiments using a combination of isotopic analysis and metabolomics studies, three catabolic pathways of HNE were delineated following HNE conversion to HNA. (i) HNA is -hydroxylated to 4,9-dihydroxynonanoic acid, which is subsequently oxidized to 4-hydroxynonanedioic acid. This is followed by the degradation of 4-hydroxynonanedioic acid via -oxidation originating from C-9 of HNA breaking down to 4-hydroxynonanedioyl-CoA, 4-hydroxyheptanedioyl-CoA, or its lactone, 2-hydroxyglutaryl-CoA, and 2-ketoglutaric acid entering the citric acid cycle. (ii) -1-hydroxylation of HNA leads to 4,8-dihydroxynonanoic acid (4,8-DHNA), which is subsequently catabolized via two parallel pathways we previously reported. In catabolic pathway A, 4,8-DHNA is catabolized to 4-phospho-8-hydroxynonanoyl-CoA, 3,8-dihydroxynonanoyl-CoA, 6-hydroxyheptanoyl-CoA, 4-hydroxypentanoyl-CoA, propionyl-CoA, and acetyl-CoA. (iii) The catabolic pathway B of 4,8-DHNA leads to 2,6-dihydroxyheptanoyl-CoA, 5-hydroxyhexanoyl-CoA, 3-hydroxybutyryl-CoA, and acetyl-CoA. Both in vivo and in vitro experiments showed that HNE can be catabolically disposed via - and -1-oxidation in rat liver and kidney, with little activity in brain and heart. Dietary experiments showed that - and -1-hydroxylation of HNA in rat liver were dramatically up-regulated by a ketogenic diet, which lowered HNE basal level. HET0016 inhibition and mRNA expression level suggested that the cytochrome P450 4A are main enzymes responsible for the NADPH-dependent - and -1-hydroxylation of HNA/HNE.	[Jin, Zhicheng; Berthiaume, Jessica M.; Li, Qingling; Henry, Fabrice; Huang, Zhong; Puchowicz, Michelle A.; Zhang, Guo-Fang] Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA; [Berthiaume, Jessica M.] Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; [Sadhukhan, Sushabhan; Gao, Peng; Tochtrop, Gregory P.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Zhang, GF (corresponding author), Case Western Reserve Univ, Dept Nutr, Sch Med, 10900 Euclid Ave,WG 48, Cleveland, OH 44106 USA.	gxz35@case.edu	Sadhukhan, Sushabhan/AAS-7136-2020; Gao, Peng/AAE-2205-2019	Gao, Peng/0000-0002-4311-584X; Jin, Zhicheng/0000-0003-2770-9549; Sadhukhan, Sushabhan/0000-0002-3302-5875	National Institutes of Health (NIH) [R33DK070291, R01ES013925]; NIH, NCI [CA157735]; Case Western Reserve University/Cleveland Clinic CTSA Grant from the National Center for Research Resources (NCRR), a component of the NIH [UL1 RR024989]; NIH Roadmap for Medical Research; National Science Foundation [MCB-084480]; American Heart Association [12GRNT12050453]; Cleveland Mt. Sinai Health Care Foundation; NATIONAL CANCER INSTITUTE [R01CA157735] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000439] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R33DK070291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013925] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Case Western Reserve University/Cleveland Clinic CTSA Grant from the National Center for Research Resources (NCRR), a component of the NIH; NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); American Heart Association(American Heart Association); Cleveland Mt. Sinai Health Care Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported, in whole or in part, by National Institutes of Health (NIH) Roadmap Grants R33DK070291 and R01ES013925 (to Henri Brunengraber) and by NIH, NCI, Grant CA157735 (to G. P. T.). This work was also supported by Case Western Reserve University/Cleveland Clinic CTSA Grant UL1 RR024989 (to G. F. Z.) from the National Center for Research Resources (NCRR), a component of the NIH and NIH Roadmap for Medical Research. This work was also supported by National Science Foundation Grant MCB-084480 (to G. P. T.), American Heart Association Grant 12GRNT12050453 (to G. F. Z.), and a grant from the Cleveland Mt. Sinai Health Care Foundation.	Akude E, 2010, NEUROTOX RES, V17, P28, DOI 10.1007/s12640-009-9074-5; Ando Y, 1998, J NEUROL SCI, V156, P172, DOI 10.1016/S0022-510X(98)00042-2; Bleicher KB, 2001, J BIOCHEM MOL TOXIC, V15, P133, DOI 10.1002/jbt.10; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BRUNENGRABER H, 1973, J BIOL CHEM, V248, P2656; Butterfield DA, 2011, FREE RADICAL RES, V45, P59, DOI 10.3109/10715762.2010.520014; Calingasan NY, 1999, J NEUROCHEM, V72, P751, DOI 10.1046/j.1471-4159.1999.0720751.x; Choudhary S, 2003, INVEST OPHTH VIS SCI, V44, P2675, DOI 10.1167/iovs.02-0965; Enoiu M, 2002, ARCH BIOCHEM BIOPHYS, V397, P18, DOI 10.1006/abbi.2001.2633; Falletti O, 2007, FREE RADICAL BIO MED, V42, P1258, DOI 10.1016/j.freeradbiomed.2007.01.024; Gioacchini AM, 1999, RAPID COMMUN MASS SP, V13, P1573, DOI 10.1002/(SICI)1097-0231(19990815)13:15<1573::AID-RCM675>3.0.CO;2-Z; Harris SR, 2013, CHEM RES TOXICOL, V26, P213, DOI 10.1021/tx3003643; Harris SR, 2011, J BIOL CHEM, V286, P5895, DOI 10.1074/jbc.M110.196808; Hayashi Seiko, 2005, Drug Metab Pharmacokinet, V20, P14, DOI 10.2133/dmpk.20.14; Johnston JB, 2011, ARCH BIOCHEM BIOPHYS, V507, P86, DOI 10.1016/j.abb.2010.08.011; Kalsotra A, 2005, BIOCHEM BIOPH RES CO, V338, P423, DOI 10.1016/j.bbrc.2005.08.101; Kalsotra A, 2002, DRUG METAB DISPOS, V30, P1022, DOI 10.1124/dmd.30.9.1022; Laurent A, 2000, TOXICOL LETT, V114, P203, DOI 10.1016/S0378-4274(99)00301-X; Li QL, 2014, J LIPID RES, V55, P592, DOI 10.1194/jlr.D045112; Li QL, 2013, FREE RADICAL BIO MED, V58, P35, DOI 10.1016/j.freeradbiomed.2013.01.005; Li QL, 2012, RAPID COMMUN MASS SP, V26, P1355, DOI 10.1002/rcm.6233; Li QL, 2012, FREE RADICAL BIO MED, V52, P1043, DOI 10.1016/j.freeradbiomed.2011.12.022; Mali VR, 2014, EXP BIOL MED, V239, P610, DOI 10.1177/1535370213520109; Manrique C, 2013, ENDOCRINOLOGY, V154, P3632, DOI 10.1210/en.2013-1256; Mattson MP, 2009, EXP GERONTOL, V44, P625, DOI 10.1016/j.exger.2009.07.003; Mobbs CV, 2013, J CHILD NEUROL, V28, P1009, DOI 10.1177/0883073813487596; OKAMOTO K, 1994, INT J CANCER, V58, P825, DOI 10.1002/ijc.2910580613; OKITA RT, 1980, DRUG METAB DISPOS, V8, P147; OKITA RT, 1979, BIOCHEM PHARMACOL, V28, P3385, DOI 10.1016/0006-2952(79)90077-7; Ramana KV, 2006, J BIOL CHEM, V281, P17652, DOI 10.1074/jbc.M600270200; Sadhukhan S, 2014, FREE RADICAL BIO MED, V70, P78, DOI 10.1016/j.freeradbiomed.2014.02.008; Sadhukhan S, 2010, J AM CHEM SOC, V132, P6309, DOI 10.1021/ja100399m; Sanders RJ, 2006, J BIOL CHEM, V281, P13180, DOI 10.1074/jbc.M513481200; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sharma S., 2013, EPILEPSY RES TREAT, V2013; Siems Werner, 2003, Molecular Aspects of Medicine, V24, P167, DOI 10.1016/S0098-2997(03)00011-6; Simpson AECM, 1997, GEN PHARMACOL-VASC S, V28, P351, DOI 10.1016/S0306-3623(96)00246-7; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Struys EA, 2006, METABOLISM, V55, P353, DOI 10.1016/j.metabol.2005.09.009; TANAKA S, 1990, BIOCHIM BIOPHYS ACTA, V1043, P177, DOI 10.1016/0005-2760(90)90293-7; Theken KN, 2012, AM J PHYSIOL-ENDOC M, V302, pE500, DOI 10.1152/ajpendo.00370.2011; Woolf EC, 2015, J LIPID RES, V56, P5, DOI 10.1194/jlr.R046797; Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-134; Zhang GF, 2012, BIOCHEM J, V444, P333, DOI 10.1042/BJ20112046; Zhang GF, 2009, J BIOL CHEM, V284, P33521, DOI 10.1074/jbc.M109.055665; Zhang XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070663	46	12	12	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2014	289	46					32327	32338		10.1074/jbc.M114.602458	http://dx.doi.org/10.1074/jbc.M114.602458			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	AU0LP	25274632	hybrid, Green Published			2023-01-03	WOS:000345314700057
J	Li, SY; Zhai, X; Rong, PJ; McCabe, MF; Wang, X; Zhao, JJ; Ben, H; Wang, SX				Li, Shaoyuan; Zhai, Xu; Rong, Peijing; McCabe, Michael F.; Wang, Xing; Zhao, Jingjun; Ben, Hui; Wang, Shuxing			Therapeutic Effect of Vagus Nerve Stimulation on Depressive-Like Behavior, Hyperglycemia and Insulin Receptor Expression in Zucker Fatty Rats	PLOS ONE			English	Article							ACUPUNCTURE; MELATONIN; DISORDER; OBESITY; MEMORY; TRIAL	Depression and type 2 diabetes (T2D) are common comorbid diseases and highly prevalent in the clinical setting with an unclarified mechanism. Zucker diabetic fatty (ZDF, fa/fa) rats natively develop T2D with hyperglycemia and hyperinsulinemia. Here we studied whether ZDF rats also innately develop depression, what a correlation is between depression and T2D, whether insulin receptor (IR) expression is involved in, and whether transcutaneous auricular vagus nerve stimulation (taVNS) would be beneficial in amelioration of the comorbidity. Six week old male ZDF and Zucker lean (ZL, fa/+) littermates were randomly divided into naive (ZDF, n = 6; ZL, n = 7) and taVNS (ZDF-taVNS, n = 8; ZL-taVNS, n = 6) groups. Once daily 30 min-taVNS sessions were administrated under anesthesia for 34 consecutive days in taVNS groups. Blood glucose levels were tested weekly, and plasma glycosylated hemoglobin (HbAlc) level and immobility time in forced swimming test were determined on day 35 in all groups. The expression of insulin receptor (IR) in various tissues was also detected by immunostaining and Western blot. We found that naive ZDF rats developed hyperglycemia steadily. These ZDF rats showed a strong positive correlation between longer immobility time and higher plasma HbAlC level. Long term taVNS treatment simultaneously prevented the development of depression-like behavior and progression of hyperglycemia in ZDF rats. The expression of IR in various tissues of naive ZDF rats is lower than in naive ZL and long-term taVNS treated ZDF rats. Collectively, our results indicate that in ZDF rats, i) depression and T2D develop simultaneously, ii) immobility time and HbAlc concentrations are highly and positively correlated, iii) a low expression of IR may be involved in the comorbidity of depression and T2D, and iv) taVNS is antidiabetic and antidepressive possibly through IR expression upregulation.	[Li, Shaoyuan; Zhai, Xu; Rong, Peijing; Zhao, Jingjun; Ben, Hui; Wang, Shuxing] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Dept Physiol, Beijing, Peoples R China; [Li, Shaoyuan; Wang, Xing; Wang, Shuxing] Xinxiang Med Univ, Dept Anat, Xinxiang, Henan, Peoples R China; [McCabe, Michael F.; Wang, Shuxing] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA; [Wang, Shuxing] Guangdong Entomol Inst, Primate Res Ctr, Guangzhou, Guangdong, Peoples R China; [Wang, Shuxing] Guangdong Landau Biotechnol Co Ltd, Guangzhou, Guangdong, Peoples R China	China Academy of Chinese Medical Sciences; Institute of Acupuncture & Moxibustion, CACMS; Xinxiang Medical University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Guangdong Academy of Sciences; Institute of Zoology, Guangdong Academy of Sciences	Rong, PJ (corresponding author), China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Dept Physiol, Beijing, Peoples R China.	rongpj@hotmail.com; 13718103762@139.com	zhao, jing/B-3868-2019		National Natural Science Foundation of China [81271243]; National Basic Research Program of China (973 Program) [2012CB518503]; Project Supported National Science and Technology Ministry [2012BAF14B10]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China (973 Program)(National Basic Research Program of China); Project Supported National Science and Technology Ministry	This work was supported by National Natural Science Foundation of China, 81271243; National Basic Research Program of China (973 Program), 2012CB518503; and Project Supported National Science and Technology Ministry, 2012BAF14B10. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agil A, 2012, J PINEAL RES, V52, P203, DOI 10.1111/j.1600-079X.2011.00928.x; Banks WA, 2012, PHARMACOL THERAPEUT, V136, P82, DOI 10.1016/j.pharmthera.2012.07.006; Belivani M, 2013, ACUPUNCT MED, V31, P88, DOI 10.1136/acupmed-2012-010247; Buhl ES, 2010, AM J PHYSIOL-ENDOC M, V298, pE920, DOI 10.1152/ajpendo.00606.2009; Cardinali DP, 2012, J PINEAL RES, V52, P365, DOI 10.1111/j.1600-079X.2011.00962.x; Cline BH, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-110; Foran E, 2014, IR J MED SCI; Frese T, 2009, LIFE SCI, V85, P526, DOI 10.1016/j.lfs.2009.08.004; Fu Z, 2013, CURR DIABETES REV, V9, P25, DOI 10.2174/157339913804143225; Grillo CA, 2011, BEHAV BRAIN RES, V222, P230, DOI 10.1016/j.bbr.2011.03.052; He W, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/615476; Huang F, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-203; La Marca R, 2010, CLIN SCI, V118, P537, DOI 10.1042/CS20090264; Lang UE, 2013, CELL PHYSIOL BIOCHEM, V31, P761, DOI 10.1159/000350094; Langenberg C, 2009, DIABETOLOGIA, V52, P1537, DOI 10.1007/s00125-009-1392-x; Liu RP, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/789674; Lyons Zaza, 2012, Complement Ther Clin Pract, V18, P216, DOI 10.1016/j.ctcp.2012.06.003; MAURIZI CP, 1984, SOUTH MED J, V77, P1516, DOI 10.1097/00007611-198412000-00010; McMullan CJ, 2013, JAMA-J AM MED ASSOC, V309, P1388, DOI 10.1001/jama.2013.2710; Mendenhall E, 2014, DIABETES RES CLIN PR, V103, P276, DOI 10.1016/j.diabres.2014.01.001; Mischoulon D, 2012, J AFFECT DISORDERS, V141, P469, DOI 10.1016/j.jad.2012.03.023; Paxinos G., 1998, RAT BRAIN STEROTAXIC; Peplow PV, 2012, J ACUPUNCT MERIDIAN, V5, P1, DOI 10.1016/j.jams.2011.11.018; Preiss K, 2013, OBES REV, V14, P906, DOI 10.1111/obr.12052; Rong PJ, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-255; Rustad JK, 2011, PSYCHONEUROENDOCRINO, V36, P1276, DOI 10.1016/j.psyneuen.2011.03.005; Smyth S, 2006, NAT MED, V12, P75, DOI 10.1038/nm0106-75; Wang Q, 2012, AM J CHINESE MED, V40, P1157, DOI 10.1142/S0192415X12500851; Wang SX, 2012, PAIN, V153, P2448, DOI 10.1016/j.pain.2012.08.016; Ward KR, 2011, HYPERTENSION, V57, P435, DOI 10.1161/HYPERTENSIONAHA.110.160671; Wilding JPH, 2014, INT J CLIN PRACT, V68, P682, DOI 10.1111/ijcp.12384; Yeung AS, 2011, J AFFECT DISORDERS, V130, P285, DOI 10.1016/j.jad.2010.07.025; Zeng Q, 2008, BRAIN RES, V1200, P27, DOI 10.1016/j.brainres.2008.01.038; Zhang ZJ, 2010, J AFFECT DISORDERS, V124, P9, DOI 10.1016/j.jad.2009.07.005; Zhao WQ, 2004, EUR J PHARMACOL, V490, P71, DOI 10.1016/j.ejphar.2004.02.045	35	19	24	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2014	9	11							e112066	10.1371/journal.pone.0112066	http://dx.doi.org/10.1371/journal.pone.0112066			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU4DB	25365428	Green Published, Green Submitted, gold			2023-01-03	WOS:000345558100144
J	Rezania, A; Bruin, JE; Arora, P; Rubin, A; Batushansky, I; Asadi, A; O'Dwyer, S; Quiskamp, N; Mojibian, M; Albrecht, T; Yang, YHC; Johnson, JD; Kieffer, TJ				Rezania, Alireza; Bruin, Jennifer E.; Arora, Payal; Rubin, Allison; Batushansky, Irina; Asadi, Ali; O'Dwyer, Shannon; Quiskamp, Nina; Mojibian, Majid; Albrecht, Tobias; Yang, Yu Hsuan Carol; Johnson, James D.; Kieffer, Timothy J.			Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells	NATURE BIOTECHNOLOGY			English	Article							PANCREATIC PROGENITOR CELLS; MAFA TRANSCRIPTION FACTOR; AIR-LIQUID INTERFACE; BETA-CELL; ISLET TRANSPLANTATION; DIFFERENTIATION; GLUCOSE; SECRETION; ENDODERM; GENERATION	Transplantation of pancreatic progenitors or insulin-secreting cells derived from human embryonic stem cells (hESCs) has been proposed as a therapy for diabetes. We describe a seven-stage protocol that efficiently converts hESCs into insulin-producing cells. Stage (S) 7 cells expressed key markers of mature pancreatic beta cells, including MAFA, and displayed glucose-stimulated insulin secretion similar to that of human islets during static incubations in vitro. Additional characterization using single-cell imaging and dynamic glucose stimulation assays revealed similarities but also notable differences between S7 insulin-secreting cells and primary human beta cells. Nevertheless, S7 cells rapidly reversed diabetes in mice within 40 days, roughly four times faster than pancreatic progenitors. Therefore, although S7 cells are not funk equivalent to mature beta cells, their capacity for glucose-responsive insulin secretion and rapid reversal of diabetes in vivo makes them a promising alternative to pancreatic progenitor cells or cadaveric islets for the treatment of diabetes.	[Rezania, Alireza; Arora, Payal; Rubin, Allison; Batushansky, Irina] Janssen R&D LLC, BetaL Venture, Raritan, NJ 08869 USA; [Bruin, Jennifer E.; Asadi, Ali; O'Dwyer, Shannon; Quiskamp, Nina; Mojibian, Majid; Albrecht, Tobias; Yang, Yu Hsuan Carol; Johnson, James D.; Kieffer, Timothy J.] Univ British Columbia, Inst Life Sci, Dept Cellular & Physiol Sci, Vancouver, BC V5Z 1M9, Canada; [Johnson, James D.; Kieffer, Timothy J.] Univ British Columbia, Dept Surg, Vancouver, BC V5Z 1M9, Canada	Johnson & Johnson; Janssen Pharmaceuticals; University of British Columbia; University of British Columbia	Kieffer, TJ (corresponding author), Janssen R&D LLC, BetaL Venture, Raritan, NJ 08869 USA.	ARezani@its.jnj.com; tim.kieffer@ubc.ca		asadi, ali/0000-0002-6224-9982; Bruin, Jennifer/0000-0003-2326-7819; Yang, Yu Hsuan Carol/0000-0001-6663-0302	JDRF; Canadian Institutes of Health Research (CIHR) Regenerative Medicine and Nanomedicine Initiative; Stem Cell Network (SCN); L'Oreal Canada; NSERC Post Graduate Scholarship; Mitacs Elevate Postdoctoral Fellowship; CIHR Transplantation Training Program; Stem Cell Technologies; JDRF postdoctoral fellowship	JDRF(Juvenile Diabetes Research Foundation); Canadian Institutes of Health Research (CIHR) Regenerative Medicine and Nanomedicine Initiative(Canadian Institutes of Health Research (CIHR)); Stem Cell Network (SCN); L'Oreal Canada; NSERC Post Graduate Scholarship(Natural Sciences and Engineering Research Council of Canada (NSERC)); Mitacs Elevate Postdoctoral Fellowship; CIHR Transplantation Training Program(Canadian Institutes of Health Research (CIHR)); Stem Cell Technologies; JDRF postdoctoral fellowship(Juvenile Diabetes Research Foundation)	This work was supported in part by funding from the JDRF, the Canadian Institutes of Health Research (CIHR) Regenerative Medicine and Nanomedicine Initiative, and the Stem Cell Network (SCN). J.E.B. was funded by a JDRF postdoctoral fellowship and L'Oreal Canada for Women in Science Research Excellence Fellowship. Y.H.C.Y. was the recipient of an NSERC Post Graduate Scholarship and M.M. was the recipient of a Mitacs Elevate Postdoctoral Fellowship. The CIHR Transplantation Training Program provided funding for J.E.B., N.Q. and M.M. We also thank Stem Cell Technologies for their financial support, T. Webber, S. Karuna and B. Hu for their technical assistance, and G. Warnock and Z. Ao from the Irving K. Barber Human Islet Isolation Laboratory (Vancouver, BC) for providing human islets.	Aguayo-Mazzucato C, 2011, DIABETOLOGIA, V54, P583, DOI 10.1007/s00125-010-2026-z; Aguayo-Mazzucato C, 2013, DIABETES, V62, P1569, DOI 10.2337/db12-0849; Aguayo-Mazzucato C, 2010, NAT REV ENDOCRINOL, V6, P139, DOI 10.1038/nrendo.2009.274; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Barton FB, 2012, DIABETES CARE, V35, P1436, DOI 10.2337/dc12-0063; Basford CL, 2012, DIABETOLOGIA, V55, P358, DOI 10.1007/s00125-011-2335-x; Bruin JE, 2014, STEM CELL RES, V12, P194, DOI 10.1016/j.scr.2013.10.003; Bruin JE, 2013, DIABETOLOGIA, V56, P1987, DOI 10.1007/s00125-013-2955-4; Chen S, 2009, NAT CHEM BIOL, V5, P258, DOI 10.1038/nchembio.154; Cho CHH, 2012, DIABETOLOGIA, V55, P3284, DOI 10.1007/s00125-012-2687-x; Choi KM, 2008, J BIOSCI BIOENG, V105, P586, DOI 10.1263/jbb.105.586; Cortijo C, 2012, CELL REP, V2, P1593, DOI 10.1016/j.celrep.2012.10.016; D'Amour KA, 2005, NAT BIOTECHNOL, V23, P1534, DOI 10.1038/nbt1163; D'Amour KA, 2006, NAT BIOTECHNOL, V24, P1392, DOI 10.1038/nbt1259; DAVALLI AM, 1995, TRANSPLANTATION, V59, P817, DOI 10.1097/00007890-199503270-00003; Haase TN, 2013, DIABETOLOGIA, V56, P763, DOI 10.1007/s00125-012-2821-9; Halban PA, 2001, DIABETES, V50, P2181, DOI 10.2337/diabetes.50.10.2181; Hang Y, 2014, DIABETES, V63, P1994, DOI 10.2337/db13-1001; Harmon JS, 2009, ENDOCRINOLOGY, V150, P4855, DOI 10.1210/en.2009-0708; Harmon JS, 2005, J BIOL CHEM, V280, P11107, DOI 10.1074/jbc.M410345200; Heinis M, 2010, DIABETES, V59, P662, DOI 10.2337/db09-0891; Johansson KA, 2007, DEV CELL, V12, P457, DOI 10.1016/j.devcel.2007.02.010; Jorgensen MC, 2007, ENDOCR REV, V28, P685, DOI 10.1210/er.2007-0016; Kelly OG, 2011, NAT BIOTECHNOL, V29, P750, DOI 10.1038/nbt.1931; Kinkel MD, 2009, BIOESSAYS, V31, P139, DOI 10.1002/bies.200800123; Kroon E, 2008, NAT BIOTECHNOL, V26, P443, DOI 10.1038/nbt1393; Kumar M, 2003, CURR OPIN GENET DEV, V13, P401, DOI 10.1016/S0959-437X(03)00089-3; Luciani DS, 2005, MOL CELL ENDOCRINOL, V241, P88, DOI 10.1016/j.mce.2005.06.006; Mahadevan J, 2013, DIABETES, V62, P3582, DOI 10.2337/db13-0357; Matsuoka T, 2004, P NATL ACAD SCI USA, V101, P2930, DOI 10.1073/pnas.0306233101; Merani S, 2008, BRIT J SURG, V95, P1449, DOI 10.1002/bjs.6391; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; Murtaugh LC, 2003, P NATL ACAD SCI USA, V100, P14920, DOI 10.1073/pnas.2436557100; NAUCK MA, 1986, J CLIN ENDOCR METAB, V63, P492, DOI 10.1210/jcem-63-2-492; Nelson SB, 2007, DEVELOPMENT, V134, P2491, DOI 10.1242/dev.002691; Nostro MC, 2011, DEVELOPMENT, V138, P861, DOI 10.1242/dev.055236; Nostro MC, 2012, SEMIN CELL DEV BIOL, V23, P701, DOI 10.1016/j.semcdb.2012.06.010; Pezzulo AA, 2011, AM J PHYSIOL-LUNG C, V300, pL25, DOI 10.1152/ajplung.00256.2010; Piper K, 2004, J ENDOCRINOL, V181, P11, DOI 10.1677/joe.0.1810011; Pisania A, 2010, LAB INVEST, V90, P1661, DOI 10.1038/labinvest.2010.124; PRUNIERAS M, 1983, J INVEST DERMATOL, V81, pS28, DOI 10.1111/1523-1747.ep12540324; Rezania A, 2013, STEM CELLS, V31, P2432, DOI 10.1002/stem.1489; Rezania A, 2012, DIABETES, V61, P2016, DOI 10.2337/db11-1711; Rezania A, 2011, DIABETES, V60, P239, DOI 10.2337/db10-0573; Rukstalis JM, 2009, ISLETS, V1, P177, DOI 10.4161/isl.1.3.9877; Sander M, 2000, DEVELOPMENT, V127, P5533; Schiesser JV, 2014, ANN NY ACAD SCI, V1311, P124, DOI 10.1111/nyas.12369; Schulz TC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037004; Seymour PA, 2007, P NATL ACAD SCI USA, V104, P1865, DOI 10.1073/pnas.0609217104; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shim JH, 2007, DIABETOLOGIA, V50, P1228, DOI 10.1007/s00125-007-0634-z; Street CN, 2004, DIABETES, V53, P3107, DOI 10.2337/diabetes.53.12.3107; TUCH BE, 1991, TRANSPLANTATION, V51, P557, DOI 10.1097/00007890-199103000-00002; TUCH BE, 1991, TRANSPLANTATION, V51, P1156, DOI 10.1097/00007890-199106000-00003; Wang H, 2007, DIABETOLOGIA, V50, P348, DOI 10.1007/s00125-006-0490-2; Warnock GL, 2008, TRANSPLANTATION, V86, P1762, DOI 10.1097/TP.0b013e318190b052; Wells JM, 1999, ANNU REV CELL DEV BI, V15, P393, DOI 10.1146/annurev.cellbio.15.1.393; Xu XF, 2011, MECH DEVELOP, V128, P412, DOI 10.1016/j.mod.2011.08.001; Zhang C, 2005, MOL CELL BIOL, V25, P4969, DOI 10.1128/MCB.25.12.4969-4976.2005	59	905	989	15	251	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2014	32	11					1121	1133		10.1038/nbt.3033	http://dx.doi.org/10.1038/nbt.3033			13	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	AT5IL	25211370				2023-01-03	WOS:000344977000017
J	Bashar, K; Healy, D; Clarke-Moloney, M; Burke, P; Kavanagh, E; Walsh, SR				Bashar, Khalid; Healy, Donagh; Clarke-Moloney, Mary; Burke, Paul; Kavanagh, Eamon; Walsh, Stewart-Redmond			Effects of Neck Radiation Therapy on Extra-Cranial Carotid Arteries Atherosclerosis Disease Prevalence: Systematic Review and a Meta-Analysis	PLOS ONE			English	Review							INTIMA-MEDIA THICKNESS; STENOSIS; RADIOTHERAPY; HEAD; IRRADIATION; STROKE	Introduction: Radiation arteritis following neck irradiation as a treatment for head and neck malignancy has been well documented. The long-term sequelae of radiation exposure of the carotid arteries may take years to manifest clinically, and extra-cranial carotid artery (ECCA) stenosis is a well-recognised vascular complication. These carotid lesions should not be regarded as benign and should be treated in the same manner as standard carotid stenosis. Previous studies have noted increased cerebrovascular events such as stroke in this cohort of patients because of high-grade symptomatic carotid stenosis resulting in emboli. Aim: To evaluate the effect of radiation therapy on ECCA atherosclerosis progression. Methods: Online search for case-control studies and randomised clinical trials that reported on stenosis in extra-cranial carotid arteries in patients with neck malignancies who received radiation therapy (RT) comparing them to patients with neck malignancies who did not receive RT. Results: Eight studies were included in the final analysis with total of 1070 patients - 596 received RT compared to 474 in the control group. There was statistically significant difference in overall stenosis rate (Pooled risk ratio = 4.38 [2.98, 6.45], P = 0.00001) and severe stenosis (Pooled risk ratio = 7.51 [2.78, 20.32], P < 0.0001), both being higher in the RT group. Pooled analysis of the five studies that reported on mild stenosis also showed significant difference (Pooled risk ratio = 2.74 [1.75, 4.30], 95% CI, P = 0.0001). Conclusion: The incidence of severe ECCA stenosis is higher among patients who received RT for neck malignancies. Those patients should be closely monitored and screening programs should be considered in all patients who receive neck RT.	[Bashar, Khalid; Healy, Donagh; Clarke-Moloney, Mary; Burke, Paul; Kavanagh, Eamon] Univ Hosp Limerick, Dept Vasc Surg, Limerick, Ireland; [Walsh, Stewart-Redmond] Natl Univ Ireland Galway, Dept Surg, Galway, Ireland	University of Limerick; Ollscoil na Gaillimhe-University of Galway	Bashar, K (corresponding author), Univ Hosp Limerick, Dept Vasc Surg, Limerick, Ireland.	khalid@live.ie	Walsh, Stewart R/AAC-1229-2021	Walsh, Stewart/0000-0002-1006-9541				BROSIUS FC, 1981, AM J MED, V70, P519, DOI 10.1016/0002-9343(81)90574-X; Carmody BJ, 1999, J VASC SURG, V30, P1045, DOI 10.1016/S0741-5214(99)70042-X; Chang YJ, 2009, J VASC SURG, V50, P280, DOI 10.1016/j.jvs.2009.01.033; Cheng SWK, 1999, AM J SURG, V178, P323, DOI 10.1016/S0002-9610(99)00184-1; Cheng SWK, 2000, ARCH OTOLARYNGOL, V126, P517, DOI 10.1001/archotol.126.4.517; CHUNG TS, 1994, J COMPUT ASSIST TOMO, V18, P533, DOI 10.1097/00004728-199407000-00003; DERSIMONIAN R, 1983, HARVARD EDUC REV, V53, P1; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Dyson P, 1993, Clin Oncol (R Coll Radiol), V5, P260, DOI 10.1016/S0936-6555(05)80243-2; Fokkema M, 2012, STROKE, V43, P793, DOI 10.1161/STROKEAHA.111.633743; FONKALSRUD EW, 1977, SURG GYNECOL OBSTET, V145, P395; GARCIAALBEA E, 1982, REV CLIN ESP, V166, P89; Greco A, 2012, CLIN OTOLARYNGOL, V37, P376, DOI 10.1111/coa.12007; Gujral DM, 2014, CLIN ONCOL-UK, V26, P94, DOI 10.1016/j.clon.2013.10.002; Gujral DM, 2013, CLIN ONCOL; Hoving S, 2008, INT J RADIAT ONCOL, V71, P848, DOI 10.1016/j.ijrobp.2008.02.031; Huang YS, 2011, ORAL ONCOL, V47, P1092, DOI 10.1016/j.oraloncology.2011.07.024; King LJ, 1999, RADIOLOGY, V213, P167, DOI 10.1148/radiology.213.1.r99oc07167; Lam WMM, 2001, CANCER, V92, P2357, DOI 10.1002/1097-0142(20011101)92:9<2357::AID-CNCR1583>3.0.CO;2-K; Lam WWM, 2002, CEREBROVASC DIS, V13, P168, DOI 10.1159/000047771; Lam WWM, 2001, HEAD NECK-J SCI SPEC, V23, P780, DOI 10.1002/hed.1111.abs; Li CS, 2010, CLIN NEUROL NEUROSUR, V112, P682, DOI 10.1016/j.clineuro.2010.05.007; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; MCGUIRT WF, 1992, ANN OTO RHINOL LARYN, V101, P222, DOI 10.1177/000348949210100305; MELLIERE D, 1983, J MAL VASCUL, V8, P321; MORITZ MW, 1990, ARCH SURG-CHICAGO, V125, P1181; Muzaffar K, 2000, LARYNGOSCOPE, V110, P1811, DOI 10.1097/00005537-200011000-00007; Protack CD, 2007, J VASC SURG, V45, P110, DOI 10.1016/j.jvs.2006.08.083; REILLY LM, 1983, AM J SURG, V146, P188, DOI 10.1016/0002-9610(83)90370-7; Rockman CB, 1996, AM J SURG, V172, P191, DOI 10.1016/S0002-9610(96)00150-X; Santoro F, 2013, INT J CARDIOL, V165, P373, DOI 10.1016/j.ijcard.2012.08.027; Shariat M, 2008, POSTGRAD MED J, V84, P609, DOI 10.1136/pgmj.2008.068569; Sterne JAC, 2011, COCHRANE HDB SYSTEMA; Thapa GB, 2013, J NEPAL MED ASSOC, V52, P251, DOI 10.31729/jnma.568; The Nordic Cochrane Centre TCc, 2012, REV MAN REVMAN COMP; Toprak U, 2012, J CLIN ULTRASOUND, V40, P566, DOI 10.1002/jcu.21971	36	26	26	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2014	9	10							e110389	10.1371/journal.pone.0110389	http://dx.doi.org/10.1371/journal.pone.0110389			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ9XC	25329500	Green Published, Green Submitted, gold			2023-01-03	WOS:000343210800082
J	Peake, SL; Delaney, A; Bailey, M; Bellomo, R; Cameron, PA; Cooper, DJ; Higgins, AM; Holdgate, A; Howe, BD; Webb, SAR; Williams, P				Peake, Sandra L.; Delaney, Anthony; Bailey, Michael; Bellomo, Rinaldo; Cameron, Peter A.; Cooper, D. James; Higgins, Alisa M.; Holdgate, Anna; Howe, Belinda D.; Webb, Steven A. R.; Williams, Patricia		ARISE Investigators; ANZICS Clinical Trials Grp	Goal-Directed Resuscitation for Patients with Early Septic Shock	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURVIVING SEPSIS CAMPAIGN; AUSTRALASIAN RESUSCITATION; EVALUATION ARISE; GUIDELINES; THERAPY; CARE; EPIDEMIOLOGY; MULTICENTER; MORTALITY	BACKGROUND Early goal-directed therapy (EGDT) has been endorsed in the guidelines of the Surviving Sepsis Campaign as a key strategy to decrease mortality among patients presenting to the emergency department with septic shock. However, its effectiveness is uncertain. METHODS In this trial conducted at 51 centers (mostly in Australia or New Zealand), we randomly assigned patients presenting to the emergency department with early septic shock to receive either EGDT or usual care. The primary outcome was all-cause mortality within 90 days after randomization. RESULTS Of the 1600 enrolled patients, 796 were assigned to the EGDT group and 804 to the usual-care group. Primary outcome data were available for more than 99% of the patients. Patients in the EGDT group received a larger mean (+/- SD) volume of intravenous fluids in the first 6 hours after randomization than did those in the usual-care group (1964 +/- 1415 ml vs. 1713 +/- 1401 ml) and were more likely to receive vasopressor infusions (66.6% vs. 57.8%), red-cell transfusions (13.6% vs. 7.0%), and dobutamine (15.4% vs. 2.6%) (P<0.001 for all comparisons). At 90 days after randomization, 147 deaths had occurred in the EGDT group and 150 had occurred in the usual-care group, for rates of death of 18.6% and 18.8%, respectively (absolute risk difference with EGDT vs. usual care, -0.3 percentage points; 95% confidence interval, -4.1 to 3.6; P=0.90). There was no significant difference in survival time, in-hospital mortality, duration of organ support, or length of hospital stay. CONCLUSIONS In critically ill patients presenting to the emergency department with early septic shock, EGDT did not reduce all-cause mortality at 90 days. (Funded by the National Health and Medical Research Council of Australia and the Alfred Foundation; ARISE ClinicalTrials.gov number, NCT00975793.)	[Peake, Sandra L.; Delaney, Anthony; Bailey, Michael; Bellomo, Rinaldo; Cooper, D. James; Higgins, Alisa M.; Howe, Belinda D.; Webb, Steven A. R.; Williams, Patricia] Monash Univ, Sch Publ Hlth & Prevent Med, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic 3004, Australia; [Cameron, Peter A.] Monash Univ, Sch Publ Hlth, Melbourne, Vic 3004, Australia; [Peake, Sandra L.; Williams, Patricia] Univ Adelaide, Adelaide, SA, Australia; [Peake, Sandra L.; Williams, Patricia] Queen Elizabeth Hosp, Adelaide, SA, Australia; [Delaney, Anthony] Royal N Shore Hosp, Sydney, NSW, Australia; [Delaney, Anthony] Univ Sydney, Sydney, NSW 2006, Australia; [Bellomo, Rinaldo] Austin Hosp, Melbourne, Vic 3084, Australia; [Cameron, Peter A.; Cooper, D. James] Alfred Hosp, Melbourne, Vic, Australia; [Holdgate, Anna] Liverpool Hosp, Sydney, NSW, Australia; [Holdgate, Anna] Univ New S Wales, Sydney, NSW, Australia; [Webb, Steven A. R.] Royal Perth Hosp, Perth, WA 6001, Australia; [Webb, Steven A. R.] Univ Western Australia, Perth, WA 6009, Australia; [Cameron, Peter A.] Hamad Med, Doha, Qatar	Monash University; Monash University; University of Adelaide; Royal North Shore Hospital; University of Sydney; University of Sydney; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Florey Institute of Neuroscience & Mental Health; Liverpool Hospital; University of New South Wales Sydney; Royal Perth Hospital; University of Western Australia; University of Western Australia; Hamad Medical Corporation	Howe, BD (corresponding author), Australian & New Zealand Intens Care Res Ctr, Alfred Ctr, Level 6 Lobby B,99 Commercial Rd, Melbourne, Vic 3004, Australia.	anzicrc@monash.edu	Graham, Colin A/B-4535-2013; Delaney, Anthony/AAE-3365-2019; Higgins, Alisa/AAM-8088-2020; Williams, Patricia/AAH-6571-2019; Cooper, D. James/G-7961-2013; Bailey, Michael J/A-4499-2012; Lam, Sin Man/ACC-8966-2022	Graham, Colin A/0000-0002-4381-7470; Higgins, Alisa/0000-0001-8295-7559; Cooper, D. James/0000-0002-5872-9051; Bailey, Michael J/0000-0002-5551-1401; Lam, Sin Man/0000-0002-1766-4271; Nichol, Alistair/0000-0002-4689-1238; Rajbhandari, Dorrilyn/0000-0001-8883-0428; Wilkman, Erika/0000-0003-4250-7523; Micallef, Sharon/0000-0002-8496-2324; Emberson, Jonathan/0000-0001-7792-9422; Cameron, Peter/0000-0002-1443-557X; Bellomo, Rinaldo/0000-0002-1650-8939; Furyk, Jeremy/0000-0002-9503-0928; SHEHABI, Yahya/0000-0003-4707-7462; Delaney, Anthony/0000-0002-1015-7146	National Health and Medical Research Council of Australia; Alfred Foundation	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Alfred Foundation	Funded by the National Health and Medical Research Council of Australia and the Alfred Foundation; ARISE ClinicalTrials.gov number, NCT00975793.	Angus DC, 2004, CRIT CARE MED, V32, P2199, DOI 10.1097/01.CCM.0000145228.62451.F6; Annane D, 2003, AM J RESP CRIT CARE, V168, P165, DOI 10.1164/rccm.2201087; [Anonymous], CRIT CARE MED; [Anonymous], 2014, NEW ENGL J MED, DOI DOI 10.1056/NEJMoa1401602; ARISE, 2007, Crit Care Resusc, V9, P8; Barochia AV, 2010, CRIT CARE MED, V38, P668, DOI 10.1097/CCM.0b013e3181cb0ddf; Bellomo R, 2009, CRIT CARE MED, V37, P3114, DOI 10.1097/CCM.0b013e3181bc7bd5; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Delaney AP, 2013, CRIT CARE RESUSC, V15, P162; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Dellinger RP, 2008, INTENS CARE MED, V34, P17, DOI 10.1007/s00134-007-0934-2; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Gaieski DF, 2013, CRIT CARE MED, V41, P1167, DOI 10.1097/CCM.0b013e31827c09f8; Harrison DA, 2006, CRIT CARE, V10, DOI 10.1186/cc4854; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; Huang DT, 2013, INTENS CARE MED, V39, P1760, DOI 10.1007/s00134-013-3024-7; Ioannidis JPA, 2005, JAMA-J AM MED ASSOC, V294, P218, DOI 10.1001/jama.294.2.218; Jawad Issrah, 2012, J Glob Health, V2, P010404, DOI 10.7189/jogh.02.010404; Jones AE, 2007, CHEST, V132, P425, DOI 10.1378/chest.07-0234; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Kjaergard LL, 2008, ANN INTERN MED, V149, P219, DOI 10.7326/0003-4819-149-3-200808050-00023; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kortgen A, 2006, CRIT CARE MED, V34, P943, DOI 10.1097/01.CCM.0000206112.32673.D4; Levy MM, 2010, INTENS CARE MED, V36, P222, DOI 10.1007/s00134-009-1738-3; Peake S, 2007, CRIT CARE MED, V35, P994, DOI 10.1097/01.CCM.0000257481.37623.3B; Peake SL, 2009, RESUSCITATION, V80, P811, DOI 10.1016/j.resuscitation.2009.03.008; Perel A, 2008, CRIT CARE, V12, DOI 10.1186/cc6979; Quenot JP, 2013, CRIT CARE, V17, DOI 10.1186/cc12598; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Stevenson EK, 2014, CRIT CARE MED, V42, P625, DOI 10.1097/CCM.0000000000000026; Wang HE, 2007, CRIT CARE MED, V35, P1928, DOI 10.1097/01.CCM.0000277043.85378.C1; Zhang ZH, 2013, CRIT CARE, V17, DOI 10.1186/cc11919	33	1234	1319	4	97	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 16	2014	371	16					1496	1506		10.1056/NEJMoa1404380	http://dx.doi.org/10.1056/NEJMoa1404380			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AQ7KV	25272316	Green Published			2023-01-03	WOS:000342994700006
J	Lee, EK; Kim, YJ; Kim, JY; Song, HB; Yu, HG				Lee, Eun Kyoung; Kim, Young Joo; Kim, Jin Young; Song, Hyun Beom; Yu, Hyeong Gon			Melissa officinalis Extract Inhibits Laser-Induced Choroidal Neovascularization in a Rat Model	PLOS ONE			English	Article							NONLETHAL OXIDANT INJURY; RETINAL-DETACHMENT; ALZHEIMERS-DISEASE; IN-VITRO; OB-X; INTRAVITREAL; GROWTH; EXPRESSION; MMP-2; ACID	Purpose: This study investigated the effect of Melissa officinalis extract on laser-induced choroidal neovascularization (CNV) in a rat model. The mechanism by which M. officinalis extract acted was also investigated. Methods: Experimental CNV was induced by laser photocoagulation in Brown Norway rats. An active fraction of the Melissa leaf extract was orally administered (50 or 100 mg/kg/day) beginning 3 days before laser photocoagulation and ending 14 days after laser photocoagulation. Optical coherence tomography and fluorescein angiography were performed in vivo to evaluate the thickness and leakage of CNV. Choroidal flat mount and histological analysis were conducted to observe the CNV in vitro. Vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-2, and MMP-9 expression were measured in retinal and choroidal-scleral lysates 7 days after laser injury. Moreover, the effect of M. officinalis extract on tertiary-butylhydroperoxide (t-BH)-induced VEGF secretion and mRNA levels of VEGF, MMP-2, and MMP-9 were evaluated in human retinal epithelial cells (ARPE-19) as well as in human umbilical vein endothelial cells (HUVECs). Results: The CNV thickness in M. officinalis-treated rats was significantly lower than in vehicle-treated rats by histological analysis. The CNV thickness was 33.93 +/- 7.64 mu m in the high-dose group (P<0.001), 44.09 +/- 12.01 mu m in the low-dose group (P = 0.016), and 51.00 +/- 12.37 mu m in the control group. The proportion of CNV lesions with clinically significant fluorescein leakage was 9.2% in rats treated with high-dose M. officinalis, which was significantly lower than in control rats (53.4%, P<0.001). The levels of VEGF, MMP-2, and MMP-9 were significantly lower in the high-dose group than in the control group. Meanwhile, M. officinalis extract suppressed t-BH-induced transcription of VEGF and MMP-9 in ARPE-19 cells and HUVECs. Conclusions: Systemic administration of M. officinalis extract suppressed laser-induced CNV formation in rats. Inhibition of VEGF and MMP-9 via anti-oxidative activity may underlie this effect.	[Lee, Eun Kyoung; Kim, Jin Young; Yu, Hyeong Gon] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Ophthalmol, Seoul, South Korea; [Kim, Young Joo] Seoul Natl Univ Hosp, Biomed Res Inst, Dept Ophthalmol, Seoul 110744, South Korea; [Song, Hyun Beom] Seoul Natl Univ, Grad Sch, Dept Biomed Sci, Seoul, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU)	Yu, HG (corresponding author), Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Ophthalmol, Seoul, South Korea.	hgonyu@snu.ac.kr		Song, Hyun Beom/0000-0002-3500-2984; Yu, Hyeong Gon/0000-0002-1795-202X; Kim, Jin Young/0000-0001-6204-9537	Korea Health technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [A121835-1201-0000103]	Korea Health technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea	This research was supported by a grant of the Korea Health technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant Number: A121835-1201-0000103). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akhondzadeh S, 2003, J NEUROL NEUROSUR PS, V74, P863, DOI 10.1136/jnnp.74.7.863; Allahverdiyev A, 2004, PHYTOMEDICINE, V11, P657, DOI 10.1016/j.phymed.2003.07.014; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026; Bolkent S, 2005, J ETHNOPHARMACOL, V99, P391, DOI 10.1016/j.jep.2005.02.038; Campochiaro P A, 1999, Mol Vis, V5, P34; de Sousa AC, 2004, J PHARM PHARMACOL, V56, P677, DOI 10.1211/0022357023321; Dimitrova Z., 1993, Acta Microbiologica Bulgarica, V29, P65; dos Santos-Neto LL, 2006, EVID-BASED COMPL ALT, V3, P441, DOI 10.1093/ecam/nel071; Ferreira A, 2006, J ETHNOPHARMACOL, V108, P31, DOI 10.1016/j.jep.2006.04.010; Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2; Hara R, 2010, CURR EYE RES, V35, P1012, DOI 10.3109/02713683.2010.500112; Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006; Hong Y, 2011, PHARM BIOL, V49, P775, DOI 10.3109/13880209.2010.547208; Huang SS, 2006, CANCER LETT, V239, P271, DOI 10.1016/j.canlet.2005.08.025; Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537; Jung JE, 2007, CARCINOGENESIS, V28, P1780, DOI 10.1093/carcin/bgm130; Kennedy DO, 2003, NEUROPSYCHOPHARMACOL, V28, P1871, DOI 10.1038/sj.npp.1300230; Kennedy DO, 2002, PHARMACOL BIOCHEM BE, V72, P953, DOI 10.1016/S0091-3057(02)00777-3; Kim JH, 2009, VASC PHARMACOL, V51, P262, DOI 10.1016/j.vph.2009.06.010; Kim JH, 2009, EUR J PHARMACOL, V615, P150, DOI 10.1016/j.ejphar.2009.05.015; Kim MY, 2010, INT J OBESITY, V34, P820, DOI 10.1038/ijo.2010.13; Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338; Kugu S, 2012, CLIN OPHTHALMOL, V6, P1399, DOI 10.2147/OPTH.S31721; Kumar A, 2012, GRAEF ARCH CLIN EXP, V250, P685, DOI 10.1007/s00417-011-1890-7; Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684; Kvanta A, 2000, EXP EYE RES, V70, P419, DOI 10.1006/exer.1999.0790; Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje; Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X; Lee SH, 2010, EYE, V24, P226, DOI 10.1038/eye.2009.86; Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230; Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224; Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673; Otsuka K, 2012, CASE REP OPHTHALM, V3, P424, DOI 10.1159/000346041; Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158; Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003; Roggia MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098864; Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194; Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4; Yamasaki K, 1998, BIOL PHARM BULL, V21, P829, DOI 10.1248/bpb.21.829; Ziakova A, 2003, J CHROMATOGR A, V983, P271, DOI 10.1016/S0021-9673(02)01712-0	41	24	24	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2014	9	10							e110109	10.1371/journal.pone.0110109	http://dx.doi.org/10.1371/journal.pone.0110109			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR5ZW	25314292	Green Published, Green Submitted, gold			2023-01-03	WOS:000343662500097
J	Zhang, YH; Xiao, YP; Wang, P; Liu, QH				Zhang, Yanhua; Xiao, Yaping; Wang, Pan; Liu, Quanhong			Compositions and Anti-Tumor Activity of Pyropolyporus fomentarius Petroleum Ether Fraction In Vitro and In Vivo	PLOS ONE			English	Article							FOMES-FOMENTARIUS; CANCER-CELLS; APOPTOSIS; EXTRACT; MUSHROOM; PATHWAY; FUNGI; DEATH; TUMOR; S180	The chemical compositions and anti-tumour activities of he petroleum ether fraction PE) from mushroom Pyropolyporus formentarius, were studied. Upon gas chromatography-mass spectrometry GC-MS analysis, nine major constituents were identified in the fraction. In vitro, the PE showed cytotoxic activity against murine sarcoma S180 (S180) cells in a dose- and time-dependent manner, and the cytotoxic effects were associated with apoptosis. The mitochondrial membrane potential loss and the intracellular ROS generation were greatly increased in the Pyropolyporus fomentarius PE treated group, suggesting cell apoptosis, induced by the PE in S180 cells, might be mitochondria dependent and ROS mediated. Consistent with in vitro findings, the in vivo study showed that the Pyropolyporus fomentarius PE was also effective in inhibiting the tumour growth induced by S180 cells and had lower immune organ toxicity. We found that the Pyropolyporus famentarius PE has significant anti-tumor activity and great potential in screening anti-tumor drugs.	[Zhang, Yanhua; Xiao, Yaping; Wang, Pan; Liu, Quanhong] Shaanxi Normal Univ, Coll Life Sci, Natl Engn Lab Resource Developing Endangered Chin, Key Lab Med Resources & Nat Pharmaceut Chem,Minis, Xian, Shaanxi, Peoples R China; [Zhang, Yanhua] Jiangsu Normal Univ, Coll Life Sci, Xuzhou, Jiangsu, Peoples R China	Shaanxi Normal University; Jiangsu Normal University	Liu, QH (corresponding author), Shaanxi Normal Univ, Coll Life Sci, Natl Engn Lab Resource Developing Endangered Chin, Key Lab Med Resources & Nat Pharmaceut Chem,Minis, Xian, Shaanxi, Peoples R China.	lshaof@snnu.edu.cn			National "Twelfth Five-Year" Plan for Science & Technology Support [2011BAI06B05]; Natural Science Foundation of Shaanxi Province, China [2014JM4137]	National "Twelfth Five-Year" Plan for Science & Technology Support; Natural Science Foundation of Shaanxi Province, China(Natural Science Foundation of Shaanxi Province)	This work was supported by National "Twelfth Five-Year" Plan for Science & Technology Support (2011BAI06B05) and Natural Science Foundation of Shaanxi Province, China (Grant No. 2014JM4137). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel Aziz A, 2009, AUST J BASIC APPL SC, V3, P2754; Aikemu A, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-157; AOKI M, 1993, BIOSCI BIOTECH BIOCH, V57, P278, DOI 10.1271/bbb.57.278; Bao XL, 2013, CARBOHYD POLYM, V98, P1236, DOI 10.1016/j.carbpol.2013.07.018; Beattie KD, 2011, MYCOLOGIA, V103, P458, DOI 10.3852/10-121; Bok JW, 1999, PHYTOCHEMISTRY, V51, P891, DOI 10.1016/S0031-9422(99)00128-4; Chalah A, 2008, ADV EXP MED BIOL, V615, P25, DOI 10.1007/978-1-4020-6554-5_3; Chen W, 2008, FREE RADICAL BIO MED, V45, P60, DOI 10.1016/j.freeradbiomed.2008.03.013; Chen W, 2011, CARBOHYD POLYM, V85, P369, DOI 10.1016/j.carbpol.2011.02.035; Cheng XX, 2012, J ETHNOPHARMACOL, V143, P49, DOI 10.1016/j.jep.2012.05.054; CHIHARA G, 1969, Nature (London), V222, P687; Chung MJ, 2010, NUTR RES PRACT, V4, P177, DOI 10.4162/nrp.2010.4.3.177; Crazzolara R, 2009, CURR CANCER DRUG TAR, V9, P19, DOI 10.2174/156800909787314057; Dou XJ, 2014, CYTOTECHNOLOGY, V66, P107, DOI 10.1007/s10616-013-9543-9; [冯薇 Feng Wei], 2010, [中国药学杂志, Chinese Pharmaceutical Journal], V45, P1528; Ferreira ICFR, 2010, ANTI-CANCER AGENT ME, V10, P424; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Fulda S, 2009, J CELL MOL MED, V13, P1221, DOI 10.1111/j.1582-4934.2009.00748.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harada H, 2002, ANTICANCER RES, V22, P2587; Huang TianZi, 2012, Mycosystema, V31, P775; INDAP M A, 1986, Indian Journal of Physiology and Pharmacology, V30, P182; Jabbour E, 2011, HEMATOL ONCOL CLIN N, V25, P981, DOI 10.1016/j.hoc.2011.09.004; Judova J, 2012, FUNGAL BIOL-UK, V116, P155, DOI 10.1016/j.funbio.2011.10.010; Keawsa-ard S, 2012, NAT PROD COMMUN, V7, P955; Krysko DV, 2008, METHODS, V44, P205, DOI 10.1016/j.ymeth.2007.12.001; Lee WY, 2005, B KOREAN CHEM SOC, V26, P1464; Li CF, 2014, BIOPHARM DRUG DISPOS, V35, P50, DOI 10.1002/bdd.1868; Magalhaes HIF, 2006, J PHARM PHARMACOL, V58, P235, DOI 10.1211/jpp.58.2.0011; Ndozangue-Touriguine O, 2008, BIOCHEM PHARMACOL, V76, P11, DOI 10.1016/j.bcp.2008.03.016; Petrova RD, 2008, ONCOL REP, V19, P299; Pezzuto J.M., 1991, METHODS PLANT BIOCH, P71; Pleyer L, 2009, NAT REV CLIN ONCOL, V6, P405, DOI 10.1038/nrclinonc.2009.72; Rello S, 2005, APOPTOSIS, V10, P201, DOI 10.1007/s10495-005-6075-6; Roussel Bertrand, 2002, Rev Hist Pharm (Paris), V50, P599; SAAR M, 1991, J ETHNOPHARMACOL, V31, P175, DOI 10.1016/0378-8741(91)90003-V; Seniuk OF, 2011, INT J MED MUSHROOMS, V13, P7, DOI 10.1615/IntJMedMushr.v13.i1.20; Shaffer BC, 2012, DRUG RESIST UPDATE, V15, P62, DOI 10.1016/j.drup.2012.02.001; Smith DJ, 2008, IUBMB LIFE, V60, P383, DOI 10.1002/iub.44; STEBBING ARD, 1982, SCI TOTAL ENVIRON, V22, P213, DOI 10.1016/0048-9697(82)90066-3; Stewart B.W., 2003, WORLD CANC REPORT; Sun B, 2011, CANCER LETT, V301, P95, DOI 10.1016/j.canlet.2010.10.010; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; W.H.O. (WHO), 2013, GLOBOCAN 2012; Wang J, 2009, CANCER LETT, V283, P193, DOI 10.1016/j.canlet.2009.03.039; Wang X, 2013, AFR J TRADIT COMPLEM, V10, P475, DOI 10.4314/ajtcam.v10i3.14; World Health Organization, 2004, WORLD HLTH REP 2004; Yan H, 2014, HUM EXP TOXICOL, V33, P522, DOI 10.1177/0960327113497771; Yuan HM, 2011, J APPL PHYCOL, V23, P59, DOI 10.1007/s10811-010-9536-4; Zaidman BZ, 2005, APPL MICROBIOL BIOT, V67, P453, DOI 10.1007/s00253-004-1787-z; Zang Y, 2013, PHYTOCHEMISTRY, V92, P137, DOI 10.1016/j.phytochem.2013.05.003; Zhang JH, 2012, AM J CHINESE MED, V40, P861, DOI 10.1142/S0192415X12500644; Zhao YY, 2011, BIOCHIM BIOPHYS ACTA, V4, P384; Zhao YY, 2010, PLANTA MEDICAX, V26, P1464; Zhong JJ, 2009, ADV BIOCHEM ENG BIOT, V113, P79, DOI 10.1007/10_2008_26; Zhou BR, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/513027	56	6	6	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2014	9	10							e109599	10.1371/journal.pone.0109599	http://dx.doi.org/10.1371/journal.pone.0109599			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR6ZS	25302783	Green Published, gold, Green Submitted			2023-01-03	WOS:000343730400070
J	Jongen, JLM; Smits, H; Pederzani, T; Bechakra, M; Hossaini, M; Koekkoek, SK; Huygen, FJPM; De Zeeuw, CI; Holstege, JC; Joosten, EAJ				Jongen, Joost L. M.; Smits, Helwin; Pederzani, Tiziana; Bechakra, Malik; Hossaini, Mehdi; Koekkoek, Sebastiaan K.; Huygen, Frank J. P. M.; De Zeeuw, Chris I.; Holstege, Jan C.; Joosten, Elbert A. J.			Spinal Autofluorescent Flavoprotein Imaging in a Rat Model of Nerve Injury-Induced Pain and the Effect of Spinal Cord Stimulation	PLOS ONE			English	Article							REFLEX SYMPATHETIC DYSTROPHY; CORTEX IN-VIVO; NEUROPATHIC PAIN; DORSAL-HORN; C-FOS; CENTRAL SENSITIZATION; NOCICEPTIVE ACTIVITY; CORTICAL ACTIVITY; INDUCED ANALGESIA; PLASTICITY	Nerve injury may cause neuropathic pain, which involves hyperexcitability of spinal dorsal horn neurons. The mechanisms of action of spinal cord stimulation (SCS), an established treatment for intractable neuropathic pain, are only partially understood. We used Autofluorescent Flavoprotein Imaging (AFI) to study changes in spinal dorsal horn metabolic activity. In the Seltzer model of nerve-injury induced pain, hypersensitivity was confirmed using the von Frey and hotplate test. 14 Days after nerve-injury, rats were anesthetized, a bipolar electrode was placed around the affected sciatic nerve and the spinal cord was exposed by a laminectomy at T13. AFI recordings were obtained in neuropathic rats and a control group of naive rats following 10 seconds of electrical stimulation of the sciatic nerve at C-fiber strength, or following non-noxious palpation. Neuropathic rats were then treated with 30 minutes of SCS or sham stimulation and AFI recordings were obtained for up to 60 minutes after cessation of SCS/sham. Although AFI responses to noxious electrical stimulation were similar in neuropathic and naive rats, only neuropathic rats demonstrated an AFI-response to palpation. Secondly, an immediate, short-lasting, but strong reduction in AFI intensity and area of excitation occurred following SCS, but not following sham stimulation. Our data confirm that AFI can be used to directly visualize changes in spinal metabolic activity following nerve injury and they imply that SCS acts through rapid modulation of nociceptive processing at the spinal level.	[Jongen, Joost L. M.] Erasmus MC, Dept Neurol, Rotterdam, Netherlands; [Smits, Helwin; Joosten, Elbert A. J.] UMC, Pain Management & Res Ctr, Maastricht, Netherlands; [Pederzani, Tiziana; Bechakra, Malik; Hossaini, Mehdi; Koekkoek, Sebastiaan K.; De Zeeuw, Chris I.; Holstege, Jan C.] Erasmus MC, Dept Neurosci, Rotterdam, Netherlands; [Huygen, Frank J. P. M.] Erasmus MC, Dept Pain Med, Rotterdam, Netherlands; [De Zeeuw, Chris I.] Royal Acad Arts & Sci, Netherlands Inst Neurosci, Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Maastricht University; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Jongen, JLM (corresponding author), Erasmus MC, Dept Neurol, Rotterdam, Netherlands.	j.jongen@erasmusmc.nl			Pain Knowledge Center Rotterdam/Dutch Ministry of Health; TREND consortium; BSIK program from the Dutch government; Dutch Organization for Medical Sciences; Life Sciences; Senter (Neuro-Basic); Prinses Beatrix Fonds; European Union	Pain Knowledge Center Rotterdam/Dutch Ministry of Health; TREND consortium; BSIK program from the Dutch government; Dutch Organization for Medical Sciences; Life Sciences(European Commission); Senter (Neuro-Basic); Prinses Beatrix Fonds; European Union(European Commission)	The development of this manuscript was supported by research grants from the Pain Knowledge Center Rotterdam/Dutch Ministry of Health (JJ), the TREND consortium (HS), the BSIK program from the Dutch government (HS), the Dutch Organization for Medical Sciences (CDZ), Life Sciences (CDZ), Senter (Neuro-Basic; CDZ), the Prinses Beatrix Fonds (CDZ), and the European Union (CDZ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barchini J, 2012, NEUROSCIENCE, V215, P196, DOI 10.1016/j.neuroscience.2012.04.057; Barnes JA, 2011, J NEUROSCI, V31, P12778, DOI 10.1523/JNEUROSCI.2579-11.2011; Bennett DLH, 1998, EUR J NEUROSCI, V10, P1282, DOI 10.1046/j.1460-9568.1998.00139.x; Catheline G, 1999, PAIN, V80, P347, DOI 10.1016/S0304-3959(98)00234-6; Costigan M, 2009, ANNU REV NEUROSCI, V32, P1, DOI 10.1146/annurev.neuro.051508.135531; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Craig AD, 2003, ANNU REV NEUROSCI, V26, P1, DOI 10.1146/annurev.neuro.26.041002.131022; Craig AD, 2004, J NEUROPHYSIOL, V92, P2604, DOI 10.1152/jn.00385.2004; Cruccu G, 2007, EUR J NEUROL, V14, P952, DOI 10.1111/j.1468-1331.2007.01916.x; Cui JG, 1997, PAIN, V73, P87, DOI 10.1016/S0304-3959(97)00077-8; de Vos CC, 2009, J DIABETES COMPLICAT, V23, P40, DOI 10.1016/j.jdiacomp.2007.08.002; Doth AH, 2010, PAIN, V149, P338, DOI 10.1016/j.pain.2010.02.034; Geurts JW, 2013, NEUROMODULATION, V16, P523, DOI 10.1111/ner.12024; Guan Y, 2010, ANESTHESIOLOGY, V113, P1392, DOI 10.1097/ALN.0b013e3181fcd95c; Hossaini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035293; Hossaini M, 2010, PAIN, V151, P356, DOI 10.1016/j.pain.2010.07.023; Husson TR, 2007, J NEUROSCI, V27, P8665, DOI 10.1523/JNEUROSCI.2156-07.2007; Janssen SP, 2012, NEUROCHEM INT, V60, P21, DOI 10.1016/j.neuint.2011.11.006; Jongen JLM, 2012, NEUROSCIENTIST, V18, P8, DOI 10.1177/1073858410391813; Jongen JLM, 2010, J NEUROSCI, V30, P4081, DOI 10.1523/JNEUROSCI.0011-10.2010; Kemler MA, 2000, NEW ENGL J MED, V343, P618, DOI 10.1056/NEJM200008313430904; Kemler MA, 2006, NEW ENGL J MED, V354, P2394, DOI 10.1056/NEJMc055504; Komagata S, 2011, J NEUROSCI, V31, P4896, DOI 10.1523/JNEUROSCI.6753-10.2011; Kubota Y, 2008, NEUROSCI RES, V60, P422, DOI 10.1016/j.neures.2007.12.013; LaCroix-Fralish ML, 2005, SPINE, V30, P1821, DOI 10.1097/01.brs.0000174122.63291.38; Latremoliere A, 2010, J PAIN, V11, P801, DOI 10.1016/j.jpain.2010.06.006; Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012; Maeda Y, 2009, BRAIN RES, V1259, P40, DOI 10.1016/j.brainres.2008.12.060; Moayedi M, 2013, J NEUROPHYSIOL, V109, P5, DOI 10.1152/jn.00457.2012; Mogil JS, 1999, P NATL ACAD SCI USA, V96, P7744, DOI 10.1073/pnas.96.14.7744; Murakami H, 2004, EUR J NEUROSCI, V19, P1352, DOI 10.1111/j.1460-9568.2004.03237.x; Oaklander AL, 2006, PAIN, V120, P235, DOI 10.1016/j.pain.2005.09.036; OCHOA JL, 1993, ANN NEUROL, V33, P465, DOI 10.1002/ana.410330509; Pluijms WA, 2012, BRIT J ANAESTH, V109, P623, DOI 10.1093/bja/aes251; Reinert KC, 2004, J NEUROPHYSIOL, V92, P199, DOI 10.1152/jn.01275.2003; Reinert KC, 2007, J NEUROSCI RES, V85, P3221, DOI 10.1002/jnr.21348; Rowbotham MC, 1996, BRAIN, V119, P347, DOI 10.1093/brain/119.2.347; Sasaki S, 2002, NEUROIMAGE, V17, P1240, DOI 10.1006/nimg.2002.1286; Schechtmann G, 2008, PAIN, V139, P136, DOI 10.1016/j.pain.2008.03.023; Schoffnegger D, 2008, PAIN, V135, P300, DOI 10.1016/j.pain.2007.12.016; SELTZER Z, 1990, PAIN, V43, P205, DOI 10.1016/0304-3959(90)91074-S; Shechter R, 2013, ANESTHESIOLOGY, V119, P422, DOI 10.1097/ALN.0b013e31829bd9e2; Shibuki K, 2003, J PHYSIOL-LONDON, V549, P919, DOI 10.1113/jphysiol.2003.040709; SHIR Y, 1991, PAIN, V45, P309, DOI 10.1016/0304-3959(91)90056-4; Smits H, 2006, NEUROSCIENCE, V143, P541, DOI 10.1016/j.neuroscience.2006.08.007; Smits H, 2012, PAIN, V153, P177, DOI 10.1016/j.pain.2011.10.015; Smits H, 2009, NEUROSCI LETT, V450, P70, DOI 10.1016/j.neulet.2008.11.013; Song ZY, 2011, PAIN, V152, P1666, DOI 10.1016/j.pain.2011.03.012; Takahashi K, 2006, EUR J NEUROSCI, V23, P1365, DOI 10.1111/j.1460-9568.2006.04662.x; Tohmi M, 2009, J NEUROCHEM, V109, P3, DOI 10.1111/j.1471-4159.2009.05926.x; Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012; Wang XM, 2011, J NEUROPHYSIOL, V105, P1732, DOI 10.1152/jn.00717.2010; Weber B, 2004, EUR J NEUROSCI, V20, P2664, DOI 10.1111/j.1460-9568.2004.03735.x; Woolf CJ, 2007, NEURON, V55, P353, DOI 10.1016/j.neuron.2007.07.016; Yamashita H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035676	55	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2014	9	10							e109029	10.1371/journal.pone.0109029	http://dx.doi.org/10.1371/journal.pone.0109029			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ3DZ	25279562	Green Published, gold, Green Submitted			2023-01-03	WOS:000342670800050
J	Lascar, N; Kennedy, A; Hancock, B; Jenkins, D; Andrews, RC; Greenfield, S; Narendran, P				Lascar, Nadia; Kennedy, Amy; Hancock, Beverley; Jenkins, David; Andrews, Robert C.; Greenfield, Sheila; Narendran, Parth			Attitudes and Barriers to Exercise in Adults with Type 1 Diabetes (T1DM) and How Best to Address Them: A Qualitative Study	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; PARTICIPATION; COMPLICATIONS; ASSOCIATION; MOTIVATORS; PROGRAM	Background: Regular physical activity has recognised health benefits for people with T1DM. However a significant proportion of them do not undertake the recommended levels of activity. Whilst questionnaire-based studies have examined barriers to exercise in people with T1DM, a formal qualitative analysis of these barriers has not been undertaken. Our aims were to explore attitudes, barriers and facilitators to exercise in patients with T1DM. Methodology: A purposeful sample of long standing T1DM patients were invited to participate in this qualitative study. Twenty-six adults were interviewed using a semi-structured interview schedule to determine their level of exercise and barriers to initiation and maintenance of an exercise programme. Principal findings: Six main barriers to exercise were identified: lack of time and work related factors; access to facilities; lack of motivation; embarrassment and body image; weather; and diabetes specific barriers (low levels of knowledge about managing diabetes and its complications around exercise). Four motivators to exercise were identified: physical benefits from exercise; improvements in body image; enjoyment and the social interaction of exercising at gym or in groups. Three facilitators to exercise were identified: free or reduced admission to gyms and pools, help with time management, and advice and encouragement around managing diabetes for exercise. Significance: Many of the barriers to exercise in people with T1DM are shared with the non-diabetic population. The primary difference is the requirement for education about the effect of exercise on diabetes control and its complications. There was a preference for support to be given on a one to one basis rather than in a group environment. This suggests that with the addition of the above educational requirements, one to one techniques that have been successful in increasing activity in patients with other chronic disease and the general public should be successful in increasing activity in patients with T1DM.	[Lascar, Nadia; Kennedy, Amy; Narendran, Parth] Univ Birmingham, Sch Clin & Expt Med, Birmingham, W Midlands, England; [Lascar, Nadia; Kennedy, Amy; Jenkins, David; Narendran, Parth] Queen Elizabeth Hosp, Dept Diabet, Birmingham B15 2TH, W Midlands, England; [Hancock, Beverley; Andrews, Robert C.] Univ Bristol, Sch Clin Sci, Bristol, Avon, England; [Greenfield, Sheila] Univ Birmingham, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; University of Bristol; University of Birmingham	Narendran, P (corresponding author), Univ Birmingham, Sch Clin & Expt Med, Birmingham, W Midlands, England.	p.narendran@bham.ac.uk		andrews, robert/0000-0003-4939-1738; Narendran, Parth/0000-0002-4583-8793	Insulin Dependent Diabetes Trust; University of Birmingham, United Kingdom; National Institute for Health Research [PB-PG-0609-19093] Funding Source: researchfish	Insulin Dependent Diabetes Trust; University of Birmingham, United Kingdom; National Institute for Health Research(National Institute for Health Research (NIHR))	The study was funded by the Insulin Dependent Diabetes Trust (http://iddt.org/). PN received the funding. The study was funded for 9,600 pound. The study was sponsored by The University of Birmingham, United Kingdom. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2003, ADHERENCE LONG TERM; Atkinson MA, 2014, LANCET, V383, P69, DOI 10.1016/S0140-6736(13)60591-7; Biedenweg K, 2014, J PRIM PREV, V35, P1, DOI 10.1007/s10935-013-0331-2; Booth AO, 2013, PRIM HEALTH CARE RES, V14, P293, DOI 10.1017/S1463423612000412; Brazeau AS, 2008, DIABETES CARE, V31, P2108, DOI 10.2337/dc08-0720; Brunet J, 2013, DISABIL REHABIL, V35, P2038, DOI 10.3109/09638288.2013.802378; Casey D, 2010, DIABETIC MED, V27, P79, DOI 10.1111/j.1464-5491.2009.02873.x; Chimen M, 2012, DIABETOLOGIA, V55, P542, DOI 10.1007/s00125-011-2403-2; Donahue Katrina E, 2006, Prev Chronic Dis, V3, pA119; Dube MC, 2006, DIABETES RES CLIN PR, V72, P20, DOI 10.1016/j.diabres.2005.08.008; Egan AM, 2013, QJM-INT J MED, V106, P635, DOI 10.1093/qjmed/hct075; Justine M, 2013, SINGAP MED J, V54, P581, DOI 10.11622/smedj.2013203; Korkiakangas EE, 2011, SCAND J CARING SCI, V25, P62, DOI 10.1111/j.1471-6712.2010.00791.x; Lilienthal KR, 2013, J AGING PHYS ACT; Makura CBT, 2013, BMC ENDOCR DISORD, V13, DOI 10.1186/1472-6823-13-37; Malone LA, 2012, DISABIL HEALTH J, V5, P254, DOI 10.1016/j.dhjo.2012.05.004; Mulligan H, 2013, J NEUROL PHYS THER, V37, P51, DOI 10.1097/NPT.0b013e318292799e; Peyrot M, 2006, DIABETOLOGIA, V49, P279, DOI 10.1007/s00125-005-0048-8; Ritchie J, 2002, ANAL QUALITATIVE DAT, P187; Roberts SH, 2011, J ADV NURS, V67, P690, DOI 10.1111/j.1365-2648.2010.05546.x; Ryden L, 2007, EUR HEART J, V28, P88, DOI [10.1093/eurheartj/ehl260, 10.1093/eurheartj/ehm124]; Sigal RJ, 2010, DIABETES CARE, V33, P147, DOI DOI 10.2337/DC10-9990; Slade SC, 2013, CLIN J PAIN; Thomas N, 2004, POSTGRAD MED J, V80, P287, DOI 10.1136/pgmj.2003.010553; Tielemans SMAJ, 2013, DIABETOLOGIA, V56, P82, DOI 10.1007/s00125-012-2743-6; Tse MMY, 2013, J CLIN NURS, V22, P1843, DOI 10.1111/j.1365-2702.2012.04317.x; Waden J, 2008, DIABETES CARE, V31, P230, DOI 10.2337/dc07-1238	27	82	82	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2014	9	9							e108019	10.1371/journal.pone.0108019	http://dx.doi.org/10.1371/journal.pone.0108019			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AQ0RY	25237905	Green Submitted, Green Published, gold			2023-01-03	WOS:000342491600076
J	Yawn, BP; Buchanan, GR; Afenyi-Annan, AN; Ballas, SK; Hassell, KL; James, AH; Jordan, L; Lanzkron, SM; Lottenberg, R; Savage, WJ; Tanabe, PJ; Ware, RE; Murad, MH; Goldsmith, JC; Ortiz, E; Fulwood, R; Horton, A; John-Sowah, J				Yawn, Barbara P.; Buchanan, George R.; Afenyi-Annan, Araba N.; Ballas, Samir K.; Hassell, Kathryn L.; James, Andra H.; Jordan, Lanetta; Lanzkron, Sophie M.; Lottenberg, Richard; Savage, William J.; Tanabe, Paula J.; Ware, Russell E.; Murad, M. Hassan; Goldsmith, Jonathan C.; Ortiz, Eduardo; Fulwood, Robinson; Horton, Ann; John-Sowah, Joylene			Management of Sickle Cell Disease Summary of the 2014 Evidence-Based Report by Expert Panel Members	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ACUTE CHEST SYNDROME; PULMONARY-HYPERTENSION; ADVISORY-COMMITTEE; CONTROLLED-TRIAL; HYDROXYUREA; CHILDREN; ANEMIA; TRANSFUSION; PREVENTION; STROKE	IMPORTANCE Sickle cell disease (SCD) is a life-threatening genetic disorder affecting nearly 100 000 individuals in the United States and is associated with many acute and chronic complications requiring immediate medical attention. Two disease-modifying therapies, hydroxyurea and long-term blood transfusions, are available but underused. OBJECTIVE To support and expand the number of health professionals able and willing to provide care for persons with SCD. EVIDENCE REVIEW Databases of MEDLINE (including in-process and other nonindexed citations), EMBASE, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, CINAHL, TOXLINE, and Scopus were searched using prespecified search terms and keywords to identify randomized clinical trials, nonrandomized intervention studies, and observational studies. Literature searches of English-language publications from 1980 with updates through April 1, 2014, addressed key questions developed by the expert panel members and methodologists. FINDINGS Strong recommendations for preventive services include daily oral prophylactic penicillin up to the age of 5 years, annual transcranial Doppler examinations from the ages of 2 to 16 years in those with sickle cell anemia, and long-term transfusion therapy to prevent stroke in those children with abnormal transcranial Doppler velocity (>= 200 cm/s). Strong recommendations addressing acute complications include rapid initiation of opioids for treatment of severe pain associated with a vasoocclusive crisis, and use of incentive spirometry in patients hospitalized for a vasoocclusive crisis. Strong recommendations for chronic complications include use of analgesics and physical therapy for treatment of avascular necrosis, and use of angiotensin-converting enzyme inhibitor therapy for microalbuminuria in adults with SCD. Strong recommendations for children and adults with proliferative sickle cell retinopathy include referral to expert specialists for consideration of laser photocoagulation and for echocardiography to evaluate signs of pulmonary hypertension. Hydroxyurea therapy is strongly recommended for adults with 3 or more severe vasoocclusive crises during any 12-month period, with SCD pain or chronic anemia interfering with daily activities, or with severe or recurrent episodes of acute chest syndrome. A recommendation of moderate strength suggests offering treatment with hydroxyurea without regard to the presence of symptoms for infants, children, and adolescents. In persons with sickle cell anemia, preoperative transfusion therapy to increase hemoglobin levels to 10 g/dL is strongly recommended with a moderate strength recommendation to maintain sickle hemoglobin levels of less than 30% prior to the next transfusion during long-term transfusion therapy. A strong recommendation to assess iron overload is accompanied by a moderate strength recommendation to begin iron chelation therapy when indicated. CONCLUSIONS AND RELEVANCE Hydroxyurea and transfusion therapy are strongly recommended for many individuals with SCD. Many other recommendations are based on quality of evidence that is less than high due to the paucity of clinical trials regarding screening, management, and monitoring for individuals with SCD.	[Yawn, Barbara P.] Olmsted Med Ctr, Rochester, MN 55904 USA; [Buchanan, George R.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Afenyi-Annan, Araba N.] Univ N Carolina, Chapel Hill, NC USA; [Ballas, Samir K.] Thomas Jefferson Univ, Cardeza Fdn, Philadelphia, PA 19107 USA; [Hassell, Kathryn L.] Univ Colorado, Denver, CO 80202 USA; [James, Andra H.] Univ Virginia, Charlottesville, VA USA; [Jordan, Lanetta] Univ Miami, Miller Sch Med, Fdn Sickle Cell Dis Res, Miami, FL 33136 USA; [Lanzkron, Sophie M.] Johns Hopkins Sch Med, Baltimore, MD USA; [Lottenberg, Richard] Univ Florida, Gainesville, FL USA; [Savage, William J.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Savage, William J.] Harvard Univ, Sch Med, Boston, MA USA; [Tanabe, Paula J.] Duke Univ, Sch Nursing, Durham, NC USA; [Tanabe, Paula J.] Duke Univ, Sch Med, Durham, NC USA; [Ware, Russell E.] Cincinnati Childrens Hosp Med, Cincinnati, OH USA; [Murad, M. Hassan] Mayo Clin, Coll Med, Rochester, MN USA; [Goldsmith, Jonathan C.; Ortiz, Eduardo; Fulwood, Robinson; John-Sowah, Joylene] NHLBI, Bethesda, MD 20892 USA; [Horton, Ann] Amer Inst Res, Silver Spring, MD USA	Olmsted Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of North Carolina; University of North Carolina Chapel Hill; Jefferson University; University of Colorado System; University of Colorado Denver; University of Virginia; University of Miami; Johns Hopkins University; Johns Hopkins Medicine; State University System of Florida; University of Florida; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Duke University; Duke University; Cincinnati Children's Hospital Medical Center; Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); American Institutes for Research	Yawn, BP (corresponding author), Olmsted Med Ctr, Dept Res & Educ, 210 Ninth St SE, Rochester, MN 55904 USA.	byawn@olmmed.org	Lanzkron, Sophie/AAD-7584-2022; Al Kindi, Salam/HGD-7360-2022; Lanzkron, Sophie/AFU-9516-2022; kindi, Salam Al/Q-5172-2019; Murad, M. Hassan/AAW-4367-2020	Lanzkron, Sophie/0000-0002-2878-0251; Lanzkron, Sophie/0000-0002-2878-0251; Murad, Mohammad Hassan/0000-0001-5502-5975; James, Andra/0000-0003-4570-6595	National Heart, Lung, and Blood Institute (NHLBI)	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The National Heart, Lung, and Blood Institute (NHLBI) sponsored the development of this guideline to assist health care professionals in the management of common issues of sickle cell disease. The NHLBI established the expert panel and invited the panel members. All members served as volunteers and received no compensation from the NHLBI or any other entity for their participation.	Adams RJ, 2005, NEW ENGL J MED, V353, P2769; Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; Ahmed F, 2011, VACCINE, V29, P9171, DOI 10.1016/j.vaccine.2011.08.005; Alio Amina P, 2005, J Natl Med Assoc, V97, P792; Anderson LM, 2013, J CLIN EPIDEMIOL, V66, P1223, DOI 10.1016/j.jclinepi.2013.06.014; Smith Nicole M., 2006, Morbidity and Mortality Weekly Report, V55, P1; Ataga KI, 2000, AM J HEMATOL, V63, P205, DOI 10.1002/(SICI)1096-8652(200004)63:4<205::AID-AJH8>3.3.CO;2-#; Aygun B, 2002, TRANSFUSION, V42, P37, DOI 10.1046/j.1537-2995.2002.00007.x; Ballas SK, 2012, BLOOD, V120, P3647, DOI 10.1182/blood-2012-04-383430; Ballas SK, 2010, AM J HEMATOL, V85, P6, DOI 10.1002/ajh.21550; Ballas SK, 2005, AM J HEMATOL, V79, P17, DOI 10.1002/ajh.20336; Ballas SK, 2004, MICROCIRCULATION, V11, P209, DOI 10.1080/10739680490279410; Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; Barfield WD, 2010, AM J PREV MED, V38, pS542, DOI 10.1016/j.amepre.2009.12.020; BELLET PS, 1995, NEW ENGL J MED, V333, P699, DOI 10.1056/NEJM199509143331104; Benjamin LJ, 1999, GUIDELINE FOR THE MA; Bennett Nancy M., 2012, Morbidity and Mortality Weekly Report, V61, P816; Booth C, 2010, INT J INFECT DIS, V14, pE2, DOI 10.1016/j.ijid.2009.03.010; Brawley OW, 2008, ANN INTERN MED, V148, P932, DOI 10.7326/0003-4819-148-12-200806170-00220; Brito JP, 2013, J CLIN ENDOCR METAB, V98, P3246, DOI 10.1210/jc.2013-1814; Bunn HF, 1997, NEW ENGL J MED, V337, P762, DOI 10.1056/NEJM199709113371107; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; CHARACHE S, 1979, ARCH INTERN MED, V139, P67, DOI 10.1001/archinte.139.1.67; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Chou ST, 2013, HEMATOL-AM SOC HEMAT, P439, DOI 10.1182/asheducation-2013.1.439; Curtis Kathryn M., 2010, Morbidity and Mortality Weekly Report, V59, P1; Dampier C, 2002, J PAIN, V3, P461, DOI 10.1054/jpai.2002.128064; Danielson CFM, 2002, THER APHER, V6, P24, DOI 10.1046/j.1526-0968.2002.00396.x; DeBaun MR, 2014, NEW ENGL J MED, V371, P699, DOI 10.1056/NEJMoa1401731; Elagouz M, 2010, SURV OPHTHALMOL, V55, P359, DOI 10.1016/j.survophthal.2009.11.004; Enninful-Eghan H, 2010, J PEDIATR-US, V157, P479, DOI 10.1016/j.jpeds.2010.03.007; Farrell K, 2010, J NATL MED ASSOC, V102, P1000, DOI 10.1016/S0027-9684(15)30726-4; Flanagan JM, 2010, MUTAT RES-GEN TOX EN, V698, P38, DOI 10.1016/j.mrgentox.2010.03.001; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; Graham R, 2011, CLINICAL PRACTICE GUIDELINES WE CAN TRUST, P1; Hebbel R.P, 1994, SICKLE CELL DIS BASI; Herrick JB., 1910, ARCH INTERN MED, V6, P517, DOI [10.1001/archinte.1910.00050330050003, DOI 10.1001/ARCHINTE.1910.00050330050003]; Howard J, 2013, LANCET, V381, P930, DOI 10.1016/S0140-6736(12)61726-7; Hsieh MM, 2014, JAMA-J AM MED ASSOC, V312, P48, DOI 10.1001/jama.2014.7192; Hsieh MM, 2009, NEW ENGL J MED, V361, P2309, DOI 10.1056/NEJMoa0904971; Jacob E, 2005, J PAIN SYMPTOM MANAG, V29, P392, DOI 10.1016/j.jpainsymman.2004.07.006; Kavanagh PL, 2011, PEDIATRICS, V128, pE1552, DOI 10.1542/peds.2010-3686; King SB, 2004, FREE RADICAL BIO MED, V37, P737, DOI 10.1016/j.freeradbiomed.2004.02.073; Klings ES, 2014, AM J RESP CRIT CARE, V189, P727, DOI 10.1164/rccm.201401-0065ST; Kochanek K. D., 2011, CTR DIS CONTROL PREV, V59, P1; Lanzkron S, 2008, ANN INTERN MED, V148, P939, DOI 10.7326/0003-4819-148-12-200806170-00221; McGann PT, 2011, BRIT J HAEMATOL, V154, P134, DOI 10.1111/j.1365-2141.2011.08698.x; Miller ST, 2001, J PEDIATR-US, V139, P385, DOI 10.1067/mpd.2001.117580; MILNER PF, 1991, NEW ENGL J MED, V325, P1476, DOI 10.1056/NEJM199111213252104; MORIARTY BJ, 1988, EYE, V2, P330, DOI 10.1038/eye.1988.62; Olujohungbe AB, 2011, J ANDROL, V32, P375, DOI 10.2164/jandrol.110.010934; Parent F, 2011, NEW ENGL J MED, V365, P44, DOI 10.1056/NEJMoa1005565; Paule I, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-30; POWARS DR, 1991, ANN INTERN MED, V115, P614, DOI 10.7326/0003-4819-115-8-614; Segal Jodi B, 2008, Evid Rep Technol Assess (Full Rep), P1; Serjeant DR, 2001, SICKLE CELL DISEASE; Shea BJ, 2009, J CLIN EPIDEMIOL, V62, P1013, DOI 10.1016/j.jclinepi.2008.10.009; Sheth S, 2013, BRIT J HAEMATOL, V162, P455, DOI 10.1111/bjh.12413; Smith WR, 2008, ANN INTERN MED, V148, P94, DOI 10.7326/0003-4819-148-2-200801150-00004; Steinberg MH, 2003, JAMA-J AM MED ASSOC, V289, P1645, DOI 10.1001/jama.289.13.1645; Strouse JJ, 2008, PEDIATRICS, V122, P1332, DOI 10.1542/peds.2008-0441; Talano JAM, 2003, PEDIATRICS, V111, pE661, DOI 10.1542/peds.111.6.e661; US Centers for Disease Control and Prevention, SICKLE CELL DISEASE; Verduzco LA, 2009, BLOOD, V114, P5117, DOI 10.1182/blood-2009-05-220921; Vichinsky EP, 2000, NEW ENGL J MED, V342, P1855, DOI 10.1056/NEJM200006223422502; VICHINSKY EP, 1995, NEW ENGL J MED, V333, P206, DOI 10.1056/NEJM199507273330402; Villers MS, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.016; Voskaridou E, 2010, BLOOD, V115, P2354, DOI 10.1182/blood-2009-05-221333; Wang WC, 2013, COCHRANE DB SYST REV, V11; Wang WC, 2011, LANCET, V377, P1663, DOI 10.1016/S0140-6736(11)60355-3; Ware RE, 2004, J PEDIATR-US, V145, P346, DOI 10.1016/j.jpeds.2004.04.058; Ware RE, 2010, BLOOD, V115, P5300, DOI 10.1182/blood-2009-04-146852; Zimmerman SA, 2004, BLOOD, V103, P2039, DOI 10.1182/blood-2003-07-2475	73	838	847	2	144	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	2014	312	10					1033	1048		10.1001/jama.2014.10517	http://dx.doi.org/10.1001/jama.2014.10517			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AO5LF	25203083				2023-01-03	WOS:000341385600021
J	Yuan, FJ; Fu, X; Shi, HF; Chen, GP; Dong, P; Zhang, WY				Yuan, Fengjiao; Fu, Xiao; Shi, Hengfei; Chen, Guopu; Dong, Ping; Zhang, Weiyun			Induction of Murine Macrophage M2 Polarization by Cigarette Smoke Extract via the JAK2/STAT3 Pathway	PLOS ONE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; NITRIC-OXIDE; STAT3; ACTIVATION; PHENOTYPE; PROLIFERATION; INFLAMMATION; EXPRESSION; CELLS; IL-6	Cigarette smoking is a major pathogenic factor in lung cancer. Macrophages play an important role in host defense and adaptive immunity. These cells display diverse phenotypes for performing different functions. M2 type macrophages usually exhibit immunosuppressive and tumor-promoting characteristics. Although macrophage polarization toward the M2 phenotype has been observed in the lungs of cigarette smokers, the molecular basis of the process remains unclear. In this study, we evaluated the possible mechanisms for the polarization of mouse macrophages that are induced by cigarette smoking (CS) or cigarette smoke extract (CSE). The results showed that exposure to CSE suppressed the production of reactive oxygen species (ROS) and nitric oxide (NO) and down-regulated the phagocytic ability of Ana-1 cells. The CD163 expressions on the surface of macrophages from different sources were significantly increased in in vivo and in vitro studies. The M1 macrophage cytokines TNF-alpha, IL-12p40 and enzyme iNOS decreased in the culture supernatant, and their mRNA levels decreased depending on the time and concentration of CSE. In contrast, the M2 phenotype macrophage cytokines IL-10, IL-6, TGF-beta 1 and TGF-beta 2 were up-regulated. Moreover, phosphorylation of JAK2 and STAT3 was observed after the Ana-1 cells were treated with CSE. In addition, pretreating the Ana-1 cells with the STAT3 phosphorylation inhibitor WP1066 inhibited the CSE-induced CD163 expression, increased the mRNA level of IL-10 and significantly decreased the mRNA level of IL-12. In conclusion, we demonstrated that the M2 polarization of macrophages induced by CS could be mediated through JAK2/STAT3 pathway activation.	[Yuan, Fengjiao; Fu, Xiao; Shi, Hengfei; Chen, Guopu; Dong, Ping; Zhang, Weiyun] Nanjing Univ, Jiangsu Key Lab Mol Med, Sch Med, Nanjing 210008, Jiangsu, Peoples R China; [Fu, Xiao] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Nanjing 210008, Jiangsu, Peoples R China	Nanjing University; Nanjing University	Dong, P (corresponding author), Nanjing Univ, Jiangsu Key Lab Mol Med, Sch Med, Nanjing 210008, Jiangsu, Peoples R China.	dongping@nju.edu.cn; zhangwy@nju.edu.cn			National Nature Science Foundation of China [81273121]; State Key Laboratory of Pharmaceutical Biotechnology [KF-GN-201301]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Laboratory of Pharmaceutical Biotechnology	This study was financed by the National Nature Science Foundation of China (No. 81273121) and by State Key Laboratory of Pharmaceutical Biotechnology (KF-GN-201301). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Boonsarngsuk V, 2009, RESPIROLOGY, V14, P1060, DOI 10.1111/j.1440-1843.2009.01604.x; Chen WX, 2010, CELL IMMUNOL, V262, P69, DOI 10.1016/j.cellimm.2010.01.001; Colomiere M, 2009, BRIT J CANCER, V100, P134, DOI 10.1038/sj.bjc.6604794; Covarrubias A, 2013, CELL RES, V23, P984, DOI 10.1038/cr.2013.88; de Jonge WJ, 2005, NAT IMMUNOL, V6, P844, DOI 10.1038/ni1229; Fabriek BO, 2005, IMMUNOBIOLOGY, V210, P153, DOI 10.1016/j.imbio.2005.05.010; Fielding CA, 2008, J IMMUNOL, V181, P2189, DOI 10.4049/jimmunol.181.3.2189; Fujiwara Y, 2011, ONCOL REP, V26, P1533, DOI 10.3892/or.2011.1454; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Hao NB, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/948098; Hasita H, 2010, CANCER SCI, V101, P1913, DOI 10.1111/j.1349-7006.2010.01614.x; Hodge S, 2011, AM J RESP CELL MOL, V44, P673, DOI 10.1165/rcmb.2009-0459OC; Isomoto H, 2009, DIGESTION, V79, P2, DOI 10.1159/000167859; Jyrkkio Sirkku, 2012, Duodecim, V128, P1081; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kunz LIZ, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-34; Lin HY, 2013, BRIT J CANCER, V109, P731, DOI 10.1038/bjc.2013.349; Looyenga BD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030820; Luo YP, 2010, ONCOGENE, V29, P662, DOI 10.1038/onc.2009.308; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mann CJ, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-21; Mantovani A, 2003, TUMORI J, V89, P459, DOI 10.1177/030089160308900501; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Matsukawa A, 2005, J IMMUNOL, V175, P3354, DOI 10.4049/jimmunol.175.5.3354; Matsukawa A, 2003, J IMMUNOL, V171, P6198, DOI 10.4049/jimmunol.171.11.6198; Mikko S, 2012, J GASTROEN HEPATOL, V27, P135, DOI 10.1111/j.1440-1746.2012.07017.x; Ohri CM, 2009, EUR RESPIR J, V33, P118, DOI 10.1183/09031936.00065708; Ruhrberg C, 2010, NAT MED, V16, P861, DOI 10.1038/nm0810-861; Satarug S, 2012, CURR DRUG METAB, V13, P257, DOI 10.2174/138920012799320446; Shapiro SD, 1999, AM J RESP CRIT CARE, V160, pS29, DOI 10.1164/ajrccm.160.supplement_1.9; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Sierra-Filardi E, 2010, IMMUNOBIOLOGY, V215, P788, DOI 10.1016/j.imbio.2010.05.020; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Wang HC, 2011, MOL ENDOCRINOL, V25, P1145, DOI 10.1210/me.2010-0495; Wang K, 2012, AM J CHINESE MED, V40, P521, DOI 10.1142/S0192415X12500401; Wittel UA, 2012, INT J ONCOL, V41, P5, DOI 10.3892/ijo.2012.1414; Yu ZY, 2002, BIOCHEM J, V367, P97, DOI 10.1042/BJ20020588; Yuan FJ, 2013, EXP TOXICOL PATHOL, V65, P1011, DOI 10.1016/j.etp.2013.02.004; Zhao X, 2012, ASIAN PAC J CANCER P, V13, P2873, DOI 10.7314/APJCP.2012.13.6.2873	41	61	65	2	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2014	9	9							e107063	10.1371/journal.pone.0107063	http://dx.doi.org/10.1371/journal.pone.0107063			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4JX	25198511	gold, Green Submitted, Green Published			2023-01-03	WOS:000341304700080
J	Chen, Q; Liu, XF; Zheng, PS				Chen, Qing; Liu, Xiao-Fang; Zheng, Peng-Sheng			Grape Seed Proanthocyanidins (GSPs) Inhibit the Growth of Cervical Cancer by Inducing Apoptosis Mediated by the Mitochondrial Pathway	PLOS ONE			English	Article							IN-VIVO GROWTH; ANTICANCER PROPERTIES; DIETARY POLYPHENOLS; COLORECTAL-CANCER; CARCINOMA-CELLS; BAX; BCL-2; EXTRACT; P53; MODULATION	Grape seed proanthocyanidins (GSPs), a biologically active component of grape seeds, have been reported to possess a wide array of pharmacological and biochemical properties. Recently, the inhibitory effects of GSPs on various cancers have been reported, but their effects on cervical cancer remain unclear. Here, we explored the effect of GSPs on cervical cancer using in vitro and in vivo models. In vitro, the treatment of HeLa and SiHa cells with GSPs resulted in a significant inhibition of cell viability. Further investigation indicated that GSPs led to the dose-dependent induction of apoptosis in cancer cells. The underlying mechanism was associated with increased expression of the pro-apoptotic protein Bak-1, decreased expression of the anti-apoptotic protein Bcl-2, the loss of mitochondrial membrane potential, and the activation of caspase-3, suggesting that GSPs induced cervical cancer cell apoptosis through the mitochondrial pathway. In addition, the administration of GSPs (0.1%, 0.2%, and 0.4%, w/v) as a supplement in drinking water significantly inhibited the tumor growth of HeLa and SiHa cells in athymic nude mice, and the number of apoptotic cells in those tumors was also increased significantly. Taken together, our studies demonstrated that GSPs could inhibit the growth of cervical cancer by inducing apoptosis through the mitochondrial pathway, which provides evidence indicating that GSPs may be a potential chemopreventive and/or chemotherapeutic agent for cervical cancer.	[Chen, Qing; Liu, Xiao-Fang; Zheng, Peng-Sheng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Reprod Med, Xian 710049, Peoples R China; [Chen, Qing; Zheng, Peng-Sheng] Xi An Jiao Tong Univ, Coll Med, Dept Biochem & Mol Biol, Xian 710049, Peoples R China; [Liu, Xiao-Fang] Xi An Jiao Tong Univ, Coll Med, Dept Pharmacol, Xian 710049, Peoples R China; [Zheng, Peng-Sheng] Minist Educ Peoples Republ China, Key Lab Environm & Genes Related Dis, Sect Canc Res, Xian, Peoples R China	Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong University; Ministry of Education, China	Zheng, PS (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Reprod Med, Xian 710049, Peoples R China.	zpsheng@mail.xjtu.edu.cn			National Natural Science Fund for Distinguished Young Scientists [30725043]; National Natural Science Foundation of China [31201118, 81270715]	National Natural Science Fund for Distinguished Young Scientists(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The work was supported by a grant from the National Natural Science Fund for Distinguished Young Scientists (No. 30725043), a general grant (No. 81270715) and a youth grant (No. 31201118) from the National Natural Science Foundation of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akhtar S, 2009, CLIN CANCER RES, V15, P821, DOI 10.1158/1078-0432.CCR-08-1901; Bagchi DB, 2003, MUTAT RES-FUND MOL M, V523, P87, DOI 10.1016/S0027-5107(02)00324-X; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Dinicola S, 2012, INT J MOL SCI, V13, P651, DOI 10.3390/ijms13010651; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fresco P, 2010, CURR PHARM DESIGN, V16, P114, DOI 10.2174/138161210789941856; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Isitor GN, 2012, W INDIAN VET J, V9, P27; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kaur M, 2008, NUTR CANCER, V60, P2, DOI 10.1080/01635580802381295; Kaur M, 2006, CLIN CANCER RES, V12, P6194, DOI 10.1158/1078-0432.CCR-06-1465; Kitamura Y, 1998, BRAIN RES, V780, P260, DOI 10.1016/S0006-8993(97)01202-X; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lamoral-Theys D, 2010, CURR MED CHEM, V17, P812, DOI 10.2174/092986710790712183; Mantena SK, 2006, CARCINOGENESIS, V27, P1682, DOI 10.1093/carcin/bgl030; Mathew A, 2009, ASIAN PAC J CANCER P, V10, P645; Mittal A, 2003, CARCINOGENESIS, V24, P1379, DOI 10.1093/carcin/bgg095; Nandakumar V, 2008, CANCER LETT, V269, P378, DOI 10.1016/j.canlet.2008.03.049; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pandey KB, 2009, CURR NUTR FOOD SCI, V5, P249, DOI 10.2174/157340109790218058; Prasad R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046404; Prasad R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043064; Riboli E, 2003, AM J CLIN NUTR, V78, p559S, DOI 10.1093/ajcn/78.3.559S; Rossi M, 2010, CANCER CAUSE CONTROL, V21, P243, DOI 10.1007/s10552-009-9455-3; Roy AM, 2005, NEOPLASIA, V7, P24, DOI 10.1593/neo.04412; Roy AM, 2005, MOL CANCER THER, V4, P81; Saavedra K, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-13; Sharma SD, 2010, MOL CANCER THER, V9, P569, DOI 10.1158/1535-7163.MCT-09-0638; Singh T, 2011, PLOS ONE, V6; Tan J, 2005, CANCER RES, V65, P9012, DOI 10.1158/0008-5472.CAN-05-1226; Vayalil PK, 2004, CARCINOGENESIS, V25, P987, DOI 10.1093/carcin/bgh095; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Ye X, 1999, MOL CELL BIOCHEM, V196, P99, DOI 10.1023/A:1006926414683; Zhang Y, 2010, CANCER-AM CANCER SOC, V116, P5207, DOI 10.1002/cncr.25449	35	29	31	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2014	9	9							e107045	10.1371/journal.pone.0107045	http://dx.doi.org/10.1371/journal.pone.0107045			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO3XV	25187959	Green Published, Green Submitted, gold			2023-01-03	WOS:000341271500113
J	Hammon, M; Kunz, B; Dinzl, V; Kammerer, FJ; Schwab, SA; Bogdan, C; Uder, M; Schlechtweg, PM				Hammon, Matthias; Kunz, Bernd; Dinzl, Veronika; Kammerer, Ferdinand J.; Schwab, Siegfried A.; Bogdan, Christian; Uder, Michael; Schlechtweg, Philipp M.			Practicability of Hygienic Wrapping of Touchscreen Operated Mobile Devices in a Clinical Setting	PLOS ONE			English	Article							CONTAMINATION; IPAD; DISINFECTION; SURVIVAL; CONTACT	Background: To prove effectiveness of wrapping tablet computers in order to reduce microbiological contamination and to evaluate whether a plastic bag-covered tablet leads to impaired user satisfaction or touchscreen functionality. Materials and Methods: Within a period of 11 days 115 patients were provided with a tablet computer while waiting for their magnetic resonance imaging examination. Every day the contamination of the surface of the tablet was determined before the first and after the final use. Before the device was handed over to a patient, it was enclosed in a customized single-use plastic bag, which was analyzed for bacterial contamination after each use. A questionnaire was applied to determine whether the plastic bag impairs the user satisfaction and the functionality of the touchscreen. Results: Following the use by patients the outside of the plastic bags was found to be contaminated with various bacteria (657.5 +/- 368.5 colony forming units/day); some of them were potentially pathogenic. In contrast, the plastic bag covered surface of the tablet was significantly less contaminated (1.7 +/- 1.9 colony forming units/day). Likewise, unused plastic bags did not show any contamination. 11% of the patients reported problems with the functionality of the touchscreen. These patients admitted that they had never used a tablet or a smartphone before. Conclusions: Tablets get severely contaminated during usage in a clinical setting. Wrapping with a customized single-use plastic bag significantly reduces microbiological contamination of the device, protects patients from the acquisition of potentially pathogenic bacteria and hardly impairs the user satisfaction and the functionality of the touchscreen.	[Hammon, Matthias; Dinzl, Veronika; Kammerer, Ferdinand J.; Schwab, Siegfried A.; Uder, Michael; Schlechtweg, Philipp M.] Univ Hosp Erlangen, Dept Radiol, Erlangen, Bavaria, Germany; [Kunz, Bernd; Bogdan, Christian] Univ Erlangen Nurnberg, Mikrobiol Inst Klin Mikrobiol Immunol & Hyg, D-91054 Erlangen, Bavaria, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg	Hammon, M (corresponding author), Univ Hosp Erlangen, Dept Radiol, Erlangen, Bavaria, Germany.	matthias.hammon@uk-erlangen.de		Bogdan, Christian/0000-0002-2300-0631				Albrecht UV, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2643; Andersen P, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1221; Apple Inc, IPAD US GUID; Apple Inc, CLEAN APPL PROD; Barker J, 2004, J HOSP INFECT, V58, P42, DOI 10.1016/j.jhin.2004.04.021; Beer D, 2006, PEDIATR INFECT DIS J, V25, P1074, DOI 10.1097/01.inf.0000242649.27400.94; Boyce JM, 1997, INFECT CONT HOSP EP, V18, P622; Brady RRW, 2009, J HOSP INFECT, V71, P295, DOI 10.1016/j.jhin.2008.12.009; Bures S, 2000, AM J INFECT CONTROL, V28, P465, DOI 10.1067/mic.2000.107267; Catalano M, 1999, J HOSP INFECT, V42, P27, DOI 10.1053/jhin.1998.0535; Howell V, 2014, J HOSP INFECT, V87, P77, DOI 10.1016/j.jhin.2014.01.012; Kampf G, 2004, CLIN MICROBIOL REV, V17, P863, DOI 10.1128/CMR.17.4.863-893.2004; Kiedrowski LM, 2013, AM J INFECT CONTROL, V41, P1136, DOI 10.1016/j.ajic.2013.01.030; Manning ML, 2013, AM J INFECT CONTROL, V41, P1073, DOI 10.1016/j.ajic.2013.03.304; MBITHI JN, 1992, J CLIN MICROBIOL, V30, P757, DOI 10.1128/JCM.30.4.757-763.1992; Schlechtweg PM, 2013, J DIGIT IMAGING, V26, P383, DOI 10.1007/s10278-012-9560-9; Schroeder A, 2009, J FAM PRACTICE, V58, P404; Sclafani J, 2013, J MED SYST, V37, DOI 10.1007/s10916-012-9903-6; von Rheinbaben F, 2000, J HOSP INFECT, V46, P61; Wang J, 2012, SEMIN CUTAN MED SURG, V31, P200, DOI 10.1016/j.sder.2012.06.007	20	8	8	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2014	9	9							e106445	10.1371/journal.pone.0106445	http://dx.doi.org/10.1371/journal.pone.0106445			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO3LR	25180580	Green Submitted, Green Published, gold			2023-01-03	WOS:000341231500099
J	Santman-Berends, I; Luttikholt, S; Van den Brom, R; Van Schaik, G; Gonggrijp, M; Hage, H; Vellema, P				Santman-Berends, Inge; Luttikholt, Saskia; Van den Brom, Rene; Van Schaik, Gerdien; Gonggrijp, Maaike; Hage, Han; Vellema, Piet			Estimation of the Use of Antibiotics in the Small Ruminant Industry in the Netherlands in 2011 and 2012	PLOS ONE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; ANTIMICROBIAL USE; DRUG-USE; SHEEP; PREVALENCE; ONTARIO; HEALTH; USAGE; HERDS	The aim of this study was to estimate the quantity of antibiotics and classes of antibiotics used in the small ruminant industry in the Netherlands in 2011 and 2012. Twelve large veterinary practices, located throughout the Netherlands were selected for this study. All small ruminant farms associated with these practices that had complete records on the quantity of antibiotics prescribed were included. The veterinary practices provided data on all antibiotics prescribed, and the estimated animal used daily dose of antibiotics per year (AUDD/Y) was calculated for each farm. The median AUDD/Y in small ruminant farms was zero in both years (mean 0.60 in 2011, and 0.62 in 2012). The largest quantity of antibiotic use was observed in the professional goat industry (herds of >= 32 goats) with a median AUDD/Y of 1.22 in 2011 and 0.73 in 2012. In the professional sheep industry (flocks of >= 32 sheep), the median AUDD/Y was 0 in 2011 and 0.10 in 2012. In the small scale industry (flocks or herds of <32 sheep or goats), the median AUDD/Y never exceeded 0. The most frequently prescribed antibiotics in the small scale industry and professional sheep farms belonged to the penicillin class. In professional goat farms, antibiotics of the aminoglycoside class were most frequently prescribed. This study provides the first assessment on the quantity of antibiotic use in the small ruminant industry. Given a comparable attitude towards antibiotic use, these results might be valid for small ruminant populations in other north-western European countries as well. The antibiotic use in the small ruminant industry appeared to be low, and is expected to play a minor role in the development of antibiotic resistance. Nevertheless, several major zoonotic bacterial pathogens are associated with the small ruminant industry, and it remains important that antibiotics are used in a prudent way.	[Santman-Berends, Inge; Van Schaik, Gerdien; Gonggrijp, Maaike] GD Anim Hlth, Dept Epidemiol, Deventer, Netherlands; [Luttikholt, Saskia; Van den Brom, Rene; Vellema, Piet] GD Anim Hlth, Dept Small Ruminant Hlth, Deventer, Netherlands; [Hage, Han] GD Anim Hlth, Dept Cattle Hlth, Deventer, Netherlands		Santman-Berends, I (corresponding author), GD Anim Hlth, Dept Epidemiol, Deventer, Netherlands.	i.santman@gddiergezondheid.nl	van Schaik, Gerdien/AAD-7771-2020	van Schaik, Gerdien/0000-0002-0460-2629	Dutch Ministry of Economic affairs	Dutch Ministry of Economic affairs(Ministry of Economic Affairs, Netherlands)	This study was funded by the Dutch Ministry of Economic affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Avery BP, 2008, CAN J VET RES, V72, P137; Callens B, 2012, PREV VET MED, V106, P53, DOI 10.1016/j.prevetmed.2012.03.001; de Neeling AJ, 2007, VET MICROBIOL, V122, P366, DOI 10.1016/j.vetmic.2007.01.027; Graveland H, 2011, INT J MED MICROBIOL, V301, P630, DOI 10.1016/j.ijmm.2011.09.004; Hendriksen RS, 2008, ACTA VET SCAND, V50, DOI 10.1186/1751-0147-50-28; Krol DJ, 2007, INVENTARISATION SMAL; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; LNV, 2008, CONV RED ANT RES LIV; MARAN, 2013, MON ANT RES ANT US A; Moon CS, 2010, CAN VET J, V51, P1373; Pardon B, 2012, J ANTIMICROB CHEMOTH, V67, P1027, DOI 10.1093/jac/dkr570; Persoons D, 2012, PREV VET MED, V105, P320, DOI 10.1016/j.prevetmed.2012.02.020; Santman-Berends I.M.G.A., 2013, DATA ANAL SMALL RUMI; Sawant AA, 2005, J DAIRY SCI, V88, P2991, DOI 10.3168/jds.S0022-0302(05)72979-9; Scott L, 2012, CAN J VET RES, V76, P109; Scott LC, 2011, VET CLIN N AM-FOOD A, V27, P23, DOI 10.1016/j.cvfa.2010.10.015; SDA, 2013, US ANT LIV SPEC 2012; Silbergeld EK, 2008, ANNU REV PUBL HEALTH, V29, P151, DOI 10.1146/annurev.publhealth.29.020907.090904; Stata Corporation, 2013, STAT SOFTW VERS 13; Tacconelli E, 2009, CURR OPIN INFECT DIS, V22, P352, DOI 10.1097/QCO.0b013e32832d52e0; Ungemach FR, 2006, INT J MED MICROBIOL, V296, P33, DOI 10.1016/j.ijmm.2006.01.059; Van den Brom R, 2013, PREV VET MED, V109, P76, DOI 10.1016/j.prevetmed.2012.09.002; Vieira AR, 2011, EPIDEMIOL INFECT, V139, P1601, DOI 10.1017/S0950268810002724	23	11	12	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2014	9	8							e105052	10.1371/journal.pone.0105052	http://dx.doi.org/10.1371/journal.pone.0105052			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO3LJ	25115998	gold, Green Submitted, Green Published			2023-01-03	WOS:000341230400117
J	Jung, YR; Kim, DH; Kim, SR; An, HJ; Lee, EK; Tanaka, T; Kim, ND; Yokozawa, T; Park, JN; Chung, HY				Jung, Yu Ri; Kim, Dae Hyun; Kim, So Ra; An, Hye Jin; Lee, Eun Kyeong; Tanaka, Takashi; Kim, Nam Deuk; Yokozawa, Takako; Park, Jin Nam; Chung, Hae Young			Anti-Wrinkle Effect of Magnesium Lithospermate B from Salvia miltiorrhiza BUNGE: Inhibition of MMPs via NF-kB Signaling	PLOS ONE			English	Article							MATRIX METALLOPROTEINASES; COX-2 EXPRESSION; KAPPA-B; SKIN; CONTRIBUTES; IRRADIATION; PROTEIN	Skin is in direct contact with the environment and therefore undergoes aging as a consequence of environmentally induce damage. Wrinkle formation is a striking feature of intrinsic and photo-induced skin aging, which are both associated with oxidative stress and inflammatory response. The present study was undertaken to identify the mechanisms responsible for the anti-wrinkle effects of MLB, and thus, we investigated whether magnesium lithospermate B (MLB) from Salvia miltiorrhiza BUNGE associated with wrinkle formation caused by intrinsic and extrinsic skin aging using Sprague-Dawley rats aged 5 and 20 months and ultraviolet B (UVB)-irradiated human skin fibroblasts cells, respectively. The results obtained showed that the oral administration of MLB significantly upregulated the level of type I procollagen and downregulated the activities and expressions of matrix-metalloproteinases (MMPs) in rat skin. In fibroblasts, MLB suppressed the transactivation of nuclear factor-kB (NF-kB) and activator protein 1(AP-1), which are the two transcription factors responsible for MMP expression, by suppressing oxidative stress and the mitogen activated protein kinase (MAPK) pathway. Our results show that the antioxidant effect of MLB is due to the direct scavenging of reactive oxygen species (ROS) and its inhibitory effects on NF-kB-dependent inflammation genes, such as, cyclooxygenase-2 and inducible nitric oxide synthase. MLB was found to reverse both age- and UVB-related reductions in skin procollagen levels by suppressing the expressions and activities of NFkB and AP-1-dependent MMPs by modulating ROS generation and the MAPK signaling pathway. We suggest that MLB potentially has anti-wrinkle and anti-skin aging effects.	[Jung, Yu Ri; Kim, Dae Hyun; Kim, So Ra; An, Hye Jin; Lee, Eun Kyeong; Kim, Nam Deuk; Chung, Hae Young] Pusan Natl Univ, Coll Pharm, Mol Inflammat Res Ctr Aging Intervent MRCA, Pusan, South Korea; [Yokozawa, Takako] Toyama Univ, Grad Sch Sci & Engn Res, Toyama 930, Japan; [Tanaka, Takashi] Nagasaki Univ, Fac Pharmaceut Sci, Nagasaki 852, Japan; [Park, Jin Nam] DrSkin, Pusan, South Korea	Pusan National University; University of Toyama; Nagasaki University	Chung, HY (corresponding author), Pusan Natl Univ, Coll Pharm, Mol Inflammat Res Ctr Aging Intervent MRCA, Pusan, South Korea.	hyjung@pusan.ac.kr		Tanaka, Takashi/0000-0001-7762-7432	Cooperative Research Program for Agriculture Science & Technology Development, Rural Development Administration, Republic of Korea [PJ006522132013]; National Research Foundation of Korea (NRF) grant - Korea government (MSIP) [2009-0083538]	Cooperative Research Program for Agriculture Science & Technology Development, Rural Development Administration, Republic of Korea(Rural Development Administration (RDA), Republic of Korea); National Research Foundation of Korea (NRF) grant - Korea government (MSIP)	This work was carried out with the support of "Cooperative Research Program for Agriculture Science & Technology Development (Project No. PJ006522132013)" Rural Development Administration, Republic of Korea. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2009-0083538). The authors also take this opportunity to thank the Aging Tissue Bank (Busan, Korea) for supplying research materials. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bohm M, 1999, ANN NY ACAD SCI, V885, P277; Brenneisen P, 2002, ANN NY ACAD SCI, V973, P31, DOI 10.1111/j.1749-6632.2002.tb04602.x; Chung JH, 2001, J INVEST DERMATOL, V117, P1218, DOI 10.1046/j.0022-202x.2001.01544.x; Egbert M, 2014, J DERMATOL SCI, V73, P40, DOI 10.1016/j.jdermsci.2013.08.010; Farage M. A., 2008, International Journal of Cosmetic Science, V30, P87, DOI 10.1111/j.1468-2494.2007.00415.x; Fisher GJ, 2002, ARCH DERMATOL, V138, P1462, DOI 10.1001/archderm.138.11.1462; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Fisher GJ, 2001, J INVEST DERMATOL, V117, P219, DOI 10.1046/j.0022-202x.2001.01432.x; HABIB A, 1993, J BIOL CHEM, V268, P23448; Halliday GA, 2005, MUTAT RES-FUND MOL M, V571, P107, DOI 10.1016/j.mrfmmm.2004.09.013; Helfrich Yolanda Rosi, 2008, Dermatol Nurs, V20, P177; Khan AQ, 2012, FOOD CHEM TOXICOL, V50, P175, DOI 10.1016/j.fct.2011.10.043; Kim JK, 2007, FREE RADICAL RES, V41, P603, DOI 10.1080/10715760701209896; Kim SR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073877; Mehta PK, 2007, AM J PHYSIOL-CELL PH, V292, pC82, DOI 10.1152/ajpcell.00287.2006; ONITSUKA M, 1983, CHEM PHARM BULL, V31, P1670; Park JE, 2014, PHOTODERMAT IN PRESS; Quan TH, 2009, J INVEST DERM SYMP P, V14, P20, DOI 10.1038/jidsymp.2009.8; Richard SF, 2013, HEPATOLOGY, V57, P1838; Rittie L, 2002, AGEING RES REV, V1, P705, DOI 10.1016/S1568-1637(02)00024-7; Soung DY, 2003, J PHARM PHARMACOL, V55, P1427, DOI 10.1211/0022357021891; Taddese S, 2010, BBA-PROTEINS PROTEOM, V1804, P731, DOI 10.1016/j.bbapap.2009.11.014; TALWAR HS, 1995, J INVEST DERMATOL, V105, P285, DOI 10.1111/1523-1747.ep12318471; TANAKA T, 1989, CHEM PHARM BULL, V37, P340; Tang S, 2013, J DERMATOL SCI, V70, P42, DOI 10.1016/j.jdermsci.2013.01.008; Tang W, 1992, CHINESE DRUGS PLANT, P891; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; YOKOZAWA T, 1990, J NAT PROD, V53, P662, DOI 10.1021/np50069a019	28	34	35	0	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2014	9	8							e102689	10.1371/journal.pone.0102689	http://dx.doi.org/10.1371/journal.pone.0102689			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6SM	25099178	gold, Green Published, Green Submitted			2023-01-03	WOS:000339995100010
J	Li, Q; Yan, H; Liu, WT; Zhen, HC; Yang, YF; Cao, BW				Li, Qin; Yan, Han; Liu, Wenting; Zhen, Hongchao; Yang, Yifan; Cao, Bangwei			Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials	PLOS ONE			English	Article							PHASE-II TRIAL; PLUS CAPECITABINE; ONCOLOGY-GROUP; S-1; MULTICENTER; SURVIVAL; ADENOCARCINOMA; CHEMOTHERAPY; 5-FU	Background: Gemcitabine (GEM) is the standard first-line chemotherapy that provides limited clinical benefits for patients with locally advanced/metastatic pancreatic adenocarcinoma (LA/MPC). However, the fluorouracil derivatives (CAP and S-1) show promising efficacy in these patients. This study compared the efficacy and safety of GEM with GEM plus fluorouracil drugs in the treatment of LA/MPC. Methods: Pubmed, EMBASE and Cochrane Library databases were searched for relevant randomized controlled trials published on or before January 2014. The Cochrane Collaboration's tool was used to assess the risk of bias in randomized trials. The primary end point was overall survival (OS); the secondary end points were one-year survival rate, objective response rate (ORR) and toxicity rates (TRs). Results: A total of 8 randomized controlled trials involving 2,126 patients were included in the systematic evaluation. The results showed that OS was significantly improved (HR 0.83, P<0.01; HR 0.87, P=0.03; HR 0.80, P=0.01; respectively) and ORR was significantly increased (OR 0.51, P<0.01; OR 0.66, P=0.03; OR 0.35, P<0.01; respectively) in the GEM+5-FU/CAP/S-1, GEM+CAP and GEM+S-1 groups compared to the GEM alone group. In addition, the one-year survival rate was significantly increased (OR 0.78 P=0.01; OR 0.47, P=0.04; respectively) in the GEM+5-FU/CAP/S-1 and GEM+S-1 groups compared to the GEM alone group. The frequency of grade 3/4 TRs were higher in GEM+5-FU/CAP/S-1 group, the significant increase of grade 3/4 neutropenia, thrombocytopenia and diarrhea were observed. Conclusions: GEM combined with fluorouracil drugs significantly improved OS and increased one-year survival rate and ORR compared to GEM alone in LA/MPC patients. GEM combined with fluorouracil drugs may be considered as an acceptable alternative treatment for LA/MPC patients.	[Li, Qin; Yan, Han; Liu, Wenting; Zhen, Hongchao; Yang, Yifan; Cao, Bangwei] Capital Med Univ, Beijing Friendship Hosp, Dept Oncol, Beijing, Peoples R China; [Liu, Wenting; Zhen, Hongchao; Yang, Yifan; Cao, Bangwei] Capital Med Univ, Beijing Friendship Hosp, Beijing Key Lab Precancerous Lesion Digest Dis, Beijing, Peoples R China; [Liu, Wenting; Zhen, Hongchao; Yang, Yifan; Cao, Bangwei] Capital Med Univ, Beijing Friendship Hosp, Beijing Digest Dis Ctr, Beijing, Peoples R China	Capital Medical University; Capital Medical University; Capital Medical University	Cao, BW (corresponding author), Capital Med Univ, Beijing Friendship Hosp, Dept Oncol, Beijing, Peoples R China.	oncologychina@163.com			Beijing Municipal Health System High-level Health Person Foundation Project [2011-3-007]; National Nature Science Foundation of China [81272615, 81301912]; Capital Medical University Sciences-clinical Research Cooperation Foundation [12JL33]	Beijing Municipal Health System High-level Health Person Foundation Project; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Capital Medical University Sciences-clinical Research Cooperation Foundation	This work was supported by grants from Beijing Municipal Health System High-level Health Person Foundation Project (No. 2011-3-007 to Bangwei Cao), National Nature Science Foundation of China (No. 81272615; No. 81301912) and Capital Medical University Sciences-clinical Research Cooperation Foundation (No. 12JL33). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berlin JD, 2002, J CLIN ONCOL, V20, P3270, DOI 10.1200/JCO.2002.11.149; Bria E, 2007, CANCER-AM CANCER SOC, V110, P525, DOI 10.1002/cncr.22809; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Cartwright TH, 2002, J CLIN ONCOL, V20, P160, DOI 10.1200/JCO.20.1.160; Chau I, 2006, BRIT J CANCER, V94, P1107, DOI 10.1038/sj.bjc.6603058; Choi Jae-Hyuk, 2008, Cancer Res Treat, V40, P22, DOI 10.4143/crt.2008.40.1.22; Choi JG, 2012, CANCER RES TREAT, V44, P127, DOI 10.4143/crt.2012.44.2.127; Ciliberto D, 2013, EUR J CANCER, V49, P593, DOI 10.1016/j.ejca.2012.08.019; Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446; Di Costanzo F, 2005, BRIT J CANCER, V93, P185, DOI 10.1038/sj.bjc.6602640; Goulart BHL, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-13; Gourgou-Bourgade S, 2013, J CLIN ONCOL, V31, P23, DOI 10.1200/JCO.2012.44.4869; Herrmann R, 2007, J CLIN ONCOL, V25, P2212, DOI 10.1200/JCO.2006.09.0886; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hu J, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-11; Hubner RA, 2013, PANCREAS, V42, P511, DOI 10.1097/MPA.0b013e31826c6aee; Ling W, 2011, J CANCER RES CLIN, V137, P927, DOI 10.1007/s00432-010-0954-0; Maisey N, 2002, J CLIN ONCOL, V20, P3130, DOI 10.1200/JCO.2002.09.029; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Nakai Y, 2012, BRIT J CANCER, V106, P1934, DOI 10.1038/bjc.2012.183; Nakamura K, 2006, BRIT J CANCER, V94, P1575, DOI 10.1038/sj.bjc.6603168; Ozaka M, 2012, CANCER CHEMOTH PHARM, V69, P1197, DOI 10.1007/s00280-012-1822-1; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Saif MW, 2009, EXPERT OPIN INV DRUG, V18, P335, DOI [10.1517/13543780902729412 , 10.1517/13543780902729412]; Scheithauer W, 2003, ANN ONCOL, V14, P97, DOI 10.1093/annonc/mdg029; Shirasaka T, 2009, JPN J CLIN ONCOL, V39, P2, DOI 10.1093/jjco/hyn127; Sun C, 2012, WORLD J GASTROENTERO, V18, P4944, DOI 10.3748/wjg.v18.i35.4944; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Ueno H, 2013, J CLIN ONCOL, V31, P1640, DOI 10.1200/JCO.2012.43.3680; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Xie DR, 2006, WORLD J GASTROENTERO, V12, P6973, DOI 10.3748/wjg.v12.i43.6973; Xie DR, 2010, JPN J CLIN ONCOL, V40, P432, DOI 10.1093/jjco/hyp198	33	37	37	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2014	9	8							e104346	10.1371/journal.pone.0104346	http://dx.doi.org/10.1371/journal.pone.0104346			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO5BW	25093849	gold, Green Submitted, Green Published			2023-01-03	WOS:000341357200100
J	Osborne, LC; Monticelli, LA; Nice, TJ; Sutherland, TE; Siracusa, MC; Hepworth, MR; Tomov, VT; Kobuley, D; Tran, SV; Bittinger, K; Bailey, AG; Laughlin, AL; Boucher, JL; Wherry, EJ; Bushman, FD; Allen, JE; Virgin, HW; Artis, D				Osborne, Lisa C.; Monticelli, Laurel A.; Nice, Timothy J.; Sutherland, Tara E.; Siracusa, Mark C.; Hepworth, Matthew R.; Tomov, Vesselin T.; Kobuley, Dmytro; Tran, Sara V.; Bittinger, Kyle; Bailey, Aubrey G.; Laughlin, Alice L.; Boucher, Jean-Luc; Wherry, E. John; Bushman, Frederic D.; Allen, Judith E.; Virgin, Herbert W.; Artis, David			Virus-helminth coinfection reveals a microbiota-independent mechanism of immunomodulation	SCIENCE			English	Article							GUT MICROBIOTA; INFLAMMATION; INFECTIONS; CHITINASE; CELLS; YM1; BACTERIA; IMMUNITY; MICROFLORA; INDUCTION	The mammalian intestine is colonized by beneficial commensal bacteria and is a site of infection by pathogens, including helminth parasites. Helminths induce potent immunomodulatory effects, but whether these effects are mediated by direct regulation of host immunity or indirectly through eliciting changes in the microbiota is unknown. We tested this in the context of virus-helminth coinfection. Helminth coinfection resulted in impaired antiviral immunity and was associated with changes in the microbiota and STAT6-dependent helminth-induced alternative activation of macrophages. Notably, helminth-induced impairment of antiviral immunity was evident in germ-free mice, but neutralization of Ym1, a chitinase-like molecule that is associated with alternatively activated macrophages, could partially restore antiviral immunity. These data indicate that helminth-induced immunomodulation occurs independently of changes in the microbiota but is dependent on Ym1.	[Osborne, Lisa C.; Monticelli, Laurel A.; Siracusa, Mark C.; Hepworth, Matthew R.; Kobuley, Dmytro; Tran, Sara V.; Bittinger, Kyle; Bailey, Aubrey G.; Laughlin, Alice L.; Bushman, Frederic D.; Artis, David] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Osborne, Lisa C.; Monticelli, Laurel A.; Siracusa, Mark C.; Hepworth, Matthew R.; Kobuley, Dmytro; Tran, Sara V.; Wherry, E. John; Artis, David] Univ Penn, Inst Immunol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Nice, Timothy J.; Virgin, Herbert W.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Sutherland, Tara E.; Allen, Judith E.] Univ Edinburgh, Inst Immunol & Infect Res, Ctr Immun Infect & Evolut, Sch Biol Sci, Edinburgh EH9 3JT, Midlothian, Scotland; [Hepworth, Matthew R.; Tomov, Vesselin T.] Univ Penn, Dept Med, Perelman Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA; [Boucher, Jean-Luc] Univ Paris 05, Chim & Biochim Pharmacol & Toxicol Lab, Paris, France; [Artis, David] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Washington University (WUSTL); University of Edinburgh; University of Pennsylvania; Pennsylvania Medicine; UDICE-French Research Universities; Universite Paris Cite; University of Pennsylvania	Artis, D (corresponding author), Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA.	dartis@mail.med.upenn.edu	Bittinger, Kyle/ABG-2342-2020; Wherry, John/ABI-1280-2020; Laughlin, Alice/HIR-4050-2022; Nice, Timothy/X-9114-2019; Osborne, Lisa/K-3027-2015; Sutherland, Tara/S-1427-2019; Allen, Judith E/C-9198-2011	Nice, Timothy/0000-0002-4471-7666; Osborne, Lisa/0000-0002-7170-3235; Sutherland, Tara/0000-0001-9334-8206; Allen, Judith E/0000-0002-3829-066X; Virgin, Herbert/0000-0001-8580-7628; Artis, David/0000-0002-1753-4100; Bailey, Aubrey/0000-0002-0712-217X; Hepworth, Matthew/0000-0002-9613-7858	NIH Tetramer Core Facility [HHSN272201300006C]; University of Pennsylvania Matthew J. Ryan Veterinary Hospital Pathology Lab; NIH/National Institute of Diabetes and Digestive and Kidney Diseases Center for Molecular Studies in Digestive and Liver Diseases [P30-DK050306]; Penn Center for AIDS Research [P30-AI045008]; Abramson Cancer Center Flow Cytometry and Cell Sorting Resource Laboratory; National Cancer Institute Comprehensive Cancer Center [2-P30 CA016520]; NIH [AI061570, AI074878, AI087990, AI095466, AI095608, AI097333, AI106697, AI102942, T32-AI007532, F32-AI085828, AI083022, AI082630, K08-DK097301, 5T32A100716334]; Crohn's and Colitis Foundation of America; Burroughs Wellcome Fund Investigator in Pathogenesis of Infectious Disease Award; Edmond J. Safra Foundation/Cancer Research Institute Irvington Fellowship; Medical Research Council UK [MR/J001929/1]; Cancer Research Institute; American Cancer Society; Crohn's and Colitis Genetics Initiative grant [274415]; Broad Foundation [IBD-0357];  [R01 AI 084887]; NATIONAL CANCER INSTITUTE [P30CA016520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI102942, U01AI095608, R01AI084887, F32AI085828, U19AI083022, P30AI045008, R01AI061570, R01AI097333, R01AI095466, P01AI106697, T32AI007532, U19AI082630, R21AI087990, R01AI074878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306, K08DK097301] Funding Source: NIH RePORTER; MRC [MR/J001929/1] Funding Source: UKRI; Medical Research Council [MR/J001929/1] Funding Source: researchfish	NIH Tetramer Core Facility(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Pennsylvania Matthew J. Ryan Veterinary Hospital Pathology Lab; NIH/National Institute of Diabetes and Digestive and Kidney Diseases Center for Molecular Studies in Digestive and Liver Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Penn Center for AIDS Research; Abramson Cancer Center Flow Cytometry and Cell Sorting Resource Laboratory; National Cancer Institute Comprehensive Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Crohn's and Colitis Foundation of America; Burroughs Wellcome Fund Investigator in Pathogenesis of Infectious Disease Award; Edmond J. Safra Foundation/Cancer Research Institute Irvington Fellowship; Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research Institute; American Cancer Society(American Cancer Society); Crohn's and Colitis Genetics Initiative grant; Broad Foundation; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank members of the Artis laboratory for discussions and critical reading of the manuscript; F. Finkelman for providing anti-IL-4 clone 1D11.2; the NIH Tetramer Core Facility (contract HHSN272201300006C) for providing MHCII IA<SUP>b</SUP> tetramers; the University of Pennsylvania Matthew J. Ryan Veterinary Hospital Pathology Lab, the NIH/National Institute of Diabetes and Digestive and Kidney Diseases Center for Molecular Studies in Digestive and Liver Diseases (P30-DK050306), and its core facilities (Molecular Pathology and Imaging, Molecular Biology, Cell Culture, and Transgenic and Chimeric Mouse); the Penn Center for AIDS Research (P30-AI045008) for assistance and support; and the Abramson Cancer Center Flow Cytometry and Cell Sorting Resource Laboratory for technical advice and support. The ACC Flow Cytometry and Cell Sorting Shared Resource is partially supported by a National Cancer Institute Comprehensive Cancer Center Support grant (2-P30 CA016520). The data tabulated in this paper are reported in the main paper and in the supplementary materials. Illumina MiSeq data can be found in the National Center for Biotechnology Information Sequence Read Archive with accession number SRP043964. Research in the Artis lab is supported by the NIH (AI061570, AI074878, AI087990, AI095466, AI095608, AI097333, AI106697, and AI102942 to D. A.; T32-AI007532 to L. A. M.; and F32-AI085828 to M. C. S.), the Crohn's and Colitis Foundation of America (D. A. and M. R. H.), the Burroughs Wellcome Fund Investigator in Pathogenesis of Infectious Disease Award (D. A.), and the Edmond J. Safra Foundation/Cancer Research Institute Irvington Fellowship (L.C.O.). E. J. W. and V. T. T. are supported by NIH grants AI083022, AI082630, and K08-DK097301. T. E. S. and J. E. A. were supported by the Medical Research Council UK (MR/J001929/1). T.J.N. was supported by NIH training grant 5T32A100716334 and postdoctoral fellowships from the Cancer Research Institute and American Cancer Society. H. W. V. was supported by grant R01 AI 084887, the Crohn's and Colitis Genetics Initiative grant 274415, and the Broad Foundation grant IBD-0357. Washington University and H. W. V. receive income based on licenses for MNV technology. The authors declare no other potential conflicts of interest.	Abt MC, 2012, IMMUNITY, V37, P158, DOI 10.1016/j.immuni.2012.04.011; Allen JE, 2011, NAT REV IMMUNOL, V11, P375, DOI 10.1038/nri2992; Arora M, 2006, P NATL ACAD SCI USA, V103, P7777, DOI 10.1073/pnas.0508492103; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Bancroft AJ, 2012, TRENDS PARASITOL, V28, P93, DOI 10.1016/j.pt.2011.12.001; Benson A, 2009, CELL HOST MICROBE, V6, P187, DOI 10.1016/j.chom.2009.06.005; Broadhurst MJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003000; Chang NCA, 2001, J BIOL CHEM, V276, P17497, DOI 10.1074/jbc.M010417200; Elliott DE, 2012, ANN NY ACAD SCI, V1247, P83, DOI 10.1111/j.1749-6632.2011.06292.x; Ford AQ, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-6; Ganal SC, 2012, IMMUNITY, V37, P171, DOI 10.1016/j.immuni.2012.05.020; Hall JA, 2008, IMMUNITY, V29, P637, DOI 10.1016/j.immuni.2008.08.009; Hayes KS, 2010, SCIENCE, V328, P1391, DOI 10.1126/science.1187703; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Ichinohe T, 2011, P NATL ACAD SCI USA, V108, P5354, DOI 10.1073/pnas.1019378108; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Leung JM, 2013, INT J PARASITOL, V43, P253, DOI 10.1016/j.ijpara.2012.10.015; Li RW, 2012, INFECT IMMUN, V80, P2150, DOI 10.1128/IAI.00141-12; Littman DR, 2011, CELL HOST MICROBE, V10, P311, DOI 10.1016/j.chom.2011.10.004; Loke P'ng, 2002, BMC Immunol, V3, P7, DOI 10.1186/1471-2172-3-7; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; McSorley HJ, 2012, CLIN MICROBIOL REV, V25, P585, DOI 10.1128/CMR.05040-11; Metenou S, 2012, CURR OPIN HIV AIDS, V7, P231, DOI 10.1097/COH.0b013e3283522c3d; Nair MG, 2009, J EXP MED, V206, P937, DOI 10.1084/jem.20082048; Nair MG, 2005, INFECT IMMUN, V73, P385, DOI 10.1128/IAI.73.1.385-394.2005; Owhashi M, 2000, J BIOL CHEM, V275, P1279, DOI 10.1074/jbc.275.2.1279; Pesce JT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000393; Pesce JT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000371; Potian JA, 2011, J EXP MED, V208, P1863, DOI 10.1084/jem.20091473; Raetz M, 2013, NAT IMMUNOL, V14, P136, DOI 10.1038/ni.2508; Rausch S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074026; Reese TA, 2014, SCIENCE, V345, P573, DOI 10.1126/science.1254517; Salgame P, 2013, NAT IMMUNOL, V14, P1118, DOI 10.1038/ni.2736; Stelekati E, 2012, CELL HOST MICROBE, V12, P458, DOI 10.1016/j.chom.2012.10.001; Sutherland TE, 2009, CLIN EXP ALLERGY, V39, P943, DOI 10.1111/j.1365-2222.2009.03243.x; Vaishnava S, 2008, P NATL ACAD SCI USA, V105, P20858, DOI 10.1073/pnas.0808723105; Walk ST, 2010, INFLAMM BOWEL DIS, V16, P1841, DOI 10.1002/ibd.21299; Wobus CE, 2004, PLOS BIOL, V2, P2076, DOI 10.1371/journal.pbio.0020432; Wolff MJ, 2012, TRENDS PARASITOL, V28, P187, DOI 10.1016/j.pt.2012.02.008; Zhao J, 2013, PARASITOL RES, V112, P2689, DOI 10.1007/s00436-013-3436-x	40	186	191	2	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 1	2014	345	6196					578	582		10.1126/science.1256942	http://dx.doi.org/10.1126/science.1256942			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM2AU	25082704	Green Accepted			2023-01-03	WOS:000339651300049
J	Shaw, RJ; McDuffie, JR; Hendrix, CC; Edie, A; Lindsey-Davis, L; Nagi, A; Kosinski, AS; Williams, JW				Shaw, Ryan J.; McDuffie, Jennifer R.; Hendrix, Cristina C.; Edie, Alison; Lindsey-Davis, Linda; Nagi, Avishek; Kosinski, Andrzej S.; Williams, John W., Jr.			Effects of Nurse-Managed Protocols in the Outpatient Management of Adults With Chronic Conditions A Systematic Review and Meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Review							ENHANCED DIABETES CARE; HEART-FAILURE; GLYCEMIC CONTROL; SPECIALIST NURSE; META-REGRESSION; HYPERTENSION; INTERVENTION; GUIDELINES; EDUCATION; PEOPLE	Background: Changes in federal health policy are providing more access to medical care for persons with chronic disease. Providing quality care may require a team approach, which the American College of Physicians calls the "medical home." One new model may involve nurse-managed protocols. Purpose: To determine whether nurse-managed protocols are effective for outpatient management of adults with diabetes, hypertension, and hyperlipidemia. Data Sources: MEDLINE, Cochrane Central Register of Controlled Trials, EMBASE, and CINAHL from January 1980 through January 2014. Study Selection: Two reviewers used eligibility criteria to assess all titles, abstracts, and full texts and resolved disagreements by discussion or by consulting a third reviewer. Data Extraction: One reviewer did data abstractions and quality assessments, which were confirmed by a second reviewer. Data Synthesis: From 2954 studies, 18 were included. All studies used a registered nurse or equivalent who titrated medications by following a protocol. In a meta-analysis, hemoglobin A1c level decreased by 0.4% (95% CI, 0.1% to 0.7%) (n = 8); systolic and diastolic blood pressure decreased by 3.68 mm Hg (CI, 1.05 to 6.31 mm Hg) and 1.56 mm Hg (CI, 0.36 to 2.76 mm Hg), respectively (n = 12); total cholesterol level decreased by 0.24 mmol/L (9.37 mg/dL) (CI, 0.54-mmol/L decrease to 0.05-mmol/L increase [20.77-mg/dL decrease to 2.02-mg/dL increase]) (n = 9); and low-density-lipoprotein cholesterol level decreased by 0.31 mmol/L (12.07 mg/dL) (CI, 0.73-mmol/L decrease to 0.11-mmol/L increase [28.27-mg/dL decrease to 4.13-mg/dL increase]) (n = 6). Limitation: Studies had limited descriptions of the interventions and protocols used. Conclusion: A team approach that uses nurse-managed protocols may have positive effects on the outpatient management of adults with chronic conditions, such as diabetes, hypertension, and hyperlipidemia.	Durham Vet Affairs Ctr Hlth Serv Res Primary Care, Durham, NC USA; Durham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC 27701 USA; Duke Univ, Durham, NC 27701 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University	Shaw, RJ (corresponding author), Hlth Serv Res & Dev 152, 411 West Chapel Hill St,Suite 600, Durham, NC 27701 USA.	ryan.shaw@duke.edu	Williams, John/AAM-4572-2020; Davis, Linda Lindsey/T-7351-2019	Williams, John/0000-0002-5267-5558; 	Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development (VA-ESP) [09-010]; Department of Veterans Affairs Health Services Research and Development Office of Academic Affiliations nursing postdoctoral research award [TPP-21-021]	Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development (VA-ESP)(US Department of Veterans Affairs); Department of Veterans Affairs Health Services Research and Development Office of Academic Affiliations nursing postdoctoral research award(US Department of Veterans Affairs)	This report is based on research conducted by the Evidence-based Synthesis Program (ESP) Center located at the Durham Veterans Affairs Medical Center, Durham, North Carolina, which is funded by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development (VA-ESP Project 09-010; 2013). The first author, Dr. Ryan Shaw, was supported by a Department of Veterans Affairs Health Services Research and Development Office of Academic Affiliations nursing postdoctoral research award (TPP-21-021).	Agency for Healthcare Research and Quality, 2013, METHODS GUIDE FOR EF; Allen JK, 2010, J CARDIOVASC NURS, V25, P207, DOI 10.1097/JCN.0b013e3181cc79be; Allison TG, 1999, MAYO CLIN PROC, V74, P466; Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS11, DOI 10.2337/dc13-S011; Arnold M, 2011, J CARD FAIL, V17, pS109, DOI 10.1016/j.cardfail.2011.06.367; Aubert RE, 1998, ANN INTERN MED, V129, P605, DOI 10.7326/0003-4819-129-8-199810150-00004; Bebb C, 2007, BRIT J GEN PRACT, V57, P136; Bellary S, 2008, LANCET, V371, P1769, DOI 10.1016/S0140-6736(08)60764-3; Berra K, 2011, J CARDIOVASC NURS, V26, P145, DOI 10.1097/JCN.0b013e3181ec1337; BROWN SA, 1992, RES NURS HEALTH, V15, P409, DOI 10.1002/nur.4770150603; Chakeabarti S, 2010, J CARD FAIL, V16, pS53, DOI 10.1016/j.cardfail.2010.04.004; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Clark CE, 2011, DIABETIC MED, V28, P250, DOI 10.1111/j.1464-5491.2010.03204.x; Clark CE, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3995; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; Denver EA, 2003, DIABETES CARE, V26, P2256, DOI 10.2337/diacare.26.8.2256; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dorr DA, 2008, J AM GERIATR SOC, V56, P2195, DOI 10.1111/j.1532-5415.2008.02005.x; Driscoll A, 2012, COCHRANE DB SYST REV; Fahey T, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005182.pub3; Fischer HH, 2012, AM J MANAG CARE, V18, P77; Gillespie C., 2011, Morbidity and Mortality Weekly Report, V60, P103; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Haskell William L, 2003, J Cardiovasc Nurs, V18, P245; Houweling ST, 2009, NETH J MED, V67, P279; Houweling ST, 2011, J CLIN NURS, V20, P1264, DOI 10.1111/j.1365-2702.2010.03562.x; Institute of Medicine, 2012, LIVING WELL WITH CHR; Jessup M, 2011, J CARD FAIL, V17, P349, DOI 10.1016/j.cardfail.2011.04.001; Joseph Philip, 2011, Curr Cardiol Rep, V13, P287, DOI 10.1007/s11886-011-0190-5; Klein S, 2011, THE VETERANS HEALTH; Knapp G, 2003, STAT MED, V22, P2693, DOI 10.1002/sim.1482; Konstam V, 2011, J CARD FAIL, V17, P151, DOI 10.1016/j.cardfail.2010.08.012; Loveman E, 2003, Cochrane Database Syst Rev, pCD003286; Martinez AS, 2013, AM J HEALTH-SYST PH, V70, P1070, DOI 10.2146/ajhp120267; Meulepas MA, 2008, QUAL SAF HEALTH CARE, V17, P324, DOI 10.1136/qshc.2006.021204; New JP, 2004, DIABETIC MED, V21, P599, DOI 10.1111/j.1464-5491.2004.01213.x; New JP, 2003, DIABETES CARE, V26, P2250, DOI 10.2337/diacare.26.8.2250; Newhouse RR, 2011, NURS ECON, V29, P230; Nichol MB, 2010, J AM PHARM ASSOC, V50, P496, DOI 10.1331/JAPhA.2010.09123; O'Hare JP, 2004, DIABETIC MED, V21, P1357, DOI 10.1111/j.1464-5491.2004.01373.x; Philis-Tsimikas A, 2004, DIABETES CARE, V27, P110, DOI 10.2337/diacare.27.1.110; Rao A, 2007, INT J CARDIOL, V115, P196, DOI 10.1016/j.ijcard.2006.03.010; Rudd P, 2004, AM J HYPERTENS, V17, P921, DOI 10.1016/j.amjhyper.2004.06.006; Senaratne MPJ, 2001, AM HEART J, V142, P975, DOI 10.1067/mhj.2001.118739; Shafazand S, 2010, CLIN THER, V32, P1642, DOI 10.1016/j.clinthera.2010.08.002; Shojania KG, 2006, JAMA-J AM MED ASSOC, V296, P427, DOI 10.1001/jama.296.4.427; Smith SC, 2000, AM J CARDIOL, V86, p62L; Stanley JM, 2011, ADVANCED PRACTICE NU; Taylor CB, 2003, DIABETES CARE, V26, P1058, DOI 10.2337/diacare.26.4.1058; Tone JM, 2009, IRISH J MED SCI, V178, P179, DOI 10.1007/s11845-009-0316-6; Tshiananga JKT, 2012, DIABETES EDUCATOR, V38, P108, DOI 10.1177/0145721711423978; Varney S, 2001, EUR J HEART FAIL, V3, P365, DOI 10.1016/S1388-9842(01)00132-5; Wallymahmed ME, 2011, DIABETIC MED, V28, P373, DOI 10.1111/j.1464-5491.2010.03224.x; Welch G, 2010, DIABETES RES CLIN PR, V88, P1, DOI 10.1016/j.diabres.2009.12.026; Wilhelmsson Susan, 2007, Int J Nurs Pract, V13, P254, DOI 10.1111/j.1440-172X.2007.00635.x; Yach D, 2004, JAMA-J AM MED ASSOC, V291, P2616, DOI 10.1001/jama.291.21.2616	56	67	68	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	2014	161	2					113	+		10.7326/M13-2567	http://dx.doi.org/10.7326/M13-2567			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AM3PJ	25023250				2023-01-03	WOS:000339764600020
J	Kasinski, AL; Kelnar, K; Stahlhut, C; Orellana, E; Zhao, J; Shimer, E; Dysart, S; Chen, X; Bader, AG; Slack, FJ				Kasinski, A. L.; Kelnar, K.; Stahlhut, C.; Orellana, E.; Zhao, J.; Shimer, E.; Dysart, S.; Chen, X.; Bader, A. G.; Slack, F. J.			A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer	ONCOGENE			English	Article							MOUSE MODELS; MIR-34A; ACTIVATION; EXPRESSION; INITIATION; DELIVERY; TARGET; GROWTH; RAS	Targeted cancer therapies, although often effective, have limited utility owing to preexisting primary or acquired secondary resistance. Consequently, agents are sometimes used in combination to simultaneously affect multiple targets. MicroRNA mimics are excellent therapeutic candidates because of their ability to repress multiple oncogenic pathways at once. Here we treated the aggressive Kras; p53 non-small cell lung cancer mouse model and demonstrated efficacy with a combination of two tumor-suppressive microRNAs (miRNAs). Systemic nanodelivery of miR-34 and let-7 suppressed tumor growth leading to survival advantage. This combinatorial miRNA therapeutic approach engages numerous components of tumor cell-addictive pathways and highlights the ability to deliver multiple miRNAs in a safe and effective manner to target lung tissue.	[Kasinski, A. L.; Stahlhut, C.; Shimer, E.; Chen, X.; Slack, F. J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA; [Kasinski, A. L.; Orellana, E.] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; [Kelnar, K.; Zhao, J.; Dysart, S.; Bader, A. G.] Mirna Therapeut Inc, Austin, TX 78744 USA; [Slack, F. J.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Yale University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Harvard University; Harvard Medical School	Slack, FJ (corresponding author), Harvard Univ, Sch Med, Dept Pathol, BIDMC, 3 Blackfan Circle CLS412, Boston, MA 02115 USA.	abader@mirnarx.com; fslack@bidmc.harvard.edu	Orellana, Esteban/N-8004-2019; Orellana, Esteban/I-3653-2014; Kasinski, Andrea/AAF-3864-2021; Kasinski, Andrea L/E-7951-2014	Orellana, Esteban/0000-0003-4369-9416; Orellana, Esteban/0000-0003-4369-9416; Kasinski, Andrea/0000-0002-9602-7827; Slack, Frank/0000-0001-8263-0409; Stahlhut, Carlos/0000-0002-8472-7156	American Cancer Society [PF-11-244-01]; NIH [CA178091, CA131301]; Cancer Prevention Research Institute of Texas (CPRIT); NATIONAL CANCER INSTITUTE [R01CA131301, R00CA178091, F32CA153885, K99CA178091] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Research Institute of Texas (CPRIT); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	ALK was supported by an American Cancer Society Fellowship (PF-11-244-01) and an NIH Pathway to Independence Award (CA178091). This work was supported by a grant to FJS from the NIH (CA131301) and by a commercialization grant from the Cancer Prevention Research Institute of Texas (CPRIT) to AGB.	Bader Andreas G., 2012, Frontiers in Genetics, V3, P120, DOI 10.3389/fgene.2012.00120; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Bouchie A, 2013, NAT BIOTECHNOL, V31, P577, DOI 10.1038/nbt0713-577; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834; Gallardo E, 2009, CARCINOGENESIS, V30, P1903, DOI 10.1093/carcin/bgp219; Gatsonis CA, 2011, RADIOLOGY, V258, P243, DOI 10.1148/radiol.10091808; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kasinski AL, 2012, CANCER RES, V72, P5576, DOI 10.1158/0008-5472.CAN-12-2001; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Kumar MS, 2008, P NATL ACAD SCI USA, V105, P3903, DOI 10.1073/pnas.0712321105; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Lin PY, 2010, BRIT J CANCER, V103, P1144, DOI 10.1038/sj.bjc.6605901; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Singh M, 2010, NAT BIOTECHNOL, V28, P585, DOI 10.1038/nbt.1640; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; Trang P, 2011, MOL THER, V19, P1116, DOI 10.1038/mt.2011.48; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Wei JS, 2008, ONCOGENE, V27, P5204, DOI 10.1038/onc.2008.154; Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655; Xue W, 2011, CANCER DISCOV, V1, P236, DOI 10.1158/2159-8290.CD-11-0073; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Zhao J, 2013, MOL THER, V21, P1678, DOI 10.1038/mt.2013.148	34	153	160	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3547	3555		10.1038/onc.2014.282	http://dx.doi.org/10.1038/onc.2014.282			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25174400	Green Accepted			2023-01-03	WOS:000357434900007
J	Bastian, AR; Nangarlia, A; Bailey, LD; Holmes, A; Sundaram, RVK; Ang, C; Moreira, DRM; Freedman, K; Duffy, C; Contarino, M; Abrams, C; Root, M; Chaiken, I				Bastian, Arangassery Rosemary; Nangarlia, Aakansha; Bailey, Lauren D.; Holmes, Andrew; Sundaram, R. Venkat Kalyana; Ang, Charles; Moreira, Diogo R. M.; Freedman, Kevin; Duffy, Caitlin; Contarino, Mark; Abrams, Cameron; Root, Michael; Chaiken, Irwin			Mechanism of Multivalent Nanoparticle Encounter with HIV-1 for Potency Enhancement of Peptide Triazole Virus Inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						Drug Design; Human Immunodeficiency Virus (HIV); Nanotechnology; Peptides; Virology; Gold Nanoparticles; Microbicide; p24 Release; Virolysis	HUMAN-IMMUNODEFICIENCY-VIRUS; GP120 ENVELOPE GLYCOPROTEIN; ENTRY INHIBITORS; GOLD NANOPARTICLES; ENV GP120; CCR5 ANTAGONISTS; CD4-BOUND STATE; DRUG-DELIVERY; TYPE-1; BINDING	Background: HIV-1 envelope spike protein remains a compelling but elusive target for preventing infection. Results: Gold nanoparticle conjugates of peptide triazole Env inhibitors demonstrated impressive picomolar antiviral potencies. Conclusion: Nanoparticle conjugates enhanced antiviral functions by multivalent attachment to virus Env spikes. Significance: Findings reveal that multispike engagement can exploit the metastability of the virus envelope to irreversibly inactivate HIV-1. Entry of HIV-1 into host cells remains a compelling yet elusive target for developing agents to prevent infection. A peptide triazole (PT) class of entry inhibitor has previously been shown to bind to HIV-1 gp120, suppress interactions of the Env protein at host cell receptor binding sites, inhibit cell infection, and cause envelope spike protein breakdown, including gp120 shedding and, for some variants, virus membrane lysis. We found that gold nanoparticle-conjugated forms of peptide triazoles (AuNP-PT) exhibit substantially more potent antiviral effects against HIV-1 than corresponding peptide triazoles alone. Here, we sought to reveal the mechanism of potency enhancement underlying nanoparticle conjugate function. We found that altering the physical properties of the nanoparticle conjugate, by increasing the AuNP diameter and/or the density of PT conjugated on the AuNP surface, enhanced potency of infection inhibition to impressive picomolar levels. Further, compared with unconjugated PT, AuNP-PT was less susceptible to reduction of antiviral potency when the density of PT-competent Env spikes on the virus was reduced by incorporating a peptide-resistant mutant gp120. We conclude that potency enhancement of virolytic activity and corresponding irreversible HIV-1 inactivation of PTs upon AuNP conjugation derives from multivalent contact between the nanoconjugates and metastable Env spikes on the HIV-1 virus. The findings reveal that multispike engagement can exploit the metastability built into virus the envelope to irreversibly inactivate HIV-1 and provide a conceptual platform to design nanoparticle-based antiviral agents for HIV-1 specifically and putatively for metastable enveloped viruses generally.	[Bastian, Arangassery Rosemary; Nangarlia, Aakansha; Bailey, Lauren D.; Holmes, Andrew; Sundaram, R. Venkat Kalyana; Ang, Charles; Duffy, Caitlin; Contarino, Mark; Chaiken, Irwin] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA; [Bastian, Arangassery Rosemary; Nangarlia, Aakansha; Sundaram, R. Venkat Kalyana; Ang, Charles] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA; [Moreira, Diogo R. M.] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, BR-40296710 Salvador, BA, Brazil; [Freedman, Kevin; Abrams, Cameron] Drexel Univ, Dept Chem & Biol Engn, Philadelphia, PA 19104 USA; [Root, Michael] Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA	Drexel University; Drexel University; Fundacao Oswaldo Cruz; Drexel University; Jefferson University	Chaiken, I (corresponding author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 245 N 15th St,Mail Stop 497, Philadelphia, PA 19102 USA.	Irwin.chaiken@drexelmed.edu	Moreira, Diogo Rodrigo M./S-9071-2019; Kalyana Sundaram, Ramalingam Venkat/T-7840-2018	Moreira, Diogo Rodrigo M./0000-0003-3323-4404; Kalyana Sundaram, Ramalingam Venkat/0000-0002-0232-4186; Holmes, Andrew/0000-0001-5012-4026; Ang, Charles/0000-0002-2368-552X; Nangarlia, Aakansha/0000-0003-2796-9092; Freedman, Kevin/0000-0001-8801-4578	National Institutes of Health [RO1GM11029]; W. W. Smith Foundation Award; National Science Foundation [CBET 0853680]; Schlumberger Foundation Faculty of the Future Award; NATIONAL CANCER INSTITUTE [P30CA056036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM111029, P01GM056550] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); W. W. Smith Foundation Award; National Science Foundation(National Science Foundation (NSF)); Schlumberger Foundation Faculty of the Future Award(Schlumberger); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant RO1GM11029. This work was also supported by a W. W. Smith Foundation Award, National Science Foundation Grant CBET 0853680, and a Schlumberger Foundation Faculty of the Future Award (to A. R. B.).	Bastian AR, 2011, CHEMMEDCHEM, V6, P1335, DOI 10.1002/cmdc.201100177; Bastian AR, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-153; Bennett A, 2007, J BIOL CHEM, V282, P27754, DOI 10.1074/jbc.M702025200; Biorn AC, 2004, BIOCHEMISTRY-US, V43, P1928, DOI 10.1021/bi035088i; Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g; Champagne K, 2009, J BIOL CHEM, V284, P3619, DOI 10.1074/jbc.M809269200; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o; Chojnacki J, 2012, SCIENCE, V338, P524, DOI 10.1126/science.1226359; Cocklin S, 2007, J VIROL, V81, P3645, DOI 10.1128/JVI.01778-06; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Contarino M, 2013, ANTIMICROB AGENTS CH, V57, P4743, DOI 10.1128/AAC.00309-13; Crooks ET, 2011, J VIROL, V85, P5825, DOI 10.1128/JVI.00154-11; Dey B, 2007, J VIROL, V81, P5579, DOI 10.1128/JVI.02500-06; Dimitrov AS, 2007, BIOCHEMISTRY-US, V46, P1398, DOI 10.1021/bi062245f; Doyle T, 2012, CURR OPIN INFECT DIS, V25, P17, DOI 10.1097/QCO.0b013e32834ef5d9; Emileh A, 2013, BIOCHEMISTRY-US, V52, P2245, DOI 10.1021/bi400166b; Emmelkamp JM, 2007, EUR J MED RES, V12, P409; Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m; Ferrer M, 1999, J VIROL, V73, P5795, DOI 10.1128/JVI.73.7.5795-5802.1999; Flint S. J., 2008, PRINCIPLES VIROLOGY, P83; Flores A, 2013, CURR MED CHEM, V20, P751; FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0; Gopi H, 2009, J MOL RECOGNIT, V22, P169, DOI 10.1002/jmr.892; Gopi HN, 2006, CHEMMEDCHEM, V1, P54, DOI 10.1002/cmdc.200500037; Granich R, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-1; Haiss W, 2007, ANAL CHEM, V79, P4215, DOI 10.1021/ac0702084; Hamidi M, 2013, CRIT REV THER DRUG, V30, P435, DOI 10.1615/CritRevTherDrugCarrierSyst.2013007419; Haqqani AA, 2013, ANTIVIR RES, V98, P158, DOI 10.1016/j.antiviral.2013.03.017; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; Heidel JD, 2011, PHARM RES-DORDR, V28, P187, DOI 10.1007/s11095-010-0178-7; Henrich TJ, 2013, CURR OPIN VIROL, V3, P51, DOI 10.1016/j.coviro.2012.12.002; Hermann FG, 2009, J VIROL, V83, P4844, DOI 10.1128/JVI.00666-08; Hughes A, 2008, J INFECTION, V57, P1, DOI 10.1016/j.jinf.2008.05.006; Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30; Johnson Victoria A, 2013, Top Antivir Med, V21, P6; Joint United Nations Programme on HIV/AIDS, 2013, GLOB REP UNAIDS REP, P198; Kim T, 2005, LANGMUIR, V21, P9524, DOI 10.1021/la0504560; Kol N, 2007, BIOPHYS J, V92, P1777, DOI 10.1529/biophysj.106.093914; Kromdijk W, 2010, EXPERT OPIN PHARMACO, V11, P1215, DOI 10.1517/14656561003801081; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Madani N, 2008, STRUCTURE, V16, P1689, DOI 10.1016/j.str.2008.09.005; Madani N, 2014, J VIROL, V88, P6542, DOI 10.1128/JVI.00540-14; Mahmoud KA, 2008, ANAL CHEM, V80, P7056, DOI 10.1021/ac801174r; Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI 10.2217/NNM.10.1; Mao YD, 2013, P NATL ACAD SCI USA, V110, P12438, DOI 10.1073/pnas.1307382110; Mao YD, 2012, NAT STRUCT MOL BIOL, V19, P893, DOI 10.1038/nsmb.2351; McFadden K, 2012, ANTIMICROB AGENTS CH, V56, P1073, DOI 10.1128/AAC.05555-11; Muranyi W, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003198; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; Nakamura M, 2000, HYBRIDOMA, V19, P427, DOI 10.1089/027245700750053913; Nettles RE, 2012, J INFECT DIS, V206, P1002, DOI 10.1093/infdis/jis432; Nichols WG, 2008, ANTIMICROB AGENTS CH, V52, P858, DOI 10.1128/AAC.00821-07; Nichols WK, 2003, TOXICOL SCI, V71, P229, DOI 10.1093/toxsci/71.2.229; Palmisano L, 2011, ANN I SUPER SANITA, V47, P44, DOI 10.4415/ANN_11_01_10; Pan CG, 2010, J FORMOS MED ASSOC, V109, P94, DOI 10.1016/S0929-6646(10)60029-0; Park EJ, 1998, J VIROL, V72, P7099, DOI 10.1128/JVI.72.9.7099-7107.1998; Perry CM, 2010, DRUGS, V70, P1189, DOI 10.2165/11203940-000000000-00000; Poignard P, 2003, J VIROL, V77, P353, DOI 10.1128/JVI.77.1.353-365.2003; Qiu S, 2012, CURR HIV RES, V10, P182, DOI 10.2174/157016212799937191; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; Tuzer F, 2013, PROTEINS, V81, P271, DOI 10.1002/prot.24184; Umashankara M, 2010, CHEMMEDCHEM, V5, P1871, DOI 10.1002/cmdc.201000222; Vogt VM, 1999, J VIROL, V73, P7050, DOI 10.1128/JVI.73.8.7050-7055.1999; Wallace BJ, 2011, AUSTRALAS J DERMATOL, V52, P19, DOI 10.1111/j.1440-0960.2010.00717.x; Wallin M, 2005, J VIROL, V79, P1678, DOI 10.1128/JVI.79.3.1678-1685.2005; White JM, 2008, CRIT REV BIOCHEM MOL, V43, P189, DOI 10.1080/10409230802058320 ; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Xiang SH, 2002, J VIROL, V76, P9888, DOI 10.1128/JVI.76.19.9888-9899.2002; Xie H, 2003, ANAL CHEM, V75, P5797, DOI 10.1021/ac034578d; Xu YY, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-123; Zhang L, 2008, CLIN PHARMACOL THER, V83, P761, DOI 10.1038/sj.clpt.6100400; Zhao Q, 2005, VIROLOGY, V339, P213, DOI 10.1016/j.virol.2005.06.008	74	29	30	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2015	290	1					529	543		10.1074/jbc.M114.608315	http://dx.doi.org/10.1074/jbc.M114.608315			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	AX9OG	25371202	Green Published, hybrid			2023-01-03	WOS:000347231200046
J	Kushwaha, KP; Sankar, J; Sankar, MJ; Gupta, A; Dadhich, JP; Gupta, YP; Bhatt, GC; Ansari, DA; Sharma, B				Kushwaha, Komal P.; Sankar, Jhuma; Sankar, M. Jeeva; Gupta, Arun; Dadhich, J. P.; Gupta, Y. P.; Bhatt, Girish C.; Ansari, Dilshad A.; Sharma, B.			Effect of Peer Counselling by Mother Support Groups on Infant and Young Child Feeding Practices: The Lalitpur Experience	PLOS ONE			English	Article							INTERVENTIONS; PROMOTION	Objective: Our primary objective was to evaluate the effect of peer counselling by mother support groups (MSG's) in improving the infant and young child feeding (IYCF) practices in the community. Methods: We conducted this repeated-measure before and after study in the Lalitpur district of Uttar Pradesh, India between 2006 and 2011. We assessed the IYCF practices before and after creating MSG's within the community. The feeding practices were reassessed at two time points-2 (T1) and 5 years (T2) after the intervention and compared with that of the pre-intervention phase (T0). Results: The total population covered by the project from the time of its initiation was 105000. A total of 425 (T0), 480 (T1) and 521 (T2) mother infant pairs were selected from this population. There was significant improvement in the following IYCF practices in the community (represented as %; adjOR (95% CI, p) such as initiation of breast feeding within 1 hour at both T1 (71% vs. 11%); 19.6 (13.6, 28.2, p = < 0.0001) and T2 (62% vs. 11%); 13.3 (9.4, 18.9, p = < 0.0001); use of prelacteal feeds at both T1 (67% vs. 15%); 12.6 (CI: 9.0, 17.6, p < 0.0001) and T2 (67% vs. 5%); 44.4 (28.8, 68.4, p = < 0.0001); rates of exclusive breast feeding for 6 months at both T1 (50% vs. 7%); 13.6 (7.6, 25.0, p = < 0.0001) and T2 (60% vs. 7%); 20.5 (11.3, 37.2, p = < 0.0001); initiation of complementary feeding at T1 (85% vs. 54%); 5.6 (3.6, 8.7, p = < 0.0001) and T2 (96% vs. 54%); 22.9 (11.8, 44.1, p = < 0.0001) and complementary feeding along with continued breast feeding at both T1 (36% vs. 4.5%); 6 (1.15, 31.4, p = 0.033) and T2 (42% vs. 4.5%); 8.06 (1.96, 49.1, p = 0.005) as compared to pre-intervention period (T0) after adjusting for important social and demographic variables. Conclusions: Peer counseling by MSG's improved the IYCF practices in the district and could be sustained.	[Kushwaha, Komal P.; Bhatt, Girish C.; Ansari, Dilshad A.; Sharma, B.] BRD Med Coll, Dept Pediat, Gorakhpur, Uttar Pradesh, India; [Sankar, Jhuma; Sankar, M. Jeeva] AIIMS, Dept Pediat, New Delhi, India; [Gupta, Arun] IBFAN Asia, Delhi, India; [Dadhich, J. P.] BPNI, Delhi, India; [Gupta, Y. P.] YG Consultants Pvt Ltd, New Delhi, India	All India Institute of Medical Sciences (AIIMS) New Delhi	Kushwaha, KP (corresponding author), BRD Med Coll, Dept Pediat, Gorakhpur, Uttar Pradesh, India.	komalpkushwaha13@gmail.com	DADHICH, JP/R-8705-2019; Sankar, Jhuma/AAE-7057-2019; Sankar, Jeeva/Q-1007-2019; Bhatt, Girish Chandra/AAH-1026-2019	Sankar, Jhuma/0000-0002-9807-6550; Sankar, Jeeva/0000-0003-1474-1451; 	UNICEF	UNICEF	The project was funded by UNICEF. The funding received was 3000000 INR/year for 5 years for implementation of the project activities only. The funding agency had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrasada GV, 2005, ACTA PAEDIATR, V94, P1109, DOI 10.1080/08035250510025752; Aidam BA, 2005, J NUTR, V135, P1691, DOI 10.1093/jn/135.7.1691; Bhandari N, 2003, LANCET, V361, P1418, DOI 10.1016/S0140-6736(03)13134-0; Bhutta ZA, 2008, LANCET, V371, P417, DOI 10.1016/S0140-6736(07)61693-6; Bland RM, 2008, AIDS, V22, P883, DOI 10.1097/QAD.0b013e3282f768de; BPNI/IBFAN, 2009, 3 1 TRAIN PROGR CAP; CEF, 2007, PROGR CHILDR REP A S; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Dennis CL, 2003, INT J NURS STUD, V40, P321, DOI 10.1016/S0020-7489(02)00092-5; Haider R, 2000, LANCET, V356, P1643, DOI 10.1016/S0140-6736(00)03159-7; Hannula L, 2008, J CLIN NURS, V17, P1132, DOI 10.1111/j.1365-2702.2007.02239.x; istrar General of India, 2011, SAMPL REG SYST SRS S; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; Kushwaha KP, 2010, REACHING 2S UNIVERSA; Malhotra N, 2013, PUBLIC HEALTH NUTR, V16, P1723, DOI 10.1017/S1368980012004065; Morrow AL, 1999, LANCET, V353, P1226, DOI 10.1016/S0140-6736(98)08037-4; Nor B, 2009, J HUM LACT, V25, P427, DOI 10.1177/0890334409341050; Quinn VJ, 2005, J HUM LACT, V21, P345, DOI 10.1177/0890334405278383; Renfrew MJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001141.pub4; Sudfeld CR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045143; WHO/UNICEF, 1991, BAB FRIENDL HOSP IN; WHO UNICEF, 2009, BAB FRIENDL HOSP IN; World Health Organization, BREASTF COUNS TRAIN; World Health Organization, 2003, GLOB STRAT INF YOUNG	24	32	34	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2014	9	11							e109181	10.1371/journal.pone.0109181	http://dx.doi.org/10.1371/journal.pone.0109181			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS6XG	25369452	Green Published, Green Submitted, gold			2023-01-03	WOS:000344402000008
J	Rotheram-Borus, MJ; Tomlinson, M; le Roux, IM; Harwood, JM; Comulada, S; O'Connor, MJ; Weiss, RE; Worthman, CM				Rotheram-Borus, Mary Jane; Tomlinson, Mark; le Roux, Ingrid M.; Harwood, Jessica M.; Comulada, Scott; O'Connor, Mary J.; Weiss, Robert E.; Worthman, Carol M.			A Cluster Randomised Controlled Effectiveness Trial Evaluating Perinatal Home Visiting among South African Mothers/Infants	PLOS ONE			English	Article							COMMUNITY-HEALTH WORKERS; SUB-SAHARAN AFRICA; NEWBORN CARE; OUTCOMES; INFANTS; PARAPROFESSIONALS; DEPRESSION; PROGRAMS; PACKAGE; NURSES	Background: Interventions are needed to reduce poor perinatal health. We trained community health workers (CHWs) as home visitors to address maternal/infant risks. Methods: In a cluster randomised controlled trial in Cape Town townships, neighbourhoods were randomised within matched pairs to 1) the control, healthcare at clinics (n = 12 neighbourhoods; n = 594 women), or 2) a home visiting intervention by CBW trained in cognitive-behavioural strategies to address health risks (by the Philani Maternal, Child Health and Nutrition Programme), in addition to clinic care (n = 12 neighbourhoods; n = 644 women). Participants were assessed during pregnancy (2% refusal) and 92% were reassessed at two weeks post-birth, 88% at six months and 84% at 18 months later. We analysed 32 measures of maternal/infant well-being over the 18 month follow-up period using longitudinal random effects regressions. A binomial test for correlated outcomes evaluated overall effectiveness over time. The 18 month post-birth assessment outcomes also were examined alone and as a function of the number of home visits received. Results: Benefits were found on 7 of 32 measures of outcomes, resulting in significant overall benefits for the intervention compared to the control when using the binomial test (p = 0.008); nevertheless, no effects were observed when only the 18 month outcomes were analyzed. Benefits on individual outcomes were related to the number of home visits received. Among women living with HIV, intervention mothers were more likely to implement the PMTCT regimens, use condoms during all sexual episodes (OR = 1.25; p = 0.014), have infants with healthy weight-for-age measurements (OR = 1.42; p = 0.045), height-for-age measurements (OR = 1.13, p<0.001), breastfeed exclusively for six months (OR = 3.59; p<0.001), and breastfeed longer (OR = 3.08; p<0.001). Number of visits was positively associated with infant birth weight >= 2500 grams (OR = 1.07; p = 0.012), healthy head-circumference-for-age measurements at 6 months (OR = 1.09, p = 0.017), and improved cognitive development at 18 months (OR = 1.02, p = 0.048). Conclusions: Home visits to neighbourhood mothers by CHWs may be a feasible strategy for enhancing maternal/child outcomes. However, visits likely must extend over several years for persistent benefits.	[Rotheram-Borus, Mary Jane; Harwood, Jessica M.; Comulada, Scott; O'Connor, Mary J.] Univ Calif Los Angeles, Semel Inst, Dept Psychiat & Biobehav Med, Los Angeles, CA 90095 USA; [Tomlinson, Mark] Univ Stellenbosch, Dept Psychol, ZA-7600 Stellenbosch, South Africa; [le Roux, Ingrid M.] Philani Maternal Child Hlth & Nutr Programme, Cape Town, South Africa; [Worthman, Carol M.] Emory Univ, Dept Anthropol, Atlanta, GA 30322 USA; [Weiss, Robert E.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA USA	University of California System; University of California Los Angeles; Stellenbosch University; Emory University; University of California System; University of California Los Angeles	Rotheram-Borus, MJ (corresponding author), Univ Calif Los Angeles, Semel Inst, Dept Psychiat & Biobehav Med, Los Angeles, CA 90095 USA.	CCHPublications@mednet.ucla.edu		Worthman, Carol M/0000-0002-5397-2298	NIAAA grant [R01 AA017104]; Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) NIMH grant [P30 MH58107]; UCLA Center for AIDS Research (CFAR) grant [P30 AI028697]; National Center for Advancing Translational Sciences through UCLA CSTI Grant [UL1 TR000124]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH058107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA017104, R24AA022919] Funding Source: NIH RePORTER	NIAAA grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) NIMH grant; UCLA Center for AIDS Research (CFAR) grant; National Center for Advancing Translational Sciences through UCLA CSTI Grant; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This work was supported by NIAAA grant R01 AA017104, the Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) NIMH grant P30 MH58107; the UCLA Center for AIDS Research (CFAR) grant P30 AI028697; and the National Center for Advancing Translational Sciences through UCLA CSTI Grant UL1 TR000124. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alamo S, 2012, AIDS PATIENT CARE ST, V26, P101, DOI 10.1089/apc.2011.0279; Bayley N, 2003, BAYLEY SCALES INFANT; Berggren WL., 2002, FOOD NUTR BULL, V23, P7; Chibanda D, 2010, ARCH WOMEN MENT HLTH, V13, P201, DOI 10.1007/s00737-009-0073-6; Cogill B, 2003, ANTHROPOMETRIC INDIC; Cooper PJ, 1999, BRIT J PSYCHIAT, V175, P554, DOI 10.1192/bjp.175.6.554; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Dawson DA, 2005, COMPR PSYCHIAT, V46, P405, DOI 10.1016/j.comppsych.2005.01.006; Flay BR, 2005, PREV SCI, V6, P151, DOI 10.1007/s11121-005-5553-y; Grantham-McGregor S, 2007, LANCET, V369, P824, DOI 10.1016/S0140-6736(07)60404-8; GROSS RT, 1990, JAMA-J AM MED ASSOC, V263, P3035; Haines A, 2007, LANCET, V369, P2121, DOI 10.1016/S0140-6736(07)60325-0; Kirkwood BR, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-58; Langer A, 2011, SUPPORT PREGNANCY WO; le Roux IM, 2013, AIDS, V27, P1461, DOI 10.1097/QAD.0b013e3283601b53; Lewin S., 2006, LAY HLTH WORKERS PRI; May PA, 2009, DEV DISABIL RES REV, V15, P176, DOI 10.1002/ddrr.68; Narman N, 2007, SAMJ S AFR MED J, V97, P733; Olds D, 1998, JUVENILE JUSTICE B; Olds DL, 2002, PEDIATRICS, V110, P486, DOI 10.1542/peds.110.3.486; Olds DL, 2004, PEDIATRICS, V114, P1560, DOI 10.1542/peds.2004-0961; Peacock S, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-17; Rotheram-Borus MJ, 2012, INT J TELEMED APPL, V2012, DOI 10.1155/2012/973237; Rotheram-Borus MJ, 2014, J CLIN CHILD ADOLESC, V43, P229, DOI 10.1080/15374416.2013.836453; Rotheram-Borus MJ, 2012, AM PSYCHOL, V67, P463, DOI 10.1037/a0028180; Rotheram-Borus MJ, 2011, PREV SCI, V12, P372, DOI 10.1007/s11121-011-0238-1; Singh P, 2013, LANCET, V382, P363, DOI 10.1016/S0140-6736(12)62002-9; Sprague C, 2011, AIDS RES THER, V8, DOI 10.1186/1742-6405-8-10; Stein AD, 2013, J PEDIATR-US, V163, P1740, DOI 10.1016/j.jpeds.2013.08.012; Suri A, 2007, J INFECT DIS, V196, pS505, DOI 10.1086/521122; Sweet MA, 2004, CHILD DEV, V75, P1435, DOI 10.1111/j.1467-8624.2004.00750.x; Tomlinson M, 2014, TROP MED INT HEALTH, V19, P256, DOI 10.1111/tmi.12257; Tomlinson M, 2013, S AFR J INFORM MANAG, V15, DOI 10.4102/sajim.v15i1.528; Tylleskar T, 2011, LANCET, V378, P420, DOI 10.1016/S0140-6736(11)60738-1; USAID, MAT HLTH S AFR; World Health Organization, 2011, WORK WHO AFR REG 201	37	52	52	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2014	9	10							e105934	10.1371/journal.pone.0105934	http://dx.doi.org/10.1371/journal.pone.0105934			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AR5ZY	25340337	gold, Green Published, Green Submitted			2023-01-03	WOS:000343662800001
J	Kadic, AJ; Zanic, M; Skaricic, N; Marusic, A				Kadic, Antonia Jelicic; Zanic, Maja; Skaricic, Natasa; Marusic, Ana			Using the WHO Essential Medicines List to Assess the Appropriateness of Insurance Coverage Decisions: A Case Study of the Croatian National Medicine Reimbursement List	PLOS ONE			English	Article							CARE; SYSTEM	Purpose: To investigate the use of the WHO EML as a tool with which to evaluate the evidence base for the medicines on the national insurance coverage list of the Croatian Institute of Health Insurance (CIHI). Methods: Medicines from 9 ATC categories with highest expenditures from 2012 CIHI Basic List (n = 509) were compared with 2011 WHO EML for adults (n = 359). For medicines with specific indication listed only in CIHI Basic List we assessed whether there was evidence in Cochrane Database of Systematic Reviews questioning their efficacy and safety. Results: The two lists shared 188 medicines (52.4% of WHO EML and 32.0% of CIHI list). CIHI Basic List had 254 medicines and 33 combinations of these medicines which were not on the WHO EML, plus 14 medicines rejected and 20 deleted from WHO EML by its Evaluation Committee. For deleted medicines, we could obtain data that showed 2,965,378 prescriptions issued to 617,684 insured patients, and the cost of approximately (sic) 41.2 million for 2012 and the first half of 2013, when the CIHI Basic List was in effect. For CIHI List-only medicines with a specific indication (n = 164 or 57.1% of the analyzed set), fewer benefits or more serious side-effects than other medicines were found for 17 (10.4%) and not enough evidence for recommendations for specific indication for 21 (12.8%) medicines in Cochrane systematic reviews. Conclusions: National health care policy should use high-quality evidence in deciding on adding new medicines and reassessing those already present on national medicines lists, in order to rationalize expenditures and ensure wider and better access to medicines. The WHO EML and recommendations from its Evaluation Committee may be useful tools in this quality assurance process.	[Kadic, Antonia Jelicic; Marusic, Ana] Univ Split, Sch Med, Dept Anat, Split, Croatia; [Zanic, Maja] Univ Split, Ctr Hosp, Dept Obstet & Gynaecol, Split, Croatia; [Skaricic, Natasa] Univ Zagreb, Sch Humanities & Social Sci, Zagreb 41000, Croatia; [Marusic, Ana] Univ Split, Sch Med, Dept Res Biomed & Hlth, Split, Croatia	University of Split; University of Split; University of Zagreb; University of Split	Marusic, A (corresponding author), Univ Split, Sch Med, Dept Anat, Split, Croatia.	ana.marusic@mefst.hr	Marusic, Ana/E-7683-2013	Marusic, Ana/0000-0001-6272-0917	Ministry of Science and Technology of the Republic of Croatia [216-1080314-0245]	Ministry of Science and Technology of the Republic of Croatia	The study was supported by the research grant from the Ministry of Science and Technology of the Republic of Croatia, No. 216-1080314-0245. The funder had no role in the study, including data collection and analysis, manuscript preparation or authorization for publication.	Agency for Medicines and Medicinal Products, 2011, 2011 CHARTB MED MARK; [Anonymous], 2013, WHO GLOBAL HLTH OBSE; Barber SL, 2013, J GLOB HEALTH, V3, DOI 10.7189/jogh.03.010303; Croatian Agency for Medicines and Medical Devices, 2012, TOT EXP MED PER MAIN; Croatian Institute for Health Insurance, MED LISTS; Gustafsson LL, 2011, BASIC CLIN PHARMACOL, V108, P224, DOI 10.1111/j.1742-7843.2011.00682.x; Hebrang A, 2003, HEALTH POLICY PLANN, V18, P421, DOI 10.1093/heapol/czg050; Hill S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038055; Laing R, 2003, LANCET, V361, P1723, DOI 10.1016/S0140-6736(03)13375-2; Millar TP, 2011, AM J PUBLIC HEALTH, V101, P1444, DOI 10.2105/AJPH.2010.300054; Ministry of Health and Social Care of the Republic of Croatia, 2009, PUBL B, V155, P3832; Moja LP, 2005, BMJ-BRIT MED J, V330, P1053, DOI 10.1136/bmj.38414.515938.8F; Moten A, 2014, J GLOB HEALTH, V4, DOI 10.7189/jogh.04.010304; Oreskovic S, 1998, Croat Med J, V39, P225; Republic of Croatia, 2009, PUBL B, V43, P985; Republic of Croatia, 2013, PUBL B, V137, P2944; Rico-Alba I, 2013, EUR J CLIN PHARMACOL, V69, P949, DOI 10.1007/s00228-012-1421-4; The Organization for Economic Co-operation and Development, 2010, VAL MON HLTH SPEND; The World Bank, 2013, DAT CROAT; Vitezic D, 2012, INT J CLIN PHARM TH, V50, P483, DOI 10.5414/CP201686; WHO, ESS MED; WHO, 2013, SEL US ESS MED; WHO Collaborating Centre for Drug Statistics Methodology, AN THER CHEM ATC DEF; World Health Organization, 2013, NAT MED LISTS; World Health Organization, 2013, CROAT COUNTR PROF MO; World Health Organization, SPEC PHARM PREP; World Health Organization, INT NONPR NAM	27	9	9	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 22	2014	9	10							e111474	10.1371/journal.pone.0111474	http://dx.doi.org/10.1371/journal.pone.0111474			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AR6DY	25337860	Green Published, gold, Green Submitted			2023-01-03	WOS:000343674800121
J	Myles, PS; Leslie, K; Chan, MTV; Forbes, A; Peyton, PJ; Paech, MJ; Beattie, WS; Sessler, DI; Devereaux, PJ; Silbert, B; Schricker, T; Wallace, S				Myles, Paul S.; Leslie, Kate; Chan, Matthew T. V.; Forbes, Andrew; Peyton, Philip J.; Paech, Michael J.; Beattie, W. Scott; Sessler, Daniel I.; Devereaux, P. J.; Silbert, Brendan; Schricker, Thomas; Wallace, Sophie		ANZCA Trials Grp ENIGMA-II Investi	The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): a randomised, single-blind trial	LANCET			English	Article							PERIOPERATIVE CARDIAC EVENTS; FOLIC-ACID SUPPLEMENTATION; SURGICAL-WOUND INFECTION; CARDIOVASCULAR-DISEASE; B-VITAMINS; POSTOPERATIVE NAUSEA; PLASMA HOMOCYSTEINE; SITE INFECTION; MORTALITY; MORBIDITY	Background Nitrous oxide is commonly used in general anaesthesia but concerns exist that it might increase perioperative cardiovascular risk. We aimed to gather evidence to establish whether nitrous oxide affects perioperative cardiovascular risk. Methods We did an international, randomised, assessor-blinded trial in patients aged at least 45 years with known or suspected coronary artery disease having major non-cardiac surgery. Patients were randomly assigned via automated telephone service, stratified by site, to receive a general anaesthetic with or without nitrous oxide. Attending anaesthetists were aware of patients' group assignments, but patients and assessors were not. The primary outcome measure was a composite of death and cardiovascular complications (non-fatal myocardial infarction, stroke, pulmonary embolism, or cardiac arrest) within 30 days of surgery. Our modified intention-to-treat population included all patients randomly assigned to groups and undergoing induction of general anaesthesia for surgery. This trial is registered at ClinicalTrials.gov, number NCT00430989. Findings Of 10 102 eligible patients, we enrolled 7112 patients between May 30, 2008, and Sept 28, 2013. 3543 were assigned to receive nitrous oxide and 3569 were assigned not to receive nitrous oxide. 3483 patients receiving nitrous oxide and 3509 not receiving nitrous oxide were assessed for the primary outcome. The primary outcome occurred in 283 (8%) patients receiving nitrous oxide and in 296 (8%) patients not receiving nitrous oxide (relative risk 0.96, 95% CI 0.83-1.12; p=0.64). Surgical site infection occurred in 321 (9%) patients assigned to nitrous oxide, and in 311 (9%) patients in the no-nitrous oxide group (p=0.61), and severe nausea and vomiting occurred in 506 patients (15%) assigned to nitrous oxide and 378 patients (11%) not assigned to nitrous oxide (p<0.0001). Interpretation Our findings support the safety profile of nitrous oxide use in major non-cardiac surgery. Nitrous oxide did not increase the risk of death and cardiovascular complications or surgical-site infection, the emetogenic effect of nitrous oxide can be controlled with antiemetic prophylaxis, and a desired effect of reduced volatile agent use was shown.	[Myles, Paul S.; Wallace, Sophie] Alfred Hosp, Melbourne, Vic 3004, Australia; [Myles, Paul S.; Leslie, Kate; Forbes, Andrew; Wallace, Sophie] Monash Univ, Melbourne, Vic 3004, Australia; [Leslie, Kate] Royal Melbourne Hosp, Parkville, Vic 3050, Australia; [Chan, Matthew T. V.] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China; [Peyton, Philip J.] Austin Hosp, Melbourne, Vic 3084, Australia; [Paech, Michael J.] Univ Western Australia, Perth, WA 6009, Australia; [Beattie, W. Scott] Toronto Gen Hosp, Toronto, ON, Canada; [Sessler, Daniel I.] Cleveland Clin, Cleveland, OH 44106 USA; [Devereaux, P. J.] Hamilton Hlth Sci, Hamilton, ON, Canada; [Silbert, Brendan] St Vincents Hosp, Melbourne, Vic, Australia; [Schricker, Thomas] Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada	Florey Institute of Neuroscience & Mental Health; Monash University; Royal Melbourne Hospital; Chinese University of Hong Kong; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Western Australia; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Cleveland Clinic Foundation; McMaster University; St Vincent's Hospital Melbourne; McGill University; Royal Victoria Hospital	Myles, PS (corresponding author), Alfred Hosp, Dept Anaesthesia & Perioperat Med, Melbourne, Vic 3004, Australia.	p.myles@alfred.org.au	Sneyd, John/AFV-7886-2022; Sessler, Daniel/D-3504-2011; Devereaux, PJ/AAF-2862-2019; Obal, Detlef/A-6542-2009; Sneyd, John Robert/B-2957-2012; Sneyd, John/AFV-7887-2022; Devereaux, PJ/AAY-1757-2021; Chan, Matthew/J-2884-2013; Myles, Paul/AAU-9524-2020	Sneyd, John/0000-0003-3546-9856; Sessler, Daniel/0000-0001-9932-3077; Obal, Detlef/0000-0002-1126-2132; Sneyd, John Robert/0000-0003-3546-9856; Sneyd, John/0000-0003-3546-9856; Chan, Matthew/0000-0002-3574-7855; Myles, Paul/0000-0002-3324-5456; Devereaux, PJ/0000-0003-2935-637X; Banner-Goodspeed, Valerie/0000-0002-7644-2521; Kunst, Gudrun/0000-0002-9789-1334; Forbes, Andrew/0000-0003-4269-914X; Leslie, Kate/0000-0001-8512-3517; Egan, Cameron/0000-0002-8927-7588; haller, guy/0000-0001-7367-7029; PAECH, MICHAEL/0000-0001-9023-6575	Australian National Health and Medical Research Council; Australian and New Zealand College of Anaesthetists; Heart and Stroke Foundation of Quebec; Heart and Stroke Foundation of Ontario, Canada; General Research Fund of the Research Grant Council, Hong Kong Special Administrative Region, China	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian and New Zealand College of Anaesthetists; Heart and Stroke Foundation of Quebec; Heart and Stroke Foundation of Ontario, Canada(Heart & Stroke Foundation of Ontario); General Research Fund of the Research Grant Council, Hong Kong Special Administrative Region, China	Funding Australian National Health and Medical Research Council; Australian and New Zealand College of Anaesthetists; Heart and Stroke Foundation of Quebec, Heart and Stroke Foundation of Ontario, Canada; General Research Fund of the Research Grant Council, Hong Kong Special Administrative Region, China.	Albert CM, 2008, JAMA-J AM MED ASSOC, V299, P2027, DOI 10.1001/jama.299.17.2027; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Badner NH, 2000, ANESTH ANALG, V91, P1073, DOI 10.1097/00000539-200011000-00006; Bistulfi G, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-6; Bonaa KH, 2006, NEW ENGL J MED, V354, P1578, DOI 10.1056/NEJMoa055227; Chan MTV, 2011, PAIN, V152, P2514, DOI 10.1016/j.pain.2011.07.015; Chen Y, 2013, ANESTHESIOLOGY, V118, P1322, DOI 10.1097/ALN.0b013e31829107b8; Clarke R, 2010, ARCH INTERN MED, V170, P1622, DOI 10.1001/archinternmed.2010.348; Devereaux PJ, 2005, CAN MED ASSOC J, V173, P627, DOI 10.1503/cmaj.050011; Durga J, 2007, LANCET, V369, P208, DOI 10.1016/S0140-6736(07)60109-3; ERMENS AAM, 1991, CLIN PHARMACOL THER, V49, P385, DOI 10.1038/clpt.1991.45; Fleischmann E, 2005, LANCET, V366, P1101, DOI 10.1016/S0140-6736(05)67422-3; Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002; Grocott MPW, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004082.pub5; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Huang T, 2012, CLIN NUTR, V31, P448, DOI 10.1016/j.clnu.2011.01.003; Imberger G, 2014, BRIT J ANAESTH, V112, P410, DOI 10.1093/bja/aet416; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Leonardi S, 2013, EUR HEART J, V34, P894, DOI 10.1093/eurheartj/eht003; Leslie K, 2013, ANESTH ANALG, V116, P1034, DOI 10.1213/ANE.0b013e318270014a; Leslie K, 2011, ANESTH ANALG, V112, P387, DOI 10.1213/ANE.0b013e3181f7e2c4; Lison S, 2011, BLOOD COAGUL FIBRIN, V22, P190, DOI 10.1097/MBC.0b013e328343f7be; Mangano DT, 1995, NEW ENGL J MED, V333, P1750, DOI 10.1056/NEJM199512283332607; Meyhoff CS, 2009, JAMA-J AM MED ASSOC, V302, P1543, DOI 10.1001/jama.2009.1452; Miller ER, 2010, AM J CARDIOL, V106, P517, DOI 10.1016/j.amjcard.2010.03.064; Myles PS, 2008, ANESTHESIOLOGY, V109, P657, DOI 10.1097/ALN.0b013e31818629db; Myles PS, 2007, ANESTHESIOLOGY, V107, P221, DOI 10.1097/01.anes.0000270723.30772.da; Myles PS, 2009, AM HEART J, V157, P488, DOI 10.1016/j.ahj.2008.11.015; Myles PS, 1999, ANESTH ANALG, V88, P83, DOI 10.1097/00000539-199901000-00016; Nagele P, 2013, ANESTHESIOLOGY, V119, P19, DOI 10.1097/ALN.0b013e31829761e3; NUNN JF, 1987, BRIT J ANAESTH, V59, P3, DOI 10.1093/bja/59.1.3; Qadan M, 2009, ARCH SURG-CHICAGO, V144, P359, DOI 10.1001/archsurg.2009.1; Thygesen K, 2012, CIRCULATION, V126, P2020, DOI 10.1161/CIR.0b013e31826e1058; Tolg C, 2011, LAB INVEST, V91, P825, DOI 10.1038/labinvest.2010.197; Turan A, 2013, ANESTH ANALG, V116, P1026, DOI 10.1213/ANE.0b013e31824590a5; Wald DS, 2002, BMJ-BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202	36	124	130	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	2014	384	9952					1446	1454		10.1016/S0140-6736(14)60893-X	http://dx.doi.org/10.1016/S0140-6736(14)60893-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AQ8TV	25142708				2023-01-03	WOS:000343107000025
J	Lucchesi, D; Russo, R; Gabriele, M; Longo, V; Del Prato, S; Penno, G; Pucci, L				Lucchesi, Daniela; Russo, Rossella; Gabriele, Morena; Longo, Vincenzo; Del Prato, Stefano; Penno, Giuseppe; Pucci, Laura			Grain and Bean Lysates Improve Function of Endothelial Progenitor Cells from Human Peripheral Blood: Involvement of the Endogenous Antioxidant Defenses	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; GINKGO-BILOBA EXTRACT; OXIDATIVE STRESS; PHASEOLUS-VULGARIS; HEALTH-BENEFITS; UP-REGULATION; WHOLE GRAINS; LISOSAN-G; AUGMENTATION; RESVERATROL	Increased oxidative stress contributes to the functional impairment of endothelial progenitor cells (EPCs), the pivotal players in the servicing of the endothelial cell lining. Several evidences suggest that decreasing oxidative stress by natural compounds with antioxidant properties may improve EPCs bioactivity. Here, we investigated the effects of Lisosan G (LG), a Triticum Sativum grain powder, and Lady Joy (LJ), a bean lysate, on function of EPCs exposed to oxidative stress. Peripheral blood mononuclear cells were isolated and plated on fibronectin-coated culture dishes; adherent cells, identified as early EPCs, were pre-treated with different concentrations of LG and LJ and incubated with hydrogen peroxide (H2O2). Viability, senescence, adhesion, ROS production and antioxidant enzymes gene expression were evaluated. Lysate-mediated Nrf-2 (nuclear factor (erythroid-derived 2)-like 2)/ARE (antioxidant response element) activation, a modulator of oxidative stress, was assessed by immunocytochemistry. Lady Joy 0.35-0.7 mg/ml increases EPCs viability; pre-treatment with either LG 0.7 mg/ml and LJ 0.35-0.7 mg/ml protect EPCs viability against H2O2-induced injury. LG 0.7 and LJ 0.35-0.7 mg/ml improve EPCs adhesion; pre-treatment with either LG 0.35 and 0.7 mg/ml or LJ 0.35, 0.7 and 1.4 mg/ml preserve adhesiveness of EPCs exposed to H2O2. Senescence is attenuated in EPCs incubated with lysates 0.35 mg/ml. After exposure to H2O2, LG pretreated cells show a lower senescence than untreated EPCs. Lysates significantly decrease H2O2-induced ROS generation. Both lysates increase glutathione peroxidase-1 and superoxide dismutase-2 (SOD-2) expression; upon H2O2 exposure, pretreatment with LJ allows higher SOD-2 expression. Heme oxigenase-1 increases in EPCs pre-treated with LG even upon H2O2 exposure. Finally, incubation with LG 0.7 mg/ml results in Nrf-2 translocation into the nucleus both at baseline and after the oxidative challenge. Our data suggest a protective effect of lysates on EPCs exposed to oxidative stress through the involvement of antioxidant systems. Lisosan G seems to activate the Nrf-2/ARE pathways.	[Lucchesi, Daniela; Del Prato, Stefano; Penno, Giuseppe] Univ Pisa, Dept Clin & Expt Med, Sect Metab Dis, Pisa, Italy; [Russo, Rossella; Gabriele, Morena; Longo, Vincenzo; Pucci, Laura] CNR, Natl Res Council, Inst Agr Biol & Biotechnol, I-56100 Pisa, Italy	University of Pisa; Consiglio Nazionale delle Ricerche (CNR)	Pucci, L (corresponding author), CNR, Natl Res Council, Inst Agr Biol & Biotechnol, I-56100 Pisa, Italy.	lauric16@yahoo.it	Del+Prato, Stefano/AAC-9197-2021; Longo, Vincenzo/K-3695-2018; Gabriele, Morena/AAU-9725-2020; Gabriele, Morena/L-1631-2018; Del Prato, Stefano/K-3405-2016; Pucci, Laura/AAU-4653-2020	Longo, Vincenzo/0000-0001-8972-8564; Gabriele, Morena/0000-0002-9456-6755; Gabriele, Morena/0000-0002-9456-6755; Del Prato, Stefano/0000-0002-5388-0270; Pucci, Laura/0000-0001-7063-6192; PUCCI, LAURA/0000-0002-8162-4039	Regione Toscana, Italy [Resolution 1157, D55E11002680005]	Regione Toscana, Italy(Regione Toscana)	This work was supported by a grant from Regione Toscana, Italy, Resolution 1157 (December 19, 2011), ID number D55E11002680005. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albiero Mattia, 2010, Cardiovascular & Hematological Disorders - Drug Targets, V10, P16; Alfadda AA, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/936486; Angeloni C, 2012, OXID MED CELL LONGEV, DOI [10.1155/2012/585901, DOI 10.1155/2012/585901]; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Badimon L, 2010, CARDIOVASC THER, V28, P202, DOI 10.1111/j.1755-5922.2010.00189.x; BANWELL JG, 1985, APPL ENVIRON MICROB, V50, P68, DOI 10.1128/AEM.50.1.68-80.1985; Basile DP, 2014, J CELL PHYSIOL, V229, P10, DOI 10.1002/jcp.24423; Bosch J, 2012, NEW ENGL J MED, V367, P309, DOI 10.1056/NEJMoa1203859; BUETLER TM, 1995, TOXICOL APPL PHARM, V135, P45, DOI 10.1006/taap.1995.1207; Cao ZX, 2004, EUR J PHARMACOL, V489, P39, DOI 10.1016/j.ejphar.2004.02.031; Chan YH, 2011, EUR J CARDIOV PREV R, V18, P360, DOI 10.1177/1741826710389385; Chen XL, 2006, AM J PHYSIOL-HEART C, V290, pH1862, DOI 10.1152/ajpheart.00651.2005; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; de Munter JSL, 2007, PLOS MED, V4, P1385, DOI 10.1371/journal.pmed.0040261; Dernbach E, 2004, BLOOD, V104, P3591, DOI 10.1182/blood-2003-12-4103; Desouza CV, 2013, J DIABETES COMPLICAT, V27, P519, DOI 10.1016/j.jdiacomp.2013.04.007; Diplock AT, 1999, BRIT J NUTR, V81, pS1, DOI 10.1017/S0007114599000471; Dong XX, 2007, J CARDIOVASC PHARM, V49, P111, DOI 10.1097/FJC.0b013e31802ef519; Eilat-Adar S, 2010, NUTR METAB CARDIOVAS, V20, P459, DOI 10.1016/j.numecd.2010.01.011; Everette JD, 2010, J AGR FOOD CHEM, V58, P8139, DOI 10.1021/jf1005935; Fadini GP, 2014, DIABETOLOGIA, V57, P4, DOI 10.1007/s00125-013-3087-6; Fadini GP, 2012, CIRC RES, V110, P624, DOI 10.1161/CIRCRESAHA.111.243386; Felice F, 2010, MICROVASC RES, V80, P332, DOI 10.1016/j.mvr.2010.05.004; Flight I, 2006, EUR J CLIN NUTR, V60, P1145, DOI 10.1038/sj.ejcn.1602435; Fraga CG, 2010, MOL ASPECTS MED, V31, P435, DOI 10.1016/j.mam.2010.09.006; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Gwarzo MY, 2009, AFR J BIOTECHNOL, V8, P5169; Hamed S, 2010, AM J CLIN NUTR, V92, P161, DOI 10.3945/ajcn.2009.28408; Harris KA, 2010, CURR ATHEROSCLER REP, V12, P368, DOI 10.1007/s11883-010-0136-1; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; He TR, 2004, ARTERIOSCL THROM VAS, V24, P2021, DOI 10.1161/01.ATV.0000142810.27849.8f; He W, 2011, J ASIAN NAT PROD RES, V13, P1, DOI 10.1080/10286020.2010.535519; Huang DJ, 2002, J AGR FOOD CHEM, V50, P4437, DOI 10.1021/jf0201529; Huang XS, 2014, MOL CELL BIOCHEM, V385, P33, DOI 10.1007/s11010-013-1812-6; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Jonnalagadda SS, 2011, J NUTR, V141, p1011S, DOI 10.3945/jn.110.132944; Lee KW, 2003, J AGR FOOD CHEM, V51, P6516, DOI 10.1021/jf034475w; Lee SH, 2013, FREE RADICAL RES, V47, P526, DOI 10.3109/10715762.2013.797080; Li YJ, 2010, J ETHNOPHARMACOL, V131, P562, DOI 10.1016/j.jep.2010.07.040; Lin CP, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/845037; Longo V, 2011, FOOD CHEM TOXICOL, V49, P233, DOI 10.1016/j.fct.2010.10.021; Longo V, 2007, BIOTECHNOL LETT, V29, P1155, DOI 10.1007/s10529-007-9378-6; Lubrano V, 2012, INDIAN J MED RES, V136, P82; Madonna R, 2011, VASC PHARMACOL, V54, P75, DOI 10.1016/j.vph.2011.03.007; Marin C, 2013, INT J MOL SCI, V14, P8869, DOI 10.3390/ijms14058869; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Obiro WC, 2008, BRIT J NUTR, V100, P1, DOI 10.1017/S0007114508879135; Okarter N, 2010, CRIT REV FOOD SCI, V50, P193, DOI 10.1080/10408390802248734; Parzonko A, 2013, PHYTOMEDICINE, V20, P1088, DOI 10.1016/j.phymed.2013.05.002; Pasciu V, 2010, TOXICOL SCI, V114, P101, DOI 10.1093/toxsci/kfp301; Preuss HG, 2009, J AM COLL NUTR, V28, P266, DOI 10.1080/07315724.2009.10719781; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Saragih H, 2014, THROMB HAEMOST, V111; Shantsila E, 2007, J AM COLL CARDIOL, V49, P741, DOI 10.1016/j.jacc.2006.09.050; Singleton VL, 1999, METHOD ENZYMOL, V299, P152; Tang YB, 2014, BRIT J PHARMACOL, V171, P2440, DOI 10.1111/bph.12611; Tang YB, 2011, EUR CELLS MATER, V21, P459, DOI 10.22203/eCM.v021a34; Turgeon J, 2013, ATHEROSCLEROSIS, V229, P295, DOI 10.1016/j.atherosclerosis.2013.05.020; Urbich C, 2002, CIRC RES, V90, P737, DOI 10.1161/01.RES.0000014081.30867.F8; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; van Oostrom O, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-47; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Wang XB, 2007, CLIN EXP PHARMACOL P, V34, P1109, DOI 10.1111/j.1440-1681.2007.04667.x; Wang XB, 2011, CHINESE MED J-PEKING, V124, P4310, DOI 10.3760/cma.j.issn.0366-6999.2011.24.033; Wong CY, 2010, DIABETIC MED, V27, P54, DOI 10.1111/j.1464-5491.2009.02869.x; Wu QQ, 2013, EUR J PHARMACOL, V707, P87, DOI 10.1016/j.ejphar.2013.03.027; Xu MG, 2009, CARDIOLOGY, V112, P279, DOI 10.1159/000157336; Yoder MC, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006692; Zhang T, 2013, BRIT J NUTR, V109, P223, DOI 10.1017/S0007114512001110; Zhao M, 2014, GENET MOL RES, V13, P220, DOI 10.4238/2014.January.14.1; Zhu JH, 2008, VASC PHARMACOL, V49, P106, DOI 10.1016/j.vph.2008.07.002	72	26	26	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2014	9	10							e109298	10.1371/journal.pone.0109298	http://dx.doi.org/10.1371/journal.pone.0109298			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8TF	25329912	gold, Green Published			2023-01-03	WOS:000345204100014
J	Chiang, C; Hsiao, CF; Liu, JP				Chiang, Chieh; Hsiao, Chin-Fu; Liu, Jen-Pei			Sample Size Determination for Individual Bioequivalence Inference	PLOS ONE			English	Article								Statistical criterion for evaluation of individual bioequivalence (IBE) between generic and innovative products often involves a function of the second moments of normal distributions. Under replicated crossover designs, the aggregate criterion for IBE proposed by the guidance of the U. S. Food and Drug Administration (FDA) contains the squared mean difference, variance of subject-by-formulation interaction, and the difference in within-subject variances between the generic and innovative products. The upper confidence bound for the linearized form of the criterion derived by the modified large sample (MLS) method is proposed in the 2001 U. S. FDA guidance as a testing procedure for evaluation of IBE. Due to the complexity of the power function for the criterion based on the second moments, literature on sample size determination for the inference of IBE is scarce. Under the two-sequence and four-period crossover design, we derive the asymptotic distribution of the upper confidence bound of the linearized criterion. Hence the asymptotic power can be derived for sample size determination for evaluation of IBE. Results of numerical studies are reported. Discussion of sample size determination for evaluation of IBE based on the aggregate criterion of the second moments in practical applications is provided.	[Chiang, Chieh; Hsiao, Chin-Fu; Liu, Jen-Pei] Natl Taiwan Univ, Dept Agron, Div Biometry, Taipei, Taiwan; [Liu, Jen-Pei] Natl Taiwan Univ, Inst Epidemiol & Prevent Med, Taipei 10764, Taiwan; [Chiang, Chieh; Hsiao, Chin-Fu; Liu, Jen-Pei] Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Biostat & Bioinformat, Zhunan, Taiwan	National Taiwan University; National Taiwan University; National Health Research Institutes - Taiwan	Liu, JP (corresponding author), Natl Taiwan Univ, Dept Agron, Div Biometry, Taipei, Taiwan.	jpliu@ntu.edu.tw	Hsiao, Chin-Fu/E-3993-2010; Chiang, Chieh/C-3815-2015	Chiang, Chieh/0000-0003-4319-4565; Liu, Jen-pei/0000-0002-9565-1812; Hsiao, Chin-Fu/0000-0003-1284-7260	Taiwan's National Science Council [NSC 101-2118-M-002-002-MY2]	Taiwan's National Science Council	This research was supported by a grant from Taiwan's National Science Council (NSC 101-2118-M-002-002-MY2) to JPL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barndorff-Nielsen OE, 1989, ASYMPTOTIC TECHNIQUE, P118; Chow SC, 2002, STAT MED, V21, P629, DOI 10.1002/sim.1056; Chow SC, 2010, DESIGN ANAL BIOAVAIL, P335; Chow SC, 2013, STAT MED, V32, P370, DOI 10.1002/sim.5571; Hyslop T, 2000, STAT MED, V19, P2885, DOI 10.1002/1097-0258(20001030)19:20<2885::AID-SIM553>3.3.CO;2-8; Serfling RJ, 1980, APPROXIMATION THEORE, p[120, 190]; The European Agency for the Evaluation of medicinal Products (EMEA), 2001, NOT GUID INV BIOAV B, P2; U.S. Food and Drug Administration (FDA), 2001, GUID IND STAT APPR E, P7; US Food and Drug Administration (FDA), 2012, GUID SCI CO IN PRESS, P12; World Health Organization (WHO), 2005, MOV TSUN WHO ST, P4	10	1	1	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2014	9	10							e109746	10.1371/journal.pone.0109746	http://dx.doi.org/10.1371/journal.pone.0109746			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ9WZ	25310592	Green Submitted, Green Published, gold			2023-01-03	WOS:000343210300070
J	Ghoneim, N; Bauchart-Thevret, C; Oosterloo, B; Stoll, B; Kulkarni, M; de Pipaon, MS; Zamora, IJ; Olutoye, OO; Berg, B; Wittke, A; Burrin, DG				Ghoneim, Nada; Bauchart-Thevret, Caroline; Oosterloo, Berthe; Stoll, Barbara; Kulkarni, Madhulika; Saenz de Pipaon, Miguel; Zamora, Irving J.; Olutoye, Oluyinka O.; Berg, Brian; Wittke, Anja; Burrin, Douglas G.			Delayed Initiation but Not Gradual Advancement of Enteral Formula Feeding Reduces the Incidence of Necrotizing Enterocolitis (NEC) in Preterm Pigs	PLOS ONE			English	Article							TOLL-LIKE RECEPTORS; HUMAN-MILK; PROTEIN; PATHOGENESIS; INFANTS; COLONIZATION; CALPROTECTIN; DYSFUNCTION; NUTRITION; RESPONSES	Enteral formula feeding is a risk factor for necrotizing enterocolitis (NEC) in premature infants, yet studies are conflicting regarding the safest timing for introduction and advancement of feeds. Our aim was to test the effects of early vs. late initiation and abrupt vs. gradual advancement of enteral feeding of an intact vs. hydrolyzed protein formula on NEC incidence and severity in preterm pigs. In Experiment 1, preterm pigs received total parenteral nutrition (TPN) at birth with abrupt initiation of enteral formula feeds (50% full intake) on d of life (DOL) 2 (EA) or 5 (LA) while PN continued. Pigs were also fed formula containing either intact or hydrolyzed protein. In Experiment 2, preterm pigs received TPN at birth with enteral, hydrolyzed-protein formula feeds introduced on DOL 2 either abruptly (EA; 50% full feeds) or gradually (EG; 10-50% full feeds over 5 d) while PN continued. NEC incidence and severity were assessed based on macroscopic and histological scoring. In Experiment 1, NEC incidence (41% vs. 70%, P<0.05) and severity were reduced in LA vs. EA groups and LA was associated with a higher survival rate, daily weight gain and jejunum villus height. Piglets fed hydrolyzed vs. intact protein formula had lower stomach content weights and similar NEC incidence. In Experiment 2, NEC incidence and severity were not different between pigs the EG vs. EA group. Proinflammatory gene expression (IL-1 beta, IL-6 and S100A9) in the ileum was lower in both LA and EG vs. EA groups. In conclusion, delayed initiation but not gradual advancement of enteral feeding is protective against NEC in preterm pigs. Feeding hydrolyzed vs. intact protein formula improved gastric transit without affecting the NEC incidence.	[Ghoneim, Nada; Kulkarni, Madhulika] Texas Childrens Hosp, Baylor Coll Med, Sect Neonatol, Div Pediat Surg,Michael E DeBakey Dept Surg, Houston, TX 77030 USA; [Bauchart-Thevret, Caroline; Oosterloo, Berthe; Stoll, Barbara; Burrin, Douglas G.] Texas Childrens Hosp, Baylor Coll Med, ARS, USDA,Childrens Nutr Res Ctr,Div Pediat Surg,Micha, Houston, TX 77030 USA; [Burrin, Douglas G.] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat,Div Pediat Surg, Michael E DeBakey Dept Surg,Sect Gastroenterol He, Houston, TX 77030 USA; [Zamora, Irving J.; Olutoye, Oluyinka O.] Texas Childrens Hosp, Baylor Coll Med, Michael E DeBakey Dept Surg, Div Pediat Surg, Houston, TX 77030 USA; [Saenz de Pipaon, Miguel] La Paz Univ Hosp, Dept Neonatol, Madrid, Spain; [Berg, Brian; Wittke, Anja] Mead Johnson Pediat Nutr Inst, Evansville, IN USA	Baylor College of Medicine; Baylor College of Medicine; United States Department of Agriculture (USDA); Baylor College of Medicine; Baylor College of Medicine; Hospital Universitario La Paz	Burrin, DG (corresponding author), Texas Childrens Hosp, Baylor Coll Med, ARS, USDA,Childrens Nutr Res Ctr,Div Pediat Surg,Micha, Houston, TX 77030 USA.	dburrin@bcm.edu	de Pipaón, Miguel Sáenz/AAA-3851-2019; Oosterloo, Neelke/AAU-4700-2020; Burrin, Douglas/AID-0081-2022; olutoye, oluyinka/AFL-2055-2022; olutoye, oluyinka/AAI-8093-2021	de Pipaón, Miguel Sáenz/0000-0002-4793-1561; Burrin, Douglas/0000-0002-8792-3339	U.S. Department of Agriculture, Agricultural Research Service [58-6250-6-001]; Spanish government [BA/12/00086]; Mead Johnson Pediatric Nutrition Institute; Whitlock Foundation; Texas Medical Center Digestive Diseases Center (NIH) [P30 DK-56338]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056338] Funding Source: NIH RePORTER; ARS [ARS-0426348] Funding Source: Federal RePORTER	U.S. Department of Agriculture, Agricultural Research Service(United States Department of Agriculture (USDA)USDA Agricultural Research Service); Spanish government(Spanish GovernmentEuropean Commission); Mead Johnson Pediatric Nutrition Institute; Whitlock Foundation; Texas Medical Center Digestive Diseases Center (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); ARS(United States Department of Agriculture (USDA)USDA Agricultural Research Service)	Funding was provided by U.S. Department of Agriculture, Agricultural Research Service under Cooperative Agreement Number 58-6250-6-001, Spanish government fund BA/12/00086 and grant support from the Mead Johnson Pediatric Nutrition Institute, the Whitlock Foundation and the Texas Medical Center Digestive Diseases Center (NIH Grant P30 DK-56338). The funder [Mead Johnson Pediatric Nutrition Institute] provided support in the form of salaries for authors [BB and AW], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Aydemir G, 2012, CLIN LAB, V58, P841, DOI 10.7754/Clin.Lab.2012.111214; BELL MJ, 1978, NEW ENGL J MED, V298, P281; Berseth CL, 2003, PEDIATRICS, V111, P529, DOI 10.1542/peds.111.3.529; Biswas SK, 2009, TRENDS IMMUNOL, V30, P475, DOI 10.1016/j.it.2009.07.009; Bjornvad CR, 2008, AM J PHYSIOL-GASTR L, V295, pG1092, DOI 10.1152/ajpgi.00414.2007; Boirie Y, 1997, P NATL ACAD SCI USA, V94, P14930, DOI 10.1073/pnas.94.26.14930; Bombell S, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000504.pub3; Caplan M, 2007, J PEDIATR-US, V150, P329, DOI 10.1016/j.jpeds.2007.01.027; Caplan Michael S, 2005, Semin Pediatr Surg, V14, P145, DOI 10.1053/j.sempedsurg.2005.05.002; Cilieborg MS, 2012, EARLY HUM DEV, V88, pS41, DOI 10.1016/j.earlhumdev.2011.12.027; Claud Erika C., 2009, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V8, P248; Ehrchen JM, 2009, J LEUKOCYTE BIOL, V86, P557, DOI 10.1189/jlb.1008647; Frost BL, 2008, SEMIN PERINATOL, V32, P100, DOI 10.1053/j.semperi.2008.01.001; Gribar SC, 2009, J IMMUNOL, V182, P636, DOI 10.4049/jimmunol.182.1.636; Hackam DJ, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/475415; Hackam DJ, 2013, SEMIN PEDIATR SURG, V22, P76, DOI 10.1053/j.sempedsurg.2013.01.003; Henry MCW, 2009, ANNU REV MED, V60, P111, DOI 10.1146/annurev.med.60.050207.092824; Lin PW, 2008, SEMIN PERINATOL, V32, P70, DOI 10.1053/j.semperi.2008.01.004; Lin PW, 2006, LANCET, V368, P1271, DOI 10.1016/S0140-6736(06)69525-1; Liu YY, 2009, AM J PHYSIOL-GASTR L, V297, pG442, DOI 10.1152/ajpgi.00182.2009; LUCAS A, 1990, LANCET, V336, P1519, DOI 10.1016/0140-6736(90)93304-8; Mihatsch WA, 2002, PEDIATRICS, V110, P1199, DOI 10.1542/peds.110.6.1199; Mihatsch WA, 2001, ACTA PAEDIATR, V90, P196, DOI 10.1080/080352501300049442; Morgan J, 2013, COCHRANE DB SYST REV, V28; NEWPORT MJ, 1985, J PEDIATR GASTR NUTR, V4, P639, DOI 10.1097/00005176-198508000-00025; Sangild PT, 2006, EXP BIOL MED, V231, P1695, DOI 10.1177/153537020623101106; Sangild PT, 2006, GASTROENTEROLOGY, V130, P1776, DOI 10.1053/j.gastro.2006.02.026; Schanler RJ, 1999, CLIN PERINATOL, V26, P379, DOI 10.1016/S0095-5108(18)30058-7; Siggers J, 2011, AM J PHYSIOL-GASTR L, V301, pG435, DOI 10.1152/ajpgi.00400.2010; Siggers RH, 2011, J NUTR BIOCHEM, V22, P511, DOI 10.1016/j.jnutbio.2010.08.002; Sisk PM, 2007, J PERINATOL, V27, P428, DOI 10.1038/sj.jp.7211758; Terrin G, 2012, ARCH DIS CHILD, V97, P1102, DOI 10.1136/archdischild-2012-302698; Thymann T, 2009, AM J PHYSIOL-GASTR L, V297, pG1115, DOI 10.1152/ajpgi.00261.2009; Tudehope DI, 2005, J PAEDIATR CHILD H, V41, P167, DOI 10.1111/j.1440-1754.2005.00581.x; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Young C, 2009, PEDIATR RES, V65, p91R, DOI 10.1203/PDR.0b013e31819dba7d; Young L, 2013, COCHRANE DB SYST REV, V5	37	19	19	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2014	9	9							e106888	10.1371/journal.pone.0106888	http://dx.doi.org/10.1371/journal.pone.0106888			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ0RY	25238061	Green Published, Green Submitted, gold			2023-01-03	WOS:000342491600013
J	Corbett, EC				Corbett, Eugene C., Jr.			In newly diagnosed type 2 diabetes, a Mediterranean diet (vs a low-fat diet) delayed start of glucose-lowering drugs	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Virginia, Charlottesville, VA 22903 USA	University of Virginia	Corbett, EC (corresponding author), Univ Virginia, Charlottesville, VA 22903 USA.							Wing R, 2013, NEW ENGL J MED, V369, P145, DOI 10.1056/NEJMoa1212914	1	0	0	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2014	161	6							JC4	10.7326/0003-4819-161-6-201409160-02004	http://dx.doi.org/10.7326/0003-4819-161-6-201409160-02004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AR9LF	25222416				2023-01-03	WOS:000343894400003
J	Liu, J; Griesman, J; Nisenbaum, R; Bell, CM				Liu, Jessica; Griesman, Joshua; Nisenbaum, Rosane; Bell, Chaim M.			Quality of Care of Hospitalized Internal Medicine Patients Bedspaced to Non-Internal Medicine Inpatient Units	PLOS ONE			English	Article							HEART-FAILURE; INDICATORS; MANAGEMENT; OUTCOMES; PNEUMONIA; SAFETY; DISEASE; STATES	Background: When the number of patients requiring hospital admission exceeds the number of available department-allotted beds, patients are often placed on a different specialty's inpatient ward, a practice known as "bedspacing''. Whether bedspacing affects quality of patient care has not been previously studied. Methods: We reviewed consecutive general internal medicine (GIM) admissions for congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), and pneumonia at St. Michael's Hospital in Toronto, Canada, from 2007 to 2011 and examined whether quality of care differs between bedspaced and nonbedspaced patients. We matched each bedspaced patient with a GIM ward patient admitted on the same call shift with the same diagnosis. The primary outcome was the ratio of the actual to the estimated length of stay (ELOS). General and disease specific measures for CHF, COPD, and pneumonia (e. g. fluid restriction) were evaluated, as well as 30-day Emergency Department (ED) and hospital readmissions. Results: Overall, 1639 consecutive admissions were reviewed, and 39 matched pairs for CHF, COPD and pneumonia were studied. Differences in both general and disease specific care measures were not detected between groups. For many disease-specific comparisons, ordering and adherence to quality of care indicators was low in both groups. Conclusions: We were unable to detect differences in quality of care between bedspaced and nonbedspaced patients. As high patient volumes and hospital overcrowding remains, bedspacing will likely continue. More research is required in order to determine if quality of care is compromised by this ongoing practice.	[Liu, Jessica] Univ Hlth Network, Dept Med, Toronto, ON, Canada; [Griesman, Joshua] Royal Coll Surgeons Ireland, Dublin 2, Ireland; [Nisenbaum, Rosane] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Nisenbaum, Rosane] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Bell, Chaim M.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Bell, Chaim M.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Bell, Chaim M.] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Royal College of Surgeons - Ireland; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Bell, CM (corresponding author), Univ Toronto, Dept Med, Toronto, ON, Canada.	cbell@mtsinai.on.ca	Bell, Chaim/C-4611-2015	Bell, Chaim/0000-0002-3778-9469				[Anonymous], 1997, THORAX S5, V52, pS1; Bekmezian A, 2012, PEDIATR EMERG CARE, V28, P236, DOI 10.1097/PEC.0b013e3182494b94; Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376; Bond Kenneth, 2007, Healthc Q, V10, P32; Choi PP, 2004, CAN MED ASSOC J, V170, P1409, DOI 10.1503/cmaj.1030713; Dedier J, 2001, ARCH INTERN MED, V161, P2099, DOI 10.1001/archinte.161.17.2099; Fallis BA, 2000, PLOS, V8; Fonarow GC, 2001, ANN INTERN MED, V135, P694, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00008; Fonarow GC, 2007, JAMA-J AM MED ASSOC, V297, P61, DOI 10.1001/jama.297.1.61; Gruneir A, 2011, OPENMEDICINE, V5; Harel Z, 2012, HEMODIAL INT, V16, P286, DOI 10.1111/j.1542-4758.2011.00633.x; Hernandez AF, 2011, CIRCULATION, V124, P712, DOI 10.1161/CIRCULATIONAHA.111.026088; Ko DT, 2005, ARCH INTERN MED, V165, P2486, DOI 10.1001/archinte.165.21.2486; Krumholz HM, 2000, CIRCULATION, V101, pE122, DOI 10.1161/01.CIR.101.12.e122; Lee DS, 2003, CAN J CARDIOL, V19, P357; Liu SW, 2011, ACAD EMERG MED, V18, P1339, DOI 10.1111/j.1553-2712.2011.01082.x; Liu SW, 2011, ACAD EMERG MED, V18, P430, DOI 10.1111/j.1553-2712.2011.01033.x; Maslove DM, 2009, J GEN INTERN MED, V24, P995, DOI 10.1007/s11606-009-1053-2; Meehan TP, 1997, JAMA-J AM MED ASSOC, V278, P2080, DOI 10.1001/jama.278.23.2080; Numminen O, 2013, J CLIN NURS, V22, P1411, DOI 10.1111/j.1365-2702.2012.04334.x; Perry S, 2009, ST HEAL T, V143, P496, DOI 10.3233/978-1-58603-979-0-496; Rhew DC, 2001, ANN INTERN MED, V135, P736, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00013; Salpeter S, 2005, COCHRANE DB SYST REV, V2005; Scott IA, 2003, INTERN MED J, V33, P140, DOI 10.1046/j.1445-5994.2003.00362.x; Sobie J M, 2000, J Emerg Nurs, V26, P549, DOI 10.1067/men.2000.110891; Staggers N, 2013, J ADV NURS, V69, P247, DOI 10.1111/j.1365-2648.2012.06087.x; Stelfox HT, 2003, JAMA-J AM MED ASSOC, V290, P1899, DOI 10.1001/jama.290.14.1899; Trzeciak S, 2003, EMERG MED J, V20, P402, DOI 10.1136/emj.20.5.402; vanWalraven C, 2011, CMAJ, V183, P1067; Viccellio A, 2009, ANN EMERG MED, V54, P487, DOI 10.1016/j.annemergmed.2009.03.005; White BA, 2013, J EMERG MED, V44, P230, DOI 10.1016/j.jemermed.2012.05.007; Wong HJ, 2010, CAN J EMERG MED, V12, P18; Zwar NA, 2012, MED J AUSTRALIA, V197, P394, DOI 10.5694/mja12.10813	34	6	6	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2014	9	9							e106763	10.1371/journal.pone.0106763	http://dx.doi.org/10.1371/journal.pone.0106763			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO3TB	25184480	gold, Green Published, Green Submitted			2023-01-03	WOS:000341257700114
J	Makris, UE; Abrams, RC; Gurland, B; Reid, MC				Makris, Una E.; Abrams, Robert C.; Gurland, Barry; Reid, M. Carrington			Management of Persistent Pain in the Older Patient A Clinical Review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LOW-BACK-PAIN; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROBLEM-SOLVING THERAPY; CHRONIC NONCANCER PAIN; MUSCULOSKELETAL PAIN; PRIMARY-CARE; KNEE PAIN; PHARMACOLOGICAL MANAGEMENT; SELF-MANAGEMENT; OPIOID USE	IMPORTANCE Persistent pain is highly prevalent, costly, and frequently disabling in later life. OBJECTIVE To describe barriers to the management of persistent pain among older adults, summarize current management approaches, including pharmacologic and nonpharmacologic modalities; present rehabilitative approaches; and highlight aspects of the patient-physician relationship that can help to improve treatment outcomes. This review is relevant for physicians who seek an age-appropriate approach to delivering pain care for the older adult. EVIDENCE ACQUISITION Search of MEDLINE and the Cochrane database from January 1990 through May 2014, using the search terms older adults, senior, ages 65 and above, elderly, and aged along with non-cancer pain, chronic pain, persistent pain, pain management, intractable pain, and refractory pain to identify English-language peer-reviewed systematic reviews, meta-analyses, Cochrane reviews, consensus statements, and guidelines relevant to the management of persistent pain in older adults. FINDINGS Of the 92 identified studies, 35 evaluated pharmacologic interventions, whereas 57 examined nonpharmacologic modalities; the majority (n = 50) focused on older adults with osteoarthritis. This evidence base supports a stepwise approach with acetaminophen as first-line therapy. If treatment goals are not met, a trial of a topical nonsteroidal anti-inflammatory drug, tramadol, or both is recommended. Oral nonsteroidal anti-inflammatory drugs are not recommended for long-term use. Careful surveillance to monitor for toxicity and efficacy is critical, given that advancing age increases risk for adverse effects. A multimodal approach is strongly recommended-emphasizing a combination of both pharmacologic and nonpharmacologic treatments to include physical and occupational rehabilitation, as well as cognitive-behavioral and movement-based interventions. An integrated pain management approach is ideally achieved by cultivating a strong therapeutic alliance between the older patient and the physician. CONCLUSIONS AND RELEVANCE Treatment planning for persistent pain in later life requires a clear understanding of the patient's treatment goals and expectations, comorbidities, and cognitive and functional status, as well as coordinating community resources and family support when available. A combination of pharmacologic, nonpharmacologic, and rehabilitative approaches in addition to a strong therapeutic alliance between the patient and physician is essential in setting, adjusting, and achieving realistic goals of therapy.Copyright 2014 American Medical Association. All rights reserved.	[Makris, Una E.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Rheumat Dis, Dallas, TX 75390 USA; [Makris, Una E.] Vet Adm Med Ctr, Dept Med, Div Rheumatol, Dallas, TX 75216 USA; [Abrams, Robert C.] Weill Cornell Med Coll, Dept Psychiat, New York, NY USA; [Abrams, Robert C.; Reid, M. Carrington] Weill Cornell Med Coll, Div Geriatr & Palliat Med, New York, NY USA; [Gurland, Barry] Columbia Univ, Stroud Ctr, New York, NY USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cornell University; Cornell University; Columbia University	Reid, MC (corresponding author), Weill Cornell Med Coll, Div Geriatr & Palliat Med, 525 E 68th St,Box 39, New York, NY 10065 USA.	mcr2004@med.cornell.edu		Reid, Cary/0000-0001-8117-662X; Makris, Una/0000-0003-4750-0777	National Institute on Aging [R03AG040653, P30AG022845]; Cornell Translational Research Institute for Pain in Later Life [P30AG022845]; Rheumatology Research Foundation/ASP Junior Career Development Award in Geriatric Medicine; Center for Translational Medicine, National Institutes of Health/National Center for Advancing Translational Sciences [KL2TR001103, UL1TR001105]; Columbia University Stroud Center; Agency for Healthcare Quality and Research [R01HS020648]; Howard and Phyllis Schwartz Philanthropic Fund; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS020648] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001105, KL2TR001103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG040653, P30AG022845] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Cornell Translational Research Institute for Pain in Later Life; Rheumatology Research Foundation/ASP Junior Career Development Award in Geriatric Medicine; Center for Translational Medicine, National Institutes of Health/National Center for Advancing Translational Sciences; Columbia University Stroud Center; Agency for Healthcare Quality and Research(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Howard and Phyllis Schwartz Philanthropic Fund; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Dr Makris was supported by a National Institute on Aging GEMSSTAR grant (R03AG040653) and a pilot grant award from the Cornell Translational Research Institute for Pain in Later Life (P30AG022845); she is currently supported by the Rheumatology Research Foundation/ASP Junior Career Development Award in Geriatric Medicine and by Center for Translational Medicine, National Institutes of Health/National Center for Advancing Translational Sciences grants KL2TR001103 and UL1TR001105. Dr Gurland is supported by the Columbia University Stroud Center. Dr Reid is supported by grants from the National Institute on Aging (P30AG022845) and Agency for Healthcare Quality and Research (R01HS020648). Dr Abrams and Dr Reid receive support from the Howard and Phyllis Schwartz Philanthropic Fund.	Abdulla A, 2013, AGE AGEING, V42, pI1, DOI 10.1093/ageing/afs200; Alexopoulos GS, 2011, ARCH GEN PSYCHIAT, V68, P33, DOI 10.1001/archgenpsychiatry.2010.177; Sansone Randy A, 2009, Psychiatry (Edgmont), V6, P17; Arean P, 2008, GERONTOLOGIST, V48, P311, DOI 10.1093/geront/48.3.311; Baer PA, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-44; Bair MJ, 2003, ARCH INTERN MED, V163, P2433, DOI 10.1001/archinte.163.20.2433; Beletsky L, 2012, JAMA-J AM MED ASSOC, V308, P1863, DOI 10.1001/jama.2012.14205; Bingel U, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001244; Bjordal JM, 2004, BMJ-BRIT MED J, V329, P1317, DOI 10.1136/bmj.38273.626655.63; Blyth FM, 2001, PAIN, V89, P127, DOI 10.1016/S0304-3959(00)00355-9; Bordin E.S., 1979, PSYCHOL PSYCHOTHER-T, V16, P252, DOI [10.1037/h0085885, DOI 10.1037/H0085885]; Boyle J, 2012, DIABETES CARE, V35, P2451, DOI 10.2337/dc12-0656; Brown CJ, 2013, JAMA-J AM MED ASSOC, V310, P1168, DOI 10.1001/jama.2013.276566; Buchman AS, 2010, ARTHRIT CARE RES, V62, P1287, DOI 10.1002/acr.20200; Buckeridge D, 2010, J AM GERIATR SOC, V58, P1664, DOI 10.1111/j.1532-5415.2010.03015.x; Burch F, 2004, OSTEOARTHR CARTILAGE, V12, P253, DOI 10.1016/j.joca.2003.10.007; Butler SF, 2004, PAIN, V112, P65, DOI 10.1016/j.pain.2004.07.026; Chappell AS, 2009, PAIN, V146, P253, DOI 10.1016/j.pain.2009.06.024; Chodosh J, 2005, ANN INTERN MED, V143, P427, DOI 10.7326/0003-4819-143-6-200509200-00007; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Dobscha SK, 2009, JAMA-J AM MED ASSOC, V301, P1242, DOI 10.1001/jama.2009.377; Dorflinger L, 2013, TRANSL BEHAV MED, V3, P39, DOI 10.1007/s13142-012-0158-z; Dworkin RH, 2010, MAYO CLIN PROC, V85, pS3, DOI 10.4065/mcp.2009.0649; Elliott AM, 1999, LANCET, V354, P1248, DOI 10.1016/S0140-6736(99)03057-3; Ferreira PH, 2013, PHYS THER, V93, P470, DOI 10.2522/ptj.20120137; Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532-5415.50.6s.1.x; Ferrell B, 2009, J AM GERIATR SOC, V57, P1331, DOI 10.1111/j.1532-5415.2009.02376.x; Fine PG, 2012, PAIN MED, V13, pS57, DOI 10.1111/j.1526-4637.2011.01307.x; Focht BC, 2006, J AGING PHYS ACTIV, V14, P212, DOI 10.1123/japa.14.2.212; Frantsve LME, 2007, PAIN MED, V8, P25, DOI 10.1111/j.1526-4637.2007.00250.x; Fried TR, 2011, ARCH INTERN MED, V171, P1854, DOI 10.1001/archinternmed.2011.424; Gaskin DJ, 2012, J PAIN, V13, P715, DOI 10.1016/j.jpain.2012.03.009; Gilron I, 2005, NEW ENGL J MED, V352, P1324, DOI 10.1056/NEJMoa042580; Goldstein DJ, 2005, PAIN, V116, P109, DOI 10.1016/j.pain.2005.03.029; Gueldner S H, 2001, J Gerontol Nurs, V27, P35; Hadjistavropoulos T, 2007, CLIN J PAIN, V23, pS1, DOI 10.1097/AJP.0b013e31802be869; Hanlon JT, 2009, PAIN MED, V10, P959, DOI 10.1111/j.1526-4637.2009.00698.x; Hasegawa R, 2010, PHYS OCCUP THER GERI, V28, P44, DOI 10.3109/02703180903381086; Helme RD, 2001, CLIN GERIATR MED, V17, P417, DOI 10.1016/S0749-0690(05)70078-1; Hicks TJ, 1999, GERIATR NURS, V20, P144, DOI 10.1016/S0197-4572(99)70006-6; Huusko TM, 2000, BRIT MED J, V321, P1107, DOI 10.1136/bmj.321.7269.1107; Inciardi JA, 2009, PAIN MED, V10, P537, DOI 10.1111/j.1526-4637.2009.00603.x; Inouye SK, 2007, J AM GERIATR SOC, V55, P780, DOI 10.1111/j.1532-5415.2007.01156.x; Jamtvedt G, 2008, PHYS THER, V88, P123, DOI 10.2522/ptj.20070043; Jena AB, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1393; Jerant AF, 2005, PATIENT EDUC COUNS, V57, P300, DOI 10.1016/j.pec.2004.08.004; Johnson CM, 2006, GERIATR NURS, V27, P309, DOI 10.1016/j.gerinurse.2006.08.010; Kang JW, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2010-000035; Karp JF, 2012, PAIN MED, V13, P405, DOI 10.1111/j.1526-4637.2011.01322.x; Katz JN, 2006, J BONE JOINT SURG AM, V88A, P21, DOI 10.2106/JBJS.E.01273; Kessner S, 2013, JAMA INTERN MED, V173, P1468, DOI 10.1001/jamainternmed.2013.6705; Kroenke CH, 2013, BREAST CANCER RES TR, V139, P515, DOI 10.1007/s10549-013-2477-2; Larson AM, 2005, HEPATOLOGY, V42, P1364, DOI 10.1002/hep.20948; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Leveille SG, 2002, J GEN INTERN MED, V17, P766, DOI 10.1046/j.1525-1497.2002.20229.x; Leveille SG, 2001, ANN INTERN MED, V135, P1038, DOI 10.7326/0003-4819-135-12-200112180-00007; Leveille SG, 2007, PAIN, V128, P69, DOI 10.1016/j.pain.2006.08.031; Leveille SG, 2009, JAMA-J AM MED ASSOC, V302, P2214, DOI 10.1001/jama.2009.1738; Levy SS, 2012, DISABIL HEALTH J, V5, P305, DOI 10.1016/j.dhjo.2012.07.003; Lin EHB, 2003, JAMA-J AM MED ASSOC, V290, P2428, DOI 10.1001/jama.290.18.2428; Lunde LH, 2009, J CLIN PSYCHOL MED S, V16, P254, DOI 10.1007/s10880-009-9162-y; Luria A.R., 1966, HIGHER CORTICAL FUNC, Vfirst; Maizels M, 2005, AM FAM PHYSICIAN, V71, P483; Makris UE, 2010, J RHEUMATOL, V37, P1236, DOI 10.3899/jrheum.090935; Malonne H, 2005, J CLIN PHARM THER, V30, P113, DOI 10.1111/j.1365-2710.2004.00624.x; Malonne H, 2004, CLIN THER, V26, P1774, DOI 10.1016/j.clinthera.2004.11.005; Manheimer E, 2007, ANN INTERN MED, V146, P868, DOI 10.7326/0003-4819-146-12-200706190-00008; Miller M, 2011, J AM GERIATR SOC, V59, P430, DOI 10.1111/j.1532-5415.2011.03318.x; Morello CM, 1999, ARCH INTERN MED, V159, P1931, DOI 10.1001/archinte.159.16.1931; Morone NE, 2009, PAIN MED, V10, P1395, DOI 10.1111/j.1526-4637.2009.00746.x; Muraven M, 1998, J PERS SOC PSYCHOL, V74, P774, DOI 10.1037/0022-3514.74.3.774; National Alliance for Model State Drug Laws (NAMSDL), STAT STAT PRESCR DRU; Nicholas MK, 2013, PAIN, V154, P824, DOI 10.1016/j.pain.2013.02.009; Nimrod G, 2010, GERONTOLOGIST, V50, P382, DOI 10.1093/geront/gnp141; Nordin C, 2013, J REHABIL MED, V45, P580, DOI 10.2340/16501977-1136; O'Neil CK, 2012, AM J GERIATR PHARMAC, V10, P331, DOI 10.1016/j.amjopharm.2012.09.004; Olfson M, 2013, J CLIN PSYCHIAT, V74, P932, DOI 10.4088/JCP.13m08349; Papaleontiou M, 2010, J AM GERIATR SOC, V58, P1353, DOI 10.1111/j.1532-5415.2010.02920.x; Park J, 2012, J AM GERIATR SOC, V60, P555, DOI 10.1111/j.1532-5415.2011.03846.x; Park J, 2011, HOLIST NURS PRACT, V25, P316, DOI 10.1097/HNP.0b013e318232c5f9; Patel KV, 2013, PAIN, V154, P2649, DOI 10.1016/j.pain.2013.07.029; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Perlman AI, 2006, ARCH INTERN MED, V166, P2533, DOI 10.1001/archinte.166.22.2533; Reid MC, 2010, PAIN MED, V11, P1063, DOI 10.1111/j.1526-4637.2010.00883.x; Reid MC, 2011, PAIN MED, V12, P1336, DOI 10.1111/j.1526-4637.2011.01211.x; Reid MC, 2005, J GERONTOL A-BIOL, V60, P793, DOI 10.1093/gerona/60.6.793; Reid MC, 2003, J AM GERIATR SOC, V51, P1092, DOI 10.1046/j.1532-5415.2003.51357.x; Saunders KW, 2010, J GEN INTERN MED, V25, P310, DOI 10.1007/s11606-009-1218-z; Schonberger M, 2006, BRAIN INJURY, V20, P1271, DOI 10.1080/02699050601049395; Shega JW, PUBLICATION PRACTICE; Shekelle PG, 1999, BRIT MED J, V318, P593, DOI 10.1136/bmj.318.7183.593; Solomon DH, 2010, ARCH INTERN MED, V170, P1979, DOI 10.1001/archinternmed.2010.450; Solomon DH, 2010, ARCH INTERN MED, V170, P1968, DOI 10.1001/archinternmed.2010.391; Spitz A, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-35; Steultjens EMJ, 2004, AGE AGEING, V33, P453, DOI 10.1093/ageing/afh174; Taylor AL, 2008, JAMA-J AM MED ASSOC, V299, P89, DOI 10.1001/jama.2007.25; Teh CF, 2009, PAIN MED, V10, P521, DOI 10.1111/j.1526-4637.2008.00556.x; Thielke S, 2012, J FAM PRACTICE, V61, P666; Thom DH, 2002, FAM PRACT, V19, P476, DOI 10.1093/fampra/19.5.476; Tobias KR, 2014, PAIN MANAG NURS, V15, P760, DOI 10.1016/j.pmn.2013.07.013; Towheed TE, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004257.pub2; Trivedi Madhukar H, 2004, Prim Care Companion J Clin Psychiatry, V6, P12; Underwood M, 2008, BMJ-BRIT MED J, V336, P138, DOI 10.1136/bmj.39399.656331.25; Varrassi G, 2010, CURR MED RES OPIN, V26, P1231, DOI 10.1185/03007991003689175; Walsh NE, 2006, PHYS THER REV, V11, P289, DOI 10.1179/108331906X163432; Whitney SL, 2013, J GERIATR PHYS THER, V36, P3, DOI 10.1519/JPT.0b013e3182550ea5; Whitson HE, 2010, J GERONTOL A-BIOL, V65, P1325, DOI 10.1093/gerona/glq139; Zhang W, 2004, ANN RHEUM DIS, V63, P901, DOI 10.1136/ard.2003.018531	108	166	176	3	62	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2014	312	8					825	836		10.1001/jama.2014.9405	http://dx.doi.org/10.1001/jama.2014.9405			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AN7NX	25157726	Green Accepted			2023-01-03	WOS:000340788500025
J	Langhorst, J; Frede, A; Knott, M; Pastille, E; Buer, J; Dobos, GJ; Westendorf, AM				Langhorst, Jost; Frede, Annika; Knott, Markus; Pastille, Eva; Buer, Jan; Dobos, Gustav J.; Westendorf, Astrid M.			Distinct Kinetics in the Frequency of Peripheral CD4(+) T Cells in Patients with Ulcerative Colitis Experiencing a Flare during Treatment with Mesalazine or with a Herbal Preparation of Myrrh, Chamomile, and Coffee Charcoal	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; ALTERNATIVE MEDICINE USE; PHARMACOLOGICAL INVESTIGATIONS; 5-AMINOSALICYLIC ACID; ANTIINFLAMMATORY ACTIVITY; INTESTINAL INFLAMMATION; MAINTAINING REMISSION; BISABOLOL OXIDES; HEME OXYGENASE-1; NATIONAL-SURVEY	Background: We found the first evidence of the efficacy of a herbal treatment with myrrh, dry extract of chamomile flowers, and coffee charcoal for ulcerative colitis (UC). However, the impact of the herbal treatment on the CD4(+) T-cell compartment, which is essential for both the induction of UC and the maintenance of tolerance in the gut, is not well understood. Aim: To analyze the frequency and functional phenotype of CD4(+) T cells and of immune-suppressive CD4+CD25(high) regulatory T cells (Tregs) in healthy control subjects, patients with UC in remission, and patients with clinical flare of UC. Methods: Patients in clinical remission were treated with either mesalazine or the herbal preparation for 12 months. The frequencies of whole CD4(+) T cells, CD4(+)CD25(med) effector T cells, and Tregs and the expression of Foxp3 within the CD4(+)CD25(hig) Tregs were determined by flow cytometry at 6 time points. We determined the suppressive capability of Tregs from healthy control subjects and from patients in remission or clinical flare. Results: A total of 79 patients (42 women, 37 men; mean age, 48.5 years; 38 with clinical flare) and 5 healthy control subjects were included in the study. At baseline the frequencies of whole CD4(+) T cells, CD4(+)CD25(med) effector cells, and Tregs did not differ between the two treatment groups and the healthy control subjects. In addition, patients with UC in sustained clinical remission showed no alteration from baseline after 1, 3, 6, 9, or 12 months of either treatment. In contrast, CD4(+) T cells, CD4(+)CD25(med) effector T cells, and Tregs demonstrated distinctly different patterns at time points pre-flare and flare. The mesalazine group showed a continuous but not statistically significant increase from baseline to pre-flare and flare (p = ns). In the herbal treatment group, however, the percentage of the CD4(+) T cells was lower at pre-flare than at baseline. This decrease was completely reversed after flare, when a significant increase was seen (CD4(+)CD25(med) pre-flare/flare p = 0.0461; CD4(+)CD25(high) baseline/flare p = 0.0269 and pre-flare/flare p = 0.0032). In contrast, no changes in the expression of Foxp3 cells were detected within the subsets of CD4(+)CD25(high) regulatory T cells. Of note, no alterations were detected in the suppressive capability of CD4(+)CD25(high) regulatory T cells isolated from the peripheral blood of healthy donors, from patients in remission, or from patients with clinical flare. Conclusions: In patients with UC experiencing acute flare, the CD4(+) T compartment demonstrates a distinctly different pattern during treatment with myrrh, chamomile extract, and coffee charcoal than during treatment with mesalazine. These findings suggest an active repopulation of regulatory T cells during active disease.	[Langhorst, Jost] Univ Duisburg Essen, Kliniken Essen Mitte, Dept Integrat Gastroenterol, Essen, Germany; [Langhorst, Jost; Dobos, Gustav J.] Univ Duisburg Essen, Kliniken Essen Mitte, Dept Internal & Integrat Med, Essen, Germany; [Frede, Annika; Knott, Markus; Pastille, Eva; Buer, Jan; Westendorf, Astrid M.] Univ Duisburg Essen, Univ Hosp Essen, Inst Med Microbiol, Essen, Germany	Kliniken Essen-Mitte; University of Duisburg Essen; Kliniken Essen-Mitte; University of Duisburg Essen; University of Duisburg Essen	Langhorst, J (corresponding author), Univ Duisburg Essen, Kliniken Essen Mitte, Dept Integrat Gastroenterol, Essen, Germany.	jost.langhorst@gmx.de	Knott, Markus/AAE-7076-2020; Westendorf, Astrid M./AAX-1937-2020	Buer, Jan/0000-0002-7602-1698; Frede, Annika/0000-0002-0075-6874	REPHA GmbH Biologische Arzneimittel, Hannover, Germany; IFORES program of the University of Duisburg-Essen, Germany	REPHA GmbH Biologische Arzneimittel, Hannover, Germany; IFORES program of the University of Duisburg-Essen, Germany	This study was performed as an independent sub-study of a drug trial comparing the efficacy of a herbal preparation of myrrh, dry extract of chamomile flowers and coffee charcoal to mesalamine as treatment for maintaining remission in ulcerative colitis which was funded in full by REPHA GmbH Biologische Arzneimittel, Hannover, Germany. The presented study was funded in part by the IFORES program of the University of Duisburg-Essen, Germany. No additional external or internal funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham C, 2009, NEW ENGL J MED, V361, P2066, DOI 10.1056/NEJMra0804647; ACHTERRATHTUCKERMANN U, 1980, PLANTA MED, V39, P38, DOI 10.1055/s-2008-1074901; Ammon HPT, 1992, KAMILLE PHARMAKOLOGI; Bhaskaran N, 2012, LIFE SCI, V90, P1027, DOI 10.1016/j.lfs.2012.05.019; Cheng YW, 2011, J PHARM PHARMACOL, V63, P1211, DOI 10.1111/j.2042-7158.2011.01329.x; Danese S, 2011, NEW ENGL J MED, V365, P1713, DOI 10.1056/NEJMra1102942; Della Loggia R, 1985, DTSCH APOTH ZTG S1, V125, P9; Dignass A, 2011, Z GASTROENTEROL, V49, P1276, DOI 10.1055/s-0031-1281666; Dignass A, 2012, J CROHNS COLITIS, V6, P991, DOI 10.1016/j.crohns.2012.09.002; Dolara P, 2000, PLANTA MED, V66, P356, DOI 10.1055/s-2000-8532; Eastaff-Leung N, 2010, J CLIN IMMUNOL, V30, P80, DOI 10.1007/s10875-009-9345-1; Ford AC, 2011, AM J GASTROENTEROL, V106, P601, DOI 10.1038/ajg.2011.67; Galvez J, 2003, INFLAMM BOWEL DIS, V9, P363, DOI 10.1097/00054725-200311000-00004; Ganguli SC, 2004, AM J GASTROENTEROL, V99, P319, DOI 10.1111/j.1572-0241.2004.04046.x; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Hansen W, 2007, J IMMUNOL, V179, P8059, DOI 10.4049/jimmunol.179.12.8059; HAWKEY CJ, 1985, DIGEST DIS SCI, V30, P1161, DOI 10.1007/BF01314051; Hilsden RJ, 1998, AM J GASTROENTEROL, V93, P697; Hilsden RJ, 2003, AM J GASTROENTEROL, V98, P1563, DOI 10.1016/S0002-9270(03)00301-0; Hilsden RJ, 2011, INFLAMM BOWEL DIS, V17, P655, DOI 10.1002/ibd.21360; Himmel ME, 2012, IMMUNOLOGY, V136, P115, DOI 10.1111/j.1365-2567.2012.03572.x; ISAAC O, 1979, PLANTA MED, V35, P118, DOI 10.1055/s-0028-1097193; JAKOVLEV V, 1979, PLANTA MED, V35, P125, DOI 10.1055/s-0028-1097194; Janicke C., 2003, HDB PHYTOTHERAPIE IN; Kao J, 2010, J CLIN GASTROENTEROL, V44, P531, DOI 10.1097/MCG.0b013e3181db1a61; Kuhn A., 1939, SUDD APOTH ZTG, V79, P434; La Scaleia R, 2010, J PEDIATR GASTR NUTR, V51, P563, DOI 10.1097/MPG.0b013e3181e4d323; Langhorst J, 2005, INFLAMM BOWEL DIS, V11, P287, DOI 10.1097/01.MIB.0000160771.71328.6c; Langhorst J, 2013, ALIMENT PHARM THER, V38, P490, DOI 10.1111/apt.12397; Langhorst J, 2008, AM J GASTROENTEROL, V103, P162, DOI 10.1111/j.1572-0241.2007.01556.x; Langhorsta J, 2007, COMPLEMENT THER MED, V15, P30, DOI 10.1016/j.ctim.2006.03.008; Langmead L, 2002, INFLAMM BOWEL DIS, V8, P174, DOI 10.1097/00054725-200205000-00003; Li Z, 2010, INFLAMM BOWEL DIS, V16, P1299, DOI 10.1002/ibd.21229; Loggia R. della, 1990, Planta Medica, V56, P657, DOI 10.1055/s-2006-961313; MACDERMOTT RP, 1989, GASTROENTEROLOGY, V96, P442, DOI 10.1016/0016-5085(89)91569-2; Maul J, 2005, GASTROENTEROLOGY, V128, P1868, DOI 10.1053/j.gastro.2005.03.043; Mottet C, 2003, J IMMUNOL, V170, P3939, DOI 10.4049/jimmunol.170.8.3939; NIELSEN OH, 1988, ALIMENT PHARM THERAP, V2, P203; RACHMILEWITZ D, 1989, BMJ-BRIT MED J, V298, P82, DOI 10.1136/bmj.298.6666.82; Rahimi R, 2009, DIGEST DIS SCI, V54, P471, DOI 10.1007/s10620-008-0368-x; Roncarolo MG, 2007, NAT REV IMMUNOL, V7, P585, DOI 10.1038/nri2138; SAFAYHI H, 1994, PLANTA MED, V60, P410, DOI 10.1055/s-2006-959520; Satsangi J, 2006, GUT, V55, P749, DOI 10.1136/gut.2005.082909; Simmonds NJ, 1999, ALIMENT PHARM THER, V13, P363; SIMMONDS NJ, 1993, GUT, V34, P865, DOI 10.1136/gut.34.7.865; Sutherland LR, 1997, INFLAMM BOWEL DIS, V3, P65, DOI 10.1002/ibd.3780030202; Takahashi M, 2006, DIGEST DIS SCI, V51, P677, DOI 10.1007/s10620-006-3191-2; TARIQ M, 1986, AGENTS ACTIONS, V17, P381, DOI 10.1007/BF01982655; TRAVIS SPL, 1994, PHARMACOL THERAPEUT, V63, P135, DOI 10.1016/0163-7258(94)90042-6; Veltkamp C, 2011, GUT, V60, P1345, DOI 10.1136/gut.2010.217117; Weizman AV, 2012, ALIMENT PHARM THER, V35, P342, DOI 10.1111/j.1365-2036.2011.04956.x; Westendorf AM, 2006, GASTROENTEROLOGY, V131, P510, DOI 10.1053/j.gastro.2006.05.015; Whittle BJR, 2010, PHARMACOL REP, V62, P548; Wildin RS, 2002, J MED GENET, V39, P537, DOI 10.1136/jmg.39.8.537; Zhu NQ, 2003, FLAVOUR FRAG J, V18, P282, DOI 10.1002/ffj.1193	55	3	3	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2014	9	8							e104257	10.1371/journal.pone.0104257	http://dx.doi.org/10.1371/journal.pone.0104257			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO1WL	25144293	Green Published, Green Submitted, gold			2023-01-03	WOS:000341106100013
J	Hutten, M; Dhanasingh, A; Hessler, R; Stover, T; Esser, KH; Moller, M; Lenarz, T; Jolly, C; Groll, J; Scheper, V				Huetten, Mareike; Dhanasingh, Anandhan; Hessler, Roland; Stoever, Timo; Esser, Karl-Heinz; Moeller, Martin; Lenarz, Thomas; Jolly, Claude; Groll, Juergen; Scheper, Verena			In Vitro and In Vivo Evaluation of a Hydrogel Reservoir as a Continuous Drug Delivery System for Inner Ear Treatment	PLOS ONE			English	Article							CROSS-LINKED STAR; CONSERVES HEARING; RESIDUAL HEARING; DEXAMETHASONE; TRAUMA; MODEL	Fibrous tissue growth and loss of residual hearing after cochlear implantation can be reduced by application of the glucocorticoid dexamethasone-21-phosphate-disodium-salt (DEX). To date, sustained delivery of this agent to the cochlea using a number of pharmaceutical technologies has not been entirely successful. In this study we examine a novel way of continuous local drug application into the inner ear using a refillable hydrogel functionalized silicone reservoir. A PEG-based hydrogel made of reactive NCO-sP(EO-stat-PO) prepolymers was evaluated as a drug conveying and delivery system in vitro and in vivo. Encapsulating the free form hydrogel into a silicone tube with a small opening for the drug diffusion resulted in delayed drug release but unaffected diffusion of DEX through the gel compared to the free form hydrogel. Additionally, controlled DEX release over several weeks could be demonstrated using the hydrogel filled reservoir. Using a guinea-pig cochlear trauma model the reservoir delivery of DEX significantly protected residual hearing and reduced fibrosis. As well as being used as a device in its own right or in combination with cochlear implants, the hydrogel-filled reservoir represents a new drug delivery system that feasibly could be replenished with therapeutic agents to provide sustained treatment of the inner ear.	[Huetten, Mareike; Lenarz, Thomas; Scheper, Verena] Hannover Med Sch, Dept Otolaryngol, Hannover, Germany; [Huetten, Mareike; Esser, Karl-Heinz] Univ Vet Med Hannover, Inst Zool, Hannover, Germany; [Dhanasingh, Anandhan; Hessler, Roland; Jolly, Claude] MED EL Innsbruck, Res & Dev, Innsbruck, Austria; [Dhanasingh, Anandhan; Moeller, Martin; Groll, Juergen] Rhein Westfal TH Aachen, Interact Mat Research DWI eV, Aachen, Germany; [Dhanasingh, Anandhan; Moeller, Martin; Groll, Juergen] Rhein Westfal TH Aachen, Inst Tech & Macromol Chem, Aachen, Germany; [Stoever, Timo] JW Goethe Univ Hosp, Frankfurt, Germany; [Stoever, Timo] Fac Med, Dept Otolaryngol, Frankfurt, Germany; [Groll, Juergen] Univ Wurzburg, Dept Funct Mat Med & Dent, D-97070 Wurzburg, Germany; [Scheper, Verena] Hannover Med Sch, Inst Audioneurotechnol, Hannover, Germany	Hannover Medical School; University of Veterinary Medicine Hannover, Foundation; RWTH Aachen University; RWTH Aachen University; Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Wurzburg; Hannover Medical School	Groll, J (corresponding author), Rhein Westfal TH Aachen, Interact Mat Research DWI eV, Aachen, Germany.	juergen.groll@fmz.uni-wuerzburg.de; scheper.verena@mh-hannover.de	Scheper, Verena/J-4298-2019; Groll, Jürgen/F-4202-2012; Möller, Martin/F-7860-2015	Scheper, Verena/0000-0001-8618-8793; Groll, Jürgen/0000-0003-3167-8466; Möller, Martin/0000-0002-5955-4185	DFG [SPP 1259]; European Community 6th Framework Programme on Research, Technological Development and Demonstration (Nanotechnology based Drug Delivery., Project acronym: NANOEAR; Hannover Medical School, MED-EL, RWTH Aachen) [NMP4-CT-2006-026556]	DFG(German Research Foundation (DFG)); European Community 6th Framework Programme on Research, Technological Development and Demonstration (Nanotechnology based Drug Delivery., Project acronym: NANOEAR; Hannover Medical School, MED-EL, RWTH Aachen)	This study was supported by the DFG within the SPP 1259 "Intelligent hydrogels" (RWTH Aachen) and the European Community 6th Framework Programme on Research, Technological Development and Demonstration (Nanotechnology based Drug Delivery. Contract Number: NMP4-CT-2006-026556, Project acronym: NANOEAR; Hannover Medical School, MED-EL, RWTH Aachen). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abi-Hachem Ralph N, 2010, Recent Pat CNS Drug Discov, V5, P147; Birman CS, 2014, OTOL NEUROTOL, V35, P1385, DOI 10.1097/MAO.0000000000000362; Borenstein JT, 2011, EXPERT OPIN DRUG DEL, V8, P1161, DOI 10.1517/17425247.2011.588207; Braun S, 2011, ORL-J OTO-RHIN-LARYN, V73, P219, DOI 10.1159/000329791; Burghard A, 2014, HEARING RES, V312, P21, DOI 10.1016/j.heares.2014.02.002; Chandrasekhar SS, 2000, OTOLARYNG HEAD NECK, V122, P521, DOI 10.1016/S0194-5998(00)70094-5; Dalton PD, 2008, MACROMOL BIOSCI, V8, P923, DOI 10.1002/mabi.200800080; Dhanasingh A, 2012, SOFT MATTER, V8, P1643, DOI 10.1039/c1sm06603j; Dhanasingh A, 2010, SOFT MATTER, V6, P618, DOI 10.1039/b917113d; ELKAFRAWY AH, 1974, J DENT RES, V53, P15, DOI 10.1177/00220345740530012001; Eshraghi AA, 2007, OTOL NEUROTOL, V28, P842, DOI 10.1097/MAO.0b013e31805778fc; Gotz H, 2002, MACROMOL MATER ENG, V287, P223, DOI 10.1002/1439-2054(20020401)287:4<223::AID-MAME223>3.0.CO;2-Z; Groll J, 2004, J AM CHEM SOC, V126, P4234, DOI 10.1021/ja0318028; Hoffman AS, 2002, ADV DRUG DELIVER REV, V54, P3, DOI 10.1016/j.addr.2012.09.010; Ito M, 2001, United States Patent, Patent No. [US 6,214,048 B1, 6214048]; James DP, 2008, AUDIOL NEURO-OTOL, V13, P86, DOI 10.1159/000111780; Jolly C, 2010, ADV OTO-RHINO-LARYNG, V67, P28, DOI 10.1159/000262594; Kim HH, 2007, LARYNGOSCOPE, V117, P1209, DOI 10.1097/MLG.0b013e318058195f; Kim P, 2005, NANOTECHNOLOGY, V16, P2420, DOI 10.1088/0957-4484/16/10/072; Lenarz Thomas, 1998, Acta Oto-Rhino-Laryngologica Belgica, V52, P183; LERVIK T, 1978, ORAL SURG ORAL MED O, V45, P123, DOI 10.1016/0030-4220(78)90235-9; Luttikhuizen DT, 2006, TISSUE ENG, V12, P1955, DOI 10.1089/ten.2006.12.1955; Meltser I, 2011, HEARING RES, V281, P47, DOI 10.1016/j.heares.2011.06.003; MERRILL EW, 1993, J BIOMAT SCI-POLYM E, V5, P1; Messmer UK, 2001, BRIT J PHARMACOL, V133, P467, DOI 10.1038/sj.bjp.0704093; Nadol JB, 2004, OTOL NEUROTOL, V25, P257, DOI 10.1097/00129492-200405000-00010; NADOL JB, 1991, ANN OTO RHINOL LARYN, V100, P712, DOI 10.1177/000348949110000904; O'Leary SJ, 2013, HEARING RES, V298, P27, DOI 10.1016/j.heares.2013.01.012; Paasche G, 2006, OTOL NEUROTOL, V27, P639, DOI 10.1097/01.mao.0000227662.88840.61; Peppas NA, 1999, J CONTROL RELEASE, V62, P81, DOI 10.1016/S0168-3659(99)00027-9; Ruben R.J., 1967, ACTA OTO-LARYNGOL, DOI DOI 10.3109/00016486709127790; Scheper V, 2009, NANOMEDICINE-UK, V4, P623, DOI 10.2217/NNM.09.41; Scheper V, 2009, J NEUROSCI RES, V87, P1389, DOI 10.1002/jnr.21964; Seltzer S, 1976, J Endod, V2, P208, DOI 10.1016/S0099-2399(76)80135-5; Takemura K, 2004, HEARING RES, V196, P58, DOI 10.1016/j.heares.2004.06.003; Tizard I.R., 2004, VET IMMUNOLOGY INTRO, P67; Vivero RJ, 2008, LARYNGOSCOPE, V118, P2028, DOI 10.1097/MLG.0b013e31818173ec	37	31	32	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2014	9	8							e104564	10.1371/journal.pone.0104564	http://dx.doi.org/10.1371/journal.pone.0104564			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR0CG	25105670	Green Published, gold, Green Submitted			2023-01-03	WOS:000343231900071
J	Press, MJ				Press, Matthew J.			Instant Replay - A Quarterback's View of Care Coordination	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Press, Matthew J.] Weill Cornell Med Coll, Dept Healthcare Policy & Res, New York, NY 10021 USA; [Press, Matthew J.] Weill Cornell Med Coll, Dept Med, New York, NY USA	Cornell University; Cornell University	Press, MJ (corresponding author), Weill Cornell Med Coll, Dept Healthcare Policy & Res, New York, NY 10021 USA.							Bodenheimer T, 2008, NEW ENGL J MED, V358, P1064, DOI 10.1056/NEJMhpr0706165; Hinds PJ, 2003, ORGAN SCI, V14, P615, DOI 10.1287/orsc.14.6.615.24872; Press MJ, 2012, AM J MANAG CARE, V18, P778; Stavert RR, 2013, NEW ENGL J MED, V368, P8, DOI 10.1056/NEJMp1210501; 2007, IMPROVING AM HOSP JO	5	44	44	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 7	2014	371	6					489	491		10.1056/NEJMp1406033	http://dx.doi.org/10.1056/NEJMp1406033			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AM5LE	25099572				2023-01-03	WOS:000339899100001
J	Hotchkiss, RS; Moldawer, LL				Hotchkiss, Richard S.; Moldawer, Lyle L.			Parallels between Cancer and Infectious Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							IMMUNOTHERAPY		[Hotchkiss, Richard S.] Washington Univ, Dept Anesthesiol, Sch Med, St Louis, MO 63130 USA; [Hotchkiss, Richard S.] Washington Univ, Dept Med, Sch Med, St Louis, MO 63130 USA; [Hotchkiss, Richard S.] Washington Univ, Dept Surg, Sch Med, St Louis, MO 63130 USA; [Moldawer, Lyle L.] Univ Florida, Coll Med, Dept Surg, Gainesville, FL USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); State University System of Florida; University of Florida	Hotchkiss, RS (corresponding author), Washington Univ, Dept Anesthesiol, Sch Med, St Louis, MO 63130 USA.			Moldawer, Lyle/0000-0002-9041-9838				Cheever MAM, 2008, IMMUNOL REV, V222, P357, DOI 10.1111/j.1600-065X.2008.00604.x; Crawford A, 2014, IMMUNITY, V40, P289, DOI 10.1016/j.immuni.2014.01.005; De Vlaminck I, 2013, CELL, V155, P1178, DOI 10.1016/j.cell.2013.10.034; Deloitte CIO Journal Editor, 2014, WALL STREET J; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Patel A, 2010, J ANTIMICROB CHEMOTH, V65, P2697, DOI 10.1093/jac/dkq359	7	128	132	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 24	2014	371	4					380	383		10.1056/NEJMcibr1404664	http://dx.doi.org/10.1056/NEJMcibr1404664			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AL7TY	25054723	Green Published			2023-01-03	WOS:000339339800017
J	Lai, NS; Tsai, TY; Koo, M; Huang, KY; Tung, CH; Lu, MC				Lai, Ning-Sheng; Tsai, Tzung-Yi; Koo, Malcolm; Huang, Kuang-Yung; Tung, Chien-Hsueh; Lu, Ming-Chi			Patterns of Ambulatory Medical Care Utilization and Rheumatologist Consultation Predating the Diagnosis of Systemic Lupus Erythematosus: A National Population-Based Study	PLOS ONE			English	Article							COLLEGE-OF-RHEUMATOLOGY; CLINICS CLASSIFICATION CRITERIA; AUTOANTIBODIES; MANIFESTATIONS; PREVALENCE; ONSET; FEATURES; DISEASE; REGION	Objective: To investigate the records of ambulatory medical care from patients predating the diagnosis of systemic lupus erythematosus (SLE) using nationwide, population-based claims data. Methods: The frequencies and costs of ambulatory medical care utilization in 337 newly-diagnosed SLE cases between 2004 and 2010, identified from Taiwan's National Health Insurance Research Database, were compared with 1,348 controls who were frequency matched for sex, age, and the catastrophic illness certificate application year of the cases. Results: Patients with SLE had a median frequency of ambulatory medical care utilization compared with controls one year prior to the index date (22 vs. 2, P<0.001). The differences were significant throughout all eight annual periods. Similarly, the inflation-adjusted costs of ambulatory medical care utilization in patients with SLE increased annually over the study period, from a median of US$18 eight years prior to the index date to US$680 one year prior to the index date. Diseases of the respiratory system (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes 460-519), digestive system (ICD-9-CM codes 520-579), musculoskeletal system and connective tissue (ICD-9-CM codes 710-739, excluding 710.0), and skin and subcutaneous tissue (ICD-9-CM codes 680-709) were the top four common causes of visits in the 0.5 to 2 year period preceding the index date and percentages of SLE patients suffered from these disorders increased progressively over the study period. Only 56.4% of the patients with SLE had consulted a rheumatologist and most of the serology tests were done within one year predating the index date. Conclusions: Increased frequencies and costs of ambulatory care utilization among Taiwanese patients with SLE occurred several years predating their definitive SLE diagnosis. When multisystemic disorders are presented in young female patients, the possibility of SLE should be considered and screened with tools such as the antinuclear antibody test.	[Lai, Ning-Sheng; Huang, Kuang-Yung; Tung, Chien-Hsueh; Lu, Ming-Chi] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Div Allergy Immunol & Rheumatol, Chiayi, Taiwan; [Lai, Ning-Sheng; Huang, Kuang-Yung; Lu, Ming-Chi] Tzu Chi Univ, Sch Med, Hualien, Taiwan; [Tsai, Tzung-Yi; Koo, Malcolm] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Med Res, Chiayi, Taiwan; [Tsai, Tzung-Yi] Tzu Chi Coll Technol, Dept Nursing, Hualien, Taiwan; [Tsai, Tzung-Yi] Natl Cheng Kung Univ, Coll Med, Dept Environm & Occupat Hlth, Tainan 70101, Taiwan; [Koo, Malcolm] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada	Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Tzu Chi University; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Tzu Chi University of Science & Technology; National Cheng Kung University; University of Toronto	Lu, MC (corresponding author), Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Div Allergy Immunol & Rheumatol, Chiayi, Taiwan.	e360187@yahoo.com.tw	Koo, Malcolm/AAE-5822-2020	Koo, Malcolm/0000-0002-9242-9167	Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan [DTCRD101-E-08]	Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan	This work was supported by a grant from the Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (DTCRD101-E-08), Taiwan. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arbuckle MR, 2001, SCAND J IMMUNOL, V54, P211, DOI 10.1046/j.1365-3083.2001.00959.x; Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933; Bernatsky S, 2013, J AUTOIMMUN, V42, P130, DOI 10.1016/j.jaut.2012.12.009; Bertsias GK, 2013, NAT REV RHEUMATOL, V9, P687, DOI 10.1038/nrrheum.2013.103; Bruner BF, 2012, ARTHRITIS RHEUM-US, V64, P3677, DOI 10.1002/art.34651; Cerovec M, 2012, CROAT MED J, V53, P149, DOI 10.3325/cmj.2012.53.149; Chen TJ, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-54; Cheng SH, 1997, JAMA-J AM MED ASSOC, V278, P89, DOI 10.1001/jama.278.2.89; D'Cruz DP, 2007, LANCET, V369, P587, DOI 10.1016/S0140-6736(07)60279-7; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Ebert EC, 2011, J CLIN GASTROENTEROL, V45, P436, DOI 10.1097/MCG.0b013e31820f81b8; Eriksson C, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3258; Heinlen LD, 2007, ARTHRITIS RHEUM, V56, P2344, DOI 10.1002/art.22665; Heinlen LD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009599; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Jakes RW, 2012, ARTHRIT CARE RES, V64, P159, DOI 10.1002/acr.20683; Jolly M, 2006, ARTHRIT RHEUM-ARTHR, V55, P821, DOI 10.1002/art.22233; Kastanioudakis I, 2002, J LARYNGOL OTOL, V116, P103; Kumar K, 2012, RHEUMATOL INT, V32, P73, DOI 10.1007/s00296-010-1556-5; Lai NS, 2014, ARTHRIT CARE RES, V66, P371, DOI 10.1002/acr.22146; Lin YJ, 2008, CLIN IMMUNOL, V129, P36, DOI 10.1016/j.clim.2008.05.011; Lin YC, 2012, RHEUMATOL INT, V32, P1669, DOI 10.1007/s00296-011-1847-5; Lionaki S, 2013, LUPUS, V22, P95, DOI 10.1177/0961203312467668; LU R, 2012, AUTOIMMUNE DIS, V2012; Manson JJ, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-6; Pego-Reigosa JM, 2009, BEST PRACT RES CL RH, V23, P469, DOI 10.1016/j.berh.2009.01.002; McClain MT, 2004, ARTHRITIS RHEUM-US, V50, P1226, DOI 10.1002/art.20120; Organisation for Economic Co-operation and Development, 2011, HLTH GLANC 2011 OECD; Petri M, 2012, ARTHRITIS RHEUM-US, V64, P2677, DOI 10.1002/art.34473; Pons-Estel GJ, 2014, LUPUS, V23, P3, DOI 10.1177/0961203313512883; Pyne D, 2002, ANN RHEUM DIS, V61, P70, DOI 10.1136/ard.61.1.70; Sivaraj RR, 2007, RHEUMATOLOGY, V46, P1757, DOI 10.1093/rheumatology/kem173; Spinillo A, 2012, ANN RHEUM DIS, V71, P918, DOI 10.1136/annrheumdis-2011-154146; Sultan SM, 1999, RHEUMATOLOGY, V38, P917, DOI 10.1093/rheumatology/38.10.917; Torre Olga, 2011, Presse Med, V40, pe19, DOI 10.1016/j.lpm.2010.11.004; VLACHOYIANNOPOULOS PG, 1993, LUPUS, V2, P303, DOI 10.1177/096120339300200505; Wichainun R, 2013, ASIAN PAC J ALLERGY, V31, P292, DOI 10.12932/AP0272.31.4.2013	37	9	9	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2014	9	7							e101485	10.1371/journal.pone.0101485	http://dx.doi.org/10.1371/journal.pone.0101485			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK7WB	24999630	Green Published, gold, Green Submitted			2023-01-03	WOS:000338637300048
J	Robertson, CS; Hannay, HJ; Yamal, JM; Gopinath, S; Goodman, JC; Tilley, BC				Robertson, Claudia S.; Hannay, H. Julia; Yamal, Jose-Miguel; Gopinath, Shankar; Goodman, J. Clay; Tilley, Barbara C.		Epo Severe TBI Trial Investigators	Effect of Erythropoietin and Transfusion Threshold on Neurological Recovery After Traumatic Brain Injury A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLASGOW OUTCOME SCALE; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; HEAD-INJURY; COMA SCALE; SURVIVAL; CARE; CLASSIFICATION; REQUIREMENTS; OXYGENATION	IMPORTANCE There is limited information about the effect of erythropoietin or a high hemoglobin transfusion threshold after a traumatic brain injury. OBJECTIVE To compare the effects of erythropoietin and 2 hemoglobin transfusion thresholds (7 and 10 g/dL) on neurological recovery after traumatic brain injury. DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial of 200 patients (erythropoietin, n = 102; placebo, n = 98) with closed head injury who were unable to follow commands and were enrolled within 6 hours of injury at neurosurgical intensive care units in 2 US level I trauma centers between May 2006 and August 2012. The study used a factorial design to test whether erythropoietin would fail to improve favorable outcomes by 20% and whether a hemoglobin transfusion threshold of greater than 10 g/dL would increase favorable outcomes without increasing complications. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (n = 74) and then the 24- and 48-hour doses were stopped for the remainder of the patients (n = 126). There were 99 patients assigned to a hemoglobin transfusion threshold of 7 g/dL and 101 patients assigned to 10 g/dL. INTERVENTIONS Intravenous erythropoietin (500 IU/kg per dose) or saline. Transfusion threshold maintained with packed red blood cells. MAIN OUTCOMES AND MEASURES Glasgow Outcome Scale score dichotomized as favorable (good recovery and moderate disability) or unfavorable (severe disability, vegetative, or dead) at 6 months postinjury. RESULTS There was no interaction between erythropoietin and hemoglobin transfusion threshold. Compared with placebo (favorable outcome rate: 34/89 [38.2%; 95% CI, 28.1% to 49.1%]), both erythropoietin groups were futile (first dosing regimen: 17/35 [48.6%; 95% CI, 31.4% to 66.0%], P=.13; second dosing regimen: 17/57 [29.8%; 95% CI, 18.4% to 43.4%], P<.001). Favorable outcome rates were 37/87 (42.5%) for the hemoglobin transfusion threshold of 7 g/dL and 31/94 (33.0%) for 10 g/dL (95% CI for the difference, -0.06 to 0.25, P=.28). There was a higher incidence of thromboembolic events for the transfusion threshold of 10 g/dL (22/101 [21.8%] vs 8/99 [8.1%] for the threshold of 7 g/dL, odds ratio, 0.32 [95% CI, 0.12 to 0.79], P=.009). CONCLUSIONS AND RELEVANCE In patients with closed head injury, neither the administration of erythropoietin nor maintaining hemoglobin concentration of greater than 10 g/dL resulted in improved neurological outcome at 6 months. The transfusion threshold of 10 g/dL was associated with a higher incidence of adverse events. These findings do not support either approach in this setting.	[Robertson, Claudia S.; Gopinath, Shankar] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Hannay, H. Julia] Univ Houston, Dept Psychol, Houston, TX USA; [Yamal, Jose-Miguel; Tilley, Barbara C.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Div Biostat, Houston, TX 77030 USA; [Goodman, J. Clay] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA	Baylor College of Medicine; University of Houston System; University of Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Baylor College of Medicine	Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, One Baylor Plaza, Houston, TX 77030 USA.	claudiar@bcm.edu	Rivera-Lara, Lucia/AAX-8233-2020	Rivera-Lara, Lucia/0000-0002-9053-2283; Hannay, H. Julia/0000-0001-7023-912X; Benoit, Julia/0000-0002-2734-5477	National Institute of Neurological Disorders and Stroke [P01-NS38660]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM074902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS038660] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was supported by grant P01-NS38660 from the National Institute of Neurological Disorders and Stroke.	Abrishamkar S, 2012, J RES MED SCI, V17, P51; [Anonymous], 2007, J NEUROTRAUMA S1, V24, pS1; [Anonymous], 2008, J NEUROTRAUMA, V25, P276; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BERNARD GR, 1994, INTENS CARE MED, V20, P225, DOI 10.1007/BF01704707; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Elterman J, 2013, J TRAUMA ACUTE CARE, V75, P8, DOI 10.1097/TA.0b013e318298492e; Figaji AA, 2010, PEDIATR CRIT CARE ME, V11, P325, DOI 10.1097/PCC.0b013e3181b80a8e; Hajjar LA, 2010, JAMA-J AM MED ASSOC, V304, P1559, DOI 10.1001/jama.2010.1446; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Napolitano LM, 2008, J TRAUMA, V65, P285, DOI 10.1097/TA.0b013e31817f2c6e; Nirula R, 2010, CRIT CARE RES PRACT, V2010, DOI 10.1155/2010/209848; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Sena MJ, 2009, INTENS CARE MED, V35, P480, DOI 10.1007/s00134-008-1289-z; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Talving P, 2012, ARCH SURG-CHICAGO, V147, P251, DOI 10.1001/archsurg.2011.1838; Talving P, 2010, ANN SURG, V251, P1, DOI 10.1097/SLA.0b013e3181b844fa; Tango HK, 2010, J TRAUMA, V68, P251; Tango HK, 2009, J TRAUMA, V66, P1748; Tango HK, 2009, J TRAUMA, V66, P720, DOI 10.1097/TA.0b013e3181719b35; Tibshirani R, 1997, STAT MED, V16, P385, DOI 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3; Tilley BC, 2006, NEUROLOGY, V66, P628, DOI 10.1212/01.wnl.0000201251.33253.fb; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Warner MA, 2010, J NEUROSURG, V113, P539, DOI 10.3171/2009.12.JNS091337; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	36	314	317	3	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2014	312	1					36	47		10.1001/jama.2014.6490	http://dx.doi.org/10.1001/jama.2014.6490			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AK0UK	25058216	Green Accepted, Bronze			2023-01-03	WOS:000338131100019
J	Lamb, SE; Williamson, EM; Heine, PJ; Adams, J; Dosanjh, S; Dritsaki, M; Glover, MJ; Lord, J; McConkey, C; Nichols, V; Rahman, A; Underwood, M; Williams, MA				Lamb, Sarah E.; Williamson, Esther M.; Heine, Peter J.; Adams, Jo; Dosanjh, Sukhdeep; Dritsaki, Melina; Glover, Matthew J.; Lord, Joanne; McConkey, Christopher; Nichols, Vivien; Rahman, Anisur; Underwood, Martin; Williams, Mark A.		Strengthening & Stretching Rheumat	Exercises to improve function of the rheumatoid hand (SARAH): a randomised controlled trial	LANCET			English	Article							DISEASE-ACTIVITY; HIGH-INTENSITY; FOLLOW-UP; CLINICAL-TRIALS; ARTHRITIS; PROGRAM; PEOPLE; DISABILITY; THERAPY	Background Disease-modifying biological agents and other drug regimens have substantially improved control of disease activity and joint damage in people with rheumatoid arthritis of the hand. However, commensurate changes in function and quality of life are not always noted. Tailored hand exercises might provide additional improvements, but evidence is lacking. We estimated the effectiveness and cost-effectiveness of tailored hand exercises in addition to usual care during 12 months. Methods In this pragmatic, multicentre, parallel-group trial, at 17 National Health Service sites across the UK we randomly assigned 490 adults with rheumatoid arthritis who had pain and dysfunction of the hands and had been on a stable drug regimen for at least 3 months, to either usual care or usual care plus a tailored strengthening and stretching hand exercise programme. Participants were randomly assigned with stratification by centre. Allocation was computer generated and unmasked to participants and therapists delivering treatment after randomisation. Outcome assessors and all investigators were masked to allocation. Physiotherapists or occupational therapists gave the treatments. The primary outcome was the Michigan Hand Outcomes Questionnaire overall hand function score at 12 months. The analysis was by intention to treat. We calculated cost per quality-adjusted life-year. This trial is registered as ISRCTN 89936343. Findings Between Oct 5, 2009, and May 10, 2011, we screened 1606 people, of whom 490 were randomly assigned to usual care (n=244) or tailored exercises (n=246). 438 of 490 participants (89%) provided 12 month follow-up data. Improvements in overall hand function were 3.6 points (95% CI 1.5-5.7) in the usual care group and 7.9 points (6.0-9.9) in the exercise group (mean difference between groups 4.3, 95% CI 1.5-7.1; p=0.0028). Pain, drug regimens, and health-care resource use were stable for 12 months, with no difference between the groups. No serious adverse events associated with the treatment were recorded. The cost of tailored hand exercise was 156 pound per person; cost per quality-adjusted life-year was 9549 pound with the EQ-5D (17941 pound with imputation for missing data). Interpretation We have shown that a tailored hand exercise programme is a worthwhile, low-cost intervention to provide as an adjunct to various drug regimens. Maximisation of the benefits of biological and DMARD regimens in terms of function, disability, and health-related quality of life should be an important treatment aim.	[Lamb, Sarah E.; Williamson, Esther M.; Williams, Mark A.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Botnar Res Ctr, Oxford OX3 7LD, England; [Lamb, Sarah E.; Heine, Peter J.; Dosanjh, Sukhdeep; Dritsaki, Melina; McConkey, Christopher; Nichols, Vivien; Underwood, Martin] Univ Warwick, Warwick Clin Trials Unit, Coventry CV4 7AL, W Midlands, England; [Adams, Jo] Univ Southampton, Fac Hlth Sci, Southampton, Hants, England; [Glover, Matthew J.; Lord, Joanne] Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England; [Rahman, Anisur] UCL, London, England	University of Oxford; University of Warwick; University of Southampton; Brunel University; University of London; University College London	Lamb, SE (corresponding author), Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Botnar Res Ctr, Windmill Rd, Oxford OX3 7LD, England.	sarah.lamb@ndorms.ox.ac.uk	Underwood, Martin/D-6364-2015; Jansen, Victoria/K-1046-2019; Evans, David/Q-2278-2019; Lord, Joanne/H-1417-2011; Glover, Matthew/ABG-3969-2021	Underwood, Martin/0000-0002-0309-1708; Jansen, Victoria/0000-0002-0700-7462; Evans, David/0000-0002-9073-5558; Lord, Joanne/0000-0003-1086-1624; Frost, Helen/0000-0001-9241-8970; Glover, Matthew/0000-0001-9454-2668; Lamb, Sarah/0000-0003-4349-7195; Williamson, Esther/0000-0003-0638-0406; Adams, Jo/0000-0003-1765-7060	UK National Institute of Health Research Health Technology Assessment Programme (NIHR HTA) [07/32/05]; National Institute for Health Research [07/32/05, NF-SI-0512-10103] Funding Source: researchfish	UK National Institute of Health Research Health Technology Assessment Programme (NIHR HTA); National Institute for Health Research(National Institute for Health Research (NIHR))	UK National Institute of Health Research Health Technology Assessment Programme (NIHR HTA), project number 07/32/05.	Abraham C, 2008, HEALTH PSYCHOL, V27, P379, DOI 10.1037/0278-6133.27.3.379; Adams J, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-230; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Boers M, 2013, ANN RHEUM DIS, V72, P406, DOI 10.1136/annrheumdis-2012-202333; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Chung KC, 1998, J HAND SURG-AM, V23A, P575, DOI 10.1016/S0363-5023(98)80042-7; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; de Jong Z, 2009, CLIN RHEUMATOL, V28, P663, DOI 10.1007/s10067-009-1125-z; Dunn G, 2005, STAT METHODS MED RES, V14, P369, DOI 10.1191/0962280205sm403oa; FELSON DT, 1993, ARTHRITIS RHEUM-US, V36, P729, DOI 10.1002/art.1780360601; FUCHS HA, 1989, ARTHRITIS RHEUM, V32, P531, DOI 10.1002/anr.1780320504; Heine PJ, 2012, PHYSIOTHERAPY, V98, P122, DOI 10.1016/j.physio.2011.03.001; Horsten NCA, 2010, J REHABIL MED, V42, P916, DOI 10.2340/16501977-0619; Kwoh CK, 2002, ARTHRITIS RHEUM-US, V46, P328; Lemmey AB, 2012, ARTHRIT CARE RES, V64, P71, DOI 10.1002/acr.20523; Lineker SC, 2000, ARTHRIT CARE RES, V13, P62, DOI 10.1002/1529-0131(200002)13:1<62::AID-ART9>3.0.CO;2-J; Lorig K., 1996, OUTCOME MEASURES HLT, VVol. 2019; Manning VL, 2013, RHEUMATOLOGY, V52, P147; McGuigan MR, 2004, J SPORT SCI MED, V3, P8; National Institute for Health and Care Excellence (NICE), 2013, GUID METH TECHN APPR; NICE, RHEUM ARTHR MAN RHEU; NICE, 2010, RHEUM ARTHR DRUGS TR; O'Brien AV, 2006, RHEUMATOLOGY, V45, P577, DOI 10.1093/rheumatology/kei215; Parsons S, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-34; Perneger TV, 2005, J CLIN EPIDEMIOL, V58, P142, DOI 10.1016/j.jclinepi.2004.06.005; Seto Y, 2013, MOD RHEUMATOL, V23, P1179, DOI [10.1007/s10165-012-0816-5, 10.3109/s10165-012-0816-5]; Toyama S, 2014, MOD RHEUMATOL, V24, P69, DOI 10.3109/14397595.2013.854054; UK Department of Health, 2012, NHS REF COSTS FIN YE; Vlieland TPMV, 2003, BEST PRACT RES CL RH, V17, P847, DOI 10.1016/S1521-6942(03)00043-3; Ware J.E., 2002, SF 12V2 SCORE VERSIO; Weinblatt Michael E, 2013, Trans Am Clin Climatol Assoc, V124, P16; Wessel Jean, 2004, J Hand Ther, V17, P174, DOI 10.1197/j.jht.2004.02.006	32	74	75	0	25	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	2015	385	9966					421	429		10.1016/S0140-6736(14)60998-3	http://dx.doi.org/10.1016/S0140-6736(14)60998-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AZ9CT	25308290	Green Accepted, Bronze			2023-01-03	WOS:000348509900029
J	Larkin, J; Ascierto, PA; Dreno, B; Atkinson, V; Liszkay, G; Maio, M; Mandala, M; Demidov, L; Stroyakovskiy, D; Thomas, L; de la Cruz-Merino, L; Dutriaux, C; Garbe, C; Sovak, MA; Chang, I; Choong, N; Hack, SP; McArthur, GA; Ribas, A				Larkin, James; Ascierto, Paolo A.; Dreno, Brigitte; Atkinson, Victoria; Liszkay, Gabriella; Maio, Michele; Mandala, Mario; Demidov, Lev; Stroyakovskiy, Daniil; Thomas, Luc; de la Cruz-Merino, Luis; Dutriaux, Caroline; Garbe, Claus; Sovak, Mika A.; Chang, Ilsung; Choong, Nicholas; Hack, Stephen P.; McArthur, Grant A.; Ribas, Antoni			Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METASTATIC MELANOMA; IMPROVED SURVIVAL; MEK INHIBITION; RAS MUTATIONS; OPEN-LABEL; RESISTANCE; CANCER; SAFETY; MULTICENTER; ANTI-PD-1	BACKGROUND The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset of resistance observed with BRAF inhibitors alone. This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib. METHODS We randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-positive melanoma to receive vemurafenib and cobimetinib (combination group) or vemurafenib and placebo (control group). The primary end point was investigator-assessed progression-free survival. RESULTS The median progression-free survival was 9.9 months in the combination group and 6.2 months in the control group (hazard ratio for death or disease progression, 0.51; 95% confidence interval [CI], 0.39 to 0.68; P<0.001). The rate of complete or partial response in the combination group was 68%, as compared with 45% in the control group (P<0.001), including rates of complete response of 10% in the combination group and 4% in the control group. Progression-free survival as assessed by independent review was similar to investigator-assessed progression-free survival. Interim analyses of overall survival showed 9-month survival rates of 81% (95% CI, 75 to 87) in the combination group and 73% (95% CI, 65 to 80) in the control group. Vemurafenib and cobimetinib was associated with a nonsignificantly higher incidence of adverse events of grade 3 or higher, as compared with vemurafenib and placebo (65% vs. 59%), and there was no significant difference in the rate of study-drug discontinuation. The number of secondary cutaneous cancers decreased with the combination therapy. CONCLUSIONS The addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity.	[Larkin, James] Royal Marsden Hosp, London, England; [Ascierto, Paolo A.] Fdn G Pascale, Ist Nazl Tumori, Naples, Italy; [Maio, Michele] Azienda Osped Univ Senese, Siena, Italy; [Mandala, Mario] Papa Giovanni XXIII Hosp, Bergamo, Italy; [Dreno, Brigitte] Hotel Dieu Pl Alexis Ricordeau, Nantes, France; [Thomas, Luc] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France; [Dutriaux, Caroline] Hop St Andre, Bordeaux, France; [Atkinson, Victoria] Princess Alexandra Hosp, Woolloongabba, Qld 4102, Australia; [McArthur, Grant A.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Liszkay, Gabriella] Natl Inst Oncol, Budapest, Hungary; [Demidov, Lev] NN Blokhin Russian Canc Res Ctr, Moscow, Russia; [Stroyakovskiy, Daniil] Moscow City Oncol Hosp 62, Krasnogorsk, Russia; [de la Cruz-Merino, Luis] Hosp Univ Virgen Macarena, Seville, Spain; [Garbe, Claus] Univ Tubingen, Tubingen, Germany; [Sovak, Mika A.; Chang, Ilsung; Choong, Nicholas; Hack, Stephen P.] Genentech Inc, San Francisco, CA 94080 USA; [Ribas, Antoni] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	Royal Marsden NHS Foundation Trust; IRCCS Fondazione Pascale; University of Siena; University Hospital of Siena; ASST Papa Giovanni XXIII; Nantes Universite; CHU de Nantes; CHU Lyon; CHU Bordeaux; Peter Maccallum Cancer Center; National Institute of Oncology Hungary; N.N. Blokhin Russian Cancer Research Center; Hospital Universitario Virgen Macarena; Eberhard Karls University of Tubingen; Roche Holding; Genentech; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Ribas, A (corresponding author), Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Jonsson Comprehens Canc Ctr, 11-934 Factor Bldg,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	aribas@mednet.ucla.edu	Mandala', Mario/AAA-4258-2019; Garbe, Claus/ABH-2128-2021; Ascierto, Paolo A/J-9106-2016; Atkinson, Victoria G/G-2507-2015; de la Cruz-Merino, Luis/K-8633-2017; mandala, mario/AAB-8637-2022	Garbe, Claus/0000-0001-8530-780X; Ascierto, Paolo A/0000-0002-8322-475X; de la Cruz-Merino, Luis/0000-0002-5333-0535; McArthur, Grant/0000-0001-8908-6071; Stroyakovskiy, Daniil/0000-0003-1973-1092; coral, sandra/0000-0002-1308-3082; Larkin, James/0000-0001-5569-9523; Thomas, Luc/0000-0003-1995-2434; Melucci, Maria Teresa/0000-0002-1677-3345; Maio, Michele/0000-0002-0323-6321	F. Hoffmann-La Roche/Genentech	F. Hoffmann-La Roche/Genentech(Hoffmann-La RocheRoche HoldingGenentech)	Supported by F. Hoffmann-La Roche/Genentech. Cobimetinib is being developed by F. Hoffmann-La Roche/Genentech, under a collaboration with Exelixis.	Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoeflich KP, 2012, CANCER RES, V72, P210, DOI 10.1158/0008-5472.CAN-11-1515; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Larkin J, 2014, LANCET ONCOL, V15, P436, DOI 10.1016/S1470-2045(14)70051-8; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; McCannel TA, 2014, JAMA OPHTHALMOL, V132, P1005, DOI 10.1001/jamaophthalmol.2014.976; Oberholzer PA, 2012, J CLIN ONCOL, V30, P316, DOI 10.1200/JCO.2011.36.7680; Ribas A, 2014, LANCET ONCOL, V15, P954, DOI 10.1016/S1470-2045(14)70301-8; SCHOUTEN HJA, 1980, BIOMETR J, V22, P241; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Shi HB, 2014, CANCER DISCOV, V4, P69, DOI 10.1158/2159-8290.CD-13-0279; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Urner-Bloch U, 2014, ANN ONCOL, V25, P1437, DOI 10.1093/annonc/mdu169; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369	26	1375	1413	3	89	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2014	371	20					1867	1876		10.1056/NEJMoa1408868	http://dx.doi.org/10.1056/NEJMoa1408868			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AT1RB	25265494	Green Published			2023-01-03	WOS:000344709800004
J	Loupakis, F; Cremolini, C; Masi, G; Lonardi, S; Zagonel, V; Salvatore, L; Cortesi, E; Tomasello, G; Ronzoni, M; Spadi, R; Zaniboni, A; Tonini, G; Buonadonna, A; Amoroso, D; Chiara, S; Carlomagno, C; Boni, C; Allegrini, G; Boni, L; Falcone, A				Loupakis, Fotios; Cremolini, Chiara; Masi, Gianluca; Lonardi, Sara; Zagonel, Vittorina; Salvatore, Lisa; Cortesi, Enrico; Tomasello, Gianluca; Ronzoni, Monica; Spadi, Rosella; Zaniboni, Alberto; Tonini, Giuseppe; Buonadonna, Angela; Amoroso, Domenico; Chiara, Silvana; Carlomagno, Chiara; Boni, Corrado; Allegrini, Giacomo; Boni, Luca; Falcone, Alfredo			Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							1ST-LINE TREATMENT; INFUSIONAL FLUOROURACIL; PHASE-III; OXALIPLATIN; IRINOTECAN; LEUCOVORIN; FOLFIRI; CHEMOTHERAPY; GUIDELINES; MANAGEMENT	BACKGROUND A fluoropyrimidine plus irinotecan or oxaliplatin, combined with bevacizumab (a monoclonal antibody against vascular endothelial growth factor), is standard first-line treatment for metastatic colorectal cancer. Before the introduction of bevacizumab, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) showed superior efficacy as compared with fluorouracil, leucovorin, and irinotecan (FOLFIRI). In a phase 2 study, FOLFOXIRI plus bevacizumab showed promising activity and an acceptable rate of adverse effects. METHODS We randomly assigned 508 patients with untreated metastatic colorectal cancer to receive either FOLFIRI plus bevacizumab (control group) or FOLFOXIRI plus bevacizumab (experimental group). Up to 12 cycles of treatment were administered, followed by fluorouracil plus bevacizumab until disease progression. The primary end point was progression-free survival. RESULTS The median progression-free survival was 12.1 months in the experimental group, as compared with 9.7 months in the control group (hazard ratio for progression, 0.75; 95% confidence interval [CI], 0.62 to 0.90; P = 0.003). The objective response rate was 65% in the experimental group and 53% in the control group (P = 0.006). Overall survival was longer, but not significantly so, in the experimental group (31.0 vs. 25.8 months; hazard ratio for death, 0.79; 95% CI, 0.63 to 1.00; P = 0.054). The incidences of grade 3 or 4 neurotoxicity, stomatitis, diarrhea, and neutropenia were significantly higher in the experimental group. CONCLUSIONS FOLFOXIRI plus bevacizumab, as compared with FOLFIRI plus bevacizumab, improved the outcome in patients with metastatic colorectal cancer and increased the incidence of some adverse events. (Funded by the Gruppo Oncologico Nord Ovest and others; ClinicalTrials.gov number, NCT00719797.)	[Loupakis, Fotios; Cremolini, Chiara; Masi, Gianluca; Salvatore, Lisa; Falcone, Alfredo] Univ Pisana, Azienda Osped, I-56126 Pisa, Italy; [Loupakis, Fotios; Cremolini, Chiara; Masi, Gianluca; Salvatore, Lisa; Falcone, Alfredo] Univ Pisa, Pisa, Italy; [Lonardi, Sara; Zagonel, Vittorina] IRCCS, Ist Oncol Veneto, Padua, Italy; [Cortesi, Enrico] Univ Roma La Sapienza, I-00185 Rome, Italy; [Tonini, Giuseppe] Univ Campus Biomed, Rome, Italy; [Tomasello, Gianluca] Azienda Ist Ospitalieri, Cremona, Italy; [Ronzoni, Monica] IRCCS, Osped San Raffaele, Milan, Italy; [Spadi, Rosella] Univ Citta Salute & Sci, Azienda Osped, Turin, Italy; [Zaniboni, Alberto] Fdn Poliambulanza, Brescia, Italy; [Buonadonna, Angela] IRCCS, Ctr Riferimento Oncol, Aviano, Italy; [Amoroso, Domenico] Osped Versilia, Lido Di Camaiore, Italy; [Chiara, Silvana] IRCCS, Osped San Martino, Genoa, Italy; [Carlomagno, Chiara] Azienda Osped Univ Federico II, Naples, Italy; [Boni, Corrado] IRCCS, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; [Allegrini, Giacomo] Osped Felice Lotti, Pontedera, Italy; [Boni, Luca] Univ Careggi, Azienda Osped, Florence, Italy; [Boni, Luca] Ist Toscano Tumori, Florence, Italy	University of Pisa; Azienda Ospedaliero Universitaria Pisana; University of Pisa; IRCCS Istituto Oncologico Veneto (IOV); Sapienza University Rome; University Campus Bio-Medico - Rome Italy; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; A.O.U. Citta della Salute e della Scienza di Torino; IRCCS Aviano (CRO); Ospedale Versilia; University of Genoa; IRCCS AOU San Martino IST; IRCCS Arcispedale S. Maria Nuova; University of Florence; Azienda Ospedaliero Universitaria Careggi; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica	Falcone, A (corresponding author), Univ Pisana, Azienda Osped, Via Roma 67, I-56126 Pisa, Italy.	alfredo.falcone@med.unipi.it	Cortesi, Enrico/AAA-2983-2019; Cremolini, Chiara/AAC-1889-2019; Lonardi, Sara/F-4228-2014; Salvatore, Lisa/L-7746-2019; zagonel, vittorina/F-4226-2014; Spadi, Rosella/AHD-6311-2022; Falcone, Alfredo/G-5217-2013; Masi, Gianluca/AAJ-8388-2020; Buonadonna, Angela/ABE-2374-2020; Boni, Luca/ABI-6243-2020; Loupakis, Fotios/I-7243-2012; Masi, Gianluca/AAD-1637-2021	Lonardi, Sara/0000-0002-7593-8138; zagonel, vittorina/0000-0002-0829-2525; Buonadonna, Angela/0000-0002-1930-0308; Boni, Luca/0000-0003-2217-4047; Loupakis, Fotios/0000-0001-9651-0395; Salvatore, Lisa/0000-0003-3864-0719; MASI, GIANLUCA/0000-0001-8329-8989; CREMOLINI, CHIARA/0000-0002-0520-4841; Tonini, Giuseppe/0000-0003-4442-8677; Ronzoni, Monica/0000-0002-2845-275X; Falcone, Alfredo/0000-0001-5840-2529	Gruppo Oncologico Nord Ovest; ARCO Foundation; F. Hoffmann-La Roche	Gruppo Oncologico Nord Ovest; ARCO Foundation; F. Hoffmann-La Roche(Hoffmann-La Roche)	Supported by the Gruppo Oncologico Nord Ovest and the ARCO Foundation. A research grant was provided by F. Hoffmann-La Roche.	[Anonymous], 2006, COMM TERM CRIT ADV E; Falcone A, 2002, J CLIN ONCOL, V20, P4006, DOI 10.1200/JCO.2002.12.075; Falcone A, 2007, J CLIN ONCOL, V25, P1670, DOI 10.1200/JCO.2006.09.0928; Goldberg RM, 2007, ONCOLOGIST, V12, P38, DOI 10.1634/theoncologist.12-1-38; Hedrick E, 2006, J CLIN ONCOL, V24, p155S; Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Kohne CH, 2002, ANN ONCOL, V13, P308, DOI 10.1093/annonc/mdf034; Koopman M, 2014, J CLIN ONCOL, V32, P388; Masi G, 2004, ANN ONCOL, V15, P1766, DOI 10.1093/annonc/mdh470; Masi G, 2010, LANCET ONCOL, V11, P845, DOI 10.1016/S1470-2045(10)70175-3; National Comprehensive Cancer Network, 2014, COL CANC VERS 3 2014; Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930; Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113	16	688	711	2	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2014	371	17					1609	1618		10.1056/NEJMoa1403108	http://dx.doi.org/10.1056/NEJMoa1403108			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AR5UF	25337750	Bronze, Green Published			2023-01-03	WOS:000343648500009
J	Yu, S; Wang, CP; Cheng, Q; Xu, H; Zhang, SB; Li, L; Zhang, Q; Gu, XS; Ding, F				Yu, Shu; Wang, Caiping; Cheng, Qiong; Xu, Hui; Zhang, Shibo; Li, Lu; Zhang, Qi; Gu, Xiaosong; Ding, Fei			An Active Component of Achyranthes bidentata Polypeptides Provides Neuroprotection through Inhibition of Mitochondrial-Dependent Apoptotic Pathway in Cultured Neurons and in Animal Models of Cerebral Ischemia	PLOS ONE			English	Article							CELL-DEATH; PERMEABILITY TRANSITION; SH-SY5Y CELLS; DYSFUNCTION; MECHANISMS; HYPOXIA; BRAIN; RECEPTORS; STROKE; OXYGEN	An active component has been isolated by reverse-phase high performance liquid chromatography (HPLC) from Achyranthes bidentata Blume polypeptides that are extracted from Achyranthes bidentata Blume, a Chinese medicinal herb. The active component is called ABPPk based on the order of HPLC elution. In this study, we used in vitro and in vivo experimental models of cerebral ischemia to investigate the possible neuroprotective effect of ABPPk. ABPPk treatment promoted neuronal survival and inhibited neuronal apoptosis in primary cortical neurons exposed to oxygen and glucose deprivation and in rats subjected to transient middle cerebral artery occlusion. The role of ABPPk in protection against ischemia-induced neuronal damage might be mediated by mitochondrial-dependent pathways, including modulation of apoptosis-related gene expression, regulation of mitochondrial dysfunction through restoring mitochondrial membrane potential, reducing release of mitochondrial apoptogenic factors, and inhibiting intracellular ROS production. The neuroprotective effect of ABPPk may suggest the possible use of this agent in the treatment and prevention of cerebral ischemic stroke.	[Yu, Shu; Wang, Caiping; Cheng, Qiong; Xu, Hui; Zhang, Shibo; Li, Lu; Zhang, Qi; Gu, Xiaosong; Ding, Fei] Nantong Univ, Jiangsu Key Lab Neuroregenerat, Collaborat Innovat Ctr Neuroregenerat, Nantong, Jiangsu, Peoples R China	Nantong University	Ding, F (corresponding author), Nantong Univ, Jiangsu Key Lab Neuroregenerat, Collaborat Innovat Ctr Neuroregenerat, Nantong, Jiangsu, Peoples R China.	dingfei@ntu.edu.cn			National Key Basic Research Program of China (973 program) [2014CB542202]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Nantong Science and Technology Innovation Project [HS2013003]; Nantong University [11Z035, 13ZY009]	National Key Basic Research Program of China (973 program)(National Basic Research Program of China); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Nantong Science and Technology Innovation Project; Nantong University	This study was supported by National Key Basic Research Program of China (973 program, Grant No. 2014CB542202), Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Nantong Science and Technology Innovation Project (Grant No. HS2013003), and the natural science research project of Nantong University (Grant No. 11Z035 and 13ZY009). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antonelli T, 2008, CEREB CORTEX, V18, P1748, DOI 10.1093/cercor/bhm217; Aquilani R, 2011, NUTR CLIN PRACT, V26, P339, DOI 10.1177/0884533611405793; Brenner C, 2012, CIRC RES, V111, P1237, DOI 10.1161/CIRCRESAHA.112.265942; Broughton BRS, 2009, STROKE, V40, pE331, DOI 10.1161/STROKEAHA.108.531632; Chazotte B, 2011, COLD SPRING HARB PRO, V2011; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Davis RE, 2012, J PHARMACOL EXP THER, V342, P598, DOI 10.1124/jpet.112.192104; Ding F, 2008, FITOTERAPIA, V79, P161, DOI 10.1016/j.fitote.2007.10.002; Faraci FM, 2011, AM J PHYSIOL-HEART C, V300, pH1566, DOI 10.1152/ajpheart.01310.2010; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Galluzzi L, 2012, CIRC RES, V111, P1198, DOI 10.1161/CIRCRESAHA.112.268946; Gao YQ, 2010, STROKE, V41, P166, DOI 10.1161/STROKEAHA.109.561852; Gong X, 2002, PHYTOMEDICINE, V9, P478, DOI 10.1078/09447110260571760; Hirooka Y, 2011, AM J PHYSIOL-REG I, V300, pR818, DOI 10.1152/ajpregu.00426.2010; Horan MP, 2012, J GERONTOL A-BIOL, V67, P1022, DOI 10.1093/gerona/glr263; Jang S, 2009, J PHARMACOL EXP THER, V328, P435, DOI 10.1124/jpet.108.144014; Johri A, 2012, J PHARMACOL EXP THER, V342, P619, DOI 10.1124/jpet.112.192138; Joshi CN, 2004, BRAIN RES PROTOC, V13, P11, DOI 10.1016/j.brainresprot.2003.12.001; Kondo K, 2010, J BIOL CHEM, V285, P13079, DOI 10.1074/jbc.M109.044206; Konstantinidou AE, 2007, APOPTOSIS, V12, P695, DOI 10.1007/s10495-006-0001-4; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Luchetti F, 2010, FASEB J, V24, P3603, DOI 10.1096/fj.10-154450; Martinive P, 2006, CANCER RES, V66, P11736, DOI 10.1158/0008-5472.CAN-06-2056; McFarland AJ, 2013, INT J TOXICOL, V32, P209, DOI 10.1177/1091581813482146; Mergenthaler P, 2011, J PHYSIOL-LONDON, V589, P4147, DOI 10.1113/jphysiol.2011.209718; Nijboer CHA, 2008, STROKE, V39, P2129, DOI 10.1161/STROKEAHA.107.504175; Ouyang YB, 2004, CELL CALCIUM, V36, P303, DOI 10.1016/j.ceca.2004.02.015; Papanicolaou KN, 2012, AM J PHYSIOL-HEART C, V303, pH243, DOI 10.1152/ajpheart.00185.2012; Picard M, 2011, J PHYSIOL-LONDON, V589, P4413, DOI 10.1113/jphysiol.2011.212712; Plesnila N, 2004, ACTA NEUROCHIR SUPPL, V89, P15; Ronaldson PT, 2013, PHARMACOL REV, V65, P291, DOI 10.1124/pr.112.005991; Russo R, 2005, NEUROTOXICOLOGY, V26, P905, DOI 10.1016/j.neuro.2005.01.009; Seo AY, 2010, J CELL SCI, V123, P2533, DOI 10.1242/jcs.070490; Sheikh AY, 2008, AM J PHYSIOL-HEART C, V294, pH88, DOI 10.1152/ajpheart.00935.2007; Shen HM, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0057055, 10.1371/journal.pone.0057746]; Shen HM, 2010, J NEUROSCI RES, V88, P669, DOI 10.1002/jnr.22221; Shen HM, 2008, BRAIN RES BULL, V77, P274, DOI 10.1016/j.brainresbull.2008.08.002; Shen YT, 2011, NEUROCHEM RES, V36, P2186, DOI 10.1007/s11064-011-0543-x; Smith MA, 2012, CARDIOVASC RES, V96, P32, DOI 10.1093/cvr/cvs163; Stefanis L, 2005, NEUROSCIENTIST, V11, P50, DOI 10.1177/1073858404271087; Stutzmann GE, 2011, PHARMACOL REV, V63, P700, DOI 10.1124/pr.110.003814; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Thapa A, 2012, J BIOL CHEM, V287, P18018, DOI 10.1074/jbc.M112.342220; Vosler PS, 2009, STROKE, V40, P3149, DOI 10.1161/STROKEAHA.108.543769; Wang X, 2009, STROKE, V40, P1877, DOI 10.1161/STROKEAHA.108.540765; Wang YX, 2013, NEUROCHEM RES, V38, P538, DOI 10.1007/s11064-012-0946-3; Xing BZ, 2008, STROKE, V39, P2362, DOI 10.1161/STROKEAHA.107.507939; Yuan Y, 2010, BRAIN RES BULL, V81, P25, DOI 10.1016/j.brainresbull.2009.07.013	49	30	32	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2014	9	10							e109923	10.1371/journal.pone.0109923	http://dx.doi.org/10.1371/journal.pone.0109923			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX2IH	25334016	gold, Green Published, Green Submitted			2023-01-03	WOS:000346766200066
J	Guo, F; Han, XH; Zhang, JH; Zhao, XX; Lou, JC; Chen, H; Huang, XL				Guo, Feng; Han, Xiaohua; Zhang, Jinghui; Zhao, Xiuxiu; Lou, Jicheng; Chen, Hong; Huang, Xiaolin			Repetitive Transcranial Magnetic Stimulation Promotes Neural Stem Cell Proliferation via the Regulation of MiR-25 in a Rat Model of Focal Cerebral Ischemia	PLOS ONE			English	Article							SUBVENTRICULAR ZONE; PARKINSONS-DISEASE; ARTERY OCCLUSION; PROGENITOR CELLS; CHRONIC STROKE; MOTOR CORTEX; NEUROGENESIS; MICRORNAS; RTMS; EXCITABILITY	Repetitive transcranial magnetic stimulation (rTMS) has increasingly been studied over the past decade to determine whether it has a therapeutic benefit on focal cerebral ischemia. However, the underlying mechanism of rTMS in this process remains unclear. In the current study, we investigated the effects of rTMS on the proliferation of adult neural stem cells (NSCs) and explored microRNAs (miRNAs) that were affected by rTMS. Our data showed that 10 Hz rTMS significantly increased the proliferation of adult NSCs after focal cerebral ischemia in the subventricular zone (SVZ), and the expression of miR-25 was obviously up-regulated in the ischemic cortex after rTMS. p57, an identified miR-25 target gene that regulates factors linked to NSC proliferation, was also evaluated, and it exhibited down-regulation. To further verify the role of miR-25, rats were injected with a single dose of antagomir-25 and were subjected to focal cerebral ischemia followed by rTMS treatment. The results confirmed that miR-25 could be repressed specifically and could drive the up-regulation of its target gene (p57), which resulted in the inhibition of adult NSC proliferation in the SVZ after rTMS. Thus, our studies strongly indicated that 10 Hz rTMS can promote the proliferation of adult NSCs in the SVZ after focal cerebral ischemia by regulating the miR-25/p57 pathway.	[Guo, Feng; Han, Xiaohua; Zhao, Xiuxiu; Chen, Hong; Huang, Xiaolin] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Rehabil Med, Wuhan 430074, Peoples R China; [Zhang, Jinghui] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Rehabil Med, Guangzhou 510275, Guangdong, Peoples R China; [Lou, Jicheng] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Obstet & Gynecol, Wuhan 430074, Peoples R China	Huazhong University of Science & Technology; Sun Yat Sen University; Huazhong University of Science & Technology	Huang, XL (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Rehabil Med, Wuhan 430074, Peoples R China.	xiaolinh2006@126.com	Zhang, Jing/GWZ-7332-2022		National Natural Science Foundation of China [81071601, 81171858, 81070986]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by National Natural Science Foundation of China (Nos: 81071601, 81171858 and 81070986). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arias-Carrion O, 2004, J NEUROSCI RES, V78, P16, DOI 10.1002/jnr.20235; Arias-Carrion Oscar, 2008, Int Arch Med, V1, P2, DOI 10.1186/1755-7682-1-2; Arnold CP, 2011, GENOME RES, V21, P798, DOI 10.1101/gr.111385.110; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Brett JO, 2011, AGING-US, V3, P108, DOI 10.18632/aging.100285; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Corti M, 2012, AM J PHYS MED REHAB, V91, P254, DOI 10.1097/PHM.0b013e318228bf0c; Deng ZD, 2014, CLIN NEUROPHYSIOL, V125, P1202, DOI 10.1016/j.clinph.2013.11.038; Dharap A, 2009, J CEREBR BLOOD F MET, V29, P675, DOI 10.1038/jcbfm.2008.157; Dziennis S, 2011, METAB BRAIN DIS, V26, P123, DOI 10.1007/s11011-011-9241-2; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Feng SF, 2012, BEHAV BRAIN RES, V232, P245, DOI 10.1016/j.bbr.2012.04.019; Ferrarelli F, 2004, BRAIN RES BULL, V64, P103, DOI 10.1016/j.brainresbull.2004.04.020; Foshay KM, 2009, DEV BIOL, V326, P431, DOI 10.1016/j.ydbio.2008.11.016; Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621; Gao F, 2010, EUR J NUCL MED MOL I, V37, P954, DOI 10.1007/s00259-009-1342-3; Hiscock A, 2008, NEUROREHAB NEURAL RE, V22, P228, DOI 10.1177/1545968307307115; Hotermans C, 2007, STROKE, V38, P253, DOI 10.1161/01.STR.0000254446.14130.aa; ISAYAMA K, 1991, STROKE, V22, P1394, DOI 10.1161/01.STR.22.11.1394; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Jeyaseelan K, 2008, STROKE, V39, P959, DOI 10.1161/STROKEAHA.107.500736; Jimenez-Mateos EM, 2012, NAT MED, V18, P1087, DOI 10.1038/nm.2834; Jimenez-Mateos EM, 2011, AM J PATHOL, V179, P2519, DOI 10.1016/j.ajpath.2011.07.036; Kee NJ, 2001, EXP BRAIN RES, V136, P313, DOI 10.1007/s002210000591; Khedr EM, 2006, MOVEMENT DISORD, V21, P2201, DOI 10.1002/mds.21089; Kim YH, 2006, STROKE, V37, P1471, DOI 10.1161/01.STR.0000221233.55497.51; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kwon TG, 2014, RESTOR NEUROL NEUROS, V32, P223, DOI 10.3233/RNN-130313; Lang N, 2006, CLIN NEUROPHYSIOL, V117, P2292, DOI 10.1016/j.clinph.2006.05.030; Le Q, 2014, AM J PHYS MED REHAB, V93, P422, DOI 10.1097/PHM.0000000000000027; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lin XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075561; Linden RD, 1999, J NEUROSURG, V91, P205, DOI 10.3171/spi.1999.91.2.0205; Liu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032230; Lomarev MP, 2007, CLIN NEUROPHYSIOL, V118, P2072, DOI 10.1016/j.clinph.2007.06.016; Lomarev MP, 2006, MOVEMENT DISORD, V21, P325, DOI 10.1002/mds.20713; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Machado S, 2008, FUNCT NEUROL, V23, P113; Mally Judit, 2007, Expert Rev Neurother, V7, P165, DOI 10.1586/14737175.7.2.165; Peck B, 2011, AGING-US, V3, P329, DOI 10.18632/aging.100302; Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Rooke HM, 2001, PATHOLOGY, V33, P73; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Sasaki N, 2013, J STROKE CEREBROVASC, V22, P413, DOI 10.1016/j.jstrokecerebrovasdis.2011.10.004; Sonkoly E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000610; Szele FG, 1996, J COMP NEUROL, V368, P439, DOI 10.1002/(SICI)1096-9861(19960506)368:3<439::AID-CNE9>3.0.CO;2-6; Taupin P, 2007, BRAIN RES REV, V53, P198, DOI 10.1016/j.brainresrev.2006.08.002; Ueyama E, 2011, PSYCHIAT CLIN NEUROS, V65, P77, DOI 10.1111/j.1440-1819.2010.02170.x; Wu XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078629; Xu XH, 2012, BIOCHEM BIOPH RES CO, V421, P640, DOI 10.1016/j.bbrc.2012.03.048; Yagita Y, 2001, STROKE, V32, P1890, DOI 10.1161/01.STR.32.8.1890; Yoon KJ, 2011, EXP BRAIN RES, V214, P549, DOI 10.1007/s00221-011-2853-2; Yozbatiran N, 2009, STROKE, V40, P309, DOI 10.1161/STROKEAHA.108.522144; Zhao ZN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045133	55	60	65	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2014	9	10							e109267	10.1371/journal.pone.0109267	http://dx.doi.org/10.1371/journal.pone.0109267			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR6ZS	25302788	gold, Green Published, Green Submitted			2023-01-03	WOS:000343730400048
J	Auer, MK; Fuss, J; Hohne, N; Stalla, GK; Sievers, C				Auer, Matthias K.; Fuss, Johannes; Hoehne, Nina; Stalla, Guenter K.; Sievers, Caroline			Transgender Transitioning and Change of Self-Reported Sexual Orientation	PLOS ONE			English	Article							GENDER IDENTITY; TRANSSEXUALISM; BEHAVIOR; AUTOGYNEPHILIA; REASSIGNMENT; DIFFERENCE; TYPOLOGY; HEALTH; BRAIN	Objective: Sexual orientation is usually considered to be determined in early life and stable in the course of adulthood. In contrast, some transgender individuals report a change in sexual orientation. A common reason for this phenomenon is not known. Methods: We included 115 transsexual persons (70 male-to-female "MtF" and 45 female-to-male "FtM") patients from our endocrine outpatient clinic, who completed a questionnaire, retrospectively evaluating the history of their gender transition phase. The questionnaire focused on sexual orientation and recalled time points of changes in sexual orientation in the context of transition. Participants were further asked to provide a personal concept for a potential change in sexual orientation. Results: In total, 32.9% (n = 23) MtF reported a change in sexual orientation in contrast to 22.2% (n = 10) FtM transsexual persons (p = 0.132). Out of these patients, 39.1% (MtF) and 60% (FtM) reported a change in sexual orientation before having undergone any sex reassignment surgery. FtM that had initially been sexually oriented towards males (= androphilic), were significantly more likely to report on a change in sexual orientation than gynephilic, analloerotic or bisexual FtM (p = 0.012). Similarly, gynephilic MtF reported a change in sexual orientation more frequently than androphilic, analloerotic or bisexual MtF transsexual persons (p = 0.05). Conclusion: In line with earlier reports, we reveal that a change in self-reported sexual orientation is frequent and does not solely occur in the context of particular transition events. Transsexual persons that are attracted by individuals of the opposite biological sex are more likely to change sexual orientation. Qualitative reports suggest that the individual's biography, autogynephilic and autoandrophilic sexual arousal, confusion before and after transitioning, social and self-acceptance, as well as concept of sexual orientation itself may explain this phenomenon.	[Auer, Matthias K.; Stalla, Guenter K.; Sievers, Caroline] Max Planck Inst Psychiat, Dept Internal Med Endocrinol & Clin Chem, Munich, Germany; [Fuss, Johannes] Univ Med Ctr Hamburg Eppendorf, Inst Sex Res & Forens Psychiat, Ctr Psychosocial Med, Hamburg, Germany; [Hoehne, Nina] Max Planck Inst Psychiat, Dept Mol Psychol, Munich, Germany	Max Planck Society; University of Hamburg; University Medical Center Hamburg-Eppendorf; Max Planck Society	Auer, MK (corresponding author), Max Planck Inst Psychiat, Dept Internal Med Endocrinol & Clin Chem, Munich, Germany.	mauer@mpipsykl.mpg.de	Auer, Matthias/AAI-5449-2021; Fuss, Johannes/AAI-6580-2021					American Psychiatric Association, 2000, DIAGN STAT MAN MENT; APA (American Psychiatric Association), 2008, ANSW YOUR QUEST BETT; Auer MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078469; Auer MK, 2013, FERTIL STERIL, V100, P1103, DOI 10.1016/j.fertnstert.2013.05.047; Bailey JM, 2009, NEBRASKA S MOTIVATIO; BLANCHARD R, 1989, ARCH SEX BEHAV, V18, P315, DOI 10.1007/BF01541951; BLANCHARD R, 1989, J NERV MENT DIS, V177, P616, DOI 10.1097/00005053-198910000-00004; BLANCHARD R, 1985, ARCH SEX BEHAV, V14, P247, DOI 10.1007/BF01542107; Bockting W, 2009, ARCH SEX BEHAV, V38, P688, DOI 10.1007/s10508-009-9489-3; Chivers ML, 2004, PSYCHOL SCI, V15, P736, DOI 10.1111/j.0956-7976.2004.00750.x; Cohen-Kettenis PT, 1993, J PSYCHOL HUMAN SEX, V5, P55, DOI DOI 10.1300/J056V05N04_; Daskalos CT, 1998, ARCH SEX BEHAV, V27, P605, DOI 10.1023/A:1018725201811; De Cuypere G, 2005, ARCH SEX BEHAV, V34, P679, DOI 10.1007/s10508-005-7926-5; DEVOR H, 1993, J SEX RES, V30, P303, DOI 10.1080/00224499309551717; DOORN CD, 1994, ARCH SEX BEHAV, V23, P185, DOI 10.1007/BF01542098; Foucault M., 1998, HIST SEXUALITY 1 WIL, V1; FREUND K, 1993, BRIT J PSYCHIAT, V162, P558, DOI 10.1192/bjp.162.4.558; Fuss J, 2013, J PSYCHIATR RES, V47, P2015, DOI 10.1016/j.jpsychires.2013.08.023; Hirschfeld M, 1918, SEXUALPATHOLOGIE; Hirschfeld M., 1948, SEXUAL ANOMALIES ORI; Jiang Y, 2006, P NATL ACAD SCI USA, V103, P17048, DOI 10.1073/pnas.0605678103; Kinnish KK, 2005, ARCH SEX BEHAV, V34, P173, DOI 10.1007/s10508-005-1795-9; Lawrence AA, 2005, ARCH SEX BEHAV, V34, P147, DOI 10.1007/s10508-005-1793-y; Lawrence AA, 2005, ARCH SEX BEHAV, V34, P135, DOI 10.1007/s10508-005-1792-z; Lawrence AA., 2013, MEN TRAPPED MENS BOD, DOI [10.1007/978-1-4614-5182-2, DOI 10.1007/978-1-4614-5182-2]; Lever J., 1994, ADVOCATE, P16; LEVINE SB, 1981, J SEX MARITAL THER, V7, P85, DOI 10.1080/00926238108406096; Meier SC, 2013, ARCH SEX BEHAV, V42, P463, DOI 10.1007/s10508-012-0052-2; Moser C, 2010, J HOMOSEXUAL, V57, P790, DOI 10.1080/00918369.2010.486241; Nieder TO, 2011, J SEX MED, V8, P783, DOI 10.1111/j.1743-6109.2010.02142.x; Pathela P, 2006, ANN INTERN MED, V145, P416; PILLARD RC, 1995, PSYCHIAT CLIN N AM, V18, P71, DOI 10.1016/S0193-953X(18)30071-6; Rowniak S, 2013, ARCH SEX BEHAV, V42, P449, DOI 10.1007/s10508-012-0036-2; Schleifer D., 2006, SEXUALITIES, V9, P57, DOI [DOI 10.1177/1363460706058397, 10.1177/1363460706058397]; SEIL D, 1997, GENDER BLENDING, P137; Seil D., 1996, TXB HOMOSEXUALITY ME, P743; Seil D, 2004, TRANSGENDER SUBJECTI, P99, DOI DOI 10.1080/; Serano JM, 2010, INT J TRANSGENDERISM, V12, P176, DOI 10.1080/15532739.2010.514223; Sigal P, 2000, MOON GOODDESS VIGING; Smith YLS, 2005, PSYCHOL MED, V35, P89, DOI 10.1017/S0033291704002776; Swaab DF, 2007, BEST PRACT RES CL EN, V21, P431, DOI 10.1016/j.beem.2007.04.003; Thompson EM, 2008, DEV PSYCHOL, V44, P15, DOI 10.1037/0012-1649.44.1.15; vanKesteren PJ, 1996, ARCH SEX BEHAV, V25, P589, DOI 10.1007/BF02437841; WEINBERG TS, 1978, J HOMOSEXUAL, V4, P143; Weyers S, 2009, J SEX MED, V6, P752, DOI 10.1111/j.1743-6109.2008.01082.x; ZHOU JN, 1995, NATURE, V378, P68, DOI 10.1038/378068a0; Zucker KJ, 2012, J SEX MARITAL THER, V38, P151, DOI 10.1080/0092623X.2011.611219	47	48	48	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2014	9	10							e110016	10.1371/journal.pone.0110016	http://dx.doi.org/10.1371/journal.pone.0110016			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AS0AP	25299675	gold, Green Submitted, Green Published			2023-01-03	WOS:000343941200097
J	Liu, YJ; Zhu, GX; Yang, J; Yuan, AH; Shen, XP				Liu, Yuanjun; Zhu, Guoxing; Yang, Jing; Yuan, Aihua; Shen, Xiaoping			Peroxidase-Like Catalytic Activity of Ag3PO4 Nanocrystals Prepared by a Colloidal Route	PLOS ONE			English	Article							ENHANCED PHOTOCATALYTIC ACTIVITY; FE3O4 MAGNETIC NANOPARTICLES; GLUCOSE DETECTION; VISIBLE-LIGHT; COLORIMETRIC DETECTION; OXIDE NANOPARTICLES; HYDROGEN-PEROXIDE; HIGHLY EFFICIENT; GRAPHENE OXIDE; SUB-MICROCRYSTALS	Nearly monodispersed Ag3PO4 nanocrystals with size of 10 nm were prepared through a colloidal chemical route. It was proven that the synthesized Ag3PO4 nanoparticles have intrinsic peroxidase-like catalytic activity. They can quickly catalyze oxidation of the peroxidase substrate 3, 3, 5, 5-tetramethylbenzidine (TMB) in the presence of H2O2, producing a blue color. The catalysis reaction follows Michaelis-Menten kinetics. The calculated kinetic parameters indicate a high catalytic activity and the strong affinity of Ag3PO4 nanocrystals to the substrate (TMB). These results suggest the potential applications of Ag3PO4 nanocrystals in fields such as biotechnology, environmental chemistry, and medicine.	[Liu, Yuanjun; Yuan, Aihua] Jiangsu Univ Sci & Technol, Sch Environm & Chem Engn, Zhenjiang, Peoples R China; [Zhu, Guoxing; Yang, Jing; Shen, Xiaoping] Jiangsu Univ, Sch Chem & Chem Engn, Zhenjiang, Peoples R China; [Zhu, Guoxing] Nanjing Univ, State Key Lab Coordinat Chem, Nanjing 210008, Jiangsu, Peoples R China	Jiangsu University of Science & Technology; Jiangsu University; Nanjing University	Zhu, GX (corresponding author), Jiangsu Univ, Sch Chem & Chem Engn, Zhenjiang, Peoples R China.	zhuguoxing@ujs.edu.cn; aihuayuan@just.edu.cn	Nanozymes, Nanozymes/D-8197-2019; Shen, Xiao Ping/AAA-1973-2022; shen, xiaoping/ABF-7863-2021	shen, xiaoping/0000-0003-0366-6433	National Natural Science Foundation of China [51203069, 51102117, 51072071]; China Postdoctoral Science Foundation [2012T50439]; Jiangsu Natural Science Foundation of China [BK2012276]; Cultivating Project of Young Academic Leader from Jiangsu University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Jiangsu Natural Science Foundation of China(Natural Science Foundation of Jiangsu Province); Cultivating Project of Young Academic Leader from Jiangsu University	Financial support was provided by the National Natural Science Foundation of China (No. 51203069, 51102117, 51072071), China Postdoctoral Science Foundation (2012T50439), Jiangsu Natural Science Foundation of China (No. BK2012276), and Cultivating Project of Young Academic Leader from Jiangsu University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andre R, 2011, ADV FUNCT MATER, V21, P501, DOI 10.1002/adfm.201001302; Asati A, 2009, ANGEW CHEM INT EDIT, V48, P2308, DOI 10.1002/anie.200805279; Bi YP, 2012, CHEM COMMUN, V48, P3748, DOI 10.1039/c2cc30363a; Bi YP, 2011, PHYS CHEM CHEM PHYS, V13, P10071, DOI 10.1039/c1cp20488b; Bi Y, 2011, J AM CHEM SOC, V133, P6490, DOI 10.1021/ja2002132; Dinh CT, 2011, CHEM COMMUN, V47, P7797, DOI 10.1039/c1cc12014j; Chen W, 2012, ANALYST, V137, P1706, DOI 10.1039/c2an35072f; Cui RJ, 2011, CHEM-EUR J, V17, P9377, DOI 10.1002/chem.201100478; Dong YL, 2012, NANOSCALE, V4, P3969, DOI 10.1039/c2nr12109c; Dutta AK, 2012, ACS APPL MATER INTER, V4, P1919, DOI 10.1021/am300408r; Fan J, 2011, BIOMATERIALS, V32, P1611, DOI 10.1016/j.biomaterials.2010.11.004; Gao LZ, 2007, NAT NANOTECHNOL, V2, P577, DOI 10.1038/nnano.2007.260; He SH, 2010, TALANTA, V82, P377, DOI 10.1016/j.talanta.2010.04.055; He WW, 2011, BIOMATERIALS, V32, P1139, DOI 10.1016/j.biomaterials.2010.09.040; He WW, 2010, CHEM MATER, V22, P2988, DOI 10.1021/cm100393v; Heckert EG, 2008, BIOMATERIALS, V29, P2705, DOI 10.1016/j.biomaterials.2008.03.014; Jiang H, 2012, ANALYST, V137, P5560, DOI 10.1039/c2an35911a; JOSEPHY PD, 1982, J BIOL CHEM, V257, P3669; Jv Y, 2010, CHEM COMMUN, V46, P8017, DOI 10.1039/c0cc02698k; Karaseva EI, 2002, RUSS J BIOORG CHEM+, V28, P128, DOI 10.1023/A:1015069424251; Katsumata H, 2013, CATAL COMMUN, V34, P30, DOI 10.1016/j.catcom.2013.01.012; Korsvik C, 2007, CHEM COMMUN, P1056, DOI 10.1039/b615134e; Li GP, 2012, RSC ADV, V2, P5108, DOI 10.1039/c2ra20504a; Liang QH, 2012, CRYSTENGCOMM, V14, P2966, DOI 10.1039/c2ce06425a; Liu JB, 2012, SENSOR ACTUAT B-CHEM, V166, P708, DOI 10.1016/j.snb.2012.03.045; Liu JB, 2011, CHEM COMMUN, V47, P10981, DOI 10.1039/c1cc14346h; Liu L, 2012, CATAL SCI TECHNOL, V2, P2525, DOI 10.1039/c2cy20483e; Liu SH, 2011, CHEM-EUR J, V17, P620, DOI 10.1002/chem.201001789; Ma M, 2011, COLLOID SURFACE A, V373, P6, DOI 10.1016/j.colsurfa.2010.08.007; Niu HY, 2011, J HAZARD MATER, V190, P559, DOI 10.1016/j.jhazmat.2011.03.086; Park KS, 2011, SMALL, V7, P1521, DOI 10.1002/smll.201001886; Pirmohamed T, 2010, CHEM COMMUN, V46, P2736, DOI 10.1039/b922024k; Qu FL, 2011, BIOSENS BIOELECTRON, V26, P3927, DOI 10.1016/j.bios.2011.03.013; Shi WB, 2011, CHEM COMMUN, V47, P10785, DOI 10.1039/c1cc14300j; Shi WB, 2011, CHEM COMMUN, V47, P6695, DOI 10.1039/c1cc11943e; Song YJ, 2011, ADV MATER, V23, P4215, DOI 10.1002/adma.201101853; Song YJ, 2011, CHEM COMMUN, V47, P4436, DOI 10.1039/c0cc05533f; Song YJ, 2010, ADV MATER, V22, P2206, DOI 10.1002/adma.200903783; Song YJ, 2010, CHEM-EUR J, V16, P3617, DOI 10.1002/chem.200902643; Sun XL, 2013, ADV MATER, V25, P132, DOI 10.1002/adma.201203218; Tian JQ, 2012, CATAL SCI TECHNOL, V2, P432, DOI 10.1039/c1cy00360g; Tian QW, 2011, ACS NANO, V5, P9761, DOI 10.1021/nn203293t; Umezawa N, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.035202; Wang N, 2010, ULTRASON SONOCHEM, V17, P526, DOI 10.1016/j.ultsonch.2009.11.001; Wang Q, 2014, IND ENG CHEM RES, V53, P7917, DOI 10.1021/ie403554v; Wang XX, 2011, BIOSENS BIOELECTRON, V26, P3614, DOI 10.1016/j.bios.2011.02.014; Wang XH, 2011, NANO RES, V4, P908, DOI 10.1007/s12274-011-0147-4; Wei H, 2008, ANAL CHEM, V80, P2250, DOI 10.1021/ac702203f; Yi ZG, 2010, NAT MATER, V9, P559, DOI [10.1038/nmat2780, 10.1038/NMAT2780]; Yu FQ, 2009, BIOMATERIALS, V30, P4716, DOI 10.1016/j.biomaterials.2009.05.005; Zhang HC, 2012, J MATER CHEM, V22, P10501, DOI 10.1039/c2jm30703k; Zhang LL, 2012, NEW J CHEM, V36, P1541, DOI 10.1039/c2nj40206h; Zhang XQ, 2010, J MATER CHEM, V20, P5110, DOI 10.1039/c0jm00174k; Zuo XL, 2009, NANO RES, V2, P617, DOI [10.1007/S12274-009-9062-3, 10.1007/s12274-009-9062-3]	54	24	24	0	86	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2014	9	10							e109158	10.1371/journal.pone.0109158	http://dx.doi.org/10.1371/journal.pone.0109158			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR6ZM	25271632	Green Submitted, Green Published, gold			2023-01-03	WOS:000343729600101
J	Lyon, RP; Setter, JR; Bovee, TD; Doronina, SO; Hunter, JH; Anderson, ME; Balasubramanian, CL; Duniho, SM; Leiske, CI; Li, F; Senter, PD				Lyon, Robert P.; Setter, Jocelyn R.; Bovee, Tim D.; Doronina, Svetlana O.; Hunter, Joshua H.; Anderson, Martha E.; Balasubramanian, Cindy L.; Duniho, Steven M.; Leiske, Chris I.; Li, Fu; Senter, Peter D.			Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates	NATURE BIOTECHNOLOGY			English	Article							ANTITUMOR-ACTIVITY; CANCER-THERAPY; TRASTUZUMAB EMTANSINE; LINKER STABILITY; BREAST-CANCER; IN-VITRO; SITE; POTENT; PIPELINE; CYSTEINE	Many antibody-drug conjugates (ADCs) are unstable in vivo because they are formed from maleimide-containing components conjugated to reactive thiols. These thiosuccinimide linkages undergo two competing reactions in plasma: elimination of the maleimide through a retro-Michael reaction, which results in loss of drug-linker from the ADC, and hydrolysis of the thiosuccinimide ring, which results in a derivative that is resistant to the elimination reaction. In an effort to create linker technologies with improved stability characteristics, we used diaminopropionic acid (DPR) to prepare a drug-linker incorporating a basic amino group adjacent to the maleimide, positioned to provide intramolecular catalysis of thiosuccinimide ring hydrolysis. This basic group induces the thiosuccinimide to undergo rapid hydrolysis at neutral pH and room temperature. Once hydrolyzed, the drug-linker is no longer subject to maleimide elimination reactions, preventing nonspecific deconjugation. In vivo studies demonstrate that the increased stability characteristics can lead to improved ADC antitumor activity and reduced neutropenia.	[Lyon, Robert P.; Setter, Jocelyn R.; Bovee, Tim D.; Doronina, Svetlana O.; Hunter, Joshua H.; Anderson, Martha E.; Balasubramanian, Cindy L.; Duniho, Steven M.; Leiske, Chris I.; Li, Fu; Senter, Peter D.] Seattle Genet, Bothell, WA 98021 USA	Seattle Genetics	Lyon, RP (corresponding author), Seattle Genet, Bothell, WA 98021 USA.	rlyon@seagen.com						Agarwal P, 2013, P NATL ACAD SCI USA, V110, P46, DOI 10.1073/pnas.1213186110; Alley SC, 2008, BIOCONJUGATE CHEM, V19, P759, DOI 10.1021/bc7004329; Badescu G, 2014, BIOCONJUGATE CHEM, V25, P460, DOI 10.1021/bc400245v; Baldwin AD, 2011, BIOCONJUGATE CHEM, V22, P1946, DOI 10.1021/bc200148v; Chari RVJ, 2014, ANGEW CHEM INT EDIT, V53, P3796, DOI 10.1002/anie.201307628; Chudasama VL, 2012, CLIN PHARMACOL THER, V92, P520, DOI 10.1038/clpt.2012.153; Doronina SO, 2003, NAT BIOTECHNOL, V21, P778, DOI 10.1038/nbt832; Dubowchik GM, 2002, BIOCONJUGATE CHEM, V13, P855, DOI 10.1021/bc025536j; Francisco JA, 2003, BLOOD, V102, P1458, DOI 10.1182/blood-2003-01-0039; Hamblett KJ, 2004, CLIN CANCER RES, V10, P7063, DOI 10.1158/1078-0432.CCR-04-0789; Hermanson GT, 2008, BIOCONJUGATE TECHNIQUES, 2ND EDITION, P1, DOI 10.1016/B978-0-12-370501-3.00001-1; Jeffrey SC, 2013, BIOCONJUGATE CHEM, V24, P1256, DOI 10.1021/bc400217g; Kalia J, 2007, BIOORG MED CHEM LETT, V17, P6286, DOI 10.1016/j.bmcl.2007.09.002; KNIGHT P, 1979, BIOCHEM J, V179, P191, DOI 10.1042/bj1790191; Lyon RP, 2012, METHOD ENZYMOL, V502, P123, DOI 10.1016/B978-0-12-416039-2.00006-9; Mullard A, 2013, NAT REV DRUG DISCOV, V12, P329, DOI 10.1038/nrd4009; Okeley NM, 2014, HEMATOL ONCOL CLIN N, V28, P13, DOI 10.1016/j.hoc.2013.10.009; Peddi PF, 2013, FUTURE ONCOL, V9, P319, DOI [10.2217/fon.13.7, 10.2217/FON.13.7]; Ryan CP, 2011, CHEM COMMUN, V47, P5452, DOI 10.1039/c1cc11114k; Sanderson RJ, 2005, CLIN CANCER RES, V11, P843; Sassoon I, 2013, METHODS MOL BIOL, V1045, P1, DOI 10.1007/978-1-62703-541-5_1; Senter PD, 2012, NAT BIOTECHNOL, V30, P631, DOI 10.1038/nbt.2289; Shen BQ, 2012, NAT BIOTECHNOL, V30, P184, DOI 10.1038/nbt.2108; Sievers EL, 2013, ANNU REV MED, V64, P15, DOI 10.1146/annurev-med-050311-201823; Strop P, 2013, CHEM BIOL, V20, P161, DOI 10.1016/j.chembiol.2013.01.010; Sun MMC, 2005, BIOCONJUGATE CHEM, V16, P1282, DOI 10.1021/bc050201y; Tian F, 2014, P NATL ACAD SCI USA, V111, P1766, DOI 10.1073/pnas.1321237111; Toda N, 2013, ANGEW CHEM INT EDIT, V52, P12592, DOI 10.1002/anie.201306241; Wahl AF, 2002, CANCER RES, V62, P3736; Zolot RS, 2013, NAT REV DRUG DISCOV, V12, P259, DOI 10.1038/nrd3980	30	277	314	13	173	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2014	32	10					1059	+		10.1038/nbt.2968	http://dx.doi.org/10.1038/nbt.2968			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	AR7MM	25194818				2023-01-03	WOS:000343763800024
J	Acevedo-Arcique, CM; Ibancovichi, JA; Chavez, JR; Gutierrez-Blanco, E; Moran-Munoz, R; Victoria-Mora, JM; Tendillo-Cortijo, F; Santos-Gonzalez, M; Sanchez-Aparicio, P				Acevedo-Arcique, Carlos M.; Ibancovichi, Jose A.; Chavez, Julio R.; Gutierrez-Blanco, Eduardo; Moran-Munoz, Rafael; Victoria-Mora, Jose M.; Tendillo-Cortijo, Francisco; Santos-Gonzalez, Martin; Sanchez-Aparicio, Pedro			Lidocaine, Dexmedetomidine and Their Combination Reduce Isoflurane Minimum Alveolar Concentration in Dogs	PLOS ONE			English	Article							CONSTANT RATE INFUSION; INTRAVENOUS LIDOCAINE; MEDETOMIDINE; SEVOFLURANE; KETAMINE; CARDIOPULMONARY; ANESTHESIA; RATES	The effects of intravenous (IV) lidocaine, dexmedetomidine and their combination delivered as a bolus followed by a constant rate infusion (CRI) on the minimum alveolar concentration of isoflurane (MAC(ISO)) in dogs were evaluated. Seven healthy adult dogs were included. Anaesthesia was induced with propofol and maintained with isoflurane. For each dog, baseline MAC (MAC(ISO/BASAL)) was determined after a 90-minute equilibration period. Thereafter, each dog received one of the following treatments (loading dose, CRI): lidocaine 2 mg kg(-1), 100 mu g kg(-1) minute(-1); dexmedetomidine 2 mu g kg(-1), 2 mu g kg(-1) hour(-1); or their combination. MAC was then determined again after 45-minutes of treatment by CRI. At the doses administered, lidocaine, dexmedetomidine and their combination significantly reduced MAC(ISO) by 27.3% (range: 12.5-39.2%), 43.4% (33.3-53.3%) and 60.9% (46.1-78.1%), respectively, when compared to MAC(ISO/BASAL). The combination resulted in a greater MAC(ISO) reduction than the two drugs alone. Their use, at the doses studied, provides a clinically important reduction in the concentration of ISO during anaesthesia in dogs.	[Acevedo-Arcique, Carlos M.; Ibancovichi, Jose A.; Chavez, Julio R.; Moran-Munoz, Rafael; Sanchez-Aparicio, Pedro] Univ Autonoma Estado Mexico, Fac Vet Med, Dept Anaesthesia & Analgesia, Toluca, State Of Mexico, Mexico; [Victoria-Mora, Jose M.] Univ Autonoma Estado Mexico, Fac Vet Med, Dept Orthopaed Surg & Trauma, Toluca, State Of Mexico, Mexico; [Gutierrez-Blanco, Eduardo] Univ Autonoma Yucatan, Fac Vet Med, Dept Anim Hlth & Prevent Med, Merida, State Of Yucata, Mexico; [Tendillo-Cortijo, Francisco; Santos-Gonzalez, Martin] Hosp Univ Clin Puerta Hierro, Madrid, Spain	Universidad Autonoma de Yucatan; Hospital Puerta de Hierro-Majadahonda	Ibancovichi, JA (corresponding author), Univ Autonoma Estado Mexico, Fac Vet Med, Dept Anaesthesia & Analgesia, Toluca, State Of Mexico, Mexico.	ibanvet@gmail.com	Gutierrez-Blanco, Eduardo/AAS-3933-2021; Santos, Martín/AAM-7198-2021; aparicio, pedro sanchez/AAS-4265-2021	Gutierrez-Blanco, Eduardo/0000-0002-8370-8367; Santos, Martín/0000-0002-5928-6010; aparicio, pedro sanchez/0000-0002-6511-6595; Ibancovichi, Jose Antonio/0000-0003-1760-687X; Chavez Monteagudo, Julio Raul/0000-0002-2078-1217	Autonomous University of State of Mexico [2762/2009]	Autonomous University of State of Mexico	The resources of this study were awarded by the Autonomous University of State of Mexico through the research project number 2762/2009. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguado D, 2011, VET J, V189, P63, DOI 10.1016/j.tvjl.2010.05.029; BADOER E, 1983, J CARDIOVASC PHARM, V5, P760, DOI 10.1097/00005344-198309000-00009; BLOOR BC, 1992, J PHARMACOL EXP THER, V263, P690; Campagnol D, 2007, AM J VET RES, V68, P1308, DOI 10.2460/ajvr.68.12.1308; Columbano N, 2012, VET J, V193, P448, DOI 10.1016/j.tvjl.2011.12.005; Doherty T, 2007, VET ANAESTH ANALG, V34, P125, DOI 10.1111/j.1467-2995.2006.00301.x; Dzikiti TB, 2003, J VET MED A, V50, P190, DOI 10.1046/j.1439-0442.2003.00523.x; EGER EI, 1965, ANESTHESIOLOGY, V26, P756, DOI 10.1097/00000542-196511000-00010; Gomez-Villamandos RJ, 2008, RES VET SCI, V84, P68, DOI 10.1016/j.rvsc.2007.02.004; Gutierrez-Blanco E, 2013, VET ANAESTH ANALG, V40, P599, DOI 10.1111/vaa.12079; Kamibayashi T, 2000, ANESTHESIOLOGY, V93, P1345, DOI 10.1097/00000542-200011000-00030; Kuusela E, 2000, J VET PHARMACOL THER, V23, P15, DOI 10.1046/j.1365-2885.2000.00245.x; Lin GY, 2008, VET ANAESTH ANALG, V35, P141, DOI 10.1111/j.1467-2995.2007.00365.x; MacDougall LM, 2009, VET ANAESTH ANALG, V36, P512, DOI 10.1111/j.1467-2995.2009.00480.x; Matsubara LM, 2009, VET ANAESTH ANALG, V36, P407, DOI 10.1111/j.1467-2995.2009.00471.x; Muir WW, 2003, AM J VET RES, V64, P1155, DOI 10.2460/ajvr.2003.64.1155; Murrell JC, 2005, VET ANAESTH ANALG, V32, P117, DOI 10.1111/j.1467-2995.2005.00233.x; Pascoe PJ, 2006, VET ANAESTH ANALG, V33, P97, DOI 10.1111/j.1467-2995.2005.00236.x; Pypendop BH, 2005, ANESTHESIOLOGY, V53, P315; QUASHA AL, 1980, ANESTHESIOLOGY, V53, P315, DOI 10.1097/00000542-198010000-00008; Shaughnessy MR, 2014, VET ANAESTH ANALG, V41, P1, DOI 10.1111/vaa.12083; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; Uilenreef JJ, 2008, VET ANAESTH ANALG, V35, P1, DOI 10.1111/j.1467-2995.2007.00344.x; Valverde A, 2004, VET ANAESTH ANALG, V31, P264, DOI 10.1111/j.1467-2995.2004.00165.x; Valverde A, 2003, AM J VET RES, V64, P957, DOI 10.2460/ajvr.2003.64.957; VIRTANEN R, 1985, J VET PHARMACOL THER, V8, P30, DOI 10.1111/j.1365-2885.1985.tb00921.x; Weitz J D, 1991, Nurse Anesth, V2, P19; Wilson J, 2008, VET ANAESTH ANALG, V35, P289, DOI 10.1111/j.1467-2995.2007.00389.x	28	23	23	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2014	9	9							e106620	10.1371/journal.pone.0106620	http://dx.doi.org/10.1371/journal.pone.0106620			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ6KR	25232737	Green Submitted, Green Published, gold			2023-01-03	WOS:000342921200008
J	Chapman, S				Chapman, Simon			E-cigarettes: the best and the worst case scenarios for public health-an essay by Simon Chapman	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SMOKING; CONSUMPTION; REDUCTION; NICOTINE; CANCER; COHORT; RISK; MEN		Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia	University of Sydney	Chapman, S (corresponding author), Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia.	simon.chapman@sydney.edu.au	Chapman, Simon/D-4114-2009					Achey TL, 1978, LORILLARD RES; Agaku IT, 2014, BMJ OPEN, V8; [Anonymous], 2014, WHO C PART WHO FRAM; Australian Institute of Health and Welfare, 2014, NDSHS 2013 DAT REF S; Brown J, 2014, ADDICTION, V109, P1531, DOI 10.1111/add.12623; Cardinale A, 2012, CRIT REV TOXICOL, V42, P68, DOI 10.3109/10408444.2011.623150; Champion D, 2005, J EPIDEMIOL COMMUN H, V59, P679, DOI 10.1136/jech.2005.035915; Etter JF, 2014, ADDICT BEHAV, V39, P491, DOI 10.1016/j.addbeh.2013.10.028; Farsalinos KE, 2014, INT J ENV RES PUB HE, V11, P4356, DOI 10.3390/ijerph110404356; Fuoco FC, 2014, ENVIRON POLLUT, V184, P523, DOI 10.1016/j.envpol.2013.10.010; Grando SA, 2014, NAT REV CANCER, V14, P419, DOI 10.1038/nrc3725; Hart C, 2013, AM J EPIDEMIOL, V178, P770, DOI 10.1093/aje/kwt038; Iacobucci G, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5335; Knight J, 2004, TOB CONTROL, V13, P13, DOI 10.1136/tc.2004.007641; Martinez-Sanchez JM, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005894; Pisinger C, 2007, NICOTINE TOB RES, V9, P631, DOI 10.1080/14622200701365327; Schober W, 2014, INT J HYG ENVIR HEAL, V217, P628, DOI 10.1016/j.ijheh.2013.11.003; Song YM, 2008, J CLIN ONCOL, V26, P5101, DOI 10.1200/JCO.2008.17.0498; Straif K, 2014, LANCET ONCOL, V15, P683, DOI 10.1016/S1470-2045(14)70168-8; Tverdal A, 2006, TOB CONTROL, V15, P472, DOI 10.1136/tc.2006.016246; Utah Department of Health, 2013, EL CIG US UT STUD GR	21	43	45	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 9	2014	349								g5512	10.1136/bmj.g5512	http://dx.doi.org/10.1136/bmj.g5512			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AO9QM	25204397				2023-01-03	WOS:000341691000007
J	Janjua, W				Janjua, Wakaas			Project flu buster	LANCET			English	Editorial Material									King Edward Five Ways Sch, Birmingham B32 4BT, W Midlands, England		Janjua, W (corresponding author), King Edward Five Ways Sch, Birmingham B32 4BT, W Midlands, England.	wakaas@hotmail.co.uk							0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	2014	384	9946					839	839		10.1016/S0140-6736(14)61465-3	http://dx.doi.org/10.1016/S0140-6736(14)61465-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AO5DK	25209475				2023-01-03	WOS:000341362200009
J	Boettiger, DC; Kerr, S; Ditangco, R; Merati, TP; Pham, TTT; Chaiwarith, R; Kiertiburanakul, S; Li, CKP; Kumarasamy, N; Vonthanak, S; Lee, C; Kinh, NV; Pujari, S; Wong, WW; Kamarulzaman, A; Zhang, FJ; Yunihastuti, E; Choi, JY; Oka, S; Ng, OT; Kantipong, P; Mustafa, M; Ratanasuwan, W; Sohn, A; Law, M				Boettiger, David Charles; Kerr, Stephen; Ditangco, Rossana; Merati, Tuti Parwati; Thuy Thi Thanh Pham; Chaiwarith, Romanee; Kiertiburanakul, Sasisopin; Li, Chung Ki Patrick; Kumarasamy, Nagalingeswaran; Vonthanak, Saphonn; Lee, Christopher; Nguyen Van Kinh; Pujari, Sanjay; Wong, Wing Wai; Kamarulzaman, Adeeba; Zhang, Fujie; Yunihastuti, Evy; Choi, Jun Yong; Oka, Shinichi; Ng, Oon Tek; Kantipong, Pacharee; Mustafa, Mahiran; Ratanasuwan, Winai; Sohn, Annette; Law, Matthew			Trends in First-Line Antiretroviral Therapy in Asia: Results from the TREAT Asia HIV Observational Database	PLOS ONE			English	Article							COMBINATION; NEVIRAPINE; EFAVIRENZ; TENOFOVIR; EFFICACY; SAFETY; RATES; STAVUDINE; REGIMENS; IMPACT	Background: Antiretroviral therapy (ART) has evolved rapidly since its beginnings. This analysis describes trends in first-line ART use in Asia and their impact on treatment outcomes. Methods: Patients in the TREAT Asia HIV Observational Database receiving first-line ART for >= 6 months were included. Predictors of treatment failure and treatment modification were assessed. Results: Data from 4662 eligible patients was analysed. Patients started ART in 2003-2006 (n = 1419), 2007-2010 (n = 2690) and 2011-2013 (n = 553). During the observation period, tenofovir, zidovudine and abacavir use largely replaced stavudine. Stavudine was prescribed to 5.8% of ART starters in 2012/13. Efavirenz use increased at the expense of nevirapine, although both continue to be used extensively (47.5% and 34.5% of patients in 2012/13, respectively). Protease inhibitor use dropped after 2004. The rate of treatment failure or modification declined over time (22.1 [95% CI 20.7-23.5] events per 100 patient/years in 2003-2006, 15.8 [14.9-16.8] in 2007-2010, and 11.6 [9.4-14.2] in 2011-2013). Adjustment for ART regimen had little impact on the temporal decline in treatment failure rates but substantially attenuated the temporal decline in rates of modification due to adverse event. In the final multivariate model, treatment modification due to adverse event was significantly predicted by earlier period of ART initiation (hazard ratio 0.52 [95% CI 0.33-0.81], p = 0.004 for 2011-2013 versus 2003-2006), older age (1.56 [1.19-2.04], p = 0.001 for >= 50 years versus,<30years), female sex (1.29 [1.11-1.50], p = 0.001 versus male), positive hepatitis C status (1.33 [1.06-1.66], p = 0.013 versus negative), and ART regimen (11.36 [6.28-20.54], p=0.001 for stavudine-based regimens versus tenofovir-based). Conclusions: The observed trends in first-line ART use in Asia reflect changes in drug availability, global treatment recommendations and prescriber preferences over the past decade. These changes have contributed to a declining rate of treatment modification due to adverse event, but not to reductions in treatment failure.	[Boettiger, David Charles; Kerr, Stephen; Law, Matthew] UNSW Australia, Kirby Inst, Sydney, NSW, Australia; [Kerr, Stephen] Thai Red Cross AIDS Res Ctr, HIV NAT, Bangkok, Thailand; [Ditangco, Rossana] Res Inst Trop Med, Manila, Philippines; [Merati, Tuti Parwati] Udayana Univ, Sanglah Hosp, Denpesar, Indonesia; [Thuy Thi Thanh Pham] Bach Mai Hosp, Hanoi, Vietnam; [Chaiwarith, Romanee] Res Inst Hlth Sci, Chiang Mai, Thailand; [Kiertiburanakul, Sasisopin] Mahidol Univ, Ramathibodi Hosp, Fac Med, Bangkok 10400, Thailand; [Li, Chung Ki Patrick] Queen Elizabeth Hosp, Hong Kong, Hong Kong, Peoples R China; [Kumarasamy, Nagalingeswaran] YRG Ctr AIDS Res & Educ, Madras, Tamil Nadu, India; [Vonthanak, Saphonn] Natl Ctr HIV AIDS Dermatol & STDs, Phnom Penh, Cambodia; [Lee, Christopher] Hosp Sungai Buloh, Sungai Buloh, Malaysia; [Nguyen Van Kinh] Natl Hosp Trop Dis, Hanoi, Vietnam; [Pujari, Sanjay] Inst Infect Dis, Pune, Maharashtra, India; [Wong, Wing Wai] Taipei Vet Gen Hosp, Taipei, Taiwan; [Kamarulzaman, Adeeba] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia; [Zhang, Fujie] Capital Med Univ, Beijing Ditan Hosp, Beijing, Peoples R China; [Yunihastuti, Evy] Univ Indonesia, Working Grp AIDS Fac Med, Cipto Mangunkusumo Hosp, Jakarta, Indonesia; [Choi, Jun Yong] Yonsei Univ, Coll Med, Dept Internal Med, Div Infect Dis, Seoul, South Korea; [Oka, Shinichi] Natl Ctr Global Hlth & Med, Tokyo, Japan; [Ng, Oon Tek] Tan Tock Seng Hosp, Singapore, Singapore; [Kantipong, Pacharee] Chiang Rai Prachanukroh Hosp, Chiang Rai, Thailand; [Mustafa, Mahiran] Hosp Raja Perempuan Zainab II, Kota Baharu, Malaysia; [Ratanasuwan, Winai] Mahidol Univ, Fac Med, Siriraj Hosp, Bangkok 10700, Thailand; [Sohn, Annette] Fdn AIDS Res, TREAT Asia, AmfAR, Bangkok, Thailand	University of New South Wales Sydney; Kirby Institute; Thai Red Cross Society; Research Institute for Tropical Medicine - Philippines; Universitas Udayana; Mahidol University; National Hospital of Tropical Diseases; Taipei Veterans General Hospital; Universiti Malaya; Capital Medical University; University of Indonesia; Yonsei University; Yonsei University Health System; National Center for Global Health & Medicine - Japan; Tan Tock Seng Hospital; Mahidol University	Boettiger, DC (corresponding author), UNSW Australia, Kirby Inst, Sydney, NSW, Australia.	dboettiger@kirby.unsw.edu.au	Kerr, Stephen/J-6126-2012; KAMARULZAMAN, ADEEBA/B-5216-2010; Yunihastuti, Evy/AGD-5382-2022; Kumarasasmy, Nagalingeswaran/AAB-7348-2021; Boettiger, David C/ABB-1694-2021	Kerr, Stephen/0000-0002-1919-4525; Yunihastuti, Evy/0000-0001-6650-0559; Law, Matthew/0000-0002-3540-8837; Boettiger, David/0000-0002-5951-4503; Chaiwarith, Romanee/0000-0002-1241-5954; Choi, Jun Yong/0000-0002-2775-3315; Oka, Shinichi/0000-0002-9283-2167	U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute [U01AI069907]; Australian Government Department of Health and Ageing; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI069907] Funding Source: NIH RePORTER	U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Australian Government Department of Health and Ageing(Australian GovernmentDepartment of Health & Ageing); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The TREAT Asia HIV Observational Database is an initiative of TREAT Asia, a program of amfAR, The Foundation for AIDS Research, with support from the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development, and National Cancer Institute, as part of the International Epidemiologic Databases to Evaluate AIDS (IeDEA; U01AI069907). Further information is available at http://www.iedea.org/. The Kirby Institute is funded by the Australian Government Department of Health and Ageing (http://www.health.gov.au/), and is affiliated with the Faculty of Medicine, UNSW Australia. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of any of the governments or institutions mentioned above. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bannister WP, 2006, JAIDS-J ACQ IMM DEF, V42, P229, DOI 10.1097/01.qai.0000214815.95786.31; Bonnet M, 2013, LANCET INFECT DIS, V13, P303, DOI 10.1016/S1473-3099(13)70007-0; Furler MD, 2006, AIDS PATIENT CARE ST, V20, P245, DOI 10.1089/apc.2006.20.245; Gatell J, 2007, CLIN INFECT DIS, V44, P1484, DOI 10.1086/517497; Geng EH, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-46; Gonzalez-Serna A, 2014, J ANTIMICROB CHEMOTH; Hamers RL, 2012, INT J EPIDEMIOL, V41, P43, DOI 10.1093/ije/dyq192; Jimenez-Nacher I, 2008, J ANTIMICROB CHEMOTH, V62, P816, DOI 10.1093/jac/dkn252; Lichterfeld M, 2003, EUR J MED RES, V8, P56; Looby SE, 2014, MENOPAUSE, V21, P403, DOI 10.1097/GME.0b013e31829d4c4c; Mbuagbaw LCE, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004246.pub3; McConnell MS, 2005, JAIDS-J ACQ IMM DEF, V38, P488, DOI 10.1097/01.qai.0000134744.72079.cc; Milinkovic A, 2007, ANTIVIR THER, V12, P407; Molina JM, 2008, LANCET, V372, P646, DOI 10.1016/S0140-6736(08)61081-8; Palmisano L, 2011, ANN I SUPER SANITA, V47, P44, DOI 10.4415/ANN_11_01_10; Ribera E, 2008, HIV CLIN TRIALS, V9, P407, DOI 10.1310/hct0906-407; Shubber Z, 2013, AIDS, V27, P1403, DOI 10.1097/QAD.0b013e32835f1db0; Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961; UNAIDS, 2012, UNAIDS REP GLOB AIDS; van den Berg-Wolf M, 2008, HIV CLIN TRIALS, V9, P324, DOI 10.1310/hct0905-324; WHO ART Guidelines Committee, 2013, CONS GUID US ANT DRU; WHO ART Guidelines Committee, 2006, ANT THER HIV INF AD; WHO ART Guidelines Committee, 2010, ANT THER HIV INF AD; Williams I, 2012, HIV MED, V13, P1, DOI [10.1111/j.1468-1293.2012.01029_1.x, 10.1111/j.1468-1293.2012.01029.x]; Wright S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064902; Zhou J, 2005, JAIDS-J ACQ IMM DEF, V38, P174, DOI 10.1097/01.qai.0000145351.96815.d5	26	16	18	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2014	9	9							e106525	10.1371/journal.pone.0106525	http://dx.doi.org/10.1371/journal.pone.0106525			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO3TB	25184314	Green Submitted, Green Published, gold			2023-01-03	WOS:000341257700083
J	Kremb, S; Helfer, M; Kraus, B; Wolff, H; Wild, C; Schneider, M; Voolstra, CR; Brack-Werner, R				Kremb, Stephan; Helfer, Markus; Kraus, Birgit; Wolff, Horst; Wild, Christian; Schneider, Martha; Voolstra, Christian R.; Brack-Werner, Ruth			Aqueous Extracts of the Marine Brown Alga Lobophora variegata Inhibit HIV-1 Infection at the Level of Virus Entry into Cells	PLOS ONE			English	Article							POLYSACCHARIDES; REPLICATION; GRIFFITHSIN	In recent years, marine algae have emerged as a rich and promising source of molecules with potent activities against various human pathogens. The widely distributed brown alga Lobophora variegata that is often associated with tropical coral reefs exerts strong antibacterial and antiprotozoal effects, but so far has not been associated with specific anti-viral activities. This study investigated potential HIV-1 inhibitory activity of L. variegata collected from different geographical regions, using a cell-based full replication HIV-1 reporter assay. Aqueous L. variegata extracts showed strong inhibitory effects on several HIV-1 strains, including drug-resistant and primary HIV-1 isolates, and protected even primary cells (PBMC) from HIV-1-infection. Anti-viral potency was related to ecological factors and showed clear differences depending on light exposition or epiphyte growth. Assays addressing early events of the HIV-1 replication cycle indicated that L. variegata extracts inhibited entry of HIV-1 into cells at a pre-fusion step possibly by impeding mobility of virus particles. Further characterization of the aqueous extract demonstrated that even high doses had only moderate effects on viability of cultured and primary cells (PBMCs). Imaging-based techniques revealed extract effects on the plasma membrane and actin filaments as well as induction of apoptosis at concentrations exceeding EC50 of anti-HIV-1 activity by more than 400 fold. In summary, we show for the first time that L. variegata extracts inhibit HIV-1 entry, thereby suggesting this alga as promising source for the development of novel HIV-1 inhibitors.	[Kremb, Stephan; Voolstra, Christian R.] KAUST, Red Sea Res Ctr, Thuwal, Saudi Arabia; [Kremb, Stephan; Helfer, Markus; Schneider, Martha; Brack-Werner, Ruth] Helmholtz Zentrum Muenchen, Inst Virol, Neuherberg, Germany; [Kraus, Birgit] Univ Regensburg, Inst Pharm, D-93053 Regensburg, Germany; [Wolff, Horst] Carl Zeiss Microscopy GmbH, Gottingen, Germany; [Wild, Christian] Leibniz Ctr Trop Marine Ecol ZMT, Coral Reef Ecol Grp CORE, Bremen, Germany; [Wild, Christian] Univ Bremen, Fac Biol & Chem, D-28359 Bremen, Germany	King Abdullah University of Science & Technology; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Regensburg; Carl Zeiss AG; Leibniz Zentrum fur Marine Tropenforschung (ZMT); University of Bremen	Kremb, S (corresponding author), KAUST, Red Sea Res Ctr, Thuwal, Saudi Arabia.	StephanGeorg.Kremb@kaust.edu.sa	Brack-Werner, Ruth/M-4615-2014; Kraus, Birgit/AAM-2985-2020; Voolstra, Christian R/H-7158-2014	Brack-Werner, Ruth/0000-0002-8651-9318; Voolstra, Christian R/0000-0003-4555-3795	Helmholtz Zentrum Munich; King Abdullah University of Science and Technology	Helmholtz Zentrum Munich; King Abdullah University of Science and Technology(King Abdullah University of Science & Technology)	This study was jointly funded by the Helmholtz Zentrum Munich (www.helmholtz-muenchen.de) and the King Abdullah University of Science and Technology (www.kaust.edu.sa). The research vessel "Aldebaran'' was provided by "ALDEBARAN Marine Research and Broadcast'' (aldebaran.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexandre KB, 2011, J VIROL, V85, P9039, DOI 10.1128/JVI.02675-10; Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387-2656(05)11004-7; Cantillo-Ciau Z, 2010, MAR DRUGS, V8, P1292, DOI 10.3390/md8041292; Chung HY, 2003, J AGR FOOD CHEM, V51, P2619, DOI 10.1021/jf026082n; Cirne-Santos CC, 2006, PLANTA MED, V72, P295, DOI 10.1055/s-2005-916209; Eggink D, 2010, CURR PHARM DESIGN, V16, P3716, DOI 10.2174/138161210794079218; Freile-Pelegrin Y, 2008, FITOTERAPIA, V79, P374, DOI 10.1016/j.fitote.2008.02.006; Helfer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087487; Huskens D, 2012, MAR DRUGS, V10, P1476, DOI 10.3390/md10071476; Jiang ZD, 1999, BIOORG MED CHEM LETT, V9, P2003, DOI 10.1016/S0960-894X(99)00337-6; Kabamba-Mukadi B, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-15; Karsten U, 2009, BOT MAR, V52, P639, DOI 10.1515/BOT.2009.077; Koppensteiner H, 2012, J VIROL, V86, P2826, DOI 10.1128/JVI.05915-11; Kouokam JC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022635; Kremb S, 2010, ANTIMICROB AGENTS CH, V54, P5257, DOI 10.1128/AAC.00515-10; Kubanek J, 2003, P NATL ACAD SCI USA, V100, P6916, DOI 10.1073/pnas.1131855100; Medeiros VP, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1018, DOI 10.1134/S0006297908090095; Moo-Puc R, 2008, J ETHNOPHARMACOL, V120, P92, DOI 10.1016/j.jep.2008.07.035; Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200; Morrow KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044859; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Paiva AAD, 2011, INT IMMUNOPHARMACOL, V11, P1241, DOI 10.1016/j.intimp.2011.04.003; Siqueira RCL, 2011, PHARM BIOL, V49, P167, DOI 10.3109/13880209.2010.505605; Suarez A.M., 2005, REV INVEST MAR, V26, P93; Teas J, 2004, MED HYPOTHESES, V62, P507, DOI 10.1016/j.mehy.2003.10.005; Teas J, 2012, J APPL PHYCOL, V24, P575, DOI 10.1007/s10811-011-9766-0; Trinchero J, 2009, PHYTOTHER RES, V23, P707, DOI 10.1002/ptr.2723; Wiencke C, 2012, ECOLOGICAL STUDIES, V219; Witvrouw M, 1997, GEN PHARMACOL-VASC S, V29, P497, DOI 10.1016/S0306-3623(96)00563-0; Wolkerstorfer A, 2009, ANTIVIR RES, V83, P171, DOI 10.1016/j.antiviral.2009.04.012	30	9	10	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2014	9	8							e103895	10.1371/journal.pone.0103895	http://dx.doi.org/10.1371/journal.pone.0103895			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO1WL	25144758	Green Published, gold			2023-01-03	WOS:000341106100010
J	Ramer, SJ; Cohen, ED; Chang, CCH; Unruh, ML; Barnato, AE				Ramer, Sarah J.; Cohen, Elan D.; Chang, Chung-Chou H.; Unruh, Mark L.; Barnato, Amber E.			Survival after Acute Hemodialysis in Pennsylvania, 2005-2007: A Retrospective Cohort Study	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; ACUTE-RENAL-FAILURE; ACUTE KIDNEY INJURY; QUALITY-OF-LIFE; REPLACEMENT THERAPY; INTENSIVE-CARE; MORTALITY; DIALYSIS; NONRECOVERY; VALIDATION	Background: Little is known about acute hemodialysis in the US. Here we describe predictors of receipt of acute hemodialysis in one state and estimate the marginal impact of acute hemodialysis on survival after accounting for confounding due to illness severity. Materials and Methods: This is a retrospective cohort study of acute-care hospitalizations in Pennsylvania from October 2005 to December 2007 using data from the Pennsylvania Health Care Cost Containment Council. Exposure variable is acute hemodialysis; dependent variable is survival following acute hemodialysis. We used multivariable logistic regression to determine propensity to receive acute hemodialysis and then, for a Cox proportional hazards model, matched acute hemodialysis and non-acute hemodialysis patients 1:5 on this propensity. Results: In 2,131,248 admissions of adults without end-stage renal disease, there were 6,657 instances of acute hemodialysis. In analyses adjusted for predicted probability of death upon admission plus other covariates and stratified on age, being male, black, and insured were independent predictors of receipt of acute hemodialysis. One-year post-admission mortality was 43% for those receiving acute hemodialysis, compared to 13% among those not receiving acute hemodialysis. After matching on propensity to receive acute hemodialysis and adjusting for predicted probability of death upon admission, patients who received acute hemodialysis had a higher risk of death than patients who did not over at least 1 year of follow-up (hazard ratio 1.82, 95% confidence interval 1.68-1.97). Conclusions: In a populous US state, receipt of acute hemodialysis varied by age, sex, race, and insurance status even after adjustment for illness severity. In a comparison of patients with similar propensity to receive acute hemodialysis, those who did receive it were less likely to survive than those who did not. These findings raise questions about reasons for lack of benefit.	[Ramer, Sarah J.] Rutgers State Univ, Newark, NJ 07102 USA; [Cohen, Elan D.; Chang, Chung-Chou H.; Barnato, Amber E.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA; [Chang, Chung-Chou H.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Unruh, Mark L.] Univ New Mexico, Sch Med, Dept Internal Med, Div Nephrol, Albuquerque, NM 87131 USA; [Barnato, Amber E.] Univ Pittsburgh, Sch Med, Dept Clin & Translat Sci, Pittsburgh, PA USA; [Barnato, Amber E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA; [Barnato, Amber E.] Univ Pittsburgh, Dept Crit Care Med, CRISMA Lab Clin Res Invest & Syst Modeling Acute, Pittsburgh, PA USA	Rutgers State University Newark; Rutgers State University New Brunswick; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of New Mexico; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ramer, SJ (corresponding author), Rutgers State Univ, Newark, NJ 07102 USA.	sramer@post.harvard.edu		Ramer, Sarah/0000-0001-8584-1148	Doris Duke Clinical Research Fellowship for Medical Students; National Institutes of Health [R01AG035112]; NATIONAL INSTITUTE ON AGING [R01AG035112] Funding Source: NIH RePORTER	Doris Duke Clinical Research Fellowship for Medical Students; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by a Doris Duke Clinical Research Fellowship for Medical Students to SR (http://www.ddcf.org/) and by National Institutes of Health grant R01AG035112 to AB (http://www.nih.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahlstrom A, 2005, INTENS CARE MED, V31, P1222, DOI 10.1007/s00134-005-2681-6; Bagshaw SM, 2005, CRIT CARE, V9, pR700, DOI 10.1186/cc3879; Barnato AE, 2009, MED CARE, V47, P1098, DOI 10.1097/MLR.0b013e3181993191; Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Clec'h C, 2012, CRIT CARE, V16, DOI 10.1186/cc11905; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Ehlenbach WJ, 2009, NEW ENGL J MED, V361, P22, DOI 10.1056/NEJMoa0810245; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Elseviers MM, 2010, CRIT CARE, V14, DOI 10.1186/cc9355; Fowler RA, 2007, CAN MED ASSOC J, V177, P1513, DOI 10.1503/cmaj.071112; Gopal I, 1997, INTENS CARE MED, V23, P766, DOI 10.1007/s001340050407; Hamel MB, 1997, ANN INTERN MED, V127, P195, DOI 10.7326/0003-4819-127-3-199708010-00003; Hsu CY, 2009, CLIN J AM SOC NEPHRO, V4, P891, DOI 10.2215/CJN.05571008; Johansen KL, 2010, CLIN J AM SOC NEPHRO, V5, P1366, DOI 10.2215/CJN.02570310; Lyon SM, 2011, AM J RESP CRIT CARE, V184, P809, DOI 10.1164/rccm.201101-0089OC; Mehta RL, 2002, JAMA-J AM MED ASSOC, V288, P2547, DOI 10.1001/jama.288.20.2547; Mehta RL, 2004, KIDNEY INT, V66, P1613, DOI 10.1111/j.1523-1755.2004.00927.x; Mehta RL, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000014692.19351.52; Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639; Pietropaoli AP, 2010, GENDER MED, V7, P422, DOI 10.1016/j.genm.2010.09.005; Pine M, 2007, JAMA-J AM MED ASSOC, V297, P71, DOI 10.1001/jama.297.1.71; Rauf Anis Abdul, 2008, J Intensive Care Med, V23, P195, DOI 10.1177/0885066608315743; Valentin A, 2003, CRIT CARE MED, V31, P1901, DOI 10.1097/01.CCM.0000069347.78151.50; Wald R, 2009, JAMA-J AM MED ASSOC, V302, P1179, DOI 10.1001/jama.2009.1322; Wilson FP, 2014, CLIN J AM SOC NEPHRO, V9, P673, DOI 10.2215/CJN.07630713; Wilson FP, 2013, CLIN J AM SOC NEPHRO, V8, P1863, DOI 10.2215/CJN.03540413; Xue JL, 2006, J AM SOC NEPHROL, V17, P1135, DOI 10.1681/ASN.2005060668	28	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2014	9	8							e105083	10.1371/journal.pone.0105083	http://dx.doi.org/10.1371/journal.pone.0105083			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ3JB	25141028	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000342687200050
J	Wilder, JR; Wegener, DT; David, MZ; Macal, C; Daum, R; Lauderdale, DS				Wilder, Jocelyn R.; Wegener, Duane T.; David, Michael Z.; Macal, Charles; Daum, Robert; Lauderdale, Diane S.			A National Survey of Skin Infections, Care Behaviors and MRSA Knowledge in the United States	PLOS ONE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; SOFT-TISSUE INFECTIONS; EMERGENCY-DEPARTMENT; SURVEILLANCE	A nationally representative sample of approximately 2000 individuals was surveyed to assess SSTI infections over their lifetime and then prospectively over six-months. Knowledge of MRSA, future likelihood to self-treat a SSTI and self-care behaviors was also queried. Chi square tests, linear and multinomial regression were used for analysis. About 50% of those with a reported history of a SSTI typical of MRSA had sought medical treatment. MRSA knowledge was low: 28% of respondents could describe MRSA. Use of protective self-care behaviors that may reduce transmission, such as covering a lesion, differed with knowledge of MRSA and socio-demographics. Those reporting a history of a MRSA-like SSTI were more likely to respond that they would self-treat than those without such a history (OR 2.05 95% CI 1.40, 3.01; p<0.001). Since half of respondents reported not seeking care for past lesions, incidence determined from clinical encounters would greatly underestimate true incidence. MRSA knowledge was not associated with seeking medical care, but was associated with self-care practices that may decrease transmission.	[Wilder, Jocelyn R.; David, Michael Z.; Macal, Charles; Daum, Robert; Lauderdale, Diane S.] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA; [Wegener, Duane T.] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA; [Macal, Charles] Argonne Natl Lab, Decis & Informat Sci Div, Argonne, IL 60439 USA	University of Chicago; University System of Ohio; Ohio State University; United States Department of Energy (DOE); Argonne National Laboratory	Wilder, JR (corresponding author), Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA.	jwilder@uchicago.edu	David, Michael Z./X-6737-2019	David, Michael Z./0000-0002-1926-7800	Time-Sharing Experiments for the Social Sciences program (TESS; National Science Foundation) [0818839]; National Institute of General Medical Sciences (NIGMS) [U01 Gm087729 MIDAS]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI095361] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM087729] Funding Source: NIH RePORTER	Time-Sharing Experiments for the Social Sciences program (TESS; National Science Foundation); National Institute of General Medical Sciences (NIGMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The survey was supported by Time-Sharing Experiments for the Social Sciences program (TESS; National Science Foundation Grant 0818839; J. Freese and P. S. Visser, principal investigators). Analysis was supported by the National Institute of General Medical Sciences (NIGMS) U01 Gm087729 MIDAS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cenizal MJ, 2007, ANTIMICROB AGENTS CH, V51, P2628, DOI 10.1128/AAC.00206-07; Chen AE, 2006, PEDIATR EMERG CARE, V22, P717, DOI 10.1097/01.pec.0000236832.23947.a0; Dukic VM, 2011, EMERG INFECT DIS, V17, P1068, DOI [10.3201/eid1706.101451, 10.3201/eid/1706.101451]; Edelsberg J, 2009, EMERG INFECT DIS, V15, P1516, DOI 10.3201/eid1509.081228; Hahn W, 2009, J PUBLIC HEALTH MAN, V15, P150, DOI 10.1097/01.PHH.0000346013.74522.f8; Hersh AL, 2008, ARCH INTERN MED, V168, P1585, DOI 10.1001/archinte.168.14.1585; Kaplan SL, 2005, CLIN INFECT DIS, V40, P1785, DOI 10.1086/430312; Kirby JB, 2010, MAIN REASON NOT HAVI; Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763; Moran GJ, 2006, NEW ENGL J MED, V355, P666, DOI 10.1056/NEJMoa055356; Purcell K, 2005, ARCH PEDIAT ADOL MED, V159, P980, DOI 10.1001/archpedi.159.10.980; Talan DA, 2011, CLIN INFECT DIS, V53, P144, DOI 10.1093/cid/cir308	12	6	6	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2014	9	8							e104277	10.1371/journal.pone.0104277	http://dx.doi.org/10.1371/journal.pone.0104277			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN6XM	25137061	gold, Green Submitted, Green Published			2023-01-03	WOS:000340742100023
J	Wang, CZ; Chen, YJ; Wang, YH; Yeh, ML; Huang, MH; Ho, ML; Liang, JI; Chen, CH				Wang, Chau-Zen; Chen, Yi-Jen; Wang, Yan-Hsiung; Yeh, Ming-Long; Huang, Mao-Hsiung; Ho, Mei-Ling; Liang, Jen-I; Chen, Chia-Hsin			Low-Level Laser Irradiation Improves Functional Recovery and Nerve Regeneration in Sciatic Nerve Crush Rat Injury Model	PLOS ONE			English	Article							ELECTRICAL-STIMULATION PROMOTES; NON-SERRATED CLAMP; MORPHOLOGICAL ASSESSMENT; AXONAL REGENERATION; SCHWANN-CELLS; 780 NM; THERAPY; INDEX; REPAIR; PHOTOTHERAPY	The development of noninvasive approaches to facilitate the regeneration of post-traumatic nerve injury is important for clinical rehabilitation. In this study, we investigated the effective dose of noninvasive 808-nm low-level laser therapy (LLLT) on sciatic nerve crush rat injury model. Thirty-six male Sprague Dawley rats were divided into 6 experimental groups: a normal group with or without 808-nm LLLT at 8 J/cm(2) and a sciatic nerve crush injury group with or without 808-nm LLLT at 3, 8 or 15 J/cm(2). Rats were given consecutive transcutaneous LLLT at the crush site and sacrificed 20 days after the crush injury. Functional assessments of nerve regeneration were analyzed using the sciatic functional index (SFI) and hindlimb range of motion (ROM). Nerve regeneration was investigated by measuring the myelin sheath thickness of the sciatic nerve using transmission electron microscopy (TEM) and by analyzing the expression of growth-associated protein 43 (GAP43) in sciatic nerve using western blot and immunofluorescence staining. We found that sciatic-injured rats that were irradiated with LLLT at both 3 and 8 J/cm(2) had significantly improved SFI but that a significant improvement of ROM was only found in rats with LLLT at 8 J/cm(2). Furthermore, the myelin sheath thickness and GAP43 expression levels were significantly enhanced in sciatic nerve-crushed rats receiving 808-nm LLLT at 3 and 8 J/cm(2). Taken together, these results suggest that 808-nm LLLT at a low energy density (3 J/cm(2) and 8 J/cm(2)) is capable of enhancing sciatic nerve regeneration following a crush injury.	[Wang, Chau-Zen; Ho, Mei-Ling] Kaohsiung Med Univ, Dept Physiol, Kaohsiung, Taiwan; [Wang, Chau-Zen; Wang, Yan-Hsiung; Ho, Mei-Ling; Chen, Chia-Hsin] Kaohsiung Med Univ, Orthopaed Res Ctr, Kaohsiung, Taiwan; [Chen, Yi-Jen; Huang, Mao-Hsiung; Chen, Chia-Hsin] Kaohsiung Med Univ Hosp, Dept Phys Med & Rehabil, Kaohsiung, Taiwan; [Chen, Yi-Jen; Chen, Chia-Hsin] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Phys Med & Rehabil, Kaohsiung, Taiwan; [Wang, Yan-Hsiung] Kaohsiung Med Univ, Coll Dent Med, Sch Dent, Kaohsiung, Taiwan; [Yeh, Ming-Long; Liang, Jen-I] Natl Cheng Kung Univ, Dept Biomed Engn, Tainan 70101, Taiwan; [Huang, Mao-Hsiung; Chen, Chia-Hsin] Kaohsiung Med Univ, Coll Med, Dept Phys Med & Rehabil, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Municipal Ta-Tung Hospital; Kaohsiung Medical University; National Cheng Kung University; Kaohsiung Medical University	Chen, CH (corresponding author), Kaohsiung Med Univ, Orthopaed Res Ctr, Kaohsiung, Taiwan.	chchen@kmu.edu.tw	Wang, Yan-Hsiung/ABD-4004-2020	Wang, Yan-Hsiung/0000-0001-8161-7472; Chen, Yi-Jen/0000-0002-5178-2335; Chen, Chia-Hsin/0000-0002-6557-9848; Ho, Mei-Ling/0000-0001-8064-8488	National Health Research Institutes (NHRI-EX) [102-9914EC]; National Science Council [101-2314-B-037-002-MY3]; Kaohsiung Medical University Research Foundation, Taiwan [KMU-Q98007]	National Health Research Institutes (NHRI-EX); National Science Council(Ministry of Science and Technology, Taiwan); Kaohsiung Medical University Research Foundation, Taiwan	This work was supported by grants from the National Health Research Institutes (NHRI-EX 102-9914EC), the National Science Council (101-2314-B-037-002-MY3) and the Kaohsiung Medical University Research Foundation (KMU-Q98007), Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Majed AA, 2000, J NEUROSCI, V20, P2602; Allodi I, 2012, PROG NEUROBIOL, V98, P16, DOI 10.1016/j.pneurobio.2012.05.005; Bae CS, 2004, IN VIVO, V18, P489; Bagis S, 2003, LASER MED SCI, V18, P83, DOI 10.1007/s10103-003-0258-6; BAIN JR, 1989, PLAST RECONSTR SURG, V83, P129, DOI 10.1097/00006534-198901000-00024; Bannaga Ahmed, 2002, J Huazhong Univ Sci Technolog Med Sci, V22, P135; Barbosa RI, 2010, LASER MED SCI, V25, P423, DOI 10.1007/s10103-009-0750-8; Brosseau L., 2005, COCHRANE DB SYST REV, V19; Chen YS, 2005, MICROSURG, V25, P83, DOI 10.1002/micr.20079; Chow RT, 2009, LANCET, V374, P1897, DOI 10.1016/S0140-6736(09)61522-1; Colen Kari L, 2009, Plast Reconstr Surg, V124, pe386, DOI 10.1097/PRS.0b013e3181bf8430; Camara CND, 2011, ACTA CIR BRAS, V26, P12, DOI 10.1590/S0102-86502011000100004; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; Erba P, 2010, J PLAST RECONSTR AES, V63, P20; Geremia NM, 2007, EXP NEUROL, V205, P347, DOI 10.1016/j.expneurol.2007.01.040; Gigo-Benato D, 2005, MUSCLE NERVE, V31, P694, DOI 10.1002/mus.20305; Gigo-Benato D, 2004, LASER MED SCI, V19, P57, DOI 10.1007/s10103-004-0300-3; Gigo-Benato D, 2010, LASER SURG MED, V42, P673, DOI 10.1002/lsm.20978; Gordon T, 2009, MOTOR CONTROL, V13, P412, DOI 10.1123/mcj.13.4.412; Gravvanis AI, 2007, ACTA NEUROCHIR SUPPL, V100, P51; Gu XS, 2011, PROG NEUROBIOL, V93, P204, DOI 10.1016/j.pneurobio.2010.11.002; Gungormus M, 2009, PHOTOMED LASER SURG, V27, P895, DOI 10.1089/pho.2008.2431; Kokai LE, 2011, TISSUE ENG PT A, V17, P1263, DOI [10.1089/ten.tea.2010.0507, 10.1089/ten.TEA.2010.0507]; Kupers R, 1998, PAIN, V76, P45, DOI 10.1016/S0304-3959(98)00022-0; Lin FM, 1996, J RECONSTR MICROSURG, V12, P173, DOI 10.1055/s-2007-1006472; Luis AL, 2007, J NEUROSCI METH, V163, P92, DOI 10.1016/j.jneumeth.2007.02.017; Madduri S, 2010, J PERIPHER NERV SYST, V15, P93, DOI 10.1111/j.1529-8027.2010.00257.x; Medalha CC, 2012, LASER MED SCI, V27, P629, DOI 10.1007/s10103-011-1008-9; MEIRI KF, 1986, P NATL ACAD SCI USA, V83, P3537, DOI 10.1073/pnas.83.10.3537; Moges H, LASERS SURG MED, V43, P901; Mohammed IFR, 2007, PHOTOMED LASER SURG, V25, P107, DOI 10.1089/pho.2006.1090; Monte-Raso VV, 2008, J NEUROSCI METH, V170, P255, DOI 10.1016/j.jneumeth.2008.01.022; Navarro X, 2007, PROG NEUROBIOL, V82, P163, DOI 10.1016/j.pneurobio.2007.06.005; Rochkind S, 2007, PHOTOMED LASER SURG, V25, P436, DOI 10.1089/pho.2007.2093; Shen CC, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/175629; Shen Ninjiang, 1995, Microsurgery, V16, P552, DOI 10.1002/micr.1920160809; SHENAQ JM, 1989, MICROSURG, V10, P214, DOI 10.1002/micr.1920100315; Shin DH, 2003, NEUROSCI LETT, V344, P71, DOI 10.1016/S0304-3940(03)00354-9; Tumilty S, 2010, PHOTOMED LASER SURG, V28, P3, DOI 10.1089/pho.2008.2470; VANBREUGEL HHFI, 1993, J NEUROCYTOL, V22, P185, DOI 10.1007/BF01246357; Varejao ASP, 2004, J NEUROTRAUM, V21, P1652, DOI 10.1089/neu.2004.21.1652; Varejao ASP, 2004, NEUROL RES, V26, P186, DOI 10.1179/016164104225013833; Varejao ASP, 2002, MUSCLE NERVE, V26, P630, DOI 10.1002/mus.10242; Xu QG, 2008, NEUROSCIENCE, V152, P877, DOI 10.1016/j.neuroscience.2008.01.060; Yu W, 2000, J PERIPHER NERV SYST, V5, P209, DOI 10.1046/j.1529-8027.2000.00024.x	45	56	61	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2014	9	8							e103348	10.1371/journal.pone.0103348	http://dx.doi.org/10.1371/journal.pone.0103348			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN9BM	25119457	gold, Green Published, Green Submitted			2023-01-03	WOS:000340900600021
J	van Zanten, ARH; Sztark, F; Kaisers, UX; Zielmann, S; Felbinger, TW; Sablotzki, AR; DeWaele, JJ; Timsit, JF; Honing, MLH; Keh, D; Vincent, JL; Zazzo, JF; Fijn, HBM; Petit, L; Preiser, JC; van Horssen, PJ; Hofman, Z				van Zanten, Arthur R. H.; Sztark, Franois; Kaisers, Udo X.; Zielmann, Siegfried; Felbinger, Thomas W.; Sablotzki, Armin R.; DeWaele, Jan J.; Timsit, Jean-Francis; Honing, Marina L. H.; Keh, Didier; Vincent, Jean-Louis; Zazzo, Jean-Fabien; Fijn, Harvey B. M.; Petit, Laurent; Preiser, Jean-Charles; van Horssen, Peter J.; Hofman, Zandrie			High-Protein Enteral Nutrition Enriched With Immune-Modulating Nutrients vs Standard High-Protein Enteral Nutrition and Nosocomial Infections in the ICU A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY-ILL PATIENTS; GAMMA-LINOLENIC ACID; PARENTERAL GLUTAMINE SUPPLEMENTATION; INTENSIVE-CARE PATIENTS; ACUTE LUNG INJURY; EICOSAPENTAENOIC ACID; VENTILATED PATIENTS; IMMUNONUTRITION; ANTIOXIDANTS; PATIENT	IMPORTANCE Enteral administration of immune-modulating nutrients (eg, glutamine, omega-3 fatty acids, selenium, and antioxidants) has been suggested to reduce infections and improve recovery from critical illness. However, controversy exists on the use of immune-modulating enteral nutrition, reflected by lack of consensus in guidelines. OBJECTIVE To determine whether high-protein enteral nutrition enriched with immune-modulating nutrients (IMHP) reduces the incidence of infections compared with standard high-protein enteral nutrition (HP) in mechanically ventilated critically ill patients. DESIGN, SETTING, AND PARTICIPANTS The MetaPlus study, a randomized, double-blind, multicenter trial, was conducted from February 2010 through April 2012 including a 6-month follow-up period in 14 intensive care units (ICUs) in the Netherlands, Germany, France, and Belgium. A total of 301 adult patients who were expected to be ventilated for more than 72 hours and to require enteral nutrition for more than 72 hours were randomized to the IMHP (n = 152) or HP (n = 149) group and included in an intention-to-treat analysis, performed for the total population as well as predefined medical, surgical, and trauma subpopulations. INTERVENTIONS High-protein enteral nutrition enriched with immune-modulating nutrients vs standard high-protein enteral nutrition, initiated within 48 hours of ICU admission and continued during the ICU stay for a maximum of 28 days. MAIN OUTCOMES AND MEASURES The primary outcome measure was incidence of new infections according to the Centers for Disease Control and Prevention (CDC) definitions. Secondary end points included mortality, Sequential Organ Failure Assessment (SOFA) scores, mechanical ventilation duration, ICU and hospital lengths of stay, and subtypes of infections according CDC definitions. RESULTS There were no statistically significant differences in incidence of new infections between the groups: 53%(95% CI, 44%-61%) in the IMHP group vs 52%(95% CI, 44%-61%) in the HP group (P = .96). No statistically significant differences were observed in other end points, except for a higher 6-month mortality rate in the medical subgroup: 54%(95% CI, 40%-67%) in the IMHP group vs 35%(95% CI, 22%-49%) in the HP group (P = .04), with a hazard ratio of 1.57 (95% CI, 1.03-2.39; P = .04) for 6-month mortality adjusted for age and Acute Physiology and Chronic Health Evaluation II score comparing the groups. CONCLUSIONS AND RELEVANCE Among adult patients breathing with the aid of mechanical ventilation in the ICU, IMHP compared with HP did not improve infectious complications or other clinical end points and may be harmful as suggested by increased adjusted mortality at 6 months. These findings do not support the use of IMHP nutrients in these patients.	[van Zanten, Arthur R. H.; Fijn, Harvey B. M.] Gelderse Vallei Hosp, NL-6716 RP Ede, Netherlands; [Sztark, Franois; Petit, Laurent] CHU Bordeaux, Grp Hop Pellegrin, Bordeaux, France; [Kaisers, Udo X.] Univ Klinikum Leipzig, Leipzig, Germany; [Zielmann, Siegfried] Heinrich Braun Klinikum, Zwickau, Germany; [Felbinger, Thomas W.] Klinikum Neuperlach, Munich, Germany; [Sablotzki, Armin R.] Klinikum St Georg, Leipzig, Germany; [DeWaele, Jan J.] Ghent Univ Hosp, Ghent, Belgium; [Timsit, Jean-Francis] Hop Univ Albert Michallon, Grenoble, France; [Honing, Marina L. H.] Med Ctr Alkmaar, Alkmaar, Netherlands; [Keh, Didier] Charite Univ Med Berlin, Berlin, Germany; [Vincent, Jean-Louis; Preiser, Jean-Charles] Univ Libre Bruxelles, Erasme Univ Hosp, Brussels, Belgium; [Zazzo, Jean-Fabien] Hop Antoine Beclere, Clamart, France; [van Horssen, Peter J.; Hofman, Zandrie] Nutricia Res, Nutricia Adv Med Nutr, Utrecht, Netherlands	Gelderse Vallei Hospital; CHU Bordeaux; Leipzig University; Munchen Klinik; Ghent University; Ghent University Hospital; CHU Grenoble Alpes; Medical Center Of Alkmaar; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Universite Libre de Bruxelles; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Danone Nutricia	van Zanten, ARH (corresponding author), Gelderse Vallei Hosp, Dept Intens Care, Willy Brandtlaan 10, NL-6716 RP Ede, Netherlands.	zantena@zgv.nl	van Zanten, Arthur R.H./ABB-1169-2021; De Waele, Jan J/E-2704-2013; Preiser, Jean-Charles/AAL-2355-2021	van Zanten, Arthur R.H./0000-0001-6276-7192; De Waele, Jan J/0000-0003-1017-9748; Preiser, Jean-Charles/0000-0003-3163-0390; Vincent, Jean-Louis/0000-0001-6011-6951; LAURENT, PETIT/0000-0003-1530-5678	Nutricia Advanced Medical Nutrition, Nutricia Research, Utrecht, the Netherlands	Nutricia Advanced Medical Nutrition, Nutricia Research, Utrecht, the Netherlands	Nutricia Advanced Medical Nutrition, Nutricia Research, Utrecht, the Netherlands was the study sponsor.	Allingstrup MJ, 2012, CLIN NUTR, V31, P462, DOI 10.1016/j.clnu.2011.12.006; Andrews PJD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1542; Avenell A, 2006, P NUTR SOC, V65, P236, DOI 10.1079/PNS2006498; Beale RJ, 1999, CRIT CARE MED, V27, P2799, DOI 10.1097/00003246-199912000-00032; Bistrian BR, 2013, NEW ENGL J MED, V369, P482, DOI 10.1056/NEJMc1306658; Blaser AR, 2012, INTENS CARE MED, V38, P384, DOI 10.1007/s00134-011-2459-y; Bollhalder L, 2013, CLIN NUTR, V32, P213, DOI 10.1016/j.clnu.2012.11.003; Calder PC, 2004, LIPIDS, V39, P1147, DOI 10.1007/s11745-004-1342-z; Drover JW, 2010, JPEN-PARENTER ENTER, V34, P644, DOI 10.1177/0148607110372391; Fadda V, 2013, CLIN NUTR, V32, P492, DOI 10.1016/j.clnu.2013.01.017; Gadek JE, 1999, CRIT CARE MED, V27, P1409, DOI 10.1097/00003246-199908000-00001; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Hegazi RA, 2011, CRIT CARE, V15, DOI 10.1186/cc10430; Heyland D, 2013, NEW ENGL J MED, V368, P1853, DOI DOI 10.1056/NEJM0A1212722.ERRATUM; Heyland D, 2013, NEW ENGL J MED, V368, P1489, DOI 10.1056/NEJMoa1212722; Heyland DK, 2005, INTENS CARE MED, V31, P327, DOI 10.1007/s00134-004-2522-z; Heyland DK, 2001, JAMA-J AM MED ASSOC, V286, P944, DOI 10.1001/jama.286.8.944; Kreymann KG, 2006, CLIN NUTR, V25, P210, DOI 10.1016/j.clnu.2006.01.021; Manzanares W, 2012, CRIT CARE, V16, DOI 10.1186/cc11316; McClave SA, 2009, JPEN-PARENTER ENTER, V33, P277, DOI 10.1177/0148607109335234; Montejo JC, 2003, CLIN NUTR, V22, P221, DOI 10.1016/S0261-5614(03)00007-4; Novak F, 2002, CRIT CARE MED, V30, P2022, DOI 10.1097/00003246-200209000-00011; Pasin L, 2013, NEW ENGL J MED, V369, P482, DOI 10.1056/NEJMc1306658; Peterson SJ, 2010, J AM DIET ASSOC, V110, P427, DOI 10.1016/j.jada.2009.11.020; Pontes-Arruda A, 2006, CRIT CARE MED, V34, P2325, DOI 10.1097/01.CCM.0000234033.65657.B6; Rice TW, 2011, JAMA-J AM MED ASSOC, V306, P1574, DOI 10.1001/jama.2011.1435; Singer P, 2006, CRIT CARE MED, V34, P1033, DOI 10.1097/01.CCM.0000206111.23629.0A; Weijs PJM, 2013, CURR OPIN CLIN NUTR, V16, P194, DOI 10.1097/MCO.0b013e32835bdf7e; Weijs PJM, 2012, JPEN-PARENTER ENTER, V36, P60, DOI 10.1177/0148607111415109; Wernerman J, 2011, ACTA ANAESTH SCAND, V55, P812, DOI 10.1111/j.1399-6576.2011.02453.x; Wernerman J, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-25	31	167	174	1	39	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	2014	312	5					514	524		10.1001/jama.2014.7698	http://dx.doi.org/10.1001/jama.2014.7698			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AM4FL	25096691	Bronze			2023-01-03	WOS:000339808600020
J	Holfeld, J; Tepekoylu, C; Blunder, S; Lobenwein, D; Kirchmair, E; Dietl, M; Kozaryn, R; Lener, D; Theurl, M; Paulus, P; Kirchmair, R; Grimm, M				Holfeld, Johannes; Tepekoeylue, Can; Blunder, Stefan; Lobenwein, Daniela; Kirchmair, Elke; Dietl, Marion; Kozaryn, Radoslaw; Lener, Daniela; Theurl, Markus; Paulus, Patrick; Kirchmair, Rudolf; Grimm, Michael			Low Energy Shock Wave Therapy Induces Angiogenesis in Acute Hind-Limb Ischemia via VEGF Receptor 2 Phosphorylation	PLOS ONE			English	Article							MYOCARDIAL VIABILITY ASSESSMENT; HEART-FAILURE; ENDOTHELIAL-CELLS; GENE-THERAPY; INFARCTION; MODEL; DYSFUNCTION; EXPRESSION; CHALLENGES	Objectives: Low energy shock waves have been shown to induce angiogenesis, improve left ventricular ejection fraction and decrease angina symptoms in patients suffering from chronic ischemic heart disease. Whether there is as well an effect in acute ischemia was not yet investigated. Methods: Hind-limb ischemia was induced in 10-12 weeks old male C57/Bl6 wild-type mice by excision of the left femoral artery. Animals were randomly divided in a treatment group (SWT, 300 shock waves at 0.1 mJ/mm(2), 5 Hz) and untreated controls (CTR), n = 10 per group. The treatment group received shock wave therapy immediately after surgery. Results: Higher gene expression and protein levels of angiogenic factors VEGF-A and PlGF, as well as their receptors Flt-1 and KDR have been found. This resulted in significantly more vessels per high-power field in SWT compared to controls. Improvement of blood perfusion in treatment animals was confirmed by laser Doppler perfusion imaging. Receptor tyrosine kinase profiler revealed significant phosphorylation of VEGF receptor 2 as an underlying mechanism of action. The effect of VEGF signaling was abolished upon incubation with a VEGFR2 inhibitor indicating that the effect is indeed VEGFR 2 dependent. Conclusions: Low energy shock wave treatment induces angiogenesis in acute ischemia via VEGF receptor 2 stimulation and shows the same promising effects as known from chronic myocardial ischemia. It may therefore develop as an adjunct to the treatment armentarium of acute muscle ischemia in limbs and myocardium.	[Holfeld, Johannes; Tepekoeylue, Can; Lobenwein, Daniela; Kirchmair, Elke; Dietl, Marion; Kozaryn, Radoslaw; Grimm, Michael] Med Univ Innsbruck, Univ Hosp Cardiac Surg, A-6020 Innsbruck, Austria; [Tepekoeylue, Can] Med Univ Innsbruck, Div Clin & Funct Anat, Dept Anat Histol & Embryol, A-6020 Innsbruck, Austria; [Blunder, Stefan] Med Univ Innsbruck, Univ Hosp Dermatol & Venerol, A-6020 Innsbruck, Austria; [Lener, Daniela; Theurl, Markus; Kirchmair, Rudolf] Med Univ Innsbruck, Univ Hosp Internal Med 3, Dept Cardiol & Angiol, A-6020 Innsbruck, Austria; [Paulus, Patrick] Goethe Univ Hosp, Clin Anaesthesiol Intens Care Med & Pain Therapy, Frankfurt, Germany	Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Holfeld, J (corresponding author), Med Univ Innsbruck, Univ Hosp Cardiac Surg, A-6020 Innsbruck, Austria.	johannes.holfeld@i-med.ac.at		Dietl, Marion/0000-0001-6171-577X; Gollmann-Tepekoylu, Can/0000-0001-6584-3488; Holfeld, Johannes/0000-0001-6623-0595; Theurl, Markus/0000-0002-3609-9730	Medizinischer Forschungsfonds Tirol (MFF) [220]; CRT - Cardiac Regeneration Technologies LLC., Woodstock, Georgia, USA	Medizinischer Forschungsfonds Tirol (MFF); CRT - Cardiac Regeneration Technologies LLC., Woodstock, Georgia, USA	This work was in part supported by a research grant of Medizinischer Forschungsfonds Tirol (MFF), project no. 220 and by a research grant provided by CRT - Cardiac Regeneration Technologies LLC., Woodstock, Georgia, USA, both to J.H. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albrecht-Schgoer K, 2012, CIRCULATION, V126, P2491, DOI 10.1161/CIRCULATIONAHA.111.076950; Baker M, 2012, NAT PROTOC, V7, P89, DOI 10.1038/nprot.2011.435; Blunder S, 2012, ATHEROSCLEROSIS, V220, P355, DOI 10.1016/j.atherosclerosis.2011.11.035; Carluccio E, 2012, ECHOCARDIOGR-J CARD, V29, P298, DOI 10.1111/j.1540-8175.2011.01575.x; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Cunningham JJ, 2012, NAT BIOTECHNOL, V30, P849, DOI 10.1038/nbt.2329; Di Carli MF, 1998, J THORAC CARDIOV SUR, V116, P997, DOI 10.1016/S0022-5223(98)70052-2; DREYFUS GD, 1994, ANN THORAC SURG, V57, P1402, DOI 10.1016/0003-4975(94)90091-4; Elster EA, 2010, J ORTHOP TRAUMA, V24, P133, DOI 10.1097/BOT.0b013e3181b26470; Fukumoto Y, 2006, CORONARY ARTERY DIS, V17, P63, DOI 10.1097/00019501-200602000-00011; Holfeld J, 2016, J TISSUE ENG REGEN M, V10, P1057, DOI 10.1002/term.1890; Holfeld J, 2014, JOVE-J VIS EXP, DOI 10.3791/51076; Isner JM, 2002, NATURE, V415, P234, DOI 10.1038/415234a; Koudstaal S, 2013, STEM CELL TRANSL MED, V2, P434, DOI 10.5966/sctm.2013-0001; Leibowitz D, 2013, INT J CARDIOL, V167, P3033, DOI 10.1016/j.ijcard.2012.11.099; Marwick TH, 1999, J AM COLL CARDIOL, V33, P750, DOI 10.1016/S0735-1097(98)00642-1; Meirer R, 2007, J RECONSTR MICROSURG, V23, P231, DOI 10.1055/s-2007-981506; Mittermayr R, 2012, WOUND REPAIR REGEN, V20, P456, DOI 10.1111/j.1524-475X.2012.00796.x; Mittermayr R, 2011, ANN SURG, V253, P1024, DOI 10.1097/SLA.0b013e3182121d6e; Nishida T, 2004, CIRCULATION, V110, P3055, DOI 10.1161/01.CIR.0000148849.51177.97; Ottomann C, 2012, ANN SURG, V255, P23, DOI 10.1097/SLA.0b013e318227b3c0; Pearle MS, 2012, NEW ENGL J MED, V367, P50, DOI 10.1056/NEJMct1103074; Pleger ST, 2013, CIRC RES, V113, P792, DOI 10.1161/CIRCRESAHA.113.300269; Post MJ, 2001, CARDIOVASC RES, V49, P522, DOI 10.1016/S0008-6363(00)00216-9; Pourrajab F, 2014, INT J CARDIOL, V173, P12, DOI 10.1016/j.ijcard.2014.02.006; Sanganalmath SK, 2013, CIRC RES, V113, P810, DOI 10.1161/CIRCRESAHA.113.300219; Sems A, 2006, J AM ACAD ORTHOP SUR, V14, P195, DOI 10.5435/00124635-200604000-00001; Shah BN, 2013, EUR HEART J, V34, P1323, DOI 10.1093/eurheartj/eht018; Siow RCM, 2012, METHODS MOL BIOL, V806, P265, DOI 10.1007/978-1-61779-367-7_18; Telukuntla KS, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000338; Tepekoylu C, 2013, J THORAC CARDIOV SUR, V146, P971, DOI 10.1016/j.jtcvs.2013.01.017; Theurl M, 2010, CIRC RES, V107, P1326, DOI 10.1161/CIRCRESAHA.110.219493; Uwatoku T, 2007, CORONARY ARTERY DIS, V18, P397, DOI 10.1097/MCA.0b013e328089f19b; Wang Y, 2010, CLIN CARDIOL, V33, P693, DOI 10.1002/clc.20811; Zhao HQ, 2013, CORONARY ARTERY DIS, V24, P493, DOI 10.1097/MCA.0b013e328363244b; Zimpfer D, 2009, J THORAC CARDIOV SUR, V137, P963, DOI 10.1016/j.jtcvs.2008.11.006	37	41	43	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2014	9	8							e103982	10.1371/journal.pone.0103982	http://dx.doi.org/10.1371/journal.pone.0103982			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO5BW	25093816	Green Submitted, Green Published, gold			2023-01-03	WOS:000341357200054
J	Choi, JG; Mun, SH; Chahar, HS; Bharaj, P; Kang, OH; Kim, SG; Shin, DW; Kwon, DY				Choi, Jang-Gi; Mun, Su-Hyun; Chahar, Harendra S.; Bharaj, Preeti; Kang, Ok-Hwa; Kim, Se-Gun; Shin, Dong-Won; Kwon, Dong-Yeul			Methyl Gallate from Galla rhois Successfully Controls Clinical Isolates of Salmonella Infection in Both In Vitro and In Vivo Systems	PLOS ONE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; ANTIMICROBIAL DRUG-RESISTANCE; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; ANTIBACTERIAL ACTIVITY; MICE; COMBINATION; ENTERICA; HOST; DISEASES	Galla rhois is a commonly used traditional medicine for the treatment of pathogenic bacteria in Korea as well as in other parts of Asia. Methyl gallate (MG), a major component of Galla Rhois, exhibits strong antibacterial activity, but its mechanism of action against Salmonella spp. is unclear. In the present study, we investigated the antibacterial actions of MG against Salmonella. The antibacterial activity determined by broth dilution method indicated that the antibacterial activity of MG against Salmonella strains ranged from 3.9 to 125 mu g/ml. In vitro bacterial viability test indicated that MG significantly decreased the viability of Salmonella over 40% when combined with ATPase inhibitors. The time-kill curves showed that a combined MG and ATPase inhibitors (DCCD and NaN3) treatment reduced the bacterial counts dramatically after 24 h. Oral administration of MG showed a strong anti-bacterial activity against WS-5 infected BALB/c mice. In contrast to the untreated Salmonella infected control animals, MG treated groups showed no clinical symptoms of the disease, such as lethargy and liver damage. It was observed that MG treatment significantly increased the survival of animals from Salmonella infection, while in untreated groups all animal succumbed to disease by the sixth day post infection. Thus, the present study demonstrates the therapeutic ability of MG against Salmonella infections.	[Choi, Jang-Gi; Kang, Ok-Hwa; Kim, Se-Gun; Kwon, Dong-Yeul] Wonkwang Univ, Wonkwang Oriental Med Res Inst, Inst Biotechnol, Dept Oriental Pharm,Coll Pharm, Jeonbuk, South Korea; [Choi, Jang-Gi; Chahar, Harendra S.; Bharaj, Preeti] Texas Tech Univ, Ctr Excellence Infect Dis Res, Dept Biomed Sci, Paul L Foster Sch Med,Hlth Sci Ctr, El Paso, TX USA; [Mun, Su-Hyun] Wonkwang Univ, Profess Grad Sch Oriental Med, Plus Team BK21, Iksan, Jeonbuk, South Korea; [Shin, Dong-Won] Sunchon Natl Univ, Dept Oriental Med Resources, Jeonnam, South Korea	Wonkwang University; Texas Tech University System; Texas Tech University; Wonkwang University; Sunchon National University	Kwon, DY (corresponding author), Wonkwang Univ, Wonkwang Oriental Med Res Inst, Inst Biotechnol, Dept Oriental Pharm,Coll Pharm, Jeonbuk, South Korea.	sssimi@wku.ac.kr	Choi, Jang-gi/AAP-6339-2020; Bharaj, Preeti/AAX-7394-2020	Bharaj, Preeti/0000-0002-9411-9373	Wonkwang University	Wonkwang University	This research was supported by Wonkwang University in 2013. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn YJ, 1998, J APPL MICROBIOL, V84, P439, DOI 10.1046/j.1365-2672.1998.00363.x; Ali NAA, 2001, J ETHNOPHARMACOL, V74, P173, DOI 10.1016/S0378-8741(00)00364-0; Alvarez J, 2004, J CLIN MICROBIOL, V42, P1734, DOI 10.1128/JCM.42.4.1734-1738.2004; Aqil F, 2005, J BASIC MICROB, V45, P106, DOI 10.1002/jobm.200410355; Barrow PA, 2011, AVIAN PATHOL, V40, P1, DOI 10.1080/03079457.2010.542575; Barthel M, 2003, INFECT IMMUN, V71, P2839, DOI 10.1128/IAI.71.5.2839-2858.2003; Belley A, 2008, ANTIMICROB AGENTS CH, V52, P3820, DOI 10.1128/AAC.00361-08; Chen AP, 2003, J BIOL CHEM, V278, P23381, DOI 10.1074/jbc.M212042200; Choi JG, 2009, MOLECULES, V14, P1773, DOI 10.3390/molecules14051773; Choi JG, 2008, J MICROBIOL BIOTECHN, V18, P1848, DOI 10.4014/jmb.0800.025; Clinical and Laboratory Standards Institute (CLSI), 2012, M100S22 CLIN LAB S S; Coburn B, 2007, IMMUNOL CELL BIOL, V85, P112, DOI 10.1038/sj.icb.7100007; Falconer SB, 2011, NAT CHEM BIOL, V7, P416, DOI [10.1038/nchembio.590, 10.1038/NCHEMBIO.590]; Fink SL, 2007, CELL MICROBIOL, V9, P2562, DOI 10.1111/j.1462-5822.2007.01036.x; Gebreyes WA, 2004, J ANTIMICROB CHEMOTH, V53, P997, DOI 10.1093/jac/dkh247; Goncalves PP, 1999, MOL BRAIN RES, V71, P178, DOI 10.1016/S0169-328X(99)00183-7; Grassl GA, 2008, GASTROENTEROLOGY, V134, P768, DOI 10.1053/j.gastro.2007.12.043; Hsieh TJ, 2004, FOOD CHEM TOXICOL, V42, P843, DOI 10.1016/j.fct.2004.01.008; IRVIN RT, 1981, J BACTERIOL, V145, P1397, DOI 10.1128/JB.145.3.1397-1403.1981; Jones RN, 2010, J CLIN MICROBIOL, V48, P972, DOI 10.1128/JCM.01829-09; Jung HJ, 2008, J MICROBIOL, V46, P462, DOI 10.1007/s12275-008-0138-7; Kim S, 2010, J KOREAN MED SCI, V25, P1893, DOI 10.3346/jkms.2010.25.12.1693; Kim SP, 2014, J AGR FOOD CHEM, V62, P2384, DOI 10.1021/jf405223q; Lee MH, 2006, INT J FOOD MICROBIOL, V111, P270, DOI 10.1016/j.ijfoodmicro.2006.06.004; LEIVE L, 1965, BIOCHEM BIOPH RES CO, V18, P13, DOI 10.1016/0006-291X(65)90874-0; Linnett P E, 1979, Methods Enzymol, V55, P472; Mascellino MT, 1998, DRUG EXP CLIN RES, V24, P139; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; Meakins S, 2008, MICROB DRUG RESIST, V14, P31, DOI 10.1089/mdr.2008.0777; Mun SH, 2014, FOODBORNE PATHOG DIS, V11, P234, DOI 10.1089/fpd.2013.1627; Myhal M L, 1982, Eur J Clin Microbiol, V1, P186, DOI 10.1007/BF02019621; Perez-Capilla T, 2005, J BACTERIOL, V187, P1515, DOI 10.1128/JB.187.4.1515-1518.2005; Perron GG, 2008, FEMS MICROBIOL LETT, V281, P17, DOI 10.1111/j.1574-6968.2007.01045.x; Poppe C, 2002, MICROB DRUG RESIST, V8, P107, DOI 10.1089/107662902760190653; Pournaras S, 2011, INT J ANTIMICROB AG, V37, P244, DOI 10.1016/j.ijantimicag.2010.10.031; Sciuto AM, 2001, J APPL TOXICOL, V21, P33, DOI 10.1002/jat.729; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; Threlfall EJ, 2002, FEMS MICROBIOL REV, V26, P141, DOI 10.1016/S0168-6445(02)00092-X; Threlfall EJ, 2000, ACTA VET SCAND, P63; Trkov M, 2003, INT J FOOD MICROBIOL, V80, P67, DOI 10.1016/S0168-1605(02)00138-1; Vidaillac C, 2009, ANTIMICROB AGENTS CH, V53, P2360, DOI 10.1128/AAC.01452-08	41	37	38	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2014	9	7							e102697	10.1371/journal.pone.0102697	http://dx.doi.org/10.1371/journal.pone.0102697			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM0SW	25048362	Green Submitted, Green Published, gold			2023-01-03	WOS:000339558100061
J	Yamanaka, S; Yokote, S; Yamada, A; Katsuoka, Y; Izuhara, L; Shimada, Y; Omura, N; Okano, HJ; Ohki, T; Yokoo, T				Yamanaka, Shuichiro; Yokote, Shinya; Yamada, Akifumi; Katsuoka, Yuichi; Izuhara, Luna; Shimada, Yohta; Omura, Nobuo; Okano, Hirotaka James; Ohki, Takao; Yokoo, Takashi			Adipose Tissue-Derived Mesenchymal Stem Cells in Long-Term Dialysis Patients Display Downregulation of PCAF Expression and Poor Angiogenesis Activation	PLOS ONE			English	Article							GENE-EXPRESSION; STROMAL CELLS; HYPOXIA; GROWTH; FIBROBLASTS; RESPONSES; RB	We previously demonstrated that mesenchymal stem cells (MSCs) differentiate into functional kidney cells capable of urine and erythropoietin production, indicating that they may be used for kidney regeneration. However, the viability of MSCs from dialysis patients may be affected under uremic conditions. In this study, we isolated MSCs from the adipose tissues of end-stage kidney disease (ESKD) patients undergoing long-term dialysis (KD-MSCs; mean: 72.3 months) and from healthy controls (HC-MSCs) to compare their viability. KD-MSCs and HC-MSCs were assessed for their proliferation potential, senescence, and differentiation capacities into adipocytes, osteoblasts, and chondrocytes. Gene expression of stem cell-specific transcription factors was analyzed by PCR array and confirmed by western blot analysis at the protein level. No significant differences of proliferation potential, senescence, or differentiation capacity were observed between KD-MSCs and HC-MSCs. However, gene and protein expression of p300/CBP-associated factor (PCAF) was significantly suppressed in KD-MSCs. Because PCAF is a histone acetyltransferase that mediates regulation of hypoxia-inducible factor-1 alpha (HIF-1 alpha), we examined the hypoxic response in MSCs. HC-MSCs but not KD-MSCs showed upregulation of PCAF protein expression under hypoxia. Similarly, HIF-1 alpha and vascular endothelial growth factor (VEGF) expression did not increase under hypoxia in KD-MSCs but did so in HC-MSCs. Additionally, a directed in vivo angiogenesis assay revealed a decrease in angiogenesis activation of KD-MSCs. In conclusion, long-term uremia leads to persistent and systematic downregulation of PCAF gene and protein expression and poor angiogenesis activation of MSCs from patients with ESKD. Furthermore, PCAF, HIF-1 alpha, and VEGF expression were not upregulated by hypoxic stimulation of KD-MSCs. These results suggest that the hypoxic response may be blunted in MSCs from ESKD patients.	[Yamanaka, Shuichiro; Katsuoka, Yuichi; Izuhara, Luna; Okano, Hirotaka James] Jikei Univ, Sch Med, Dept Internal Med, Div Regenerat Med, Tokyo, Japan; [Yamanaka, Shuichiro; Yokote, Shinya; Yokoo, Takashi] Jikei Univ, Sch Med, Dept Internal Med, Div Nephrol & Hypertens, Tokyo, Japan; [Yamada, Akifumi] Jikei Univ, Dept Pediat, Sch Med, Tokyo, Japan; [Shimada, Yohta] Jikei Univ, Dept Gene Therapy, Inst DNA Med, Sch Med, Tokyo, Japan; [Omura, Nobuo; Ohki, Takao] Jikei Univ, Dept Surg, Sch Med, Tokyo, Japan	Jikei University; Jikei University; Jikei University; Jikei University; Jikei University	Yokoo, T (corresponding author), Jikei Univ, Sch Med, Dept Internal Med, Div Nephrol & Hypertens, Tokyo, Japan.	tyokoo@jikei.ac.jp		Okano, Hirotaka James/0000-0003-4611-7098; Shimada, Yohta/0000-0003-2003-1552	Ministry of Education, Culture, Sports, Science and Technology; Ministry of Health, Labour and Welfare of Japan	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology and Ministry of Health, Labour and Welfare of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aust L, 2004, CYTOTHERAPY, V6, P7, DOI 10.1080/14653240310004539; Badylak SF, 2011, ANNU REV BIOMED ENG, V13, P27, DOI 10.1146/annurev-bioeng-071910-124743; Banas A, 2007, HEPATOLOGY, V46, P219, DOI 10.1002/hep.21704; Basile JR, 2007, J BIOL CHEM, V282, P6899, DOI 10.1074/jbc.M609570200; Bastiaansen AJNM, 2013, ARTERIOSCL THROM VAS, V33, P1902, DOI 10.1161/ATVBAHA.113.301579; Bechtel-Walz W, 2014, CELL TISSUE RES, V356, P601, DOI 10.1007/s00441-014-1884-y; Berger A, 2009, AM J MANAG CARE, V15, P509; Bernhardt WM, 2006, KIDNEY INT, V69, P114, DOI 10.1038/sj.ki.5000062; Chen SW, 2011, J BIOL CHEM, V286, P32775, DOI 10.1074/jbc.M111.248278; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Drewa T, 2008, TRANSPL P, V40, P1668, DOI 10.1016/j.transproceed.2008.03.141; Ferrari R, 2008, SCIENCE, V321, P1086, DOI 10.1126/science.1155546; Gonzalez-Cruz RD, 2012, P NATL ACAD SCI USA, V109, pE1523, DOI 10.1073/pnas.1120349109; Guedez L, 2003, AM J PATHOL, V162, P1431, DOI 10.1016/S0002-9440(10)64276-9; Huang J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001710; Japanese Society of Nephrology, 2012, JPN J NEPHROL, V54, P1031; Jin YT, 2002, J BIOL CHEM, V277, P30838, DOI 10.1074/jbc.M204078200; Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; Linares LK, 2007, NAT CELL BIOL, V9, P331, DOI 10.1038/ncb1545; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Meyer TW, 2007, NEW ENGL J MED, V357, P1316, DOI 10.1056/NEJMra071313; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nekanti U, 2010, INT J BIOL SCI, V6, P499; Noh H, 2012, NEPHROL DIAL TRANSPL, V27, P218, DOI 10.1093/ndt/gfr267; Okuyama H, 2006, J BIOL CHEM, V281, P15554, DOI 10.1074/jbc.M602003200; Pillai S, 2010, CANCER RES, V70, P4931, DOI 10.1158/0008-5472.CAN-10-0501; Ravnskjaer K, 2013, J CLIN INVEST, V123, P4318, DOI 10.1172/JCI69035; Roemeling-van Rhijn M, 2012, KIDNEY INT, V82, P748, DOI 10.1038/ki.2012.187; SAHAGUN G, 1989, AM J PATHOL, V134, P1227; Shakib K, 2005, PROTEOMICS, V5, P2819, DOI 10.1002/pmic.200401108; Shimada Y, 2011, BIOCHEM BIOPH RES CO, V415, P274, DOI 10.1016/j.bbrc.2011.10.038; Sonoda T, 2003, TRANSPLANTATION, V75, P199, DOI 10.1097/01.TP.0000040867.67360.9F; Wagner W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002213; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303; Xenaki G, 2008, ONCOGENE, V27, P5785, DOI 10.1038/onc.2008.192; Xinaris C, 2012, J AM SOC NEPHROL, V23, P1857, DOI 10.1681/ASN.2012050505; Yamada A, 2014, HUM CELL, V27, P59, DOI 10.1007/s13577-013-0082-7; Yokoo T, 2005, P NATL ACAD SCI USA, V102, P3296, DOI 10.1073/pnas.0406878102; Yokoo T, 2008, TRANSPLANTATION, V85, P1654, DOI 10.1097/TP.0b013e318173a35d; Yokoo T, 2006, J AM SOC NEPHROL, V17, P1026, DOI 10.1681/ASN.2005101043; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	42	29	31	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2014	9	7							e102311	10.1371/journal.pone.0102311	http://dx.doi.org/10.1371/journal.pone.0102311			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6RN	25025381	Green Published, gold, Green Submitted			2023-01-03	WOS:000339992400063
J	Richardson-Harman, N; Hendrix, CW; Bumpus, NN; Mauck, C; Cranston, RD; Yang, K; Elliott, J; Tanner, K; McGowan, I; Kashuba, A; Anton, PA				Richardson-Harman, Nicola; Hendrix, Craig W.; Bumpus, Namandje N.; Mauck, Christine; Cranston, Ross D.; Yang, Kuo; Elliott, Julie; Tanner, Karen; McGowan, Ian; Kashuba, Angela; Anton, Peter A.			Correlation between Compartmental Tenofovir Concentrations and an Ex Vivo Rectal Biopsy Model of Tissue Infectibility in the RMP-02/MTN-006 Phase 1 Study	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CANDIDATE MICROBICIDES; TOPICAL MICROBICIDES; HIV-INFECTION; TRANSMISSION; CULTURE; SAFETY	Objectives: This study was designed to assess the dose-response relationship between tissue, blood, vaginal and rectal compartment concentrations of tenofovir (TFV) and tenofovir diphosphate (TFVdp) and ex vivo rectal HIV suppression following oral tenofovir disoproxil fumarate (TDF) and rectal administration of TFV 1% vaginally-formulated gel. Design: Phase 1, randomized, two-site (US), double-blind, placebo-controlled study of sexually-abstinent males and females. Methods: Eighteen participants received a single 300 mg exposure of oral TDF and were then randomized 2: 1 to receive a single then seven-daily rectal exposures of TFV 1% gel (40 mg TFV per 4 ml gel application) or hydroxyethyl-cellulose (HEC) placebo gel. Blood and rectal biopsies were collected for pharmacokinetic TDF and TFVdp analyses and ex vivo HIV-1 challenge. Results: There was a significant fit for the TFVdp dose-response model for rectal tissue (p = 0.0004), CD4(MMC)(+) (p<0.0001), CD4(MMC)(-) (p<0.0001), and Total(MMC) (p<0.0001) compartments with r(2) ranging 0.36-0.64. Higher concentrations of TFVdp corresponded with lower p24, consistent with drug-mediated virus suppression. The single oral treatment failed to provide adequate compartment drug exposure to reach the EC50 of rectal tissue TFVdp predicted to be necessary to suppress HIV in rectal tissue. The EC50 for CD4(MMC)(+) was within the single topical treatment range, providing evidence that a 1% topical, vaginally-formulated TFV gel provided in-vivo doses predicted to provide for 50% efficacy in the ex vivo assay. The 7-daily topical TFV gel treatment provided TFVdp concentrations that reached EC90 biopsy efficacy for CD4(MMC)(-), CD4(MMC)(+) and TotalMMC compartments. Conclusion: The TFVdp MMC compartment (CD4+, CD4- and Total) provided the best surrogate for biopsy infectibility and the 7-daily topical TFV gel treatment provided the strongest PK profile for HIV suppression.	[Richardson-Harman, Nicola] Alpha StatConsult LLC, Damascus, MD 20872 USA; [Hendrix, Craig W.; Bumpus, Namandje N.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Hendrix, Craig W.; Bumpus, Namandje N.] Johns Hopkins Univ, Sch Med, Dept Pharmacol, Baltimore, MD 21205 USA; [Mauck, Christine] CONRAD, Arlington, VA USA; [Cranston, Ross D.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA; [McGowan, Ian] Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Pittsburgh, PA USA; [Elliott, Julie; Tanner, Karen; Anton, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Ctr HIV Prevent Res,UCLA AIDS Inst, Los Angeles, CA 90095 USA; [Yang, Kuo; Kashuba, Angela] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA	Johns Hopkins University; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of North Carolina; University of North Carolina Chapel Hill	Richardson-Harman, N (corresponding author), Alpha StatConsult LLC, Damascus, MD 20872 USA.	nicola@alphastatconsult.com	Hendrix, Craig W/G-4182-2014; M, i/HCI-9242-2022; M, Ian/AAP-1032-2021	Hendrix, Craig W/0000-0002-5696-8665; M, Ian/0000-0002-6470-8476; Cranston, Ross/0000-0002-2687-6217	Integrated Preclinical-Clinical Program for HIV Topical Microbicides (IPCP-HTM), Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) [U19, AI060614]; NIAID's Microbicide Trials Network [5UM1AI068633]; Gilead Sciences Inc.; University of California, Los Angeles Center for AIDS Research [5P30 AI28697]; Cores of Mucosal Immunology, Flow Cytometry and Biostatistics; University of North Carolina-Chapel Hill Center for AIDS Research, Clinical Pharmacology/Analytical Chemistry Core [P30 AI50410]; Johns Hopkins Clinical Pharmacology Analytical Laboratory; CONRAD; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI106707, UM1AI068633, P30AI050410, U19AI060614, P30AI028697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301] Funding Source: NIH RePORTER	Integrated Preclinical-Clinical Program for HIV Topical Microbicides (IPCP-HTM), Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH); NIAID's Microbicide Trials Network; Gilead Sciences Inc.(Gilead Sciences); University of California, Los Angeles Center for AIDS Research; Cores of Mucosal Immunology, Flow Cytometry and Biostatistics; University of North Carolina-Chapel Hill Center for AIDS Research, Clinical Pharmacology/Analytical Chemistry Core; Johns Hopkins Clinical Pharmacology Analytical Laboratory; CONRAD(United States Agency for International Development (USAID)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The study was funded by a U19 grant under the Integrated Preclinical-Clinical Program for HIV Topical Microbicides (IPCP-HTM), Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) (AI060614) and the NIAID's Microbicide Trials Network (5UM1AI068633). Additional support was provided by Gilead Sciences Inc.; the University of California, Los Angeles Center for AIDS Research (5P30 AI28697) Cores of Mucosal Immunology, Flow Cytometry and Biostatistics; the University of North Carolina-Chapel Hill Center for AIDS Research, Clinical Pharmacology/Analytical Chemistry Core (P30 AI50410); the Johns Hopkins Clinical Pharmacology Analytical Laboratory and CONRAD. The RMP-02/MTN-006 study was registered at http://www.ClinicalTrials.gov (NCT00984971) and the protocol can be found at http://www.mtnstopshiv.org. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Co-author Nicola Richardson-Harman is employed by Apha StatConsult, LLC. Alpha StatConsult, LLC provided support in the form of salary for author NR-H, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The co-author NR-H, as a statistical consultant, analyzed data and contributed to the statistical sections of the manuscript. The specific role of this author is articulated in the "author contributions" section.	Abner SR, 2005, J INFECT DIS, V192, P1545, DOI 10.1086/462424; Anton PA, 2000, AIDS, V14, P1761, DOI 10.1097/00002030-200008180-00011; Anton PA, 2012, AIDS RES HUM RETROV, V28, P1412, DOI [10.1089/aid.2012.0262, 10.1089/AID.2012.0262]; Anton PA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023243; BATMAN PA, 1994, AIDS, V8, P161, DOI 10.1097/00002030-199402000-00003; Fischetti L, 2009, AIDS, V23, P319, DOI 10.1097/QAD.0b013e328321b778; Fletcher PS, 2006, AIDS, V20, P1237, DOI 10.1097/01.aids.0000232230.96134.80; Glatting G, 2007, MED PHYS, V34, P4285, DOI 10.1118/1.2794176; Greenhead P, 2000, J VIROL, V74, P5577, DOI 10.1128/JVI.74.12.5577-5586.2000; Hendrix CW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055013; Hladik F, 2010, ANTIVIR RES, V88, pS3, DOI 10.1016/j.antiviral.2010.09.011; Richardson-Harman N, 2012, AIDS RES HUM RETROV, V28, P1422, DOI [10.1089/aid.2012.0073, 10.1089/AID.2012.0073]; Richardson-Harman N, 2009, J CLIN MICROBIOL, V47, P3530, DOI 10.1128/JCM.00673-09; SAS Institute, 1999, SAS STAT US GUID VER, P1903; Tebit DM, 2012, CURR HIV RES, V10, P3, DOI 10.2174/157016212799304689; Tien D, 2005, AIDS RES HUM RETROV, V21, P845, DOI 10.1089/aid.2005.21.845; Yang K-H, PLOS ONE	17	29	29	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2014	9	10							e111507	10.1371/journal.pone.0111507	http://dx.doi.org/10.1371/journal.pone.0111507			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0BH	25350130	Green Published, Green Accepted, gold			2023-01-03	WOS:000343943100076
J	Pan, YS; Chen, QD; Zhao, XQ; Liao, XL; Wang, CJ; Du, WL; Liu, GF; Liu, LP; Wang, CX; Wang, YL; Wang, YJ				Pan, Yuesong; Chen, Qidong; Zhao, Xingquan; Liao, Xiaoling; Wang, Chunjuan; Du, Wanliang; Liu, Gaifen; Liu, Liping; Wang, Chunxue; Wang, Yilong; Wang, Yongjun		TIMS-CHINA Investigators	Cost-Effectiveness of Thrombolysis within 4.5 Hours of Acute Ischemic Stroke in China	PLOS ONE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; INTRAVENOUS THROMBOLYSIS; UTILITY ANALYSIS; POOLED ANALYSIS; ALTEPLASE; HEALTH; PREVENTION; REIMBURSEMENT; ATLANTIS; WINDOW	Background: Previous economic studies conducted in developed countries showed intravenous tissue-type plasminogen activator (tPA) is cost-effective for acute ischemic stroke. The present study aimed to determine the cost-effectiveness of tPA treatment in China, the largest developing country. Methods: A combination of decision tree and Markov model was developed to determine the cost-effectiveness of tPA treatment versus non-tPA treatment within 4.5 hours after stroke onset. Outcomes and costs data were derived from the database of Thrombolysis Implementation and Monitor of acute ischemic Stroke in China (TIMS-China) study. Efficacy data were derived from a pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Costs and quality-adjusted life-years (QALYs) were compared in both short term (2 years) and long term (30 years). One-way and probabilistic sensitivity analyses were performed to test the robustness of the results. Results: Comparing to non-tPA treatment, tPA treatment within 4.5 hours led to a short-term gain of 0.101 QALYs at an additional cost of CNY 9,520 (US$ 1,460), yielding an incremental cost-effectiveness ratio (ICER) of CNY 94,300 (US$ 14,500) per QALY gained in 2 years; and to a long-term gain of 0.422 QALYs at an additional cost of CNY 6,530 (US$ 1,000), yielding an ICER of CNY 15,500 (US$ 2,380) per QALY gained in 30 years. Probabilistic sensitivity analysis showed that tPA treatment is cost-effective in 98.7% of the simulations at a willingness-to-pay threshold of CNY 105,000 (US$ 16,200) per QALY. Conclusions: Intravenous tPA treatment within 4.5 hours is highly cost-effective for acute ischemic strokes in China.	[Pan, Yuesong; Chen, Qidong; Zhao, Xingquan; Liao, Xiaoling; Wang, Chunjuan; Du, Wanliang; Liu, Gaifen; Liu, Liping; Wang, Chunxue; Wang, Yilong; Wang, Yongjun] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China	Capital Medical University	Wang, YL (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China.	yongjunwang1962@gmail.com	liu, li/HGC-0900-2022; Pan, Yuesong/AAI-6303-2020	Pan, Yuesong/0000-0003-3082-6789; Xu, An-Ding/0000-0003-3154-0985; Wang, Shaoshi/0000-0003-2547-0247	State Key Development Program of Basic Research of China [2009CB521905]; National Science and Technology Major Project of China [2011BAI08B02]	State Key Development Program of Basic Research of China(State Key Development Program for Basic Research of China); National Science and Technology Major Project of China	This study was funded by the State Key Development Program of Basic Research of China (2009CB521905), and National Science and Technology Major Project of China (2011BAI08B02). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beijing Municipal Commission of Development and Reform, MAX RET PRIC W MED C; Boudreau DM, 2013, ANN EMERG MED, V61, P46, DOI 10.1016/j.annemergmed.2012.04.020; Commission on Macroeconomics and Health of World Health Organization, CHOOSING INT AR COST; Demaerschalk BM, 2007, STROKE, V38, P1309, DOI 10.1161/01.STR.0000260185.74694.a7; Ehlers L, 2007, STROKE, V38, P85, DOI 10.1161/01.STR.0000251790.19419.a8; Fagan SC, 1998, NEUROLOGY, V50, P883, DOI 10.1212/WNL.50.4.883; Gao YL, 2009, CHIN J CONVALESCENT, V18, P472; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hacke W, 2004, LANCET, V363, P768; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Heeley E, 2009, STROKE, V40, P2149, DOI 10.1161/STROKEAHA.108.540054; Hylek EM, 2003, NEW ENGL J MED, V349, P1019, DOI 10.1056/NEJMoa022913; Jung KT, 2010, J CLIN NEUROL, V6, P117, DOI 10.3988/jcn.2010.6.3.117; Kim AS, 2013, STROKE, V44, pS123, DOI 10.1161/STROKEAHA.111.000067; Kim AS, 2011, STROKE, V42, P2013, DOI 10.1161/STROKEAHA.110.606889; Lee S, 2012, AM J CARDIOL, V110, P845, DOI 10.1016/j.amjcard.2012.05.011; Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6; Liao XL, 2012, CNS NEUROSCI THER, V19, P43; Liu H.T., 2009, CHIN J REHABIL THEOR, V15, P252; Ma RH, 2008, NEUROL RES, V30, P383, DOI 10.1179/174313208X300404; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Ministry of Health of the People's Republic of China, 2012, CHIN HLTH STAT YB 20; National Bureau of Statistics of China, 2010 POP CENS PEOPL; Peltola M, 2013, CEREBROVASC DIS, V35, P113, DOI 10.1159/000346092; Samsa GP, 1999, J CLIN EPIDEMIOL, V52, P259, DOI 10.1016/S0895-4356(98)00151-6; Sandercock P, 2004, STROKE, V35, P1490, DOI 10.1161/01.STR.0000126871.98801.6E; Sinclair SE, 2001, PHARMACOECONOMICS, V19, P927, DOI 10.2165/00019053-200119090-00004; Tanny SPT, 2013, STROKE, V44, P2269, DOI 10.1161/STROKEAHA.113.001295; Tung CE, 2011, STROKE, V42, P2257, DOI 10.1161/STROKEAHA.111.615682; Wahlgren N, 2008, LANCET, V372, P1303, DOI 10.1016/S0140-6736(08)61339-2; Wang YL, 2011, STROKE, V42, P1658, DOI 10.1161/STROKEAHA.110.604249; Wang YJ, 2011, INT J STROKE, V6, P355, DOI 10.1111/j.1747-4949.2011.00584.x; Wei JW, 2010, STROKE, V41, P967, DOI 10.1161/STROKEAHA.109.571463; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; Yang GH, 2013, LANCET, V381, P1987, DOI 10.1016/S0140-6736(13)61097-1; You JHS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039640	36	23	24	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2014	9	10							e110525	10.1371/journal.pone.0110525	http://dx.doi.org/10.1371/journal.pone.0110525			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0AY	25329637	Green Published, Green Submitted, gold			2023-01-03	WOS:000343942100067
J	Park, H; Shimamura, T; Miyano, S; Imoto, S				Park, Heewon; Shimamura, Teppei; Miyano, Satoru; Imoto, Seiya			Robust Prediction of Anti-Cancer Drug Sensitivity and Sensitivity-Specific Biomarker	PLOS ONE			English	Article							FEATURE-SELECTION; EXPRESSION; CANCER; GENE; IDENTIFICATION; REGRESSION; REGULARIZATION; LASSO	The personal genomics era has attracted a large amount of attention for anti-cancer therapy by patient-specific analysis. Patient-specific analysis enables discovery of individual genomic characteristics for each patient, and thus we can effectively predict individual genetic risk of disease and perform personalized anti-cancer therapy. Although the existing methods for patient-specific analysis have successfully uncovered crucial biomarkers, their performance takes a sudden turn for the worst in the presence of outliers, since the methods are based on non-robust manners. In practice, clinical and genomic alterations datasets usually contain outliers from various sources (e.g., experiment error, coding error, etc.) and the outliers may significantly affect the result of patient-specific analysis. We propose a robust methodology for patient-specific analysis in line with the NetwrokProfiler. In the proposed method, outliers in high dimensional gene expression levels and drug response datasets are simultaneously controlled by robust Mahalanobis distance in robust principal component space. Thus, we can effectively perform for predicting anti-cancer drug sensitivity and identifying sensitivity-specific biomarkers for individual patients. We observe through Monte Carlo simulations that the proposed robust method produces outstanding performances for predicting response variable in the presence of outliers. We also apply the proposed methodology to the Sanger dataset in order to uncover cancer biomarkers and predict anti-cancer drug sensitivity, and show the effectiveness of our method.	[Park, Heewon; Shimamura, Teppei; Miyano, Satoru; Imoto, Seiya] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo, Japan	University of Tokyo	Park, H (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo, Japan.	hwpark@ims.u-tokyo.ac.jp		Shimamura, Teppei/0000-0003-2994-872X; Miyano, Satoru/0000-0002-1753-6616	RIKEN Advanced Institute for Computational Science through the HPCI System Research project [hp140230]	RIKEN Advanced Institute for Computational Science through the HPCI System Research project	This research used computational resources of the K computer provided by the RIKEN Advanced Institute for Computational Science through the HPCI System Research project (Project ID:hp140230) and the Super Computer System, Human Genome Center, Institute of Medical Science, University of Tokyo. The authors would like to thank the associate editor and anonymous reviewers for the constructive and valuable comments that improved the quality of the paper.	Alfons A, 2013, ANN APPL STAT, V7, P226, DOI 10.1214/12-AOAS575; Chin L, 2011, NAT MED, V17, P297, DOI 10.1038/nm.2323; Efron B, 2004, ANN STAT, V32, P407, DOI 10.1214/009053604000000067; Fan JW, 2008, CANCER-AM CANCER SOC, V113, P266, DOI 10.1002/cncr.23551; Filzmoser P, 2008, COMPUT STAT DATA AN, V52, P1694, DOI 10.1016/j.csda.2007.05.018; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Fujimoto K, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-159; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gu X, 2013, CONTEMP CLIN TRIALS, V36, P642, DOI 10.1016/j.cct.2013.09.009; Helleman J, 2008, CLIN CANC RES, V19; HOERL AE, 1970, TECHNOMETRICS, V12, P55, DOI 10.1080/00401706.1970.10488634; Hubert M, 2005, TECHNOMETRICS, V47, P64, DOI 10.1198/004017004000000563; Jacob L., 2009, P 26 ANN INT C MACH, P433; Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431; Korkola JE, 2009, J CLIN ONCOL, V27, P5240, DOI 10.1200/JCO.2008.20.0386; Kristiansen G, 2003, CLIN CANCER RES, V9, P4906; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Li XX, 2014, COMPUT STAT DATA AN, V79, P203, DOI 10.1016/j.csda.2014.05.017; Liang Y, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-198; Loss LA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-305; Ma SG, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-60; McCleland ML, 2012, CANCER RES, V72, P5812, DOI 10.1158/0008-5472.CAN-12-1098; Meeh PF, 2009, NEOPLASIA, V11, P1074, DOI 10.1593/neo.09808; Park H, 2014, COMMUN STAT IN PRESS; Peralta B, 2014, INFORM SCIENCES, V269, P176, DOI 10.1016/j.ins.2014.01.008; Shimamura T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020804; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Wang Lily, 2012, J Biom Biostat, VSuppl 8, P7313; Wu M, 2011, BMC GENOMICS, V12; Xue L, 2012, J MACH LEARN RES, V13, P1973; Yamada M, 2014, NEURAL COMPUT, V26, P185, DOI 10.1162/NECO_a_00537; Yin H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024080; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x; Zou H, 2009, ANN STAT, V37, P1733, DOI 10.1214/08-AOS625	35	4	4	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2014	9	10							e108990	10.1371/journal.pone.0108990	http://dx.doi.org/10.1371/journal.pone.0108990			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8TF	25329067	Green Submitted, Green Published, gold			2023-01-03	WOS:000345204100007
J	Huang, NY; Chen, JH; Fan, L; Zhou, Q; Xu, QD; Xu, RC; Xiong, LP; Yu, XQ; Mao, HP				Huang, Naya; Chen, Jiehui; Fan, Li; Zhou, Qian; Xu, Qingdong; Xu, Ricong; Xiong, Liping; Yu, Xueqing; Mao, Haiping			High Peritoneal Transport Status Was Not Associated with Mortality in Peritoneal Dialysis Patients with Diabetes	PLOS ONE			English	Article							INDEPENDENT RISK-FACTOR; MEMBRANE-TRANSPORT; TECHNIQUE FAILURE; NUTRITIONAL-STATUS; PREDICTS SURVIVAL; DISEASE; PERMEABILITY; REMOVAL; IMPACT; COHORT	Background: Continuous ambulatory peritoneal dialysis (CAPD) patients with diabetes are at increased risk of mortality and high peritoneal transporters appear to contribute to poor survival. However, little is known about the combined impacts of high peritoneal transporters and diabetes on mortality. Methods: This was a prospective observational cohort study. 776 incident CAPD patients were enrolled. Unadjusted and adjusted Cox proportional regression models were used to evaluate the association and interaction of peritoneal transport and diabetic status with mortality. Results: In the entire cohort, high peritoneal transport status was associated with an increased risk of all-cause mortality in unadjusted model [hazard ratio (HR) 2.35, 95% confidence interval (CI) 1.30 to 4.25, P = 0.01], but this association was not significant in multivariable model. There was an interaction between peritoneal membrane transport status and diabetes (P = 0.028). Subgroup analyses showed that compared to low and low average transporters, high transporters was associated with a higher risk of all-cause mortality (adjusted HR 1.78, 95% CI 1.07 to 4.70, P = 0.04) in CAPD patients without diabetes, but not in those with diabetes (adjusted HR 0.79, 95% CI 0.33 to 1.89, P = 0.59). Results were similar when transport status was assessed as a continuous variable. Conclusions: The association between high peritoneal transport and all-cause mortality was likely to vary with diabetes status. High peritoneal transport was associated with an elevated risk of death among CAPD patients without diabetes, but not in those with diabetes.	[Huang, Naya; Chen, Jiehui; Fan, Li; Xu, Qingdong; Xu, Ricong; Xiong, Liping; Yu, Xueqing; Mao, Haiping] Sun Yat Sen Univ, Dept Nephrol, Affiliated Hosp 1, Key Lab Nephrol,Minist Hlth China,Guangdong Prov, Guangzhou 510275, Guangdong, Peoples R China; [Chen, Jiehui] Sixth Peoples Hosp Shenzhen, Dept Nephrol, Shenzhen, Guangdong, Peoples R China; [Zhou, Qian] Sun Yat Sen Univ, Affiliated Hosp 1, Translat Med Res Ctr, Epidemiol Res Unit, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Mao, HP (corresponding author), Sun Yat Sen Univ, Dept Nephrol, Affiliated Hosp 1, Key Lab Nephrol,Minist Hlth China,Guangdong Prov, Guangzhou 510275, Guangdong, Peoples R China.	haipingmao@126.com		Qian, Zhou/0000-0003-3954-5449; Mao, Haiping/0000-0002-3608-3851	National Key Technology Research and Development Program of the Ministry of Science and Technology of China [2011BAI10B05]; National Basic Research Program of China [2012CB517700-2012CB517706]; Guangzhou Committee of Science and Technology, China [2010U1-E00831]; Sun Yat-sen University [2007007]	National Key Technology Research and Development Program of the Ministry of Science and Technology of China(National Key Technology R&D Program); National Basic Research Program of China(National Basic Research Program of China); Guangzhou Committee of Science and Technology, China; Sun Yat-sen University	This work was supported by the National Key Technology Research and Development Program of the Ministry of Science and Technology of China (2011BAI10B05), the National Basic Research Program of China (2012CB517700-2012CB517706), the Guangzhou Committee of Science and Technology, China (2010U1-E00831), and 5010 Clinical Program of Sun Yat-sen University (2007007). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brimble KS, 2006, J AM SOC NEPHROL, V17, P2591, DOI 10.1681/ASN.2006030194; Brown EA, 2003, J AM SOC NEPHROL, V14, P2948, DOI 10.1097/01.ASN.0000092146.67909.E2; Chang TI, 2010, J KOREAN MED SCI, V25, P1313, DOI 10.3346/jkms.2010.25.9.1313; Chung SH, 2003, PERITON DIALYSIS INT, V23, P174; Churchill DN, 1998, J AM SOC NEPHROL, V9, P1285; Cueto-Manzano AM, 2000, KIDNEY INT, V57, P314, DOI 10.1046/j.1523-1755.2000.00817.x; Davies SJ, 1998, NEPHROL DIAL TRANSPL, V13, P962, DOI 10.1093/ndt/13.4.962; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Honda K, 2008, CLIN J AM SOC NEPHRO, V3, P720, DOI 10.2215/CJN.03630807; Johnson DW, 2010, NEPHROL DIAL TRANSPL, V25, P1973, DOI 10.1093/ndt/gfp780; Ma Seung Hyun, 2012, J Prev Med Public Health, V45, P394, DOI 10.3961/jpmph.2012.45.6.394; Magliano DJ, 2010, DIABETES CARE, V33, P1983, DOI 10.2337/dc10-0312; Margetts PJ, 2000, PERITON DIALYSIS INT, V20, P14; Morgan CL, 2000, DIABETES CARE, V23, P1103, DOI 10.2337/diacare.23.8.1103; Paniagua R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1351307; Parfrey PS, 1999, J AM SOC NEPHROL, V10, P1606; Park HC, 2001, PERITON DIALYSIS INT, V21, pS80; Perl J, 2009, CLIN J AM SOC NEPHRO, V4, P1201, DOI 10.2215/CJN.01910309; Rumpsfeld M, 2006, J AM SOC NEPHROL, V17, P271, DOI 10.1681/ASN.2005050566; Szeto CC, 2001, AM J KIDNEY DIS, V37, P329, DOI 10.1053/ajkd.2001.21298; Tobias D, 2014, NEW ENGL J MED, V370, P1363, DOI 10.1056/NEJMc1401876; TURNER RC, 1991, DIABETOLOGIA, V34, P877; TWARDOWSKI ZJ, 1987, PERITON DIALYSIS INT, V7, P138; Wang T, 1998, NEPHROL DIAL TRANSPL, V13, P1242, DOI 10.1093/ndt/13.5.1242; Xu R, 2013, PLOS ONE IN PRESS, V8; Yang X, 2008, PERITON DIALYSIS INT, V28, P82; Yang X, 2013, DIABETES RES CLIN PR, V100, P354, DOI 10.1016/j.diabres.2013.03.030; Zitt E, 2011, CLIN J AM SOC NEPHRO, V6, P2650, DOI 10.2215/CJN.03780411	28	4	7	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2014	9	10							e110445	10.1371/journal.pone.0110445	http://dx.doi.org/10.1371/journal.pone.0110445			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ9XC	25329459	gold, Green Published, Green Submitted			2023-01-03	WOS:000343210800088
J	Tao, CJ; Lin, L; Zhou, GQ; Tang, LL; Chen, L; Mao, YP; Zeng, MS; Kang, TB; Jia, WH; Shao, JY; Mai, HQ; Lin, AH; Ma, J; Sun, Y				Tao, Chang-Juan; Lin, Li; Zhou, Guan-Qun; Tang, Ling-Long; Chen, Lei; Mao, Yan-Ping; Zeng, Mu-Sheng; Kang, Tie-Bang; Jia, Wei-Hua; Shao, Jian-Yong; Mai, Hai-Qiang; Lin, Ai-Hua; Ma, Jun; Sun, Ying			Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma	PLOS ONE			English	Article							ADJUVANT CHEMOTHERAPY; PHASE-III; RANDOMIZED-TRIAL; CHEMORADIOTHERAPY; CANCER; METAANALYSIS	Background: We aimed to compare the long-term survival outcomes and acute toxicity of cisplatin administered weekly versus every three weeks concurrently with intensity-modulated radiotherapy (IMRT) in patients with nasopharyngeal carcinoma (NPC). Methods: This was a retrospective review of 154 patients with histologically proven, non-disseminated NPC who were treated using IMRT between January 2003 and December 2007. Seventy-three patients (47.4%) received 5-7 weeks of 30-40 mg/m(2) cisplatin weekly; 81 patients (52.6%) received two or three cycles of 80 mg/m(2) cisplatin every three weeks. IMRT was delivered at 68 Gy/30 fractions to the nasopharyngeal gross target volume and 60-66 Gy to the involved neck area. Results: The clinical characteristics and treatment factors of the two groups were well-balanced. The median follow-up was 74 months (range, 6-123 months), and the 5-year overall survival, disease-free survival, locoregional relapse-free survival, and distant metastasis-free survival rates were 85.2% vs. 78.9% (P = 0.318), 71.6% vs. 71.0% (P = 0.847), 93.5% vs. 92.6% (P = 0.904), and 80.9% vs. 80.1% (P = 0.925) for the group treated every three weeks and weekly, respectively. Subgroup analyses indicated no significant differences in the survival rates of the two groups among patients with early-or advanced-stage disease. The incidence of acute toxicities was similar between groups. Conclusion: IMRT with concurrent cisplatin administered weekly or every three weeks leads to similar long-term survival outcomes and acute toxicity in NPC regardless of whether patients have early- or advanced-stage disease.	[Tao, Chang-Juan; Lin, Li; Zhou, Guan-Qun; Tang, Ling-Long; Chen, Lei; Mao, Yan-Ping; Ma, Jun; Sun, Ying] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Dept Radiat Oncol, Guangzhou 510275, Guangdong, Peoples R China; [Tao, Chang-Juan] Zhejiang Canc Hosp, Dept Radiat Oncol, Hangzhou, Zhejiang, Peoples R China; [Zeng, Mu-Sheng; Kang, Tie-Bang; Jia, Wei-Hua] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Dept Expt Res, Guangzhou 510275, Guangdong, Peoples R China; [Shao, Jian-Yong] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Dept Pathol, Guangzhou 510275, Guangdong, Peoples R China; [Mai, Hai-Qiang] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Dept Nasopharynge, Guangzhou 510275, Guangdong, Peoples R China; [Lin, Ai-Hua] Sun Yat Sen Univ, Sch Publ Hlth, Dept Med Stat & Epidemiol, Guangzhou 510275, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Zhejiang Cancer Hospital; State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University	Sun, Y (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Dept Radiat Oncol, Guangzhou 510275, Guangdong, Peoples R China.	sunying@sysucc.org.cn			National Natural Science Foundation of China [8172409]; Sun Yat-Sen University Clinical Research 5010 Program [2012011]; Natural Science Foundation of Guangdong Province [S2013010012220]; Science and Technology project of Guangzhou City, China [132000507]; Health & Medical Collaborative Innovation Project of Guangzhou City, China [201400000001]; National Science & Technology Pillar Program during the Twelfth Five-year Plan Period [2014BAI09B10]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sun Yat-Sen University Clinical Research 5010 Program; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Science and Technology project of Guangzhou City, China; Health & Medical Collaborative Innovation Project of Guangzhou City, China; National Science & Technology Pillar Program during the Twelfth Five-year Plan Period	This work was supported by grants from the National Natural Science Foundation of China (No. 8172409), the Sun Yat-Sen University Clinical Research 5010 Program (No. 2012011), the Natural Science Foundation of Guangdong Province (No. S2013010012220), the Science and Technology project of Guangzhou City, China (No. 132000507), the Health & Medical Collaborative Innovation Project of Guangzhou City, China (201400000001), and the National Science & Technology Pillar Program during the Twelfth Five-year Plan Period (2014BAI09B10). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; Baujat B, 2006, INT J RADIAT ONCOL, V64, P47, DOI 10.1016/j.ijrobp.2005.06.037; Chan ATC, 2005, J NATL CANCER I, V97, P536, DOI 10.1093/jnci/dji084; Chen L, 2012, RADIOTHER ONCOL, V104, P331, DOI 10.1016/j.radonc.2011.10.009; Chen L, 2012, LANCET ONCOL, V13, P163, DOI 10.1016/S1470-2045(11)70320-5; Chen QY, 2011, JNCI-J NATL CANCER I, V103, P1761, DOI 10.1093/jnci/djr432; Chen Y, 2013, CANCER-AM CANCER SOC, V119, P2230, DOI 10.1002/cncr.28049; COX DR, 1972, J R STAT SOC B, V34, P187; Edge SB., 2009, AM JOINT COMMITTEE C; Ho KF, 2008, ACTA ONCOL, V47, P1513, DOI 10.1080/02841860701846160; Jagdis A, 2012, AM J CLIN ONCOL 1029, P29; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lee AWM, 2012, J RADIOL ONCOL, V1, P107, DOI 10.1007/s13566-012-0032-0; Lee AWM, 2010, JNCI-J NATL CANCER I, V102, P1188, DOI 10.1093/jnci/djq258; Lee AWM, 2005, J CLIN ONCOL, V23, P6966, DOI 10.1200/JCO.2004.00.7542; Liang SB, 2009, INT J RADIAT ONCOL, V75, P742, DOI 10.1016/j.ijrobp.2008.11.053; Lin JC, 2003, J CLIN ONCOL, V21, P631, DOI 10.1200/JCO.2003.06.158; Loong HH, 2012, RADIOTHER ONCOL, V104, P300, DOI 10.1016/j.radonc.2011.12.022; OuYang PY, 2013, ANN ONCOL, V24, P2136, DOI 10.1093/annonc/mdt146; Peng G, 2012, RADIOTHER ONCOL, V104, P286, DOI 10.1016/j.radonc.2012.08.013; Zhao Chong, 2004, Ai Zheng, V23, P1532	22	27	30	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2014	9	10							e110765	10.1371/journal.pone.0110765	http://dx.doi.org/10.1371/journal.pone.0110765			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ9XC	25329593	gold, Green Published			2023-01-03	WOS:000343210800110
J	Ofri, D				Ofri, Danielle			The Little Things	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Ofri, Danielle] NYU, Sch Med, New York, NY 10012 USA; [Ofri, Danielle] Bellevue Hosp, New York, NY USA	New York University; Bellevue Hospital Center	Ofri, D (corresponding author), NYU, Sch Med, New York, NY 10012 USA.			Ofri, Danielle/0000-0001-9865-7104					0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 9	2014	371	15					1378	1379		10.1056/NEJMp1408761	http://dx.doi.org/10.1056/NEJMp1408761			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AQ3FJ	25295499				2023-01-03	WOS:000342674800006
J	Zhang, ZH; Huang, Y; Xie, H; Pan, JX; Liu, FF; Li, XZ; Chen, WS; Hu, JY; Liu, ZG				Zhang, Zhenhao; Huang, Yue; Xie, Hui; Pan, Juxin; Liu, Fanfei; Li, Xuezhi; Chen, Wensheng; Hu, Jiaoyue; Liu, Zuguo			Benzalkonium Chloride Suppresses Rabbit Corneal Endothelium Intercellular Gap Junction Communication	PLOS ONE			English	Article							CONNEXIN43 PHOSPHORYLATION; DOWN-REGULATION; CELLS; PROTEIN; ZO-1; OCCLUDENS-1; INHIBITION; TRANSITION; EXPRESSION; EPITHELIUM	Purpose: Gap junction intercellular communication (GJIC) plays a critical role in the maintenance of corneal endothelium homeostasis. We determined if benzalkonium chloride (BAK) alters GJIC activity in the rabbit corneal endothelium since it is commonly used as a drug preservative in ocular eyedrop preparations even though it can have cytotoxic effects. Methods: Thirty-six adult New Zealand albino rabbits were randomly divided into three groups. BAK at 0.01%, 0.05%, and 0.1% was applied twice daily to one eye of each of the rabbits in one of the three groups for seven days. The contralateral untreated eyes were used as controls. Corneal endothelial morphological features were observed by in vivo confocal microscopy (IVCM). Immunofluorescent staining resolved changes in gap junction integrity and localization. Western blot analysis and RT-PCR evaluated changes in levels of connexin43 (Cx43) and tight junction zonula occludens-1 (ZO-1) gene and protein expression, respectively. Cx43 and ZO-1 physical interaction was detected by immunoprecipitation (IP). Primary rabbit corneal endothelial cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) containing BAK for 24 hours. The scrape-loading dye transfer technique (SLDT) was used to assess GJIC activity. Results: Topical administration of BAK (0.05%, 0.1%) dose dependently disrupted corneal endothelial cell morphology, altered Cx43 and ZO-1 distribution and reduced Cx43 expression. BAK also markedly induced increases in Cx43 phosphorylation status concomitant with decreases in the Cx43-ZO-1 protein-protein interaction. These changes were associated with marked declines in GJIC activity. Conclusions: The dose dependent declines in rabbit corneal endothelial GJIC activity induced by BAK are associated with less Cx43-ZO-1 interaction possibly arising from increases in Cx43 phosphorylation and declines in its protein expression. These novel changes provide additional evidence that BAK containing eyedrop preparations should be used with caution to avoid declines in corneal transparency resulting from losses in GJIC activity and endothelial function.	[Zhang, Zhenhao; Xie, Hui; Pan, Juxin; Liu, Fanfei; Li, Xuezhi; Chen, Wensheng; Hu, Jiaoyue; Liu, Zuguo] Xiamen Univ, Inst Eye, Xiamen, Fujian, Peoples R China; [Zhang, Zhenhao; Xie, Hui; Pan, Juxin; Liu, Fanfei; Li, Xuezhi; Chen, Wensheng; Hu, Jiaoyue; Liu, Zuguo] Xiamen Univ, Affiliated Xiamen Eye Ctr, Xiamen, Fujian, Peoples R China; [Zhang, Zhenhao; Xie, Hui; Pan, Juxin; Liu, Fanfei; Li, Xuezhi; Chen, Wensheng; Hu, Jiaoyue; Liu, Zuguo] Xiamen Univ, Fujian Prov Key Lab Ophthalmol & Vis Sci, Xiamen, Fujian, Peoples R China; [Huang, Yue] Xiamen Univ, Coll Med, Inst Stem Cell & Regenerat Med, Xiamen, Fujian, Peoples R China	Xiamen University; Xiamen University; Xiamen University; Xiamen University	Hu, JY (corresponding author), Xiamen Univ, Inst Eye, Xiamen, Fujian, Peoples R China.	mydear_22000@163.com; zuguoliu@xmu.edu.cn	Huang, Yue/ABD-7847-2021		National Natural Science Foundation of China, Beijing, China [81100638, 81270978]; Key Program of National Natural Science of China, Beijing, China [81330022]; Cross-Straits Science Foundation, Beijing, China [U1205025]	National Natural Science Foundation of China, Beijing, China(National Natural Science Foundation of China (NSFC)); Key Program of National Natural Science of China, Beijing, China; Cross-Straits Science Foundation, Beijing, China	This work was supported by National Natural Science Foundation of China, Beijing, China (81100638, 81270978); Key Program of National Natural Science of China, Beijing, China (81330022) and Cross-Straits Science Foundation, Beijing, China (U1205025). The funders had no role in study design, data collection and analysis, decision on publish, or preparation of the manuscript.	Alves LA, 1996, BLOOD, V88, P328; Baudouin C, 2010, PROG RETIN EYE RES, V29, P312, DOI 10.1016/j.preteyeres.2010.03.001; Bourne WM, 2010, EYE CONTACT LENS, V36, P310, DOI 10.1097/ICL.0b013e3181ee1450; BOURNE WM, 1976, AM J OPHTHALMOL, V81, P482, DOI 10.1016/0002-9394(76)90305-6; Bourne WM, 2004, EXP EYE RES, V78, P561, DOI 10.1016/j.exer.2003.08.002; Bourne WM, 2003, EYE, V17, P912, DOI 10.1038/sj.eye.6700559; Bourne WM, 1997, INVEST OPHTH VIS SCI, V38, P779; BOURNE WM, 1976, AM J OPHTHALMOL, V82, P44, DOI 10.1016/0002-9394(76)90662-0; Chen J, 2008, EMBO J, V27, P2113, DOI 10.1038/emboj.2008.138; Chen WS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026103; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Gilleron J, 2008, J CELL SCI, V121, P4069, DOI 10.1242/jcs.033373; Gomes P, 2006, EXP EYE RES, V83, P1225, DOI 10.1016/j.exer.2006.06.012; Gong XH, 1997, CELL, V91, P833, DOI 10.1016/S0092-8674(00)80471-7; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Gros DB, 1996, BIOESSAYS, V18, P719, DOI 10.1002/bies.950180907; Grupcheva CN, 2012, INVEST OPHTH VIS SCI, V53, P1130, DOI 10.1167/iovs.11-8711; Joyce NC, 2003, PROG RETIN EYE RES, V22, P359, DOI 10.1016/S1350-9462(02)00065-4; Joyce NC, 1998, INVEST OPHTH VIS SCI, V39, P2572; Kimura K, 2010, INVEST OPHTH VIS SCI, V51, P1943, DOI 10.1167/iovs.09-3573; LAING RA, 1976, AM J OPHTHALMOL, V82, P459, DOI 10.1016/0002-9394(76)90495-5; Laird DW, 2005, BBA-BIOMEMBRANES, V1711, P172, DOI 10.1016/j.bbamem.2004.09.009; LAIRD DW, 1991, BIOCHEM J, V273, P67, DOI 10.1042/bj2730067; LAIRD DW, 1995, J CELL BIOL, V131, P1193, DOI 10.1083/jcb.131.5.1193; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; LOEWENSTEIN WR, 1966, NATURE, V209, P1248, DOI 10.1038/2091248a0; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; Miura T, 2004, AM J PHYSIOL-HEART C, V286, pH214, DOI 10.1152/ajpheart.00441.2003; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; Nakano Y, 2008, INVEST OPHTH VIS SCI, V49, P93, DOI 10.1167/iovs.07-0255; Oyamada M, 2005, BBA-BIOMEMBRANES, V1719, P6, DOI 10.1016/j.bbamem.2005.11.002; Rhett JM, 2011, MOL BIOL CELL, V22, P1516, DOI 10.1091/mbc.E10-06-0548; Richard G, 2005, CLIN DERMATOL, V23, P23, DOI 10.1016/j.clindermatol.2004.09.010; Rivedal E, 2001, CARCINOGENESIS, V22, P1543, DOI 10.1093/carcin/22.9.1543; Roh DS, 2011, INVEST OPHTH VIS SCI, V52, P5174, DOI 10.1167/iovs.11-7272; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; Solan JL, 2005, BBA-BIOMEMBRANES, V1711, P154, DOI 10.1016/j.bbamem.2004.09.013; Solan JL, 2009, BIOCHEM J, V419, P261, DOI 10.1042/BJ20082319; Sumide T, 2003, J BIOMED MATER RES B, V64B, P57, DOI 10.1002/jbm.b.10510; Tien T, 2013, INVEST OPHTH VIS SCI, V54, P6518, DOI 10.1167/iovs.13-11763; Warn-Cramer BJ, 2004, BBA-BIOMEMBRANES, V1662, P81, DOI 10.1016/j.bbamem.2003.10.018; Williams KK, 2004, CURR EYE RES, V28, P109, DOI 10.1076/ceyr.28.2.109.26234; Williams KK, 2002, CURR EYE RES, V25, P29	44	5	5	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2014	9	10							e109708	10.1371/journal.pone.0109708	http://dx.doi.org/10.1371/journal.pone.0109708			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0AP	25299343	Green Published, gold, Green Submitted			2023-01-03	WOS:000343941200069
J	Tsai, YC; Chiu, YW; Tsai, JC; Kuo, HT; Lee, SC; Hung, CC; Lin, MY; Hwang, SJ; Kuo, MC; Chen, HC				Tsai, Yi-Chun; Chiu, Yi-Wen; Tsai, Jer-Chia; Kuo, Hung-Tien; Lee, Su-Chu; Hung, Chi-Chih; Lin, Ming-Yen; Hwang, Shang-Jyh; Kuo, Mei-Chuan; Chen, Hung-Chun			Association of Angiopoietin-2 with Renal Outcome in Chronic Kidney Disease	PLOS ONE			English	Article							EXCESS CIRCULATING ANGIOPOIETIN-2; GROWTH-FACTOR LEVELS; RECEPTOR TIE-2; PLASMA ANGIOPOIETIN-1; DIABETES-MELLITUS; EXPRESSION; ANGIOGENESIS; HYPERTENSION; PROTEINURIA; MORTALITY	Background: The pathophysiological mechanisms of renal function progression in chronic kidney disease (CKD) have still not been completely explored. In addition to well-known traditional risk factors, non-traditional risk factors, such as endothelial dysfunction, have gradually attracted physicians' attention. Angiopoietin-2 (Ang-2) impairs endothelial function through preventing angiopoietin-1 from binding to Tie2 receptor. Whether Ang-2 is associated with renal function progression in CKD is unknown. Methods: This study enrolled 621 patients with stages 3-5 CKD to assess the association of circulating Ang-2 with commencing dialysis, doubling creatinine and rapid decline in renal function (the slope of estimated glomerular filtration rate (eGFR) greater than 5 ml/min per 1.73 m(2)/y) over follow-up of more than 3 years. Results: Of all patients, 224 patients (36.1%) progressed to commencing dialysis and 165 (26.6%) reached doubling creatinine. 85 subjects (13.9%) had rapid decline in renal function. Ang-2 quartile was divided at 1494.1, 1948.8, and 2593.1 pg/ml. The adjusted HR of composite outcomes, either commencing dialysis or doubling creatinine was 1.53 (95% CI: 1.06-2.23) for subjects of quartile 4 compared with those of quartile 1. The adjusted OR for rapid decline in renal function was 2.96 (95% CI: 1.13-7.76) for subjects of quartile 4 compared with those of quartile 1. The linear mixed-effects model shows a more rapid decrease in eGFR over time in patients with quartile 3 or more of Ang-2 than those with the lowest quartile of Ang-2. Conclusions: Ang-2 is an independent predictor of adverse renal outcome in CKD. Further study is needed to identify the pathogenic role of Ang-2 in CKD progression.	[Tsai, Yi-Chun; Hwang, Shang-Jyh; Kuo, Mei-Chuan] Kaohsiung Med Univ, Grad Inst Clin Med, Kaohsiung, Taiwan; [Tsai, Yi-Chun; Chiu, Yi-Wen; Tsai, Jer-Chia; Kuo, Hung-Tien; Lee, Su-Chu; Hung, Chi-Chih; Hwang, Shang-Jyh; Kuo, Mei-Chuan; Chen, Hung-Chun] Kaohsiung Med Univ Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan; [Tsai, Yi-Chun; Chiu, Yi-Wen; Tsai, Jer-Chia; Kuo, Hung-Tien; Hung, Chi-Chih; Lin, Ming-Yen; Hwang, Shang-Jyh; Kuo, Mei-Chuan; Chen, Hung-Chun] Kaohsiung Med Univ, Coll Med, Fac Renal Care, Kaohsiung, Taiwan; [Hwang, Shang-Jyh] Natl Hlth Res Inst, Inst Populat Sci, Miaoli, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; National Health Research Institutes - Taiwan	Kuo, MC (corresponding author), Kaohsiung Med Univ, Grad Inst Clin Med, Kaohsiung, Taiwan.	mechku@cc.kmu.edu.tw	Lin, Ming Yen/A-8637-2010	Lin, Ming Yen/0000-0002-8194-4833; lee, su-chu/0000-0002-8587-7324; Kuo, Hung-Tien/0000-0002-9931-4354	Kaohsiung Medical University Faculty of Renal Care	Kaohsiung Medical University Faculty of Renal Care	Dr. Tsai's research was supported by the Kaohsiung Medical University Faculty of Renal Care.	Anuradha S, 2010, METABOLISM, V59, P774, DOI 10.1016/j.metabol.2009.09.022; Baylis C, 2012, CURR OPIN NEPHROL HY, V21, P1, DOI 10.1097/MNH.0b013e32834d54ca; Brindle NPJ, 2006, CIRC RES, V98, P1014, DOI 10.1161/01.RES.0000218275.54089.12; Chang FC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054668; Chang FC, 2013, J FORMOS MED ASSOC, V112, P175, DOI 10.1016/j.jfma.2012.07.028; Chen JX, 2012, AM J PHYSIOL-HEART C, V302, pH1003, DOI 10.1152/ajpheart.00866.2011; Chong AY, 2004, J AM COLL CARDIOL, V43, P423, DOI 10.1016/j.jacc.2003.08.042; Cui X, 2011, NEUROBIOL DIS, V43, P285, DOI 10.1016/j.nbd.2011.04.005; David S, 2012, NEPHROL DIAL TRANSPL, V27, P1867, DOI 10.1093/ndt/gfr551; David S, 2010, NEPHROL DIAL TRANSPL, V25, P2571, DOI 10.1093/ndt/gfq060; David S, 2009, AM J KIDNEY DIS, V53, P770, DOI 10.1053/j.ajkd.2008.11.030; Davis B, 2007, J AM SOC NEPHROL, V18, P2320, DOI 10.1681/ASN.2006101093; Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423; Fam NP, 2003, CIRCULATION, V108, P2613, DOI 10.1161/01.CIR.0000102939.04279.75; Fiedler U, 2004, BLOOD, V103, P4150, DOI 10.1182/blood-2003-10-3685; Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351; Fiedler U, 2006, TRENDS IMMUNOL, V27, P552, DOI 10.1016/j.it.2006.10.004; Futrakul N, 2008, CLIN HEMORHEOL MICRO, V38, P201; Huang YQ, 2002, BLOOD, V99, P1646, DOI 10.1182/blood.V99.5.1646; Kielstein JT, 2005, AM J KIDNEY DIS, V46, P186, DOI 10.1053/j.ajkd.2005.05.009; Kumpers P, 2010, INTENS CARE MED, V36, P462, DOI 10.1007/s00134-009-1726-7; Kumpers P, 2008, CRIT CARE, V12, DOI 10.1186/cc7130; Lee KW, 2004, CIRCULATION, V110, P2355, DOI 10.1161/01.CIR.0000138112.90641.7F; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Levin A, 2014, KIDNEY INT, V85, P49, DOI 10.1038/ki.2013.444; Lim HS, 2005, ATHEROSCLEROSIS, V180, P113, DOI 10.1016/j.atherosclerosis.2004.11.004; Nadar SK, 2005, J INTERN MED, V258, P336, DOI 10.1111/j.1365-2796.2005.01550.x; Nugent RA, 2011, NEPHRON CLIN PRACT, V118, pC269, DOI 10.1159/000321382; Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046; Rengo G, 2013, CIRC-HEART FAIL, V6, P1259, DOI 10.1161/CIRCHEARTFAILURE.113.000329; Rondaij MG, 2006, ARTERIOSCL THROM VAS, V26, P1002, DOI 10.1161/01.ATV.0000209501.56852.6c; SERON D, 1990, NEPHROL DIAL TRANSPL, V5, P889, DOI 10.1093/ndt/5.10.889; Shroff RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056273; Shurraw S, 2011, ARCH INTERN MED, V171, P1920, DOI 10.1001/archinternmed.2011.537; Tryggvason K, 2006, NEW ENGL J MED, V354, P1387, DOI 10.1056/NEJMra052131; Tsai YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052775; Wever R, 1999, ARTERIOSCL THROM VAS, V19, P1168, DOI 10.1161/01.ATV.19.5.1168; Woolf AS, 2009, J AM SOC NEPHROL, V20, P239, DOI 10.1681/ASN.2008020243	38	20	20	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2014	9	10							e108862	10.1371/journal.pone.0108862	http://dx.doi.org/10.1371/journal.pone.0108862			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ3DZ	25279852	Green Submitted, Green Published, gold			2023-01-03	WOS:000342670800030
J	Gauld, NJ; Kelly, FS; Kurosawa, N; Bryant, LJM; Emmerton, LM; Buetow, SA				Gauld, Natalie J.; Kelly, Fiona S.; Kurosawa, Nahoko; Bryant, Linda J. M.; Emmerton, Lynne M.; Buetow, Stephen A.			Widening Consumer Access to Medicines through Switching Medicines to Non-Prescription: A Six Country Comparison	PLOS ONE			English	Article							OVER-THE-COUNTER; DRUGS; CARE	Background: Switching or reclassifying medicines with established safety profiles from prescription to non-prescription aims to increase timely consumer access to medicines, reduce under-treatment and enhance self-management. However, risks include suboptimal therapy and adverse effects. With a long-standing government policy supporting switching or reclassifying medicines from prescription to non-prescription, the United Kingdom is believed to lead the world in switch, but evidence for this is inconclusive. Interest in switching medicines for certain long-term conditions has arisen in the United Kingdom, United States, and Europe, but such switches have been contentious. The objective of this study was then to provide a comprehensive comparison of progress in switch for medicines across six developed countries: the United States; the United Kingdom; Australia; Japan; the Netherlands; and New Zealand. Methods: A list of prescription-to-non-prescription medicine switches was systematically compiled. Three measures were used to compare switch activity across the countries: "progressive" switches from 2003 to 2013 (indicating incremental consumer benefit over current non-prescription medicines); "first-in-world" switches from 2003 to 2013; and switch date comparisons for selected medicines. Results: New Zealand was the most active in progressive switches from 2003 to 2013, with the United Kingdom and Japan not far behind. The United States, Australia and the Netherlands showed the least activity in this period. Few medicines for long-term conditions were switched, even in the United Kingdom and New Zealand where first-in-world switches were most likely. Switch of certain medicines took considerably longer in some countries than others. For example, a consumer in the United Kingdom could self-medicate with a non-sedating antihistamine 19 years earlier than a consumer in the United States. Conclusion: Proactivity in medicines switching, most notably in New Zealand and the United Kingdom, questions missed opportunities to enhance consumers' self-management in countries such as the United States.	[Gauld, Natalie J.; Bryant, Linda J. M.; Buetow, Stephen A.] Univ Auckland, Dept Gen Practice & Primary Hlth Care, Auckland 1, New Zealand; [Kelly, Fiona S.] Univ Auckland, Sch Pharm, Auckland 1, New Zealand; [Kelly, Fiona S.] Griffith Univ, Griffith Hlth Inst, Brisbane, Qld 4111, Australia; [Kurosawa, Nahoko] Hokkaido Pharmaceut Univ, Sch Pharm, Otaru, Hokkaido, Japan; [Emmerton, Lynne M.] Curtin Univ, Fac Hlth Sci, Sch Pharm, Perth, WA 6845, Australia	University of Auckland; University of Auckland; Griffith University; Menzies Health Institute Queensland; Curtin University	Gauld, NJ (corresponding author), Univ Auckland, Dept Gen Practice & Primary Hlth Care, Auckland 1, New Zealand.	n.gauld@auckland.ac.nz	Gauld, Natalie/I-6018-2019	Gauld, Natalie/0000-0003-0366-0357; Buetow, Stephen/0000-0002-9771-248X; Kelly, Fiona/0000-0001-7360-4655				AESGP, 2011, EC LEG FRAM NONPR ME; American Pharmacists Association, 2012, PHARM ADM VACC TYP V; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; [Anonymous], 2004, LANCET, V363, P1659; [Anonymous], 2006, INT J PHARM PRACT; Armstrong ME, 2006, PLAN B CONTRACEPTIVE; Blenkinsopp A, 2005, COUNTER MED; Bowden M, 1993, SCHEDULE 3 MED PRESC; Canfield DV, 2012, AVIAT SPACE ENVIR MD, V83, P764, DOI 10.3357/ASEM.3306.2012; Clark D, 2001, BMJ-BRIT MED J, V323, P706, DOI 10.1136/bmj.323.7315.706; Cohen Joshua, 2003, Am J Ther, V10, P370, DOI 10.1097/00045391-200309000-00010; Committee on Gynecologic Practice, 2012, OBSTET GYNECOL, V120, P1527; Consumer Healthcare Products Association, 2013, INGR DOS TRANSF RX T; Dryden MS, 2009, J ANTIMICROB CHEMOTH, V64, P885, DOI 10.1093/jac/dkp305; Editorial, 2005, LANCET NEUROL, V4, P587; Editorial, 2008, LANCET, V371, P275; Emanuel EJ, 2013, JAMA-J AM MED ASSOC, V310, P374, DOI 10.1001/jama.2013.60073; Gauld N, 2012, SELFCARE, V3, P88; Ghorob A, 2012, NEW ENGL J MED, V366, P1955, DOI 10.1056/NEJMp1202775; HENDELES L, 1984, NEW ENGL J MED, V310, P207, DOI 10.1056/NEJM198401193100326; Juul P, 1991, SWISS PHARM, V13, P100; Kay GG, 2000, J ALLERGY CLIN IMMUN, V105, pS622; Kux L, 2012, FED REGISTER, V77, P12059; Maekawa H, 2012, IYAKU J, V48, P883; Millier A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084088; Pharmaceutical and Medical Devices Agency, 2012, INF APPR ASS OTC MED; Pharmaceuticals and Medical Devices Agency (PMDA), 2007, EX REP APPR; Proprietary Association of Great Britain, 2002, POT CAND RECL POM P; Proprietary Association of Great Britain (PAGB), 2012, POM P SWITCH; Raine J, 2008, BMJ; Roussin A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076499; Sasaki K, 2003, SCHEDULE 3 MED PRESC, V8; Sihvo S, 1999, MED CARE, V37, P518, DOI 10.1097/00005650-199905000-00011; TAYLOR CA, 1994, J FAM PRACTICE, V38, P157; TEMIN P, 1992, J LAW ECON, V35, P351, DOI 10.1086/467258; The Royal Pharmaceutical Society of Great Britain, 2008, RPS E PIC REF PRESCR; Tinetti ME, 2008, NEW ENGL J MED, V358, P2728, DOI 10.1056/NEJMsb0801202; United Nations Development Programme, 2010, HUM DEV REP; United States Government Accountability Office, 2009, NONPR DRUGS CONS REG; World Self-Medication Industries, 2009, SWITCH PRESCR NONPR	40	33	33	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2014	9	9							e107726	10.1371/journal.pone.0107726	http://dx.doi.org/10.1371/journal.pone.0107726			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ0SJ	25251434	gold, Green Published, Green Submitted			2023-01-03	WOS:000342492700042
J	Bakal, JA; McAlister, FA; Liu, W; Ezekowitz, JA				Bakal, Jeffrey A.; McAlister, Finlay A.; Liu, Wei; Ezekowitz, Justin A.			Heart Failure Re-Admission: Measuring the Ever Shortening Gap between Repeat Heart Failure Hospitalizations	PLOS ONE			English	Article							COMORBIDITIES; READMISSION; DIAGNOSIS; OUTCOMES	Many quality-of-care and risk prediction metrics rely on time to first rehospitalization even though heart failure (HF) patients may undergo several repeat hospitalizations. The aim of this study is to compare repeat hospitalization models. Using a population-based cohort of 40,667 patients, we examined both HF and all cause re-hospitalizations using up to five years of follow-up. Two models were examined: the gap-time model which estimates the adjusted time between hospitalizations and a multistate model which considered patients to be in one of four states; community-dwelling, in hospital for HF, in hospital for any reason, or dead. The transition probabilities and times were then modeled using patient characteristics and number of repeat hospitalizations. We found that during the five years of follow-up roughly half of the patients returned for a subsequent hospitalization for each repeat hospitalization. Additionally, we noted that the unadjusted time between hospitalizations was reduced similar to 40% between each successive hospitalization. After adjustment each additional hospitalization was associated with a 28 day (95% CI: 22-35) reduction in time spent out of hospital. A similar pattern was seen when considering the four state model. A large proportion of patients had multiple repeat hospitalizations. Extending the gap between hospitalizations should be an important goal of treatment evaluation.	[Bakal, Jeffrey A.; McAlister, Finlay A.] Univ Alberta, Patient Hlth Outcomes Res & Clin Effectiveness Un, Edmonton, AB, Canada; [Bakal, Jeffrey A.; McAlister, Finlay A.] Univ Alberta, Div Gen Internal Med, Edmonton, AB, Canada; [Liu, Wei; Ezekowitz, Justin A.] Univ Alberta, Div Cardiol, Edmonton, AB, Canada	University of Alberta; University of Alberta; University of Alberta	Ezekowitz, JA (corresponding author), Univ Alberta, Div Cardiol, Edmonton, AB, Canada.	jae2@ualberta.ca	Bakal, Jeff/ABE-4051-2021; Ezekowitz, Justin A/C-4579-2013; McAlister, Finlay/C-4151-2013	Ezekowitz, Justin A/0000-0002-2724-4086; Bakal, Jeffrey/0000-0002-3658-2554; McAlister, Finlay/0000-0001-7435-3341				Anker SD, 2012, EUR HEART J, V33, P2764, DOI 10.1093/eurheartj/ehs277; Au AG, 2012, AM HEART J, V164, P365, DOI 10.1016/j.ahj.2012.06.010; Claggett B, 2013, EUR HEART J, V34, P869, DOI 10.1093/eurheartj/ehs485; Clement DY, 2009, BIOSTATISTICS, V10, P451, DOI 10.1093/biostatistics/kxp004; Cuffe MS, 2002, JAMA-J AM MED ASSOC, V287, P1541, DOI 10.1001/jama.287.12.1541; Dunlay SM, 2009, J AM COLL CARDIOL, V54, P1695, DOI 10.1016/j.jacc.2009.08.019; Ezekowitz JA, 2011, EUR J HEART FAIL, V13, P142, DOI 10.1093/eurjhf/hfq185; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; Goff DC, 2000, ARCH INTERN MED, V160, P197, DOI 10.1001/archinte.160.2.197; Hardin J, 2003, GEN ESTIMATING EQUAT, V68, P373; Jackson CH, 2011, J STAT SOFTW, V38, P1; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Kelly PJ, 2000, STAT MED, V19, P13, DOI 10.1002/(SICI)1097-0258(20000115)19:1&lt;13::AID-SIM279&gt;3.0.CO;2-5; Lee DS, 2005, MED CARE, V43, P182, DOI 10.1097/00005650-200502000-00012; McAlister FA, 2013, CIRC-HEART FAIL, V6, P76, DOI 10.1161/CIRCHEARTFAILURE.112.971119; O'Connor C M, 2011, N Engl J Med, V365, P32, DOI 10.1056/NEJMoa1100171; Putter H, 2007, STAT MED, V26, P2389, DOI 10.1002/sim.2712; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Teerlink JR, 2013, LANCET, V381, P29, DOI 10.1016/S0140-6736(12)61855-8; van Walraven C, 2010, CAN MED ASSOC J, V182, P551, DOI 10.1503/cmaj.091117	20	29	29	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2014	9	9							e106494	10.1371/journal.pone.0106494	http://dx.doi.org/10.1371/journal.pone.0106494			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AP1UA	25211034	Green Published, Green Submitted, gold			2023-01-03	WOS:000341855900013
J	Duarte, NDC; Grecco, LAC; Galli, M; Fregni, F; Oliveira, CS				Carvalho Duarte, Natalia de Almeida; Collange Grecco, Luanda Andre; Galli, Manuela; Fregni, Felipe; Oliveira, Claudia Santos			Effect of Transcranial Direct-Current Stimulation Combined with Treadmill Training on Balance and Functional Performance in Children with Cerebral Palsy: A Double-Blind Randomized Controlled Trial	PLOS ONE			English	Article							MAGNETIC STIMULATION; MOTOR CORTEX; CONNECTIVITY; CONCURRENT; GAIT	Background: Cerebral palsy refers to permanent, mutable motor development disorders stemming from a primary brain lesion, causing secondary musculoskeletal problems and limitations in activities of daily living. The aim of the present study was to determine the effects of gait training combined with transcranial direct-current stimulation over the primary motor cortex on balance and functional performance in children with cerebral palsy. Methods: A double-blind randomized controlled study was carried out with 24 children aged five to 12 years with cerebral palsy randomly allocated to two intervention groups (blocks of six and stratified based on GMFCS level (levels I-II or level III). The experimental group (12 children) was submitted to treadmill training and anodal stimulation of the primary motor cortex. The control group (12 children) was submitted to treadmill training and placebo transcranial direct-current stimulation. Training was performed in five weekly sessions for 2 weeks. Evaluations consisted of stabilometric analysis as well as the administration of the Pediatric Balance Scale and Pediatric Evaluation of Disability Inventory one week before the intervention, one week after the completion of the intervention and one month after the completion of the intervention. All patients and two examiners were blinded to the allocation of the children to the different groups. Results: The experimental group exhibited better results in comparison to the control group with regard to anteroposterior sway (eyes open and closed; p<0.05), mediolateral sway (eyes closed; p<0.05) and the Pediatric Balance Scale both one week and one month after the completion of the protocol. Conclusion: Gait training on a treadmill combined with anodal stimulation of the primary motor cortex led to improvements in static balance and functional performance in children with cerebral palsy.	[Carvalho Duarte, Natalia de Almeida; Collange Grecco, Luanda Andre; Oliveira, Claudia Santos] Univ Nove de Julho, Movement Anal Lab, Sao Paulo, Brazil; [Galli, Manuela] Politecn Milan, Dept Elect Informat & Bioengn, Rome, Italy; [Galli, Manuela] IRCCS San Raffaele Pisana, Rome, Italy; [Fregni, Felipe] Harvard Univ, Lab Neuromodulat, Sch Med, Boston, MA USA; [Fregni, Felipe] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Ctr Clin Res Learning,Dept Phys Med & Rehabil, Boston, MA USA; [Fregni, Felipe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA	Universidade Nove de Julho; Polytechnic University of Milan; IRCCS San Raffaele Pisana; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Spaulding Rehabilitation Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Duarte, NDC (corresponding author), Univ Nove de Julho, Movement Anal Lab, Sao Paulo, Brazil.	natycarvalho_fisio@hotmail.com	Duarte, Natália AC/K-5260-2016; Galli, Manuela/AAH-8783-2019; Grecco, Luanda C/N-5075-2015; Oliveira, Claudia/H-2328-2013	Duarte, Natália AC/0000-0003-1486-1330; Oliveira, Claudia/0000-0001-8509-4576; Fregni, Felipe/0000-0001-9359-8643; Galli, Manuela/0000-0003-2772-4837	Brazilian fostering agencies Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Fundacao de Amparo a Pesquisa (FAPESP) [2012/24019-0]	Brazilian fostering agencies Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundacao de Amparo a Pesquisa (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	The authors gratefully acknowledge financial support from the Brazilian fostering agencies Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), and Fundacao de Amparo a Pesquisa (FAPESP - 2012/24019-0). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Burton H, 2009, SOMATOSENS MOT RES, V26, P90, DOI 10.3109/08990220903335742; Chagas PS, 2004, REV BRAS FISIOTER, V8, P155; Grecco LAC, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-168; Grecco LAC, 2013, CLIN REHABIL, V27, P686, DOI 10.1177/0269215513476721; Dinomais M, 2013, RES DEV DISABIL, V34, P1928, DOI 10.1016/j.ridd.2013.03.020; FELDMAN AB, 1990, PHYS THER, V70, P602, DOI 10.1093/ptj/70.10.602; Garvey MA, 2008, CLIN NEUROPHYSIOL, V119, P973, DOI 10.1016/j.clinph.2007.11.048; Grecco LAC, 2013, BRAZ J PHYS THER, V17, P17, DOI 10.1590/S1413-35552012005000066; Haley SM., 1991, PEDIATR PHYS THER, V3, P177; HOMAN RW, 1987, ELECTROEN CLIN NEURO, V66, P376, DOI 10.1016/0013-4694(87)90206-9; Inder TE, 1999, ANN NEUROL, V46, P755, DOI 10.1002/1531-8249(199911)46:5<755::AID-ANA11>3.0.CO;2-0; Kaski D, 2012, J NEUROPHYSIOL, V107, P2493, DOI 10.1152/jn.00223.2011; Kaski D, 2013, NEUROREHAB NEURAL RE, V27, P864, DOI 10.1177/1545968313496328; Kesar TM, 2012, CLIN NEUROPHYSIOL, V123, P1383, DOI 10.1016/j.clinph.2011.11.005; Kurz MJ, 2011, NEUROSCI LETT, V490, P1, DOI 10.1016/j.neulet.2010.11.053; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Marchese R, 2000, MOVEMENT DISORD, V15, P879, DOI 10.1002/1531-8257(200009)15:5<879::AID-MDS1018>3.0.CO;2-9; Mendonca ME, 2012, CONDUTAS PRATICAS FI, P307; Minhas P, 2012, IEEE ENG MED BIO, P859, DOI 10.1109/EMBC.2012.6346067; Miranda PC, 2006, CLIN NEUROPHYSIOL, V117, P1623, DOI 10.1016/j.clinph.2006.04.009; Moher David, 2010, BMJ, V340, pc869, DOI [10.1016/j.jclinepi.2010.03.004, 10.1136/bmj.c869]; Morris M, 2000, GAIT POSTURE, V12, P205, DOI 10.1016/S0966-6362(00)00076-X; Nevalainen P, 2012, DEV MED CHILD NEUROL, V54, P361, DOI 10.1111/j.1469-8749.2011.04165.x; Pitcher JB, 2012, J PHYSIOL-LONDON, V590, P5827, DOI 10.1113/jphysiol.2012.239269; Ries LGK, 2012, BRAZ J PHYS THER, V16, P205, DOI 10.1590/S1413-35552012005000026; Rose J, 2002, DEV MED CHILD NEUROL, V44, P58, DOI 10.1017/S0012162201001669; Rose S, 2011, BRAIN CONNECT, V1, P309, DOI 10.1089/brain.2011.0034; Sadeghi H, 2000, GAIT POSTURE, V12, P34, DOI 10.1016/S0966-6362(00)00070-9; Shin YK, 2012, NEUROREHABILITATION, V31, P349, DOI 10.3233/NRE-2012-00803; Stagg Charlotte Jane, 2012, Brain, V135, P276, DOI 10.1093/brain/awr313; Valle AC, 2007, DEV MED CHILD NEUROL, V49, P534, DOI 10.1111/j.1469-8749.2007.00534.x; Wagner T, 2007, NEUROIMAGE, V35, P1113, DOI 10.1016/j.neuroimage.2007.01.027	32	63	65	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2014	9	8							e105777	10.1371/journal.pone.0105777	http://dx.doi.org/10.1371/journal.pone.0105777			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO2EE	25171216	Green Published, Green Submitted, gold			2023-01-03	WOS:000341127500067
J	Towns, AM; Eyi, SM; van Andel, T				Towns, Alexandra M.; Eyi, Sandra Mengue; van Andel, Tinde			Traditional Medicine and Childcare in Western Africa: Mothers' Knowledge, Folk Illnesses, and Patterns of Healthcare-Seeking Behavior	PLOS ONE			English	Article							SICKLE-CELL-DISEASE; SUB-SAHARAN AFRICA; MORTALITY; MALARIA; MANAGEMENT; DIARRHEA	Background: In spite of the strong role of traditional medicine in childcare in the pluralistic healthcare system in Western Africa, little information is known on mothers' domestic plant knowledge. Identifying local perspectives and treatments of children's illnesses, including folk illnesses, is essential to having a comprehensive understanding of how mothers make healthcare treatment decisions. We aimed to identify which infant illnesses Beninese and Gabonese mothers knew to treat with medicinal plants and for which illnesses they sought biomedical care or traditional healers. Methods: We conducted 81 questionnaires with mothers in Benin and Gabon and made 800 botanical specimens of cited medicinal plants. We calculated the number of species cited per illness and the proportion of participants knowledgeable on at least one herbal remedy per illness. Using qualitative data, we described folk illnesses in each country and summarized responses on preferences for each of the three healthcare options. Results: Participants from both countries were most knowledgeable on plants to treat respiratory illnesses, malaria, diarrhea, and intestinal ailments. Mothers also frequently mentioned the use of plants to encourage children to walk early, monitor the closure of fontanels, and apply herbal enemas. Major folk illnesses were atita and ka in Benin and la rate and fesses rouges in Gabon. Traditional healers were reported to have specialized knowledge of cultural bound illnesses. Malaria was frequently cited as an illness for which mothers would directly seek biomedical treatment. Conclusion: Mothers largely saw the three systems as complementary, seamlessly switching between different healing options until a remedy was found. Folk illnesses were found to give insight into local treatments and may reveal important neglected diseases. Due to high reported levels of knowledge on treating top statistical causes of infant mortality and folk illnesses, mothers' medicinal plant knowledge should be included in the analysis of healthcare-seeking behavior for childcare.	[Towns, Alexandra M.; van Andel, Tinde] Leiden Univ, Naturalis Biodivers Ctr, Leiden, Netherlands; [Eyi, Sandra Mengue] Ctr Natl Rech Sci & Technol, Libreville, Gabon	Leiden University; Leiden University - Excl LUMC; Naturalis Biodiversity Center	Towns, AM (corresponding author), Leiden Univ, Naturalis Biodivers Ctr, Leiden, Netherlands.	alexandra.towns@naturalis.nl		Towns, Alexandra/0000-0002-1886-9447	Netherlands Organization for Scientific Research (NWO) [864.09.00]	Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	This research was funded by the Netherlands Organization for Scientific Research (NWO), Vidi grant nr. 864.09.00 (http://www.nwo.nl/en). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bakshi SS, 2013, ACTA TROP, V127, P46, DOI 10.1016/j.actatropica.2013.03.010; Beiersmann C, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-106; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Bland RM, 2004, TROP MED INT HEALTH, V9, P118, DOI 10.1046/j.1365-3156.2003.01148.x; Colvin CJ, 2013, SOC SCI MED, V86, P66, DOI 10.1016/j.socscimed.2013.02.031; DEZOYSA I, 1984, SOC SCI MED, V19, P727, DOI 10.1016/0277-9536(84)90245-4; Etkin NL, 1998, CONTEXT MED DEV COUN, P299; Friend-du Preez N, 2013, SOC SCI MED, V92, P43, DOI 10.1016/j.socscimed.2013.05.014; Geissler PW, 2002, J ETHNOPHARMACOL, V83, P39, DOI 10.1016/S0378-8741(02)00191-5; Gottlieb A, 2004, AFTERLIFE IS WE COME, P1; GREEN EC, 1985, SOC SCI MED, V20, P277, DOI 10.1016/0277-9536(85)90242-4; Grosse SD, 2011, AM J PREV MED, V41, pS398, DOI 10.1016/j.amepre.2011.09.013; Helman CG, 2007, CULTURE HLTH ILLNESS, P266; Kay M A, 1993, Med Anthropol, V15, P137; Kiesler J, 2003, AM FAM PHYSICIAN, V67, P2547; Langwick SA, 2008, AM ETHNOL, V35, P428, DOI 10.1111/j.1548-1425.2008.00044.x; Makani J, 2007, ANN TROP MED PARASIT, V101, P3, DOI 10.1179/136485907X154638; Martin, 2004, ETHNOBOTANY METHODS; Mathez-Stiefel SL, 2012, J ETHNOBIOL ETHNOMED, V8, DOI 10.1186/1746-4269-8-26; McDade TW, 2007, P NATL ACAD SCI USA, V104, P6134, DOI 10.1073/pnas.0609123104; Meier ER, 2012, DRUGS, V72, P895, DOI 10.2165/11632890-000000000-00000; Miller EM, 2011, SOC SCI MED, V73, P1266, DOI 10.1016/j.socscimed.2011.07.009; Mogensen HO, 2000, CULT MED PSYCHIAT, V24, P331, DOI 10.1023/A:1005615619241; Montgomery CM, 2006, TROP MED INT HEALTH, V11, P1661, DOI 10.1111/j.1365-3156.2006.01719.x; Nsungwa-Sabiiti J, 2004, TROP MED INT HEALTH, V9, P1191, DOI 10.1111/j.1365-3156.2004.01319.x; Nyamongo IK, 2002, SOC SCI MED, V54, P377, DOI 10.1016/S0277-9536(01)00036-3; Pearce TO, 1993, KNOWLEDGE POWER PRAC, P150; Pfeiffer Jeanine M., 2005, Journal of Ethnobiology, V25, P240, DOI 10.2993/0278-0771(2005)25[240:ACAEVI]2.0.CO;2; Quinlan MB, 2010, J ETHNOBIOL ETHNOMED, V6, DOI 10.1186/1746-4269-6-9; Reyes-Garcia V, 2010, J ETHNOBIOL ETHNOMED, V6, DOI 10.1186/1746-4269-6-32; Rutherford ME, 2010, TROP MED INT HEALTH, V15, P508, DOI 10.1111/j.1365-3156.2010.02497.x; Ryan GW, 1998, SOC SCI MED, V46, P209, DOI 10.1016/S0277-9536(97)00151-2; Straus L, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-556; Tanner S, 2011, SOC SCI MED, V72, P701, DOI 10.1016/j.socscimed.2010.12.012; Towns AM, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-113; Vandebroek I, 2013, J ETHNOPHARMACOL, V148, P746, DOI 10.1016/j.jep.2013.05.039; vanderGeest S, 1997, TROP MED INT HEALTH, V2, P903, DOI 10.1046/j.1365-3156.1997.d01-410.x; World Health Organization, TRAD MED	38	25	25	0	132	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2014	9	8							e105972	10.1371/journal.pone.0105972	http://dx.doi.org/10.1371/journal.pone.0105972			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AO3LL	25147924	Green Published, gold, Green Submitted			2023-01-03	WOS:000341230600102
J	Andrews, PW; Cavagnaro, J; Deans, R; Feigal, E; Horowitz, E; Keating, A; Rao, M; Turner, M; Wilmut, I; Yamanaka, S				Andrews, Peter W.; Cavagnaro, Joy; Deans, Robert; Feigal, Ellen; Horowitz, Ed; Keating, Armand; Rao, Mahendra; Turner, Marc; Wilmut, Ian; Yamanaka, Shinya			Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells	NATURE BIOTECHNOLOGY			English	Letter							CELLULAR THERAPY; INFORMED-CONSENT		[Andrews, Peter W.] Univ Sheffield, Dept Biomed Sci, Ctr Stem Cell Biol, Western Bank, Sheffield S10 2TN, S Yorkshire, England; [Andrews, Peter W.] Int Stem Cell Initiat, Harbor, ME USA; [Cavagnaro, Joy] Access BIO, Boyce, VA USA; [Deans, Robert] Alliance Regenerat Med Athersys, Cleveland, OH USA; [Feigal, Ellen] Calif Inst Regenerat Med, San Francisco, CA USA; [Horowitz, Ed] Int Soc Cell Therapy, Vancouver, BC, Canada; [Keating, Armand] Univ Toronto, Amer Soc Hematol, Toronto, ON, Canada; [Keating, Armand] Princess Margaret Canc Ctr, Toronto, ON, Canada; [Rao, Mahendra] NIH, Ctr Regenerat Med, Bethesda, MD 20892 USA; [Turner, Marc] Scottish Natl Blood Transfus Serv Headquarters, Edinburgh, Midlothian, Scotland; [Wilmut, Ian] Univ Edinburgh, Scottish Ctr Regenerat Med, Edinburgh BioQuarter, Edinburgh, Midlothian, Scotland; [Yamanaka, Shinya] Kyoto Univ, Kyoto Ctr iPS Cell Res & Applicat, Sakyo Ku, Kyoto, Japan; [Yamanaka, Shinya] Int Soc Stem Cell Res, Northbrook, IL USA	University of Sheffield; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; National Institutes of Health (NIH) - USA; University of Edinburgh; Kyoto University	Andrews, PW (corresponding author), Univ Sheffield, Dept Biomed Sci, Ctr Stem Cell Biol, Western Bank, Sheffield S10 2TN, S Yorkshire, England.	mrao@nyscf.org		Andrews, Peter/0000-0001-7215-4410				Ahrlund-Richter L, 2009, CELL STEM CELL, V4, P20, DOI 10.1016/j.stem.2008.11.012; Allison M, 2012, NAT BIOTECHNOL, V30, P304, DOI 10.1038/nbt0412-304; Bravery CA, 2013, CYTOTHERAPY, V15, P9, DOI 10.1016/j.jcyt.2012.10.008; Carpenter MK, 2010, REGEN MED, V5, P569, DOI [10.2217/rme.10.55, 10.2217/RME.10.55]; Clarke D, 2012, CYTOTHERAPY, V14, P1032, DOI 10.3109/14653249.2012.706709; Georgieva BP, 2010, REGEN MED, V5, P581, DOI 10.2217/RME.10.43; Lomax GP, 2013, STEM CELL TRANSL MED, V2, P727, DOI 10.5966/sctm.2013-0099; Lowenthal J, 2012, STEM CELL TRANSL MED, V1, P409, DOI 10.5966/sctm.2012-0029; Magnus D, 2010, J LAW MED ETHICS, V38, P267, DOI 10.1111/j.1748-720X.2010.00487.x; Obasogie Osagie K., 2012, STANFORD TECHNOLOGY, V16, P51; Rao MS, 2013, STEM CELL RES THER, V4, DOI [10.1186/1757-6512-4-98, 10.1186/scrt309]; Rao MM, 2012, ELECTROCHEM COMMUN, V17, P1, DOI 10.1016/j.elecom.2011.12.022; Rawley J., 2012, BIOPROCESS INT, V10, P16; Sipp D, 2012, SCIENCE, V338, P1296, DOI 10.1126/science.1229918; Turner M, 2013, CELL STEM CELL, V13, P382, DOI 10.1016/j.stem.2013.08.003; Yamanaka S, 2012, CELL STEM CELL, V10, P678, DOI 10.1016/j.stem.2012.05.005	16	46	47	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2014	32	8					724	726		10.1038/nbt.2973	http://dx.doi.org/10.1038/nbt.2973			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	AW7PF	25093882				2023-01-03	WOS:000346455900009
J	Stephenson, J; Patel, D; Barrett, G; Howden, B; Copas, A; Ojukwu, O; Pandya, P; Shawe, J				Stephenson, Judith; Patel, Dilisha; Barrett, Geraldine; Howden, Beth; Copas, Andrew; Ojukwu, Obiamaka; Pandya, Pranav; Shawe, Jill			How Do Women Prepare for Pregnancy? Preconception Experiences of Women Attending Antenatal Services and Views of Health Professionals	PLOS ONE			English	Article							UNINTENDED PREGNANCY; UNPLANNED PREGNANCY; CARE; BEHAVIORS; COHORT	Main objective: To determine the extent to which women plan and prepare for pregnancy. Methods: Cross-sectional questionnaire survey of pregnant women attending three maternity services in London about knowledge and uptake of preconception care; including a robust measure of pregnancy planning, and phone interviews with a range of health care professionals. Main results: We recruited 1173/1288 (90%) women, median age of 32 years. 73% had clearly planned their pregnancy, 24% were ambivalent and only 3% of pregnancies were unplanned. 51% of all women and 63% of those with a planned pregnancy took folic acid before pregnancy. 21% of all women reported smoking and 61% reported drinking alcohol in the 3 months before pregnancy; 48% of smokers and 41% of drinkers reduced or stopped before pregnancy. The 51% of all women who reported advice from a health professional before becoming pregnant were more likely to adopt healthier behaviours before pregnancy [adjusted odds ratios for greatest health professional input compared with none were 2.34 (95% confidence interval 1.54-3.54) for taking folic acid and 2.18 (95% CI 1.42-3.36) for adopting a healthier diet before pregnancy]. Interviews with 20 health professionals indicated low awareness of preconception health issues, missed opportunities and confusion about responsibility for delivery of preconception care. Significance of the findings: Despite a high level of pregnancy planning, awareness of preconception health among women and health professionals is low, and responsibility for providing preconception care is unclear. However, many women are motivated to adopt healthier behaviours in the preconception period, as indicated by halving of reported smoking rates in this study. The link between health professional input and healthy behaviour change before pregnancy is a new finding that should invigorate strategies to improve awareness and uptake of pre-pregnancy health care, and bring wider benefits for public health.	[Stephenson, Judith; Patel, Dilisha; Howden, Beth; Ojukwu, Obiamaka; Shawe, Jill] UCL, Inst Womens Hlth, London, England; [Barrett, Geraldine] Brunel Univ, Uxbridge UB8 3PH, Middx, England; [Copas, Andrew] UCL, Inst Epidemiol, London, England; [Pandya, Pranav] Univ Coll London Hosp, London, England	University of London; University College London; Brunel University; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London	Stephenson, J (corresponding author), UCL, Inst Womens Hlth, London, England.	judith.stephenson@ucl.ac.uk		Copas, Andrew/0000-0001-8968-5963; Patel, Dilisha/0000-0002-3746-8171; Barrett, Geraldine/0000-0002-9738-1051; SHAWE, JILL/0000-0002-2766-7302	Department of Health [006/0068]; Medical Research Council [MR/K006584/1] Funding Source: researchfish; National Institute for Health Research [NF-SI-0513-10099] Funding Source: researchfish	Department of Health; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	The study was funded by the Policy Research Programme of the Department of Health. http://www.prp-ccf.org.uk. The PRP Reference number for the project is 006/0068. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barrett G, 2004, J EPIDEMIOL COMMUN H, V58, P426, DOI 10.1136/jech.2003.014787; Ben-Shlomo Y, 2002, INT J EPIDEMIOLOGY, V31; Bitzer J, 2013, INT J WOMENS HEALTH, V5, P201, DOI 10.2147/IJWH.S40149; Bukowski R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000061; Cemach, 2011, BJOG INT J OBSTET GY, V118; Cheng D, 2009, CONTRACEPTION, V79, P194, DOI 10.1016/j.contraception.2008.09.009; Chuang CH, 2010, MATERN CHILD HLTH J, V14, P501, DOI 10.1007/s10995-009-0453-6; Cragan JD, 2006, MATERN CHILD HLTH J, V10, pS129, DOI 10.1007/s10995-006-0102-2; Department of Health, 2007, 11 DEP HLTH NAT SERV; Dott M, 2010, MATERN CHILD HLTH J, V14, P373, DOI 10.1007/s10995-009-0458-1; Food Standards Agency & COI, 2007, HLTH; Frey K, 2008, AM J OBSTET GYNEC S6, V6; Gardiner H, 2009, BMJ-BRIT MED J, V338, P1144; Gluckman PD, 2009, NAT REV ENDOCRINOL, V5, P401, DOI 10.1038/nrendo.2009.102; Green-Raleigh K, 2005, PERSPECT SEX REPRO H, V37, P179, DOI 10.1363/3717905; Gynaecology RCoOa, 2010, CMACE RCOG JOINT GUI; Hansen M, 2009, EARLY LIFE NUTR LIFE; Inskip H, 2009, BMJ-BRIT MED J, pb481; Inskip HM, 2006, INT J EPIDEMIOL, V35, P42, DOI 10.1093/ije/dyi202; Johnson Kay, 2006, Morbidity and Mortality Weekly Report, V55, P1; Lakha F, 2006, LANCET, V368, P1782, DOI 10.1016/S0140-6736(06)69737-7; Lewis G, 2007, 7 CEMACH; Mazza D, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-36; Mccory C, 2013, PAEDIATR PERINAT EP, V27, P208; Morin P, 2002, PREV MED, V35, P143, DOI 10.1006/pmed.2002.1041; Neergaard MA, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-52; Nice, 2004, EP DIAGN MAN EP AD C; Nice, 2011, QUAL STAND DIAB AD P; Nice, 2007, CLIN KNOWL SUMM PREC; PATIENT.CO.UK, 2009, DIAB PREG; Sandelowski M, 2000, RES NURSING HLTH, V23; Stern J, 2013, HUM REPROD, V28, P2450, DOI 10.1093/humrep/det279; Wellings K, 2013, LANCET, V382, P1807, DOI 10.1016/S0140-6736(13)62071-1; WHO, 2013, WHO GLOB ACT PLAN PR; Xaverius PK, 2009, J WOMENS HEALTH, V18, P49, DOI 10.1089/jwh.2007.0629	35	105	108	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2014	9	7							e103085	10.1371/journal.pone.0103085	http://dx.doi.org/10.1371/journal.pone.0103085			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO5BG	25058333	Green Published, gold			2023-01-03	WOS:000341354800061
J	Kwon, YD; Yoon, SS; Chang, H				Kwon, Young Dae; Yoon, Sung Sang; Chang, Hyejung			High Total Hospitalization Cost but Low Cost of Imaging Studies in Recurrent Acute Ischemic Stroke Patients	PLOS ONE			English	Article							CEREBRAL INFARCTION; COMMUNITY; EPIDEMIOLOGY; PREDICTORS; LENGTH; STAY; RISK	Background: Due to the high risk and severity of recurrence after stroke attack, recurrence is a major reason contributing to the disease burden. This study aims to determine whether recurrence is a significant contributor of hospitalization cost in items for ischemic stroke patients. Methods: This study assessed acute ischemic stroke patients admitted to an academic medical center in 2003 through 2009. The t-test and Chi-square tests were used to compare first-ever and recurrent ischemic stroke groups in terms of total and categorized hospitalization cost, and multiple regression was performed to assess the influence of stroke recurrence. Results: Recurrent ischemic strokes were associated with higher total cost, but examination cost showed no difference between the two groups. The recurrent stroke group showed higher laboratory but lower imaging cost. Of imaging studies, there was no significant difference in computed tomography scan cost while the first-ever stroke group spent more on magnetic resonance imaging and sonography. Controlling for other influential factors, recurrence was discovered to be a significant factor in lowering examination cost. Conclusions: The findings of stroke recurrence in lowering examination cost could be explained from two perspectives, different clinical patterns of healthcare utilization and patients' economic status in recurrent stroke.	[Kwon, Young Dae] Catholic Univ Korea, Coll Med, Dept Humanities & Social Med, Seoul, South Korea; [Kwon, Young Dae] Catholic Univ Korea, Catholic Inst Healthcare Management, Seoul, South Korea; [Yoon, Sung Sang] Kyung Hee Univ, Coll Med, Dept Neurol, Seoul, South Korea; [Chang, Hyejung] Kyung Hee Univ, Sch Management, Dept Hlth Serv Management, Seoul, South Korea	Catholic University of Korea; Catholic University of Korea; Kyung Hee University; Kyung Hee University	Chang, H (corresponding author), Kyung Hee Univ, Sch Management, Dept Hlth Serv Management, Seoul, South Korea.	hjchang@khu.ac.kr	Kwon, Young Dae/T-1591-2017; Chang, Hyejung/K-5764-2013	Kwon, Young Dae/0000-0002-8781-6832; 	Kyung Hee University [KHU-2009554]	Kyung Hee University	This study was supported by a Faculty Research Grant from the Kyung Hee University in 2009 (KHU-2009554). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; BURN J, 1994, STROKE, V25, P333, DOI 10.1161/01.STR.25.2.333; Chang Hyejung, 2011, [Journal of the Korean Neurological Association, 대한신경과학회지], V29, P9; Chang KC, 2002, STROKE, V33, P2670, DOI 10.1161/01.STR.0000034396.68980.39; Fine MJ, 2000, AM J MED, V109, P378, DOI 10.1016/S0002-9343(00)00500-3; Gumbinger C, 2013, NEUROEPIDEMIOLOGY, V41, P161, DOI 10.1159/000354356; Hacke W, 2000, EUR J NEUROL, V7, P607, DOI 10.1046/j.1468-1331.2000.00137.x; HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P541; Jorgensen HS, 1997, NEUROLOGY, V48, P891; Keerthi MM, 2011, STROKE, V42, P1489; Leoo T, 2008, CEREBROVASC DIS, V25, P254, DOI 10.1159/000113864; Modrego PJ, 2000, NEUROL SCI, V21, P355, DOI 10.1007/s100720070050; Mohr JP, 2004, STROKE PATHOPHYSIOLO, P42; Neumann PJ, 2010, HEALTH AFFAIR, V29, P196, DOI 10.1377/hlthaff.2009.0077; Paul AT, 2000, J AM COLL SURGEONS, V191, P123; Peltola M, 2013, CEREBROVASC DIS, V35, P113, DOI 10.1159/000346092; Ryglewicz D, 1997, NEUROL RES, V19, P377, DOI 10.1080/01616412.1997.11740828; SACCO RL, 1994, NEUROLOGY, V44, P626, DOI 10.1212/WNL.44.4.626; Samsa GP, 1999, STROKE, V30, P338, DOI 10.1161/01.STR.30.2.338; Schmidt EV, 1988, STROKE, V19, P942; Spieler JF, 2003, EUR J NEUROL, V10, P621, DOI 10.1046/j.1468-1331.2003.00665.x; YASAKA M, 1993, STROKE, V24, P1681, DOI 10.1161/01.STR.24.11.1681	22	1	1	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2014	9	7							e101360	10.1371/journal.pone.0101360	http://dx.doi.org/10.1371/journal.pone.0101360			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM0SW	25047140	Green Published, gold, Green Submitted			2023-01-03	WOS:000339558100008
J	Ferrer, MCC; Shuvaev, VV; Zern, BJ; Composto, RJ; Muzykantov, VR; Eckmann, DM				Ferrer, M. Carme Coll; Shuvaev, Vladimir V.; Zern, Blaine J.; Composto, Russell J.; Muzykantov, Vladimir R.; Eckmann, David M.			ICAM-1 Targeted Nanogels Loaded with Dexamethasone Alleviate Pulmonary Inflammation	PLOS ONE			English	Article							CELL-ADHESION MOLECULE-1; ACUTE LUNG INJURY; DRUG-DELIVERY; INTRACELLULAR DELIVERY; POSTOPERATIVE NAUSEA; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; IN-VIVO; NANOPARTICLES; ANTIOXIDANT	Lysozyme dextran nanogels (NG) have great potential in vitro as a drug delivery platform, combining simple chemistry with rapid uptake and cargo release in target cells with "stealth'' properties and low toxicity. In this work, we study for the first time the potential of targeted NG as a drug delivery platform in vivo to alleviate acute pulmonary inflammation in animal model of LPS-induced lung injury. NG are targeted to the endothelium via conjugation with an antibody (Ab) directed to Intercellular Adhesion Molecule-1(ICAM-NG), whereas IgG conjugated NG (IgG-NG) are used for control formulations. The amount of Ab conjugated to the NG and distribution in the body after intravenous (IV) injection have been quantitatively analyzed using a tracer isotope-labeled [I-125]IgG. As a proof of concept, Ab-NG are loaded with dexamethasone, an anti-inflammatory therapeutic, and the drug uptake and release kinetics are measured by HPLC. In vivo studies in mice showed that: i) ICAM-NG accumulates in mouse lungs (similar to 120% ID/g vs similar to 15% ID/g of IgG-NG); and, ii) DEX encapsulated in ICAM-NG, but not in IgG-NG practically blocks LPS-induced overexpression of pro-inflammatory cell adhesion molecules including ICAM-1 in the pulmonary inflammation.	[Ferrer, M. Carme Coll; Eckmann, David M.] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Shuvaev, Vladimir V.; Zern, Blaine J.; Muzykantov, Vladimir R.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Shuvaev, Vladimir V.; Zern, Blaine J.; Muzykantov, Vladimir R.] Univ Penn, Ctr Targeted Therapeut & Translat Nanomed, Philadelphia, PA 19104 USA; [Ferrer, M. Carme Coll; Composto, Russell J.] Univ Penn, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Eckmann, DM (corresponding author), Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA.	eckmanndm@uphs.upenn.edu	Shuvaev, Vladimir/O-1719-2014; Eckmann, David/O-5472-2016	Eckmann, David/0000-0002-8954-8827	National Institutes of Health [NIH R01 EB006818]; NSF Nano-Bio Interface Center [DMR08-32802]; NSF [DMR09-07493]; NSF/CEMRI [DMR11-20901]; Center for Translational Targeted Therapeutics and Nanomedicine (CT3) of the National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR000003]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000003] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL110860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB006818] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF Nano-Bio Interface Center; NSF(National Science Foundation (NSF)); NSF/CEMRI; Center for Translational Targeted Therapeutics and Nanomedicine (CT3) of the National Center for Advancing Translational Sciences of the National Institutes of Health; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	The National Institutes of Health provided support via grant NIH R01 EB006818 (DME). A pilot grant from NSF Nano-Bio Interface Center DMR08-32802 (RJC) facilitated this work, as well as partial support from NSF DMR09-07493 (RJC). Facilities at the Nanoscale Characterization Center supported by NSF/CEMRI (DMR11-20901) are acknowledged. Research reported in this publication was supported in part by the Center for Translational Targeted Therapeutics and Nanomedicine (CT3) of the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR000003. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armstrong JK, 2004, BIOPHYS J, V87, P4259, DOI 10.1529/biophysj.104.047746; Arruebo M, 2009, J NANOMATER, V2009, DOI 10.1155/2009/439389; Asgeirdottir SA, 2007, MOL PHARMACOL, V72, P121, DOI 10.1124/mol.107.034140; Buxton DB, 2009, NANOMEDICINE-UK, V4, P331, DOI [10.2217/nnm.09.8, 10.2217/NNM.09.8]; Carnemolla R, 2010, SEMIN THROMB HEMOST, V36, P332, DOI 10.1055/s-0030-1253455; Charoenphol P, 2011, ATHEROSCLEROSIS, V217, P364, DOI 10.1016/j.atherosclerosis.2011.04.016; Chen CC, 2012, WORLD J SURG, V36, P61, DOI 10.1007/s00268-011-1343-9; Cheng ZL, 2012, SCIENCE, V338, P903, DOI 10.1126/science.1226338; Chittasupho C, 2009, EUR J PHARM SCI, V37, P141, DOI 10.1016/j.ejps.2009.02.008; Christofidou-Solomidou M, 2003, AM J PHYSIOL-LUNG C, V285, pL283, DOI 10.1152/ajplung.00021.2003; Cliffel DE, 2009, WIRES NANOMED NANOBI, V1, P47, DOI 10.1002/wnan.20; Coll Ferrer M. C., 2013, J NANOTECHNOLOGY ENG, V4; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DANILOV SM, 1991, LAB INVEST, V64, P118; De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596; Eberhart LHJ, 2000, ANAESTHESIST, V49, P713, DOI 10.1007/PL00002508; El Azab SR, 2002, BRIT J ANAESTH, V88, P496, DOI 10.1093/bja/88.4.496; Everts M, 2002, J IMMUNOL, V168, P883, DOI 10.4049/jimmunol.168.2.883; Ferrer M.C.C., 2013, J NANOTECHNOLOGY ENG, V4, P1; Ferrer MCC, 2012, SOFT MATTER, V8, P2423, DOI 10.1039/c2sm06969e; Ferrer MCC, 2014, ACTA BIOMAT IN PRESS; Ferrer MCC, 2013, J NANOPART RES, V15, P1; Greineder CF, 2013, BLOOD, V122, P1565, DOI 10.1182/blood-2013-03-453498; Henzi I, 2000, ANESTH ANALG, V90, P186, DOI 10.1097/00000539-200001000-00038; Howard MD, 2014, ANNU REV PHARMACOL, V54, P205, DOI 10.1146/annurev-pharmtox-011613-140002; Hua S, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00127; Iiyama K, 1999, CIRC RES, V85, P199, DOI 10.1161/01.RES.85.2.199; Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775; Kabanov AV, 2009, ANGEW CHEM INT EDIT, V48, P5418, DOI 10.1002/anie.200900441; Li J, 2008, LANGMUIR, V24, P3486, DOI 10.1021/la702785b; Liu J, 2010, P NATL ACAD SCI USA, V107, P16530, DOI 10.1073/pnas.1006611107; MARUYAMA K, 1990, J PHARM SCI, V79, P978, DOI 10.1002/jps.2600791107; MITTAL V., 2012, ANAL IMAGING TECHNIQ; Mochalin VN, 2012, NAT NANOTECHNOL, V7, P11, DOI [10.1038/NNANO.2011.209, 10.1038/nnano.2011.209]; Muro S, 2005, CURR PHARM DESIGN, V11, P2383, DOI 10.2174/1381612054367274; Muro S, 2008, MOL THER, V16, P1450, DOI 10.1038/mt.2008.127; Muzykantov VR, 1999, P NATL ACAD SCI USA, V96, P2379, DOI 10.1073/pnas.96.5.2379; Muzykantov VR, 1996, P NATL ACAD SCI USA, V93, P5213, DOI 10.1073/pnas.93.11.5213; Pan H, 2013, FASEB J, V27, P255, DOI 10.1096/fj.12-218081; Rocksen D, 2000, CLIN EXP IMMUNOL, V122, P249, DOI 10.1046/j.1365-2249.2000.01373.x; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Shuvaev VV, 2011, FASEB J, V25, P348, DOI 10.1096/fj.10-169789; Simionescu M, 2002, MICROSC RES TECHNIQ, V57, P269, DOI 10.1002/jemt.10086; TAKEI F, 1985, J IMMUNOL, V134, P1403; Vinogradov SV, 2002, ADV DRUG DELIVER REV, V54, P135, DOI 10.1016/S0169-409X(01)00245-9; Zern BJ, 2013, ACS NANO, V7, P2461, DOI 10.1021/nn305773f; Zhang N, 2008, BIOCONJUGATE CHEM, V19, P145, DOI 10.1021/bc700227z	47	54	55	1	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2014	9	7							e102329	10.1371/journal.pone.0102329	http://dx.doi.org/10.1371/journal.pone.0102329			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM1PC	25019304	Green Submitted, gold, Green Published			2023-01-03	WOS:000339618600069
J	Edwards, JK; Cole, SR; Westreich, D; Moore, R; Mathews, C; Geng, E; Eron, JJ; Mugavero, MJ				Edwards, Jessie K.; Cole, Stephen R.; Westreich, Daniel; Moore, Richard; Mathews, Christopher; Geng, Elvin; Eron, Joseph J.; Mugavero, Michael J.		CNICS Res Network	Loss to Clinic and Five-Year Mortality among HIV-Infected Antiretroviral Therapy Initiators	PLOS ONE			English	Article							MARGINAL STRUCTURAL MODELS; FOLLOW-UP; PRIMARY-CARE; RETENTION; PROGRAMS; AFRICA; NONADHERENCE; PREVENTION; SURVIVAL; OUTCOMES	Missing outcome data due to loss to follow-up occurs frequently in clinical cohort studies of HIV-infected patients. Censoring patients when they become lost can produce inaccurate results if the risk of the outcome among the censored patients differs from the risk of the outcome among patients remaining under observation. We examine whether patients who are considered lost to follow up are at increased risk of mortality compared to those who remain under observation. Patients from the US Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) who newly initiated combination antiretroviral therapy between January 1, 1998 and December 31, 2009 and survived for at least one year were included in the study. Mortality information was available for all participants regardless of continued observation in the CNICS. We compare mortality between patients retained in the cohort and those lost-to-clinic, as commonly defined by a 12-month gap in care. Patients who were considered lost-to-clinic had modestly elevated mortality compared to patients who remained under observation after 5 years (risk ratio (RR): 1.2; 95% CI: 0.9, 1.5). Results were similar after redefining loss-to-clinic as 6 months (RR: 1.0; 95% CI: 0.8, 1.3) or 18 months (RR: 1.2; 95% CI: 0.8, 1.6) without a documented clinic visit. The small increase in mortality associated with becoming lost to clinic suggests that these patients were not lost to care, rather they likely transitioned to care at a facility outside the study. The modestly higher mortality among patients who were lost-to-clinic implies that when we necessarily censor these patients in studies of time-varying exposures, we are likely to incur at most a modest selection bias.	[Edwards, Jessie K.; Cole, Stephen R.; Westreich, Daniel] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; [Moore, Richard] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Mathews, Christopher] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; [Geng, Elvin] Univ Calif San Francisco, Sch Med, San Francisco, CA USA; [Eron, Joseph J.] Univ N Carolina, Sch Med, Chapel Hill, NC USA; [Mugavero, Michael J.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA	University of North Carolina; University of North Carolina Chapel Hill; Johns Hopkins University; University of California System; University of California San Diego; University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Alabama System; University of Alabama Birmingham	Edwards, JK (corresponding author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.	jessedwards@unc.edu		Edwards, Jessie/0000-0002-1741-335X; Westreich, Daniel/0000-0003-3069-1650	National Institutes of Health [NIH R01AI100654, NIH R24AI067039]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R24AI067039, P30AI050410, R01AI100654, U01AI069918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [U01DA036935] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	National Institutes of Health [NIH R01AI100654 and NIH R24AI067039]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berg MB, 2005, AIDS CARE, V17, P902, DOI 10.1080/09540120500101658; Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790; Cole SR, 2008, AM J EPIDEMIOL, V168, P656, DOI 10.1093/aje/kwn164; Efron B., 1993, INTRO BOOTSTRAP; Egger M, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000390; Fox MP, 2010, TROP MED INT HEALTH, V15, P405, DOI 10.1111/j.1365-3156.2010.02473.x; Geng EH, 2008, JAMA-J AM MED ASSOC, V300, P506, DOI 10.1001/jama.300.5.506; Geng EH, 2012, AM J EPIDEMIOL, V175, P1080, DOI 10.1093/aje/kwr444; Geng Elvin H, 2010, Curr HIV/AIDS Rep, V7, P234, DOI 10.1007/s11904-010-0061-5; Giordano TP, 2007, CLIN INFECT DIS, V44, P1493, DOI 10.1086/516778; Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43; Hill T, 2010, J CLIN EPIDEMIOL, V63, P1101, DOI 10.1016/j.jclinepi.2009.12.007; Horberg MA, 2013, AIDS PATIENT CARE ST, V27, P442, DOI 10.1089/apc.2013.0073; Howe CJ, 2011, EPIDEMIOLOGY, V22, P874, DOI 10.1097/EDE.0b013e31823029dd; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kitahata MM, 2008, INT J EPIDEMIOL, V37, P948, DOI 10.1093/ije/dym231; Klein JP, 2005, SURVIVAL ANAL TECHNI; Lanoy E, 2009, HIV MED, V10, P236, DOI 10.1111/j.1468-1293.2008.00678.x; Little RJ, 2012, NEW ENGL J MED, V367, P1355, DOI 10.1056/NEJMsr1203730; Mugavero MJ, 2012, JAIDS-J ACQ IMM DEF, V61, P574, DOI 10.1097/QAI.0b013e318273762f; Mugavero MJ, 2012, JAIDS-J ACQ IMM DEF, V59, P86, DOI 10.1097/QAI.0b013e318236f7d2; Pacheco AG, 2008, AM J EPIDEMIOL, V168, P1326, DOI 10.1093/aje/kwn249; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Sitapati AM, 2012, J HEALTH CARE POOR U, V23, P81, DOI 10.1353/hpu.2012.0139; Toh S, 2010, EPIDEMIOLOGY, V21, P528, DOI 10.1097/EDE.0b013e3181df1b69; Westreich D, 2010, AM J EPIDEMIOL, V171, P691, DOI 10.1093/aje/kwp418; Yiannoutsos CT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003843; Yu JKL, 2007, B WORLD HEALTH ORGAN, V85, P550, DOI 10.2471/BLT.06.037739	29	13	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2014	9	7							e102305	10.1371/journal.pone.0102305	http://dx.doi.org/10.1371/journal.pone.0102305			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK9RG	25010739	Green Submitted, Green Published, gold			2023-01-03	WOS:000338763800089
J	Hou, DP; Wang, QS; Jiang, CH; Tian, C; Li, HQ; Ji, B				Hou, Dapeng; Wang, Qiushi; Jiang, Cuihua; Tian, Cui; Li, Huaqing; Ji, Bo			Evaluation of the Short-Term Effects of Antimicrobial Stewardship in the Intensive Care Unit at a Tertiary Hospital in China	PLOS ONE			English	Article							PSEUDOMONAS-AERUGINOSA; ANTIBIOTIC-RESISTANCE; RESTRICTION POLICY; IMPACT; SURVEILLANCE; STATES; SUSCEPTIBILITY; PATTERNS; PROGRAM; SYSTEMS	Antibiotic abuse can lead to antibiotic resistance, which is a severe problem in China. The purpose of this study is to evaluate the short-term effects of antimicrobial stewardship strategies, including formulary restriction, preauthorization, perioperative quinolone restriction, and control of total antibiotic consumption in the ICU at a tertiary hospital in China. After implementation of antimicrobial stewardship, the total antibiotic consumption in the ICU significantly decreased. The defined daily doses (DDDs) per 100 patient-days decreased from 197.65 to 143.41; however, the consumption of cephalosporins increased from 53.65 to 63.17 DDDs. Significant improvements in resistance to amikacin, gentamicin, ciprofloxacin, ofloxacin, ceftriaxone, ceftazidime, and piperacillin in Enterobacteriaceae and resistance to ceftazidime, imipenem, and meropenem in non-fermenting Gram-negative rods were observed. In addition, the initial use of no antibiotics or of a single antibiotic significantly increased (P<0.001) and the use of two antibiotics in combination significantly decreased (P<0.001). Our results demonstrate that implementation of antimicrobial stewardship in a short period in the ICU dramatically reduced antibiotic consumption and significantly improved antibiotic resistance, which leads to more reasonable antibiotic selections by ICU physicians.	[Hou, Dapeng; Wang, Qiushi; Jiang, Cuihua; Tian, Cui; Li, Huaqing] Taishan Med Coll, Affiliated Hosp, Dept Intens Care Unit, Tai An, Shandong, Peoples R China; [Ji, Bo] Taishan Med Coll, Affiliated Hosp, Dept Thorac Surg, Tai An, Shandong, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences	Hou, DP (corresponding author), Taishan Med Coll, Affiliated Hosp, Dept Intens Care Unit, Tai An, Shandong, Peoples R China.	hdptyfy@163.com; jibotyty@163.com						Armstrong GL, 1999, JAMA-J AM MED ASSOC, V281, P61, DOI 10.1001/jama.281.1.61; Bassetti M, 2000, INT J ANTIMICROB AG, V16, P295, DOI 10.1016/S0924-8579(00)00249-1; Belongia EA, 2005, EMERG INFECT DIS, V11, P912; Bliziotis IA, 2005, CLIN INFECT DIS, V41, P149, DOI 10.1086/430912; Brown EM, 2005, J ANTIMICROB CHEMOTH, V55, P6, DOI 10.1093/jac/dkh482; Clinical and Laboratory Standards Institute, 2005, PERF STAND ANT SUS S; Cook PP, 2008, INFECT CONT HOSP EP, V29, P716, DOI 10.1086/589813; Fridkin SK, 1999, CLIN INFECT DIS, V29, P245, DOI 10.1086/520193; Hidron AI, 2008, INFECT CONT HOSP EP, V29, P996, DOI 10.1086/591861; Kaki R, 2011, J ANTIMICROB CHEMOTH, V66, P1223, DOI 10.1093/jac/dkr137; Kohler T, 1999, ANTIMICROB AGENTS CH, V43, P424, DOI 10.1128/AAC.43.2.424; Livermore DM, 2002, CLIN INFECT DIS, V34, P634, DOI 10.1086/338782; MacDougall C, 2005, CLIN MICROBIOL REV, V18, P638, DOI 10.1128/CMR.18.4.638-656.2005; Meyer E, 2006, INFECTION, V34, P303, DOI 10.1007/s15010-006-6619-x; Mohr JF, 2004, INT J ANTIMICROB AG, V24, P346, DOI 10.1016/j.ijantimicag.2004.06.002; Ntagiopoulos PG, 2007, INT J ANTIMICROB AG, V30, P360, DOI 10.1016/j.ijantimicag.2007.05.012; Ochs MM, 1999, ANTIMICROB AGENTS CH, V43, P1085, DOI 10.1128/AAC.43.5.1085; Reynolds L, 2009, HEALTH POLICY, V90, P32, DOI 10.1016/j.healthpol.2008.09.002; Wang H, 2005, DIAGN MICR INFEC DIS, V51, P201, DOI 10.1016/j.diagmicrobio.2004.09.001; Zhang RF, 2006, GLOBALIZATION HEALTH, V2, DOI 10.1186/1744-8603-2-6	20	28	29	3	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2014	9	7							e101447	10.1371/journal.pone.0101447	http://dx.doi.org/10.1371/journal.pone.0101447			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK7WB	25000225	Green Published, gold, Green Submitted			2023-01-03	WOS:000338637300044
J	George, R				George, Rob			ASSISTED DYING BILL We must not deprive dying people of the most important protection	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CROSS-SECTIONAL SURVEY; PREDICTING SURVIVAL; EUTHANASIA; DISEASE; NETHERLANDS; SUICIDE		[George, Rob] Kings Coll London, Cicely Saunders Inst, London WC2R 2LS, England; [George, Rob] Guys & St Thomas Hosp NHS Fdn Trust, London, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	George, R (corresponding author), Kings Coll London, Cicely Saunders Inst, London WC2R 2LS, England.	rob.george@kcl.ac.uk						Beckford M., 2008, TELEGRAPH; Butler-Schloss E, 2013, TELEGRAPH; Coventry PA, 2005, AGE AGEING, V34, P218, DOI 10.1093/ageing/afi054; Ganzini L, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1682; Glare P, 2008, EUR J CANCER, V44, P1146, DOI 10.1016/j.ejca.2008.02.030; Goeman JJ, 2004, STAT NEERL, V58, P21, DOI 10.1111/j.1467-9574.2004.00244.x; Groenewoud JH, 2000, NEW ENGL J MED, V342, P551, DOI 10.1056/NEJM200002243420805; Hendin H, 2008, MICH LAW REV, V106, P1613; House of Lords, 2005, ASS DYING TERM ILL B; Onwuteaka-Philipsen BD, 2012, LANCET, V380, P908, DOI 10.1016/S0140-6736(12)61034-4; Oregon Health Authority, DEATH DIGN ACT ANN R; Royal College of Physicians, 2014, NAT CAR DYING AUD HO; Tallis R, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3532	13	3	3	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	2014	349								g4311	10.1136/bmj.g4311	http://dx.doi.org/10.1136/bmj.g4311			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AK7ZE	24994758				2023-01-03	WOS:000338646100007
J	Chen, T; Sun, Y; Ji, P; Kopetz, S; Zhang, W				Chen, T.; Sun, Y.; Ji, P.; Kopetz, S.; Zhang, W.			Topoisomerase II alpha in chromosome instability and personalized cancer therapy	ONCOGENE			English	Review							SPINDLE ASSEMBLY CHECKPOINT; ANAPHASE-PROMOTING COMPLEX; IN-SITU HYBRIDIZATION; BREAST-CANCER; CELL-CYCLE; MITOTIC CHECKPOINT; DNA TOPOISOMERASES; GENE-EXPRESSION; DOWN-REGULATION; CHROMATID COHESION	Genome instability is a hallmark of cancer cells. Chromosome instability (CIN), which is often mutually exclusive from hypermutation genotypes, represents a distinct subtype of genome instability. Hypermutations in cancer cells are due to defects in DNA repair genes, but the cause of CIN is still elusive. However, because of the extensive chromosomal abnormalities associated with CIN, its cause is likely a defect in a network of genes that regulate mitotic checkpoints and chromosomal organization and segregation. Emerging evidence has shown that the chromosomal decatenation checkpoint, which is critical for chromatin untangling and packing during genetic material duplication, is defective in cancer cells with CIN. The decatenation checkpoint is known to be regulated by a family of enzymes called topoisomerases. Among them, the gene encoding topoisomerase II alpha (TOP2A) is commonly altered at both gene copy number and gene expression level in cancer cells. Thus, abnormal alterations of TOP2A, its interacting proteins, and its modifications may have a critical role in CIN in human cancers. Clinically, a large arsenal of topoisomerase inhibitors has been used to suppress DNA replication in cancer. However, they often lead to the secondary development of leukemia because of their effect on the chromosomal decatenation checkpoint. Therefore, topoisomerase drugs must be used judiciously and administered on an individual basis. In this review, we highlight the biological function of TOP2A in chromosome segregation and the mechanisms that regulate this enzyme's expression and activity. We also review the roles of TOP2A and related proteins in human cancers, and raise a perspective for how to target TOP2A in personalized cancer therapy.	[Chen, T.; Ji, P.; Zhang, W.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Chen, T.] Fudan Univ, Zhongshan Hosp, Dept Endoscopy Ctr, Shanghai 200433, Peoples R China; [Sun, Y.] Tianjin Med Univ, Canc Inst & Hosp, Dept Pathol, Tianjin, Peoples R China; [Kopetz, S.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Fudan University; Tianjin Medical University; University of Texas System; UTMD Anderson Cancer Center	Zhang, W (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85,1515 Holcombe Blvd, Houston, TX 77030 USA.	wzhang@mdanderson.org	Kopetz, Scott/AAC-1387-2019	Kopetz, Scott/0000-0001-9647-3416	MD Anderson's National Cancer Institute core grant [CA16672]; National Foundation for Cancer Research; China Education Council; A Lavoy Moore Endowment Fund; Tianjin Municipal Science and Technology Commission [14JCYBJC27500]; NSFC [81472263]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	MD Anderson's National Cancer Institute core grant; National Foundation for Cancer Research; China Education Council; A Lavoy Moore Endowment Fund; Tianjin Municipal Science and Technology Commission; NSFC(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ms Ann Sutton in the Department of Scientific Publications for editing this manuscript. This work was partially supported by MD Anderson's National Cancer Institute core grant (CA16672), a Sister Institute Network Fund and a grant from the National Foundation for Cancer Research. Dr Tao Chen was supported by a Fellowship from the China Education Council. Dr Y Sun was supported by The A Lavoy Moore Endowment Fund, a grant from the Tianjin Municipal Science and Technology Commission (14JCYBJC27500), and a grant from NSFC (81472263).	Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Akimitsu N, 2003, GENES CELLS, V8, P393, DOI 10.1046/j.1365-2443.2003.00643.x; ANDOH T, 1993, BIOTECHNOL APPL BIOC, V18, P165; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Azuma Y, 2005, EMBO J, V24, P2172, DOI 10.1038/sj.emboj.7600700; Azuma Y, 2009, METHODS MOL BIOL, V582, P221, DOI 10.1007/978-1-60761-340-4_17; Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Barber TD, 2008, P NATL ACAD SCI USA, V105, P3443, DOI 10.1073/pnas.0712384105; Belluti S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.287; Bhargava R, 2005, AM J CLIN PATHOL, V123, P889, DOI 10.1309/PCFK8YTQPYWD534F; Bordeleau L, 2010, BREAST CANCER RES TR, V119, P13, DOI 10.1007/s10549-009-0566-z; Bower JJ, 2010, ONCOGENE, V29, P4787, DOI 10.1038/onc.2010.232; Buffin E, 2005, CURR BIOL, V15, P856, DOI 10.1016/j.cub.2005.03.052; Carpenter AJ, 2004, MOL BIOL CELL, V15, P5700, DOI 10.1091/mbc.E04-08-0732; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chang CJ, 2003, J CELL SCI, V116, P4715, DOI 10.1242/jcs.00797; Chen J, 2012, GYNECOL ONCOL, V126, P109, DOI 10.1016/j.ygyno.2012.03.051; Chen J, 2012, CHIN J CANCER, V31, P215, DOI 10.5732/cjc.011.10364; CHEN M, 1995, ONCOL RES, V7, P103; CHEN M, 1993, CANCER RES, V53, P5946; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Chikamori K, 2003, J BIOL CHEM, V278, P12696, DOI 10.1074/jbc.M300837200; CLARKE DJ, 1993, J CELL SCI, V105, P563; Coelho PA, 2008, PLOS BIOL, V6, P1758, DOI 10.1371/journal.pbio.0060207; Cortes F, 2003, MUTAT RES-REV MUTAT, V543, P59, DOI 10.1016/S1383-5742(02)00070-4; CUMMINGS J, 1995, MUTAT RES-GENET TOX, V344, P55, DOI 10.1016/0165-1218(95)90038-1; Dal Molin M, 2012, HUM PATHOL, V43, P585, DOI 10.1016/j.humpath.2011.06.009; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; Dawlaty MM, 2008, CELL, V133, P103, DOI 10.1016/j.cell.2008.01.045; de Voer RM, 2013, GASTROENTEROLOGY, V145, P544, DOI 10.1053/j.gastro.2013.06.001; Deming PB, 2001, P NATL ACAD SCI USA, V98, P12044, DOI 10.1073/pnas.221430898; Depowski PL, 2000, MODERN PATHOL, V13, P542, DOI 10.1038/modpathol.3880094; Diaz-Martinez LA, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000053; Dorairaj JJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-421; Duesberg P, 2003, CELL CYCLE, V2, P202, DOI 10.4161/cc.2.3.382; Duijf PHG, 2013, ONCOGENE, V32, P4727, DOI 10.1038/onc.2012.616; Dykhuizen EC, 2013, NATURE, V497, P624, DOI 10.1038/nature12146; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; Faggad A, 2009, MODERN PATHOL, V22, P579, DOI 10.1038/modpathol.2009.14; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Ferguson LR, 1998, ENVIRON MOL MUTAGEN, V27, P255; Ganapathi RN, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00089; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; Geigl JB, 2008, TRENDS GENET, V24, P64, DOI 10.1016/j.tig.2007.11.006; Gilmore PM, 2003, BIOCHEM SOC T, V31, P257, DOI 10.1042/bst0310257; Gimenez-Abian JF, 2004, CURR BIOL, V14, P1187, DOI 10.1016/j.cub.2004.06.052; Glaros S, 2008, CANCER RES, V68, P3689, DOI 10.1158/0008-5472.CAN-07-6652; Gunduz E, 2006, MED HYPOTHESES, V67, P1313, DOI 10.1016/j.mehy.2006.05.032; Habu T, 2002, EMBO J, V21, P6419, DOI 10.1093/emboj/cdf659; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hande KR, 2008, UPDATE CANC THERAPEU, V3, P13, DOI DOI 10.1016/J.UCT.2008.02.001; Hasinoff BB, 2001, MOL PHARMACOL, V59, P453, DOI 10.1124/mol.59.3.453; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; Huang B, 2014, J CELL BIOCHEM, V115, P1077, DOI 10.1002/jcb.24703; Iida M, 2008, BIOCHEM J, V411, P27, DOI 10.1042/BJ20071394; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; ISHIDA R, 1991, CANCER RES, V51, P4909; Ishida R, 1996, J BIOL CHEM, V271, P30077, DOI 10.1074/jbc.271.47.30077; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Jeganathan K, 2007, J CELL BIOL, V179, P255, DOI 10.1083/jcb.200706015; Jeganathan KB, 2006, CELL CYCLE, V5, P366, DOI 10.4161/cc.5.4.2483; Ji P, 2010, ONCOGENE, V29, P3501, DOI 10.1038/onc.2010.114; Johnson M, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp480; Kaitna S, 2000, CURR BIOL, V10, P1172, DOI 10.1016/S0960-9822(00)00721-1; Kallio M, 1997, ENVIRON MOL MUTAGEN, V29, P16, DOI 10.1002/(SICI)1098-2280(1997)29:1<16::AID-EM3>3.0.CO;2-B; Kallio MJ, 2001, FASEB J, V15, P2721, DOI 10.1096/fj.01-0280fje; Kang R, 2013, CLIN CANCER RES, V19, P4046, DOI 10.1158/1078-0432.CCR-13-0495; Kennedy RD, 2005, CANCER RES, V65, P10265, DOI 10.1158/0008-5472.CAN-05-1841; Koivunen J, 2006, CANCER LETT, V235, P1, DOI 10.1016/j.canlet.2005.03.033; Kolb RH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050281; Kops GJPL, 2005, J CELL BIOL, V169, P49, DOI 10.1083/jcb.200411118; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lan J, 2014, TUMOR BIOL, V35, P179, DOI 10.1007/s13277-013-1022-6; Lee BH, 2003, SCIENCE, V300, P482, DOI 10.1126/science.1081846; Lee WY, 1999, HISTOPATHOLOGY, V34, P106; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li H, 2008, J BIOL CHEM, V283, P6209, DOI 10.1074/jbc.M709007200; Li L, 2010, ANN ANAT, V192, P275, DOI 10.1016/j.aanat.2010.07.010; Li Y, 2012, CHIN J CANCER, V31, P364, DOI 10.5732/cjc.012.10086; Lin WC, 2013, BBA-MOL CELL RES, V1833, P3206, DOI 10.1016/j.bbamcr.2013.08.020; Lin YT, 2006, ONCOGENE, V25, P6901, DOI 10.1038/sj.onc.1209687; Liu DG, 2002, CANCER, V94, P2239, DOI 10.1002/cncr.10450; Liu H, 2013, CURR BIOL, V23, P1927, DOI 10.1016/j.cub.2013.07.078; Liu Y, 2010, EUR J CANCER, V46, P3007, DOI 10.1016/j.ejca.2010.07.016; London N, 2014, GENE DEV, V28, P140, DOI 10.1101/gad.233700.113; Lou ZK, 2005, NAT STRUCT MOL BIOL, V12, P589, DOI 10.1038/nsmb953; Luo KT, 2009, NAT CELL BIOL, V11, P204, DOI 10.1038/ncb1828; Luo XL, 2000, NAT STRUCT BIOL, V7, P224; Lynch HT, 2005, CANCER GENET CYTOGEN, V158, P119, DOI 10.1016/j.cancergencyto.2004.01.032; Maney T, 1998, J CELL BIOL, V142, P787, DOI 10.1083/jcb.142.3.787; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Meng H, 2012, PATHOL INT, V62, P391, DOI 10.1111/j.1440-1827.2012.02808.x; Michor F, 2005, SEMIN CANCER BIOL, V15, P43, DOI 10.1016/j.semcancer.2004.09.007; Mo YY, 1997, CANCER RES, V57, P5004; Mueller RE, 2004, GENE CHROMOSOME CANC, V39, P288, DOI 10.1002/gcc.20008; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; Nitiss JL, 2009, NAT REV CANCER, V9, P338, DOI 10.1038/nrc2607; Obado SO, 2011, NUCLEIC ACIDS RES, V39, P1023, DOI 10.1093/nar/gkq839; Parker BC, 2013, CHIN J CANCER, V32, P594, DOI 10.5732/cjc.013.10178; Patel AN, 2011, BREAST CANCER RES TR, V126, P601, DOI 10.1007/s10549-010-0960-6; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PEDERSENBJERGAARD J, 1991, LANCET, V338, P359, DOI 10.1016/0140-6736(91)90490-G; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; Privette LM, 2008, NEOPLASIA, V10, P643, DOI 10.1593/neo.08176; Qi XM, 2006, CANCER RES, V66, P7540, DOI 10.1158/0008-5472.CAN-05-4639; Qi XM, 2011, J BIOL CHEM, V286, P35883, DOI 10.1074/jbc.M111.229260; Redwood C, 1998, J BIOL CHEM, V273, P3635, DOI 10.1074/jbc.273.6.3635; Reisman DN, 2003, CANCER RES, V63, P560; Ricke RM, 2008, TRENDS GENET, V24, P457, DOI 10.1016/j.tig.2008.07.002; RITKE MK, 1995, MOL PHARMACOL, V48, P798; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; Schmidt BH, 2012, NAT STRUCT MOL BIOL, V19, P1147, DOI 10.1038/nsmb.2388; Schmidt BH, 2010, NATURE, V465, P641, DOI 10.1038/nature08974; Seery LT, 1999, INT J CANCER, V84, P258, DOI 10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.0.CO;2-H; Shain AH, 2012, P NATL ACAD SCI USA, V109, pE252, DOI 10.1073/pnas.1114817109; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shinagawa H, 2008, ANTIOXID REDOX SIGN, V10, P939, DOI 10.1089/ars.2007.1851; Stros M, 2009, NUCLEIC ACIDS RES, V37, P2070, DOI 10.1093/nar/gkp067; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; SUMNER AT, 1995, EXP CELL RES, V217, P440, DOI 10.1006/excr.1995.1107; Sumner AT, 1998, CHROMOSOMA, V107, P486, DOI 10.1007/s004120050333; Takahashi Y, 2006, GENETICS, V172, P783, DOI 10.1534/genetics.105.047167; Tang ZY, 2004, MOL CELL, V16, P387, DOI 10.1016/j.molcel.2004.09.031; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tipton AR, 2013, J BIOL CHEM, V288, P35149, DOI 10.1074/jbc.M113.522375; Tsai SC, 2000, NAT GENET, V26, P349, DOI 10.1038/81671; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Villman K, 2002, MODERN PATHOL, V15, P486, DOI 10.1038/modpathol.3880552; Wang H, 1997, BIOCHEM BIOPH RES CO, V237, P217, DOI 10.1006/bbrc.1997.7115; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang LHC, 2008, CHROMOSOMA, V117, P123, DOI 10.1007/s00412-007-0131-7; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Wang XS, 2013, CHIN J CANCER, V32, P155, DOI 10.5732/cjc.012.10114; Washiro M, 2008, J CANCER RES CLIN, V134, P793, DOI 10.1007/s00432-007-0348-0; Watanabe T, 2012, J CLIN ONCOL, V30, P2256, DOI 10.1200/JCO.2011.38.6490; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; Weaver BAA, 2003, J CELL BIOL, V162, P551, DOI 10.1083/jcb.200303167; Wendorff TJ, 2012, J MOL BIOL, V424, P109, DOI 10.1016/j.jmb.2012.07.014; Williams AO, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-36; Williams BC, 2003, MOL BIOL CELL, V14, P1379, DOI 10.1091/mbc.E02-09-0624; Wirth KG, 2006, J CELL BIOL, V172, P847, DOI 10.1083/jcb.200506119; Wu D, 2008, J PATHOL, V216, P167, DOI 10.1002/path.2391; Xia GH, 2004, EMBO J, V23, P3133, DOI 10.1038/sj.emboj.7600322; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yamasaki Lili, 2003, Cancer Treat Res, V115, P209; Yanagida M, 2005, PHILOS T R SOC B, V360, P609, DOI 10.1098/rstb.2004.1615; Yang D, 2011, JAMA-J AM MED ASSOC, V306, P1557, DOI 10.1001/jama.2011.1456; Yang GL, 2012, J SURG ONCOL, V106, P57, DOI 10.1002/jso.23040; Yang X, 2000, SCIENCE, V287, P131, DOI 10.1126/science.287.5450.131; Yuan CF, 2012, MOL CELL BIOCHEM, V359, P333, DOI 10.1007/s11010-011-1027-7	161	108	115	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4019	4031		10.1038/onc.2014.332	http://dx.doi.org/10.1038/onc.2014.332			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25328138	Green Accepted			2023-01-03	WOS:000358780500001
J	Su, R; Lin, HS; Zhang, XH; Yin, XL; Ning, HM; Liu, B; Zhai, PF; Gong, JN; Shen, C; Song, L; Chen, J; Wang, F; Zhao, HL; Ma, YN; Yu, J; Zhang, JW				Su, R.; Lin, H-S; Zhang, X-H; Yin, X-L; Ning, H-M; Liu, B.; Zhai, P-F; Gong, J-N; Shen, C.; Song, L.; Chen, J.; Wang, F.; Zhao, H-L; Ma, Y-N; Yu, J.; Zhang, J-W			MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets	ONCOGENE			English	Article							PROTEIN-KINASE-C; RETINOIC ACID; CELL-DIFFERENTIATION; MICRORNA EXPRESSION; TUMOR-SUPPRESSOR; GENE-EXPRESSION; PKC-DELTA; CARDIAC FIBROBLASTS; DOWN-REGULATION; BREAST-CANCER	MicroRNAs have been shown to play an important role in normal hematopoisis and leukemogenesis. Here, we report function and mechanisms of miR-181 family in myeloid differentiation and acute myeloid leukemia (AML). The aberrant overexpression of all the miR-181 family members (miR-181a/b/c/d) was detected in French-American-British M1, M2 and M3 subtypes of adult AML patients. By conducting gain-and loss-of-function experiments, we demonstrated that miR-181a inhibits granulocytic and macrophage-like differentiation of HL-60 cells and CD34+ hematopoietic stem/progenitor cells (HSPCs) by directly targeting and downregulating the expression of PRKCD (which then affected the PRKCD-P38-C/EBPa pathway), CTDSPL (which then affected the phosphorylation of retinoblastoma protein) and CAMKK1. The three genes were also demonstrated to be the targets of miR-181b, miR-181c and miR-181d, respectively. Significantly decreases in the expression levels of the target proteins were detected in AML patients. Inhibition of the expression of miR-181 family members owing to Lenti-miRZip-181a infection in bone marrow blasts of AML patients increased target protein expression levels and partially reversed myeloid differentiation blockage. In the mice implanted with AML CD34+ HSPCs, expression inhibition of the miR-181 family by Lenti-miRZip-181a injection improved myeloid differentiation, inhibited engraftment and infiltration of the leukemic CD34+ cells into the bone marrow and spleen, and released leukemic symptoms. In conclusion, our findings revealed new mechanism of miR-181 family in normal hematopoiesis and AML development, and suggested that expression inhibition of the miR-181 family could provide a new strategy for AML therapy.	[Su, R.; Lin, H-S; Zhai, P-F; Gong, J-N; Shen, C.; Song, L.; Chen, J.; Wang, F.; Zhao, H-L; Ma, Y-N; Yu, J.; Zhang, J-W] Chinese Acad Med Sci, Key State Lab Med Mol Biol, Dept Biochem & Mol Biol, Inst Basic Med Sci, Beijing 100730, Peoples R China; [Su, R.; Lin, H-S; Zhai, P-F; Gong, J-N; Shen, C.; Song, L.; Chen, J.; Wang, F.; Zhao, H-L; Ma, Y-N; Yu, J.; Zhang, J-W] Peking Union Med Coll, Beijing 100021, Peoples R China; [Zhang, X-H; Yin, X-L] 303 Hosp, Dept Hematol, Nanning, Guangxi, Peoples R China; [Ning, H-M] Acad Mil Med Sci, Inst Mil Hemopoiet Stem Cell, Dept Stem Cell Transplantat Ctr, Hosp, Beijing, Peoples R China; [Ning, H-M] Acad Mil Med Sci, Affiliated Hosp, Lvy Translat Med Ctr 307, Lab Oncol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Academy of Military Medical Sciences - China; Academy of Military Medical Sciences - China	Zhang, JW (corresponding author), Chinese Acad Med Sci, Key State Lab Med Mol Biol, Dept Biochem & Mol Biol, Inst Basic Med Sci, Beijing 100730, Peoples R China.	junwu_zhang@pumc.edu.cn	Su, Rui/Y-8157-2018	Shen, Chao/0000-0002-9406-7075; Su, Rui/0000-0002-4807-6229	National Natural Science Foundation of China [31171311, 30970616, 81070435]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was funded by the National Natural Science Foundation of China grants 31171311 and 30970616 (to J-WZ) and 81070435 (to H-MN).	BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Bisso A, 2013, CELL CYCLE, V12, P1679, DOI 10.4161/cc.24757; Careccia S, 2009, ONCOGENE, V28, P4034, DOI 10.1038/onc.2009.255; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; Chen C, 2012, BRIT J PHARMACOL, V166, P676, DOI 10.1111/j.1476-5381.2011.01785.x; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen G, 2010, ONCOL REP, V23, P997, DOI 10.3892/or_00000725; Cuesta R, 2009, MOL CELL BIOL, V29, P2841, DOI 10.1128/MCB.01971-08; Debernardi S, 2007, LEUKEMIA, V21, P912, DOI 10.1038/sj.leu.2404605; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; EGELAND T, 1991, BLOOD, V78, P3192; Feng W, 2010, BRIT J PHARMACOL, V159, P1598, DOI 10.1111/j.1476-5381.2009.00558.x; Fragoso R, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002855; Gan XQ, 2012, NAT CELL BIOL, V14, P686, DOI 10.1038/ncb2507; Garzon R, 2007, ONCOGENE, V26, P4148, DOI 10.1038/sj.onc.1210186; Garzon R, 2008, BLOOD, V111, P3183, DOI 10.1182/blood-2007-07-098749; Georgantas RW, 2007, P NATL ACAD SCI USA, V104, P2750, DOI 10.1073/pnas.0610983104; Guest CB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001606; Hampson P, 2005, BLOOD, V106, P1362, DOI 10.1182/blood-2004-10-4117; Ji JF, 2009, HEPATOLOGY, V50, P472, DOI 10.1002/hep.22989; Kambhampati S, 2003, J BIOL CHEM, V278, P32544, DOI 10.1074/jbc.M301523200; Kashuba VI, 2004, P NATL ACAD SCI USA, V101, P4906, DOI 10.1073/pnas.0401238101; Ke G, 2013, ONCOGENE, V32, P3019, DOI 10.1038/onc.2012.323; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; Lawson ND, 1999, EXP HEMATOL, V27, P1682, DOI 10.1016/S0301-472X(99)00108-3; Li QJ, 2007, CELL, V129, P147, DOI 10.1016/j.cell.2007.03.008; Li ZJ, 2012, BLOOD, V119, P2314, DOI 10.1182/blood-2011-10-386235; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Marcucci G, 2008, NEW ENGL J MED, V358, P1919, DOI 10.1056/NEJMoa074256; Naguibneva I, 2006, NAT CELL BIOL, V8, P278, DOI 10.1038/ncb1373; Nitti M, 2010, CELL SIGNAL, V22, P828, DOI 10.1016/j.cellsig.2010.01.007; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Ouyang YB, 2012, MITOCHONDRION, V12, P213, DOI 10.1016/j.mito.2011.09.001; Pichiorri F, 2008, P NATL ACAD SCI USA, V105, P12885, DOI 10.1073/pnas.0806202105; Pons A, 2009, LEUKEMIA LYMPHOMA, V50, P1854, DOI 10.3109/10428190903147645; Pulikkan JA, 2010, BLOOD, V115, P1768, DOI 10.1182/blood-2009-08-240101; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Rosenbauer F, 2007, NAT REV IMMUNOL, V7, P105, DOI 10.1038/nri2024; Schwind S, 2010, J CLIN ONCOL, V28, P5257, DOI 10.1200/JCO.2010.29.2953; Senchenko VN, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-75; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Studzinski GP, 2005, J STEROID BIOCHEM, V97, P47, DOI 10.1016/j.jsbmb.2005.06.010; Taylor MA, 2013, J CLIN INVEST, V123, P150, DOI 10.1172/JCI64946; Verploegen S, 2005, BLOOD, V106, P1076, DOI 10.1182/blood-2004-09-3755; Wang B, 2010, ONCOGENE, V29, P1787, DOI 10.1038/onc.2009.468; Wang XS, 2012, BLOOD, V119, P4992, DOI 10.1182/blood-2011-10-385716; Wang XN, 2009, CELL CYCLE, V8, P736, DOI 10.4161/cc.8.5.7870; Yendamuri S, 2009, LEUKEMIA, V23, P1257, DOI 10.1038/leu.2008.382; Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630; Zheng YS, 2012, ONCOGENE, V31, P80, DOI 10.1038/onc.2011.208	50	118	120	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3226	3239		10.1038/onc.2014.274	http://dx.doi.org/10.1038/onc.2014.274			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25174404				2023-01-03	WOS:000356592300002
J	Rubin, R				Rubin, Rita			Analysis Reveals Large Increase in Hospitalizations in Recent Years Among Older Patients Prescribed Opioids	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item							COMPARATIVE SAFETY; ADULTS; PAIN						Rubin, Rita/AAD-1259-2020					Colliver JD, 2006, ANN EPIDEMIOL, V16, P257, DOI 10.1016/j.annepidem.2005.08.003; Hanlon JT, 2009, PAIN MED, V10, P959, DOI 10.1111/j.1526-4637.2009.00698.x; Solomon DH, 2010, ARCH INTERN MED, V170, P1979, DOI 10.1001/archinternmed.2010.450; Solomon DH, 2010, ARCH INTERN MED, V170, P1968, DOI 10.1001/archinternmed.2010.391	4	5	5	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	2014	312	16					1621	1623		10.1001/jama.2014.13249	http://dx.doi.org/10.1001/jama.2014.13249			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AR0YF	25335129				2023-01-03	WOS:000343301400002
J	Chen, PC; Yang, CC; Wu, CJ; Liu, WS; Huang, WL; Lee, CC				Chen, Po-Chun; Yang, Ching-Chieh; Wu, Cheng-Jung; Liu, Wen-Shan; Huang, Wei-Lun; Lee, Ching-Chih			Factors Predict Prolonged Wait Time and Longer Duration of Radiotherapy in Patients with Nasopharyngeal Carcinoma: A Multilevel Analysis	PLOS ONE			English	Article							PHASE-III; CONCURRENT CHEMORADIOTHERAPY; SOCIOECONOMIC-STATUS; COMORBIDITY; HEAD; INSURANCE; COHORT; DELAY	Purpose: Radiotherapy with or without chemotherapy is the primary treatment for patients with nasopharyngeal carcinoma (NPC). It wastes time from diagnosis to treatment. Treatment time of radiotherapy generally takes at least seven weeks. The current study aimed to evaluate factors associated with prolonged wait time and longer duration of radiotherapy in NPC patients. Methods and Materials: From Taiwan's National Health Insurance research database, we identified 3,605 NPC patients treated with radiotherapy between 2008 and 2011. Wait time was calculated from the date of diagnosis to the start of radiotherapy. The impact of each variable on wait time and duration of radiotherapy was examined by multilevel analysis using a random-intercept model. Results: The mean wait time and duration of radiotherapy were 1.78 +/- 3.33 and 9.72 +/- 7.27 weeks, respectively. Multilevel analysis revealed prolonged wait time in patients aged 45-65 years, those receiving radiotherapy alone, those with more comorbidities, those with low SES, and those living in eastern Taiwan. A prolonged duration of radiotherapy was associated with receipt of concurrent chemoradiotherapy, more comorbidities, and moderate SES. Conclusions: Understanding the factors associated with longer wait times and duration of radiotherapy in patients with NPC may help healthcare providers better assist both these patients and potentially those with other head-and-neck cancers.	[Chen, Po-Chun] Pingtung Christian Hosp, Dept Radiat Oncol, Pingtung, Taiwan; [Yang, Ching-Chieh] Chi Mei Med Ctr, Dept Radiat Oncol, Tainan, Taiwan; [Wu, Cheng-Jung] Kaohsiung Vet Gen Hosp, Dept Otolaryngol, Kaohsiung, Taiwan; [Liu, Wen-Shan; Huang, Wei-Lun] Kaohsiung Vet Gen Hosp, Dept Radiat Oncol, Kaohsiung, Taiwan; [Lee, Ching-Chih] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Otolarygol, Chiayi, Taiwan; [Lee, Ching-Chih] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Ctr Canc, Chiayi, Taiwan; [Lee, Ching-Chih] Tzu Chi Univ, Sch Med, Hualin, Taiwan	Chi Mei Hospital; Kaohsiung Veterans General Hospital; Kaohsiung Veterans General Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Tzu Chi University	Lee, CC (corresponding author), Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Otolarygol, Chiayi, Taiwan.	hematcd2@hotmail.com						Abdel-Wahab M, 2013, LANCET ONCOL, V14, pE168, DOI 10.1016/S1470-2045(12)70532-6; [Anonymous], 2001, TAIW CANC REG ANN RE; Baijal G, 2012, HEAD NECK-J SCI SPEC, V34, P1251, DOI 10.1002/hed.21897; Boje CR, 2014, RADIOTHER ONCOL, V110, P91, DOI 10.1016/j.radonc.2013.11.009; Cannon DM, 2013, HEAD NECK-J SCI SPEC, V36, P1120; Chan ATC, 2002, J CLIN ONCOL, V20, P2038, DOI 10.1200/JCO.2002.08.149; Chang JT, 1998, JPN J CLIN ONCOL, V28, P207, DOI 10.1093/jjco/28.3.207; Chang TS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073889; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Fortin A, 2002, INT J RADIAT ONCOL, V52, P929, DOI 10.1016/S0360-3016(01)02606-2; Huang J, 2003, J CLIN ONCOL, V21, P555, DOI 10.1200/JCO.2003.04.171; Kim Tae Hee, 2008, Cancer Res Treat, V40, P62, DOI 10.4143/crt.2008.40.2.62; Kwong DLW, 1997, INT J RADIAT ONCOL, V39, P703, DOI 10.1016/S0360-3016(97)00339-8; Lin JC, 2003, J CLIN ONCOL, V21, P631, DOI 10.1200/JCO.2003.06.158; Paleri V, 2010, ORAL ONCOL, V46, P712, DOI 10.1016/j.oraloncology.2010.07.008; Round CE, 2013, CLIN ONCOL-UK, V25, P522, DOI 10.1016/j.clon.2013.05.005; Sher DJ, 2011, INT J RADIAT ONCOL, V81, pE813, DOI 10.1016/j.ijrobp.2010.12.005; Takahashi PY, 2009, OSTOMY WOUND MANAG, V55, P32; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Willems S, 2005, PATIENT EDUC COUNS, V56, P139, DOI 10.1016/j.pec.2004.02.011; Wu XC, 2012, J CLIN ONCOL, V30, P142, DOI 10.1200/JCO.2011.36.8399; Zhang L, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-558	23	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2014	9	10							e109930	10.1371/journal.pone.0109930	http://dx.doi.org/10.1371/journal.pone.0109930			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR5ZW	25314009	gold, Green Published, Green Submitted			2023-01-03	WOS:000343662500088
J	Rosa, RG; Goldani, LZ				Rosa, Regis G.; Goldani, Luciano Z.			Factors Associated with Hospital Length of Stay among Cancer Patients with Febrile Neutropenia	PLOS ONE			English	Article							COLONY-STIMULATING FACTORS; CHEMOTHERAPY; MANAGEMENT; COMPLICATIONS; METAANALYSIS; BACTEREMIA; MORTALITY; CHILDREN; COST	Purpose: This study sought to evaluate factors associated with hospital length of stay in cancer patients with febrile neutropenia. Methods: A prospective cohort study was performed at a single tertiary referral hospital in southern Brazil from October 2009 to August 2011. All adult cancer patients with febrile neutropenia admitted to the hematology ward were evaluated. Stepwise random-effects negative binomial regression was performed to identify risk factors for prolonged length of hospital stay. Results: In total, 307 cases of febrile neutropenia were evaluated. The overall median length of hospital stay was 16 days (interquartile range 18 days). According to multiple negative binomial regression analysis, hematologic neoplasms (P = 0.003), high-dose chemotherapy regimens (P<0.001), duration of neutropenia (P<0.001), and bloodstream infection involving Gram-negative multi-drug-resistant bacteria (P = 0.003) were positively associated with prolonged hospital length of stay in patients with febrile neutropenia. The condition index showed no evidence of multi-collinearity effect among the independent variables. Conclusions: Hematologic neoplasms, high-dose chemotherapy regimens, prolonged periods of neutropenia, and bloodstream infection with Gram-negative multi-drug-resistant bacteria are predictors of prolonged length hospital of stay among adult cancer patients with febrile neutropenia.	[Rosa, Regis G.; Goldani, Luciano Z.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Infect Dis Unit, Porto Alegre, RS, Brazil	Universidade Federal do Rio Grande do Sul	Goldani, LZ (corresponding author), Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Infect Dis Unit, Porto Alegre, RS, Brazil.	lgoldani@ufrgs.br	Goldani, Luciano Zubaran/U-4617-2019; Rosa, Regis/M-2291-2015; Rosa, Regis/V-2859-2017; Rosa, Regis Goulart/P-6422-2019	Rosa, Regis/0000-0001-7881-9866; Rosa, Regis/0000-0001-7881-9866; 	FIPE/HCPA (Incentive Fund for Research and Events of Hospital de Clinicas de Porto Alegre)	FIPE/HCPA (Incentive Fund for Research and Events of Hospital de Clinicas de Porto Alegre)	This study received financial support from FIPE/HCPA (Incentive Fund for Research and Events of Hospital de Clinicas de Porto Alegre). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Basu SK, 2005, J CLIN ONCOL, V23, P7958, DOI 10.1200/JCO.2005.01.6378; Bow EJ, 2013, CRIT CARE CLIN, V29, P411, DOI 10.1016/j.ccc.2013.03.002; Callaghan K, 2008, PRACTICAL ASSESSMENT, V13; Cameron D, 2009, BRIT J CANCER, V101, pS18, DOI 10.1038/sj.bjc.6605272; Clinical and Laboratory Standards Institute, 2012, M100S22 CLIN LAB STA; de Naurois J, 2010, ANN ONCOL, V21, pv252, DOI 10.1093/annonc/mdq196; De Pauw B, 2008, CLIN INFECT DIS, V46, P1813, DOI 10.1086/588660; Dulisse Brian, 2013, J Med Econ, V16, P720, DOI 10.3111/13696998.2013.782034; Freifeld AG, 2011, CLIN INFECT DIS, V52, pE56, DOI 10.1093/cid/cir073; Haeusler GM, 2013, PEDIATR INFECT DIS J, V32, P723, DOI 10.1097/INF.0b013e31828aebc8; Kim S, 2012, ARCH PHARM RES, V35, P2013, DOI 10.1007/s12272-012-1119-2; Kirkwood BR, 2003, ESSENTIALS MED STAT, P355; Klastersky J, 2000, J CLIN ONCOL, V18, P3038, DOI 10.1200/JCO.2000.18.16.3038; Klastersky J, 2004, CLIN INFECT DIS, V39, pS32, DOI 10.1086/383050; Kuderer NM, 2006, CANCER-AM CANCER SOC, V106, P2258, DOI 10.1002/cncr.21847; Lee YM, 2013, INT J NURS PRACT, V19, P557, DOI 10.1111/ijn.12099; Montassier E, 2013, EUR J CLIN MICROBIOL, V32, P841, DOI 10.1007/s10096-013-1819-7; Renner P, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007913.pub2; Sasse EC, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004139.pub2; Schilling MB, 2011, EXP THER MED, V2, P859, DOI 10.3892/etm.2011.312; Sutter DE, 2011, INFECT CONT HOSP EP, V32, P854, DOI 10.1086/661284; Taccone FS, 2009, CRIT CARE, V13, DOI 10.1186/cc7713; Weycker D, 2008, ANN ONCOL, V19, P454, DOI 10.1093/annonc/mdm525; Weycker D, 2014, J ONCOL PHARM PRACT, V20, P190, DOI 10.1177/1078155213492450; Zhou YP, 2014, SUPPORT CARE CANCER, V22, P1447, DOI 10.1007/s00520-013-2055-5	25	17	17	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2014	9	10							e108969	10.1371/journal.pone.0108969	http://dx.doi.org/10.1371/journal.pone.0108969			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU6XC	25285790	gold, Green Published, Green Submitted			2023-01-03	WOS:000345743700041
J	Bardi, DA; Halabi, MF; Hassandarvish, P; Rouhollahi, E; Paydar, M; Moghadamtousi, SZ; Al-Wajeeh, NS; Ablat, A; Abdullah, NA; Abdulla, MA				Bardi, Daleya Abdulaziz; Halabi, Mohammed Farouq; Hassandarvish, Pouya; Rouhollahi, Elham; Paydar, Mohammadjavad; Moghadamtousi, Soheil Zorofchian; Al-Wajeeh, Nahla Saeed; Ablat, Abdulwali; Abdullah, Nor Azizan; Abdulla, Mahmood Ameen			Andrographis paniculata Leaf Extract Prevents Thioacetamide-Induced Liver Cirrhosis in Rats	PLOS ONE			English	Article							CELL-CYCLE ARREST; MITOCHONDRIAL-MEDIATED APOPTOSIS; NITRIC-OXIDE SYNTHASE; TOXICITY; ANTIOXIDANT; EXPRESSION; INDUCTION	This study investigated the hepatoprotective effects of ethanolic Andrographis paniculata leaf extract (ELAP) on thioacetamide-induced hepatotoxicity in rats. An acute toxicity study proved that ELAP is not toxic in rats. To examine the effects of ELAP in vivo, male Sprague Dawley rats were given intraperitoneal injections of vehicle 10% Tween-20, 5 mL/kg (normal control) or 200 mg/kg TAA thioacetamide (to induce liver cirrhosis) three times per week. Three additional groups were treated with thioacetamide plus daily oral silymarin (50 mg/kg) or ELAP (250 or 500 mg/kg). Liver injury was assessed using biochemical tests, macroscopic and microscopic tissue analysis, histopathology, and immunohistochemistry. In addition, HepG2 and WRL-68 cells were treated in vitro with ELAP fractions to test cytotoxicity. Rats treated with ELAP exhibited significantly lower liver/body weight ratios and smoother, more normal liver surfaces compared with the cirrhosis group. Histopathology using Hematoxylin and Eosin along with Masson's Trichrome stain showed minimal disruption of hepatic cellular structure, minor fibrotic septa, a low degree of lymphocyte infiltration, and minimal collagen deposition after ELAP treatment. Immunohistochemistry indicated that ELAP induced down regulation of proliferating cell nuclear antigen. Also, hepatic antioxidant enzymes and oxidative stress parameters in ELAP-treated rats were comparable to silymarin-treated rats. ELAP administration reduced levels of altered serum liver biomarkers. ELAP fractions were non-cytotoxic to WRL-68 cells, but possessed anti-proliferative activity on HepG2 cells, which was confirmed by a significant elevation of lactate dehydrogenase, reactive oxygen species, cell membrane permeability, cytochrome c, and caspase-8,-9, and, -3/7 activity in HepG2 cells. A reduction of mitochondrial membrane potential was also detected in ELAP-treated HepG2 cells. The hepatoprotective effect of 500 mg/kg of ELAP is proposed to result from the reduction of thioacetamide-induced toxicity, normalizing reactive oxygen species levels, inhibiting cellular proliferation, and inducing apoptosis in HepG2 cells.	[Bardi, Daleya Abdulaziz; Halabi, Mohammed Farouq; Al-Wajeeh, Nahla Saeed; Abdulla, Mahmood Ameen] Univ Malaya, Fac Med, Dept Biomed Sci, Kuala Lumpur, Malaysia; [Hassandarvish, Pouya] Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur, Malaysia; [Rouhollahi, Elham; Paydar, Mohammadjavad] Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur 50603, Malaysia; [Moghadamtousi, Soheil Zorofchian] Univ Malaya, Fac Sci, Inst Biol Sci, Biomol Res Grp,Biochem Program, Kuala Lumpur, Malaysia; [Ablat, Abdulwali] Univ Malaya, Fac Sci, Inst Biol Sci, Kuala Lumpur, Malaysia	Universiti Malaya; Universiti Malaya; Universiti Malaya; Universiti Malaya; Universiti Malaya	Abdulla, MA (corresponding author), Univ Malaya, Fac Med, Dept Biomed Sci, Kuala Lumpur, Malaysia.	ammeen@um.edu.my	Halabi, Mohammed/N-4574-2019; Bardi, Daleya Abdulaziz M/C-9901-2010; Hassandarvish, Pouya/K-8112-2012; ABDULLAH, NOR AZIZAN/B-9302-2010; Paydar, Mohammadjavad/V-4800-2018; Bardi/ABD-2699-2020	Halabi, Mohammed/0000-0001-7114-515X; Bardi, Daleya Abdulaziz M/0000-0001-9091-2908; Hassandarvish, Pouya/0000-0003-0364-5587; Paydar, Mohammadjavad/0000-0002-0569-7017; 	University of Malaya [PV046/2012A]; Ministry of Higher Education Malaysia [UM.C/625/1/HIR/MOHE/SC/09]	University of Malaya(Universiti Malaya); Ministry of Higher Education Malaysia(Ministry of Education, Malaysia)	This research is supported by University of Malaya grant PV046/2012A, and High Impact Research Grant UM-MOHE UM.C/625/1/HIR/MOHE/SC/09 from the Ministry of Higher Education Malaysia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Bayaty FH, 2012, NAT PROD RES, V26, P423, DOI 10.1080/14786419.2010.496114; Alkiyumi SS, 2012, MOLECULES, V17, P6146, DOI 10.3390/molecules17056146; Alshawsh MA, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/103039; Amin ZA, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/241583; Aoyama T, 2010, HEPATOLOGY, V52, P1390, DOI 10.1002/hep.23795; Arunadevi R, 2010, J THEORETICAL EXPT B, V6; Bardi DA, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/918460; Brenner David A, 2009, Trans Am Clin Climatol Assoc, V120, P361; Chandrasekaran CV, 2009, FOOD CHEM TOXICOL, V47, P1892, DOI 10.1016/j.fct.2009.05.006; Chao WW, 2012, CHIN MED-UK, V3, P136; Cheung HY, 2005, PLANTA MED, V71, P1106, DOI 10.1055/s-2005-873128; Chiou WF, 1998, BRIT J PHARMACOL, V125, P327, DOI 10.1038/sj.bjp.0702073; Chiou WF, 2000, BRIT J PHARMACOL, V129, P1553, DOI 10.1038/sj.bjp.0703191; Garber J, 2010, GUIDE CARE USE LAB A, V8, P220; Geethangilil M, 2008, PHYTOTHER RES, V22, P1336, DOI 10.1002/ptr.2493; Ghosh M.N., 2005, FUNDAMENTALS EXPT PH; Govindarajan M, 2011, ASIAN PAC J TROP MED, V4, P176, DOI 10.1016/S1995-7645(11)60064-3; Hsiao TJ, 2007, ANN EPIDEMIOL, V17, P479, DOI 10.1016/j.annepidem.2006.12.007; Jarukamjorn K, 2008, J HEALTH SCI, V54, P370, DOI 10.1248/jhs.54.370; Kadir FA, 2014, SCI WORLD J, DOI 10.1155/2014/301879; Kadir FA, 2011, INDIAN J PHARMACOL, V43, P64, DOI 10.4103/0253-7613.75673; Karunagaran D, 2005, CURR CANCER DRUG TAR, V5, P117, DOI 10.2174/1568009053202081; Kisseleva T, 2011, BEST PRACT RES CL GA, V25, P305, DOI 10.1016/j.bpg.2011.02.011; Kumar RA, 2004, J ETHNOPHARMACOL, V92, P291, DOI 10.1016/j.jep.2004.03.004; Lee TY, 2010, APOPTOSIS, V15, P904, DOI 10.1007/s10495-010-0502-z; Li JL, 2007, EUR J PHARMACOL, V568, P31, DOI 10.1016/j.ejphar.2007.04.027; Ljubuncic P, 2005, J ETHNOPHARMACOL, V100, P198, DOI 10.1016/j.jep.2005.03.006; Luo WM, 2013, EXP THER MED, V6, P743, DOI 10.3892/etm.2013.1196; Mandal S, 2013, FOOD CHEM TOXICOLOGY; Mittal DK, 2012, INT J PHARM SCI, V3, P150; Murugan K, 2011, WORLD J MICROB BIOT, V27, P1661, DOI 10.1007/s11274-010-0620-3; Nagalekshmi R, 2011, FOOD CHEM TOXICOL, V49, P3367, DOI 10.1016/j.fct.2011.09.026; Natarajan SK, 2006, J GASTROEN HEPATOL, V21, P947, DOI 10.1111/j.1440-1746.2006.04231.x; Ng IOL, 2006, CANCER, V73, P2268; OECD, 2002, OECD ENV HLTH SAF MO, V01-24; Oyewo EB, 2012, NATURE SCI, V10, P91; Paik Yong Han, 2011, Korean J Hepatol, V17, P251, DOI 10.3350/kjhep.2011.17.4.251; Parra AL, 2001, PHYTOMEDICINE, V8, P395, DOI 10.1078/0944-7113-00044; Poli G, 1997, FREE RADICAL BIO MED, V22, P287, DOI 10.1016/S0891-5849(96)00327-9; Qader SW, 2011, MOLECULES, V16, P3433, DOI 10.3390/molecules16043433; Rajalakshmi G., 2012, Journal of Pharmacy Research, V5, P2983; Ramya M, 2012, INT J PHYTOPHARMACY, V3, P83; Salama SM, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/137083; Saraswat Binduja, 1996, Indian Journal of Pharmacology, V28, P232; Schuppan D, 2008, LANCET, V371, P838, DOI 10.1016/S0140-6736(08)60383-9; Sheeja B. D., 2012, Asian Pacific Journal of Tropical Disease, pS574; Shivaprakash G., 2011, Journal of Pharmacy Research, V4, P3375; Singha PK, 2003, FITOTERAPIA, V74, P692, DOI [10.1016/S0367-326X(03)00159-X, 10.1016/s0367-326X(03)00159-X]; Singha PK, 2007, J ETHNOPHARMACOL, V111, P13, DOI 10.1016/j.jep.2006.10.026; Sivaraj A., 2011, Journal of Applied Pharmaceutical Science, V1, P204; Stankova P, 2010, TOXICOL IN VITRO, V24, P2097, DOI 10.1016/j.tiv.2010.06.011; Takasaki Yoshinari, 2010, Nihon Rinsho, V68 Suppl 6, P578; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Varma A, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep135; Wang JH, 1998, AM J PHYSIOL-GASTR L, V275, pG1117, DOI 10.1152/ajpgi.1998.275.5.G1117; Wasman SQ, 2011, INDIAN J EXP BIOL, V49, P767; Wong WL, 2012, EVID-BASED COMPL ALT, V2012, P10; Yang S, 2010, CLIN CANCER RES, V16, P4755, DOI 10.1158/1078-0432.CCR-10-0883; Yen TL, 2013, PHARM BIOL, V51, P1150, DOI 10.3109/13880209.2013.782051; Zhang CY, 1999, PHYTOTHER RES, V13, P157, DOI 10.1002/(SICI)1099-1573(199903)13:2&lt;157::AID-PTR388&gt;3.0.CO;2-B	60	34	38	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2014	9	10							e109424	10.1371/journal.pone.0109424	http://dx.doi.org/10.1371/journal.pone.0109424			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ3DZ	25280007	Green Submitted, Green Published, gold			2023-01-03	WOS:000342670800080
J	Zhou, W; Tan, XB; Shan, JJ; Wang, SC; Yin, AL; Cai, BC; Di, LQ				Zhou, Wei; Tan, Xiaobin; Shan, Jinjun; Wang, Shouchuan; Yin, Ailing; Cai, Baochang; Di, Liuqing			Study on the Main Components Interaction from Flos Lonicerae and Fructus Forsythiae and Their Dissolution In Vitro and Intestinal Absorption in Rats	PLOS ONE			English	Article							COMBINATION; EXTRACT; BLOOD	The Flos Lonicerae-Fructus Forsythiae herb couple is the basic components of Chinese herbal preparations (Shuang-HuangLian tablet, Yin-Qiao-Jie-Du tablet and Fufang Qin-Lan oral liquid), and its pharmacological effects were significantly higher than that in Flos Lonicerae or Fructus Forsythiae, but the reasons remained unknown. In the present study, pattern recognition analysis (hierarchical cluster analysis (HCA) and principal component analysis (PCA)) combined with UHPLC-ESI/LTQ-Orbitrap MS system were performed to study the chemical constitution difference between co-decoction and mixed decoction in the term of chemistry. Besides, the pharmacokinetics in vivo and intestinal absorption in vitro combined with pattern recognition analysis were used to reveal the discrepancy between herb couple and single herbs in the view of biology. The observation from the chemical view in vitro showed that there was significant difference in quantity between co-decoction and mixed decoction by HCA, and the exposure level of isoforsythoside and 3, 5-dicaffeoylquinic acid in codecoction, higher than that in mixed decoction, directly resulted in the discrepancy between co-decoction and mixed decoction using both PCA and HCA. The observation from the pharmacokinetics displayed that the exposure level in vivo of neochlorogenic acid, 3, 4-dicaffeoylquinic acid, isoforsythoside and forsythoside A, higher than that in single herbs, was the main factor contributing to the difference by both PCA and HCA, interestingly consistent with the results obtained from Caco-2 cells in vitro, which indicated that it was because of intestinal absorption improvement of neochlorogenic acid, 3, 4-dicaffeoylquinic acid, isoforsythoside and forsythoside A that resulted in a better efficacy of herb couple than that of single herbs from the perspective of biology. The results above illustrated that caffeic acid derivatives in Flos Lonicerae-Fructus Forsythiae herb couple could be considered as chemical markers for quality control of its preparations.	[Zhou, Wei; Yin, Ailing; Cai, Baochang; Di, Liuqing] Nanjing Univ Chinese Med, Coll Pharm, Nanjing, Jiangsu, Peoples R China; [Zhou, Wei; Di, Liuqing] Jiangsu Engn Res Ctr Efficient Delivery Syst TCM, Nanjing, Jiangsu, Peoples R China; [Zhou, Wei; Di, Liuqing] Nanjing Engn Res Ctr Industrializat Chinese Med P, Nanjing, Jiangsu, Peoples R China; [Tan, Xiaobin] Jiangsu Provin Acad Chinese Med, Lab New Drug Delivery Syst Chinese Meteria Med, Nanjing, Jiangsu, Peoples R China; [Shan, Jinjun; Wang, Shouchuan] Nanjing Univ Chinese Med, Inst Paediat, Jiangsu Key Lab Pediat Resp Dis, Nanjing, Jiangsu, Peoples R China	Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine	Di, LQ (corresponding author), Nanjing Univ Chinese Med, Coll Pharm, Nanjing, Jiangsu, Peoples R China.	diliuqing@hotmail.com	Zhou, Wei/I-5964-2014; tan, xiao/GZL-0264-2022		National Natural Science Foundation of China [81001499]; Jiangsu Natural Science Foundation [BK2010560]; "Qing Lan" Project from Jiangsu Provincial Technology Innovation Team Support Scheme; priority Academic Program Development of Jiangsu Higher Education Institution [ysxk-2010]; program sponsored for scientific innovation research of college graduate in Jiangsu province [623]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Natural Science Foundation(Natural Science Foundation of Jiangsu Province); "Qing Lan" Project from Jiangsu Provincial Technology Innovation Team Support Scheme; priority Academic Program Development of Jiangsu Higher Education Institution; program sponsored for scientific innovation research of college graduate in Jiangsu province	The present study is supported financially by the National Natural Science Foundation of China (81001499), the Jiangsu Natural Science Foundation (BK2010560), "Qing Lan" Project from Jiangsu Provincial Technology Innovation Team Support Scheme, the priority Academic Program Development of Jiangsu Higher Education Institution (No. ysxk-2010), and 2012 program sponsored for scientific innovation research of college graduate in Jiangsu province (623). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Huang Mei-Yan, 2013, Zhongguo Zhong Yao Za Zhi, V38, P234; Huang Mei-yan, 2013, Zhongguo Zhong Xi Yi Jie He Za Zhi, V33, P516; Keith CT, 2005, NAT REV DRUG DISCOV, V4, P71, DOI 10.1038/nrd1609; KLAYMAN DL, 1985, SCIENCE, V228, P1049, DOI 10.1126/science.3887571; Li YY, 2008, THESIS ACAD CHINESE; Lin LM, 2008, THESIS CHINA ACAD CH; PAN SY, 2011, EVID-BASED COMPL ALT, DOI DOI 10.1093/ECAM/NEQ056; Shang XF, 2011, J ETHNOPHARMACOL, V138, P1, DOI 10.1016/j.jep.2011.08.016; Shi Xu-qin, 2012, Yaoxue Xuebao, V47, P1375; Wang L., 2010, THESIS CHENGDU U TRA; Wang L, 2008, P NATL ACAD SCI USA, V105, P4826, DOI 10.1073/pnas.0712365105; WANG LQ, 2008, THESIS AGR U HENAN; Wang XJ, 2005, BIOL PHARM BULL, V28, P1106, DOI 10.1248/bpb.28.1106; Wang ZP, 2011, THESIS GUANGZHOU U C; Xia BH, 2009, CHIN J EXPT TRAD MED, V15, P80; Zhang LW, 2002, THESIS SHANXI U; Zhou W, 2014, PHYTOMEDICINE, V21, P1549, DOI 10.1016/j.phymed.2014.06.016; Zhou W, 2014, PHYTOMEDICINE, V21, P184, DOI 10.1016/j.phymed.2013.08.001; Zhou W, 2014, J CHROMATOGR B, V949, P7, DOI 10.1016/j.jchromb.2013.12.035; Zhou W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063348; Zhou W, 2012, PHYTOMEDICINE, V20, P47, DOI 10.1016/j.phymed.2012.09.014; 李建波, 2013, [中医杂志, Journal of Traditional Chinese Medicine], V54, P1335	22	10	10	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2014	9	10							e109619	10.1371/journal.pone.0109619	http://dx.doi.org/10.1371/journal.pone.0109619			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ2BX	25275510	Green Published, Green Submitted, gold			2023-01-03	WOS:000342591500108
J	Shahul, S; Hacker, MR; Novack, V; Mueller, A; Shaefi, S; Mahmood, B; Ali, SH; Talmor, D				Shahul, Sajid; Hacker, Michele R.; Novack, Victor; Mueller, Ariel; Shaefi, Shahzad; Mahmood, Bilal; Ali, Syed Haider; Talmor, Daniel			The Effect of Hospital Volume on Mortality in Patients Admitted with Severe Sepsis	PLOS ONE			English	Article							SURGERY; CARE; OUTCOMES; PROGRAM; TRENDS	Importance: The association between hospital volume and inpatient mortality for severe sepsis is unclear. Objective: To assess the effect of severe sepsis case volume and inpatient mortality. Design Setting and Participants: Retrospective cohort study from 646,988 patient discharges with severe sepsis from 3,487 hospitals in the Nationwide Inpatient Sample from 2002 to 2011. Exposures: The exposure of interest was the mean yearly sepsis case volume per hospital divided into tertiles. Main Outcomes and Measures: Inpatient mortality. Results: Compared with the highest tertile of severe sepsis volume (>60 cases per year), the odds ratio for inpatient mortality among persons admitted to hospitals in the lowest tertile (<= 10 severe sepsis cases per year) was 1.188 (95% CI: 1.074-1.315), while the odds ratio was 1.090 (95% CI: 1.031-1.152) for patients admitted to hospitals in the middle tertile. Similarly, improved survival was seen across the tertiles with an adjusted inpatient mortality incidence of 35.81 (95% CI: 33.64-38.03) for hospitals with the lowest volume of severe sepsis cases and a drop to 32.07 (95% CI: 31.51-32.64) for hospitals with the highest volume. Conclusions and Relevance: We demonstrate an association between a higher severe sepsis case volume and decreased mortality. The need for a systems-based approach for improved outcomes may require a high volume of severely septic patients.	[Shahul, Sajid; Mueller, Ariel; Shaefi, Shahzad; Mahmood, Bilal; Talmor, Daniel] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Anesthesiol, Sch Med, Boston, MA 02215 USA; [Hacker, Michele R.] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Obstet & Gynecol, Sch Med, Boston, MA 02215 USA; [Novack, Victor] Ben Gurion Univ Negev, Clin Res Ctr, Soroka Univ Med Ctr, IL-84105 Beer Sheva, Israel; [Novack, Victor] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel; [Ali, Syed Haider] Washington & Lee Univ, Lexington, VA 24450 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Ben Gurion University; Soroka Medical Center; Ben Gurion University; Washington & Lee University	Shahul, S (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Anesthesiol, Sch Med, Boston, MA 02215 USA.	sshahul@bidmc.harvard.edu	Hacker, Michele/ABC-5031-2021	Ali, Syed/0000-0003-0524-5376	FAER (foundation for anesthesia research); The Harvard Clinical and Translational Science Center (NIH) [UL1 RR 025758]; Harvard University; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025758] Funding Source: NIH RePORTER	FAER (foundation for anesthesia research); The Harvard Clinical and Translational Science Center (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard University; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	S. Shahul is funded by FAER (foundation for anesthesia research). MH is funded by The Harvard Clinical and Translational Science Center (NIH Award #UL1 RR 025758 and financial contributions from Harvard University and its affiliated academic health care centers). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], MED CARE; Birkmeyer JD, 2007, ANN SURG, V245, P777, DOI 10.1097/01.sla.0000252402.33814.dd; Birkmeyer NJO, 2010, JAMA-J AM MED ASSOC, V304, P435, DOI 10.1001/jama.2010.1034; Carey JS, 2003, AM SURGEON, V69, P63; Checkley W, 2014, CRIT CARE MED, V42, P344, DOI 10.1097/CCM.0b013e3182a275d7; Chen YC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077414; Djogovic D, 2012, CAN J EMERG MED, V14, P36, DOI 10.2310/8000.2011.110610; Ferrer R, 2008, JAMA-J AM MED ASSOC, V299, P2294, DOI 10.1001/jama.299.19.2294; Hendryx MS, 1998, AM J RESP CRIT CARE, V158, P418, DOI 10.1164/ajrccm.158.2.9608068; Kahn JM, 2006, NEW ENGL J MED, V355, P41, DOI 10.1056/NEJMsa053993; Kumar G, 2011, CHEST, V140, P1223, DOI 10.1378/chest.11-0352; Levy MM, 2010, CRIT CARE MED, V38, P367, DOI 10.1097/CCM.0b013e3181cb0cdc; Mayr FB, 2013, VIRULENCE, V5; Powell ES, 2010, CRIT CARE MED, V38, P2161, DOI 10.1097/CCM.0b013e3181f3e09c; Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433; Reinikainen M, 2010, INTENS CARE MED, V36, P673, DOI 10.1007/s00134-009-1688-9; Ross JS, 2010, NEW ENGL J MED, V362, P1110, DOI 10.1056/NEJMsa0907130; Shahin J, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3394; Stevenson EK, 2014, CRIT CARE MED, V42, P625, DOI 10.1097/CCM.0000000000000026; Walkey AJ, 2014, AM J RESP CRIT CARE; Walkey AJ, 2011, JAMA-J AM MED ASSOC, V306, P2248, DOI 10.1001/jama.2011.1615	21	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2014	9	9							e108754	10.1371/journal.pone.0108754	http://dx.doi.org/10.1371/journal.pone.0108754			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU6XR	25264788	gold, Green Submitted, Green Published			2023-01-03	WOS:000345745400116
J	Oliver, D				Oliver, David			Preventing hospital admission: we need evidence based policy rather than "policy based evidence"	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Oliver, David] Dept Hlth, New Delhi, India		Oliver, D (corresponding author), City Univ London, Sch Hlth Sci, London EC1V OHB, England.	David.Oliver@royalberkshire.nhs.uk						*AUD COMM, 2000, WAY GO HOM REH REM S; Ayling M, 2012, HLTH SERVICE S 1129; Bardsley M, 2013, NUFFIELD TRUST; Department of Health, 2011, WHOL SYST DEM PROGR; Easton J, 2012, HLTH SERVICE J; Gravelle H, 2007, BMJ-BRIT MED J, V334, P31, DOI 10.1136/bmj.39020.413310.55; Ham C., 2011, INTEGRATED CARE WHAT; Health Foundation, 2013, UNBL HOSP GRIDL S WA; Hutt R, 2004, CASE MANAGING LONG T; NHS Confederation, 2010, DEAL DOWNT US EV; NHS England, 2019, NHS INT PEOPL PLAN; *PERS SOC SERV RES, 2010, NAT EV PARTN OLD PEO; Purdy S, 2012, INTERVENTIONS REDUCE; Rand Europe, 2012, EV UK INT CAR PIL; Singh D, 2005, TRANSFORMING CHRONIC; Steventon A, 2012, BMJ-BRIT MED J, V344, pe374; Steventon A, 2011, PARTNERSHIPS OLDER P; West D, 2014, HLTH SERVICE J, V26	18	6	6	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 23	2014	349								g5538	10.1136/bmj.g5538	http://dx.doi.org/10.1136/bmj.g5538			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AP9UL	25249450				2023-01-03	WOS:000342425700002
J	Nogrady, B				Nogrady, Bianca			Chemical tricks	NATURE			English	Editorial Material							B7 FAMILY; CANCER; MEMBER											Butts C, 2014, LANCET ONCOL, V15, P59, DOI 10.1016/S1470-2045(13)70510-2; Dong HD, 1999, NAT MED, V5, P1365; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690	4	3	3	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2014	513	7517					S10	S11		10.1038/513S10a	http://dx.doi.org/10.1038/513S10a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO5DP	25208066	Bronze			2023-01-03	WOS:000341362800006
J	Kuper, H; Monteath-van Dok, A; Wing, K; Danquah, L; Evans, J; Zuurmond, M; Gallinetti, J				Kuper, Hannah; Monteath-van Dok, Adrienne; Wing, Kevin; Danquah, Lisa; Evans, Jenny; Zuurmond, Maria; Gallinetti, Jacqueline			The Impact of Disability on the Lives of Children; Cross-Sectional Data Including 8,900 Children with Disabilities and 898,834 Children without Disabilities across 30 Countries	PLOS ONE			English	Article							NUTRITION; POVERTY; HEALTH	Background: Children with disabilities are widely believed to be less likely to attend school or access health care, and more vulnerable to poverty. There is currently little large-scale or internationally comparable evidence to support these claims. The aim of this study was to investigate the impact of disability on the lives of children sponsored by Plan International across 30 countries. Methods and Findings: We conducted a cross-sectional survey including 907,734 children aged 0-17 participating in the Plan International Sponsorship Programme across 30 countries in 2012. Parents/guardians were interviewed using standardised questionnaires including information on: age, sex, health, education, poverty, and water and sanitation facilities. Disability was assessed through a single question and information was collected on type of impairment. The dataset included 8,900 children with reported disabilities across 30 countries. The prevalence of disability ranged from 0.4%-3.0% and was higher in boys than girls in 22 of the 30 countries assessed - generally in the range of 1.3-1.4 fold higher. Children with disabilities were much less likely to attend formal education in comparison to children without disabilities in each of the 30 countries, with age-sex adjusted odds ratios exceeding 10 for nearly half of the countries. This relationship varied by impairment type. Among those attending school, children with disabilities were at a lower level of schooling for their age compared to children without disabilities. Children with disabilities were more likely to report experiencing a serious illness in the last 12 months, except in Niger. There was no clear relationship between disability and poverty. Conclusions: Children with disabilities are at risk of not fulfilling their educational potential and are more vulnerable to serious illness. This exclusion is likely to have a long-term deleterious impact on their lives unless services are adapted to promote their inclusion.	[Kuper, Hannah; Danquah, Lisa; Evans, Jenny; Zuurmond, Maria] Univ London London Sch Hyg & Trop Med, Dept Clin Res, Int Ctr Evidence Disabil, London WC1E 7HT, England; [Monteath-van Dok, Adrienne; Gallinetti, Jacqueline] Plan Int, Woking, Surrey, England; [Wing, Kevin] Univ London London Sch Hyg & Trop Med, Non Communicable Dis Epidemiol Dept, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Kuper, H (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Clin Res, Int Ctr Evidence Disabil, Keppel St, London WC1E 7HT, England.	hannah.kuper@lshtm.ac.uk	Evans, Jennifer/F-4672-2012; Wing, Kevin/I-7807-2015	Evans, Jennifer/0000-0002-6137-2030; Wing, Kevin/0000-0003-2335-9641	Plan International; STFC [ST/J001465/1] Funding Source: UKRI	Plan International; STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))	This work was funded by Plan International. The data collection was the responsibility of Plan International. The funders had no role in study design, analysis, decision to publish, or preparation of the manuscript.	Alavi Y, 2012, DISABIL REHABIL, V34, P1736, DOI 10.3109/09638288.2012.662260; [Anonymous], 2005, STAT WORLDS CHILDR 2; Bornstein MH, 2013, SOC SCI MED, V97, P307, DOI 10.1016/j.socscimed.2012.09.049; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; Filmer D, 2008, WORLD BANK ECON REV, V22, P141, DOI 10.1093/wber/lhm021; Gottlieb CA, 2009, LANCET, V374, P1831, DOI 10.1016/S0140-6736(09)61871-7; Groce NE, 2013, LANCET GLOB HEALTH, V1, pE180, DOI 10.1016/S2214-109X(13)70056-1; Jeffery R., 2011, INCLUSIVE ED EXAMINI; Kalyanpur Maya., 2007, J INT ASS SPECIAL ED, V8, P69; Maas C., 2009, MEDIA RELEASE COALIT; Mont D, 2013, WORLD DEV, V48, P88, DOI 10.1016/j.worlddev.2013.04.001; Nanoo N, 2011, LIVES CHILDREN DISAB; Nesbitt RC, 2012, DISABIL REHABIL, V34, P1089, DOI 10.3109/09638288.2011.634943; Rischewski D, 2008, T ROY SOC TROP MED H, V102, P608, DOI 10.1016/j.trstmh.2008.02.023; Simkiss DE, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-119; Singal N, 2008, TEACH TEACH EDUC, V24, P1516, DOI 10.1016/j.tate.2008.01.008; Tomlinson M, 2009, LANCET, V374, P1857, DOI 10.1016/S0140-6736(09)61910-3; Trani JF, 2011, SOC SCI MED, V73, P1477, DOI 10.1016/j.socscimed.2011.08.040; UN General Assembly, 1989, CONV RIGHTS CHILD; UNICEF, 2013, STAT WORLDS CHILDR 2; United Nations, 2011, REP SECR GEN STAT CO; United Nations, 2006, CONV RIGHTS PERS DIS; United Nations Population Division, 2011, SEX DIFF CHILDH MORT; WHO, 2011, WORLD REPORT ON DISABILITY, P1; Wu L, 2010, J HEALTH POPUL NUTR, V28, P585, DOI 10.3329/jhpn.v28i6.6607; Yousafzai AK, 2003, BRIT J NUTR, V90, P1097, DOI 10.1079/BJN2003991; Yousafzai AK, 2014, ARCH DIS CHILD, V0, P1	27	72	72	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2014	9	9							e107300	10.1371/journal.pone.0107300	http://dx.doi.org/10.1371/journal.pone.0107300			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AQ3IF	25202999	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000342684500080
J	Wang, JX; Rogers, LM; Gross, EZ; Ryals, AJ; Dokucu, ME; Brandstatt, KL; Hermiller, MS; Voss, JL				Wang, Jane X.; Rogers, Lynn M.; Gross, Evan Z.; Ryals, Anthony J.; Dokucu, Mehmet E.; Brandstatt, Kelly L.; Hermiller, Molly S.; Voss, Joel L.			Targeted enhancement of cortical-hippocampal brain networks and associative memory	SCIENCE			English	Article							MEDIAL TEMPORAL-LOBE; RHESUS-MONKEY; STIMULATION; CONNECTIVITY; SYSTEMS; CORTEX; AREA	The influential notion that the hippocampus supports associative memory by interacting with functionally distinct and distributed brain regions has not been directly tested in humans. We therefore used targeted noninvasive electromagnetic stimulation to modulate human cortical-hippocampal networks and tested effects of this manipulation on memory. Multiple-session stimulation increased functional connectivity among distributed cortical-hippocampal network regions and concomitantly improved associative memory performance. These alterations involved localized long-term plasticity because increases were highly selective to the targeted brain regions, and enhancements of connectivity and associative memory persisted for similar to 24 hours after stimulation. Targeted cortical-hippocampal networks can thus be enhanced noninvasively, demonstrating their role in associative memory.	[Wang, Jane X.; Gross, Evan Z.; Ryals, Anthony J.; Brandstatt, Kelly L.; Hermiller, Molly S.; Voss, Joel L.] Northwestern Univ, Feinberg Sch Med, Ken & Ruth Davee Dept Neurol, Dept Med Social Sci, Chicago, IL 60611 USA; [Wang, Jane X.; Gross, Evan Z.; Ryals, Anthony J.; Brandstatt, Kelly L.; Hermiller, Molly S.; Voss, Joel L.] Northwestern Univ, Feinberg Sch Med, Interdept Neurosci Program, Chicago, IL 60611 USA; [Rogers, Lynn M.] Rehabil Inst Chicago, Sensory Motor Performance Program, Chicago, IL 60611 USA; [Dokucu, Mehmet E.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Shirley Ryan AbilityLab; Northwestern University; Feinberg School of Medicine	Voss, JL (corresponding author), Northwestern Univ, Feinberg Sch Med, Ken & Ruth Davee Dept Neurol, Dept Med Social Sci, Chicago, IL 60611 USA.	joel-voss@northwestern.edu		Dokucu, Mehmet/0000-0002-1720-3467; Voss, Joel/0000-0003-4180-9335; Hermiller, Molly/0000-0001-7234-4695	National Institute of Mental Health [P50-MH094263]; National Institute of Neurological Disorders and Stroke [F32-NS083340]; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH094263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS083340] Funding Source: NIH RePORTER	National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Research was supported by awards P50-MH094263 from the National Institute of Mental Health and F32-NS083340 from the National Institute of Neurological Disorders and Stroke. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Neuroimaging was performed at the Northwestern University Center for Translational Imaging facility supported by the Northwestern University Department of Radiology. All primary behavioral data are archived in paper and electronic format in the Laboratory for Human Neuroscience of the Northwestern University Feinberg School of Medicine. All primary MRI data are archived in the Northwestern University Neuroimaging Data Archive (https://nunda.northwestern.edu).	Aggleton JP, 2012, NEUROSCI BIOBEHAV R, V36, P1579, DOI 10.1016/j.neubiorev.2011.09.005; Alvarez-Salvado E, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0152; Andrews-Hanna JR, 2010, NEURON, V65, P550, DOI 10.1016/j.neuron.2010.02.005; Battaglia FP, 2011, TRENDS COGN SCI, V15, P310, DOI 10.1016/j.tics.2011.05.008; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; CAVADA C, 1989, J COMP NEUROL, V287, P393, DOI 10.1002/cne.902870402; Dayan E, 2013, NAT NEUROSCI, V16, P838, DOI 10.1038/nn.3422; Eichenbaum H, 2007, ANNU REV NEUROSCI, V30, P123, DOI 10.1146/annurev.neuro.30.051606.094328; Eichenbaum H., 2004, CONDITIONING CONSCIO; Finke C, 2013, J NEUROSCI, V33, P11061, DOI 10.1523/JNEUROSCI.0744-13.2013; Fox MD, 2012, NEUROIMAGE, V62, P2232, DOI 10.1016/j.neuroimage.2012.03.035; Kahn I, 2008, J NEUROPHYSIOL, V100, P129, DOI 10.1152/jn.00077.2008; La Joie R, 2014, NEURON, V81, P1417, DOI 10.1016/j.neuron.2014.01.026; MESULAM MM, 1977, BRAIN RES, V136, P393, DOI 10.1016/0006-8993(77)90066-X; Mullally SL, 2012, J NEUROSCI, V32, P5646, DOI 10.1523/JNEUROSCI.5522-11.2012; Olsen RK, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00146; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ranganath C, 2012, NAT REV NEUROSCI, V13, P713, DOI 10.1038/nrn3338; Shohamy D, 2013, J EXP PSYCHOL GEN, V142, P1159, DOI 10.1037/a0034461; Staresina BP, 2013, J NEUROSCI, V33, P14184, DOI 10.1523/JNEUROSCI.1987-13.2013; Suthana N, 2012, NEW ENGL J MED, V366, P502, DOI 10.1056/NEJMoa1107212; Wagner AD, 2005, TRENDS COGN SCI, V9, P445, DOI 10.1016/j.tics.2005.07.001; Wassermann EM, 2012, PHARMACOL THERAPEUT, V133, P98, DOI 10.1016/j.pharmthera.2011.09.003; Zanto TP, 2011, NAT NEUROSCI, V14, P656, DOI 10.1038/nn.2773	25	303	318	10	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2014	345	6200					1054	1057		10.1126/science.1252900	http://dx.doi.org/10.1126/science.1252900			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN8RE	25170153	Green Accepted			2023-01-03	WOS:000340870900041
J	Zhang, CL; Ren, HJ; Liu, MM; Li, XG; Sun, DL; Li, N; Ming, L				Zhang, Chun Li; Ren, Hui Jun; Liu, Meng Meng; Li, Xiao Gai; Sun, De Li; Li, Nan; Ming, Liang			Modulation of Intestinal Epithelial Cell Proliferation, Migration, and Differentiation In Vitro by Astragalus Polysaccharides	PLOS ONE			English	Article							ORNITHINE-DECARBOXYLASE; RESTITUTION; PROTEIN; GROWTH; RATS; POLYAMINES; EXPRESSION; IMMUNITY; MUCOSA; MODEL	Previous studies have shown that Astragalus polysaccharides (APS) can be used to treat general gastrointestinal disturbances including intestinal mucosal injury. However, the mechanism by which APS mediate this effect is unclear. In the present study, the effects of APS on proliferation, migration, and differentiation of intestinal epithelial cells (IEC-6) were assessed using an in vitro wounding model and colorimetric thiazolyl blue (MTT) assays. The effect of APS on IEC-6 cell differentiation was observed using a light microscope and scanning electron microscope, and the expression of differentiation-specific markers of IEC-6 cells, such as cytokeratin 18 (CK18), alkaline phosphatase (ALP), tight junction protein ZO-2, and sucrase-isomaltase (SI), was determined by immunofluorescence assay (IFA) and real-time PCR. In addition, APS-induced signaling pathways in IEC-6 cells were characterized. Our results indicated that APS significantly enhance migration and proliferation of IEC-6 cells in vitro. APS-treated IEC-6 cells have numerous microvilli on their apical surface and also highly express CK18, ALP, ZO-2, and SI. Moreover, APS-treated IEC-6 cells, in which the activity and expression level of ornithine decarboxylase (ODC) were significantly elevated, also exhibited an increase in cellular putrescine, whereas no significant increase in TGF-beta levels was observed. These findings suggest that APS may enhance intestinal epithelial cell proliferation, migration, and differentiation in vitro by stimulating ODC gene expression and activity and putrescine production, independent of TGF-beta. Exogenous administration of APS may provide a new approach for modulating intestinal epithelial wound restitution in vivo.	[Zhang, Chun Li; Sun, De Li] Peoples Hosp Zhengzhou, Dept Gen Surg, Zhengzhou, Peoples R China; [Ren, Hui Jun; Li, Xiao Gai; Li, Nan] Zhengzhou Univ, Affiliated Hosp 1, Dept Clin Lab, Zhengzhou 450052, Peoples R China; [Liu, Meng Meng] Third Peoples Hosp Zhengzhou, Dept Pathol, Zhengzhou, Peoples R China	Zhengzhou University	Ming, L (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Clin Lab, Zhengzhou 450052, Peoples R China.	mingliang@zzu.edu.cn						BJARNASON I, 1995, GASTROENTEROLOGY, V108, P1566, DOI 10.1016/0016-5085(95)90708-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chen AQ, 2009, ANIM REPROD SCI, V115, P39, DOI 10.1016/j.anireprosci.2008.10.022; Cheng YJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027437; CIACCI C, 1993, GASTROENTEROLOGY, V105, P93, DOI 10.1016/0016-5085(93)90014-4; Dalloul RA, 2006, POULTRY SCI, V85, P446, DOI 10.1093/ps/85.3.446; Dang SS, 2009, WORLD J GASTROENTERO, V15, P5669, DOI 10.3748/wjg.15.5669; DIGNASS AU, 1994, GASTROENTEROLOGY, V106, P1254, DOI 10.1016/0016-5085(94)90017-5; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GROBLEWSKI GE, 1992, AM J PHYSIOL, V263, pG742, DOI 10.1152/ajpgi.1992.263.5.G742; Guo FC, 2004, POULTRY SCI, V83, P175, DOI 10.1093/ps/83.2.175; Hei ZQ, 2005, WORLD J GASTROENTERO, V11, P4986, DOI 10.3748/wjg.v11.i32.4986; Hikita C, 2000, J CELL BIOL, V151, P1235, DOI 10.1083/jcb.151.6.1235; Huang XY, 2008, INT J BIOL MACROMOL, V42, P166, DOI 10.1016/j.ijbiomac.2007.10.019; Hwang S, 2012, J BIOL CHEM, V287, P22227, DOI 10.1074/jbc.M112.367979; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; Lange I, 2014, J MOL BIOL, V426, P332, DOI 10.1016/j.jmb.2013.09.037; Li RJ, 2007, BIOL PHARM BULL, V30, P470, DOI 10.1248/bpb.30.470; Li SG, 2007, INT IMMUNOPHARMACOL, V7, P23, DOI 10.1016/j.intimp.2006.08.016; NUSRAT A, 1992, J CLIN INVEST, V89, P1501, DOI 10.1172/JCI115741; Paclik D, 2008, INFLAMM BOWEL DIS, V14, P1366, DOI 10.1002/ibd.20499; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Rao JN, 2002, AM J PHYSIOL-CELL PH, V282, pC885, DOI 10.1152/ajpcell.00361.2001; Ray RM, 2012, J BIOL CHEM, V287, P3674, DOI 10.1074/jbc.M111.232561; Ren HJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027010; Samal K, 2013, INT J CANCER, V133, P1323, DOI 10.1002/ijc.28139; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Song HP, 2014, J ETHNOPHARMACOL, V152, P163, DOI 10.1016/j.jep.2013.12.049; Stettler M, 2001, ANTIMICROB AGENTS CH, V45, P2256, DOI 10.1128/AAC.45.8.2256-2262.2001; Sturm A, 1999, GASTROENTEROLOGY, V117, P368, DOI 10.1053/gast.1999.0029900368; Turner JR, 2006, AM J PATHOL, V169, P1901, DOI 10.2353/ajpath.2006.060681; Tzianabos AO, 2000, CLIN MICROBIOL REV, V13, P523, DOI 10.1128/CMR.13.4.523-533.2000; WANG JY, 1991, GASTROENTEROLOGY, V100, P333, DOI 10.1016/0016-5085(91)90200-5; Wargovich MJ, 2001, J NUTR, V131, p3034S, DOI 10.1093/jn/131.11.3034S; Wu F, 2009, FASEB J, V23, P565, DOI 10.1096/fj.08-115121; Xu DJ, 2008, MOLECULES, V13, P2408, DOI 10.3390/molecules13102408; Yamada Y, 2013, DIGEST DIS SCI, V58, P1207, DOI 10.1007/s10620-012-2515-7; Zhao P, 2008, TOXICOL LETT, V182, P29, DOI 10.1016/j.toxlet.2008.08.002	40	29	36	0	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2014	9	8							e106674	10.1371/journal.pone.0106674	http://dx.doi.org/10.1371/journal.pone.0106674			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4JK	25157577	Green Published, Green Submitted, gold			2023-01-03	WOS:000341303200093
J	Wagg, AS; Newman, DK; Leichsenring, K; van Houten, P				Wagg, Adrian S.; Newman, Diane K.; Leichsenring, Kai; van Houten, Paul			Developing an Internationally-Applicable Service Specification for Continence Care: Systematic Review, Evidence Synthesis and Expert Consensus	PLOS ONE			English	Review							QUALITY-OF-LIFE; URINARY-INCONTINENCE; COST-EFFECTIVENESS; GENERAL-PRACTITIONERS; NURSE-PRACTITIONER; ADULT PATIENTS; PREVALENCE; WOMEN; UROGYNAECOLOGY; EPIDEMIOLOGY	Background: Global demographic trends suggest that the incidence of both urinary and faecal incontinence will rise in the coming years, bringing significant health and economic implications for both patients and payers. There is limited organisational evidence to guide payers and providers about service configuration which will deliver efficient guideline-compliant, high-quality patient care. Objectives: To create, using evidence from a systematic review, qualitative data and expert consensus an internationally applicable service specification for continence care. Method: Evidence was obtained from a systematic and grey literature review of published randomised controlled trials and quasi-experimental studies reporting efficacy of continence service design at the level of the community dwelling patient with either bladder or bowel incontinence, governmental reports and policy frameworks supplemented by data from 47 semi-structured interviews with clinicians, patients, patient-representatives and policy experts from four geographies broadly representative of different healthcare systems. Results: A number of themes related to current and potential future organisation of continence care were identified from the data. A modular service specification with eight core components was created including case detection, initial assessment and treatment, case co-ordination, caregiver support, community-based support, specialist assessment and treatment, use of containment products, and use of technology. Within this framework important key recommendations are: ensure robust referral pathways, shift assessment for case coordination to nurses specializing in continence care, promote self-management and technology, use comprehensive assessment tools and service performance targets based on outcome and operational measures. Conclusions: This study has defined practice gaps in the provision of continence services and described eight core components of a service specification for incontinence that commissioners and payers of health and social care could consider using to provide high-quality continence care. A shift towards a community-delivered, nurse-led model appears to be associated with clinical and cost-effective care for people with bladder and bowel incontinence.	[Wagg, Adrian S.] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Newman, Diane K.] Univ Penn, Div Urol, Philadelphia, PA USA; [Leichsenring, Kai] European Ctr Social Welf Policy & Res, Vienna, Austria; [van Houten, Paul] Zonnhuisgroep Amstelland, Elderly Med, Amstelveen, Netherlands	University of Alberta; University of Pennsylvania	Wagg, AS (corresponding author), Univ Alberta, Dept Med, Edmonton, AB, Canada.	adrian.wagg@ualberta.ca	Leichsenring, Kai/J-5943-2014	Leichsenring, Kai/0000-0002-4448-1585	SCA (Svenska Cellulosa Aktiebolaget)	SCA (Svenska Cellulosa Aktiebolaget)	The study was funded by SCA (Svenska Cellulosa Aktiebolaget). The funders had no role in the design and conduct of the study, collection, management, analysis and interpretation of data, or preparation, review and approval of the manuscript.	Abrams P, 2013, INCONTINENCE, P1895; Albers-Heitner CP, 2012, NEUROUROL URODYNAM, V31, P526, DOI 10.1002/nau.21204; Albers-Heitner P, 2011, WHO CARES STUDYING V; Albers-Heitner P, 2008, J EVAL CLIN PRACT, V14, P807, DOI 10.1111/j.1365-2753.2007.00925.x; Albers-Heitner P, 2013, SCAND J CARING SCI, V27, P253, DOI 10.1111/j.1471-6712.2012.01023.x; Albers-Heitner P, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-84; All-Party Parliamentary Group for Bladder and Bowel Continence Care, 2011, COST EFF COMM CONT C; Appleby I, 2013, INCONTINENCE AUSTR; Berg M, 2012, CONTRACTING VALUE SH; Borrie MJ, 2002, CAN MED ASSOC J, V166, P1267; Coyne KS, 2009, BJU INT, V104, P352, DOI 10.1111/j.1464-410X.2009.08427.x; de Bruin M, 2013, NEW EHEALTH SERVICE; Deglise C, 2012, J TELEMED TELECARE, V18, P273, DOI 10.1258/jtt.2012.110810; Du Moulin MFMT, 2009, SCAND J CARING SCI, V23, P222, DOI 10.1111/j.1471-6712.2008.00610.x; Ebbesen MH, 2013, BMC UROL, V13, DOI 10.1186/1471-2490-13-27; Farrell SA, 2009, J OBSTET GYNAECOL CA, V31, P247, DOI 10.1016/S1701-2163(16)34123-8; Gawande A., 2009, COST CONUNDRUM NEW Y; Gemmill Robin, 2010, Urol Nurs, V30, P336; Georgiou EX, 2011, J OBSTET GYNAECOL, V31, P156, DOI 10.3109/01443615.2010.541569; Ginsburg PB, 2012, HEALTH AFFAIR, V31, P1977, DOI 10.1377/hlthaff.2012.0350; Gotoh M, 2009, NEUROUROL URODYNAM, V28, P492, DOI 10.1002/nau.20675; GRIMBY A, 1993, AGE AGEING, V22, P82, DOI 10.1093/ageing/22.2.82; Harari D, 2013, CONTINENCE CARE SERV; Horng SS, 2013, NEUROUROL URODYNAM, V32, P371, DOI 10.1002/nau.22302; Hsiao CJ, 2014, AM J MED QUAL, V29, P44, DOI 10.1177/1062860613483870; Imamura M, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14400; Kaplan RS, 2011, HARVARD BUS REV, V89, P46; Katon WJ, 2010, NEW ENGL J MED, V363, P2611, DOI 10.1056/NEJMoa1003955; Krissovich M, 1998, GERIATR NURS, V19, P91, DOI 10.1016/S0197-4572(98)90045-3; Laurant M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001271.pub2; Lee YS, 2011, WORLD J UROL, V29, P185, DOI 10.1007/s00345-009-0490-1; Lugtenberg M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025987; Matharu G S, 2004, Br J Nurs, V13, P140; McClurg D, 2013, NEUROUROL URODYNAM, V32, P224, DOI 10.1002/nau.22284; McFall S, 1997, ARCH FAM MED, V6, P114, DOI 10.1001/archfami.6.2.114; Milsom I., 2017, INCONTINENCE, V6th ed., P15; Moore K, 2013, INCONTINENCE, P1831; Moore KH, 2003, BJOG-INT J OBSTET GY, V110, P649, DOI 10.1046/j.1471-0528.2003.02264.x; MT Ho, 2012, AUSTR NZ CONTINENCE, V18; Munneke M, 2010, LANCET NEUROL, V9, P46, DOI 10.1016/S1474-4422(09)70327-8; National Collaborating Centre for Women's & Children's Health, 2006, UR INC MAN UR INC WO; Newman D, 2013, INCONTINENCE; Newman D, 2006, TXB FEMALE UROLOGY U, P91; NICE, 2007, FAEC INC MAN FAEC IN, P6; NICE, 2013, INT METH GUID DEV SE; Noimark D, 2009, NEUROUROL URODYNAM, V28, P567; O'Donnell Maire, 2007, Eur J Gen Pract, V13, P20, DOI 10.1080/14017430601049381; Oliver R, 2009, INT UROGYNECOL J, V20, P913, DOI 10.1007/s00192-009-0878-x; Paterson J, 2003, DISABIL REHABIL, V25, P955, DOI 10.1080/096382809210142211; Paterson J, 2006, CONSULTATION C UNPUB; Ploeg J, 2010, WORLDV EVID-BASED NU, V7, P238, DOI 10.1111/j.1741-6787.2010.00202.x; Porter ME, 2009, NEW ENGL J MED, V361, P109, DOI 10.1056/NEJMp0904131; Reuben DB, 2013, J AM GERIATR SOC, V61, P857, DOI 10.1111/jgs.12268; Rice KL, 2010, AM J RESP CRIT CARE, V182, P890, DOI 10.1164/rccm.200910-1579OC; Roberts M., 2008, GETTING HLTH REFORM, DOI DOI 10.1093/ACPROF:OSO/9780195371505.001.0001; Royal College of Physicians, 2012, NAT AUD CONT CAR NAC; Schultz Susan E, 2003, Health Rep, V14, P41; Shaw C, 2000, J CLIN NURS, V9, P574, DOI 10.1046/j.1365-2702.2000.00414.x; Shaw C, 2007, FAM PRACT, V24, P461, DOI 10.1093/fampra/cmm041; Sirls LT, 2013, J UROLOGY, V189, P204, DOI 10.1016/j.juro.2012.09.050; Stephen K, 2012, INT C TEL TEL LOND U; Stewart WF, 2002, WORLD J UROL, V20, P327, DOI 10.1007/s00345-002-0301-4; Stothers L, 2008, CAN J UROL, V15, P4084; Swanson JG, 2002, CAN FAM PHYSICIAN, V48, P86; Tarricone R, 2010, EC INCONTINENCE; Tennstedt SL, 2008, AM J EPIDEMIOL, V167, P390, DOI 10.1093/aje/kwm356; Thomas P, 2004, INT J GERIATR PSYCH, V19, P127, DOI 10.1002/gps.1039; van der Veen R, 2011, QUALITY LIFE CARERS; Viktrup Lars, 2004, BMC Fam Pract, V5, P13, DOI 10.1186/1471-2296-5-13; Wagg A, 2005, J EVAL CLIN PRACT, V11, P525, DOI 10.1111/j.1365-2753.2005.00570.x; Wagg A, 2009, AGE AGEING, V38, P730, DOI 10.1093/ageing/afp177; Wicks P, 2014, QUAL LIFE RES, V23, P195, DOI 10.1007/s11136-013-0458-x; Williams KS, 2005, BRIT J GEN PRACT, V55, P696; Wilson L, 2001, OBSTET GYNECOL, V98, P398, DOI 10.1016/S0029-7844(01)01464-8	74	14	14	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2014	9	8							e104129	10.1371/journal.pone.0104129	http://dx.doi.org/10.1371/journal.pone.0104129			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AO0QT	25121511	gold, Green Submitted, Green Published			2023-01-03	WOS:000341017000029
J	Chen, CH; Tang, SC; Tsai, LK; Hsieh, MJ; Yeh, SJ; Huang, KY; Jeng, JS				Chen, Chih-Hao; Tang, Sung-Chun; Tsai, Li-Kai; Hsieh, Ming-Ju; Yeh, Shin-Joe; Huang, Kuang-Yu; Jeng, Jiann-Shing			Stroke Code Improves Intravenous Thrombolysis Administration in Acute Ischemic Stroke	PLOS ONE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; TO-NEEDLE TIMES; IN-HOSPITAL MORTALITY; SAFE IMPLEMENTATION; GUIDELINES-STROKE; CASE-FATALITY; ADMISSION; TAIWAN; IMPACT; CARE	Background and Purpose: Timely intravenous (IV) thrombolysis for acute ischemic stroke is associated with better clinical outcomes. Acute stroke care implemented with "Stroke Code'' (SC) may increase IV tissue plasminogen activator (tPA) administration. The present study aimed to investigate the impact of SC on thrombolysis. Methods: The study period was divided into the "pre-SC era'' (January 2006 to July 2010) and "SC era'' (August 2010 to July 2013). Demographics, critical times (stroke symptom onset, presentation to the emergency department, neuroimaging, thrombolysis), stroke severity, and clinical outcomes were recorded and compared between the two eras. Results: During the study period, 5957 patients with acute ischemic stroke were admitted; of these, 1301 (21.8%) arrived at the emergency department within 3 h of stroke onset and 307 (5.2%) received IV-tPA. The number and frequency of IV-tPA treatments for patients with an onset-to-door time of <3 h increased from the pre-SC era (n = 91, 13.9%) to the SC era (n = 216, 33.3%) (P < 0.001). SC also improved the efficiency of IV-tPA administration; the median door-to-needle time decreased (88 to 51 min, P < 0.001) and the percentage of door-to-needle times <= 60 min increased (14.3% to 71.3%, P < 0.001). The SC era group tended to have more patients with good outcome (modified Rankin Scale <= 2) at discharge (49.5 vs. 39.6%, P = 0.11), with no difference in symptomatic hemorrhage events or in-hospital mortality. Conclusion: The SC protocol increases the percentage of acute ischemic stroke patients receiving IV-tPA and decreases door-to-needle time.	[Chen, Chih-Hao; Tang, Sung-Chun; Tsai, Li-Kai; Yeh, Shin-Joe; Huang, Kuang-Yu; Jeng, Jiann-Shing] Natl Taiwan Univ Hosp, Stroke Ctr, Taipei, Taiwan; [Chen, Chih-Hao; Tang, Sung-Chun; Tsai, Li-Kai; Yeh, Shin-Joe; Huang, Kuang-Yu; Jeng, Jiann-Shing] Natl Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan; [Chen, Chih-Hao] Far Eastern Mem Hosp, Dept Internal Med, Div Neurol, New Taipei City, Taiwan; [Hsieh, Ming-Ju] Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan; [Hsieh, Ming-Ju] Natl Taiwan Univ, Grad Inst Epidemiol & Prevent Med, Taipei 10764, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Far Eastern Memorial Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Jeng, JS (corresponding author), Natl Taiwan Univ Hosp, Stroke Ctr, Taipei, Taiwan.	jsjeng@ntu.edu.tw	Chen, Chih-Hao/AAA-7297-2022; yeh, shin-joe/HGV-0244-2022; Tsai, Li-Kai/HJA-2534-2022	Chen, Chih-Hao/0000-0002-1258-8775; Tang, Sung-Chun/0000-0003-3731-5973; HSIEH, MING-JU/0000-0003-3636-6250; Yeh, Shin-Joe/0000-0003-1511-6295; Tsai, Li-Kai/0000-0001-8420-6951; JENG, JIANN-SHING/0000-0002-1456-3686	National Taiwan University Hospital [A116]	National Taiwan University Hospital(National Taiwan University)	The work was supported by grant A116 from National Taiwan University Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acker JE, 2007, STROKE, V38, P3097, DOI 10.1161/STROKEAHA.107.186094; ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Albright KC, 2012, CEREBROVASC DIS, V34, P424, DOI 10.1159/000345077; [Anonymous], TAIW GUID MAN STROK; Arora S, 2005, STROKE, V36, P1232, DOI 10.1161/01.STR.0000165902.18021.5b; Balami JS, 2013, BRAIN, V136, P3528, DOI 10.1093/brain/awt201; Dalloz MA, 2012, J NEUROL SCI, V314, P120, DOI 10.1016/j.jns.2011.10.009; de la Ossa NP, 2008, NEUROLOGY, V70, P1238, DOI 10.1212/01.wnl.0000291008.63002.a5; Etgen T, 2011, ACTA NEUROL SCAND, V123, P390, DOI 10.1111/j.1600-0404.2010.01413.x; Fonarow GC, 2014, JAMA-J AM MED ASSOC, V311, P1632, DOI 10.1001/jama.2014.3203; Fonarow GC, 2011, STROKE, V42, P2983, DOI 10.1161/STROKEAHA.111.621342; Fonarow GC, 2011, CIRCULATION, V123, P750, DOI 10.1161/CIRCULATIONAHA.110.974675; Ford AL, 2012, STROKE, V43, P3395, DOI 10.1161/STROKEAHA.112.670687; Gladstone DJ, 2009, STROKE, V40, P3841, DOI 10.1161/STROKEAHA.108.540377; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Hacke Werner, 2008, N Engl J Med, V359, P1317, DOI 10.1056/NEJMoa0804656; Hamidon BB, 2007, J CLIN NEUROSCI, V14, P831, DOI 10.1016/j.jocn.2006.03.029; Hasegawa Y, 2005, CEREBROVASC DIS, V20, P325, DOI 10.1159/000087932; Heo JH, 2010, STROKE, V41, P1978, DOI 10.1161/STROKEAHA.110.583591; Heuschmann PU, 2003, STROKE, V34, P1106, DOI 10.1161/01.STR.0000065198.80347.C5; Hoh BL, 2010, STROKE, V41, P2323, DOI 10.1161/STROKEAHA.110.591081; Hsieh CY, 2014, J FORMOS MED ASSOC, V113, P929, DOI 10.1016/j.jfma.2013.11.012; Hsieh FI, 2010, CIRCULATION, V122, P1116, DOI 10.1161/CIRCULATIONAHA.110.936526; Kim SK, 2009, EUR J NEUROL, V16, P1331, DOI 10.1111/j.1468-1331.2009.02762.x; Lee HY, 2010, STROKE, V41, P739, DOI 10.1161/STROKEAHA.109.573543; Lin CB, 2012, CIRC-CARDIOVASC QUAL, V5, P514, DOI 10.1161/CIRCOUTCOMES.112.965210; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Nazir FS, 2009, J CLIN NEUROSCI, V16, P21, DOI 10.1016/j.jocn.2008.02.004; Ogbu UC, 2011, J NEUROL NEUROSUR PS, V82, P8, DOI 10.1136/jnnp.2009.202176; Reeves MJ, 2009, STROKE, V40, P569, DOI 10.1161/STROKEAHA.108.519355; Rizos T, 2009, STROKE, V40, P3547, DOI 10.1161/STROKEAHA.109.562769; Ruff IM, 2014, STROKE, V45, P504, DOI 10.1161/STROKEAHA.113.004073; Saposnik G, 2007, STROKE, V38, P1211, DOI 10.1161/01.STR.0000259622.78616.ea; Saposnik G, 2012, STROKE, V43, P1315, DOI 10.1161/STROKEAHA.111.646265; Saver JL, 2013, JAMA-J AM MED ASSOC, V309, P2480, DOI 10.1001/jama.2013.6959; Seshadri S, 2007, LANCET NEUROL, V6, P1106, DOI 10.1016/S1474-4422(07)70291-0; Sobesky J, 2007, CEREBROVASC DIS, V24, P56, DOI 10.1159/000103117; Summers D, 2009, STROKE, V40, P2911, DOI 10.1161/STROKEAHA.109.192362; Sung Sheng-Feng, 2010, Acta Neurol Taiwan, V19, P246; Tai YJ, 2012, INTERN MED J, V42, P1316, DOI 10.1111/j.1445-5994.2011.02709.x; Truelsen T, 2005, EUR J NEUROL, V12, P78, DOI 10.1111/j.1468-1331.2005.01199.x; Tung YC, 2009, MED CARE, V47, P1018, DOI 10.1097/MLR.0b013e3181a81144; Tveiten A, 2009, EMERG MED J, V26, P324, DOI 10.1136/emj.2008.063610; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4; Wahlgren N, 2008, STROKE, V39, P3316, DOI 10.1161/STROKEAHA.107.510768; Wardlaw JM, 2012, LANCET, V379, P2364, DOI 10.1016/S0140-6736(12)60738-7; Yip PK, 1997, STROKE, V28, P2507, DOI 10.1161/01.STR.28.12.2507	47	32	41	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 11	2014	9	8							e104862	10.1371/journal.pone.0104862	http://dx.doi.org/10.1371/journal.pone.0104862			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO1WB	25111200	Green Published, Green Submitted, gold			2023-01-03	WOS:000341105100107
J	Ishihara, M; Seo, N; Mitsui, J; Muraoka, D; Tanaka, M; Mineno, J; Ikeda, H; Shiku, H				Ishihara, Mikiya; Seo, Naohiro; Mitsui, Jun; Muraoka, Daisuke; Tanaka, Maki; Mineno, Junichi; Ikeda, Hiroaki; Shiku, Hiroshi			Systemic CD8(+) T Cell-Mediated Tumoricidal Effects by Intratumoral Treatment of Oncolytic Herpes Simplex Virus with the Agonistic Monoclonal Antibody for Murine Glucocorticoid-Induced Tumor Necrosis Factor Receptor	PLOS ONE			English	Article							COLONY-STIMULATING FACTOR; CLINICAL-TRIAL; VIRAL THERAPY; HSV TYPE-1; CANCER; HF10; POXVIRUS; JX-594; SAFETY; IPILIMUMAB	Oncolytic virotherapy combined with immunomodulators is a novel noninvasive strategy for cancer treatment. In this study, we examined the tumoricidal effects of oncolytic HF10, a naturally occurring mutant of herpes simplex virus type-1, combined with an agonistic DTA-1 monoclonal antibody specific for the glucocorticoid-induced tumor necrosis factor receptor. Two murine tumor models were used to evaluate the therapeutic efficacies of HF10 virotherapy combined with DTA-1. The kinetics and immunological mechanisms of DTA-1 in HF10 infection were examined using flow cytometry and immunohistochemistry. Intratumoral administration of HF10 in combination with DTA-1 at a low dose resulted in a more vigorous attenuation of growth of the untreated contralateral as well as the treated tumors than treatment with either HF10 or DTA-1 alone. An accumulation of CD8(+) T cells, including tumor- and herpes simplex virus type-1-specific populations, and a decrease in the number of CD4(+) Foxp3(+) T regulatory cells were seen in both HF10- and DTA-1-treated tumors. Studies using Fc-digested DTA-1 and Fc gamma receptor knockout mice demonstrated the direct participation of DTA-1 in regulatory T cell depletion by antibody-dependent cellular cytotoxicity primarily via macrophages. These results indicated the potential therapeutic efficacy of a glucocorticoid-induced tumor necrosis factor receptor-specific monoclonal antibody in oncolytic virotherapy at local tumor sites.	[Ishihara, Mikiya; Seo, Naohiro; Muraoka, Daisuke; Ikeda, Hiroaki; Shiku, Hiroshi] Mie Univ, Grad Sch Med, Dept Immunogene Therapy, Tsu, Mie, Japan; [Mitsui, Jun] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol Surg 2, Sapporo, Hokkaido 060, Japan; [Tanaka, Maki; Mineno, Junichi] Takara Bio Inc, Gene Med Business Unit, Tokyo, Shiga, Japan	Mie University; Hokkaido University; Takara Bio Inc.	Seo, N (corresponding author), Mie Univ, Grad Sch Med, Dept Immunogene Therapy, Tsu, Mie, Japan.	seo-naohiro@clin.medic.mie-u.ac.jp; shiku@clin.medic.mie-u.ac.jp	Shiku, Hiroshi/U-7321-2019	Shiku, Hiroshi/0000-0002-0362-755X; ISHIHARA, Mikiya/0000-0002-7581-2615	Ministry of Education, Culture, Sports, Science and Technology of Japan [24390300, 24800033]; Grants-in-Aid for Scientific Research [24390300] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by grants from Ministry of Education, Culture, Sports, Science and Technology of Japan (24390300 and 24800033). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Breitbach CJ, 2011, NATURE, V477, P99, DOI 10.1038/nature10358; Breitbach CJ, 2010, CYTOKINE GROWTH F R, V21, P85, DOI 10.1016/j.cytogfr.2010.02.001; Campadelli-Fiume G, 2011, REV MED VIROL, V21, P213, DOI 10.1002/rmv.691; Cohen AD, 2006, CANCER RES, V66, P4904, DOI 10.1158/0008-5472.CAN-05-2813; Cohen AD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010436; Cote AL, 2011, J IMMUNOL, V186, P275, DOI 10.4049/jimmunol.1001308; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Eager RM, 2011, CANCER GENE THER, V18, P305, DOI 10.1038/cgt.2011.7; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Fujimoto Y, 2006, ACTA OTO-LARYNGOL, V126, P1115, DOI 10.1080/00016480600702100; Goshima F, 2014, INT J CANCER, V134, P2865, DOI 10.1002/ijc.28631; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hans R, 2013, J CLIN ONCOL, V31; Huang AYC, 1996, P NATL ACAD SCI USA, V93, P9730, DOI 10.1073/pnas.93.18.9730; Hwang TH, 2011, MOL THER, V19, P1913, DOI 10.1038/mt.2011.132; Ikeda H, 1997, P NATL ACAD SCI USA, V94, P6375, DOI 10.1073/pnas.94.12.6375; Imai N, 2009, CANCER SCI, V100, P1317, DOI 10.1111/j.1349-7006.2009.01179.x; Kaufman HL, 2010, FUTURE ONCOL, V6, P941, DOI 10.2217/FON.10.66; Kaufman HL, 2010, ANN SURG ONCOL, V17, P718, DOI 10.1245/s10434-009-0809-6; Kim JH, 2006, MOL THER, V14, P361, DOI 10.1016/j.ymthe.2006.05.008; Kimata H, 2006, ANN SURG ONCOL, V13, P1078, DOI 10.1245/ASO.2006.08.035; Ko K, 2005, J EXP MED, V202, P885, DOI 10.1084/jem.20050940; Kohno SI, 2007, CANCER GENE THER, V14, P918, DOI 10.1038/sj.cgt.7701070; La S, 2005, EXP MOL MED, V37, P193, DOI 10.1038/emm.2005.26; LERNER WA, 1983, INT J CANCER, V31, P463, DOI 10.1002/ijc.2910310411; Li YJ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0070390, 10.1371/journal.pone.0080475]; Liu BL, 2003, GENE THER, V10, P292, DOI 10.1038/sj.gt.3301885; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; Merrick AE, 2009, CURR OPIN INVEST DR, V10, P1372; Mitsui J, 2010, CLIN CANCER RES, V16, P2781, DOI 10.1158/1078-0432.CCR-09-3243; Mori I, 2005, MICROBES INFECT, V7, P1492, DOI 10.1016/j.micinf.2005.05.007; Muraoka D, 2010, J IMMUNOL, V185, P3768, DOI 10.4049/jimmunol.0903649; Nakao A, 2004, ANN ONCOL, V15, P988, DOI 10.1093/annonc/mdh225; Nakao A, 2011, CANCER GENE THER, V18, P167, DOI 10.1038/cgt.2010.65; Nishikawa H, 2008, CANCER RES, V68, P5948, DOI 10.1158/0008-5472.CAN-07-5839; NISHIYAMA Y, 1991, J VIROL, V65, P4520, DOI 10.1128/JVI.65.8.4520-4524.1991; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Park BH, 2008, LANCET ONCOL, V9, P533, DOI 10.1016/S1470-2045(08)70107-4; Postow MA, 2013, ONCOLOGIST, V18, P726, DOI 10.1634/theoncologist.2012-0464; Ribas A, 2013, J CLIN ONCOL, V31, P616, DOI 10.1200/JCO.2012.44.6112; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Rosenzweig M, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.e13028; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Vaha-Koskela MJV, 2007, CANCER LETT, V254, P178, DOI 10.1016/j.canlet.2007.02.002; Wang W, 2012, INT J CANCER, V131, pE928, DOI 10.1002/ijc.27613; Weber JS, 2013, CANCER-AM CANCER SOC, V119, P1675, DOI 10.1002/cncr.27969; Wolf D, 2005, CLIN CANCER RES, V11, P8326, DOI 10.1158/1078-0432.CCR-05-1244	52	8	10	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2014	9	8							e104669	10.1371/journal.pone.0104669	http://dx.doi.org/10.1371/journal.pone.0104669			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR0CG	25105508	gold, Green Submitted, Green Published			2023-01-03	WOS:000343231900077
J	Bailey, AM; Mendicino, M; Au, P				Bailey, Alexander M.; Mendicino, Michael; Au, Patrick			An FDA perspective on preclinical development of cell-based regenerative medicine products	NATURE BIOTECHNOLOGY			English	Letter									[Bailey, Alexander M.; Mendicino, Michael; Au, Patrick] US FDA, Ctr Biol Evaluat & Res, Off Cellular Tissue & Gene Therapies, Silver Spring, MD 20993 USA; [Mendicino, Michael] US FDA, Off Commissioner, Off Chief Scientist, Off Regulatory Sci & Innovat, Silver Spring, MD USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Bailey, AM (corresponding author), US FDA, Ctr Biol Evaluat & Res, Off Cellular Tissue & Gene Therapies, Silver Spring, MD 20993 USA.	alexander.bailey@fda.hhs.gov; m.mendicino.phd@gmail.com; pakwai.au@fda.hhs.gov						Anatol R, 2014, PRINCIPLES OF TISSUE ENGINEERING, 4TH EDITION, P1781, DOI 10.1016/B978-0-12-398358-9.00086-0; Bailey AM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003685; Mendicino M, 2014, CELL STEM CELL, V14, P141, DOI 10.1016/j.stem.2014.01.013; Robinson R, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003394	4	47	50	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2014	32	8					721	723		10.1038/nbt.2971	http://dx.doi.org/10.1038/nbt.2971			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	AW7PF	25093890				2023-01-03	WOS:000346455900008
J	Ziegler, YS; Moresco, JJ; Tu, PG; Yates, JR; Nardulli, AM				Ziegler, Yvonne S.; Moresco, James J.; Tu, Patricia G.; Yates, John R., III; Nardulli, Ann M.			Plasma Membrane Proteomics of Human Breast Cancer Cell Lines Identifies Potential Targets for Breast Cancer Diagnosis and Treatment	PLOS ONE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; BETA-TUBULIN EXPRESSION; GENE-EXPRESSION; PROSTATE-CANCER; ADHESION MOLECULE; POOR-PROGNOSIS; OVARIAN-CANCER; TUMOR-CELLS; MYOSIN-II; RECEPTOR	The use of broad spectrum chemotherapeutic agents to treat breast cancer results in substantial and debilitating side effects, necessitating the development of targeted therapies to limit tumor proliferation and prevent metastasis. In recent years, the list of approved targeted therapies has expanded, and it includes both monoclonal antibodies and small molecule inhibitors that interfere with key proteins involved in the uncontrolled growth and migration of cancer cells. The targeting of plasma membrane proteins has been most successful to date, and this is reflected in the large representation of these proteins as targets of newer therapies. In view of these facts, experiments were designed to investigate the plasma membrane proteome of a variety of human breast cancer cell lines representing hormone-responsive, ErbB2 over-expressing and triple negative cell types, as well as a benign control. Plasma membranes were isolated by using an aqueous two-phase system, and the resulting proteins were subjected to mass spectrometry analysis. Overall, each of the cell lines expressed some unique proteins, and a number of proteins were expressed in multiple cell lines, but in patterns that did not always follow traditional clinical definitions of breast cancer type. From our data, it can be deduced that most cancer cells possess multiple strategies to promote uncontrolled growth, reflected in aberrant expression of tyrosine kinases, cellular adhesion molecules, and structural proteins. Our data set provides a very rich and complex picture of plasma membrane proteins present on breast cancer cells, and the sorting and categorizing of this data provides interesting insights into the biology, classification, and potential treatment of this prevalent and debilitating disease.	[Ziegler, Yvonne S.; Nardulli, Ann M.] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; [Moresco, James J.; Tu, Patricia G.; Yates, John R., III] Scripps Res Inst, Dept Physiol Chem, La Jolla, CA 92037 USA	University of Illinois System; University of Illinois Urbana-Champaign; Scripps Research Institute	Nardulli, AM (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA.	anardull@life.illinois.edu		Moresco, James/0000-0003-1178-1642	National Institutes of Health [R01 DK053884]; National Institute of General Medical Sciences [8 P41 GM103533]; National Institute on Aging [R01AG027463]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027463] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	YSZ and AMN were supported by the National Institutes of Health (R01 DK053884 to AMN, www.nih.gov). PGT, JJM, and JRY were supported by the National Institute of General Medical Sciences (8 P41 GM103533 to JRY, www.nigms.nih.gov). JJM and JRY were supported by the National Institute on Aging (R01AG027463 to JRY, www.nia.nih.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Ejeh F, 2013, J NUCL MED, V54, P913, DOI 10.2967/jnumed.112.111534; Alshareeda AT, 2013, BREAST CANCER RES TR, V139, P23, DOI 10.1007/s10549-013-2518-x; Aptsiauri N, 2013, SPRINGER BRIEFS CANC, V6, P13; Arjonen A, 2014, J CLIN INVE IN PRESS; Bao SD, 2008, CANCER RES, V68, P6043, DOI 10.1158/0008-5472.CAN-08-1079; Baselga J, 2012, LANCET, V379, P633, DOI 10.1016/S0140-6736(11)61847-3; Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129; Betapudi V, 2006, CANCER RES, V66, P4725, DOI 10.1158/0008-5472.CAN-05-4236; Boichuk S, 2014, CANCER RES, V74, P1200, DOI 10.1158/0008-5472.CAN-13-1955; Bozic I, 2013, ELIFE, V2, DOI 10.7554/eLife.00747; Carvalho PC, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-316; Carvalho PC, 2010, ANONYMOUS CURRENT PR; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chen HJ, 2006, GENE DEV, V20, P1933, DOI 10.1101/gad.1411206; Chettouh H, 2013, CANCER RES, V73, P3974, DOI 10.1158/0008-5472.CAN-12-3824; Cho SH, 2012, INT J ONCOL, V41, P211, DOI 10.3892/ijo.2012.1453; Christiansen DH, 2005, LEUKEMIA, V19, P2232, DOI 10.1038/sj.leu.2404009; Clucas J, 2014, J CELL SCI, V127, P267, DOI 10.1242/jcs.133108; Cooper ZA, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24320; Daaka Y., 2004, SCI STKE, V2004, pre2, DOI [10.1126/stke.2162004re2, DOI 10.1126/STKE.2162004RE2]; de Groote ML, 2014, INT J CANCER, V134, P280, DOI 10.1002/ijc.28375; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Doherty GJ, 2008, ANNU REV BIOPHYS, V37, P65, DOI 10.1146/annurev.biophys.37.032807.125912; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Draeger A, 2011, BIOCHEM PHARMACOL, V81, P703, DOI 10.1016/j.bcp.2010.12.027; Drews-Elger K, 2014, BREAST CANCER RES TR, V144, P503, DOI 10.1007/s10549-014-2887-9; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Fujihara Tomofumi, 1999, Gastric Cancer, V2, P221, DOI 10.1007/s101200050067; Giarnieri E, 2005, ANTICANCER RES, V25, P3237; Gonzalez L, 2012, ANN DIAGN PATHOL, V16, P260, DOI 10.1016/j.anndiagpath.2011.11.004; Gusterson BA, 2005, BREAST CANCER RES, V7, P143, DOI 10.1186/bcr1041; Haeuw JF, 2011, BIOCHEM SOC T, V39, P553, DOI 10.1042/BST0390553; Hai J, 2012, CLIN CANCER RES, V18, P1914, DOI 10.1158/1078-0432.CCR-11-2893; Heideman MR, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3564; Hsu KS, 2013, VITAM HORM, V93, P323, DOI 10.1016/B978-0-12-416673-8.00005-8; Hutchings CJ, 2010, MABS-AUSTIN, V2, P594, DOI 10.4161/mabs.2.6.13420; Hwang JR, 2012, CARCINOGENESIS, V33, P77, DOI 10.1093/carcin/bgr257; Imbert AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043752; Iwanicki MP, 2011, CANCER DISCOV, V1, P144, DOI 10.1158/2159-8274.CD-11-0010; Jensen M, 2007, CANCER LETT, V258, P9, DOI 10.1016/j.canlet.2007.09.004; Kaneko K, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-454; Kischel P, 2012, ANTICANCER RES, V32, P5211; Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545; Kohmo S, 2010, CANCER RES, V70, P8025, DOI 10.1158/0008-5472.CAN-10-0996; Leandro-Garcia LJ, 2010, CYTOSKELETON, V67, P214, DOI 10.1002/cm.20436; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Lennartsson J, 2006, CURR CANCER DRUG TAR, V6, P65, DOI 10.2174/156800906775471725; Levallet G, 2012, MOL CANCER THER, V11, P1203, DOI 10.1158/1535-7163.MCT-11-0899; Li DQ, 2006, PROTEOMICS, V6, P3352, DOI 10.1002/pmic.200500617; Li R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039766; Lili LN, 2014, PANCREAS, V43, P198, DOI 10.1097/MPA.0000000000000020; Liu D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039989; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; Liu ZF, 2008, DRUG DEVELOP RES, V69, P329, DOI 10.1002/ddr.20265; Liu Z, 2014, INT J MOL MED, V33, P589, DOI 10.3892/ijmm.2013.1598; Malaguarnera Roberta, 2011, Front Endocrinol (Lausanne), V2, P93, DOI 10.3389/fendo.2011.00093; Matteucci E, 2009, CARCINOGENESIS, V30, P937, DOI 10.1093/carcin/bgp080; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Meyer AS, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004155; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morre DM, 2000, J CHROMATOGR B, V743, P377, DOI 10.1016/S0378-4347(00)00058-X; Muller-Tidow C, 2005, CANCER RES, V65, P1778, DOI 10.1158/0008-5472.CAN-04-3388; Murayama Y, 2008, J CELL PHYSIOL, V216, P135, DOI 10.1002/jcp.21384; Nakopoulou L, 2002, HISTOPATHOLOGY, V40, P536, DOI 10.1046/j.1365-2559.2002.01392.x; Nallapalli RK, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-50; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Ou YQ, 2014, UROL ONCOL-SEMIN ORI, V32, DOI 10.1016/j.urolonc.2013.06.017; Park SJ, 2013, CELL SIGNAL, V25, P2147, DOI 10.1016/j.cellsig.2013.07.001; Pillai SKK, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-18; Rangel LBA, 2004, CANCER BIOL THER, V3, P1021, DOI 10.4161/cbt.3.10.1142; Raymond JR, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-6; Roland CL, 2007, SURGERY, V141, P705, DOI 10.1016/j.surg.2007.01.016; Ross DT, 2001, DIS MARKERS, V17, P99, DOI 10.1155/2001/850531; Rysman E, 2010, CANCER RES, V70, P8117, DOI 10.1158/0008-5472.CAN-09-3871; Saifo MS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-310; Samuel J, 2014, NEW ENGL J MED, V370, P286, DOI 10.1056/NEJMc1310849; Sandberg R, 2005, P NATL ACAD SCI USA, V102, P2052, DOI 10.1073/pnas.0408105102; Schindler J, 2006, MOL CELL PROTEOMICS, V5, P390, DOI 10.1074/mcp.T500017-MCP200; Schneider SA, 2013, MOD PATHOL IN PRESS; Schroder C, 2011, J CANCER RES CLIN, V137, P1193, DOI 10.1007/s00432-011-0984-2; Schulz WA, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-505; Seve P, 2005, MOL CANCER THER, V4, P2001, DOI 10.1158/1535-7163.MCT-05-0244; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Siu IM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078895; Smith DC, 2013, J CLIN ONCOL, V31, P412, DOI 10.1200/JCO.2012.45.0494; Stevenson RP, 2012, J CELL SCI, V125, P1073, DOI 10.1242/jcs.093799; Suizu F, 2000, J BIOCHEM-TOKYO, V128, P435, DOI 10.1093/oxfordjournals.jbchem.a022771; Tsang Stella W Y, 2003, Methods Mol Biol, V227, P351, DOI 10.1385/1-59259-387-9:351; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Veitonmaki N, 2013, CANCER CELL, V23, P502, DOI 10.1016/j.ccr.2013.02.026; Volakis LI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086110; Wang T, 2005, BLOOD, V105, P2836, DOI 10.1182/blood-2004-07-2878; Ward Y, 2013, ONCOGENE, V32, P2726, DOI 10.1038/onc.2012.301; Ward Y, 2011, CANCER RES, V71, P7301, DOI 10.1158/0008-5472.CAN-11-2381; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wazir U, 2013, CANCER GENOM PROTEOM, V10, P69; Weaver AM, 2006, CLIN EXP METASTAS, V23, P97, DOI 10.1007/s10585-006-9014-1; Wobus M, 2006, MOL CARCINOGEN, V45, P881, DOI 10.1002/mc.20262; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Woolner S, 2009, TRENDS CELL BIOL, V19, P245, DOI 10.1016/j.tcb.2009.03.003; Yan J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065463; Yao Jian, 2012, Cancer Biology Medicine, V9, P234, DOI 10.7497/j.issn.2095-3941.2012.04.003; Yates JR, 2005, NAT REV MOL CELL BIO, V6, P702, DOI 10.1038/nrm1711; Yu JW, 2013, GASTROENT RES PRACT, V2013, DOI 10.1155/2013/210205; Yue JY, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-7; Zabouo G, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2215; Zeimet AG, 2013, JNCI-J NATL CANCER I, V105, P1142, DOI 10.1093/jnci/djt144	110	32	35	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2014	9	7							e102341	10.1371/journal.pone.0102341	http://dx.doi.org/10.1371/journal.pone.0102341			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4KM	25029196	Green Submitted, Green Published, gold			2023-01-03	WOS:000341306600067
J	Goyama, S; Huang, G; Kurokawa, M; Mulloy, JC				Goyama, S.; Huang, G.; Kurokawa, M.; Mulloy, J. C.			Posttranslational modifications of RUNX1 as potential anticancer targets	ONCOGENE			English	Review							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; FAMILIAL PLATELET DISORDER; HEMATOPOIETIC STEM-CELLS; E3 UBIQUITIN LIGASE; POINT MUTATIONS; MYELODYSPLASTIC SYNDROME; TUMOR-SUPPRESSOR; AML1/RUNX1 GENE; DOWN-REGULATION	The transcription factor RUNX1 is a master regulator of hematopoiesis. Disruption of RUNX1 activity has been implicated in the development of hematopoietic neoplasms. Recent studies also highlight the importance of RUNX1 in solid tumors both as a tumor promoter and a suppressor. Given its central role in cancer development, RUNX1 is an excellent candidate for targeted therapy. A potential strategy to target RUNX1 is through modulation of its posttranslational modifications (PTMs). Numerous studies have shown that RUNX1 activity is regulated by PTMs, including phosphorylation, acetylation, methylation and ubiquitination. These PTMs regulate RUNX1 activity either positively or negatively by altering RUNX1-mediated transcription, promoting protein degradation and affecting protein interactions. In this review, we first summarize the available data on the context-and dosagedependent roles of RUNX1 in various types of neoplasms. We then provide a comprehensive overview of RUNX1 PTMs from biochemical and biologic perspectives. Finally, we discuss how aberrant PTMs of RUNX1 might contribute to tumorigenesis and also strategies to develop anticancer therapies targeting RUNX1 PTMs.	[Goyama, S.; Huang, G.; Mulloy, J. C.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Kurokawa, M.] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo, Japan	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Tokyo	Mulloy, JC (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA.	susumu.goyama@cchmc.org; james.mulloy@cchmc.org			Grants-in-Aid for Scientific Research [15H01481] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Aho TL, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-21; Aikawa Y, 2006, EMBO J, V25, P3955, DOI 10.1038/sj.emboj.7601273; Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Ben-Ami O, 2013, CELL REP, V4, P1131, DOI 10.1016/j.celrep.2013.08.020; Biggs JR, 2006, MOL CELL BIOL, V26, P7420, DOI 10.1128/MCB.00597-06; Biggs JR, 2005, MOL CANCER RES, V3, P391, DOI 10.1158/1541-7786.MCR-04-0184; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Bresciani E, 2014, BLOOD, V124, P70, DOI 10.1182/blood-2013-10-531988; Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Chimge NO, 2013, ONCOGENE, V32, P2121, DOI 10.1038/onc.2012.328; Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88; Cunningham L, 2012, P NATL ACAD SCI USA, V109, P14592, DOI 10.1073/pnas.1200037109; Della Gatta G, 2012, NAT MED, V18, P436, DOI 10.1038/nm.2610; Dulak AM, 2012, CANCER RES, V72, P4383, DOI 10.1158/0008-5472.CAN-11-3893; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Fijneman RJA, 2012, CANCER SCI, V103, P593, DOI 10.1111/j.1349-7006.2011.02189.x; Gaidzik VI, 2011, J CLIN ONCOL, V29, P1364, DOI 10.1200/JCO.2010.30.7926; Giambra V, 2012, NAT MED, V18, P1693, DOI 10.1038/nm.2960; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Gorczynski MJ, 2007, CHEM BIOL, V14, P1186, DOI 10.1016/j.chembiol.2007.09.006; Goyama S, 2004, BLOOD, V104, P3558, DOI 10.1182/blood-2004-04-1535; Goyama S, 2013, J CLIN INVEST, V123, P3876, DOI 10.1172/JCI68557; Goyama S, 2011, INT J HEMATOL, V94, P126, DOI 10.1007/s12185-011-0858-z; Greif PA, 2012, HAEMATOL-HEMATOL J, V97, P1909, DOI 10.3324/haematol.2012.064667; Grossmann V, 2013, GENE CHROMOSOME CANC, V52, P410, DOI 10.1002/gcc.22039; Grossmann V, 2011, HAEMATOL-HEMATOL J, V96, P1874, DOI 10.3324/haematol.2011.043919; Gu JA, 2010, CANCER PREV RES, V3, P1176, DOI 10.1158/1940-6207.CAPR-09-0265; Guo H, 2011, J BIOL CHEM, V286, P208, DOI 10.1074/jbc.M110.149013; Haferlach T, 2014, LEUKEMIA, V28, P241, DOI 10.1038/leu.2013.336; Harada H, 2004, BLOOD, V103, P2316, DOI 10.1182/blood-2003-09-3074; Herglotz J, 2013, ONCOGENE, V32, P2565, DOI 10.1038/onc.2012.274; Hoi CSL, 2010, MOL CELL BIOL, V30, P2518, DOI 10.1128/MCB.01308-09; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Huang G, 2011, BLOOD, V118, P6544, DOI 10.1182/blood-2010-11-317909; Huang H, 2012, GENE DEV, V26, P1587, DOI 10.1101/gad.192054.112; Huang SP, 2011, BJU INT, V107, P486, DOI 10.1111/j.1464-410X.2010.09512.x; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033-1043.2004; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Itzykson R, 2013, J CLIN ONCOL, V31, P2428, DOI 10.1200/JCO.2012.47.3314; Jacob B, 2010, BLOOD, V115, P1610, DOI 10.1182/blood-2009-07-232249; Kadota M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009201; Kamikubo Y, 2010, CANCER CELL, V17, P455, DOI 10.1016/j.ccr.2010.03.022; Kawazu M, 2005, J IMMUNOL, V174, P3526, DOI 10.4049/jimmunol.174.6.3526; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Komeno Y, 2014, BLOOD, V123, P3760, DOI 10.1182/blood-2013-08-521252; Kurokawa M, 2006, INT J HEMATOL, V84, P136, DOI 10.1532/IJH97.06070; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Levanon D, 2004, ONCOGENE, V23, P4211, DOI 10.1038/sj.onc.1207670; Link KA, 2010, J CELL PHYSIOL, V222, P50, DOI 10.1002/jcp.21950; Lo-Coco F, 2013, NEW ENGL J MED, V369, P111, DOI 10.1056/NEJMoa1300874; Ma SK, 2001, LEUKEMIA, V15, P1442, DOI 10.1038/sj.leu.2402202; Mendler JH, 2012, J CLIN ONCOL, V30, P3109, DOI 10.1200/JCO.2011.40.6652; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Migas A, 2011, PEDIATR BLOOD CANCER, V57, P583, DOI 10.1002/pbc.22980; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; Motoda L, 2007, STEM CELLS, V25, P2976, DOI 10.1634/stemcells.2007-0061; Neel BG, 2012, GENE DEV, V26, P1520, DOI 10.1101/gad.198051.112; Niebuhr B, 2013, BLOOD, V122, P413, DOI 10.1182/blood-2013-01-480244; Nishimoto N, 2011, BLOOD, V118, P2541, DOI 10.1182/blood-2010-10-315440; Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Owen CJ, 2008, BLOOD, V112, P4639, DOI 10.1182/blood-2008-05-156745; Peter A, 2009, EUR J HAEMATOL, V83, P420, DOI 10.1111/j.1600-0609.2009.01315.x; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Reed-Inderbitzin E, 2006, ONCOGENE, V25, P5777, DOI 10.1038/sj.onc.1209591; Rocquain J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-401; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Scheitz CJF, 2013, J CELL BIOCHEM, V114, P985, DOI 10.1002/jcb.24453; Scheitz CJF, 2012, EMBO J, V31, P4124, DOI 10.1038/emboj.2012.270; Schwaab J, 2013, BLOOD, V122, P2460, DOI 10.1182/blood-2013-04-496448; Shang Y, 2009, BIOCHEM BIOPH RES CO, V386, P242, DOI 10.1016/j.bbrc.2009.06.043; Shia WJ, 2012, BLOOD, V119, P4953, DOI 10.1182/blood-2011-04-347476; Slattery ML, 2011, CARCINOGENESIS, V32, P318, DOI 10.1093/carcin/bgq245; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Tachibana M, 2008, BIOCHEM BIOPH RES CO, V368, P536, DOI 10.1016/j.bbrc.2008.01.124; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Tang JL, 2009, BLOOD, V114, P5352, DOI 10.1182/blood-2009-05-223784; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; Vu LP, 2013, CELL REP, V5, P1625, DOI 10.1016/j.celrep.2013.11.025; Wang CQ, 2014, CELL REP, V8, P767, DOI 10.1016/j.celrep.2014.06.046; Wang L, 2011, SCIENCE, V333, P765, DOI 10.1126/science.1201662; Wang L, 2009, BLOOD CELL MOL DIS, V43, P30, DOI 10.1016/j.bcmd.2009.03.005; Wang LX, 2011, P NATL ACAD SCI USA, V108, pE803, DOI 10.1073/pnas.1103423108; Wee HJ, 2008, BLOOD, V112, P3777, DOI 10.1182/blood-2008-01-134122; Wilkinson AC, 2013, CELL REP, V3, P116, DOI 10.1016/j.celrep.2012.12.016; Wotton S, 2002, CANCER RES, V62, P7181; Yamaguchi Y, 2004, J BIOL CHEM, V279, P15630, DOI 10.1074/jbc.M400355200; Yan CH, 2013, BBA-REV CANCER, V1835, P76, DOI 10.1016/j.bbcan.2012.11.002; Yan M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443; Yoshimi M, 2012, EUR J IMMUNOL, V42, P1044, DOI 10.1002/eji.201040746; Zelent A, 2004, ONCOGENE, V23, P4275, DOI 10.1038/sj.onc.1207672; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725; Zhang LS, 2008, BLOOD, V111, P1193, DOI 10.1182/blood-2007-08-109702; Zhang YH, 2004, J BIOL CHEM, V279, P53116, DOI 10.1074/jbc.M405502200; Zhao XH, 2014, BLOOD, V123, P1729, DOI 10.1182/blood-2013-03-489575; Zhao X, 2008, GENE DEV, V22, P640, DOI 10.1101/gad.1632608	102	40	41	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3483	3492		10.1038/onc.2014.305	http://dx.doi.org/10.1038/onc.2014.305			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25263451				2023-01-03	WOS:000357434900001
J	Ernstbrunner, M; Kostner, L; Kimberger, O; Wabel, P; Saemann, M; Markstaller, K; Fleischmann, E; Kabon, B; Hecking, M				Ernstbrunner, Matthaeus; Kostner, Lisa; Kimberger, Oliver; Wabel, Peter; Saeemann, Marcus; Markstaller, Klaus; Fleischmann, Edith; Kabon, Barbara; Hecking, Manfred			Bioimpedance Spectroscopy for Assessment of Volume Status in Patients before and after General Anaesthesia	PLOS ONE			English	Article							BIOELECTRICAL-IMPEDANCE ANALYSIS; RANDOMIZED CONTROLLED-TRIAL; MAJOR ABDOMINAL-SURGERY; HEMODIALYSIS-PATIENTS; DILUTION METHODS; FLUID BALANCE; EXCESS FLUID; BODY; TISSUE; OPTIMIZATION	Background: Technically assisted assessment of volume status before surgery may be useful to direct intraoperative fluid administration. We therefore tested a recently developed whole-body bioimpedance spectroscopy device to determine pre-to postoperative fluid distribution. Methods: Using a three-compartment physiologic tissue model, the body composition monitor (BCM, Fresenius Medical Care, Germany) measures total body fluid volume, extracellular volume, intracellular volume and fluid overload as surplus or deficit of 'normal' extracellular volume. BCM-measurements were performed before and after standardized general anaesthesia for gynaecological procedures (laparotomies, laparoscopies and vaginal surgeries). BCM results were blinded to the attending anaesthesiologist and data analysed using the 2-sided, paired Student's t-test and multiple linear regression. Results: In 71 females aged 45 +/- 15 years with body weight 67 +/- 13 kg and duration of anaesthesia 154 +/- 68 min, pre-to postoperative fluid overload increased from -0.7 +/- 1.1 L to 0.1 +/- 1.0 L, corresponding to 25.1 +/- 7.5% and 0.8 +/- 6.7% of normal extracellular volume, respectively (both p<0.001), after patients had received 1.9 +/- 0.9 L intravenous crystalloid fluid. Perioperative urinary excretion was 0.4 +/- 0.3 L. The increase in extracellular volume was paralleled by an increase in total body fluid volume, while intracellular volume increased only slightly and without reaching statistical significance (p = 0.15). Net perioperative fluid balance (administered fluid volume minus urinary excretion) was significantly associated with change in extracellular volume (r(2) = 0.65), but was not associated with change in intracellular volume (r(2) = 0.01). Conclusions: Routine intraoperative fluid administration results in a significant, and clinically meaningful increase in the extracellular compartment. BCM-measurements yielded plausible results and may become useful to guide intraoperative fluid therapy in future studies.	[Ernstbrunner, Matthaeus; Kostner, Lisa; Kimberger, Oliver; Markstaller, Klaus; Fleischmann, Edith; Kabon, Barbara; Hecking, Manfred] Med Univ Vienna, Dept Anaesthesiol & Crit Care Med, Vienna, Austria; [Wabel, Peter] Fresenius Med Care, Bad Homburg, Germany; [Saeemann, Marcus; Hecking, Manfred] Med Univ Vienna, Dept Internal Med 3, Clin Div Nephrol & Dialysis, Vienna, Austria	Medical University of Vienna; Medical University of Vienna	Hecking, M (corresponding author), Med Univ Vienna, Dept Anaesthesiol & Crit Care Med, Vienna, Austria.	manfred.hecking@meduniwien.ac.at	Hecking/AAK-7399-2021	Kabon, Barbara/0000-0002-9269-4657; Hecking, Manfred/0000-0002-8047-2395; Kimberger, Oliver/0000-0002-9766-1360				[Anonymous], 2010, MILLERS ANESTHESIA; [Anonymous], 2012, US MAN FRESN MED CAR; Bracco D, 1998, CRIT CARE MED, V26, P1065, DOI 10.1097/00003246-199806000-00029; Brandstrup B, 2003, ANN SURG, V238, P641, DOI 10.1097/01.sla.0000094387.50865.23; Cagini L, 2011, EUR J CARDIO-THORAC, V40, pE71, DOI 10.1016/j.ejcts.2011.03.030; Chamney PW, 2007, AM J CLIN NUTR, V85, P80, DOI 10.1093/ajcn/85.1.80; Chazot C, 2012, NEPHROL DIAL TRANSPL, V27, P2404, DOI 10.1093/ndt/gfr678; COLE KS, 1969, EXP NEUROL, V24, P459, DOI 10.1016/0014-4886(69)90149-6; Cordemans C, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-S1-S1; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Doherty M, 2012, BRIT J ANAESTH, V109, P69, DOI 10.1093/bja/aes171; Elliott S, 1998, EUR J ANAESTH, V15, P50, DOI 10.1097/00003643-199801000-00010; FLECK A, 1985, LANCET, V1, P781; Forbes GB, 1987, TECHNIQUES ESTIMATIN; Frumento RJ B-GE, 2003, PERIOPERATIVE ORGAN, P1; Gulec B, 2006, ANZ J SURG, V76, P904, DOI 10.1111/j.1445-2197.2006.03906.x; Hecking M, 2013, AM J NEPHROL, V38, P78, DOI 10.1159/000353104; Holte K, 2003, ANESTH ANALG, V96, P1504, DOI 10.1213/01.ANE.0000055820.56129.EE; Holte K, 2006, J AM COLL SURGEONS, V202, P971, DOI 10.1016/j.jamcollsurg.2006.01.003; Itobi E, 2006, BRIT J SURG, V93, P354, DOI 10.1002/bjs.5259; Kyle UG, 2004, CLIN NUTR, V23, P1430, DOI 10.1016/j.clnu.2004.09.012; Kyle UG, 2004, CLIN NUTR, V23, P1226, DOI 10.1016/j.clnu.2004.06.004; Lang K, 2001, ANESTH ANALG, V93, P405, DOI 10.1097/00000539-200108000-00034; LJUNGGREN H, 1957, Acta Endocrinol Suppl (Copenh), V25, P1; Lobo DN, 2002, LANCET, V359, P1812, DOI 10.1016/S0140-6736(02)08711-1; LOWELL JA, 1990, CRIT CARE MED, V18, P728, DOI 10.1097/00003246-199007000-00010; Lyons FM, 1997, INT ANESTHESIOL CLIN, V35, P1, DOI 10.1097/00004311-199703540-00002; Machek P, 2010, NEPHROL DIAL TRANSPL, V25, P538, DOI 10.1093/ndt/gfp487; Moissl U, 2008, NDT PLUS S2, V1, P215; Moissl UM, 2006, PHYSIOL MEAS, V27, P921, DOI 10.1088/0967-3334/27/9/012; Moller AM, 2002, EUR J ANAESTH, V19, P57, DOI 10.1017/S0265021502000091; Morgan GEM, 2005, FLUID MANAGEMENT TRA; MORSE WI, 1963, METABOLISM, V12, P99; Nisanevich V, 2005, ANESTHESIOLOGY, V103, P25, DOI 10.1097/00000542-200507000-00008; Passauer J, 2010, NEPHROL DIAL TRANSPL, V25, P545, DOI 10.1093/ndt/gfp517; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; Piccoli A, 2014, KIDNEY INT, V85, P738, DOI 10.1038/ki.2013.434; Raimann JG, 2014, KIDNEY INT, V85, P898, DOI 10.1038/ki.2013.358; Rasmussen L A, 1996, Ugeskr Laeger, V158, P5286; Reich DL, 2005, ANESTH ANALG, V101, P622, DOI 10.1213/01.ANE.0000175214.38450.91; Sheeran P, 1997, BRIT J ANAESTH, V78, P201, DOI 10.1093/bja/78.2.201; Sinclair S, 1997, BMJ-BRIT MED J, V315, P909; Smith TPC, 2009, BODY FLUIDS FUNDAMEN; Tatara T, 1998, CRIT CARE MED, V26, P470, DOI 10.1097/00003246-199803000-00017; Tsai YC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082566; Van Biesen W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017148; Wabel P, 2007, NEPHROL DIAL TRAN S6, V22, pVI129; Wabel P, 2009, BLOOD PURIFICAT, V27, P75, DOI 10.1159/000167013; WANG J, 1976, J NUTR, V106, P1687, DOI 10.1093/jn/106.12.1687; Wizemann V, 2008, CONTRIB NEPHROL, V161, P115, DOI 10.1159/000130423; Wizemann V, 2009, NEPHROL DIAL TRANSPL, V24, P1574, DOI 10.1093/ndt/gfn707	51	20	22	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2014	9	10							e111139	10.1371/journal.pone.0111139	http://dx.doi.org/10.1371/journal.pone.0111139			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0BN	25360698	Green Published, gold, Green Submitted			2023-01-03	WOS:000343943700065
J	Pan, XF; Zhao, ZM; Sun, J; Chen, F; Wen, QL; Liu, K; Song, GQ; Zhang, JJ; Wen, Y; Fu, CJ; Yang, CX				Pan, Xiong-Fei; Zhao, Zhi-Mei; Sun, Jing; Chen, Feng; Wen, Qing-Lian; Liu, Kang; Song, Gui-Qin; Zhang, Jing-Jing; Wen, Ying; Fu, Chun-Jing; Yang, Chun-Xia			Acceptability and Correlates of Primary and Secondary Prevention of Cervical Cancer among Medical Students in Southwest China: Implications for Cancer Education	PLOS ONE			English	Article							HUMAN-PAPILLOMAVIRUS HPV; VISUAL INSPECTION; VACCINE INTRODUCTION; SCREENING BEHAVIOR; MULTICENTER SURVEY; ACETIC-ACID; KNOWLEDGE; WOMEN; ATTITUDES; PERCEPTIONS	Objectives: To understand knowledge about, and acceptability of, cervical cancer screening and HPV vaccines among medical students; and to explore potential factors that influence their acceptability in China. Methods: We conducted a survey among medical students at six universities across southwest China using a 58-item questionnaire regarding knowledge and perceptions of HPV, cervical cancer, and HPV vaccines. Results: We surveyed 1878 medical students with a mean age of 20.8 years (standard deviation: 1.3 years). Of these, 48.8% and 80.1% believed cervical cancer can be prevented by HPV vaccines and screening respectively, while 60.2% and 71.2% would like to receive or recommend HPV vaccines and screening. 35.4% thought HPV vaccines ought to be given to adolescents aged 13-18 years. 32% stated that women should start to undergo screening from the age of 25. 49.2% felt that women should receive screening every year. Concern about side effects (38.3% and 39.8%), and inadequate information (42.4% and 35.0%) were the most cited barriers to receiving or recommending HPV vaccination and cervical cancer screening. Females were more likely to accept HPV vaccines (OR, 1.86; 95% CI: 1.47-2.35) or cervical cancer screening (OR, 3.69; 95% CI: 2.88-4.74). Students with a higher level of related knowledge were much more willing to receive or recommend vaccines (P<0.001) or screening (P<0.001). Students who showed negative or uncertain attitudes towards premarital sex were less likely to accept either HPV vaccines (OR, 0.67; 95% CI: 0.47-0.96), or screening (OR, 0.68; 0.47-0.10). Non-clinical students showed lower acceptability of cervical screening compared to students in clinical medicine (OR, 0.74; 95% CI: 0.56-0.96). Conclusions: The acceptability of HPV vaccines and cervical cancer screening is relatively low among medical students in southwest China. Measures should be taken to improve knowledge about cervical cancer and awareness of HPV vaccines and screening among medical students at university.	[Pan, Xiong-Fei; Zhao, Zhi-Mei; Wen, Ying; Yang, Chun-Xia] Sichuan Univ, West China Sch Publ Hlth, Dept Epidemiol, Chengdu 610064, Peoples R China; [Sun, Jing] Chengdu Med Coll, Dept Pathol, Dev & Regenerat Key Lab Sichuan Prov, Chengdu, Peoples R China; [Chen, Feng] Deyang Peoples Hosp, Dept Prevent Healthcare & Hosp Infect Control, Deyang, Peoples R China; [Wen, Qing-Lian] Luzhou Med Coll, Affiliated Hosp, Dept Oncol, Luzhou, Peoples R China; [Liu, Kang] North Sichuan Med Coll, Clin Hosp 2, Inst Tissue Engn & Stem Cells, Nanchong, Peoples R China; North Sichuan Med Coll, Dept Biol, Nanchong, Peoples R China; [Zhang, Jing-Jing] Kunming Med Univ, Sch Publ Hlth, Kunming, Peoples R China; [Fu, Chun-Jing] Chongqing Med Univ, Sch Publ Hlth & Management, Dept Hlth Stat & Informat Management, Chongqing, Peoples R China	Sichuan University; Chengdu Medical College; Southwest Medical University; North Sichuan Medical University; North Sichuan Medical University; Kunming Medical University; Chongqing Medical University	Yang, CX (corresponding author), Sichuan Univ, West China Sch Publ Hlth, Dept Epidemiol, Chengdu 610064, Peoples R China.	chunxia815@aliyun.com	Pan, Xiongfei/G-7882-2011; Liu, Kang/AAE-9964-2020	Pan, Xiongfei/0000-0002-9350-9230; Liu, Kang/0000-0002-4640-0849				Adams M, 2007, VACCINE, V25, P3007, DOI 10.1016/j.vaccine.2007.01.016; Agorastos T, 2009, VACCINE, V27, P7270, DOI 10.1016/j.vaccine.2009.09.097; [Anonymous], 2009, Lancet, V374, P358, DOI 10.1016/S0140-6736(09)61394-5; Brotherton JML, 2011, LANCET, V377, P2085, DOI 10.1016/S0140-6736(11)60551-5; Chang IJ, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-916; Chelimo C, 2009, NEW ZEAL MED J, V122, P33; Chesson HW, 2011, VACCINE, V29, P8443, DOI 10.1016/j.vaccine.2011.07.096; Cutts FT, 2007, B WORLD HEALTH ORGAN, V85, P719, DOI 10.2471/BLT.06.038414; Dempsey AF, 2006, AM J MANAG CARE, V12, pS484; Deng L, 2014, LANCET ONCOL, V15, pE300, DOI 10.1016/S1470-2045(14)70278-5; Deng L, 2011, ASIAN PAC J CANCER P, V12, P2801; Dijkstra MG, 2014, ANN ONCOL; Dong Z, 2005, RECOMMENDAT IN PRESS; Ferlay J, 2013, GLOBOCAN 2012 V1 0 C; Goss PE, 2014, LANCET ONCOL, V15, P489, DOI 10.1016/S1470-2045(14)70029-4; Gu C, 2013, EUR J ONCOL NURS, V17, P154, DOI 10.1016/j.ejon.2012.04.005; Gu C, 2012, PSYCHO-ONCOLOGY, V21, P1299, DOI 10.1002/pon.2037; Gu C, 2010, CANCER NURS, V33, P445, DOI 10.1097/NCC.0b013e3181e456dc; Hong Y, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-696; Jeronimo J, 2014, INT J GYNECOL CANCER, V24, P576, DOI 10.1097/IGC.0000000000000084; Jia Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067005; Jit M, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a769; Kahn JA, 2009, NEW ENGL J MED, V361, P271, DOI 10.1056/NEJMct0806938; Kavanagh K, 2014, BRIT J CANCER, V110, P2804, DOI 10.1038/bjc.2014.198; Kim JJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3884; Kuznetsov L, 2012, INT J PUBLIC HEALTH, V57, P651, DOI 10.1007/s00038-012-0351-3; Kwan TTC, 2011, PATIENT EDUC COUNS, V84, P118, DOI 10.1016/j.pec.2010.06.018; Li J, 2009, VACCINE, V27, P1210, DOI 10.1016/j.vaccine.2008.12.020; Li R, 2013, TROP DOCT, V43, P96, DOI 10.1177/0049475513495615; Lu BB, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-13; Madhivanan P, 2009, VACCINE, V27, P5203, DOI 10.1016/j.vaccine.2009.06.073; Marek E, 2011, VACCINE, V29, P5122, DOI 10.1016/j.vaccine.2011.05.048; Markowitz LE, 2013, J INFECT DIS, V208, P385, DOI 10.1093/infdis/jit192; Markowitz LE, 2012, VACCINE, V30, pF139, DOI 10.1016/j.vaccine.2012.05.039; McCusker SM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-264; Mehta Sumita, 2013, Indian J Community Med, V38, P92, DOI 10.4103/0970-0218.112438; Mesher D, 2013, VACCINE, V32, P26, DOI 10.1016/j.vaccine.2013.10.085; Pandey D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040619; Paul P, 2013, ONCOLOGIST, V18, P1278, DOI 10.1634/theoncologist.2013-0253; Rashwan HH, 2012, ASIAN PAC J CANCER P, V13, P2279, DOI 10.7314/APJCP.2012.13.5.2279; Sauvageau C, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-304; Shetty P, 2014, NATURE, V507, pS12, DOI 10.1038/507S12a; Shi JF, 2012, INT J CANCER, V130, P641, DOI 10.1002/ijc.26042; Vesco KK, 2011, ANN INTERN MED, V155, P698, DOI 10.7326/0003-4819-155-10-201111150-00377; Wei Min-xi, 2009, Chinese Journal of Virology, V25, P245; Wen Y, 2014, ASIAN PAC J CANCER P, V15, P5773, DOI 10.7314/APJCP.2014.15.14.5773; Who, 2009, Biologicals, V37, P338, DOI 10.1016/j.biologicals.2009.04.005; Yang L, 2003, INT J CANCER, V106, P771, DOI 10.1002/ijc.11300; Zhang SK, 2013, VACCINE, V31, P3244, DOI 10.1016/j.vaccine.2013.05.046; Zhao FH, 2012, ASIAN PAC J CANCER P, V13, P2369, DOI 10.7314/APJCP.2012.13.5.2369; Zhao FH, 2012, CANCER EPIDEMIOL, V36, P384, DOI 10.1016/j.canep.2012.01.009; Zheng JS, 2010, VACCINE, V28, pA84, DOI 10.1016/j.vaccine.2010.02.039; Zimet GD, 2010, GYNECOL ONCOL, V117, pS26, DOI 10.1016/j.ygyno.2010.01.028	53	10	12	2	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2014	9	10							e110353	10.1371/journal.pone.0110353	http://dx.doi.org/10.1371/journal.pone.0110353			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0BN	25360743	Green Published, Green Submitted, gold			2023-01-03	WOS:000343943700032
J	Li, SY; Zhai, X; Rong, PJ; McCabe, MF; Zhao, JJ; Ben, H; Wang, X; Wang, SX				Li, Shaoyuan; Zhai, Xu; Rong, Peijing; McCabe, Michael F.; Zhao, Jingjun; Ben, Hui; Wang, Xing; Wang, Shuxing			Transcutaneous Auricular Vagus Nerve Stimulation Triggers Melatonin Secretion and Is Antidepressive in Zucker Diabetic Fatty Rats	PLOS ONE			English	Article							MAJOR DEPRESSIVE DISORDER; NMDA RECEPTORS; ACUPUNCTURE; HYPNOSIS; INSOMNIA; BEHAVIOR; SYSTEM; MOUSE; TRIAL	Decreased circulating melatonin is implicated in depression. We recently found that Zucker diabetic fatty rats (ZDF, fa/fa) develop depression-like behaviors and that transcutaneous auricular vagus nerve stimulation (taVNS) is antidepressive in ZDF rats. Here we studied whether the ZDF rats could be used as a depression rodent model and whether the antidepressive effect of taVNS is mediated through modulation of melatonin secretion. Adult male ZDF and Zucker lean (ZL, fa/+) littermates were used. 30 min-taVNS procedures (2/15 Hz, 2 mA) were administered once daily under anesthesia for 34 consecutive days in pineal intact ZDF (n = 8) and ZL (n = 6) rats, as well as in pinealectomized ZDF rats (n = 8). Forced swimming test (FST) was used to determine depression-like behavior and ELISA to detect plasma melatonin concentration on day 35. We found that naive ZDF rats had a longer immobility time in FST and that long-term (34 days) taVNS treatment ameliorated the depression-like behavior. In both pineal intact and pinealectomized ZDF rats, taVNS induced acute melatonin secretion, both during and after the taVNS session. A low melatonin level is related to the poor FST performance in ZDF rats (R = -0.544) in contrast to ZL rats (R = 0.247). In conclusion, our results show that ZDF rats are ideal candidates of innate depression and that taVNS is antidepressive through triggering melatonin secretion and increasing its production.	[Li, Shaoyuan; Zhai, Xu; Rong, Peijing; Zhao, Jingjun; Ben, Hui; Wang, Shuxing] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Dept Physiol, Beijing, Peoples R China; [Li, Shaoyuan; Wang, Xing; Wang, Shuxing] Xinxiang Med Univ, Dept Anat, Xinxiang, Henan Province, Peoples R China; [McCabe, Michael F.; Wang, Shuxing] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA	China Academy of Chinese Medical Sciences; Institute of Acupuncture & Moxibustion, CACMS; Xinxiang Medical University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Rong, PJ (corresponding author), China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Dept Physiol, Beijing, Peoples R China.	rongpj@hotmail.com; wshuxing@mgh.harvard.edu	zhao, jing/B-3868-2019		National Natural Science Foundation of China [81271243, 81473780]; Natural Science Foundation of Beijing [7111007]; National Basic Research Program of China (973 Program) [2012CB518503]; Project Supported National Science and Technology Ministry [2012BAF14B10]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Beijing(Beijing Natural Science Foundation); National Basic Research Program of China (973 Program)(National Basic Research Program of China); Project Supported National Science and Technology Ministry	This work was supported by National Natural Science Foundation of China-81271243, 81473780; Natural Science Foundation of Beijing, 7111007; National Basic Research Program of China (973 Program)-2012CB518503; and Project Supported National Science and Technology Ministry-2012BAF14B10. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bardgett ME, 2010, HYPERTENSION, V55, P284, DOI 10.1161/HYPERTENSIONAHA.109.146605; Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186; Bubenik GA, 2002, DIGEST DIS SCI, V47, P2336, DOI 10.1023/A:1020107915919; Cardinali DP, 2012, J PINEAL RES, V52, P365, DOI 10.1111/j.1600-079X.2011.00962.x; Chao DM, 2001, ACUPUNCTURE ELECTRO, V26, P39, DOI 10.3727/036012901816356027; Conti A, 2000, J PINEAL RES, V28, P193, DOI 10.1034/j.1600-079X.2000.280401.x; DEBENEDITTIS G, 1994, INT J CLIN EXP HYP, V42, P140, DOI 10.1080/00207149408409347; Dubocovich ML, 2010, PHARMACOL REV, V62, P343, DOI 10.1124/pr.110.002832; Esposito E, 2010, CURR NEUROPHARMACOL, V8, P228, DOI 10.2174/157015910792246155; Ghasemi M, 2010, J PSYCHOPHARMACOL, V24, P585, DOI 10.1177/0269881109104845; Guo M, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.9; Huang F, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-203; Kaster MP, 2012, PHARMACOL REP, V64, P706, DOI 10.1016/S1734-1140(12)70865-4; La Marca R, 2010, CLIN SCI, V118, P537, DOI 10.1042/CS20090264; Lee JH, 2013, CLIN J PAIN, V29, P172, DOI 10.1097/AJP.0b013e31824909f9; Liu RP, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/789674; Lyons Zaza, 2012, Complement Ther Clin Pract, V18, P216, DOI 10.1016/j.ctcp.2012.06.003; Maganhin CC, 2009, ACTA CIR BRAS, V24, P321, DOI 10.1590/S0102-86502009000400013; Mathews DC, 2012, DRUGS, V72, P1313, DOI 10.2165/11633130-000000000-00000; MAURIZI CP, 1984, SOUTH MED J, V77, P1516, DOI 10.1097/00007611-198412000-00010; Mischoulon D, 2012, J AFFECT DISORDERS, V141, P469, DOI 10.1016/j.jad.2012.03.023; NELSON E, 1994, PHARMACOL BIOCHEM BE, V49, P327, DOI 10.1016/0091-3057(94)90429-4; Paul P, 1999, J PHARMACOL EXP THER, V290, P334; Preiss K, 2013, OBES REV, V14, P906, DOI 10.1111/obr.12052; Rong PJ, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-255; Samuels N, 2005, AM J CLIN HYPN, V47, P243, DOI 10.1080/00029157.2005.10403638; Spence DW, 2004, J NEUROPSYCH CLIN N, V16, P19, DOI 10.1176/appi.neuropsych.16.1.19; Wang SX, 2012, PAIN, V153, P2448, DOI 10.1016/j.pain.2012.08.016; Wang SX, 2009, BRAIN RES, V1288, P42, DOI 10.1016/j.brainres.2009.06.094; Ward KR, 2011, HYPERTENSION, V57, P435, DOI 10.1161/HYPERTENSIONAHA.110.160671; Yeung AS, 2011, J AFFECT DISORDERS, V130, P285, DOI 10.1016/j.jad.2010.07.025; Zeng Q, 2008, BRAIN RES, V1200, P27, DOI 10.1016/j.brainres.2008.01.038; Zhang ZJ, 2010, J AFFECT DISORDERS, V124, P9, DOI 10.1016/j.jad.2009.07.005	33	16	20	3	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2014	9	10							e111100	10.1371/journal.pone.0111100	http://dx.doi.org/10.1371/journal.pone.0111100			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AZ1JF	25347185	Green Published, gold, Green Submitted			2023-01-03	WOS:000347994900046
J	Lopez-Campos, JL; Asensio-Cruz, MI; Castro-Acosta, A; Calero, C; Pozo-Rodriguez, F				Luis Lopez-Campos, Jose; Isabel Asensio-Cruz, M.; Castro-Acosta, Ady; Calero, Carmen; Pozo-Rodriguez, Francisco		AUDIPOC; European COPD Audit Studies	Results from an Audit Feedback Strategy for Chronic Obstructive Pulmonary Disease In-Hospital Care: A Joint Analysis from the AUDIPOC and European COPD Audit Studies	PLOS ONE			English	Article							CLINICAL-PRACTICE; CONTROLLED-TRIAL; QUALITY; EXACERBATIONS; IMPROVEMENT; MORTALITY; MONITOR	Background: Clinical audits have emerged as a potential tool to summarize the clinical performance of healthcare over a specified period of time. However, the effectiveness of audit and feedback has shown inconsistent results and the impact of audit and feedback on clinical performance has not been evaluated for COPD exacerbations. In the present study, we analyzed the results of two consecutive nationwide clinical audits performed in Spain to evaluate both the in-hospital clinical care provided and the feedback strategy. Methods: The present study is an analysis of two clinical audits performed in Spain that evaluated the clinical care provided to COPD patients who were admitted to the hospital for a COPD exacerbation. The first audit was performed from November-December 2008. The feedback strategy consisted of personalized reports for each participant center, the presentation and discussion of the results at regional, national and international meetings and the creation of health-care quality standards for COPD. The second audit was part of a European study during January and February 2011. The impact of the feedback strategy was evaluated in term of clinical care provided and in-hospital survival. Results: A total of 94 centers participated in the two audits, recruiting 8,143 admissions (audit 1: 3,493 and audit 2: 4,650). The initially provided clinical care was reasonably acceptable even though there was considerable variability. Several diagnostic and therapeutic procedures improved in the second audit. Although the differences were significant, the degree of improvement was small to moderate. We found no impact on in-hospital mortality. Conclusions: The present study describes COPD hospital care in Spanish hospitals and evaluates the impact of peer-benchmarked, individually written and group-oral feedback strategy on the clinical outcomes for treating COPD exacerbations. It describes small to moderate improvements in the clinical care provided to COPD patients with no impact on in-hospital mortality.	[Luis Lopez-Campos, Jose; Isabel Asensio-Cruz, M.; Calero, Carmen] Univ Seville, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBiS, Unidad Med Quirurg Enfermedades Resp, Seville, Spain; [Luis Lopez-Campos, Jose; Castro-Acosta, Ady; Calero, Carmen; Pozo-Rodriguez, Francisco] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain; [Castro-Acosta, Ady; Pozo-Rodriguez, Francisco] Hosp 12 Octubre, Inst Invest I 12, E-28041 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III; Hospital Universitario 12 de Octubre	Lopez-Campos, JL (corresponding author), Univ Seville, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBiS, Unidad Med Quirurg Enfermedades Resp, Seville, Spain.	lcampos@separ.es	Bodineau, José Luis López-Campos/AAG-5203-2019; Guardia, Sergi Pascual/L-7652-2014; Castro-Acosta, Ady Angelica/H-4163-2011; Asensio, Maria Isabel MAC/F-1431-2015; López-Quílez, Antonio/H-5945-2011	Bodineau, José Luis López-Campos/0000-0003-1703-1367; Guardia, Sergi Pascual/0000-0002-6567-0916; Castro-Acosta, Ady Angelica/0000-0001-7591-6011; López-Quílez, Antonio/0000-0002-7022-9260; Asensio-Cruz, Maria Isabel/0000-0002-7377-9065; CORBACHO, DOLORES/0000-0003-1239-5276	Fondo de Investigacion Sanitaria, Spanish Ministry of Health [PI07/90129, PI07/90309, PI07/90486, PI07/90503, PI07/90516, PI07/90721, PI08/90129, PI08/90578, PI08/90251, PI08/90529, PI07/90403, PI08/90447, PI08/90457, PI08/90486, PI08/90550]; European Respiratory Society	Fondo de Investigacion Sanitaria, Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); European Respiratory Society	AUDIPOC study was funded by Fondo de Investigacion Sanitaria, Spanish Ministry of Health, project numbers PI07/90129, PI07/90309, PI07/90486, PI07/90503, PI07/90516, PI07/90721, PI08/90129, PI08/90578, PI08/90251, PI08/90529, PI08/90129, PI07/90403, PI08/90447, PI08/90457, PI08/90486, and PI08/90550. The European COPD audit was funded by the European Respiratory Society. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agabiti N, 2010, EUR RESPIR J, V35, P1031, DOI 10.1183/09031936.00056209; Asch SM, 2006, NEW ENGL J MED, V354, P1147, DOI 10.1056/NEJMsa044464; Berwick DM, 2003, MED CARE, V41, pI30; Dalal AA, 2011, RESP MED, V105, P454, DOI 10.1016/j.rmed.2010.09.003; Flottorp SA, 2010, COPENHAGEN EUROPEAN; Hopkinson NS, 2012, THORAX, V67, P90, DOI 10.1136/thoraxjnl-2011-200233; Ivers N, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000259.pub3; Ivers NM, 2014, J GEN INTERN MED; Soler-Cataluna JJ, 2009, ARCH BRONCONEUMOL, V45, P196, DOI 10.1016/j.arbres.2008.05.008; Kiefe CI, 2001, JAMA-J AM MED ASSOC, V285, P2871, DOI 10.1001/jama.285.22.2871; Lilford RJ, 2007, BMJ-BRIT MED J, V335, P648, DOI 10.1136/bmj.39317.641296.AD; Lopez-Campos JL, 2014, INT J CLIN IN PRESS; Lopez-Campos JL, 2014, LANCET RESP MED, V2, P54, DOI 10.1016/S2213-2600(13)70232-7; Lopez-Campos JL, 2013, CHEST, V144, P601, DOI 10.1378/chest.12-2690; Lopez-Campos JL, 2013, EUR RESPIR J, V41, P270, DOI 10.1183/09031936.00021812; McCarthy C, 2013, INT J CHRONIC OBSTR, V8, P605, DOI 10.2147/COPD.S52883; Miravitlles M, 2004, THORAX, V59, P387, DOI 10.1136/thx.2003.008730; Miravitlles M, 2009, THORAX, V64, P863, DOI 10.1136/thx.2009.115725; Miravitlles M, 2014, ARCH BRONCONEUMOL, V50, P1, DOI 10.1016/S0300-2896(14)70070-5; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; Pozo-Rodriguez F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042156; Roberts CM, 2013, THORAX, V68, P1169, DOI 10.1136/thoraxjnl-2013-203465; Soler-Cataluna JJ, 2005, THORAX, V60, P925, DOI 10.1136/thx.2005.040527; Sondergaard J, 2003, SCAND J PRIM HEALTH, V21, P47, DOI 10.1080/02813430310000564; Stone EG, 2002, ANN INTERN MED, V136, P641, DOI 10.7326/0003-4819-136-9-200205070-00006; Tsai CL, 2009, INT J EMERG MED, V2, P111, DOI 10.1007/s12245-009-0089-8; van der Veer SN, 2010, INT J MED INFORM, V79, P305, DOI 10.1016/j.ijmedinf.2010.01.011	27	17	19	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2014	9	10							e110394	10.1371/journal.pone.0110394	http://dx.doi.org/10.1371/journal.pone.0110394			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX2IH	25333953	Green Submitted, gold, Green Published			2023-01-03	WOS:000346766200117
J	Pavelitz, T; Renfro, L; Foster, NR; Caracol, A; Welsch, P; Lao, VV; Grady, WB; Niedzwiecki, D; Saltz, LB; Bertagnolli, MM; Goldberg, RM; Rabinovitch, PS; Emond, M; Monnat, RJ; Maizels, N				Pavelitz, Thomas; Renfro, Lindsay; Foster, Nathan R.; Caracol, Amber; Welsch, Piri; Lao, Victoria Valinluck; Grady, William B.; Niedzwiecki, Donna; Saltz, Leonard B.; Bertagnolli, Monica M.; Goldberg, Richard M.; Rabinovitch, Peter S.; Emond, Mary; Monnat, Raymond J., Jr.; Maizels, Nancy			MRE11-Deficiency Associated with Improved Long-Term Disease Free Survival and Overall Survival in a Subset of Stage III Colon Cancer Patients in Randomized CALGB 89803 Trial	PLOS ONE			English	Article							DNA MISMATCH REPAIR; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; MRE11 EXPRESSION; IRINOTECAN; FLUOROURACIL; LEUCOVORIN; MUTATIONS; THERAPY; CELLS	Purpose: Colon cancers deficient in mismatch repair (MMR) may exhibit diminished expression of the DNA repair gene, MRE11, as a consequence of contraction of a T-11 mononucleotide tract. This study investigated MRE11 status and its association with prognosis, survival and drug response in patients with stage III colon cancer. Patients and Methods: Cancer and Leukemia Group B 89803 (Alliance) randomly assigned 1,264 patients with stage III colon cancer to postoperative weekly adjuvant bolus 5-fluorouracil/leucovorin (FU/LV) or irinotecan+FU/LV (IFL), with 8 year follow-up. Tumors from these patients were analyzed to determine stability of a T-11 tract in the MRE11 gene. The primary endpoint was overall survival (OS), and a secondary endpoint was disease-free survival (DFS). Non-proportional hazards were addressed using time-dependent covariates in Cox analyses. Results: Of 625 tumor cases examined, 70 (11.2%) exhibited contraction at the T-11 tract in one or both MRE11 alleles and were thus predicted to be deficient in MRE11 (dMRE11). In pooled treatment analyses, dMRE11 patients showed initially reduced DFS and OS but improved long-term DFS and OS compared with patients with an intact MRE11 T-11 tract. In the subgroup of dMRE11 patients treated with IFL, an unexplained early increase in mortality but better long-term DFS than IFL-treated pMRE11 patients was observed. Conclusions: Analysis of this relatively small number of patients and events showed that the dMRE11 marker predicts better prognosis independent of treatment in the long-term. In subgroup analyses, dMRE11 patients treated with irinotecan exhibited unexplained short-term mortality. MRE11 status is readily assayed and may therefore prove to be a useful prognostic marker, provided that the results reported here for a relatively small number of patients can be generalized in independent analyses of larger numbers of samples.	[Pavelitz, Thomas; Caracol, Amber; Maizels, Nancy] Univ Washington, Dept Immunol, Seattle, WA 98195 USA; [Renfro, Lindsay; Foster, Nathan R.] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA; [Caracol, Amber; Maizels, Nancy] Univ Washington, Mol & Cellular Biol Grad Program, Seattle, WA 98195 USA; [Welsch, Piri; Monnat, Raymond J., Jr.] Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA 98195 USA; [Lao, Victoria Valinluck; Grady, William B.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; [Lao, Victoria Valinluck] Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA; [Grady, William B.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; [Niedzwiecki, Donna] Duke Univ, Med Ctr, Canc & Leukemia Grp B, Ctr Stat, Durham, NC USA; [Saltz, Leonard B.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Bertagnolli, Monica M.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Bertagnolli, Monica M.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Goldberg, Richard M.] Ohio State Univ, Columbus, OH 43210 USA; [Rabinovitch, Peter S.; Monnat, Raymond J., Jr.; Maizels, Nancy] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; [Emond, Mary] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Maizels, Nancy] Univ Washington, Dept Biochem, Seattle, WA 98195 USA; [Pavelitz, Thomas; Renfro, Lindsay] Univ Washington, Dept Chem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Mayo Clinic; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Duke University; Memorial Sloan Kettering Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; University System of Ohio; Ohio State University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Maizels, N (corresponding author), Univ Washington, Dept Immunol, Seattle, WA 98195 USA.	maizels@u.washington.edu	Goldberg, Richard/O-1871-2017	Goldberg, Richard/0000-0003-3713-6895; Saltz, Leonard/0000-0001-8353-4670; Niedzwiecki, Donna/0000-0002-3566-0450	National Institutes of Health National Cancer Institute [P01 CA077852]; NIH [F31 GM073318]; HHMI MedIntoGrad Scholar Awards; NATIONAL CANCER INSTITUTE [U24CA196171, U10CA180850, P01CA077852, U10CA180821, U10CA180882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM073318] Funding Source: NIH RePORTER	National Institutes of Health National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); HHMI MedIntoGrad Scholar Awards; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Research reported here was supported by National Institutes of Health National Cancer Institute P01 CA077852 (WBG, PSR, RJM, NM); and NIH F31 GM073318 and HHMI MedIntoGrad Scholar Awards (AC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adelman CA, 2009, CELL CYCLE, V8, P1510, DOI 10.4161/cc.8.10.8380; Attwooll CL, 2009, MOL CELL BIOL; Bertagnolli MM, 2011, J CLIN ONCOL, V29, P3153, DOI 10.1200/JCO.2010.33.0092; Bertagnolli MM, 2009, J CLIN ONCOL, V27, P1814, DOI 10.1200/JCO.2008.18.2071; Boland CR, 1998, CANCER RES, V58, P5248; Giannini G, 2004, ONCOGENE, V23, P2640, DOI 10.1038/sj.onc.1207409; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Gomez-Herreros F, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003226; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hamilton NK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015387; Hewish M, 2010, NAT REV CLIN ONCOL, V7, P197, DOI 10.1038/nrclinonc.2010.18; Kakar S, 2004, MODERN PATHOL, V17, P696, DOI 10.1038/modpathol.3800093; Kim NG, 2001, CANCER RES, V61, P36; Klein JP, 2003, SURVIVAL ANAL TECHNI, V2nd, DOI DOI 10.1007/B97377; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; Miquel C, 2007, ONCOGENE, V26, P5919, DOI 10.1038/sj.onc.1210419; Ottini L, 2004, CARCINOGENESIS, V25, P2337, DOI 10.1093/carcin/bgh257; Peltomaki P, 2001, HUM MOL GENET, V10, P735, DOI 10.1093/hmg/10.7.735; Peltomaki P, 2001, MUTAT RES-REV MUTAT, V488, P77, DOI 10.1016/S1383-5742(00)00058-2; Popat S, 2005, J CLIN ONCOL, V23, P609, DOI 10.1200/JCO.2005.01.086; Rustgi AK, 2007, GENE DEV, V21, P2525, DOI 10.1101/gad.1593107; Sacho EJ, 2011, J BIOL CHEM, V286, P44945, DOI 10.1074/jbc.M111.299347; Saltz LB, 2007, J CLIN ONCOL, V25, P3456, DOI 10.1200/JCO.2007.11.2144; Sinicrope FA, 2011, JNCI-J NATL CANCER I, V103, P863, DOI 10.1093/jnci/djr153; Stracker Travis H., 2013, Frontiers in Genetics, V4, P37, DOI 10.3389/fgene.2013.00037; Truong LN, 2013, P NATL ACAD SCI USA, V110, P7720, DOI 10.1073/pnas.1213431110; Vilar E, 2008, BRIT J CANCER, V99, P1607, DOI 10.1038/sj.bjc.6604691; Wen Q, 2008, MOL BIOL CELL, V19, P1693, DOI 10.1091/mbc.E07-09-0975; Williams RS, 2008, CELL, V135, P97, DOI 10.1016/j.cell.2008.08.017; Zeng ZH, 2011, J BIOL CHEM, V286, P403, DOI 10.1074/jbc.M110.181016	31	15	15	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2014	9	10							e108483	10.1371/journal.pone.0108483	http://dx.doi.org/10.1371/journal.pone.0108483			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ9WZ	25310185	Green Published, Green Submitted, gold			2023-01-03	WOS:000343210300019
J	Barnable, P; Calenda, G; Ouattara, L; Gettie, A; Blanchard, J; Jean-Pierre, N; Kizima, L; Rodriguez, A; Abraham, C; Menon, R; Seidor, S; Cooney, ML; Roberts, KD; Sperling, R; Piatak, M; Lifson, JD; Fernandez-Romero, JA; Zydowsky, TM; Robbiani, M; Teleshova, N				Barnable, Patrick; Calenda, Giulia; Ouattara, Louise; Gettie, Agegnehu; Blanchard, James; Jean-Pierre, Ninochka; Kizima, Larisa; Rodriguez, Aixa; Abraham, Ciby; Menon, Radhika; Seidor, Samantha; Cooney, Michael L.; Roberts, Kevin D.; Sperling, Rhoda; Piatak, Michael, Jr.; Lifson, Jeffrey D.; Fernandez-Romero, Jose A.; Zydowsky, Thomas M.; Robbiani, Melissa; Teleshova, Natalia			A MIV-150/Zinc Acetate Gel Inhibits SHIV-RT Infection in Macaque Vaginal Explants	PLOS ONE			English	Article							IMMUNE FUNCTION; ZINC; TRANSMISSION; MICROBICIDES; RESISTANCE; TYPE-1; SEMEN	To extend our observations that single or repeated application of a gel containing the NNRTI MIV-150 (M) and zinc acetate dihydrate (ZA) in carrageenan (CG) (MZC) inhibits vaginal transmission of simian/human immunodeficiency virus (SHIV)-RT in macaques, we evaluated safety and anti-SHIV-RT activity of MZC and related gel formulations ex vivo in macaque mucosal explants. In addition, safety was further evaluated in human ectocervical explants. The gels did not induce mucosal toxicity. A single ex vivo exposure to diluted MZC (1:30, 1:100) and MC (1:30, the only dilution tested), but not to ZC gel, up to 4 days prior to viral challenge, significantly inhibited SHIV-RT infection in macaque vaginal mucosa. MZC's activity was not affected by seminal plasma. The antiviral activity of unformulated MIV-150 was not enhanced in the presence of ZA, suggesting that the antiviral activity of MZC was mediated predominantly by MIV-150. In vivo administration of MZC and CG significantly inhibited ex vivo SHIV-RT infection (51-62% inhibition relative to baselines) of vaginal (but not cervical) mucosa collected 24 h post last gel exposure, indicating barrier effect of CG. Although the inhibitory effect of MZC (65-74%) did not significantly differ from CG (32-45%), it was within the range of protection (similar to 75%) against vaginal SHIV-RT challenge 24 h after gel dosing. Overall, the data suggest that evaluation of candidate microbicides in macaque explants can inform macaque efficacy and clinical studies design. The data support advancing MZC gel for clinical evaluation.	[Barnable, Patrick; Calenda, Giulia; Ouattara, Louise; Jean-Pierre, Ninochka; Kizima, Larisa; Rodriguez, Aixa; Abraham, Ciby; Menon, Radhika; Seidor, Samantha; Cooney, Michael L.; Roberts, Kevin D.; Fernandez-Romero, Jose A.; Zydowsky, Thomas M.; Robbiani, Melissa; Teleshova, Natalia] Populat Council, New York, NY 10021 USA; [Gettie, Agegnehu] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10021 USA; [Blanchard, James] Tulane Univ, Tulane Natl Primate Res Ctr, Covington, LA USA; [Sperling, Rhoda] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Piatak, Michael, Jr.; Lifson, Jeffrey D.] Frederick Natl Lab Canc Res, SAIC Frederick Inc, AIDS & Canc Virus Program, Frederick, MD USA	Population Council; Rockefeller University; Tulane University; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Teleshova, N (corresponding author), Populat Council, 1230 York Ave, New York, NY 10021 USA.	nteleshova@popcouncil.org		Cooney, Michael/0000-0001-7943-1951	United States Agency for International Development (USAID) [GPO-A-00-04-00019-00]; Swedish Ministry of Foreign Affairs (SMFA); Primate Center base grant [P51 OD011104-51]; National Cancer Institute, National Institutes of Health (NIH) [HHSN261200800001E]; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P51OD011104] Funding Source: NIH RePORTER	United States Agency for International Development (USAID)(United States Agency for International Development (USAID)); Swedish Ministry of Foreign Affairs (SMFA); Primate Center base grant; National Cancer Institute, National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the United States Agency for International Development (USAID) Cooperative Agreement GPO-A-00-04-00019-00, by the Swedish Ministry of Foreign Affairs (SMFA) and Primate Center base grant P51 OD011104-51. This research is made possible by the generous support of the American people through the USAID and supported in part with federal funds from the National Cancer Institute, National Institutes of Health (NIH), under contract HHSN261200800001E (J.D.L.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1985, COMM CAR US LAB AN I, VMD 85-23, P1; Aravantinou M, 2012, AIDS RES HUM RETROVI; Cline AN, 2005, J MED PRIMATOL, V34, P303; Crostarosa F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008060; Cummins JE, 2007, ANTIMICROB AGENTS CH, V51, P1770, DOI 10.1128/AAC.01129-06; Fenstermacher KJ, 2011, J BIOL CHEM, V286, P40433, DOI 10.1074/jbc.M111.289850; Fernandez-Romero JA, 2007, SEX TRANSM DIS, V34, P9, DOI 10.1097/01.olq.0000223287.46097.4b; Heffron R, 2012, LANCET INFECT DIS, V12, P19, DOI 10.1016/S1473-3099(11)70247-X; Ibs KH, 2003, J NUTR, V133, p1452S, DOI 10.1093/jn/133.5.1452S; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Katz DF, 2011, DRUG DELIV TRANSL RE, V1, P256, DOI 10.1007/s13346-011-0029-z; Kenney J, 2012, AIDS RES HUM RETROVI; Kenney J, 2013, ANTIMICROB AGENTS CH; Kenney J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015835; Kizima L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094547; Lai BE, 2008, J PHARM SCI-US, V97, P1030, DOI 10.1002/jps.21132; Lifson JD, 2001, J VIROL, V75, P10187, DOI 10.1128/JVI.75.21.10187-10199.2001; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Malcolm RK, 2012, ANTIMICROB AGENTS CH, V56, P2251, DOI 10.1128/AAC.05810-11; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; Ouattara LA, 2014, ANTIMICROB AGENTS CH; Owen DH, 2005, J ANDROL, V26, P459, DOI 10.2164/jandrol.04104; Richardson-Harman N, 2012, AIDS RES HUM RETROV, V28, P1422, DOI [10.1089/aid.2012.0073, 10.1089/AID.2012.0073]; Richardson-Harman N, 2009, J CLIN MICROBIOL, V47, P3530, DOI 10.1128/JCM.00673-09; Rink L, 2000, J NUTR, V130, p1407S, DOI 10.1093/jn/130.5.1407S; Shankar AH, 1998, AM J CLIN NUTR, V68, p447S, DOI 10.1093/ajcn/68.2.447S; Singer R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003936; Turville SG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003162; Wellinghausen N, 1997, IMMUNOL TODAY, V18, P519, DOI 10.1016/S0167-5699(97)01146-8	29	14	14	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2014	9	9							e108109	10.1371/journal.pone.0108109	http://dx.doi.org/10.1371/journal.pone.0108109			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ3IP	25259616	Green Published, Green Submitted, gold			2023-01-03	WOS:000342685600047
J	DeLoughery, TG				DeLoughery, Thomas G.			Review: Restrictive RBC transfusion strategies reduce nosocomial infections compared with liberal strategies	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Oregon Hlth & Sci Univ, Portland, OR 97207 USA	Oregon Health & Science University	DeLoughery, TG (corresponding author), Oregon Hlth & Sci Univ, Portland, OR 97207 USA.							Carson JL, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002042.pub3; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hod EA, 2010, BLOOD, V115, P4284, DOI 10.1182/blood-2009-10-245001; Salpeter SR, 2014, AM J MED, V127, P124, DOI 10.1016/j.amjmed.2013.09.017	4	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2014	161	6							JC11	10.7326/0003-4819-161-6-201409160-02011	http://dx.doi.org/10.7326/0003-4819-161-6-201409160-02011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AR9LF	25222411				2023-01-03	WOS:000343894400010
J	Ensing, EP; Ciuti, S; de Wijs, FALM; Lentferink, DH; ten Hoedt, A; Boyce, MS; Hut, RA				Ensing, Erik P.; Ciuti, Simone; de Wijs, Freek A. L. M.; Lentferink, Dennis H.; ten Hoedt, Andre; Boyce, Mark S.; Hut, Roelof A.			GPS Based Daily Activity Patterns in European Red Deer and North American Elk (Cervus elaphus): Indication for a Weak Circadian Clock in Ungulates	PLOS ONE			English	Article							GLOBAL POSITIONING SYSTEM; BODY-TEMPERATURE; ROE DEER; BEHAVIOR; REINDEER; RHYTHMS; RADIOTELEMETRY; ORGANIZATION; MELATONIN; PREDATOR	Long-term tracking using global positioning systems (GPS) is widely used to study vertebrate movement ecology, including fine-scale habitat selection as well as large-scale migrations. These data have the potential to provide much more information about the behavior and ecology of wild vertebrates: here we explore the potential of using GPS datasets to assess timing of activity in a chronobiological context. We compared two different populations of deer (Cervus elaphus), one in the Netherlands (red deer), the other in Canada (elk). GPS tracking data were used to calculate the speed of the animals as a measure for activity to deduce unbiased daily activity rhythms over prolonged periods of time. Speed proved a valid measure for activity, this being validated by comparing GPS based activity data with head movements recorded by activity sensors, and the use of GPS locations was effective for generating long term chronobiological data. Deer showed crepuscular activity rhythms with activity peaks at sunrise (the Netherlands) or after sunrise (Canada) and at the end of civil twilight at dusk. The deer in Canada were mostly diurnal while the deer in the Netherlands were mostly nocturnal. On an annual scale, Canadian deer were more active during the summer months while deer in the Netherlands were more active during winter. We suggest that these differences were mainly driven by human disturbance (on a daily scale) and local weather (on an annual scale). In both populations, the crepuscular activity peaks in the morning and evening showed a stable timing relative to dawn and dusk twilight throughout the year, but marked periods of daily a-rhythmicity occurred in the individual records. We suggest that this might indicate that (changes in) light levels around twilight elicit a direct behavioral response while the contribution of an internal circadian timing mechanism might be weak or even absent.	[Ensing, Erik P.; de Wijs, Freek A. L. M.; Lentferink, Dennis H.; Hut, Roelof A.] Univ Groningen, Ctr Behaviour & Neurosci, Chronobiol Unit, Groningen, Netherlands; [Ciuti, Simone] Univ Freiburg, Dept Biometry & Environm Syst Anal, D-79106 Freiburg, Germany; [Ciuti, Simone; Boyce, Mark S.] Univ Alberta, Dept Biol Sci, Edmonton, AB, Canada; [ten Hoedt, Andre] Nat Monumenten, Eenheid Veluwezoom, Rheden, Netherlands	University of Groningen; University of Freiburg; University of Alberta	Hut, RA (corresponding author), Univ Groningen, Ctr Behaviour & Neurosci, Chronobiol Unit, Groningen, Netherlands.	r.a.hut@rug.nl	Hut, Roelof A./I-3483-2012; Ciuti, Simone/D-7283-2013; Boyce, Mark S/A-2620-2014	Ciuti, Simone/0000-0003-1052-9509; Boyce, Mark S/0000-0001-5811-325X; Lentferink, Dennis/0000-0002-8747-1336	Alberta Conservation Association (ACA - Grant Eligible Conservation Fund) [ACA GECF 030-00-90-176]; Natural Sciences and Engineering Research Council of Canada (NSERC-CRD) [CRD 364323]; Shell Canada limited; Alberta Conservation Association (ACA - Grant Eligible Conservation Fund); Natural Sciences and Engineering Research Council of Canada (NSERC-CRD)	Alberta Conservation Association (ACA - Grant Eligible Conservation Fund); Natural Sciences and Engineering Research Council of Canada (NSERC-CRD)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Shell Canada limited; Alberta Conservation Association (ACA - Grant Eligible Conservation Fund); Natural Sciences and Engineering Research Council of Canada (NSERC-CRD)(Natural Sciences and Engineering Research Council of Canada (NSERC))	MSB and SC received funding from the Alberta Conservation Association (ACA - Grant Eligible Conservation Fund; ACA GECF 030-00-90-176 Boyce), the Natural Sciences and Engineering Research Council of Canada (NSERC-CRD; CRD 364323), and Shell Canada limited. URLs: http://www.montaneelk.com/; http://www.ab-conservation.com/go/default/; http://www.businessbiodiversity.ca/documents/14-Shell.pdf; http://www.nserc-crsng.gc.ca/Professors-Professeurs/rpp-pp/crd-rdc_eng.asp. Sponsor role: This study was funded by Alberta Conservation Association (ACA - Grant Eligible Conservation Fund), the Natural Sciences and Engineering Research Council of Canada (NSERC-CRD), and Shell Canada limited, as declared in the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Boyce MS, 2010, PHILOS T R SOC B, V365, P2213, DOI 10.1098/rstb.2010.0080; Cagnacci F, 2010, PHILOS T R SOC B, V365, P2157, DOI 10.1098/rstb.2010.0107; Ciuti S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050611; Clair CCS, 2009, BEHAVIOUR, V146, P393, DOI 10.1163/156853909X410973; DAAN S, 1975, OECOLOGIA, V18, P269, DOI 10.1007/BF00345851; EBLING FJP, 1988, J BIOL RHYTHM, V3, P365, DOI 10.1177/074873048800300406; Fortin D, 2005, ECOLOGY, V86, P1320, DOI 10.1890/04-0953; GEORGII B, 1981, OECOLOGIA, V49, P127, DOI 10.1007/BF00376910; GEORGII B, 1983, OECOLOGIA, V58, P238, DOI 10.1007/BF00399224; Hut RA, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0433; Hut RA, 2012, PROG BRAIN RES, V199, P281, DOI 10.1016/B978-0-444-59427-3.00017-4; Jayakody S, 2008, WILDLIFE BIOL, V14, P81, DOI 10.2981/0909-6396(2008)14[81:RDCEVB]2.0.CO;2; Krop-Benesch A, 2013, ITAL J ZOOL, V80, P69, DOI 10.1080/11250003.2012.725777; Loe LE, 2010, J ZOOL, V280, P84, DOI 10.1111/j.1469-7998.2009.00647.x; Loe LE, 2007, OECOLOGIA, V152, P617, DOI 10.1007/s00442-007-0681-7; Loe LE, 2009, P ROY SOC B-BIOL SCI, V276, P2581, DOI 10.1098/rspb.2009.0224; Long RA, 2005, J MAMMAL, V86, P314, DOI 10.1644/BRG-224.1; Murphy Barbara A, 2011, J Circadian Rhythms, V9, P3, DOI 10.1186/1740-3391-9-3; Northrup JM, 2012, J APPL ECOL, V49, P1159, DOI 10.1111/j.1365-2664.2012.02180.x; Pagon N, 2013, CHRONOBIOL INT, V30, P772, DOI 10.3109/07420528.2013.765887; Piccione G, 2013, BIOL RHYTHM RES, V44, P143, DOI 10.1080/09291016.2012.656245; Pipia A, 2008, BEHAVIOUR, V145, P1723, DOI 10.1163/156853908786279628; Ryan PG, 2004, MAR BIOL, V145, P215, DOI 10.1007/s00227-004-1328-4; Sibbald AM, 2011, EUR J WILDLIFE RES, V57, P817, DOI 10.1007/s10344-011-0493-2; Stokkan KA, 2007, J PINEAL RES, V43, P289, DOI 10.1111/j.1600-079X.2007.00476.x; Tomkiewicz SM, 2010, PHILOS T R SOC B, V365, P2163, DOI 10.1098/rstb.2010.0090; van Oort BEH, 2005, NATURE, V438, P1095, DOI 10.1038/4381095a; van Oort BEH, 2007, NATURWISSENSCHAFTEN, V94, P183, DOI 10.1007/s00114-006-0174-2; Williams CT, 2012, BIOL LETTERS, V8, P31, DOI 10.1098/rsbl.2011.0435	29	76	82	5	128	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2014	9	9							e106997	10.1371/journal.pone.0106997	http://dx.doi.org/10.1371/journal.pone.0106997			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AP4EP	25208246	Green Published, gold, Green Submitted			2023-01-03	WOS:000342030300053
J	Camargos, HS; Moreira, RA; Mendanha, SA; Fernandes, KS; Dorta, ML; Alonso, A				Camargos, Heverton Silva; Moreira, Rodrigo Alves; Mendanha, Sebastiao Antonio; Fernandes, Kelly Souza; Dorta, Miriam Leandro; Alonso, Antonio			Terpenes Increase the Lipid Dynamics in the Leishmania Plasma Membrane at Concentrations Similar to Their IC50 Values	PLOS ONE			English	Article							SPIN-LABELED LIPIDS; STRATUM-CORNEUM; CANCER CHEMOPREVENTION; ERYTHROCYTE-MEMBRANE; PROTEIN DYNAMICS; MILTEFOSINE; AMAZONENSIS; COMPONENTS; MONOTERPENES; BREAST	Although many terpenes have shown antitumor, antibacterial, antifungal, and antiparasitic activity, the mechanism of action is not well established. Electron paramagnetic resonance (EPR) spectroscopy of the spin-labeled 5-doxyl stearic acid revealed remarkable fluidity increases in the plasma membrane of terpene-treated Leishmania amazonensis promastigotes. For an antiproliferative activity assay using 5x10(6) parasites/mL, the sesquiterpene nerolidol and the monoterpenes(+)-limonene, alpha-terpineol and 1,8-cineole inhibited the growth of the parasites with IC50 values of 0.008, 0.549, 0.678 and 4.697 mM, respectively. The IC50 values of these terpenes increased as the parasite concentration used in the cytotoxicity assay increased, and this behavior was examined using a theoretical treatment of the experimental data. Cytotoxicity tests with the same parasite concentration as in the EPR experiments revealed a correlation between the IC50 values of the terpenes and the concentrations at which they altered the membrane fluidity. In addition, the terpenes induced small amounts of cell lysis (4-9%) at their respective IC50 values. For assays with high cell concentrations (2 x 10(9) parasites/mL), the incorporation of terpene into the cell membrane was very fast, and the IC50 values observed for 24 h and 5 min-incubation periods were not significantly different. Taken together, these results suggest that terpene cytotoxicity is associated with the attack on the plasma membrane of the parasite. The in vitro cytotoxicity of nerolidol was similar to that of miltefosine, and nerolidol has high hydrophobicity; thus, nerolidol might be used in drug delivery systems, such as lipid nanoparticles to treat leishmaniasis.	[Camargos, Heverton Silva; Moreira, Rodrigo Alves; Mendanha, Sebastiao Antonio; Fernandes, Kelly Souza; Alonso, Antonio] Univ Fed Goias, Inst Fis, Goiania, Go, Brazil; [Camargos, Heverton Silva] Fundacao Univ Fed Tocantins, Palmas, TO, Brazil; [Dorta, Miriam Leandro] Univ Fed Goias, Dept Imunol & Patol Geral, Inst Patol Trop & Saude Publ, Goiania, Go, Brazil	Universidade Federal de Goias; Universidade Federal do Tocantins (UFT); Universidade Federal de Goias	Alonso, A (corresponding author), Univ Fed Goias, Inst Fis, Goiania, Go, Brazil.	alonso@ufg.br	Mendanha, Sebastião A/E-4523-2013; Alonso, Antonio/I-8969-2012	Mendanha, Sebastião A/0000-0002-9545-5248; Alonso, Antonio/0000-0003-4768-6372	Brazilian research funding agency CNPq; Brazilian research funding agency CAPES; Brazilian research funding agency FAPEG; CAPES; CNPq	Brazilian research funding agency CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Brazilian research funding agency CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Brazilian research funding agency FAPEG; CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was financially supported by grants from the Brazilian research funding agencies CNPq, CAPES and FAPEG. Rodrigo A. Moreira, Sebastiao Antonio Mendanha and Kelly Souza Fernandes are recipients of fellowships from CAPES. Antonio Alonso is the recipient of a research grant from CNPq. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alonso A, 1997, BBA-BIOMEMBRANES, V1323, P75, DOI 10.1016/S0005-2736(96)00177-0; Alonso L, 2012, INT J PHARMACEUT, V434, P391, DOI 10.1016/j.ijpharm.2012.06.006; Arruda DC, 2005, ANTIMICROB AGENTS CH, V49, P1679, DOI 10.1128/AAC.49.5.1679-1687.2005; Arruda DC, 2009, BIOMED PHARMACOTHER, V63, P643, DOI 10.1016/j.biopha.2009.02.004; Bardon S, 2002, CANCER LETT, V181, P187, DOI 10.1016/S0304-3835(02)00047-2; Budil DE, 1996, J MAGN RESON SER A, V120, P155, DOI 10.1006/jmra.1996.0113; Camargos HS, 2013, QUIM NOVA, V36, P815, DOI 10.1590/S0100-40422013000600013; Camargos HS, 2010, LIPIDS, V45, P419, DOI 10.1007/s11745-010-3407-2; Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748; Croft SL, 2003, TRENDS PARASITOL, V19, P502, DOI 10.1016/j.pt.2003.09.008; Crowell PL, 1999, J NUTR, V129, p775S, DOI 10.1093/jn/129.3.775S; Desoti VC, 2012, MAR DRUGS, V10, P1631, DOI 10.3390/md10081631; Dorlo TPC, 2012, J ANTIMICROB CHEMOTH, V67, P2576, DOI 10.1093/jac/dks275; dos Anjos JLV, 2007, INT J PHARMACEUT, V345, P81, DOI 10.1016/j.ijpharm.2007.05.041; dos Santos AO, 2013, MEM I OSWALDO CRUZ, V108, P59, DOI 10.1590/S0074-02762013000100010; Gould MN, 1997, ENVIRON HEALTH PERSP, V105, P977, DOI 10.2307/3433313; Greay SJ, 2010, CANCER CHEMOTH PHARM, V65, P877, DOI 10.1007/s00280-009-1093-7; Guerin PJ, 2002, LANCET INFECT DIS, V2, P494, DOI 10.1016/S1473-3099(02)00347-X; Laxmi Y, 2007, CANCER LETT, V257, P216, DOI 10.1016/j.canlet.2007.07.020; Maciel-Rezende CM, 2013, BIOORGAN MED CHEM, V21, P3114, DOI 10.1016/j.bmc.2013.03.045; MCGARVEY DJ, 1995, PLANT CELL, V7, P1015, DOI 10.1105/tpc.7.7.1015; Mendanha SA, 2013, TOXICOL IN VITRO, V27, P323, DOI 10.1016/j.tiv.2012.08.022; Miguel DC, 2007, J ANTIMICROB CHEMOTH, V60, P526, DOI 10.1093/jac/dkm219; Moreira RA, 2014, ANTIMICROB AGENTS CH, V58, P3021, DOI 10.1128/AAC.01332-13; Moreira RA, 2013, J PHARM SCI-US, V102, P1661, DOI 10.1002/jps.23496; Olagnier D, 2007, BIOORG MED CHEM LETT, V17, P6075, DOI 10.1016/j.bmcl.2007.09.056; Oliva B, 2003, LETT APPL MICROBIOL, V37, P185, DOI 10.1046/j.1472-765X.2003.01375.x; de Oliveira MAP, 2010, REV INST MED TROP SP, V52, P83, DOI 10.1590/S0036-46652010000200004; Rabi T, 2009, BREAST CANCER RES TR, V115, P223, DOI 10.1007/s10549-008-0118-y; Sharma M, 2013, J MED CHEM, V56, P4374, DOI 10.1021/jm400053v; Thoppil RJ, 2011, WORLD J HEPATOL, V3, P228, DOI 10.4254/wjh.v3.i9.228; Tiuman TS, 2011, INT J INFECT DIS, V15, pE525, DOI 10.1016/j.ijid.2011.03.021; Anjos JLV, 2011, COLLOID SURFACE B, V88, P463, DOI 10.1016/j.colsurfb.2011.07.030; Dos Anjos JLV, 2008, INT J PHARMACEUT, V350, P103, DOI 10.1016/j.ijpharm.2007.08.024; dos Anjos JLV, 2007, EUR J PHARM BIOPHARM, V67, P406, DOI 10.1016/j.ejpb.2007.02.004; Wu CS, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI 10.1155/2012/818261; Yang HJ, 2010, CURR DRUG TARGETS, V11, P733, DOI 10.2174/138945010791170842	37	49	52	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 7	2014	9	8							e104429	10.1371/journal.pone.0104429	http://dx.doi.org/10.1371/journal.pone.0104429			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6SB	25101672	Green Published, gold, Green Submitted			2023-01-03	WOS:000339993900062
J	Maizels, RM; Gause, WC				Maizels, Rick M.; Gause, William C.			How helminths go viral	SCIENCE			English	Editorial Material							INFECTION; IMMUNITY; MICROBIOTA		[Maizels, Rick M.] Univ Edinburgh, Inst Immunol & Infect Res, Edinburgh, Midlothian, Scotland; [Maizels, Rick M.] Univ Edinburgh, Ctr Immun Infect & Evolut, Edinburgh, Midlothian, Scotland; [Gause, William C.] Rutgers State Univ, Ctr Immun & Infammat, Dept Med, New Jersey Med Sch, Newark, NJ 07102 USA	University of Edinburgh; University of Edinburgh; Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University Medical Center	Maizels, RM (corresponding author), Univ Edinburgh, Inst Immunol & Infect Res, Edinburgh, Midlothian, Scotland.	r.maizels@ed.ac.uk						Allen JE, 2011, NAT REV IMMUNOL, V11, P375, DOI 10.1038/nri2992; Gause WC, 2013, NAT REV IMMUNOL, V13, P607, DOI 10.1038/nri3476; Griffiths EC, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2013.2286; Kjetland EF, 2014, INT J STD AIDS, V25, P705, DOI 10.1177/0956462414523743; Kreider T, 2007, CURR OPIN IMMUNOL, V19, P448, DOI 10.1016/j.coi.2007.07.002; Osborne LC, 2014, SCIENCE, V345, P578, DOI 10.1126/science.1256942; Rausch S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074026; Reese TA, 2014, SCIENCE, V345, P573, DOI 10.1126/science.1254517; Salgame P, 2013, NAT IMMUNOL, V14, P1118, DOI 10.1038/ni.2736; Taylor MD, 2012, TRENDS IMMUNOL, V33, P181, DOI 10.1016/j.it.2012.01.001; Walk ST, 2010, INFLAMM BOWEL DIS, V16, P1841, DOI 10.1002/ibd.21299; Weinstock JV, 2013, INT J PARASITOL, V43, P245, DOI 10.1016/j.ijpara.2012.10.016	12	15	15	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 1	2014	345	6196					517	518		10.1126/science.1258443	http://dx.doi.org/10.1126/science.1258443			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM2AU	25082688				2023-01-03	WOS:000339651300026
J	Sanchez, LT				Sanchez, Luis T.			Disruptive Behaviors Among Physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Sanchez, Luis T.] Massachusetts Med Soc, Phys Hlth Serv, Waltham, MA USA		Sanchez, LT (corresponding author), Phys Hlth Serv Inc, 860 Winter St, Waltham, MA 02451 USA.	ltsanchez@verizon.net						American Medical Association Council on Ethical and Judicial Affairs, 2000, 2A00 AM MED ASS; [Anonymous], 2008, SENTINEL EVENT ALERT, P1; Friedberg MW, 2013, FACTORS AFFECTING PR; Joint Commission Hospital Accreditation Standards, LD030303LD18; Joint Commission on Accreditation of Healthcare Organizations, 2012, JT COMM PERSPECT, V32, P7; Leape LL, 2006, ANN INTERN MED, V144, P107, DOI 10.7326/0003-4819-144-2-200601170-00008; MacDonald O., 2011, DISRUPTIVE PHYS BEHA; Rosenstein AH, 2008, JT COMM J QUAL PATIE, V34, P464, DOI 10.1016/S1553-7250(08)34058-6	8	15	15	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	2014	312	21					2209	2210		10.1001/jama.2014.10218	http://dx.doi.org/10.1001/jama.2014.10218			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AU6AP	25144182				2023-01-03	WOS:000345684800010
J	Hodi, FS; Lee, S; McDermott, DF; Rao, UN; Butterfield, LH; Tarhini, AA; Leming, P; Puzanov, I; Shin, D; Kirkwood, JM				Hodi, F. Stephen; Lee, Sandra; McDermott, David F.; Rao, Uma N.; Butterfield, Lisa H.; Tarhini, Ahmad A.; Leming, Philip; Puzanov, Igor; Shin, Donghoon; Kirkwood, John M.			Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLONY-STIMULATING FACTOR; LYMPHOCYTE-ASSOCIATED ANTIGEN-4; BONE-MARROW CULTURES; REGULATORY T-CELLS; GM-CSF; COMBINATION IMMUNOTHERAPY; PROSTATE-CANCER; ANTIBODY BLOCKADE; CTLA4 BLOCKADE; IMMUNE	IMPORTANCE Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blockade with ipilimumab prolongs survival in patients with metastatic melanoma. CTLA-4 blockade and granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccine combinations demonstrate therapeutic synergy in preclinical models. A key unanswered question is whether systemic GM-CSF (sargramostim) enhances CTLA-4 blockade. OBJECTIVE To compare the effect of ipilimumab plus sargramostim vs ipilimumab alone on overall survival (OS) in patients with metastatic melanoma. DESIGN, SETTING, AND PARTICIPANTS The Eastern Cooperative Oncology Group (ECOG) conducted a US-based phase 2 randomized clinical trial from December 28, 2010, until July 28, 2011, of patients (N = 245) with unresectable stage III or IV melanoma, at least 1 prior therapy, no central nervous system metastases, and ECOG performance status of 0 or 1. INTERVENTIONS Patients were randomized to receive ipilimumab, 10mg/kg, intravenously on day 1 plus sargramostim, 250 mu g subcutaneously, on days 1 to 14 of a 21-day cycle (n = 123) vs ipilimumab alone (n = 122). Ipilimumab treatment included induction for 4 cycles followed by maintenance every fourth cycle. MAIN OUTCOMES AND MEASURES Primary end point: comparison of length of OS. Secondary end point: progression-free survival (PFS), response rate, safety, and tolerability. RESULTS Median follow-up was 13.3 months (range, 0.03-19.9). As of December 2012, median OS and 1-year survival for the ipilimumab plus sargramostim group vs ipilimumab alone were significantly different. [GRAPHICS] A planned interim analysis was conducted at 69.8% of expected events (104 observed of 149 expected deaths) and the O'Brien-Fleming boundary was crossed for improvement in OS. There was no difference in PFS. Adverse events were more common in the ipilimumab-only group. CONCLUSION AND RELEVANCE Among patients with unresectable stage III or IV melanoma, treatment with ipilimumab plus sargramostim vs ipilimumab alone resulted in longer OS and lower toxicity, but no difference in PFS. These findings require confirmation in larger studies with longer follow-up. Copyright 2014 American Medical Association. All rights reserved.	[Hodi, F. Stephen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Lee, Sandra; Shin, Donghoon] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA; [Lee, Sandra; McDermott, David F.; Shin, Donghoon] Harvard Univ, Sch Med, Boston, MA USA; [McDermott, David F.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; [Rao, Uma N.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA; [Butterfield, Lisa H.; Tarhini, Ahmad A.; Kirkwood, John M.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA; [Leming, Philip] Christ Hosp Canc Ctr, Cincinnati, OH USA; [Leming, Philip] Univ Cincinnati, Dept Med, Cincinnati, OH USA; [Puzanov, Igor] Vanderbilt Univ, Dept Med, Div Hematol & Oncol, Nashville, TN USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Christ Hospital - Ohio; University System of Ohio; University of Cincinnati; Vanderbilt University	Hodi, FS (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.	stephen_hodi@dfci.harvard.edu	Butterfield, Lisa H./W-1564-2019; PUZANOV, IGOR/AAP-2966-2020	Butterfield, Lisa H./0000-0002-3439-9844; PUZANOV, IGOR/0000-0002-9803-3497; Shin, Donghoon/0000-0003-1582-6190	Public Health Service [CA23318, CA66636, CA21115, CA80775, CA39229, CA49957, CA32291]; NCI; NATIONAL CANCER INSTITUTE [U10CA066636, U10CA180794, U10CA080775, U10CA023318, P50CA121973, U10CA180867, U10CA180820, U10CA039229, U24CA114737, U10CA032291, U10CA021115, U10CA049957] Funding Source: NIH RePORTER	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding/Support: This study was coordinated by ECOG (Robert L. Comis, MD, Chair); supported in part by Public Health Service grants CA23318, CA66636, CA21115, CA80775, CA39229, CA49957, CA32291; and the NCI; NIH; the US Department of Health and Human Services; Bristol-Myers Squibb; and Genzyme.	Agresti A., 1990, CATEGORICAL DATA ANA; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; COX DR, 1972, J R STAT SOC B, V34, P187; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; Dranoff G, 2011, GASTROENTEROLOGY, V141, P28, DOI 10.1053/j.gastro.2011.05.023; Egea L, 2010, EXPERT REV GASTROENT, V4, P723, DOI [10.1586/egh.10.73, 10.1586/EGH.10.73]; Everly JJ, 2005, EXPERT OPIN BIOL TH, V5, P293, DOI 10.1517/14712598.5.3.293; Filipazzi P, 2007, J CLIN ONCOL, V25, P2546, DOI 10.1200/JCO.2006.08.5829; FISCHER HG, 1988, J IMMUNOL, V141, P3882; Fong L, 2009, CANCER RES, V69, P609, DOI 10.1158/0008-5472.CAN-08-3529; Fu TH, 2011, CANCER RES, V71, P5445, DOI 10.1158/0008-5472.CAN-11-1138; Fukuzawa H, 2003, BIOCHEM BIOPH RES CO, V312, P897, DOI 10.1016/j.bbrc.2003.11.009; Goldstein JI, 2011, GASTROENTEROLOGY, V141, P208, DOI 10.1053/j.gastro.2011.03.060; Han XN, 2009, GASTROENTEROLOGY, V136, P1261, DOI 10.1053/j.gastro.2008.12.046; Hercus TR, 2009, BLOOD, V114, P1289, DOI 10.1182/blood-2008-12-164004; Hodi FS, 2008, P NATL ACAD SCI USA, V105, P3005, DOI 10.1073/pnas.0712237105; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jennison C, 1997, J AM STAT ASSOC, V92, P1330; Jinushi M, 2007, J CLIN INVEST, V117, P1902, DOI 10.1172/JCI30966; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Korn EL, 2008, J CLIN ONCOL, V26, P527, DOI 10.1200/JCO.2007.12.7837; Tang DN, 2014, CANCER IMMUNOL RES, V2, P501, DOI 10.1158/2326-6066.CIR-14-0056; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Parmiani G, 2007, ANN ONCOL, V18, P226, DOI 10.1093/annonc/mdl158; Quezada SA, 2006, J CLIN INVEST, V116, P1935, DOI 10.1172/JCI27745; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Selby MJ, 2013, CANCER IMMUNOL RES, V1, P32, DOI 10.1158/2326-6066.CIR-13-0013; Slingluff CL, 2009, CLIN CANCER RES, V15, P7036, DOI 10.1158/1078-0432.CCR-09-1544; Small EJ, 1999, CLIN CANCER RES, V5, P1738; Soroosh P, 2013, J EXP MED, V210, P775, DOI 10.1084/jem.20121849; SOTOMAYOR EM, 1991, J IMMUNOL, V147, P2816; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; van den Eertwegh AJM, 2012, LANCET ONCOL, V13, P509, DOI 10.1016/S1470-2045(12)70007-4; van Elsas A, 1999, J EXP MED, V190, P355, DOI 10.1084/jem.190.3.355; WEISBART RH, 1985, NATURE, V314, P361, DOI 10.1038/314361a0; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624; Xu YH, 2008, CELL RES, V18, P1220, DOI 10.1038/cr.2008.310	40	80	80	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	2014	312	17					1744	1753		10.1001/jama.2014.13943	http://dx.doi.org/10.1001/jama.2014.13943			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AS3QX	25369488	Bronze, Green Accepted			2023-01-03	WOS:000344194500012
J	Salanova, M; Gelfi, C; Moriggi, M; Vasso, M; Vigano, A; Minafra, L; Bonifacio, G; Schiffl, G; Gutsmann, M; Felsenberg, D; Cerretelli, P; Blottner, D				Salanova, Michele; Gelfi, Cecilia; Moriggi, Manuela; Vasso, Michele; Vigano, Agnese; Minafra, Luigi; Bonifacio, Gaetano; Schiffl, Gudrun; Gutsmann, Martina; Felsenberg, Dieter; Cerretelli, Paolo; Blottner, Dieter			Disuse deterioration of human skeletal muscle challenged by resistive exercise superimposed with vibration: evidence from structural and proteomic analysis	FASEB JOURNAL			English	Article						bed rest; atrophy; ultrastructure; countermeasures; protein expression	FOCAL ADHESION KINASE; HEAVY-CHAIN ISOFORMS; TERM BED REST; TENASCIN-C; SHORTENING VELOCITY; FAST HINDLIMB; FIBERS; EXPRESSION; RAT; PROTEIN	In the present bed rest (BR) study, 23 volunteers were randomized into 3 subgroups: 60 d BR control (Ctr); BR with resistive exercise (RE; lower-limb load); and resistive vibration exercise (RVE; RE with superimposed vibration). The aim was to analyze by confocal and electron microscopy the effects of vibration on myofibril and filament integrity in soleus (Sol) and vastus lateralis (VL) muscle; differential proteomics of contractile, cytoskeletal, and costameric proteins (TN-C, ROCK1, and FAK); and expression of PGC1 and atrophy-related master genes MuRF1 and MuRF2. RVE (but not RE) preserved myofiber size and phenotype in Sol and VL by overexpressing MYBPC1 (42%, P0.01), WDR1 (39%, P0.01), sarcosin (84%, P0.01), and CKM (20%, P0.01) and prevented myofibrillar ultrastructural damage as detectable by MuRF1 expression. In Sol, cytoskeletal and contractile proteins were normalized by RVE, and TN-C increased (59%, P0.01); the latter also with RE (108%, P0.01). In VL, the outcomes of both RVE (acting on sarcosin and desmin) and RE (by way of troponinT-slow and MYL2) were similar. RVE appears to be a highly efficient countermeasure protocol against muscle atrophy and ultrastructural and molecular dysregulation induced by chronic disuse.Salanova, M., Gelfi, C., Moriggi, M., Vasso, M., Vigan, A., Minafra, L., Bonifacio, G., Schiffl, G., Gutsmann, M., Felsenberg, D., Cerretelli, P., Blottner, D. Disuse deterioration of human skeletal muscle challenged by resistive exercise superimposed with vibration: evidence from structural and proteomic analysis.	[Salanova, Michele; Schiffl, Gudrun; Gutsmann, Martina; Blottner, Dieter] Charite, Inst Anat, Neuromuscular Grp, Ctr Space Med Berlin, D-10115 Berlin, Germany; [Felsenberg, Dieter] Charite, Ctr Muscle & Bone Res ZMK, D-10115 Berlin, Germany; [Gelfi, Cecilia; Moriggi, Manuela; Vigano, Agnese] Univ Milan, Dept Biomed Sci Hlth, Milan, Italy; [Gelfi, Cecilia; Vasso, Michele; Cerretelli, Paolo] CNR, Inst Bioimaging & Mol Physiol, Segrate, Italy; [Gelfi, Cecilia] Ist Ricovero & Cura Carattere Sci IRCCS Policlin, San Donato Milanese, Italy; [Vasso, Michele; Minafra, Luigi] CNR Lab Tecnol Oncol LATO, Inst Bioimaging & Mol Physiol, Cefalu, Italy; [Bonifacio, Gaetano] Univ Lausanne, Dept Pharmacol & Toxicol, Lausanne, Switzerland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Milan; Consiglio Nazionale delle Ricerche (CNR); IRCCS Policlinico San Donato; University of Lausanne	Salanova, M (corresponding author), Charite, Neuromuscular Grp, Campus Charite Mitte,Philippstr 12, D-10115 Berlin, Germany.	michele.salanova@charite.de; cecilia.gelfi@unimi.it	MORIGGI, MANUELA/AAB-5477-2021; Minafra, L/AFR-1042-2022; Gelfi, Cecilia/L-1490-2016	MORIGGI, MANUELA/0000-0002-4718-0307; Minafra, L/0000-0003-3112-4519; Gelfi, Cecilia/0000-0002-2996-6912; VASSO, MICHELE/0000-0003-0431-0981; Blottner, Dieter/0000-0003-0355-3340	European Space Agency (ESA) [14431/02/NL/SH2]; German Aerospace Center (DER) [50WB0821, 50WB0720]; Fondo per gli Investimenti della Ricerca di Base (FIRB) [RBRN07BMCF]; Agenzia Spaziale Italiana (ASI); Telethon [GGP11082]; FP7-BIO-NMD project [241665]	European Space Agency (ESA)(European Space Agency); German Aerospace Center (DER); Fondo per gli Investimenti della Ricerca di Base (FIRB)(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Agenzia Spaziale Italiana (ASI)(Agenzia Spaziale Italiana (ASI)); Telethon(Fondazione Telethon); FP7-BIO-NMD project	The Second Berlin Bed Rest Study (BBR-2) was supported by grant 14431/02/NL/SH2 from the European Space Agency (ESA) and German Aerospace Center (DER), grant 50WB0821 (D.B.), and grant 50WB0720 (D.F.). The authors thank D. L. Belavy for his help as BBR-2 study coordinator; Ms. Petra Schrade for the technical support during the ultrastuctural analysis; S. Krasnici and J. Fakler (Traumatology Unit, Charite Campus Benjamin Franklin, Berlin, Germany) for excellence in muscle biopsy sampling; and Andrew Clarke for the language editorial work. Anti-MuRF2 antibodies were a kind gift of C. Krone and S. Labeit (Mannheim University, Mannheim, Germany). BBR-2 was also sponsored by Novotec Medical GmbH (Pforzheim, Germany) and Charite Universitatsmedizin Berlin. Special thanks to the volunteers and the staff of the Radiology Department and all the enthusiastic :members participating in BBR-2. Proteomics and mechanotransduction assessment were carried out at die University of Milan by the node of The Italian Human Proteomic Network, coordinated by C.G. and financially supported by Fondo per gli Investimenti della Ricerca di Base (FIRB; grant. RBRN07BMCF to CC.), Agenzia Spaziale Italiana (ASI; to P.C.), Telethon (grant GGP11082 to C.G.), and the FP7-BIO-NMD project (grant 241665 to C.G.).	Adams GR, 2003, J APPL PHYSIOL, V95, P2185, DOI 10.1152/japplphysiol.00346.2003; Andersen JL, 1999, J APPL PHYSIOL, V86, P455, DOI 10.1152/jappl.1999.86.2.455; Baldwin KM, 1996, MED SCI SPORT EXER, V28, P983, DOI 10.1097/00005768-199608000-00008; BAR A, 1988, FEBS LETT, V235, P153, DOI 10.1016/0014-5793(88)81253-5; Belavy DL, 2010, J MUSCULOSKEL NEURON, V10, P207; Benjamini Y, 2000, J EDUC BEHAV STAT, V25, P60, DOI 10.3102/10769986025001060; Bershadsky AD, 2003, ANNU REV CELL DEV BI, V19, P677, DOI 10.1146/annurev.cellbio.19.111301.153011; BETTO DD, 1986, BIOCHEM BIOPH RES CO, V138, P981, DOI 10.1016/S0006-291X(86)80592-7; Blottner D, 2006, EUR J APPL PHYSIOL, V97, P261, DOI 10.1007/s00421-006-0160-6; Booth FW, 1997, INT J SPORTS MED, V18, pS265, DOI 10.1055/s-2007-972723; BOTTINELLI R, 1994, J MUSCLE RES CELL M, V15, P413, DOI 10.1007/BF00122115; Caiozzo VJ, 1996, J APPL PHYSIOL, V80, P1503, DOI 10.1152/jappl.1996.80.5.1503; CHIQUETEHRISMANN R, 1994, J CELL BIOL, V127, P2093, DOI 10.1083/jcb.127.6.2093; Cochrane DJ, 2009, MUSCLE NERVE, V40, P420, DOI 10.1002/mus.21330; Durieux AC, 2007, BIOCHEM SOC T, V35, P1312, DOI 10.1042/BST0351312; EDGERTON VR, 1995, J APPL PHYSIOL, V78, P1733, DOI 10.1152/jappl.1995.78.5.1733; Ervasti JM, 2003, J BIOL CHEM, V278, P13591, DOI 10.1074/jbc.R200021200; Fluck M, 2002, J EXP BIOL, V205, P2337; Fluck M, 2008, P NATL ACAD SCI USA, V105, P13662, DOI 10.1073/pnas.0805365105; GRANIT R, 1956, ACTA PHYSIOL SCAND, V37, P114, DOI 10.1111/j.1748-1716.1956.tb01347.x; Ito K, 2004, HYPERTENSION, V43, P156, DOI 10.1161/01.HYP.0000114602.82140.a4; Jarvinen TAH, 2003, J CELL SCI, V116, P857, DOI 10.1242/jcs.00303; Leger B, 2006, J PHYSIOL-LONDON, V576, P923, DOI 10.1113/jphysiol.2006.116715; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Mackey AL, 2011, FASEB J, V25, P1943, DOI 10.1096/fj.10-176487; Marouga R, 2005, ANAL BIOANAL CHEM, V382, P669, DOI 10.1007/s00216-005-3126-3; Midwood KS, 2009, J CELL COMMUN SIGNAL, V3, P287, DOI 10.1007/s12079-009-0075-1; Moriggi M, 2010, PROTEOMICS, V10, P3756, DOI 10.1002/pmic.200900817; Pasini E, 2012, EXP GERONTOL, V47, P23, DOI 10.1016/j.exger.2011.10.003; Quach NL, 2006, DEV BIOL, V293, P38, DOI 10.1016/j.ydbio.2005.12.040; Rittweger J, 2010, BONE, V46, P137, DOI 10.1016/j.bone.2009.08.051; Salanova M, 2008, J ANAT, V212, P306, DOI 10.1111/j.1469-7580.2008.00854.x; Salanova M, 2008, HISTOCHEM CELL BIOL, V130, P105, DOI 10.1007/s00418-008-0399-6; Salanova M, 2011, FASEB J, V25, P4312, DOI 10.1096/fj.11-186049; Salanova M, 2009, HISTOCHEM CELL BIOL, V132, P383, DOI 10.1007/s00418-009-0624-y; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Schenck U, 1996, ACTA CYTOL, V40, P73; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; Schiaffino S, 2011, PHYSIOL REV, V91, P1447, DOI 10.1152/physrev.00031.2010; Schuenke MD, 2009, EUR J APPL PHYSIOL, V106, P885, DOI 10.1007/s00421-009-1091-9; Smith Temple F., 2008, V48, P20, DOI 10.1007/978-0-387-09595-0_3; TERMIN A, 1989, EUR J BIOCHEM, V186, P749, DOI 10.1111/j.1432-1033.1989.tb15269.x; Traon APL, 2007, EUR J APPL PHYSIOL, V101, P143, DOI 10.1007/s00421-007-0474-z; Trappe S, 2004, J PHYSIOL-LONDON, V557, P501, DOI 10.1113/jphysiol.2004.062166; Vigano A, 2011, PROTEOMICS, V11, P4202, DOI 10.1002/pmic.201000804; Viswanathan S, 2006, NAT PROTOC, V1, P1351, DOI 10.1038/nprot.2006.234; Widrick JJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1690	48	34	36	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4748	4763		10.1096/fj.14-252825	http://dx.doi.org/10.1096/fj.14-252825			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25122557				2023-01-03	WOS:000344050900015
J	Fralick, M; Macdonald, EM; Gomes, T; Antoniou, T; Hollands, S; Mamdani, MM; Juurlink, DN				Fralick, Michael; Macdonald, Erin M.; Gomes, Tara; Antoniou, Tony; Hollands, Simon; Mamdani, Muhammad M.; Juurlink, David N.		CDSERN	Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONVERTING ENZYME-INHIBITOR; INDUCED HYPERKALEMIA; ADMINISTRATIVE DATA; TRIMETHOPRIM; CIPROFLOXACIN; COMBINATION; MECHANISM; ONTARIO; RATES	Objective To determine whether the prescription of co-trimoxazole with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker is associated with sudden death. Design Population based nested case-control study. Setting Ontario, Canada, from 1 April 1994 to 1 January 2012. Participants Ontario residents aged 66 years or older treated with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker. Cases were those who died suddenly shortly after receiving an outpatient prescription for one of co-trimoxazole, amoxicillin, ciprofloxacin, norfloxacin, or nitrofurantoin. Each case was matched with up to four controls on age, sex, chronic kidney disease, and diabetes. Main outcome measure Odds ratio for the association between sudden death and exposure to each antibiotic relative to amoxicillin, after adjustment for predictors of sudden death according to a disease risk index. Results Of 39 879 sudden deaths, 1027 occurred within seven days of exposure to an antibiotic and were matched to 3733 controls. Relative to amoxicillin, co-trimoxazole was associated with an increased risk of sudden death (adjusted odds ratio 1.38, 95% confidence interval 1.09 to 1.76). The risk was marginally higher at 14 days (adjusted odds ratio 1.54, 1.29 to 1.84). This corresponds to approximately three sudden deaths within 14 days per 1000 co-trimoxazole prescriptions. Ciprofloxacin (a known cause of QT interval prolongation) was also associated with an increased risk of sudden death (adjusted odds ratio 1.29, 1.03 to 1.62), but no such risk was observed with nitrofurantoin or norfloxacin. Conclusions In older patients receiving angiotensin converting enzyme inhibitors or angiotensin receptor blockers, co-trimoxazole is associated with an increased risk of sudden death. Unrecognized severe hyperkalemia may underlie this finding. When appropriate, alternative antibiotics should be considered in such patients.	[Fralick, Michael] Univ Toronto, Dept Internal Med, Toronto, ON M5G 2C4, Canada; [Macdonald, Erin M.; Gomes, Tara; Antoniou, Tony; Hollands, Simon; Mamdani, Muhammad M.; Juurlink, David N.] Inst Clin Evaluat Sci, Toronto, ON M5N 4M5, Canada; St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Gomes, Tara; Antoniou, Tony; Mamdani, Muhammad M.; Juurlink, David N.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON M5T 3M7, Canada; [Antoniou, Tony] St Michaels Hosp, Dept Family & Community Med, Toronto, ON M5B 1W8, Canada; [Mamdani, Muhammad M.] St Michaels Hosp, Appl Hlth Res Ctr, Toronto, ON M5B 1W8, Canada; [Mamdani, Muhammad M.] King Saud Univ, Riyadh, Saudi Arabia; [Juurlink, David N.] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada	University of Toronto; University of Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; King Saud University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Juurlink, DN (corresponding author), Sunnybrook Hlth Sci Ctr, 2075 Bayview Ave G106, Toronto, ON M4N 3M5, Canada.	dnj@ices.on.ca		Gomes, Tara/0000-0002-1468-1965	Canadian Drug Safety and Effectiveness Research Network (CDSERN); Institute for Clinical Evaluative Sciences (ICES) - Ontario Ministry of Health and Long-Term Care (MOHLTC); Canadian Institute for Health Research; Ontario HIV Treatment Network	Canadian Drug Safety and Effectiveness Research Network (CDSERN); Institute for Clinical Evaluative Sciences (ICES) - Ontario Ministry of Health and Long-Term Care (MOHLTC)(Ministry of Health and Long-Term Care, Ontario); Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Ontario HIV Treatment Network	This study was supported in part by a grant from the Canadian Drug Safety and Effectiveness Research Network (CDSERN) and by the Institute for Clinical Evaluative Sciences (ICES), a non-profit research institute sponsored by the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. TA is supported by a new investigator award from the Canadian Institute for Health Research and Ontario HIV Treatment Network.	Alappan R, 1999, AM J NEPHROL, V19, P389, DOI 10.1159/000013483; Antoniou T, 2010, ARCH INTERN MED, V170, P1045, DOI 10.1001/archinternmed.2010.142; Arbogast PG, 2009, STAT METHODS MED RES, V18, P67, DOI 10.1177/0962280208092347; Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580; Bugge JF, 1996, J INTERN MED, V240, P249, DOI 10.1046/j.1365-2796.1996.43869000.x; Canaday D, 2013, ARCH INTERN MED, V120, P437; Chung CP, 2010, PHARMACOEPIDEM DR S, V19, P563, DOI 10.1002/pds.1888; Desai AS, 2007, J AM COLL CARDIOL, V50, P1959, DOI 10.1016/j.jacc.2007.07.067; EiamOng S, 1996, KIDNEY INT, V49, P1372, DOI 10.1038/ki.1996.193; Eschmann E, 2014, EUR J CLIN PHARMACOL, V70, P215, DOI 10.1007/s00228-013-1597-2; Flanagan MC, 2006, INT J CARDIOL, V113, P239, DOI 10.1016/j.ijcard.2005.08.048; Frothingham R, 2001, PHARMACOTHERAPY, V21, P1468, DOI 10.1592/phco.21.20.1468.34482; Gupta K, 2011, CLIN INFECT DIS, V52, pE103, DOI [10.1093/cid/ciq257, 10.1093/cid/cir102]; Health and Social Care Information Centre, 2013, PRESCR DIS COMM ENGL; Hicks LA, 2013, NEW ENGL J MED, V368, P1461, DOI 10.1056/NEJMc1212055; Hux JE, 2002, DIABETES CARE, V25, P512, DOI 10.2337/diacare.25.3.512; Ibrahim M, 2012, AM J EMERG MED, V30, DOI 10.1016/j.ajem.2010.09.039; IMS Institute for Healthcare Informatics, 2012, NAT PRESCR AUD, P46; Izzo JL, 2011, J CLIN HYPERTENS, V13, P667, DOI 10.1111/j.1751-7176.2011.00508.x; Jolobe OMP, 1997, J INTERN MED, V242, P88; Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135; Juurlink DN, 2003, JAMA-J AM MED ASSOC, V289, P1652, DOI 10.1001/jama.289.13.1652; Kang JS, 2001, MOL PHARMACOL, V59, P122, DOI 10.1124/mol.59.1.122; Knorr JP, 2008, AM J HEALTH-SYST PH, V65, P547, DOI 10.2146/ajhp070081; Lam N, 2011, AM J KIDNEY DIS, V57, P521, DOI 10.1053/j.ajkd.2010.11.006; Margassery S, 2001, J NEPHROL, V14, P410; Marinella MA, 1999, GERONTOLOGY, V45, P209, DOI 10.1159/000022089; Motiwala SS, 2006, CAN J AGING, V25, P363, DOI 10.1353/cja.2007.0019; National Health Services Business Association, 2009, ANT PRESCR EXCL TOP; Palmer BF, 2004, NEW ENGL J MED, V351, P585, DOI 10.1056/NEJMra035279; Prabhakar M, 2004, HEART RHYTHM, V1, P624, DOI 10.1016/j.hrthm.2004.06.020; Reardon LC, 1998, ARCH INTERN MED, V158, P26, DOI 10.1001/archinte.158.1.26; Schaefer TJ, 2005, EMERG MED CLIN N AM, V23, P723, DOI 10.1016/j.emc.2005.03.016; Schultz SE, 2013, CHRON DIS INJ CAN, V33, P160; van Walraven C, 2013, CAN MED ASSOC J, V185, pE755, DOI 10.1503/cmaj.130875; VELAZQUEZ H, 1993, ANN INTERN MED, V119, P296, DOI 10.7326/0003-4819-119-4-199308150-00008; World Health Organization, 2013, WHO MOD LIST ESS MED; Wright AJ, 2011, CAN MED ASSOC J, V183, P303, DOI 10.1503/cmaj.100702	38	47	48	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 30	2014	349								g6196	10.1136/bmj.g6196	http://dx.doi.org/10.1136/bmj.g6196			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AS3DI	25359996	hybrid, Green Published			2023-01-03	WOS:000344156100002
J	Goldman, LE; Sarkar, U; Kessell, E; Guzman, D; Schneidermann, M; Pierluissi, E; Walter, B; Vittinghoff, E; Critchfield, J; Kushel, M				Goldman, L. Elizabeth; Sarkar, Urmimala; Kessell, Eric; Guzman, David; Schneidermann, Michelle; Pierluissi, Edgar; Walter, Barbara; Vittinghoff, Eric; Critchfield, Jeff; Kushel, Margot			Support From Hospital to Home for Elders A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							VULNERABLE PATIENTS; PRIMARY-CARE; FOLLOW-UP; DISCHARGE; READMISSIONS; UTILITY; REHOSPITALIZATION; RELIABILITY; PROGRAM; BOOST	Background: Hospitals are implementing discharge support programs to reduce readmissions, and these programs have had mixed success. Objective: To examine whether a peridischarge, nurse-led intervention decreased emergency department (ED) visits or readmissions among ethnically and linguistically diverse older patients admitted to a safety-net hospital. Design: Randomized, controlled trial using computer-generated randomization with 1: 1 allocation, stratified by language. (Clinical Trials.gov: NCT01221532) Setting: Publicly funded urban hospital in Northern California. Patients: Hospitalized adults aged 55 years or older with anticipated discharge to the community who spoke English, Spanish, or Chinese (Mandarin or Cantonese). Intervention: Usual care versus in-hospital, one-on-one, self-management education given by a dedicated language-concordant registered nurse combined with a telephone follow-up after discharge from a nurse practitioner. Measurements: Staff blinded to the study groups determined ED visits or readmissions to any facility at 30, 90, and 180 days after initial hospital discharge using administrative data from several hospitals. Results: There were 700 low-income, ethnically and linguistically diverse patients with a mean age of 66.2 years (SD, 9.0). The primary outcome of ED visits or readmissions did not differ between the intervention and usual care groups (hazard ratio, 1.26 [95% CI, 0.89 to 1.78] at 30 days, 1.21 [ CI, 0.91 to 1.62] at 90 days, and 1.11 [ CI, 0.86 to 1.43] at 180 days). Limitations: This study was done at a single acute-care hospital. There were fewer outcomes than expected, which may have caused the study to be underpowered. Conclusion: A nurse-led, in-hospital discharge support intervention did not show a reduction in readmissions or ED visits among diverse, low-income older adults at a safety-net hospital. Although wide CIs preclude firm conclusions, the intervention may have increased ED visits. Alternative readmission prevention strategies should be tested in this population.	[Goldman, L. Elizabeth; Sarkar, Urmimala; Kessell, Eric; Guzman, David; Schneidermann, Michelle; Pierluissi, Edgar; Walter, Barbara; Vittinghoff, Eric; Critchfield, Jeff; Kushel, Margot] Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA 94110 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Goldman, LE (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Div Gen Med, Dept Internal Med, 1001 Potrero Ave,Box 1364, San Francisco, CA 94110 USA.	legoldman@medsfgh.ucsf.edu		Kushel, Margot/0000-0002-1361-6889	Gordon and Betty Moore Foundation; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS018090] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024130] Funding Source: NIH RePORTER	Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Primary Funding Source: Gordon and Betty Moore Foundation.	Ali R, 2002, ADDICTION, V97, P1183; Altman S, 2000, AM HLTH CARE SAFETY; Balaban RB, 2008, J GEN INTERN MED, V23, P1228, DOI 10.1007/s11606-008-0618-9; Brown-Williams H., 2006, HOSP HOME IMPROVING; Campbell SE, 2004, AGE AGEING, V33, P110, DOI 10.1093/ageing/afh036; Cawthon PM, 2009, J AM GERIATR SOC, V57, P1411, DOI 10.1111/j.1532-5415.2009.02366.x; Centers for Disease Control and Prevention, 2009, 2008 NAT HLTH INT SU; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chew LD, 2004, FAM MED, V36, P588; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Cunningham PJ, 2008, HEALTH AFFAIR, V27, pW374, DOI 10.1377/hlthaff.27.5.w374; de Jager CA, 2003, INT J GERIATR PSYCH, V18, P318, DOI 10.1002/gps.830; Debling D, 2005, Z GERONTOL GERIATR, V38, P360, DOI 10.1007/s00391-005-0299-5; Dudas V, 2002, DM-DIS MON, V48, P239, DOI 10.1016/S0011-5029(02)90031-3; Fan VS, 2012, ANN INTERN MED, V156, P673, DOI 10.7326/0003-4819-156-10-201205150-00003; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Gerhardt G, 2013, DATA SHOWS REDUCTION, V3; Hansen LO, 2013, J HOSP MED, V8, P421, DOI 10.1002/jhm.2054; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Hernan MA, 2013, ANN INTERN MED, V159, P560, DOI 10.7326/0003-4819-159-8-201310150-00709; Hesselink G, 2012, ANN INTERN MED, V157, P417, DOI 10.7326/0003-4819-157-6-201209180-00006; Huang L, 2006, J MED LIBR ASSOC, V94, P234; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; Jha AK, 2013, J HOSP MED, V8, P470, DOI 10.1002/jhm.2069; Joynt KE, 2013, NEW ENGL J MED, V368, P1175, DOI 10.1056/NEJMp1300122; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kleinbaum DG, 2012, STAT BIOL HEALTH, P1, DOI 10.1007/978-1-4419-6646-9; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Marengoni A, 2008, AM J PUBLIC HEALTH, V98, P1198, DOI 10.2105/AJPH.2007.121137; McCarthy D, 2013, JAMA-J AM MED ASSOC, V309, P351, DOI 10.1001/jama.2013.1; Naylor Mary D, 2002, Annu Rev Nurs Res, V20, P127; Naylor Mary D, 2004, LDI Issue Brief, V9, P1; Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Ness D, 2013, REDUCING HOSP READMI; Oddone EZ, 1996, J GEN INTERN MED, V11, P597, DOI 10.1007/BF02599027; Operario D, 2004, PSYCHOL HEALTH, V19, P237, DOI 10.1080/08870440310001638098; Project BOOST Team, 2014, OV PROJ BOOST IMPL T; Reuland DS, 2009, ANN FAM MED, V7, P455, DOI 10.1370/afm.981; Sarkar U, 2011, J GEN INTERN MED, V26, P265, DOI 10.1007/s11606-010-1552-1; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Schillinger D, 2003, ARCH INTERN MED, V163, P83, DOI 10.1001/archinte.163.1.83; Schillinger D, 2009, DIABETES CARE, V32, P559, DOI 10.2337/dc08-0787; Searight HR, 2007, PRIMARY CARE, V34, P551, DOI 10.1016/j.pop.2007.05.012; Shepperd S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000313.pub3; SHIN HB, 2003, LANGUAGE USE ENGLISH; Society of Hospital Medicine, 2014, USE PROJ BOOST IMPL; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Sudore RL, 2006, J GEN INTERN MED, V21, P867, DOI 10.1111/j.1525-1497.2006.00535.x; Urbach DR, 2014, NEW ENGL J MED, V370, P1029, DOI 10.1056/NEJMsa1308261; Volz A, 2011, J BEHAV MED, V34, P13, DOI 10.1007/s10865-010-9282-8; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Williams MV, 2002, FAM MED, V34, P383	53	49	49	1	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 7	2014	161	7					472	+		10.7326/M14-0094	http://dx.doi.org/10.7326/M14-0094			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AR9LU	25285540				2023-01-03	WOS:000343896700006
J	McGlothlin, AE; Lewis, RJ				McGlothlin, Anna E.; Lewis, Roger J.			Minimal Clinically Important Difference Defining What Really Matters to Patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							OSTEOARTHRITIS		[McGlothlin, Anna E.; Lewis, Roger J.] Berry Consultants, Austin, TX USA; [Lewis, Roger J.] Harbor UCLA Med Ctr, Dept Emergency Med, Torrance, CA 90509 USA; [Lewis, Roger J.] Los Angeles Biomed Res Inst, Torrance, CA USA; [Lewis, Roger J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lewis, RJ (corresponding author), Harbor UCLA Med Ctr, Dept Emergency Med, Bldg D9,1000 W Carson St, Torrance, CA 90509 USA.	roger@emedharbor.edu		McGlothlin, Anna/0000-0002-9079-6166				BELLAMY N, 1992, J RHEUMATOL, V19, P451; Hinman RS, 2014, JAMA-J AM MED ASSOC, V312, P1313, DOI 10.1001/jama.2014.12660; Ikramuddin S, 2014, JAMA-J AM MED ASSOC, V312, P915, DOI 10.1001/jama.2014.10540; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Livingston EH, 2009, ARCH SURG-CHICAGO, V144, P706, DOI 10.1001/archsurg.2009.150; Tubach F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ard.2004.022905; Turner D, 2010, J CLIN EPIDEMIOL, V63, P28, DOI 10.1016/j.jclinepi.2009.01.024	7	272	277	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2014	312	13					1342	1343		10.1001/jama.2014.13128	http://dx.doi.org/10.1001/jama.2014.13128			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AP8RB	25268441				2023-01-03	WOS:000342345400020
J	Tamanai-Shacoori, Z; Chandad, F; Rebillard, A; Cillard, J; Bonnaure-Mallet, M				Tamanai-Shacoori, Zohreh; Chandad, Fatiha; Rebillard, Amelie; Cillard, Josiane; Bonnaure-Mallet, Martine			Silver-Zeolite Combined to Polyphenol-Rich Extracts of Ascophyllum nodosum: Potential Active Role in Prevention of Periodontal Diseases	PLOS ONE			English	Article							PORPHYROMONAS-GINGIVALIS; BACTERICIDAL ACTIVITY; ESCHERICHIA-COLI; OXIDATIVE STRESS; BROWN ALGA; ANTIOXIDANT; LIPOPOLYSACCHARIDE; HEALTH; NANOPARTICLES; INFLAMMATION	The purpose of this study was to evaluate various biological effects of silver-zeolite and a polyphenol-rich extract of A. nodosum (ASCOP) to prevent and/or treat biofilm-related oral diseases. Porphyromonas gingivalis and Streptococcus gordonii contribute to the biofilm formation associated with chronic periodontitis. In this study, we evaluated in vitro antibacterial and anti-biofilm effects of silver-zeolite (Ag-zeolite) combined to ASCOP on P. gingivalis and S. gordonii growth and biofilm formation capacity. We also studied the anti-inflammatory and antioxidant capacities of ASCOP in cell culture models. While Ag-zeolite combined with ASCOP was ineffective against the growth of S. gordonii, it showed a strong bactericidal effect on P. gingivalis growth. Ag-zeolite combined with ASCOP was able to completely inhibit S. gordonii monospecies biofilm formation as well as to reduce the formation of a bi-species S. gordonii/P. gingivalis biofilm. ASCOP alone was ineffective towards the growth and/or biofilm formation of S. gordonii and P. gingivalis while it significantly reduced the secretion of inflammatory cytokines (TNF alpha and IL-6) by LPS-stimulated human like-macrophages. It also exhibited antioxidant properties and decreased LPS induced lipid peroxidation in gingival epithelial cells. These findings support promising use of these products in future preventive or therapeutic strategies against periodontal diseases.	[Tamanai-Shacoori, Zohreh; Bonnaure-Mallet, Martine] Univ Rennes 1, Equipe Microbiol, EA 1254, UEB, Rennes, France; [Chandad, Fatiha] Univ Laval, Grp Rech Ecol Buccale, Fac Med Dent, Quebec City, PQ, Canada; [Rebillard, Amelie; Cillard, Josiane] Univ Rennes 2, EA 1274, UEB, Lab Mouvement,Univ Rennes 1, F-35043 Rennes, France; [Bonnaure-Mallet, Martine] Ctr Hosp Univ, Rennes, France	Universite de Rennes; Laval University; Universite de Rennes; Universite Rennes 2; CHU Rennes	Tamanai-Shacoori, Z (corresponding author), Univ Rennes 1, Equipe Microbiol, EA 1254, UEB, Rennes, France.	zohreh.shacoori@univ-rennes1.fr		TAMANAI-SHACOORI, Zohreh/0000-0003-2287-3438; Bonnaure-Mallet, martine/0000-0001-5214-7803	Region Bretagne; Conseil General du Finistere; OSEO Innovation	Region Bretagne(Region Bretagne); Conseil General du Finistere(Region Bretagne); OSEO Innovation	Region Bretagne, Conseil General du Finistere and OSEO Innovation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abu R, 2013, INT J BIOL MACROMOL, V59, P305, DOI 10.1016/j.ijbiomac.2013.04.035; Bahar B, 2012, J ANIM SCI, V90, P46, DOI 10.2527/jas.53944; Cha B, 2010, INT J BIOCHEM CELL B, V42, P1455, DOI 10.1016/j.biocel.2010.04.015; CHANDLER S F, 1983, Plant Cell Reports, V2, P205, DOI 10.1007/BF00270105; Choi EM, 2005, J MED FOOD, V8, P446, DOI 10.1089/jmf.2005.8.446; Darveau RP, 1998, INFECT IMMUN, V66, P1660, DOI 10.1128/IAI.66.4.1660-1665.1998; De la Rosa-Gomez I, 2008, J ENVIRON MANAGE, V88, P853, DOI 10.1016/j.jenvman.2007.04.005; De Muynck W, 2010, J APPL MICROBIOL, V108, P62, DOI 10.1111/j.1365-2672.2009.04395.x; Dixon DR, 2004, PERIODONTOL 2000, V35, P53, DOI 10.1111/j.0906-6713.2004.003556.x; Dutot M, 2012, APPL BIOCHEM BIOTECH, V167, P2234, DOI 10.1007/s12010-012-9761-1; Fravalo P, 1996, INFECT IMMUN, V64, P4940, DOI 10.1128/IAI.64.12.4940-4945.1996; Guerra R, 2012, MICROPOR MESOPOR MAT, V147, P267, DOI 10.1016/j.micromeso.2011.06.031; HARTFORD CE, 1972, J TRAUM, V12, P682, DOI 10.1097/00005373-197208000-00005; Holt SC, 2005, PERIODONTOL 2000, V38, P72, DOI 10.1111/j.1600-0757.2005.00113.x; Holt SC, 1999, PERIODONTOL 2000, V20, P168, DOI 10.1111/j.1600-0757.1999.tb00162.x; Huang GTJ, 2001, INFECT IMMUN, V69, P1364, DOI 10.1128/IAI.69.3.1364-1372.2001; Inoue Y, 2002, J INORG BIOCHEM, V92, P37, DOI 10.1016/S0162-0134(02)00489-0; Kantarci A, 2006, PERIODONTOL 2000, V40, P144, DOI 10.1111/j.1600-0757.2005.00145.x; Kolenbrander PE, 2010, NAT REV MICROBIOL, V8, P471, DOI 10.1038/nrmicro2381; Kornman KS, 1999, CLIN INFECT DIS, V28, P520, DOI 10.1086/515165; Lamont RJ, 2000, ORAL MICROBIOL IMMUN, V15, P341, DOI 10.1034/j.1399-302x.2000.150601.x; LAMONT RJ, 1993, ORAL MICROBIOL IMMUN, V8, P272, DOI 10.1111/j.1399-302X.1993.tb00573.x; Lamont RJ, 2002, PERIODONTOL 2000, V30, P61, DOI 10.1034/j.1600-0757.2002.03006.x; Lima E, 2013, CHEM CENT J, V7, DOI 10.1186/1752-153X-7-11; MARSH PD, 1992, J DENT RES, V71, P1431, DOI 10.1177/00220345920710071501; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Mizuno M, 2009, BIOSCI BIOTECH BIOCH, V73, P2324, DOI 10.1271/bbb.90326; Mourao PAS, 2004, CURR PHARM DESIGN, V10, P967, DOI 10.2174/1381612043452730; Nagayama K, 2002, J ANTIMICROB CHEMOTH, V50, P889, DOI 10.1093/jac/dkf222; Nishio K, 2013, REDOX BIOL, V1, P97, DOI 10.1016/j.redox.2012.10.002; O'Sullivan AM, 2011, FOOD CHEM, V126, P1064, DOI 10.1016/j.foodchem.2010.11.127; Odabas ME, 2011, DENT TRAUMATOL, V27, P189, DOI 10.1111/j.1600-9657.2011.00986.x; Okada H, 1998, CRIT REV ORAL BIOL M, V9, P248, DOI 10.1177/10454411980090030101; Petersen PE, 2005, B WORLD HEALTH ORGAN, V83, P3; Prior RL, 2003, J AGR FOOD CHEM, V51, P3273, DOI 10.1021/jf0262256; Qi HM, 2005, INT J BIOL MACROMOL, V37, P195, DOI 10.1016/j.ijbiomac.2005.10.008; Sabbani S, 2010, MICROPOR MESOPOR MAT, V135, P131, DOI 10.1016/j.micromeso.2010.06.020; Sandsdalen E, 2003, WORLD J MICROB BIOT, V19, P777, DOI 10.1023/A:1026052715260; Socransky SS, 2005, PERIODONTOL 2000, V38, P135, DOI 10.1111/j.1600-0757.2005.00107.x; Takai K, 2002, MICROBIOL IMMUNOL, V46, P75, DOI 10.1111/j.1348-0421.2002.tb02661.x; TOKUMARU T, 1974, RES COMMUN CHEM PATH, V8, P151; Tonetti MS, 2011, J CLIN PERIODONTOL, V38, P114, DOI 10.1111/j.1600-051X.2010.01675.x; Travis J, 2000, BBA-PROTEIN STRUCT M, V1477, P35, DOI 10.1016/S0167-4838(99)00278-2; Trinchero J, 2009, PHYTOTHER RES, V23, P707, DOI 10.1002/ptr.2723; Wang Q, 2009, MED HYPOTHESES, V72, P71, DOI 10.1016/j.mehy.2008.04.030; Ximenez-Fyvie LA, 2000, J CLIN PERIODONTOL, V27, P648, DOI 10.1034/j.1600-051x.2000.027009648.x; Yoshida K, 1999, J BIOMED MATER RES, V47, P516, DOI 10.1002/(SICI)1097-4636(19991215)47:4<516::AID-JBM7>3.0.CO;2-E; Youssef H, 2009, INT J OBESITY, V33, P447, DOI 10.1038/ijo.2009.49; Zdarilova A, 2010, FOOD CHEM TOXICOL, V48, P1555, DOI 10.1016/j.fct.2010.03.024	49	12	12	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2014	9	10							e105475	10.1371/journal.pone.0105475	http://dx.doi.org/10.1371/journal.pone.0105475			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR6ZM	25272151	gold, Green Published, Green Submitted			2023-01-03	WOS:000343729600003
J	Sveaas, SH; Berg, IJ; Provan, SA; Semb, AG; Hagen, KB; Vollestad, N; Fongen, C; Olsen, IC; Michelsen, A; Ueland, T; Aukrust, P; Kvien, TK; Dagfinrud, H				Sveaas, Silje Halvorsen; Berg, Inger Jorid; Provan, Sella Aarrestad; Semb, Anne Grete; Hagen, Kare Birger; Vollestad, Nina; Fongen, Camilla; Olsen, Inge C.; Michelsen, Annika; Ueland, Thor; Aukrust, Pal; Kvien, Tore K.; Dagfinrud, Hanne			Efficacy of High Intensity Exercise on Disease Activity and Cardiovascular Risk in Active Axial Spondyloarthritis: A Randomized Controlled Pilot Study	PLOS ONE			English	Article							ASAS/EULAR MANAGEMENT RECOMMENDATIONS; ALL-CAUSE MORTALITY; ANKYLOSING-SPONDYLITIS; CARDIORESPIRATORY FITNESS; WAVE REFLECTION; AORTIC PRESSURE; 1ST UPDATE; MECHANISMS; EVENTS; WOMEN	Background: Physical therapy is recommended for the management of axial spondyloarthritis (axSpA) and flexibility exercises have traditionally been the main focus. Cardiovascular (CV) diseases are considered as a major health concern in axSpA and there is strong evidence that endurance and strength exercise protects against CV diseases. Therefore, the aim of this study was to investigate the efficacy of high intensity endurance and strength exercise on disease activity and CV health in patients with active axSpA. Methods: In a single blinded randomized controlled pilot study the exercise group (EG) performed 12 weeks of endurance and strength exercise while the control group (CG) received treatment as usual. The primary outcome was the Ankylosing Spondylitis (AS) Disease Activity Score (ASDAS). Secondary outcomes included patient reported disease activity (Bath AS Disease Activity Index [BASDAI]), physical function (Bath AS Functional Index [BASFI]), and CV risk factors measured by arterial stiffness (Augmentation Index [Alx]) and Pulse Wave Velocity [PWV]), cardiorespiratory fitness (VO2 peak) and body composition. ANCOVA on the post intervention values with baseline values as covariates was used to assess group differences, and Mann Whitney U-test was used for outcomes with skewed residuals. Results: Twenty-eight patients were included and 24 (EG, n = 10, CG, n = 14) completed the study. A mean treatment effect of -0.7 (95%CI: -1.4, 0.1) was seen in ASDAS score. Treatment effects were also observed in secondary outcomes (mean group difference [95%CI]): BASDAI: -2.0 (-3.6, -0.4), BASFI: -1.4 (-2.6, -0.3), arterial stiffness (estimated median group differences [95% CI]): AIx (%): -5.3 (-11.0, -0.5), and for PVW (m/s): -0.3 (-0.7, 0.0), VO2 peak (ml/kg/min) (mean group difference [95% CI]: 3.7 (2.1, 5.2) and trunk fat (%): -1.8 (-3.0, -0.6). No adverse events occurred. Conclusion: High intensity exercise improved disease activity and reduced CV risk factors in patients with active axSpA. These effects will be further explored in a larger trial.	[Sveaas, Silje Halvorsen; Hagen, Kare Birger; Fongen, Camilla; Dagfinrud, Hanne] Diakonhjemmet Hosp, Dept Rheumatol, Natl Advisory Unit Rehabil Rheumatol, Oslo, Norway; [Sveaas, Silje Halvorsen; Hagen, Kare Birger; Vollestad, Nina; Dagfinrud, Hanne] Univ Oslo, Dept Hlth Sci, Oslo, Norway; [Berg, Inger Jorid; Provan, Sella Aarrestad; Semb, Anne Grete; Olsen, Inge C.; Kvien, Tore K.] Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway; [Michelsen, Annika; Ueland, Thor; Aukrust, Pal] Oslo Univ Hosp, Internal Med Res Inst, Rikshosp, Oslo, Norway; [Aukrust, Pal] Oslo Univ Hosp, Sect Clin Immunol & Infect Dis, Rikshosp, Oslo, Norway; [Ueland, Thor; Aukrust, Pal] Univ Oslo, Inst Clin Med, Oslo, Norway; [Aukrust, Pal] Univ Oslo, KG Jebsen Inflammatory Res Ctr, Oslo, Norway	Diakonhjemmet Hospital; University of Oslo; Diakonhjemmet Hospital; University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Oslo; University of Oslo	Sveaas, SH (corresponding author), Diakonhjemmet Hosp, Dept Rheumatol, Natl Advisory Unit Rehabil Rheumatol, Oslo, Norway.	silje.halvorsen@medisin.uio.no	emery, paul/B-3560-2013; Olsen, Inge Christoffer/R-9128-2019; Vøllestad, Nina/AAA-3274-2021	Olsen, Inge Christoffer/0000-0001-6889-5873; Vøllestad, Nina/0000-0002-7575-6625; Provan, Sella/0000-0001-5442-902X	Norwegian Foundation for Postgraduate Physiotherapist	Norwegian Foundation for Postgraduate Physiotherapist	The present study was supported by grants from the Norwegian Foundation for Postgraduate Physiotherapist. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andreoli A, 2009, RADIOL MED, V114, P286, DOI 10.1007/s11547-009-0369-7; Armijo-Olivo S, 2009, PHYS THER REV, V14, P36, DOI 10.1179/174328809X405928; Aspenes ST, 2011, MED SCI SPORT EXER, V43, P1465, DOI 10.1249/MSS.0b013e31820ca81c; Baeten D, 2013, LANCET, V382, P1705, DOI 10.1016/S0140-6736(13)61134-4; Baraliakos X, 2012, RHEUMATOLOGY, V51, P1378, DOI 10.1093/rheumatology/kes026; Braun J, 2011, ANN RHEUM DIS, V70, P896, DOI 10.1136/ard.2011.151027; Bremander A, 2011, ARTHRIT CARE RES, V63, P550, DOI 10.1002/acr.20408; CALIN A, 1994, J RHEUMATOL, V21, P2281; Cornelissen VA, 2005, HYPERTENSION, V46, P667, DOI 10.1161/01.HYP.0000184225.05629.51; Corrigan B, 1978, Aust Fam Physician, V7, P1007; Crilly MA, 2013, SCAND J RHEUMATOL, V42, P27, DOI 10.3109/03009742.2012.697915; D'Ascenzo F, 2012, EUR HEART J, V33, P875, DOI 10.1093/eurheartj/ehr456; Dagfinrud H, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002822.pub3; Dougados M, 2011, LANCET, V377, P2127, DOI 10.1016/S0140-6736(11)60071-8; Edwards DG, 2004, AM J HYPERTENS, V17, P540, DOI 10.1016/j.amjhyper.2003.12.001; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; GARRETT S, 1994, J RHEUMATOL, V21, P2286; Halvorsen S, 2012, PHYS THER, V92, P298, DOI 10.2522/ptj.20110137; Helgerud J, 2007, MED SCI SPORT EXER, V39, P665, DOI 10.1249/mss.0b013e3180304570; Heydari M, 2013, CLIN AUTON RES, V23, P57, DOI 10.1007/s10286-012-0179-1; Kodama S, 2009, JAMA-J AM MED ASSOC, V301, P2024, DOI 10.1001/jama.2009.681; Laukkanen JA, 2004, EUR HEART J, V25, P1428, DOI 10.1016/j.ehj.2004.06.013; Laurent S, 2006, EUR HEART J, V27, P2588, DOI 10.1093/eurheartj/ehl254; Leon AS, 2001, MED SCI SPORT EXER, V33, pS502, DOI 10.1097/00005768-200106001-00021; Mathieu S, 2011, ARTHRIT CARE RES, V63, P557, DOI 10.1002/acr.20364; McEniery CM, 2005, J AM COLL CARDIOL, V46, P1753, DOI 10.1016/j.jacc.2005.07.037; Niedermann K, 2013, ARTHRITIS CARE RES H; Pauca AL, 2001, HYPERTENSION, V38, P932, DOI 10.1161/hy1001.096106; Perk Joep, 2012, Int J Behav Med, V19, P403, DOI [10.1016/j.atherosclerosis.2012.05.007, 10.1093/eurheartj/ehs092, 10.1007/s12529-012-9242-5]; Pischon T, 2008, NEW ENGL J MED, V359, P2105, DOI 10.1056/NEJMoa0801891; Poddubnyy D, 2014, ANN RHEUM DIS, V73, P817, DOI 10.1136/annrheumdis-2013-204248; Rehn TA, 2013, OPEN CARDIOVASC MED, V7, P1, DOI 10.2174/1874192401307010001; Rudwaleit M, 2009, ANN RHEUM DIS, V68, P777, DOI 10.1136/ard.2009.108233; Schuler G, 2013, EUR HEART J, V34, P1790, DOI 10.1093/eurheartj/eht111; Scotece M, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/125458; Sherlock JP, 2012, NAT MED, V18, P1069, DOI 10.1038/nm.2817; Stavropoulos-Kalinoglou A, 2012, ANN RHEUM DIS; Stavropoulos-Kalinoglou A, 2013, ANN RHEUM DIS, V72, P1819, DOI 10.1136/annrheumdis-2012-202075; Szabo SM, 2011, ARTHRITIS RHEUM-US, V63, P3294, DOI 10.1002/art.30581; van den Berg R, 2012, RHEUMATOLOGY, V51, P1388, DOI 10.1093/rheumatology/kes066; van der Heijde D, 2008, ANN RHEUM DIS, V67, P489, DOI 10.1136/ard.2007.074724; van der Heijde D, 2009, ANN RHEUM DIS, V68, P1811, DOI 10.1136/ard.2008.100826; Vlachopoulos C, 2010, EUR HEART J, V31, P1865, DOI 10.1093/eurheartj/ehq024; Walsh NP, 2011, EXERC IMMUNOL REV, V17, P64; Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD; Zieman SJ, 2005, ARTERIOSCL THROM VAS, V25, P932, DOI 10.1161/01.ATV.0000160548.78317.29	47	62	63	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2014	9	9							e108688	10.1371/journal.pone.0108688	http://dx.doi.org/10.1371/journal.pone.0108688			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR6CW	25268365	gold, Green Published, Green Submitted			2023-01-03	WOS:000343671700140
J	Tchalla, AE; Dufour, AB; Travison, TG; Habtemariam, D; Iloputaife, I; Manor, B; Lipsitz, LA				Tchalla, Achille E.; Dufour, Alyssa B.; Travison, Thomas G.; Habtemariam, Daniel; Iloputaife, Ikechukwu; Manor, Brad; Lipsitz, Lewis A.			Patterns, Predictors, and Outcomes of Falls Trajectories in Older Adults: The MOBILIZE Boston Study with 5 Years of Follow-Up	PLOS ONE			English	Article							MINI-MENTAL-STATE; RESTRICTED ACTIVITY; COMMUNITY; HOSPITALIZATION; POPULATION; DISABILITY; INJURIES; PEOPLE	Background: Falls may occur as unpredictable events or in patterns indicative of potentially modifiable risks and predictive of adverse outcomes. Knowing the patterns, risks, and outcomes of falls trajectories may help clinicians plan appropriate preventive measures. We hypothesized that clinically distinct trajectories of falls progression, baseline predictors and their coincident clinical outcomes could be identified. Methods: We studied 765 community-dwelling participants in the MOBILIZE Boston Study, who were aged 70 and older and followed prospectively for falls over 5 years. Baseline demographic and clinical data were collected by questionnaire and a comprehensive clinic examination. Falls, injuries, and hospitalizations were recorded prospectively on daily calendars. Group-Based Trajectory Modeling (GBTM) was used to identify trajectories. Results: We identified 4 distinct trajectories: No Falls (30.1%), Cluster Falls (46.1%), Increasing Falls (5.8%) and Chronic Recurring Falls (18.0%). Predictors of Cluster Falls were faster gait speed (OR 1.69 (95CI, 1.50-2.56)) and fall in the past year (OR 3.52 (95CI, 2.16-6.34)). Predictors of Increasing Falls were Diabetes Mellitus (OR 4.3 (95CI, 1.4-13.3)) and Cognitive Impairment (OR 2.82 (95CI, 1.34-5.82)). Predictors of Chronic Recurring Falls were multi-morbidity (OR 2.24 (95CI, 1.60-3.16)) and fall in the past year (OR 3.82 (95CI, 2.34-6.23)). Symptoms of depression were predictive of all falls trajectories. In the Chronic Recurring Falls trajectory group the incidence rate of Hospital visits was 121 (95% CI 63-169) per 1,000 person-years; Injurious falls 172 (95% CI 111-237) per 1,000 person-years and Fractures 41 (95% CI 9-78) per 1,000 person-years. Conclusions: Falls may occur in clusters over discrete intervals in time, or as chronically increasing or recurring events that have a relatively greater risk of adverse outcomes. Patients with multiple falls, multimorbidity, and depressive symptoms should be targeted for preventive measures.	[Tchalla, Achille E.; Dufour, Alyssa B.; Travison, Thomas G.; Manor, Brad; Lipsitz, Lewis A.] Harvard Univ, Sch Med, Boston, MA USA; [Tchalla, Achille E.; Dufour, Alyssa B.; Travison, Thomas G.; Manor, Brad; Lipsitz, Lewis A.] Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA; [Tchalla, Achille E.; Dufour, Alyssa B.; Travison, Thomas G.; Habtemariam, Daniel; Iloputaife, Ikechukwu; Manor, Brad; Lipsitz, Lewis A.] Hebrew SeniorLife, Inst Aging Res, Boston, MA USA; [Tchalla, Achille E.] Univ Limoges, Univ Hosp Ctr Limoges, Dept Geriatr Med, EA HAVAE Disabil Act Aging Auton & Environm 6310, Limoges, France	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Hebrew SeniorLife; CHU Limoges; Universite de Limoges	Lipsitz, LA (corresponding author), Harvard Univ, Sch Med, Boston, MA USA.	lipsitz@hsl.harvard.edu		Dufour, Alyssa/0000-0001-8061-9599; Tchalla, Achille/0000-0003-3457-5219	US National-Institute on Aging [P01 AG04390, R37 AG25037]; NATIONAL INSTITUTE ON AGING [R01AG041785, P01AG004390, R37AG025037] Funding Source: NIH RePORTER	US National-Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Grant P01 AG04390 and R37 AG25037 from the US National-Institute on Aging. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cohen J., 2002, APPL MULTIPLE REGRES, V3rd, DOI 10.4324/9780203774441; ESCOBAR JI, 1986, J NERV MENT DIS, V174, P607, DOI 10.1097/00005053-198610000-00005; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gates S, 2008, BRIT MED J, V336, P130, DOI 10.1136/bmj.39412.525243.BE; GIBSON MJ, 1987, DAN MED BULL, V34, P1; Gill TM, 2010, JAMA-J AM MED ASSOC, V304, P1919, DOI 10.1001/jama.2010.1568; Gill TM, 2004, JAMA-J AM MED ASSOC, V292, P2115, DOI 10.1001/jama.292.17.2115; Gillespie L. D., 2012, COCHRANE DB SYST REV, V9, DOI DOI 10.1002/14651858.CD007146; Gorina Yelena, 2005, Aging Trends, P1; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Jones DJ, 2010, J CLIN CHILD ADOLESC, V39, P667, DOI 10.1080/15374416.2010.501286; Kohout F J, 1993, J Aging Health, V5, P179, DOI 10.1177/089826439300500202; Leveille Suzanne G, 2008, BMC Geriatr, V8, P16, DOI 10.1186/1471-2318-8-16; LIPSITZ LA, 1991, J GERONTOL, V46, pM114, DOI 10.1093/geronj/46.4.M114; Marengoni A, 2011, AGEING RES REV, V10, P430, DOI 10.1016/j.arr.2011.03.003; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Nagin D.S., 2005, GROUP BASED MODELING; Nagin DS, 2010, ANNU REV CLIN PSYCHO, V6, P109, DOI 10.1146/annurev.clinpsy.121208.131413; Nagin DS, 2005, ANN AM ACAD POLIT SS, V602, P82, DOI 10.1177/0002716205280565; Pepe M.S., 2003, OXFORD STAT SCI SERI; Rubenstein LZ, 2006, AGE AGEING, V35, P37, DOI 10.1093/ageing/afl084; Samelson EJ, 2008, AM J EPIDEMIOL, V168, P1444, DOI 10.1093/aje/kwn277; Sibley KM, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-22; Stevens JA, 2006, INJURY PREV, V12, P290, DOI 10.1136/ip.2005.011015; Tinetti ME, 2008, NEW ENGL J MED, V359, P252, DOI 10.1056/NEJMoa0801748; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4	29	24	24	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2014	9	9							e106363	10.1371/journal.pone.0106363	http://dx.doi.org/10.1371/journal.pone.0106363			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO3TB	25184785	Green Published, gold			2023-01-03	WOS:000341257700059
J	Castro, RAO; Silva-Barcellos, NM; Licio, CSA; Souza, JB; Souza-Testasicca, MC; Ferreira, FM; Batista, MA; Silveira-Lemos, D; Moura, SL; Frezard, F; Rezende, SA				Castro, Renata A. O.; Silva-Barcellos, Neila M.; Licio, Carolina S. A.; Souza, Janine B.; Souza-Testasicca, Miriam C.; Ferreira, Flavia M.; Batista, Mauricio A.; Silveira-Lemos, Denise; Moura, Sandra L.; Frezard, Frederic; Rezende, Simone A.			Association of Liposome-Encapsulated Trivalent Antimonial with Ascorbic Acid: An Effective and Safe Strategy in the Treatment of Experimental Visceral Leishmaniasis	PLOS ONE			English	Article							MEGLUMINE ANTIMONIATE; ARSENIC TRIOXIDE; IMMUNE-RESPONSE; BONE-MARROW; GLUTATHIONE; DONOVANI; SIZE; METABOLISM; SYSTEMS; LIVER	Background:: Visceral leishmaniasis (VL) is a chronic debilitating disease endemic in tropical and subtropical areas, caused by protozoan parasites of the genus Leishmania. Annually, it is estimated the occurrence of 0.2 to 0.4 million new cases of the disease worldwide. Considering the lack of an effective vaccine the afflicted population must rely on both, an accurate diagnosis and successful treatment to combat the disease. Here we propose to evaluate the efficacy of trivalent antimonial encapsulated in conventional liposomes, in association with ascorbic acid, by monitoring its toxicity and efficacy in BALB/c mice infected with Leishmania infantum. Methodology/Principal Findings:: Infected mice were subjected to single-dose treatments consisting in the administration of either free or liposome-encapsulated trivalent antimony (SbIII), in association or not with ascorbic acid. Parasite burden was assessed in the liver, spleen and bone marrow using the serial limiting dilution technique. After treatment, tissue alterations were examined by histopathology of liver, heart and kidney and confirmed by serum levels of classic biomarkers. The phenotypic profile of splenocytes was also investigated by flow cytometry. Treatment with liposome-encapsulated SbIII significantly reduced the parasite burden in the liver, spleen and bone marrow. Co-administration of ascorbic acid, with either free SbIII or its liposomal form, did not interfere with its leishmanicidal activity and promoted reduced toxicity particularly to the kidney and liver tissues. Conclusions/Significance:: Among the evaluated posological regimens treatment of L. infantum-infected mice with liposomal SbIII, in association with ascorbic acid, represented the best alternative as judged by its high leishmanicidal activity and absence of detectable toxic effects. Of particular importance, reduction of parasite burden in the bone marrow attested to the ability of SbIII-carrying liposomes to efficiently reach this body compartment.	[Castro, Renata A. O.; Silva-Barcellos, Neila M.; Licio, Carolina S. A.; Souza, Janine B.; Ferreira, Flavia M.; Rezende, Simone A.] Univ Fed Ouro Preto, Programa Posgrad Ciencias Farmaceut Cipharma, Ouro Preto, MG, Brazil; [Souza-Testasicca, Miriam C.] Inst Fed Minas Gerais, Coordenadoria Area Ciencias Biol, Ouro Preto, MG, Brazil; [Batista, Mauricio A.; Silveira-Lemos, Denise; Moura, Sandra L.] Univ Fed Ouro Preto, Programa Posgrad Ciencias Biol NUPEB, Ouro Preto, MG, Brazil; [Frezard, Frederic] Univ Fed Minas Gerais, Dept Fisiol & Biofis, Belo Horizonte, MG, Brazil	Universidade Federal de Ouro Preto; Instituto Federal de Educacao, Ciencia e Tecnologia de Minas Gerais (IFMG); Universidade Federal de Ouro Preto; Universidade Federal de Minas Gerais	Rezende, SA (corresponding author), Univ Fed Ouro Preto, Programa Posgrad Ciencias Farmaceut Cipharma, Ouro Preto, MG, Brazil.	rezende@ef.ufop.br	de Moura, Sandra Aparecida Lima/AAW-3214-2021; Frezard, Frederic/Q-7714-2019; Souza-Testasicca, Miriam Conceição/ABG-6651-2021	Frezard, Frederic/0000-0003-3783-5717; Souza-Testasicca, Miriam Conceição/0000-0001-7010-3118; Silveira Lemos, Denise/0000-0003-0955-458X	"Fundacao de Amparo a Pesquisa de Minas Gerais" (FAPEMIG) [REDE-40/11, APQ-01327-09, APQ-00780-12, 297491]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)	"Fundacao de Amparo a Pesquisa de Minas Gerais" (FAPEMIG)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by "Fundacao de Amparo a Pesquisa de Minas Gerais" at http://www.fapemig.br (FAPEMIG, grant numbers REDE-40/11, APQ-01327-09, APQ-00780-12, and 297491). FF is a recipient of a research fellowship from the "Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq).'' The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; Andersen EM, 2005, AM J TROP MED HYG, V72, P133, DOI 10.4269/ajtmh.2005.72.133; Awasthi A, 2004, INDIAN J MED RES, V119, P238; Bachleitner-Hofmann T, 2001, BRIT J HAEMATOL, V112, P783, DOI 10.1046/j.1365-2141.2001.02608.x; Bahlis NJ, 2002, CLIN CANCER RES, V8, P3658; Bajaj G, 2010, PHARM RES-DORDR, V27, P735, DOI 10.1007/s11095-009-0031-z; Biyani N, 2011, MOL BIOCHEM PARASIT, V180, P76, DOI 10.1016/j.molbiopara.2011.08.005; Carrion J, 2006, PARASITE IMMUNOL, V28, P173, DOI 10.1111/j.1365-3024.2006.00817.x; CARTER KC, 1989, J PHARM PHARMACOL, V41, P87, DOI 10.1111/j.2042-7158.1989.tb06399.x; Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748; Croft SL, 2001, TROP MED INT HEALTH, V6, P899, DOI 10.1046/j.1365-3156.2001.00754.x; CUNNINGHAM ML, 1995, EUR J BIOCHEM, V230, P460, DOI 10.1111/j.1432-1033.1995.tb20583.x; Demicheli C, 2008, CHEM COMMUN, P4828, DOI 10.1039/b809186b; DERKSEN JTP, 1988, BIOCHIM BIOPHYS ACTA, V971, P127, DOI 10.1016/S0005-2728(88)80099-9; Frezard F, 2005, QUIM NOVA, V28, P511, DOI 10.1590/S0100-40422005000300025; Frezard F, 2001, ANTIMICROB AGENTS CH, V45, P913, DOI 10.1128/AAC.45.3.913-916.2001; Frezard F, 2010, EXPERT OPIN DRUG DEL, V7, P1343, DOI 10.1517/17425247.2010.529897; Frezard F, 2009, MOLECULES, V14, P2317, DOI 10.3390/molecules14072317; Gebel T, 1997, CHEM-BIOL INTERACT, V107, P131, DOI 10.1016/S0009-2797(97)00087-2; GREGORIADIS G, 1972, BIOCHEM J, V129, P123, DOI 10.1042/bj1290123; Hantson P, 2000, PHARMACOTHERAPY, V20, P1141, DOI 10.1592/phco.20.13.1141.35032; HARASHIMA H, 1992, BIOPHARM DRUG DISPOS, V13, P549, DOI 10.1002/bdd.2510130708; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; HIRANO K, 1985, J PHARM SCI, V74, P915, DOI 10.1002/jps.2600740902; Hunter DG, 1998, BIOPHYS J, V74, P2996, DOI 10.1016/S0006-3495(98)78006-3; Kato KC, 2014, ANTIMICROB AGENTS CH, V58, P481, DOI 10.1128/AAC.01499-13; Lambertz U, 2012, J LEUKOCYTE BIOL, V91, P887, DOI 10.1189/jlb.0611326; Marques-da-Silva EA, 2005, PARASITOL RES, V98, P67, DOI 10.1007/s00436-005-0008-8; MAYER LD, 1985, BIOCHIM BIOPHYS ACTA, V817, P193, DOI 10.1016/0005-2736(85)90084-7; McConville MJ, 2007, TRENDS PARASITOL, V23, P368, DOI 10.1016/j.pt.2007.06.009; Moghimi SM, 2012, J INNATE IMMUN, V4, P509, DOI 10.1159/000339153; NAYAR R, 1989, BIOCHIM BIOPHYS ACTA, V986, P200, DOI 10.1016/0005-2736(89)90468-9; NEW RRC, 1978, NATURE, V272, P55, DOI 10.1038/272055a0; Ribeiro RR, 2008, ANTIMICROB AGENTS CH, V52, P2564, DOI 10.1128/AAC.00223-08; Salaun P, 2013, ANAL BIOANAL CHEM, V405, P5201, DOI 10.1007/s00216-013-6947-5; Schettini DA, 2006, INT J PHARMACEUT, V315, P140, DOI 10.1016/j.ijpharm.2006.01.048; Serafim TD, 2010, MEM I OSWALDO CRUZ, V105, P811, DOI 10.1590/S0074-02762010000600014; Shio MT, 2012, J TROP MED-US, V2012, DOI 10.1155/2012/819512; Singh S, 2007, J ENVIRON BIOL, V28, P377; Sohini, 2007, INDIAN J EXP BIOL, V45, P371; Sun HZ, 2000, EUR J BIOCHEM, V267, P5450, DOI 10.1046/j.1432-1327.2000.01605.x; Sundar S, 2010, NEW ENGL J MED, V362, P504, DOI 10.1056/NEJMoa0903627; Therien HM, 1996, BBA-BIOMEMBRANES, V1280, P91, DOI 10.1016/0005-2736(95)00282-0; TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x; Wortmann G, 2002, CLIN INFECT DIS, V35, P261, DOI 10.1086/341406; Wyllie S, 2004, J BIOL CHEM, V279, P39925, DOI 10.1074/jbc.M405635200	46	16	16	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2014	9	8							e104055	10.1371/journal.pone.0104055	http://dx.doi.org/10.1371/journal.pone.0104055			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR0CG	25105501	Green Published, gold			2023-01-03	WOS:000343231900035
J	Hubert, D; Soubeiran, L; Gourmelon, F; Grenet, D; Serreau, R; Perrodeau, E; Zegarra-Parodi, R; Boutron, I				Hubert, Dominique; Soubeiran, Lucile; Gourmelon, Fabrice; Grenet, Dominique; Serreau, Raphael; Perrodeau, Elodie; Zegarra-Parodi, Rafael; Boutron, Isabelle			Impact of Osteopathic Treatment on Pain in Adult Patients with Cystic Fibrosis - A Pilot Randomized Controlled Study	PLOS ONE			English	Article							LOW-BACK-PAIN; MANIPULATIVE TREATMENT; ALTERNATIVE MEDICINE; QUALITY	Background: Pain is a common complication in patients with cystic fibrosis (CF) and is associated with shorter survival. We evaluated the impact of osteopathic manipulative treatment (OMT) on pain in adults with CF. Methods: A pilot multicenter randomized controlled trial was conducted with three parallel arms: OMT (group A, 16 patients), sham OMT (sham treatment, group B, 8 patients) and no treatment (group C, 8 patients). Medical investigators and patients were double-blind to treatment for groups A and B, who received OMT or sham OMT monthly for 6 months. Pain was rated as a composite of its intensity and duration over the previous month. The evolution of chest/back pain after 6 months was compared between group A and groups B+C combined (control group). The evolution of cervical pain, headache and quality of life (QOL) were similarly evaluated. Results: There was no statistically significant difference between the treatment and control groups in the decrease of chest/back pain (difference = -2.20 IC95% [-4.81; 0.42], p = 0.098); also, group A did not differ from group B. However, chest/back pain decreased more in groups A (p = 0.002) and B (p = 0.006) than in group C. Cervical pain, headache and QOL scores did not differ between the treatment and control groups. Conclusion: This pilot study demonstrated the feasibility of evaluating the efficacy of OMT to treat the pain of patients with CF. The lack of difference between the group treated with OMT and the control group may be due to the small number of patients included in this trial, which also precludes any definitive conclusion about the greater decrease of pain in patients receiving OMT or sham OMT than in those with no intervention.	[Hubert, Dominique] Hop Cochin, APHP, Adult CF Ctr, F-75674 Paris, France; [Hubert, Dominique] Hop Cochin, APHP, Dept Pulmonol, F-75674 Paris, France; [Hubert, Dominique; Boutron, Isabelle] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Soubeiran, Lucile; Gourmelon, Fabrice; Serreau, Raphael] Hop Cochin, APHP, Dept Clin Res, F-75674 Paris, France; [Grenet, Dominique] Hop Foch, Adult CF Ctr, Suresnes, France; [Grenet, Dominique] Hop Foch, Dept Pulmonol, Suresnes, France; [Perrodeau, Elodie; Boutron, Isabelle] Hop Hotel Dieu, APHP, Clin Epidemiol Ctr, F-75181 Paris, France; [Zegarra-Parodi, Rafael] AT Still Univ, AT Still Res Inst, Kirksville, MO USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Hospital Foch; Hospital Foch; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; A.T. Still University of Health Sciences	Hubert, D (corresponding author), Hop Cochin, APHP, Adult CF Ctr, 27 Rue Faubourg St Jacques, F-75674 Paris, France.	dominique.hubert@cch.aphp.fr	Serreau, Raphael/ABC-7602-2021	Serreau, Raphael/0000-0003-4430-2046; Boutron, Isabelle/0000-0002-5263-6241; Zegarra-Parodi, Rafael/0000-0002-2418-8592	Vaincre la Mucoviscidose and Fondation de France, Paris, France	Vaincre la Mucoviscidose and Fondation de France, Paris, France	This work was supported by Vaincre la Mucoviscidose and Fondation de France, Paris, France, who had no role in the design of the study, the collection or analysis of the data, or the preparation of the manuscript.	Abbott J, 2009, AM J RESP CRIT CARE, V179, P54, DOI 10.1164/rccm.200802-220OC; Agrario L, 2006, J CYST FIBROS S1, V5, pS90; American Academy of Osteopathy, 2002, OUTP OST SOAP NOT FO; American Association of Colleges of Osteopathic Medicine, AUTH OST THES; Andersson GBJ, 1999, NEW ENGL J MED, V341, P1426, DOI 10.1056/NEJM199911043411903; Cystic Fibrosis Foundation, 2012, CYST FIBR FDN PAT RE; Davies JC, 2007, BMJ-BRIT MED J, V335, P1255, DOI 10.1136/bmj.39391.713229.AD; Degenhardt BF, 2014, J AM OSTEOPATH ASSOC, V114, P154, DOI 10.7556/jaoa.2014.033; Festini Filippo, 2004, J Cyst Fibros, V3, P51, DOI 10.1016/j.jcf.2003.12.001; Flume PA, 2009, J CYST FIBROS, V8, P321, DOI 10.1016/j.jcf.2009.07.004; Havermans T, 2013, J CYST FIBROS, V12, P423, DOI 10.1016/j.jcf.2013.04.001; Hayes M, 2011, CHEST, V140, P1598, DOI 10.1378/chest.11-0132; Henry B, 2003, QUAL LIFE RES, V12, P63, DOI 10.1023/A:1022037320039; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; Jakel A, 2012, COMPLEMENT THER MED, V20, P456, DOI 10.1016/j.ctim.2012.07.009; Kaptchuk TJ, 2002, ANN INTERN MED, V136, P817, DOI 10.7326/0003-4819-136-11-200206040-00011; Kelemen L, 2012, PHYSIOTHER RES INT, V17, DOI 10.1002/pri.524; Lee A, 2009, J CYST FIBROS, V8, P79, DOI 10.1016/j.jcf.2008.07.002; Licciardone JC, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-43; Licciardone JC, 2003, SPINE, V28, P1355, DOI 10.1097/00007632-200307010-00002; Licciardone JC, 2006, J AM OSTEOPATH ASSOC, V106, P457; Moulson A, 2006, MANUAL THER, V11, P214, DOI 10.1016/j.math.2006.04.003; Noll Donald R, 2010, Osteopath Med Prim Care, V4, P2, DOI 10.1186/1750-4732-4-2; Noll DR, 2008, J AM OSTEOPATH ASSOC, V108, P508; Pinheiro J., 2011, NLME LINEAR NONLINEA; R Core Team, 2021, R LANG ENV STAT COMP; Ravilly S, 1996, PEDIATRICS, V98, P741; Sergueef N, 2002, ALTERN THER HEALTH M, V8, P74; Sermet-Gaudelus I, 2009, J PAIN SYMPTOM MANAG, V38, P281, DOI 10.1016/j.jpainsymman.2008.08.009; Soubeiran L., 2011, J PHYS THER, V4, P18; Staud R, 2011, RHEUM DIS CLIN N AM, V37, P9, DOI 10.1016/j.rdc.2010.11.009; Stenekes SI, 2009, J PAIN SYMPTOM MANAG, V38, P387; STERN RC, 1992, J ADOLESCENT HEALTH, V13, P612, DOI 10.1016/1054-139X(92)90376-M; Sweezey NB, 2014, PEDIATR PULM, V49, P309, DOI 10.1002/ppul.22967; Tanase A, 2008, J ALTERN COMPLEM MED, V14, P1271, DOI 10.1089/acm.2008.0185; Vaincre la Mucoviscidose INED, 2013, REG FRANC MUC BIL DO; VANBUSKIRK RL, 1990, J AM OSTEOPATH ASSOC, V90, P792; WHO, 2010, BENCHM TRAIN TRAD CO	38	9	9	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2014	9	7							e102465	10.1371/journal.pone.0102465	http://dx.doi.org/10.1371/journal.pone.0102465			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4KM	25029347	Green Published, gold, Green Submitted			2023-01-03	WOS:000341306600076
J	Lansdorp-Vogelaar, I; Gulati, R; Mariotto, AB; Schechter, CB; de Carvalho, TM; Knudsen, AB; van Ravesteyn, NT; Heijnsdijk, EAM; Pabiniak, C; van Ballegooijen, M; Rutter, CM; Kuntz, KM; Feuer, EJ; Etzioni, R; de Koning, HJ; Zauber, AG; Mandelblatt, JS				Lansdorp-Vogelaar, Iris; Gulati, Roman; Mariotto, Angela B.; Schechter, Clyde B.; de Carvalho, Tiago M.; Knudsen, Amy B.; van Ravesteyn, Nicolien T.; Heijnsdijk, Eveline A. M.; Pabiniak, Chester; van Ballegooijen, Marjolein; Rutter, Carolyn M.; Kuntz, Karen M.; Feuer, Eric J.; Etzioni, Ruth; de Koning, Harry J.; Zauber, Ann G.; Mandelblatt, Jeanne S.			Personalizing Age of Cancer Screening Cessation Based on Comorbid Conditions: Model Estimates of Harms and Benefits	ANNALS OF INTERNAL MEDICINE			English	Article							SERVICES TASK-FORCE; COLORECTAL-CANCER; PROSTATE-CANCER; LIFE-STYLE; RECOMMENDATION STATEMENT; POTENTIAL BENEFITS; COST-EFFECTIVENESS; DECISION-ANALYSIS; ELDERLY-PATIENTS; BREAST	Background: Harms and benefits of cancer screening depend on age and comorbid conditions, but reliable estimates are lacking. Objective: To estimate the harms and benefits of cancer screening by age and comorbid conditions to inform decisions about screening cessation. Design: Collaborative modeling with 7 cancer simulation models and common data on average and comorbid condition level-specific life expectancy. Setting: U. S. population. Patients: U. S. cohorts aged 66 to 90 years in 2010 with average health or 1 of 4 comorbid condition levels: none, mild, moderate, or severe. Intervention: Mammography, prostate-specific antigen testing, or fecal immunochemical testing. Measurements: Lifetime cancer deaths prevented and life-years gained (benefits); false-positive test results and overdiagnosed cancer cases (harms). For each comorbid condition level, the age at which harms and benefits of screening were similar to that for persons with average health having screening at age 74 years. Results: Screening 1000 women with average life expectancy at age 74 years for breast cancer resulted in 79 to 96 (range across models) false-positive results, 0.5 to 0.8 overdiagnosed cancer cases, and 0.7 to 0.9 prevented cancer deaths. Although absolute numbers of harms and benefits differed across cancer sites, the ages at which to cease screening were consistent across models and cancer sites. For persons with no, mild, moderate, and severe comorbid conditions, screening until ages 76, 74, 72, and 66 years, respectively, resulted in harms and benefits similar to average-health persons. Limitation: Comorbid conditions influenced only life expectancy. Conclusion: Comorbid conditions are an important determinant of harms and benefits of screening. Estimates of screening benefits and harms by comorbid condition can inform discussions between providers and patients about personalizing screening cessation decisions.	Erasmus Univ, Med Ctr, NL-3000 CA Rotterdam, Netherlands; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Grp Hlth Res Inst, Seattle, WA 98101 USA; NCI, Bethesda, MD 20892 USA; Yeshiva Univ, Albert Einstein Coll Med, Bronx, NY USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Univ Minnesota, Minneapolis, MN 55455 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA; Georgetown Univ, Washington, DC 20007 USA	Erasmus University Rotterdam; Erasmus MC; Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Yeshiva University; Albert Einstein College of Medicine; Harvard University; Massachusetts General Hospital; University of Minnesota System; University of Minnesota Twin Cities; Memorial Sloan Kettering Cancer Center; Georgetown University	Lansdorp-Vogelaar, I (corresponding author), Erasmus Univ, Med Ctr, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands.	i.vogelaar@erasmusmc.nl	Gulati, Roman/AAE-4298-2019; de+Koning, Harry/AAF-9062-2019; Rutter, Carolyn/AAZ-3677-2021	Gulati, Roman/0000-0002-7592-6567; de+Koning, Harry/0000-0003-4682-3646; 	National Cancer Institute at the National Institutes of Health; Centers for Disease Control and Prevention [U01CA097426, U01CA115953, U01CA152959, U01CA157224, U01CA088283, U01CA152958]; National Cancer Institute at the National Institutes of Health [KO5CA96940, P01CA154292, U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, U01CA70040, HHSN261201100031C]; Dutch Cancer Society [94-869, 98-1657, 2002-277, 2006-3518]; Netherlands Organisation for Health Research and Development [002822820, 22000106, 50-50110-98-311]; NATIONAL CANCER INSTITUTE [UM1CA182883, U01CA115953, U01CA086082, U01CA070040, K05CA096940, U01CA152958, U01CA070013, U01CA097426, U01CA086076, P30CA008748, U01CA088283, U01CA063736, U01CA152959, U01CA063731, U01CA069976, U01CA063740, U01CA157224, P01CA154292] Funding Source: NIH RePORTER	National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Dutch Cancer Society(KWF Kankerbestrijding); Netherlands Organisation for Health Research and Development(Netherlands Organization for Health Research and Development); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	By the National Cancer Institute at the National Institutes of Health and the Centers for Disease Control and Prevention (grants U01CA097426, U01CA115953, U01CA152959, U01CA157224, U01CA088283, and U01CA152958) and in part by the National Cancer Institute at the National Institutes of Health (grants KO5CA96940 to Dr. Mandelblatt and P01CA154292 to Drs. Mandelblatt, Schechter, van Ravesteyn, Heijnsdijk, and de Koning), the Dutch Cancer Society (grants 94-869, 98-1657, 2002-277, and 2006-3518 to Drs. Heijnsdijk and de Koning), and the Netherlands Organisation for Health Research and Development (grants 002822820, 22000106, and 50-50110-98-311 to Drs. Heijnsdijk and de Koning). Breast Cancer Surveillance Consortium data collection and sharing used in some variables for modeling breast cancer screening was supported by the National Cancer Institute at the National Institutes of Health (grants U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, U01CA70040, and HHSN261201100031C).	Begg CB, 2010, ANN INTERN MED, V152, P540, DOI 10.7326/0003-4819-152-8-201004200-00203; Braithwaite RS, 2010, ANN INTERN MED, V152, P539, DOI 10.7326/0003-4819-152-8-201004200-00201; Calonge N, 2008, ANN INTERN MED, V149, P627, DOI 10.7326/0003-4819-149-9-200811040-00243; Calonge N, 2009, ANN INTERN MED, V151, P716, DOI 10.7326/0003-4819-151-10-200911170-00008; Carter HB, 2013, J UROLOGY, V190, P419, DOI 10.1016/j.juro.2013.04.119; Chang YJ, 2012, BREAST CANCER RES TR, V136, P823, DOI 10.1007/s10549-012-2274-3; Cho H, 2013, ANN INTERN MED, V159, P667, DOI 10.7326/0003-4819-159-10-201311190-00005; Col NF, 2010, ANN INTERN MED, V152, P542, DOI 10.7326/0003-4819-152-8-201004200-00206; Dinh TA, 2012, J GEN INTERN MED, V27, P730, DOI 10.1007/s11606-011-1972-6; Draisma G, 2003, J NATL CANCER I, V95, P868, DOI 10.1093/jnci/95.12.868; Frazier AL, 2000, JAMA-J AM MED ASSOC, V284, P1954, DOI 10.1001/jama.284.15.1954; Gong ZH, 2006, CANCER EPIDEM BIOMAR, V15, P1977, DOI 10.1158/1055-9965.EPI-06-0477; Greene KL, 2009, J UROLOGY, V182, P2232, DOI 10.1016/j.juro.2009.07.093; Gulati R, 2013, ANN INTERN MED, V158, P145, DOI 10.7326/0003-4819-158-3-201302050-00003; Gulati R, 2011, CANCER EPIDEM BIOMAR, V20, P740, DOI 10.1158/1055-9965.EPI-10-0718; Gulati R, 2010, BIOSTATISTICS, V11, P707, DOI 10.1093/biostatistics/kxq036; Harewood GC, 2006, J GASTROEN HEPATOL, V21, P1021, DOI 10.1111/j.1440-1746.2006.04218.x; Harris R, 2011, EPIDEMIOL REV, V33, P20, DOI 10.1093/epirev/mxr005; Heijnsdijk EAM, 2012, NEW ENGL J MED, V367, P595, DOI 10.1056/NEJMoa1201637; Ho A, 2010, ANN INTERN MED, V152, P542, DOI 10.7326/0003-4819-152-8-201004200-00207; Huxley RR, 2009, INT J CANCER, V125, P171, DOI 10.1002/ijc.24343; Kawachi Mark H, 2007, J Natl Compr Canc Netw, V5, P714; Klabunde CN, 2007, ANN EPIDEMIOL, V17, P584, DOI 10.1016/j.annepidem.2007.03.011; Klabunde CN, 2000, J CLIN EPIDEMIOL, V53, P1258, DOI 10.1016/S0895-4356(00)00256-0; Klijs B, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-378; Ko CW, 2005, GASTROENTEROLOGY, V129, P1163, DOI 10.1053/j.gastro.2005.07.027; Lee SJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e8441; Loeve F, 1999, COMPUT BIOMED RES, V32, P13, DOI 10.1006/cbmr.1998.1498; Maheshwari S, 2008, J AGING HEALTH, V20, P126, DOI 10.1177/0898264307309939; Mandelblatt Jeanne, 2006, J Natl Cancer Inst Monogr, P47, DOI 10.1093/jncimonographs/lgj008; Mandelblatt JS, 2013, JAMA INTERN MED, V173, P227, DOI 10.1001/jamainternmed.2013.2127; Mandelblatt JS, 2009, ANN INTERN MED, V151, P738, DOI 10.7326/0003-4819-151-10-200911170-00010; Mandelblatt JS, 2005, J GEN INTERN MED, V20, P487, DOI 10.1111/j.1525-1497.2005.0116.x; MANDELBLATT JS, 1992, ANN INTERN MED, V116, P722, DOI 10.7326/0003-4819-116-9-722; Nelson NJ, 2012, J NATL CANCER I, V104, P574, DOI 10.1093/jnci/djs213; Qaseem A, 2013, ANN INTERN MED, V158, P761, DOI 10.7326/0003-4819-158-10-201305210-00633; Rich J S, 2000, Eff Clin Pract, V3, P78; Rutter CM, 2010, CANCER EPIDEM BIOMAR, V19, P1992, DOI 10.1158/1055-9965.EPI-09-0954; Schonberg MA, 2011, J AM GERIATR SOC, V59, P1444, DOI 10.1111/j.1532-5415.2011.03523.x; Schonberg MA, 2009, J GEN INTERN MED, V24, P1115, DOI 10.1007/s11606-009-1073-y; Smith RA, 2012, CA CANCER J CLIN; Stevens T, 2003, AM J GASTROENTEROL, V98, P1881, DOI 10.1016/S0002-9270(03)00425-8; Tan Sita Y G L, 2006, J Natl Cancer Inst Monogr, P56, DOI 10.1093/jncimonographs/lgj009; U.S. Census Bureau, 2013, 2012 NATIONAL POPULA; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2750, DOI 10.1001/jama.285.21.2750; Warren JL, 2009, ANN INTERN MED, V150, P849, DOI 10.7326/0003-4819-150-12-200906160-00008; Wolf AMD, 2010, CA-CANCER J CLIN, V60, P70, DOI 10.3322/caac.20066; Wolk A, 2005, ACTA ONCOL, V44, P277, DOI 10.1080/02841860510029572; Yourman LC, 2012, JAMA-J AM MED ASSOC, V307, P182, DOI 10.1001/jama.2011.1966; Zauber AG, 2008, ANN INTERN MED, V149, P659, DOI 10.7326/0003-4819-149-9-200811040-00244	50	91	92	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	2014	161	2					104	+		10.7326/M13-2867	http://dx.doi.org/10.7326/M13-2867			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AM3PJ	25023249	Green Accepted			2023-01-03	WOS:000339764600019
J	Thompson, BT				Thompson, B. Taylor			In patients with severe sepsis, adding albumin to crystalloid solution did not reduce 28-or 90-day mortality	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RESUSCITATION; SALINE; FLUID		Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Thompson, BT (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.							Delaney AP, 2011, CRIT CARE MED, V39, P386, DOI 10.1097/CCM.0b013e3181ffe217; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finfer S, 2011, INTENS CARE MED, V37, P86, DOI 10.1007/s00134-010-2039-6; Russell JA, 2014, NEW ENGL J MED, V370, P1649, DOI 10.1056/NEJMe1402066	5	1	1	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	2014	161	2							JC6	10.7326/0003-4819-161-2-201407150-02006	http://dx.doi.org/10.7326/0003-4819-161-2-201407150-02006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AM3PJ	25023272				2023-01-03	WOS:000339764600007
J	Zanetti, M; Zenti, M; Barazzoni, R; Zardi, F; Semolic, A; Messa, MG; Mearelli, F; Russi, G; Fonda, M; Scarano, L; Bonora, E; Cattin, L				Zanetti, Michela; Zenti, Mariagrazia; Barazzoni, Rocco; Zardi, Federica; Semolic, Annamaria; Messa, Michele Giuseppe; Mearelli, Filippo; Russi, Gianpaolo; Fonda, Maurizio; Scarano, Luca; Bonora, Enzo; Cattin, Luigi			HELP LDL Apheresis Reduces Plasma Pentraxin 3 in Familial Hypercholesterolemia	PLOS ONE			English	Article							DENSITY LIPOPROTEIN-APHERESIS; NECROSIS-FACTOR-ALPHA; C-REACTIVE PROTEIN; ENDOTHELIAL-CELLS; PTX3; ATHEROSCLEROSIS; INFLAMMATION; CHOLESTEROL; EXPRESSION; CHILDREN	Background: Pentraxin 3 (PTX3), a key component of the humoral arm of innate immunity, is secreted by vascular cells in response to injury, possibly aiming at tuning arterial activation associated with vascular damage. Severe hypercholesterolemia as in familial hypercholesterolemia (FH) promotes vascular inflammation and atherosclerosis; low-density lipoprotein (LDL) apheresis is currently the treatment of choice to reduce plasma lipids in FH. HELP LDL apheresis affects pro-and antiinflammatory biomarkers, however its effects on PTX3 levels are unknown. We assessed the impact of FH and of LDL removal by HELP apheresis on PTX3. Methods: Plasma lipids, PTX3, and CRP were measured in 19 patients with FH undergoing chronic HELP LDL apheresis before and after treatment and in 20 control subjects. In the patients assessment of inflammation and oxidative stress markers included also plasma TNF alpha, fibrinogen and TBARS. Results: At baseline, FH patients had higher (p = 0.0002) plasma PTX3 than matched control subjects. In FH PTX3 correlated positively (p <= 0.05) with age, gender and CRP and negatively (p = 0.01) with HELP LDL apheresis vintage. The latter association was confirmed after correction for age, gender and CRP. HELP LDL apheresis acutely reduced (p <= 0.04) plasma PTX3, CRP, fibrinogen, TBARS and lipids, but not TNF alpha. No association was observed between mean decrease in PTX3 and in LDL cholesterol. PTX3 paralleled lipids, oxidative stress and inflammation markers in time-course study. Conclusion: FH is associated with increased plasma PTX3, which is acutely reduced by HELP LDL apheresis independently of LDL cholesterol, as reflected by the lack of association between change in PTX3 and in LDL levels. These results, together with the finding of a negative relationship between PTX3 and duration of treatment suggest that HELP LDL apheresis may influence both acutely and chronically cardiovascular outcomes in FH by modulating PTX3.	[Zanetti, Michela; Barazzoni, Rocco; Semolic, Annamaria; Mearelli, Filippo] Univ Trieste, Med Clin, Dept Med Surg & Hlth Sci, Trieste, Italy; [Zenti, Mariagrazia; Zardi, Federica; Messa, Michele Giuseppe; Bonora, Enzo] Univ Verona, I-37100 Verona, Italy; [Zenti, Mariagrazia; Zardi, Federica; Messa, Michele Giuseppe; Bonora, Enzo] Azienda Osped Univ Integrata Verona, Verona, Italy; [Fonda, Maurizio; Cattin, Luigi] Univ Trieste, Dept Med Surg & Hlth Sci, Diabet & Metab Dis Unit, Trieste, Italy; [Russi, Gianpaolo; Scarano, Luca] Osped Santa Maria Nuova, Immunohematol & Transfus Unit, Reggio Emilia, Italy	University of Trieste; University of Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Trieste; IRCCS Arcispedale S. Maria Nuova	Zanetti, M (corresponding author), Univ Trieste, Med Clin, Dept Med Surg & Hlth Sci, Trieste, Italy.	zanetti@units.it	Bonora, Enzo/AAA-5300-2022	BONORA, Enzo/0000-0003-1074-5164; ZANETTI, MICHELA/0000-0002-2634-6363; Mearelli, Filippo/0000-0002-5862-9077	Regione FVG [LR26/2005]	Regione FVG(Regione Friuli Venezia Giulia)	Funding provided by Grant LR26/2005, Regione FVG to L. Cattin. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abderrahim-Ferkoune A, 2003, J LIPID RES, V44, P994, DOI 10.1194/jlr.M200382-JLR200; Bambauer R, 2012, SCI WORLD J, DOI 10.1100/2012/314283; Banerjee S, 2014, J CLIN APHERESIS, V29, P97, DOI 10.1002/jca.21298; Basile A, 1997, J BIOL CHEM, V272, P8172, DOI 10.1074/jbc.272.13.8172; Bondarenko S, 2014, J INNATE IMMUN, V6, P3, DOI 10.1159/000351034; Bosutti A, 2007, CLIN EXP MED, V7, P16, DOI 10.1007/s10238-007-0118-y; Cattin L, 1997, ASAIO J, V43, P209; Charakida M, 2009, ATHEROSCLEROSIS, V204, P532, DOI 10.1016/j.atherosclerosis.2008.09.025; El Messal M, 2006, CLIN CHIM ACTA, V366, P185, DOI 10.1016/j.cca.2005.09.027; Garlanda C, 2011, CURR PHARM DESIGN, V17, P38, DOI 10.2174/138161211795049750; Hemphill LC, 2010, J CLIN LIPIDOL, V4, P346, DOI 10.1016/j.jacl.2010.08.013; Hovland A, 2012, SCAND J IMMUNOL, V76, P229, DOI 10.1111/j.1365-3083.2012.02734.x; Iwata A, 2012, CORONARY ARTERY DIS, V23, P315, DOI 10.1097/MCA.0b013e328352ffec; Jylhava J, 2011, CLIN EXP IMMUNOL, V164, P211, DOI 10.1111/j.1365-2249.2011.04354.x; Kaptoge S, 2012, NEW ENGL J MED, V367, P1310, DOI 10.1056/NEJMoa1107477; Karakas MF, 2013, J INVEST MED, V61, P278, DOI 10.2310/JIM.0b013e31827c2971; Knoflach M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031474; Koga N, 1999, J INTERN MED, V246, P35, DOI 10.1046/j.1365-2796.1999.00466.x; Latini R, 2004, CIRCULATION, V110, P2349, DOI 10.1161/01.CIR.0000145167.30987.2E; Leren TP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016721; Libby P, 2013, IMMUNITY, V38, P1092, DOI 10.1016/j.immuni.2013.06.009; Matsuzaki M, 2002, J AM COLL CARDIOL, V40, P220, DOI 10.1016/S0735-1097(02)01955-1; McGowan MP, 2013, J CLIN LIPIDOL, V7, pS21, DOI 10.1016/j.jacl.2013.03.002; Mellwig KP, 2012, CLIN RES CARDIOL S7, V7, pS45; Moriarty PM, 2001, ATHEROSCLEROSIS, V158, P495, DOI 10.1016/S0021-9150(01)00633-5; Narverud I, 2011, ATHEROSCLEROSIS, V214, P163, DOI 10.1016/j.atherosclerosis.2010.10.002; Norata GD, 2008, ARTERIOSCL THROM VAS, V28, P925, DOI 10.1161/ATVBAHA.107.160606; Norata GD, 2009, CIRCULATION, V120, P699, DOI 10.1161/CIRCULATIONAHA.108.806547; Ohbayashi H, 2009, J ATHEROSCLER THROMB, V16, P490, DOI 10.5551/jat.No613; Savchenko AS, 2008, J PATHOL, V215, P48, DOI 10.1002/path.2314; Schaumann D, 1996, EUR J CLIN INVEST, V26, P1033, DOI 10.1046/j.1365-2362.1996.2320587.x; Suzuki M, 1996, ARTIF ORGANS, V20, P296, DOI 10.1111/j.1525-1594.1996.tb04448.x; van Buuren Frank, 2012, Clin Res Cardiol Suppl, V7, P24; Wang Y, 2004, ATHEROSCLEROSIS, V175, P145, DOI 10.1016/j.atherosclerosis.2004.03.011; Yamasaki K, 2009, CLIN CHEM LAB MED, V47, P471, DOI 10.1515/CCLM.2009.110	35	18	19	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2014	9	7							e101290	10.1371/journal.pone.0101290	http://dx.doi.org/10.1371/journal.pone.0101290			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AL8HH	25014007	Green Submitted, Green Published, gold			2023-01-03	WOS:000339378400023
J	Genovese, F; Karsdal, MA; Leeming, DJ; Scholze, A; Tepel, M				Genovese, Federica; Karsdal, Morten A.; Leeming, Diana J.; Scholze, Alexandra; Tepel, Martin			Association of Versican Turnover with All-Cause Mortality in Patients on Haemodialysis	PLOS ONE			English	Article							STAGE RENAL-DISEASE; HEART-DISEASE; CALCIFICATION; PROTEOGLYCANS; HYPERTROPHY; DIALYSIS	Objective: Cardiovascular diseases are among the most common causes of mortality in renal failure patients undergoing haemodialysis. A high turnover rate of the proteoglycan versican, represented by the increased presence of its fragmentation products in plasma, has previously been associated with cardiovascular diseases. The objective of the study was to investigate the association of versican turnover assessed in plasma with survival in haemodialysis patients. Methods: A specific matrix metalloproteinase-generated neo-epitope fragment of versican (VCANM) was measured in plasma of 364 haemodialysis patients with a 5-years follow-up, using a robust competitive enzyme-linked immunosorbent assays. Association between VCANM plasma concentration and survival was assessed by Kaplan-Meier analysis and adjusted Cox model. Results: Haemodialysis patients with plasma VCANM concentrations in the lowest quartile had increased risk of death (odds ratio, as compared to the highest quartile: 7.1, p < 0.001), with a reduced survival of 152 days compared to 1295 days for patients with plasma VCANM in the highest quartile. Multivariate analysis showed that low VCANM (p < 0.001) and older age (p < 0.001) predicted death in haemodialysis patients. Conclusions: Low concentrations of the versican fragment VCANM in plasma were associated with higher risk of death among haemodialysis patients. A possible protective role for the examined versican fragment is suggested.	[Genovese, Federica; Karsdal, Morten A.; Leeming, Diana J.] Nord Biosci, Fibrosis Biol & Biomarkers, Herlev, Denmark; [Scholze, Alexandra; Tepel, Martin] Univ Southern Denmark, Odense Univ Hosp, Dept Nephrol, Inst Mol Med Cardiovasc & Renal Res,Inst Clin Res, Odense, Denmark	Nordic Bioscience; University of Southern Denmark; Odense University Hospital	Genovese, F (corresponding author), Nord Biosci, Fibrosis Biol & Biomarkers, Herlev, Denmark.	fge@nordicbioscience.com	Scholze, Alexandra/ABD-2442-2020; Tepel, Martin/GRS-9581-2022	Scholze, Alexandra/0000-0002-3100-8692; Genovese, Federica/0000-0003-1984-1881; Tepel, Martin/0000-0002-0086-0997; Karsdal, Morten/0000-0001-5026-8740	Danish Research Fund (Den Danske Forskningfond); Nordic Bioscience	Danish Research Fund (Den Danske Forskningfond); Nordic Bioscience	The authors acknowledge the Danish Research Fund (Den Danske Forskningfond) for providing the funding for this research. FG, DJL, and MAK are full-time employees at Nordic Bioscience. Nordic Bioscience provided support in the form of salaries for authors FG, DJL, and MAK, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Al-Dadah Ashraf, 2012, Adv Perit Dial, V28, P56; Barascuk N, 2013, INT J CLIN EXP MED, V6, P174; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; de Jager DJ, 2009, JAMA-J AM MED ASSOC, V302, P1782, DOI 10.1001/jama.2009.1488; Genovese F, 2014, FIBROGENESIS TISSUE, V7, DOI 10.1186/1755-1536-7-4; Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003; Gross ML, 2008, SEMIN DIALYSIS, V21, P308, DOI 10.1111/j.1525-139X.2008.00454.x; Hallan SI, 2012, JAMA-J AM MED ASSOC, V308, P2349, DOI 10.1001/jama.2012.16817; Karsdal MA, 2013, ASSAY DRUG DEV TECHN, V11, P70, DOI 10.1089/adt.2012.474; Karsdal MA, 2010, CLIN BIOCHEM, V43, P793, DOI 10.1016/j.clinbiochem.2010.03.015; Melk A, 2005, KIDNEY INT, V68, P2667, DOI 10.1111/j.1523-1755.2005.00738.x; Merrilees MJ, 2012, ELSEVIER CURRENT OPI, DOI [10.1016/j.ceb.2013.01.001, DOI 10.1016/J.CEB.2013.01.001]; Raggi P, 2002, J AM COLL CARDIOL, V39, P695, DOI 10.1016/S0735-1097(01)01781-8; Rudnicki M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044891; Selbi W, 2006, KIDNEY INT, V70, P1287, DOI 10.1038/sj.ki.5001760; Stokes MB, 2001, KIDNEY INT, V59, P532, DOI 10.1046/j.1523-1755.2001.059002532.x; Wight TN, 2014, MATRIX BIOL, V35, P152, DOI 10.1016/j.matbio.2014.01.015; Wight TN, 2004, CIRC RES, V94, P1158, DOI 10.1161/01.RES.0000126921.29919.51; Wu YJ, 2005, CELL RES, V15, P483, DOI 10.1038/sj.cr.7290318; Yamaguchi Y, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003421; Yamamoto Y, 2004, DIABETES, V53, P1831, DOI 10.2337/diabetes.53.7.1831	21	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2014	9	10							e111134	10.1371/journal.pone.0111134	http://dx.doi.org/10.1371/journal.pone.0111134			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8TG	25354390	Green Published, Green Submitted, gold			2023-01-03	WOS:000345204200060
J	Wang, W; He, M; Zhang, XL				Wang, Wei; He, Miao; Zhang, Xiulan			Combined Intravitreal Anti-VEGF and Photodynamic Therapy versus Photodynamic Monotherapy for Polypoidal Choroidal Vasculopathy: A Systematic Review and Meta-Analysis of Comparative Studies	PLOS ONE			English	Article							COMBINATION THERAPY; RANIBIZUMAB; BEVACIZUMAB; VERTEPORFIN; EFFICACY	Purpose: The aim of this study was to evaluate the efficacy and safety of photodynamic therapy (PDT) combined with intravitreal vascular endothelial growth factor (VEGF) inhibitors compared to those of PDT alone in the treatment of polypoidal choroidal vasculopathy (PCV). Methods: A systematic search of Pubmed, Embase, and the Cochrane Library was performed to identify all comparative studies that compared the outcomes of the two approaches. Outcomes of interest included visual outcomes, anatomic variables, and adverse events. Results: Two randomised controlled trials and nine retrospective studies including a total of 543 cases were identified. At three and six months post-injection, no significant difference in visual acuity was found in the combined therapy group compared with the PDT monotherapy group, with pooled weighted mean differences (WMDs) of 0.074 (-0.021, 0.17) at three months and 0.082 (-0.013, 0.18) at six months. However, the mean changes in visual acuity at month 12 in the combined therapy group were significantly better than those in the PDT monotherapy group, with pooled WMDs of 0.11 (0.012, 0.21). Similar efficacy was found at 24 months (WMD: 0.21; 95% CI: 0.054, 0.36; P = 0.008). Patients in the combined therapy group also might benefit from reduced retinal haemorrhage (OR: 0.32; 95% CI: 0.14, 0.74; P = 0.008). Polyp regression, recurrence of PCV, central retinal thickness reduction, and pigment epithelial detachment resolution did not differ significantly between the two treatments. Conclusions: Combined treatment appeared to result in better visual acuity and lower retinal haemorrhage. However, combined treatment did not affect the resolution and recurrence of lesions. Given the inherent limitations of the included studies, future well-designed RCTs are awaited to confirm and update the findings of this analysis.	[Wang, Wei; He, Miao; Zhang, Xiulan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University	Zhang, XL (corresponding author), Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.	zhangxl2@mail.sysu.edu.cn			National Natural Science Foundation of China [81170849, 81371008]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This research was supported by the National Natural Science Foundation of China (81170849, 81371008). No additional external funding was received. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9; Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002; de Crecchio G, 2011, CURR DRUG TARGETS, V12, P206, DOI 10.2174/138945011794182782; Englander M, 2013, CURR OPIN OPHTHALMOL, V24, P233, DOI 10.1097/ICU.0b013e32835f8eaa; Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33; Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004; Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179; Kang HM, 2014, OPHTHALMOLOGICA, V231, P86, DOI 10.1159/000354546; Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e; Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020; Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8; Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446; Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391; Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103; Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f; Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001; Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051; Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053; Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Nowak-Sliwinska P, 2013, PROG RETIN EYE RES; Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024; Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec; Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120; Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6; Saito M, 2012, RETINA-J RET VIT DIS, V32, P1272, DOI 10.1097/IAE.0b013e318236e624; Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044; Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d; Sato T, 2013, AM J OPHTHALMOL, V156, P95, DOI 10.1016/j.ajo.2013.02.006; Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466; Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001; Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001; Wells GA, NEWCASTLE OTTAWA SCA	36	43	43	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2014	9	10							e110667	10.1371/journal.pone.0110667	http://dx.doi.org/10.1371/journal.pone.0110667			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0BL	25343244	Green Submitted, Green Published, gold			2023-01-03	WOS:000343943500044
J	Lamontagne, F; Clement, C; Fletcher, T; Jacob, ST; Fischer, WA; Fowler, RA				Lamontagne, Francois; Clement, Christophe; Fletcher, Thomas; Jacob, Shevin T.; Fischer, William A., II; Fowler, Robert A.			Doing Today's Work Superbly Well - Treating Ebola with Current Tools	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Lamontagne, Francois] Univ Sherbrooke, Ctr Rech Clin, Ctr Hosp, Sherbrooke, PQ, Canada; [Clement, Christophe] Polyclin Bordeaux Nord Aquitaine, Bordeaux, France; [Fletcher, Thomas] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; [Jacob, Shevin T.] Univ Washington, Seattle, WA 98195 USA; [Fischer, William A., II] Univ N Carolina, Chapel Hill, NC USA; [Fowler, Robert A.] Univ Toronto, Toronto, ON, Canada	University of Sherbrooke; Liverpool School of Tropical Medicine; University of Liverpool; University of Washington; University of Washington Seattle; University of North Carolina; University of North Carolina Chapel Hill; University of Toronto	Lamontagne, F (corresponding author), Univ Sherbrooke, Ctr Rech Clin, Ctr Hosp, Sherbrooke, PQ, Canada.		Jacob, Shevin/CAF-0449-2022	Lamontagne, Francois/0000-0002-0360-3427; Jacob, Shevin/0000-0003-2425-9394; Fletcher, Tom/0000-0002-3712-415X	Wellcome Trust [100890] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)			0	69	70	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2014	371	17					1565	1566		10.1056/NEJMp1411310	http://dx.doi.org/10.1056/NEJMp1411310			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AR5UF	25251518	Green Published, Green Accepted			2023-01-03	WOS:000343648500002
J	Jacobs, C; Graham, ID; Makarski, J; Chasse, M; Fergusson, D; Hutton, B; Clemons, M				Jacobs, Carmel; Graham, Ian D.; Makarski, Julie; Chasse, Michael; Fergusson, Dean; Hutton, Brian; Clemons, Mark			Clinical Practice Guidelines and Consensus Statements in Oncology - An Assessment of Their Methodological Quality	PLOS ONE			English	Article							CANCER AMERICAN SOCIETY; CELL LUNG-CANCER; INDUCED FEBRILE NEUTROPENIA; ONTARIO PRACTICE GUIDELINE; COLONY-STIMULATING FACTOR; CONFLICTS-OF-INTEREST; SOFT-TISSUE SARCOMA; LYMPH-NODE BIOPSY; COLORECTAL-CANCER; GROWTH-FACTOR	Background: Consensus statements and clinical practice guidelines are widely available for enhancing the care of cancer patients. Despite subtle differences in their definition and purpose, these terms are often used interchangeably. We systematically assessed the methodological quality of consensus statements and clinical practice guidelines published in three commonly read, geographically diverse, cancer-specific journals. Methods Consensus statements and clinical practice guidelines published between January 2005 and September 2013 in Current Oncology, European Journal of Cancer and Journal of Clinical Oncology were evaluated. Each publication was assessed using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) rigour of development and editorial independence domains. For assessment of transparency of document development, 7 additional items were taken from the Institute of Medicine's standards for practice guidelines and the Journal of Clinical Oncology guidelines for authors of guidance documents. Methods: Consensus statements and clinical practice guidelines published between January 2005 and September 2013 in Current Oncology, European Journal of Cancer and Journal of Clinical Oncology were evaluated. Each publication was assessed using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) rigour of development and editorial independence domains. For assessment of transparency of document development, 7 additional items were taken from the Institute of Medicine's standards for practice guidelines and the Journal of Clinical Oncology guidelines for authors of guidance documents. Findings: Thirty-four consensus statements and 67 clinical practice guidelines were evaluated. The rigour of development score for consensus statements over the three journals was 32% lower than that of clinical practice guidelines. The editorial independence score was 15% lower for consensus statements than clinical practice guidelines. One journal scored consistently lower than the others over both domains. No journals adhered to all the items related to the transparency of document development. One journal's consensus statements endorsed a product made by the sponsoring pharmaceutical company in 64% of cases. Conclusion: Guidance documents are an essential part of oncology care and should be subjected to a rigorous and validated development process. Consensus statements had lower methodological quality than clinical practice guidelines using AGREE II. At a minimum, journals should ensure that that all consensus statements and clinical practice guidelines adhere to AGREE II criteria. Journals should consider explicitly requiring guidelines to declare pharmaceutical company sponsorship and to identify the sponsor's product to enhance transparency.	[Jacobs, Carmel; Clemons, Mark] Ottawa Hosp, Ctr Canc, Div Med Oncol, Ottawa, ON, Canada; [Jacobs, Carmel; Graham, Ian D.; Fergusson, Dean; Clemons, Mark] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Graham, Ian D.; Chasse, Michael; Fergusson, Dean; Hutton, Brian] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada; [Graham, Ian D.; Fergusson, Dean; Clemons, Mark] Ottawa Hosp, Res Inst, Ottawa, ON, Canada; [Makarski, Julie] Independent Consultant, Hamilton, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Jacobs, C (corresponding author), Ottawa Hosp, Ctr Canc, Div Med Oncol, Ottawa, ON, Canada.	cjacobs@toh.on.ca	Chassé, Michaël/L-7906-2017; Chassé, Michaël/Y-7820-2019; Graham, Ian D./ABD-5259-2021	Chassé, Michaël/0000-0001-7075-1924; Graham, Ian D./0000-0002-3669-1216; Hutton, Brian/0000-0001-5662-8647; Jacobs, Carmel/0000-0001-5178-7307; Fergusson, Dean/0000-0002-3389-2485	Canadian Institutes of Health Research (CHIR) [FRN: IOP 123548]	Canadian Institutes of Health Research (CHIR)(Canadian Institutes of Health Research (CIHR))	IG received funding from the Canadian Institutes of Health Research (CHIR) number; FRN: IOP 123548 (http://www.cihr-irsc.gc.ca/e/193.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aapro MS, 2006, EUR J CANCER, V42, P2433, DOI 10.1016/j.ejca.2006.05.002; Aapro MS, 2011, EUR J CANCER, V47, P8, DOI 10.1016/j.ejca.2010.10.013; Amant F, 2010, EUR J CANCER, V46, P3158, DOI 10.1016/j.ejca.2010.09.010; American Society of Clinical Oncology, 2013, CONFL INT POL IMPL C; [Anonymous], 2009, MOSBYS MED DICT, V8th; Asmis T, 2010, CURR ONCOL, V17, P6; Aubin F, 2011, CURR ONCOL, V18, pE180; Azzoli CG, 2011, J CLIN ONCOL, V29, P3825, DOI 10.1200/JCO.2010.34.2774; Azzoli CG, 2009, J CLIN ONCOL, V27, P6251, DOI 10.1200/JCO.2009.23.5622; Basch E, 2011, J CLIN ONCOL, V29, P4189, DOI [10.1200/JCO.2010.34.4614, 10.1200/JOP.2011.000397]; Basch EM, 2007, J CLIN ONCOL, V25, P5313, DOI 10.1200/JCO.2007.13.4536; Becker G, 2006, EUR J CANCER, V42, P589, DOI 10.1016/j.ejca.2005.11.018; Bokemeyer C, 2007, EUR J CANCER, V43, P258, DOI 10.1016/j.ejca.2006.10.014; Brock PR, 2012, J CLIN ONCOL, V30, P2408, DOI 10.1200/JCO.2011.39.1110; Brouwers, 2010, STAND GUID EV SAG DI; Brouwers MC, 2011, EXPERT REV PHARM OUT, V11, P151, DOI [10.1586/ERP.11.11, 10.1586/erp.11.11]; Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449; Burgers JS, 2004, J CLIN ONCOL, V22, P2000, DOI 10.1200/JCO.2004.06.157; Burstein HJ, 2011, J CLIN ONCOL, V29, P3328, DOI 10.1200/JCO.2011.36.0354; Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI [10.1200/JCO.2009.26.3756, 10.1200/JOP.000082]; Cataliotti L, 2007, EUR J CANCER, V43, P660, DOI 10.1016/j.ejca.2006.12.008; Chen C, 2013, CURR ONCOL, V20, pE136, DOI 10.3747/co.20.1252; Collaboration TC, 2014, IND SEARCH TECHN INF; Colorectal Cancer Association of Canada, 2009, Curr Oncol, V16, P50; Cosgrove L, 2013, J EVAL CLIN PRACT, V19, P674, DOI 10.1111/jep.12016; Cripps C, 2010, CURR ONCOL, V17, P37; Czauderna P, 2005, EUR J CANCER, V41, P1031, DOI 10.1016/j.ejca.2005.02.004; Darling GE, 2011, CURR ONCOL, V18, pE304; Dawson AJ, 2011, CURR ONCOL, V18, pE250; De Haas E, 2007, J EUR ACAD DERMATOL, V21, P1193, DOI 10.1111/j.1468-3083.2007.02216.x; Desch CE, 2005, J CLIN ONCOL, V23, P8512, DOI 10.1200/JCO.2005.04.0063; Di Valentin T, 2013, CURR ONCOL, V20, pE455, DOI 10.3747/co.20.1638; Dimopoulos MA, 2010, J CLIN ONCOL, V28, P4976, DOI 10.1200/JCO.2010.30.8791; Dodge JE, 2012, CURR ONCOL, V19, pE244, DOI 10.3747/co.19.980; Duffy MJ, 2007, EUR J CANCER, V43, P1348, DOI 10.1016/j.ejca.2007.03.021; Elit L, 2010, CURR ONCOL, V17, P65; Ellis PM, 2009, CURR ONCOL, V16, P27; Fervers B, 2005, INT J QUAL HEALTH C, V17, P123, DOI 10.1093/intqhc/mzi011; Flowers CR, 2013, J CLIN ONCOL, V31, P794, DOI 10.1200/JCO.2012.45.8661; Fraser G SC, 2007, CURRENT ONCOLOGY, P14; Gallinger S, 2013, CURR ONCOL, V20, pE255, DOI 10.3747/co.20.1341; Garbe C, 2012, EUR J CANCER, V48, P2375, DOI 10.1016/j.ejca.2012.06.013; Garbe C, 2010, EUR J CANCER, V46, P270, DOI 10.1016/j.ejca.2009.10.032; Gilligan TD, 2010, J CLIN ONCOL, V28, P3388, DOI 10.1200/JCO.2009.26.4481; Glenny AM, EUROPEAN J CANC, V46, P1399; Graham R, 2011, CLINICAL PRACTICE GUIDELINES WE CAN TRUST, P1; Graham RMM, COMMITTEE STANDARDS; Gridelli C, 2011, EUR J CANCER, V47, pS248, DOI 10.1016/S0959-8049(11)70171-X; Griggs JJ, 2012, J CLIN ONCOL, V30, P1553, DOI 10.1200/JCO.2011.39.9436; Griggs JJ, 2011, J CLIN ONCOL, V29, P3939, DOI 10.1200/JCO.2011.36.4950; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Gupta AA, 2013, CURR ONCOL, V20, pE448, DOI 10.3747/co.20.1357; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI [10.1200/JCO.2009.25.6529, 10.1043/1543-2165-134.6.907, 10.1200/JOP.777003]; Hanna W, 2007, Curr Oncol, V14, P149, DOI 10.3747/co.2007.131; Hensley ML, 2009, J CLIN ONCOL, V27, P127, DOI 10.1200/JCO.2008.17.2627; Herkert JC, 2011, EUR J CANCER, V47, P965, DOI 10.1016/j.ejca.2011.01.013; Hogeveen SE, 2012, CURR ONCOL, V19, pE184, DOI 10.3747/co.19.930; Howell D, 2013, CURR ONCOL, V20, pE233, DOI 10.3747/co.20.1302; Howell D, 2011, CURR ONCOL, V18, pE265; Jonker D, 2006, Curr Oncol, V13, P173; Juweid ME, 2007, J CLIN ONCOL, V25, P571, DOI 10.1200/JCO.2006.08.2305; Kandel R, 2013, CURR ONCOL, V20, pE247, DOI 10.3747/co.20.1308; Khatcheressian JL, 2013, J CLIN ONCOL, V31, P961, DOI 10.1200/JCO.2012.45.9859; Khorana AA, 2009, J CLIN ONCOL, V27, P4919, DOI 10.1200/JCO.2009.22.3214; Kocha W, 2010, CURR ONCOL, V17, P49; Kramer BS, 2009, J CLIN ONCOL, V27, P1502, DOI 10.1200/JCO.2008.16.9599; Kris MG, 2006, J CLIN ONCOL, V24, P2932, DOI 10.1200/JCO.2006.06.9591; Kulke MH, 2011, J CLIN ONCOL, V29, P934, DOI 10.1200/JCO.2010.33.2056; Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269; Laneuville P, 2006, Curr Oncol, V13, P201; Langton JM, 2011, BRIT J CANCER, V105, P1166, DOI 10.1038/bjc.2011.378; Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001; Loblaw DA, 2007, J CLIN ONCOL, V25, P1596, DOI 10.1200/JCO.2006.10.1949; Lokhorst H, 2010, J CLIN ONCOL, V28, P4521, DOI 10.1200/JCO.2010.29.7929; Lopez-Olivo MA, 2008, ARTHRIT RHEUM-ARTHR, V59, P1625, DOI 10.1002/art.24207; Loren AW, 2013, J CLIN ONCOL, V31, P2500, DOI 10.1200/JCO.2013.49.2678; Lutz MP, 2012, EUR J CANCER, V48, P2941, DOI 10.1016/j.ejca.2012.07.029; Lyman GH, 2007, J CLIN ONCOL, V25, P5490, DOI 10.1200/JCO.2007.14.1283; Lyman GH, 2005, J CLIN ONCOL, V23, P7703, DOI 10.1200/JCO.2005.08.001; MacKenzie M, 2011, CURR ONCOL, V18, pE202; Maroun J, 2006, Curr Oncol, V13, P67; Maschmeyer G, 2009, EUR J CANCER, V45, P2462, DOI 10.1016/j.ejca.2009.05.001; Mason W P, 2007, Curr Oncol, V14, P110, DOI 10.3747/co.2007.119; McEwen S, 2013, CURR ONCOL, V20, P64, DOI 10.3747/co.20.1277; Mendelson TB, 2011, ARCH INTERN MED, V171, P577, DOI 10.1001/archinternmed.2011.96; Mintz A, 2007, Curr Oncol, V14, P131, DOI 10.3747/co.2007.129; Norris SL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025153; Olsen EA, 2011, J CLIN ONCOL, V29, P2598, DOI 10.1200/JCO.2010.32.0630; Petrella T, 2007, Curr Oncol, V14, P21, DOI 10.3747/co.2007.97; Pfister DG, 2006, J CLIN ONCOL, V24, P3693, DOI 10.1200/JCO.2006.07.4559; Philip PA, 2009, J CLIN ONCOL, V27, P5660, DOI 10.1200/JCO.2009.21.9022; Pisters KMW, 2007, J CLIN ONCOL, V25, P5506, DOI 10.1200/JCO.2007.14.1226; Ponzoni M, 2007, J CLIN ONCOL, V25, P3168, DOI 10.1200/JCO.2006.08.2313; Pritchard KI, 2013, CURR ONCOL, V20, P48, DOI 10.3747/co.20.1316; Quinn B, 2008, EUR J CANCER, V44, P61, DOI 10.1016/j.ejca.2007.09.014; Quirt I, 2007, CURRENT ONCOLOGY, P14; Rayner L, 2011, EUR J CANCER, V47, P702, DOI 10.1016/j.ejca.2010.11.027; Reece D, 2006, Curr Oncol, V13, P160; Rizzo JD, 2010, J ONCOL PRACT, V6, P317, DOI 10.1200/JOP.2010.000132; Schiffer CA, 2013, J CLIN ONCOL, V31, P1357, DOI 10.1200/JCO.2012.45.5733; Sherman M, 2011, CURR ONCOL, V18, P228; Shimbo T, 2010, INT J CLIN ONCOL, V15, P227, DOI 10.1007/s10147-010-0060-y; Smith TJ, 2006, J CLIN ONCOL, V24, P3187, DOI 10.1200/JCO.2006.06.4451; Thomas MB, 2010, J CLIN ONCOL, V28, P3994, DOI 10.1200/JCO.2010.28.7805; Trautinger F, 2006, EUR J CANCER, V42, P1014, DOI 10.1016/j.ejca.2006.01.025; Tsukasaki K, 2009, J CLIN ONCOL, V27, P453, DOI 10.1200/JCO.2008.18.2428; Van Cutsem E, 2006, EUR J CANCER, V42, P2212, DOI 10.1016/j.ejca.2006.04.012; Verma S, 2008, CURR ONCOL, V15, P85; Verma S, 2008, CURR ONCOL, V15, P80; Verma S, 2007, Curr Oncol, V14, P144; Vickers M, 2010, CURR ONCOL, V17, P116; Vickers MM, 2012, CURR ONCOL, V19, pE468, DOI 10.3747/co.19.1167; Visvanathan K, 2013, J CLIN ONCOL, V31, P2942, DOI 10.1200/JCO.2013.49.3122; Visvanathan K, 2009, J CLIN ONCOL, V27, P3235, DOI 10.1200/JCO.2008.20.5179; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Wong SL, 2012, J CLIN ONCOL, V30, P2912, DOI 10.1200/JCO.2011.40.3519; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527; Yoo J, 2013, CURR ONCOL, V20, pE132, DOI 10.3747/co.20.1237; Zinzani PL, 2008, EUR J CANCER, V44, P366, DOI 10.1016/j.ejca.2007.12.008	120	15	16	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2014	9	10							e110469	10.1371/journal.pone.0110469	http://dx.doi.org/10.1371/journal.pone.0110469			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8TF	25329669	gold, Green Published, Green Submitted			2023-01-03	WOS:000345204100078
J	Hsiao, PC; Chu, CM; Sung, PY; Perng, WC; Wang, KY				Hsiao, Peng-Ching; Chu, Chi-Ming; Sung, Pei-Yi; Perng, Wann-Cherng; Wang, Kwua-Yun			Differences in COPD Patient Care by Primary Family Caregivers: An Age-Based Study	PLOS ONE			English	Article							EDUCATION-PROGRAM; ELDERLY-PATIENTS; OLDER-ADULTS; HONG-KONG; IMPAIRMENTS; PREVALENCE; COMMUNITY; BURDEN; TAIWAN; HEALTH	Background: Because Taiwan has the fastest aging rate among developed countries, care for the elderly is becoming more prominent in the country. Primary family caregivers play an important role in patient health and health promotion behavior. Chronic obstructive pulmonary disease (COPD), an age-related disease, is a major public health problem with high morbidity and mortality and can be a long-term burden for family members; however, little attention has been given to the differences in COPD care between elder caregivers and other caregivers. This study aimed to investigate the differences between elder family caregivers and non-elder family caregivers caring for COPD patients in Taiwan, including caring behavior, caregiver response, and caring knowledge. Methods: This cross-sectional study was conducted between March 2007 and January 2008; 406 primary family caregivers of COPD patients from the thoracic outpatient departments of 6 hospitals in north-central Taiwan were recruited to answer questionnaires measuring COPD characteristics, care behavior, caregiver response, and COPD knowledge. All questionnaires, which addressed caregiver knowledge, care behaviors, and care reactions, were shown to have acceptable validity and reliability, and the data were analyzed using univariate and generalized linear model techniques. Results: The elder caregivers group had 79 participants, and the non-elder caregivers comprised 327 participants. The COPD-related knowledge scale results were positively correlated with the family caregiver caring behavior scale, suggesting that better COPD-related knowledge among family caregivers may result in improved caring behavior. After adjusting for all possible confounding factors, the elder caregivers had significantly lower COPD-related knowledge than the non-elder caregivers (P < 0.001). However, there were no significant differences in the family caregiver caring behavior scale or the caregiver reaction assessment scale between the two groups. Conclusions: Elder family caregivers require increased education regarding medications and preventive care in COPD patient care.	[Hsiao, Peng-Ching] Tri Serv Gen Hosp, Natl Def Med Ctr, Grad Inst Med Sci, Dept Nursing, Taipei, Taiwan; [Chu, Chi-Ming] Natl Def Med Ctr & Univ, Inst Publ Hlth, Sect Hlth Informat, Taipei, Taiwan; [Sung, Pei-Yi] Taipei Vet Gen Hosp, Dept Nursing, Taoyuan Branch, Taoyuan, Taiwan; [Perng, Wann-Cherng] Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Internal Med, Div Pulm & Crit Care Med, Taipei, Taiwan; [Wang, Kwua-Yun] Taipei Vet Gen Hosp, Natl Def Med Ctr, Grad Inst Med Sci, Dept Nursing, Taipei, Taiwan	National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; Taipei Veterans General Hospital; National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; Taipei Veterans General Hospital	Wang, KY (corresponding author), Taipei Vet Gen Hosp, Natl Def Med Ctr, Grad Inst Med Sci, Dept Nursing, Taipei, Taiwan.	kywang7@vghtpe.gov.tw		Chu, Cordia/0000-0002-3683-5638	Health Promotion Administration, Ministry of Health and Welfare, Taiwan [DOH96-HP-1101]	Health Promotion Administration, Ministry of Health and Welfare, Taiwan	This study was supported by a grant from Health Promotion Administration, Ministry of Health and Welfare, Taiwan (DOH96-HP-1101). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alpass F, 2013, J GERONTOL B-PSYCHOL, V68, P783, DOI 10.1093/geronb/gbt060; [Anonymous], 2012, GLOB BRIEF WORLD HLT; Baty F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063285; Bookman A, 2011, FUTURE CHILD, V21, P117; Buurman BM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026951; Chan RCK, 2011, BEHAV BRAIN FUNCT, V7, DOI 10.1186/1744-9081-7-32; Chau PH, 2012, J AM MED DIR ASSOC, V13, P169, DOI 10.1016/j.jamda.2010.07.011; Chen CY, 2010, ARCH GERONTOL GERIAT, V50, pS43, DOI 10.1016/S0167-4943(10)70012-1; Chen J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024348; Chiu MYL, 2013, INT J SOC PSYCHIATR, V59, P28, DOI 10.1177/0020764011423171; Coventry PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060532; de Marco R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062985; Dias A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002333; Friedemann ML, 2014, J ADV NURS, V70, P662, DOI 10.1111/jan.12230; Gallart A, 2013, J ADV NURS, V69, P642, DOI 10.1111/j.1365-2648.2012.06049.x; Garrod R, 2002, RESP MED, V96, P725, DOI 10.1053/rmed.2002.1338; GIVEN CW, 1992, RES NURS HEALTH, V15, P271, DOI 10.1002/nur.4770150406; Hiyoshi K, 2009, GAN TO KAGAKU RYO S1, P30; Kernisan LP, 2010, J MED INTERNET RES, V12, DOI 10.2196/jmir.1548; Lange JW, 2011, GERONTOL GERIATR EDU, V32, P164, DOI 10.1080/02701960.2011.572056; Limpawattana P, 2013, J COMMUN HEALTH, V38, P40, DOI 10.1007/s10900-012-9576-6; Lucksted A, 2013, ACTA PSYCHIAT SCAND, V127, P279, DOI 10.1111/j.1600-0447.2012.01901.x; Martin P, 2013, PATIENT EDUC COUNS, V92, P81, DOI 10.1016/j.pec.2013.02.016; Alvarenga MRM, 2011, CIENC SAUDE COLETIVA, V16, P2603, DOI 10.1590/S1413-81232011000500030; Ministry of Health and Welfare, 2011, AG TSUN STRUCK TAIW; Najafzadeh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046746; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Pennacchini M, 2014, Clin Ter, V165, pe219, DOI 10.7417/CT.2014.1723; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; Rubio DM, 2003, SOC WORK RES, V27, P94, DOI 10.1093/swr/27.2.94; Smith GR, 2011, PSYCHOL AGING, V26, P584, DOI 10.1037/a0022263; Thielman N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038109; Tsai HH, 2013, SOC PSYCH PSYCH EPID, V48, P1145, DOI 10.1007/s00127-013-0652-8; Vellone Ercole, 2011, Prof Inferm, V64, P237; Wang JJ, 2009, INT PSYCHOGERIATR, V21, P314, DOI 10.1017/S1041610208008211; White R, 2006, Chron Respir Dis, V3, P123, DOI 10.1191/1479972306cd117oa; Woo J, 2011, MED CLIN N AM, V95, P477, DOI 10.1016/j.mcna.2011.02.009; Wu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033857; Yang C, 2000, DEV TESTING CANC CAR	39	6	6	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2014	9	9							e107870	10.1371/journal.pone.0107870	http://dx.doi.org/10.1371/journal.pone.0107870			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AQ0SJ	25250897	gold, Green Submitted, Green Published			2023-01-03	WOS:000342492700054
J	Goikoetxea, E; Murgia, X; Serna-Grande, P; Valls-i-Soler, A; Rey-Santano, C; Rivas, A; Anton, R; Basterretxea, FJ; Minambres, L; Mendez, E; Lopez-Arraiza, A; Larrabe-Barrena, JL; Gomez-Solaetxe, MA				Goikoetxea, Estibalitz; Murgia, Xabier; Serna-Grande, Pablo; Valls-i-Soler, Adolf; Rey-Santano, Carmen; Rivas, Alejandro; Anton, Raul; Basterretxea, Francisco J.; Minambres, Lorena; Mendez, Estibaliz; Lopez-Arraiza, Alberto; Luis Larrabe-Barrena, Juan; Angel Gomez-Solaetxe, Miguel			In Vitro Surfactant and Perfluorocarbon Aerosol Deposition in a Neonatal Physical Model of the Upper Conducting Airways	PLOS ONE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; DOSE-RESPONSE; GAS-EXCHANGE; BLOOD-FLOW; OPEN-LABEL; THERAPY; INHALATION; NEBULIZATION; VENTILATION	Objective: Aerosol delivery holds potential to release surfactant or perfluorocarbon (PFC) to the lungs of neonates with respiratory distress syndrome with minimal airway manipulation. Nevertheless, lung deposition in neonates tends to be very low due to extremely low lung volumes, narrow airways and high respiratory rates. In the present study, the feasibility of enhancing lung deposition by intracorporeal delivery of aerosols was investigated using a physical model of neonatal conducting airways. Methods: The main characteristics of the surfactant and PFC aerosols produced by a nebulization system, including the distal air pressure and air flow rate, liquid flow rate and mass median aerodynamic diameter (MMAD), were measured at different driving pressures (4-7 bar). Then, a three-dimensional model of the upper conducting airways of a neonate was manufactured by rapid prototyping and a deposition study was conducted. Results: The nebulization system produced relatively large amounts of aerosol ranging between 0.3 +/- 0.0 ml/min for surfactant at a driving pressure of 4 bar, and 2.0 +/- 0.1 ml/min for distilled water (H(2)Od) at 6 bar, with MMADs between 2.61 +/- 0.1 mu m for PFD at 7 bar and 10.18 +/- 0.4 mu m for FC-75 at 6 bar. The deposition study showed that for surfactant and H(2)Od aerosols, the highest percentage of the aerosolized mass (similar to 65%) was collected beyond the third generation of branching in the airway model. The use of this delivery system in combination with continuous positive airway pressure set at 5 cmH(2)O only increased total airway pressure by 1.59 cmH(2)O at the highest driving pressure (7 bar). Conclusion: This aerosol generating system has the potential to deliver relatively large amounts of surfactant and PFC beyond the third generation of branching in a neonatal airway model with minimal alteration of pre-set respiratory support.	[Goikoetxea, Estibalitz; Murgia, Xabier; Serna-Grande, Pablo; Rey-Santano, Carmen] Cruces Univ Hosp, Res Unit Expt Neonatal Resp Physiol, Baracaldo, Bizkaia, Spain; [Valls-i-Soler, Adolf] Cruces Univ Hosp, Neonatal Intens Care Unit, Baracaldo, Bizkaia, Spain; [Rivas, Alejandro; Anton, Raul] Univ Navarra, TECNUN, Dept Mech Engn, Thermal & Fluids Engn Div, San Sebastian, Gipuzkoa, Spain; [Basterretxea, Francisco J.; Minambres, Lorena; Mendez, Estibaliz] Univ Basque Country, Fac Sci & Technol, Dept Phys Chem, Leioa, Bizkaia, Spain; [Lopez-Arraiza, Alberto; Luis Larrabe-Barrena, Juan; Angel Gomez-Solaetxe, Miguel] Univ Basque Country, High Tech Sch Maritime Studies, Dept Elect & Electrotech, Bilbao, Bizkaia, Spain	Hospital Universitario Cruces; Hospital Universitario Cruces; University of Navarra; University of Basque Country; University of Basque Country	Goikoetxea, E (corresponding author), Cruces Univ Hosp, Res Unit Expt Neonatal Resp Physiol, Baracaldo, Bizkaia, Spain.	esti-goikoetxea@hotmail.com	Anton, Raul/E-8504-2013; Rivas, Alejandro/A-3281-2009; SOLAECHE, MIGUEL ANGEL GOMEZ/ABH-3309-2020; Lopez-Arraiza, Alberto/C-6519-2014	Anton, Raul/0000-0003-1329-5891; Rivas, Alejandro/0000-0001-7755-8748; SOLAECHE, MIGUEL ANGEL GOMEZ/0000-0003-1509-046X; BASTERRECHEA ELGUEZABAL, FRANCISCO JOSE/0000-0002-0420-2625; Lopez-Arraiza, Alberto/0000-0002-3258-1888; Serna Grande, Pablo/0000-0002-3701-0822	SAIOTEK program of the Basque Government [HODEI01, SA-2011/00227]; University of the Basque Country [IT 583-13, IT 520-10, UFI 11/23]	SAIOTEK program of the Basque Government; University of the Basque Country	This work has been supported by the SAIOTEK 2011 program of the Basque Government (HODEI01, SA-2011/00227) and by the University of the Basque Country (consolidated groups IT 583-13, IT 520-10 and UFI 11/23). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arroe M, 1998, PRENAT NEONAT MED, V3, P346; Berggren E, 2000, ACTA PAEDIATR, V89, P460, DOI 10.1080/080352500750028195; Capstick TGD, 2012, EXPERT REV RESP MED, V6, P91, DOI [10.1586/ers.11.89, 10.1586/ERS.11.89]; CARLTON DP, 1995, PEDIATR RES, V37, P265, DOI 10.1203/00006450-199503000-00003; Dijk PH, 1997, INTENS CARE MED, V23, P1070, DOI 10.1007/s001340050458; Dijk PH, 1997, INTENS CARE MED, V23, P1077, DOI 10.1007/s001340050459; Dubus JC, 2005, PEDIATR RES, V58, P10, DOI 10.1203/01.PDR.0000156244.84422.55; ENHORNING G, 1972, PEDIATRICS, V50, P58; Finer NN, 2010, J AEROSOL MED PULM D, V23, P303, DOI 10.1089/jamp.2009.0758; Fok TF, 1996, PEDIATR PULM, V21, P301, DOI 10.1002/(SICI)1099-0496(199605)21:5<301::AID-PPUL5>3.0.CO;2-P; FUHRMAN BP, 1991, CRIT CARE MED, V19, P712, DOI 10.1097/00003246-199105000-00019; Gastiasoro-Cuesta E, 2001, Pediatr Crit Care Med, V2, P334, DOI 10.1097/00130478-200110000-00010; Gopel W, 2011, LANCET, V378, P1627, DOI 10.1016/S0140-6736(11)60986-0; Hinds W.C, 1999, AEROSOL TECHNOLOGY P; Janssens HM, 2001, J AEROSOL MED, V14, P433, DOI 10.1089/08942680152744640; Jeng MJ, 2003, PEDIATR RES, V53, P81, DOI 10.1203/01.PDR.0000041520.50792.0A; Jobe AH, 2001, CURR OPIN PEDIATR, V13, P124, DOI 10.1097/00008480-200104000-00006; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; Jorch G, 1997, PEDIATR PULM, V24, P222, DOI 10.1002/(SICI)1099-0496(199709)24:3<222::AID-PPUL9>3.0.CO;2-O; Kacmarek RM, 2006, AM J RESP CRIT CARE, V173, P882, DOI 10.1164/rccm.200508-1196OC; Kandler MA, 2004, PEDIATR RES, V56, P191, DOI 10.1203/01.PDR.0000132667.47744.F4; Kandler MA, 2001, AM J RESP CRIT CARE, V164, P31, DOI 10.1164/ajrccm.164.1.2010049; Kohler E, 2008, ARCH DIS CHILD-FETAL, V93, pF275, DOI 10.1136/adc.2007.121285; Mazela J, 2007, CURR OPIN PEDIATR, V19, P155, DOI 10.1097/MOP.0b013e32807fb013; Mazela J, 2011, EUR J PEDIATR, V170, P433, DOI 10.1007/s00431-010-1292-6; Minocchieri S, 2008, PEDIATR RES, V64, P141, DOI 10.1203/PDR.0b013e318175dcfa; Murgia X, 2012, PEDIATR RES, V72, P393, DOI 10.1038/pr.2012.90; Murgia X, 2011, J AEROSOL MED PULM D, V24, P81, DOI 10.1089/jamp.2010.0831; Rey-Santano C, 2013, PEDIATR RES, V73, P639, DOI 10.1038/pr.2013.24; Rozanek M, 2007, INT J BIOMEDICAL SCI, P249; Rudiger M, 2004, J CRIT CARE, V19, P42, DOI 10.1016/j.jcrc.2004.02.008; SEIDNER SR, 1995, AM J RESP CRIT CARE, V152, P113, DOI 10.1164/ajrccm.152.1.7599809; Sinha IP, 2011, RES REP NEONATOL, V1, P67, DOI 10.2147/RRN.S24050; Sweet DG, 2013, NEONATOLOGY, V103, P353, DOI 10.1159/000349928; Tashiro K, 1996, CRIT CARE MED, V24, P488, DOI 10.1097/00003246-199603000-00020; von der Hardt K, 2004, CRIT CARE MED, V32, P1200, DOI 10.1097/01.CCM.0000124876.31138.F6; Walsh BK, 2013, RESP CARE, V58, P367, DOI 10.4187/respcare.02189; Rojas-Reyes MX, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000510.pub2; YEH HC, 1980, B MATH BIOL, V42, P461, DOI 10.1007/BF02460796	39	10	10	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2014	9	9							e106835	10.1371/journal.pone.0106835	http://dx.doi.org/10.1371/journal.pone.0106835			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AP1UA	25211475	gold, Green Published, Green Submitted			2023-01-03	WOS:000341855900025
J	Puri, S				Puri, Sunita			Extraordinary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Stanford Univ, Dept Gen Med Disciplines, Div Palliat Med, Hosp & Clin, Palo Alto, CA 94304 USA	Stanford University	Puri, S (corresponding author), Stanford Univ, Dept Gen Med Disciplines, Div Palliat Med, Hosp & Clin, Palo Alto, CA 94304 USA.	sunita.puri@gmail.com							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2014	312	8					793	794		10.1001/jama.2014.6776	http://dx.doi.org/10.1001/jama.2014.6776			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AN7NX	25157720				2023-01-03	WOS:000340788500019
J	Kwon, O; Kim, KB; Lee, YI; Byun, SS; Kim, JS; Lee, SE; Hong, SK				Kwon, Ohseong; Kim, Ki Bom; Lee, Young Ik; Byun, Seok-Soo; Kim, Jae-Sung; Lee, Sang Eun; Hong, Sung Kyu			Salvage Radiotherapy after Radical Prostatectomy: Prediction of Biochemical Outcomes	PLOS ONE			English	Article							ANDROGEN-DEPRIVATION THERAPY; CANCER-SPECIFIC MORTALITY; RADIATION-THERAPY; PROGNOSTIC-FACTORS; NATURAL-HISTORY; IMPACT; RECURRENCE; MEN; PSA	Introduction: A significant proportion of patients undergoing salvage radiotherapy (RT) for biochemical recurrence (BCR) following radical prostatectomy (RP) may again experience BCR after salvage RT. Thus, we evaluated the clinical significances of different parameters on the biochemical outcome of RT in salvage setting. Methods: We reviewed the records of 212 patients who underwent salvage RT between November 2003 and December 2012 for BCR following primary RP. BCR-free survivals after salvage RT were estimated using the Kaplan-Meier method. Cox proportional hazard regression models were used to evaluate the impacts of clinicopathologic parameters on BCR following salvage RT. Results: The overall median follow-up duration was 63.5 months. The BCR-free survival rate after salvage RT was 58.2% at 5 years. Multivariate analysis showed that a pre-RT prostate-specific antigen (PSA) level of <= 0.5 ng/mL, a pre-RT PSA doubling time (PSADT) of >4.5 months, concomitant androgen deprivation therapy (ADT) with salvage RT, and a positive surgical margin were independent predictors of favorable biochemical outcomes after salvage RT (hazard ratios [HR] = 3.012, 1.132, 2.000, and 1.805, respectively, p = less than 0.001, 0.013, 0.005, and 0.036, respectively). In the early (pre-RT PSA <= 0.5 ng/mL) salvage RT setting, concomitant ADT administration was also shown to be significantly associated with higher risk of BCR-free survival following salvage RT (HR = 2.611, p = 0.038). Conclusion: Lower pre-RT PSA value, longer PSADT before salvage RT, concomitant ADT administration, and a positive surgical margin were significant predictors of favorable biochemical outcomes following salvage RT performed for BCR after primary RP.	[Kwon, Ohseong; Lee, Young Ik; Byun, Seok-Soo; Lee, Sang Eun; Hong, Sung Kyu] Seoul Natl Univ, Bundang Hosp, Dept Urol, Songnam, South Korea; [Kim, Jae-Sung] Seoul Natl Univ, Bundang Hosp, Dept Radiat Oncol, Songnam, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Hong, SK (corresponding author), Seoul Natl Univ, Bundang Hosp, Dept Urol, Songnam, South Korea.	hsk823@chol.com	Kwon, Ohseong/W-8318-2019; Kwon, OhSeong/DBV-0709-2022	Kwon, Ohseong/0000-0002-8933-6656; Kim, Jae-Sung/0000-0001-5348-9178				Blute ML, 1997, UROLOGY, V50, P733, DOI 10.1016/S0090-4295(97)00450-0; Boorjian SA, 2012, J UROLOGY, V188, P1761, DOI 10.1016/j.juro.2012.07.037; Boorjian SA, 2012, EUR UROL, V61, P664, DOI 10.1016/j.eururo.2011.11.053; Briganti A, 2013, EUR UROL IN PRESS; Buskirk SJ, 2006, J UROLOGY, V176, P985, DOI 10.1016/j.juro.2006.04.083; Bylow K, 2007, CANCER-AM CANCER SOC, V110, P2604, DOI 10.1002/cncr.23084; D'Amico AV, 2003, J NATL CANCER I, V95, P1376, DOI 10.1093/jnci/djg043; Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296; Hayashi S, 2012, J RADIAT RES, V53, P727, DOI 10.1093/jrr/rrs034; Hong SK, 2010, UROLOGY, V76, P723, DOI 10.1016/j.urology.2010.03.081; Karlin JD, 2013, J UROLOGY, V190, P1410, DOI 10.1016/j.juro.2013.04.078; Katz MS, 2003, J CLIN ONCOL, V21, P483, DOI 10.1200/JCO.2003.12.043; King CR, 2012, INT J RADIAT ONCOL, V84, P104, DOI 10.1016/j.ijrobp.2011.10.069; Kinoshita H, 2013, INT J UROL, V20, P806, DOI 10.1111/iju.12049; Lohm G, 2014, STRAHLENTHE IN PRESS; Lohm G, 2013, WORLD J UROL, V31, P423, DOI 10.1007/s00345-012-0860-y; Milecki P, 2011, CENT EUR J UROL, V64, P67, DOI 10.5173/ceju.2011.02.art3; Mottet N, 2011, EUR UROL, V59, P572, DOI 10.1016/j.eururo.2011.01.025; Mullins JK, 2012, J UROLOGY, V188, P2219, DOI 10.1016/j.juro.2012.08.028; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; Soto DE, 2012, INT J RADIAT ONCOL, V82, P1227, DOI 10.1016/j.ijrobp.2010.08.030; Stephenson AJ, 2004, JAMA-J AM MED ASSOC, V291, P1325, DOI 10.1001/jama.291.11.1325; Stephenson AJ, 2007, J CLIN ONCOL, V25, P2035, DOI 10.1200/JCO.2006.08.9607; Swanson GP, 2007, J CLIN ONCOL, V25, P2225, DOI 10.1200/JCO.2006.09.6495; Taylor LG, 2009, CANCER-AM CANCER SOC, V115, P2388, DOI 10.1002/cncr.24283; Teeter AE, 2008, J UROLOGY, V180, P1980, DOI 10.1016/j.juro.2008.07.031; Trock BJ, 2008, JAMA-J AM MED ASSOC, V299, P2760, DOI 10.1001/jama.299.23.2760; Umezawa R, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-150; van der Poel HG, 2013, UROLOGY, V82, P834, DOI 10.1016/j.urology.2013.04.057; Zhou P, 2005, J CLIN ONCOL, V23, P6992, DOI 10.1200/JCO.2005.01.2906	30	18	18	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2014	9	7							e103574	10.1371/journal.pone.0103574	http://dx.doi.org/10.1371/journal.pone.0103574			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4KU	25072938	Green Published, gold, Green Submitted			2023-01-03	WOS:000341307600065
J	Lin, J; Shigdar, S; Fang, DZ; Xiang, DX; Wei, MQ; Danks, A; Kong, LX; Li, LH; Qiao, L; Duan, W				Lin, Jia; Shigdar, Sarah; Fang, Ding Zhi; Xiang, Dognxi; Wei, Ming Q.; Danks, Andrew; Kong, Lingxue; Li, Lianghong; Qiao, Liang; Duan, Wei			Improved Efficacy and Reduced Toxicity of Doxorubicin Encapsulated in Sulfatide-Containing Nanoliposome in a Glioma Model	PLOS ONE			English	Article							STERICALLY STABILIZED LIPOSOMES; TENASCIN-C; IN-VITRO; ANTITUMOR-ACTIVITY; MULTIDRUG-RESISTANCE; EXTRACELLULAR-MATRIX; DRUG-DELIVERY; CELL-ADHESION; INDUCED CARDIOMYOPATHY; THERAPEUTIC ACTIVITY	As a glycosphingolipid that can bind to several extracellular matrix proteins, sulfatide has the potential to become an effective targeting agent for tumors overexpressing tenasin-C in their microenvironment. To overcome the dose-limiting toxicity of doxorubicin (DOX), a sulfatide-containing nanoliposome (SCN) encapsulation approach was employed to improve treatment efficacy and reduce side effects of free DOX. This study analysed in vitro characteristics of sulfatide-containing nanoliposomal DOX (SCN-DOX) and assessed its cytotoxicity in vitro, as well as biodistribution, therapeutic efficacy, and systemic toxicity in a human glioblastoma U-118MG xenograft model. SCN-DOX was shown to achieve highest drug to lipid ratio (0.5:1) and a remarkable in vitro stability. Moreover, DOX encapsulated in SCN was shown to be delivered into the nuclei and displayed prolonged retention over free DOX in U-118MG cells. This simple two-lipid SCN-DOX nanodrug has favourable pharmacokinetic attributes in terms of prolonged circulation time, reduced volume of distribution and enhanced bioavailability in healthy rats. As a result of the improved biodistribution, an enhanced treatment efficacy of SC-NDOX was found in glioma-bearing mice compared to the free drug. Finally, a reduction in the accumulation of DOX in the drug's principal toxicity organs achieved by SCN-DOX led to the diminished systemic toxicity as evident from the plasma biochemical analyses. Thus, SCN has the potential to be an effective and safer nano-carrier for targeted delivery of therapeutic agents to tumors with elevated expression of tenascin-C in their microenvironment.	[Lin, Jia; Shigdar, Sarah; Xiang, Dognxi; Duan, Wei] Deakin Univ, Fac Hlth, Sch Med, Waurn Ponds, Vic, Australia; [Lin, Jia; Fang, Ding Zhi] Sichuan Univ, West China Sch Preclin & Forens Med, Dept Biochem & Mol Biol, Chengdu 610064, Peoples R China; [Wei, Ming Q.] Griffith Univ, Sch Med Sci, Southport, Qld 4215, Australia; [Wei, Ming Q.] Griffith Univ, Griffith Hlth Inst, Southport, Qld 4215, Australia; [Danks, Andrew] Monash Univ, Southern Clin Sch, Dept Surg, Clayton, Vic, Australia; [Kong, Lingxue] Deakin Univ, Inst Frontier Mat, Waurn Ponds, Vic, Australia; [Li, Lianghong] Dalian Med Univ, Liaoning Key Lab Canc Stem Cell Res, Dalian, Peoples R China; [Qiao, Liang] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Storr Liver Unit, Westmead, NSW 2145, Australia	Deakin University; Sichuan University; Griffith University; Griffith University; Menzies Health Institute Queensland; Monash University; Deakin University; Dalian Medical University; University of Sydney; Westmead Institute for Medical Research	Duan, W (corresponding author), Deakin Univ, Fac Hlth, Sch Med, Waurn Ponds, Vic, Australia.	wduan@deakin.edu.au	Kong, Lingxue/D-8216-2011; Shigdar, Sarah/AFR-0438-2022; Duan, Wei/A-5181-2015	Kong, Lingxue/0000-0001-6219-3897; Duan, Wei/0000-0001-5782-9184; Shigdar, Sarah/0000-0001-8084-8447	National Health and Medical Research Council, Australia [479505]; Australia-India Strategic Research Fund Programme-Indo-Australia Science and Technology Fund [ST040007]	National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia); Australia-India Strategic Research Fund Programme-Indo-Australia Science and Technology Fund(Australian GovernmentDepartment of Industry, Innovation and Science)	This work was supported by a grants from National Health and Medical Research Council, Australia (#479505), www.nhmrc.gov.au and Australia-India Strategic Research Fund Programme-Indo-Australia Science and Technology Fund (#ST040007), http://www.innovation.gov.au/Science/InternationalCollaboration/aisrf/Pages/default.aspx. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams M, 2002, CANCER RES, V62, P3289; Adamsky K, 2001, ONCOGENE, V20, P609, DOI 10.1038/sj.onc.1204119; Alexis F, 2008, UROL ONCOL-SEMIN ORI, V26, P74, DOI 10.1016/j.urolonc.2007.03.017; Allen Theresa M., 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P513, DOI 10.2174/187152006778699121; Alvarez-Cedron L, 1999, J CHROMATOGR B, V721, P271, DOI 10.1016/S0378-4347(98)00475-7; Bagchi DB, 2003, MUTAT RES-FUND MOL M, V523, P87, DOI 10.1016/S0027-5107(02)00324-X; Bawarski WE, 2008, NANOMED-NANOTECHNOL, V4, P273, DOI 10.1016/j.nano.2008.06.002; Cabanes A, 1999, CLIN CANCER RES, V5, P687; Campbell Robert B., 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P503, DOI 10.2174/187152006778699077; Charrois GJR, 2003, BBA-BIOMEMBRANES, V1609, P102, DOI 10.1016/S0005-2736(02)00661-2; Chen MH, 2010, ANTICANCER RES, V30, P65; Chen ZY, 2012, INT J NANOMED, V7, P3803, DOI 10.2147/IJN.S33541; Cheng Cai, 2009, Interact Cardiovasc Thorac Surg, V8, P635, DOI 10.1510/icvts.2008.194720; Cosan D, 2008, FOLIA HISTOCHEM CYTO, V46, P367, DOI 10.2478/v10042-008-0048-x; Cui J, 2008, J PHARM PHARMACOL, V60, P1651, DOI 10.1211/jpp/60.12.0011; de Menezes DEL, 2000, CLIN CANCER RES, V6, P2891; Drummond DC, 1999, PHARMACOL REV, V51, P691; El Bayoumil T, 2009, CLIN CANCER RES, V15, P1973, DOI 10.1158/1078-0432.CCR-08-2392; Farr KP, 2011, CASE REP ONCOL, V4, P229, DOI 10.1159/000327767; Fernando NT, 2008, CLIN CANCER RES, V14, P1529, DOI 10.1158/1078-0432.CCR-07-4126; Foti C, 2009, MOL CANCER THER, V8, P3140, DOI 10.1158/1535-7163.MCT-09-0431; Fritze A, 2006, BBA-BIOMEMBRANES, V1758, P1633, DOI 10.1016/j.bbamem.2006.05.028; Ganta S, 2008, J CONTROL RELEASE, V126, P187, DOI 10.1016/j.jconrel.2007.12.017; Goren D, 1996, BRIT J CANCER, V74, P1749, DOI 10.1038/bjc.1996.625; Hancox RA, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2251; Herman EH, 1999, J CLIN ONCOL, V17, P2237, DOI 10.1200/JCO.1999.17.7.2237; HERNANDEZ J, 1991, BIOCONJUGATE CHEM, V2, P398, DOI 10.1021/bc00012a003; Huang Y, 2010, AAPS PHARMSCITECH, V11, P752, DOI 10.1208/s12249-010-9430-z; Hussain S, 2007, MOL CANCER THER, V6, P3019, DOI 10.1158/1535-7163.MCT-07-0615; Ishida T, 2002, INT J PHARMACEUT, V232, P59, DOI 10.1016/S0378-5173(01)00896-1; Jung SH, 2009, INT J PHARMACEUT, V382, P254, DOI 10.1016/j.ijpharm.2009.08.002; Koh E, 2004, CIRC J, V68, P163, DOI 10.1253/circj.68.163; Li B, 2012, INT J NANOMED, V7, P187, DOI 10.2147/IJN.S27864; Li XM, 2009, INT J PHARMACEUT, V373, P116, DOI 10.1016/j.ijpharm.2009.01.023; Lim HJ, 1997, J PHARMACOL EXP THER, V281, P566; Lin J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049277; Liu F, 2008, NEOPLASIA, V10, P1275, DOI 10.1593/neo.08810; Mackie EJ, 1999, J CELL SCI, V112, P3847; MAYER LD, 1989, CANCER RES, V49, P5922; Mercuro G, 2007, ONCOLOGIST, V12, P1124, DOI 10.1634/theoncologist.12-9-1124; Orend G, 2006, CANCER LETT, V244, P143, DOI 10.1016/j.canlet.2006.02.017; Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387; Quemener C, 2007, CANCER RES, V67, P9, DOI 10.1158/0008-5472.CAN-06-2448; RAHMAN A, 1986, CANCER RES, V46, P2295; Rai S, 2008, J DRUG TARGET, V16, P455, DOI 10.1080/10611860802088481 ; Reardon DA, 2007, EXPERT REV ANTICANC, V7, P675, DOI 10.1586/14737140.7.5.675; Sadzuka Y, 2003, J CONTROL RELEASE, V91, P271, DOI 10.1016/S0168-3659(03)00248-7; Sapra Puja, 2005, Current Drug Delivery, V2, P369, DOI 10.2174/156720105774370159; Shao K, 2006, J CONTROL RELEASE, V115, P150, DOI 10.1016/j.jconrel.2006.07.024; Shmeeda H, 2010, J CONTROL RELEASE, V146, P76, DOI 10.1016/j.jconrel.2010.04.028; Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307; Song HF, 2006, CANCER CHEMOTH PHARM, V57, P591, DOI 10.1007/s00280-005-0076-6; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; Sugiyama Ikumi, 2011, Curr Drug Discov Technol, V8, P357; Tanaka T, 2010, CANCER RES, V70, P3687, DOI 10.1158/0008-5472.CAN-09-3931; Tang N, 2007, JNCI-J NATL CANCER I, V99, P1004, DOI 10.1093/jnci/djm027; Tokarska-Schlattner M, 2005, AM J PHYSIOL-HEART C, V289, pH37, DOI 10.1152/ajpheart.01057.2004; Townson K, 2007, GLYCOBIOLOGY, V17, P1156, DOI 10.1093/glycob/cwm095; UNEZAKI S, 1994, PHARMACEUT RES, V11, P1180, DOI 10.1023/A:1018949218380; Wang JC, 2005, BIOL PHARM BULL, V28, P822, DOI 10.1248/bpb.28.822; Wei GL, 2008, BIOMED CHROMATOGR, V22, P1252, DOI 10.1002/bmc.1054; Wu J, 2007, J PHARM PHARM SCI, V10, P350; Wu XF, 1999, BBA-BIOMEMBRANES, V1416, P285, DOI 10.1016/S0005-2736(98)00229-6; Xiong XB, 2005, J CONTROL RELEASE, V107, P262, DOI 10.1016/j.jconrel.2005.03.030; Xiong XB, 2005, PHARM RES-DORDR, V22, P933, DOI 10.1007/s11095-005-4588-x; Xu L, 2011, J PHARM SCI-US, V100, P38, DOI 10.1002/jps.22243; Yokogwa K, 2006, BIOL PHARM BULL, V29, P141, DOI 10.1248/bpb.29.141; Zhang FY, 2009, PHARM RES-DORDR, V26, P914, DOI 10.1007/s11095-008-9793-y; Zhu QQ, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-65	69	15	15	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2014	9	7							e103736	10.1371/journal.pone.0103736	http://dx.doi.org/10.1371/journal.pone.0103736			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4KU	25072631	Green Submitted, Green Published, gold			2023-01-03	WOS:000341307600082
J	Dinh, J; Angeloni, JT; Pederson, DB; Wang, XX; Cao, M; Dong, YQ				Dinh, Jessica; Angeloni, Joseph T.; Pederson, Daniel B.; Wang, Xiaoxia; Cao, Min; Dong, Yuqing			Cranberry Extract Standardized for Proanthocyanidins Promotes the Immune Response of Caenorhabditis elegans to Vibrio cholerae through the p38 MAPK Pathway and HSF-1	PLOS ONE			English	Article							VIRULENCE GENE-EXPRESSION; EL-TOR BIOTYPE; HEAT-SHOCK; TEMPORAL REQUIREMENTS; MODEL HOST; LIFE-SPAN; GROWTH; MUTANT; PHYTOCHEMICALS; STERILIZATION	Botanicals are rich in bioactive compounds and some offer numerous beneficial effects to animal and human consumed. It is well known that phytochemicals in cranberries have anti-oxidative and antimicrobial activities. Recently, an increasing body of evidence has demonstrated that cranberry phytochemicals may have potential benefits that promote healthy aging. Here, we use Caenarhabditis elegans as a model to show that water-soluble cranberry extract standardized to 4.0% proanthocyanidins (WCESP), a major component of cranberries, can enhance host innate immunity resist against Vibro cholerae (V. cholerae; wild type C6706 (O1 El Tor biotype)) infection. Supplementationof WCESPdid not significantly alter the intestinal colonization of V. cholerae, but upregulated the expression of C. elegans innate immune genes, such as clec-7 clec-71, fmo-2, pqn-5 and C23G10.1. Additionally, WCESP treatment did not affect the growth of V. cholerae and expression of he major bacterial virulence genes, and only slightly reduced bacterial colonization within C. elegans intestine. These findings indicate that the major components Of WCESP, including proanthocyanidins (PACs), may play an important role in enhancing the host innate immunity. Moreover, we engaged C. elegans mutants and identified that the p38 MAPK signaling, insulin/IGF-1 signaling (IIS), and HSF-1 play pivotal roles in the WCESP-mediated host immune response. Considering the level of conservation between the innate immune pathways of C. elegans and humans, the results of this study suggest that WCESP may also play an immunity-promoting role in higher order organism.	[Dinh, Jessica; Angeloni, Joseph T.; Pederson, Daniel B.; Wang, Xiaoxia; Cao, Min; Dong, Yuqing] Clemson Univ, Dept Biol Sci, Clemson, SC 29634 USA; [Cao, Min; Dong, Yuqing] Clemson Univ, Inst Engaged Aging, Clemson, SC 29634 USA	Clemson University; Clemson University	Cao, M (corresponding author), Clemson Univ, Dept Biol Sci, Clemson, SC 29634 USA.	mcao@clemson.edu; ydong@clemson.edu	Cao, Min/A-3532-2013	Cao, Min/0000-0003-1592-8111				ALM RA, 1991, J CLIN MICROBIOL, V29, P2438, DOI 10.1128/JCM.29.11.2438-2445.1991; Blumberg JB, 2013, ADV NUTR, V4, P618, DOI 10.3945/an.113.004473; Bradford PG, 2013, BIOFACTORS, V39, P78, DOI 10.1002/biof.1074; Chiang WC, 2012, CELL, V148, P322, DOI 10.1016/j.cell.2011.12.019; Cinar HN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011558; Cohen E, 2010, AGING CELL, V9, P126, DOI 10.1111/j.1474-9726.2009.00541.x; Engelmann I, 2010, ADV EXP MED BIOL, V708, P105; Ferguson PJ, 2006, NUTR CANCER, V56, P86, DOI 10.1207/s15327914nc5601_12; GANDHI S, 1980, MECH AGEING DEV, V12, P137, DOI 10.1016/0047-6374(80)90090-1; Gardel CL, 1996, INFECT IMMUN, V64, P2246, DOI 10.1128/IAI.64.6.2246-2255.1996; Garsin DA, 2003, SCIENCE, V300, P1921, DOI 10.1126/science.1080147; Gonzalez-Vallinas M, 2013, NUTR REV, V71, P585, DOI 10.1111/nure.12051; Guha S, 2014, NUTRIENTS, V6, P911, DOI 10.3390/nu6020911; Guha S, 2013, AGE, V35, P1559, DOI 10.1007/s11357-012-9459-x; HOSONO R, 1978, EXP GERONTOL, V13, P369, DOI 10.1016/0531-5565(78)90047-5; HOSONO R, 1982, EXP GERONTOL, V17, P163, DOI 10.1016/0531-5565(82)90052-3; Howell AB, 2005, PHYTOCHEMISTRY, V66, P2281, DOI 10.1016/j.phytochem.2005.05.022; Hsiao JY, 2013, J MICROBIOL, V51, P367, DOI 10.1007/s12275-013-2589-8; Joshua GWP, 2003, MICROBIOL-SGM, V149, P3221, DOI 10.1099/mic.0.26475-0; Kim DH, 2002, SCIENCE, V297, P623, DOI 10.1126/science.1073759; Krueger CG, 2013, ANAL BIOANAL CHEM, V405, P4385, DOI 10.1007/s00216-013-6750-3; Kurz CL, 2003, NAT REV GENET, V4, P380, DOI 10.1038/nrg1067; Labrousse A, 2000, CURR BIOL, V10, P1543, DOI 10.1016/S0960-9822(00)00833-2; Liu Y, 2008, EMBO J, V27, P1049, DOI 10.1038/emboj.2008.42; Liu Z, 2011, P NATL ACAD SCI USA, V108, P810, DOI 10.1073/pnas.1014640108; Mahajan-Miklos S, 1999, CELL, V96, P47, DOI 10.1016/S0092-8674(00)80958-7; Marsh EK, 2012, APPL ENVIRON MICROB, V78, P2075, DOI 10.1128/AEM.07486-11; MITCHELL DH, 1979, J GERONTOL, V34, P28, DOI 10.1093/geronj/34.1.28; Moy TI, 2006, P NATL ACAD SCI USA, V103, P10414, DOI 10.1073/pnas.0604055103; Muralidharan S, 2013, J LEUKOCYTE BIOL, V94, P1167, DOI 10.1189/jlb.0313153; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Neto CC, 2007, MOL NUTR FOOD RES, V51, P652, DOI 10.1002/mnfr.200600279; Neto CC, 2007, J NUTR, V137, p186S, DOI 10.1093/jn/137.1.186S; Neto CC, 2011, J SCI FOOD AGR, V91, P2303, DOI 10.1002/jsfa.4621; Pappas E, 2009, CRIT REV FOOD SCI, V49, P741, DOI 10.1080/10408390802145377; Ray S, 2011, INFECT IMMUN, V79, P258, DOI 10.1128/IAI.00663-10; Sacco SM, 2013, BRIT J CLIN PHARMACO, V75, P697, DOI 10.1111/bcp.12033; Sahu SN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038200; Scalbert A, 2005, CRIT REV FOOD SCI, V45, P287, DOI 10.1080/1040869059096; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schulenburg H, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-49; Shivers RP, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000892; Shmuely H, 2012, CURR OPIN BIOTECH, V23, P148, DOI 10.1016/j.copbio.2011.10.009; Sies H, 2010, ARCH BIOCHEM BIOPHYS, V501, P2, DOI 10.1016/j.abb.2010.04.006; Sifri CD, 2003, INFECT IMMUN, V71, P2208, DOI 10.1128/IAI.71.4.2208-2217.2003; Singh V, 2006, CELL CYCLE, V5, P2443, DOI 10.4161/cc.5.21.3434; Singh V, 2006, P NATL ACAD SCI USA, V103, P13092, DOI 10.1073/pnas.0604050103; Son MS, 2011, J CLIN MICROBIOL, V49, P3739, DOI 10.1128/JCM.01286-11; Sun YN, 2014, EXP GERONTOL, V50, P57, DOI 10.1016/j.exger.2013.11.020; Tan MW, 1999, P NATL ACAD SCI USA, V96, P715, DOI 10.1073/pnas.96.2.715; Thelin KH, 1996, INFECT IMMUN, V64, P2853, DOI 10.1128/IAI.64.7.2853-2856.1996; Troemel ER, 2006, PLOS GENET, V2, P1725, DOI 10.1371/journal.pgen.0020183; Vaitkevicius K, 2006, P NATL ACAD SCI USA, V103, P9280, DOI 10.1073/pnas.0601754103; Volovik Y, 2012, AGING CELL, V11, P491, DOI 10.1111/j.1474-9726.2012.00811.x; Wang C, 2013, J GERONTOL A; Weisberg SP, 2008, ENDOCRINOLOGY, V149, P3549, DOI 10.1210/en.2008-0262; Wilson T, 1998, LIFE SCI, V62, pPL381; Zhu J, 2002, P NATL ACAD SCI USA, V99, P3129, DOI 10.1073/pnas.052694299; Zou S, 2012, AGE, V34, P269, DOI 10.1007/s11357-011-9230-8; Zugasti O, 2009, NAT IMMUNOL, V10, P249, DOI 10.1038/ni.1700	60	24	24	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2014	9	7							e103290	10.1371/journal.pone.0103290	http://dx.doi.org/10.1371/journal.pone.0103290			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6RP	25062095	Green Published, Green Submitted, gold			2023-01-03	WOS:000339992600053
J	Enarson, PM; Gie, RP; Mwansambo, CC; Maganga, ER; Lombard, CJ; Enarson, DA; Graham, SM				Enarson, Penelope M.; Gie, Robert P.; Mwansambo, Charles C.; Maganga, Ellubey R.; Lombard, Carl J.; Enarson, Donald A.; Graham, Stephen M.			Reducing Deaths from Severe Pneumonia in Children in Malawi by Improving Delivery of Pneumonia Case Management	PLOS ONE			English	Article							DEVELOPING-COUNTRIES; CHILDHOOD PNEUMONIA; AFRICAN CHILDREN; DISEASE; TUBERCULOSIS; MORTALITY; INFECTION; ETIOLOGY; MALARIA	Objective: To evaluate the pneumonia specific case fatality rate over time following the implementation of a Child Lung Health Programme (CLHP) within the existing government health services in Malawi to improve delivery of pneumonia case management. Methods: A prospective, nationwide public health intervention was studied to evaluate the impact on pneumonia specific case fatality rate (CFR) in infants and young children (0 to 59 months of age) following the implementation of the CLHP. The implementation was step-wise from October 1st 2000 until 31st December 2005 within paediatric inpatient wards in 24 of 25 district hospitals in Malawi. Data analysis compared recorded outcomes in the first three months of the intervention (the control period) to the period after that, looking at trend over time and variation by calendar month, age group, severity of disease and region of the country. The analysis was repeated standardizing the follow-up period by using only the first 15 months after implementation at each district hospital. Findings: Following implementation, 47,228 children were admitted to hospital for severe/very severe pneumonia with an overall CFR of 9N8%. In both analyses, the highest CFR was in the children 2 to 11 months, and those with very severe pneumonia. The majority (64%) of cases, 2-59 months, had severe pneumonia. In this group there was a significant effect of the intervention Odds Ratio (OR) 0N70 (95% CI: 0.50-0.98); p = 0.036), while in the same age group children treated for very severe pneumonia there was no interventional benefit (OR 0.97 (95% CI: 0.72-1.30); p = 0.8). No benefit was observed for neonates (OR 0.83 (95% CI: 0.56-1.22); p = 0.335). Conclusions: The nationwide implementation of the CLHP significantly reduced CFR in Malawian infants and children (2-59 months) treated for severe pneumonia. Reasons for the lack of benefit for neonates, infants and children with very severe pneumonia requires further research.	[Enarson, Penelope M.; Enarson, Donald A.; Graham, Stephen M.] Int Union TB & Lung Dis, Child Lung Hlth Div, Paris, France; [Enarson, Penelope M.; Enarson, Donald A.] Univ Stellenbosch, Desmond Tutu TB Ctr, Dept Paediat & Child Hlth, Fac Med & Hlth Sci, ZA-7505 Tygerberg, South Africa; [Gie, Robert P.] Univ Stellenbosch, Dept Paediat & Child Hlth, Fac Med & Hlth Sci, ZA-7505 Tygerberg, South Africa; [Mwansambo, Charles C.] Minist Hlth, Lilongwe, Malawi; [Maganga, Ellubey R.] UNICEF Malawi, Lilongwe, Malawi; [Lombard, Carl J.] South Africa Med Res Council MRC, Biostat Unit, Cape Town, South Africa; [Graham, Stephen M.] Univ Melbourne, Ctr Int Child Hlth, Dept Paediat, Melbourne, Vic, Australia; [Graham, Stephen M.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia	Stellenbosch University; Stellenbosch University; University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Enarson, PM (corresponding author), Int Union TB & Lung Dis, Child Lung Hlth Div, Paris, France.	penarson@theunion.org		Lombard, Carl/0000-0002-2136-6533; Graham, Stephen/0000-0003-3525-2294	MoH of Malawi; Bill and Melinda Gates Foundation [413]	MoH of Malawi; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	The CLHP was primarly funded by the MoH of Malawi, who contributed 69% of the running costs comprising facilities and human resources that are part of the existing health system. The Bill and Melinda Gates Foundation funded the remaining 31% of the costs, 21% of which was investment and 79% operating costs. The Bill & Melinda Gates Foundation grant ID#: 413 http://www.gatesfoundation.org/Pages/home.aspx). The external funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2005, HOSP CAR CHILDR GUID; Ayieko P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047622; Bronzan RN, 2007, J INFECT DIS, V195, P895, DOI 10.1086/511437; Bukhman G, 2008, AM J PUBLIC HEALTH, V98, P44, DOI 10.2105/AJPH.2007.110841; Chisti MJ, 2009, TROP MED INT HEALTH, V14, P1173, DOI 10.1111/j.1365-3156.2009.02364.x; Duke T, 2008, LANCET, V372, P1328, DOI 10.1016/S0140-6736(08)61164-2; Ellis J, 2007, ANN TROP PAEDIATR, V27, P261, DOI 10.1179/146532807X245643; ENARSON DA, 1995, TUBERCLE LUNG DIS, V76, P95, DOI 10.1016/0962-8479(95)90548-0; Enarson P, 2000, INTEGRATED CHILD LUN; Enarson PM, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000137; Enarson P, 2008, B WORLD HEALTH ORGAN, V86, P344, DOI 10.2471/BLT.07.048017; Enarson Penny M, 2010, Expert Rev Respir Med, V4, P211, DOI 10.1586/ers.10.14; Enarson PM, 2005, GUIDE LOW INCOME COU; Everett DB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044250; Gonani A, 2005, IMPACT HIV AIDS HLTH; Gordon MA, 2008, CLIN INFECT DIS, V46, P963, DOI 10.1086/529146; Government of Malawi, 2001, MAL DEM HLTH SURV 20; Government of Malawi, 1999, MAL 4 NATL HLTH PLAN; Government of Malawi, 2005, INT HOUS SURV 2004 2; Government of Malawi, 2011, MAL DEM HLTH SURV 20; Graham SM, 2000, LANCET, V355, P369, DOI 10.1016/S0140-6736(98)11074-7; Graham SM, 2001, INT J TUBERC LUNG D, V5, P12; Graham SM, 2011, PEDIATR INFECT DIS J, V30, P33, DOI 10.1097/INF.0b013e3181fcabe4; Graham SM, 2009, LANCET, V373, P267, DOI 10.1016/S0140-6736(09)60073-8; Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1; McNally LM, 2007, LANCET, V369, P1440, DOI 10.1016/S0140-6736(07)60670-9; Nantongo JM, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-16; National AIDS Control Commission Malawi, 2001, EST NAT HIV PREV MAL; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; ONeil M, 2010, EVALUATION MALAWIS E; Reed C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0027793; Rice AL, 2000, B WORLD HEALTH ORGAN, V78, P1207; Roca-Feltrer A, 2012, EMERG INFECT DIS, V18, P272, DOI 10.3201/eid1802.111008; Rogerson SR, 2004, T ROY SOC TROP MED H, V98, P544, DOI 10.1016/j.trstmh.2003.12.011; SHANN F, 1984, B WORLD HEALTH ORGAN, V62, P749; Theodoratou E, 2010, INT J EPIDEMIOL, V39, P155, DOI 10.1093/ije/dyq032; UNICEF, 2012, STAT WORLDS CHILDR 2; UNICEF, 2002, SENT SURV REP; United Nations Childrens Fund, 2007, STAT WORLDS CHILDR 2; *WORLD BANK, 1993, WORLD DEV REP 1993 I; World Health Organization, 2013, POCK BOOK HOSP CAR C; World Health Organization UNICEF, 2000, MAN CHILD SER INF SE	42	27	27	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2014	9	7							e102955	10.1371/journal.pone.0102955	http://dx.doi.org/10.1371/journal.pone.0102955			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM0QO	25050894	Green Published, gold			2023-01-03	WOS:000339551100070
J	Guo, L; Shen, SM; Harris, E; Wang, Z; Jiang, W; Guo, Y; Feng, YM				Guo, Lu; Shen, Shuming; Harris, Eleanor; Wang, Zheng; Jiang, Wei; Guo, Yu; Feng, Yuanming			A Tri-Modality Image Fusion Method for Target Delineation of Brain Tumors in Radiotherapy	PLOS ONE			English	Article							CLINICAL-EXPERIENCE; VOLUME DELINEATION; OBSERVER VARIATION; PET; CT; THERAPY; SYSTEM	Purpose: To develop a tri-modality image fusion method for better target delineation in image-guided radiotherapy for patients with brain tumors. Methods: A new method of tri-modality image fusion was developed, which can fuse and display all image sets in one panel and one operation. And a feasibility study in gross tumor volume (GTV) delineation using data from three patients with brain tumors was conducted, which included images of simulation CT, MRI, and F-18-fluorodeoxyglucose positron emission tomography (F-18-FDG PET) examinations before radiotherapy. Tri-modality image fusion was implemented after image registrations of CT+PET and CT+MRI, and the transparency weight of each modality could be adjusted and set by users. Three radiation oncologists delineated GTVs for all patients using dual-modality (MRI/CT) and tri-modality (MRI/CT/PET) image fusion respectively. Inter-observer variation was assessed by the coefficient of variation (COV), the average distance between surface and centroid (ADSC), and the local standard deviation (SDlocal). Analysis of COV was also performed to evaluate intra-observer volume variation. Results: The inter-observer variation analysis showed that, the mean COV was 0.14(+/- 0.09) and 0.07(+/- 0.01) for dual-modality and tri-modality respectively; the standard deviation of ADSC was significantly reduced (p<0.05) with tri-modality; SDlocal averaged over median GTV surface was reduced in patient 2 (from 0.57 cm to 0.39 cm) and patient 3 (from 0.42 cm to 0.36 cm) with the new method. The intra-observer volume variation was also significantly reduced (p = 0.00) with the tri-modality method as compared with using the dual-modality method. Conclusion: With the new tri-modality image fusion method smaller inter-and intra-observer variation in GTV definition for the brain tumors can be achieved, which improves the consistency and accuracy for target delineation in individualized radiotherapy.	[Guo, Lu; Shen, Shuming; Guo, Yu; Feng, Yuanming] Tianjin Univ, Dept Biomed Engn, Tianjin 300072, Peoples R China; [Harris, Eleanor; Feng, Yuanming] E Carolina Univ, Dept Radiat Oncol, Greenville, NC USA; [Wang, Zheng; Jiang, Wei] Tianjin Huanhu Hosp, Dept Radiat Oncol, Tianjin, Peoples R China	Tianjin University; University of North Carolina; East Carolina University	Feng, YM (corresponding author), Tianjin Univ, Dept Biomed Engn, Tianjin 300072, Peoples R China.	fengyu@ecu.edu		Harris, Eleanor/0000-0002-7529-7473				Caldwell CB, 2001, INT J RADIAT ONCOL, V51, P923, DOI 10.1016/S0360-3016(01)01722-9; Chen W, 2007, J NUCL MED, V48, P1468, DOI 10.2967/jnumed.106.037689; Deurloo KEI, 2005, INT J RADIAT ONCOL, V61, P228, DOI 10.1016/j.ijrobp.2004.09.023; Dirix P, 2009, J NUCL MED, V50, P1020, DOI 10.2967/jnumed.109.062638; Goldman S, 2011, MED NUCL, V35, P347, DOI 10.1016/j.mednuc.2011.02.003; Graf R, 2013, INT J RADIAT ONCOL, V85, P68, DOI 10.1016/j.ijrobp.2012.03.021; Grosu AL, 2005, INT J RADIAT ONCOL, V63, P64, DOI 10.1016/j.ijrobp.2005.01.045; Grosu AL, 2003, INT J RADIAT ONCOL, V56, P1450, DOI 10.1016/S0360-3016(03)00279-7; Grosu AL, 2010, RADIOTHER ONCOL, V96, P325, DOI 10.1016/j.radonc.2010.08.001; Grosu AL, 2006, INT J RADIAT ONCOL, V66, P339, DOI 10.1016/j.ijrobp.2006.02.047; Levivier M, 2004, J NUCL MED, V45, P1146; Lorensen C.H.E., 1987, ACM SIGGRAPH COMPUTE, V21, DOI 10.1145/37401.37422; Newell ME, 1972, P ACM ANN C, V1, P443; Rogers DF, 1998, PROCEDURAL ELEMENTS, P498; Steenbakkers RJHM, 2006, INT J RADIAT ONCOL, V64, P435, DOI 10.1016/j.ijrobp.2005.06.034; Veit-Haibach P, 2013, MAGN RESON MATER PHY, V26, P25, DOI 10.1007/s10334-012-0344-5; Verellen D, 2008, RADIOTHER ONCOL, V86, P4, DOI 10.1016/j.radonc.2007.11.023	17	7	7	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2014	9	11							e112187	10.1371/journal.pone.0112187	http://dx.doi.org/10.1371/journal.pone.0112187			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS6XM	25375123	Green Published, gold, Green Submitted			2023-01-03	WOS:000344402600115
J	Jones, CM; Lurie, P; Woodcock, J				Jones, Christopher M.; Lurie, Peter; Woodcock, Janet			Addressing Prescription Opioid Overdose Data Support a Comprehensive Policy Approach	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MORTALITY; DEATHS		[Jones, Christopher M.; Lurie, Peter] US FDA, Off Commissioner, Silver Spring, MD 20993 USA; [Woodcock, Janet] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Jones, CM (corresponding author), US FDA, Off Commissioner, 10903 New Hampshire Ave,WO32 RM4220, Silver Spring, MD 20993 USA.	Christopher.M.Jones@fda.hhs.gov						Authority OH, OREGON PRESCRIPTION; Centers for Disease Control and Prevention (CDC), 2013, ADD PRESCR DRUG AB U; Dhalla IA, 2011, CAN FAM PHYSICIAN, V57, pE92; Franklin GM, 2012, AM J IND MED, V55, P325, DOI 10.1002/ajim.21998; IMS Health, 2014, NATL PRESCR AUD; Johnson H, 2014, MMWR-MORBID MORTAL W, V63, P569; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Rosenblum A, 2007, DRUG ALCOHOL DEPEN, V90, P64, DOI 10.1016/j.drugalcdep.2007.02.012; US Food and Drug Administration (FDA), GUID IND AB IN PRESS; US Food and Drug Administration (FDA), 2012, AN AN DRUG PROD ADV	10	28	28	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	2014	312	17					1733	1734		10.1001/jama.2014.13480	http://dx.doi.org/10.1001/jama.2014.13480			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AS3QX	25275855				2023-01-03	WOS:000344194500006
J	Thompson, ACS; Bruss, MD; Nag, N; Kharitonenkov, A; Adams, AC; Hellerstein, MK				Thompson, Airlia C. S.; Bruss, Matthew D.; Nag, Nitish; Kharitonenkov, Alexei; Adams, Andrew C.; Hellerstein, Marc K.			Fibroblast Growth Factor 21 Is Not Required for the Reductions in Circulating Insulin-Like Growth Factor-1 or Global Cell Proliferation Rates in Response to Moderate Calorie Restriction in Adult Mice	PLOS ONE			English	Article							INCREASES ENERGY-EXPENDITURE; FATAL NEOPLASTIC DISEASES; IGF-BINDING-PROTEINS; LIFE-SPAN EXTENSION; DIETARY RESTRICTION; PPAR-ALPHA; DELAYED OCCURRENCE; FACTOR SYSTEM; DWARF MICE; HORMONE	Calorie restriction (CR) delays aging and extends lifespan in numerous organisms, including mice. Down-regulation of the somatotropic axis, including a reduction in insulin-like growth factor-1 (IGF-1), likely plays an important role in CR-induced lifespan extension, possibly by reducing cell proliferation rates, thereby delaying replicative senescence and inhibiting tumor promotion. Accordingly, elucidating the mechanism(s) by which IGF-1 is reduced in response to CR holds therapeutic potential in the fight against age-related diseases. Up-regulation of fibroblast growth factor 21 (FGF21) is one possible mechanism given that FGF21 expression is induced in response to nutritional deprivation and has been implicated as a negative regulator of IGF-1 expression. Here we investigated alterations in hepatic growth hormone (GH)-mediated IGF-1 production and signaling as well as the role of FGF21 in the regulation of IGF-1 levels and cell proliferation rates in response to moderate CR in adult mice. We found that in response to moderate CR, circulating GH and hepatic janus kinase 2 (JAK2) phosphorylation levels are unchanged but that hepatic signal transducer and activator of transcription 5 (STAT5) phosphorylation levels are reduced, identifying STAT5 phosphorylation as a potential key site of CR action within the somatotropic axis. Circadian measurements revealed that the relative level of FGF21 expression is both higher and lower in CR vs. ad libitum (AL)-fed mice, depending on the time of measurement. Employing FGF21-knockout mice, we determined that FGF21 is not required for the reduction in IGF-1 levels or cell proliferation rates in response to moderate CR. However, compared to AL-fed WT mice, AL-fed FGF21-knockout mice exhibited higher basal rates of cell proliferation, suggesting antimitotic effects of FGF21. This work provides insights into both GH-mediated IGF-1 production in the context of CR and the complex network that regulates FGF21 and IGF-1 expression and cell proliferation rates in response to nutritional status.	[Thompson, Airlia C. S.; Bruss, Matthew D.; Nag, Nitish; Hellerstein, Marc K.] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; [Kharitonenkov, Alexei; Adams, Andrew C.] Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA; [Hellerstein, Marc K.] KineMed Inc, Emeryville, CA USA	University of California System; University of California Berkeley; Eli Lilly	Thompson, ACS (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA.	airlia.thompson@gmail.com; march@berkeley.edu	Nag, Nitish/H-8033-2016	Nag, Nitish/0000-0002-8409-1223	College of Natural Resources at the University of California at Berkeley; KineMed, Inc.; Lilly Research Laboratories (Lilly Corporate Center, Indianapolis, Indiana); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK061918, P30DK026743] Funding Source: NIH RePORTER	College of Natural Resources at the University of California at Berkeley; KineMed, Inc.; Lilly Research Laboratories (Lilly Corporate Center, Indianapolis, Indiana); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This research was supported by funding from the College of Natural Resources at the University of California at Berkeley. MKH is an employee of KineMed, Inc., and received salary from them. ACA is currently and AK was previously employed at Lilly Research Laboratories (Lilly Corporate Center, Indianapolis, Indiana). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams AC, 2013, MOL METAB, V2, P205, DOI 10.1016/j.molmet.2013.05.005; Alderman JM, 2010, GERONTOLOGY, V56, P404, DOI 10.1159/000235720; Alderman JM, 2009, EXP GERONTOL, V44, P26, DOI 10.1016/j.exger.2008.05.014; ARMARIO A, 1987, ANN NUTR METAB, V31, P81, DOI 10.1159/000177254; Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002; Badman MK, 2009, ENDOCRINOLOGY, V150, P4931, DOI 10.1210/en.2009-0532; Berglund ED, 2009, ENDOCRINOLOGY, V150, P4084, DOI 10.1210/en.2009-0221; BIELSCHOWSKY F, 1961, BRIT J CANCER, V15, P257, DOI 10.1038/bjc.1961.32; Boisclair YR, 2001, J ENDOCRINOL, V170, P63, DOI 10.1677/joe.0.1700063; Bruss MD, 2011, AM J PHYSIOL-ENDOC M, V300, pE735, DOI 10.1152/ajpendo.00661.2010; Bruss MD, 2010, AM J PHYSIOL-ENDOC M, V298, pE108, DOI 10.1152/ajpendo.00524.2009; Busch R, 2007, NAT PROTOC, V2, P3045, DOI 10.1038/nprot.2007.420; Chacon F, 2005, CHRONOBIOL INT, V22, P253, DOI 10.1081/CBI-200053522; Coskun T, 2008, ENDOCRINOLOGY, V149, P6018, DOI 10.1210/en.2008-0816; de Magalhaes JP, 2008, BIOESSAYS, V30, P567, DOI 10.1002/bies.20760; Dunn SE, 1997, CANCER RES, V57, P4667; Ferry RJ, 1999, HORM RES, V51, P53; Fisher FM, 2010, DIABETES, V59, P2781, DOI 10.2337/db10-0193; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; Fontana L, 2008, AGING CELL, V7, P681, DOI 10.1111/j.1474-9726.2008.00417.x; Heilbronn LK, 2003, AM J CLIN NUTR, V78, P361, DOI 10.1093/ajcn/78.3.361; Herington A, 2012, OPEN ENDOCRINOL J, V6, P13, DOI DOI 10.2174/1874216501206010013; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; Hotta Y, 2009, ENDOCRINOLOGY, V150, P4625, DOI 10.1210/en.2009-0119; Hsieh EA, 2005, AM J PHYSIOL-ENDOC M, V288, pE965, DOI 10.1152/ajpendo.00368.2004; Huang XQ, 2006, MOL CARCINOGEN, V45, P934, DOI 10.1002/mc.20241; HURSTING SD, 1993, CANCER RES, V53, P2750; Ikeno Y, 2003, J GERONTOL A-BIOL, V58, P291; Ikeno Y, 2009, J GERONTOL A-BIOL, V64, P522, DOI 10.1093/gerona/glp017; Inagaki T, 2008, CELL METAB, V8, P77, DOI 10.1016/j.cmet.2008.05.006; Inagaki T, 2007, CELL METAB, V5, P415, DOI 10.1016/j.cmet.2007.05.003; Katewa SD, 2010, AGING CELL, V9, P105, DOI 10.1111/j.1474-9726.2010.00552.x; Kemnitz JW, 2011, ILAR J, V52, P66, DOI 10.1093/ilar.52.1.66; Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606; Kubicky RA, 2012, ENDOCRINOLOGY, V153, P2287, DOI 10.1210/en.2011-1909; Kuhla A, 2014, J GERONTOL A-BIOL, V69, P915, DOI 10.1093/gerona/glt160; Lelbach A., 2005, ACTA PHYSIOLOGICA HUNGARICA, V92, P97, DOI 10.1556/APhysiol.92.2005.2.1; Liang HY, 2003, EXP GERONTOL, V38, P1353, DOI 10.1016/j.exger.2003.10.019; Lips MA, 2014, CLIN ENDOCRINOL, V81, P862, DOI 10.1111/cen.12496; LOK E, 1990, CANCER LETT, V51, P67, DOI 10.1016/0304-3835(90)90232-M; LOK E, 1988, CANCER LETT, V38, P249, DOI 10.1016/0304-3835(88)90016-X; Lundasen T, 2007, BIOCHEM BIOPH RES CO, V360, P437, DOI 10.1016/j.bbrc.2007.06.068; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; McCarty MF, 1997, MED HYPOTHESES, V48, P297, DOI 10.1016/S0306-9877(97)90098-0; Mendenhall CL, 1997, ALCOHOL CLIN EXP RES, V21, P1; Rosenfeld RG, 2009, HORM RES, V71, P36, DOI 10.1159/000192434; Sanchez J, 2009, ENDOCRINOLOGY, V150, P5341, DOI 10.1210/en.2009-0466; Sandhu MS, 2002, J NATL CANCER I, V94, P972; Sarruf DA, 2010, DIABETES, V59, P1817, DOI 10.2337/db09-1878; Sharma N, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-90; SONNTAG WE, 1995, NEUROENDOCRINOLOGY, V61, P601, DOI 10.1159/000126885; Sonntag WE, 1999, J GERONTOL A-BIOL, V54, pB521, DOI 10.1093/gerona/54.12.B521; Tacer KF, 2010, MOL ENDOCRINOL, V24, P2050, DOI 10.1210/me.2010-0142; THISSEN JP, 1994, ENDOCR REV, V15, P80, DOI 10.1210/er.15.1.80; Touvier T, 2009, J CLIN INVEST, V119, P3830, DOI 10.1172/JCI34997; WOLF NS, 1995, EXP CELL RES, V217, P317, DOI 10.1006/excr.1995.1092; Wu SF, 2013, J BIOL CHEM, V288, P27375, DOI 10.1074/jbc.M113.462218; Xu J, 2009, AM J PHYSL ENDOCRINO; Xu J, 2009, DIABETES, V58, P250, DOI 10.2337/db08-0392; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Zhang Y, 2012, ELIFE, V1, DOI 10.7554/eLife.00065; Zhao TJ, 2010, P NATL ACAD SCI USA, V107, P7467, DOI 10.1073/pnas.1002271107	62	10	11	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2014	9	11							e111418	10.1371/journal.pone.0111418	http://dx.doi.org/10.1371/journal.pone.0111418			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS6XG	25369265	gold, Green Submitted, Green Published			2023-01-03	WOS:000344402000055
J	Harvey, SE; Parrott, F; Harrison, DA; Bear, DE; Segaran, E; Beale, R; Bellingan, G; Leonard, R; Mythen, MG; Rowan, KM				Harvey, Sheila E.; Parrott, Francesca; Harrison, David A.; Bear, Danielle E.; Segaran, Ella; Beale, Richard; Bellingan, Geoff; Leonard, Richard; Mythen, Michael G.; Rowan, Kathryn M.		CALORIES Trial Investigators	Trial of the Route of Early Nutritional Support in Critically Ill Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARE-NATIONAL-AUDIT; PARENTERAL-NUTRITION; ENTERAL NUTRITION; PATIENT; GUIDELINES; PROVISION; PROGRAM; DISEASE; MODEL; UNITS	BACKGROUND Uncertainty exists about the most effective route for delivery of early nutritional support in critically ill adults. We hypothesized that delivery through the parenteral route is superior to that through the enteral route. METHODS We conducted a pragmatic, randomized trial involving adults with an unplanned admission to one of 33 English intensive care units. We randomly assigned patients who could be fed through either the parenteral or the enteral route to a delivery route, with nutritional support initiated within 36 hours after admission and continued for up to 5 days. The primary outcome was all-cause mortality at 30 days. RESULTS We enrolled 2400 patients; 2388 (99.5%) were included in the analysis (1191 in the parenteral group and 1197 in the enteral group). By 30 days, 393 of 1188 patients (33.1%) in the parenteral group and 409 of 1195 patients (34.2%) in the enteral group had died (relative risk in parenteral group, 0.97; 95% confidence interval, 0.86 to 1.08; P = 0.57). There were significant reductions in the parenteral group, as compared with the enteral group, in rates of hypoglycemia (44 patients [3.7%] vs. 74 patients [6.2%]; P = 0.006) and vomiting (100 patients [8.4%] vs. 194 patients [16.2%]; P<0.001). There were no significant differences between the parenteral group and the enteral group in the mean number of treated infectious complications (0.22 vs. 0.21; P = 0.72), 90-day mortality (442 of 1184 patients [37.3%] vs. 464 of 1188 patients [39.1%], P = 0.40), in rates of 14 other secondary outcomes, or in rates of adverse events. Caloric intake was similar in the two groups, with the target intake not achieved in most patients. CONCLUSIONS We found no significant difference in 30-day mortality associated with the route of delivery of early nutritional support in critically ill adults.	[Harvey, Sheila E.; Parrott, Francesca; Harrison, David A.; Rowan, Kathryn M.] Intens Care Natl Audit & Res Ctr, Clin Trials Unit, London WC1V 6AZ, England; [Bear, Danielle E.] Guys & St Thomas NHS Fdn Trust, Dept Nutr & Dietet, London, England; [Bear, Danielle E.; Beale, Richard] Guys & St Thomas NHS Fdn Trust, Dept Adult Crit Care, London, England; [Segaran, Ella; Leonard, Richard] Imperial Coll Healthcare NHS Trust, Dept Intens Care, London, England; [Beale, Richard] Kings Coll London, Div Asthma Allergy & Lung Biol, London WC2R 2LS, England; [Bellingan, Geoff; Mythen, Michael G.] Univ Coll London Hosp NHS Fdn Trust, Natl Inst Hlth Res Biomed Res Ctr, London, England; [Bellingan, Geoff; Mythen, Michael G.] UCL, London WC1E 6BT, England; [Leonard, Richard] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London SW7 2AZ, England	Intensive Care National Audit & Research Centre; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; Imperial College London; University of London; King's College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London; Imperial College London	Rowan, KM (corresponding author), Intens Care Natl Audit & Res Ctr, Napier House,24 High Holborn, London WC1V 6AZ, England.	kathy.rowan@icnarc.org	Harrison, David/O-4355-2018; Montgomery, Hugh/C-2592-2008; Preller, Jacobus/AAD-4334-2022	Harrison, David/0000-0002-9002-9098; Brealey, David/0000-0002-1982-3379; Forbes, Alastair/0000-0001-7416-9843; Grieve, Richard/0000-0001-8899-1301; Montgomery, Hugh/0000-0001-8797-5019; Preller, Jacobus/0000-0001-5706-816X; Terblanche MBE, Ella/0000-0002-1761-8996; Bercades, Georgia/0000-0002-5961-3149; Harvey, Sheila/0000-0001-7604-8607; Rowan, Kathryn/0000-0001-8217-5602	Health Technology Assessment Program of the United Kingdom National Institute for Health Research [07/52/03]; Nutricia; Nestle Nutrition; Corpak MedSystems UK; Fresenius Kabi; Nestle Nutrition (through the European Society of Intensive Care Medicine); Baxter; National Institute for Health Research [07/52/03] Funding Source: researchfish	Health Technology Assessment Program of the United Kingdom National Institute for Health Research; Nutricia(Danone Nutricia); Nestle Nutrition(Nestle SA); Corpak MedSystems UK; Fresenius Kabi; Nestle Nutrition (through the European Society of Intensive Care Medicine)(Nestle SA); Baxter; National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by a grant from the Health Technology Assessment Program of the United Kingdom National Institute for Health Research (project no. 07/52/03).; Ms. Bear reports receiving consulting fees from Nutricia, lecture fees from Nestle Nutrition, travel support from Nutricia and Baxter, and grant support through her institution from Corpak MedSystems UK; Ms. Segaran, receiving travel support from Abbott Nutrition; Dr. Beale, receiving consulting and lecture fees from Nestle Nutrition and grant support from Fresenius Kabi (all through his institution), and negotiating an unrestricted research grant from Nestle Nutrition (through the European Society of Intensive Care Medicine); and Dr. Mythen, receiving lecture fees from Fresenius Kabi and Baxter and grant support from Fresenius Kabi and holding a patent related to methods and apparatus for guiding medical care based on detected gastric function through Medical Defence Technologies. No other potential conflict of interest relevant to this article was reported.	Bion J, 2013, BMJ QUAL SAF, V22, P110, DOI 10.1136/bmjqs-2012-001325; Boitano M, 2010, NUTR CLIN PRACT, V25, P663, DOI 10.1177/0884533610385349; Casaer MP, 2013, AM J RESP CRIT CARE, V187, P247, DOI 10.1164/rccm.201206-0999OC; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; De Jonghe B, 2001, CRIT CARE MED, V29, P8, DOI 10.1097/00003246-200101000-00002; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Dellinger RP, 2013, INTENS CARE MED, V41, P580, DOI DOI 10.1007/s00134-012-2769-8; Doig GS, 2013, JAMA-J AM MED ASSOC, V309, P2130, DOI 10.1001/jama.2013.5124; Engel JM, 2003, CLIN NUTR, V22, P187, DOI 10.1054/clnu.2002.0622; Fischer K, 2011, BIOSTATISTICS, V12, P247, DOI 10.1093/biostatistics/kxq053; Gramlich L, 2004, NUTRITION, V20, P843, DOI 10.1016/j.nut.2004.06.003; Grant AM, 2005, HEALTH TECHNOL ASSES, V9, P1; Greenland S, 2000, INT J EPIDEMIOL, V29, P722, DOI 10.1093/ije/29.4.722; Harrison DA, 2004, CRIT CARE, V8, pR99, DOI 10.1186/cc2834; Harrison DA, 2007, CRIT CARE MED, V35, P1091, DOI 10.1097/01.CCM.0000259468.24532.44; Harvey S, 2005, LANCET, V366, P472, DOI 10.1016/S0140-6736(05)67061-4; Heidegger CP, 2013, LANCET, V381, P385, DOI 10.1016/S0140-6736(12)61351-8; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P355, DOI 10.1177/0148607103027005355; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Martindale RG, 2009, CRIT CARE MED, V37, P1757, DOI 10.1097/CCM.0b013e3181a40116; National Patient Safety Agency, 2005, RED HARM CAUS MISPL; Naylor CJ, 2004, JPEN-PARENTER ENTER, V28, P251, DOI 10.1177/0148607104028004251; Reignier J, 2013, JAMA-J AM MED ASSOC, V309, P249, DOI 10.1001/jama.2012.196377; Simpson F, 2005, INTENS CARE MED, V31, P12, DOI 10.1007/s00134-004-2511-2; Singer P, 2009, CLIN NUTR, V28, P387, DOI 10.1016/j.clnu.2009.04.024; Thompson SG, 2000, BRIT MED J, V320, P1197, DOI 10.1136/bmj.320.7243.1197; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.3.CO;2-I; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; [No title captured]; [No title captured]; [No title captured]	31	325	360	2	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 30	2014	371	18					1673	1684		10.1056/NEJMoa1409860	http://dx.doi.org/10.1056/NEJMoa1409860			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AR7OG	25271389	Green Accepted, Green Published			2023-01-03	WOS:000343768500005
J	Chang, TI; Kim, YL; Kim, H; Ryu, GW; Kang, EW; Park, JT; Yoo, TH; Shin, SK; Kang, SW; Choi, KH; Han, DS; Han, SH				Chang, Tae Ik; Kim, Yung Ly; Kim, Hyungwoo; Ryu, Geun Woo; Kang, Ea Wha; Park, Jung Tak; Yoo, Tae-Hyun; Shin, Sug Kyun; Kang, Shin-Wook; Choi, Kyu Hun; Han, Dae Suk; Han, Seung Hyeok			Hyponatremia as a Predictor of Mortality in Peritoneal Dialysis Patients	PLOS ONE			English	Article							MAINTENANCE HEMODIALYSIS-PATIENTS; SERUM SODIUM CONCENTRATION; OUTCOMES; LEVEL; RISK	Background and Aim: Hyponatremia is common in patients with chronic kidney disease and is associated with increased mortality in hemodialysis patients. However, few studies have addressed this issue in peritoneal dialysis (PD) patients. Methods: This prospective observational study included a total of 441 incident patients who started PD between January 2000 and December 2005. Using time-averaged serum sodium (TA-Na) levels, we aimed to investigate whether hyponatremia can predict mortality in these patients. Results: Among the baseline parameters, serum sodium level was positively associated with serum albumin (beta = 0.145; p = 0.003) and residual renal function (RRF) (beta = 0.130; p = 0.018) and inversely associated with PD ultrafiltration (beta = 20.114; p = 0.024) in a multivariable linear regression analysis. During a median follow-up of 34.8 months, 149 deaths were recorded. All-cause death occurred in 81 (55.9%) patients in the lowest tertile compared to 37 (25.0%) and 31 (20.9%) patients in the middle and highest tertiles, respectively. After adjusting for multiple potentially confounding covariates, increased TA-Na level was associated with a significantly decreased risk of all-cause (HR per 1 mEq/L increase, 0.79; 95% CI, 0.73-0.86; p<0.001) and infection-related (HR per 1 mEq/L increase, 0.77; 95% CI, 0.70-0.85; p<0.001) deaths. Conclusions: This study showed that hyponatremia is an independent predictor of mortality in PD patients. Nevertheless, whether correcting hyponatremia improves patient survival is unknown. Future interventional studies should address this question more appropriately.	[Chang, Tae Ik; Kang, Ea Wha; Shin, Sug Kyun] Ilsan Hosp, NHIS Med Ctr, Dept Internal Med, Goyangshi, Gyeonggi Do, South Korea; [Kim, Yung Ly; Kim, Hyungwoo; Ryu, Geun Woo; Park, Jung Tak; Yoo, Tae-Hyun; Kang, Shin-Wook; Choi, Kyu Hun; Han, Dae Suk; Han, Seung Hyeok] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Kang, Shin-Wook] Yonsei Univ, Severance Biomed Sci Inst, Brain Korea Med Sci 21, Seoul 120749, South Korea	NHIS Ilsan Hospital; Yonsei University; Yonsei University Health System; Yonsei University	Han, SH (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea.	hansh@yuhs.ac	Han, Seung Hyeok/W-8825-2019; Han, Seung Hyeok/K-4559-2018; Barretti, Pasqual/K-4156-2012	Han, Seung Hyeok/0000-0001-7923-5635; Han, Seung Hyeok/0000-0001-7923-5635; Barretti, Pasqual/0000-0003-4979-4836; Choi, Kyu Hun/0000-0003-0095-9011; Park, Jung Tak/0000-0002-2325-8982; Kang, Shin-Wook/0000-0002-5677-4756; Yoo, Tae-Hyun/0000-0002-9183-4507; Kim, Hyung Woo/0000-0002-6305-452X	Brain Korea 21 Project for Medical Science, Yonsei University; National Research Foundation of Korea (NRF) grant - Korean government (MEST) [2011-0030711]; Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [A102065]	Brain Korea 21 Project for Medical Science, Yonsei University(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea); National Research Foundation of Korea (NRF) grant - Korean government (MEST); Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea	This work was supported by the Brain Korea 21 Project for Medical Science, Yonsei University, by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) (No. 2011-0030711), and by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A102065). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107; ARROYO V, 1976, AM J DIG DIS, V21, P249, DOI 10.1007/BF01095898; Bettari L, 2012, J CARD FAIL, V18, P74, DOI 10.1016/j.cardfail.2011.09.005; Beukhof CM, 2007, CLIN ENDOCRINOL, V66, P367, DOI 10.1111/j.1365-2265.2007.02741.x; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cherney DZ, 2001, PERITON DIALYSIS INT, V21, P7; Combs S, 2014, AM J KIDNEY DIS, V63, P294, DOI 10.1053/j.ajkd.2013.09.017; Dimitriadis C, 2014, PERITON DIALYSIS INT, V34, P260, DOI 10.3747/pdi.2012.00095; EDELMAN IS, 1958, J CLIN INVEST, V37, P1236, DOI 10.1172/JCI103712; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Gokal R, 2002, KIDNEY INT, V62, pS62, DOI 10.1046/j.1523-1755.62.s81.9.x; Han SH, 2012, NAT REV NEPHROL, V8, P163, DOI 10.1038/nrneph.2012.12; Hecking M, 2012, AM J KIDNEY DIS, V59, P238, DOI 10.1053/j.ajkd.2011.07.013; Hoorn EJ, 2008, NEPHRON PHYSIOL, V108, P46, DOI 10.1159/000119709; Hoorn EJ, 2013, AM J KIDNEY DIS, V62, P139, DOI 10.1053/j.ajkd.2012.09.019; Kang SH, 2013, NEPHROLOGY, V18, P132, DOI 10.1111/nep.12013; KATZ MA, 1973, NEW ENGL J MED, V289, P843, DOI 10.1056/NEJM197310182891607; KESHAVIAH PR, 1994, J AM SOC NEPHROL, V4, P1475; Kim HT, 2007, CLIN CANCER RES, V13, P559, DOI 10.1158/1078-0432.CCR-06-1210; Kovesdy CP, 2012, CIRCULATION, V125, P677, DOI 10.1161/CIRCULATIONAHA.111.065391; Mandai S, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-276; Mc Causland FR, 2012, NEPHROL DIAL TRANSPL, V27, P1613, DOI 10.1093/ndt/gfr497; Nguyen MK, 2005, AM J PHYSIOL-RENAL, V288, pF1113, DOI 10.1152/ajprenal.00387.2004; Nigwekar SU, 2013, AM J KIDNEY DIS, V62, P755, DOI 10.1053/j.ajkd.2013.02.367; NOLPH KD, 1993, PERITON DIALYSIS INT, V13, P178; Posthuma N, 1997, PERITON DIALYSIS INT, V17, P602; Randerson DH, 1981, PERITONEAL DIALYSIS, P180; Swart RM, 2011, NEPHRON PHYSIOL, V118, P45, DOI 10.1159/000322238; Tseng MH, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-113; Upadhyay A, 2006, AM J MED, V119, pS30, DOI 10.1016/j.amjmed.2006.05.005; Verduijn M, 2011, NEPHROL DIAL TRANSPL, V26, P56, DOI 10.1093/ndt/gfq661; Vilar E, 2011, SEMIN DIALYSIS, V24, P487, DOI 10.1111/j.1525-139X.2011.00968.x; Waikar SS, 2011, AM J MED, V124, P77, DOI 10.1016/j.amjmed.2010.07.029; Wang AYM, 2011, SEMIN NEPHROL, V31, P159, DOI 10.1016/j.semnephrol.2011.01.005; WATSON PE, 1980, AM J CLIN NUTR, V33, P27, DOI 10.1093/ajcn/33.1.27; Zevallos G, 2001, PERITON DIALYSIS INT, V21, P72; 이현희, 2010, Kidney Research and Clinical Practice, V29, P31	38	26	26	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2014	9	10							e111373	10.1371/journal.pone.0111373	http://dx.doi.org/10.1371/journal.pone.0111373			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8TG	25354265	Green Published, Green Submitted, gold			2023-01-03	WOS:000345204200076
J	Zhang, M; Shang, MQ; Yang, WW; Chen, JL; Wang, Z; Shang, H				Zhang, Min; Shang, Mingquan; Yang, Weiwei; Chen, Junli; Wang, Zhe; Shang, Hong			Treatment Effect and Drug-Resistant Mutations in Chinese AIDS Patients Switching to Second-Line Antiretroviral Therapy	PLOS ONE			English	Article							RESOURCE-LIMITED SETTINGS; COUNTRIES; MORTALITY	This study aimed to investigate treatment effect, drug resistance changes, and their influencing factors in Chinese AIDS patients after switching to second-line antiretroviral therapy, and thus provide important information for the scale-up of second-line antiretroviral treatment in China. In Weishi county of Henan province, where second-line antiretroviral therapy was introduced early in China, 195 AIDS patients were enrolled, of which 127 patients met the switching criterion and 68 patients volunteered to switch drugs without meeting the switching criterion. CD4 cell count, viral load and in-house PCR genotyping for drug resistance were measured for all 195 subjects before drug switch, as well as 6 and 12 months after drug switch. Extensive secondary mutations to the protease inhibitor were observed, which suggested that long-term drug resistance surveillance is necessary for patients switching to second-line antiretroviral therapy. Multidrug resistance and cross-resistance were extensive in Chinese patients that experienced first-line treatment failure. Patients need timely CD4 count, viral load, and drug resistance monitoring in order to switch to second-line therapy under conditions of relatively good immunity and low viral duplication levels.	[Zhang, Min; Shang, Mingquan; Yang, Weiwei; Chen, Junli; Shang, Hong] China Med Univ, Affiliated Hosp 1, Dept Lab Med, Key Lab AIDS Immunol Natl Hlth & Family Planning, Shenyang, Peoples R China; [Zhang, Min; Shang, Mingquan; Yang, Weiwei; Chen, Junli; Shang, Hong] Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China; [Wang, Zhe] Dis Prevent & Control Ctr Henan Prov, Zhengzhou, Peoples R China	China Medical University; Collaborative Innovation Center for Diagnosis & Treatment of Infectious Diseases	Shang, H (corresponding author), China Med Univ, Affiliated Hosp 1, Dept Lab Med, Key Lab AIDS Immunol Natl Hlth & Family Planning, Shenyang, Peoples R China.	hongshang100@hotmail.com			Twelfth Five-Year Project on Tackling Key Problems of National Science and Technology [2012ZX10001002-002-013]; National Natural Science Foundation of China [81171619]	Twelfth Five-Year Project on Tackling Key Problems of National Science and Technology; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the Twelfth Five-Year Project on Tackling Key Problems of National Science and Technology (2012ZX10001002-002-013) and National Natural Science Foundation of China (81171619). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2009, CHINESE NATL FREE AI; Boyd MA, 2007, AIDS, V21, pS55, DOI 10.1097/01.aids.0000279707.01557.b2; Galarraga O, 2007, AIDS, V21, pS97, DOI 10.1097/01.aids.0000279712.32051.29; Hosseinipour MC, 2010, HIV MED, V11, P510, DOI 10.1111/j.1468-1293.2010.00825.x; Kempf DJ, 2004, J INFECT DIS, V189, P51, DOI 10.1086/380509; Pujades-Rodriguez M, 2008, AIDS, V22, P1305, DOI 10.1097/QAD.0b013e3282fa75b9; Pujades-Rodriguez M, 2010, JAMA-J AM MED ASSOC, V304, P303, DOI 10.1001/jama.2010.980; World Health Organization, 2009, RAP ADV ANT THER HIV; Zhang FJ, 2011, LANCET INFECT DIS, V11, P516, DOI 10.1016/S1473-3099(11)70097-4; Zhang M, 2008, JPN J INFECT DIS, V61, P361; [张昊 ZHANG Min], 2008, [中华检验医学杂志, Chinese Journal of Laboratory Medicine], V31, P1101	11	6	8	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2014	9	10							e110259	10.1371/journal.pone.0110259	http://dx.doi.org/10.1371/journal.pone.0110259			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AT8TF	25330204	Green Submitted, gold, Green Published			2023-01-03	WOS:000345204100053
J	Foo, NP; Chang, JH; Su, SB; Chen, KT; Cheng, CF; Chen, PC; Lin, TY; Guo, HR				Foo, Ning-Ping; Chang, Jer-Hao; Su, Shih-Bin; Chen, Kow-Tong; Cheng, Ching-Fa; Chen, Pei-Chung; Lin, Tsung-Yi; Guo, How-Ran			A Stabilization Device That Promotes the Efficiency of Cardiopulmonary Resuscitation during Ambulance Transportation to the Level as under Non-Moving Conditions	PLOS ONE			English	Article							HOSPITAL CARDIAC-ARREST; CLOSED-CHEST COMPRESSION; RANDOMIZED-TRIAL; QUALITY; SURVIVAL	Background: The survival rate of patients with out-of-hospital cardiac arrest is low, and measures to improve the quality of cardiopulmonary resuscitation (CPR) during ambulance transportation are desirable. We designed a stabilization device, and in a randomized crossover trial we found performing CPR in a moving ambulance with the device (MD) could achieve better efficiency than that without the device (MND), but the efficiency was lower than that in a non-moving ambulance (NM). Purpose: To evaluate whether a modified version of the stabilization device, can promote further the quality of CPR during ambulance transportation. Methods: Participants of the previous study were recruited, and they performed CPR for 10 minutes in a moving ambulance with the modified version of the stabilization device (MVSD). The primary outcomes were effective chest compressions and no-flow fraction recorded by a skill-reporter manikin. The secondary outcomes included back pain, physiological parameters, and the participants' rating about the device after performing CPR. Results: The overall effective compressions in 10 minutes were 86.4+/-17.5% for NM, 60.9+/-14.6% for MND, 69.7+/-22.4% for MD, and 86.6%+/-13.2% for MVSD (p<0.001). Whereas changes in back pain severity and physiology parameters were similar under all conditions, MVSD had the lowest no-flow fraction. Differences in effective compressions and the no-flow fraction between MVSD and NM did not reach statistical significance. Conclusions: The use of the modified device can improve quality of CPR in a moving ambulance to a level similar to that in a non-moving condition without increasing the severity of back pain.	[Foo, Ning-Ping] China Med Univ, An Nan Hosp, Dept Emergency Med, Taichung, Taiwan; [Foo, Ning-Ping; Guo, How-Ran] Natl Cheng Kung Univ, Coll Med, Dept Environm & Occupat Hlth, Tainan 70101, Taiwan; [Foo, Ning-Ping] Chiayi Christian Hosp, Ditmanson Med Fdn, Dept Emergency Med, Chiayi, Taiwan; [Chang, Jer-Hao] Natl Cheng Kung Univ, Coll Med, Dept Occupat Therapy, Tainan 70101, Taiwan; [Su, Shih-Bin] Chi Mei Med Ctr, Dept Occupat Med, Tainan, Taiwan; [Su, Shih-Bin] Southern Taiwan Univ Sci & Technol, Dept Leisure Recreat & Tourism Management, Tainan, Taiwan; [Chen, Kow-Tong] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan 70101, Taiwan; [Chen, Kow-Tong] Tainan Municipal Hosp, Dept Occupat Med, Tainan, Taiwan; [Cheng, Ching-Fa] Tainan City Fire Bur, Div Emergency Med Serv, Tainan, Taiwan; [Chen, Pei-Chung; Lin, Tsung-Yi] Southern Taiwan Univ Sci & Technol, Dept Mech Engn, Tainan, Taiwan; [Guo, How-Ran] Natl Cheng Kung Univ Hosp, Dept Occupat & Environm Med, Tainan 70428, Taiwan	China Medical University Taiwan; National Cheng Kung University; Chia-Yi Christian Hospital; National Cheng Kung University; Chi Mei Hospital; Southern Taiwan University of Science & Technology; National Cheng Kung University; Southern Taiwan University of Science & Technology; National Cheng Kung University; National Cheng Kung University Hospital	Guo, HR (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Environm & Occupat Hlth, Tainan 70101, Taiwan.	hrguo@mail.ncku.edu.tw	Guo, How-Ran/AAK-9063-2020; Chang, Jer-Hao/HDN-8114-2022	Guo, How-Ran/0000-0003-3343-3446; 	Ministry of Science and Technology of Taiwan, R.O.C. [NSC 101-2314-B-705-002]	Ministry of Science and Technology of Taiwan, R.O.C.	This study was supported by Grants NSC 101-2314-B-705-002 from the National Science Council (currently the Ministry of Science and Technology) of Taiwan, R.O.C.(http://www.most.gov.tw/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berdowski J, 2010, RESUSCITATION, V81, P1479, DOI 10.1016/j.resuscitation.2010.08.006; Brooks SC, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007260.pub3; Chung TN, 2010, RESUSCITATION, V81, P841, DOI 10.1016/j.resuscitation.2010.02.024; Cleeland C S, 1985, Semin Oncol Nurs, V1, P87, DOI 10.1016/S0749-2081(85)80041-3; Foo NP, 2013, RESUSCITATION, V84, P1579, DOI 10.1016/j.resuscitation.2013.06.015; Fox Julia, 2013, Acute Card Care, V15, P1, DOI 10.3109/17482941.2012.735675; Ger LP, 1999, J PAIN SYMPTOM MANAG, V18, P316, DOI 10.1016/S0885-3924(99)00087-1; Hallstrom A, 2006, JAMA-J AM MED ASSOC, V295, P2620, DOI 10.1001/jama.295.22.2620; Havel C, 2007, RESUSCITATION, V73, P264, DOI 10.1016/j.resuscitation.2006.09.007; Jones AYM, 2004, RESUSCITATION, V61, P63, DOI 10.1016/j.resuscitation.2003.12.007; Kim JA, 2006, PREHOSP EMERG CARE, V10, P68, DOI 10.1080/10903120500373108; Kurz MC, 2012, RESUSCITATION, V83, P1085, DOI 10.1016/j.resuscitation.2012.01.033; Odegaard S, 2009, RESUSCITATION, V80, P843, DOI 10.1016/j.resuscitation.2009.03.032; Olasveengen TM, 2008, RESUSCITATION, V76, P185, DOI 10.1016/j.resuscitation.2007.07.001; Ong MEH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-39; Rubertsson S, 2014, JAMA-J AM MED ASSOC, V311, P53, DOI 10.1001/jama.2013.282538; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; Stone C K, 1995, Prehosp Disaster Med, V10, P121; Travers AH, 2010, CIRCULATION, V122, pS676, DOI 10.1161/CIRCULATIONAHA.110.970913; Valenzuela TD, 2005, CIRCULATION, V112, P1259, DOI 10.1161/CIRCULATIONAHA.105.537282	21	2	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2014	9	10							e107960	10.1371/journal.pone.0107960	http://dx.doi.org/10.1371/journal.pone.0107960			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX2IH	25329643	Green Published, Green Submitted, gold			2023-01-03	WOS:000346766200007
J	Kang, D; Yun, JS; Ko, SH; Lim, TS; Ahn, YB; Park, YM; Ko, SH				Kang, Donghoon; Yun, Jae-Seung; Ko, Sun-Hye; Lim, Tae-Seok; Ahn, Yu-Bae; Park, Yong-Moon; Ko, Seung-Hyun			Higher Prevalence of Metformin-Induced Vitamin B-12 Deficiency in Sulfonylurea Combination Compared with Insulin Combination in Patients with Type 2 Diabetes: A Cross-Sectional Study	PLOS ONE			English	Article							NUTRITION EXAMINATION SURVEY; SERUM CONCENTRATIONS; NATIONAL-HEALTH; ASSOCIATION; DIAGNOSIS; ANEMIA; POLYNEUROPATHY; MALABSORPTION; HOMOCYSTEINE; MANAGEMENT	Long-term and high-dose treatment with metformin is known to be associated with vitamin B-12 deficiency in patients with type 2 diabetes. We investigated whether the prevalence of B-12 deficiency was different in patients treated with different combination of hypoglycemic agents with metformin during the same time period. A total of 394 patients with type 2 diabetes treated with metformin and sulfonylurea (S+M group, n = 299) or metformin and insulin (I+M group, n = 95) were consecutively recruited. The vitamin B-12 and folate levels were quantified using the chemiluminescent enzyme immunoassay. Vitamin B-12 deficiency was defined as vitamin B-12 <= 300 pg/mL without folate deficiency (folate>4 ng/mL). The mean age of and duration of diabetes in the subjects were 59.4 +/- 10.5 years and 12.2 +/- 6.7 years, respectively. The mean vitamin B-12 level of the total population was 638.0 +/- 279.6 pg/mL. The mean serum B12 levels were significantly lower in the S+M group compared with the I+M group (600.0 +/- 266.5 vs. 757.7 +/- 287.6 pg/mL, P<0.001). The prevalence of vitamin B-12 deficiency in the metformin-treated patients was significantly higher in the S+M group compared with the I+M group (17.4% vs. 4.2%, P = 0.001). After adjustment for various factors, such as age, sex, diabetic duration, duration or daily dose of metformin, diabetic complications, and presence of anemia, sulfonylurea use was a significant independent risk factor for B-12 deficiency (OR = 4.74, 95% CI 1.41-15.99, P = 0.012). In conclusion, our study demonstrated that patients with type 2 diabetes who were treated with metformin combined with sulfonylurea require clinical attention for vitamin B-12 deficiency and regular monitoring of their vitamin B-12 levels.	[Kang, Donghoon; Yun, Jae-Seung; Ko, Sun-Hye; Lim, Tae-Seok; Ahn, Yu-Bae; Ko, Seung-Hyun] Catholic Univ Korea, St Vincents Hosp, Coll Med, Dept Internal Med,Div Endocrinol & Metab, Seoul, South Korea; [Park, Yong-Moon] Univ S Carolina, Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC 29208 USA	Catholic University of Korea; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Ko, SH (corresponding author), Catholic Univ Korea, St Vincents Hosp, Coll Med, Dept Internal Med,Div Endocrinol & Metab, Seoul, South Korea.	kosh@catholic.ac.kr	PARK, YONG-MOON ("MARK")/ABA-2765-2021	PARK, YONG-MOON ("MARK")/0000-0002-5879-6879; Kang, Donghoon/0000-0002-7278-2174; Ko, Sun Hye/0000-0003-3387-3986				ADAMS JF, 1983, DIABETOLOGIA, V24, P16, DOI 10.1007/BF00275941; Agarwal DP, 2002, ALCOHOL ALCOHOLISM, V37, P409, DOI 10.1093/alcalc/37.5.409; Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; Andres E, 2002, ARCH INTERN MED, V162, P2251, DOI 10.1001/archinte.162.19.2251-a; Bauman WA, 2000, DIABETES CARE, V23, P1227, DOI 10.2337/diacare.23.9.1227; Bell DSH, 2010, SOUTH MED J, V103, P265, DOI 10.1097/SMJ.0b013e3181ce0e4d; Bouchoucha M, 2011, DIABETES METAB, V37, P90, DOI 10.1016/j.diabet.2010.11.002; CARMEL R, 1988, ARCH INTERN MED, V148, P1712, DOI 10.1001/archinte.148.8.1712; Chan CWJ, 2007, INT J LAB HEMATOL, V29, P163, DOI 10.1111/j.1751-553X.2007.00911.x; de Jager J, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2181; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; Filioussi Kalitsa, 2003, Aust Fam Physician, V32, P383; Galer BS, 2000, DIABETES RES CLIN PR, V47, P123, DOI 10.1016/S0168-8227(99)00112-6; Hermann LS, 2004, BRIT J DIABETES VASC, V4, P401; Hin H, 2006, AGE AGEING, V35, P416, DOI 10.1093/ageing/afl033; Kibirige D, 2013, J DIABETES METAB DIS, V12, DOI 10.1186/2251-6581-12-17; Ko SH, 2014, DIABETES METAB J, V38, P51, DOI 10.4093/dmj.2014.38.1.51; Ko SH, 2011, DIABETES METAB J, V35, P431, DOI 10.4093/dmj.2011.35.5.431; Ko SH, 2014, J KOREAN MED SCI, V29, P965, DOI 10.3346/jkms.2014.29.7.965; Leishear K, 2012, J AM GERIATR SOC, V60, P1057, DOI 10.1111/j.1532-5415.2012.03998.x; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; Liu KW, 2006, AGE AGEING, V35, P200, DOI 10.1093/ageing/afj042; Long AN, 2012, DIABETES CARE, V35, pE84, DOI 10.2337/dc12-0980; Mazokopakis EE, 2012, DIABETES RES CLIN PR, V97, P359, DOI 10.1016/j.diabres.2012.06.001; Meijer JWG, 2002, DIABETIC MED, V19, P962, DOI 10.1046/j.1464-5491.2002.00819.x; Molitch ME, 2004, DIABETES CARE, V27, P1240, DOI 10.2337/diacare.27.5.1240-a; Naha K, 2012, BMJ CASE REP, V2012; Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08-9025; Pflipsen MC, 2009, J AM BOARD FAM MED, V22, P528, DOI 10.3122/jabfm.2009.05.090044; Reinstatler L, 2012, DIABETES CARE, V35, P327, DOI 10.2337/dc11-1582; Sahin M, 2007, J DIABETES COMPLICAT, V21, P118, DOI 10.1016/j.jdiacomp.2005.10.005; Schernthaner G, 2004, EUR J CLIN INVEST, V34, P535, DOI 10.1111/j.1365-2362.2004.01381.x; STABLER SP, 1990, BLOOD, V76, P871; Ting RZW, 2006, ARCH INTERN MED, V166, P1975, DOI 10.1001/archinte.166.18.1975; TOMKIN GH, 1971, BMJ-BRIT MED J, V2, P685, DOI 10.1136/bmj.2.5763.685; Turner LW, 2014, DIABETES CARE, V37, P985, DOI 10.2337/dc13-2097; Wickramasinghe SN, 2006, BLOOD REV, V20, P299, DOI 10.1016/j.blre.2006.02.002; Wile DJ, 2010, DIABETES CARE, V33, P156, DOI 10.2337/dc09-0606; World Health Organization, 2001, INT CLASS FUNCT DIS, P1; Wulffele MG, 2003, J INTERN MED, V254, P455, DOI 10.1046/j.1365-2796.2003.01213.x	40	18	21	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2014	9	10							e109878	10.1371/journal.pone.0109878	http://dx.doi.org/10.1371/journal.pone.0109878			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0AP	25299054	Green Published, gold, Green Submitted			2023-01-03	WOS:000343941200082
J	Morris, MD; Evans, J; Montgomery, M; Yu, M; Briceno, A; Page, K; Hahn, JA				Morris, Meghan D.; Evans, Jennifer; Montgomery, Martha; Yu, Michelle; Briceno, Alya; Page, Kimberly; Hahn, Judith A.			Intimate Injection Partnerships Are at Elevated Risk of High-Risk Injecting: A Multi-Level Longitudinal Study of HCV-Serodiscordant Injection Partnerships in San Francisco, CA	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; 5 US CITIES; DRUG-USERS; HEPATITIS-C; GENDER-DIFFERENCES; HETEROSEXUAL COUPLES; SEXUAL RELATIONSHIPS; PREVENTION PROGRAM; HIV-INFECTION; CONDOM USE	Background: It is increasingly recognized that the risk for HIV and hepatitis C (HCV) transmission among people who inject drugs (PWID), such as syringe sharing, occurs in the context of relationships between (at least) two people. Evidence suggests that the risk associated with injection behavior varies with injection partner types. Methods: We utilized longitudinal dyad-level data from a study of young PWID from San Francisco (2006 to 2013) to investigate the relationship-level factors influencing high-risk injecting within HCV-serodiscordant injection partners (i.e., individuals who injected together >= 5 times in the prior month). Utilizing data from 70 HCV-serodiscordant injection partnerships, we used generalized linear models to examine relationship-level predictors (i.e., partnership composition, partnership closeness, and partnership dynamics) of: (1) receptive syringe sharing (RSS); and (2) receptive cooker use (RCU), as reported by the HCV-negative injection partner. Results: As reported by the "at-risk'' HCV-negative injection partner, receptive syringe sharing (RSS) and receptive cooker use (RCU) were 19% and 33% at enrollment, and 11% and 12% over all visits (total follow-up time 55 person-years) resulting in 13 new HCV-infections (incidence rate: 23.8/100 person-years). Person-level factors, injection partnership composition, and partnership dynamics were not significantly associated with either RSS or RCU. Instead, intimate injection partnerships (those who lived together and were also in a sexual relationship) were independently associated with a 5-times greater risk of both RSS and a 7-times greater risk of RCU when compared to injecting only partnerships. Conclusion: Our findings suggest a positive, and amplified effect of relationship factors on injecting drug risk behaviors among young PWID injection partnerships. The majority of interventions to reduce injection drug use related harms focus on individual-based education to increase drug use knowledge. Our findings support the need to expand harm reduction strategies to relationship-based messaging and interventions.	[Morris, Meghan D.; Evans, Jennifer; Yu, Michelle; Briceno, Alya] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Montgomery, Martha] Univ Calif San Francisco, Joint Med Program, San Francisco, CA 94143 USA; [Montgomery, Martha] Univ Calif San Francisco, Program Med Educ Urban Underserved, San Francisco, CA 94143 USA; [Montgomery, Martha] Univ Calif Berkeley, San Francisco, CA USA; [Page, Kimberly] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA; [Hahn, Judith A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of New Mexico; University of New Mexico's Health Sciences Center; University of California System; University of California San Francisco	Morris, MD (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.	Meghan.Morris@ucsf.edu	Hahn, Judith/J-5813-2014	Hahn, Judith/0000-0002-2697-8264; Page, Kimberly/0000-0002-7120-1673	National Institute on Drug Abuse Award [R01DA16017, R01DA031056, K01DA023365]; University of California San Francisco CTSI (NIH) [UL1-RR02431]; University of California San Francisco Liver Center (NIH) [P30-DK026743]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K24AA022586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA016017, K01DA023365, K01DA037802, R01DA031056] Funding Source: NIH RePORTER	National Institute on Drug Abuse Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); University of California San Francisco CTSI (NIH); University of California San Francisco Liver Center (NIH); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The UFO Study is supported by the National Institute on Drug Abuse Award number R01DA16017. MDM is supported by a National Institute on Drug Abuse Award number R01DA031056. JAH is supported by a National Institute on Drug Abuse Award number K01DA023365. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Drug Abuse or the National Institute of Health. The authors also acknowledge support from the University of California San Francisco CTSI (NIH UL1-RR02431) and the University of California San Francisco Liver Center (NIH P30-DK026743). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALLEN S, 1992, BRIT MED J, V304, P1605, DOI 10.1136/bmj.304.6842.1605; [Anonymous], 2012, MMWR MORBIDITY MORTA, V61, P133; [Anonymous], 2002, AIDS BEHAV; BARNARD MA, 1993, ADDICTION, V88, P805, DOI 10.1111/j.1360-0443.1993.tb02094.x; Bennett GA, 2000, AIDS CARE, V12, P77, DOI 10.1080/09540120047495; Bing S, 2004, FORTUNE, V150, P140; Bourgois P, 2004, HUM ORGAN, V63, P253, DOI 10.17730/humo.63.3.h1phxbhrb7m4mlv0; Bryant J, 2010, DRUG ALCOHOL REV, V29, P364, DOI 10.1111/j.1465-3362.2009.00154.x; Burt RD, 2009, DRUG ALCOHOL DEPEN, V105, P215, DOI 10.1016/j.drugalcdep.2009.07.005; Cavacuiti CA, 2004, SUBST USE MISUSE, V39, P645, DOI 10.1081/JA-120030064; Costenbader EC, 2006, ADDICTION, V101, P1003, DOI 10.1111/j.1360-0443.2006.01431.x; Cox J, 2009, SUBST USE MISUSE, V44, P548, DOI 10.1080/10826080802544349; Davey-Rothwell MA, 2007, J URBAN HEALTH, V84, P691, DOI 10.1007/s11524-007-9215-1; De P, 2009, SCAND J INFECT DIS, V41, P206, DOI 10.1080/00365540902721376; Desgrees-du-Lou A, 2008, REPROD HEALTH MATTER, V16, P151, DOI 10.1016/S0968-8080(08)32407-0; El-Bassel N, 2003, AM J PUBLIC HEALTH, V93, P963, DOI 10.2105/AJPH.93.6.963; Evans JL, 2014, DRUG ALCOHOL DEPEN, V142, P239, DOI 10.1016/j.drugalcdep.2014.06.028; Evans JL, 2003, J URBAN HEALTH, V80, P137, DOI 10.1093/jurban/jtg137; Frajzyngier V, 2007, DRUG ALCOHOL DEPEN, V89, P145, DOI 10.1016/j.drugalcdep.2006.12.021; Gyarmathy VA, 2006, DRUG ALCOHOL DEPEN, V82, pS65, DOI 10.1016/S0376-8716(06)80011-6; Gyarmathy VA, 2010, AIDS BEHAV, V14, P141, DOI 10.1007/s10461-008-9518-6; Hagan H, 2001, AM J PUBLIC HEALTH, V91, P42, DOI 10.2105/AJPH.91.1.42; Hagan H, 2010, J INFECT DIS, V201, P378, DOI 10.1086/649783; Hahn JA, 2002, J INFECT DIS, V186, P1558, DOI 10.1086/345554; Hahn JA, 2010, ADDICTION, V105, P1254, DOI 10.1111/j.1360-0443.2010.02949.x; Hardin J.W., 2013, GEN ESTIMATING EQUAT, V2nd, DOI [10.1201/b13880, DOI 10.1201/B13880]; Harvey SM, 2002, WOMEN HEALTH, V36, P69, DOI 10.1300/J013v36n04_06; Horyniak D, 2013, DRUG ALCOHOL DEPEN, V132, P541, DOI 10.1016/j.drugalcdep.2013.03.021; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; Lakon CM, 2006, SOC SCI MED, V63, P2489, DOI 10.1016/j.socscimed.2006.06.015; Lazuardi E, 2012, CULT HEALTH SEX, V14, P491, DOI 10.1080/13691058.2012.671960; LOXLEY W, 1995, AIDS CARE, V7, P337, DOI 10.1080/09540129550126551; Mathers BM, 2008, LANCET, V372, P1733, DOI 10.1016/S0140-6736(08)61311-2; McMahon James M, 2003, BMC Med Res Methodol, V3, P24, DOI 10.1186/1471-2288-3-24; Miller Cari L, 2007, Harm Reduct J, V4, P1, DOI 10.1186/1477-7517-4-1; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; Musaba E, 1998, SEX TRANSM DIS, V25, P260, DOI 10.1097/00007435-199805000-00008; NEAIGUS A, 1994, SOC SCI MED, V38, P67, DOI 10.1016/0277-9536(94)90301-8; Neaigus A, 1995, NIDA Res Monogr, V151, P20; PADIAN NS, 1993, J ACQ IMMUN DEF SYND, V6, P1043; Page K, 2009, J INFECT DIS, V200, P1216, DOI 10.1086/605947; Porco TC, 2001, AM J PUBLIC HEALTH, V91, P636, DOI 10.2105/AJPH.91.4.636; Pulerwitz J, 2002, AIDS CARE, V14, P789, DOI 10.1080/0954012021000031868; Rhodes T, 1998, SOC SCI MED, V46, P157, DOI 10.1016/S0277-9536(97)00156-1; Rhodes T, 2008, ADDICTION, V103, P1593, DOI 10.1111/j.1360-0443.2008.02306.x; Riehman KS, 2004, J URBAN HEALTH, V81, P249, DOI 10.1093/jurban/jth111; Roy E, 2007, INT J STD AIDS, V18, P23, DOI 10.1258/095646207779949880; Roy E, 2007, INT J DRUG POLICY, V18, P397, DOI 10.1016/j.drugpo.2007.02.005; Rusbult CE, 2003, ANNU REV PSYCHOL, V54, P351, DOI 10.1146/annurev.psych.54.101601.145059; Shaw SY, 2007, ADDICTION, V102, P1626, DOI 10.1111/j.1360-0443.2007.01940.x; Simmons J., 2006, SUBSTANCE ABUSE TREA, V1, P1; SPANIER GB, 1976, J MARRIAGE FAM, V38, P15, DOI 10.2307/350547; Stephenson R, 2011, AIDS BEHAV, V15, pS80, DOI 10.1007/s10461-011-9893-2; Thiede H, 2007, DRUG ALCOHOL DEPEN, V91, pS39, DOI 10.1016/j.drugalcdep.2007.03.001; Thorpe LE, 2002, AM J EPIDEMIOL, V155, P645, DOI 10.1093/aje/155.7.645; Tsui JI, 2009, DRUG ALCOHOL DEPEN, V105, P160, DOI 10.1016/j.drugalcdep.2009.05.022; Weeks MR, 2009, SUBST USE MISUSE, V44, P253, DOI 10.1080/10826080802347677; Wu Elwin, 2010, Open AIDS J, V4, P123, DOI 10.2174/1874613601004030123	58	37	37	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2014	9	10							e109282	10.1371/journal.pone.0109282	http://dx.doi.org/10.1371/journal.pone.0109282			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AU6XC	25286346	Green Submitted, Green Published, gold			2023-01-03	WOS:000345743700056
J	Giri, J				Giri, J.			Review: In pulmonary embolism, thrombolytic therapy reduces all-cause mortality but increases major bleeding	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Hosp Univ Penn, Philadelphia, PA 19104 USA	University of Pennsylvania	Giri, J (corresponding author), Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA.	giri.jay@gmail.com	Akl, Elie A/R-2079-2016	Akl, Elie A/0000-0002-3444-8618					0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2014	161	6							JC9	10.7326/0003-4819-161-6-201409160-02009	http://dx.doi.org/10.7326/0003-4819-161-6-201409160-02009			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AR9LF	25222421				2023-01-03	WOS:000343894400008
J	Song, E; Fu, JL; Xia, XM; Su, CY; Song, Y				Song, Erqun; Fu, Juanli; Xia, Xiaomin; Su, Chuanyang; Song, Yang			Bazhen Decoction Protects against Acetaminophen Induced Acute Liver Injury by Inhibiting Oxidative Stress, Inflammation and Apoptosis in Mice	PLOS ONE			English	Article							CELL-DEATH; ENDOTHELIAL-CELLS; TNF-ALPHA; HEPATOTOXICITY; ANTIOXIDANT; PAEONIFLORIN; DAMAGE; LPS; MITOCHONDRIA; MECHANISMS	Bazhen decoction is a widely used traditional Chinese medicinal decoction, but the scientific validation of its therapeutic potential is lacking. The objective of this study was to investigate corresponding anti-oxidative, anti-inflammatory and antiapoptosis activities of Bazhen decoction, using acetaminophen-treated mice as a model system. A total of 48 mice were divided into four groups. Group I, negative control, treated with vehicle only. Group II, fed with 500 mg/kg/day Bazhen decoction for 10 continuous days. Group III, received a single dose of 900 mg/kg acetaminophen. Group IV, fed with 500 mg/kg/day Bazhen decoction for 10 continuous days and a single dose of 900 mg/kg acetaminophen 30 min before last Bazhen decoction administration. Bazhen decoction administration significantly decrease acetaminophen-induced serum ALT, AST, ALP, LDH, TNF-alpha, IL-1 beta, ROS, TBARS and protein carbonyl group levels, as well as GSH depletion and loss of MMP. Bazhen decoction restore SOD, CAT, GR and GPx activities and depress the expression of pro-inflammatory factors, such as iNOS, COX-2, TNF-alpha, NF-kappa B, IL-1 beta and IL-6, respectively. Moreover, Bazhen decoction down-regulate acetaminophen-induced Bax/Bcl-2 ratio, caspase 3, caspase 8 and caspase 9. These results suggest the anti-oxidative, anti-inflammatory and anti-apoptosis properties of Bazhen decoction towards acetaminophen-induced liver injury in mice.	[Song, Erqun; Fu, Juanli; Xia, Xiaomin; Su, Chuanyang; Song, Yang] Southwest Univ, Coll Pharmaceut Sci, Key Lab Luminescence & Real Time Analyt Chem, Minist Educ, Chongqing, Peoples R China	Southwest University - China	Song, Y (corresponding author), Southwest Univ, Coll Pharmaceut Sci, Key Lab Luminescence & Real Time Analyt Chem, Minist Educ, Chongqing, Peoples R China.	songyangwenrong@hotmail.com	Song, Yang/ABE-9615-2021; Song, Yangyi/HGU-4953-2022	Song, Yangyi/0000-0002-3649-014X	Fundamental Research Funds for the Central Universities [XDJK2014A020, XDJK2013B009]	Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by the Fundamental Research Funds for the Central Universities (XDJK2014A020, XDJK2013B009). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams ML, 2001, MOL PHARMACOL, V60, P907, DOI 10.1124/mol.60.5.907; Amor S, 2010, IMMUNOLOGY, V129, P154, DOI 10.1111/j.1365-2567.2009.03225.x; ARNAIZ SL, 1995, FREE RADICAL BIO MED, V19, P303, DOI 10.1016/0891-5849(95)00023-Q; Botta D, 2006, J BIOL CHEM, V281, P28865, DOI 10.1074/jbc.M605143200; Boulares AH, 2002, PHARMACOL TOXICOL, V90, P38, DOI 10.1034/j.1600-0773.2002.900108.x; Brown JM, 2012, TOXICOL LETT, V212, P320, DOI 10.1016/j.toxlet.2012.05.018; Cheng Y, 2005, ACTA PHARMACOL SIN, V26, P143, DOI 10.1111/j.1745-7254.2005.00034.x; Choi JH, 2009, J MED FOOD, V12, P320, DOI 10.1089/jmf.2007.0691; Colle D, 2012, J MED FOOD, V15, P549, DOI 10.1089/jmf.2011.0282; El-Hassan H, 2003, TOXICOL APPL PHARM, V191, P118, DOI 10.1016/S0041-008X(03)00240-0; Ghosh J, 2010, TOXICOLOGY, V268, P8, DOI 10.1016/j.tox.2009.11.011; Gujral JS, 2002, TOXICOL SCI, V67, P322, DOI 10.1093/toxsci/67.2.322; Hinson Jack A, 2010, Handb Exp Pharmacol, P369, DOI 10.1007/978-3-642-00663-0_12; Huang ZF, 2000, BIOCHEM PHARMACOL, V59, P187, DOI 10.1016/S0006-2952(99)00312-3; Jaeschke Hartmut, 2005, Expert Opin Drug Metab Toxicol, V1, P389, DOI 10.1517/17425255.1.3.389; Jaeschke H, 2012, DRUG METAB REV, V44, P88, DOI 10.3109/03602532.2011.602688; Jaeschke H, 2012, LIVER INT, V32, P8, DOI 10.1111/j.1478-3231.2011.02501.x; Jaeschke H, 2011, LIFE SCI, V88, P737, DOI 10.1016/j.lfs.2011.01.025; Ji QL, 2012, TOXICOL IN VITRO, V26, P455, DOI 10.1016/j.tiv.2012.01.016; Kim ID, 2010, ARCH PHARM RES, V33, P959, DOI 10.1007/s12272-010-0620-8; Kim TG, 2013, J ENDODONT, V39, P461, DOI 10.1016/j.joen.2012.11.022; Kim TW, 2012, INT IMMUNOPHARMACOL, V12, P110, DOI 10.1016/j.intimp.2011.10.023; Kumari A, 2012, FOOD CHEM TOXICOL, V50, P1781, DOI 10.1016/j.fct.2012.02.042; Kumari A, 2012, LIFE SCI, V90, P561, DOI 10.1016/j.lfs.2012.01.012; Lee KJ, 2001, CANCER LETT, V174, P73, DOI 10.1016/S0304-3835(01)00678-4; Li G, 2013, WORLD J GASTROENTERO, V19, P7440, DOI 10.3748/wjg.v19.i42.7440; Li WenLan, 2012, Journal of Medicinal Plants Research, V6, P2601; Liu WX, 2012, WORLD J GASTROENTERO, V18, P2197, DOI 10.3748/wjg.v18.i18.2197; Liu Y, 2006, J PHARMACEUT BIOMED, V41, P1642, DOI 10.1016/j.jpba.2006.02.033; Muir KW, 2007, CURR OPIN NEUROL, V20, P334, DOI 10.1097/WCO.0b013e32813ba151; O'Brien PJ, 2000, HUM EXP TOXICOL, V19, P277, DOI 10.1191/096032700678815918; Olaleye MT, 2008, EXP TOXICOL PATHOL, V59, P319, DOI 10.1016/j.etp.2007.10.003; Ray SD, 1996, J PHARMACOL EXP THER, V279, P1470; Sener G, 2006, HEPATOL RES, V35, P62, DOI 10.1016/j.hepres.2006.02.005; Shang XF, 2010, J ETHNOPHARMACOL, V128, P279, DOI 10.1016/j.jep.2010.01.006; Su SL, 2013, CHIN MED-UK, V8, DOI 10.1186/1749-8546-8-5; Sun YX, 2010, J ASIAN NAT PROD RES, V12, P1051, DOI 10.1080/10286020.2010.535520; Wang L, 2012, CAN J PHYSIOL PHARM, V90, P229, DOI [10.1139/Y11-127, 10.1139/y11-127]; Wang YH, 2008, BRIT J PHARMACOL, V154, P1327, DOI 10.1038/bjp.2008.202; Williams CD, 2010, TOXICOL APPL PHARM, V247, P169, DOI 10.1016/j.taap.2010.07.004; Wu YL, 2010, PHYTOMEDICINE, V17, P475, DOI 10.1016/j.phymed.2009.07.011; Xu YM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068757; Yu J, 2013, TOXICOL LETT, V218, P224, DOI 10.1016/j.toxlet.2013.01.028; Yuan HD, 2010, J ETHNOPHARMACOL, V127, P528, DOI 10.1016/j.jep.2009.10.002	44	47	51	3	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2014	9	9							e107405	10.1371/journal.pone.0107405	http://dx.doi.org/10.1371/journal.pone.0107405			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AP0SR	25222049	Green Published, Green Submitted, gold			2023-01-03	WOS:000341774800065
J	Sherrington, C; Lord, SR; Vogler, CM; Close, JCT; Howard, K; Dean, CM; Heller, GZ; Clemson, L; O'Rourke, SD; Ramsay, E; Barraclough, E; Herbert, RD; Cumming, RG				Sherrington, Catherine; Lord, Stephen R.; Vogler, Constance M.; Close, Jacqueline C. T.; Howard, Kirsten; Dean, Catherine M.; Heller, Gillian Z.; Clemson, Lindy; O'Rourke, Sandra D.; Ramsay, Elisabeth; Barraclough, Elizabeth; Herbert, Robert D.; Cumming, Robert G.			A Post-Hospital Home Exercise Program Improved Mobility but Increased Falls in Older People: A Randomised Controlled Trial	PLOS ONE			English	Article							MULTIFACTORIAL INTERDISCIPLINARY INTERVENTION; PHYSICAL PERFORMANCE; PREVENT FALLS; FRAIL; RISK; DISABILITY; WOMEN; REHABILITATION; ASSOCIATION; TIME	Background: Home exercise can prevent falls in the general older community but its impact in people recently discharged from hospital is not known. The study aimed to investigate the effects of a home-based exercise program on falls and mobility among people recently discharged from hospital. Methods and Findings: This randomised controlled trial (ACTRN12607000563460) was conducted among 340 older people. Intervention group participants (n = 171) were asked to exercise at home for 15-20 minutes up to 6 times weekly for 12 months. The control group (n = 169) received usual care. Primary outcomes were rate of falls (assessed over 12 months using monthly calendars), performance-based mobility (Lower Extremity Summary Performance Score, range 0-3, at baseline and 12 months, assessor unaware of group allocation) and self-reported ease of mobility task performance (range 0-40, assessed with 12 monthly questionaries). Participants had an average age of 81.2 years (SD 8.0) and 70% had fallen in the past year. Complete primary outcome data were obtained for at least 92% of randomised participants. Participants in the intervention group reported more falls than the control group (177 falls versus 123 falls) during the 12-month study period and this difference was statistically significant (incidence rate ratio 1.43, 95% CI 1.07 to 1.93, p = 0.017). At 12-months, performance-based mobility had improved significantly more in the intervention group than in the control group (between-group difference adjusted for baseline performance 0.13, 95% CI 0.04 to 0.21, p = 0.004). Self-reported ease in undertaking mobility tasks over the 12-month period was not significantly different between the groups (0.49, 95% CI -0.91 to 1.90, p = 0.488). Conclusions: An individualised home exercise prescription significantly improved performance-based mobility but significantly increased the rate of falls in older people recently discharged from hospital.	[Sherrington, Catherine] Univ Sydney, George Inst Global Hlth, Sydney, NSW 2006, Australia; [Lord, Stephen R.; Close, Jacqueline C. T.; O'Rourke, Sandra D.; Ramsay, Elisabeth; Barraclough, Elizabeth; Herbert, Robert D.] Univ New S Wales, Neurosci Res Australia, Randwick, NSW, Australia; [Vogler, Constance M.] Univ Sydney, Northern Clin Sch, Sydney, NSW 2006, Australia; [Vogler, Constance M.] Royal N Shore Hosp, Dept Aged Care & Rehabil, St Leonards, NSW 2065, Australia; [Close, Jacqueline C. T.] Univ New S Wales, Prince Wales Clin Sch, Randwick, NSW, Australia; [Howard, Kirsten; Cumming, Robert G.] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia; [Dean, Catherine M.] Macquarie Univ, Fac Human Sci, Dept Hlth Profess, Macquarie Pk, NSW, Australia; [Heller, Gillian Z.] Macquarie Univ, Dept Stat, Macquarie Pk, NSW, Australia; [Clemson, Lindy] Univ Sydney, Fac Hlth Sci, Discipline Occupat Therapy, Sydney, NSW 2006, Australia	George Institute for Global Health; University of Sydney; Neuroscience Research Australia; University of New South Wales Sydney; University of Sydney; Royal North Shore Hospital; University of New South Wales Sydney; University of Sydney; Macquarie University; Macquarie University; University of Sydney	Sherrington, C (corresponding author), Univ Sydney, George Inst Global Hlth, Sydney, NSW 2006, Australia.	csherrington@georgeinstitute.org.au	Herbert, Rob/E-9442-2012; Sherrington, Catherine/S-9196-2019; Lord, Stephen R/C-9612-2011; Cumming, Robert G/R-1548-2016	Herbert, Rob/0000-0003-4188-9195; Sherrington, Catherine/0000-0001-8934-4368; Cumming, Robert G/0000-0002-0261-6103; Dean, Catherine/0000-0001-7502-1138; Close, Jacqueline/0000-0003-2908-9507; Howard, Kirsten/0000-0002-0918-7540; Lord, Stephen R/0000-0002-7111-8802; Heller, Gillian/0000-0003-1270-1499	Australian National Health and Medical Research Council (NHMRC) [457464]; Australian National Health and Medical Research Council Research Fellowships	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Australian National Health and Medical Research Council Research Fellowships(National Health and Medical Research Council (NHMRC) of Australia)	This trial received project grant funding from the Australian National Health and Medical Research Council (NHMRC ID: 457464). Authors Sherrington, Clemson and Lord receive salary funding from Australian National Health and Medical Research Council Research Fellowships. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629; Brooks R., 2003, MEASUREMENT VALUATIO; Cameron ID, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-65; Campbell AJ, 2005, BMJ-BRIT MED J, V331, P817, DOI 10.1136/bmj.38601.447731.55; Campbell AJ, 1997, BMJ-BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065; Clemson L, 2004, J AM GERIATR SOC, V52, P1487, DOI 10.1111/j.1532-5415.2004.52411.x; Dean CM, 2012, NEUROREHAB NEURAL RE, V26, P1046, DOI 10.1177/1545968312441711; Delbaere K, 2010, BRIT J SPORT MED, V44, P1029, DOI 10.1136/bjsm.2009.060350; Faber MJ, 2006, ARCH PHYS MED REHAB, V87, P885, DOI 10.1016/j.apmr.2006.04.005; Fairhall N, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-120; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GIBSON MJ, 1987, DAN MED BULL, V34, P1; Gill TM, 2004, JAMA-J AM MED ASSOC, V292, P2115, DOI 10.1001/jama.292.17.2115; Gillespie L. D., 2012, COCHRANE DB SYST REV, V9, DOI DOI 10.1002/14651858.CD007146; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Haley SM, 2004, ARCH PHYS MED REHAB, V85, P649, DOI 10.1016/j.apmr.2003.08.098; Hauer K, 2001, J AM GERIATR SOC, V49, P10, DOI 10.1046/j.1532-5415.2001.49004.x; Latham NK, 2003, J AM GERIATR SOC, V51, P291, DOI 10.1046/j.1532-5415.2003.51101.x; Lord SR, 2003, PHYS THER, V83, P237, DOI 10.1093/ptj/83.3.237; Lord SR, 1996, ARCH PHYS MED REHAB, V77, P232, DOI 10.1016/S0003-9993(96)90103-3; Lord SR, 2001, J GERONTOL A-BIOL, V56, pM627, DOI 10.1093/gerona/56.10.M627; MAHONEY J, 1994, J AM GERIATR SOC, V42, P269, DOI 10.1111/j.1532-5415.1994.tb01750.x; Mahoney JE, 2000, ARCH INTERN MED, V160, P2788, DOI 10.1001/archinte.160.18.2788; Marcus B H, 1992, Am J Health Promot, V6, P424; Moseley A, 1991, Aust J Physiother, V37, P175, DOI 10.1016/S0004-9514(14)60540-7; Onder G, 2002, J GERONTOL A-BIOL, V57, pM289, DOI 10.1093/gerona/57.5.M289; Pahor M, 2006, J GERONTOL A-BIOL, V61, P1157; Perera S, 2006, J AM GERIATR SOC, V54, P743, DOI 10.1111/j.1532-5415.2006.00701.x; Robertson MC, 2002, J AM GERIATR SOC, V50, P905, DOI 10.1046/j.1532-5415.2002.50218.x; Robertson MC, 2001, BRIT MED J, V322, P697, DOI 10.1136/bmj.322.7288.697; Sherrington C, 2008, J AM GERIATR SOC, V56, P2234, DOI 10.1111/j.1532-5415.2008.02014.x; Sherrington Catherine, 2011, N S W Public Health Bull, V22, P78, DOI 10.1071/NB10056; Sherrington C, 2011, J CLIN EPIDEMIOL, V64, P779, DOI 10.1016/j.jclinepi.2010.09.015; Sherrington Catherine, 2009, BMC Geriatr, V9, P8, DOI 10.1186/1471-2318-9-8; Shrier I, 2014, CLIN TRIALS, V11, P28, DOI 10.1177/1740774513504151; Skelton D, 2005, AGE AGEING, V34, P636, DOI 10.1093/ageing/afi174; Timonen L, 2002, SCAND J MED SCI SPOR, V12, P186, DOI 10.1034/j.1600-0838.2002.120310.x; Vogler CM, 2009, ARCH PHYS MED REHAB, V90, P1317, DOI 10.1016/j.apmr.2009.01.030; Yardley L, 2005, AGE AGEING, V34, P614, DOI 10.1093/ageing/afi196	39	54	54	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2014	9	9							e104412	10.1371/journal.pone.0104412	http://dx.doi.org/10.1371/journal.pone.0104412			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO3LR	25180702	Green Accepted, Green Published, gold			2023-01-03	WOS:000341231500010
J	Gong, XC; Chen, HL; Chen, T; Qu, HB				Gong, Xingchu; Chen, Huali; Chen, Teng; Qu, Haibin			Unit Operation Optimization for the Manufacturing of Botanical Injections Using a Design Space Approach: A Case Study of Water Precipitation	PLOS ONE			English	Article							MICROWAVE-ASSISTED EXTRACTION; PANAX-GINSENG; QUALITY; GINSENOSIDES; FORMULATION; CHROMATOGRAPHY; FLAVONOIDS; SEPARATION; STRATEGY; PRODUCT	Quality by design (QbD) concept is a paradigm for the improvement of botanical injection quality control. In this work, water precipitation process for the manufacturing of Xueshuantong injection, a botanical injection made from Notoginseng Radix et Rhizoma, was optimized using a design space approach as a sample. Saponin recovery and total saponin purity (TSP) in supernatant were identified as the critical quality attributes (CQAs) of water precipitation using a risk assessment for all the processes of Xueshuantong injection. An Ishikawa diagram and experiments of fractional factorial design were applied to determine critical process parameters (CPPs). Dry matter content of concentrated extract (DMCC), amount of water added (AWA), and stirring speed (SS) were identified as CPPs. Box-Behnken designed experiments were carried out to develop models between CPPs and process CQAs. Determination coefficients were higher than 0.86 for all the models. High TSP in supernatant can be obtained when DMCC is low and SS is high. Saponin recoveries decreased as DMCC increased. Incomplete collection of supernatant was the main reason for the loss of saponins. Design space was calculated using a Monte-Carlo simulation method with acceptable probability of 0.90. Recommended normal operation region are located in DMCC of 0.38-0.41 g/g, AWA of 3.7-4.9 g/g, and SS of 280-350 rpm, with a probability more than 0.919 to attain CQA criteria. Verification experiment results showed that operating DMCC, SS, and AWA within design space can attain CQA criteria with high probability.	[Gong, Xingchu; Chen, Huali; Chen, Teng; Qu, Haibin] Zhejiang Univ, Coll Pharmaceut Sci, Pharmaceut Informat Inst, Hangzhou 310003, Zhejiang, Peoples R China	Zhejiang University	Qu, HB (corresponding author), Zhejiang Univ, Coll Pharmaceut Sci, Pharmaceut Informat Inst, Hangzhou 310003, Zhejiang, Peoples R China.	quhb@zju.edu.cn			National S&T Major Project of China [2012ZX09101201-003]; Research Fund for the Doctoral Program of Higher Education of China [20110101120149]	National S&T Major Project of China; Research Fund for the Doctoral Program of Higher Education of China(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	This work was supported by the National S&T Major Project of China (2012ZX09101201-003) and Research Fund for the Doctoral Program of Higher Education of China (20110101120149). Haibin Qu received the first fund. The website is http://www.most.gov.cn/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Xingchu Gong received the second fund. The website is http://www.cutech.edu.cn/cn/kyjj/gdxxbsdkyjj/A010301index_1.htm. Fund were used to buy materials, chemicals, and pay labor costs.	Bhambure R, 2013, BIOTECHNOL PROGR, V29, P403, DOI 10.1002/btpr.1705; Charoo NA, 2012, INT J PHARMACEUT, V423, P167, DOI 10.1016/j.ijpharm.2011.12.024; Chen X, 2007, CHINA PHARM, V18, P41; Chinese Pharmacopoeia Commission, 2011, ZHUSH XUESH DONGG; Debrus B, 2011, ANAL CHIM ACTA, V691, P33, DOI 10.1016/j.aca.2011.02.035; Duan MH, 2013, SEP PURIF TECHNOL, V107, P26, DOI 10.1016/j.seppur.2013.01.003; Gong XC, 2013, SEP PURIF TECHNOL, V107, P273, DOI 10.1016/j.seppur.2013.01.029; Gui QF, 2013, NEURAL REGEN RES, V8, P792, DOI 10.3969/j.issn.1673-5374.2013.09.003; HAN BH, 1982, PLANTA MED, V44, P146, DOI 10.1055/s-2007-971425; Ingvarsson PT, 2013, PHARM RES; Kim SJ, 2007, SEP PURIF TECHNOL, V56, P401, DOI 10.1016/j.seppur.2007.06.014; Korakianiti E, 2011, PHARM RES-DORDR, V28, P1465, DOI 10.1007/s11095-010-0315-3; Li RY, 2012, IND ENG CHEM RES, V51, P8141, DOI 10.1021/ie300945p; [李晓海 Li Xiaohai], 2012, [中国新药杂志, Chinese Journal New Drugs], V21, P1362; Looby M, 2011, BIOTECHNOL PROGR, V27, P1718, DOI 10.1002/btpr.672; Lourenco V, 2012, EUR J PHARM BIOPHARM, V81, P438, DOI 10.1016/j.ejpb.2012.03.003; Martins PF, 2012, SEP PURIF TECHNOL, V98, P464, DOI 10.1016/j.seppur.2012.08.009; Mbinze JK, 2012, J CHROMATOGR A, V1263, P113, DOI 10.1016/j.chroma.2012.09.038; Mockus LN, 2011, PHARM DEV TECHNOL, V16, P549, DOI 10.3109/10837450.2011.611138; Nistor I, 2011, J PHARMACEUT BIOMED, V56, P30, DOI 10.1016/j.jpba.2011.04.027; Nistor I, 2013, J PHARMACEUT BIOMED, V74, P273, DOI 10.1016/j.jpba.2012.10.015; Popovich DG, 2004, PHYTOCHEMISTRY, V65, P337, DOI 10.1016/j.phytochem.2003.11.020; Rozet E, 2013, TRAC-TREND ANAL CHEM, V42, P157, DOI 10.1016/j.trac.2012.09.007; Rozet E, 2012, ANAL CHEM, V84, P106, DOI 10.1021/ac202664s; Wang YT, 2008, FOOD CHEM, V110, P161, DOI 10.1016/j.foodchem.2008.01.028; Xiao WH, 2008, SEP PURIF TECHNOL, V62, P614, DOI 10.1016/j.seppur.2008.03.025; Xiao XH, 2009, SEP PURIF TECHNOL, V68, P250, DOI 10.1016/j.seppur.2009.05.011; Xu XM, 2012, INT J PHARMACEUT, V434, P349, DOI 10.1016/j.ijpharm.2012.06.002; Yu LX, 2008, PHARM RES, V25, P781, DOI 10.1007/s11095-007-9511-1; Zhang L, 2013, AAPS PHARMSCITECH, V14, P277, DOI 10.1208/s12249-012-9919-8; Zheng XZ, 2009, SEP PURIF TECHNOL, V70, P34, DOI 10.1016/j.seppur.2009.08.008	31	12	23	0	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 7	2014	9	8							e104493	10.1371/journal.pone.0104493	http://dx.doi.org/10.1371/journal.pone.0104493			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6SB	25101624	Green Published, gold, Green Submitted			2023-01-03	WOS:000339993900069
J	Patel, A; Laffan, MA; Waheed, U; Brett, SJ				Patel, Amit; Laffan, Michael A.; Waheed, Umeer; Brett, Stephen J.			Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CRITICALLY-ILL PATIENTS; HYDROXYETHYL STARCH 130/0.4; DIFFERENT VOLUME THERAPIES; RETRACTED ARTICLE. SEE; ACUTE KIDNEY INJURY; FLUID RESUSCITATION; SEPTIC SHOCK; HYPOPROTEINEMIC PATIENTS; HYPOALBUMINEMIC PATIENTS; HYPERONCOTIC COLLOIDS	Objective To assess the efficacy and safety of pooled human albumin solutions as part of fluid volume expansion and resuscitation (with or without improvement of baseline hypoalbuminaemia) in critically unwell adults with sepsis of any severity. Design Systematic review and meta-analysis of randomised clinical trials, with trial sequential analysis, subgroup, and meta-regression analyses. Data sources PubMed, PubMed Central, Web of Science (includes Medline, Conference Proceedings Citation Index, Data Citation Index, Chinese Science Citation Database, CAB abstracts, Derwent Innovations Index), OvidSP (includes Embase, Ovid Medline, HMIC, PsycINFO, Maternity and Infant Care, Transport Database), Cochrane Library, clinicaltrials.gov, controlled-trials.com, online material, relevant conference proceedings, hand searching of reference lists, and contact with authors as necessary. Eligibility criteria Prospective randomised clinical trials of adults with sepsis of any severity (with or without baseline hypoalbuminaemia) in critical or intensive care who received pooled human albumin solutions as part of fluid volume expansion and resuscitation (with or without improvement of hypoalbuminaemia) compared with those who received control fluids (crystalloid or colloid), were included if all-cause mortality outcome data were available. No restriction of language, date, publication status, or primary study endpoint was applied. Data extraction Two reviewers independently assessed articles for inclusion, extracted data to assess risk of bias, trial methods, patients, interventions, comparisons, and outcome. The relative risk of all-cause mortality was calculated using a random effects model accounting for clinical heterogeneity. Primary outcome measure All-cause mortality at final follow-up. Results Eighteen articles reporting on 16 primary clinical trials that included 4190 adults in critical or intensive care with sepsis, severe sepsis, or septic shock. A median of 70.0 g daily of pooled human albumin was received over a median of 3 days by adults with a median age of 60.8 years as part of fluid volume expansion and resuscitation, with or without correction of hypoalbuminaemia. The relative risk of death was similar between albumin groups (that received a median of 175 g in total) and control fluid groups (relative risk 0.94; 95% confidence interval 0.87 to 1.01; P=0.11; I-2=0%). Trial sequential analysis corrected the 95% confidence interval for random error (0.85 to 1.02; D-2=0%). Eighty eight per cent of the required information size (meta-analysis sample size) of 4894 patients was achieved, and the cumulative effect size measure (z score) entered the futility area, supporting the notion of no relative benefit of albumin (GRADE quality of evidence was moderate). Evidence of no difference was also found when albumin was compared with crystalloid fluid (relative risk 0.93; 0.86 to 1.01; P=0.07; I-2=0%) in 3878 patents (GRADE quality of evidence was high; 79.9% of required information size) or colloid fluids in 299 patients (relative risk 1.04; 0.79 to 1.38; P=0.76; I-2=0%) (GRADE quality of evidence was very low; 5.8% of required information size). When studies at high risk of bias were excluded in a predefined subgroup analysis, the finding of no mortality benefit remained, and the cumulative z score was just outside the boundary of futility. Overall, the meta-analysis was robust to sensitivity, subgroup, meta-regression, and trial sequential analyses. Conclusions In this analysis, human albumin solutions as part of fluid volume expansion and resuscitation for critically unwell adults with sepsis of any severity (with or without baseline hypoalbuminaemia) were not robustly effective at reducing all-cause mortality. Albumin seems to be safe in this setting, as a signal towards harm was not detected, but this analysis does not support a recommendation for use.	[Patel, Amit; Waheed, Umeer; Brett, Stephen J.] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Ctr Perioperat Med & Crit Care Res, London W12 0HS, England; [Patel, Amit] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, MRC Clin Sci Ctr, London, England; [Patel, Amit; Laffan, Michael A.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Ctr Haematol, London, England	Imperial College London; Imperial College London; Imperial College London	Patel, A (corresponding author), Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Ctr Perioperat Med & Crit Care Res, London W12 0HS, England.	amit.patel@imperial.ac.uk		Laffan, Michael/0000-0002-8268-3268	Medical Research Council (MRC); National Institute for Health Research (NIHR) Biomedical Research Centre	Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research (NIHR) Biomedical Research Centre(National Institute for Health Research (NIHR))	This research was not directly funded. AP is funded by the Medical Research Council (MRC) Chain-Florey Fellowship scheme based at the Clinical Sciences Centre, Imperial College London. All authors are supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the authors and not necessarily those of the NHS, NIHR, or Department of Health. The research and authors are independent of funders.	Administration UFaD, 2013, FDA SAF COMM BOX WAR; Agency EM, 2013, EMA8094702013 AG EM; Almeida A, 2013, LACTATED RINGER VERS; Annane D, 2013, JAMA-J AM MED ASSOC, V310, P1809, DOI 10.1001/jama.2013.280502; [Anonymous], 2013, 174 NICE CLIN; [Anonymous], 2009, CHEST; [Anonymous], 2013, BRIT NAT FORM BNF; Artero A, 2010, J CRIT CARE, V25, P276, DOI 10.1016/j.jcrc.2009.12.004; Bansal M, 2013, CURR DRUG SAF, V8, P236, DOI 10.2174/15748863113089990046; Bar-Or D, 2005, CRIT CARE MED, V33, P1638, DOI 10.1097/01.CCM.0000169876.14858.91; Boldt J, 1996, INTENS CARE MED, V22, P1075, DOI 10.1007/s001340050216; BOLDT J, 1995, BRIT J ANAESTH, V75, P740, DOI 10.1093/bja/75.6.740; Boldt J, 1996, CRIT CARE MED, V24, P385, DOI 10.1097/00003246-199603000-00005; Boldt J, 2014, BRIT J ANAESTH, V112, P397, DOI 10.1093/bja/aet488; Boldt J, 2014, INTENS CARE MED, V40, P145, DOI 10.1007/s00134-013-3164-9; Boldt J, 1996, ANESTH ANALG, V83, P254, DOI 10.1097/00000539-199608000-00010; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Bulanov A Iu, 2004, Anesteziol Reanimatol, P25; Bunn F, 2012, COCHRANE DB SYST REV, V7; Caironi P, 2014, NEW ENGL J MED, V370, P1412, DOI 10.1056/NEJMoa1305727; Charpentier J, 2011, INTENS CARE MED, V37, pS115; Christopher KB, 2012, INTENS CARE MED, V38, P1; COHEN IL, 1993, CRIT CARE MED, V21, P476, DOI 10.1097/00003246-199303000-00032; Cohen J, 2001, CRIT CARE MED, V29, P880, DOI 10.1097/00003246-200104000-00039; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; Cui Jin-ying, 2012, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V24, P18; Dechartres A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2304; Delaney AP, 2011, CRIT CARE MED, V39, P386, DOI 10.1097/CCM.0b013e3181ffe217; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Dellinger RP, 2004, INTENS CARE MED, V30, P536, DOI 10.1007/s00134-004-2210-z; Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dolecek M, 2009, HEPATO-GASTROENTEROL, V56, P1622; Dubois MJ, 2006, CRIT CARE MED, V34, P2536, DOI 10.1097/01.CCM.0000239119.57544.0C; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ernest D, 1999, CRIT CARE MED, V27, P46, DOI 10.1097/00003246-199901000-00025; FALK JL, 1988, J CLIN PHARMACOL, V28, P412, DOI 10.1002/j.1552-4604.1988.tb05751.x; Farrugia A, 2014, REV RECENT CLIN TRIA, V9, P21, DOI 10.2174/1574887108666131213120816; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finfer S, 2004, VOX SANG, V87, P123, DOI 10.1111/j.1741-6892.2004.00468.x; Finfer S, 2006, BRIT MED J, V333, P1044, DOI 10.1136/bmj.38985.398704.7C; Finfer S, 2011, INTENS CARE MED, V37, P86, DOI 10.1007/s00134-010-2039-6; Finfer S, 2010, CRIT CARE, V14, DOI 10.1186/cc9293; FOLEY EF, 1990, ARCH SURG-CHICAGO, V125, P739; Friedman G, 2008, J CLIN ANESTH, V20, P528, DOI 10.1016/j.jclinane.2008.05.022; Gattas DJ, 2013, INTENS CARE MED, V39, P558, DOI 10.1007/s00134-013-2840-0; Goldwasser P, 1997, J CLIN EPIDEMIOL, V50, P693, DOI 10.1016/S0895-4356(97)00015-2; GOLUB R, 1994, CRIT CARE MED, V22, P613, DOI 10.1097/00003246-199404000-00017; Gondos T, 2010, EUR J ANAESTH, V27, P794, DOI 10.1097/EJA.0b013e32833b3504; Guidet B, 2007, J CRIT CARE, V22, P197, DOI 10.1016/j.jcrc.2006.11.005; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Haase N, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f839; Hartog CS, 2010, INTENS CARE MED, V36, P553, DOI 10.1007/s00134-009-1736-5; HAUPT MT, 1982, CRIT CARE MED, V10, P159, DOI 10.1097/00003246-198203000-00004; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hondebrink Y, 1997, INTENSIVE CARE ME S1, V23, pS184; Hospital L., 2012, HOSP PRES RES FIN RE; Jacob M, 2008, CRIT CARE, V12, DOI 10.1186/cc6812; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Leitch A, 2013, J INTENSIVE CARE SOC, V14, P45, DOI DOI 10.1177/175114371301400110; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Martin GS, 2005, CRIT CARE MED, V33, P1681, DOI 10.1097/01.CCM.0000171539.47006.02; Martin GS, 2002, CRIT CARE MED, V30, P2175, DOI 10.1097/00003246-200210000-00001; Matejtschuk P, 2000, BRIT J ANAESTH, V85, P887, DOI 10.1093/bja/85.6.887; Mayr W, 2004, VOX SANG, V87, P142, DOI 10.1111/j.1423-0410.2004.00547.x; McIntyre L, 2012, TRANSFUS MED REV, V26, P333, DOI 10.1016/j.tmrv.2011.11.003; McIntyre LA, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.10.007; METILDI LA, 1984, SURG GYNECOL OBSTET, V158, P207; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Onwuegbuzie A.J., 2004, UNDERSTANDING STAT, V3, P201, DOI DOI 10.1207/S15328031US0304_1; Palumbo D, 2006, MINERVA ANESTESIOL, V72, P655; Panagiotou OA, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f707; Patel Amit, 2013, Br J Hosp Med (Lond), V74, P657; Patel A, 2013, INTENS CARE MED, V39, P811, DOI 10.1007/s00134-013-2863-6; Perel P, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub5; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; Quinlan GJ, 1998, CLIN SCI, V95, P459, DOI 10.1042/CS19980191; Quinlan GJ, 2004, CRIT CARE MED, V32, P755, DOI 10.1097/01.CCM.0000114574.18641.5D; RACKOW EC, 1983, CRIT CARE MED, V11, P839, DOI 10.1097/00003246-198311000-00001; RACKOW EC, 1989, CRIT CARE MED, V17, P394, DOI 10.1097/00003246-198905000-00003; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Ranieri VM, 2012, NEW ENGL J MED, V366, P2055, DOI 10.1056/NEJMoa1202290; Roberts I, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001208.pub4, 10.1002/14651858.CD001208.pub3]; Rubin H, 1997, CRIT CARE MED, V25, P249, DOI 10.1097/00003246-199702000-00009; Russell JA, 2008, NEW ENGL J MED, V358, P877, DOI 10.1056/NEJMoa067373; Salerno F, 2013, CLIN GASTROENTEROL H, V11, P123, DOI 10.1016/j.cgh.2012.11.007; Schortgen F, 2001, LANCET, V357, P911, DOI 10.1016/S0140-6736(00)04211-2; Schortgen F, 2008, INTENS CARE MED, V34, P2157, DOI 10.1007/s00134-008-1225-2; Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0; Sterne JAC, 2001, BMJ-BRIT MED J, V322, P226, DOI 10.1136/bmj.322.7280.226; STOCKWELL MA, 1992, ANAESTHESIA, V47, P7, DOI 10.1111/j.1365-2044.1992.tb01942.x; STOCKWELL MA, 1992, ANAESTHESIA, V47, P3, DOI 10.1111/j.1365-2044.1992.tb01941.x; Tabor E, 1999, TRANSFUSION, V39, P1160, DOI 10.1046/j.1537-2995.1999.39111160.x; Thomas-Rueddel DO, 2012, INTENS CARE MED, V38, P1134, DOI 10.1007/s00134-012-2560-x; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187; Thorlund K., 2011, USER MANUAL TRIAL SE; Thorlund K, 2009, INT J EPIDEMIOL, V38, P276, DOI 10.1093/ije/dyn179; Timmer B, 1998, NETHERLANDS J MED, V52, pA42; Trof RJ, 2010, INTENS CARE MED, V36, P697, DOI 10.1007/s00134-010-1776-x; van der Heijden M, 2009, CRIT CARE MED, V37, P1275, DOI 10.1097/CCM.0b013e31819cedfd; Veneman TF, 2004, WIEN KLIN WOCHENSCHR, V116, P305, DOI 10.1007/BF03040900; Verheij J, 2006, INTENS CARE MED, V32, P1030, DOI 10.1007/s00134-006-0195-5; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Vincent JL, 2004, CRIT CARE MED, V32, P2029, DOI 10.1097/01.CCM.0000142574.00425.E9; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Vincent JL, 2003, BRIT J ANAESTH, V91, P625, DOI 10.1093/bja/aeg233; Vincent JL, 2003, ANN SURG, V237, P319, DOI 10.1097/00000658-200303000-00005; von Hoegen I, 2001, CRIT CARE MED, V29, P994, DOI 10.1097/00003246-200105000-00021; Wang Y, 2013, CHINESE MED J-PEKING, V126, P3379, DOI 10.3760/cma.j.issn.0366-6999.20130743; Wetterslev J, 2008, J CLIN EPIDEMIOL, V61, P64, DOI 10.1016/j.jclinepi.2007.03.013; Wetterslev J, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-86; Wiedermann CJ, 2013, SWISS MED WKLY, V143, DOI 10.4414/smw.2013.13747; Wiedermann CJ, 2010, CRIT CARE, V14, DOI 10.1186/cc9308; Wise J, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1738; WOJTYSIAK SL, 1992, CRIT CARE MED, V20, P164, DOI 10.1097/00003246-199202000-00005; YIM JM, 1995, ARCH INTERN MED, V155, P2450, DOI 10.1001/archinte.155.22.2450; Zarychanski R, 2013, JAMA-J AM MED ASSOC, V309, P678, DOI 10.1001/jama.2013.430; Zhang ZH, 2013, CRIT CARE, V17, DOI 10.1186/cc11919	124	122	132	1	39	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 22	2014	349								g4561	10.1136/bmj.g4561	http://dx.doi.org/10.1136/bmj.g4561			28	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AM0VN	25099709	Green Published, hybrid			2023-01-03	WOS:000339565700001
J	Rachlis, B; Cole, DC; van Lettow, M; Escobar, M; Muula, AS; Ahmad, F; Orbinski, J; Chan, AK				Rachlis, Beth; Cole, Donald C.; van Lettow, Monique; Escobar, Michael; Muula, Adamson S.; Ahmad, Farah; Orbinski, James; Chan, Adrienne K.			Follow-Up Visit Patterns in an Antiretroviral Therapy (ART) Programme in Zomba, Malawi	PLOS ONE			English	Article							HIV-INFECTED PATIENTS; SUB-SAHARAN AFRICA; SOUTH-AFRICA; PATIENTS LOST; ADULT PATIENTS; PATIENT RETENTION; DRUG-RESISTANCE; UNITED-STATES; HIV/AIDS CARE; 1ST YEAR	Background: Identifying follow-up (FU) visit patterns, and exploring which factors influence them are likely to be useful in determining which patients on antiretroviral therapy (ART) may become Lost to Follow-Up (LTFU). Using an operation and implementation research approach, we sought 1) to describe the timing of FU visits amongst patients who have been on ART for shorter and longer periods of time; and 2) to determine the median time to late visits, and 3) to identify specific factors that may be associated with these patterns in Zomba, Malawi. Methods and Findings: Using routinely collected programme monitoring data from Zomba District, we performed descriptive analyses on all ART visits among patients who initiated ART between Jan. 1, 2007-June 30, 2010. Based on an expected FU date, each FU visit was classified as early (>= 4 day before an expected FU date), on time (3 days before an expected FU date/up to 6 days after an expected FU date), or late (>= 7 days after an expected FU date). In total, 7,815 patients with 76417 FU visits were included. Ninety-two percent of patients had >= 2 FU visits. At the majority of visits, patients were either on time or late. The median time to a first late visit among those with 2 or more visits was 216 days (IQR: 128-359). Various patient-and visit-level factors differed significantly across Early, On Time, and Late visit groups including ART adherence and frequency of, and type of side effects. Discussion: The majority of patients do not demonstrate consistent FU visit patterns. Individuals were generally on ART for at least 6 months before experiencing their first late visit. Our findings have implications for the development of effective interventions that meet patient needs when they present early and can reduce patient losses to follow-up when they are late. In particular, time-varying visit characteristics need further research.	[Rachlis, Beth; Cole, Donald C.; van Lettow, Monique; Escobar, Michael; Chan, Adrienne K.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [van Lettow, Monique; Chan, Adrienne K.] Dignitas Int, Zomba, Malawi; [Muula, Adamson S.] Univ Malawi, Coll Med, Blantyre, Malawi; [Ahmad, Farah] York Univ, Sch Hlth Policy & Management, Toronto, ON M3J 2R7, Canada; [Orbinski, James] Ctr Int Governance Innovat, Waterloo, ON, Canada; [Chan, Adrienne K.] Sunnybrook Hlth Sci Ctr, Div Infect Dis, Toronto, ON M4N 3M5, Canada	University of Toronto; University of Malawi; York University - Canada; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Rachlis, B (corresponding author), Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.	beth.rachlis@utoronto.ca	Ahmad, Farah/B-4261-2008; Muula, Adamson/AAF-1153-2020	Ahmad, Farah/0000-0001-9747-1148; Escobar, Michael/0000-0001-9055-4709	Canadian Institutes of Health Research Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Alamo ST, 2012, JAIDS-J ACQ IMM DEF, V60, pE36, DOI 10.1097/FTD.0b013e3182526e6a; ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; [Anonymous], 2012, GLOB REP UNAIDS REP; Bangsberg DR, 2003, AIDS, V17, P1925, DOI 10.1097/00002030-200309050-00011; Bastard M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049091; Bedelu M, 2007, J INFECT DIS, V196, pS464, DOI 10.1086/521114; Birbeck GL, 2009, AM J TROP MED HYG, V80, P669, DOI 10.4269/ajtmh.2009.80.669; Bisson GP, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000174; Bisson GP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001725; Braitstein P, 2008, J WOMENS HEALTH, V17, P47, DOI 10.1089/jwh.2007.0353; Braitstein P, 2012, J INT AIDS SOC, V15, DOI 10.1186/1758-2652-15-7; Brennan AT, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-49; Brinkhof MWG, 2008, B WORLD HEALTH ORGAN, V86, P559, DOI 10.2471/BLT.07.044248; Brugha R, 2003, BRIT MED J, V326, P1382, DOI 10.1136/bmj.326.7403.1382; Callaghan M, 2010, HUM RESOUR HEALTH, V8, DOI 10.1186/1478-4491-8-8; Chalker John, 2008, J Int Assoc Physicians AIDS Care (Chic), V7, P193, DOI 10.1177/1545109708320687; Chan AK, 2010, TROP MED INT HEALTH, V15, P90, DOI 10.1111/j.1365-3156.2010.02503.x; Chen SCC, 2008, TROP MED INT HEALTH, V13, P513, DOI 10.1111/j.1365-3156.2008.02029.x; Chimbwandira F, 2013, MMWR-MORBID MORTAL W, V62, P148; Cornell M, 2010, AIDS, V24, P2263, DOI 10.1097/QAD.0b013e32833d45c5; Cornell M, 2009, TROP MED INT HEALTH, V14, P722, DOI 10.1111/j.1365-3156.2009.02290.x; Dahab M, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-63; Dalal RP, 2008, JAIDS-J ACQ IMM DEF, V47, P101, DOI 10.1097/QAI.0b013e31815b833a; Daniel O. J., 2008, African Journal of Biomedical Research, V11, P221; Davies MA, 2009, CLIN INFECT DIS, V49, P973, DOI 10.1086/605501; Eholie SP, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17334; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Fatti G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012888; Ford N, 2010, AIDS, V24, P2645, DOI 10.1097/QAD.0b013e32833ec5b2; Fox MP, 2010, TROP MED INT HEALTH, V15, P1, DOI 10.1111/j.1365-3156.2010.02508.x; Geng Elvin H, 2010, Curr HIV/AIDS Rep, V7, P234, DOI 10.1007/s11904-010-0061-5; Geng EH, 2010, TROP MED INT HEALTH, V15, P63, DOI 10.1111/j.1365-3156.2010.02507.x; Geng EH, 2010, JAIDS-J ACQ IMM DEF, V53, P405, DOI 10.1097/QAI.0b013e3181b843f0; Gilbert L, 2010, HEALTH SOC CARE COMM, V18, P139, DOI 10.1111/j.1365-2524.2009.00881.x; Harries AD, 2010, TROP MED INT HEALTH, V15, P70, DOI 10.1111/j.1365-3156.2010.02506.x; Horberg MA, 2013, AIDS PATIENT CARE ST, V27, P442, DOI 10.1089/apc.2013.0073; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2008, GLOB REP UNAIDS REP; Joint United Nations Programme on HIV/AIDS Website (UNAIDS), 2012, REP GLOB AIDS PAND; Kalichman SC, 1999, J GEN INTERN MED, V14, P267, DOI 10.1046/j.1525-1497.1999.00334.x; Kunutsor S, 2010, AIDS RES TREAT, V2010, DOI 10.1155/2010/872396; Malawi Ministry of Health, 2008, TREATM AIDS GUID US; Malawi National Statistical Office and MEASURE DHS, 2010, MAL DEM HLTH SURV 20; Massaquoi M, 2009, T ROY SOC TROP MED H, V103, P594, DOI 10.1016/j.trstmh.2009.02.012; McGuire M, 2010, TROP MED INT HEALTH, V15, P55, DOI 10.1111/j.1365-3156.2010.02504.x; Miller CM, 2010, TROP MED INT HEALTH, V15, P48, DOI 10.1111/j.1365-3156.2010.02514.x; Mills EJ, 2006, PLOS MED, V3, P2039, DOI 10.1371/journal.pmed.0030438; Ministry of Health Government of Malawi, 2012, INT HIV PROGR REP JU; Mugavero MJ, 2009, CLIN INFECT DIS, V48, P248, DOI 10.1086/595705; Mukora R, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-205; Murray LK, 2009, AIDS CARE, V21, P78, DOI 10.1080/09540120802032643; Mutevedzi PC, 2013, TROP MED INT HEALTH, V18, P934, DOI 10.1111/tmi.12135; Muula AS, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-63; Norman A, 2007, AM J PUBLIC HEALTH, V97, P1775, DOI 10.2105/AJPH.2005.082511; O'Connor C, 2011, JAIDS-J ACQ IMM DEF, V58, P429, DOI 10.1097/QAI.0b013e318230d507; Ochieng-Ooko V, 2010, B WORLD HEALTH ORGAN, V88, P681, DOI 10.2471/BLT.09.064329; Peters DH, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6753; Pinto AD, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18055; Rachlis BS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018948; Ramadhani HO, 2007, CLIN INFECT DIS, V45, P1492, DOI 10.1086/522991; Remien RH, 2003, ADHERENCE MEDICATION; Rich ML, 2012, JAIDS-J ACQ IMM DEF, V59, pE35, DOI 10.1097/QAI.0b013e31824476c4; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Rougemont Mathieu, 2009, AIDS Res Ther, V6, P21, DOI 10.1186/1742-6405-6-21; Samitz G, 2011, INT J EPIDEMIOL, V40, P1382, DOI 10.1093/ije/dyr112; Schouten Erik J, 2011, J Int AIDS Soc, V14 Suppl 1, pS4, DOI 10.1186/1758-2652-14-S1-S4; Skiest DJ, 2007, J INFECT DIS, V195, P1426, DOI 10.1086/512681; Torpey KE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002204; Tuller DM, 2010, AIDS BEHAV, V14, P778, DOI 10.1007/s10461-009-9533-2; Tweya H, 2010, TROP MED INT HEALTH, V15, P82, DOI 10.1111/j.1365-3156.2010.02509.x; Uzochukwu BSC, 2009, HEALTH POLICY PLANN, V24, P189, DOI 10.1093/heapol/czp006; van Oosterhout JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042029; Watt MH, 2009, SOC SCI MED, V68, P1793, DOI 10.1016/j.socscimed.2009.02.037; Weigel R, 2012, AIDS, V26, P365, DOI 10.1097/QAD.0b013e32834ed814; World Health Organization Website, 2009, PRIOR INT HIV AIDS P; Yiannoustos CT, 2008, PLOS ONE, V3, pe38	75	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2014	9	7							e101875	10.1371/journal.pone.0101875	http://dx.doi.org/10.1371/journal.pone.0101875			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AL8VR	25033285	Green Published, gold, Green Submitted			2023-01-03	WOS:000339418300028
J	Nageshwaran, S; Davies, LM; Rafi, I; Radunovic, A				Nageshwaran, Saiji; Davies, Lucy Medina; Rafi, Imran; Radunovic, Aleksandar			EASILY MISSED? Motor neurone disease	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							MANAGEMENT; DIAGNOSIS		[Nageshwaran, Saiji; Rafi, Imran] Univ London, Dept Populat Hlth Sci & Educ, London SW17 0RE, England; [Davies, Lucy Medina; Rafi, Imran] Royal Coll Gen Practitioners, Clin Innovat & Res Ctr, London, England; [Radunovic, Aleksandar] Royal London Hosp, Barts Motor Neurone Dis Ctr, London E1 1BB, England	University of London; Barts Health NHS Trust; Royal London Hospital	Nageshwaran, S (corresponding author), Univ London, Dept Populat Hlth Sci & Educ, London SW17 0RE, England.	saiji@doctors.org.uk						Hardiman O, 2011, NAT REV NEUROL, V7, P639, DOI 10.1038/nrneurol.2011.153; Leigh PN, 2003, J NEUROL NEUROSUR PS, V74, P32; McDermott CJ, 2008, BMJ-BRIT MED J, V336, P658, DOI 10.1136/bmj.39493.511759.BE; Miller RG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001447.pub3; Mitchell JD, 2010, AMYOTROPH LATERAL SC, V11, P537, DOI 10.3109/17482968.2010.495158; National Institute for Health and Care Excellence, 2010, MOT NEUR DIS US NON; National Institute for Health and Care Excellence, 2001, GUID US RIL RIL TREA; Radunovic A, 2013, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD004427.PUB.3; Radunovic A, 2007, LANCET NEUROL, V6, P913, DOI 10.1016/S1474-4422(07)70244-2; Royal College of General Practitioners, RAR DIS RED FLAGS TO; Turner Martin R, 2013, Pract Neurol, V13, P153, DOI 10.1136/practneurol-2013-000557	11	8	8	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 9	2014	349								g4052	10.1136/bmj.g4052	http://dx.doi.org/10.1136/bmj.g4052			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AL2ZD	25008100				2023-01-03	WOS:000338993500002
J	Harris, JK; El Kasmi, KC; Anderson, AL; Devereaux, MW; Fillon, SA; Robertson, CE; Wagner, BD; Stevens, MJ; Pace, NR; Sokol, RJ				Harris, J. Kirk; El Kasmi, Karim C.; Anderson, Aimee L.; Devereaux, Michael W.; Fillon, Sophie A.; Robertson, Charles E.; Wagner, Brandie D.; Stevens, Mark J.; Pace, Norman R.; Sokol, Ronald J.			Specific Microbiome Changes in a Mouse Model of Parenteral Nutrition Associated Liver Injury and Intestinal Inflammation	PLOS ONE			English	Article							BARCODED PRIMERS; DISEASE; CHOLESTASIS; INFANTS; FAILURE; CHILDREN	Background: Parenteral nutrition (PN) has been a life-saving treatment in infants intolerant of enteral feedings. However, PN is associated with liver injury (PN Associated Liver Injury: PNALI) in a significant number of PN-dependent infants. We have previously reported a novel PNALI mouse model in which PN infusion combined with intestinal injury results in liver injury. In this model, lipopolysaccharide activation of toll-like receptor 4 signaling, soy oil-derived plant sterols, and proinflammatory activation of Kupffer cells (KCs) played key roles. The objective of this study was to explore changes in the intestinal microbiome associated with PNALI. Methodology and Principal Findings: Microbiome analysis in the PNALI mouse identified specific alterations within colonic microbiota associated with PNALI and further association of these communities with the lipid composition of the PN solution. Intestinal inflammation or soy oil-based PN infusion alone (in the absence of enteral feeds) caused shifts within the gut microbiota. However, the combination resulted in accumulation of a specific taxon, Erysipelotrichaceae (23.8% vs. 1.7% in saline infused controls), in PNALI mice. Moreover, PNALI was markedly attenuated by enteral antibiotic treatment, which also was associated with significant reduction of Erysipelotrichaceae (0.6%) and a Gram-negative constituent, the S24-7 lineage of Bacteroidetes (53.5% in PNALI vs. 0.8%). Importantly, removal of soy oil based-lipid emulsion from the PN solution resulted in significant reduction of Erysipelotrichaceae as well as attenuation of PNALI. Finally, addition of soy-derived plant sterol (stigmasterol) to fish oil-based PN restored Erysipelotrichaceae abundance and PNALI. Conclusions: Soy oil-derived plant sterols and the associated specific bacterial groups in the colonic microbiota are associated with PNALI. Products from these bacteria may directly trigger activation of KCs and promote PNALI. Furthermore, the results indicate that lipid modification of PN solutions may alter specific intestinal bacterial species associated with PNALI, and thus suggest strategies for management of PNALI.	[Harris, J. Kirk; Stevens, Mark J.] Univ Colorado, Sect Pulm Med, Dept Pediat, Aurora, CO 80045 USA; [El Kasmi, Karim C.; Anderson, Aimee L.; Devereaux, Michael W.; Fillon, Sophie A.; Sokol, Ronald J.] Univ Colorado, Sch Med, Childrens Hosp Colorado, Dept Pediat,Sect Gastroenterol Hepatol & Nutr,Dig, Aurora, CO USA; [Robertson, Charles E.; Pace, Norman R.] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; [Wagner, Brandie D.] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Boulder; Children's Hospital Colorado; Colorado School of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus	Harris, JK (corresponding author), Univ Colorado, Sect Pulm Med, Dept Pediat, Aurora, CO 80045 USA.	jonathan.harris@ucdenver.edu		ROBERTSON, CHARLES/0000-0002-4136-4121; Harris, Jonathan/0000-0002-2378-4202; Wagner, brandie/0000-0002-2745-0103	NIH [3P30DK048520]; NIH/NCATS Colorado CTSA [KL2 TR000156-05, UL1 TR000154-05]; Children's Hospital Colorado Research Institute; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082, UL1TR000154, KL2TR001080, KL2TR000156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048520] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCATS Colorado CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Children's Hospital Colorado Research Institute; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported in part by NIH grant 3P30DK048520 and by NIH/NCATS Colorado CTSA Grants KL2 TR000156-05 (SAF) and UL1 TR000154-05 (RJS), and Children's Hospital Colorado Research Institute (KCE and RJS). Its contents are the authors' sole responsibility and do not necessarily represent official NIH views. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aitchinson EJ, 1986, STAT ANAL COMPOSITIO; BEALE EF, 1979, PEDIATRICS, V64, P342; Beath SV, 1996, J PEDIATR SURG, V31, P604, DOI 10.1016/S0022-3468(96)90507-2; BELL RL, 1986, JPEN-PARENTER ENTER, V10, P356, DOI 10.1177/0148607186010004356; BENJAMIN DR, 1981, AM J CLIN PATHOL, V76, P276; Botha JF, 2006, LIVER TRANSPLANT, V12, P1062, DOI 10.1002/lt.20763; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Brown EM, 2013, NAT IMMUNOL, V14, P660, DOI 10.1038/ni.2611; Btaiche IF, 2002, PHARMACOTHERAPY, V22, P188, DOI 10.1592/phco.22.3.188.33553; Buchman A, 2002, JPEN-PARENTER ENTER, V26, pS43, DOI 10.1177/014860710202600512; Buchman AL, 2006, HEPATOLOGY, V43, P9, DOI 10.1002/hep.20997; Carter BA, 2007, SEMIN LIVER DIS, V27, P251, DOI 10.1055/s-2007-985070; Carter BA, 2007, NAT CLIN PRACT GASTR, V4, P277, DOI 10.1038/ncpgasthep0796; COHEN C, 1981, ARCH PATHOL LAB MED, V105, P152; COLOMB V, 1994, TRANSPLANT P, V26, P1467; Conterno L, 2011, GENES NUTR, V6, P241, DOI 10.1007/s12263-011-0230-1; Duro D, 2008, J PEDIATR GASTR NUTR, V47, pS33, DOI 10.1097/MPG.0b013e3181819007; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; El Kasmi KC, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006898; El Kasmi KC, 2012, HEPATOLOGY, V55, P1518, DOI 10.1002/hep.25500; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Filzmoser P, 2009, SCI TOTAL ENVIRON, V407, P6100, DOI 10.1016/j.scitotenv.2009.08.008; Fouts DE, 2012, J HEPATOL, V56, P1283, DOI 10.1016/j.jhep.2012.01.019; Frank DN, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-362; Gura KM, 2006, PEDIATRICS, V118, pE197, DOI 10.1542/peds.2005-2662; Haas BJ, 2011, GENOME RES; Hamady M, 2008, NAT METHODS, V5, P235, DOI 10.1038/NMETH.1184; Harris JK, 2012, J ALLERGY CLIN IMMUN, V129, P441, DOI 10.1016/j.jaci.2011.12.969; Harris JK, 2010, APPL ENVIRON MICROB, V76, P3863, DOI 10.1128/AEM.02585-09; HODES JE, 1982, J PEDIATR SURG, V17, P463, DOI 10.1016/S0022-3468(82)80090-0; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Jeejeebhoy KN, 2001, AM J CLIN NUTR, V74, P160; Kaufman SS, 1997, J PEDIATR-US, V131, P356, DOI 10.1016/S0022-3476(97)80058-3; Kaufman Stuart S, 2003, Semin Neonatol, V8, P375, DOI 10.1016/S1084-2756(03)00094-0; Kelly DA, 2006, GASTROENTEROLOGY, V130, pS70, DOI 10.1053/j.gastro.2005.10.066; Martinez I, 2012, APPL ENV MICROBIOL; Martinez I, 2009, APPL ENVIRON MICROB, V75, P4175, DOI 10.1128/AEM.00380-09; Miyasaka EA, 2013, J IMMUNOL, V190, P6607, DOI 10.4049/jimmunol.1201746; MOSS RL, 1993, J PEDIATR SURG, V28, P1270, DOI 10.1016/S0022-3468(05)80311-2; MULLICK FG, 1994, MODERN PATHOL, V7, P190; Neil C, 2007, J AM COLL SURGEONS, V205, P755, DOI 10.1016/j.jamcollsurg.2007.06.299; Pruesse E, 2012, BIOINFORMATICS, V28, P1823, DOI 10.1093/bioinformatics/bts252; Quast Christian, 2013, Nucleic Acids Res, V41, pD590, DOI 10.1093/nar/gks1219; Robertson CE, 2013, BIOINFORMATICS; Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515; Salzman NH, 2002, MICROBIOL-SGM, V148, P3651, DOI 10.1099/00221287-148-11-3651; Schloss PD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027310; Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663; Sokol Ronald J., 1997, Acta Paediatrica Sinica, V38, P418; Spor A, 2011, NAT REV MICROBIOL, V9, P279, DOI 10.1038/nrmicro2540; TAYLOR SF, 1991, J PEDIATR-US, V119, P24, DOI 10.1016/S0022-3476(05)81033-9; Teitelbaum D H, 2001, Semin Pediatr Surg, V10, P72, DOI 10.1053/spsu.2001.22386; Teitelbaum DH, 1997, CURR OPIN PEDIATR, V9, P270; Trauner M, 2003, CURR OPIN GASTROEN, V19, P216, DOI 10.1097/00001574-200305000-00005; Turnbaugh PJ, 2008, CELL HOST MICROBE, V3, P213, DOI 10.1016/j.chom.2008.02.015; Werner JJ, 2012, ISME J, V6, P94, DOI 10.1038/ismej.2011.82; WILMORE DW, 1968, J AMER MED ASSOC, V203, P860, DOI 10.1001/jama.203.10.860; Yan AW, 2011, HEPATOLOGY, V53, P96, DOI 10.1002/hep.24018; Zambrano E, 2004, PEDIATR DEVEL PATHOL, V7, P425, DOI 10.1007/s10024-001-0154-7	59	49	52	3	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2014	9	10							e110396	10.1371/journal.pone.0110396	http://dx.doi.org/10.1371/journal.pone.0110396			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0AY	25329595	Green Published, gold, Green Submitted			2023-01-03	WOS:000343942100060
J	Tan, LBG; Lo, BCY; Macrae, CN				Tan, Lucy B. G.; Lo, Barbara C. Y.; Macrae, C. Neil			Brief Mindfulness Meditation Improves Mental State Attribution and Empathizing	PLOS ONE			English	Article							MIND; MECHANISMS; ATTENTION	The ability to infer and understand the mental states of others (i.e., Theory of Mind) is a cornerstone of human interaction. While considerable efforts have focused on explicating when, why and for whom this fundamental psychological ability can go awry, considerably less is known about factors that may enhance theory of mind. Accordingly, the current study explored the possibility that mindfulness-based meditation may improve people's mindreading skills. Following a 5-minute mindfulness induction, participants with no prior meditation experience completed tests that assessed mindreading and empathic understanding. The results revealed that brief mindfulness meditation enhanced both mental state attribution and empathic concern, compared to participants in the control group. These findings suggest that mindfulness may be a powerful technique for facilitating core aspects of social-cognitive functioning.	[Tan, Lucy B. G.] Univ Queensland, Sch Med, Psychiat Discipline, Brisbane, Qld, Australia; [Lo, Barbara C. Y.] Univ Hong Kong, Dept Psychol, Hong Kong, Hong Kong, Peoples R China; [Macrae, C. Neil] Univ Aberdeen, Sch Psychol, Aberdeen AB9 1FX, Scotland	University of Queensland; University of Hong Kong; University of Aberdeen	Tan, LBG (corresponding author), Univ Queensland, Sch Med, Psychiat Discipline, Brisbane, Qld, Australia.	lucy.tan@uq.edu.au			Australia Prime Minister's Endeavour Asia Award	Australia Prime Minister's Endeavour Asia Award(Australian GovernmentDepartment of Industry, Innovation and Science)	LBGT was supported by an Australia Prime Minister's Endeavour Asia Award. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Baer Ruth A., 2009, Cognitive Behaviour Therapy, V38, P15, DOI 10.1080/16506070902980703; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1111/1469-7610.00715; Baron-Cohen S, 1995, MINDBLINDNESS ESSAY; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Bishop SR, 2004, CLIN PSYCHOL-SCI PR, V11, P230, DOI 10.1093/clipsy/bph077; Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822; Creswell JD, 2007, PSYCHOSOM MED, V69, P560, DOI 10.1097/PSY.0b013e3180f6171f; Decety Jean, 2004, Behav Cogn Neurosci Rev, V3, P71, DOI 10.1177/1534582304267187; Dekeyser M, 2008, PERS INDIV DIFFER, V44, P1235, DOI 10.1016/j.paid.2007.11.018; Farb NAS, 2007, SOC COGN AFFECT NEUR, V2, P313, DOI 10.1093/scan/nsm030; Frith CD, 2012, ANNU REV PSYCHOL, V63, P287, DOI 10.1146/annurev-psych-120710-100449; Gallagher HL, 2003, TRENDS COGN SCI, V7, P77, DOI 10.1016/S1364-6613(02)00025-6; Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020; HAPPE FGE, 1995, CHILD DEV, V66, P843, DOI 10.2307/1131954; Holzel BK, 2011, PERSPECT PSYCHOL SCI, V6, P537, DOI 10.1177/1745691611419671; Holzel BK, 2011, PSYCHIAT RES-NEUROIM, V191, P36, DOI 10.1016/j.pscychresns.2010.08.006; Ickes, 2010, EVERYDAY MIND READIN; Kabat-Zinn J, 2003, CLIN PSYCHOL-SCI PR, V10, P144, DOI 10.1093/clipsy/bpg016; Kidd DC, 2013, SCIENCE, V342, P377, DOI 10.1126/science.1239918; Mascaro JS, 2013, SOC COGN AFFECT NEUR, V8, P48, DOI 10.1093/scan/nss095; Masten CL, 2011, NEUROIMAGE, V55, P381, DOI 10.1016/j.neuroimage.2010.11.060; Mrazek MD, 2012, EMOTION, V12, P442, DOI 10.1037/a0026678; Papies EK, 2012, SOC PSYCHOL PERS SCI, V3, P291, DOI 10.1177/1948550611419031; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Siegel DJ, 2007, SOC COGN AFFECT NEUR, V2, P259, DOI 10.1093/scan/nsm034; Tan L, 2015, CHILD ADOL MENT H-UK, V20, P49, DOI 10.1111/camh.12057; Tan L, 2013, CLIN CHILD PSYCHOL P, V18, P300, DOI 10.1177/1359104512455182; Tang YY, 2009, P NATL ACAD SCI USA, V106, P8865, DOI 10.1073/pnas.0904031106; van Beest I, 2006, J PERS SOC PSYCHOL, V91, P918, DOI 10.1037/0022-3514.91.5.918; Vellante M, 2013, COGN NEUROPSYCHIATRY, V18, P326, DOI 10.1080/13546805.2012.721728; Williams KD, 2000, J PERS SOC PSYCHOL, V79, P748, DOI 10.1037/0022-3514.79.5.748; Zeidan F, 2010, CONSCIOUS COGN, V19, P597, DOI 10.1016/j.concog.2010.03.014	32	60	60	2	58	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2014	9	10							e110510	10.1371/journal.pone.0110510	http://dx.doi.org/10.1371/journal.pone.0110510			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AT8TF	25329321	gold, Green Published			2023-01-03	WOS:000345204100086
J	Sabir, H; Walloe, L; Dingley, J; Smit, E; Liu, X; Thoresen, M				Sabir, Hemmen; Walloe, Lars; Dingley, John; Smit, Elisa; Liu, Xun; Thoresen, Marianne			Combined Treatment of Xenon and Hypothermia in Newborn Rats - Additive or Synergistic Effect?	PLOS ONE			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; NEONATAL ENCEPHALOPATHY; BRAIN-DAMAGE; SYSTEMIC HYPOTHERMIA; MODERATE HYPOTHERMIA; NEUROPROTECTION; INJURY; ASPHYXIA; OUTCOMES; TRIAL	Background: Breathing the inert gas Xenon (Xe) enhances hypothermic (HT) neuroprotection after hypoxia-ischemia (HI) in small and large newborn animal models. The underlying mechanism of the enhancement is not yet fully understood, but the combined effect of Xe and HT could either be synergistic (larger than the two effects added) or simply additive. A previously published study, using unilateral carotid ligation followed by hypoxia in seven day old (P7) rats, showed that the combination of mild HT (35 degrees C) and low Xe concentration (20%), both not being neuroprotective alone, had a synergistic effect and was neuroprotective when both were started with a 4 h delay after a moderate HI insult. To examine whether another laboratory could confirm this finding, we repeated key aspects of the study. Design/ Methods: After the HI-insult 120 pups were exposed to different post-insult treatments: three temperatures (normothermia (NT) NT37 degrees C, HT35 degrees C, HT32 degrees C) or Xe concentrations (0%, 20% or 50%) starting either immediately or with a 4 h delay. To assess the synergistic potency of Xe-HT, a second set (n = 101) of P7 pups were exposed to either HT35 degrees C+Xe-0%, NT+ Xe-20% or a combination of HT35 degrees C+Xe-20% starting with a 4 h delay after the insult. Brain damage was analyzed using relative hemispheric (ligated side/ unligated side) brain tissue area loss after seven day survival. Results: Immediate HT32 degrees C (p = 0.042), but not HT35 degrees C significantly reduced brain injury compared to NT37 degrees C. As previously shown, adding immediate Xe-50% to HT32 degrees C increased protection. Neither 4 h-delayed Xe-20%, nor Xe-50% at (37 degrees C) significantly reduced brain injury (p>0.050). In addition, neither 4 h-delayed HT35 degrees C alone, nor HT35 degrees C+Xe-20% reduced brain injury. Wefound no synergistic effect of the combined treatments in this experimental model. Conclusions: Combining two treatments that individually were ineffective (delayed HT35 degrees C and delayed Xe-20%) did not exert neuroprotection when combined, and therefore did not show a synergistic treatment effect.	[Sabir, Hemmen; Smit, Elisa; Liu, Xun; Thoresen, Marianne] Univ Bristol, Sch Clin Sci, Bristol, Avon, England; [Walloe, Lars; Thoresen, Marianne] Univ Oslo, Inst Basic Med Sci, Dept Physiol, Oslo, Norway; [Dingley, John] Swansea Univ, Coll Med, Swansea, W Glam, Wales; [Sabir, Hemmen] Univ Dusseldorf, Dept Gen Pediat Neonatol & Pediat Cardiol, Dusseldorf, Germany	University of Bristol; University of Oslo; Swansea University; Heinrich Heine University Dusseldorf	Thoresen, M (corresponding author), Univ Bristol, Sch Clin Sci, Bristol, Avon, England.	marianne.thoresen@bristol.ac.uk	walloe, lars/P-6947-2018	Smit, Elisa/0000-0002-3039-7251	Norwegian Research Council; Laerdal Foundation for Acute Medicine; SPARKS UK; Sparks Charity [05BTL01] Funding Source: researchfish	Norwegian Research Council(Research Council of NorwayEuropean Commission); Laerdal Foundation for Acute Medicine; SPARKS UK; Sparks Charity	This work received support from the following sources of funding: Norwegian Research Council, Laerdal Foundation for Acute Medicine and SPARKS UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDINE P, 1990, J NEUROSCI METH, V35, P253, DOI 10.1016/0165-0270(90)90131-X; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Baumert JH, 2007, ANESTH ANALG, V105, P1200, DOI 10.1213/01.ane.0000284697.73471.9c; Chakkarapani E, 2009, ANESTH ANALG, V109, P451, DOI 10.1213/ane.0b013e3181aa9550; Chakkarapani E, 2010, ANN NEUROL, V68, P330, DOI 10.1002/ana.22016; Charriaut-Marlangue C, 2013, EXP NEUROL, V248, P316, DOI 10.1016/j.expneurol.2013.06.022; Dingley J, 2006, STROKE, V37, P501, DOI 10.1161/01.STR.0000198867.31134.ac; Edwards AD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c363; Faulkner S, 2011, ANN NEUROL, V70, P133, DOI 10.1002/ana.22387; Feng YZ, 2006, BRAIN RES BULL, V69, P117, DOI 10.1016/j.brainresbull.2005.11.011; Gessner PK, 1995, TOXICOLOGY, V105, P161, DOI 10.1016/0300-483X(95)03210-7; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Guillet R, 2012, PEDIATR RES, V71, P205, DOI 10.1038/pr.2011.30; Hobbs C, 2008, STROKE, V39, P1307, DOI 10.1161/STROKEAHA.107.499822; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Ma DQ, 2009, J AM SOC NEPHROL, V20, P713, DOI 10.1681/ASN.2008070712; Ma DQ, 2005, ANN NEUROL, V58, P182, DOI 10.1002/ana.20547; Martin JL, 2007, BRIT J ANAESTH, V98, P236, DOI 10.1093/bja/ael340; McQuillen PS, 2004, PEDIATR NEUROL, V30, P227, DOI 10.1016/j.pediatrneurol.2003.10.001; Perlman JM, 2010, CIRCULATION, V122, P8516, DOI 10.1161/CIRCULATIONAHA.110.971127; Preckel B, 2000, ANESTH ANALG, V91, P1327, DOI 10.1097/00000539-200012000-00003; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Sabir H, 2013, ANESTHESIOLOGY, V119, P345, DOI 10.1097/ALN.0b013e318294934d; Sabir H, 2012, STROKE, V43, P3364, DOI 10.1161/STROKEAHA.112.674481; Scafidi J, 2009, INT J DEV NEUROSCI, V27, P863, DOI 10.1016/j.ijdevneu.2009.05.009; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shankaran S, 2012, NEW ENGL J MED, V366, P2085, DOI 10.1056/NEJMoa1112066; Simbruner G, 2010, PEDIATRICS, V126, pE771, DOI 10.1542/peds.2009-2441; Tagin MA, 2012, ARCH PEDIAT ADOL MED, V166, P558, DOI 10.1001/archpediatrics.2011.1772; Tallarida RJ, 2006, J PHARMACOL EXP THER, V319, P1, DOI 10.1124/jpet.106.104117; Thoresen M, 1996, NEUROREPORT, V7, P481, DOI 10.1097/00001756-199601310-00025; Thoresen M, 1996, ARCH DIS CHILD-FETAL, V74, pF3, DOI 10.1136/fn.74.1.F3; YOUNG R S K, 1983, Stroke, V14, P929; Zhao P, 2004, ANESTHESIOLOGY, V101, P695, DOI 10.1097/00000542-200409000-00018; Zhou WH, 2010, J PEDIATR-US, V157, P367, DOI 10.1016/j.jpeds.2010.03.030; Zhuang L, 2012, CRIT CARE MED, V40, P1724, DOI 10.1097/CCM.0b013e3182452164	36	18	18	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2014	9	10							e109845	10.1371/journal.pone.0109845	http://dx.doi.org/10.1371/journal.pone.0109845			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU6XC	25286345	Green Published, Green Submitted, gold			2023-01-03	WOS:000345743700095
J	Zheng, BH; Huang, ZY; Li, JL				Zheng, Buhong; Huang, Zhiyu; Li, Jinluan			The Effects of the Shape and Size of the Clinical Target Volume on the Planning Target Volume Margin	PLOS ONE			English	Article							GEOMETRICAL UNCERTAINTIES; RADIOTHERAPY; PROBABILITY	Purpose: To investigate the impact of clinical target volume (CTV) shape and size on CTV to planning target volume (PTV) margin expansion. Methods and Materials: Using numerical integration methods, margins accounting for random errors and systematic errors were calculated for CTVs of different shapes and sizes. We use k(r-95) and k(s-95) to represent the coefficients, for random errors and systematic errors, respectively, that ensure that every point of the CTV receives >= 95% of the prescribed dose. Results: The part of the margin accounting for random errors depends on CTV shape and size; generally, a convex part of a CTV would have a larger margin than a concave part. However, the part of the margin accounting for systematic errors is independent of CTV shape and size. Conclusions: CTV shape and size should be considered when generating a PTV. For a complex CTV, the margins of the various parts of the CTV are different and related to local forms.	[Zheng, Buhong; Huang, Zhiyu; Li, Jinluan] Fujian Med Univ, Teaching Hosp, Dept Radiat Oncol, Fujian Prov Canc Hosp, Fuzhou, Fujian, Peoples R China	Fujian Medical University	Li, JL (corresponding author), Fujian Med Univ, Teaching Hosp, Dept Radiat Oncol, Fujian Prov Canc Hosp, Fuzhou, Fujian, Peoples R China.	lijinluan@pku.org.cn	Li, Jinluan/J-8096-2013	Li, Jinluan/0000-0002-3533-898X; Zheng, Buhong/0000-0003-2886-2270	National Clinical Key Specialty Construction Program; Key Clinical Specialty Discipline Construction Program of Fujian, P. R. China; Fujian Province Natural Science Foundation [2012J05139]	National Clinical Key Specialty Construction Program; Key Clinical Specialty Discipline Construction Program of Fujian, P. R. China; Fujian Province Natural Science Foundation(Natural Science Foundation of Fujian Province)	This work was supported by National Clinical Key Specialty Construction Program, Key Clinical Specialty Discipline Construction Program of Fujian, P. R. China and Fujian Province Natural Science Foundation (No. 2012J05139). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antolak JA, 1999, INT J RADIAT ONCOL, V44, P1165, DOI 10.1016/S0360-3016(99)00117-0; Antolak JA, 1998, INT J RADIAT ONCOL, V42, P661, DOI 10.1016/S0360-3016(98)00248-X; AustinSeymour M, 1995, INT J RADIAT ONCOL, V33, P1073, DOI 10.1016/0360-3016(95)00217-0; Craig T, 2001, INT J RADIAT ONCOL, V49, P241, DOI 10.1016/S0360-3016(00)01354-7; Hodapp N, 2012, STRAHLENTHER ONKOL, V188, P97, DOI 10.1007/s00066-011-0015-x; Kutcher, 1995, Semin Radiat Oncol, V5, P134, DOI 10.1016/S1053-4296(95)80006-9; Mageras GS, 1999, INT J RADIAT ONCOL, V43, P437, DOI 10.1016/S0360-3016(98)00386-1; Stroom JC, 1999, INT J RADIAT ONCOL, V43, P905, DOI 10.1016/S0360-3016(98)00468-4; Stroom JC, 2002, RADIOTHER ONCOL, V64, P75, DOI 10.1016/S0167-8140(02)00140-8; van Herk M, 2000, INT J RADIAT ONCOL, V47, P1121, DOI 10.1016/S0360-3016(00)00518-6; Witte MG, 2004, MED PHYS, V31, P3068, DOI 10.1118/1.1809991; Zhang Q, 2012, IJMPCERO, V1, P15, DOI [10.4236/ijmpcero.2012.12003, DOI 10.4236/IJMPCERO.2012.12003]; Zhang QH, 2013, MED PHYS, V40, DOI 10.1118/1.4829517	13	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2014	9	10							e109244	10.1371/journal.pone.0109244	http://dx.doi.org/10.1371/journal.pone.0109244			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ2BX	25275442	Green Published, gold, Green Submitted			2023-01-03	WOS:000342591500081
J	McCoy, CP; O'Neil, EJ; Cowley, JF; Carson, L; De Baroid, AT; Gdowski, GT; Gorman, SP; Jones, DS				McCoy, Colin P.; O'Neil, Edward J.; Cowley, John F.; Carson, Louise; De Baroid, Aine T.; Gdowski, Greg T.; Gorman, Sean P.; Jones, David S.			Photodynamic Antimicrobial Polymers for Infection Control	PLOS ONE			English	Article							SINGLET OXYGEN; RESISTANCE; SUSCEPTIBILITY; PHOTOSENSITIZERS; DISINFECTANTS; INACTIVATION; BIOMATERIALS; PREVENTION; STRATEGIES; BIOFILMS	Hospital-acquired infections pose both a major risk to patient wellbeing and an economic burden on global healthcare systems, with the problem compounded by the emergence of multidrug resistant and biocide tolerant bacterial pathogens. Many inanimate surfaces can act as a reservoir for infection, and adequate disinfection is difficult to achieve and requires direct intervention. In this study we demonstrate the preparation and performance of materials with inherent photodynamic, surface-active, persistent antimicrobial properties through the incorporation of photosensitizers into high density poly(ethylene) (HDPE) using hot-melt extrusion, which require no external intervention except a source of visible light. Our aim is to prevent bacterial adherence to these surfaces and eliminate them as reservoirs of nosocomial pathogens, thus presenting a valuable advance in infection control. A two-layer system with one layer comprising photosensitizer-incorporated HDPE, and one layer comprising HDPE alone is also described to demonstrate the versatility of our approach. The photosensitizer-incorporated materials are capable of reducing the adherence of viable bacteria by up to 3.62 Log colony forming units (CFU) per square centimeter of material surface for methicillin resistant Staphylococcus aureus (MRSA), and by up to 1.51 Log CFU/cm(2) for Escherichia coli. Potential applications for the technology are in antimicrobial coatings for, or materials comprising objects, such as tubing, collection bags, handrails, finger-plates on hospital doors, or medical equipment found in the healthcare setting.	[McCoy, Colin P.; Cowley, John F.; Carson, Louise; De Baroid, Aine T.; Gdowski, Greg T.; Gorman, Sean P.; Jones, David S.] Queens Univ Belfast, Sch Pharm, Belfast, Antrim, North Ireland; [O'Neil, Edward J.] Syracuse Univ, Ctr Sci & Technol, Blue Highway Inc, Syracuse, NY 13244 USA	Queens University Belfast; Syracuse University	McCoy, CP (corresponding author), Queens Univ Belfast, Sch Pharm, Belfast, Antrim, North Ireland.	c.mccoy@qub.ac.uk	McCoy, Colin P/A-6815-2008	McCoy, Colin P/0000-0002-6468-2018; Carson, Louise/0000-0002-2551-7730	Department for Employment and Learning (Northern Ireland); Blue Highway, Inc.; Engineering and Physical Sciences Research Council [1232186] Funding Source: researchfish	Department for Employment and Learning (Northern Ireland); Blue Highway, Inc.; Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was supported by funding from the Department for Employment and Learning (Northern Ireland), and Blue Highway, Inc. Blue Highway, Inc. assisted in the study design, data analysis, preparation of the manuscript and decision to publish. The Department of Employment and Learning, Northern Ireland, had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bardouniotis E, 2001, FEMS MICROBIOL LETT, V203, P263, DOI 10.1111/j.1574-6968.2001.tb10851.x; Block C, 2002, J HOSP INFECT, V51, P201, DOI 10.1053/jhin.2002.1246; Brady C, 2007, J PHYS CHEM B, V111, P527, DOI 10.1021/jp066217i; Craig RA, 2010, J PHARM PHARMACOL, V62, P1359; Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167-193.2002; Enright MC, 2002, P NATL ACAD SCI USA, V99, P7687, DOI 10.1073/pnas.122108599; Epstein AK, 2011, P NATL ACAD SCI USA, V108, P995, DOI 10.1073/pnas.1011033108; Fulmer PA, 2011, ACS APPL MATER INTER, V3, P2878, DOI 10.1021/am2005465; Alvarez MG, 2012, BIOORGAN MED CHEM, V20, P4032, DOI 10.1016/j.bmc.2012.05.012; Graves N, 2004, EMERG INFECT DIS, V10, P561, DOI 10.3201/eid1004.020754; Hall-Stoodley L, 2004, NAT REV MICROBIOL, V2, P95, DOI 10.1038/nrmicro821; Hamblin MR, 2004, PHOTOCH PHOTOBIO SCI, V3, P436, DOI 10.1039/b311900a; Hamblin MR, 2002, J ANTIMICROB CHEMOTH, V49, P941, DOI 10.1093/jac/dkf053; Hamill TM, 2007, EXPERT REV MED DEVIC, V4, P215, DOI 10.1586/17434440.4.2.215; Hancock REW, 2007, NAT REV DRUG DISCOV, V6, P28, DOI 10.1038/nrd2223; Hota B, 2004, CLIN INFECT DIS, V39, P1182, DOI 10.1086/424667; Johnson JR, 2006, ANN INTERN MED, V144, P116, DOI 10.7326/0003-4819-144-2-200601170-00009; KENNEDY JC, 1992, J PHOTOCH PHOTOBIO B, V14, P275, DOI 10.1016/1011-1344(92)85108-7; Knobloch JKM, 2002, J ANTIMICROB CHEMOTH, V49, P683, DOI 10.1093/jac/49.4.683; Krouit M, 2006, BIOORG MED CHEM LETT, V16, P1651, DOI 10.1016/j.bmcl.2005.12.008; Maisch T, 2007, PHOTOCH PHOTOBIO SCI, V6, P545, DOI 10.1039/b614770d; Mathai S, 2007, PHOTOCH PHOTOBIO SCI, V6, P995, DOI 10.1039/b705853e; Mc Cay PH, 2010, MICROBIOL-SGM, V156, P30, DOI 10.1099/mic.0.029751-0; McBain AJ, 2001, INT BIODETER BIODEGR, V47, P55, DOI 10.1016/S0964-8305(01)00037-3; Mccoy CP, 2012, BIOMATERIALS, V33, P7952, DOI 10.1016/j.biomaterials.2012.07.052; McDonnell G, 1999, CLIN MICROBIOL REV, V12, P147, DOI 10.1128/CMR.12.1.147; Nikaido H, 2009, ANNU REV BIOCHEM, V78, P119, DOI 10.1146/annurev.biochem.78.082907.145923; Noguchi N, 1999, FEMS MICROBIOL LETT, V172, P247, DOI 10.1111/j.1574-6968.1999.tb13475.x; O'Hanlon SJ, 2009, INT J ANTIMICROB AG, V33, P427, DOI 10.1016/j.ijantimicag.2008.10.020; Parsons C, 2009, BIOMATERIALS, V30, P597, DOI 10.1016/j.biomaterials.2008.10.015; Pasquier N, 2007, BIOMACROMOLECULES, V8, P2874, DOI 10.1021/bm070353r; Plowman R, 2001, J HOSP INFECT, V47, P198, DOI 10.1053/jhin.2000.0881; Rajamohan G, 2009, J HOSP INFECT, V73, P287, DOI 10.1016/j.jhin.2009.07.015; Ringot C, 2011, BIOMACROMOLECULES, V12, P1716, DOI 10.1021/bm200082d; Russell A.D., 2002, BR J INFECT CONTROL, V3, P22, DOI [10.1177/175717740200300306, DOI 10.1177/175717740200300306]; Ryskova L, 2010, CENT EUR J BIOL, V5, P400, DOI 10.2478/s11535-010-0032-2; Wainwright M, 2004, DRUG FUTURE, V29, P85, DOI 10.1358/dof.2004.029.01.777826; Wainwright M, 1998, J ANTIMICROB CHEMOTH, V42, P13, DOI 10.1093/jac/42.1.13; Wilson BC, 2008, PHYS MED BIOL, V53, pR61, DOI 10.1088/0031-9155/53/9/R01; Yates RR, 1999, CHEST, V115, p24S, DOI 10.1378/chest.115.suppl_1.24S	40	24	24	0	52	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2014	9	9							e108500	10.1371/journal.pone.0108500	http://dx.doi.org/10.1371/journal.pone.0108500			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ0SJ	25250740	Green Published, Green Submitted, gold			2023-01-03	WOS:000342492700135
J	Lou, PH; Lucchinetti, E; Zhang, LY; Affolter, A; Gandhi, M; Hersberger, M; Warren, BE; Lemieux, H; Sobhi, HF; Clanachan, AS; Zaugg, M				Lou, Phing-How; Lucchinetti, Eliana; Zhang, Liyan; Affolter, Andreas; Gandhi, Manoj; Hersberger, Martin; Warren, Blair E.; Lemieux, Helene; Sobhi, Hany F.; Clanachan, Alexander S.; Zaugg, Michael			Loss of Intralipid (R)- but Not Sevoflurane-Mediated Cardioprotection in Early Type-2 Diabetic Hearts of Fructose-Fed Rats: Importance of ROS Signaling	PLOS ONE			English	Article							CYTOCHROME-C-OXIDASE; FATTY-ACID OXIDATION; IN-VIVO; MITOCHONDRIAL; ISOFLURANE; REPERFUSION; SUPEROXIDE; ISCHEMIA; ISCHAEMIA/REPERFUSION; MYOCARDIUM	Background: Insulin resistance and early type-2 diabetes are highly prevalent. However, it is unknown whether Intralipid (R) and sevoflurane protect the early diabetic heart against ischemia-reperfusion injury. Methods: Early type-2 diabetic hearts from Sprague-Dawley rats fed for 6 weeks with fructose were exposed to 15 min of ischemia and 30 min of reperfusion. Intralipid (R) (1%) was administered at the onset of reperfusion. Peri-ischemic sevoflurane (2 vol.-%) served as alternative protection strategy. Recovery of left ventricular function was recorded and the activation of Akt and ERK 1/2 was monitored. Mitochondrial function was assessed by high-resolution respirometry and mitochondrial ROS production was measured by Amplex Red and aconitase activity assays. Acylcarnitine tissue content was measured and concentration-response curves of complex IV inhibition by palmitoylcarnitine were obtained. Results: Intralipid (R) did not exert protection in early diabetic hearts, while sevoflurane improved functional recovery. Sevoflurane protection was abolished by concomitant administration of the ROS scavenger N-2-mercaptopropionyl glycine. Sevoflurane, but not Intralipid (R) produced protective ROS during reperfusion, which activated Akt. Intralipid (R) failed to inhibit respiratory complex IV, while sevoflurane inhibited complex I. Early diabetic hearts exhibited reduced carnitine-palmitoyl-transferase-1 activity, but palmitoylcarnitine could not rescue protection and enhance postischemic functional recovery. Cardiac mitochondria from early diabetic rats exhibited an increased content of subunit IV-2 of respiratory complex IV and of uncoupling protein-3. Conclusions: Early type-2 diabetic hearts lose complex IV-mediated protection by Intralipid (R) potentially due to a switch in complex IV subunit expression and increased mitochondrial uncoupling, but are amenable to complex I-mediated sevoflurane protection.	[Lou, Phing-How] Univ Alberta, Cardiovasc Res Ctr, Edmonton, AB, Canada; [Lucchinetti, Eliana; Zhang, Liyan; Zaugg, Michael] Univ Alberta, Dept Anesthesiol & Pain Med, Edmonton, AB, Canada; [Affolter, Andreas; Hersberger, Martin] Univ Childrens Hosp Zurich, Dept Clin Chem, Zurich, Switzerland; [Gandhi, Manoj; Clanachan, Alexander S.] Univ Alberta, Dept Pharmacol, Edmonton, AB, Canada; [Warren, Blair E.; Lemieux, Helene] Univ Alberta, Edmonton, AB, Canada; [Sobhi, Hany F.] Coppin State Univ, Coppin Ctr Organ Synth, Baltimore, MD USA	University of Alberta; University of Alberta; University Children's Hospital Zurich; University of Alberta; University of Alberta; University System of Maryland; Coppin State University	Zaugg, M (corresponding author), Univ Alberta, Dept Anesthesiol & Pain Med, Edmonton, AB, Canada.	michael.zaugg@ualberta.ca	Zaugg, Michael/G-4287-2016; Zhang, Li/GWM-7501-2022	Lucchinetti, Eliana/0000-0003-3338-1279; Hersberger, Martin/0000-0002-4472-329X; Zaugg, Michael/0000-0002-2016-8973; lemieux, Helene/0000-0002-8864-6062	Heart and Stroke Foundation of Alberta; Northwest Territories; Canadian Institutes of Health Research [MOP115055]; Natural Sciences and Engineering Research Council of Canada; Mazankowski Alberta Heart Institute, Edmonton, Canada; "Bourse pour apprentis-chercheurs" from the Campus Saint-Jean of the University of Alberta, Edmonton, Canada; Nunavut (Canada)	Heart and Stroke Foundation of Alberta; Northwest Territories; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Mazankowski Alberta Heart Institute, Edmonton, Canada; "Bourse pour apprentis-chercheurs" from the Campus Saint-Jean of the University of Alberta, Edmonton, Canada; Nunavut (Canada)	The study was supported by grants from the Heart and Stroke Foundation of Alberta, Northwest Territories, and Nunavut (Canada), and the Canadian Institutes of Health Research (MOP115055), a discovery grant from the Natural Sciences and Engineering Research Council of Canada, and a grant from the Mazankowski Alberta Heart Institute, Edmonton, Canada. BEW was supported by a "Bourse pour apprentis-chercheurs" from the Campus Saint-Jean of the University of Alberta, Edmonton, Canada. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABBOTT RD, 1988, JAMA-J AM MED ASSOC, V260, P3456, DOI 10.1001/jama.260.23.3456; Agarwal B, 2014, BBA-BIOENERGETICS, V1837, P354, DOI 10.1016/j.bbabio.2013.11.006; Boudina S, 2005, CIRCULATION, V112, P2686, DOI 10.1161/CIRCULATIONAHA.105.554360; Bourens M, 2013, ANTIOXID REDOX SIGN, V19, P1940, DOI 10.1089/ars.2012.4847; Burwell LS, 2009, J MOL CELL CARDIOL, V46, P804, DOI 10.1016/j.yjmcc.2009.02.026; Cacho J, 2008, AM J PHYSIOL-ENDOC M, V295, pE1269, DOI 10.1152/ajpendo.90207.2008; Cline GW, 2001, J BIOL CHEM, V276, P20240, DOI 10.1074/jbc.M102540200; DAI S, 1995, J PHARMACOL TOX MET, V33, P101, DOI 10.1016/1056-8719(94)00063-A; De Hert SG, 2004, ANESTHESIOLOGY, V101, P299, DOI 10.1097/00000542-200408000-00009; Deyhimy DI, 2007, ANESTH ANALG, V105, P316, DOI 10.1213/01.ane.0000267524.71445.e7; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Franks NP, 1996, ANESTHESIOLOGY, V84, P716, DOI 10.1097/00000542-199603000-00027; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Gardner PR, 2002, METHOD ENZYMOL, V349, P9, DOI 10.1016/S0076-6879(02)49317-2; Gonsolin D, 2007, MOL CELL BIOCHEM, V295, P217, DOI 10.1007/s11010-006-9291-7; Hanley PJ, 2002, J PHYSIOL-LONDON, V544, P687, DOI 10.1113/jphysiol.2002.025015; Harmancey R, 2013, FASEB J, V27, P3966, DOI 10.1096/fj.13-234914; Herlitz J, 1996, DIABETES CARE, V19, P698, DOI 10.2337/diacare.19.7.698; Hirata N, 2011, ANESTHESIOLOGY, V115, P531, DOI 10.1097/ALN.0b013e31822a2316; Hiser C, 2013, BIOCHEMISTRY-US, V52, P1385, DOI 10.1021/bi3014505; Huttemann M, 2007, FEBS J, V274, P5737, DOI 10.1111/j.1742-4658.2007.06093.x; Huhn R, 2010, NUTR METAB CARDIOVAS, V20, P706, DOI 10.1016/j.numecd.2009.06.010; Huisamen B, 2003, MOL CELL BIOCHEM, V249, P31, DOI 10.1023/A:1024749614222; Hulver MW, 2005, CELL METAB, V2, P251, DOI 10.1016/j.cmet.2005.09.002; Kadenbach B, 2000, FREE RADICAL BIO MED, V29, P211, DOI 10.1016/S0891-5849(00)00305-1; Kevin LG, 2003, ANESTH ANALG, V96, P949, DOI 10.1213/01.ANE.0000052515.25465.35; Lemoine S, 2010, DIABETES METAB, V36, P21, DOI 10.1016/j.diabet.2009.06.006; Li JY, 2012, ANESTHESIOLOGY, V117, P836, DOI 10.1097/ALN.0b013e3182655e73; Liu JJ, 2013, ANTIOXID REDOX SIGN, V19, P1916, DOI 10.1089/ars.2012.4589; Lloyd-Jones D, 2010, CIRCULATION, V121, P948, DOI 10.1161/CIRCULATIONAHA.109.192666; Lou PH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087205; Lou PH, 2013, CARDIOVASC RES, V97, P251, DOI 10.1093/cvr/cvs323; Makino A, 2011, AM J PHYSIOL-REG I, V300, pR1296, DOI 10.1152/ajpregu.00437.2010; Malingriaux EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077786; Morel S, 2003, CLIN EXP PHARMACOL P, V30, P446, DOI 10.1046/j.1440-1681.2003.03858.x; Morrish NJ, 2001, DIABETOLOGIA, V44, pS14, DOI 10.1007/PL00002934; Motulsky H., 2004, FITTING MODELS BIOL, P352, DOI 10.1002/pst.167; Mullenheim J, 2002, ANESTHESIOLOGY, V96, P934; Muravyeva M, 2014, ANESTHESIOLOGY, V120, P870, DOI 10.1097/ALN.0000000000000107; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; Rahman S, 2011, ANESTHESIOLOGY, V115, P242, DOI 10.1097/ALN.0b013e318223b8b9; Samuel VT, 2011, TRENDS ENDOCRIN MET, V22, P60, DOI 10.1016/j.tem.2010.10.003; Saotome M, 2009, AM J PHYSIOL-HEART C, V296, pH1125, DOI 10.1152/ajpheart.00436.2008; Sedlic F, 2009, ANESTH ANALG, V109, P405, DOI 10.1213/ane.0b013e3181a93ad9; Sharpe M, 1997, BIOCHEM CELL BIOL, V75, P71, DOI 10.1139/bcb-75-1-71; Srere P.A., 1969, METHODS ENZYMOLOGY, V13, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Srinivasan S, 2012, FREE RADICAL BIO MED, V53, P1252, DOI 10.1016/j.freeradbiomed.2012.07.021; Stewart JM, 2000, BIOCHEM CELL BIOL, V78, P675, DOI 10.1139/bcb-78-6-675; Tanaka K, 2002, AM J PHYSIOL-HEART C, V282, pH2018, DOI 10.1152/ajpheart.01130.2001; Toime LJ, 2010, FREE RADICAL BIO MED, V49, P606, DOI 10.1016/j.freeradbiomed.2010.05.010; Tsutsumi YM, 2007, LIFE SCI, V81, P1223, DOI 10.1016/j.lfs.2007.08.031; Wang LG, 2010, ANESTHESIOLOGY, V113, P541, DOI 10.1097/ALN.0b013e3181e2c1a1; WINKLER E, 1994, J BIOL CHEM, V269, P2508; Zaugg M, 2012, ANESTHESIOLOGY, V116, P648, DOI 10.1097/ALN.0b013e318247225a; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	55	7	7	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2014	9	8							e104971	10.1371/journal.pone.0104971	http://dx.doi.org/10.1371/journal.pone.0104971			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN8UD	25127027	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000340879300066
J	Wang, GF; Liu, BJ; Cao, YX; Du, YJ; Zhang, HY; Luo, QL; Li, B; Wu, JF; Lv, YB; Sun, J; Jin, HL; Wei, K; Zhao, ZX; Kong, LW; Zhou, XM; Miao, Q; Wang, G; Zhou, QW; Dong, JC				Wang, Genfa; Liu, Baojun; Cao, Yuxue; Du, Yijie; Zhang, Hongying; Luo, Qingli; Li, Bei; Wu, Jinfeng; Lv, Yubao; Sun, Jing; Jin, Hualiang; Wei, Kai; Zhao, Zhengxiao; Kong, Lingwen; Zhou, Xianmei; Miao, Qing; Wang, Gang; Zhou, Qingwei; Dong, Jingcheng			Effects of Two Chinese Herbal Formulae for the Treatment of Moderate to Severe Stable Chronic Obstructive Pulmonary Disease: A Multicenter, Double-Blind, Randomized Controlled Trial	PLOS ONE			English	Article							INHALED CORTICOSTEROIDS; COPD; METAANALYSIS; MEDICINE; TGF-BETA(1); PNEUMONIA; 4-CENTER; THERAPY; PATHWAY; UPDATE	Objective: The study aims to evaluate the efficacy and safety of two Chinese herbal formulae for the treatment of stable COPD. Methods: A multicenter, double-blind, double-dummy, and randomized controlled trial (RCT) was conducted. All groups were treated with additional conventional medicines. There were a 6-month treatment and a 12-month follow-up for 5 times. Primary outcomes included lung function test, exacerbation frequency, score of SGRQ. Second outcomes consisted of 6MWD, BODE index, psychological field score, inflammatory factors and cortisol. Results: A total of 331 patients were randomly divided into two active treatment groups (Bushen Yiqi (BY) granule group, n = 109; Bushen Fangchuan (BF) tablet group, n = 109) and a placebo group (n = 113). Finally 262 patients completed the study. BY granule & BF tablet increased the values of VC, FEV1 (%) and FEV1/FVC (%), compared with placebo. BY granule improved PEF. Both treatments reduced acute exacerbation frequency (P = 0.067), BODE index and psychological field score, while improved 6MWD. In terms of descent rang of SGRQ score, both treatments increased (P = 0.01). Both treatments decreased inflammatory cytokines, such as IL-8, and IL-17(P = 0.0219). BY granule obviously descended IL-17(P<0.05), IL-1 beta (P = 0.05), IL-6, compared with placebo. They improved the level of IL-10 and cortisol. BY granule raised cortisol (P = 0.07) and decreased TNF-alpha. Both treatments slightly descended TGF-beta 1. In terms of safety, subject compliance and drug combination, there were no differences (P>0.05) among three groups. Conclusions: BY granule and BF tablet were positively effective for the treatment of COPD, and the former performed better in general.	[Wang, Genfa; Liu, Baojun; Cao, Yuxue; Du, Yijie; Zhang, Hongying; Luo, Qingli; Li, Bei; Wu, Jinfeng; Lv, Yubao; Sun, Jing; Jin, Hualiang; Wei, Kai; Zhao, Zhengxiao; Kong, Lingwen; Dong, Jingcheng] Fudan Univ, Huashan Hosp, Dept Integrated Tradit Chinese & Western Med, Shanghai 200433, Peoples R China; [Wang, Genfa; Liu, Baojun; Cao, Yuxue; Du, Yijie; Zhang, Hongying; Luo, Qingli; Li, Bei; Wu, Jinfeng; Lv, Yubao; Sun, Jing; Jin, Hualiang; Wei, Kai; Zhao, Zhengxiao; Kong, Lingwen; Dong, Jingcheng] Fudan Univ, Inst Integrated Tradit Chinese & Western Med, Shanghai, Peoples R China; [Zhou, Xianmei] Nanjing Univ TCM, Jiangsu Prov Hosp TCM, Resp Dept, Nanjing, Jiangsu, Peoples R China; [Miao, Qing] CACMS, Xiyuan Hosp, Resp Dept, Beijing, Peoples R China; [Wang, Gang] Sichuan Univ, West China Hosp, Resp Dept, Chengdu, Peoples R China; [Zhou, Qingwei] Henan Univ TCM, Affiliated Hosp 1, Resp Dept, Zhengzhou, Peoples R China	Fudan University; Fudan University; Nanjing University of Chinese Medicine; China Academy of Chinese Medical Sciences; Xiyuan Hospital, CACMS; Sichuan University; Henan University of Traditional Chinese Medicine	Dong, JC (corresponding author), Fudan Univ, Huashan Hosp, Dept Integrated Tradit Chinese & Western Med, Shanghai 200433, Peoples R China.	jcdong2004@126.com		Wu, Jinfeng/0000-0002-9579-9163; Dong, Jingcheng/0000-0002-5194-367X	China National Basic Research Program (China National 973 Program) [2009 CB 523000]; National Natural Science Foundation of China [81173390, 81102541, 81302931]	China National Basic Research Program (China National 973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the grants from China National Basic Research Program (China National 973 Program) (2009 CB 523000) and National Natural Science Foundation of China (81173390, 81102541, 81302931). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	An XD, 2012, J ALTERN COMPLEM MED, V18, P731, DOI 10.1089/acm.2011.0389; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; Bohy ME, 2010, ARCH MED SCI, V6, P71; Cafarella PA, 2012, RESPIROLOGY, V17, P627, DOI 10.1111/j.1440-1843.2012.02148.x; Calverley PMA, 2011, CHEST, V139, P505, DOI 10.1378/chest.09-2992; Celik P, 2005, RESP MED, V99, P444, DOI 10.1016/j.rmed.2004.09.008; Chen R, 2010, EVID-BASED COMPL ALT, V7, P3, DOI 10.1093/ecam/nen017; Decramer M, 2012, LANCET, V379, P1341, DOI 10.1016/S0140-6736(11)60968-9; Drummond MB, 2008, JAMA-J AM MED ASSOC, V300, P2407, DOI 10.1001/jama.2008.717; Gao JX, 2012, MOL MED REP, V6, P1155, DOI 10.3892/mmr.2012.1059; George J, 2004, MED J AUSTRALIA, V181, P248, DOI 10.5694/j.1326-5377.2004.tb06262.x; Guo R, 2006, EUR RESPIR J, V28, P330, DOI 10.1183/09031936.06.00119905; Hothersall E, 2006, THORAX, V61, P729, DOI 10.1136/thx.2005.057976; Kinoshita M, 2012, RESPIROLOGY, V17, P379, DOI 10.1111/j.1440-1843.2011.02107.x; Kucich U, 2002, AM J RESP CELL MOL, V26, P183, DOI 10.1165/ajrcmb.26.2.4666; Li JS, 2012, J ETHNOPHARMACOL, V141, P584, DOI 10.1016/j.jep.2011.08.060; Li SY, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-197; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Meyer KC, 2013, J AM PHARM ASSOC, V53, pE219, DOI 10.1331/JAPhA.2013.13535; Nathell L, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-89; Puhan MA, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-2; Rabe KF, 2011, BRIT J PHARMACOL, V163, P53, DOI 10.1111/j.1476-5381.2011.01218.x; Ram A, 2011, FITOTERAPIA, V82, P141, DOI 10.1016/j.fitote.2010.09.005; Ren S, 2013, J TRADIT CHIN MED, V33, P413, DOI 10.1016/S0254-6272(13)60189-2; Singh S, 2009, ARCH INTERN MED, V169, P219, DOI 10.1001/archinternmed.2008.550; Stoll P, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-116; Tonnesen P, 2013, EUR RESPIR REV, V22, P37, DOI 10.1183/09059180.00007212; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP; Xu CQ, 2010, EUR J PHARMACOL, V642, P146, DOI 10.1016/j.ejphar.2010.05.012; Zhang AH, 2009, EXP TOXICOL PATHOL, V61, P461, DOI 10.1016/j.etp.2008.10.010	31	16	19	4	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2014	9	8							e103168	10.1371/journal.pone.0103168	http://dx.doi.org/10.1371/journal.pone.0103168			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AN9BM	25118962	Green Published, gold, Green Submitted			2023-01-03	WOS:000340900600018
J	Singh, P; Jayaramaiah, RH; Sarate, P; Thulasiram, HV; Kulkarni, MJ; Giri, AP				Singh, Priyanka; Jayaramaiah, Ramesha H.; Sarate, Priya; Thulasiram, Hirekodathakallu V.; Kulkarni, Mahesh J.; Giri, Ashok P.			Insecticidal Potential of Defense Metabolites from Ocimum kilimandscharicum against Helicoverpa armigera	PLOS ONE			English	Article							PLANT; AMYLASES; PEST	Genus Ocimum contains a reservoir of diverse secondary metabolites, which are known for their defense and medicinal value. However, the defense-related metabolites from this genus have not been studied in depth. To gain deeper insight into inducible defense metabolites, we examined the overall biochemical and metabolic changes in Ocimum kilimandscharicum that occurred in response to the feeding of Helicoverpa armigera larvae. Metabolic analysis revealed that the primary and secondary metabolism of local and systemic tissues in O. kilimandscharicum was severely affected following larval infestation. Moreover, levels of specific secondary metabolites like camphor, limonene and beta-caryophyllene (known to be involved in defense) significantly increased in leaves upon insect attack. Choice assays conducted by exposing H. armigera larvae on O. kilimandscharicum and tomato leaves, demonstrated that O. kilimandscharicum significantly deters larval feeding. Further, when larvae were fed on O. kilimandscharicum leaves, average body weight decreased and mortality the larvae increased. Larvae fed on artificial diet supplemented with O. kilimandscharicum leaf extract, camphor, limonene and beta-caryophyllene showed growth retardation, increased mortality rates and pupal deformities. Digestive enzymes of H. armigera - namely, amylase, protease and lipase- showed variable patterns after feeding on O. kilimandscharicum, which implies striving of the larvae to attain required nutrition for growth, development and metamorphosis. Evidently, selected metabolites from O. kilimandscharicum possess significant insecticidal activity.	[Singh, Priyanka; Jayaramaiah, Ramesha H.; Sarate, Priya; Giri, Ashok P.] CSIR, Natl Chem Lab, Div Biochem Sci, Plant Mol Biol Unit, Pune, Maharashtra, India; [Singh, Priyanka; Thulasiram, Hirekodathakallu V.] CSIR, Natl Chem Lab, Div Organ Chem, Chem Biol Unit, Pune, Maharashtra, India; [Thulasiram, Hirekodathakallu V.] CSIR, Inst Genom & Integrat Biol, New Delhi 110001, India; [Kulkarni, Mahesh J.] CSIR, Natl Chem Lab, Div Biochem Sci, Prote Facil, Pune, Maharashtra, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Chemical Laboratory (NCL); Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Chemical Laboratory (NCL); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Chemical Laboratory (NCL)	Giri, AP (corresponding author), CSIR, Natl Chem Lab, Div Biochem Sci, Plant Mol Biol Unit, Pune, Maharashtra, India.	ap.giri@ncl.res.in	Jayaramaiah, Ramesha H./AAR-7246-2020; Kulkarni, Mahesh J/G-1473-2010	Jayaramaiah, Ramesha H./0000-0003-4237-9664; 	CSIR, New Delhi [BSC0124]	CSIR, New Delhi(Council of Scientific & Industrial Research (CSIR) - India)	This work is financially supported by CSIR, New Delhi sponsored network project (BSC0124). The funders had no role in study design, data and analysis, decision to publish, or preparation of the manuscript.	Bekele J, 2001, PHYTOCHEMISTRY, V57, P385, DOI 10.1016/S0031-9422(01)00067-X; BENNETT RN, 1994, NEW PHYTOL, V127, P617, DOI 10.1111/j.1469-8137.1994.tb02968.x; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BHARGAVA KP, 1981, INDIAN J MED RES, V73, P443; BROCK FM, 1982, APPL ENVIRON MICROB, V44, P561, DOI 10.1128/AEM.44.3.561-569.1982; Chen H, 2005, P NATL ACAD SCI USA, V102, P19237, DOI 10.1073/pnas.0509026102; Devi PU, 2000, RADIAT RES, V154, P455, DOI 10.1667/0033-7587(2000)154[0455:RPBTOF]2.0.CO;2; Dinant S, 2012, SIGNALING COMMUNICAT, V6, P89; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FITT GP, 1989, ANNU REV ENTOMOL, V34, P17, DOI 10.1146/annurev.en.34.010189.000313; Furch ACU, 2008, PLANT SIGNAL BEHAV, V3, P858, DOI 10.4161/psb.3.10.6040; Gendo JO, 2008, J STORED PROD RES, V44, P328, DOI 10.1016/j.jspr.2008.02.009; Hakkim FL, 2008, J MED PLANTS RES, V2, P250; Hao PY, 2008, PLANT PHYSIOL, V146, P1810, DOI 10.1104/pp.107.111484; Harborne JB, 2001, SECONDARY METABOLITE; Holopainen JK, 2004, TRENDS PLANT SCI, V9, P529, DOI 10.1016/j.tplants.2004.09.006; Isman MB, 2000, CROP PROT, V19, P603, DOI 10.1016/S0261-2194(00)00079-X; JEMBERE B, 1995, B ENTOMOL RES, V85, P361, DOI 10.1017/S0007485300036099; Kachroo A, 2007, PLANT MOL BIOL, V63, P257, DOI 10.1007/s11103-006-9086-y; Kamaraj C, 2008, PARASITOL RES, V103, P1361, DOI 10.1007/s00436-008-1142-x; Karthikeyan K, 1999, PHARM BIOL, V37, P285, DOI 10.1076/phbi.37.4.285.5801; Khan A, 2010, NAT PROD COMMUN, V5, P345; Khan M.R., 2010, J SCI RES, V2, P158, DOI DOI 10.3329/JSR.V2IL.2769; Kjeldahl J., 1883, ANAL BIOANAL CHEM, V22, P366, DOI DOI 10.1007/BF01338151; Kotkar HM, 2009, J INSECT PHYSIOL, V55, P663, DOI 10.1016/j.jinsphys.2009.05.004; Leon J, 2001, J EXP BOT, V52, P1, DOI 10.1093/jexbot/52.354.1; Liska A., 2010, 10 INT WORK C STOR P, P716, DOI DOI 10.5073/JKA.2010.425.093; Maor R, 2005, CURR OPIN MICROBIOL, V8, P399, DOI 10.1016/j.mib.2005.06.008; Nagarkatti S, 1974, COMMONWEALTH I BIOL, V17, P169; Prakash P, 2005, Indian J Physiol Pharmacol, V49, P125; Qiantai L, 1998, P 7 INT C STOR PROD, V1, P836; Rajapakse CNK, 2007, ARTHROPOD-PLANT INTE, V1, P17, DOI 10.1007/s11829-007-9003-6; Roitsch T, 2004, TRENDS PLANT SCI, V9, P606, DOI 10.1016/j.tplants.2004.10.009; Rolland F, 2006, ANNU REV PLANT BIOL, V57, P675, DOI 10.1146/annurev.arplant.57.032905.105441; Rozman V, 2007, J STORED PROD RES, V43, P349, DOI 10.1016/j.jspr.2006.09.001; Sarate PJ, 2012, J INSECT SCI, V12, DOI 10.1673/031.012.4201; Schwachtje J, 2006, P NATL ACAD SCI USA, V103, P12935, DOI 10.1073/pnas.0602316103; Tamhane VA, 2005, BBA-GEN SUBJECTS, V1722, P156, DOI 10.1016/j.bbagen.2004.12.017; WINKLER UK, 1979, J BACTERIOL, V138, P663, DOI 10.1128/JB.138.3.663-670.1979; Zavala JA, 2004, PLANT PHYSIOL, V134, P1181, DOI 10.1104/pp.103.035634; ZOLLNER N., 1962, ZEIT GES EXPTL MED, V135, P545, DOI 10.1007/BF02045455	41	22	24	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2014	9	8							e104377	10.1371/journal.pone.0104377	http://dx.doi.org/10.1371/journal.pone.0104377			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6SM	25098951	Green Published, Green Submitted, gold			2023-01-03	WOS:000339995100067
J	Zhang, LZ; Liu, RH; Niu, W				Zhang, Lizhen; Liu, Ruihai; Niu, Wei			Phytochemical and Antiproliferative Activity of Proso Millet	PLOS ONE			English	Article							CELLULAR ANTIOXIDANT ACTIVITY; ANTI PROLIFERATIVE ACTIVITIES; PROTEIN; CAROTENOIDS; PHENOLICS; PROFILES; MAIZE; FOODS; ASSAY	The phytochemical content, antioxidant activity and antiproliferative properties of three diverse varieties of proso millet are reported. The free phenolic content ranged from 27.48 (Gumi 20) to 151.14 (Mi2504-6) mg gallic acid equiv/100 g DW. The bound phenolic content ranged from 55.95 (Gumi20) to 305.81 (Mi2504-6) mg gallic acid equiv/100 g DW. The percentage contribution of bound phenolic to the total phenolic content of genotype samples analyzed ranged between 62.08% and 67.05%. Ferulic acid and chlorogenic acid are the predominant phenolic acid found in bound fraction. Caffeic acid and p-coumaric acid were also detected. Syringic acid was detected only in the free fraction. The antioxidant activity was assessed using the hydrophilic peroxyl radical scavenging capacity (PSC) assay. The PSC antioxidant activity of the free fraction ranged from 57.68 (Mi2504-6) to 147.32 (Gumi20) mu mol of vitamin C equiv/100 g DW. The PSC antioxidant activity of the bound fraction ranged from 95.38 (Mizao 52) to 136.48 (Gumi 20) mu mol of vitamin C equiv/100 g DW. The cellular antioxidant activity (CAA) of the extract was assessed using the HepG2 model. CAA value ranged from 2.51 to 6.10 mu mol equiv quercetin/100 g DW. Antiproliferative activities were also studied in vitro against MDA human breast cancer and HepG2 human liver cancer cells. Results exhibited a differential and possible selective antiproliferative property of the proso millet. These results may be used to direct the consumption of proso millet with improved health properties.	[Zhang, Lizhen] Shanxi Univ, Coll Life Sci, Taiyuan, Peoples R China; [Liu, Ruihai] Cornell Univ, Dept Food Sci, Ithaca, NY 14853 USA; [Niu, Wei] Shanxi Acad Agr Sci, Taiyuan, Peoples R China	Shanxi University; Cornell University; Shanxi Agricultural University	Liu, RH (corresponding author), Cornell Univ, Dept Food Sci, Ithaca, NY 14853 USA.	RL23@cornell.edu	Liu, Rui Hai/AAE-4865-2019; Liu, Rui Hai/C-2865-2008	Liu, Rui Hai/0000-0002-7018-7929; 				Adom KK, 2005, J AGR FOOD CHEM, V53, P6572, DOI 10.1021/jf048318o; Adom KK, 2003, J AGR FOOD CHEM, V51, P7825, DOI 10.1021/jf030404l; Adom KK, 2002, J AGR FOOD CHEM, V50, P6182, DOI 10.1021/jf0205099; Asharani VT, 2010, INT J FOOD PROP, V13, P41, DOI 10.1080/10942910802163105; Birgit J, 2011, NUTR CANC, V63, P611; Chandrasekara A, 2011, J AGR FOOD CHEM, V59, P428, DOI 10.1021/jf103896z; Chandrasekara A, 2010, J AGR FOOD CHEM, V58, P6706, DOI 10.1021/jf100868b; Denery-Papini S, 1999, J CEREAL SCI, V30, P121, DOI 10.1006/jcrs.1999.0268; Eberhardt MV, 2000, NATURE, V405, P903, DOI 10.1038/35016148; Hentschel V, 2002, J AGR FOOD CHEM, V50, P6663, DOI 10.1021/jf025701p; Hu XY, 2009, J GENET GENOMICS, V36, P491, DOI 10.1016/S1673-8527(08)60139-3; Hulshof PJM, 2007, J FOOD COMPOS ANAL, V20, P655, DOI 10.1016/j.jfca.2006.04.014; Kalinova J, 2006, PLANT FOOD HUM NUTR, V61, P45, DOI 10.1007/s11130-006-0013-9; Kampa M, 2004, BREAST CANCER RES, V6, pR63, DOI 10.1186/bcr752; Kean EG, 2011, J CEREAL SCI, V54, P450, DOI 10.1016/j.jcs.2011.08.010; Kimura M, 2007, FOOD CHEM, V100, P1734, DOI 10.1016/j.foodchem.2005.10.020; Kumari SK, 1998, PLANT FOOD HUM NUTR, V53, P47, DOI 10.1023/A:1008083020810; Liu CS, 2004, J AGR FOOD CHEM, V52, P4330, DOI 10.1021/jf040028k; Liu M, 2002, J AGR FOOD CHEM, V50, P2926, DOI 10.1021/jf0111209; MCDONOUGH CM, 1985, CEREAL FOOD WORLD, V30, P550; Neelam Chaturvedi, 2011, Journal of Applied Pharmaceutical Science, V1, P6; Nishizawa N, 2002, BIOSCI BIOTECH BIOCH, V66, P92, DOI 10.1271/bbb.66.92; NISHIZAWA N, 1995, BIOSCI BIOTECH BIOCH, V59, P333, DOI 10.1271/bbb.59.333; Okarter N, 2010, FOOD CHEM, V119, P249, DOI 10.1016/j.foodchem.2009.06.021; Singleton VL, 1999, METHOD ENZYMOL, V299, P152; Song W, 2010, J AGR FOOD CHEM, V58, P6621, DOI 10.1021/jf9035832; Sun J, 2008, J AGR FOOD CHEM, V56, P11661, DOI 10.1021/jf8021223; Wang L., 2005, J PLANT GENET RESOUR, V6, P471; Wolfe KL, 2008, J AGR FOOD CHEM, V56, P8418, DOI 10.1021/jf801381y; Wolfe KL, 2007, J AGR FOOD CHEM, V55, P8896, DOI 10.1021/jf0715166; Xu BJ, 2012, FOOD CHEM, V134, P1287, DOI 10.1016/j.foodchem.2012.02.212; YANEZ GA, 1991, J CEREAL SCI, V13, P299, DOI 10.1016/S0733-5210(09)80008-8; Yang J, 2004, J AGR FOOD CHEM, V52, P6787, DOI 10.1021/jf0307144; Yang J, 2009, FOOD CHEM, V116, P332, DOI 10.1016/j.foodchem.2009.02.021	34	57	58	2	91	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2014	9	8							e104058	10.1371/journal.pone.0104058	http://dx.doi.org/10.1371/journal.pone.0104058			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6SM	25098952	Green Published, Green Submitted, gold			2023-01-03	WOS:000339995100047
J	Bjorkenstam, E; Narusyte, J; Alexanderson, K; Ropponen, A; Kjeldgard, L; Svedberg, P				Bjorkenstam, Emma; Narusyte, Jurgita; Alexanderson, Kristina; Ropponen, Annina; Kjeldgard, Linnea; Svedberg, Pia			Associations between Childbirth, Hospitalization and Disability Pension: A Cohort Study of Female Twins	PLOS ONE			English	Article							RISK-FACTORS; SICK LEAVE; FOLLOW-UP; BEHAVIORAL-DISORDERS; BACK-PAIN; HEALTH; WOMEN; PREGNANCY; PREVALENCE; MORTALITY	Background: As the literature on long-term effects of childbirth on risk of morbidity or permanent work incapacity (DP) is limited, we aimed to study associations of childbirth with hospitalization and DP, adjusting for familial factors. Methods: This cohort study included female twins, i.e. women with twin sister, born 1959-1990 in Sweden (n = 5 118). At least one in the twin pair had their first childbirth 1994-2009. Women were followed regarding all-cause and cause-specific (mental or musculoskeletal diagnoses) DP during year 2-5 after first delivery or equivalent. Associations between childbirth, hospitalization and DP were calculated as hazard ratios (HR) with 95% confidence intervals (CI). Results: Women who did not give birth had markedly higher number of DP days/year compared to those giving birth. Hospitalization after first childbirth was associated with a higher HR of DP. Those hospitalized at least once after their first childbirth had a three-fold DP risk (HR: 3.2; 95% CI 1.1-9.6), DP due to mental diagnoses (HR: 3.2; 1.2-8.8), and of DP due to musculoskeletal diagnoses (HR: 6.1; 1.6-22.9). Lower HRs in the discordant twin pair analyses indicated that familial factors may influence the studied associations. Conclusions: Women who did not give birth had a much higher risk for DP than those who did. Among those who gave birth, the risk for DP was markedly higher among those with a previous hospitalization, and especially in women with repeated hospitalizations. The results indicate a health selection into giving birth as well as the importance of morbidity for DP.	[Bjorkenstam, Emma; Narusyte, Jurgita; Alexanderson, Kristina; Kjeldgard, Linnea; Svedberg, Pia] Karolinska Inst, Div Insurance Med, Dept Clin Neurosci, Stockholm, Sweden; [Ropponen, Annina] Finnish Inst Occupat Hlth, Helsinki, Finland	Karolinska Institutet; Finnish Institute of Occupational Health	Bjorkenstam, E (corresponding author), Karolinska Inst, Div Insurance Med, Dept Clin Neurosci, Stockholm, Sweden.	emma.bjorkenstam@ki.se		Kjeldgard, Linnea/0000-0002-4575-7483; Ropponen, Annina/0000-0003-3031-5823	Karolinska Institutet Strategic Research Program in Epidemiology [Dnr 7340/2012]; Swedish Society of Medicine [Dnr SLS-250931, SLS-171611]; Ministry of Health and Social Affairs [S2012/7938/SF]; Swedish Research Council for Health, Working Life and Welfare [2007-1762]; Swedish Research Council; Ministry for Higher Education; AstraZeneca	Karolinska Institutet Strategic Research Program in Epidemiology; Swedish Society of Medicine; Ministry of Health and Social Affairs; Swedish Research Council for Health, Working Life and Welfare(Swedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte)); Swedish Research Council(Swedish Research CouncilEuropean Commission); Ministry for Higher Education; AstraZeneca(AstraZeneca)	This work was supported by funding from the Karolinska Institutet Strategic Research Program in Epidemiology (Dnr 7340/2012), The Swedish Society of Medicine (Dnr SLS-250931 and SLS-171611), the Ministry of Health and Social Affairs (S2012/7938/SF), and the Swedish Research Council for Health, Working Life and Welfare (2007-1762). The Swedish Twin Registry is supported by the Swedish Research Council, the Ministry for Higher Education, and AstraZeneca. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexanderson K, 2004, SCAND J PUBLIC HEALT, V32, P12, DOI 10.1080/14034950410021808; Allebeck P, 2004, SCAND J PUBLIC HEALT, V32, P49, DOI 10.1080/14034950410021853; Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21; Battie MC, 2007, PAIN, V131, P272, DOI 10.1016/j.pain.2007.01.010; Beckmann CR, 2010, OBSTET GYNECOLOGY; Bienvenu OJ, 2011, PSYCHOL MED, V41, P33, DOI 10.1017/S003329171000084X; Borg K, 2004, SCAND J PUBLIC HEALT, V32, P272, DOI 10.1080/14034940310019524; Borg-Stein Joanne, 2007, Phys Med Rehabil Clin N Am, V18, P459, DOI 10.1016/j.pmr.2007.05.005; Cheng CY, 2008, WOMEN HEALTH ISS, V18, P267, DOI 10.1016/j.whi.2008.02.004; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; Cwikel J, 2006, SOC SCI MED, V62, P1991, DOI 10.1016/j.socscimed.2005.09.006; Floderus B, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000840; Furberg H, 2008, NICOTINE TOB RES, V10, P1727, DOI 10.1080/14622200802443551; Gissler M, 1997, ACTA OBSTET GYN SCAN, V76, P651, DOI 10.3109/00016349709024605; Gjerde LC, 2013, TWIN RES HUM GENET, V16, P759, DOI 10.1017/thg.2013.36; Gustafsson K, 2013, INT J BEHAV MED; Halford C, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1103; Harkonmaki K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003402; Haukenes I, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-720; Jocums SB, 1998, OBSTET GYNECOL, V91, P766, DOI 10.1016/S0029-7844(98)00063-5; KENDLER KS, 1995, ARCH GEN PSYCHIAT, V52, P895; Koropeckyj-Cox T, 2007, INT J AGING HUM DEV, V64, P299, DOI 10.2190/8PTL-P745-58U1-3330; Kujala UM, 2002, AM J EPIDEMIOL, V156, P985, DOI 10.1093/aje/kwf151; Lichtenstein P, 2002, J INTERN MED, V252, P184, DOI 10.1046/j.1365-2796.2002.01032.x; Lichtenstein P, 2006, TWIN RES HUM GENET, V9, P875, DOI 10.1375/183242706779462444; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Ludvigsson JF, 2009, EUR J EPIDEMIOL, V24, P659, DOI 10.1007/s10654-009-9350-y; MacGregor AJ, 2000, ARTHRITIS RHEUM, V43, P30, DOI 10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B; Mykletun A, 2006, AM J PSYCHIAT, V163, P1412, DOI 10.1176/appi.ajp.163.8.1412; Narusyte J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023143; National Records of Scotland, 2011, CHANG COD CAUS DEATH; OECD, 2009, SICKN DIS WORK BREAK; Pietikainen S, 2011, OCCUPATIONAL ENV MED, V53; PLOMIN R, 1994, SCIENCE, V264, P1733, DOI 10.1126/science.8209254; Plomin R., 2000, BEHAV GENETICS; Ronsmans C, 2001, INT J EPIDEMIOL, V30, P467, DOI 10.1093/ije/30.3.467; Ropponen A, 2013, EUR J PUBLIC HLTH; Schytt E, 2005, BJOG-INT J OBSTET GY, V112, P210, DOI 10.1111/j.1471-0528.2004.00319.x; Statistics Sweden, 2012, LONG INT DAT HLTH IN; Thorlacius S, 2010, J MENT HEALTH, V19, P176, DOI 10.3109/09638230902968316; To WWK, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-55; Vistnes JP, 1997, IND LABOR RELAT REV, V50, P304, DOI 10.2307/2525088; Williams D, 2003, CURR OPIN OBSTET GYN, V15, P465, DOI 10.1097/00001703-200312000-00002; World Health Organization, 1992, ICD 10 INT STAT CLAS	44	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2014	9	7							e101566	10.1371/journal.pone.0101566	http://dx.doi.org/10.1371/journal.pone.0101566			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AK7WB	24999632	Green Submitted, gold, Green Published			2023-01-03	WOS:000338637300056
J	Gingras, B; Pohler, G; Fitch, WT				Gingras, Bruno; Pohler, Gerald; Fitch, W. Tecumseh			Exploring Shamanic Journeying: Repetitive Drumming with Shamanic Instructions Induces Specific Subjective Experiences but No Larger Cortisol Decrease than Instrumental Meditation Music	PLOS ONE			English	Article							SALIVARY CORTISOL; SEX-DIFFERENCES; RELAXING MUSIC; HEART-RATE; RELAXATION; RESPONSES; IMAGERY; INCREASES; STRESS; STATES	Exposure to repetitive drumming combined with instructions for shamanic journeying has been associated with physiological and therapeutic effects, such as an increase in salivary immunoglobulin A. In order to assess whether the combination of repetitive drumming and shamanic instructions is specifically associated with these effects, we compared the effect of listening to either repetitive drumming or instrumental meditation music for 15 minutes on salivary cortisol concentration and on self-reported physiological and psychological states. For each musical style, two groups of participants were exposed to two conditions: instructions for shamanic journeying or relaxation instructions. A total of 39 participants (24 females) inexperienced in shamanic journeying completed the experiment. Salivary cortisol concentrations were measured before and after exposure to music. In addition, participants filled out a mood questionnaire before and after the experiment and completed a post experiment questionnaire on their experiences. A significant decrease in the concentration in salivary cortisol was observed across all musical styles and instructions, indicating that exposure to 15 minutes of either repetitive drumming or instrumental meditation music, while lying down, was sufficient to induce a decrease in cortisol levels. However, no differences were observed across conditions. Significant differences in reported emotional states and subjective experiences were observed between the groups. Notably, participants exposed to repetitive drumming combined with shamanic instructions reported experiencing heaviness, decreased heart rate, and dreamlike experiences significantly more often than participants exposed to repetitive drumming combined with relaxation instructions. Our findings suggest that the subjective effects specifically attributed to repetitive drumming and shamanic journeying may not be reflected in differential endocrine responses.	[Gingras, Bruno; Pohler, Gerald; Fitch, W. Tecumseh] Univ Vienna, Dept Cognit Biol, Vienna, Austria	University of Vienna	Gingras, B (corresponding author), Univ Vienna, Dept Cognit Biol, Vienna, Austria.	brunogingras@gmail.com	Campailla, Jasmin/AAK-2420-2021		European Research Council (ERC) Advanced Grant SOMACCA [230604]; University of Vienna	European Research Council (ERC) Advanced Grant SOMACCA; University of Vienna	This research was supported by European Research Council (ERC) Advanced Grant SOMACCA [grant number 230604] and a University of Vienna startup grant to W.T.F. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achterberg J, 1990, GEDANKEN HEILEN KRAF; Atsumi T, 2007, PSYCHIAT RES, V150, P89, DOI 10.1016/j.psychres.2005.12.012; Banks SL, 1998, J MUSCULOSKELET PAIN, V6, P23, DOI 10.1300/J094v06n04_03; Bernardi L, 2006, HEART, V92, P445, DOI 10.1136/hrt.2005.064600; BLIZARD DA, 1975, BIOL PSYCHOL, V3, P49, DOI 10.1016/0301-0511(75)90005-8; Boersma P., 2009, PRAAT DOING PHONETIC; Bonny HL, 1999, NORD J MUSIC THER, V8, P171; Borkenau P., 2008, NEO FFI NEO FUNF FAK, V2.; Cowan T., 1996, SHAMANISM SPIRITUAL; Cruess DG, 2000, J BEHAV MED, V23, P107, DOI 10.1023/A:1005419917023; Eliade M., 2004, SHAMANISM ARCHAIC TE; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fletcher H, 1933, J ACOUST SOC AM, V5, P82, DOI 10.1121/1.1915637; GATCHEL RJ, 1976, J CONSULT CLIN PSYCH, V44, P381, DOI 10.1037/0022-006X.44.3.381; Goodman F. D., 1990, SPIRITS RIDE WIND TR; Goodman FD, 1999, ANTHROPOL CONSCIOUS, V10, P54, DOI [10.1525/ac.1999.10.1.54, DOI 10.1525/AC.1999.10.1.54]; Grosche P, 2011, IEEE T AUDIO SPEECH, V19, P1688, DOI 10.1109/TASL.2010.2096216; Guttman G, 1988, RES B, V27; Harner M, 1997, SHAMANIC JOURNEY SER, V6; Harner M, 1997, SHAMANIC JOURNEY SER, V1; HARNER Michael, 1982, WAY SHAMAN GUIDE POW; Harner S., 2010, J FDN SHAMANIC STUD, V23, P31; Harner S, 2001, SHAMANISM, V14, P19; Haubenhofer DK, 2007, SOC ANIM, V15, P127, DOI 10.1163/156853007X187090; Hevner K, 1937, AM J PSYCHOL, V49, P621, DOI 10.2307/1416385; Hodges, 2010, HDB MUSIC EMOTION TH, P279; Kanji N, 1997, COMPLEMENT THER MED, V5, P162, DOI [10.1016/S0965-2299(97)80060-X, DOI 10.1016/S0965-2299(97)80060-X]; Khalfa S, 2003, ANN NY ACAD SCI, V999, P374, DOI 10.1196/annals.1284.045; KIRSCHBAUM C, 1994, PSYCHONEUROENDOCRINO, V19, P313, DOI 10.1016/0306-4530(94)90013-2; KIRSCHBAUM C, 1989, NEUROPSYCHOBIOLOGY, V22, P150, DOI 10.1159/000118611; Kjellgren A, 2010, INT J TRANSPERS, V29, P1; Knight WEJ, 2001, J MUSIC THER, V38, P254, DOI 10.1093/jmt/38.4.254; Kreutz G, 2004, J BEHAV MED, V27, P623, DOI 10.1007/s10865-004-0006-9; Luthe W, 1969, AUTOGENIC THERAPY ME; Maurer RL, 1997, AM J CLIN HYPN, V40, P130, DOI 10.1080/00029157.1997.10403417; MCFARLAND RA, 1991, INT J PSYCHOPHYSIOL, V11, P295, DOI 10.1016/0167-8760(91)90024-R; MOCKEL M, 1995, DEUT MED WOCHENSCHR, V120, P745, DOI 10.1055/s-2008-1055403; Nater UM, 2006, INT J PSYCHOPHYSIOL, V62, P300, DOI 10.1016/j.ijpsycho.2006.05.011; NEHER A, 1961, ELECTROEN CLIN NEURO, V13, P449, DOI 10.1016/0013-4694(61)90014-1; NEHER A, 1962, HUM BIOL, V34, P151; Nelson D.L., 2008, LEHNINGER PRINCIPLES; NOLL R, 1985, CURR ANTHROPOL, V26, P443, DOI 10.1086/203305; Palme R, 1997, Z SAUGETIERKD, V62, P192; Pawlow LA, 2002, BIOL PSYCHOL, V60, P1, DOI 10.1016/S0301-0511(02)00010-8; Pelletier CL, 2004, J MUSIC THER, V41, P192, DOI 10.1093/jmt/41.3.192; Pohler G, 1989, ENTSPANNUNG STRESSAB; Pohler G, 2009, PROMED KOMPLEMENTAR, V16, P26; Rock AJ, 2005, ANTHROPOL CONSCIOUS, V16, P72, DOI 10.1525/ac.2005.16.2.72; Rock AJ, 2006, ANTHROPOL CONSCIOUS, V17, P65, DOI 10.1525/ac.2006.17.1.65; SAPOLSKY R M, 1992, P287; Schultz J, 1973, AUTOGENE TRAINING; Shanti O, 2003, LISTENING HEART; SHAPIRO S, 1980, BIOFEEDBACK SELF-REG, V5, P249, DOI 10.1007/BF00998600; Silbernagel S, 1991, TASCHENBUCH PHYSL; Steyer R., 1994, DIAGNOSTICA, V40, P320; Steyer R., 1997, MEHRDIMENSIONALE BEF; Sumioka H, 2013, SCI REP-UK, V3, DOI 10.1038/srep03034; Szabo Csaba, 2004, MUSIC THER TODAY, V1, P1; Tang YY, 2007, P NATL ACAD SCI USA, V104, P17152, DOI 10.1073/pnas.0707678104; TART CT, 1972, SCIENCE, V176, P1203, DOI 10.1126/science.176.4040.1203; Thoma MV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070156; Vandana B, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/379645; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; Vuckovic NH, 2007, ALTERN THER HEALTH M, V13, P18; Walsh R, 1990, SPIRIT SHAMANISM; Will U, 2007, NEUROSCI LETT, V424, P55, DOI 10.1016/j.neulet.2007.07.036; WINKELMAN M, 1986, ETHOS, V14, P174, DOI 10.1525/eth.1986.14.2.02a00040; Woodside L. N., 1997, ANTHR CONSCIOUSNESS, V8, P69, DOI [DOI 10.1525/AC.1997.8.2-3.69, 10.1525/ac.1997.8.2-3.69]; Wooten HR, 2007, J HEART CTR THER, V10, P3	69	11	12	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2014	9	7							e102103	10.1371/journal.pone.0102103	http://dx.doi.org/10.1371/journal.pone.0102103			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AK7WB	24999623	Green Submitted, Green Published, gold			2023-01-03	WOS:000338637300120
J	Kortepeter, MG; Smith, PW; Hewlett, A; Cieslak, TJ				Kortepeter, Mark G.; Smith, Philip W.; Hewlett, Angela; Cieslak, Theodore J.			Caring for Patients With Ebola: A Challenge in Any Care Facility	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							VIRUS; UNIT		[Kortepeter, Mark G.] Uniformed Serv Univ Hlth Sci, Sch Med, Bethesda, MD 20814 USA; [Smith, Philip W.; Hewlett, Angela] Univ Nebraska Med Ctr, Div Infect Dis, Biocontainment Unit, Omaha, NE USA; [Cieslak, Theodore J.] San Antonio Mil Med Ctr, Dept Pediat, Ft Sam Houston, TX USA	Uniformed Services University of the Health Sciences - USA; University of Nebraska System; University of Nebraska Medical Center; San Antonio Military Medical Center	Kortepeter, MG (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.							Armstrong LR, 1999, INFECT CONT HOSP EP, V20, P176, DOI 10.1086/501607; Centers for Disease Control and Prevention, 2014, INFECT PREV CONTR RE; Centers for Disease Control and Prevention; Assistant Secretary of Preparedness and Response, HLTH CAR PROV PREP C; Fischer WA, 2014, ANN INTERN MED, V161, P753, DOI 10.7326/M14-1953; Kortepeter MG, 2008, EMERG INFECT DIS, V14, P881, DOI 10.3201/eid1406.071489; Smith PW, 2006, BIOSECUR BIOTERROR, V4, P351, DOI 10.1089/bsp.2006.4.351	6	13	13	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 6	2015	162	1					68	U112		10.7326/M14-2289	http://dx.doi.org/10.7326/M14-2289			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CC1LU	25320965				2023-01-03	WOS:000350103000010
J	Hewitt, PE; Ijaz, S; Brailsford, SR; Brett, R; Dicks, S; Haywood, B; Kennedy, ITR; Kitchen, A; Patel, P; Poh, J; Russell, K; Tettmar, KI; Tossell, J; Ushiro-Lumb, I; Tedder, RS				Hewitt, Patricia E.; Ijaz, Samreen; Brailsford, Su R.; Brett, Rachel; Dicks, Steven; Haywood, Becky; Kennedy, Iain T. R.; Kitchen, Alan; Patel, Poorvi; Poh, John; Russell, Katherine; Tettmar, Kate I.; Tossell, Joanne; Ushiro-Lumb, Ines; Tedder, Richard S.			Hepatitis E virus in blood components: a prevalence and transmission study in southeast England	LANCET			English	Article							NON-B HEPATITIS; NON-A; INFECTION; DONORS; WALES; RNA; RECIPIENTS; THERAPY; HIV	Background The prevalence of hepatitis E virus (HEV) genotype 3 infections in the English population (including blood donors) is unknown, but is probably widespread, and the virus has been detected in pooled plasma products. HEV-infected donors have been retrospectively identified through investigation of reported cases of possible transfusion-transmitted hepatitis E. The frequency of HEV transmission by transfusion and its outcome remains unknown. We report the prevalence of HEV RNA in blood donations, the transmission of the virus through a range of blood components, and describe the resulting morbidity in the recipients. Methods From Oct 8, 2012, to Sept 30, 2013, 225 000 blood donations that were collected in southeast England were screened retrospectively for HEV RNA. Donations containing HEV were characterised by use of serology and genomic phylogeny. Recipients, who received any blood components from these donations, were identified and the outcome of exposure was ascertained. Findings 79 donors were viraemic with genotype 3 HEV, giving an RNA prevalence of one in 2848. Most viraemic donors were seronegative at the time of donation. The 79 donations had been used to prepare 129 blood components, 62 of which had been transfused before identification of the infected donation. Follow-up of 43 recipients showed 18 (42%) had evidence of infection. Absence of detectable antibody and high viral load in the donation rendered infection more likely. Recipient immunosuppression delayed or prevented seroconversion and extended the duration of viraemia. Three recipients cleared longstanding infection after intervention with ribavirin or alteration in immunosuppressive therapy. Ten recipients developed prolonged or persistent infection. Transaminitis was common, but short-term morbidity was rare; only one recipient developed apparent but clinically mild post-transfusion hepatitis. Interpretation Our findings suggest that HEV genotype 3 infections are widespread in the English population and in blood donors. Transfusion-transmitted infections rarely caused acute morbidity, but in some immunosuppressed patients became persistent. Although at present blood donations are not screened, an agreed policy is needed for the identification of patients with persistent HEV infection, irrespective of origin, so that they can be offered antiviral therapy.	[Hewitt, Patricia E.; Brailsford, Su R.; Brett, Rachel; Dicks, Steven; Kitchen, Alan; Patel, Poorvi; Tettmar, Kate I.; Tossell, Joanne; Ushiro-Lumb, Ines; Tedder, Richard S.] Natl Hlth Serv Blood & Transplant, London, England; [Ijaz, Samreen; Dicks, Steven; Haywood, Becky; Patel, Poorvi; Tettmar, Kate I.; Ushiro-Lumb, Ines; Tedder, Richard S.] Publ Hlth England, Virus Reference Dept, Microbiol Serv, Blood Borne Virus Unit, London NW9 5EQ, England; [Brailsford, Su R.; Kennedy, Iain T. R.; Russell, Katherine] Publ Hlth England, Infect Dis Surveillance Ctr, London NW9 5EQ, England; [Tedder, Richard S.] UCL, London, England	NHS Blood & Transplant (NHSBT); Public Health England; Public Health England; University of London; University College London	Tedder, RS (corresponding author), Publ Hlth England, Virus Reference Dept, Microbiol Serv, Blood Borne Virus Unit, London NW9 5EQ, England.	richard.tedder@phe.gov.uk	Ushiro-Lumb, Ines/GXM-3502-2022	Ushiro-Lumb, Ines/0000-0003-0989-8091; Ijaz, Samreen/0000-0001-6658-3542; Tedder, Richard/0000-0002-9672-5721; Haywood, Becky/0000-0002-1461-9619; Kennedy, Iain/0000-0003-0395-1269	Public Health England; National Health Service Blood and Transplant	Public Health England; National Health Service Blood and Transplant	Public Health England and National Health Service Blood and Transplant.	Andersson MI, 2013, AIDS, V27, P487, DOI 10.1097/QAD.0b013e32835b1074; BALAYAN MS, 1983, INTERVIROLOGY, V20, P23, DOI 10.1159/000149370; BALAYAN MS, 1990, J MED VIROL, V32, P58, DOI 10.1002/jmv.1890320110; Baylis SA, 2012, VOX SANG, V103, P89, DOI 10.1111/j.1423-0410.2011.01583.x; Beale MA, 2011, VOX SANG, V100, P340, DOI 10.1111/j.1423-0410.2010.01412.x; Boxall E, 2006, TRANSFUSION MED, V16, P79, DOI 10.1111/j.1365-3148.2006.00652.x; Casas M, 2009, VET MICROBIOL, V138, P78, DOI 10.1016/j.vetmic.2009.03.008; Cleland A, 2013, VOX SANG, V105, P283, DOI 10.1111/vox.12056; Coilly A, 2013, TRANSPLANTATION, V96, pE4, DOI 10.1097/TP.0b013e318296c9f7; Colson P, 2010, J INFECT DIS, V202, P825, DOI 10.1086/655898; Corman VM, 2013, VOX SANG, V104, P179, DOI 10.1111/j.1423-0410.2012.01638.x; Dalton HR, 2009, NEW ENGL J MED, V361, P1025, DOI 10.1056/NEJMc0903778; Feray C, 2014, LANCET, V383, P218, DOI 10.1016/S0140-6736(14)60072-6; Garson JA, 2012, J VIROL METHODS, V186, P157, DOI 10.1016/j.jviromet.2012.07.027; Gottstein B, 2009, CLIN MICROBIOL REV, V22, P127, DOI 10.1128/CMR.00026-08; Ijaz S, 2005, J INFECT DIS, V192, P1166, DOI 10.1086/444396; Ijaz S, 2012, VOX SANG, V102, P272, DOI 10.1111/j.1423-0410.2011.01554.x; Ijaz S, 2014, J INFECT DIS, V209, P1212, DOI 10.1093/infdis/jit652; Ijaz S, 2009, J CLIN VIROL, V44, P272, DOI 10.1016/j.jcv.2009.01.005; Juhl D, 2014, TRANSFUSION, V54, P49, DOI 10.1111/trf.12121; Kamar N, 2008, NEW ENGL J MED, V358, P811, DOI 10.1056/NEJMoa0706992; Kamar N, 2013, SEMIN LIVER DIS, V33, P62, DOI 10.1055/s-0033-1338115; KHUROO MS, 1980, AM J MED, V68, P818, DOI 10.1016/0002-9343(80)90200-4; Lewis HC, 2008, EMERG INFECT DIS, V14, P165, DOI 10.3201/eid1401.070307; Masuda JI, 2005, HEPATOL RES, V31, P178, DOI 10.1016/j.hepres.2005.01.008; REYES GR, 1990, SCIENCE, V247, P1335, DOI 10.1126/science.2107574; Said B, 2014, EPIDEMIOL INFECT, V142, P1467, DOI 10.1017/S0950268813002318; Singh GKJ, 2013, J INFECTION, V66, P103, DOI 10.1016/j.jinf.2011.11.027; Tei S, 2003, LANCET, V362, P371, DOI 10.1016/S0140-6736(03)14025-1; Versluis J, 2013, BLOOD, V122, P1079, DOI 10.1182/blood-2013-03-492363	30	352	360	0	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	2014	384	9956					1766	1773		10.1016/S0140-6736(14)61034-5	http://dx.doi.org/10.1016/S0140-6736(14)61034-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AT7KX	25078306	Green Submitted			2023-01-03	WOS:000345116400027
J	Schilling, S; Fusco, FM; De Iaco, G; Bannister, B; Maltezou, HC; Carson, G; Gottschalk, R; Brodt, HR; Brouqui, P; Puro, V; Ippolito, G				Schilling, Stefan; Fusco, Francesco Maria; De Iaco, Giuseppina; Bannister, Barbara; Maltezou, Helena C.; Carson, Gail; Gottschalk, Rene; Brodt, Hans-Reinhard; Brouqui, Philippe; Puro, Vincenzo; Ippolito, Giuseppe		European Network Highly Infectious	Isolation Facilities for Highly Infectious Diseases in Europe - A Cross-Sectional Analysis in 16 Countries	PLOS ONE			English	Article							LEVEL ISOLATION UNITS; MANAGEMENT; NETWORK; CONSENSUS; CORONAVIRUS	Background: Highly Infectious Diseases (HIDs) are (i) easily transmissible form person to person; (ii) cause a life-threatening illness with no or few treatment options; and (iii) pose a threat for both personnel and the public. Hence, even suspected HID cases should be managed in specialised facilities minimizing infection risks but allowing state-of-the-art critical care. Consensus statements on the operational management of isolation facilities have been published recently. The study presented was set up to compare the operational management, resources, and technical equipment among European isolation facilities. Due to differences in geography, population density, and national response plans it was hypothesized that adherence to recommendations will vary. Methods and Findings: Until mid of 2010 the European Network for Highly Infectious Diseases conducted a cross-sectional analysis of isolation facilities in Europe, recruiting 48 isolation facilities in 16 countries. Three checklists were disseminated, assessing 44 items and 148 specific questions. The median feedback rate for specific questions was 97.9% (n = 47/48) (range: n = 7/48 (14.6%) to n = 48/48 (100%). Although all facilities enrolled were nominated specialised facilities' serving countries or regions, their design, equipment and personnel management varied. Eighteen facilities fulfilled the definition of a High Level Isolation Unit'. In contrast, 24 facilities could not operate independently from their co-located hospital, and five could not ensure access to equipment essential for infection control. Data presented are not representative for the EU in general, as only 16/27 (59.3%) of all Member States agreed to participate. Another limitation of this study is the time elapsed between data collection and publication; e. g. in Germany one additional facility opened in the meantime. Conclusion: There are disparities both within and between European countries regarding the design and equipment of isolation facilities. With regard to the International Health Regulations, terminology, capacities and equipment should be standardised.	[Schilling, Stefan] Staedt Kliniken Moenchengladbach, Dept Internal Med, Monchengladbach, Germany; [Fusco, Francesco Maria; Puro, Vincenzo; Ippolito, Giuseppe] Natl Inst Infect Dis Lazarro Spallanzani, Dept Infect Dis, Rome, Italy; [De Iaco, Giuseppina] Univ Osped Riuniti Marche, Azienda Osped, Dept Internal Med, Torrette, Italy; [Bannister, Barbara] Royal Free Hosp, Dept Infect Dis, London NW3 2QG, England; [Maltezou, Helena C.] Hellen Ctr Dis Control & Prevent, Dept Intervent Healthcare Facil, Athens, Greece; [Carson, Gail] Hlth Protect Agcy, Dept Rare & Imported Pathogens, Porton Down, England; [Gottschalk, Rene] Port Hlth Author, Dept Infect Dis, Frankfurt, Germany; [Brodt, Hans-Reinhard] Goethe Univ Frankfurt, Dept Infect Dis, D-60054 Frankfurt, Germany; [Brouqui, Philippe] Marseilles Univ, Dept Infect Dis & Trop Med, Marseille, France	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Health Protection Agency; Goethe University Frankfurt; UDICE-French Research Universities; Aix-Marseille Universite	Schilling, S (corresponding author), Staedt Kliniken Moenchengladbach, Dept Internal Med, Monchengladbach, Germany.	stefan.schilling@kgu.de	Ippolito, Giuseppe/J-7207-2017; Brouqui, Philippe/P-5771-2016; Fusco, Francesco Maria/AFO-1279-2022; Lanini, Simone/C-7523-2012	Fusco, Francesco Maria/0000-0002-1293-5976; Lanini, Simone/0000-0002-6743-4001; Ippolito, Giuseppe/0000-0002-1076-2979; puro, vincenzo/0000-0003-0291-4490; Gottschalk, Professor M. D., Ph. D, Rene/0000-0003-0422-6456	European Commission/DG SANCO under the EU [2006205]	European Commission/DG SANCO under the EU	The "European Network for Highly Infectious Diseases - EuroNHID" is co-funded by the European Commission/DG SANCO under the EU contract number 2006205. Neither the Commission nor DG SANCO had an influence on the study design, data collection, or interpretation of results. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atkin S, 2009, EUROSURVEILLANCE, V14; Baka A, 2007, Euro Surveill, V12, pE5; Bannister B, 2009, LANCET INFECT DIS, V9, P45, DOI 10.1016/S1473-3099(08)70304-9; Barr DA, 2013, LANCET, V382, P1458, DOI 10.1016/S0140-6736(13)61718-3; Bork KH, 2006, EURO SURVEILL, V11; Brouqui P, 2009, LANCET INFECT DIS, V9, P301, DOI 10.1016/S1473-3099(09)70070-2; Danielsson N, 2012, EUROSURVEILLANCE, V17, P9; De Iaco G, 2012, INFECT CONT HOSP EP, V33, P1008, DOI 10.1086/667729; Drosten C, 2003, TRENDS MOL MED, V9, P325, DOI 10.1016/S1471-4914(03)00133-3; Ergonul O, 2006, LANCET INFECT DIS, V6, P203, DOI 10.1016/S1473-3099(06)70435-2; European Commission, 1989, OFFICIAL J, V183; Fusco FM, 2009, J HOSP INFECT, V73, P15, DOI 10.1016/j.jhin.2009.06.009; Fusco FM, 2009, CLIN MICROBIOL INFEC, V15, P711, DOI 10.1111/j.1469-0691.2009.02874.x; Fusco FM, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-27; Gunther S, 2011, J INFECT DIS, V204, pS785, DOI 10.1093/infdis/jir298; Kaji AH, 2007, JAMA-J AM MED ASSOC, V298, P2188, DOI 10.1001/jama.298.18.2188; Kitching A, 2009, EUROSURVEILLANCE, V14; Maltezou HC, 2012, J HOSP INFECT, V81, P184, DOI 10.1016/j.jhin.2012.04.019; Menne J, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e4565; Nisii C, 2009, CLIN MICROBIOL INFEC, V15, P720, DOI 10.1111/j.1469-0691.2009.02946.x; Rodier G, 2006, EURO SURVEILL, V11; Schilling S, 2019, CLIN MICROBIOL INFEC, V21, pE1, DOI 10.1111/1469-0691.12290; Smith PW, 2006, BIOSECUR BIOTERROR, V4, P351, DOI 10.1089/bsp.2006.4.351; Thiberville Simon-Djamel, 2012, BMC Res Notes, V5, P527, DOI 10.1186/1756-0500-5-527; U.S. Department of Health and Human Services, 2005, NAT BIOT HOSP PERP P; van Paassen J, 2012, LANCET INFECT DIS, V12, P635, DOI 10.1016/S1473-3099(12)70018-X; World Health Organization Regional Office for Europe, 2012, ASS HEATH SYST CRIS; Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721	28	15	18	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2014	9	10							e100401	10.1371/journal.pone.0100401	http://dx.doi.org/10.1371/journal.pone.0100401			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AS0BH	25350843	Green Published, Green Submitted, gold			2023-01-03	WOS:000343943100002
J	Choi, SG; Lee, SE; Kang, BS; Ng, CL; Davaa, E; Park, JS				Choi, Soon Gil; Lee, Sang-Eun; Kang, Bong-Seok; Ng, Choon Lian; Davaa, Enkhzaya; Park, Jeong-Sook			Thermosensitive and Mucoadhesive Sol-Gel Composites of Paclitaxel/Dimethyl-beta-Cyclodextrin for Buccal Delivery	PLOS ONE			English	Article							CANCER-CELLS; IN-VITRO; ANTITUMOR-ACTIVITY; HYDROGEL; CURCUMIN; RELEASE; COMPLEXATION; CARRIER; SYSTEM; VIVO	The purpose of this study was to develop a buccal paclitaxel delivery system using the thermosensitive polymer Pluronic F127 (PF127) and the mucoadhesive polymer polyethylene oxide (PEO). The anticancer agent paclitaxel is usually used to treat ovarian, breast, and non-small-cell lung cancer. To improve its aqueous solubility, paclitaxel was incorporated into an inclusion complex with (2,6-di-O-methyl)-beta-cyclodextrin (DM beta CD). The formation of the paclitaxel inclusion complex was evaluated using various techniques, including x-ray diffractometry (XRD), Fourier-transform infrared (FT-IR) spectrophotometry, differential scanning calorimetry (DSC), and scanning electron microscopy (SEM). Hydrogels were prepared using a cold method. Concentrations of 18, 20, and 23% (w/v) PF127 were dissolved in distilled water including paclitaxel and stored overnight in a refrigerator at 4 degrees C. PEO was added at concentrations of 0.1, 0.2, 0.4, 0.8, and 1% (w/v). Each formulation included paclitaxel (0.5 mg/mL). The sol-gel transition temperature of the hydrogels was measured using the tube-inverting method. Drug release from the hydrogels was measured using a Franz diffusion cell containing pH 7.4 phosphate-buffered solution (PBS) buffer at 37 degrees C. The cytotoxicity of each formulation was measured using the MTT assay with a human oral cancer cell (KB cell). The sol-gel transition temperature of the hydrogel decreased when PF127 was present and varied according to the presence of mucoadhesive polymers. The in vitro release was sustained and the release rate was slowed by the addition of the mucoadhesive polymer. The cytotoxicity of the blank formulation was low, although the drug-loaded hydrogel showed acceptable cytotoxicity. The results of our study suggest that the combination of a PF 127-based mucoadhesive hydrogel formulation and inclusion complexes improves the in vitro release and cytotoxic effect of paclitaxel.	[Choi, Soon Gil; Lee, Sang-Eun; Kang, Bong-Seok; Ng, Choon Lian; Davaa, Enkhzaya; Park, Jeong-Sook] Chungnam Natl Univ, Coll Pharm, Taejon, South Korea	Chungnam National University	Park, JS (corresponding author), Chungnam Natl Univ, Coll Pharm, Taejon, South Korea.	eicosa@cnu.ac.kr		Park, Jeong-Sook/0000-0002-4081-213X	Priority Research Centers Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2012-0006681]	Priority Research Centers Program through the National Research Foundation of Korea (NRF) - Ministry of Education	This research was supported by the Priority Research Centers Program (No. 2012-0006681) through the National Research Foundation of Korea (NRF), funded by the Ministry of Education. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abouzeid AH, 2014, PHARM RES-DORDR, V31, P1938, DOI 10.1007/s11095-013-1295-x; Ahn Byeong Kil, 2013, Journal of Pharmaceutical Investigation, V43, P453, DOI 10.1007/s40005-013-0089-9; Al-Marzouqi AH, 2009, J PHARMACEUT BIOMED, V49, P227, DOI 10.1016/j.jpba.2008.10.032; Baek JS, 2013, J PHARM PHARMACOL, V65, P72, DOI 10.1111/j.2042-7158.2012.01578.x; Boztas AO, 2013, MOL PHARMACEUT, V10, P2676, DOI 10.1021/mp400101k; Calleja P, 2014, NANOMEDICIN IN PRESS; Choi SG, 2013, INT J PHARMACEUT, V447, P102, DOI 10.1016/j.ijpharm.2013.02.053; Choudhury H, 2014, INT J PHARMACEUT, V460, P131, DOI 10.1016/j.ijpharm.2013.10.055; Feng SS, 2001, J CONTROL RELEASE, V71, P53, DOI 10.1016/S0168-3659(00)00364-3; Groo AC, 2014, PHARM RES-DORDR, V31, P1753, DOI 10.1007/s11095-013-1280-4; He HM, 2013, BIOMATERIALS, V34, P5344, DOI 10.1016/j.biomaterials.2013.03.068; Hedges AR, 1998, CHEM REV, V98, P2035, DOI 10.1021/cr970014w; Hiremath JG, 2013, SAUDI PHARM J, V21, P85, DOI 10.1016/j.jsps.2011.12.002; Ju CY, 2013, J PHARM SCI-US, V102, P2707, DOI 10.1002/jps.23649; Kim YT, 2010, EUR J PHARM SCI, V41, P399, DOI 10.1016/j.ejps.2010.07.009; Lin ZQ, 2014, J CONTROL RELEASE, V174, P161, DOI 10.1016/j.jconrel.2013.10.026; Mitra A, 2003, J PHARM PHARMACOL, V55, P895, DOI 10.1211/0022357021341; Okamatsu A, 2013, BIOCONJUGATE CHEM, V24, P724, DOI 10.1021/bc400015r; Park JS, 2002, J BIOMED MATER RES, V59, P144, DOI 10.1002/jbm.1227; Rowinsky EK, 1997, ANNU REV MED, V48, P353; Sharma A, 2010, J GLOBAL PHARM TECH, V2, P18; Shin BK, 2013, DRUG DEV IND PHARM, V39, P1874, DOI 10.3109/03639045.2012.665925; Singh S, 2010, CHEM PHARM BULL, V58, P307, DOI 10.1248/cpb.58.307; Tong LX, 2014, ANTI-CANCER DRUG, V25, P244, DOI 10.1097/CAD.0000000000000047; Tonnesen HH, 2002, INT J PHARMACEUT, V244, P127, DOI 10.1016/S0378-5173(02)00323-X; Yallapu MM, 2010, COLLOID SURFACE B, V79, P113, DOI 10.1016/j.colsurfb.2010.03.039; YEH MK, 1995, J CONTROL RELEASE, V33, P437, DOI 10.1016/0168-3659(94)00123-C; Yu SL, 2013, ANGEW CHEM INT EDIT, V52, P7272, DOI 10.1002/anie.201301397; Zarei M, 2013, Pak J Biol Sci, V16, P295, DOI 10.3923/pjbs.2013.295.298	29	34	34	1	61	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2014	9	10							e109090	10.1371/journal.pone.0109090	http://dx.doi.org/10.1371/journal.pone.0109090			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ2BX	25275485	Green Published, Green Submitted, gold			2023-01-03	WOS:000342591500057
J	Kim, HR; Kim, JH; Choi, EJ; Lee, YK; Kie, JH; Jang, MH; Seoh, JY				Kim, Hyung-Ran; Kim, Jung-Hwan; Choi, Eun-Jeong; Lee, Yeo Kyong; Kie, Jeong-Hae; Jang, Myoung Ho; Seoh, Ju-Young			Hyperoxygenation Attenuated a Murine Model of Atopic Dermatitis through Raising Skin Level of ROS	PLOS ONE			English	Article							HYPERBARIC-OXYGEN THERAPY; REGULATORY T-CELLS; CHRONIC GRANULOMATOUS-DISEASE; TRYPTOPHAN CATABOLISM; INDOLEAMINE 2,3-DIOXYGENASE; GLUTATHIONE PEROXIDASE-1; EXPERIMENTAL COLITIS; AUTOIMMUNE-DISEASE; OXIDATIVE DAMAGE; MICE DEFICIENT	Atopic dermatitis (AD) is a chronic inflammatory skin disease resulting from excessive stimulation of immune cells. Traditionally, reactive oxygen species (ROS) have been implicated in the progression of inflammatory diseases, but several opposing observations suggest the protective role of ROS in inflammatory disease. Recently, we demonstrated ROS prevented imiquimod-induced psoriatic dermatitis through enhancing regulatory T cell function. Thus, we hypothesized AD might also be attenuated in elevated levels of ROS through tissue hyperoxygenation, such as by hyperbaric oxygen therapy (HBOT) or applying an oxygen-carrying chemical, perfluorodecalin (PFD). Elevated levels of ROS in the skin have been demonstrated directly by staining with dihydroethidum as well as indirectly by immunohistochemistry (IHC) for indoleamine 2,3-dioxygenase (IDO). A murine model of AD was developed by repeated application of a chemical irritant (1% 2,4-dinitrochlorobenzene) and house dust mite (Dermatophagoide farinae) extract on one ear of BALB/c mice. The results showed treatment with HBOT or PFD significantly attenuated AD, comparably with 0.1% prednicarbate without any signs of side effects, such as telangiectasia. The expressions of interleukin-17A and interferon-gamma were also decreased in the AD lesions by treatment with HBOT or PFD. Enhanced expression of IDO and reduced level of hypoxia-inducible factor-1 alpha, in association with increased frequency of FoxP3(+) regulatory T cells in the AD lesions, might be involved in the underlying mechanism of oxygen therapy. Taken together, it was suggested that tissue hyperoxygenation, by HBOT or treatment with PFD, might attenuate AD through enhancing skin ROS level.	[Kim, Hyung-Ran; Choi, Eun-Jeong; Seoh, Ju-Young] Ewha Womans Univ, Grad Sch Med, Dept Microbiol, Seoul, South Korea; [Kim, Jung-Hwan; Jang, Myoung Ho] Inst for Basic Sci Korea, Acad Immunol & Microbiol, Pohang, South Korea; [Kim, Jung-Hwan; Jang, Myoung Ho] Pohang Univ Sci & Technol, Div Integrat Biosci & Biotechnol IBB, Pohang, South Korea; [Lee, Yeo Kyong] Ewha Womans Univ, High Sch, Seoul, South Korea; [Kie, Jeong-Hae] Ilsan Hosp, Natl Hlth Insurance Cooperat, Koyang, South Korea	Ewha Womans University; Institute for Basic Science - Korea (IBS); Pohang University of Science & Technology (POSTECH); Ewha Womans University; NHIS Ilsan Hospital	Jang, MH (corresponding author), Inst for Basic Sci Korea, Acad Immunol & Microbiol, Pohang, South Korea.	jangmh@ibs.re.kr; jyseoh@ewha.ac.kr	Jang, Myoung Ho/D-1714-2009	Jang, Myoung Ho/0000-0001-8909-4725; Kie, Jeong Hae/0000-0003-1782-5650	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [2013R1A1A2008077]; Ewha Womans University; Institute for Basic Science (IBS)	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology; Ewha Womans University; Institute for Basic Science (IBS)	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2013R1A1A2008077), RP-Grant 2010 of Ewha Womans University and Institute for Basic Science (IBS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berke R, 2012, AM FAM PHYSICIAN, V86, P35; Brahimi-Horn MC, 2007, CURR OPIN CELL BIOL, V19, P223, DOI 10.1016/j.ceb.2007.02.003; Buchman AL, 2001, J CLIN GASTROENTEROL, V33, P337, DOI 10.1097/00004836-200110000-00018; Butler Glenn, 2009, J Med Case Rep, V3, P7023, DOI 10.4076/1752-1947-3-7023; Chen SY, 2003, CLIN IMMUNOL, V108, P103, DOI 10.1016/S1521-6616(03)00091-3; Choi EJ, 2011, INT IMMUNOPHARMACOL, V11, P1260, DOI 10.1016/j.intimp.2011.04.005; CLARK LC, 1966, SCIENCE, V152, P1755, DOI 10.1126/science.152.3730.1755; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; de Haan JB, 2006, J LIPID RES, V47, P1157, DOI 10.1194/jlr.M500377-JLR200; De Ravin SS, 2008, J ALLERGY CLIN IMMUN, V122, P1097, DOI 10.1016/j.jaci.2008.07.050; Del Rosso J, 2005, J AM ACAD DERMATOL, V53, pS50, DOI 10.1016/j.jaad.2005.04.030; Dennog C, 1996, MUTAGENESIS, V11, P605, DOI 10.1093/mutage/11.6.605; Dennog C, 1999, MUTAT RES-FUND MOL M, V431, P351, DOI 10.1016/S0027-5107(99)00178-5; Di Cesare A, 2008, J INVEST DERMATOL, V128, P2569, DOI 10.1038/jid.2008.283; Efimova O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016013; Esworthy RS, 2001, AM J PHYSIOL-GASTR L, V281, pG848, DOI 10.1152/ajpgi.2001.281.3.G848; Faleo G, 2012, DIABETES, V61, P1769, DOI 10.2337/db11-0516; Fallarino F, 2006, TRANSPL IMMUNOL, V17, P58, DOI 10.1016/j.trim.2006.09.017; Favre D, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000632; George-Chandy A, 2008, EUR J IMMUNOL, V38, P1118, DOI 10.1002/eji.200737348; GEWIESE BKO, 1992, RADIOLOGY, V185, P131, DOI 10.1148/radiology.185.1.1523296; Gorlach A, 2009, CURR PHARM DESIGN, V15, P3844, DOI 10.2174/138161209789649420; Guzman JA, 2012, CRIT CARE CLIN, V28, P537, DOI 10.1016/j.ccc.2012.07.007; Harden JL, 2011, J IMMUNOL, V187, P126, DOI 10.4049/jimmunol.1100168; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; Hultqvist M, 2004, P NATL ACAD SCI USA, V101, P12646, DOI 10.1073/pnas.0403831101; Hultqvist M, 2009, TRENDS IMMUNOL, V30, P201, DOI 10.1016/j.it.2009.03.004; Jang MH, 2011, REGULATORY T CELLS, P201; Jung YJ, 2009, IMMUNOBIOLOGY, V214, P291, DOI 10.1016/j.imbio.2008.09.004; Kim HR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091146; Korhonen K, 2000, ANN CHIR GYNAEC S214, V89, P7; Kraaij MD, 2011, MOL IMMUNOL, V49, P549, DOI 10.1016/j.molimm.2011.10.002; Kraaij MD, 2010, P NATL ACAD SCI USA, V107, P17686, DOI 10.1073/pnas.1012016107; Kudchodkar B, 2008, CLIN IMMUNOL, V128, P435, DOI 10.1016/j.clim.2008.05.004; Kurien BT, 2008, AUTOIMMUN REV, V7, P567, DOI 10.1016/j.autrev.2008.04.019; Lee K, 2011, P NATL ACAD SCI USA, V108, P9548, DOI 10.1073/pnas.1012645108; Liu R, 2013, MAYO CLIN PROC, V88, P166, DOI 10.1016/j.mayocp.2012.10.021; Lowe KC, 2003, TISSUE ENG, V9, P389, DOI 10.1089/107632703322066570; Miller FJ, 1998, CIRC RES, V82, P1298, DOI 10.1161/01.RES.82.12.1298; Munn DH, 2013, TRENDS IMMUNOL, V34, P137, DOI 10.1016/j.it.2012.10.001; Nagatomo F, 2010, CLIN EXP MED, V10, P7, DOI 10.1007/s10238-009-0064-y; NARKOWICZ CK, 1993, FREE RADICAL RES COM, V19, P71, DOI 10.3109/10715769309056501; Ogasawara N, 2009, J CELL BIOCHEM, V108, P716, DOI 10.1002/jcb.22308; Olivieri AN, 2010, ITAL J PEDIATR, V36, DOI 10.1186/1824-7288-36-72; Olszanski Romuald, 1992, Bulletin of the Institute of Maritime and Tropical Medicine in Gdynia, V43, P79; Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200; Rachmilewitz D, 1998, GUT, V43, P512, DOI 10.1136/gut.43.4.512; Rezvani HR, 2011, J INVEST DERMATOL, V131, P1793, DOI 10.1038/jid.2011.141; Rizzo S, 2012, GRAEF ARCH CLIN EXP, V250, P653, DOI 10.1007/s00417-011-1874-7; Romani L, 2008, NATURE, V451, P211, DOI 10.1038/nature06471; Selman C, 2012, TRENDS ECOL EVOL, V27, P570, DOI 10.1016/j.tree.2012.06.006; Stanzl K., 1996, International Journal of Cosmetic Science, V18, P137, DOI 10.1111/j.1467-2494.1996.tb00143.x; Takeshima F, 1999, AM J GASTROENTEROL, V94, P3374, DOI 10.1111/j.1572-0241.1999.03374.x; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; Thom SR, 2011, PLAST RECONSTR SURG, V127, p131S, DOI 10.1097/PRS.0b013e3181fbe2bf; Thom SR, 2009, J APPL PHYSIOL, V106, P988, DOI 10.1152/japplphysiol.91004.2008; Thomas SR, 1999, REDOX REP, V4, P199, DOI 10.1179/135100099101534927; Vann RD, 2011, LANCET, V377, P153, DOI 10.1016/S0140-6736(10)61085-9; Won HY, 2013, J IMMUNOL, V191, P4029, DOI 10.4049/jimmunol.1203247; Won Hee Yeon, 2011, Immune Netw, V11, P169, DOI 10.4110/in.2011.11.3.169; Won HY, 2010, ANTIOXID REDOX SIGN, V13, P575, DOI 10.1089/ars.2009.2989; Yan YP, 2010, J IMMUNOL, V185, P5953, DOI 10.4049/jimmunol.1001628; Zhang YQ, 2009, J GERONTOL A-BIOL, V64, P1212, DOI 10.1093/gerona/glp132	63	13	14	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2014	9	10							e109297	10.1371/journal.pone.0109297	http://dx.doi.org/10.1371/journal.pone.0109297			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ2BX	25275529	Green Submitted, Green Published, gold			2023-01-03	WOS:000342591500092
J	Chen, XS; Yuan, Y; Garfield, DH; Wu, JY; Huang, O; Shen, KW				Chen, Xiao-song; Yuan, Ying; Garfield, David H.; Wu, Jia-yi; Huang, Ou; Shen, Kun-wei			Both Carboplatin and Bevacizumab Improve Pathological Complete Remission Rate in Neoadjuvant Treatment of Triple Negative Breast Cancer: A Meta-Analysis	PLOS ONE			English	Article							INTERNATIONAL EXPERT PANEL; PRIMARY SYSTEMIC TREATMENT; OPEN-LABEL; PHASE-III; PREOPERATIVE CHEMOTHERAPY; PACLITAXEL; THERAPY; TRASTUZUMAB; EFFICACY; WOMEN	Triple negative breast cancer (TNBC) is associated with high pathological complete remission (pCR) rate in neoadjuvant treatment (NAT). TNBC patients who achieve pCR have superior outcome than those without pCR. A meta-analysis was done to evaluate whether integrating novel approaches into NAT can improve the pCR rate in TNBC. Medical subject heading terms (Breast Neoplasm) and key words (triple negative OR estrogen receptor (ER) negative OR HER2 negative) AND (primary systemic OR neoadjuvant OR preoperative) were used to select eligible studies. Experimental arm in each study was considered as the testing regimen, and control arm was defined as the standard regimen in this meta-analysis. A total of 11 studies with 14 paired regimens were included in the final analysis. Aggregate pCR rate was 37.3% and 44.6% in the standard and testing group, respectively. Novel approaches in the testing regimen significantly improved the pCR rate in NAT of TNBC patients compared with the standard regimen, with an odds ratio (OR) of 1.34 (95% confidence interval (CI) 1.11-1.62, P=0.002). Considering specific regimens, we demonstrated the pCR rate to be much higher in the carboplatin-containing (OR=1.80, 95% CI 1.39-2.32, P<0.001) or bevacizumab-containing regimens (OR=1.36, 95% CI 1.11-1.66, P=0.003) than in the control regimens. The addition of carboplatin in NAT had a pCR rate as high as 51.2% in TNBC patients, with an absolute pCR difference of 13.8% as compared with control regimens. No significant heterogeneity was identified among studies evaluating the addition of carboplatin or bevacizumab efficacy in NAT. This meta-analysis indicates that these novel NAT regimens have achieved a significant pCR improvement in TNBC patients, especially among patients treated with carboplatin-containing or bevacizumab-containing regimen. This can help us design appropriate trials in the adjuvant setting and guide clinical practice.	[Chen, Xiao-song; Wu, Jia-yi; Huang, Ou; Shen, Kun-wei] Shanghai Jiao Tong Univ, Ruijin Hosp, Comprehens Breast Hlth Ctr, Sch Med, Shanghai 200030, Peoples R China; [Yuan, Ying] Shanghai Jiao Tong Univ, Shanghai Ninth Peoples Hosp, Sch Med, Dept Radiol, Shanghai 200030, Peoples R China; [Garfield, David H.] Univ Colorado, Ctr Comprehens Canc, Aurora, CO USA	Shanghai Jiao Tong University; Shanghai Jiao Tong University; University of Colorado System; University of Colorado Anschutz Medical Campus	Shen, KW (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Comprehens Breast Hlth Ctr, Sch Med, Shanghai 200030, Peoples R China.	kwshen@medmail.com.cn	吴, 家怡/GSI-7419-2022; Hatzis, Christos/M-3867-2015	Hatzis, Christos/0000-0002-8120-2290	National Natural Science Foundation of China [81202087, 81172520, 81202088]; Natural Science Foundation of Shanghai Municipal Science and Technology Commission [12ZR1446400, 12140901503]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai Municipal Science and Technology Commission(Natural Science Foundation of Shanghai)	Decision to publish and study design: National Natural Science Foundation of China (Grant Number: 81202087; 81172520; 81202088); Data collection and analysis, manuscript preparation: Natural Science Foundation of Shanghai Municipal Science and Technology Commission (Grant Number: 12ZR1446400; 12140901503).	Abu-Khalaf MM, 2013, CANCER RES, V73, DOI 10.1158/0008-5472.SABCS13-P6-11-03; Aft R, 2010, LANCET ONCOL, V11, P421, DOI 10.1016/S1470-2045(10)70054-1; Alba E, 2012, BREAST CANCER RES TR, V136, P487, DOI 10.1007/s10549-012-2100-y; Albain K, 2012, LANCET, V379, P432, DOI 10.1016/S0140-6736(11)61625-5; Alvarez RH, 2010, CANC RES, V70; Bardia A, 2013, CLIN CANCER RES, V19, P6360, DOI 10.1158/1078-0432.CCR-13-0916; Baselga J, 2012, LANCET, V379, P633, DOI 10.1016/S0140-6736(11)61847-3; Bear HD, 2012, NEW ENGL J MED, V366, P310, DOI 10.1056/NEJMoa1111097; Byrski T, 2010, J CLIN ONCOL, V28, P375, DOI 10.1200/JCO.2008.20.7019; Cameron D, 2013, LANCET ONCOL, V14, P933, DOI 10.1016/S1470-2045(13)70335-8; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Charehbili A, 2013, J CLIN ONCOL, V31; Chen XS, 2010, ANN ONCOL, V21, P961, DOI 10.1093/annonc/mdq041; Chia S, 2008, J CLIN ONCOL, V26, P786, DOI 10.1200/JCO.2008.15.0243; Colleoni M, 2014, LANCET ONCOL, V15, P131, DOI 10.1016/S1470-2045(13)70584-9; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; Earl HM, 2014, LANCET ONCOL, V15, P201, DOI 10.1016/S1470-2045(13)70554-0; Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Guo BQ, 2004, BREAST CANCER RES TR, V85, P31, DOI 10.1023/B:BREA.0000021046.29834.12; Horiguchi J, 2013, J CLIN ONCOL, V31; Huober J, 2013, EUR J CANCER, V49, P2284, DOI 10.1016/j.ejca.2013.02.027; Huober J, 2010, BREAST CANCER RES TR, V124, P133, DOI 10.1007/s10549-010-1103-9; Hurley J, 2013, BREAST CANCER RES TR, V138, P783, DOI 10.1007/s10549-013-2497-y; Kaufmann M, 2007, ANN ONCOL, V18, P1927, DOI 10.1093/annonc/mdm201; Kaufmann M, 2006, J CLIN ONCOL, V24, P1940, DOI 10.1200/JCO.2005.02.6187; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113; Ohno S, 2013, BREAST CANCER RES TR, V142, P69, DOI 10.1007/s10549-013-2691-y; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rastogi P, 2008, J CLIN ONCOL, V26, P778, DOI 10.1200/JCO.2007.15.0235; Rugo HS, 2013, CANCER RES, V73, DOI 10.1158/0008-5472.SABCS13-S5-02; Saura C, 2013, ONCOLOGIST, V18, P787, DOI 10.1634/theoncologist.2013-0075; Sikov WM, 2013, CANCER RES, V73, pS5; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Simon L, 2012, J CLIN ONCOL, V30; Slamon D, 2011, NEW ENGL J MED, V365, P1273, DOI 10.1056/NEJMoa0910383; Smith I, 2011, BREAST CANCER RES TR, V130, P133, DOI 10.1007/s10549-011-1695-8; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Steger GG, 2014, ANN ONCOL, V25, P366, DOI 10.1093/annonc/mdt508; Valachis A, 2012, BREAST CANCER RES TR, V135, P655, DOI 10.1007/s10549-012-2189-z; Valentin MD, 2012, BREAST CANCER RES TR, V134, P21, DOI 10.1007/s10549-011-1934-z; von Minckwitz G, 2012, ANN ONCOL, V23, P35, DOI 10.1093/annonc/mds193; von Minckwitz G, 2008, JNCI-J NATL CANCER I, V100, P552, DOI 10.1093/jnci/djn089; von Minckwitz G, 2008, JNCI-J NATL CANCER I, V100, P542, DOI 10.1093/jnci/djn085; Von Minckwitz G, 2013, J CLIN ONCOL, V31; von Minckwitz G, 2013, J CLIN ONCOL, V31, P3623, DOI 10.1200/JCO.2012.45.0940; von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595; von Minckwitz G, 2012, NEW ENGL J MED, V366, P299, DOI 10.1056/NEJMoa1111065; Wagner AD, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008941.pub2; Zhang P, 2013, CANC RES, V73	52	18	22	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2014	9	9							e108405	10.1371/journal.pone.0108405	http://dx.doi.org/10.1371/journal.pone.0108405			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AP8TL	25247558	Green Published, Green Submitted, gold			2023-01-03	WOS:000342351800085
J	Ruetsch, C				Ruetsch, Charles			Treating Prescription Opioid Dependence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SAMPLE	IMPORTANCE Although abuse of prescription opioids (POs) is a significant public health problem, few experimental studies have investigated the treatment needs of this growing population. OBJECTIVE To evaluate, following brief stabilization with a combination of buprenorphine hydrochloride and naloxone hydrochloride dihydrate, the relative efficacy of 1-, 2-, and 4-week buprenorphine tapering regimens and subsequent naltrexone hydrochloride therapy in PO-dependent outpatients. DESIGN, SETTING, AND PARTICIPANTS A double-blind, 12-week randomized clinical trial was conducted in an outpatient research clinic. Following a brief period of buprenorphine stabilization, 70 PO-dependent adults were randomized to receive 1-, 2-, or 4-week tapers followed by naltrexone therapy. INTERVENTION During phase 1 (weeks 1-5 after randomization), participants visited the clinic daily; during phase 2 (weeks 6-12), visits were reduced to thrice weekly. Participants received behavioral therapy and urine toxicology testing throughout the trial. MAIN OUTCOMES AND MEASURES The percentage of participants negative for illicit opioid use, retention, naltrexone ingestion, and favorable treatment response (ie, retained in treatment, opioid abstinent, and receiving naltrexone at the end of the study). RESULTS Opioid abstinence at the end of phase 1was greater in the 4-week compared with the 2- and 1-week taper conditions (P = .02), with 63%(n = 14), 29% (n = 7), and 29% (n = 7) of participants abstinent in the 4-, 2-, and 1-week conditions, respectively. Abstinence at the end of phase 2 was also greater in the 4-week compared with the 2- and 1-week conditions (P = .03), with 50% (n = 11), 16%(n = 4), and 20%(n = 5) of participants abstinent in the 4-, 2-, and 1-week conditions, respectively. There were more treatment responders in the 4-week condition (P = .03), with 50% (n = 11), 17%(n = 4), and 21% (n = 5) of participants in the 4-, 2-, and 1-week groups considered responders at the end of treatment, respectively. Retention and naltrexone ingestion also were superior in the 4-week vs briefer tapers (both P = .04). Experimental condition (ie, taper duration) was the strongest predictor of treatment response, followed by buprenorphine stabilization dose. CONCLUSIONS AND RELEVANCE This study represents a rigorous experimental evaluation of outpatient buprenorphine stabilization, brief taper, and naltrexone maintenance for treatment of PO dependence. Results suggest that a meaningful subset of PO-dependent outpatients may respond positively to a 4-week taper plus naltrexone maintenance intervention.	Hlth Analyt, Sci, 9200 Rumsey Rd,Ste 215, Columbia, MD 21045 USA		Ruetsch, C (corresponding author), Hlth Analyt, Sci, 9200 Rumsey Rd,Ste 215, Columbia, MD 21045 USA.	charles.ruetsch@healthanalytic.com						Albright J, 2010, J ADDICT MED, V4, P197, DOI 10.1097/ADM.0b013e3181c816f3; [Anonymous], 2014, RESULTS FROM THE 199; Hillhouse M, 2011, AM J DRUG ALCOHOL AB, V37, P453, DOI 10.3109/00952990.2011.596974; McLellan AT, 2006, AM J ADDICTION, V15, P113, DOI 10.1080/10550490500528316; Olsen Y, 2014, JAMA-J AM MED ASSOC, V311, P1393, DOI 10.1001/jama.2014.2147; Ruetsch C, 2010, J SUBST ABUSE TREAT, V39, P307, DOI 10.1016/j.jsat.2010.07.003; Ruetsch C, 2010, J MANAGE CARE PHARM, V16, pS9; Sigmon SC, 2013, JAMA PSYCHIAT, V70, P1347, DOI 10.1001/jamapsychiatry.2013.2216; Westermeyer J, 2004, AM J ADDICTION, V13, P151, DOI 10.1080/10550490490435948	9	0	0	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	2014	312	11					1145	+		10.1001/jama.2014.4318	http://dx.doi.org/10.1001/jama.2014.4318			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AO8SN	25226480				2023-01-03	WOS:000341624700024
J	Latus, J; Habib, SM; Kitterer, D; Korte, MR; Ulmer, C; Fritz, P; Davies, S; Lambie, M; Alscher, MD; Betjes, MGH; Segerer, S; Braun, N				Latus, Joerg; Habib, Sayed M.; Kitterer, Daniel; Korte, Mario R.; Ulmer, Christoph; Fritz, Peter; Davies, Simon; Lambie, Mark; Alscher, M. Dominik; Betjes, Michiel G. H.; Segerer, Stephan; Braun, Niko		European EPS Study Grp	Histological and Clinical Findings in Patients with Post-Transplantation and Classical Encapsulating Peritoneal Sclerosis: A European Multicenter Study	PLOS ONE			English	Article							KIDNEY-TRANSPLANTATION; MORPHOLOGIC CHANGES; DIALYSIS PATIENTS; DUTCH EPS; DIAGNOSIS; MEMBRANE; JAPAN; INFLAMMATION; MORTALITY; PATHOLOGY	Background: Encapsulating peritoneal sclerosis (EPS) commonly presents after peritoneal dialysis has been stopped, either post-transplantation (PT-EPS) or after switching to hemodialysis (classical EPS, cEPS). The aim of the present study was to investigate whether PT-EPS and cEPS differ in morphology and clinical course. Methods: In this European multicenter study we included fifty-six EPS patients, retrospectively paired-matched for peritoneal dialysis (PD) duration. Twenty-eight patients developed EPS after renal transplantation, whereas the other twenty-eight patients were classical EPS patients. Demographic data, PD details, and course of disease were documented. Peritoneal biopsies of all patients were investigated using histological criteria. Results: Eighteen patients from the Netherlands and thirty-eight patients from Germany were included. Time on PD was 78(64-95) in the PT-EPS and 72(50-89) months in the cEPS group (p>0.05). There were no significant differences between the morphological findings of cEPS and PT-EPS. Podoplanin positive cells were a prominent feature in both groups, but with a similar distribution of the podoplanin patterns. Time between cessation of PD to the clinical diagnosis of EPS was significantly shorter in the PT-EPS group as compared to cEPS (4(2-9) months versus 23(7-24) months, p<0.001). Peritonitis rate was significantly higher in cEPS. Conclusions: In peritoneal biopsies PT-EPS and cEPS are not distinguishable by histomorphology and immunohistochemistry, which argues against different entities. The critical phase for PT-EPS is during the first year after transplantation and therefore earlier after PD cessation then in cEPS.	[Latus, Joerg; Kitterer, Daniel; Alscher, M. Dominik; Braun, Niko] Robert Bosch Krankenhaus, Dept Internal Med, Div Nephrol, Stuttgart, Germany; [Habib, Sayed M.; Betjes, Michiel G. H.] Erasmus MC, Dept Internal Med, Div Nephrol & Transplantat, Rotterdam, Netherlands; [Korte, Mario R.] Albert Schweitzer Hosp, Dept Internal Med, Div Nephrol, Dordrecht, Netherlands; [Ulmer, Christoph] Robert Bosch Krankenhaus, Dept Gen Visceral & Trauma Surg, Stuttgart, Germany; [Fritz, Peter] Robert Bosch Krankenhaus, Dept Diagnost Med, Div Pathol, Stuttgart, Germany; [Davies, Simon] Keele Univ, Inst Sci & Technol Med, Keele ST5 5BG, Staffs, England; [Lambie, Mark] Univ Hosp North Staffordshire, Dept Nephrol, Stoke On Trent, Staffs, England; [Segerer, Stephan] Univ Zurich Hosp, Div Nephrol, CH-8091 Zurich, Switzerland	Bosch; Robert Bosch Krankenhaus; Erasmus University Rotterdam; Erasmus MC; Albert Schweitzer Ziekenhuis; Bosch; Robert Bosch Krankenhaus; Bosch; Robert Bosch Krankenhaus; Keele University; University of Zurich; University Zurich Hospital	Braun, N (corresponding author), Robert Bosch Krankenhaus, Dept Internal Med, Div Nephrol, Stuttgart, Germany.	Niko.braun@rbk.de	Lambie, Mark/AAA-9104-2020	Lambie, Mark/0000-0002-6285-5368; Betjes, Michiel/0000-0001-9435-6208; Segerer, Stephan/0000-0002-1936-9719	Baxter	Baxter	The EPS-study group is supported by Baxter. Baxter did not fund this study. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.	Alscher DM, 2007, AM J KIDNEY DIS, V49, P452, DOI 10.1053/j.ajkd.2006.11.040; Balasubramaniam G, 2009, NEPHROL DIAL TRANSPL, V24, P3209, DOI 10.1093/ndt/gfp008; Bozkurt D, 2009, PERITON DIALYSIS INT, V29, pS206; Braun N, 2009, NEPHRON CLIN PRACT, V113, pC88, DOI 10.1159/000228540; Braun N, 2010, NEPHROL DIAL TRANSPL; Braun N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053382; Braun N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048647; Braun N, 2011, NEPHROL DIAL TRANSPL, V26, P1033, DOI 10.1093/ndt/gfq488; Brown EA, 2009, PERITON DIALYSIS INT, V29, P595; Brown MC, 2009, CLIN J AM SOC NEPHRO, V4, P1222, DOI 10.2215/CJN.01260209; Fieren MWJA, 2007, PERITON DIALYSIS INT, V27, P619; Fontana I, 2012, TRANSPL P, V44, P1918, DOI 10.1016/j.transproceed.2012.06.010; Garosi G, 2005, PERITON DIALYSIS INT, V25, pS110; Guest S, 2009, PERITON DIALYSIS INT, V29, P489; Habib SM, 2011, NETH J MED, V69, P500; Habib SM, 2013, AM J NEPHROL, V37, P223, DOI 10.1159/000348267; Honda K, 2005, PERITON DIALYSIS INT, V25, pS19; Honda K, 2008, CLIN J AM SOC NEPHRO, V3, P720, DOI 10.2215/CJN.03630807; Honda Kazuho, 2003, Adv Perit Dial, V19, P169; Hurst H, 2014, LIVING ENCAPSULATING; Johnson DW, 2010, KIDNEY INT, V77, P904, DOI 10.1038/ki.2010.16; Kalof AN, 2009, ADV ANAT PATHOL, V16, P62, DOI 10.1097/PAP.0b013e3181915e94; Kawaguchi Y, 2000, PERITON DIALYSIS INT, V20, pS43; Kawanishi H, 2005, PERITON DIALYSIS INT, V25, pS14; Kawanishi H, 2004, AM J KIDNEY DIS, V44, P729, DOI 10.1053/j.ajkd.2004.06.020; Khanna A, 2002, KIDNEY INT, V62, P2257, DOI 10.1046/j.1523-1755.2002.00668.x; Kinashi H, 2013, J AM SOC NEPHROL, V24, P1627, DOI 10.1681/ASN.2012030226; Korte MR, 2011, AM J TRANSPLANT, V11, P599, DOI 10.1111/j.1600-6143.2010.03434.x; Korte MR, 2009, NETH J MED, V67, P359; Korte MR, 2007, NEPHROL DIAL TRANSPL, V22, P2412, DOI 10.1093/ndt/gfm171; Korte MR, 2011, PERITON DIALYSIS INT, V31, P269, DOI 10.3747/pdi.2010.00167; Lambie M, 2013, PERITON DIALYSIS INT, V33, P482, DOI 10.3747/pdi.2013.00165; Lambie ML, 2010, KIDNEY INT, V78, P611, DOI 10.1038/ki.2010.186; Latus J, 2013, PERITON DIALYSIS INT, V33, P495, DOI 10.3747/pdi.2012.00019; Latus J, 2013, NEPHROL DIAL TRANSPL, V28, P1021, DOI 10.1093/ndt/gfs159; Margetts PJ, 2005, J AM SOC NEPHROL, V16, P425, DOI 10.1681/ASN.2004060436; Martikainen TA, 2005, PERITON DIALYSIS INT, V25, P453; Maruyama Y, 2008, PERITON DIALYSIS INT, V28, pS201; Nakamoto H, 2005, PERITON DIALYSIS INT, V25, pS30; Oules R, 1988, Nephrol Dial Transplant, V3, P66; Posthuma N, 2000, PERITON DIALYSIS INT, V20, P174; Saito A, 2005, PERITON DIALYSIS INT, V25, pS77; Sampimon DE, 2010, PERITON DIALYSIS INT, V30, P163, DOI 10.3747/pdi.2009.00022; Sherif AM, 2008, THER APHER DIAL, V12, P33, DOI 10.1111/j.1744-9987.2007.00538.x; Shimaoka T, 2010, NEPHROL DIAL TRANSPL, V25, P3379, DOI 10.1093/ndt/gfq194; Summers AM, 2011, PERITON DIALYSIS INT, V31, P245, DOI 10.3747/pdi.2010.00086; Tarzi RM, 2008, CLIN J AM SOC NEPHRO, V3, P1702, DOI 10.2215/CJN.01820408; van Westrhenen R, 2007, BLOOD PURIFICAT, V25, P466, DOI 10.1159/000112475; Vlijm A, 2009, PERITON DIALYSIS INT, V29, P517; Williams JD, 2002, J AM SOC NEPHROL, V13, P470, DOI 10.1681/ASN.V132470	50	11	12	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2014	9	8							e106511	10.1371/journal.pone.0106511	http://dx.doi.org/10.1371/journal.pone.0106511			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO2EE	25171219	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000341127500165
J	Kim, C; Jang, MU; Oh, MS; Park, JH; Jung, S; Lee, JH; Yu, KH; Han, MK; Kim, BJ; Park, TH; Park, SS; Lee, KB; Cha, JK; Kim, DH; Lee, J; Kim, SH; Lee, SJ; Ko, Y; Park, JM; Kang, K; Cho, YJ; Hong, KS; Cho, KH; Kim, JT; Kim, DE; Choi, JC; Jang, MS; Bae, HJ; Lee, BC				Kim, Chulho; Jang, Min Uk; Oh, Mi Sun; Park, Jong-Ho; Jung, San; Lee, Ju-Hun; Yu, Kyung-Ho; Han, Moon-Ku; Kim, Beom Joon; Park, Tai Hwan; Park, Sang-Soon; Lee, Kyung Bok; Cha, Jae Kwan; Kim, Dae-Hyun; Lee, Jun; Kim, Sung-Hun; Lee, Soo Joo; Ko, Youngchai; Park, Jong-Moo; Kang, Kyusik; Cho, Young-Jin; Hong, Keun-Sik; Cho, Ki-Hyun; Kim, Joon-Tae; Kim, Dong-Eog; Choi, Jay Chol; Jang, Myung Suk; Bae, Hee-Joon; Lee, Byung-Chul		CRCS-5 Investigators	Off-Hour Effect on 3-Month Functional Outcome after Acute Ischemic Stroke: A Prospective Multicenter Registry	PLOS ONE			English	Article							KOREAN STROKE; CASE-FATALITY; SCALE SCORE; WEEKEND; MORTALITY; ADMISSION; CARE; CENTERS; IMPACT; UNITS	Background and Purpose: The time of hospital arrival may have an effect on prognosis of various vascular diseases. We examined whether off-hour admission would affect the 3-month functional outcome in acute ischemic stroke patients admitted to tertiary hospitals. Methods: We analyzed the 'off-hour effect' in consecutive patients with acute ischemic stroke using multi-center prospective stroke registry. Work-hour admission was defined as when the patient arrived at the emergency department between 8 AM and 6 PM from Monday to Friday and between 8 AM and 1 PM on Saturday. Off-hour admission was defined as the rest of the work-hours and statutory holidays. Multivariable logistic regression was used to analyze the association between off-hour admission and 3-month unfavorable functional outcome defined as modified Rankin Scale (mRS) 3-6. Multivariable model included age, sex, risk factors, prehospital delay time, intravenous thrombolysis, stroke subtypes and severity as covariates. Results: A total of 7075 patients with acute ischemic stroke were included in this analysis: mean age, 67.5 (+/- 13.0) years; male, 58.6%. In multivariable analysis, off-hour admission was not associated with unfavorable functional outcome (OR, 0.89; 95% CI, 0.72-1.09) and mortality (OR, 1.09; 95% CI, 0.77-1.54) at 3 months. Moreover, off-hour admission did not affect a statistically significant shift of 3-month mRS distributions (OR, 0.90; 95% CI, 0.78-1.05). Conclusions: 'Off-hour' admission is not associated with an unfavorable 3-month functional outcome in acute ischemic stroke patients admitted to tertiary hospitals in Korea. This finding indicates that the off-hour effects could be overcome with well-organized stroke management strategies.	[Kim, Chulho; Jang, Min Uk] Hallym Univ, Sacred Heart Hosp, Dept Neurol, Chuncheon Si, South Korea; [Oh, Mi Sun; Yu, Kyung-Ho; Lee, Byung-Chul] Hallym Univ, Sacred Heart Hosp, Dept Neurol, Anyang Si, South Korea; [Park, Jong-Ho] Myongji Hosp, Dept Neurol, Goyang Si, South Korea; [Jung, San] Kangnam Sacred Heart Hosp, Dept Neurol, Seoul, South Korea; [Lee, Ju-Hun] Kangdong Sacred Heart Hosp, Dept Neurol, Seoul, South Korea; [Han, Moon-Ku; Kim, Beom Joon; Jang, Myung Suk; Bae, Hee-Joon] Seoul Natl Univ, Bundang Hosp, Dept Neurol, Songnam, Gyeonggi Do, South Korea; [Han, Moon-Ku; Kim, Beom Joon; Jang, Myung Suk; Bae, Hee-Joon] Seoul Natl Univ, Bundang Hosp, Cerebrovasc Ctr, Songnam, Gyeonggi Do, South Korea; [Park, Tai Hwan; Park, Sang-Soon] Seoul Med Ctr, Dept Neurol, Seoul, South Korea; [Lee, Kyung Bok] Soonchunhyang Univ Hosp, Dept Neurol, Seoul, South Korea; [Cha, Jae Kwan; Kim, Dae-Hyun] Dong A Univ, Dept Neurol, Seoul, South Korea; [Lee, Jun] Yeungnam Univ, Med Ctr, Dept Neurol, Taegu, South Korea; [Kim, Sung-Hun] Kangwon Natl Univ, Coll Med, Dept Neurol, Chuncheon Si, South Korea; [Lee, Soo Joo; Ko, Youngchai] Eulji Univ Hosp, Dept Neurol, Taejon, South Korea; [Park, Jong-Moo; Kang, Kyusik] Eulji Gen Hosp, Dept Neurol, Seoul, South Korea; [Cho, Young-Jin; Hong, Keun-Sik] Inje Univ, Ilsan Paik Hosp, Dept Neurol, Goyang Si, Gyeonggi Do, South Korea; [Cho, Ki-Hyun; Kim, Joon-Tae] Chonnam Natl Univ Hosp, Dept Neurol, Kwangju, South Korea; [Kim, Dong-Eog] Dongguk Univ, Ilsan Hosp, Dept Neurol, Goyang Si, Gyeonggi Do, South Korea; [Choi, Jay Chol] Jeju Natl Univ Hosp, Dept Neurol, Cheju, Jeju Do, South Korea	Hallym University; Hallym University; Myongji Hospital; Seoul National University (SNU); Seoul National University (SNU); Seoul Medical Center; Soonchunhyang University; Soonchunhyang University Hospital; Dong A University; Yeungnam University; Kangwon National University; Eulji University; Eulji University; Inje University; Chonnam National University; Chonnam National University Hospital; Dongguk University; NHIS Ilsan Hospital; Jeju National University	Lee, BC (corresponding author), Hallym Univ, Sacred Heart Hosp, Dept Neurol, Anyang Si, South Korea.	ssbrain@hallym.ac.kr	Kim, Beom Joon/C-2904-2011; Kim, Chulho/AAC-8708-2022	Kim, Beom Joon/0000-0002-2719-3012; Kim, Chulho/0000-0001-8762-8340; HAN, MOON-KU/0000-0003-0166-387X; Kim, Beom Joon/0000-0003-2320-7621; Hong, Keun-Sik/0000-0002-4684-6111	Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HI10C2020]; Hallym University Specialization Fund [HRF-S-51]	Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea; Hallym University Specialization Fund	This study was supported by a grant from the Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020), and by Hallym University Specialization Fund (HRF-S-51). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams HP, 1999, NEUROLOGY, V53, P126, DOI 10.1212/WNL.53.1.126; Albright KC, 2012, CEREBROVASC DIS, V34, P424, DOI 10.1159/000345077; Bejot Y, 2013, EUR J NEUROL, V20, P1177, DOI 10.1111/ene.12154; Bell CM, 2004, AM J MED, V117, P175, DOI 10.1016/j.amjmed.2004.02.047; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Choi HY, 2012, INT J STROKE, V7, P336, DOI 10.1111/j.1747-4949.2012.00788.x; Fang JM, 2010, NEUROLOGY, V75, P1589, DOI 10.1212/WNL.0b013e3181fb84bc; Fonarow GC, 2012, JAMA-J AM MED ASSOC, V308, P257, DOI 10.1001/jama.2012.7870; Haeusler KG, 2011, STROKE, V42, P2521, DOI 10.1161/STROKEAHA.110.612697; Harraf F, 2002, BMJ-BRIT MED J, V325, P17, DOI 10.1136/bmj.325.7354.17; Hasegawa Y, 2005, CEREBROVASC DIS, V20, P325, DOI 10.1159/000087932; 유경호, 2006, [Journal of the Korean Neurological Association, 대한신경과학회지], V24, P535; Hoh BL, 2010, STROKE, V41, P2323, DOI 10.1161/STROKEAHA.110.591081; Hong KS, 2013, J STROKE, V15, P2, DOI 10.5853/jos.2013.15.1.2; Jauss M, 2009, EUR J NEUROL, V16, P1165, DOI 10.1111/j.1468-1331.2009.02656.x; Jung KH, 2012, CIRC-CARDIOVASC QUAL, V5, P327, DOI 10.1161/CIRCOUTCOMES.111.963736; Kazley AS, 2010, ARCH NEUROL-CHICAGO, V67, P39, DOI 10.1001/archneurol.2009.286; Kim BJ, 2014, INT J STROKE, V9, P514, DOI 10.1111/ijs.12199; Kim YS, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-2; Kimberly WT, 2013, NEUROLOGY, V80, P719, DOI 10.1212/WNL.0b013e31828250ff; Kwan J, 2004, AGE AGEING, V33, P116, DOI 10.1093/ageing/afh064; Lee BC, 2006, AM J PREV MED, V31, pS243, DOI 10.1016/j.amepre.2006.08.019; Martinez-Martinez MM, 2012, EUR J NEUROL, V19, P1140, DOI 10.1111/j.1468-1331.2012.03692.x; McKinney JS, 2011, STROKE, V42, P2403, DOI 10.1161/STROKEAHA.110.612317; Nedeltchev K, 2005, J NEUROL NEUROSUR PS, V76, P191, DOI 10.1136/jnnp.2004.040543; O'Rourke K, 2010, EUR J NEUROL, V17, P247, DOI 10.1111/j.1468-1331.2009.02782.x; Ogbu UC, 2011, J NEUROL NEUROSUR PS, V82, P8, DOI 10.1136/jnnp.2009.202176; Palmer WL, 2012, ARCH NEUROL-CHICAGO, V69, P1296, DOI 10.1001/archneurol.2012.1030; Reeves MJ, 2009, STROKE, V40, P569, DOI 10.1161/STROKEAHA.108.519355; Saposnik G, 2007, STROKE, V38, P1211, DOI 10.1161/01.STR.0000259622.78616.ea; Saposnik G, 2009, STROKE, V40, P3321, DOI 10.1161/STROKEAHA.109.554907; Streifler JY, 2012, EUR J NEUROL, V19, P643, DOI 10.1111/j.1468-1331.2011.03603.x; Stroke Unit Trialists' Collaboration, 2000, COCHRANE DB SYST REV, V2; Tung YC, 2009, MED CARE, V47, P1018, DOI 10.1097/MLR.0b013e3181a81144; Weimar C, 2004, STROKE, V35, P158, DOI 10.1161/01.STR.0000106761.94985.8B; Yahalom G, 2009, STROKE, V40, P1296, DOI 10.1161/STROKEAHA.108.520882	36	10	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2014	9	8							e105799	10.1371/journal.pone.0105799	http://dx.doi.org/10.1371/journal.pone.0105799			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO4JP	25165816	gold, Green Published, Green Submitted			2023-01-03	WOS:000341303700046
J	Mathis, SE; Alberico, A; Nande, R; Neto, W; Lawrence, L; McCallister, DR; Denvir, J; Kimmey, GA; Mogul, M; Oakley, G; Denning, KL; Dougherty, T; Valluri, JV; Claudio, PP				Mathis, Sarah E.; Alberico, Anthony; Nande, Rounak; Neto, Walter; Lawrence, Logan; McCallister, Danielle R.; Denvir, James; Kimmey, Gerrit A.; Mogul, Mark; Oakley, Gerard, III; Denning, Krista L.; Dougherty, Thomas; Valluri, Jagan V.; Claudio, Pier Paolo			Chemo-Predictive Assay for Targeting Cancer Stem-Like Cells in Patients Affected by Brain Tumors	PLOS ONE			English	Article							INTRADURAL EXTRAMEDULLARY EPENDYMOMA; EX-VIVO CHEMOSENSITIVITY; SPINAL-CORD EPENDYMOMAS; OVARIAN-CANCER; CHEMORESPONSE ASSAY; ISOTHIOCYANATES; CHEMOTHERAPY; MECHANISM; SERIES	Administration of ineffective anticancer therapy is associated with unnecessary toxicity and development of resistant clones. Cancer stem-like cells (CSLCs) resist chemotherapy, thereby causing relapse of the disease. Thus, development of a test that identifies the most effective chemotherapy management offers great promise for individualized anticancer treatments. We have developed an ex vivo chemotherapy sensitivity assay (ChemoID), which measures the sensitivity of CSLCs as well as the bulk of tumor cells to a variety of chemotherapy agents. Two patients, a 21-year old male (patient 1) and a 5-month female (patient 2), affected by anaplastic WHO grade-III ependymoma were screened using the ChemoID assay. Patient 1 was found sensitive to the combination of irinotecan and bevacizumab, which resulted in a prolonged disease progression free period of 18 months. Following recurrence, the combination of various chemotherapy drugs was tested again with the ChemoID assay. We found that benzyl isothiocyanate (BITC) greatly increased the chemosensitivity of the ependymoma cells to the combination of irinotecan and bevacizumab. After patient 1 was treated for two months with irinotecan, bevacizumab and supplements of cruciferous vegetable extracts containing BITC, we observed over 50% tumoral regression in comparison with pre-ChemoID scan as evidenced by MRI. Patient 2 was found resistant to all treatments tested and following 6 cycles of vincristine, carboplatin, cyclophosphamide, etoposide, and cisplatin in various combinations, the tumor of this patient rapidly progressed and proton beam therapy was recommended. As expected animal studies conducted with patient derived xenografts treated with ChemoID screened drugs recapitulated the clinical observation. This assay demonstrates that patients with the same histological stage and grade of cancer may vary considerably in their clinical response, suggesting that ChemoID testing which measures the sensitivity of CSLCs as well as the bulk of tumor cells to a variety of chemotherapy agents could lead to more effective and personalized anticancer treatments in the future.	[Mathis, Sarah E.; Nande, Rounak; Neto, Walter; Lawrence, Logan; McCallister, Danielle R.; Denvir, James; Claudio, Pier Paolo] Marshall Univ, Dept Biochem & Microbiol, Joan C Edwards Sch Med, Huntington, WV 25755 USA; [Mathis, Sarah E.; Nande, Rounak; Neto, Walter; Lawrence, Logan; McCallister, Danielle R.; Denvir, James; Claudio, Pier Paolo] Marshall Univ, Translat Genom Res Inst, Huntington, WV USA; [Alberico, Anthony] Marshall Univ, Dept Neurosurg, Joan C Edwards Sch Med, Huntington, WV USA; [Kimmey, Gerrit A.] St Marys Hosp, Dept Med Oncol, Huntington, WV USA; [Mogul, Mark] Marshall Univ, Dept Pediat, Joan C Edwards Sch Med, Huntington, WV USA; [Oakley, Gerard, III; Denning, Krista L.; Dougherty, Thomas] Marshall Univ, Dept Pathol, Joan C Edwards Sch Med, Huntington, WV USA; [Valluri, Jagan V.] Marshall Univ, Dept Biol, Huntington, WV USA; [Claudio, Pier Paolo] Marshall Univ, Dept Surg, Joan C Edwards Sch Med, Huntington, WV USA	Marshall University; Marshall University; Marshall University; Marshall University; Marshall University; Marshall University; Marshall University	Claudio, PP (corresponding author), Marshall Univ, Dept Biochem & Microbiol, Joan C Edwards Sch Med, Huntington, WV 25755 USA.	claudiop@marshall.edu	Claudio, Pier Paolo/AAW-7282-2021	Claudio, Pier Paolo/0000-0001-7790-1622	National Center for Advancing Translational Sciences, National Institutes of Health through the National Center for Research Resources (NCRR) [UL1TR000117]; National Cancer Institute [5P20RR020180]; WV-INBRE [5P20RR016477]; Marshall University; Marshall University Department of Neuroscience; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020180, P20RR016477] Funding Source: NIH RePORTER	National Center for Advancing Translational Sciences, National Institutes of Health through the National Center for Research Resources (NCRR); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); WV-INBRE; Marshall University; Marshall University Department of Neuroscience; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	The present studies were supported in part by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant number UL1TR000117 from the National Center for Research Resources (NCRR), and 5P20RR020180 from the National Cancer Institute, WV-INBRE 5P20RR016477, and in part by a Marshall University Translational Award, and an award from the Marshall University Department of Neuroscience (to PPC). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of NCRR and NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aimola P, 2010, DRUG NEWS PERSPECT, V23, P175, DOI 10.1358/dnp.2010.23.3.1489979; Ballard KS, 2010, INT J GYNECOL CANCER, V20, P561, DOI 10.1111/IGC.0b013e3181d320dd; Bouffet E, 1999, CHILD NERV SYST, V15, P563, DOI 10.1007/s003810050544; Breidenbach M, 2002, ANTI-CANCER DRUG, V13, P173, DOI 10.1097/00001813-200202000-00010; Brower Stacey L., 2008, V414, P57; Chamberlain MC, 2011, CURR NEUROL NEUROSCI, V11, P320, DOI 10.1007/s11910-011-0190-2; Chou PM, 1996, PEDIATR PATHOL LAB M, V16, P551, DOI 10.1080/107710496175499; COOPER IS, 1951, SURG GYNECOL OBSTET, V92, P183; Di Pasqua AJ, 2010, CHEM RES TOXICOL, V23, P1307, DOI 10.1021/tx100187f; Duffau H, 2000, SPINE, V25, P1993, DOI 10.1097/00007632-200008010-00021; Duncan John A. Iii, 1995, P493; Gallion H, 2006, INT J GYNECOL CANCER, V16, P194, DOI 10.1111/j.1525-1438.2006.00301.x; Hanbali F, 2002, NEUROSURGERY, V51, P1162, DOI 10.1097/00006123-200211000-00010; Herzog TJ, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.01.059; Huh WK, 2011, INT J GYNECOL CANCER, V21, P494, DOI 10.1097/IGC.0b013e31820c4cb5; Iunes EA, 2011, J NEUROSURG-SPINE, V14, P65, DOI 10.3171/2010.9.SPINE09963; Kelloff GJ, 1999, ANN NY ACAD SCI, V889, P1, DOI 10.1111/j.1749-6632.1999.tb08718.x; Kelly SE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010035; Kleinhans R, 2012, MED BIOL ENG COMPUT, V50, P117, DOI 10.1007/s11517-011-0855-7; Kocak Z, 2004, J EXP CLIN CANC RES, V23, P201; Lamy E, 2011, DRUG METAB REV, V43, P387, DOI 10.3109/03602532.2011.569551; Lin YH, 2005, J NEURO-ONCOL, V71, P205, DOI 10.1007/s11060-004-1386-y; Malik Babar, 2012, Front Biosci (Elite Ed), V4, P2142; McCormick P C, 1990, Neurosurg Clin N Am, V1, P591; Merchant TE, 2002, ONCOLOGY-NY, V16, P629; Metellus P, 2008, CANCER, V113, P175, DOI 10.1002/cncr.23530; Mi LX, 2011, CHEM RES TOXICOL, V24, P1735, DOI 10.1021/tx2002806; Michalova E, 2008, Klin Onkol, V21, P93; Modena P, 2012, NEURO-ONCOLOGY, V14, P1346, DOI 10.1093/neuonc/nos245; Myatt N, 1997, ANTI-CANCER DRUG, V8, P756, DOI 10.1097/00001813-199709000-00004; Ness RB, 2002, ANTICANCER RES, V22, P1145; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Ochs RL, 2005, METH MOLEC MED, V110, P155; Pejavar S, 2012, J NEURO-ONCOL, V106, P367, DOI 10.1007/s11060-011-0671-9; Peters D, 2005, MOL CANCER THER, V4, P1605, DOI 10.1158/1535-7163.MCT-04-0311; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Reni M, 2004, CANCER, V100, P1221, DOI 10.1002/cncr.20074; Reni M, 2007, CRIT REV ONCOL HEMAT, V63, P81, DOI 10.1016/j.critrevonc.2007.03.004; Rice SD, 2011, CANCER BIOL THER, V11, P196, DOI 10.4161/cbt.11.2.13701; Rice SD, 2010, ANTICANCER RES, V30, P2805; Song KW, 2009, CLIN ORTHOP SURG, V1, P74, DOI 10.4055/cios.2009.1.2.74; Suchy SL, 2011, CANCER BIOL THER, V11, P1059, DOI 10.4161/cbt.11.12.15710; Tsubouchi H, 2000, Hum Cell, V13, P203; van Meerloo J, 2011, METHODS MOL BIOL, V731, P237, DOI 10.1007/978-1-61779-080-5_20; Vandertop WP, 2003, NEUROSURGERY, V53, P246, DOI 10.1227/01.NEU.0000072306.16102.BD; Wichmann G, 2009, ONKOLOGIE, V32, P264, DOI 10.1159/000209148; Wu X, 2009, ACTA PHARMACOL SIN, V30, P501, DOI 10.1038/aps.2009.50; Yu Yang, 2012, Front Biosci (Elite Ed), V4, P1528; Zhang YS, 2001, CARCINOGENESIS, V22, P425, DOI 10.1093/carcin/22.3.425	49	12	13	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2014	9	8							e105710	10.1371/journal.pone.0105710	http://dx.doi.org/10.1371/journal.pone.0105710			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO1WL	25144312	Green Submitted, Green Published, gold			2023-01-03	WOS:000341106100113
J	Park, SM; Cha, JM; Nam, J; Kim, MS; Park, SJ; Park, ES; Lee, H; Kim, HR				Park, Sun Min; Cha, Jae Min; Nam, Jungyong; Kim, Min Sang; Park, Sang-Jun; Park, Eun Sung; Lee, Hwankyu; Kim, Hyun Ryoung			Formulation Optimization and in Vivo Proof-of-Concept Study of Thermosensitive Liposomes Balanced by Phospholipid, Elastin-Like Polypeptide, and Cholesterol	PLOS ONE			English	Article							COARSE-GRAINED MODEL; DRUG-DELIVERY SYSTEMS; MOLECULAR SIMULATION; LOCAL HYPERTHERMIA; ENHANCED DELIVERY; MILD HYPERTHERMIA; LIPID-BILAYERS; FORCE-FIELD; DOXORUBICIN; RELEASE	One application of nanotechnology in medicine that is presently being developed involves a drug delivery system (DDS) employing nanoparticles to deliver drugs to diseased sites in the body avoiding damage of healthy tissue. Recently, the mild hyperthermia-triggered drug delivery combined with anticancer agent-loaded thermosensitive liposomes was widely investigated. In this study, thermosensitive liposomes (TSLs), composed of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DSPE-PEG), cholesterol, and a fatty acid conjugated elastin-like polypeptide (ELP),were developed and optimized for triggered drug release, controlled by external heat stimuli. We introduced modified ELP, tunable for various biomedical purposes, to our thermosensitive liposome (e-TSL) to convey a high thermoresponsive property. We modulated thermosensitivity and stability by varying the ratios of e-TSL components, such as phospholipid, ELP, and cholesterol. Experimental data obtained in this study corresponded to results from a simulation study that demonstrated, through the calculation of the lateral diffusion coefficient, increased permeation of the lipid bilayer with higher ELP concentrations, and decreased permeation in the presence of cholesterol. Finally, we identified effective drug accumulation in tumor tissues and antitumor efficacy with our optimized e-TSL, while adjusting lag-times for systemic accumulation.	[Park, Sun Min; Cha, Jae Min; Nam, Jungyong; Kim, Min Sang; Park, Sang-Jun; Park, Eun Sung; Kim, Hyun Ryoung] SAIT, Bio Res Ctr, Drug Delivery Syst Grp, Yongin, Gyeonggi Do, South Korea; [Lee, Hwankyu] Dankook Univ, Dept Chem Engn, Yongin, Gyeonggi Do, South Korea	Samsung; Dankook University	Kim, HR (corresponding author), SAIT, Bio Res Ctr, Drug Delivery Syst Grp, Yongin, Gyeonggi Do, South Korea.	hyunryoung.kim@samsung.com		Lee, Hwankyu/0000-0002-2036-1490	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science, and Technology [2012R1A1A1001196]; National Institute of Supercomputing and Networking/Korea Institute of Science and Technology Information with supercomputing resources [KSC-2013-C2-18]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science, and Technology; National Institute of Supercomputing and Networking/Korea Institute of Science and Technology Information with supercomputing resources	The simulation part of this research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science, and Technology (2012R1A1A1001196), and by the National Institute of Supercomputing and Networking/Korea Institute of Science and Technology Information with supercomputing resources, including technical support (KSC-2013-C2-18). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037; BAE YH, 1987, MAKROMOL CHEM-RAPID, V8, P481; Banno B, 2010, J PHARM SCI-US, V99, P2295, DOI 10.1002/jps.21988; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Betre H, 2006, BIOMATERIALS, V27, P91, DOI 10.1016/j.biomaterials.2005.05.071; Dreher MR, 2003, J CONTROL RELEASE, V91, P31, DOI 10.1016/S0168-3659(03)00216-5; GABIZON AA, 1992, CANCER RES, V52, P891; Haidar ZS, 2010, POLYMERS-BASEL, V2, P323, DOI 10.3390/polym2030323; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; HUANG SK, 1994, CANCER RES, V54, P2186; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jeong B, 1997, NATURE, V388, P860, DOI 10.1038/42218; Kong G, 2000, CANCER RES, V60, P6950; Koo OM, 2005, NANOMED-NANOTECHNOL, V1, P193, DOI 10.1016/j.nano.2005.06.004; Koynova R, 1998, BBA-REV BIOMEMBRANES, V1376, P91, DOI 10.1016/S0304-4157(98)00006-9; Lee H, 2012, MACROMOLECULES, V45, P7304, DOI 10.1021/ma301327j; Li L, 2013, J CONTROL RELEASE, V168, P142, DOI 10.1016/j.jconrel.2013.03.011; Li L, 2013, J CONTROL RELEASE, V167, P130, DOI 10.1016/j.jconrel.2013.01.026; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Liu WE, 2006, J CONTROL RELEASE, V116, P170, DOI 10.1016/j.jconrel.2006.06.026; Manzoor AA, 2012, CANCER RES, V72, P5566, DOI 10.1158/0008-5472.CAN-12-1683; Marrink SJ, 2007, J PHYS CHEM B, V111, P7812, DOI 10.1021/jp071097f; Marrink SJ, 2005, CHEM PHYS LIPIDS, V135, P223, DOI 10.1016/j.chemphyslip.2005.03.001; Marrink SJ, 2004, J PHYS CHEM B, V108, P750, DOI 10.1021/jp036508g; MARUYAMA K, 1993, BIOCHIM BIOPHYS ACTA, V1149, P209, DOI 10.1016/0005-2736(93)90203-C; Monticelli L, 2008, J CHEM THEORY COMPUT, V4, P819, DOI 10.1021/ct700324x; Nagle JF, 2000, BBA-REV BIOMEMBRANES, V1469, P159, DOI 10.1016/S0304-4157(00)00016-2; Nettles DL, 2010, ADV DRUG DELIVER REV, V62, P1479, DOI 10.1016/j.addr.2010.04.002; Park SM, 2013, J CONTROL RELEASE, V170, P373, DOI 10.1016/j.jconrel.2013.06.003; Salata OV, 2004, J Nanobiotechnology, V2, P3, DOI 10.1186/1477-3155-2-3; Sandstrom MC, 2005, J CONTROL RELEASE, V107, P131, DOI 10.1016/j.jconrel.2005.06.001; Tabata Y, 2009, J R SOC INTERFACE, V6, pS311, DOI 10.1098/rsif.2008.0448.focus; Tagami T, 2011, J CONTROL RELEASE, V152, P303, DOI 10.1016/j.jconrel.2011.02.009; UNEZAKI S, 1994, PHARMACEUT RES, V11, P1180, DOI 10.1023/A:1018949218380; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291	35	16	22	1	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2014	9	7							e103116	10.1371/journal.pone.0103116	http://dx.doi.org/10.1371/journal.pone.0103116			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6RZ	25068721	Green Published, Green Submitted, gold			2023-01-03	WOS:000339993700035
J	Shinko, A; Agari, T; Kameda, M; Yasuhara, T; Kondo, A; Tayra, JT; Sato, K; Sasaki, T; Sasada, S; Takeuchi, H; Wakamori, T; Borlongan, CV; Date, I				Shinko, Aiko; Agari, Takashi; Kameda, Masahiro; Yasuhara, Takao; Kondo, Akihiko; Tayra, Judith Thomas; Sato, Kenichiro; Sasaki, Tatsuya; Sasada, Susumu; Takeuchi, Hayato; Wakamori, Takaaki; Borlongan, Cesario V.; Date, Isao			Spinal Cord Stimulation Exerts Neuroprotective Effects against Experimental Parkinson's Disease	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CEREBRAL-BLOOD-FLOW; SUBTHALAMIC NUCLEUS STIMULATION; DORSAL COLUMN STIMULATION; ELECTRICAL-STIMULATION; SUBARACHNOID HEMORRHAGE; DOPAMINERGIC-NEURONS; RAT MODEL; IN-VITRO; PAIN	In clinical practice, deep brain stimulation (DBS) is effective for treatment of motor symptoms in Parkinson's disease (PD). However, the mechanisms have not been understood completely. There are some reports that electrical stimulation exerts neuroprotective effects on the central nervous system diseases including cerebral ischemia, head trauma, epilepsy and PD, although there are a few reports on neuroprotective effects of spinal cord stimulation (SCS). We investigated the neuroprotective effects of high cervical SCS on PD model of rats. Adult female Sprague-Dawley rats received hour-long SCS (2, 50 or 200 Hz) with an epidural electrode at C1-2 level for 16 consecutive days. At 2 days after initial SCS, 6-hydroxydopamine (6-OHDA) was injected into the right striatum of rats. Behavioral evaluations of PD symptoms were employed, including cylinder test and amphetamine-induced rotation test performed at 1 and 2 weeks after 6-OHDA injection. Animals were subsequently euthanized for immunohistochemical investigations. In order to explore neurotrophic and growth factor upregulation induced by SCS, another cohort of rats that received 50 Hz SCS was euthanized at 1 and 2 weeks after lesion for protein assays. Behavioral tests revealed that the number of amphetamine-induced rotations decreased in SCS groups. Immunohistochemically, tyrosine hydroxylase (TH)-positive fibers in the striatum were significantly preserved in SCS groups. TH-positive neurons in the substantia nigra pars compacta were significantly preserved in 50 Hz SCS group. The level of vascular endothelial growth factor (VEGF) was upregulated by SCS at 1 week after the lesion. These results suggest that high cervical SCS exerts neuroprotection in PD model of rats, at least partially by upregulation of VEGF. SCS is supposed to suppress or delay PD progression and might become a less invasive option for PD patients, although further preclinical and clinical investigations are needed to confirm the effectiveness and safety.	[Shinko, Aiko; Agari, Takashi; Kameda, Masahiro; Yasuhara, Takao; Kondo, Akihiko; Tayra, Judith Thomas; Sato, Kenichiro; Sasaki, Tatsuya; Sasada, Susumu; Takeuchi, Hayato; Wakamori, Takaaki; Date, Isao] Okayama Univ, Grad Sch Med, Dept Neurol Surg, Okayama, Japan; [Borlongan, Cesario V.] Univ S Florida, Coll Med, Dept Neurosurg, Tampa, FL USA	Okayama University; State University System of Florida; University of South Florida	Agari, T (corresponding author), Okayama Univ, Grad Sch Med, Dept Neurol Surg, Okayama, Japan.	agarit@cc.okayama-u.ac.jp	Yasuhara, Takao/AEU-1075-2022; Borlongan, Cesar/I-5696-2012; Kondo, Akihiko/A-2130-2015; Sheshukova, Ekaterina/O-1365-2013	Borlongan, Cesar/0000-0002-2966-9782; Shindyapina, Anastasia/0000-0002-7336-3086; Sheshukova, Ekaterina/0000-0002-0934-3902				Baba T, 2009, STROKE, V40, pE598, DOI 10.1161/STROKEAHA.109.563627; CHANDLER MJ, 1993, EUR HEART J, V14, P96, DOI 10.1093/eurheartj/14.1.96; Cui JG, 1996, PAIN, V66, P287, DOI 10.1016/0304-3959(96)03069-2; Cui JG, 1997, PAIN, V73, P87, DOI 10.1016/S0304-3959(97)00077-8; DRAKE CJ, 1995, P NATL ACAD SCI USA, V92, P7657, DOI 10.1073/pnas.92.17.7657; EDVINSSON L, 1989, J CEREBR BLOOD F MET, V9, P212, DOI 10.1038/jcbfm.1989.31; Fuentes R, 2009, SCIENCE, V323, P1578, DOI 10.1126/science.1164901; Goksel HM, 2001, ACTA NEUROCHIR, V143, P383, DOI 10.1007/s007010170094; Gurelik M, 2005, NEUROSCIENCE, V134, P827, DOI 10.1016/j.neuroscience.2005.04.062; Harnack D, 2008, EXP NEUROL, V210, P257, DOI 10.1016/j.expneurol.2007.10.002; HOSOBUCHI Y, 1991, PACE, V14, P122, DOI 10.1111/j.1540-8159.1991.tb04056.x; HOSOBUCHI Y, 1985, APPL NEUROPHYSIOL, V48, P372, DOI 10.1159/000101161; Isono M, 1995, STEREOT FUNCT NEUROS, V64, P40, DOI 10.1159/000098732; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kadota T, 2009, BRAIN RES, V1254, P120, DOI 10.1016/j.brainres.2008.11.094; Kemler MA, 2000, NEW ENGL J MED, V343, P618, DOI 10.1056/NEJM200008313430904; Kumar K, 2007, PAIN, V132, P179, DOI 10.1016/j.pain.2007.07.028; Lee JY, 2008, J NEUROSURG, V109, P1148, DOI 10.3171/JNS.2008.109.12.1148; LEVIN BE, 1980, NEUROLOGY, V30, P65, DOI 10.1212/WNL.30.1.65; LINDEROTH B, 1995, NEUROSURGERY, V37, P266, DOI 10.1227/00006123-199508000-00011; LINDEROTH B, 1992, NEUROSURGERY, V31, P289, DOI 10.1227/00006123-199208000-00014; Maesawa S, 2004, J NEUROSURG, V100, P679, DOI 10.3171/jns.2004.100.4.0679; Maher J, 2009, NEUROGASTROENT MOTIL, V21, DOI 10.1111/j.1365-2982.2008.01237.x; Maher J, 2009, NEUROGASTROENT MOTIL, V21, pe633; MEGLIO M, 1991, PACE, V14, P127, DOI 10.1111/j.1540-8159.1991.tb04057.x; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Morimoto T, 2011, CELL TRANSPLANT, V20, P1049, DOI 10.3727/096368910X544915; Patel S, 2004, NEUROSURGERY, V55, P201, DOI 10.1227/01.NEU.0000126949.28912.71; Patel S, 2003, J NEUROSURG, V99, P754, DOI 10.3171/jns.2003.99.4.0754; Paxions G, 1998, RAT BRAIN STEREOTAXI; Pitzer MR, 2003, EXP NEUROL, V182, P435, DOI 10.1016/S0014-4886(03)00100-6; Rajput AH, 2004, PARKINSONISM RELAT D, V10, P221, DOI 10.1016/j.parkreldis.2004.01.004; Roof RL, 2001, STROKE, V32, P2648, DOI 10.1161/hs1101.097397; Sagher O, 2003, J NEUROSURG, V99, P131, DOI 10.3171/jns.2003.99.1.0131; Sagher Oren, 2006, Neurosurg Focus, V21, pE2; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schechtmann G, 2008, PAIN, V139, P136, DOI 10.1016/j.pain.2008.03.023; SHEALY CN, 1967, ANESTH ANAL CURR RES, V46, P489; Silverman WF, 1999, NEUROSCIENCE, V90, P1529, DOI 10.1016/S0306-4522(98)00540-5; Song ZY, 2008, NEUROSCI LETT, V436, P7, DOI 10.1016/j.neulet.2008.02.044; Spieles-Engemann AL, 2011, J PARKINSON DIS, V1, P123, DOI 10.3233/JPD-2011-11008; Stiller CO, 1996, NEUROSURGERY, V39, P367, DOI 10.1097/00006123-199608000-00026; Temel Y, 2006, BRAIN RES, V1120, P100, DOI 10.1016/j.brainres.2006.08.082; Thevathasan W, 2010, NEUROLOGY, V74, P1325, DOI 10.1212/WNL.0b013e3181d9ed58; Vajkoczy P, 2005, J NEUROSURG, V103, P9, DOI 10.3171/jns.2005.103.1.0009; Visocchi M, 2001, STEREOT FUNCT NEUROS, V76, P262, DOI 10.1159/000066729; Visocchi M, 2001, STEREOT FUNCT NEUROS, V76, P269, DOI 10.1159/000066730; Visocchi M, 2001, ACTA NEUROCHIR, V143, P177; Yadav AP, 2014, SCI REP-UK, V4, DOI 10.1038/srep03839; Yakhnitsa V, 1999, PAIN, V79, P223, DOI 10.1016/S0304-3959(98)00169-9; Yang X, 2008, NEUROSCIENCE, V152, P950, DOI 10.1016/j.neuroscience.2008.01.009; Yasuhara T, 2004, REV NEUROSCIENCE, V15, P293; Yuan WJ, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-75; Zhong J, 2004, ACTA NEUROCHIR, V146, P1227, DOI 10.1007/s00701-004-0364-7	55	24	27	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2014	9	7							e101468	10.1371/journal.pone.0101468	http://dx.doi.org/10.1371/journal.pone.0101468			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK9RG	25009993	Green Submitted, Green Published, gold			2023-01-03	WOS:000338763800025
J	Zhang, QZ; Dijkstra, FA; Liu, XR; Wang, YD; Huang, J; Lu, N				Zhang, Qing-zhong; Dijkstra, Feike A.; Liu, Xing-ren; Wang, Yi-ding; Huang, Jian; Lu, Ning			Effects of Biochar on Soil Microbial Biomass after Four Years of Consecutive Application in the North China Plain	PLOS ONE			English	Article							FUMIGATION-EXTRACTION; MINERALIZATION; CARBON; DECOMPOSITION; CALIBRATION; COMMUNITY; NITROGEN; RELEASE; RESIDUE; IMPACT	The long term effect of biochar application on soil microbial biomass is not well understood. We measured soil microbial biomass carbon (MBC) and nitrogen (MBN) in a field experiment during a winter wheat growing season after four consecutive years of no (CK), 4.5 (B4.5) and 9.0 t biochar ha(-1) yr(-1) (B9.0) applied. For comparison, a treatment with wheat straw residue incorporation (SR) was also included. Results showed that biochar application increased soil MBC significantly compared to the CK treatment, and that the effect size increased with biochar application rate. The B9.0 treatment showed the same effect on MBC as the SR treatment. Treatments effects on soil MBN were less strong than for MBC. The microbial biomass C:N ratio was significantly increased by biochar. Biochar might decrease the fraction of biomass N mineralized (K-N), which would make the soil MBN for biochar treatments underestimated, and microbial biomass C: N ratios overestimated. Seasonal fluctuation in MBC was less for biochar amended soils than for CK and SR treatments, suggesting that biochar induced a less extreme environment for microorganisms throughout the season. There was a significant positive correlation between MBC and soil water content (SWC), but there was no significant correlation between MBC and soil temperature. Biochar amendments may therefore reduce temporal variability in environmental conditions for microbial growth in this system thereby reducing temporal fluctuations in C and N dynamics.	[Zhang, Qing-zhong; Liu, Xing-ren; Wang, Yi-ding; Huang, Jian; Lu, Ning] Chinese Acad Agr Sci, Key Lab Agr Environm, Sinoaustralian Joint Lab Sustainable Agroecosyst, Minist Agr,Inst Environm & Sustainable Dev Agr, Beijing 100193, Peoples R China; [Dijkstra, Feike A.] Univ Sydney, Ctr Carbon Water & Food, Dept Environm Sci, Camden, NSW, Australia	Chinese Academy of Agricultural Sciences; Institute of Environment & Sustainable Development in Agriculture, CAAS; Ministry of Agriculture & Rural Affairs; University of Sydney	Zhang, QZ (corresponding author), Chinese Acad Agr Sci, Key Lab Agr Environm, Sinoaustralian Joint Lab Sustainable Agroecosyst, Minist Agr,Inst Environm & Sustainable Dev Agr, Beijing 100193, Peoples R China.	ecologyouth@126.com	Dijkstra, Feike A/H-2182-2012	Dijkstra, Feike A/0000-0002-6191-6018; Zhang, Yunchun/0000-0001-8259-5850	S & T Innovation Program of Chinese Academy of Agricultural Sciences	S & T Innovation Program of Chinese Academy of Agricultural Sciences	This work was supported by the S & T Innovation Program of Chinese Academy of Agricultural Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BROOKES PC, 1985, SOIL BIOL BIOCHEM, V17, P837, DOI 10.1016/0038-0717(85)90144-0; Castaldi S, 2011, CHEMOSPHERE, V85, P1464, DOI 10.1016/j.chemosphere.2011.08.031; Chen Y, 2010, AUST J SOIL RES, V48, P526, DOI 10.1071/SR10011; Contin M, 2000, SOIL BIOL BIOCHEM, V32, P1219, DOI 10.1016/S0038-0717(00)00038-9; Cross A, 2011, SOIL BIOL BIOCHEM, V43, P2127, DOI 10.1016/j.soilbio.2011.06.016; Dempster DN, 2012, PLANT SOIL, V354, P311, DOI 10.1007/s11104-011-1067-5; GREENFIELD LG, 1995, SOIL BIOL BIOCHEM, V27, P1235, DOI 10.1016/0038-0717(95)00023-8; [郭伟 GUO Wei], 2011, [生态环境学报, Ecology and Environmental Sciences], V20, P425; Joergensen RG, 1996, SOIL BIOL BIOCHEM, V28, P25, DOI 10.1016/0038-0717(95)00102-6; JOERGENSEN RG, 1990, SOIL BIOL BIOCHEM, V22, P1129, DOI 10.1016/0038-0717(90)90039-3; Kallenbach C, 2011, AGR ECOSYST ENVIRON, V144, P241, DOI 10.1016/j.agee.2011.08.020; Keith A, 2011, ENVIRON SCI TECHNOL, V45, P9611, DOI 10.1021/es202186j; Kolb SE, 2009, SOIL SCI SOC AM J, V73, P1173, DOI 10.2136/sssaj2008.0232; Kumar K, 2000, ADV AGRON, V68, P197; Kushwaha CP, 2000, SOIL TILL RES, V56, P153, DOI 10.1016/S0167-1987(00)00135-5; Lehmann J., 2009, BIOCHAR ENV MANAGEME, V1, P1, DOI [10.4324/9780203762264, DOI 10.4324/9780203762264]; Lehmann J, 2007, NATURE, V447, P143, DOI 10.1038/447143a; Lehmann J, 2011, SOIL BIOL BIOCHEM, V43, P1812, DOI 10.1016/j.soilbio.2011.04.022; Liang BQ, 2010, ORG GEOCHEM, V41, P206, DOI 10.1016/j.orggeochem.2009.09.007; Lou YS, 2004, SOIL BIOL BIOCHEM, V36, P1835, DOI 10.1016/j.soilbio.2004.05.006; Luo Y, 2013, SOIL BIOL BIOCHEM, V57, P513, DOI 10.1016/j.soilbio.2012.10.033; Luo Y, 2011, SOIL BIOL BIOCHEM, V43, P2304, DOI 10.1016/j.soilbio.2011.07.020; Nicolardot B, 2001, PLANT SOIL, V228, P83, DOI 10.1023/A:1004813801728; O'Neill B, 2009, MICROB ECOL, V58, P23, DOI 10.1007/s00248-009-9515-y; Piccolo A, 1996, SOIL USE MANAGE, V12, P209, DOI 10.1111/j.1475-2743.1996.tb00545.x; SPARLING G, 1993, SOIL BIOL BIOCHEM, V25, P1793, DOI 10.1016/0038-0717(93)90185-E; Steinbeiss S, 2009, SOIL BIOL BIOCHEM, V41, P1301, DOI 10.1016/j.soilbio.2009.03.016; Steiner C, 2008, PEDOBIOLOGIA, V51, P359, DOI 10.1016/j.pedobi.2007.08.002; Thiessen S, 2013, SOIL BIOL BIOCHEM, V57, P739, DOI 10.1016/j.soilbio.2012.10.029; WARDLE DA, 1992, BIOL REV, V67, P321, DOI 10.1111/j.1469-185X.1992.tb00728.x; WU J, 1990, SOIL BIOL BIOCHEM, V22, P1167, DOI 10.1016/0038-0717(90)90046-3; Zavalloni C, 2011, APPL SOIL ECOL, V50, P45, DOI 10.1016/j.apsoil.2011.07.012; Zhang QZ, 2013, SOIL RES, V51, P521, DOI 10.1071/SR13153; Zhang QZ, 2013, SOIL SCI SOC AM J, V77, P1478, DOI 10.2136/sssaj2012.0180; Zimmerman AR, 2011, SOIL BIOL BIOCHEM, V43, P1169, DOI 10.1016/j.soilbio.2011.02.005	35	79	90	12	141	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2014	9	7							e102062	10.1371/journal.pone.0102062	http://dx.doi.org/10.1371/journal.pone.0102062			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6RN	25025330	Green Submitted, gold, Green Published			2023-01-03	WOS:000339992400041
J	Choi, BY; Kim, J; Chung, J; Kim, AR; Mun, SJ; Kang, SI; Lee, SH; Kim, N; Oh, SH				Choi, Byung Yoon; Kim, Jiwoong; Chung, Juyong; Kim, Ah Reum; Mun, Sue Jean; Kang, Seong Il; Lee, Sang-Heon; Kim, Namshin; Oh, Seung-Ha			Whole-Exome Sequencing Identifies a Novel Genotype-Phenotype Correlation in the Entactin Domain of the Known Deafness Gene TECTA	PLOS ONE			English	Article							NONSYNDROMIC HEARING IMPAIRMENT; TECTORIAL MEMBRANE; MUTATIONS; PROTEIN; EXPRESSION; CONFIRMS; DELETION; FAMILIES; OTOGELIN; DFNA12	Postlingual progressive hearing loss, affecting primarily the high frequencies, is the clinical finding in most cases of autosomal dominant nonsyndromic hearing loss (ADNSHL). The molecular genetic etiology of ADNSHL is extremely heterogeneous. We applied whole-exome sequencing to reveal the genetic etiology of high-frequency hearing loss in a mid-sized Korean family without any prior linkage data. Whole-exome sequencing of four family members (two affected and two unaffected), together with our filtering strategy based on comprehensive bioinformatics analyses, identified 21 potential pathogenic candidates. Sanger validation of an additional five family members excluded 20 variants, leaving only one novel variant, TECTA c.710C>T (p.T237I), as the strongest candidate. This variant resides in the entactin (ENT) domain and co-segregated perfectly with non-progressive high-frequency hearing loss in the family. It was absent among 700 ethnically matched control chromosomes, and the T237 residue is conserved among species, which supports its pathogenicity. Interestingly, this finding contrasted with a previously proposed genotype-phenotype correlation in which variants of the ENT domain of TECTA were associated with mid-frequency hearing loss. Based upon what we observed, we propose a novel "genotype to phenotype'' correlation in the ENT domain of TECTA. Our results shed light on another important application of whole-exome sequencing: the establishment of a novel genotype-phenotype in the molecular genetic diagnosis of autosomal dominant hearing loss.	[Choi, Byung Yoon] Seoul Natl Univ, Dept Otorhinolaryngol, Bundang Hosp, Songnam, South Korea; [Kim, Jiwoong; Lee, Sang-Heon; Kim, Namshin] KRIBB, Korean Bioinformat Ctr, Taejon, South Korea; [Chung, Juyong] Ajou Univ, Dept Otolaryngol, Sch Med, Suwon 441749, South Korea; [Kim, Ah Reum; Mun, Sue Jean; Kang, Seong Il; Oh, Seung-Ha] Seoul Natl Univ, Coll Med, Dept Otorhinolaryngol, Seoul, South Korea; [Lee, Sang-Heon; Kim, Namshin] Univ Sci & Technol, Dept Bioinformat, Taejon, South Korea	Seoul National University (SNU); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Ajou University; Seoul National University (SNU)	Kim, N (corresponding author), KRIBB, Korean Bioinformat Ctr, Taejon, South Korea.	n@rna.kr; shaoh@snu.ac.kr	Kim, Namshin/Q-6491-2017	Kim, Namshin/0000-0001-6361-274X	Ministry for Health, Welfare and Family Affairs, Republic of Korea [A080588, A111377]; National Research Foundation of Korea - Korean government (Ministry of Education, Science, and Technology) [20120009215]	Ministry for Health, Welfare and Family Affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); National Research Foundation of Korea - Korean government (Ministry of Education, Science, and Technology)	This study was supported by the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (Nos. A080588 and A111377), and the National Research Foundation of Korea grant funded by the Korean government (Ministry of Education, Science, and Technology; No. 20120009215). The funding bodies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Alasti F, 2008, INT J PEDIATR OTORHI, V72, P249, DOI 10.1016/j.ijporl.2007.09.023; Alloisio N, 1999, EUR J HUM GENET, V7, P255, DOI 10.1038/sj.ejhg.5200273; Balciuniene J, 1999, HUM GENET, V105, P211, DOI 10.1007/s004390051091; Choi M, 2009, P NATL ACAD SCI USA, V106, P19096, DOI 10.1073/pnas.0910672106; CHUNG AE, 1993, KIDNEY INT, V43, P13, DOI 10.1038/ki.1993.4; Collin RWJ, 2008, EUR J HUM GENET, V16, P1430, DOI 10.1038/ejhg.2008.110; Delmaghani S, 2012, HUM MOL GENET, V21, P3835, DOI 10.1093/hmg/dds212; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; DZIADEK M, 1985, EMBO J, V4, P2513, DOI 10.1002/j.1460-2075.1985.tb03964.x; Govaerts PJ, 1998, AM J OTOL, V19, P718; Hildebrand MS, 2011, HUM MUTAT, V32, P825, DOI 10.1002/humu.21512; Hilgert N, 2009, MUTAT RES-REV MUTAT, V681, P189, DOI 10.1016/j.mrrev.2008.08.002; Huygen PL, 2007, GENES HEARING DEAFNE, P185; Iwasaki S, 2002, ARCH OTOLARYNGOL, V128, P913, DOI 10.1001/archotol.128.8.913; King KA, 2010, LARYNGOSCOPE, V120, P384, DOI 10.1002/lary.20722; Knipper M, 2001, J BIOL CHEM, V276, P39046, DOI 10.1074/jbc.M103385200; Legan PK, 2000, NEURON, V28, P273, DOI 10.1016/S0896-6273(00)00102-1; Legan PK, 2005, NAT NEUROSCI, V8, P1035, DOI 10.1038/nn1496; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; Lezirovitz K, 2012, GENE, V511, P280, DOI 10.1016/j.gene.2012.09.023; Maeda Y, 2001, NEUROREPORT, V12, P3223, DOI 10.1097/00001756-200110290-00016; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Meyer NC, 2007, CLIN GENET, V72, P130, DOI 10.1111/j.1399-0004.2007.00828.x; Meyer NC, 2007, AM J MED GENET A, V143A, P1623, DOI 10.1002/ajmg.a.31718; Moreno-Pelayo M A, 2001, J Med Genet, V38, pE13, DOI 10.1136/jmg.38.5.e13; Mustapha M, 1999, HUM MOL GENET, V8, P409, DOI 10.1093/hmg/8.3.409; Naz S, 2003, J MED GENET, V40, P360, DOI 10.1136/jmg.40.5.360; Ng SB, 2010, NAT GENET, V42, P30, DOI 10.1038/ng.499; Pfister M, 2004, CELL PHYSIOL BIOCHEM, V14, P369, DOI 10.1159/000080347; Plantinga RF, 2006, JARO-J ASSOC RES OTO, V7, P173, DOI 10.1007/s10162-006-0033-z; Rau A, 1999, J COMP NEUROL, V405, P271; Rehman AU, 2014, AM J HUM GENET, V94, P144, DOI 10.1016/j.ajhg.2013.12.004; Reva B, 2011, NUCLEIC ACIDS RES, V39, pE118, DOI 10.1093/nar/gkr407; Sagong B, 2012, GENE, V492, P239, DOI 10.1016/j.gene.2011.10.022; Sagong B, 2010, ANN CLIN LAB SCI, V40, P380; Santos-Cortez RLP, 2013, AM J HUM GENET, V93, P132, DOI 10.1016/j.ajhg.2013.05.018; Schraders M, 2012, AM J HUM GENET, V91, P883, DOI 10.1016/j.ajhg.2012.09.012; Schraders M, 2011, AM J HUM GENET, V88, P628, DOI 10.1016/j.ajhg.2011.04.012; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Sim NL, 2012, NUCLEIC ACIDS RES, V40, pW452, DOI 10.1093/nar/gks539; Tekin M, 2013, J CLIN INVEST, V123, P2094, DOI 10.1172/JCI65853; Verhoeven K, 1997, AM J HUM GENET, V60, P1168; Verhoeven K, 1998, NAT GENET, V19, P60, DOI 10.1038/ng0598-60; Walsh T, 2010, AM J HUM GENET, V87, P90, DOI 10.1016/j.ajhg.2010.05.010; Yariz KO, 2012, AM J HUM GENET, V91, P872, DOI 10.1016/j.ajhg.2012.09.011	46	37	39	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2014	9	5							e97040	10.1371/journal.pone.0097040	http://dx.doi.org/10.1371/journal.pone.0097040			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI4LX	25226504	gold, Green Published, Green Submitted			2023-01-03	WOS:000336838000097
J	Wu, CC; Tsai, TH; Chang, C; Lee, TT; Lin, C; Cheng, IHJ; Sun, MC; Chuang, YJ; Chen, BS				Wu, Chia-Chou; Tsai, Tsung-Han; Chang, Chieh; Lee, Tian-Thai; Lin, Che; Cheng, Irene Han-Juo; Sun, Mu-Chien; Chuang, Yung-Jen; Chen, Bor-Sen			On the Crucial Cerebellar Wound Healing-Related Pathways and Their Cross-Talks after Traumatic Brain Injury in Danio rerio	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; ZEBRAFISH MODEL; CELL-MIGRATION; IMMUNE-SYSTEM; REGENERATION; NEUROTRANSMITTERS; NEUROGENESIS; CANNABINOIDS; PATHOGENESIS; MECHANISMS	Upon injury, the direct damage and the subsequent secondary injury in the brain often result in chronic neurological disorders. Due to multifactorial nature of secondary injury and subsequent complex cellular responses, much of the underlying mechanisms are unclear. This study used an adult zebrafish cerebellum injury model to investigate the phenotypes and the secondary injury responses for recovery mechanisms of injured brain. Using the time course microarray analysis, a candidate protein-protein interaction (PPI) network was refined as cerebellar wound healing PPI network by dynamic modeling and big data mining. Pathway enrichment and ontological analysis were incorporated into the refined network to highlight the main molecular scheme of cerebellar wound healing. Several significant pathways, including chemokine, Phosphatidylinositide 3-kinases, and axon guidance signaling pathway and their cross-talks through PI3K, PAK2, and PLXNA3 were identified to coordinate for neurogenesis and angiogenesis, which are essential for the restoration of the injured brain. Our finding provides an insight into the molecular restoration mechanisms after traumatic brain injury, and open up new opportunity to devise the treatment for traumatic brain injury in human.	[Wu, Chia-Chou; Tsai, Tsung-Han; Lin, Che; Chen, Bor-Sen] Natl Tsing Hua Univ, Deptartment Elect Engn, Hsinchu, Taiwan; [Chang, Chieh; Lee, Tian-Thai; Chuang, Yung-Jen] Natl Tsing Hua Univ, Deptartment Med Sci, Hsinchu, Taiwan; [Chang, Chieh; Lee, Tian-Thai; Chuang, Yung-Jen] Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu, Taiwan; [Cheng, Irene Han-Juo] Natl Yang Ming Univ, Inst Brain Sci, Taipei 112, Taiwan; [Sun, Mu-Chien] Changhua Christian Hosp, Stroke Ctr, Changhua, Taiwan; [Sun, Mu-Chien] Changhua Christian Hosp, Deptartment Neurol, Changhua, Taiwan	National Tsing Hua University; National Tsing Hua University; National Tsing Hua University; National Yang Ming Chiao Tung University; Changhua Christian Hospital; Changhua Christian Hospital	Chen, BS (corresponding author), Natl Tsing Hua Univ, Deptartment Elect Engn, Hsinchu, Taiwan.	bschen@ee.nthu.edu.tw	Wu, Chia-Chou/L-1058-2013; Chen, Bor-Sen/D-9114-2017; Hsu, Yuan-Man/K-7074-2015	Wu, Chia-Chou/0000-0002-4009-6858; Chang, Jia-Hao/0000-0001-7843-2688; Hsu, Yuan-Man/0000-0002-4575-7475; Chang, Chiung-Hung/0000-0001-6917-4875	National Science Council of Taiwan, R.O.C. [NSC 102-2745-E-007-001-ASP]	National Science Council of Taiwan, R.O.C.(Ministry of Science and Technology, Taiwan)	The work was supported by the National Science Council of Taiwan, R.O.C. [NSC 102-2745-E-007-001-ASP]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antos CL, 2010, ADV EXP MED BIOL, V695, P184, DOI 10.1007/978-1-4419-7037-4_13; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Basu S, 2000, J NEUROIMMUNOL, V102, P113, DOI 10.1016/S0165-5728(99)00176-9; Berg DA, 2013, DEVELOPMENT, V140, P2548, DOI 10.1242/dev.088005; BLALOCK JE, 1992, CHEM IMMUNOL, V52, P1; Bradford Y, 2011, NUCLEIC ACIDS RES, V39, pD822, DOI 10.1093/nar/gkq1077; Cameron DA, 2005, MOL VIS, V11, P775; Chen BS, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-46; Craig Sonya E L, 2008, J Ocul Biol Dis Infor, V1, P73, DOI 10.1007/s12177-008-9011-5; Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Ernst J, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-191; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Feala JD, 2013, J NEUROTRAUM, V30, P1101, DOI 10.1089/neu.2012.2631; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Guingab-Cagmat JD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00061; Guo Y, 2011, NEUROSCIENCE, V172, P329, DOI 10.1016/j.neuroscience.2010.10.026; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Hui SP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084212; Jiang W, 2005, J CLIN INVEST, V115, P3104, DOI 10.1172/JCI25509; Kalueff AV, 2013, ZEBRAFISH, V10, P70, DOI 10.1089/zeb.2012.0861; Kishimoto N, 2012, DIS MODEL MECH, V5, P200, DOI 10.1242/dmm.007336; Kizil C, 2012, DEV NEUROBIOL, V72, P429, DOI 10.1002/dneu.20918; Kyritsis N, 2012, SCIENCE, V338, P1353, DOI 10.1126/science.1228773; Levin ED, 2009, FRONT NEUROSCI, P293; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Lukacs NW, 2001, NAT REV IMMUNOL, V1, P108, DOI 10.1038/35100503; Martins RAP, 2008, BRAIN RES, V1192, P37, DOI 10.1016/j.brainres.2007.04.076; McCurley AT, 2010, J EXP NEUROSCI, V4, P17; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; Mi HY, 2013, NUCLEIC ACIDS RES, V41, pD377, DOI 10.1093/nar/gks1118; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Poss KD, 2002, SCIENCE, V298, P2188, DOI 10.1126/science.1077857; Postlethwait J, 1999, METHOD CELL BIOL, V60, P149; Qin Z, 2009, P NATL ACAD SCI USA, V106, P9310, DOI 10.1073/pnas.0811186106; Qiu YH, 1996, ADV NEUROIMMUNOL, V6, P223, DOI 10.1016/S0960-5428(96)00018-6; Rajaram MVS, 2006, J IMMUNOL, V177, P6317, DOI 10.4049/jimmunol.177.9.6317; Ridley AJ, 2001, J CELL SCI, V114, P2713; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Stadelmann WK, 1998, AM J SURG, V176, p39S, DOI 10.1016/S0002-9610(98)00184-6; Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109; Tanaka EM, 2009, NAT REV NEUROSCI, V10, P713, DOI 10.1038/nrn2707; Vicente-Manzanares M, 2002, INT REV CYTOL, V216, P233; Wang YC, 2010, BMC SYST BIOL, V4, DOI [10.1186/1752-0509-4-S2-S1, 10.1186/1752-0509-4-20]; Webster JI, 2002, ANNU REV IMMUNOL, V20, P125, DOI 10.1146/annurev.immunol.20.082401.104914; Yang SK, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-19	49	16	18	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2014	9	6							e97902	10.1371/journal.pone.0097902	http://dx.doi.org/10.1371/journal.pone.0097902			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AK2VQ	25133542	Green Published, Green Submitted, gold			2023-01-03	WOS:000338278100009
J	Thompson, MB; Tangen, JM				Thompson, Matthew B.; Tangen, Jason M.			The Nature of Expertise in Fingerprint Matching: Experts Can Do a Lot with a Little	PLOS ONE			English	Article							DECISION-MAKING; INFORMATION; IDENTIFICATION; RECOGNITION; ERROR	Expert decision making often seems impressive, even miraculous. People with genuine expertise in a particular domain can perform quickly and accurately, and with little information. In the series of experiments presented here, we manipulate the amount of "information'' available to a group of experts whose job it is to identify the source of crime scene fingerprints. In Experiment 1, we reduced the amount of information available to experts by inverting fingerprint pairs and adding visual noise. There was no evidence for an inversion effect-experts were just as accurate for inverted prints as they were for upright prints-but expert performance with artificially noisy prints was impressive. In Experiment 2, we separated matching and nonmatching print pairs in time. Experts were conservative, but they were still able to discriminate pairs of fingerprints that were separated by five-seconds, even though the task was quite different from their everyday experience. In Experiment 3, we separated the print pairs further in time to test the long-term memory of experts compared to novices. Long-term recognition memory for experts and novices was the same, with both performing around chance. In Experiment 4, we presented pairs of fingerprints quickly to experts and novices in a matching task. Experts were more accurate than novices, particularly for similar nonmatching pairs, and experts were generally more accurate when they had more time. It is clear that experts can match prints accurately when there is reduced visual information, reduced opportunity for direct comparison, and reduced time to engage in deliberate reasoning. These findings suggest that non-analytic processing accounts for a substantial portion of the variance in expert fingerprint matching accuracy. Our conclusion is at odds with general wisdom in fingerprint identification practice and formal training, and at odds with the claims and explanations that are offered in court during expert testimony.	[Thompson, Matthew B.; Tangen, Jason M.] Univ Queensland, Sch Psychol, St Lucia, Qld, Australia	University of Queensland	Thompson, MB (corresponding author), Univ Queensland, Sch Psychol, St Lucia, Qld, Australia.	mbthompson@gmail.com; jtangen@psy.uq.edu.au	Tangen, Jason/ABH-8577-2020; Thompson, Matthew/J-9922-2012	Tangen, Jason/0000-0002-0649-2566; Thompson, Matthew/0000-0002-5649-1203; Poulsen, Mette Homann/0000-0003-2162-3007; Mathiesen, Joachim/0000-0002-5621-5487; Feidenhansl, Robert/0000-0002-7963-3649; Tarnow, Lise/0000-0002-8735-966X	Australian Research Council Linkage Grant to Tangen [LP120100063]; Fulbright Scholarship; Villum Fonden [00007172] Funding Source: researchfish	Australian Research Council Linkage Grant to Tangen(Australian Research Council); Fulbright Scholarship; Villum Fonden(Villum Fonden)	This research was supported by an Australian Research Council Linkage Grant to Tangen (LP120100063; www.arc.gov.au; see The Forensic Reasoning Project at ForensicReasoning. com), and a Fulbright Scholarship to Thompson (www.fulbright.com.au). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABERNETHY B, 1991, INT J SPORT PSYCHOL, V22, P189; [Anonymous], 2009, STRENGTHENING FORENS; BARROWS HS, 1982, CLIN INVEST MED, V5, P49; Barton JJS, 2006, PERCEPTION, V35, P1089, DOI 10.1068/p5547; Brooks L, 1987, EMORY S COGNITION 1, P141; Brooks LR, 2005, CAN J EXP PSYCHOL, V59, P62, DOI 10.1037/h0087462; BROOKS LR, 1978, NON ANALYTIC CONCEPT; BUSEY T, 2011, J FORENSIC IDENTIF, V60, P61; Busey TA, 2005, VISION RES, V45, P431, DOI 10.1016/j.visres.2004.08.021; Busey TA, 2010, PSYCHON B REV, V17, P155, DOI 10.3758/PBR.17.2.155; CAMPBELL A, 2011, THE FINGERPRINT INQU, P790; Cole SA, 2009, LP R, V8, P233, DOI DOI 10.1093/LPR/MGP016; Cole SA, 2005, J CRIM LAW CRIM, V95, P985; Cowan N, 2008, PROG BRAIN RES, V169, P323, DOI 10.1016/S0079-6123(07)00020-9; DEGROOT AD, 1978, THOUGHT AND CHOICE I; Dodson CS, 1997, MEM COGNITION, V25, P129, DOI 10.3758/BF03201107; Dror I.E., 2006, J FORENSIC IDENTIFIC, V56, P600, DOI DOI 10.1016/S1355-0306(98)72118-5; Dror IE, 2006, FORENSIC SCI INT, V156, P74, DOI 10.1016/j.forsciint.2005.10.017; Dror IE, 2011, FORENSIC SCI INT, V208, P10, DOI 10.1016/j.forsciint.2010.10.013; Edmond G, 2015, LAW PROBAB RISK, V14, P1, DOI [10.1093/lpr/mgu018, 10.1093/lpr/mgt011]; ERICSSON KA, 1993, PSYCHOL REV, V100, P363, DOI 10.1037/0033-295X.100.3.363; Ericsson KA, 1996, ANNU REV PSYCHOL, V47, P273, DOI 10.1146/annurev.psych.47.1.273; ERICSSON KA, 1991, TOWARD A GENERAL THE; Evans KK, 2013, PSYCHON B REV, V20, P1170, DOI 10.3758/s13423-013-0459-3; Evans KK, 2011, PSYCHOL SCI, V22, P739, DOI 10.1177/0956797611407930; Evans KK, 2011, ATTEN PERCEPT PSYCHO, V73, P30, DOI 10.3758/s13414-010-0022-5; *FED BUR INV, 1984, THE SCIENCE OF FINGE; Gauthier I, 1997, VISION RES, V37, P1673, DOI 10.1016/S0042-6989(96)00286-6; Gobet F, 2006, CAMBRIDGE HANDBOOK OF EXPERTISE AND EXPERT PERFORMANCE, P523; Greene MR, 2009, COGNITIVE PSYCHOL, V58, P137, DOI 10.1016/j.cogpsych.2008.06.001; HENRY ER, 1900, CLASSIFICATION AND U; Hughson AL, 2001, AUST J PSYCHOL, V53, P103, DOI 10.1080/00049530108255130; INTRAUB H, 1981, J EXP PSYCHOL HUMAN, V7, P604, DOI 10.1037/0096-1523.7.3.604; Joubert OR, 2007, VISION RES, V47, P3286, DOI 10.1016/j.visres.2007.09.013; Kahneman D., 2011, THINKING FAST AND SL; Kahneman D, 2009, AM PSYCHOL, V64, P515, DOI 10.1037/a0016755; Kassin SM, 2013, J APPL RES MEM COGN, V2, P42, DOI 10.1016/j.jarmac.2013.01.001; KLEIN GA, 1998, SOURCES OF POWER; Loftus EF, 2004, SCIENCE, V304, P959; Medin DL., 1989, ADV PSYCHOL HUMAN IN, P189, DOI [10.4324/9781315807768-13, DOI 10.4324/9781315807768-13]; Mnookin JL, 2011, UCLA LAW REV, V58, P725; MYLESWORSLEY M, 1988, J EXP PSYCHOL LEARN, V14, P553, DOI 10.1037/0278-7393.14.3.553; NISBETT RE, 1977, PSYCHOL REV, V84, P231, DOI 10.1037/0033-295X.84.3.231; Norman GR, 2010, MED EDUC, V44, P94, DOI 10.1111/j.1365-2923.2009.03507.x; Norman GR, 1997, ADV HEALTH SCI EDUC, V2, P173, DOI 10.1023/A:1009784330364; NORMAN GR, 1989, ARCH DERMATOL, V125, P1063, DOI 10.1001/archderm.125.8.1063; POTTER MC, 1975, NATURE, V253, P437, DOI 10.1038/253437a0; Rossion Bruno, 2002, Behav Cogn Neurosci Rev, V1, P63, DOI 10.1177/1534582302001001004; Saks MJ, 2005, SCIENCE, V309, P892, DOI 10.1126/science.1111565; SEARSTON RA, PUTTING BIAS INTO CO; Spinney L, 2010, NATURE, V464, P344, DOI 10.1038/464344a; Tangen JM, 2011, PSYCHOL SCI, V22, P995, DOI 10.1177/0956797611414729; Thompson MB, 2014, LAW HUMAN BEHAV, V38, P84, DOI 10.1037/lhb0000051; Thompson MB, 2013, J FORENSIC SCI, V58, P1519, DOI 10.1111/1556-4029.12203; Ulery BT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032800; Ulery BT, 2011, P NATL ACAD SCI USA, V108, P7733, DOI 10.1073/pnas.1018707108; Vokey JR, 2009, Q J EXP PSYCHOL, V62, P1023, DOI 10.1080/17470210802372987; Wilson T., 2002, STRANGERS TO OURSELV	58	51	51	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2014	9	12							e114759	10.1371/journal.pone.0114759	http://dx.doi.org/10.1371/journal.pone.0114759			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AX9IA	25517509	Green Published, gold, Green Submitted			2023-01-03	WOS:000347215600026
J	Thomsen, M; Hernandez-Garcia, A; Mathiesen, J; Poulsen, M; Sorensen, DN; Tarnow, L; Feidenhansl, R				Thomsen, Maria; Hernandez-Garcia, Anier; Mathiesen, Joachim; Poulsen, Mette; Sorensen, Dan N.; Tarnow, Lise; Feidenhansl, Robert			Model Study of the Pressure Build-Up during Subcutaneous Injection	PLOS ONE			English	Article							INSULIN; INFUSION; TISSUE	In this study we estimate the subcutaneous tissue counter pressure during drug infusion from a series of injections of insulin in type 2 diabetic patients using a non-invasive method. We construct a model for the pressure evolution in subcutaneous tissue based on mass continuity and the flow laws of a porous medium. For equivalent injection forces we measure the change in the infusion rate between injections in air at atmospheric pressure and in tissue. From a best fit with our model, we then determine the flow permeability as well as the bulk modulus of the tissue, estimated to be of the order 10(-11) - 10(-10) m(2) and 10(5) Pa, respectively. The permeability is in good agreement with reported values for adipose porcine tissue. We suggest our model as a general way to estimate the pressure build-up in tissue during subcutaneous injection.	[Thomsen, Maria; Hernandez-Garcia, Anier; Mathiesen, Joachim; Feidenhansl, Robert] Univ Copenhagen, Niels Bohr Inst, DK-2100 Copenhagen, Denmark; [Thomsen, Maria; Poulsen, Mette; Sorensen, Dan N.] Novo Nordisk AS, Hillerod, Denmark; [Tarnow, Lise] Nordsjae llands Hosp, Hillerod, Denmark; [Tarnow, Lise] Aarhus Univ Hosp, Klin Epidemiol Afdeling, DK-8000 Aarhus, Denmark; [Tarnow, Lise] Steno Diabet Ctr AS, Gentofte, Denmark	University of Copenhagen; Niels Bohr Institute; Novo Nordisk; Aarhus University; Steno Diabetes Center	Thomsen, M (corresponding author), Univ Copenhagen, Niels Bohr Inst, Blegdamsvej 17, DK-2100 Copenhagen, Denmark.	mariath@fys.ku.dk	Tangen, Jason/ABH-8577-2020; Thompson, Matthew/J-9922-2012	Tangen, Jason/0000-0002-0649-2566; Thompson, Matthew/0000-0002-5649-1203; Poulsen, Mette Homann/0000-0003-2162-3007; Mathiesen, Joachim/0000-0002-5621-5487; Feidenhansl, Robert/0000-0002-7963-3649; Tarnow, Lise/0000-0002-8735-966X	Villum Fonden [00007172] Funding Source: researchfish	Villum Fonden(Villum Fonden)		Agache PG, 2004, MEASURING SKIN; AUKLAND K, 1993, PHYSIOL REV, V73, P1, DOI 10.1152/physrev.1993.73.1.1; Comley KSC, 2010, THESIS U CAMBRIDGE E; Darcy H., 1856, FONTAINES PUBLIQUES, DOI [10.2307/1467138, DOI 10.2307/1467138]; De Coninck C, 2010, J DIABETES, V2, P168, DOI 10.1111/j.1753-0407.2010.00077.x; Gentile S, 2011, ACTA DIABETOL, V48, P121, DOI 10.1007/s00592-009-0172-x; Heinemann L, 2013, DIABETES TECHNOL THE, V15, pS48, DOI 10.1089/dia.2013.1506; Holstein A, 2010, EXPERT OPIN DRUG SAF, V9, P225, DOI 10.1517/14740330903496402; Johansson UB, 2005, DIABETES CARE, V28, P2025, DOI 10.2337/diacare.28.8.2025; Johnsen O, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.011301; MCGILL R, 1978, AM STAT, V32, P12, DOI 10.2307/2683468; Milan G, 2010, J CLIN ENDOCR METAB, V95, P3126, DOI 10.1210/jc.2009-2773; Omar Magdy A, 2011, BMC Res Notes, V4, P290, DOI 10.1186/1756-0500-4-290; Patte C, 2013, DIABETES TECHNOL THE, V15, P289, DOI 10.1089/dia.2012.0319; Pearson Teresa L, 2010, J Diabetes Sci Technol, V4, P522; Peteiro-Gonzalez D, 2011, DIABETES RES CLIN PR, V91, pE61, DOI 10.1016/j.diabres.2010.11.026; SPIEGELMAN M, 1993, J FLUID MECH, V247, P17, DOI 10.1017/S0022112093000369; STRANDEN E, 1982, MICROVASC RES, V24, P241, DOI 10.1016/0026-2862(82)90015-2; Strauss K, 2002, PRACT DIAB INT, P71, DOI 10.1002/pdi.314; Thomsen M, 2012, PHYS MED BIOL, V57, P7191, DOI 10.1088/0031-9155/57/21/7191; Vardar B, 2007, DIABETES RES CLIN PR, V77, P231, DOI 10.1016/j.diabres.2006.12.023; Wang H.F, 2000, PRI SER GEO, V2; Wielandt JO, 2011, EXPERT OPIN DRUG DEL, V8, P1271, DOI 10.1517/17425247.2011.615308; Wiig H, 2003, ACTA ANAESTH SCAND, V47, P111, DOI 10.1034/j.1399-6576.2003.00050.x	24	51	51	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2014	9	8							e104054	10.1371/journal.pone.0104054	http://dx.doi.org/10.1371/journal.pone.0104054			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO0QT	25517509	gold, Green Published			2023-01-03	WOS:000341017000026
J	Wu, CH; Chen, LS; Yen, MF; Chiu, YH; Fann, CY; Chen, HH; Pan, SL				Wu, Chueh-Hung; Chen, Li-Sheng; Yen, Ming-Fang; Chiu, Yueh-Hsia; Fann, Ching-Yuan; Chen, Hsiu-Hsi; Pan, Shin-Liang			Does Non-Central Nervous System Tuberculosis Increase the Risk of Ischemic Stroke? A Population-Based Propensity Score-Matched Follow-Up Study	PLOS ONE			English	Article							CAROTID ATHEROSCLEROSIS; CHRONIC INFECTIONS; CIGARETTE-SMOKING; HEALTH-INSURANCE; PREVALENCE; TAIWAN; SEX; AGE	Background: Previous studies on the association between tuberculosis and the risk of developing ischemic stroke have generated inconsistent results. We therefore performed a population-based, propensity score-matched longitudinal follow-up study to investigate whether contracting non-central nervous system (CNS) tuberculosis leads to an increased risk of ischemic stroke. Methods: We used a logistic regression model that includes age, sex, pre-existing comorbidities and socioeconomic status as covariates to compute the propensity score. A total of 5804 persons with at least three ambulatory visits in 2001 with the principal diagnosis of non-CNS tuberculosis were enrolled in the tuberculosis group. The non-tuberculosis group consisted of 5804, propensity score-matched subjects without tuberculosis. The three-year ischemic stroke-free survival rates for these 2 groups were estimated using the Kaplan-Meier method. The stratified Cox proportional hazards regression was used to estimate the effect of tuberculosis on the occurrence of ischemic stroke. Results: During three-year follow-up, 176 subjects in the tuberculosis group (3.0%) and 207 in the non-tuberculosis group (3.6%) had ischemic stroke. The hazard ratio for developing ischemic stroke in the tuberculosis group was 0.92 compared to the non-tuberculosis group (95% confidence interval: 0.73-1.14, P = 0.4299). Conclusions: Non-CNS tuberculosis does not increase the risk of subsequent ischemic stroke.	[Wu, Chueh-Hung; Pan, Shin-Liang] Natl Taiwan Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Wu, Chueh-Hung; Pan, Shin-Liang] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan; [Chen, Li-Sheng; Yen, Ming-Fang] Taipei Med Univ, Coll Oral Med, Sch Oral Hyg, Taipei, Taiwan; [Chiu, Yueh-Hsia] Chang Gung Univ, Dept & Grad Inst Hlth Care Management, Taoyuan, Taiwan; [Fann, Ching-Yuan] Kainan Univ, Dept Nutr & Hlth Sci, Taoyuan, Taiwan; [Chen, Hsiu-Hsi] Natl Taiwan Univ, Coll Publ Hlth, Ctr Biostat Consultat, Taipei 10764, Taiwan; [Chen, Hsiu-Hsi] Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol, Div Biostat, Taipei 10764, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; Taipei Medical University; Chang Gung University; Nan Kai University Technology; National Taiwan University; National Taiwan University	Pan, SL (corresponding author), Natl Taiwan Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan.	panslcb@gmail.com		Chen, Hsiu-Hsi/0000-0002-5799-6705; Chiu, Sherry Yueh-Hsia/0000-0002-7207-7088; PAN, SHIN-LIANG/0000-0001-6451-4666; WU, CHUEH-HUNG/0000-0002-3979-3541	Department of Health, Executive Yuan, Republic of China [DOH93-TD-M-113-030, DOH94-TD-M-113-004, DOH95-TD-M-113-002]	Department of Health, Executive Yuan, Republic of China	This study was supported by grants DOH93-TD-M-113-030, DOH94-TD-M-113-004, and DOH95-TD-M-113-002 from the Department of Health, Executive Yuan, Republic of China. This study used the complete National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health. The interpretation and conclusions contained in this study do not necessarily represent those of the Department of Health, Executive Yuan, Republic of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arcavi L, 2004, ARCH INTERN MED, V164, P2206, DOI 10.1001/archinte.164.20.2206; Asplund K, 2009, STROKE, V40, P2319, DOI 10.1161/STROKEAHA.109.547869; Byberg S, 2012, EUR RESPIR J, V40, P1289, DOI 10.1183/09031936.00039612; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; DAVIS PH, 1987, ANN NEUROL, V22, P319, DOI 10.1002/ana.410220307; De Silva DA, 2009, J NEUROL SCI, V285, P118, DOI 10.1016/j.jns.2009.06.013; Dobler CC, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000666; Elkind MSV, 2006, STROKE, V37, P790, DOI 10.1161/01.STR.0000202624.89869.e9; Engstrom G, 2001, STROKE, V32, P1098, DOI 10.1161/01.STR.32.5.1098; Espinola-Klein C, 2002, STROKE, V33, P2581, DOI 10.1161/01.STR.0000034789.82859.A4; Faurholt-Jepsen D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024215; Giral P, 2007, ATHEROSCLEROSIS, V190, P150, DOI 10.1016/j.atherosclerosis.2006.01.008; Hagiwara Noriko, 2007, J Stroke Cerebrovasc Dis, V16, P145, DOI 10.1016/j.jstrokecerebrovasdis.2007.02.001; Holmes CB, 1998, INT J TUBERC LUNG D, V2, P96; Hsieh FY, 2000, CONTROL CLIN TRIALS, V21, P552, DOI 10.1016/S0197-2456(00)00104-5; Huang YP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068314; Jeon CY, 2008, PLOS MED, V5, P1091, DOI 10.1371/journal.pmed.0050152; Kalayoglu MV, 2002, JAMA-J AM MED ASSOC, V288, P2724, DOI 10.1001/jama.288.21.2724; Kiechl S, 2001, CIRCULATION, V103, P1064, DOI 10.1161/01.CIR.103.8.1064; Kiechl S, 2002, STROKE, V33, P2170, DOI 10.1161/01.STR.0000027209.59821.98; Lin HC, 2007, J URBAN HEALTH, V84, P604, DOI 10.1007/s11524-007-9195-1; Lin HC, 2010, NEUROLOGY, V74, P792, DOI 10.1212/WNL.0b013e3181d31e5c; Liu C.Y., 2006, J HEALTH MANAG, V4, P1; McNamee R, 2005, OCCUP ENVIRON MED, V62, P500, DOI 10.1136/oem.2002.001115; Mori T, 2010, INFECT DIS CLIN N AM, V24, P751, DOI 10.1016/j.idc.2010.04.011; Parsons L, 2004, SUGI 29 P SAS US GRO; Prasad A, 2002, CIRCULATION, V106, P184, DOI 10.1161/01.CIR.0000021125.83697.21; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Schneeweiss S, 2000, INT J EPIDEMIOL, V29, P891, DOI 10.1093/ije/29.5.891; Sheu JJ, 2010, STROKE, V41, P244, DOI 10.1161/STROKEAHA.109.567735; Simons LA, 1998, STROKE, V29, P1341, DOI 10.1161/01.STR.29.7.1341; Viswanathan V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041367; Wang JM, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-292; Wen CP, 2008, ANN INTERN MED, V148, P258, DOI 10.7326/0003-4819-148-4-200802190-00004; WHO, 2009, GLOB TUB CONTR EP ST, P6; WOLF PA, 1985, STROKE, V16, P359, DOI 10.1161/01.STR.16.3.359; Wu CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049343	38	20	21	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2014	9	7							e98158	10.1371/journal.pone.0098158	http://dx.doi.org/10.1371/journal.pone.0098158			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM0SW	25133789	Green Published, Green Submitted, gold			2023-01-03	WOS:000339558100001
